0001682852-24-000015.txt : 20240223 0001682852-24-000015.hdr.sgml : 20240223 20240223160310 ACCESSION NUMBER: 0001682852-24-000015 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 125 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240223 DATE AS OF CHANGE: 20240223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 24671067 BUSINESS ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 10-K 1 mrna-20231231.htm 10-K mrna-20231231
false2023FY0001682852http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent5397400016828522023-01-012023-12-3100016828522023-06-30iso4217:USD00016828522024-02-16xbrli:shares00016828522023-12-3100016828522022-12-31iso4217:USDxbrli:shares0001682852mrna:ProductSalesMember2023-01-012023-12-310001682852mrna:ProductSalesMember2022-01-012022-12-310001682852mrna:ProductSalesMember2021-01-012021-12-310001682852us-gaap:ProductAndServiceOtherMember2023-01-012023-12-310001682852us-gaap:ProductAndServiceOtherMember2022-01-012022-12-310001682852us-gaap:ProductAndServiceOtherMember2021-01-012021-12-3100016828522022-01-012022-12-3100016828522021-01-012021-12-310001682852us-gaap:CommonStockMember2020-12-310001682852us-gaap:AdditionalPaidInCapitalMember2020-12-310001682852us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001682852us-gaap:RetainedEarningsMember2020-12-3100016828522020-12-310001682852us-gaap:CommonStockMember2021-01-012021-12-310001682852us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001682852us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001682852us-gaap:RetainedEarningsMember2021-01-012021-12-310001682852us-gaap:CommonStockMember2021-12-310001682852us-gaap:AdditionalPaidInCapitalMember2021-12-310001682852us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001682852us-gaap:RetainedEarningsMember2021-12-3100016828522021-12-310001682852us-gaap:CommonStockMember2022-01-012022-12-310001682852us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001682852us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001682852us-gaap:RetainedEarningsMember2022-01-012022-12-310001682852us-gaap:CommonStockMember2022-12-310001682852us-gaap:AdditionalPaidInCapitalMember2022-12-310001682852us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001682852us-gaap:RetainedEarningsMember2022-12-310001682852us-gaap:CommonStockMember2023-01-012023-12-310001682852us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310001682852us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001682852us-gaap:RetainedEarningsMember2023-01-012023-12-310001682852us-gaap:CommonStockMember2023-12-310001682852us-gaap:AdditionalPaidInCapitalMember2023-12-310001682852us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001682852us-gaap:RetainedEarningsMember2023-12-31mrna:candidatemrna:developmentProgrammrna:segment0001682852us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembermrna:FFFEnterprisesMember2023-01-012023-12-31xbrli:pure0001682852mrna:EuropeanCommissionMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310001682852mrna:EuropeanCommissionMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2021-01-012021-12-310001682852mrna:EuropeanCommissionMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001682852us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMembermrna:USGovermentMember2022-01-012022-12-310001682852us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMembermrna:USGovermentMember2021-01-012021-12-310001682852mrna:TakedaPharmaceuticalCompanyMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310001682852mrna:MinistryOfHealthLaborAndWelfareOfJapanMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310001682852mrna:MinistryOfHealthLaborAndWelfareOfJapanMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001682852us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembermrna:UKHealthSecurityAgencyMember2023-01-012023-12-310001682852us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembermrna:UKHealthSecurityAgencyMember2022-01-012022-12-310001682852us-gaap:EquipmentMember2023-12-310001682852us-gaap:ComputerEquipmentMembersrt:MinimumMember2023-12-310001682852srt:MaximumMemberus-gaap:ComputerEquipmentMember2023-12-310001682852us-gaap:PropertyPlantAndEquipmentOtherTypesMember2023-12-310001682852mrna:OriCiroGenomicsKKMember2023-01-312023-01-310001682852mrna:OriCiroGenomicsKKMember2023-01-310001682852us-gaap:TechnologyBasedIntangibleAssetsMembermrna:OriCiroGenomicsKKMember2023-01-312023-01-310001682852us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310001682852us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310001682852us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310001682852us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-12-310001682852us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-12-310001682852us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-12-310001682852us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310001682852us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310001682852us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310001682852us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-12-310001682852us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-12-310001682852us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-12-310001682852us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-310001682852us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310001682852us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310001682852mrna:ProductSalesMembercountry:US2023-01-012023-12-310001682852mrna:ProductSalesMembercountry:US2022-01-012022-12-310001682852mrna:ProductSalesMembercountry:US2021-01-012021-12-310001682852mrna:ProductSalesMembersrt:EuropeMember2023-01-012023-12-310001682852mrna:ProductSalesMembersrt:EuropeMember2022-01-012022-12-310001682852mrna:ProductSalesMembersrt:EuropeMember2021-01-012021-12-310001682852mrna:ProductSalesMembermrna:RestOfTheWorldMember2023-01-012023-12-310001682852mrna:ProductSalesMembermrna:RestOfTheWorldMember2022-01-012022-12-310001682852mrna:ProductSalesMembermrna:RestOfTheWorldMember2021-01-012021-12-310001682852mrna:ProductSalesMember2023-12-310001682852mrna:ProductSalesMember2022-12-310001682852us-gaap:GrantMember2023-01-012023-12-310001682852us-gaap:GrantMember2022-01-012022-12-310001682852us-gaap:GrantMember2021-01-012021-12-310001682852mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember2023-01-012023-12-310001682852mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember2022-01-012022-12-310001682852mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember2021-01-012021-12-310001682852mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember2020-04-012020-04-30mrna:participant0001682852mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember2020-04-202023-12-310001682852mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember2023-12-310001682852mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMemberus-gaap:GrantMember2023-01-012023-12-310001682852mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMemberus-gaap:GrantMember2022-01-012022-12-310001682852mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMemberus-gaap:GrantMember2021-01-012021-12-310001682852us-gaap:GrantMembermrna:OtherGrantRevenueMember2023-01-012023-12-310001682852us-gaap:GrantMembermrna:OtherGrantRevenueMember2022-01-012022-12-310001682852us-gaap:GrantMembermrna:OtherGrantRevenueMember2021-01-012021-12-310001682852mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMembermrna:VertexMember2023-01-012023-12-310001682852mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMembermrna:VertexMember2022-01-012022-12-310001682852mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMembermrna:VertexMember2021-01-012021-12-310001682852mrna:MerckMembermrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember2023-01-012023-12-310001682852mrna:MerckMembermrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember2022-01-012022-12-310001682852mrna:MerckMembermrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember2021-01-012021-12-310001682852mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMembermrna:AstraZenecaMember2023-01-012023-12-310001682852mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMembermrna:AstraZenecaMember2022-01-012022-12-310001682852mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMembermrna:AstraZenecaMember2021-01-012021-12-310001682852mrna:OtherCollaborativePartiesMembermrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember2023-01-012023-12-310001682852mrna:OtherCollaborativePartiesMembermrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember2022-01-012022-12-310001682852mrna:OtherCollaborativePartiesMembermrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember2021-01-012021-12-310001682852mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember2016-06-012016-06-300001682852mrna:MerckMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-10-310001682852mrna:MerckMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-01-012023-12-310001682852mrna:MerckMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-12-310001682852mrna:MRNAVertex2020AgreementMemberMember2020-09-012020-09-300001682852mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember2013-03-012013-03-3100016828522022-07-012022-09-300001682852us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrna:ImmaticsMember2023-10-310001682852us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Member2023-12-310001682852us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMember2023-12-310001682852us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852us-gaap:CashAndCashEquivalentsMemberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852mrna:CurrentMarketableSecuritiesMemberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852mrna:NoncurrentMarketableSecuritiesMemberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852us-gaap:CashAndCashEquivalentsMemberus-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852mrna:CurrentMarketableSecuritiesMemberus-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852mrna:NoncurrentMarketableSecuritiesMemberus-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852us-gaap:USTreasuryNotesSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852us-gaap:USTreasuryNotesSecuritiesMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852mrna:CurrentMarketableSecuritiesMemberus-gaap:USTreasuryNotesSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852us-gaap:USTreasuryNotesSecuritiesMembermrna:NoncurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852us-gaap:CashAndCashEquivalentsMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852mrna:CurrentMarketableSecuritiesMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852mrna:NoncurrentMarketableSecuritiesMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852mrna:CurrentMarketableSecuritiesMemberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852mrna:NoncurrentMarketableSecuritiesMemberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852us-gaap:FairValueInputsLevel2Member2023-12-310001682852us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852mrna:CurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852mrna:NoncurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Member2022-12-310001682852us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMember2022-12-310001682852us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852us-gaap:CashAndCashEquivalentsMemberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852mrna:CurrentMarketableSecuritiesMemberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852mrna:NoncurrentMarketableSecuritiesMemberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852us-gaap:CashAndCashEquivalentsMemberus-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852mrna:CurrentMarketableSecuritiesMemberus-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852mrna:NoncurrentMarketableSecuritiesMemberus-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852us-gaap:USTreasuryNotesSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852us-gaap:USTreasuryNotesSecuritiesMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852mrna:CurrentMarketableSecuritiesMemberus-gaap:USTreasuryNotesSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852us-gaap:USTreasuryNotesSecuritiesMembermrna:NoncurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852us-gaap:CashAndCashEquivalentsMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852mrna:CurrentMarketableSecuritiesMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852mrna:NoncurrentMarketableSecuritiesMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852mrna:CurrentMarketableSecuritiesMemberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852mrna:NoncurrentMarketableSecuritiesMemberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852us-gaap:FairValueInputsLevel2Member2022-12-310001682852us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852mrna:CurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852mrna:NoncurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852us-gaap:USTreasuryBillSecuritiesMember2023-12-310001682852us-gaap:USTreasuryNotesSecuritiesMember2023-12-310001682852us-gaap:CorporateDebtSecuritiesMember2023-12-310001682852us-gaap:USGovernmentDebtSecuritiesMember2023-12-310001682852us-gaap:USTreasurySecuritiesMember2022-12-310001682852us-gaap:USTreasuryNotesSecuritiesMember2022-12-310001682852us-gaap:CorporateDebtSecuritiesMember2022-12-310001682852us-gaap:USGovernmentDebtSecuritiesMember2022-12-31mrna:security0001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2023-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2023-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMember2023-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2023-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBillSecuritiesMember2023-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852us-gaap:USTreasuryNotesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001682852us-gaap:USTreasuryNotesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310001682852us-gaap:USTreasuryNotesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2023-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentDebtSecuritiesMember2023-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001682852us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310001682852us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852us-gaap:FairValueMeasurementsRecurringMember2023-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2022-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2022-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMember2022-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2022-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBillSecuritiesMember2022-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852us-gaap:USTreasuryNotesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001682852us-gaap:USTreasuryNotesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310001682852us-gaap:USTreasuryNotesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2022-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2022-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentDebtSecuritiesMember2022-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852us-gaap:FairValueMeasurementsRecurringMember2022-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001682852us-gaap:PublicUtilitiesInventoryRawMaterialsMember2023-01-012023-12-310001682852us-gaap:LandAndLandImprovementsMember2023-12-310001682852us-gaap:LandAndLandImprovementsMember2022-12-310001682852us-gaap:EquipmentMember2022-12-310001682852us-gaap:LeaseholdImprovementsMember2023-12-310001682852us-gaap:LeaseholdImprovementsMember2022-12-310001682852us-gaap:PropertyPlantAndEquipmentOtherTypesMember2022-12-310001682852us-gaap:ComputerEquipmentMember2023-12-310001682852us-gaap:ComputerEquipmentMember2022-12-310001682852us-gaap:ConstructionInProgressMember2023-12-310001682852us-gaap:ConstructionInProgressMember2022-12-310001682852mrna:FinancingRightOfUseAssetMember2023-12-310001682852mrna:FinancingRightOfUseAssetMember2022-12-310001682852us-gaap:GrantMember2022-12-310001682852us-gaap:GrantMember2023-12-310001682852mrna:CollaborationArrangementMember2022-12-310001682852mrna:CollaborationArrangementMember2023-01-012023-12-310001682852mrna:CollaborationArrangementMember2023-12-31mrna:campus0001682852mrna:CambridgeMassachusettsMember2023-12-31utr:sqft0001682852mrna:CambridgeMassachusettsMember2021-09-300001682852mrna:CambridgeMassachusettsMember2021-09-012021-09-30mrna:numberOfExtensionPeriod0001682852mrna:MTCSouthMTCNorthAndMTCEastMember2023-12-31mrna:numberOfBuilding0001682852mrna:EmbeddedLeasesMember2023-07-012023-09-300001682852mrna:EmbeddedLeasesMember2023-01-012023-12-310001682852mrna:EmbeddedLeasesMember2023-12-310001682852mrna:EmbeddedLeasesMember2022-12-310001682852mrna:MTCSouthMTCNorthAndMTCEastMembermrna:NorwoodMassachusettsMember2023-12-310001682852us-gaap:IndemnificationGuaranteeMember2023-01-012023-12-310001682852us-gaap:IndemnificationGuaranteeMember2022-01-012022-12-310001682852us-gaap:IndemnificationGuaranteeMember2022-12-31mrna:claim0001682852us-gaap:IndemnificationGuaranteeMember2023-12-310001682852mrna:SupplyAndManufacturingAgreementsMember2023-12-310001682852mrna:ClinicalServicesMember2023-12-310001682852mrna:ClinicalOperationsAndSupportCommitmentMember2023-12-310001682852us-gaap:LicenseAndServiceMembermrna:NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember2022-12-012022-12-310001682852mrna:ServiceBasedAwardsMember2023-01-012023-12-310001682852us-gaap:ShareBasedCompensationAwardTrancheOneMembermrna:ServiceBasedAwardsMember2023-01-012023-12-310001682852us-gaap:ShareBasedCompensationAwardTrancheTwoMembermrna:ServiceBasedAwardsMember2023-01-012023-12-31mrna:installment0001682852us-gaap:EmployeeStockOptionMembermrna:StockOptionAndGrantPlan2016Member2023-01-012023-12-310001682852us-gaap:EmployeeStockOptionMember2023-12-310001682852mrna:StockOptionAndIncentivePlan2018Member2023-12-310001682852mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember2022-12-310001682852mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember2023-01-012023-12-310001682852mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember2023-12-310001682852mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember2022-01-012022-12-310001682852mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember2021-01-012021-12-310001682852us-gaap:PerformanceSharesMember2021-01-012021-12-310001682852us-gaap:PerformanceSharesMember2022-01-012022-12-310001682852us-gaap:PerformanceSharesMembersrt:MinimumMember2022-12-310001682852us-gaap:PerformanceSharesMembersrt:MinimumMember2021-12-310001682852us-gaap:PerformanceSharesMembersrt:MaximumMember2021-12-310001682852us-gaap:PerformanceSharesMembersrt:MaximumMember2022-12-310001682852us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001682852us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001682852us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001682852us-gaap:EmployeeStockOptionMembersrt:WeightedAverageMember2023-12-310001682852us-gaap:EmployeeStockOptionMembersrt:WeightedAverageMember2022-12-310001682852us-gaap:EmployeeStockOptionMembersrt:WeightedAverageMember2021-12-310001682852mrna:RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember2023-01-012023-12-310001682852mrna:RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember2022-01-012022-12-310001682852mrna:RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember2021-01-012021-12-310001682852us-gaap:EmployeeStockMember2023-01-012023-12-310001682852us-gaap:EmployeeStockMember2022-01-012022-12-310001682852us-gaap:EmployeeStockMember2021-01-012021-12-310001682852us-gaap:CostOfSalesMember2023-01-012023-12-310001682852us-gaap:CostOfSalesMember2022-01-012022-12-310001682852us-gaap:CostOfSalesMember2021-01-012021-12-310001682852us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-12-310001682852us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310001682852us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001682852us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-12-310001682852us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-310001682852us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-310001682852us-gaap:PerformanceSharesMember2023-01-012023-12-310001682852mrna:A2021RepurchaseProgramMember2021-08-020001682852mrna:A2021RepurchaseProgramMember2022-01-012022-01-310001682852mrna:A2022RepurchaseProgramMember2022-02-220001682852mrna:A2022RepurchaseProgramMember2022-08-010001682852mrna:A2022RepurchaseProgramMember2023-12-310001682852us-gaap:StateAndLocalJurisdictionMember2023-01-012023-12-310001682852us-gaap:StateAndLocalJurisdictionMember2023-12-310001682852us-gaap:ResearchMemberus-gaap:StateAndLocalJurisdictionMember2023-12-310001682852us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001682852us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001682852us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001682852us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001682852us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001682852us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001682852country:US2023-01-012023-12-310001682852country:US2022-01-012022-12-310001682852country:US2021-01-012021-12-310001682852srt:EuropeMember2023-01-012023-12-310001682852srt:EuropeMember2022-01-012022-12-310001682852srt:EuropeMember2021-01-012021-12-310001682852mrna:RestOfWorldMember2023-01-012023-12-310001682852mrna:RestOfWorldMember2022-01-012022-12-310001682852mrna:RestOfWorldMember2021-01-012021-12-310001682852country:US2023-12-310001682852country:US2022-12-310001682852srt:EuropeMember2023-12-310001682852srt:EuropeMember2022-12-310001682852mrna:RestOfWorldMember2023-12-310001682852mrna:RestOfWorldMember2022-12-3100016828522023-10-012023-12-310001682852mrna:NoubarAfeyanMember2023-01-012023-12-310001682852mrna:NoubarAfeyanMember2023-10-012023-12-310001682852mrna:NoubarAfeyanMember2023-12-310001682852mrna:ArpaGarayMember2023-01-012023-12-310001682852mrna:ArpaGarayMember2023-10-012023-12-310001682852mrna:ArpaGarayMembermrna:ArpaGarayCommonStockMember2023-12-310001682852mrna:ArpaGarayMembermrna:ArpaGarayStockOptionsMember2023-12-31


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM10-K
(Mark One)
☒    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2023
OR
☐    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _ to _
Commission File Number: 001-38753

modernalogo.jpg

Moderna, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware81-3467528
(State or Other Jurisdiction of Incorporation or Organization)(IRS Employer Identification No.)
200 Technology Square
Cambridge, Massachusetts
02139
(Address of Principal Executive Offices)(Zip Code)
(617) 714-6500
(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.0001 per shareMRNAThe Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☑ No ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☑

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑    No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☑
Accelerated filer ☐
Non-accelerated filer ☐
Smaller reporting company ☐
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes ☑ No ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☑
As of June 30, 2023, the aggregate market value of voting and non-voting common equity held by non-affiliates of the registrant was approximately $40.2 billion based on the closing sale price on that date of $121.50. Shares of common stock held by each executive officer and director and by each other person who may be deemed to be an affiliate of the Registrant have been excluded from this computation. The determination of affiliate status for this purpose is not necessarily a conclusive determination for other purposes.

As of February 16, 2024, there were 382,073,208 shares of the registrant’s common stock, par value $0.0001 per share, outstanding.

DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s Definitive Proxy Statement relating to its 2024 Annual Meeting of Stockholders to be filed hereafter are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.



Table of Contents

PART I.
Page
Item 1.Business
Item 1A.Risk Factors
Item 1B.Unresolved Staff Comments
Item 1C.Cybersecurity
Item 2.Properties
Item 3.Legal Proceedings
Item 4.Mine Safety Disclosures
PART II.
Item 5.
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Item 6.[Reserved]
Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations
Item 7A.Quantitative and Qualitative Disclosures about Market Risk
Item 8.Financial Statements and Supplementary Data
Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Item 9A.Controls and Procedures
Item 9B.Other Information
Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
PART III.
Item 10.
Directors, Executive Officers and Corporate Governance
Item 11.Executive Compensation
Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Item 13.Certain Relationships and Related Transactions, and Director Independence
Item 14.Principal Accountant Fees and Services
PART IV.
Item 15.
Exhibits, Financial Statement Schedules
Item 16.Form 10-K Summary
Signatures



SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS

Our business is subject to numerous risks and uncertainties that you should be aware of before making an investment decision, including those highlighted in the section entitled “Risk Factors.” These risks include, but are not limited to, the following:

•Evolving dynamics in the market for COVID-19 vaccines are likely to impact our financial results, which are likely to result in lower product revenues in 2024 than we have experienced in recent years;
•We may encounter difficulties producing or shipping our products consistent with our projections or future contractual commitments;
•We have limited sales, distribution and marketing experience and may be unable to effectively establish such capabilities or supplement our capabilities by entering into agreements with third parties;
•The pharmaceutical market is intensely competitive, and we may not compete effectively in the market for existing products, new treatment methods and new technologies;
•We may be unsuccessful or delayed in updating our COVID-19 vaccine to protect against future variants of the SARS-CoV-2 virus, and updated versions of our COVID-19 vaccine may not protect against such variants;
•The commercial success of our products will depend on the degree of market acceptance by physicians, patients, third-party payors and others in the medical community;
•Sales of pharmaceutical products depend on the availability and extent of reimbursement from third-party payors, and we may be adversely impacted by changes to such reimbursement policies or rules;
•Preclinical development is lengthy and uncertain, especially for mRNA medicines, and our preclinical programs or product candidates may be delayed or terminated;
•Clinical development is lengthy and uncertain, and our clinical programs may be delayed or terminated, or may be more costly to conduct than we anticipate;
•If we cannot obtain, or are delayed in obtaining, required regulatory approvals, we will be unable to commercialize, or will be delayed in commercializing, product candidates we may develop;
•Our mRNA products and product candidates are based on novel technologies and are complex and difficult to manufacture. We or our third-party manufacturers may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management or shipping for any of our products;
•As we grow as a commercial company and our drug development pipeline increases and matures, the increased demand for clinical and commercial supplies from our facilities and third parties may impact our ability to operate. We rely on third-party service providers, all of whom have inherent risks in their operations;
•We are subject to operational risks associated with the physical and digital infrastructure at our manufacturing facilities and those of our external service providers;
•Our individualized neoantigen therapy (INT) product candidates are uniquely manufactured for each patient using a novel, complex manufacturing process and we may encounter difficulties in producing INT;
•We are dependent on single-source suppliers for some of the components and materials used in, and the processes required to develop, our products and product candidates;
•We have entered into, and in the future may enter into, strategic alliances with third parties for the development and commercialization of products and product candidates. If these strategic alliances are not successful, our business could be adversely affected;
•We may seek to establish additional strategic alliances and, if we are unable to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans. Certain of our strategic alliance agreements may restrict our ability to develop certain products;
•We may be unable to obtain and enforce patent protection for our discoveries and the intellectual property rights therein, or protect the confidentiality of our trade secrets;
•Uncertainty over intellectual property in the pharmaceutical and biotechnology industry has been the source of litigation and other disputes, which is inherently costly and unpredictable and can have adverse financial and freedom-to-operate consequences;
•We incurred net losses in 2023 and we are likely to incur losses again in the future; we have a limited history of recognizing revenue from product sales and may be unable to achieve long-term sustainable profitability;
•We may encounter difficulties in managing the development and expansion of our company;
•Our internal computer systems and physical premises, or those of third parties with which we share sensitive data or information, may fail or suffer security breaches, including from cybersecurity incidents, which could materially disrupt our product development programs and manufacturing operations; and
•The price of our common stock has been volatile, which could result in substantial losses for stockholders.

You should consider carefully the risks and uncertainties described below, in the section entitled “Risk Factors” and the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes, before you decide whether to purchase our common stock. The risks described above are not the only risks that we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.



SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K, including the sections entitled “Business,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains express or implied forward-looking statements within the meaning of the federal securities laws, Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). All statements other than statements of historical facts contained in this Annual Report are forward-looking statements. Forward-looking statements in this Annual Report on Form 10-K include, but are not limited to, statements about:

•our expectations regarding the future profitability of our COVID-19 vaccine franchise, as well as our ability to grow and maintain market share;

•our expectations regarding the evolution of the endemic, commercial COVID-19 vaccine market and future demand for COVID-19 vaccines;

•our expectations regarding sales of our COVID-19 vaccine in 2024 and beyond;

•our ability to continue to develop variant-specific versions of our COVID-19 vaccine that are able to effectively combat COVID-19 as the SARS-CoV-2 virus continues to evolve;

•the potential launch, following regulatory approvals, of our respiratory syncytial virus (RSV) vaccine for adults in the first half of 2024, as well as additional respiratory product launches in 2024 and 2025;

•the durability of our individualized neoantigen therapy (INT) candidate, the ability of our INT candidate to address different types of cancer, our Phase 3 clinical trials in adjuvant melanoma and non-small cell lung cancer (NSCLC) and our plans to rapidly expand to additional tumor types;

•our goal to launch up to 15 new products over the next five years;

•our discussions with regulators regarding our first-generation seasonal influenza vaccine candidate (mRNA-1010), and our intent to file for regulatory approval in 2024;

•the potential of our platform to address rare genetic diseases, and our plans to advance propionic acidemia (PA) and methylmalonic acidemia (MMA) programs into pivotal studies in 2024;

•our ability to deliver on the next-generation pipeline and platform, including the commencement of additional clinical trials;

•our ability to successfully contract with third-party suppliers, distributors and manufacturers;

•our ability and the ability of third parties with whom we contract to successfully manufacture, supply and distribute our products, at scale, as well as drug substances, delivery vehicles and product candidates for preclinical and clinical use;

•the scope of protection we are able to establish and maintain for intellectual property rights covering our commercial products, product candidates and technology, including our ability to enter into license agreements, and our expectations regarding pending legal proceedings related to our intellectual property;

•the timing of initiation, progress, completion, results (including interim data) and cost of our clinical trials, preclinical studies and research and development programs, as well as those of our collaborators;

•participant enrollment in our clinical trials, including enrollment demographics and timing;

•potential advantages of mRNA as compared to traditional medicine;

•our ability to obtain and maintain regulatory approval for our products;

•our ability to successfully commercialize our products, if approved, including in light of the size and growth potential of the markets for our products and the degree of market acceptance of our products;

•the pricing and reimbursement of our medicines, if approved;



•the buildout of our manufacturing and commercial operations, including our partnerships with various governments to establish mRNA vaccine manufacturing facilities;

•our financial performance and estimates of our future expenses, revenues and capital requirements;

•the potential benefits of strategic collaboration agreements and our ability to enter into strategic collaborations or other agreements with collaborators with development, regulatory and commercialization expertise;

•legal and regulatory developments in the United States and foreign countries;

•our ability to produce our products or product candidates with advantages in turnaround times or manufacturing cost;

•our ability to attract and retain key scientific, manufacturing, regulatory, commercial and management personnel; and

•developments relating to our competitors and our industry.

In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on our management’s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on forward-looking statements. Factors that may cause actual results or events to differ materially from current expectations include, among other things, those listed under the section entitled “Risk Factors” and elsewhere in this Annual Report on Form 10-K. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those expressed or implied by the forward-looking statements. No forward-looking statement is a guarantee of future performance.

The forward-looking statements in this Annual Report on Form 10-K represent our views as of the date of this Annual Report on Form 10-K. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report on Form 10-K.

This Annual Report on Form 10-K includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We have not independently verified the information contained in such sources.

NOTE REGARDING COMPANY REFERENCES

Unless the context otherwise requires, the terms “Moderna,” the “Company,” “we,” “us” and “our” in this Annual Report on Form 10-K refer to Moderna, Inc. and its consolidated subsidiaries.

TRADEMARKS

This Annual Report on Form 10-K contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to, including logos, artwork and other visual displays, may appear without the ® or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Table of Contents
PART I

Item 1. Business

Moderna is a leader in the creation of the field of messenger RNA (mRNA) medicine. By working at the intersection of science, technology and health for more than a decade, we have developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Our mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, we strive to deliver the greatest possible impact to people through mRNA medicines.

Our first commercial product, Spikevax (our COVID-19 vaccine), has helped hundreds of millions of people worldwide combat COVID-19. SARS-CoV-2, the virus that causes COVID-19, continues to evolve and in 2023, the COVID-19 vaccine market transitioned to an endemic, seasonal commercial market. To adapt to the evolving market, we significantly resized our manufacturing infrastructure to help position our COVID-19 franchise for future profitability. We achieved 2023 net product sales of $6.7 billion, with $6.1 billion of COVID-19 vaccine sales, and recognition of approximately $0.6 billion of deferred revenue related to our efforts with Gavi, The Vaccine Alliance. In the United States, we achieved 48% market share in the retail market for the 2023 fall season, compared to 37% in the 2022 fall season.

Beyond COVID-19, in 2023, we prepared for the potential 2024 launch of our investigational respiratory syncytial virus (RSV) vaccine for adults, which we expect to further demonstrate the commercial potential of our mRNA platform. In cancer, we reported additional data from our Phase 2b trial evaluating our individualized neoantigen therapy (INT) in combination with Merck’s KEYTRUDA in melanoma patients compared to KEYTRUDA alone. The treatment continued to show significant and clinically meaningful improvement in recurrence-free survival and reduced the risk of recurrence or death by 49%. We believe that these data, with a median follow-up of approximately three years, demonstrate the durability of the therapy, and we have initiated Phase 3 studies in the adjuvant setting in patients with high-risk melanoma and non-small cell lung cancer. We and Merck plan to rapidly expand our clinical trials to additional tumor types.

Having demonstrated clinical benefit in multiple infectious disease areas and skin cancer, as well as potential clinical benefit for several rare genetic diseases, we continue to advance a broad and diverse pipeline and are focused on execution to deliver for patients. Our pipeline includes 45 therapeutic and vaccine programs, nine of which are in late-stage development.

THE mRNA OPPORTUNITY

mRNA, the software of life
mRNA transfers the information stored in our genes to the cellular machinery that makes all the proteins required for life. Our genes are stored as sequences of DNA which contain the instructions to make specific proteins. DNA serves as a hard drive, safely storing these instructions in the cell’s nucleus until they are needed by the cell.

When a cell needs to produce a protein, the instructions to make that protein are copied from the DNA to mRNA, which serves as the template for protein production. Each mRNA molecule contains the instructions to produce a specific protein with a distinct function in the body. mRNA transmits those instructions to cellular machinery, called ribosomes, that make copies of the required protein.

We see mRNA functioning as the “software of life.” Every cell uses mRNA to provide real time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. This was codified as the central dogma of molecular biology over 60 years ago, and is exemplified in the schematic below.

6
Table of Contents
image (26).jpg
The structure of mRNA
mRNA is a linear polymer comprising four monomers called nucleotides: adenosine (A), guanosine (G), cytosine (C) and uridine (U). Within the region of the molecule that codes for a protein (the coding region), the sequence of these four nucleotides forms a language made up of three-letter words called codons. The first codon, or start codon (AUG), signals where the ribosome should start protein synthesis. To know what protein to make, the ribosome then progresses along the mRNA one codon at a time, appending the appropriate amino acid to the growing protein. To end protein synthesis, three different codons (UAA, UAG, and UGA) serve as stop signals, telling the ribosome where to terminate protein synthesis. In total, there are 64 potential codons, but only 20 amino acids that are used to build proteins; therefore, multiple codons can encode for the same amino acid.

The process of protein production is called translation because the ribosome is reading in one language (a sequence of codons) and outputting in another language (a sequence of amino acids). The coding region is analogous to a sentence in English. Much like a start codon, a capitalized word can indicate the start of a sentence. Codons within the coding region resemble groups of letters representing words. The end of the sentence is signaled by a period in English, or a stop codon for mRNA.

Image_1.jpg
In every cell, hundreds of thousands of mRNAs make hundreds of millions of proteins every day. A typical protein contains 200-600 amino acids; therefore, a typical mRNA coding region ranges from 600-1,800 nucleotides. In addition to the coding region, mRNAs contain four other key features: (1) the 5’ untranslated region (5’-UTR); (2) the 3’ untranslated region (3’-UTR); (3) the 5’ cap; and (4) a 3’ polyadenosine (poly-A) tail. The sequence of nucleotides in the 5’-UTR influences how efficiently the ribosome initiates protein synthesis, whereas the sequence of nucleotides in the 3’-UTR contains information about which cell types should translate that mRNA and how long the mRNA should last. The 5’ cap and 3’ poly-A tail enhance ribosome engagement and protect the mRNA from attack by intracellular enzymes that digest mRNA from its ends.

7
Table of Contents
The intrinsic advantages of using mRNA as a medicine

mRNA possesses inherent characteristics that we believe position it to have a profound impact on human health:
•mRNA is used by every cell to produce all proteins: mRNA is used to make every type of protein, including secreted, membrane and intracellular proteins, in varying quantities over time, in different locations and in various combinations. Given the universal role of mRNA in protein production, we believe that mRNA medicines could have broad applicability across human disease.
•Making proteins inside one’s own cells mimics human biology: Tailored mRNA can be sent into cells to instruct them to produce specific protein therapeutics or vaccine antigens and provides certain advantages over traditional approaches to medicine, where a protein or chemical is introduced to the body.
•mRNA has a simple and flexible chemical structure: Each mRNA molecule comprises four chemically similar nucleotides to encode proteins made from up to 20 chemically different amino acids. To make the full diversity of possible proteins, only simple sequence changes are required in mRNA, instead of starting from scratch for each new vaccine or therapy.
•mRNA has classic pharmacologic features: mRNA possesses many of the attractive pharmacologic features of most modern medicines, including reproducible activity, predictable potency and well-behaved dose dependency; mRNA also provides the ability to adjust dosing based on an individual patient’s needs, including stopping or lowering the dose, to seek to promote safety and tolerability.
Our ability to rapidly develop, manufacture and commercialize vaccines against COVID-19 demonstrates the potential mRNA medicines have to help people and patients in far-reaching ways that could exceed the impact of traditional approaches to medicine.
We believe that the main advantages of mRNA as compared to traditional medicine are:

1.mRNA could create an unprecedented abundance and diversity of medicines. mRNA’s breadth of applicability has the potential to create an extraordinary number of new mRNA medicines that are currently beyond the reach of recombinant protein technology.

2.Advances in the development of our mRNA medicines reduce risks across our portfolio. mRNA medicines share fundamental features that can be leveraged across our portfolio. We believe that once safety and proof of protein production has been established in one program, the technology and biology risks of related programs that use similar mRNA technologies, delivery technologies and manufacturing processes will decrease significantly.

3.mRNA technology can accelerate discovery and development. The software-like features of mRNA enable rapid in silico design and the use of automated high-throughput synthesis processes that permit discovery to proceed in parallel rather than sequentially. We believe these mRNA features can also accelerate drug development by allowing the use of shared manufacturing processes and infrastructure.

4.The ability to leverage shared processes and infrastructure can drive significant capital efficiency over time. We believe the manufacturing requirements of different mRNA medicines are similar and that at commercial scale, a portfolio of mRNA medicines will benefit from shared capital expenditures.

OUR STRATEGY
We believe that the development of mRNA medicines represents a significant breakthrough for patients, our industry and human health globally. Our success in developing one of the earliest and most effective COVID-19 vaccines, at unprecedented speed and efficiency, demonstrates the promise of mRNA medicine. Our COVID-19 vaccine has helped hundreds of millions of people worldwide combat COVID-19. Beyond COVID-19, our platform continues to be highly productive, with 45 programs currently in development, spanning infectious diseases, immuno-oncology, rare diseases and autoimmune diseases.

Across our respiratory vaccines, latent and other vaccines, oncology and rare disease franchises, we are aiming to launch up to 15 new products over the next five years. We have formulated strategic objectives to help enable our near- and long-term goals:

1.Deliver an unrivalled respiratory vaccine franchise. We are developing vaccines against COVID-19, seasonal flu and RSV individually, while pursuing parallel development of combination vaccines. Recognizing that COVID-19 is likely to pose an ongoing health burden, we are making it an important piece of our business with our vaccines against COVID-19 and our investigational combination vaccine against flu and COVID-19. In parallel, we are preparing for the potential 2024 launch of our investigational RSV vaccine for older adults, which is expected to further demonstrate the commercial potential of our mRNA platform. We expect that our anticipated respiratory product launches in 2024 and 2025 will allow us to recognize efficiencies from our growing pipeline.

8
Table of Contents
2.Advance multiple latent virus and other vaccines. We are developing vaccines against latent and other viruses with unmet or underserved needs, including cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus (HSV), varicella zoster virus (VZV), norovirus, HIV and Lyme disease. We anticipate potential efficacy data from the pivotal Phase 3 study of our CMV vaccine candidate in 2024. CMV is the most common infectious cause of birth defects in the United States and has been designated as a top priority in new vaccine development by the U.S. National Academy of Medicine for more than two decades.

3.Accelerate a large portfolio of late-stage clinical trials in INT to deliver a transformative impact in cancer treatments. In 2023, we reported data from our Phase 2b trial evaluating our INT in combination with Merck’s KEYTRUDA in melanoma patients compared to KEYTRUDA alone, which we believe demonstrates the durability of the therapy. We have launched Phase 3 trials for both adjuvant melanoma and non-small cell lung cancer (NSCLC), and plan to expand the development program to additional tumor types.

4.Accelerate investment in three rare disease programs to pursue potential launches. We have demonstrated the potential for clinical benefit in three different rare genetic diseases (propionic acidemia (PA), methylmalonic acidemia (MMA) and glycogen storage disease type 1a (GSD1a)), and expect to advance our PA and MMA programs into pivotal studies in 2024.

5.Deliver the next-generation pipeline and platform. We have demonstrated clinical benefit in multiple infectious disease vaccines and in skin cancer, as well as potential clinical benefit in three different rare genetic diseases. Based on these clinical successes, we continue to advance a broad and diverse pipeline and are focused on execution to deliver for patients. We plan to continue to invest in our science and our platform to expand mRNA applications and advance new programs into clinical studies.


OUR PLATFORM

Overview of our platform

Our mRNA “platform” refers to our accumulated knowledge and capabilities in basic and applied sciences. Our platform incorporates advances across three key components—mRNA, delivery and the manufacturing process— to advance our medicines. We integrate these components and combine different versions of mRNA delivery and process into each of our medicines.

Our platform: mRNA science advancements

We continue to invest in both basic and applied research, seeking to advance both the state of our technology and the state of the scientific community’s understanding of mRNA. Examples of advances in mRNA science that combine nucleotide chemistry, sequence engineering and targeting elements are described below.

mRNA chemistry: Modified nucleotides to mitigate immune system activation: The innate immune system has evolved to protect cells from foreign RNA, such as viral RNA, by inducing inflammation and suppressing mRNA translation once detected. Many cells surveil their environment through sensors called toll-like-receptors (TLRs). These include types that are activated by the presence of double-stranded RNA (TLR3) or uridine containing RNA fragments (TLR7, TLR8). Additionally, all cells have cytosolic double-stranded RNA, sensors, including retinoic acid inducible gene-I (RIG-I) that are sensitive to foreign RNA inside the cell.

The immune and cellular response to mRNA is complex, context specific, and often linked to the sensing of uridine. To minimize undesired immune responses to our potential mRNA medicines, our platform employs chemically-modified uridine nucleotides to minimize recognition by both immune cell sensors such as TLR3/7/8, and broadly-distributed cytosolic receptors such as RIG-I.

mRNA sequence engineering: Maximizing protein expression: mRNA exists transiently in the cytoplasm, during which time it can be translated into thousands of proteins before eventually being degraded. Our platform applies bioinformatic, biochemical, and biological screening capabilities, most of which have been invented internally that aim to optimize the amount of protein produced per mRNA. We have identified proprietary sequences for the 5’-UTR that have been observed to increase the likelihood that a ribosome bound to the 5’-end of the mRNA transcript will find the desired start codon and reliably initiate translation of the coding region. We additionally design the nucleotide sequence of the coding region to maximize its successful translation into protein.

Targeting elements: Enabling tissue-targeted translation: All nucleated cells in the body are capable of translating mRNA, resulting in pharmacologic activity in any cell in which mRNA is delivered and translated. To minimize or prevent potential off-target effects, our platform employs technologies that regulate mRNA translation in select cell types. Cells often contain short RNA sequences, called microRNAs or miRNAs, that bind to mRNA to regulate protein translation at the mRNA level. Different cell types have different concentrations of specific microRNAs, in effect giving cells a microRNA signature. microRNA binding directly to mRNA effectively silences or reduces mRNA translation and promotes mRNA degradation. We design microRNA binding sites into
9
Table of Contents
the 3’-UTR of our potential mRNA medicines so that if our mRNA is delivered to cells with such microRNAs, it will be minimally translated and rapidly degraded.

Our platform: Delivery science

Our mRNA can, in specific instances, be delivered by direct injection to a tissue in a simple saline formulation without lipid nanoparticles (LNPs) to locally produce small amounts of pharmacologically active protein. However, the blood and interstitial fluids in humans contain significant RNA degrading enzymes that rapidly degrade any extracellular mRNA and prevent broader distribution without LNPs. Additionally, cell membranes tend to act as a significant barrier to entry of large, negatively-charged molecules such as mRNA. We have therefore invested heavily in delivery science and have developed LNP technologies to enable delivery of larger quantities of mRNA to target tissues.

LNPs are generally composed of four components: an amino lipid, a phospholipid, cholesterol, and a pegylated-lipid (PEG-lipid). Each component, as well as the overall composition, or mix of components, contributes to the properties of each LNP system. LNPs containing mRNA injected into the body rapidly bind proteins that can drive uptake of LNPs into cells. Once internalized in endosomes within cells, the LNPs are designed to escape the endosome and release their mRNA cargo into the cell cytoplasm, where the mRNA can be translated to make a protein and have the desired therapeutic effect. Any mRNA and LNP components that do not escape the endosome are typically delivered to lysosomes where they are degraded by the natural process of cellular digestion. Examples of tools we developed by using our platform include proprietary LNP formulations that address the steps of mRNA delivery, including cell uptake, endosomal escape, and subsequent lipid metabolism, and for avoidance of counterproductive interactions with the immune system.

Chemistry: Novel lipid chemistry to potentially improve safety and tolerability: Our proprietary LNP systems are designed to be highly tolerated and minimize any LNP vehicle-related toxicities with repeat administration in vivo. To overcome limitations of previous LNP formulations, we have engineered amino lipids to avoid the immune system and to be rapidly biodegradable relative to prior lipids.

Composition: Proprietary LNPs enhance delivery efficiency: Our platform includes extensive in-house expertise in medicinal chemistry, which we have applied to design large libraries of novel lipids. Using these libraries in combination with our discovery biology capabilities, we have conducted high throughput screens for desired LNP properties and believe that we have made fundamental discoveries in preclinical studies about the relationships between structural motifs of lipids and LNP performance for protein expression.

Surface properties: Novel LNP design to avoid immune recognition: We have designed our proprietary LNP systems for sustained pharmacology upon repeat dosing by eliminating or altering features that activate the immune system. These are based on insights into the surface properties of LNPs. Upon repeated dosing, surface features on traditional LNPs such as amino lipids, phospholipids, and PEG-lipids, can be recognized by the immune system, leading to rapid clearance from the bloodstream, a decrease in potency upon repeat dosing, and an increase in inflammation. Based on our insights into these mechanisms, we have engineered our LNP systems to reduce or eliminate undesirable surface features. In clinical studies for our systemic therapeutic product candidates that use our novel LNP systems, we have been able to repeat dose with negligible or undetectable loss in potency, liver damage, and immune system activation.

Our platform: Manufacturing process science

We invest significantly in manufacturing process science to impart more potent features to our mRNA and LNPs, and to invent the technological capabilities necessary to manufacture our mRNA medicines at scales ranging from micrograms to kilograms, as well as achieve pharmaceutical properties such as solubility and shelf life. We view developing these goals of manufacturing and pharmaceutical properties as appropriate for each program, based on its stage of development.

mRNA manufacturing process: Improving pharmacology: Our platform creates mRNA using a cell-free approach called in vitro transcription in which an RNA polymerase enzyme binds to and transcribes a DNA template, adding the nucleotides encoded by the DNA to the growing RNA strand. Following transcription, we employ proprietary purification techniques to ensure that our mRNA is free from undesired synthesis components and impurities that could activate the immune system in an indiscriminate manner. Applying our understanding of the basic science underlying each step in the manufacturing process, we have designed proprietary manufacturing processes to impart desirable pharmacologic features, for example increasing potency in a vaccine.

10
Table of Contents
LNP manufacturing process: Improving pharmacology: Our platform technology includes synthetic processes to produce LNPs. Traditionally LNPs are assembled by dissolving the four molecular components, amino lipid, phospholipid, cholesterol, and PEG-lipid, in ethanol and then mixing this with mRNA in an aqueous buffer. The resulting mixture is then purified to isolate LNPs from impurities. Such impurities include molecular components that have not been incorporated into particles, un-encapsulated mRNA that could activate the immune system, and particles outside of the desired size range. Going beyond optimization of traditional manufacturing processes, we have invested in understanding and measuring the various biochemical and physical interactions during LNP assembly and purification. We have additionally developed state-of-the-art analytical techniques necessary to characterize our LNPs and biological systems to analyze their in vitro and in vivo performance. With these insights, we have identified manufacturing process parameters that drive LNP performance, for example, the potency in a secreted therapeutic setting. These insights have allowed us to make significant improvements in the efficiency of our processing and the potency of our LNPs.

OUR MODALITIES

Our vision for harnessing the power of mRNA through modalities
Within our platform, we invest in science to invent novel ways to deliver mRNA into various cell types. Each novel delivery system is a new application, which we call a “modality.” While the programs within a modality may target diverse diseases, they share similar mRNA characteristics and manufacturing processes to achieve shared product features.

We believe that the high technological correlation within a modality allows us to rapidly accelerate the expansion of programs within that modality based on learnings from the earlier programs, while the lower technology correlation between modalities allows us to compartmentalize the technology risks. Additionally, because programs within a modality pursue diverse diseases, they often have uncorrelated biology risk. Each time we add a modality and a new product candidate to our portfolio, we create a network effect because each incremental program can help us gain additional insight into the other programs in our pipeline.

Although developing a new modality is difficult, time-consuming and expensive, we believe our experience and technology provide us with unique advantages in the development of mRNA medicines. Over the last decade, we have developed a number of modalities, each with one or many product candidates in the clinic. We believe that our ongoing investments in our platform will lead to the identification of additional modalities and expand the utility of our existing modalities and the diversity of our pipeline.

Our current modalities

Our current modalities are described below. More detail regarding our current programs in each modality is provided below under “—Our Pipeline.”

•Infectious disease vaccines: The goal of our infectious disease vaccines is to safely pre-expose the immune system to a small quantity of a protein from a pathogen, called an antigen, so that the immune system is prepared to fight the pathogen if exposed in the future, and prevent infection or disease. Our infectious disease vaccines include those targeting respiratory viruses, latent viruses and enteric viruses, as well as bacterial vaccines and public health vaccines. We believe mRNA vaccines have several advantages, including the ability to mimic many aspects of various infections, the ability to combine antigens for compelling product profiles, the rapid discovery and advancement of programs into the clinic and the capital efficiency and speed from shared manufacturing processes and infrastructure.

•Cancer vaccines and therapeutics: The goal of a cancer therapy is to safely expose the patient’s immune system to tumor-related antigens, known as neoantigens, to enable the immune system to elicit a more effective antitumor response. Our cancer therapies modality is focused on the use of mRNA to express neoantigens found in a particular tumor in order to elicit an immune response via T cells that recognize those neoantigens, and therefore the tumor. These neoantigens can either be unique to a patient or can be related to a driver oncogene found across subsets of patients. Recent breakthroughs in cancer immunotherapy, such as checkpoint inhibitors and chimeric antigen receptor T cell therapies, have demonstrated that powerful antitumor responses can be achieved by activating antigen specific T cells. We believe one approach to improve the efficacy of checkpoint inhibitors is to develop vaccines that increase both the number and antitumor activity of a patient’s T cells that recognize tumor neoantigens. We believe that mRNA technology is an attractive approach for cancer therapies for several reasons, including the ability to deliver multiple personalized neoantigens in a single mRNA molecule, and that mRNA encoding for neoantigens is translated and processed by patients’ endogenous cellular mechanisms for presentation to the immune system.

•Rare disease intracellular therapeutics: The goal of this modality is to provide intracellular proteins, such as intracellular enzymes and organelle-specific proteins, as safe, tolerable, and efficacious therapies. Our mRNA medicines aim to increase levels of intracellular proteins to achieve a therapeutic effect in one or more tissues or cell types and our initial focus is on rare genetic diseases. Intracellular therapeutics are not currently addressable with recombinant proteins, which are typically
11
Table of Contents
administered systematically and cannot reach inside of the cell. Our potential advantages in these areas include encoding for intracellular and organelle-specific proteins and the production of hard-to-make or complex proteins with native post-translational modifications.

•Intratumoral immuno-oncology: The goal of this modality is to treat or cure cancer by transforming the tumor microenvironment to drive anti-cancer T cell responses against tumors. The outlook for any patients with advanced cancer remains poor, especially in patients with tumors that have little immune system engagement, sometimes termed immunologically “cold.” In conjunction with a checkpoint inhibitor, we aim to activate the immune system against these otherwise immunologically cold tumors. Intratumoral administration allows for localized effect of these therapeutics that could be toxic if administered systemically. We believe our approach to intratumoral immuno-oncology using mRNA medicines could complement checkpoint inhibitors and has several advantages over recombinant protein-based drugs, including production of membrane-associated immune stimulatory proteins, multiplexing of mRNA to access multiple immune stimulatory pathways and creation of engineered mRNA sequences to reduce off-target effects.

•Inhaled pulmonary therapeutics: The goal of this modality is to develop mRNA medicines that can be delivered to the lung as safe, tolerable and efficacious therapies. We are developing nebulized LNP formulations that can transfect airway epithelial cells to deliver mRNA into the lungs of patients in order to express proteins coded in the mRNA. We aim to leverage our technology for pulmonary diseases in patients for whom there are no existing effective therapies. Our potential advantages in these areas include lung-associated production of secreted, membrane-associated or intracellular hard-to-make or complex proteins.

•Systemic secreted and cell surface therapeutics: The goal of this modality is to provide secreted proteins, such as antibodies or enzyme replacement therapies across a wide range of diseases, such as heart failure, infectious diseases, and rare genetic diseases. Our mRNA medicines instruct various cells of the human body to secrete proteins for therapeutic effect. Systemically delivered, secreted and cell surface therapeutics, we believe, would allow us to target areas of biology that cannot be addressed using recombinant proteins. Our potential advantages in this area include encoding for hard-to-make or complex secreted or membrane-associated proteins, multiplexing of mRNA to encode for multiple proteins with complementary activity, native post-translational modifications and sustained production of proteins, which can increase exposure to proteins with short half-lives.

OUR PIPELINE

Over the last decade, we have advanced in parallel a diverse development pipeline that currently consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. The scope of our pipeline reflects the breadth of biology addressable using mRNA technology. Our selection process for advancing new product candidates reflects both program-specific and portfolio-wide considerations. Program-specific criteria include, among other relevant factors, the severity of the unmet medical need, the biology risk of our chosen target or disease, the feasibility of clinical development, the costs of development and the commercial opportunity. Portfolio-wide considerations include the ability to demonstrate technical success for our platform components within a modality, thereby increasing the probability of success and learnings for subsequent programs in the modality and in some cases in other modalities.

The diversity of proteins made from mRNA within our development pipeline is shown in the figure below.
image (27).jpg
12
Table of Contents
Our full pipeline, grouped by modalities, is shown in the figure below:
SEC FIling - Full pipeline chart - 4Q23 (02.22.24) (002).jpg

13
Table of Contents
INFECTIOUS DISEASE VACCINES MODALITY

We have 31 different infectious disease vaccine programs, of which 30 have entered the clinic. Our infectious disease vaccines modality includes vaccines against respiratory viruses, latent viruses and enteric viruses, as well as bacterial vaccines and public health vaccines.

Infectious disease vaccines: Vaccines against respiratory viruses

COVID-19 vaccines (mRNA-1273/Spikevax®, next-generation mRNA-1283)

Our COVID-19 vaccine is approved or authorized for use in more than 70 countries. COVID-19 is caused by the SARS-CoV-2 virus that was first identified in humans in 2019, driving a global pandemic resulting in millions of deaths. The risk of mortality increases with age and the risk of severe disease and mortality increases for persons with certain pre-existing diseases or comorbid conditions, such as cardiovascular disease, diabetes, chronic lung disease and obesity.

Our COVID-19 vaccine continues to be a key tool in fighting COVID-19 as the SARS-CoV-2 virus evolves. As part of our strategy to combat the virus, we have continued to develop and assess variant-specific versions of our COVID-19 vaccine. In September 2023, we received regulatory approvals in major markets for our updated COVID-19 vaccine (mRNA-1273.815), which targets the XBB.1.5 subvariant of SARS-CoV-2. We developed mRNA-1273.815 in accordance with regulatory guidance, with the goal of broadening vaccine-induced immunity and providing protection against circulating SARS-CoV-2 XBB lineage variants. We have also observed preliminary clinical trial data showing that mRNA-1273.815 generates a robust immune response against other variants of SARS-CoV-2.

The FDA has approved mRNA-1273.815 for individuals ages 12 years and older, and granted Emergency Use Authorization for individuals six months through 11 years of age. mRNA-1273.815 has also been authorized for individuals six months and older in other key markets, including the EU, Canada and Japan.

Forward-looking references to our COVID-19 vaccine in this Annual Report on Form 10-K may include future modifications to mRNA-1273 or other product candidates that are designed to provide protection against variants of the SARS-CoV-2 virus.

In addition to our approved or authorized COVID-19 vaccines, we have advanced other COVID-19 vaccine candidates into the clinic as part of our effort to fight the evolving SARS-CoV-2 virus. Our next-generation COVID-19 vaccine, which is designed to be refrigerator-stable (mRNA-1283), is in a pivotal Phase 3 study, and we anticipate data from the trial in the first half of 2024. Our goal with mRNA-1283 is to facilitate easier distribution and administration by healthcare providers. Further, as SARS-CoV-2 evolves, we continue to perform continuous epidemiological monitoring, genomic surveillance and risk assessments of variants of concern to determine which new variants may have the ability to circumvent immunity provided by currently approved COVID-19 vaccines. For variants that appear to be growing in circulation and have evolved the ability to evade immunity, we proactively develop new product candidates. We have taken several of these candidates to clinical trials, and our monitoring activities allow for expedited delivery of new vaccines in the event that regulatory agencies request specific vaccine composition updates to address public health needs.

COVID-19 Commercial, Manufacturing and Supply Updates

Net product sales of our COVID-19 vaccine were $6.7 billion in 2023, which accounted for all of our product revenues. We anticipate that sales of our COVID-19 vaccine in 2024 will provide a significant portion of our commercial revenues for the coming year. Prior to the third quarter of 2023, we sold our COVID-19 vaccine to the U.S. Government, foreign governments and international organizations. In the third quarter of 2023, we commenced sales of our latest COVID-19 vaccine to the U.S. commercial market, in addition to continuing sales to foreign governments and international organizations.

With COVID-19 entering an endemic phase in 2023, we saw increased seasonality for sales, with greater demand in the fall/winter season in each hemisphere as countries sought to provide vaccinations to their populations. We expect this seasonality to continue in future years in the endemic market. As such, we resized our global manufacturing footprint in 2023 to account for demand in the endemic market. For further information on the sales and manufacturing of our COVID-19 vaccine, see “–Manufacturing” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” below.

14
Table of Contents
RSV vaccine (mRNA-1345)

Respiratory syncytial virus (RSV) is one of the most common causes of lower respiratory disease in children under the age of five and in older adults. Populations that are especially vulnerable to developing severe RSV infections include infants, young children, children and adults with chronic medical conditions and older adults. Most children are infected at least once by age two. In the United States, it is estimated that over two million children younger than five receive medical attention and up to 80,000 are hospitalized due to RSV infection annually. RSV also causes a substantial burden of respiratory illness in older adults. RSV infection causes up to 160,000 hospitalizations and up to 10,000 deaths per year in adults aged 65 years or older in the United States.

We are developing an RSV vaccine (mRNA-1345) for children, pregnant women and adults. mRNA-1345 encodes an engineered form of the RSV F protein stabilized in the prefusion conformation and is formulated in our proprietary LNP. In January 2023, we announced that mRNA-1345 had met primary efficacy endpoints in the pivotal Phase 3 trial in older adults, ages 60 and older. mRNA-1345 demonstrated vaccine efficacy (VE) of 83.7% (95.88% CI: 66.1%, 92.2%; p<0.0001) against RSV-associated lower respiratory tract disease (RSV-LRTD) as defined by two or more symptoms. The other primary efficacy endpoint against RSV-LRTD defined by three or more symptoms was also met, with a VE of 82.4% (96.36% CI: 34.8%, 95.3%; p=0.0078). mRNA-1345 was generally well-tolerated with no safety concerns identified. Based on the positive topline data from the pivotal Phase 3 efficacy trial, the FDA granted mRNA-1345 Breakthrough Therapy Designation for the prevention of RSV-LRTD in adults 60 years or older.

We have submitted marketing authorization applications in several major markets for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD) in adults 60 years or older. We expect regulatory approvals beginning in the first half of 2024.

We have additional Phase 3 studies ongoing in adults to explore co-administration with licensed flu or COVID-19 vaccines, revaccination with mRNA-1345 and expansion to adults aged 18 and older who are at high risk for severe RSV disease. In pediatrics, mRNA-1345 is ongoing in Phase 1 and Phase 2 studies, and we are conducting a Phase 2 study in maternal populations.

Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030)

The World Health Organization (WHO) estimates that seasonal influenza viruses cause three to five million cases of severe illness and 290,000 to 650,000 deaths each year, resulting in a severe challenge to public health. Currently licensed seasonal influenza vaccines rarely exceed 60% overall effectiveness and can provide low effectiveness during years when the circulating viruses do not match the strains selected for the vaccine antigens.

Our mRNA seasonal influenza vaccine program is taking an iterative approach to development. Our first-generation seasonal influenza vaccine candidate (mRNA-1010) encodes for the hemagglutinin (HA) proteins of the strains recommended by the WHO. We are intending to subsequently improve upon the first-generation candidate through inclusion of additional HA antigens that could provide expanded coverage of co-circulating strains, as well as broadening protection through the addition of another influenza protein, the neuraminidase (NA). We also aim to work with the WHO, regulators and public health authorities to enable strain selection closer to the influenza season to provide a better match to the circulating viruses.

The inclusion of additional HA antigens is being tested in our mRNA-1011/1012 programs, and the addition of NA antigens is being tested in our mRNA-1020/1030 programs. We aim to ultimately combine both approaches into a single next-generation vaccine.

In February 2023, we announced interim results from the P301 study of mRNA-1010. The results indicated that mRNA-1010 achieved higher seroconversion rates for A/H3N2 and A/H1N1, as well as superiority on geometric mean titer ratios for A/H3N2 and non-inferiority on geometric mean titer rations for A/H1N1. Non-inferiority was not met for either endpoints for the influenza B/Victoria- or B/Yamagata-lineage strains. mRNA-1010 showed an acceptable safety and tolerability profile. In April 2023, we announced the P302 study of mRNA-1010 did not accrue sufficient cases at the interim efficacy analysis to declare early success in the Phase 3 Northern Hemisphere efficacy trial. In September 2023, we announced the P303 immunogenicity and safety study of mRNA-1010 met all 8 co-primary endpoints with an updated formulation that was able to generate an improved immune response to influenza B strains. mRNA-1010 also elicited higher titers than the licensed comparator against all strains in this study. An additional study to compare immunogenicity of mRNA-1010 against an enhanced influenza vaccine comparator is currently ongoing. Conversations with regulators regarding filing for approval of mRNA-1010 are currently ongoing and we intend to file for regulatory approval in 2024.

Phase 1/2 studies for our mRNA-1011/1012 and mRNA-1020/1030 programs have been initiated and interim results have been presented at scientific meetings.

Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365)

We are developing combination vaccine candidates to protect against a range of respiratory diseases.

15
Table of Contents
mRNA-1083, our next-generation COVID-19 and seasonal influenza combination vaccine, encodes the same antigens as our first-generation seasonal influenza vaccine (mRNA-1010) and our next-generation COVID-19 vaccine (mRNA-1283). In a Phase 1/2 trial, mRNA-1083 showed strong immunogenicity against influenza and COVID-19 compared to licensed standalone vaccines, with an acceptable reactogenicity and safety profile. In October 2023, we initiated a Phase 3 trial in adults 50 years and older. The trial is fully enrolled and data is anticipated in 2024.

We are also conducting Phase 1 studies for mRNA-1230, our COVID-19, seasonal flu and RSV combination vaccine, and mRNA-1045, our seasonal flu and RSV combination vaccine.

Enrollment is ongoing in a Phase 1 trial of mRNA-1365, our RSV and hMPV combination vaccine, in children five to under 24 months of age. In February 2024, the FDA granted Fast Track Designation for mRNA-1365.

Infectious disease vaccines: Vaccines against latent viruses

CMV vaccine (mRNA-1647)

Human cytomegalovirus (CMV) is a common human pathogen and member of the herpes virus family. Congenital CMV results from infected mothers transmitting the virus to their unborn child and it is the leading infectious cause of birth defects in the United States, with approximately 25,000 newborns in the U.S. infected annually. There is currently no available vaccine for CMV and a vaccine that leads to durable immunity in women of child-bearing age would address a critical unmet need in the prevention of congenital CMV infection.

Our CMV vaccine candidate, mRNA-1647, combines six mRNAs in one vaccine, which encode for two proteins located on the surface of CMV: five mRNAs encode the subunits that form the membrane-bound pentamer complex and one mRNA encodes the full-length membrane-bound glycoprotein B (gB). Both pentamer and gB are essential for CMV to infect barrier epithelial surfaces and gain access to the body, which is the first step in CMV infection. mRNA-1647 is designed to produce an immune response against both pentamer and gB for the prevention of CMV infection, which could reduce the risk of birth defects and post-transplant infections.

We are conducting an ongoing Phase 3 study for mRNA-1647, known as CMVictory, to evaluate the safety and efficacy of mRNA-1647 against primary CMV infection in female participants 16 to 40 years of age. The study is fully enrolled, both for the adult and adolescent (ages 16 to <18) cohorts. Timing of the readout will depend upon the number of CMV cases accrued in the study. We anticipate potential efficacy data from the study in 2024.

We are also conducting a Phase 1/2a study of mRNA-1647 in participants 9 to 15 years of age. We enrolled the first participant in November 2022, and the study is evaluating the safety and immunogenicity of mRNA-1647 to inform the selection of a dose level for subsequent development in this age group.

Additionally, in April 2023 we announced that a Phase 2 proof-of-concept study for mRNA-1647 in allogeneic hematopoietic cell transplant (HCT) patients had started enrollment.

EBV vaccine (mRNA-1189 and mRNA-1195)

Epstein-Barr virus (EBV) is a member of the herpesvirus family that is related to CMV and infects approximately 90% of people in the U.S. by adulthood, with primary infection typically occurring during childhood or late adolescence (approximately 50% and 89% seropositivity, respectively). EBV is the major cause of infectious mononucleosis, accounting for over 90% of the approximately one to two million cases in the U.S. each year. Infectious mononucleosis can debilitate patients for weeks to months and, in some cases, can lead to hospitalization due to complications such as splenic rupture. EBV infection is also associated with the development and progression of certain lymphoproliferative disorders, cancers and autoimmune diseases. In particular, EBV infection and infectious mononucleosis are associated with increased risk of developing multiple sclerosis, an autoimmune disease of the central nervous system.

We are developing two EBV vaccine candidates—a vaccine to prevent infectious mononucleosis (mRNA-1189) and a vaccine to prevent the longer-term sequelae of EBV infection (mRNA-1195). Similar to our CMV vaccine (mRNA-1647) product concept, we believe that an effective EBV vaccine must generate an immune response to antigens that are required for viral entry in susceptible cell types. mRNA-1189 is designed to elicit an immune response to EBV envelope glycoproteins, which are required for infection of both epithelial and B cells. mRNA-1189 contains four mRNAs encoding for these proteins encapsulated in our proprietary LNPs. mRNA-1195 encodes for entry glycoproteins and latent antigens and will be investigated in the context of post-transplant lymphoproliferative disorders and multiple sclerosis.

We are conducting Phase 1, randomized, observer-blind, placebo-controlled studies of mRNA-1189 and mRNA-1195. The primary purpose of these studies is to assess the safety, tolerability and immunogenicity of these vaccine candidates.
16
Table of Contents

HSV vaccine (mRNA-1608)

Herpes simplex viruses (HSV), commonly known as herpes, are categorized into two types: HSV-1 primarily spreads by oral contact and is most commonly associated with cold sores, and HSV-2 spreads through sexual contact and is the major cause of recurrent genital herpes. Both viruses establish life-long latent infections within nearby sensory neurons from which they can reactivate and re-infect the skin. There is a significant burden of disease from HSV genital infections. Diagnosed, symptomatic genital herpes causes a reduction in quality of life, which antivirals (current standard of care) only partially restore. In the United States, approximately 18.6 million adults ages 18 to 49 years are living with HSV-2. Globally, an estimated 492 million persons have HSV-2 infection, representing 13% of the world’s population aged 15 to 49 years. We believe that an HSV vaccine could deliver similar efficacy as suppressive antiviral treatments and could improve compliance and quality of life. We aim to induce a strong antibody response with neutralizing and effector functionality combined with cell-mediated immunity.

We are conducting a Phase 1/2, randomized, observer-blind, controlled, dose-ranging study of mRNA-1608, our HSV vaccine candidate against recurrent HSV-2 disease, in health adults 18 to 55 years of age with recurrent HSV-2 genital herpes. The primary purpose of this study is to assess safety and immunogenicity data, and establish a proof-of-concept of clinical benefit.

VZV vaccine (mRNA-1468)

Herpes zoster, also known as shingles, is caused by the varicella zoster virus (VZV) and occurs in approximately one in three adults in their lifetime and incidence significantly increases at approximately 50 years of age. Protective immunity against VZV wanes as the immune system ages, allowing reactivation of the virus from latently infected neurons, causing painful and itchy lesions. Serious herpes zoster complications include postherpetic neuralgia (10-13% of herpes zoster cases), bacterial coinfections and cranial and peripheral palsies; 1-4% of individuals with herpes zoster cases are hospitalized for complications. Severity of disease and likelihood of complications, including postherpetic neuralgia (PHN) also increases with age. People with immunocompromising conditions, people with autoimmune disease using immunosuppressive therapies, people living with HIV and hematopoietic stem cell (HSCT) and organ transplant recipients have an increased risk of developing herpes zoster. The current standard of care is Shingrix, an FDA-approved vaccine for the prevention of shingles in adults 50 years and older. It is more than 90% effective against herpes zoster in adults aged 50-70 with only a slight reduction in efficacy for adults over age 70.

We are conducting an ongoing Phase 1/2, randomized, observer-blind, active-controlled, dose-ranging study to evaluate the safety, reactogenicity and immunogenicity of mRNA-1468, compared head-to-head with Shingrix, in healthy adults, aged 50 years and older. The first participant was dosed in February 2023 and enrollment of 500 participants was completed in June 2023.

HIV vaccine (mRNA-1644 and mRNA-1574)

HIV is the virus responsible for acquired immunodeficiency syndrome (AIDS), a lifelong, progressive illness with no effective cure. Approximately 38 million people worldwide are currently living with HIV, with 1.2 million in the U.S. Approximately 1.5 million new infections of HIV are acquired worldwide every year and approximately 680,000 people die annually due to complications from HIV/AIDS. The primary routes of transmission are sexual intercourse and IV drug use, putting young adults at the highest risk of infection. From 2000 to 2015, a total of $562.6 billion globally was spent on care, treatment and prevention of HIV, representing a significant economic burden.

We are developing two HIV vaccine candidates—mRNA-1644 and mRNA-1574—both of which are in ongoing Phase 1 clinical trials. In collaboration with the International AIDS Vaccine Initiative (IAVI) and the Bill & Melinda Gates Foundation, mRNA-1644 is testing a novel HIV vaccine strategy in humans as delivered by mRNA to elicit broadly neutralizing HIV-1 antibodies (bnAbs) through sequential vaccination of novel prime and boost antigens that induce specific B-cell responses. In collaboration with IAVI, Scripps, NIH and the HIV Vaccine Trials Network, mRNA-1574 is testing multiple native-like HIV trimer mRNAs in humans to improve our understanding of how to make stable and immunogenic native-HIV trimers.

17
Table of Contents
Infectious disease vaccines: Vaccines against enteric viruses

Norovirus vaccines (mRNA-1403 and mRNA-1405)

Among enteric viruses, norovirus is a leading cause of diarrheal disease, also referred to as acute gastroenteritis (AGE) globally, resulting in substantial health care burden. Norovirus is estimated to be the causative agent in 18% of all AGE cases worldwide. The highest incidence globally is in young children, and in low-income countries, there are approximately 70,000 deaths annually caused by norovirus in children under 5 years of age. In high-income countries, incidence is also highest among young children, but deaths and other severe outcomes are concentrated primarily among older adults and immunocompromised patients. Norovirus is also associated with large, costly and difficult to control outbreaks in closed and semi-closed settings, such as daycares, cruise ships, long term care facilities and other healthcare settings. The burden of norovirus among older adults is expected to rise along with societal aging and an increased need for institutionalized care. In the U.S., norovirus causes an estimated 20 million infections, 100,000 hospitalizations and 900 deaths per year. Globally, there are approximately 650 million infections annually with approximately 200,000 deaths across all ages.

Norovirus has broad genetic diversity; the virus is classified into 10 genogroups and 49 genotypes, 30 of which are known to infect humans. Vaccine development has been challenging to date for many reasons, including the lack of a robust cell culture system, no reliable immune markers of norovirus protection and the broad and shifting diversity of genotypes. A multivalent vaccine with broad genotype coverage is needed to maximize protection against the genotypes most frequently associated with AGE in young children and older adults.

We are currently developing pentavalent (mRNA-1405) and trivalent (mRNA-1403) vaccine candidates for norovirus. Both candidates are in a Phase 1 study to evaluate safety, reactogenicity and immunogenicity in healthy adult participants 18 to 49 years of age and 60 to 80 years of age. Approximately 660 participants were enrolled in the Phase 1 study, and dosing was completed in December 2023.

Infectious disease vaccines: Bacterial vaccines

Lyme vaccines (mRNA-1975 and mRNA-1982)

Approximately 120,000 Lyme disease cases are reported per year in the U.S. and Europe. With rising atmospheric temperatures, Lyme territory continues to increase in the U.S. Lyme disease burden follows a bimodal age distribution, affecting mainly children under 15 and older adults. Patients can develop rash, fever, headaches, fatigue, joint pain, swelling, stiffness and headaches. Older adults appear more likely to have an unfavorable treatment response and more common neurologic manifestations as compared with younger patients. There are no approved vaccines to prevent Lyme disease in humans currently on the market.

To address Lyme's biological complexity, we are advancing a seven-valent and single-valent approach with two Lyme disease vaccine candidates being developed in parallel. mRNA-1982 is designed to elicit antibodies specific for Borrelia burgdorferi, which causes almost all Lyme disease in the U.S. mRNA-1975 is designed to elicit antibodies specific for the four major Borrelia species causing disease in the U.S. and Europe.

Both the seven-valent (mRNA-1975) and single-valent (mRNA-1982) vaccines are in a Phase 1/2, randomized, observer-blind, placebo-controlled, dose-ranging study to evaluate safety and immunogenicity in healthy participants 18 through 70 years of age. We have completed enrollment of approximately 800 participants in this study. In January 2024, the FDA granted Fast Track Designation to our Lyme disease program.

Infectious disease vaccines: Public health vaccines

Zika vaccine (mRNA-1893)

The Zika virus is a single stranded RNA virus of the Flaviviridae family. Seroepidemiology data suggest that it is endemic to regions of Africa and Asia, where the Aedes mosquito vectors are found. Zika virus is predominantly spread by mosquitos from the Aedes genus, but it can also be transmitted congenitally, sexually and through blood donation. Zika infection is usually asymptomatic or mild in adults, leading to fever, rash and conjunctivitis. However, infection of women during pregnancy can result in devastating microcephaly in newborns. Microcephaly is a birth defect characterized by an abnormally small head and brain, associated with lifelong neurodevelopmental delay, seizures, intellectual disability, balance problems and dwarfism/short stature, resulting in significant disability and requiring lifelong support. In 2007, a Zika infection outbreak progressed across the Pacific islands. An outbreak observed in Brazil in 2015 soon spread across the Americas, which led the WHO to declare Zika a public health emergency of international concern in 2016. During the period, tens of thousands of cases of microcephaly and congenital Zika syndrome were reported in infants. Zika has also been associated with certain neurological sequelae, such as Guillain-Barré syndrome, reported in adults.

Our Zika vaccine candidate, mRNA-1893, encodes for the prME structural protein encapsulated in our proprietary LNP. In partnership with BARDA, we are conducting a Phase 2 study in the United States and Puerto Rico to evaluate mRNA-1893 in approximately 800
18
Table of Contents
participants. The randomized, placebo-controlled study aims to evaluate the safety, tolerability and reactogenicity of mRNA-1893, as well as evaluate the immunogenicity of two dose levels of mRNA-1893 (one-dose or two-dose schedule) compared to placebo. The study is fully enrolled. We do not anticipate advancing the Zika program into further studies in the absence of further outside funding.

Nipah vaccine (mRNA-1215)

Nipah virus (NiV) is a zoonotic virus transmitted to humans from animals, contaminated food or through direct human-to-human transmission and causes a range of illnesses including fatal encephalitis. Severe respiratory and neurologic complications from NiV have no treatment other than intensive supportive care. The case fatality rate among those infected is estimated at 40-75%. NiV outbreaks cause significant economic burden to impacted regions due to loss of human life and interventions to prevent further spread, such as the slaughter of infected animals. NiV has been identified as the cause of isolated outbreaks in India, Bangladesh, Malaysia and Singapore since 2000 and is included on the WHO R&D Blueprint list of epidemic threats needing urgent R&D action.

In collaboration with the NIH-Vaccine Research Center (VRC), we are conducting an ongoing Phase 1 clinical trial of mRNA-1215, our vaccine candidate against NiV, and testing will be focused on pandemic preparedness. This Phase 1 dose-escalation, open-label clinical trial is the first study of mRNA-1215 in healthy adults to evaluate the safety, tolerability and immunogenicity of a NiV mRNA vaccine candidate. The trial is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID).

Mpox vaccine (mRNA-1769)

Mpox is an infectious viral disease that can occur in humans and some other animals. It is caused by the monkeypox virus, a zoonotic virus in the genus Orthopoxvirus. Transmission of mpox has been associated with direct contact with bodily fluid or sores. Mpox may also be transmitted via respiratory secretion with close face-to-face contact.

The most widely known member of the Orthopoxvirus genus is Variola virus, which causes smallpox. Although smallpox was eradicated in 1977, continued protection from smallpox is of great interest given the lethality of the infection and potential for use as an agent of bioterrorism. Other diseases associated with the Orthopoxvirus genus include cowpox, horsepox and camelpox.

There are two subtypes of the monkeypox virus—Clade I and Clade II. In 2022, an outbreak of the Clade II mpox virus was declared a Public Health Emergency of International Concern by the WHO. The outbreak resulted in approximately 93,000 confirmed cases across 117 countries. More recently, the Clade I monkeypox virus, which is associated with greater mortality, has been reported to be sexual transmitted and there is concern that it may lead to further global outbreaks.

The current standard of care for mpox is Jynneos, which is approved by the FDA for the prevention of mpox and smallpox disease. Our mpox vaccine (mRNA-1769) is designed to express four antigens from the monkeypox virus to provide a range of protection.

We are conducting a randomized, placebo-controlled, dose-ranging, observer-blind Phase 1/2 study to evaluate the safety, tolerability and immunogenicity of mRNA-1769 in healthy participants.

CANCER VACCINES AND THERAPEUTICS MODALITY

Our cancer vaccines and therapeutics modality currently has three development programs, all of which have entered the clinic.

Individualized Neoantigen Therapy (INT) (mRNA-4157)

As tumors grow, they acquire mutations, some of which create new protein segments, or neoantigens, that can be presented on human leukocyte antigen (HLA) molecules in the tumor and recognized as non-self by T cells. While some of these neoantigens could be shared across tumors, the majority are completely unique to an individual patient’s tumor, in addition the presentation of those neoantigens is also dependent on a patient’s specific HLA type.

Our INT, mRNA-4157, uses next generation sequencing and our proprietary algorithm to design an mRNA that encodes up to 34 neoantigens against each individual patient’s tumor mutations with specificity to their HLA type, and is predicted to elicit both class I (CD8) and class II (CD4) responses. The neoantigens are encoded in a single mRNA sequence and formulated in our proprietary LNPs designed for intramuscular injection. INT is manufactured using an automated workflow to enable a rapid turnaround time.

We are developing mRNA-4157 in collaboration with Merck. In September 2022, Merck exercised its option for personalized cancer vaccines, including mRNA-4157, pursuant to the terms of our existing PCV Collaboration and License Agreement with Merck, which was amended and restated in 2018 (PCV Agreement). Pursuant to the PCV Agreement, we and Merck will collaborate on further development and commercialization of mRNA-4157, and we will share costs and any profits and losses worldwide related to mRNA-4157 equally.

In December 2022, we announced that the randomized Phase 2 trial of mRNA-4157 had met its primary endpoint. The open-label Phase 2 study is investigating a 1 mg dose of mRNA-4157 in combination with Merck’s pembrolizumab (KEYTRUDA®), compared
19
Table of Contents
to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma. The study showed that mRNA-4157 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% (HR=0.56 [95% CI, 0.31-1.02]; one-sided p value=0.0266) compared with KEYTRUDA alone. The results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial in melanoma. Adverse events observed were consistent with those previously reported in a Phase 1 clinical trial, which showed mRNA-4157 to be well-tolerated at all dose levels.

In February 2023, mRNA-4157 received a Breakthrough Therapy Designation from the FDA, and in April 2023 mRNA-4157 received PRIME Scheme Designation from the EMA.

In December 2023, we announced that at a planned median follow-up of approximately three years, mRNA-4157 in combination with KEYTRUDA showed sustained benefit, reducing the risk of recurrence or death by 49% (HR=0.510 [95% CI, 0.288-0.906]; one-sided nominal p=0.0095) and the risk of distant metastasis or death by 62% (HR=0.384 [95% CI, 0.172-0.858]; one-sided nominal p= 0.0077) compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following complete resection. We and Merck have initiated Phase 3 studies in the adjuvant setting in patients with high-risk melanoma and non-small cell lung cancer (NSCLC), and plan to expand to additional tumor types.

KRAS Vaccine (mRNA-5671)

We are evaluating next steps for our KRAS vaccine program (mRNA-5671), having retained all rights to the program from Merck. Enrollment closed in the Phase 1 study led by Merck in early 2022. KRAS is a frequently mutated oncogene in epithelial cancers, primarily lung, colorectal cancer (CRC) and pancreatic cancers. mRNA-5671 is designed to present neoantigens for the four most prevalent KRAS mutations.

Checkpoint cancer vaccine (mRNA-4359)

We are developing a checkpoint cancer vaccine (mRNA-4359) that express Indoleamine 2,3-dioxygenase (IDO) and programmed death-ligand 1 (PD-L1) antigens. We designed mRNA-4359 with the goal of stimulating effector T cells that target and kill suppressive immune and tumor cells that express target antigens. Our initial indications for mRNA-4359 are advanced or metastatic cutaneous melanoma and NSCLC. Our Phase 1 study of mRNA-4359 is ongoing.


INTRATUMORAL IMMUNO-ONCOLOGY MODALITY

Our intratumoral immuno-oncology modality currently has one development program, which is in the clinic.

OX40L/IL-23/IL-36γ (Triplet) (mRNA-2752)

Despite recent advances in immune-mediated therapies for cancer, the outlook for many patients with advanced cancer is poor. We are developing Triplet (mRNA-2752) to drive anti-cancer T cell responses by transforming cold tumor microenvironments into productive, “hotter” immune landscapes with local intratumoral therapies. mRNA-2752 utilizes the intrinsic advantage of mRNA to multiplex and to produce membrane and secreted proteins with mRNA in a single product candidate. Triplet (mRNA-2752) includes three mRNAs encoding human OX40L, IL-23 and IL-36γ that are encapsulated in our proprietary LNP and administered intratumorally. OX40L is a membrane protein, whereas IL-23 and IL-36γ are secreted cytokines. We believe our approach has the advantage of localized high concentration gradients of IL-23 and IL-36γ compared to recombinant proteins administered systemically or intratumorally. Additionally, the mRNA for OX40L encodes for the wild type membrane protein, which we believe recombinant protein technologies cannot enable.

In December 2023, we completed enrollment in our ongoing Phase 1 dose-escalation study of mRNA-2752 for the treatment of advanced or metastatic solid tumor malignancies or lymphoma (as a single agent or in combination with checkpoint inhibitors).

RARE DISEASE INTRACELLULAR THERAPEUTICS

Our rare disease intracellular therapeutics modality currently has six development programs, three of which are in the clinic.

Propionic acidemia (PA) (mRNA-3927)

PA is a rare, inherited metabolic disorder with significant morbidity and mortality, affecting one in 100,000-150,000 individuals worldwide. PA is caused by pathogenic variants in the propionyl-coenzyme A carboxylase (PCC) α or β subunits (PCCA and PCCB genes, respectively), leading to PCC deficiency and subsequent accumulation of toxic metabolites. PA is characterized by recurrent life-threatening metabolic decompensation events (MDEs) and multisystemic complications. Multisystemic complications include neurological manifestations, cardiomyopathy, arrythmias, growth retardation, recurrent pancreatitis, bone marrow suppression and predisposition to infection. Long-term, insults by toxic metabolites cause complications in various organs, and cognitive outcome is
20
Table of Contents
negatively correlated with the number of MDEs. Currently, there is no approved therapy for PA that targets the underlying root cause of the disease.

Our PA therapy candidate, mRNA-3927, is a novel, IV-administered, LNP-encapsulated dual mRNA therapy that encodes for PCCA and PCCB subunit proteins to restore functional PCC enzyme activity in the liver. By encoding for intracellular proteins, mRNA therapy has a potential role in preventing and treating acute metabolic decompensations.

The global Phase 1/2 clinical trial for mRNA-3927, the Paramount Study, is ongoing and we have fully enrolled all five dose optimization cohorts, as well as a dose confirmation cohort. The objective of the study is to evaluate the safety and pharmacology of mRNA-3927 in patients 1 year of age and older with PA. The primary endpoints are safety and pharmacokinetics and pharmacodynamics. Secondary endpoints include incidence and severity of adverse events (AEs) and change in plasma biomarkers: methylcitric acid (2-MC) and 3-Hydroxypropionic acid (3-HP). We have received Rare Pediatric Disease Designation, Orphan Drug Designation and Fast Track Designation from the FDA and Orphan Designation from the European Commission for the PA program. Several critical milestones have been reached in the trial. mRNA-3927 has been generally well-tolerated to date with no drug-related serious adverse events, no discontinuations due to safety and only mild-to-moderate infusion related reactions (<10% of doses). Due to the objective and disease-defining nature of MDEs, regulators have provided initial support for MDE as a clinically meaningful, preferred primary clinical endpoint for development. Based on the preliminary data, there was a decrease in the number of MDEs post-mRNA-3927 treatment. We expect to advance mRNA-3927 into a pivotal study in 2024.

Methylmalonic acidemia (MMA) (mRNA-3705)

MMA is a rare, inherited metabolic disorder with significant morbidity and mortality caused by a deficiency in an enzyme called methylmalonyl-CoA mutase (MUT). There are an estimated 500-2,000 people with MMA MUT deficiency in the United States based on estimated birth prevalence (0.3-1.2:100,000 newborns) and mortality rates. Mortality is significant, with mortality rates of 50% for those with complete MUT deficiency (mut 0) (median age of death 2 years) and 40% for MMA patients with partial MUT deficiency (mut -) (median age of death 4.5 years) reported in a large European study. MMA mainly affects the pediatric population and usually presents in the first few days or weeks of life. The occurrence of acute metabolic decompensations is the hallmark of the disorder and decompensations are typically more frequent in the first few years of life. Each decompensation is life-threatening and often requires hospitalization and management at an intensive care unit. Survivors often suffer from numerous complications including chronic renal failure and neurologic complications such as movement disorders, developmental delays, and seizures. Consequently, the health-related quality of life for MMA patients and their families is significantly impaired. There are currently no approved therapies that address the underlying defect for MMA.

Our MMA therapy candidate, mRNA-3705, encodes for a missing or deficient hepatic enzyme. In an ongoing Phase 1/2 study, fifteen participants have been dosed. Thus far, all eligible participants have opted to participate in the Open-Label Extension study. To date, mRNA-3705 has generally been well-tolerated with no discontinuations due to safety or meeting protocol defined dose limiting toxicity criteria. Interim results demonstrated encouraging initial pharmacodynamic data, with dose-dependent reductions in methylmalonic acid in cohorts 2 and 3. Early results suggest potential promising changes in clinical endpoints. We are currently dosing our fifth cohort as we prepare to select an optimal dose for expansion. We expect to advance mRNA-3705 into a pivotal study in 2024.
Glycogen storage disease type 1a (GSD1a) (mRNA-3745)

GSD1a is a rare, inherited metabolic disorder caused by a deficiency in the catalytic activity of the intracellular protein glucose 6-phostphatase (G6Pase). GSD1a patients suffer from severe fasting hypoglycemia, hepatomegaly, nephromegaly, lactic acidemia, hypertriglyceridemia, hyperuricemia, hypercholesterolemia, hepatic steatosis and growth retardation. In addition, hepatocellular adenomas occur in 70% to 80% of GSD1a patients by their third decade of life and carries risk of transformation into hepatocellular carcinomas. Proteinuria has been observed in over half of patients above 25 years of age. GSD1a occurs in approximately 1:100,000 live births in the United States and European Union but is more common in Ashkenazi Jews where the incidence is reported to be 1:20,000 live births. There are an estimated 2,500 people in the United States and over 4,000 people in the European Union with GSD1a. Although strict diet therapy, including frequent feeding with uncooked cornstarch, allows GSD1a patients to live into adulthood by preventing hypoglycemia, the underlying pathological processes remain uncorrected resulting in the development of many long-term complications including liver adenomas and hepatocellular carcinoma.

Our GSD1a therapy candidate, mRNA-3745, consists of an mRNA encoding for modified human G6Pase, and has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA). A Phase 1/2 study to evaluate the safety and pharmacology of mRNA-3745 in GSD1a patients 18 years of age and older is ongoing. We have observed encouraging signs of clinical benefit with mRNA-3745.

21
Table of Contents
Ornithine transcarbamylase (OTC) deficiency (mRNA-3139)

Ornithine transcarbamylase (OTC) deficiency (OTCD) is an X-linked recessive disorder that is the most common urea cycle disorders (UCDs) in humans. OTCD prevents the breakdown and excretion of ammonia, allowing ammonia to accumulate, rising to toxic levels where it affects the central nervous system. With an incidence of approximately 1:57,000 live births, OTCD accounts for nearly half of all UCDs. OTCD causes high mortality and morbidity, particularly in males.

Our OTCD therapy candidate, mRNA-3139, is in preclinical development. mRNA-3139 is a chronic intravenous, mRNA, enzyme replacement therapy for OTCD, which may act as a bridge to liver transplant or a standalone therapeutic depending on efficacy. mRNA-3139 uses the same LNP as in our GSD1a program.

Phenylketonuria (PKU) (mRNA-3210)

PKU is a rare inherited metabolic disease, affecting approximately 40,000 patients in the United States, France, Germany, Italy, Spain and the UK. Mutations in the phenylalanine hydroxylase (PAH) gene encoding the PAH enzyme result in the inability to metabolize the essential amino acid Phe to Tyr in the liver. There is a high unmet medical need for patients with PKU with early and continuous treatment throughout life being fundamental to prevent the development of irreversible neuropsychiatric outcomes.

Our PKU therapy candidate, mRNA-3210, which is in preclinical development, is an mRNA encoding the PAH enzyme encapsulated in the same LNP as that used in our MMA and PA product candidates, with the potential to address the unmet need in PKU patients.

Crigler-Najjar Syndrome Type 1 (CN-1) (mRNA-3351)

CN-1 is a severe condition caused by the mutations in the UGT1A1 gene. CN-1 is characterized by high levels of a toxic substance called bilirubin in the blood (hyperbilirubinemia). It is caused by mutations in the UGT1A1 gene, which results in an inability to break down bilirubin, a substance made by the liver. Without the UGT1A1 enzyme, bilirubin can build up in the body and lead to jaundice and damage to the brain, muscles and nerves. The symptoms become apparent shortly after birth and can be life-threatening. It is estimated that there are only approximately 70-100 known cases of CN-1 in the world. Affected individuals rely on current standard of care, phototherapy treatments of up to 12 hours a day, throughout life. The only definitive treatment is liver transplant, which is associated with its own set of side effects and risk of death.

Our CN-1 therapy candidate, mRNA-3351, consists of an mRNA encoding human UGT1A1 encapsulated in our proprietary LNPs. It is designed to restore the missing or dysfunctional protein that causes CN-1. We have licensed mRNA-3351 to Institute for Life Changing Medicines (ILCM) with no upfront fees and without any downstream payments. The goal of the collaboration is to make an mRNA therapy for the treatment of CN-1 available at no cost to patients. We are collaborating with the ILCM in developing a preclinical package for Investigational New Drug application and Clinical Trial Application filings. ILCM will be responsible for the clinical development of mRNA-3351.

INHALED PULMONARY THERAPEUTICS

Our inhaled pulmonary therapeutics modality currently has one product candidate.

Cystic Fibrosis (CF) (mRNA-3692/VX-522)

CF is a rare genetic disease, which is progressive from birth and leads to multi-organ damage and early death due to lung dysfunction. It is caused by the mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which results in the loss of CFTR chloride ion channel function. This decreased function of CFTR at the cell surface leads to thick, sticky mucus in multiple organ systems but most pathologically the lungs. There are approximately 92,000 patients living with cystic fibrosis in the United States, Europe, Australia and Canada, with over 5,000 of these patients not being able to benefit from the approved CFTR modulators.

We are collaborating with Vertex on our CF candidate, mRNA-3692/VX-522, which is designed to treat the underlying cause of CF by enabling cells in the lungs to produce functional CFTR protein for the treatment of the 10% of patients who do not produce any modulator-responsive CFTR protein. This would be our first demonstration of a nebulized mRNA therapy.

Vertex has initiated a Phase 1, single ascending dose clinical trial in CF patients who cannot benefit from CFTR modulators, and the FDA has granted VX-522 Fast Track designation. The trial is active and enrolling patients. Vertex expects to complete the single ascending dose study and to initiate the multiple ascending dose study.
22
Table of Contents

SYSTEMIC SECRETED AND CELL SURFACE THERAPEUTICS MODALITY

Our systemic secreted and cell surface therapeutics modality currently has two active development programs, of which one has entered the clinic.

Relaxin (mRNA-0184)

Relaxin is a naturally occurring hormone that has been shown to promote vasodilation and angiogenesis, regulate extracellular matrix turnover and suppress arrhythmias post myocardial infarction. Relaxin plays an important role in women in pregnancy, but in addition, studies have pointed to its vasodilatory, antifibrotic, anti-inflammatory and other protective effects on multiple organs. There is a large body of evidence to support relaxin’s clinical potential in several therapeutic areas, with its impact on cardiovascular diseases having been studied in both preclinical and clinical settings. Though prior studies have failed to demonstrate long-term benefit in clinical studies, we believe a novel approach can overcome potential flaws of previous approaches.

We are developing mRNA-0184, which encodes for a relaxin fusion protein, to treat decompensated heart failure. Acute heart failure is defined as the new onset or worsening of symptoms and signs of heart failure. In developed countries, heart failure has become a substantial public health problem, affecting 2% of the adult population and acute heart failure is the most frequent cause of unplanned hospital admission in patients over 65 years of age. mRNA-0184 encodes for the relaxin fusion protein. The mRNA sequence of mRNA-0184 is engineered to increase protein expression and prolong half-life.

In December 2022, we initiated dosing in a Phase 1 trial for mRNA-0184 and the trial is ongoing. Our Phase 1 trial is an adaptive, open-label, single ascending dose to single-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mRNA-0184 in participants with chronic heart failure.

PD-L1 (mRNA-6981)

PD-L1 is a co-inhibitory receptor that can induce anergy in programmed cell death protein 1 (PD-1)-expressing T cells. We intend to induce expression of PD-L1 on myeloid cells to send a tolerizing signal to immune cells in their environment in order to treat autoimmune diseases.

The PD-L1/PD-1 pathway has a critical function in immune regulation and promotes development and function of regulatory T (Treg) cells. PD-L1 is a transmembrane protein expressed on antigen presenting cells, such as dendritic cells and macrophages, activated T cells, B cells and monocytes, as well as peripheral tissues. Its cognate receptor, PD-1, is a co-inhibitory transmembrane protein expressed on T cells, B cells, natural killer cells and thymocytes. Preclinical mouse models deficient in PD-1 spontaneously develop a variety of autoimmune diseases such as arthritis, myocarditis, lupus-like glomerulonephritis and type 1 diabetes, demonstrating the critical role of the PD-L1/PD-1 interaction in maintaining tolerance to self-antigens. Additionally, treatment of cancer patients with PD-1 or PD-L1 inhibitors sometimes results in immune-related adverse events, including the development of hepatitis, dermatitis and colitis, demonstrating the role of PD-1/PD-L1 in human autoimmune reactions.

We believe our PD-L1 therapy may augment PD-L1 expression on cell types similar to those that endogenously express it, and by reducing immune activation, potentially reduce the clinical manifestations of a variety of autoimmune diseases. Our intent is to use our platform to influence myeloid cells, including dendritic cells, to provide additional co-inhibitory signals by augmenting endogenous expression of PD-L1. We believe that this tolerizing signal to lymphocytes may limit autoreactivity in the context of ongoing autoimmune pathology without severe and global suppression of the immune system. Given that our platform allows us to modify myeloid cells in situ, our approach to the creation of a tolerogenic environment may provide unique benefits in treating autoimmune diseases by seeking to restore immune homeostasis.

After undertaking preclinical development, we determined that the current design of mRNA-6981 does not meet our criteria for advancement to the clinic. PD-L1 continues to be an area of interest, and we are currently evaluating other preclinical mRNA candidates.


23
Table of Contents
MANUFACTURING

Manufacturing plays a critical role in our value chain and our ability to develop our medicines. Our manufacturing capabilities support every stage of the development of our products, from discovery to commercialization. During the research stage of product development, manufacturing provides mRNA drug substance and drug product for platform research and therapeutic area drug discovery. During early development of our product candidates, we manufacture mRNA and drug product for IND-enabling GLP toxicology studies and initial human clinical studies. For late clinical development, we produce mRNA and drug product for Phase 3 trials. At the commercial stage, we manufacture drug substance and drug product in collaboration with our contract manufacturing organizations (CMOs), both in the United States and internationally.

In 2023, as the COVID-19 vaccine market moved from a pandemic to an endemic market, we significantly resized our manufacturing infrastructure and reshaped our supply capabilities to help position our COVID-19 franchise for future profitability.

Overview of our manufacturing operating model

Our manufacturing activities generally focus on:

•Commercial Production: Our manufacturing capabilities include state-of-the-art technologies for mRNA and drug substance manufacturing, as well as quality control testing to attain a robust and consistent supply that matches target product profiles. Our manufacturing technology is built to scale-up and support production of products for commercial approval. Our platform allows for efficient manufacturing at scale.
•Research and Development Support: The product supply enables platform research and drug discovery in our therapeutic and vaccine areas, in addition to activities related to clinical studies of our product candidates.

We have built a dedicated in-house, multi-building manufacturing campus in Norwood, Massachusetts, the Moderna Technology Center (MTC). The MTC provides supply for our preclinical research, IND-enabling GLP toxicology study supplies, our Phase 1 and Phase 2 pipeline activities, later-stage clinical development activities (e.g., Phase 3 CMV vaccine clinical trials), as well as drug substance commercial production for vaccines. Our vaccine drug substance production for the U.S. market is completed at our MTC campus. The MTC has been designed to allow us to continue to optimize our mRNA products as we explore new pharmaceutical delivery forms in our manufacturing network such as prefilled syringes. The MTC campus has been designed with a high level of automation and state-of-the-art digital integration to handle manufacturing execution, product testing and release, and regulatory filings.

In the second quarter of 2023, we acquired a newly constructed, 140,000 square feet biomanufacturing facility in Marlborough, Massachusetts. The facility is currently undergoing enhancements, including the addition of 60,000 square feet. We expect the facility to be operational in 2025. This new site is strategically intended to support our INT program.

We have also announced agreements with the governments of Australia, Canada and the United Kingdom to establish state-of-the-art mRNA manufacturing facilities in those countries, pursuant to which each government has entered into a multi-year commitment to purchase mRNA products from us, once approved. We expect that these local manufacturing facilities will provide direct access to rapid pandemic response capabilities and our respiratory virus vaccine candidates. We may seek to enter into future agreements with other governments to provide similar manufacturing capabilities in other geographies.

In addition to our internal manufacturing facilities, we also maintain relationships with CMOs in the United States and abroad, providing drug substance and fill-finish capacity for our vaccines. As noted above, during the third quarter of 2023, we resized our manufacturing footprint to reduce our commitments to certain CMOs as a result of lower anticipated demand for COVID-19 vaccines in the endemic market.

Manufacturing technology development

To support our broad pipeline of products, which span multiple therapeutic areas and routes of administration, our platform research and technical development teams closely collaborate to facilitate rapid and seamless clinical translation of scientific breakthroughs. This enables us to develop potential medicines to serve a broad patient population.

Technical development encompasses the design and optimization of robust and consistent manufacturing processes, product characterization, fit-for-purpose formulations and product presentations. For instance, our novel hardware platforms’ automation and robotics, coupled with the flexibility of our in-house digital development systems, allows for thousands of experiments and process parameters across our projects, thus supporting our drug product pharmaceutical readiness. Moreover, our recent technical manufacturing advances have enabled internalization of new key capabilities, including DNA plasmids and small molecules.

24
Table of Contents
In parallel, we have refined existing processes, resulting in increased manufacturing scale and more robust stability profiles. These improvements allow us significant control over our supply chain, resulting in larger production yields and longer shelf life of our products. Furthermore, formulation development advancements have added new drug product images, including lyophilization, giving us a path from frozen to refrigerated storage conditions.

Our substantial investments in recent years in technical development has enabled the breadth and depth of our pipeline, and laid the foundation to help meet the needs and requirements associated with late-stage development and the commercialization of our products.

Supply of mRNA for All Stages of Product Development and Commercialization

Supply for Research

High-throughput automation and custom engineered equipment allow us to produce and deliver high quality mRNA and formulated constructs in a short period of time: our proprietary platform is capable of producing up to 1,000 lots of mRNA sequences and formulations per month with a turnaround time of a few weeks from sequence to final product. The typical scale of mRNA manufactured by this team is 1-1,000 mg. This has been possible, in part, due to the ability of researchers in the Moderna ecosystem to order constructs through an integrated digital portal that tracks materials end-to-end in less than 45 days. In addition, multiple integrated algorithms that leverage artificial intelligence and machine learning optimize manufacturability, reduce failures and increase quality of mRNA sequences.

Supply for Clinical Development

We have established manufacturing capabilities that support the early development stage of product development in three key areas: GLP Tox, Clinical Studies and INTs. We supply formulated product to conduct IND-enabling GLP toxicology studies. In addition, human clinical studies rely on supply to meet required cGMP standards. This is achieved via internal manufacturing at the MTC campus. Our MTC campus is also suited to enable rapid technology development and scale-up for future needs.

Our manufacturing also produces cGMP INTs. Due to the specialized nature of personalized medicine (i.e., where a batch is specifically designed and manufactured for a single patient), the manufacturing process for INTs has unique requirements. We digitally integrate patient-specific data from sequencing tumor samples to automatically design INTs for patients. We have developed proprietary bioinformatics designed algorithms linked to an automated manufacturing process for rapid production of formulated mRNA, with a typical turnaround time of a few weeks. We have operationalized INT manufacturing at the MTC campus to meet our Phase 1 and 2 pipeline supply needs by using single-use systems with fast “needle-to-needle” turnaround times. Unlike traditional process development, each INT batch is manufactured for a single patient and thus scaled-out (in parallel) with extensive use of automation and robotics to account for the larger number of patients involved in later phases of development and commercialization. We have shown consistent quality in our production of many patient batches, each with unique mRNA sequences. In the second quarter of 2023, we acquired a new manufacturing facility in Marlborough, Massachusetts, which we expect to support our INT program.

Our manufacturing capabilities have allowed us to build our broad pipeline of development programs, including the output required to supply related toxicological and human clinical studies. While the technology that underpins these programs is the same, each program typically requires customization based on target product profiles. These custom features range from varying molecular architecture to different routes of administration, often requiring multivalent products. All programs, with the exception of INT, require that we progressively scale up supply to meet clinical demand requirements across development phases, in addition to the necessary preparation for regulatory approval and commercial production, which demand larger batch sizes. In contrast, the INT program seeks to develop a cancer therapeutic that is designed and manufactured for a specific patient, thus increasing the number of unique batches. As we scale manufacturing output for each program, we plan to continuously improve yield, purity and the pharmaceutical properties of our product candidates.

Supply for Late-Stage Development and Commercialization

As we continue to manufacture our COVID-19 vaccines, our development pipeline continues to advance to later-stage development and towards commercialization. Our platform approach allows us to continue to evolve our manufacturing suites and other capabilities at our manufacturing facilities. mRNA manufacturing is flexible and one plant can manufacture multiple vaccines and therapeutics. Our manufacturing facilities also permit us to manufacture products in parallel. For instance, we can produce drug substance and drug product for our Phase 3 CMV clinical trial while manufacturing COVID-19 drug substance in the same facilities.

25
Table of Contents
Quality Unit

Quality is core to the way we operate. We seek to ensure quality at Moderna through a combination of a robust Quality Management System (QMS), our quality culture and our people. In accordance with applicable regulations, we have established, documented and implemented a QMS to assure continued compliance with the requirements therein. The QMS facilitates cGMP compliance by implementing practices that identify the various required processes, their application throughout the organization and the sequence of interaction of these processes.

The primary mode of documenting these key practices is through policies, standard operating procedures (SOPs), forms and other quality records, which include an overarching Quality Policy and Quality Manual. We have implemented measurement tools and metrics to monitor, measure, and analyze these practices to support cGMP operations, achieve planned results, and support continuous improvement. We monitor these quality metrics through formal governance processes, including Quality Management Review (QMR), to enable continuous improvement. We have also established an independent Quality Unit that fulfills quality assurance and quality control responsibilities.

Environment, Health, and Safety

We have established a global Environment, Health, and Safety (EHS) organization to foster a safe and healthy work environment with a focus on compliance and sustainability. We achieve this through a combination of training, procedures, digital data collection and reporting tools, and corporate programs that drive towards continuous improvement.

Supply Chain Unit

We have established a global supply chain to enable supply of the raw materials and components used to produce our products, consistent with clinical and preclinical demands. We have worked with our external vendors to characterize critical raw materials and to understand their impact on the quality of drug substance and formulated drug product. We also assess the quality system and performance of our external vendors and work with them to comply with regulatory requirements.

DIGITAL AND AI STRATEGY

Since our founding, we have been a digital-first company, seeking to use the power of digital information to maximize our impact on patients. mRNA is an information molecule, and our company was built on the premise that the natural flow of information in life can be used to develop medicines. Leveraging over a decade of experience developing mRNA medicines, we have built a large library of data that, combined with our platform approach and cloud-native infrastructure, positions us well to scale a digital operating model using artificial intelligence (AI).

Led by our Chief Information Officer, our digital organization partners across all Moderna functions to create an integrated AI ecosystem intended to drive performance and, ultimately, greater patient and business impact. To that end, in 2021, we launched our AI Academy, which offers cross-organization training to all of our employees on topics such as data visualization, machine learning algorithms and AI ethics. Through the AI Academy, our employees learn how to leverage AI in their specific job functions. By embedding AI across our organization, we are able to scale the value of our people and progress toward our goal of becoming a real-time AI company.

AI helps optimize each aspect of our value chain, from drug design to commercial manufacturing and beyond. At the research stage, our digital and AI infrastructure allows our scientists to design novel mRNA constructs, use AI algorithms to optimize them and order them from our high throughput preclinical scale production line. Our capabilities allow us to design mRNA, protein and LNP components with desired properties, such as reduced toxicity or increased stability. At the product development stage, AI helps to improve the efficiency of our clinical trial operations by, for example, forecasting participant enrollment and automating clinical trial data processing.

Our manufacturing processes likewise utilize the power of AI. For example, we leverage a series of fully autonomous, integrated AI algorithms in connection with manufacturing mRNA-4157, our INT candidate. Our proprietary algorithms design the specific therapy for each individual patient and optimize the timely manufacture and delivery of INT to each patient.

At the commercial stage, our digital and commercial organizations came together in 2023 to drive performance and prepare for product launches. Digital and AI are key components of our commercialization strategy, and are vital to our ability to increase our speed to market, enhance our commercial capabilities and continuously improve the quality of our products. We believe that our ability to move with both scale and speed positions us well to pursue our goals related to future product launches.

Further, as generative AI (GenAI) emerged as a transformative technology in 2023, we moved quickly to develop and launch our own internal GenAI product. Recognizing the unique value of Large Language Models (LLMs) to streamline tasks across departments, we launched our internal product in May 2023 after two weeks of development and improved it sequentially thanks to the capabilities of our updated machine learning platform Compute 4.0 for rigorous data management. Approximately 75% of our employees are
26
Table of Contents
currently active users, embedding the tool into their specific functions for customized support and meaningful improvements to their everyday workflows. This rapid adoption across our company demonstrates the power of our AI-centric culture.

We believe that the integrated AI ecosystem we are building at Moderna will accelerate our mission to deliver the greatest possible impact to people through mRNA medicines.

COMMERCIAL

We are building a differentiated commercial model, with active commercial subsidiaries in key markets across North America, Europe and the Asia-Pacific region. Our growing commercial footprint provides us with local commercial teams in major markets where respiratory vaccines have high utilization rates and sales. To support the build out of our commercial activities in markets around the globe, we have hired talent with extensive pharmaceutical company experience. Our commercial teams also work with third-party distributors and other partners in countries where we do not have a direct presence. Our commercial activities are dependent on regulatory approvals and on agreements that we have made or may make in the future with strategic collaborators.

Before 2023, we sold our COVID-19 vaccine to the U.S. Government, foreign governments and health ministries, Gavi, on behalf of the COVAX Facility, and other international organizations. During the pandemic, these sales were characterized by a relatively limited number of customers that purchased multi-dose vials for distribution through mass vaccination campaigns. As we have transitioned to an endemic market, we have witnessed a shift in demand to single-dose presentations and pre-filled syringes. In 2023, the COVID-19 vaccine market transitioned to an endemic, seasonal commercial market, characterized particularly in the U.S. (our largest market) by a fragmented customer base, less predictability in orders, seasonality of deliveries, significantly lower demand than during the pandemic and the assumption by us of full distribution costs. The private vaccine market is also characterized by market practices regarding rebates, discounts and returns. The COVID-19 vaccine market continues to depend on many evolving factors such as medical need, viral evolution, public health authority recommendations and consumer motivation to vaccinate.

We are also advancing a broader seasonal respiratory vaccine franchise, consisting of single-agent and combination vaccines against RSV, seasonal influenza and COVID-19, which have the highest medical burden among respiratory diseases. We expect regulatory approvals beginning in the first half of 2024 for our RSV vaccine, with multiple respiratory vaccine commercial launches globally over the next several years.

As we advance our portfolio beyond respiratory diseases toward approval, we are also investing in building out our commercial capabilities for other franchises. These franchises include our latent vaccine, rare disease and oncology products, which we expect to launch in the next several years.

We are also working to establish state-of-the-art mRNA manufacturing facilities in Australia, Canada and the United Kingdom, and the government in each of these countries has entered into a multi-year commitment to purchase mRNA products from us, once approved. See “—Manufacturing” above for further detail.

THIRD-PARTY STRATEGIC ALLIANCES

Strategic alliances

We have entered into strategic alliances with a diverse group of collaborators, including pharmaceutical and biotechnology companies, government agencies, academic laboratories, foundations and research institutes with therapeutic area expertise and resources. Through our collaborations, we seek to advance our discovery and development programs, while leveraging our platform and our research and early development capabilities. We also seek to partner with and invest in companies developing other types of therapeutics, such as gene editing and cell-therapy, where we believe we can leverage our core mRNA and LNP capabilities to expand the reach of our technology.

Through certain of our strategic alliances, we share the rewards and risks of developing a new mRNA modality or program, where we may have early research data and desire a strategic collaborator to join us in advancing early development candidates within such modality into the clinic. Representative relationships and associated programs include those with Merck, for our INT programs (mRNA-4157), and Vertex, for our CF program (mRNA-3692).

We view strategic alliances as important drivers for accelerating execution of our goal of rapidly developing mRNA medicines to treat patients across a wide range of medical and disease challenges. To maintain the integrity of our platform, the terms of our strategic collaboration agreements generally provide that either we receive rights to develop and commercialize potential mRNA medicines that we design and manufacture or our strategic collaborators receive rights to develop and commercialize potential mRNA medicines that we design and manufacture, as opposed to granting rights to our strategic collaborators to use our platform to generate new mRNA technologies, and that we generally own intellectual property related to our platform arising from research activities performed under
27
Table of Contents
the strategic alliance. We plan to continue to identify potential strategic collaborators who can contribute meaningful technology and insights to our programs and allow us to more rapidly expand our impact to broader patient populations.

Below are brief descriptions of certain of our ongoing collaborations. In the fourth quarter of 2023, our Strategic Collaboration and License Agreement with Vertex (the Vertex 2020 Agreement) was concluded and terminated in accordance with the terms of the agreement. The Vertex 2020 Agreement had been aimed at the discovery and development of potential medicines to treat cystic fibrosis (CF) with gene-editing therapies. For additional information on this collaboration, please see Note 5. Collaboration Agreements, to our consolidated financial statements included in this Annual Report on Form 10-K.

Merck—Strategic Alliance for Individualized Neoantigen Therapies

In June 2016, we entered into a Collaboration and License Agreement with Merck for the development and commercialization of personalized mRNA cancer vaccines (also known as INTs), which was subsequently amended and restated in 2018 (the INT Agreement), to develop and commercialize INTs for individual patients using our mRNA vaccine and formulation technology. Under the strategic alliance, we identify genetic mutations present in a particular patient’s tumor cells, synthesize mRNA for these mutations, encapsulate the mRNA in one of our proprietary LNPs and administer to each patient a unique INT designed to specifically activate the patient’s immune system against her or his own cancer cells.

Pursuant to the INT Agreement, we received an upfront payment of $200 million from Merck and we were responsible for designing and researching INTs, providing manufacturing capacity and manufacturing INTs and conducting Phase 1 and Phase 2 clinical trials for INTs, alone and in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, all in accordance with an agreed upon development plan and budget.

In September 2022, Merck exercised its option for INTs, including mRNA-4157, pursuant to the terms of the INT Agreement and in October 2022 paid us an option exercise fee of $250 million. Pursuant to the INT Agreement, we and Merck have agreed to collaborate on further development and commercialization of INTs, and we will share costs and any profits or losses worldwide equally.

Vertex—2016 Strategic Alliance in Cystic Fibrosis

In July 2016, we entered into a Strategic Collaboration and License Agreement (Vertex Agreement) with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited (together, Vertex). The Vertex Agreement is aimed at the discovery and development of potential mRNA medicines for the treatment of CF by enabling cells in the lungs of people with CF to produce functional cystic fibrosis transmembrane conductance regulator (CFTR) proteins.

Other Collaborations

In September 2020, we entered into a collaboration with Chiesi Farmaceutici S.p.A. (Chiesi), an international research-focused healthcare group, aimed at the discovery and development of mRNA medicines for the treatment of pulmonary arterial hypertension (PAH), a rare disease characterized by high blood pressure in the arteries of the lungs. Under the terms of the Chiesi agreement, we will lead discovery efforts, and Chiesi will lead development and worldwide commercialization activities and will fund all expenses related to the collaboration.

We have entered into additional collaborations where we have agreed to provide funding in areas where we believe we can leverage our mRNA technology. These collaborations include those with:

•Carisma Therapeutics, to discover, develop and commercialize in vivo engineered chimeric antigen receptor monocyte (CAR-M) therapeutics for the treatment of cancer, including solid tumors.
•CytomX Therapeutics, to create investigational mRNA-based conditionally activated therapies utilizing our mRNA technologies and CytomX’s Probody platform.
•Generation Bio Co., to combine our biological and technical expertise with core technologies of Generation Bio's non-viral genetic platform.
•Immatics N.V., to pioneer novel and transformative therapies for cancer patients with high unmet medical need.
•Life Edit Therapeutics, to discover and develop in vivo mRNA gene editing therapies.
•Metagenomi, focused on discovering and advancing new gene editing systems for in vivo human therapeutic applications.

We have made equity investments in Carisma, Generation Bio and Metagenomi pursuant to those collaborations.

28
Table of Contents
Strategic alliances with government organizations and foundations

Defense Advanced Research Projects Agency (DARPA)

In September 2020, we entered into an agreement with DARPA to fund development of a mobile manufacturing prototype leveraging our existing manufacturing technology that is capable of rapidly producing vaccines and therapeutics.

Biomedical Advanced Research and Development Authority (BARDA)

In September 2016, we received an award of up to approximately $126 million, subsequently adjusted to $117 million in 2021, from BARDA, a component of the Office of the Assistant Secretary for Preparedness and Response (ASPR), within the U.S. Department of Health and Human Services (HHS), to help fund our Zika vaccine program. In September 2022, the performance period of the grant expired, and BARDA was released of the obligation to fund the remaining $36 million of the award.

In April 2020, we entered into an agreement with BARDA for an award of up to $483 million to accelerate development of mRNA-1273, our original COVID-19 vaccine. The agreement has been subsequently amended to provide for additional commitments to support various late-stage clinical development efforts of mRNA-1273, including a 30,000 participant Phase 3 study, pediatric clinical trials, adolescent clinical trials and pharmacovigilance studies. The maximum award from BARDA, inclusive of all amendments, was approximately $1.8 billion. All contract options have been exercised. As of December 31, 2023, the remaining available funding, net of revenue earned was $97 million.

Institute for Life Changing Medicines (ILCM)

In September 2021, we entered into a collaboration agreement with the ILCM to develop a new mRNA therapeutic (mRNA-3351) for type 1 Crigler-Najjar syndrome (CN-1). Under the terms of the agreement, we agreed to license mRNA-3351 to ILCM with no upfront fees, and without any downstream payments. ILCM will be responsible for the clinical development of mRNA-3351.

The Bill & Melinda Gates Foundation

In January 2016, we entered a global health project framework agreement with the Bill & Melinda Gates Foundation to advance mRNA development projects for various infectious diseases. The Bill & Melinda Gates Foundation has committed up to $20 million in grant funding to support our initial project related to the evaluation of antibody combinations in a preclinical setting as well as the conduct of a first-in-human Phase 1 clinical trial of a potential mRNA medicine to help prevent HIV infections. Follow-on projects, which could bring total potential funding under the framework agreement up to $100 million (including the HIV antibody project) to support the development of additional mRNA projects for various infectious diseases, can be proposed and approved until the sixth anniversary of the framework agreement, subject to the terms of the framework agreement, including our obligation to grant to the Bill & Melinda Gates Foundation certain non-exclusive licenses.

INTELLECTUAL PROPERTY

We rely on a combination of intellectual property laws, including patent, trademark, copyright and trade secret, as well as confidentiality and license agreements, to protect our intellectual property and proprietary rights.

Protecting our platform, modality and program investments: Building an expansive, multi-layered IP estate
We have built a substantial IP estate that includes numerous patents and patent applications related to the development and commercialization of mRNA vaccine and therapeutic development candidates, including related platform technologies. Our platform IP protects advances in mRNA design and engineering, proprietary LNP components, delivery systems, processes for the manufacture and purification of drug substances and products and analytical methods. A significant portion of our platform IP estate further provides multi-layered protection for our modalities and programs.
With respect to our IP estate, our solely-owned patent portfolio consists of more than 230 issued or allowed U.S. patents or patent applications and more than 170 granted or allowed patents in jurisdictions outside of the U.S. (including granted European patents that have been validated in numerous European countries) covering certain of our proprietary platform technology, inventions and improvements, and covering key aspects of our clinical and most advanced development candidates. We have over 400 additional pending patent applications that, in many cases, are counterparts to the foregoing U.S. and foreign patents.
Most of the patents and applications (if issued) in our portfolio will not expire until 2033 at the earliest. Any patent that may issue from our most recently filed patent applications is projected to expire between 2042 and 2043, at the earliest. We file additional U.S. and foreign patent applications as necessary to protect our evolving intellectual property positions.
29
Table of Contents
We also rely on trademarks, copyright, trade secrets and know-how relating to our proprietary technology and programs, continuing innovation, and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of mRNA therapeutic and vaccine technologies. We take additional steps, such as entering into confidentiality and license agreements, to protect our intellectually property and proprietary rights. We additionally plan to rely on data exclusivity, market exclusivity and patent term extensions when and where available, and plan to seek and rely on regulatory protection afforded through orphan drug designations. We also possess substantial proprietary know-how associated with related manufacturing processes and expertise.

IP protecting our platform

We have a broad IP estate covering key aspects of our platform. This estate provides multiple layers of protection covering the making and use of the mRNA drug substance and delivery technologies.
With respect to our platform, we have a portfolio that includes U.S. and foreign patents or patent applications covering platform innovations that are related to the design, manufacturing and formulating of mRNA medicines. For example, these patents and patent applications include claims directed to:
•mRNA chemistry imparting improved properties for vaccine and therapeutic uses;
•methods for mRNA sequence optimization to enhance the levels and fidelity of proteins expressed from our mRNA medicines;
•methods for identifying epitopes having superior suitability in cancer vaccine contexts;
•engineering elements tailored to enhance stability and the in vivo performance of mRNA medicines;
•LNP delivery systems, including novel lipid components designed for optimal delivery and expression of both therapeutic and vaccine nucleic acids, in particular, prophylactic infectious disease and cancer vaccine nucleic acids, intratumoral immuno-oncology therapeutics, local regenerative therapeutics, systemic therapeutics, and inhaled pulmonary therapeutics; and
•innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product.

IP protection

Our IP estate provides protection for the multiple programs both at the product-specific level and at various broader levels. For example, we have patent coverage for LNP-encapsulated mRNAs having specific chemical modification suited for vaccine and therapeutic mRNA use. Our estate also includes IP covering certain LNP-encapsulated mRNAs coding for infectious disease antigens for use in preventing or treating infectious diseases, including those caused by respiratory and latent viruses, as well as bacterial, viral and parasitic diseases known to threaten public health. Our mRNA chemistry, formulation and manufacturing patent applications and related know-how, along with trade secrets, may also provide us with additional IP protection relating to our development candidates.

Respiratory vaccines

For our respiratory vaccines programs, we have pursued patent protection featuring composition of matter and method of use claims. Where we may pursue patent protection may vary based on the unique geographic prevalence of various infectious diseases.

We have filed several patent applications covering our betacoronavirus vaccine program. We are pursuing patent protection for both our existing and next generation betacoronavirus vaccines. A non-exhaustive list of granted patents covering our COVID-19 vaccine can be found in the following table.
30
Table of Contents

Patent NumberCountry/Region*Patent TypeExpiration Date**
11,524,023
United States
Composition of Matter
October 22, 2041
11,485,972
United States
Composition of Matter
May 18, 2038
10,898,574
United States
Composition of Matter and Method of Use
April 2, 2032
10,703,789
United States
Composition of Matter
March 9, 2033
10,702,600
United States
Composition of Matter
October 21, 2036
10,577,403
United States
Composition of Matter
March 9, 2033
10,442,756
United States
Composition of Matter
September 16, 2036
10,266,485
United States
Composition of Matter
September 16, 2036
10,064,959
United States
Composition of Matter
October 3, 2031
9,868,692
United States
Composition of Matter
September 16, 2036
3 590 949
Europe
Composition of Matter and Method of Use
October 3, 2031
3 718 565
Europe
Composition of Matter
October 21, 2036
* Selected granted patents in the U.S. and Europe only. Additional granted and pending patents in the U.S., Europe and other countries may be available.
** Expiration dates listed here include any granted or anticipated patent term adjustment (PTA), but not any patent term extension (PTE) or supplementary protection certificates (SPC).

RSV

We have filed multiple patent families directed to RSV vaccines, including a U.S. patent that issued on October 11, 2022. Our RSV patent portfolio includes multiple families of differing patent breadth. At least four U.S. and European patent applications are pending.

Influenza

We have multiple patent families spanning different levels of breadth, design and antigen valency pending in the U.S., Europe and around the world, including several granted patents.

hMPV

Human metapneumovirus (hMPV) is a single-stranded RNA virus that is used in a combination program. We have patent applications covering our hMPV vaccine pending in the U.S. and Europe, with a granted patent in the U.S.

Latent vaccines

We have vaccine programs and patent applications directed to both the acute and latent forms of diseases caused by various viruses, including CMV, EBV, HSV, VZV and HIV, using both preventative vaccines targeting the acute phase and therapeutic vaccines for treating the latent diseases in those who do become infected.

CMV

The patent coverage for our human CMV vaccine candidate is extensive and is based on a vaccine with six mRNAs encoding a pentamer surface glycoprotein complex and the gB surface glycoprotein. Both pentamer and gB facilitate entry of the virus into different cell types and therefore immune responses targeting these proteins can block virus entry, spread and reactivation. The current patent portfolio contains both compositions of matter and methods of treating subjects using the vaccine. In the U.S., our CMV vaccine is covered by multiple issued U.S. patents of differing breadth. Each family has counterparts consisting of pending applications and issued patents in non-U.S. jurisdictions, including Europe and Japan. A separate family of CMV patents, which includes mRNA-1647 plus mRNA-1443 for use in CMV vaccines for transplant indications, is also yielding patents and applications in foreign jurisdictions are pending.

EBV, HSV and VZV

Similar to CMV, we have multiple patent families pending for each of EBV, HSV and VZV, covering both prophylactic and therapeutic indications. These patent families have also been filed in Europe and Japan.

Public health vaccines

We maintain a multi-program effort at developing vaccines for potential future pandemics and for use in parts of the world with less well-established health care systems. This group of programs include infectious diseases such as flaviviruses such as Zika and dengue
31
Table of Contents
viruses, HIV, Nipah virus, and the Mpox virus. In addition, programs are ongoing in many bacterial diseases. Specific patent families are being filed on most potential public health programs where possible, but in some scenarios, platform patents may be used to augment patent protection for public health target vaccines.

Individualized neoantigen therapy (INT)

Composition of matter and method claims are being pursued to protect programs within our cancer vaccines modality. Proprietary methods around the making and therapeutic use of our INTs and resulting vaccine compositions are described and claimed in seven pending U.S. patent applications, six pending European patent applications, five pending patent applications in Japan, three pending patent applications and one granted patent in China, and several pending patent applications in New Zealand, South Africa, Asian and South American countries, as well as one PCT application. These applications also relate to various vaccine design formats, in particular, polyepitopic vaccine formats, and methods of treating cancer with such INTs. We also possess substantial know-how and trade secrets relating to the development and commercialization of our cancer vaccine programs, including related manufacturing process and technology.

Likewise, our KRAS antigen cancer vaccine and methods of treating cancer featuring such vaccines are covered in an issued U.S. patent, which includes claims to LNP-encapsulated mRNA encoding mutant KRAS antigens.

Intratumoral immuno-oncology

We have filed numerous patent applications featuring claims to mRNAs encoding immune-stimulatory proteins and methods of treating cancer using such compositions.

Our immuno-oncology programs are designed to be administered intratumorally to alter the tumor microenvironment in favor of mounting an immune response against tumors. Our mRNA program that includes mRNAs that encode OX40L, IL-23 and IL-36γ are covered by two granted European patents, by more than 10 issued U.S. patents, by several pending U.S. and European patent applications and by several pending patent applications in other foreign jurisdictions. These applications feature claims to the mRNA therapeutics as compositions of matter, formulations that include such mRNAs and methods of reducing tumors and treating cancer using these development candidates.

Rare diseases

We have programs featuring expression of therapeutic proteins, e.g., intracellular enzymes for the treatment of rare diseases. For our rare disease programs, we generally pursue patent protection featuring composition of matter and method of use claims, for example, pharmaceutical composition and method of treatment claims. Our most advanced rare disease development candidate is for PA. For this candidate, we have patent applications pending in the United States, Europe, and Japan which cover mRNA encoding the alpha and beta subunits of the enzyme propionyl-CoA carboxylase (PCCA and PCCB, respectively), for the treatment of PA.

For MMA, we have patent applications issued and pending in the U.S. and foreign applications filed in Japan and Europe.

For our PKU development candidate, we have a pending PCT and pending patent applications in the U.S., Europe and Japan covering mRNA encoding phenylalanine hydroxylase (PAH) for the treatment of PKU.

For our Glycogen Storage Disorder, Type 1a (GSD1a) development candidate, we have filed several patent families, including pending U.S. and European patent applications, as well as applications pending in China and Japan covering mRNA encoding glucose 6-phosphatase (G6Pase) for the treatment of this disorder.

For our Crigler-Najjar Syndrome Type 1 (CN-1) development candidate, we have patent applications pending in the U.S., Europe and Japan.

Our ornithine transcarbamylase deficiency (OTC) development candidate is covered by a pending PCT application.

Any U.S. and foreign patents that may issue from these patent families would be expected to expire in 2036 for the earliest of the MMA patents and 2038 to 2042 for the remaining MMA, PA, PKU, GSD1a and CN-1 patents, excluding any patent term adjustments, any patent term extensions and any terminal disclaimers.

As further described below, we have filed or intend to file patent applications on these and other aspects of our technology and development candidates, and as we continue the development of our intended products, we plan to identify additional means of obtaining patent protection that would potentially enhance commercial success, including protection for additional methods of use, formulation, or manufacture.

32
Table of Contents
Systemic secreted and cell-surface therapeutics

Our systemic secreted and cell-surface therapeutics modality features programs directed to expression of secreted or cell-surface proteins including antibodies, circulating immune modulation factors, secreted enzymes and transmembrane proteins.

Our Relaxin development candidate is covered by several patent families, including granted patents in Japan, China and the U.S., and by additional applications in the U.S. and additional foreign jurisdictions and a pending PCT application.

Our PD-L1 development candidate is covered in pending patent applications filed in the U.S., Japan and Europe.

Inhaled pulmonary therapeutics

Our inhaled pulmonary therapeutics modality currently has one development candidate directed to expression of therapeutic protein in the lungs. This Cystic Fibrosis (CF) development candidate is covered by pending U.S., European and PCT patent applications.

Gene editing

Our gene editing program currently has one filed patent family that includes issued patents in the U.S., Europe and Japan, and also pending applications in these jurisdictions. We plan to file patent applications on development candidates and other aspects of gene editing technology as we continue to innovate both internally and through strategic collaborations.

Trademarks

Our trademark portfolio currently contains at least 1,000 trademark registrations, including at least 22 registrations in the United States and the remaining in Canada, the European Union, the United Kingdom, Israel, China, Japan, Australia, and elsewhere. In addition, we have at least 600 pending trademark applications in more than 95 jurisdictions, including in the aforementioned locations and additional countries throughout Africa, Asia, and South America.

In-licensed intellectual property

While we develop and manufacture our potential mRNA medicines using our internally created mRNA technology platform, we also seek out and evaluate third party technologies and IP that may be complementary to our platform.
Patent sublicense agreements with Cellscript and mRNA RiboTherapeutics
The Trustees of the University of Pennsylvania owns several issued U.S. patents, granted European patents and pending U.S. patent applications directed, in part, to nucleoside-modified mRNAs and their uses (the Penn Modified mRNA Patents). mRNA RiboTherapeutics, Inc. (MRT) obtained an exclusive license to the Penn Modified mRNA Patents and granted its affiliate, Cellscript, LLC (Cellscript), a sublicense to the Penn Modified mRNA Patents in certain fields of use.
In June 2017, we entered into two sublicense agreements, one with Cellscript, and one with MRT, which agreements we collectively refer to as the Cellscript-MRT Agreements. Together, the Cellscript-MRT Agreements grant us a worldwide, sublicensable sublicense to the Penn Modified mRNA Patents to research, develop, make, and commercialize products covered by the Penn Modified mRNA Patents (licensed products), for all in vivo uses in humans and animals, including therapeutic, prophylactic, and diagnostic applications. The Cellscript-MRT Agreements are non-exclusive, although Cellscript and MRT are subject to certain time restrictions on granting additional sublicenses for in vivo uses in humans under the Penn Modified mRNA Patents. The Cellscript-MRT Agreements require us to pay royalties based on annual net sales of licensed products at rates in the low single digits for therapeutic, prophylactic, and diagnostic uses, and royalties based on annual net sales of licensed products sold for research uses at rates in the mid-single digits, subject to certain reductions, with an aggregate minimum floor.
The Cellscript-MRT Agreements will terminate upon the expiration or abandonment of the last to expire or become abandoned of the Penn Modified mRNA Patents. Cellscript or MRT, as applicable, may terminate its respective Cellscript-MRT Agreement if we fail to make required payments or otherwise materially breach the applicable agreement, subject to specified notice and cure provisions. Cellscript or MRT, as applicable, may also terminate the applicable Cellscript-MRT Agreement upon written notice in the event of our bankruptcy or insolvency or if we challenge the validity or enforceability of the Penn Modified mRNA Patents. We have the right to terminate each Cellscript-MRT Agreement at will upon 60 days’ prior notice to Cellscript or MRT, as applicable, provided that we cease all development and commercialization of licensed products upon such termination. If rights to MRT or Cellscript under the Penn Modified mRNA Patents are terminated (e.g., due to bankruptcy of MRT or Cellscript), the terminated party will assign its interest in the respective Cellscript-MRT Agreement to the licensor from which it received rights under the Penn Modified mRNA Patents and our rights will continue under the new licensor.

33
Table of Contents
Patent license agreement with NIAID

In December 2022, we entered into a non-exclusive patent license agreement with the National Institute of Allergy and Infectious Diseases (NIAID), an Institute or Center of the National Institutes of Health (NIH) to license certain patent rights concerning stabilizing prefusion coronavirus spike proteins and the resulting stabilized proteins for use in COVID-19 vaccine products. Pursuant to the agreement, we have agreed to pay low single-digit royalties on future net sales, a minimum annual royalty payment and certain contingent development, regulatory and commercial milestone payments on a licensed product-by-licensed product basis.

Formulation technology in-licenses

Our development candidates use internally developed formulation technology that we own. We do, however, have rights to use and exploit multiple issued and pending patents covering formulation technologies under licenses from other entities. If in the future we elect to use or to grant our strategic collaborators sublicenses to use these in-licensed formulation technologies, we or our strategic collaborators may be liable for milestone and royalty payment obligations arising from such use. We consider the commercial terms of these licenses and their provisions regarding diligence, insurance, indemnification and other similar matters, to be reasonable and customary for our industry.

HUMAN CAPITAL

We had approximately 5,600 full-time employees in 19 countries around the world as of December 31, 2023. We operate in a highly competitive environment for talent, particularly as we seek to attract and retain talent with experience in the biotechnology and pharmaceutical sectors. Our workforce is highly educated, and as of December 31, 2023, 41% of our employees hold Ph.D., Doctorate, M.D., J.D. or Master’s degrees. Among our employees, as of December 31, 2023, 49% are female. Among our leadership (which we define as employees at the vice president level and above), as of December 31, 2023, approximately 39% are female. 45% of our U.S. employees identify as racially or ethnically diverse as of December 31, 2023, an increase from the prior year. In 2023, for the second year in a row, an outside statistical pay equity analysis confirmed zero statistically significant differences in pay across gender globally and across gender, race and ethnicity in the United States.

Our focus on belonging, inclusion and diversity

We are committed to building a culture of inclusion and belonging for all. In 2023, we continued to act on our commitment to belonging, inclusion and diversity by, among other things:

•continuing our monitoring and reporting of company-wide gender and ethnicity data;
•including a belonging, inclusion and diversity focus in every employee engagement survey;
•continuing to invest in our Employee Resource Groups, which are voluntary, employee-led groups that harness the power of belonging in service to our people, our company and the community at large, including by introducing mCARE, a group dedicated to supporting and empowering our employees who are caregivers and parents;
•receiving recognition from Disability:IN Inclusion and the American Association of People with Disabilities as a best place to work for Disability Inclusion; and
•conducting diversity-related events, celebrations and learning opportunities for all employees throughout the year.

Our approach to attracting and retaining talent

We are committed to ensuring that our employees find that their careers at Moderna are filled with purpose, growth and fulfillment. We believe that a career at Moderna provides opportunity for:
•Impact: Our people will have the opportunity to do work that is unparalleled in terms of its innovation and scope of impact on people’s lives.
•Growth: We provide incredible opportunities for growth and we obsess over learning (as demonstrated, in part, by our Mindsets (see below). We invest substantially in the development of our people.
•Well-being: We are committed to the health and well-being of our employees and their families and provide numerous family-friendly benefits and opportunities to be healthy, including monthly contributions to employee lifestyle spending accounts.
•Inclusion: We believe in the benefits of bringing together a diverse set of perspectives and backgrounds, and creating an environment where differences are celebrated and leveraged. We measure and hold management accountable to creating an environment of psychological safety.
•Compelling rewards: To attract and retain the best talent, we provide competitive rewards that help to drive groundbreaking work and allow employees to share in the value we will create together, including through our equity programs.
•Giving and volunteering: Our people have the opportunity to give back to their communities and directly support causes that they are passionate about through volunteer and employee matching donation programs.

34
Table of Contents
To help promote alignment between our employees and our shareholders, all employees participate in our corporate equity programs through the receipt of equity awards, and the percentage of equity as a component of overall pay mix increases with seniority. We also allow our employees to select how they want the value of their award to be split between stock options and restricted stock units (RSUs). We believe that in addition to incentivizing growth that leads to shareholder value, broad eligibility for our equity programs further embeds our "We behave like owners" mindset and helps promote employee retention as these awards generally vest over a four-year period.

None of our employees are represented by a labor union or works councils, and none of our employees have entered into a collective bargaining agreement with us. A small number of employees in France, Italy and Spain are covered by statutory collective bargaining agreements governing certain benefits and working conditions. We consider our employee relations to be good.

We believe that our employees are highly engaged, and our company and team have been publicly recognized for our leadership, innovation and good corporate citizenship. Science magazine ranked us as a top employer for each of the last nine years. Additionally, in 2023, Biospace ranked us the number one large employer in its 2024 Best Places to Work in Biopharma report for the third consecutive year. We also received a perfect score from the Human Rights Campaign's Equality Index for 2023-2024. We measure employee engagement through a vendor-supplied engagement software, using validated external benchmarks to track employee engagement factors.

We continually monitor employee turnover rates, as our success depends upon retaining our highly trained personnel. We believe that the competitive compensation we offer, along with the combination of the factors listed above, among other factors, have helped reduce voluntary turnover. In 2023, our voluntary turnover rate was approximately 6%.

Our approach to training our employees

To further invest in our teams, we have established a structured training curriculum for our employees so that every employee becomes deeply familiar with our core technology and technologies that might further enable our innovation. In addition, we are focused on creating strong leaders through various management and leadership trainings. We have also built an online library of videos of a variety of scientific material that our employees can access flexibly. This content includes presentations by external speakers at in-house scientific seminars, scientific courses at external universities and peer-to-peer video series in which in-house experts provide an introductory view of complex topics they tackle within their teams.

New employees participate in our Moderna ONE onboarding program, which is an interactive learning experience designed to immerse our people in our culture and Mindsets from day one. Following onboarding, our employees continue to learn throughout their careers at Moderna and we deploy a digital learning management system to track and administer training programs for each of employee.

In December 2021, we launched our Artificial Intelligence (AI) Academy in partnership with Carnegie Mellon University. The AI Academy is intended to educate and empower our employees to identify and integrate AI and machine learning solutions into every Moderna system and process to bring mRNA medicines to patients.

Our culture

As an organization, we are bold, collaborative, curious and relentless. These values are underpinned by a core set of what we call “basecamp” values— integrity, quality, respect. Additionally, with the continued rapid growth of our company, we articulated the Moderna Mindsets, which define how we behave, lead and make decisions. We believe our Mindsets will be integral to our future success, and we integrate them into every facet of how we identify, onboard, grow and manage our talent.

To further develop and retain our workforce, we conduct periodic talent reviews that identify key talent within the organization. We use that data to inform specific development opportunities for key current and potential future leaders, and to support our periodic succession planning activities for key roles. These steps together ensure we have a robust understanding of our workforce and a talent pipeline to grow future leaders, and provide our employees an opportunity to continuously grow and advance in a way that meets their aspirations and talents.

35
Table of Contents
CORPORATE SOCIAL RESPONSIBILITY

As we pursue our mission to deliver the greatest possible impact to people through mRNA medicines, we have developed a corporate social responsibility (CSR) program that demonstrates our commitment to patients, employees, the environment and local communities. Our CSR framework consists of five key focus areas: medicines for patients, community, governance and ethics, employees and environment. Please refer to our 2022 ESG Report under the “Responsibility—Corporate policies” section of our website, which can be found at www.modernatx.com/responsibility/corporate-policies, as well as our proxy statement related to our 2024 Annual Meeting of Stockholders that we will file with the SEC, for a description of some of the measures we have taken to progress our commitment to corporate social responsibility.

COMPETITION

The biotechnology and pharmaceutical industries utilize rapidly advancing technologies and are characterized by intense competition. There is also a strong emphasis on defense of intellectual property and proprietary products.
mRNA Medicines

We believe that mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage. However, we face competition from others developing mRNA vaccines and therapeutics, as well as other medicines that compete or could compete with our products. We face competition from various sources, including large pharmaceutical companies, biotechnology companies, academic institutions, government agencies and public and private research institutions. The continued growth of the mRNA field is leading to increased competitive pressure, including from large and more established pharmaceutical companies. We also face competition when entering into strategic alliances to advance and grow our pipeline.

Our COVID-19 vaccine largely competes against Pfizer/BioNTech’s COVID-19 vaccine, which is also based on mRNA technology. We also compete against other approved or authorized products, including Novavax’s COVID-19 vaccine. Additionally, some competitors have developed COVID-19 treatments, including Pfizer’s antiviral pill, and the existence of such treatments may reduce demand for vaccines.

Competition for the sale of our COVID-19 vaccine is impacted by many factors, including, among others, actual and perceived vaccine efficacy (including against emerging SARS-CoV-2 variants), safety and tolerability, perceptions of mRNA technology, storage and handling conditions and the relative ease of distribution and administration, the timing and scope of regulatory approvals, reimbursement coverage and production and distribution costs. The competitiveness of our COVID-19 vaccines in the future may also depend on whether we successfully produce combination respiratory vaccines, which would combine in a single shot protection against various respiratory diseases, such as seasonal flu, RSV and COVID-19.

Our RSV vaccine, which we expect to launch in 2024, will face competition from existing RSV vaccines, including those produced by Pfizer and GlaxoSmithKline. We are also developing a seasonal flu vaccine, for which there is an existing, well-developed market.

In markets that we enter after competitors have already introduced a competing product, we may have difficulty achieving market share. See “Risk Factors—The pharmaceutical market is intensely competitive, and we may not compete effectively in the market for existing products, new treatment methods and new technologies.”

There are additional companies working on mRNA medicines, some of which have reached commercialization. These companies include BioNTech and Pfizer (alone and in partnership with BioNTech, Beam Therapeutics and others). Others include Sanofi, GlaxoSmithKline and CureVac.

Our Collaborations

We and our strategic collaborators face competition from companies developing therapies in various areas, other than the development of mRNA medicines, related to our collaborations. For example, there are a growing number of pharmaceutical, biotechnology and academic institutions researching and developing autologous and allogeneic CAR-T therapies in both the solid and liquid tumor setting. These CAR-T cell therapies are at various stages of development and approval and could compete against any CAR-M therapeutics we discover, develop and commercialize in collaboration with Carisma Therapeutics.

Similarly, there are many companies and institutions researching and developing other nucleic acid and genetic medicines, which could compete against any therapies for genetic diseases we develop and commercialize in collaboration with Metagenomi or other collaborators.

36
Table of Contents
Our Growing Commercial Footprint

Our commercial organization was established in 2020 and we have less commercial experience than many of our competitors. We are still growing our commercial footprint, and compete against other companies that have certain competitive advantages over us. See “Risk Factors—Risks related to commercialization and our products.”

GOVERNMENT REGULATION

Government authorities in the United States at the federal, state and local level and in other countries and regions, such as in the European Union (EU) regulate, among other things, the research, development, manufacture and marketing of our products. Generally, before a new medicine can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained and submitted for review and approved by the competent regulatory authority.

U.S. drug and biological product development

In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations and biologics under the FDCA, the Public Health Service Act (PHSA), and their implementing regulations. Both drugs and biologics also are subject to other federal, state and local statutes and regulations. Failure to comply with applicable U.S. requirements at any time during the product development process, approval process or following approval may subject us to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA’s refusal to approve pending applications, license revocation, a clinical hold, untitled or warning letters, product recalls, market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties.
Any of our product candidates must be approved by the FDA through a BLA or new drug application (NDA), or supplemental BLA or supplemental NDA, process before they may be legally marketed in the United States.

Preclinical studies

Before any of our development candidates may be tested in humans, the development candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as in vitro and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin. Unless the FDA raises concerns, an IND automatically becomes effective 30 days after receipt by the FDA. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin.
Clinical trials
The clinical stage of development involves the administration of the investigational medicine to healthy volunteers or patients under the supervision of qualified investigators and in accordance with GCP requirements. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an Institutional Review Board (IRB) for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to clinical trial subjects and monitors the clinical trial until completed. Further, progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and more frequently in other situations, including the occurrence of serious adverse events. Information about certain clinical trials must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website.
Under the U.S. National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines), supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee (IBC), a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. While the NIH Guidelines are only mandatory for research being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.
37
Table of Contents
Foreign studies conducted under an IND must meet the same requirements that apply to studies being conducted in the United States. Data from a foreign study not conducted under an IND may be submitted in support of a BLA if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data.
Clinical trials generally are conducted in three sequential phases, which may overlap:
•Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients to assess the metabolism, pharmacologic action, side effect tolerability, and safety of the investigational medicine.
•Phase 2 clinical trials generally involve disease-affected patients to evaluate proof of concept and/or determine the dosing regimen(s) for subsequent investigations. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy is conducted.
•Phase 3 clinical trials generally involve a large number of disease-affected patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the investigational medicine for its intended use, its safety in use and to establish the overall benefit/risk relationship of the investigational medicine, and provide an adequate basis for product labeling.

The FDA may also require post-approval Phase 4 non-registrational studies to explore scientific questions to further characterize safety and efficacy during commercial use of a drug.
The FDA or the clinical trial site may suspend or terminate a clinical trial at any time on various grounds, including a finding that the patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the drug or biologic has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a clinical trial may move forward at designated check points based on access to certain data from the clinical trial.

FDA review process

Following completion of the clinical trials, data are analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of a BLA or NDA, along with proposed labeling, chemistry, and manufacturing information to ensure product quality and other relevant data. A BLA is a request for approval to market a biologic for one or more specified indications and must contain proof of the biologic’s safety, purity, and potency. An NDA for a new drug must contain proof of the drug’s safety and efficacy. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. FDA approval of a BLA or NDA must be obtained before a biologic or drug may be marketed in the United States.

Before approving a BLA or NDA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether the facilities comply with cGMP requirements and are adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications for novel products or products which present difficult questions of safety or efficacy to an advisory committee of expert advisors for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The committee makes a recommendation to the FDA that is not binding but is generally followed.

After the FDA evaluates a BLA or NDA, it will grant marketing approval, request additional information or issue a complete response letter (CRL) outlining the deficiencies in the submission. The CRL may require additional testing or information, including additional preclinical or clinical data, for the FDA to reconsider the BLA or NDA. Even if such additional information and data are submitted, the FDA may decide that the BLA or NDA still does not meet the standards for approval. If the FDA grants approval, it issues an approval letter that authorizes commercial marketing of the product with specific prescribing information for specific indications.
Orphan drug designation
Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product.

38
Table of Contents
If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in very limited circumstances, such as if the latter product is shown to be clinically superior to the orphan product.

Expedited development and review programs

The FDA may employ one of several tools to facilitate and expedite the development and review of a medicine, including fast track designation, breakthrough therapy designation, accelerated approval and priority review designation. Fast track designation is designed to facilitate the development and review of a medicine that treats a serious condition and fills an unmet medical need. Breakthrough therapy designation is designed to expedite the development and review of a medicine that treats a serious condition and preliminary clinical evidence demonstrates substantial improvement over available therapies. Priority review designation means the FDA’s goal is to take action on an application within six months of filing. The FDA may grant priority review designation to a medicine that would provide significant improvement in the safety or effectiveness of a treatment, diagnosis or prevention of a serious condition.

A product may also be eligible for accelerated approval if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, such product must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (IMM) that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials with due diligence. If the FDA concludes that a drug or biologic shown to be effective can be safely used only if distribution or use is restricted, it will require such post-marketing restrictions, as it deems necessary to assure safe use of the product. Under the Food and Drug Omnibus Reform Act of 2022 (FDORA), the FDA is now permitted to require, as appropriate, that such trials be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Additionally, under FDORA, the FDA has increased authority for expedited procedures to withdraw its accelerated approval for such drug or biologic if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product.

Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or that the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, priority review, accelerated approval, and breakthrough therapy designation do not change the standards for approval.

Emergency Use Authorization (EUA)

The Secretary of Health and Human Services (HHS) may authorize unapproved medical products to be marketed in the context of an actual or potential emergency that has been designated by the U.S. government. The COVID-19 pandemic has been designated as such an emergency. After an emergency has been announced, the Secretary of HHS may authorize the issuance of and thereafter, the FDA Commissioner may issue EUAs for the use of specific products based on certain criteria, including that the product may be effective in diagnosing, treating, or preventing serious or life-threatening diseases when there are no adequate, approved, and available alternatives. An EUA terminates when the emergency determination underlying the EUA terminates. An EUA is not a long-term alternative to obtaining FDA approval, licensure, or clearance for a product. The FDA may revoke an EUA for a variety of reasons, including if the underlying health emergency no longer exists or warrants such authorization.

In the United States, the Public Readiness and Emergency Preparedness Act (PREP Act) provides immunity for manufacturers from all claims under state or federal law for “loss” arising out of the administration or use of a “covered countermeasure.” However, injured persons may still bring a suit for “willful misconduct” against the manufacturer under some circumstances. “Covered countermeasures” include “qualified pandemic or epidemic products,” including products intended to diagnose or treat pandemic or epidemic disease, such as pandemic vaccines. For these immunities to apply, the Secretary of HHS must issue a declaration in cases of public health emergency or “credible risk” of a future public health emergency. On March 17, 2020, the Secretary of HHS issued a declaration under the PREP Act and has issued subsequent amendments thereto to provide liability immunity for activities related to certain countermeasures against COVID-19. While we believe our products sold to the U.S. Government would be covered under the provisions of the PREP Act, this cannot be assured.

Pediatric information
Under the Pediatric Research Equity Act of 2003, all marketing applications for new active ingredients, indications, dosage forms, dosing regimens or routes of administration must contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred or inapplicable.

39
Table of Contents
Under the Best Pharmaceuticals for Children Act, a product may be eligible for pediatric exclusivity, which adds six months to existing exclusivity periods and patent terms. This exclusivity may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued written request for such a study.

Post-approval requirements

Following approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and record-keeping activities, reporting of adverse experiences, complying with promotion and advertising requirements, and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available products for off-label uses, manufacturers may not market or promote such uses. Prescription drug and biologic promotional materials must be submitted to the FDA in conjunction with their first use. Further, if there are any modifications to the drug or biologic, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new BLA or NDA or BLA or NDA supplement, which may require the development of additional data or preclinical studies and clinical trials.

The FDA may also place other conditions on approvals including the requirement for a Risk Evaluation and Mitigation Strategy (REMS) to assure that the benefits of the product outweigh the risks. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. Newly discovered or developed safety or effectiveness data may require changes to a product’s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures, including a REMS or the conduct of post-marketing studies to assess a newly discovered safety issue. Product approvals may be withdrawn for non-compliance with regulatory standards, or if problems occur following initial marketing.

FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMP regulations. Entities involved in the manufacture and distribution of approved drugs or biologics and their third-party manufacturers must comply with cGMP regulations that require, among other things, quality control and quality assurance, the maintenance of records and documentation, and the obligation to investigate and correct any deviations from cGMP. Such entities are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections for compliance with cGMP requirements and other laws. The discovery of violations could result in enforcement actions, and the discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA or NDA, including recall.

U.S. patent term restoration and regulatory data exclusivity

In certain circumstances, some U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch Waxman Amendments. The Hatch Waxman Amendments permit restoration of the patent term of up to five years as compensation for patent term lost during product development and FDA regulatory review process. Patent term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product’s approval date. The patent term restoration period is generally one half the time between the effective date of an IND and the submission date of a BLA or NDA, plus the time between the submission date of a BLA or NDA and the approval of that application. Only one patent applicable to an approved product is eligible for such an extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.

If the FDA approves a drug product that contains an active ingredient not previously approved, the product is typically entitled to five years of non-patent regulatory data exclusivity. Other products may be entitled to three years of regulatory data exclusivity if approval was based on the FDA’s reliance on new clinical studies essential to approval submitted by the NDA applicant. If the NDA applicant studies the product for use by children, the FDA may grant pediatric exclusivity, which extends by 180 days each existing exclusivity (patent and regulatory) related to the product.

An abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product was created by the Biologics Price Competition and Innovation Act of 2009 (the BPCI Act). Biosimilarity requires a showing that the product is “highly similar” to the reference product notwithstanding minor differences in clinically inactive components and that there are no clinically meaningful differences between the product and the reference product in terms of safety, purity, and potency. Interchangeability requires that a biological product be biosimilar to the reference product and that the product can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product. A reference biological product is granted 12 years of regulatory data exclusivity from the time of first licensure of the product
40
Table of Contents
and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product.

Drug development in the European Economic Area (EEA)

Medicinal products can be marketed in the EEA, which is comprised of the 27 Member States of the EU and Norway, Iceland and Liechtenstein, only if a marketing authorization from the competent regulatory agency has been obtained. Similar to the United States, the various phases of preclinical and clinical research in the EU are subject to significant regulatory controls. Effective since January 2022, the Clinical Trials Regulation (No. 536/2014) aims to streamline and harmonize the procedures for assessment and governance of clinical trials throughout the EU and to require that information on the authorization, conduct and results of each clinical trial conducted in the EU be publicly available.

Pediatric investigation plan

An application for marketing authorization of a medicinal product for human use that is not yet authorized in the EU must include a Pediatric Investigational Plan (PIP) pursuant to the regulation on medicinal products for pediatric use (known as the Paediatric Regulation), unless a waiver applies. A scientific committee established at the European Medicines Agency (EMA), the Paediatric Committee (PDCO) assesses the content of any PIP, waivers, and deferrals for a medicinal product submitted to it and formulates an opinion thereon.

Review and approval process

In the EEA, in order to obtain a marketing authorization from the applicable regulatory authority, a company may submit marketing authorization applications either under a centralized or decentralized procedure. The centralized procedure, which is compulsory for medicines produced by certain biotechnological processes, advanced therapy medicinal products (ATMPs), orphan medicinal products, or those medicines containing a new active substance and intended to treat specific diseases (HIV/AIDS, cancer, neurodegenerative disorders, diabetes, autoimmune and other immune dysfunctions and viral diseases), and optional for those medicines that are highly innovative or contain a new active substance, provides for the grant of a single marketing authorization that is valid throughout the EEA. In addition to the centralized procedure, a marketing authorization can also be obtained in the EEA through a national procedure, which requires a separate application to and approval determination by each country; a decentralized procedure, whereby applicants submit identical applications to several countries and receive simultaneous approval; and a mutual recognition procedure, where applicants submit an application to one country for review and other countries may accept or reject the initial decision.

A conditional marketing authorization may be granted in the EU when comprehensive clinical data for the safety and efficacy of the medicinal product have not been supplied but all the following requirements are met: (i) the risk-benefit balance of the medicine is positive; (ii) it is likely that the applicant will be in a position to provide the comprehensive clinical data post-authorization; (iii) the medicine fulfills an unmet medical need; and (iv) the benefit to public health of the immediate availability on the market of the medicine outweighs the risk that additional data is still required. Conditional marketing authorizations are valid for one year, on a renewable basis. The marketing authorization holder will be required to fulfil specific obligations within certain timeframes, which may include completing ongoing trials or conducting new trials to confirm that the benefit-risk balance is positive. Once such obligations are fulfilled, provided the benefit-risk balance is still positive, a conditional marketing authorization can be converted into a standard marketing authorization.

European regulatory data protection

In the EU, new innovative products authorized for marketing (i.e., reference products) qualify for regulatory data protection consisting of eight years of data exclusivity and an additional two years of market protection upon the grant of a marketing authorization. Data exclusivity prevents generic or biosimilar applicants from referencing the innovator’s data when applying for a generic or biosimilar marketing authorization. During the additional two-year period of market protection, a generic or biosimilar marketing authorization application can be submitted, and the innovator’s data may be referenced, but no generic or biosimilar product can be marketed until the expiration of the market protection period. There is no guarantee that a product will be considered by the EU’s regulatory authorities to be an innovative medicinal product, and products may not qualify for regulatory data protection.

European orphan designation and exclusivity

Orphan drug designation is available in the EU to promote the development of products that are intended for the diagnosis, prevention, or treatment of life threatening or chronically debilitating conditions affecting not more than five in 10,000 persons in the EU community, or where it is unlikely that the development of the medicine would generate sufficient return to justify the necessary investment in its development, and in each case for which no satisfactory method of diagnosis, prevention, or treatment has been
41
Table of Contents
authorized (or, if a method exists, the product would be a significant benefit to those affected). Medicinal products that receive and maintain orphan drug designation following approval are entitled to 10 years of market exclusivity, which protects against applications for and the grant of marketing authorizations for similar medicinal products in the same therapeutic indication. This period may be reduced to six years if, at the end of the fifth year, it is established that the orphan drug designation criteria are no longer met. During the period of market exclusivity, marketing authorization may only be granted to a similar medicinal product for the same therapeutic indication if: (i) a second applicant can establish that its product, although similar to the authorized product, is safer, more effective or otherwise clinically superior; (ii) the marketing authorization holder for the authorized product consents to a second orphan medicinal product application; or (iii) the marketing authorization holder for the authorized product cannot supply enough orphan medicinal product

The aforementioned EU rules are generally applicable in the EEA.

European data protection regulations

The EU General Data Protection Regulation (GDPR) governs the collection and use of personal data in the EU. The GDPR imposes strict requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third-party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the EU, provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to €20.0 million or 4% of the annual global revenues of the infringer, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with competent national data protection authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. Non-compliance could also result in the imposition of orders to stop data processing activities.
The UK has incorporated the GDPR into UK law (the UK GDPR).The UK GDPR and the UK Data Protection Act 2018 set out the UK’s data protection regime, which is independent from but aligned to the EU’s data protection regime. Although the UK is regarded as a third country under the EU’s GDPR, the European Commission has issued a decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EU to the UK remain unrestricted. Like the GDPR, the UK GDPR restricts personal data transfers outside the UK to countries not regarded by the UK as providing adequate protection. The UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing. Non-compliance with the UK GDPR may result in monetary penalties of up to £17.5 million or 4% of worldwide revenue, whichever is higher.

Marketing of medicines in the EU

Similar to the Anti-Kickback Statute prohibition in the United States discussed below, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order, or use of medicinal products is prohibited in the EU. Infringement of relevant EU laws could result in substantial fines and imprisonment. Payments may be made to physicians in limited circumstances, and in certain EU Member States such payments must be publicly disclosed. Moreover, agreements with physicians for the provision of services often must be the subject of prior notification and approval by the physician’s employer, his or her competent professional organization, and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines, or imprisonment.

Rest of the world regulation

Outside of the United States and the EU, the requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary from country to country. If we fail to comply with such requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, or criminal prosecution.

Coverage and reimbursement

Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which drugs and treatments they will cover and the amount of reimbursement.

42
Table of Contents
In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. As a result, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our products on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare & Medicaid Services (CMS). CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require co-payments that patients find unacceptably high. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term follow-up evaluations required following the use of product candidates, once approved. Patients are unlikely to use our product candidates, once approved, unless coverage is provided and reimbursement is adequate to cover a significant portion of their cost. There is significant uncertainty related to insurance coverage and reimbursement of newly approved products. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.

Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely.

We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Additionally, legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products.

In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower.

For further information on certain risks associated with the pricing and reimbursement of our products see “Risk Factors—Sales of pharmaceutical products depend on the availability and extent of reimbursement from third-party payors, and we may be adversely impacted by changes to such reimbursement policies or rules.”

Other healthcare laws

Healthcare providers, physicians, and third-party payors, including governmental payors, such as Medicare and Medicaid in the United States, will play a primary role in the recommendation and prescription of any marketed products. Any arrangements with these parties implicate certain fraud and abuse and other healthcare laws and regulations. In the United States, these laws include, among others:

•The Anti-Kickback Statute, which makes it illegal for any person to knowingly and willfully solicit, receive, offer, or pay any remuneration, directly or indirectly, in cash or in kind, that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug or any other good or service, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid.
•The federal False Claims Act, which imposes civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities (including manufacturers) for, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment by a federal healthcare program or making a false statement or record material to payment of a false claim or avoiding, decreasing, or concealing an obligation to pay money to the federal government.
•Health Insurance Portability and Accountability Act of 1996 (HIPAA), which imposes criminal and civil liability for, among other things, knowingly and willfully executing a scheme, or attempting to execute a scheme, to defraud any healthcare benefit program, including private payors, or falsifying, concealing, or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services.
•HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH), and their respective implementing regulations, which impose, among other things, requirements on covered entities and their business associates relating to the privacy and security of individually identifiable health information.
43
Table of Contents
•The Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act (ACA), which requires certain pharmaceutical manufacturers with products reimbursed under certain government programs to disclose annually to the federal government (for re-disclosure to the public) certain payments and other transfers of value provided to physicians, teaching hospitals and certain other licensed health care practitioners.
•Federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs.
•Federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.
•Analogous state fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, which may be broader in scope and apply regardless of payor.

Additionally, certain state and foreign laws also govern the privacy and security of health information. Such data privacy and security laws may differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts. For example, the California Consumer Protection Act (CCPA) established a comprehensive privacy framework for covered businesses by creating an expanded definition of personal information, establishing new data privacy rights for consumers in the State of California, imposing special rules on the collection of consumer data from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches. Further, the California Privacy Rights Act (CPRA), which took effect on January 1, 2023, has established additional obligations with respect to processing and storing personal information. The CPRA significantly modified the CCPA, including by expanding customers' rights with respect to certain sensitive personal information. While clinical trial data and information governed by HIPAA are currently exempt from the current versions of the CCPA and CPRA, other personal information is applicable due to the CPRA’s broader scope. Similar laws have been passed or proposed in numerous other states.

The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform.

Current and future healthcare reform legislation
In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our investigational medicines, restrict or regulate post-approval activities and affect our ability to profitably sell any approved products. The ACA, for example, contains provisions that subject biological products to potential competition by lower-cost biosimilars and may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and, annual fees based on pharmaceutical companies’ share of sales to federal health care programs. Current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price for any approved products.

In the United States, it is unclear whether the ACA will be overturned or further amended. We cannot predict what effect further changes to the ACA would have on our business. Additionally, other federal health reform measures have been proposed and adopted in the United States since the ACA was enacted, including the Budget Control Act of 2011, which includes provisions to reduce the federal deficit. The Budget Control Act, as amended, resulted in the imposition of 2% reductions in Medicare payments to providers, which began in April 2013 and will remain in effect through 2031 unless additional Congressional action is taken. In 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminated the statutory Medicaid drug rebate cap, previously set at 100% of a drug’s average manufacturer price, for single source and innovator multiple source drugs, beginning in 2024. Due to the Statutory Pay-As-You-Go Act of 2010, estimated budget deficit increases resulting from the American Rescue Plan Act of 2021, and subsequent legislation, Medicare payments to providers will be further reduced starting in 2025 absent further legislation. These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.

In August 2022, the Inflation Reduction Act of 2022 (IRA) was signed into law. The IRA includes several provisions that will impact our business to varying degrees, including provisions that create a $2,000 out-of-pocket cap for Medicare Part D beneficiaries, impose new manufacturer financial liability on all drugs in Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, require companies to pay rebates to Medicare for drug prices that increase faster than inflation and delay the rebate rule that would require pass through of pharmacy benefit manager rebates to beneficiaries. The effect of IRA on our business and the healthcare industry in general is not yet known.

Further, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which have resulted in several Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for products. In addition, the federal government, state legislatures, and foreign governments have shown significant interest in implementing cost containment programs, including price-controls and price transparency,
44
Table of Contents
restrictions on reimbursement, and requirements for substitution of generic products for branded prescription drugs to limit the growth of government paid health care costs. For example, the federal government has passed legislation requiring pharmaceutical manufacturers to provide rebates and discounts to certain entities and governmental payors to participate in federal healthcare programs.

Environment

We are subject to state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act. These and other laws govern the use, handling and disposal of various biologic, chemical and radioactive substances used in, and wastes generated by, operations. If our operations result in contamination of the environment, breach of our regulatory obligations or expose individuals to harm, we could be liable for damages and governmental fines. Equivalent laws have been adopted in foreign countries that impose similar obligations.

CORPORATE INFORMATION

We were incorporated under the laws of the State of Delaware on July 22, 2016. We are the successor in interest to Moderna LLC, a limited liability company formed under the laws of the State of Delaware in 2013. Moderna LLC was the successor in interest to Moderna Therapeutics, Inc., a Delaware corporation incorporated in 2009 as Newco LS18, Inc. by Flagship Pioneering. In August 2018, we changed our name from Moderna Therapeutics, Inc. to Moderna, Inc. Our principal corporate office is located at 200 Technology Square, Cambridge, MA 02139, and our telephone number is (617) 714-6500.

Our website, www.modernatx.com, including the Investor Relations section, www.investors.modernatx.com; corporate blog www.modernatx.com/moderna-blog, and our Statements and Perspectives webpage, https://investors.modernatx.com/Statements--Perspectives/default.aspx; as well as our social media channels: Facebook, www.facebook.com/modernatx; X, www.twitter.com/moderna_tx; and LinkedIn, www.linkedin.com/company/modernatx; contain a significant amount of information about us, including financial and other information for investors. We encourage investors to visit these websites and social media channels as information is frequently updated and new information is shared. The information on our website and that we disclose through social media channels is not incorporated by reference in this Annual Report on Form 10-K or in any other filings we make with the Securities and Exchange Commission (the SEC).

We make available free of charge on or through our website certain reports and amendments to those reports that we file with or furnish to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. These include our Annual Reports on Form 10-K, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K, and amendments to those reports.

The SEC also maintains an Internet site (http://www.sec.gov) that contains reports, proxy and information statements, and other information regarding us and other issuers that file electronically with the SEC.
45
Table of Contents

Item 1A. Risk Factors

You should carefully consider the following risks and uncertainties, together with all other information in this Annual Report on Form 10-K. Any of the risk factors we describe below could adversely affect our business, financial condition or results of operations and the market price of our common stock.

Risks related to commercialization and our products

Evolving dynamics in the market for COVID-19 vaccines are likely to impact our financial results, which are likely to result in lower product revenues in 2024 than we have experienced in recent years.

Through 2023, our only approved product and sole source of product sales has been our COVID-19 vaccine. The global market is transitioning to an endemic, commercial market for COVID-19 vaccine sales, resulting in different market and production dynamics than during the pandemic, including a more fragmented customer base, less predictability in orders, greater seasonality of demand, increased distribution costs, and higher costs of goods sold. Furthermore, our assumptions regarding the product presentation that will be accepted or preferred by the market (e.g., single-dose presentation), which could vary by market, may prove incorrect. In addition, certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices. We may also be adversely affected by similar market practices outside of the United States.

We recognized $6.7 billion of sales for COVID-19 vaccines delivered in 2023, compared to $18.4 billion in 2022 and $17.7 billion in 2021, as demand for COVID-19 vaccines declined. We anticipate that sales of COVID-19 vaccines are likely to be lower in 2024 than 2023. We expect the market for COVID-19 vaccines to evolve based on a number of factors, including medical need, viral evolution, public health authority recommendations and consumer motivation to vaccinate. In the third quarter of 2023, we significantly resized our manufacturing infrastructure as we shifted to an endemic COVID-19 vaccine market, and we may in the future incur additional costs associated with exiting commitments with suppliers for raw materials and contract manufacturing organization (CMOs). As a result of lower demand, we have experienced, and may in the future experience, increased costs with respect to raw material suppliers as we seek to exit or modify our purchase commitments. Further, we have entered, and may in the future enter, into non-cancellable or take-or-pay purchase commitments for raw materials that require a long lead time to procure, increasing our commitment exposure. If we cannot effectively manage evolving demand dynamics, our business, financial condition, results of operations and prospects may suffer.

Additionally, we may not see demand materialize for our products consistent with our projections. This may lead to lower than expected commercial sales or requests to defer, renegotiate or cancel existing contracts. Further, we may find that we need to dedicate greater resources to our commercial efforts than anticipated, and we may not realize a return on this investment.

We may encounter difficulties producing or shipping our products consistent with our projections or future contractual commitments.

We may encounter difficulties producing or shipping our products, including our COVID-19 vaccine or other future products, consistent with our current expectations or on the terms set forth in our supply agreements or future sales contracts. Our ability to commercialize our products depends on our manufacturing capability, both at our own facilities and those of our partners, particularly for fill-finish capabilities. Further, adapting our COVID-19 vaccine to new variants requires significant coordination with our partners, including for the sourcing of raw materials and production. Any capacity or production issues or delays experienced by our partners may cause us to fail to meet obligations under our supply agreements.

We have limited sales, distribution and marketing experience and may be unable to effectively establish such capabilities or supplement our capabilities by entering into agreements with third parties.

We have limited experience as a commercial organization and face risks and uncertainties as we shift to an endemic COVID-19 vaccine market and prepare for the commercial launch of other medicines, including our anticipated RSV vaccine launch in 2024. As a result of this limited commercial experience, we may be unsuccessful in accurately anticipating future rates of return for our products, which may adversely impact our accounting estimates. Additionally, we may seek to enter into agreements with others to utilize their marketing and distribution capabilities, but may be unable to enter into agreements on favorable terms, if at all. If we rely on others to commercialize our products, our revenues may be lower than if we commercialized these products ourselves. In addition, we may have little or no control over such third parties’ sales efforts. If our partners commit insufficient resources to commercialize our products, and we cannot independently develop necessary marketing capabilities, we may be unable to generate sufficient product revenue to sustain our business.
46


The pharmaceutical market is intensely competitive, and we may not compete effectively in the market for existing products, new treatment methods and new technologies.

The pharmaceutical market is intensely competitive and evolving. Many companies, academic institutions, governmental agencies and public and private research organizations are developing products for the same diseases that we are targeting or expect to target and such other parties may have:
•greater resources and experience than us at every stage of drug discovery, development, testing, approval, manufacturing and commercialization;
•multiple products that have been approved or are in late stages of development; and
•arrangements in our target markets with purchasers, governments, leading companies and research institutions.

We face intense competition with respect to our COVID-19 vaccine, and it may not continue to compete favorably with existing or future vaccines and treatments. Other vaccines or treatments could prove to be safer, more effective, more convenient, have fewer side effects, be easier to ship or distribute or able to be developed at a lower cost than our vaccine. Even if our products demonstrate superiority to those of competitors, consumers and the public may fail to appreciate that benefit, or existing purchase commitments for a competitor’s product may discourage them from purchasing from us. These factors, or the perception of these factors, could lead to a competitor’s vaccine or treatment being more successfully commercialized. Further, the mRNA medicines field is growing rapidly, with increased competitive pressure from large and more established pharmaceutical companies. The actual or perceived success or failure of others may adversely impact our ability to commercialize our products.

We also will face competition from products that have already been approved and accepted by the medical community to treat certain conditions we target. For example, we are developing a seasonal flu vaccine, for which there is a well-developed market, and we may be unsuccessful in developing a product or achieving market share. Our RSV vaccine, which we expect to launch beginning in 2024, will also face competition from existing RSV vaccines. In markets that we enter after competitors have already introduced a competing product, we may have difficulty achieving market share. Further, we may need to offer more favorable terms to gain market share in an existing market or to compete in a new market, which may negatively impact our profitability.

If we successfully develop and obtain approval for other product candidates, we may compete with products under development by competitors based on many factors, including the relative safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Our competitors may be more successful in commercializing their products, which would adversely affect our business. Competitive products may make any products we develop obsolete or noncompetitive before we can recover the expenses of developing and commercializing our products, if approved.

We may be unsuccessful or delayed in updating our COVID-19 vaccine to protect against future variants of the SARS-CoV-2 virus, and updated versions of our COVID-19 vaccine may not protect against such variants.

As the SARS-CoV-2 virus continues to evolve, new strains of the virus may prove more transmissible or cause more severe forms of COVID-19 than earlier strains. Our current COVID-19 vaccines could be ineffective, or less effective than desired, in protecting against these new variants. Additionally, our decisions regarding vaccine development will be informed by guidance from the FDA and foreign regulatory authorities, which may impact the timing of development for our COVID-19 vaccines.

We may experience delays in producing variant-specific vaccines. Further, different regulators may issue differing guidance regarding vaccine composition or populations who should receive a vaccine. If our efforts to develop variant-specific vaccines against future variants are unsuccessful, we are slower than competitors to develop such vaccines or our vaccines prove less effective than competitors’ vaccines, we could suffer reputational harm, loss of market share and adverse financial results. Additionally, we may expend significant resources adapting our vaccines or conducting clinical trials to protect against variants, but a market for our adapted vaccines may fail to develop or demand may not align with our projections or cost expenditures.

The commercial success of our products will depend on the degree of market acceptance by physicians, patients, third-party payors and others in the medical community.

The commercial success of our products will depend in part on the medical community, patients and third-party or governmental payors accepting mRNA medicines, and our products in particular, as medically useful, cost-effective and safe. The degree of market acceptance of our products will depend on numerous factors, including:
•the potential efficacy and advantages over alternative treatments;
47

•the ability to offer products at competitive prices;
•the duration of protection provided by our products compared to those of competitors;
•acceptance of mRNA products generally and the availability of competing non-mRNA medicines that may be preferred by the medical community or the public;
•the prevalence and severity of any side effects, including any limitations, restrictions (including for use together with other medicines) or warnings contained in a product’s approved labeling;
•the prevalence and severity of any side effects resulting from checkpoint inhibitors or other products or therapies with which our products are co-administered;
•relative convenience and ease of administration;
•the willingness of the target patient population to try, and physicians to prescribe, new therapies;
•the strength of marketing and distribution support and timing of market introduction of competitive products;
•whether our product presentation meets customer demand (e.g., for single-dose presentations, or combination vaccines);
•publicity concerning our products or competing products and treatments; and
•sufficient third-party insurance coverage or reimbursement, and patients’ willingness to pay out-of-pocket in the absence of third-party coverage or adequate reimbursement.

Even if a potential product displays a favorable efficacy and safety profile in clinical trials, market acceptance will be unknown until after it is launched. Our efforts to educate the medical community and third-party payors on the benefits of our products may require significant resources, especially due to the complexity of our programs, and may never be successful.

Sales of pharmaceutical products depend on the availability and extent of reimbursement from third-party payors, and we may be adversely impacted by changes to such reimbursement policies or rules.

Sales of pharmaceutical products in general depends to a significant extent on adequate coverage, pricing and reimbursement from third-party payors. When a new product is approved, the availability and extent of government and private reimbursement, and the pricing, for that product may be uncertain. For example, it is uncertain whether any combination respiratory vaccine we develop, if approved, would qualify for coverage under Medicare Part B. Additionally, pricing and reimbursement for any product we develop may be adversely affected by a number of factors, including:
•changes in, and implementation of, federal, state or foreign government regulations or private third-party payors’ reimbursement policies;
•pressure by employers on private health insurance plans to reduce costs; and
•consolidation and increasing assertiveness of payors seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value.

Our ability to set the price for any product we develop will vary significantly by country. Our inability to obtain and maintain adequate prices in a particular country may limit the revenues from our products within that country and adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth. This may create the opportunity for third-party cross-border trade or influence our decision whether to sell a product, thus adversely affecting our geographic expansion plans and revenues.

Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients, including more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients’ use of commercial manufacturer co-pay payment assistance programs. Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors would increase the negotiating leverage such entities have over us and other drug manufacturers. Additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products, particularly our therapeutic products or those that are individualized for a particular patient. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor’s determination that use of a product is a covered benefit under its health plan, safe, effective and medically necessary, appropriate for the specific patient, cost-effective and neither experimental nor investigational.

Additionally, target patient populations for some of our product candidates may be small (e.g., for rare genetic diseases) or require individual customization (e.g., for our INTs). The pricing and reimbursement of our medicines, if approved, must be adequate to support commercial infrastructure. If we cannot obtain adequate levels of reimbursement, we may be unable to successfully market and sell our products. The manner and level at which reimbursement is provided for services related to our products (e.g., for administration to patients) is also important. Inadequate reimbursement for such services may discourage physicians from prescribing or recommending our products, adversely affecting our ability to market or sell those products.
48


The market opportunities for our products and product candidates may be smaller than we believe, or we may be unable to successfully identify clinical trial participants.

We focus certain of our research and product development activities on treatments for severe rare genetic diseases, where the patient populations are difficult to ascertain or small. Additionally, we expect to initially seek approval of our INT and intratumoral immuno-oncology product candidates for use by patients with relapsed or refractory advanced disease, i.e., the populations the FDA often approves new therapies for initially. If any such medicines prove to be sufficiently beneficial, we would expect to seek approval in earlier lines of treatment and potentially as a first-line therapy. There is no guarantee that our products, if approved, would be approved for earlier lines of therapy and, prior to any such approvals, we may have to conduct additional clinical trials.

Our estimates of addressable patient populations are based on our beliefs, and have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of trial participants may be lower than expected and potential clinical trial participants or patients may not be otherwise amenable to treatment with our product candidates or products, or new clinical trial participants or patients may become increasingly difficult to identify or gain access to. Even if we obtain significant market share for our products, if approved, because the potential target populations are small, these medicines may never be profitable.

Risks related to our pipeline, product development and regulatory review

Preclinical development is lengthy and uncertain, especially for mRNA medicines, and our preclinical programs or product candidates may be delayed or terminated.

Much of our pipeline is in preclinical development, and these programs could be delayed or not advanced into the clinic. Before we can initiate clinical trials for a product candidate, we must complete extensive preclinical studies, including IND-enabling good laboratory practice (GLP) toxicology testing. We must also complete extensive work on Chemistry, Manufacturing, and Controls (CMC) activities to be included in an IND submission. CMC activities for mRNA medicines require extensive manufacturing processes and analytical development, which is uncertain and lengthy. We have had and may in the future have difficulty identifying appropriate buffers and storage conditions to enable sufficient shelf life of batches of our product candidates. If we must produce new batches, our preclinical studies could be delayed. We cannot be certain of the timely completion of our preclinical testing and studies, whether the FDA or other regulators will accept the results or if the outcome of our preclinical testing, studies and CMC activities will ultimately support further development of our programs. As a result, we may be unable to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and such applications may not result in the FDA or other regulators allowing clinical trials to begin.

Clinical development is lengthy and uncertain, and our clinical programs may be delayed or terminated, or may be more costly to conduct than we anticipate.

Clinical testing is expensive, complex and lengthy, and its outcome is inherently uncertain. Most product candidates that commence clinical trials are never approved as products. We may be unable to initiate, may experience delays in or may have to discontinue clinical trials for our product candidates. We and our strategic collaborators also may experience unforeseen events during, or as a result of, any clinical trials that we or they conduct that could delay or prevent us or them from successfully developing our product candidates and gaining approval from regulators. Events that might prevent us from proceeding with clinical trials could include:
•regulators, Institutional Review Boards (IRBs) or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;
•we may experience delays in reaching, or fail to reach, agreement on favorable terms with prospective trial sites and prospective contract research organizations (CROs);
•changes to the scale or site of our manufacturing could cause significant delays or changes in our clinical trial designs;
•the outcome of our preclinical studies and our early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results;
•we may be unable to establish or achieve clinically meaningful endpoints for our studies;
•if we make changes to our product candidates after clinical trials have commenced (which we have done in the past), we may be required to repeat earlier stages or delay later stages of clinical testing;
•clinical trials of any product candidates may fail to show safety or efficacy, or may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional nonclinical studies or clinical trials, or we may decide to abandon product development programs;
49

•our product candidates, or other medicines in the same class as ours, may have undesirable side effects, such as the immunogenicity of the LNPs or their components, the immunogenicity of the protein made by the mRNA or degradation products, any of which could lead to serious adverse events, or other effects;
•administration of our LNPs could lead to systemic side effects related to the components of the LNPs and could contribute to immune reactions, infusion reactions, complement reactions, opsonization reactions, antibody reactions or reactions to PEG-lipids;
•significant adverse events or other side effects could be observed in our clinical trials;
•our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the applicable clinical trial protocol or withdraw from the applicable clinical trial, which may require that we add new clinical trial sites;
•regulators may impose a complete or partial clinical hold on a clinical trial, or we or our investigators, IRBs or ethics committees may suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that participants are being exposed to an unacceptable benefit-risk ratio;
•regulators may impose a complete or partial clinical hold on clinical trials of other companies working on mRNA medicines;
•the cost of preclinical or nonclinical testing and studies and clinical trials of product candidates may be greater than anticipated;
•the supply or quality of our product candidates or other materials necessary to conduct clinical trials may be insufficient or inadequate;
•safety and efficacy concerns regarding our product candidates will be considered by us and by the FDA and other regulators as we pursue clinical trials of new product candidates, develop effective informed consent documentation and work with IRBs and scientific review committees (SRCs);
•safety or efficacy concerns could arise from nonclinical or clinical testing of other therapies targeting a similar disease state or other therapies, such as gene therapy, that are perceived as similar to ours;
•adverse side effects could be observed in future clinical trials where our product candidates are administered in combination with other therapies (such as the co-administration of our INT product candidate, mRNA-4157); and
•a lack of adequate funding to continue a particular clinical trial.

Before commencing later-stage clinical trials for our programs, we must develop assays to measure and predict the potency of a given dose of our product candidates. Any delay in developing assays that are acceptable to the FDA or other regulators could delay the start of future clinical trials.

Additionally, we have conducted and may conduct in the future “open-label” clinical trials, where both the patient and investigator know whether the patient is receiving the investigational product candidate, an approved drug or a placebo. The results from an open-label clinical trial may not be predictive of future clinical trial results from a controlled environment with a placebo or active control. Further, the FDA or other regulators may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials. Significant preclinical or nonclinical testing and studies or clinical trial delays for our product candidates could allow our competitors to bring products to market before we do and could harm our business, financial condition and prospects significantly.

There are risks that are unique to each of our programs and modalities and risks that are applicable across programs and modalities. These risks may impair our ability to advance one or more of our programs in clinical development, obtain regulatory approval or commercialize our products, or cause us to experience significant delays in doing so.

Certain features in our product candidates, including those related to mRNA, chemical modifications, surface chemistries, LNPs and their components, may result in risks that apply to some or all of our programs and modalities. As our product candidates progress, we or others may determine that certain of our risk allocation decisions were incorrect or insufficient, we made platform-level technology mistakes, individual programs or our mRNA science in general has technology or biology risks that were unknown or under-appreciated, our choices on how to develop our infrastructure to support our scale will result in an inability to manufacture our product candidates for clinical trials or otherwise impair our manufacturing or we have allocated resources in such a way that we cannot recover large investments or rapidly re-direct capital.

We utilize earlier programs in a modality to understand the technology risks within the modality, including the program’s manufacturing and pharmaceutical properties. Even if our earlier programs in a modality are successful in any phase of development, any program may fail at a later phase of development, and other programs within the same modality may fail at any phase of development, including at phases where earlier programs in that modality were successful. This may be a result of technical challenges or biology risk unique to that program. The biology risk across the majority of our pipeline represents targets and pathways not clinically validated by one or more approved drugs, and the risk that the targets or pathways that we have selected may not be effective will continue to apply across the majority of our current and future programs.

50

As we progress our programs through clinical development, new technical challenges may arise that cause an entire modality to fail. Additionally, any portfolio-spanning risks, whether known or unknown, such as an increased risk of a particular type of side effect, if realized in any one of our programs, would have a material and adverse effect on our other programs and on our business as a whole.

There are also specific additional risks to certain of our modalities and programs. For example, prophylactic vaccines typically require clinical testing in up to tens of thousands of healthy volunteers to define an approvable benefit-risk profile. The need to show a high degree of safety and tolerability when dosing healthy individuals could result in rare and even spurious safety findings, negatively impacting a program prior to or after commercial launch. Even if we observe positive safety, tolerability and levels of immunogenicity in early clinical trials, we may not observe acceptable safety or efficacy profiles in later-stage trials required for approval of these programs.

There are many clinical and manufacturing challenges specific to our INT product candidates and any other neoantigen cancer vaccines we may develop. These risks include a rapid production turn-around time measured in weeks in order to supply patients in our clinical trials before further progression and mutation of their tumors, the significant costs incurred in making individualized medicines and potential lack of immune responses due to the biology of the tumor or immune status of the patient. These risks apply to our INT product candidates and other neoepitope investigational medicine programs.

Additionally, there may be challenges in delivering an adequate quantity of active pharmaceutical ingredient (API) required to drive efficacy due to the limitation in volume of API that can be delivered to a specific location, like a tumor or injured tissue. Our investigational therapies for local injections often require specialized skills for conducting a clinical trial that could delay clinical trials or slow or impair commercialization of a product due to the poor adoption of injected local therapeutics or intratumoral therapies. In addition, the uncertain translatability of target selection from preclinical animal models, including mouse and non-human primate models, to successful clinical trial results may be impossible, particularly for immuno-oncology and systemic therapies, and cancer vaccines. In general, several biological steps are required for delivery of mRNA to translate into therapeutically active medicines. These processing steps may differ between individuals or tissues, potentially leading to variable levels of therapeutic protein, variable activity, immunogenicity or variable distribution to tissues for a therapeutic effect. Gene therapies and mRNA medicines may activate one or more immune responses against any and all components of the drug product (e.g., the mRNA or the delivery vehicle, such as an LNP) as well as against the encoded protein, giving rise to potential immune reaction related adverse events. Eliciting an immune response against the encoded protein may impede our ability to achieve a pharmacologic effect upon repeat administration or a side effect. These risks apply to all of our programs, including our systemic secreted therapeutics and systemic intracellular therapeutics modalities.

We may experience delays in enrolling participants in our clinical trials.

Enrolling participants in our clinical trials is critical to our success. Difficulties or delays in enrolling a sufficient number of clinical trial participants, or those with required or desired characteristics, may result in increased costs or affect the timing or outcome of our planned clinical trials, which could prevent trial completion and adversely affect our ability to advance the development of and obtain regulatory approval for our product candidates. We may slow enrollment in a trial to focus on achieving greater diversity in the subject population, as we did in the Phase 3 clinical trial of our original COVID-19 vaccine.

Participant enrollment is affected by many factors, including:
•severity of the disease under investigation;
•complexity and design of the clinical trial protocol;
•size of the patient population;
•eligibility criteria for the clinical trial in question, including age-based eligibility criteria limiting subject enrollment to adolescent or pediatric populations;
•proximity and availability of clinical trial sites for prospective trial participants;
•availability of competing therapies and clinical trials;
•patient referral practices of physicians;
•ability to monitor trial participants adequately during and after treatment;
•ability to recruit qualified clinical trial investigators;
•clinicians’ and trial participants’ perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating;
•adverse results or other adverse safety signals in our trials or related to other product candidates, and the resulting negative publicity, could discourage potential clinical trial participants and their doctors from participating in our trials; and
•our ability to obtain and maintain participant informed consent.

51

Additionally, we may have limited or no ability to influence enrollment in clinical trials where we have entered into strategic alliances pursuant to which our collaborators control clinical development. Even if we or our strategic collaborators can enroll clinical trial participants, there is no guarantee that such participants will ultimately be dosed as part of, or complete, a clinical trial.

mRNA drug development has substantial clinical development and regulatory risks due to the novel nature of this new class of medicines, and the negative perception of the efficacy, safety or tolerability profile of any product candidates that we or others develop could adversely affect our ability to conduct our business, advance our product candidates or obtain regulatory approvals.

Very few mRNA medicines have been authorized or approved to date by the FDA or other regulators, and efficacy, safety and immunogenicity data and real-world evidence with respect to mRNA medicines continue to accumulate. We may observe new, more frequent or more severe adverse events in subjects participating in ongoing clinical trials or among individuals vaccinated with our COVID-19 vaccine. For example, some studies have suggested that our COVID-19 vaccine may be associated with higher rates of myocarditis and pericarditis in young males compared to other COVID-19 vaccines. If similar observations are made in recipients of our other products or product candidates, or if other unexpected safety issues arise, we could suffer significant damage to our reputation and that of our mRNA platform. Such events could lead to other issues, including delays in our other programs, the need to re-design our clinical trials and the need for significant additional financial resources. In addition, the FDA and other regulators may interpret data from our clinical trials differently than we do and such agencies may require us to conduct additional studies or analyses, which could delay or prevent us from obtaining full regulatory approvals in certain jurisdictions or for certain demographics. For example, in October 2021, the FDA requested that we explore a lower dosage for our COVID-19 vaccine in adolescents, which extended the length of clinical trials in this population prior to receiving regulatory authorization.

Successful discovery and development of mRNA medicines by us or our strategic collaborators is highly uncertain and depends on many factors beyond our or their control. We constantly make business decisions and take calculated risks to advance our development efforts and pipeline, including those related to mRNA technology, delivery technology and manufacturing processes, which ultimately may be unsuccessful.

Our product candidates that appear promising in the early phases of development may fail to advance, experience delays in the clinic, experience clinical holds or fail to reach the market for many reasons, including:
•nonclinical or preclinical study, or clinical trial, results may show potential mRNA medicines to be less effective than desired or to have harmful or problematic side effects or toxicities;
•adverse results in our clinical trials, or in those of others developing similar products, or adverse effects relating to mRNA, or our LNPs, may lead to negative publicity or delays in or termination of our programs;
•the efficacy or safety of a combination vaccine product candidate could be less than that seen with the administration of the vaccines separately, which could prevent the combination product from obtaining regulatory approval;
•adverse events related to products that are perceived to be similar to mRNA medicines, such as those related to gene therapy or gene editing, could result in a decrease in the perceived benefit of one or more of our programs, increased regulatory scrutiny, decreased confidence by patients and clinical trial collaborators in our product candidates and less demand for any product that we may develop;
•the insufficient ability of our translational models to reduce risk or predict outcomes in humans, particularly given that each component of our product candidates may have a dependent or independent effect on safety, tolerability and efficacy, which may be species-dependent;
•manufacturing failures or insufficient supply of cGMP materials for clinical trials, or higher than expected cost could delay or set back clinical trials, or make mRNA medicines commercially unattractive;
•changes that we make to optimize our manufacturing, testing or formulating of cGMP materials could impact the safety, tolerability and efficacy profile of our product candidates;
•pricing or reimbursement issues or other factors that delay clinical trials or make any mRNA medicine uneconomical or noncompetitive with other therapies;
•our large pipeline of product candidates could result in a greater quantity of reportable adverse events, including suspected unexpected serious adverse reactions, other reportable negative clinical outcomes, manufacturing reportable events or material clinical events that could lead to clinical delay or hold by the FDA or applicable regulatory authority or other clinical delays, any of which could negatively impact the perception of one or more of our programs, as well as our business as a whole;
•failure to timely advance our programs or a failure or delay in receiving necessary regulatory approvals due to, among other factors, slow or failure to complete enrollment in clinical trials, withdrawal by trial participants from trials, failure to achieve trial endpoints, additional time requirements for data analysis, data integrity issues, preparation of a BLA, or the equivalent application, discussions with the FDA or EMA, a regulatory request for additional nonclinical or clinical data or safety formulation or manufacturing issues may lead to our inability to obtain sufficient funding;
•new legislation or regulations passed by U.S., state or foreign governments in response to negative public perception of mRNA medicines; and
52

•the proprietary rights of others and their competing products and technologies that may prevent our mRNA medicines from being commercialized.

Because we are developing some of our product candidates for the treatment of diseases in which there is little clinical experience and, in some cases, using new endpoints or methodologies, the FDA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results.

There are no pharmacologic therapies approved to treat the underlying causes of many diseases that we are currently attempting to address or may address in the future. For instance, for many of the rare diseases for which we are developing treatments, few clinical trials have been attempted, and there are no approved drugs to treat these diseases. As a result, the design and conduct of clinical trials of product candidates for the treatment of these disorders and other disorders may take longer, be more costly or be less effective due to the novelty of development in these diseases.

Even if the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we or our strategic collaborators conduct. Further, even if we achieve the pre-specified criteria, our clinical trials may produce unpredictable or inconsistent results compared against the more traditional efficacy endpoints in the trial. The FDA could give overriding weight to other efficacy endpoints over a primary endpoint, even if we achieve statistically significant results on that endpoint, if we do not do so on our secondary efficacy endpoints. The FDA also weighs the benefits of a product against its risks and may view the efficacy results in the context of safety as not being supportive of licensure. Regulators in other countries may make similar findings with respect to these endpoints.

Certain mRNA therapies are classified as gene therapies by the FDA and the EMA. The association of our medicines with gene therapies could result in increased regulatory burdens, impair the reputation of our investigational medicines or negatively impact our platform or our business.

There are only a few approved gene therapy products in the United States or foreign jurisdictions, and there have been well-reported significant adverse events associated with their testing and use. Regulatory requirements governing gene therapy products have evolved and may continue to change in the future, and the implications for mRNA therapies are unknown. For example, the FDA has established an office, now called the Office of Therapeutics Products (OTP), within its Center for Biologics Evaluation and Research (CBER) to consolidate the review of gene therapy and related products, and convenes the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. In the EU, certain mRNA therapies have been characterized as gene therapy medicinal products, which falls within a broader category known as Advanced Therapy Medicinal Products (ATMPs), which are subject to additional regulatory requirements. In certain countries, mRNA therapies have not yet been classified or any such classification is not known to us; for example, in Japan, the Pharmaceuticals and Medical Devices Agency has not taken a position on the regulatory classification of mRNA therapies. Notwithstanding the differences between mRNA medicines and gene therapies, the classification of some of our mRNA product candidates as gene therapies in the United States, the EU and potentially other countries could adversely impact our ability to develop our product candidates. For instance, a clinical hold on gene therapy products may apply to our mRNA product candidates irrespective of the differences between gene therapies and mRNA.

Adverse events reported with respect to gene therapies could adversely impact one or more of our programs. Although our mRNA product candidates are designed not to make any permanent changes to cell DNA, regulatory agencies or others could believe that adverse effects of gene therapies caused by introducing new DNA and irreversibly changing the DNA in a cell could also be a risk for our mRNA investigational therapies, and as a result may delay one or more of our clinical trials or impose additional testing for long-term side effects. Any new requirements and guidelines promulgated by regulatory agencies may negatively affect our business by lengthening the regulatory review process, requiring us to perform additional or larger studies or increasing our development costs, any of which could lead to changes in regulatory positions and interpretations, delay or prevent advancement or approval and commercialization of our product candidates, or lead to significant post-approval studies, limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory agencies and advisory committees and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of some or all of our product candidates.

Our work in genomic editing is subject to all risks associated with gene therapies. Although there have been significant advances in recent years in fields of gene therapy and genome editing, in vivo CRISPR-based genome editing technologies are relatively new and their therapeutic utility is largely unproven. Public perception and related media coverage of potential therapy-related efficacy or safety issues, as well as ethical concerns related specifically to genome editing, may adversely influence the willingness of subjects to participate in clinical trials. In addition, any review conducted by an institutional biosafety committee may result in delay or prevent initiation of a gene therapy clinical trial.

53

Additionally, if any such therapeutic is approved, physicians and patients may be slow or fail to accept these novel and personalized treatments. Physicians, health care providers and third-party payors often are slow to adopt new products, technologies and treatment practices, particularly those that may also require additional upfront costs and training. Physicians may not be willing to undergo training to adopt these novel and potentially personalized therapies, may decide the particular therapy is too complex or potentially risky to adopt without appropriate training and may choose not to administer the therapy. Further, due to health conditions, genetic profile or other reasons, certain patients may not be candidates for the therapies. In addition, responses by federal and state agencies, congressional committees and foreign governments to negative public perception, ethical concerns or financial considerations may result in new legislation, regulations or medical standards that could limit our ability to develop or commercialize any product candidates, obtain or maintain regulatory approval or otherwise achieve profitability. Based on these and other factors, health care providers and payors may decide that the benefits of these new therapies do not or will not outweigh their costs.

If we cannot obtain, or are delayed in obtaining, required regulatory approvals, we will be unable to commercialize, or will be delayed in commercializing, product candidates we may develop.

Any mRNA medicine we may develop and the activities associated with its development and commercialization are subject to comprehensive regulation by the FDA and comparable foreign regulators. To obtain required regulatory approvals to commercialize any product candidate, we and our strategic collaborators must demonstrate through extensive preclinical studies and clinical trials that our products are safe, pure and potent in humans, including the target population. Successful completion of clinical trials is a prerequisite to submitting a BLA to the FDA, a marketing authorization application (MAA) to the EMA, and similar marketing applications to comparable foreign regulators, for each product candidate and, consequently, the ultimate approval and commercial marketing of any product.

To date, we have only received regulatory authorizations for our COVID-19 vaccine, and our current or future product candidates may never obtain regulatory approval. We have limited experience in filing and supporting the necessary applications for marketing approvals and may need to rely on third parties to assist us in this process. Although we expect to submit BLAs for our mRNA product candidates in the United States, other jurisdictions may consider our mRNA product candidates to be new drugs, not biologics, and require different marketing approval applications. Preclinical studies and clinical trials conducted in one country may not be accepted by regulatory authorities elsewhere, and approval in one country does not guarantee regulatory approval in another.

Additionally, the process of obtaining marketing approvals, both in the United States and abroad, is expensive, time-consuming and uncertain, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in law or changes in regulatory review may delay the review of a submitted product application. The FDA and comparable foreign regulators have substantial discretion in the approval process and may refuse to accept any marketing approval application or may decide that our data are insufficient for marketing approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Additional delays or non-approval may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval.

The FDA and other foreign regulators review the CMC section of regulatory filings. Any aspects found unsatisfactory by regulatory agencies may result in delays in clinical trials and commercialization. In addition, the regulatory agencies conduct pre-approval inspections at the time of a BLA. Any negative findings by regulatory agencies and failure to comply with requirements may lead to delay in approval and failure to commercialize the product candidate.

If we experience delays in obtaining, or fail to obtain, regulatory approval of any product candidate we develop, the commercial prospects for such product candidate would be harmed, and our ability to generate revenues will be materially impaired.

Emergency authorizations that we have received for our COVID-19 vaccine for certain demographics, including pediatrics, are temporary and could be revoked.

We currently operate under an EUA provided by the FDA for our COVID-19 vaccines that are administered as a primary series in pediatric populations. The FDA may revoke this authorization for a variety of reasons, including if it determines that the underlying health emergency no longer exists or warrants such authorization. If new data emerges that shows the benefits of our vaccine do not continue to outweigh its risks, emergency authorizations that we have received for our COVID-19 vaccines from the FDA or other regulators could be revoked if the conditions for granting such authorizations no longer apply. If such authorizations were revoked, without receiving final approval to distribute our COVID-19 vaccines, our business would be adversely impacted.

54

Our products are, and any future products will be, subject to regulatory scrutiny.

Even if we obtain regulatory approval in a jurisdiction, we may remain subject to significant restrictions on the indicated uses or marketing of our product and ongoing requirements for potentially costly post-approval studies-such as those required under an accelerated approval by the FDA or other similar type of approval-or post-market surveillance. For example, the holder of an approved BLA must monitor and report adverse events and monitor and report any failure of a product to meet the specifications in the BLA, as well as submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process. Additionally, pharmacovigilance obligations under the regulatory regimes of the jurisdictions where our products are distributed require us to collect, process, analyze and monitor safety data and to identify and evaluate adverse reactions to our products as they are administered in those jurisdictions. If we or any of our partners assisting us in meeting these obligations cannot comply with relevant regulations, we may be subject to sanctions, increased costs and reputational harm, or our regulatory authorizations to distribute our vaccines in the relevant jurisdiction may be revoked or curtailed.

Furthermore, advertising and promotional materials must comply with FDA rules and regulations and are subject to FDA review, in addition to other potentially applicable federal and state laws. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates.

We are required by the FDA to conduct post-marketing studies for our COVID-19 vaccine (mRNA-1273) to further assess the risks of myocarditis and pericarditis following vaccination. Additionally, we have committed to conducting additional post-marketing safety studies, including conducting a study to evaluate pregnancy and infant outcomes after receipt of mRNA-1273 during pregnancy. We or others could identify previously unknown side effects, or known side effects could be observed as being more frequent or severe than in clinical trials or earlier post-marketing periods. If we, our contract manufacturers or other strategic collaborators fail to comply with applicable post-approval regulatory requirements, a regulatory agency may issue a warning letter asserting that we are in violation of the law, seek an injunction or impose civil or criminal penalties or monetary fines, suspend or withdraw regulatory approval or revoke a license, suspend any ongoing clinical trials, refuse to approve a pending BLA or supplements to a BLA submitted by us, seize or recall products or product candidates, or require field alerts to physicians, pharmacists and hospitals or refuse to allow us to enter into supply contracts. We could also be required to conduct additional nonclinical studies or clinical trials, or implement changes in labeling or to our manufacturing processes, specifications or facilities. Initiation of any government investigation or lawsuit, including class-action lawsuits, would require us to expend significant time and resources in response and would likely generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our COVID-19 vaccine, or any future approved products, and generate revenues.

Additionally, the FDA or other foreign regulators could require us to adopt Risk Evaluation and Mitigation Strategies (REMS) for any product to ensure that the benefits of treatment outweigh the risks for each potential patient, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients, a communication plan to health care practitioners, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. Furthermore, if we or others later identify undesirable side effects caused by any product that we develop, several potentially significant negative consequences could result, including the suspension or withdrawal of approvals and licenses, the addition of warning labels, changes to the way a product is administered, the requirement to conduct further clinical trials, lawsuits or increased liability for harm to patients and their children and reputational harm to us. Any of these events could prevent us from achieving or maintaining market acceptance of any products we develop and could have a material adverse impact on our business, financial condition, results of operations and prospects.

Risks related to the manufacturing of our commercial products and product candidates

Our mRNA products and product candidates are based on novel technologies and are complex and difficult to manufacture. We or our third-party manufacturers may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management or shipping for any of our products.

The manufacturing processes for our mRNA medicines are novel and complex. We and our collaborators have experienced and may continue to encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management or shipping, including delays as our supply chain expands and grows more complex. We could experience issues resulting from complexities of producing batches at larger scale, equipment failure, human error, choice and quality of raw materials and excipients, analytical testing technology and product instability. Further, mRNA medicines encapsulated in LNPs must be developed and manufactured under well-controlled conditions, or pharmacological activity can be adversely impacted.

In an effort to optimize product features, we have in the past and may in the future make changes to our product candidates in their manufacturing and stability formulation and conditions. This has in the past and may in the future result in our having to resupply
55

batches for preclinical or clinical activities when there is insufficient product stability during storage and insufficient supply. Insufficient stability or shelf life of our product candidates could materially delay our or our strategic collaborators’ ability to continue clinical trials or require us to begin a new clinical trial with a newly formulated drug product, due to the need to manufacture additional preclinical or clinical supply.

Our high rate of innovation causes a high degree of technology change that can negatively impact product comparability during and after clinical development. Furthermore, technology changes may drive the need for changes in, modification to, or the sourcing of new manufacturing infrastructure or may adversely affect third-party relationships.

In many cases, we may need to utilize multiple batches of drug substance and drug product to meet the supply requirement of a single preclinical study or clinical trial. Failure in our ability to scale up batch size or failure in any batch, which we have experienced in the past, may lead to a substantial delay in our clinical trials or in the commercialization of any approved product. For example, the changes we make as we continue developing new manufacturing processes for our drug substance and drug product may impact specification and stability of the drug product, and may lead to failure of batches, resulting in a substantial delay in delivery of commercial product or conduct of our clinical trials. Our mRNA product candidates may prove to have a stability profile that leads to a lower than desired shelf life of the final approved medicine. This poses risk in supply requirements, wasted stock and higher cost of goods.

We are dependent on a number of equipment providers who are also implementing novel technology. Further, we have developed our own custom manufacturing equipment for certain of our medicines. If we encounter unexpected performance issues with such equipment, we could encounter delays or interruptions to clinical and commercial supply. Due to the number of different programs, we may have cross contamination of product candidates inside of our factories, CROs, suppliers or in the clinic that affect the integrity of our product candidates.

As we scale the manufacturing output for commercial production and particular programs, we plan to continuously improve yield, purity and the pharmaceutical properties of our products and product candidates from IND-enabling studies through commercial launch, including shelf-life stability, and solubility properties of drug product and drug substance. Because of continuous improvement in manufacturing processes, we may switch processes for a particular program during development. However, after a change in process, more time will be required for pharmaceutical property testing, such as 6 or 12 month stability testing. That may require resupplying clinical material or making additional cGMP batches to keep up with clinical trial demand before such pharmaceutical property testing is completed.

We are utilizing a number of raw materials and excipients that have a single source of supply, are new to the pharmaceutical industry and are being employed in a novel manner. Some of these raw materials and excipients have not been scaled to a level to support commercial supply and could experience unexpected manufacturing or testing failures or supply shortages. Such issues with raw materials and excipients could cause delays or interruptions to clinical and commercial supply of our products or product candidates.

We have established several analytical assays and may have to establish several more to assess the quality of our mRNA product candidates. We may identify gaps in our analytical testing strategy that might prevent release of product or could require product withdrawal or recall. For example, we may discover new impurities that have an impact on product safety, efficacy or stability. This may lead to an inability to release mRNA product candidates until the manufacturing or testing process is rectified.

As we grow as a commercial company and our drug development pipeline increases and matures, the increased demand for clinical and commercial supplies from our facilities and third parties may impact our ability to operate. We rely on third-party service providers, all of whom have inherent risks in their operations.

We have limited experience at larger scale production necessary to support large-scale clinical trials and commercial sales. Completion of our trials and commercialization of our product candidates require access to, or development of, facilities to manufacture our vaccine candidates at sufficient yields and at commercial scale. We expect to continue to make significant investments in our manufacturing capacity and commercial network as we continue to expand our commercial launch efforts. We are building regional manufacturing capability globally and are subject to risks associated with building and operating in foreign jurisdictions.

To supplement our internal manufacturing infrastructure, we have entered into agreements for the production, as well as for commercial fill-finish manufacturing, of our products to supply markets globally. We may need to engage additional third parties in the future to meet our capacity needs. If we cannot enter into such arrangements on favorable terms, or at all, our ability to develop, manufacture and distribute our products would be adversely affected. Further, efforts to establish these capabilities may not meet initial expectations as to scheduling, scale-up, reproducibility, yield, purity, cost, potency or quality. If we are unable to institute
56

necessary controls related to product development, manufacturing and quality, we may encounter difficulties producing our products on the timelines and in the quantities set forth in our supply agreements or to meet potential future demand.

We currently utilize, and expect to continue to utilize, third parties to, among other things, manufacture raw materials, components, parts, and consumables and to perform quality testing. If the field of mRNA and other nucleic acid medicines continues to expand, we may encounter increasing competition for these materials and services. Demand for third-party manufacturing or testing facilities may grow at a faster rate than their existing capacity, which could disrupt our ability to find and retain third-party manufacturers capable of producing sufficient quantities of such raw materials, components, parts and consumables required to manufacture our mRNA product candidates. The use of service providers and suppliers could expose us to risks, including:
•termination or non-renewal of supply and service agreements in a manner or at a time that is costly or damaging to us;
•disruptions to the operations of these suppliers and service providers caused by conditions unrelated to our business or operations, including the bankruptcy of the supplier or service provider; and
•inspections of third-party facilities by regulatory authorities that could have a negative outcome and result in delays to or termination of their ability to supply our requirements.

Our reliance on third-party manufacturers may adversely affect our operations or result in unforeseen delays or other problems beyond our control. Because of contractual restraints and the limited number of third-party manufacturers with the expertise, required regulatory approvals and facilities to manufacture our bulk vaccines on a commercial scale, replacement of a manufacturer may be expensive and time-consuming and may cause interruptions in the production of our vaccine. Regulatory authorities may also require us to register our facilities or those of another supplier if we terminate an existing third-party manufacturer relationship, which could lead to delays or our inability to supply a particular market. A third-party manufacturer may also encounter difficulties in production, including:
•difficulties with production costs, scale up and yields;
•availability of raw materials and supplies;
•quality control and assurance;
•shortages of qualified personnel;
•compliance with strictly enforced regulations that vary in each country where products might be sold; and
•lack of capital funding.

Any delay or interruption could adversely affect our business, financial condition or results of operations.

We are subject to operational risks associated with the physical and digital infrastructure at our manufacturing facilities and those of our external service providers.

Our manufacturing facilities incorporate a significant level of automation of equipment with integration of several digital systems to improve efficiency of operations. The digitization of our facilities exposes us to the risk of process equipment malfunctions. These risks include potential system failures or shutdowns due to internal or external factors including, design issues, system compatibility or potential cybersecurity compromises, incidents or breaches. Upgrades or changes to our systems, infrastructure or the software that we implement, use, or upon which our business relies, may result in the introduction of new cybersecurity vulnerabilities and risks.

Our facilities and infrastructure or those of our contract manufacturers or other third-party providers may also be subject to attacks or acts of sabotage by outside actors, contractors or employees. Any disruption in our or our contract manufacturers’ manufacturing capabilities could cause delays in production capacity for our drug substances or products or a shutdown of facilities, could impose additional costs, cause us to fail to meet certain product volume or delivery timing obligations, or may require us to identify, qualify and establish an alternative manufacturing site, the occurrence of which could adversely affect our business, financial condition, results of operations, and prospects.

As we expand our development and commercial capacities, we have and expect that we will continue to establish additional manufacturing capabilities in the United States, as well as in other countries, such as Australia, Canada and the United Kingdom. This expansion may lead to regulatory delays or prove more costly than anticipated. If we fail to select suitable locations, complete construction in an efficient manner, engage effectively with local regulators, recruit the required personnel or manage our growth effectively, the development and production of products or our product candidates could be delayed or curtailed. We will require significant additional investments in our manufacturing processes as we expand our manufacturing infrastructure.

57

Our products and product candidates are sensitive to shipping and storage conditions, which, in some cases, requires cold-chain logistics and subjects them to risk of loss or damage.

Our products and product candidates are sensitive to temperature, storage and handling conditions, and we could lose medicines if the product or product intermediates are not stored or handled properly. Shelf life for our products and product candidates is variable, and they may expire prior to use. Cold-chain logistics are required for certain of our products and product candidates. If we or third-party distributors do not maintain effective cold-chain supply logistics, then we may experience returned or out of date products and product may be rendered unusable. This has led and could lead to additional manufacturing costs and delays in our ability to supply required quantities for clinical trials or commercial sale. In addition, the cost associated with such transportation services and the limited pool of vendors could cause supply disruptions.

We are subject to significant regulatory oversight regarding manufacturing our products and product candidates. Our manufacturing facilities or those of our third-party manufacturers or suppliers may not meet regulatory requirements. Failure to meet current Good Manufacturing Practice (cGMP) requirements could result in significant delays in any approval of and costs of our products.

The manufacturing of medicines for clinical trials or commercial sale is subject to extensive regulation, and components of such products must be manufactured in accordance with cGMP requirements, which are enforced, in the case of the FDA, in part through its facilities inspection program. The regulations govern manufacturing processes and procedures, including record keeping, and the implementation and operation of quality systems to control and assure the quality of products and materials used in clinical trials. Poor control of cGMP production processes can lead to product quality failures that can impact our ability to supply product, resulting in cost overruns and delays to clinical timelines, which could be extensive. Such production process issues include:
•critical deviations in the manufacturing process;
•facility and equipment failures;
•contamination of the product due to an ineffective quality control strategy;
•facility contamination as assessed by the facility and utility environmental monitoring program;
•raw material failures due to ineffective supplier qualification or regulatory compliance issues at critical suppliers;
•ineffective product stability;
•ineffective corrective actions or preventative actions taken to correct or avoid critical deviations due to our developing understanding of the manufacturing process as we scale; and
•failed or defective components or consumables.

Regulatory authorities typically require representative manufacturing site inspections to assess adequate compliance with cGMP and manufacturing controls. If we or one of our third-party manufacturing sites fails to provide sufficient quality assurance or control, the product approval to commercialize may not be granted. Inspections by regulatory authorities may occur at any time during the development or commercialization phase of products. The inspections may be product specific or facility specific for broader cGMP inspections, or as a follow up to market or development issues that the regulatory agency may identify. Deficient inspection outcomes may negatively impact the ability of our third-party manufacturers or suppliers to fulfill their supply obligations, impacting or delaying supply or delaying programs.

The manufacturing process for our products is subject to the FDA and foreign regulatory authority approval process. If we or our third-party manufacturers are unable to reliably produce products or product candidates to specifications acceptable to regulatory authorities, we or our strategic collaborators may not obtain or maintain the approvals needed to commercialize such products. Even if regulatory approval is obtained for any of our mRNA medicines, there is no assurance that either we or our CMOs will be able to manufacture the approved medicine to specifications acceptable to the FDA or other regulatory authorities. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates, impair commercialization efforts or increase our cost of goods, which, in turn, could have an adverse effect on our business, financial condition, results of operations and prospects.

In addition, we may not have direct control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. Our contract manufacturers supply or manufacture materials or products for other companies and their failure to meet applicable regulatory requirements may affect the regulatory status of their facilities. In addition, to the extent that we rely on foreign contract manufacturers, we are subject to additional risks, including the need to comply with import and export regulations.

The FDA, the EMA and other foreign regulatory authorities may require us to submit product samples of any lot of any approved product, together with the protocols showing the results of applicable tests, at any time. In some cases, regulators may prohibit us from distributing a lot or lots until it authorizes release. Deviations in the manufacturing process, including those affecting quality attributes and stability, may cause unacceptable changes in the product, resulting in lot failures or product recalls. Our third-party contract
58

manufacturers have experienced lot failures resulting in product recalls of our COVID-19 vaccine. Lot failures have caused, and lot failures or product recalls in the future with respect to product produced by either our own or our third-party manufacturers’ facilities could cause, us and our strategic collaborators to delay clinical trials or product launches, which could harm our business, financial condition, results of operations and prospects.

We and our manufacturing partners also may encounter problems hiring and retaining the experienced scientific, quality control and manufacturing personnel needed to operate our manufacturing processes and operations or those of our manufacturing partners, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. Additionally, we may not be able to control for or detect intentional sabotage or negligence by any employee or contractor.

Our INT product candidates are uniquely manufactured for each patient using a novel, complex manufacturing process and we may encounter difficulties in production.

We custom design and manufacture INTs that are unique and tailored specifically for each patient. Manufacturing unique lots of INTs is susceptible to product loss or failure due to issues with:
•logistics associated with the collection of a patient’s tumor, blood or other tissue sample;
•shipping such samples to a facility for genetic sequencing;
•next-generation sequencing of the tumor mRNA;
•identification of appropriate tumor-specific mutations;
•the use of a software program, including proprietary and open source components, which is hosted in the cloud and a part of our product candidate, to assist with the design of the patient-specific mRNA, which software must be maintained and secured;
•effective design of the patient-specific mRNA that encodes for the required neoantigens;
•batch specific manufacturing failures or issues that arise due to the uniqueness of each patient-specific batch;
•quality control testing failures;
•unexpected failures of batches placed on stability;
•shortages or quality control issues with single-use assemblies, consumables or critical parts sourced from third-party vendors that must be changed out for each patient-specific batch;
•significant costs associated with individualized manufacturing that may adversely affect our ability to continue development;
•successful and timely manufacture and release of the patient-specific batch;
•shipment issues encountered during transport of the batch to the patient site of care; and
•the ability to define a consistent safety profile at a given dose when each participant receives a unique therapy.

We have built and installed custom manufacturing equipment for INTs incorporated into a dedicated unit at our Norwood, Massachusetts facility. This equipment may not function as designed, resulting in deviations in the drug product produced, which could lead to increased batch failure and the inability to supply patients enrolled in a clinical trial. Additionally, as we continue our current Phase 3 INT trials, expand to additional tumor types and prepare for commercialization, we anticipate an increase in manufacturing demand for our INTs that will require ongoing investments. Some of the additional equipment that will be required will be custom-made for us, which will lead to long lead times and expedited procurement to meet our timelines. In addition, it may take longer than anticipated to scale up our facilities and to complete our Marlborough, Massachusetts facility (which we expect to dedicate to INTs) to meet commercial demand, if our INT product candidate is approved. This expansion and addition of new facilities could also lead to product comparability issues, which could further delay introduction of new capacity.

Because our INTs are manufactured for each individual patient, we are required to maintain a chain of identity with respect to each patient’s tissue sample, sequence data derived from such tissue sample, results of analysis of such patient’s genomic analysis and the custom manufactured product for each patient. Maintaining such a chain of identity is difficult and complex, and failure to do so has resulted and may in the future result in product mix up, adverse patient outcomes, loss of product or regulatory action, including withdrawal of any approved products from the market. Further, as our INTs are developed through clinical trials towards approval and commercialization, we expect that multiple aspects of the complicated collection, analysis, manufacture and delivery process will be modified in an effort to optimize processes and results. These changes may not achieve the intended objectives, and any of these changes could cause our INTs to perform differently than we expect, potentially affecting the results of clinical trials.

Risks related to our reliance on third parties

We are dependent on single-source suppliers for some of the components and materials used in, and the processes required to develop, our products and product candidates.

We depend on single-source suppliers for some of the components and materials used in, and manufacturing processes required to develop and commercialize, our products and product candidates. We cannot ensure that these suppliers will remain in business, have
59

sufficient capacity or supply to meet our needs or that they will not be purchased by one of our competitors or another company that will cease working with us. Our use of single-source suppliers exposes us to several risks, including disruptions in supply, price increases, late deliveries or business interruptions.

There are, in general, few alternative sources of supply for substitute components. If we have to switch suppliers, the manufacture and delivery of our products or product candidates could be interrupted for an extended period. Establishing additional or replacement suppliers for any of the components or processes used in our products or product candidates, if required, may not be accomplished quickly, if at all. Any replacement supplier (or us, if we produced directly) would need to be qualified and may require additional regulatory authority approval, resulting in further delay. Any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand for our products or product candidates. Additionally, as part of the FDA’s approval of our product candidates, the FDA will review the manufacturing processes and facilities of our single-source suppliers.

We have entered into, and in the future may enter into, strategic alliances with third parties for the development and commercialization of products and product candidates. If these strategic alliances are not successful, our business could be adversely affected.

We have entered into strategic alliances with collaborators that have provided, and may in the future provide, funding, intellectual property licenses and other resources for developing, manufacturing and commercializing our product candidates. Additionally, we have entered into, and expect to enter into future, strategic alliances where we agree to provide funding, intellectual property licenses and other resources to third parties. Our existing and any future strategic alliances may pose a number of risks, including:
•strategic collaborators may not perform their obligations as expected;
•strategic collaborators may not pursue development and commercialization of any products that achieve regulatory approval or may elect not to continue or renew development or commercialization of programs based on clinical trial results, changes in the strategic collaborators’ focus or available funding or external factors that divert resources or create competing priorities;
•strategic collaborators may delay clinical trials, provide insufficient funding or resources for clinical trials (whether as a result of a business decision or necessitated by financial difficulties of such collaborator), stop a clinical trial, abandon a product candidate or repeat or conduct new clinical trials;
•products or product candidates developed in strategic alliances with us may be viewed by our collaborators as competitive with their own products or product candidates, which may cause them to cease to devote resources to development or commercialization;
•a strategic collaborator with marketing and distribution rights to one or more of our products may commit insufficient resources to the marketing and distribution of any such product;
•disagreements with strategic collaborators, including over proprietary rights, contract interpretation or the course of development of any product candidates, may cause delays or termination of the research, development or commercialization of such product candidates, lead to additional responsibilities for us with respect to such product candidates or result in litigation or arbitration, any of which would be time-consuming and expensive;
•strategic collaborators may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our IP or proprietary information;
•disputes may arise with respect to the ownership of IP developed pursuant to our strategic alliances;
•strategic collaborators may infringe the IP rights of third parties, exposing us to potential litigation and liability;
•future relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business;
•any equity investments we make in collaborators could decrease in value or become worthless; and
•our international operations through any future collaborations, acquisitions or joint ventures may expose us to certain operating, legal and other risks not encountered in the United States.

Our strategic collaborators generally may materially amend or terminate their agreements with us, which has happened in the past. If any collaboration agreement is terminated, we may not receive anticipated future research or development funding or milestone, earn-out royalty, profit share or other contingent payments and the research or development of our product candidates may be delayed or discontinued. It may also be difficult to attract new strategic collaborators to continue development or commercialization of the applicable product candidate, and our reputation could be adversely affected. All the risks relating to product development, regulatory approval and commercialization described elsewhere in these Risk Factors apply to our strategic collaboration activities.

We may seek to establish additional strategic alliances and, if we are unable to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans. Certain of our strategic alliance agreements may restrict our ability to develop certain products.

60

Our development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. We may collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of some of our product candidates, and we face significant competition in seeking appropriate strategic collaborators. Our ability to establish additional strategic alliances will depend, among other things, on our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed strategic alliance and the proposed collaborator’s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to trial participants, the potential of competing drugs, the existence of uncertainty with respect to our or the proposed collaborator’s ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally.

We are also restricted under some of our existing strategic alliance agreements from entering into agreements on certain terms with potential strategic collaborators to pursue other targets on our own. These restrictions on working with targets, polypeptides, routes of administration and fields could limit our ability to enter into strategic collaborations with other collaborators or to pursue certain potentially valuable product candidates.

Strategic alliances are complex and time-consuming to negotiate and document. If we cannot enter into new strategic alliances on a timely basis, on favorable terms or at all, we may need to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense.

We rely on and expect to continue to rely on third parties to conduct aspects of our research, preclinical studies, protocol development and clinical trials for our product candidates. If these third parties do not perform satisfactorily, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates.

We rely on third parties such as CROs to help manage certain preclinical work and our clinical trials, and on medical institutions, clinical investigators and CROs to assist in the design and review of, and to conduct, our clinical trials, including enrolling qualified patients. In addition, we engage third-party contractors and collaborators to support numerous other research, commercial and administrative activities, which reduces our control over these activities but does not relieve us of our responsibilities, such as ensuring that each of our clinical trials is conducted in accordance with its general investigational plan and protocols. Moreover, the FDA requires us to comply with GLPs and good clinical practices for conducting, recording and reporting the results of preclinical studies and clinical trials to assure that data and reported results are credible and accurate and that in the case of clinical trials the rights, integrity and confidentiality of trial participants are protected. Such standards will evolve and subject us and third parties to new or changing requirements.

If third parties do not successfully carry out their contractual duties or meet expected deadlines, we may need to replace them, which could cause a delay of the affected clinical trial, drug development program or applicable activity. If clinical trials are not conducted in accordance with our contractual expectations or regulatory requirements, action by regulatory authorities may significantly and adversely affect the conduct or progress of such trials or even require a clinical trial to be redone. Accordingly, our efforts to obtain regulatory approvals for and commercialize our drug candidates could be delayed. In addition, failure of any third-party contractor to conduct activities in accordance with our expectations could adversely affect the relevant research, development, commercial or administrative activity. Failure of any third-party contractor to timely provide access to our data in a format that is acceptable to us may result in delays or impediments to our regulatory submissions or other development activities.

Risks related to our intellectual property

We may be unable to obtain and enforce patent protection for our discoveries and the intellectual property rights therein, or protect the confidentiality of our trade secrets.

Our success depends, in part, on our ability to protect proprietary methods and technologies that we develop under the patent and other IP laws of the United States and other countries, so that we can prevent others from unlawfully using our inventions and proprietary information. Because certain U.S. patent applications are confidential until the patents issue, third parties may have filed patent applications for technology covered by our pending patent applications without our being aware of those applications, and our patent applications may not have priority over those applications. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, if at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or
61

pending patent applications or that we were the first to file for patent protection of such inventions. We therefore may be unable to secure desired patent rights, thereby losing exclusivity. In the past, we have obtained licenses under third-party patents to market our products or conduct our research and development or other activities, and we may do so in the future if necessary. If licenses are not available to us on favorable terms, we may not be able to market the affected products or conduct the desired activities.

The process of obtaining and enforcing patent protection is expensive and time-consuming and our pending patent applications may not result in issued patents. Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent applications may fail to result in valid enforceable patents, or our patent protection could be reduced or eliminated, for non-compliance with these requirements. If we or our strategic collaborators fail to file and prosecute all necessary and desirable patent applications at a reasonable cost and in a timely manner, our business may be adversely affected.

Despite our and our strategic collaborators’ efforts to protect our proprietary rights, unauthorized parties may obtain and use information that we regard as proprietary. While issued patents are presumed valid, they may not survive a validity challenge and could be held unenforceable. Any patents we have obtained, or obtain in the future, may be challenged, invalidated, adjudged unenforceable or circumvented by parties seeking to design around our IP. Also, third parties or the USPTO may commence patent office proceedings involving our patents or patent applications. Any challenge to, finding of unenforceability or invalidation, or circumvention of, our patents or patent applications, would be costly, would require significant time and attention of our management, could reduce or eliminate royalty payments to us from third-party licensors and could have a material adverse impact on our business.

The standards that the USPTO and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. Similarly, the ultimate degree of protection that will be afforded to biotechnology inventions, including ours, in the United States and foreign countries, remains uncertain and is dependent upon the scope of the protection decided upon by patent offices, courts and lawmakers. For example, the America Invents Act included a number of changes to the patent laws of the United States. If any of the enacted changes prevent us from adequately protecting our discoveries, including our ability to pursue infringers of our patents to obtain injunctive relief or for substantial damages, our business could be adversely affected. One major provision of the America Invents Act changed U.S. patent practice from a first-to-invent to a first-to-file system. If we fail to file an invention before a competitor files on the same invention, we no longer have the ability to provide proof that we were in possession of the invention prior to the competitor’s filing date, and thus would not be able to obtain patent protection for our invention. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. In certain countries, for example, methods for the medical treatment of humans are not patentable.

Accordingly, we do not know the degree of future protection for our proprietary rights or the breadth of claims that will be allowed in any patents issued to us or to others. We also rely to a certain extent on trade secrets, know-how and technology, which are not protected by patents, to maintain our competitive position. We also rely on non-disclosure agreements and invention assignment agreements entered into with our employees, consultants and third parties. If any trade secret, know-how or other technology not protected by a patent were to be disclosed to or independently developed by a competitor, our business and financial condition could be materially adversely affected.

Failure to obtain and maintain all available regulatory exclusivities and broad patent scope and to maximize patent term restoration or extension on patents covering our products may lead to loss of exclusivity and early biosimilar entry resulting in a loss of market share or revenue.

In addition, we may choose not to enforce our IP rights in certain circumstances or for certain periods of time. For example, in March 2022, we announced that we will not enforce our patents for COVID-19 vaccines against companies manufacturing in or for the Gavi COVAX Advance Market Commitment countries, provided that the manufactured vaccines are solely for use in the AMC 92 countries. In addition, we are willing to license our IP for COVID-19 vaccines to manufacturers, but we may never enter into such licenses of our IP, and our business may be otherwise adversely impacted if we are unable to enforce our IP.

Uncertainty over IP in the pharmaceutical and biotechnology industry has been the source of litigation and other disputes, which is inherently costly and unpredictable and can have adverse financial and freedom-to-operate consequences.

mRNA medicines are a relatively new scientific field and, as the field continues to mature, patent applications are being processed by national patent offices globally. There is uncertainty about which patents will issue, and, if they do, as to when, to whom and with what claims. Litigation is ongoing over the underlying technology to mRNA medicines between many mRNA market participants. It is likely that there will continue to be significant litigation and patent office proceedings in various patent offices relating to patent rights in the mRNA field.

62

We have issued patents and pending patent applications in the United States and in key markets around the world that claim many different methods, compositions and processes relating to the discovery, development, manufacture and commercialization of mRNA medicines and our delivery technology, including LNPs. Oppositions and inter partes review petitions have been filed against some of our patents, and we expect that further proceedings will be filed in the European Patent Office (EPO), USPTO and elsewhere relating to patents and patent applications in our portfolio. In many cases, the possibility of appeal exists for any party, and it may be years before final, unappealable rulings are made with respect to these patents in certain jurisdictions. The timing and outcome of these and other proceedings is uncertain and may adversely affect our business if we are not successful in defending the patentability and scope of our pending and issued patent claims. We cannot be certain that any patent will survive or that the claims will remain in the current form. Even if our rights are not directly challenged, disputes could lead to the weakening of our IP rights.

In certain instances, we have instituted and may in the future institute inter partes review proceedings against issued U.S. patents and opposition proceedings against European patents owned by third parties in the field of mRNA medicines. We have a number of these proceedings ongoing against third-party patents. If we are unsuccessful in narrowing or invalidating such third-party patents, those third parties may attempt to assert those patents against our products. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our products or product candidates may be subject to claims of infringement of the patent rights of third parties.

We have invested billions of dollars in creating our patented mRNA platform, which is integral to the development of our mRNA medicines, and we are involved in various intellectual property litigation as described under Part I, Item 3, “Legal Proceedings.” We expect to expend substantial financial and managerial resources in connection with these legal proceedings, and the ultimate outcome of each proceeding is uncertain.

We are, and may in the future become, involved in patent litigation or other proceedings related to a determination of rights, we could incur substantial costs and expenses, substantial liability for damages or be required to stop our product development and commercialization efforts.

There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our products and product candidates, and third parties may assert that we are employing their proprietary technology without authorization. In addition, third parties may obtain patents in the future and claim that our technologies infringe upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our products or product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may obtain injunctive or other equitable relief, which could effectively block our ability to commercialize such product unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product or product candidate unless we obtained a license or until such patent expires.

Defense of infringement and other claims, regardless of their merit, would involve substantial litigation expense and divert employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may not be made available on commercially favorable terms, if at all, or may require substantial time and expense.

In addition, any such licenses are likely to be non-exclusive and, therefore, our competitors may have access to the same technology licensed to us. If we fail to obtain a required license and are unable to design around a patent, we may be unable to effectively market some of our technology and products, which could limit our ability to generate revenues or achieve profitability, which could jeopardize our ability to sustain our operations. Moreover, we expect that a number of our collaborations will provide that royalties payable to us for licenses to our IP may be offset by amounts paid by our collaborators to third parties who have competing or superior IP positions in the relevant fields, which could result in significant reductions in our revenues from products developed through collaborations.

In addition, in connection with certain license and strategic alliance agreements, we have agreed to indemnify certain third parties for certain costs incurred in connection with litigation relating to IP rights or the subject matter of the agreements. The cost to us of any litigation or other proceeding relating to IP rights, even if resolved in our favor, could be substantial, and litigation would divert our management’s efforts. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of any litigation could delay our research, development and commercialization efforts and limit our ability to continue our operations.

63

If third-party owners of any patent rights that we license do not properly or successfully obtain, maintain or enforce the patents underlying such licenses, our competitive position and business prospects may be harmed.

We may become a party to licenses that give us rights to third-party IP that is necessary or useful for our business. In such a case, our success may depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed IP. Our licensors may not successfully prosecute the patent applications we license. Even if patents issue in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents or may pursue such litigation less aggressively than we would. Without protection for the IP we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects. In addition, we sublicense our rights under various third-party licenses to our strategic collaborators. Any impairment of these sublicensed rights could result in reduced revenues under our strategic alliance agreements or result in termination of an agreement by one or more of our strategic collaborators.

If we fail to comply with our obligations in the agreements under which we license IP rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.

We license IP, which involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. We are a party to certain IP license agreements and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license and may be subject to additional liabilities.

In certain cases, we control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our strategic collaborators. Disputes may arise regarding IP subject to a licensing agreement, including:
•the scope of rights granted under the license agreement and other interpretation-related issues;
•whether our technology and processes that are not subject to the licensing agreement infringe on IP of the licensor;
•the sublicensing of patent and other rights under our collaborative development relationships;
•our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
•the ownership of inventions and know-how resulting from the joint creation or use of IP by our licensors and us and our strategic collaborators; and
•the priority of invention of patented technology.

If disputes over IP that we have licensed prevent or impair our ability to maintain our current licensing arrangements on favorable terms, we may be unable to successfully develop and commercialize the affected product candidates. We are generally also subject to all of the same risks with respect to protection of IP that we license as we are for IP that we own. If we or our licensors fail to adequately protect this IP, our ability to commercialize products could suffer.

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.

We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. From time to time, we are subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed IP, including trade secrets or other proprietary information, of third parties, including our employees’ former employers. Litigation may be necessary to defend against these claims. If we fail to defend such claims, in addition to paying monetary damages, we may lose valuable IP rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

We may be subject to claims challenging the inventorship or ownership of our patents and other IP.

We may be and have been subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other IP. Ownership disputes may arise, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable IP
64

rights, including exclusive ownership of, or right to use, valuable IP. Such an outcome could have a material adverse impact on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distract management and other employees, and could impact or patenting strategy.

Changes in U.S. patent and regulatory law could impair our ability to protect our products.

Our success is heavily dependent on IP, particularly patents. U.S. patent law continues to evolve, and certain U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. These rulings have increased uncertainty with regard to our ability to obtain patents in the future, as well as with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.

We may be unable to protect our IP rights throughout the world.

Filing, prosecuting and defending patents in every country would be prohibitively expensive, and our foreign IP rights can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect IP rights to the same extent as U.S. federal and state laws. Consequently, we may be unable to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies to develop their own products in jurisdictions where we have not obtained patent protection or may export infringing products to territories where we have patent protection, but enforcement is not as strong as in the United States.

Many companies have encountered significant problems in protecting and defending IP rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other IP protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our IP rights around the world may be inadequate to obtain a significant commercial advantage from the IP that we develop or license.

Additionally, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. For example, during the COVID-19 pandemic, certain countries threatened steps to facilitate compulsory licenses to permit the distribution of a COVID-19 vaccine in those countries. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the relevant patent rights. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.

Our reliance on government funding and collaboration from governmental and quasi-governmental entities for certain of our programs adds uncertainty to our research and development efforts with respect to those programs and may impose requirements related to intellectual property rights and requirements that increase the costs of development, commercialization and production of any programs developed under those government-funded programs.

Contracts and grants funded by the U.S. government and its agencies, including our agreements funded by BARDA and DARPA and our collaboration with NIAID, include provisions that reflect the government’s substantial rights and remedies, many of which are not typically found in commercial contracts, including powers of the government to:
•terminate agreements, in whole or in part, for any reason or no reason;
•reduce or modify the government’s obligations under such agreements without the consent of the other party;
•claim rights, including IP rights, in products and data developed under such agreements;
•audit contract-related costs and fees, including allocated indirect costs;
•suspend the contractor or grantee from receiving new contracts pending resolution of alleged violations of procurement laws or regulations;
•impose U.S. manufacturing requirements for products that embody inventions conceived or first reduced to practice under such agreements;
•suspend or debar the contractor or grantee from doing future business with the government;
65

•control and potentially prohibit the export of products;
•pursue criminal or civil remedies under the False Claims Act, False Statements Act and similar remedy provisions specific to government agreements; and
•limit the government’s financial liability to amounts appropriated by the U.S. Congress on a fiscal-year basis, thereby leaving some uncertainty about the future availability of funding for a program even after it has been funded for an initial period.

We may not have the right to prohibit the U.S. government from using certain technologies developed by us and we may be unable to prohibit other companies, including our competitors, from using those technologies in providing products and services to the U.S. government. The U.S. government generally takes the position that it has the right to royalty-free use of technologies that are developed under U.S. government contracts.

In addition, government contracts and grants, and subcontracts and subawards awarded in the performance of those contracts and grants, normally contain additional requirements that may increase our costs of doing business, reduce our profits and expose us to liability for failure to comply with these terms and conditions. These requirements include, for example:
•specialized accounting systems unique to government contracts and grants;
•mandatory financial audits and potential liability for price adjustments or recoupment of government funds after such funds have been spent;
•public disclosures of certain contract and grant information, which may enable competitors to gain insights into our research program; and
•mandatory socioeconomic compliance requirements, including labor standards, non-discrimination, and affirmative action programs and environmental compliance requirements.

Further, under these agreements we are subject to the obligations to and the rights of the U.S. government set forth in the Bayh-Dole Act of 1980 (Bayh-Dole Act). As a result, the U.S. government may have rights in certain inventions developed under these government-funded programs, including a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive or nonexclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations, also referred to as “march-in rights.” Any exercise of the march-in rights by the U.S. government could harm our competitive position, business, financial condition, results of operations and prospects. In December 2023, the Biden administration released a proposed framework specifying for the first time that price can be a factor in considering whether an invention is sufficiently available to the public. The proposed framework could potentially enable march-in rights to be used as a tool to regulate drug pricing. The potential inclusion of price as a factor in a march-in determination is expected to draw extensive criticism and challenge, and the ultimate impact is currently unknown. If the U.S. government exercises such march-in rights, we may receive compensation that is deemed reasonable by the U.S. government in its sole discretion, which may be less than what we might be able to obtain in the open market. IP generated under a government-funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources.

As an organization, we are relatively new to government contracting and the related regulatory compliance obligations. If we fail to maintain compliance with those obligations, we may be subject to potential liability and to termination of our contracts.

Risks related to our financial condition and results of operations

We incurred net losses in 2023 and we may incur losses again in the future; we have a limited history of recognizing revenue from product sales and may be unable to achieve long-term sustainable profitability.

We incurred a net loss of $4.7 billion in 2023, and other than in 2021 and 2022, we have incurred net losses in each year since our inception. Currently, our COVID-19 vaccine is our only commercial product. While preparations are underway for additional potential product launches, including our anticipated RSV launch in 2024, the ultimate occurrence and timing of these launches is uncertain. Our ability to generate revenue and maintain profitability depends on our ability to successfully develop and obtain the regulatory approvals necessary to commercialize our products.

We have incurred, and expect to continue to incur, significant costs associated with commercializing our COVID-19 vaccine and our clinical and preclinical development activities. In addition, we incurred significant costs in 2023 as we resized our manufacturing capacity. We may be unable to achieve long-term sustainable profitability and may need additional funding to continue operations.

We anticipate that our expenses may increase substantially if and as we:
66

•expand our research or development of our programs in preclinical development;
•initiate additional preclinical, clinical or other studies for our product candidates, particularly large pivotal trials;
•continue to invest in our platform to conduct research to identify novel mRNA technology improvements;
•change or add to internal manufacturing capabilities, or additional manufacturers or suppliers;
•add additional infrastructure to our quality control and quality assurance groups to support our operations as we progress our product candidates toward commercialization;
•attract and retain skilled personnel;
•create additional infrastructure to support our product development and commercialization efforts, including new sites globally;
•seek marketing approvals and reimbursement for our product candidates;
•build out a sales, marketing and distribution infrastructure to commercialize any products;
•acquire or in-license other product candidates and technologies;
•make milestone or other payments under any in-license agreements; and
•experience any delays or encounter issues with any of the above.

Our quarterly and annual operating results may fluctuate. As a result, we may fail to meet or exceed the expectations of research analysts or investors, which could cause our stock price to decline and negatively impact our financing or funding ability, as well as our ability to exist as a standalone company.

Our financial condition and operating results may fluctuate from quarter-to-quarter and year-to-year due to many factors, many of which are beyond our control. As such, a period-to-period comparison of our operating results may not be predictive of our future performance. In any particular quarter, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline. Our stock price could be affected by events not necessarily tied to our actual operating results, including recommendations by securities analysts, the timing of certain public disclosures by us, our collaborators or our competitors and our ability to accurately report our financial results in a timely manner. Other factors relating to our business that may contribute to these fluctuations include those described in these Risk Factors and elsewhere in this Annual Report on Form 10-K.

The investment of our cash, cash equivalents and investments is subject to risks which may cause losses and affect the liquidity of these investments.

As of December 31, 2023, we had approximately $13.3 billion in cash, cash equivalents and investments, which are subject to general credit, liquidity, market, inflation and interest rate risks. We may realize losses in the fair value of these investments. In addition, if our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. These and other market risks associated with our investment portfolio may adversely affect our results of operations, liquidity and financial condition.

Risks related to our business and operations

We may encounter difficulties in managing the development and expansion of our company.

As of December 31, 2023, we had approximately 5,600 full-time employees in 19 countries, and we may increase our number of employees and the scope of our operations. To manage this global expansion, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and recruit and train qualified personnel. Our management may need to divert significant attention away from our day-to-day activities to manage these development activities.

Successfully developing products for and fully understanding the regulatory and manufacturing pathways for the many therapeutic areas and diseases we seek to address requires significant depth of talent, resources and corporate processes to allow simultaneous execution across multiple areas. We may be unable to effectively manage this simultaneous execution and expansion of our operations or recruit and train qualified personnel, which could cause weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of our operations, including the expansion of our Norwood and Marlborough campuses in Massachusetts and the construction of manufacturing facilities overseas, may lead to significant costs and may divert financial resources from other projects, such as the development of our product candidates. If our management is unable to effectively manage our development and expansion, our financial performance and ability to commercialize our products may be affected negatively, and we may not be able to implement our business strategy.

67

We are subject to the risks of doing business outside of the United States.

Our business is subject to risks associated with doing business outside of the United States, and we have limited experience operating internationally. We are not permitted to market or promote any of our product candidates before we receive regulatory approval or other authorization from an applicable authority, and we may never receive such approval. To obtain regulatory approval in various jurisdictions, we must comply with numerous regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, manufacturing, commercial sales, pricing and distribution of our product candidates, and we may fail to obtain approval. We have rapidly expanded our global operations, establishing commercial subsidiaries and entering into arrangements to support the worldwide manufacture and distribution of our products, which is a complex task. For example, we are building regional manufacturing facilities and investing in research and development in several countries. Our business may be adversely affected by many factors associated with our expanding global business, including:
•efforts to develop an international commercial sales, marketing and supply chain and distribution organization, including efforts to mitigate longer accounts receivable collection times, longer lead times for shipping and potential language barriers;
•our customers’ ability to obtain reimbursement for our products in foreign markets;
•our inability to directly control commercial activities because we rely on third parties;
•different medical practices and customs in foreign countries affecting acceptance in the marketplace;
•changes in a specific country’s or region’s political and cultural climate or economic condition;
•an increased legal and compliance burden to establish, maintain and operate legal entities in foreign countries;
•the burden of complying with complex and changing foreign regulatory, tax, accounting, reporting and legal requirements, including the European General Data Protection Regulation 2016/679 (GDPR);
•the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute, and the difficulty of effective enforcement of contractual provisions in local jurisdictions;
•inadequate IP protection in foreign countries and the existence of potentially relevant third-party IP rights;
•trade-protection measures including trade restrictions, import or export licensing requirements such as Export Administration Regulations promulgated by the U.S. Department of Commerce and fines, penalties, or suspension or revocation of export privileges, the imposition of government controls and changes in tariffs;
•the effects of applicable foreign tax structures and potentially adverse tax consequences; and
•significant adverse changes in foreign currency exchange rates.

We are also subject to extensive federal, state and foreign anti-bribery regulations, including the U.S. Foreign Corrupt Practices Act (FCPA), the UK Bribery Act and similar laws in other countries. Compliance with the FCPA is expensive and difficult, particularly in countries where corruption is a recognized problem. Additionally, the FCPA presents particular challenges to the pharmaceutical industry because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. Various laws, regulations and executive orders also restrict the use and dissemination outside the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. As we expand our presence outside the United States, we will need to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing or selling certain products and product candidates outside the United States, which could limit our growth potential and increase our development costs.

We cannot guarantee that we, or our employees, consultants or third-party contractors are or will be in compliance with all federal, state and foreign regulations regarding bribery and corruption. Moreover, our strategic collaborators and third-party contractors outside the United States may have inadequate compliance programs or fail to respect the laws and guidance of the territories where they operate, which may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA’s accounting provisions. Even if we are not determined to have violated these laws, government investigations typically require the expenditure of significant resources and generate negative publicity, which could adversely affect our business, financial condition and results of operations.

68

Our failure to upgrade and maintain our enterprise resource planning (ERP) system could adversely impact our business and results of operations.

We are upgrading our global ERP system to support our continued growth as a commercial operation. We have incurred substantial costs in implementing our ERP system, and any disruptions or difficulties in implementing or using our system could adversely affect our controls, resulting in harm to our business, including our ability to forecast or make sales and collect our receivables. Significant delays in documenting, reviewing and testing our internal controls could cause our non-compliance with our SEC reporting obligations related to our management’s assessment of our internal control over financial reporting. Moreover, such disruptions or difficulties could result in unanticipated costs and diversion of management’s attention.

Our success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel.

Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends on our ability to attract and retain highly qualified managerial, scientific, technical, quality-control, manufacturing, medical, regulatory and commercial personnel. The turnover rate in our industry is high and we compete with other companies, as well as academic institutions, for individuals with certain skill sets. Failure to attract and retain personnel could result in delays in production or difficulties in maintaining compliance with regulatory requirements. In addition, adverse publicity, including as the result of failure to succeed in clinical trials or obtain marketing approvals, may make it difficult to recruit and retain qualified personnel.

We are highly dependent on members of our management and scientific teams. Each of our executive officers and employees, including key scientists and clinicians, are employed “at will,” meaning we or they may terminate the employment relationship at any time. The loss of any of these persons’ services may adversely impact the achievement of our research, development, financing and commercialization objectives. We do not have “key person” insurance on any of our employees. Several of our key employees, including executives, have been with us for a long period of time, and have valuable, fully vested stock options or other long-term equity incentives. We may not be able to retain these employees due to the competitive environment in the biotechnology industry, particularly in Cambridge, Massachusetts.

In addition, we rely on consultants, contractors and advisors, including scientific and clinical advisors, to help us formulate our research and development, regulatory approval, manufacturing and commercialization strategies. These individuals may be employed by other employers and may have commitments under contracts with others that limit their availability to us. The loss of the services of these individuals might impede the achievement of our research, development, regulatory approval, manufacturing and commercialization objectives.

If we cannot maintain our corporate culture, we could lose the innovation, teamwork and passion that we believe contribute to our success.

We invest substantial time and resources in building and maintaining our culture and developing our personnel; however, as we continue to expand, it may be increasingly difficult to maintain our culture. The dramatic growth of our workforce, coupled with recent shifts in workplace and workstyle, increase the risk of our ability to maintain culture. Any failure to preserve our culture could negatively affect our future success, including our ability to retain and recruit personnel and to effectively pursue our strategic plans.

Our internal computer systems and physical premises, or those of third parties with which we share sensitive data or information, may fail or suffer security breaches, including from cybersecurity incidents, which could materially disrupt our product development programs and manufacturing operations.

Our internal computer systems and infrastructure and those of our strategic collaborators, vendors, contractors, consultants or regulatory authorities with whom we share confidential, protected or sensitive data or information, or upon which our business relies, are vulnerable to damage from computer viruses, unauthorized access, misuse, natural disasters, terrorism, cybersecurity threats, war and telecommunication and electrical failures, as well as security compromises or breaches, which may compromise our systems, infrastructure, data or that of those with whom we share such data or information or upon which our business relies, or lead to data compromise, misuse, misappropriation or leakage. We have experienced, and may experience additional, cyber-attacks on our information technology systems and infrastructure by threat actors of all types (including nation states, criminal enterprises, individual actors or advanced persistent threat groups). In addition, we may experience intrusions on our physical premises by these threat actors. In addition to extracting sensitive information, such attacks could include the deployment of harmful malware, ransomware, digital extortion, business email compromise and denial-of-service attacks, social engineering and other means to affect server reliability and threaten the confidentiality, integrity and availability of information, systems or infrastructure. If any such cyber-attack or physical intrusion against us or those with whom we share confidential, protected or sensitive data or information, or upon which our business
69

relies, were to result in a loss of or damage to our data, systems or infrastructure, or interrupt our operations, such as a material disruption of our development programs or our manufacturing operations, or due to a loss of any of our proprietary or confidential information, it would have a material adverse effect on us. For example, the loss of clinical trial data could delay our regulatory approval efforts and increase our costs to recover or reproduce the data. In addition, because we run multiple clinical trials in parallel, any breach or compromise of our computer systems or infrastructure or physical premises may result in a loss of data or compromised data integrity across multiple programs in many stages of development. While we seek to take steps to address cybersecurity risks, our efforts may not wholly mitigate such risks. Further, our cybersecurity liability insurance may not cover all damages we would sustain based on any breach or compromise of our computer security protocols or cybersecurity attack.

Any data breach, security incident or compromise of confidential, protected or personal information, including any clinical trial participant personal data, may also subject us to civil fines and penalties, litigation, regulatory investigations or enforcement actions, or claims for damages under the GDPR and UK GDPR and relevant member state law in the EU, other foreign laws, and the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), and other relevant state and federal privacy laws in the United States including the California Consumer Privacy Act, as amended by the California Privacy Rights Act (the CCPA). We have from time to time received information that companies working on vaccine research and development may be a particular focus for those planning cyberattacks, including by nation states and affiliated cyber actors. To the extent that any disruption or security compromise incident or breach were to result in a loss of, or damage to, our data, systems, infrastructure or applications, or inappropriate use or disclosure of confidential or proprietary information, including information related to the research and manufacturing of our products, we could incur liability, our competitive and reputational position could be harmed and the further development and commercialization of our product candidates could be delayed.

We may use our financial and human capital to pursue a particular research program or product candidate and fail to capitalize on programs that may be more profitable or for which there is a greater likelihood of success.

We pursue and fund the development of selected research programs or product candidates and may choose to forego or delay pursuit of other opportunities that could later prove to have greater commercial potential. For example, we have focused a significant amount of resources on our COVID-19 vaccines and other respiratory programs, for which preparations are underway for multiple vaccine launches. Additionally, we are increasing our investments in our INT programs. Our resource allocation decisions, or our contractual commitments to provide resources to our strategic collaborators, may cause us to fail to capitalize on certain commercial products or profitable market opportunities. Our spending on research and development programs for product candidates may not yield commercially viable products. We may also seek to enter into strategic collaborations or financing arrangements pursuant to which we may relinquish valuable rights to product candidates, including the rights to a portion of future revenues, through a strategic alliance, licensing or other royalty arrangements in cases where it would have been more advantageous for us to retain sole development and commercialization rights. Additionally, we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a strategic alliance.

If we are not successful in discovering, developing and commercializing additional products, our ability to expand our business and achieve our strategic objectives would be impaired.

A key element of our strategy is to discover, develop and commercialize products beyond our current portfolio to treat various conditions and in a variety of therapeutic areas. We intend to do so by investing in our drug discovery efforts, exploring potential strategic alliances for the development of new products and in-licensing technologies. Identifying new product candidates requires substantial technical, financial and human resources. We may fail to identify promising candidates or to successfully develop and commercialize products for many reasons, which would impair our potential for growth.

Our business could be harmed if we suffer damage to our reputation, including as a result of a product recall.

The FDA or foreign regulators could require the recall of our products. The FDA has authority to recall a biologic product if it finds that a batch, lot or other quantity of the biologic product presents an imminent or substantial hazard to the public health. In addition, foreign governmental bodies may require the recall of any products in the event of material deficiencies or defects in design or manufacture. Manufacturers may independently recall a product if a material deficiency in a product is found. A government-mandated or voluntary recall by us or our strategic collaborators could occur as a result of manufacturing errors, design or labeling defects or other deficiencies and issues, as occurred with the recall in 2021 of certain batches of our COVID-19 vaccine shipped to Japan that were found to contain foreign particulate. Recalls of any of our products would divert managerial and financial resources and adversely affect our financial condition and results of operations. A recall announcement could harm our reputation and negatively affect our sales. Our reputation could be further impacted by public discourse regarding our business and perception of our business strategy.

70

Product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of our products.

We are exposed to product liability risk related to the development, testing, manufacturing and marketing of our products and product candidates in clinical trials. Product liability claims and related cross-claims and claims for indemnification may be brought against us by patients, healthcare providers or others using, prescribing, selling or otherwise coming into contact with our products or product candidates. For example, we may be sued if any product or product candidate allegedly causes injury or is found to be otherwise unsuitable during clinical trials, manufacturing or, if approved, marketing, sale or commercial use. If we cannot successfully defend ourselves against such claims, we could incur substantial liabilities.

We could also face product liability claims relating to the worsening of a patient’s condition, injury or death alleged to have been caused by our products or product candidates. Any such claims may include allegations of defects in manufacturing or design, a failure to warn of dangers inherent in the product, including as a result of interactions with alcohol or other drugs, knowledge of risks, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. Such claims might not be fully covered by product liability insurance. For any marketed products, product liability claims could result in an FDA investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs, and potentially a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used, suspension or withdrawal of approvals or license revocation. Regardless of the merits or eventual outcome, liability claims may cause decreased demand for our products, injury to our reputation and significant negative media attention, costs to defend the related litigation, withdrawal of clinical trial participants, loss of revenue, a diversion of management’s time and our resources, substantial monetary awards to trial participants, patients or their family members, payments to indemnify clinical trial sites and other clinical trial partners and a decline in our stock price. On occasion, large judgments have been awarded in individual, mass tort and class-action lawsuits based on drugs or medical treatments that had unanticipated adverse effects.

With respect to our COVID-19 vaccine, although the U.S. and certain foreign governments have contractually agreed to indemnify us or make statutory immunity available to us, such indemnification or statutory immunity may be unavailable to cover potential claims or liabilities resulting from the research, development, manufacture, distribution or commercialization of the vaccine. Additionally, other foreign governments that we contract with may not provide us with similar contractual indemnity or statutory immunity, and we will not have the benefit of such indemnities or immunities in the future as the COVID-19 vaccine market transitions to a commercial market in the United States and elsewhere. Substantial claims arising from the vaccine outside the scope of or in excess of U.S. or foreign government indemnity or statutory immunity could harm our financial condition and operating results. Moreover, any adverse event or injury for which we are liable, even if fully covered under an indemnity or immunity, could negatively affect our reputation.

We may be unable to maintain our product liability insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If the costs of maintaining adequate insurance coverage increase significantly in the future, our operating results could be materially adversely affected. Likewise, if insurance coverage should become unavailable to us or become economically impractical, we would be required to operate our business without indemnity from commercial insurance providers. Additionally, even if we maintain insurance coverage for a type of liability, a particular claim may not be covered if it is subject to a coverage exclusion or we do not otherwise meet the conditions for coverage. If we operate our business with inadequate insurance, we could be responsible for paying claims or judgments against us, which could adversely affect our results of operations or financial condition.

Federal legislation and actions by federal, state and local governments may permit reimportation into the United States of drugs from foreign countries where the drugs are sold at lower prices.

We may face competition in the United States for our products from therapies sourced from foreign countries with price controls on pharmaceutical products. For example, in October 2020, the FDA published a final rule that would allow for the importation of certain prescription drugs from Canada, where there are government price controls. In January 2024, the FDA approved Florida’s request to import certain lower-priced medications from Canada. While the full implications of the final rule are currently unknown, legislation or regulations allowing the reimportation of drugs could decrease the price we receive for any products we may develop and adversely affect our future revenues and potential profitability.

71

Healthcare legislative reform discourse and potential or enacted measures may have a material adverse impact on our business and results of operations and legislative or political discussions surrounding the desire for and implementation of pricing reforms may adversely impact our business.

In the United States, federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the ACA have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the PHSA. Additionally, the Inflation Reduction Act of 2022 includes several provisions such as drug pricing controls and Medicare redesign that are likely to impact our business to varying degrees, but its ultimate effect on our business and the healthcare industry in general is not yet known. See “Business—Government Regulation-Current and future healthcare reform legislation.”

We may face uncertainties as a result of efforts to repeal, substantially modify or invalidate some or all of the provisions of the ACA. There is no assurance that the ACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.

There is increasing public attention on the costs of prescription drugs and there have been, and are expected to continue to be, legislative proposals to address prescription drug pricing, which could have significant effects on our business. These actions and the uncertainty about the future of the ACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs.

There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for drugs or that would allow for importation of pharmaceutical products from lower cost jurisdictions outside the United States. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products, if approved.

In the EU and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures may adversely affect our revenues and results of operations.

We are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws and false claims laws. If we cannot comply, or have not fully complied, with such laws, we could face substantial penalties.

Healthcare providers, physicians and third-party payors in the United States and elsewhere play a primary role in the recommendation and prescription of pharmaceutical products. Arrangements with third-party payors and customers can expose pharmaceutical manufacturers to broadly applicable fraud and abuse and other healthcare laws and regulations, which may constrain the business or financial arrangements and relationships through which such companies sell, market and distribute pharmaceutical products. In particular, the promotion, sales and marketing of healthcare items and services, as well as a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commissions, certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. See “Business—Government Regulation—Other healthcare laws.”

The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Ensuring business arrangements comply with applicable
72

healthcare laws, as well as responding to possible investigations by government authorities, is time- and resource-consuming and can divert a company’s attention from the business. If our operations are found to violate any of these laws or any other regulations, we may be subject to significant sanctions, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, reputational harm, exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance. Furthermore, if any physician or other healthcare provider or entity with whom we do business is found to be not in compliance with applicable laws, they may be subject to similar penalties. Any action for violation of these laws, even if successfully defended, could cause us to incur significant legal expenses and divert management’s attention from the operation of the business. In addition, the approval and commercialization of any product candidate we develop outside the United States will subject us to foreign healthcare laws.

The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the EU and the UK. The provision of benefits or advantages to induce or reward improper performance generally is also governed by the national anti-bribery laws of EU Member States, and the Bribery Act 2010 in the UK. Infringement of these laws could result in substantial fines and imprisonment. The EU Directive (2001/83/EC, as amended) governing medicinal products for human use provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains applicable in the UK despite its departure from the EU.

Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often are the subject of prior notification and approval by the physician’s employer, his or her competent professional organization, or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.

We are subject to various and evolving laws and regulations governing the privacy and security of personal data, and our failure to comply could result in fines or criminal penalties and damage our reputation.

Privacy and data security are significant issues in the United States, Europe and many other jurisdictions where we operate or collect personal information. We are subject to data privacy and security laws and regulations in various jurisdictions that apply to the collection, storage, use, sharing and security of personal data, including health information, and impose significant compliance obligations. In addition, numerous other federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection and privacy laws, govern the collection, use, disclosure and security of personal information.

The GDPR and UK GDPR impose stringent obligations on us with respect to our processing and the cross-border transfer of personal data, including higher standards of obtaining consent or ensuring another appropriate legal basis or condition applies to the processing of personal data, more robust transparency requirements, data breach notification requirements, requirements for contractual language with our processors and stronger individual data rights. Different EEA Member States have interpreted the GDPR differently and many have imposed additional requirements, adding to the complexity of processing personal data in the EEA. The GDPR and UK GDPR also impose strict rules on the transfer of personal data to countries outside the EEA that are not considered to provide “adequate” protection to personal data, including the United States, and permits data protection authorities to impose large penalties for violations. Compliance with the GDPR and UK GDPR is a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices. We could be subject to fines and penalties, litigation and reputational harm in connection with any activities falling within the scope of the GDPR or UK GDPR.

In the United States, California has passed the CCPA and numerous other states have passed their own similar comprehensive consumer privacy laws. There are also states that are specifically regulating health information. Further, a small number of states have passed laws that regulate biometric data specifically. In addition, numerous states and the federal government are actively considering proposed legislation governing the protection of personal data. State laws are changing rapidly and there is discussion in the U.S. Congress of a new comprehensive federal data privacy law to which we may likely become subject, if enacted.

Additionally, many foreign jurisdictions have passed data privacy legislation and others are considering various proposals for new privacy and data protection laws. Data privacy remains an evolving landscape at the domestic and international levels, with new laws and regulations being considered and coming into effect and continued legal challenges. We must devote significant resources to understanding and complying with the changing landscape in this area. Each law is also subject to various interpretations by courts and regulatory agencies, creating additional uncertainty, and we may fail to comply with the evolving data protection laws, which may expose us to risk of enforcement actions taken by authorities, private rights of action in some jurisdictions and potential significant
73

penalties if we are found to be non-compliant. Some of these laws and regulations also carry the possibility of criminal sanctions. For example, we could be subject to penalties, including criminal penalties, if we knowingly obtain or disclose individually identifiable health information from a HIPAA-covered health care provider or research institution that has not complied with HIPAA’s requirements for disclosing such information. Furthermore, the number of government investigations related to data security incidents and privacy violations continues to increase and government investigations typically require significant resources and generate negative publicity, which could harm our business and our reputation.

The Clinical Trials Regulation (EU) No. 536/2014 (the Clinical Trial Regulation) and the EMA policy on publication of clinical data for medicinal products for human use both permit the EMA to publish clinical information submitted in MAAs. The ability of third parties to review or analyze data from our clinical trials may increase the risk of commercial confidentiality breaches and result in enhanced scrutiny of our clinical trial results. Such scrutiny could result in public misconceptions regarding our drugs and drug candidates. These publications could also result in the disclosure of information to our competitors that we might otherwise deem confidential, which could harm our business.

Our use of GenAI and other AI technologies presents certain risks and challenges given the emerging nature of AI technologies.

The development and use of GenAI and other AI technologies (collectively, AI Technologies), along with an uncertain regulatory landscape, pose risks that could harm our reputation, expose us to liability or adversely affect our business. The integration of AI Technologies into our and our vendors’ systems (potentially without the vendor disclosing such use to us) subjects us to the risk that the providers of AI Technologies may not meet existing or rapidly evolving regulatory or industry standards with respect to privacy and data protection. This may lead to breaches of security or privacy, reduced levels of service or experience, loss of intellectual property or exposure of confidential or proprietary information. Sophisticated cyber-attacks, including those using AI, could exacerbate these risks. Additionally, GenAI’s potential for producing false or misleading outputs, reflecting biases or generating content that may not be subject to intellectual property protection or that infringes proprietary rights of others, poses additional risks to our business. Regulatory changes or reinterpretations could introduce new compliance risks, including potential government enforcement actions or civil lawsuits. Our competitors’ faster or more effective adoption of AI could also disadvantage us.

We could be adversely affected by outbreaks of epidemic, pandemic or other contagious diseases.

In the event of a future epidemic or pandemic, our clinical trials could be paused or delayed due to restrictions (such as quarantines or travel limitations) or reprioritization of resources. Travel limitations could also create challenges and potential delays in our development and production activities, increasing the expense and timelines for producing our products and product candidates.

We utilize third parties to, among other things, manufacture raw materials, components, parts and consumables, perform quality testing and ship our products. If these third parties were to experience delays or disruptions in providing their services in response to an epidemic or pandemic, our supply chain could be disrupted, limiting our ability to manufacture and sell our products and manufacture product candidates for our clinical trials, as well as negatively impacting our research and development operations. Such delays or disruptions could adversely impact our strategic collaborators’ ability to fulfill their obligations, which could affect the clinical development or regulatory approvals of product candidates under joint development.

In addition, during a global health crisis, one or more government entities could take actions (such as via the Defense Production Act in the U.S.) that diminish our rights or economic opportunities with respect to our products. Our third-party service providers could be impacted by government-imposed restrictions on services they might otherwise offer. Any such action could cause us to experience delays in the development, production, distribution or export of our products and product candidates and increased expenses.

Engaging in acquisitions, joint ventures or strategic collaborations may increase our capital requirements, dilute our stockholders and cause us to incur debt or assume contingent liabilities.

We may engage in acquisitions, joint ventures and collaborations, including licensing or acquiring complementary products, IP rights, technologies or businesses. Such transactions and relationships may entail numerous risks, including:
•increased operating expenses and cash requirements;
•assimilation of operations, IP and products, including difficulties associated with integrating new personnel;
•the diversion of management’s attention from our existing product programs and initiatives;
•the loss of key personnel and uncertainties in our ability to maintain key business relationships;
•risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and
•our inability to generate revenue from acquired technology or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.

74

If we undertake acquisitions, we may utilize cash, issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, if we cannot locate suitable acquisition or strategic collaboration opportunities, our ability to grow or obtain access to technology or products that may be important to the development of our business may be impaired.

The illegal distribution and sale by third parties of counterfeit or stolen versions of mRNA products, or the unauthorized donation or re-sale of mRNA products, could negatively impact our financial performance or reputation.

Third parties could illegally distribute and sell, especially online, counterfeit versions of mRNA products that do not meet the rigorous cGMP manufacturing and testing standards. Counterfeit medicines may contain harmful substances or the wrong dose, are frequently unsafe or ineffective and could be life-threatening. However, to distributors and users, counterfeit products may be visually indistinguishable from the authentic version.

Reports of adverse reactions to counterfeit products, increased levels of counterfeiting or unsafe mRNA products could materially affect patient confidence in our mRNA products. Adverse events caused by unsafe counterfeit or other non-mRNA products could mistakenly be attributed to our mRNA products. In addition, thefts of inventory at warehouses, plants or while in-transit, which are not properly stored and which are sold through unauthorized channels, could adversely impact patient safety, our reputation and our business. Public loss of confidence in the integrity in mRNA products as a result of counterfeiting, theft or improper manufacturing processes could have a material adverse effect on our business, results of operations and financial condition. Further, the unauthorized donation or resale of our product could adversely affect our ability to sell in a particular territory, and have other adverse effects on our business, results of operations and financial condition.

Climate change or legal, regulatory or market measures to address climate change may negatively affect our business, results of operations and financial condition.

We are exposed to physical risks (such as rising temperatures, flooding and severe storms), risks in transitioning to a low-carbon economy (such as additional legal or regulatory requirements, changes in customer behavior and cost and availability of raw materials) and social and human effects (such as population dislocations and harm to health and well-being) associated with climate change. These risks can be either acute (short-term) or chronic (long-term). Climate-related physical risks to our facilities and those of our suppliers could disrupt our operations and supply chain, which may result in increased costs.

New legal or regulatory requirements may be enacted to prevent, mitigate or adapt to the implications of a changing climate and its effects on the environment. These regulations, which may differ across jurisdictions, could subject us to new or expanded carbon pricing or taxes, increased compliance costs, restrictions on greenhouse gas emissions, investment in new technologies, increased carbon disclosure and transparency, investments in data gathering and reporting systems, upgrades of facilities to meet new building codes and the redesign of utility systems, which could increase our operating costs, including the cost of electricity and energy we use. Our supply chain would likely be subject to these same transitional risks and would likely pass along any increased costs to us, which may affect our ability to procure raw materials or other supplies required to operate our business at the quantities and levels we require.

Our aspirations, goals and disclosures related to environmental, social and governance (ESG) matters expose us to numerous risks.

Institutional and individual investors are increasingly using ESG screening criteria to determine whether we qualify for inclusion in their investment portfolios. We are frequently asked by investors and other stakeholders to set ambitious ESG goals and provide new and more robust disclosure on goals, progress toward goals and other matters of interest to ESG stakeholders. In response, we have adapted the tracking and reporting of our corporate responsibility program to various evolving ESG frameworks, and we have established and announced goals and other objectives related to ESG matters. Statements about these goals reflect our current plans and aspirations and are not guarantees that we will be able to achieve them. Our efforts to accomplish and accurately report on these goals and objectives, including with respect to environmental and diversity initiatives, are subject to numerous risks, many of which are outside of our control, which could have a material negative impact, including on our reputation and stock price.

Further, the standards for tracking and reporting on ESG matters are relatively new, have not been harmonized and continue to evolve. Our selection of disclosure frameworks that seek to align with various reporting standards may change from time to time and may result in a lack of consistent or meaningful comparative data from period to period. In addition, our processes and controls may not always comply with evolving standards for identifying, measuring and reporting ESG metrics, our interpretation of reporting standards may differ from those of others and such standards may change over time, any of which could result in significant revisions to our goals or reported progress in achieving such goals.

75

If our ESG practices do not meet evolving investor or other stakeholder expectations and standards, then our reputation, our ability to attract or retain employees and our attractiveness as an investment, business partner or acquiror could be negatively impacted. Similarly, our failure or perceived failure to pursue or fulfill our goals, targets and objectives or to satisfy various reporting standards within the timelines we announce, or at all, could also have similar negative impacts and expose us to government enforcement actions and private litigation.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.

We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous and flammable materials and wastes, including chemicals and biological materials. We generally contract with third parties for the disposal of these materials and waste products, and we cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from any use by us of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines, penalties or other sanctions for failure to comply with such laws and regulations. We may also incur substantial costs to comply with such laws and regulations, and these laws and regulations could impair our research, development or production efforts.

Our workers’ compensation insurance may not provide adequate coverage against potential liabilities due to injuries to our employees resulting from the use of hazardous materials. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials.

Risks related to ownership of our common stock

The price of our common stock has been volatile, which could result in substantial losses for stockholders.

Our stock price has been, and is expected to continue to be, subject to substantial volatility. Since our IPO in December 2018, our stock price has ranged from a high of $497.49 to a low of $11.54 per share. Since we began our COVID-19 vaccine development efforts in early 2020, our stock has experienced pronounced and extended periods of volatility, which could cause our stockholders to incur substantial losses. Public statements by us, government agencies, the media, competitors, financial analysts or others relating to COVID-19 have resulted, and may result, in significant fluctuations in our stock price. Information in the public arena on this topic, whether or not accurate, has had and will likely continue to have an outsized impact (positive or negative) on our stock price.

The stock market in general, and the market for biopharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating performance of particular companies, and you may not be able to sell your shares at or above your initial purchase price. The market price for our common stock may be influenced by many factors, including:
•our COVID-19 vaccine sales and anticipated product revenue;
•the commercial launch of any additional products;
•timing and results of clinical trials or progress of our product candidates or those of our competitors;
•the success of competitive products or technologies;
•the emergence or decline of new or existing variants of the SARS-CoV-2 virus;
•developments regarding our manufacturing, regulatory and commercialization efforts, or information regarding such efforts by competitors;
•regulatory or legal developments in the United States and other countries;
•developments or disputes concerning patent applications, issued patents or other proprietary rights;
•the recruitment or departure of key personnel;
•expenses related to any of our products or clinical development programs;
•the results of our efforts to discover, develop, acquire or in-license additional product candidates;
•actual or anticipated changes in estimates of financial results, development timelines or recommendations by securities analysts;
•variations in our financial results or those of companies that are perceived to be similar to us;
•changes in the structure of healthcare payment systems;
•economic, industry and market conditions generally, and in the biopharmaceutical sector specifically; and
•announcement by us or our competitors of the commencement or termination of significant acquisitions, strategic partnerships, joint ventures or capital commitments.

Securities class-action litigation often has been instituted against companies following periods of volatility in their stock price. If such litigation were instituted against us, we could incur substantial costs in defense and management’s attention and resources could be diverted, which could adversely affect our business, financial condition and results of operations and prospects.
76


Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

As of February 16, 2024, our executive officers, directors and affiliated stockholders owned, directly or indirectly, approximately 12% of our outstanding common stock. In addition, non-affiliated five percent or greater stockholders owned approximately 27% of our outstanding common stock. These stockholders will have the ability to influence us through their ownership positions. For example, if they were to act together, they could exert significant influence over matters such as elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that our stockholders may believe to be in their best interests.

Provisions in our organizational documents, as well as provisions of Delaware law, could make it more difficult or costly for a third party to acquire us or remove our current management, even if doing so would benefit our stockholders.

Our amended and restated certificate of incorporation (charter), amended and restated by-laws (by-laws) and Delaware law contain provisions that could delay or prevent a hostile takeover or change in control of us or changes in our management. Our charter and by-laws include provisions that:
•authorize “blank check” preferred stock, which could be authorized for issuance by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock;
•create a classified board of directors whose members serve staggered three-year terms;
•specify that special meetings of our stockholders can be called only by our board of directors;
•prohibit stockholder action by written consent;
•establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;
•provide that our directors may be removed only for cause;
•provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;
•specify that no stockholder is permitted to cumulate votes at any election of directors;
•expressly authorize our board of directors to modify, alter or repeal our by-laws; and
•require supermajority votes of the holders of our common stock to amend specified provisions of our charter and by-laws.

In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. Any provision of our charter, by-laws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares, and could also affect the price that some investors are willing to pay for our common stock.

Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.

We do not currently intend to declare or pay cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business or to return cash to shareholders through share repurchases. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.

Our by-laws designate the Court of Chancery of the State of Delaware or the U.S. District Court for the District of Massachusetts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us.

Pursuant to by-laws, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for state law claims for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of or based on a breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees to us or our stockholders, (3) any action asserting a claim against us or any of our current or former directors, officers, employees or stockholders arising pursuant to any provision of the Delaware General Corporation Law or our by-laws or (4) any action asserting a claim governed by the internal affairs doctrine (the Delaware Forum Provision). The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our by-laws further provide that the U.S. District Court for the District of Massachusetts is the exclusive forum for resolving any complaint asserting a cause of action arising
77

under the Securities Act (the Federal Forum Provision). Our by-laws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the Delaware Forum Provision and the Federal Forum Provision.

The Delaware Forum Provision and the Federal Forum Provision may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or the Commonwealth of Massachusetts, as applicable. Additionally, the forum selection clauses in our by-laws may limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our stockholders. While the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are “facially valid” under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is unenforceable or invalid, and if the Federal Forum Provision is found to be unenforceable, we may incur additional costs in resolving such matters. The Court of Chancery of the State of Delaware and the U.S. District Court for the District of Massachusetts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.

General risk factors

Our employees, principal investigators and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.

We are exposed to the risk of fraud or other misconduct by our employees, principal investigators leading our clinical trials and consultants. Such misconduct could include failures to comply with FDA regulations or similar regulations in other jurisdictions, provide accurate information to the FDA, the EMA and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad or report financial information or data accurately or disclose unauthorized activities to us. Such misconduct also could involve improper use of information obtained during clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and serious harm to our reputation. Sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. It is not always possible to identify and deter employee misconduct, and we may fail to control unknown or unmanaged risks or losses or take steps that protect us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, those actions could have a significant impact on our business, financial condition, results of operations and prospects, including through the imposition of significant fines or other sanctions.

Unfavorable U.S. or global economic conditions, including as a result of disease outbreak, war, conflict or other political instability, or geopolitical risks, could adversely affect our business, financial condition or results of operations.

Our results of operations could be adversely affected by general conditions in the global economy and financial markets, including disruptions caused by pandemic, war, conflict or other political instability, including Russia’s invasion of Ukraine and resulting sanctions against Russia or conflict in the Middle East. Adverse macroeconomic conditions, and perceptions or expectations about current or future conditions, such as inflation, slowing growth, rising interest rates, rising unemployment and recession, could negatively affect our business and financial condition. Additionally, global events, including war, conflict, political instability or other adverse economic conditions have and may in the future cause governments to divert spending away from healthcare, negatively impacting the marketability of our products.

Any severe or prolonged economic downturn could create a variety of risks to our business, including weakened demand for our medicines, and negatively impacting our ability to raise additional capital or financing when needed on favorable terms, if at all. A weak or declining economy could strain our suppliers, possibly resulting in supply disruption, or cause delays in payments for our services by third-party payors or our collaborators. Any of the foregoing could harm our business and we cannot anticipate all the ways in which the current economic climate and financial market conditions could adversely impact our business.

Additionally, geopolitical tensions could adversely impact our business and our commercial plans. For instance, restrictions by the U.S. government on the export of mRNA technology or our products to certain markets, or restrictions on the establishment of manufacturing in certain foreign jurisdictions, may prevent us from seeking commercial growth opportunities in a manner that harms our competitive position.
78


Employee litigation and unfavorable publicity could negatively affect our future business.

Our employees may, from time to time, bring lawsuits against us regarding injury, creating a hostile workplace, discrimination, wage and hour disputes, sexual harassment or other employment issues. Recently, there has been an increase in the number of discrimination and harassment claims generally. Coupled with the expansion of social media platforms and similar devices that allow individuals access to a broad audience, these claims have had a significant negative impact on some businesses. Certain companies that have faced employment- or harassment-related lawsuits have had to terminate management or other key personnel, and have suffered reputational harm. Any employment-related claim could negatively affect our business.

Ineffective internal controls could adversely impact our business and operating results.

Our internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, failure or interruption of information technology systems, the circumvention or overriding of controls, or fraud. Even effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. If we fail to maintain the adequacy of our internal controls, including any failure to implement required new or improved controls, or if we experience difficulties in their implementation, our business and operating results could be harmed and we could fail to meet our financial reporting obligations.

Changes in tax law could adversely affect our business and financial condition.

We are subject to evolving and complex tax laws in the jurisdictions in which we operate. The rules dealing with U.S. federal, state, local and non-U.S. income taxation are constantly under review by legislative and tax authorities. Changes to tax laws (which could apply retroactively) could adversely affect us and our stockholders. In recent years, such changes have been made and changes are likely to occur in the future, which could have a material adverse effect on our business, cash flow, financial condition and results of operations.

The increasing use of social media platforms presents risks and challenges.

Social media is increasingly being used to communicate about our research, product candidates, commercial products and the diseases our products and product candidates are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This uncertainty creates risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, subjects may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event. When such disclosures occur, we may fail to monitor and comply with applicable adverse event reporting obligations or we may be unable to defend our business in the face of political and market pressures generated by social media due to restrictions on what we may say about our product candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to our business.

Item 1B. Unresolved Staff Comments
None.

Item 1C. Cybersecurity
Cyber Risk Management and Strategy

Our cybersecurity organization’s mission is to provide a targeted set of services, support and capabilities to reduce the risk of cyberattacks, rapidly detect and contain threats, and mitigate risks to critical data.

Recognizing the threat of security breaches and cyberattacks globally, we have developed a cybersecurity program, overseen by our Chief Information Security Officer (CISO) and Chief Information Officer (CIO), that is designed to protect patient trust, defend the Moderna brand, and reduce the risk and impact of cyber-attacks. Our cybersecurity program is informed by industry standards and includes periodic risk assessments and security testing supported by cybersecurity technologies, including third-party security solutions, vulnerability management, and monitoring tools, designed to monitor, identify, and manage risks from cyber threats. In addition, we have implemented employee security and awareness training.

79

Management has established a cyber incident response plan (CIRP) designed to assess, identify and manage risks from cybersecurity threats and enable prompt response in the event that a cybersecurity incident is detected. We have a process in place for notification to our leadership response team in the event of a significant cyber incident, and for escalation of these events to our Audit Committee and Board, as appropriate. To date, we have not experienced a cybersecurity incident that has had a material impact on our business strategy, results of operations, or financial condition.

We undergo several annual internal compliance audits and external reviews to evaluate our controls, including cybersecurity controls. In an effort to minimize third-party risk, we have established a process to assess the security practices of third-party suppliers and related risks, including through review of relevant supplier certifications and security and responses to standardized information gathering (SIG) questionnaires, as applicable and appropriate.

Governance Related to Cybersecurity Risks

Our Board of Directors oversees Moderna’s overall risk management strategy. The Board exercises oversight of risks from cybersecurity threats primarily through its Audit Committee, which oversees our risk management processes for information security and technology risks. Our cybersecurity risk management processes are integrated into our overall risk management strategy, which is overseen by the Audit Committee. At least annually, the Audit Committee discusses our risk management program, including information security and technology risks and findings from any audits, with our internal audit staff.

The Audit Committee receives cyber-related updates from management, including our CISO at committee meetings. During meetings, our CISO updates the committee on Moderna’s cybersecurity posture, potential threats and risk mitigation strategies, and the progress of the Company’s cybersecurity initiatives, as appropriate. The Chair of the Audit Committee and management provide regular briefings on such matters to the full Board of Directors, as appropriate.

At the management level, our CISO is primarily responsible for leading our cybersecurity strategy for assessing and managing material risks from cybersecurity threats. Our current CISO has over 25 years of cybersecurity experience across a wide array of industries, most recently serving in leadership positions at two different public companies and previous roles of increasing responsibility at multinational technology companies. Our CISO reports directly to our CIO, who is a member of our Executive Committee and reports to our Chief Executive Officer.

We have built a cybersecurity leadership team designed to align with key services, with a separate lead overseeing each service offering, all reporting to the CISO. We also maintain relationships with law enforcement and industry groups to support our cybersecurity intelligence and risk management efforts.

Item 2. Properties
We have two main campuses in Massachusetts. During the third quarter of 2023, we commenced a lease for a property in Cambridge, Massachusetts. This building, spanning approximately 462,000 square feet, is designated as our new Moderna Science Center (MSC). The MSC will accommodate a combination of scientific and office spaces, including our principal executive offices. The lease has a term of 15 years, with options for us to extend the lease for up to two additional seven-year terms. We expect to begin a phased move-in process starting in early 2024. Additionally, we occupy a multi-building campus at Technology Square in Cambridge, Massachusetts, consisting of a mix of offices and research laboratory space, totaling approximately 292,000 square feet. The lease will expire in early 2025. The Cambridge campus is the location of our corporate headquarters, platform, drug discovery and clinical development.
The Moderna Technology Center (MTC) is located in Norwood, Massachusetts and is primarily comprised of three buildings (MTC South, MTC North and MTC East). The MTC campus is approximately 686,000 square feet which includes lab and office space, directly supporting our manufacturing capabilities and commercial and clinical activities. The MTC campus is leased through 2042 and we have the option to extend it for three additional five-year terms.

In the second quarter of 2023, we acquired a newly constructed biomanufacturing facility, encompassing 140,000 square feet, in Marlborough, Massachusetts. This facility is undergoing enhancements, including the addition of 60,000 square feet to the existing structure. Upon completion, the facility will feature office and mRNA manufacturing areas, including a full manufacturing clean room, quality control laboratories, a just-in-time satellite warehouse, and additional office spaces. We expect the facility to be operational in 2025. This new site is strategically intended to support our INT program.

We also own and lease various parcels of land, office and lab spaces across the globe for our business operations.

Item 3. Legal Proceedings

We are involved in various claims and legal proceedings of a nature considered ordinary course in our business, including the
80

intellectual property litigation described below. Most of the issues raised by these claims are highly complex and subject to substantial uncertainties. For a description of risks relating to these and other legal proceedings we face, see Part I, Item 1A, “Risk Factors,” including the discussion under the headings entitled “Risks related to our intellectual property” and “Risks related to the manufacturing of our commercial products and product candidates.”

The outcome of any such proceedings, regardless of the merits, is inherently uncertain; therefore, assessing the likelihood of loss and any estimated damages is difficult and subject to considerable judgment. We describe below those legal matters for which a material loss is either (i) possible but not probable, and/or (ii) not reasonably estimable at this time.

Pfizer/BioNTech Patent Litigation

In August 2022, we filed a lawsuit in the U.S. District Court for the District of Massachusetts against Pfizer Inc. (Pfizer) and BioNTech SE, BioNTech Manufacturing GmbH and BioNTech US Inc. (collectively, BioNTech), asserting infringement of certain U.S. patents concerning our mRNA platform technology and disease-specific vaccine designs in Pfizer and BioNTech’s manufacture and sale of their mRNA COVID-19 vaccines. The complaint seeks a judgment of infringement of the asserted patents and monetary damages.

Also in August 2022, we initiated patent infringement proceedings in Germany (in the Dusseldorf Regional Court), the Netherlands (in the District Court of The Hague) and the UK (in the High Court of Justice of England & Wales) against Pfizer, BioNTech and related entities with respect to certain European patents that also concern our mRNA platform technology and disease-specific vaccine designs, including coronaviruses. In May 2023, we initiated patent infringement proceedings in Ireland (in the High Court) and Belgium (Brussels Business Court) against Pfizer, BioNTech and related entities with respect to the same European patents. As in the U.S. action, we seek a judgment of infringement of the asserted patents and monetary damages.

Pfizer Inc. and BioNTech SE have also filed an action seeking revocation of certain Moderna patents in the UK. In addition, the Moderna patents being asserted in the European actions are subject to notices of opposition, including by Pfizer and BioNTech SE and others. These actions seek to revoke the patents, which have been filed at the European Patent Office.

Proceedings Related to Patents Owned by Arbutus

In February 2022, Arbutus Biopharma Corporation (Arbutus) and Genevant Sciences GmbH (Genevant) filed a complaint against us in the U.S. District Court for the District of Delaware asserting that our manufacture and sale of our COVID-19 vaccine willfully infringes certain U.S. patents concerning lipid nanoparticles. The complaint seeks a judgment of infringement of the asserted patents and monetary damages, but does not seek to prevent or stop the marketing or sales of our COVID-19 vaccines.

Proceedings Related to Patents Owned by Alnylam

In March 2022 and July 2022, Alnylam Pharmaceuticals, Inc. (Alnylam) filed two complaints against us in the U.S. District Court for the District of Delaware asserting that our manufacture and sale of our COVID-19 vaccine infringes certain U.S. patents concerning cationic lipids. On August 25, 2023, the Court entered a Final Judgment of non-infringement of all asserted patents in these lawsuits. Alnylam has appealed this judgment to the Federal Circuit Court of Appeals. In May 2023, Alnylam filed a third complaint against us in the U.S. District Court for the District of Delaware asserting three additional U.S. patents concerning cationic lipids. The complaints seek judgments of infringement of the asserted patents and monetary damages, but do not seek to prevent or stop the marketing or sales of our COVID-19 vaccines.

Item 4. Mine Safety Disclosures
Not applicable.
81

PART II

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market for Our Common Stock
Our common stock trades on the Nasdaq Global Select Market under the symbol “MRNA”.
Stock Performance Graph

The following performance graph shall not be deemed “soliciting material” or to be “filed” with the SEC for purposes of the Exchange Act or otherwise subject to the liabilities under that section, and shall not be deemed to be incorporated by reference into any filing of Moderna, Inc. under the Securities Act or the Exchange Act.

The following graph illustrates a comparison for the five years ended December 31, 2023 of the cumulative total return for our common stock, the Nasdaq Biotechnology Index, and the Standard & Poor’s 500 Stock Index (the S&P 500) each of which assumes an initial investment of $100 and reinvestment of all dividends. Such returns are based on historical results and are not intended to suggest future performance.

The comparisons shown in the graph below are based upon historical data. We caution that the stock price performance shown in the graph below is not necessarily indicative of, nor is it intended to forecast, the potential future performance of our common stock.

1445

Stockholders
We had approximately 75 stockholders of record as of February 16, 2024. Because many of our outstanding shares are held in accounts with brokers and other institutions, the number of beneficial owners is significantly greater than the number of record holders. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.

Dividend Policy

We have never declared or paid cash dividends on our common stock and do not expect to pay dividends on our common stock for the foreseeable future.
82


Securities Authorized for Issuance Under Equity Compensation Plans

Information about our equity compensation plans in Item 12 of Part III of this Annual Report on Form 10-K is incorporated herein by reference. Any future determination to pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects, then applicable contractual restrictions and any other factors deemed relevant by our board of directors. Investors should not purchase our common stock with the expectation of receiving cash dividends.

Recent Sales of Unregistered Securities

None.

Issuer Purchases of Equity Securities

On August 1, 2022, our Board of Directors authorized a share repurchase program for our common stock of up to $3.0 billion, with no expiration date. During the three months ended December 31, 2023, there were no shares repurchased. As of December 31, 2023, $1.7 billion of our Board of Directors’ authorization for repurchases of our common stock remains outstanding, with no expiration date.

Refer to Note 12 to consolidated financial statements for information regarding our share repurchase programs.

Item 6. [Reserved]

83

Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes and other financial information appearing elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in “Part I, Item 1A - Risk Factors” section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

We are a biotechnology company advancing a new class of medicines made of messenger RNA (mRNA). mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates. We are developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with our strategic collaborators.

Since our founding in 2010, we have transformed from a research-stage company advancing programs in the field of mRNA to a commercial enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio and integrated manufacturing capabilities that allow for rapid clinical and commercial production at scale. We have a diverse and extensive development pipeline of 42 development candidates across our 45 development programs, of which 40 are in clinical studies currently.

Our COVID-19 vaccine is our first commercial product and is marketed, where approved, under the name Spikevax®. Our original vaccine, mRNA-1273, targeted the SARS-CoV-2 ancestral strain, and we have leveraged our mRNA platform to rapidly adapt our vaccine to emerging SARS-CoV-2 strains to provide protection as the virus evolves and regulatory guidance is updated.

2023 Business Highlights

On September 11, 2023, we received approval of the supplemental Biologics License Application from the U.S. Food and Drug Administration (FDA) for our updated COVID-19 vaccine, which targets the Omicron XBB.1.5 sublineage of SARS-CoV-2 (mRNA-1273.815), for individuals 12 years and older. The FDA also issued an Emergency Use Authorization for mRNA-1273.815 for children aged 6 months to 11 years old. We subsequently received authorization from regulatory authorities around the globe for mRNA-1273.815 and initiated the shipment of doses both in the U.S. and internationally.

For the year ended December 31, 2023, we recognized net product sales of $6.7 billion from sales of our COVID-19 vaccines, compared to $18.4 billion and $17.7 billion for the years ended December 31, 2022 and 2021, respectively.

In January 2023, we announced positive data from the interim analysis of our pivotal ConquerRSV study of our vaccine candidate against respiratory syncytial virus (RSV) (mRNA-1345). In the study, mRNA-1345 met primary efficacy endpoints, demonstrating vaccine efficacy of 83.7% against RSV lower respiratory tract disease in older adults. We have filed for a Biologics License Application to the FDA for our RSV vaccine for adults aged 60 years or older, and used a Priority Review Voucher to accelerate review. We have also submitted marketing authorization applications for the vaccine for adults aged 60 years or older to medical authorities in several countries beyond the U.S. We have initiated the manufacturing of mRNA-1345 and are preparing for a marketing launch in 2024, subject to approval.

During the third quarter of 2023, we embarked on a strategic initiative to optimize the cost structure of our COVID-19 business, with a focus on resizing our manufacturing cost structure. The launch of this initiative was prompted by the completion of our long-range planning within the third quarter of 2023, which incorporated revised forecasts of vaccination rates. These projections accounted for the market’s transition from COVID-19 pandemic conditions towards an endemic seasonal market. Consequently, this strategic shift resulted in charges of $1.4 billion for the quarter. In the fourth quarter of 2023, we incurred additional charges of $169 million related to this initiative. Despite the immediate impact to our financial statements, we believe this strategic initiative will enhance the efficiency of our manufacturing operations and equip us with the agility to better adjust our scale according to future market demands.

84

Program Developments

As of December 31, 2023, nine of our 45 development programs are in late-stage development, including seven programs in Phase 3 and two rare disease programs that are expected to enter pivotal studies in 2024.

Respiratory Vaccines

•Respiratory syncytial virus (RSV) vaccine: We have filed for regulatory approvals for our vaccine for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD) in adults ages 60 years or older (mRNA-1345). We expect regulatory approvals beginning in the first half of 2024. We anticipate entering the RSV market with a strong competitive profile as the only pre-filled syringe product available at the time of launch, along with robust efficacy data, a well-established safety and tolerability profile, and widespread consumer awareness and demand established in 2023.

•Next-generation COVID-19 vaccine: Our next-generation COVID-19 vaccine candidate, which is designed to be refrigerator-stable (mRNA-1283), is currently in its pivotal Phase 3 study. We anticipate data from the study in the first half of 2024.

•Seasonal flu vaccine: Our seasonal flu vaccine candidate (mRNA-1010) demonstrated consistently acceptable safety and tolerability across three Phase 3 trials. In the most recent Phase 3 trial, mRNA-1010 met all immunogenicity endpoints, demonstrating higher titers compared to a currently licensed vaccine. mRNA-1010 has also shown higher or comparable titers compared to a currently licensed enhanced vaccine (Fluzone HD®) in a separate Phase 1/2 study. We are in discussions with regulators and intend to file in 2024.

•Seasonal flu + COVID-19 vaccine: The Phase 3 trial of our combination vaccine candidate against seasonal flu and COVID-19 (mRNA-1083) is fully enrolled. We anticipate data from the study in 2024.

Latent and Other Vaccines

•Cytomegalovirus (CMV) vaccine: The pivotal Phase 3 study of our CMV vaccine candidate (mRNA-1647) is fully enrolled and accruing cases, evaluating its efficacy, safety and immunogenicity in the prevention of primary infection in women of childbearing age. We anticipate potential efficacy data from the study in 2024.

Oncology Therapeutics

•Individualized Neoantigen Therapy (INT): We continue to demonstrate the potential clinical benefit of our INT program (mRNA-4157), which we are developing in collaboration with Merck. Two separate Phase 3 trials continue to enroll patients with resected high-risk (stage III/IV) melanoma and completely resected stage II, IIIA or IIIB non-small cell lung cancer. We and Merck plan to expand their clinical studies to additional tumor types in 2024.

In December 2023, we announced results of a three-year analysis of our Phase 2b study evaluating INT in combination with KEYTRUDA®, Merck’s anti-PD-1 therapy, in patients with resected high-risk melanoma. Compared to KEYTRUDA alone, this combination continued to show an improvement in recurrence-free survival, reducing the risk of recurrence or death by 49%, as well as in distant metastasis-free survival, reducing the risk of developing distant metastasis or death by 62%.

Rare Diseases

•Propionic acidemia (PA) & methylmalonic acidemia (MMA): We expect to advance our rare disease therapeutic programs for PA (mRNA-3927) and MMA (mRNA-3705) into pivotal studies in 2024.

Other Business Updates

In January 2023, we acquired OriCiro Genomics K.K., a Japan-based, privately held biotech company primarily focused on cell-free DNA synthesis and amplification technologies, for $86 million. With this acquisition, we obtained tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing. OriCiro’s technology strategically complements our manufacturing process, and we expect it will allow us to further accelerate our research and development efforts.

In February 2023, we entered into a strategic collaboration and license agreement with Life Edit Therapeutics Inc. (Life Edit) to collaborate on the discovery and development of in vivo mRNA gene editing therapies. The partnership will combine Life Edit’s suite of proprietary gene editing technologies, including base editing, with our mRNA platform to advance in vivo gene editing therapies against a select set of therapeutic targets.
85


In March 2023, we entered into a strategic collaboration and license agreement with Generation Bio Co. (GBIO). The collaboration aims to expand the application of each company’s platform by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate our respective pipelines of non-viral genetic medicines. Under the agreement, we have the option to license GBIO’s proprietary cell-targeted lipid nanoparticle (ctLNP) and closed-ended DNA (ceDNA) technology for two immune cell programs and two liver programs, with an additional option for either a third immune cell or liver program.

In September 2023, we announced a strategic research and development collaboration agreement with Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies. Upon effectiveness of the agreement in October 2023, we made an upfront payment of $120 million to Immatics. This collaboration between Moderna and Immatics centers on combining mRNA technology and T-cell receptor (TCR) platforms to develop cancer therapies, focusing on in vivo expression of TCR bispecifics (TCER®), creation of mRNA-based cancer vaccine utilizing extensive tumor data, and enhancing TCR-T cell therapy through combined preclinical and clinical studies.

86

Financial Operations Overview

Revenue

Net product sales

Net product sales by customer geographic location were as follows for the periods presented (in millions):
Years Ended December 31,
202320222021
United States$1,720 $4,405 $5,393 
Europe1,353 6,732 6,834 
Rest of world
3,598 7,298 5,448 
Total $6,671 $18,435 $17,675 

In the third quarter of 2023, we commenced sales of our COVID-19 vaccine to the U.S. commercial market, in addition to continuing sales to foreign governments and organizations. In the U.S., our COVID-19 vaccine is now sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns, and other related deductions. Please refer to Note 3 to our consolidated financial statements.

The following table summarizes product sales provision for the periods presented (in millions):
Years Ended December 31,
202320222021
Gross product sales $8,203 $18,435 $17,675 
Product sales provision:
Wholesaler chargebacks, discounts and fees
(976)— — 
Returns and other fees(556)— — 
Total product sales provision
$(1,532)$— $— 
Net product sales $6,671 $18,435 $17,675 

As of December 31, 2023, our COVID-19 vaccine was our only commercial product authorized for use.

As of December 31, 2023, we had deferred revenue of $613 million associated with customer deposits received or billable under supply agreements for delivery of our COVID-19 vaccine primarily in 2024.

Our net product sales for the full year 2023 declined significantly as compared to the full year 2022, reflecting the ongoing shift of the COVID-19 vaccine market toward a seasonal commercial market. In addition, we experienced greater seasonality for sales, with greater demand in the fall/winter seasons in each hemisphere as countries seek to provide booster vaccinations to their populations. For 2024, we expect the progression toward a seasonal commercial market to persist, resulting in further projected reductions in net product sales for our COVID-19 vaccine relative to 2023.

Other revenue

Other than net product sales, our revenue has been primarily derived from government-sponsored and private organizations including the Biomedical Advanced Research and Development Authority (BARDA), the Defense Advanced Research Projects Agency (DARPA) and the Bill & Melinda Gates Foundation and from strategic alliances with Merck & Co., Inc (Merck), Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, Vertex) and others to discover, develop, and commercialize potential mRNA medicines.

87

The following table summarizes other revenue for the periods presented (in millions):
Years Ended December 31,
202320222021
Grant revenue$94 $388 $735 
Collaboration revenue83 440 61 
Total other revenue$177 $828 $796 

Cost of sales

Cost of sales includes raw materials, personnel and facility and other costs associated with manufacturing our commercial products. These costs include production materials, production costs at our manufacturing facilities, third-party manufacturing costs, and final formulation and packaging costs. Cost of sales also includes shipping costs, indirect overhead costs associated with our product sales during the period, third-party royalties on net sales of our products, and charges for inventory valuation, excess and obsolete inventory and losses on firm purchase commitments.

Research and development expenses

The nature of our business and primary focus of our activities generate a significant amount of research and development costs.

Research and development expenses represent costs incurred by us for the following:

•cost to develop our platform;
•discovery efforts leading to development candidates;
•preclinical, nonclinical, and clinical development costs for our programs;
•cost to develop our manufacturing technology and infrastructure; and
•digital infrastructure costs related to our drug discovery efforts and clinical trials.

The costs above comprise the following categories:

•personnel-related expenses, including salaries, benefits, and stock-based compensation expense;
•expenses incurred under agreements with third parties, such as consultants, investigative sites, contract research organizations (CROs), that conduct our preclinical studies and clinical trials, and in-licensing arrangements;
•expenses associated with developing manufacturing, modification of formulation or design of a product or process, advancing the design to meet specific functional and economic requirements for manufacture and obtaining materials for preclinical studies, clinical trials and pre-launch inventory from internal and third-party contract manufacturing organizations (CMOs);
•expenses incurred for the procurement of materials, laboratory supplies, and non-capital equipment used in the research and development process;
•upfront fees and milestones paid to third-parties for licenses and technologies that had not reached technological feasibility and did not have an alternative future use; and
•facilities, depreciation, and amortization, and other direct and allocated expenses incurred as a result of research and development activities.

We use our employee and infrastructure resources for the advancement of our platform, and for discovering and developing programs. Due to the number of ongoing programs and our ability to use resources across several projects, indirect or shared operating costs incurred for our research and development programs are generally not recorded or maintained on a program- or modality-specific basis.
88


The following table reflects our research and development expenses, including direct program specific expenses summarized by modality and indirect or shared operating costs summarized under other research and development expenses during the years ended December 31, 2023, 2022, and 2021 (in millions):
Years Ended December 31,
202320222021
Program expenses by modality:
Infectious disease vaccines$2,344 $1,734 $1,099 
Cancer vaccines & therapeutics
70 14 47 
Rare disease intracellular therapeutics
75 42 26 
Intratumoral immuno-oncology23 10 20 
Inhaled pulmonary therapeutics17 18 1 
Systemic secreted and cell surface therapeutics33 23 3 
Total program-specific expenses by modality (1)
$2,562 $1,841 $1,196 
Other research and development expenses:
Discovery programs$106 $69 $85 
Platform research254 169 125 
Technical development and unallocated manufacturing expenses821 464 275 
Shared discovery and development expenses945 658 242 
Stock-based compensation157 94 68 
Total research and development expenses
$4,845 $3,295 $1,991 
__________
(1)Includes a total of 42 development candidates at December 31, 2023, 45 development candidates at December 31, 2022, and 37 development candidates at December 31, 2021. Program-specific expenses are reflected as of the beginning of the period in which the program was internally advanced to development or removed if development was ceased.

A “modality” refers to a group of programs with common product features and the associated combination of enabling mRNA technologies, delivery technologies, and manufacturing processes. The program-specific expenses by modality summarized in the table above include expenses we directly attribute to our programs, which consist primarily of external costs, such as fees paid to outside consultants, central laboratories, investigative sites, and CROs in connection with our preclinical studies and clinical trials, CMOs, and allocated manufacturing costs of pre-launch inventory, mRNA supply and consumables. Costs to acquire and manufacture pre-launch inventory, mRNA supply for preclinical studies and clinical trials are recognized and included in unallocated manufacturing expenses when incurred, and subsequently allocated to program-specific manufacturing costs after completion of the program-specific production. The timing of allocating manufacturing costs to the specific program varies depending on the program development and production schedule. We generally do not allocate personnel-related costs, including stock-based compensation, costs associated with our general platform research, technical development, and other shared costs on a program-specific basis. These costs were therefore excluded from the summary of program-specific expenses by modality.

Discovery program expenses are costs associated with research activities for our programs in the preclinical discovery stage, and primarily consist of external costs for CROs and lab services, and allocated manufacturing cost of preclinical mRNA supply and consumables.

Platform research expenses are mainly costs to develop technical advances in mRNA science, delivery science, and manufacturing process design. These costs include personnel-related costs, computer equipment, facilities, preclinical mRNA supply and consumables, and other administrative costs to support our platform research.

Technology development and unallocated manufacturing expenses are primarily related to non-program-specific manufacturing process development and manufacturing costs.

Shared discovery and development expenses are research and development costs such as personnel-related costs and other costs, which are not otherwise included in development programs, discovery programs, platform research, technical development, certain collaborative and licensing arrangements, and unallocated manufacturing expenses, stock-based compensation, and other expenses.

89

Historically, we have made substantial investments in research and development activities, including development of our platform, mRNA technologies, and manufacturing technologies. We expense research and development costs as incurred and cannot reasonably estimate the nature, timing, and estimated costs required to complete the development of the development candidates and investigational medicines we are currently developing or may develop in the future.

Changes in expectations or outcomes of any of the known or unknown risks and uncertainties may materially impact our expected research and development expenditures. Continued research and development is central to the ongoing activities of our business. Investigational medicines in later stages of clinical development, such as our RSV vaccine, seasonal flu vaccine, CMV vaccine, new generations of COVID-19 vaccines, combination vaccines, and our INT program, generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development costs to be substantial in the near term as our investigational medicines advance through development phases and as we identify and develop additional programs. We expect a modest reduction in research and development costs in 2024. There are numerous factors associated with the successful commercialization of any of our investigational medicines, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time due to the early stage of development of many of our investigational medicines. Moreover, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans.

Selling, general and administrative expenses

Selling, general and administrative expenses consist primarily of personnel-related costs, including stock-based compensation, for executives, finance, legal, human resources, business development, commercial, marketing, and other administrative and operational functions, professional fees, accounting and legal services, information technology and facility-related costs, and expenses associated with obtaining and maintaining intellectual property (IP). These costs relate to the operation of the business, unrelated to the research and development function, or any individual program.

We anticipate selling, general and administrative expenses to decrease marginally in 2024 compared to 2023. This is due to the continued development of our programs and preparations for commercial activities both within and outside the United States. Our global expansion has already led to increased expenses, particularly as we build our regulatory, sales and marketing teams to support the commercialization of our COVID-19 vaccines and extend our global presence, with active subsidiaries in 19 countries as of December 31, 2023. Commercial and marketing efforts were significant contributors to our selling, general and administrative expenses in 2023, making up a substantial portion of these costs. If we obtain regulatory approval for additional investigational medicines without establishing third-party commercialization collaboration and manufacturing collaborations, we may incur further costs in developing these operational capacities. However, we anticipate selling, general and administrative expenses to decrease slightly compared to 2024, reflecting efficiencies gained from our established infrastructure and operations.

We have a broad IP portfolio covering our development and commercialization of mRNA vaccine and therapeutic programs, including those related to mRNA design, formulation, and manufacturing platform technologies. We regularly file patent applications to protect innovations arising from our research and development. We also hold trademarks and trademark applications in the United States and foreign jurisdictions. Costs to secure and defend our IP are expensed as incurred, and are classified as selling, general and administrative expenses.

Interest income

Interest income consists of interest generated from our investments in cash and cash equivalents, money market funds, and high-quality fixed income securities.

Other expense, net

Other expense, net consists of interest expense, gains (losses) from the sale of investments in marketable securities, gains (losses) related to changes in fair value of investments in equity securities, and other income and expense unrelated to our core operations. Interest expense is primarily derived from our finance leases related to our Moderna Technology Center and certain contract manufacturing service agreements.

90

Critical accounting policies and significant judgments and estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, and experience. The effects of material revisions in estimates, if any, are reflected in the consolidated financial statements prospectively from the date of change in estimates.

While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies used in the preparation of our
consolidated financial statements require the most significant judgments and estimates.

Net product sales

Prior to the third quarter of 2023, we sold our COVID-19 vaccine to the U.S. Government, foreign governments and organizations. The agreements and related amendments with these entities generally do not include variable consideration, such as discounts, rebates or returns. In the third quarter of 2023, we commenced sales of our latest COVID-19 vaccine to the U.S. commercial market, in addition to continuing sales to foreign governments and organizations. In the U.S., our COVID-19 vaccine is sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers.

We recognize net product sales when control of the product transfers to the customer, typically upon delivery. Net product sales in the U.S. are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns, and other related deductions. These provisions are recorded based on contractual terms and our estimate of returns for product sold during the period, using the expected value method or the most likely amount method. Estimates are assessed each period and adjusted as required to revise information or actual experience. Please refer to Note 2 to our consolidated financial statements for further discussion and analysis of each significant category of product sales provisions and the accounting policy.

The application of our critical accounting policies necessitates substantial management judgment and estimation, particularly when determining the amount of variable consideration to recognize. The subjectivity of this process is heightened when assessing factors outside our direct control such as lack of pertinent historical data and limited third-party information. Among all variables, estimating returns presents the most significant judgment due to the broad range of potential outcomes and the current lack of return history with our customers. As we receive more historical data on our product returns, we will integrate this information to refine our estimates and enhance the precision of our financial projections. The actual results could differ from our estimates, and such differences could have a material impact to our financial statements.

Inventory

Inventory is recorded at the lower of cost or net realizable value, with cost determined using first-in, first-out and average cost methods for different inventory components. We periodically review the composition of inventory in order to identify excess, obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, we will record a write-down to net realizable value in the period that the decline in value is first recognized through a charge to cost of sales. The process of determining whether inventory cost will be realizable requires significant judgment and estimates by management. If actual market conditions prove less favorable than projected by management, additional write-downs of inventory may be required. On a quarterly basis, we also assess whether we have any excess firm, non-cancelable, purchase commitment liabilities, resulting from our supply agreements with third-party vendors. The determination of net realizable value and firm purchase commitment liabilities requires significant judgment, including consideration of many factors, such as estimates of future product demand, current and future market conditions, potential product obsolescence, expiration and utilization of raw materials under firm purchase commitments and contractual minimums, among others. In 2023, the significant judgment included the write-down of raw materials due to our revised long-range plan, reflecting lower expected future demand for our COVID-19 vaccine. In prior years, this significant judgement was related to excess raw material purchase commitments from firm, non-cancelable purchase contracts with third-party vendors.

We maintain raw materials beyond our one-year forecasted production plan, which were classified as non-current and included in other non-current assets in our consolidated balance sheets. The classification and valuation of these materials involve significant
91

judgment and estimates. While we consider the assumptions used in estimating inventory write-downs to be reasonable, any significant future changes in these assumptions or shifts in future events and market conditions could lead to different estimates. Please refer to Note 7 to our consolidated financial statements for further discussion and analysis of these inventory related charges.

Income taxes

We account for income taxes based on an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. We determine our deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Significant management judgment is required in assessing the realizability of our deferred tax assets. In performing this assessment, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, we consider the scheduled reversal of deferred tax liabilities, uncertain tax positions, projected future taxable income and the effects of tax planning strategies in assessing the need for a valuation allowance.

During 2023, our assessment included consideration of a full-year pre-tax loss and a projected three-year cumulative loss as determined by our long-range financial planning process. This process indicated a significant decrease in expected sales of our COVID-19 vaccine as we transition to a seasonal market and substantial research and development expenses for ongoing Phase 3 clinical trials and the advancement of product candidates into later-stage development. These factors were considered as negative evidence in the realizability of our deferred tax assets. Furthermore, in assessing the need for a valuation allowance, we evaluated other sources of taxable income, such as taxable income in carryback years, available tax planning strategies, and the future reversals of taxable temporary differences. After a thorough evaluation of all available evidence, we determined it was more likely than not that we would not realize the majority of our deferred tax assets, leading us to maintain a valuation allowance of $2.2 billion against our deferred tax assets as of December 31, 2023. In the event that actual results differ from our estimates, or if future changes in estimates occur, the adjustments to the valuation allowance could materially impact our financial results. Such changes may result in significant increases or decreases to our tax provision in a period in which such estimates are changed, which in turn would affect net income or loss.

Recently issued accounting pronouncements

See Note 2 - Summary of Significant Accounting Policies, to the consolidated financial statements, under the caption “Recently Issued Accounting Standards Not Yet Adopted”.
92


Results of operations

A discussion regarding our results of operations for the year ended December 31, 2023 compared to 2022 is presented below. A discussion regarding our results of operations for the year ended December 31, 2022 compared to 2021 can be found under Part II -Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission (SEC) on February 24, 2023.

The following table summarizes our consolidated statements of operations for the periods presented (in millions):
Years Ended December 31,
Change 2023 vs. 2022
20232022Change%
Revenue:
Net product sales$6,671 $18,435 $(11,764)(64)%
Other revenue177 828 (651)(79)%
Total revenue6,848 19,263 (12,415)(64)%
Operating expenses:
Cost of sales4,693 5,416 (723)(13)%
Research and development4,845 3,295 1,550 47 %
Selling, general and administrative1,549 1,132 417 37 %
Total operating expenses11,087 9,843 1,244 13 %
(Loss) income from operations(4,239)9,420 (13,659)(145)%
Interest income421 200 221 111 %
Other expense, net(124)(45)(79)176 %
(Loss) income before income taxes(3,942)9,575 (13,517)(141)%
Provision for income taxes772 1,213 (441)(36)%
Net (loss) income$(4,714)$8,362 $(13,076)(156)%

Revenue

Total revenue decreased by $12.4 billion, or 64%, in 2023, primarily attributable to a significant reduction in net product sales of our COVID-19 vaccine. Net product sales decreased by $11.8 billion, or 64%, in 2023, mainly due to lower sales volume across all regions in 2023, reflecting the market's transition to a seasonal commercial market for COVID-19 vaccine. The decline was partially offset by a higher average selling price, particularly in the United States, where commercial market sales commenced in the third quarter of 2023. Other revenue decreased by $651 million, or 79%, in 2023, mainly due to a decrease in grant revenue under our agreement with BARDA for the development of our COVID-19 vaccine, and lower collaboration revenue following the recognition of Merck's $250 million participation payment related to our INT collaboration in 2022.

Operating expenses

Cost of sales

In the third quarter 2023, we launched a strategic initiative aimed at optimizing the cost structure of our COVID-19 business, with an emphasis on resizing our manufacturing cost structure. This initiative was triggered by the completion of our long-range planning within the third quarter of 2023, which incorporated revised forecasts of vaccination rates reflecting the market's transition from COVID-19 pandemic conditions to an endemic seasonal market. The initiative involved scaling down our capacity and commitments with our third-party CMOs, reevaluating our raw material inventory levels, and reducing our purchase commitments related to raw materials not anticipated to be consumed before expiration. As a result of this initiative, we incurred inventory write-downs of $903 million related to raw materials, and CMO wind down costs and cancellation fees of $513 million. Furthermore, as a continuation of this strategic initiative during the fourth quarter of 2023, we incurred $153 million in CMO wind down costs and $16 million in inventory write-downs. We believe that this strategic initiative will enhance the efficiency of our manufacturing operations and provide us with the flexibility to better scale according to future market needs.

Our cost of sales was $4.7 billion, or 70% of our net product sales, in 2023, including third-party royalties of $301 million, inventory write-downs of $2.2 billion, unutilized manufacturing capacity and wind down costs of $981 million, and losses on firm purchase
93

commitments and cancellation fees of $205 million. Our cost of sales was $5.4 billion, or 29% of our net product sales, in 2022, including third-party royalties of $1.1 billion, inventory write-downs of $1.3 billion, unutilized manufacturing capacity and wind down costs of $677 million, and losses on firm purchase commitments and cancellation fees of $725 million. These charges, other than royalties, were largely attributable to a shift in product demand to the latest variant-targeted COVID-19 vaccine and a decline in customer demand, which ultimately led to our strategic initiative implemented in the third quarter of 2023.

Cost of sales for 2023 decreased by $723 million, or 13%, compared to 2022. The decrease in cost of sales was primarily driven by lower sales volume, partially offset by an increase in inventory write-downs. Cost of sales as a percentage of net product sales for 2023 increased by 41 percentage points to 70% from 29% in 2022. The increase in cost of sales as a percentage of net product sales was mainly due to the strategic initiative described above, and other aforementioned charges (excluding royalties) over lower net product sales, driven by a decline in product demand and increased product seasonality. In light of our recent strategic initiative implemented in the third quarter of 2023, we expect a reduction in our cost of sales as a percentage of net product sales for the full year 2024, compared to the full year 2023.

Research and development expenses

Research and development expenses increased by $1.6 billion, or 47%, in 2023. The increase was primarily attributable to increases in clinical trial expenses of $411 million, clinical manufacturing expenses of $335 million, personnel-related costs of $286 million, and consulting and outside services of $267 million. The increase in 2023 was largely attributable to the late-stage clinical development associated with our RSV vaccine, CMV vaccine and combination vaccine against seasonal influenza and COVID-19, as well as our INT program. The increase in personnel-related costs was mainly driven by an increase in the number of employees supporting our increased research and development programs and activities.

We anticipate a modest reduction in research and development expenses in 2024 compared to the current levels of 2023, as we continue to advance the development of variant-specific and next-generation COVID-19 vaccine candidates and continue to develop our pipeline and advance our product candidates into later-stage development, in particular those in ongoing Phase 3 studies, including our RSV, CMV, seasonal flu and combination vaccine programs, as well as our INT program.

Selling, general and administrative expenses

Selling, general and administrative expenses increased by $417 million, or 37%, in 2023. The increase was mainly due to increases in personnel-related costs of $188 million, consulting and outside services of $148 million, and marketing expense of $118 million, partially offset by an endowment to the Moderna Charitable Foundation of $50 million contributed in 2022 that did not recur in 2023. The increase in 2023 was primarily driven by increased headcount and spend in digital, medical affairs and commercial functions to support our digital initiatives, marketed product and Company expansion.

We anticipate that selling, general and administrative expenses in 2024 will be slightly lower than the levels experienced in 2023. This reflects our ongoing commitment to efficiency as we expand our global commercial, regulatory, sales and marketing infrastructure. Moreover, it aligns with our strategic focus on advancing our program development and enhancing our overall business processes.

Interest income

Interest income generated from our investments in marketable securities increased by $221 million in 2023, mainly attributable to an overall higher interest rate environment, partially offset by lower average investment balances.

Other expense, net

The following table summarizes other expense, net for the periods presented (in millions):
Years Ended December 31,
Change 2023 vs. 2022
20232022Change%
Loss on investments
$(72)$(20)$(52)260 %
Interest expense
(38)(29)(9)31 %
Other (expense) income, net
(14)4 (18)(450)%
Total other expense, net$(124)$(45)$(79)176 %

Total other expense, net increased by $79 million, or 176%, in 2023. The increase was primarily due to losses on equity investments and a net realized loss on available-for-sale debt securities as well as an increase in interest expense. Our interest expense is primarily
94

related to our finance leases. The increase in interest expense was driven by new finance leases that commenced in 2023. Please refer to Note 10 to our consolidated financial statements.

Provision for income taxes

Provision for income taxes decreased by $441 million, or 36%, in 2023, primarily due to a significant decrease in pre-tax income, partially offset by an increase in valuation allowance on deferred tax assets of $2.1 billion. Our effective tax rate for the year ended December 31, 2023 was (19.6)%, which is higher than the statutory rate. It is mainly driven by an increase in valuation allowances on deferred tax assets, partially offset by tax benefits from research and development credits and stock-based compensation. As a result of the significant reduction in pre-tax income and the valuation allowance, the 2023 effective tax rate is not comparable to the prior year. Please refer to Note 13 to our consolidated financial statements.

Liquidity and capital resources

The following table summarizes our cash, cash equivalents, investments and working capital for each period presented (in millions):
December 31,
20232022
Financial assets:
Cash and cash equivalents$2,907 $3,205 
Investments5,697 6,697 
Investments, non-current4,677 8,318 
Total$13,281 $18,220 
Working capital:
Current assets$10,325 $13,431 
Current liabilities3,015 4,923 
Total$7,310 $8,508 

Our cash, cash equivalents and investments are invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Our investments, consisting primarily of government and corporate debt securities, are stated at fair value. Cash, cash equivalents and investments as of December 31, 2023 decreased by $4.9 billion, or 27%, compared to December 31, 2022. For the year ended December 31, 2023, we had a net cash outflow from operations of $3.1 billion, repurchases of our common stock of $1.2 billion, and purchases of property, plant and equipment of $707 million.

Working capital, which is current assets less current liabilities, as of December 31, 2023 decreased by $1.2 billion, or 14%, compared to December 31, 2022, primarily due to a decrease in cash, cash equivalents and short-term investments of $1.3 billion, primarily to fund our operating activities and repurchases of our common stock, a decrease in inventory of $747 million, a decrease in prepaid and other current assets of $568 million, and a decrease in accounts receivable, net of $493 million. This was partially offset by a decrease in short-term deferred revenue of $1.5 billion, mainly driven by revenue recognized from deferred revenue in excess of customer deposits received.

Cash flow

The following table summarizes the primary sources and uses of cash for the periods presented (in millions):
Years Ended December 31,
20232022
Net cash (used in) provided by:
Operating activities
$(3,118)$4,981 
Investing activities
4,206 (5,176)
Financing activities
(1,377)(3,448)
Net decrease in cash and cash equivalents
$(289)$(3,643)

95

Operating activities

We derive cash flows from operations primarily from cash collected from customer deposits and accounts receivable, net related to our COVID-19 vaccine product sales, as well as certain government-sponsored and private organizations and strategic alliances. Our cash flows from operating activities are significantly affected by our use of cash for operating expenses and working capital to support the business. Beginning in the third quarter of 2020, we entered into supply agreements with the U.S. Government and foreign governments and organizations for the supply of our COVID-19 vaccine and received upfront deposits. In the third quarter of 2023, we commenced sales of our COVID-19 vaccine to the U.S. commercial market, in addition to continuing sales to foreign governments and organizations. In the U.S., our COVID-19 vaccine is sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Wholesalers and distributors typically do not make upfront payments to us. As of December 31, 2023, we had $613 million in deferred revenue related to customer deposits received or billable.

Net cash used by operating activities in 2023 was $3.1 billion and consisted of net loss of $4.7 billion and non-cash adjustments of $1.7 billion, plus a net change in assets and liabilities of $139 million. Non-cash items primarily included deferred income taxes of $828 million, depreciation and amortization of $621 million, and stock-based compensation of $305 million. The net change in assets and liabilities was primarily due to a decrease in deferred revenue of $2.1 billion due to revenue recognized upon shipments of our COVID-19 vaccine, partially offset by a decrease in prepaid expenses and other assets of $1.0 billion, primarily driven by write-downs of long term inventory, decrease in income tax receivable due to receipt of tax refunds and decrease in pre-tax income, and reductions in vendor prepayments and down payments as well as a decrease in inventory of $747 million due to inventory write-downs.

Net operating cash flows decreased by $8.1 billion, or 163%, in 2023 compared to 2022, primarily attributable to a decrease in net income of $13.1 billion, a $1.3 billion change in accounts receivable due to lower product sales and timing of collection, and a $1.2 billion change in accounts payable and accrued liabilities driven by higher vendor spend and timing of payments. This was partially offset by a change in prepaid expenses and other assets of $2.7 billion primarily driven by inventory write-downs and reductions in vendor down payments, a change in deferred revenue of $2.1 billion due to less revenue recognized from deferred revenue in excess of customer deposits received, and a decrease in deferred income tax assets of $1.4 billion due to an increase in valuation allowance.

Investing activities

Our primary investing activities consist of purchases, sales, and maturities of our investments, capital expenditures for land, leasehold improvements, manufacturing, laboratory, computer equipment and software, and business development.

Net cash provided by investing activities in 2023 was $4.2 billion, which primarily included proceeds from maturities of marketable securities of $5.6 billion and proceeds from sales of marketable securities of $3.2 billion, partially offset by purchases of marketable securities of $3.8 billion, and purchases of property, plant and equipment of $707 million.

Net investing cash flows increased by $9.4 billion, or 181%, in 2023 compared to 2022, primarily due to a decrease in purchases of marketable securities of $7.7 billion and an increase in proceeds from maturities of marketable securities of $2.4 billion.

Financing activities

Our primary financing activities consist of repurchases of common stock, issuance of common stock related to our equity plans, and finance leases.

Net cash used in financing activities in 2023 was $1.4 billion, primarily from repurchases of common stock of $1.2 billion and changes in financing lease liabilities of $270 million, partially offset by net proceeds from the issuance of common stock in connection with the exercise of stock options and employee stock purchases under our equity plans of $46 million.

Net cash used in financing activities decreased by $2.1 billion, or 60%, in 2023 compared to 2022, mainly due to a decrease in repurchases of common stock.

Operation and funding requirements

Our principal sources of funding as of December 31, 2023 consisted of cash and cash equivalents, investments, and cash we may generate from operations. We generated net income of $8.4 billion and $12.2 billion for the years ended 2022 and 2021, respectively,
96

following the authorization of our first commercial product in December 2020. We also incurred a net loss of $4.7 billion for the year ended December 31, 2023. We have retained earnings of $13.6 billion as of December 31, 2023.

We have significant future capital requirements including expected operating expenses to conduct research and development activities, operate our organization, and meet capital expenditure needs. We anticipate maintaining substantial expenses across all areas of our ongoing activities, particularly as we continue research and development of our development candidates and clinical activities for our investigational medicines. This also extends to our manufacturing costs, including our arrangements with our supply and manufacturing partners. Our ongoing work on our RSV, seasonal flu and CMV vaccine candidates, individualized neoantigen therapy, COVID-19 vaccines, including development of any new vaccines against variants of SARS-CoV-2, combination vaccines, late-stage clinical development, and buildout of global commercial, regulatory, sales and marketing infrastructure and manufacturing facilities will require significant cash outflows in future periods, most of which may not be reimbursed or otherwise paid for by our partners or collaborators. In addition, we have substantial facility, lease and purchase obligations. We have also entered into certain collaboration agreements with third parties that include the funding of certain research and development activities and potential future milestone and royalty payments by us.

We believe that our cash, cash equivalents, and investments as of December 31, 2023, together with cash expected to be generated from product sales, will be sufficient to enable us to fund our projected operations and capital expenditures through at least the next 12 months from the issuance of the financial statements included in this Annual Report on Form 10-K. We are subject to all the risks related to the development and commercialization of novel medicines, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors, which may adversely affect our business. For example, we have experienced a decline in customer demand for our COVID-19 vaccine, reflecting the market's ongoing transition to a seasonal model in an endemic market in 2023. We foresee that our commitment to investing in our business for future product launches may lead to continued negative cash flows from operations in upcoming periods. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.

Contractual obligations and commitments

The following table summarizes our contractual obligations as of December 31, 2023 and the effects that such obligations are expected to have on our liquidity and cash flows in future periods (in millions):
Payments Due by Period
Total
Less than 1
year
1 - 3 years3 - 5 years
More than 5
years
Operating leases
$1,133 $72 $134 $142 $785 
Financing leases(1)
1,184 20 44 46 1,074 
Purchase obligations(2)
2,103 1,002 685 272 144 
Total contractual cash obligations$4,420 $1,094 $863 $460 $2,003 
_______

(1)The amounts in the table include a total payment of $668 million associated with our MTC leases for the optional lease extension periods. For accounting purposes, a lease term is the non-cancelable period of the lease and includes options to extend or terminate the lease when it is reasonably certain that an option will be exercised. Please refer to Note 10 to our consolidated financial statements.
(2)The amounts represent non-cancelable fixed payment obligations related to purchases of raw materials, contract manufacturing services, clinical services and other goods or services in the normal course of business. As of December 31, 2023, $79 million of the purchase commitments related to raw materials was recorded as an accrued liability for loss on future firm purchase commitments.

We have agreements with certain vendors for various services, including services related to clinical operations, and support and contract manufacturing, which we are not contractually able to terminate for convenience. Certain agreements provide for termination rights subject to termination fees or wind down costs. Under such agreements, we are contractually obligated to make certain payments to vendors, mainly to reimburse them for their unrecoverable outlays incurred prior to cancellation. The exact amounts of such obligations are dependent on the timing of termination, and the exact terms of the relevant agreement and cannot be reasonably estimated. At December 31, 2023, we had cancelable open purchase orders of $3.0 billion in total under such agreements for our clinical operations and support and contract manufacturing. These amounts represent only our estimate of those items for which we
97

had a contractual commitment to pay at December 31, 2023, assuming we would not cancel these agreements. The actual amounts we pay in the future to the vendors under such agreements may differ from the cancelable open purchase order amounts of $3.0 billion.

In addition to the above obligations, we enter into a variety of agreements and financial commitments in the normal course of business. The terms generally allow us the option to cancel, reschedule, and adjust our requirements based on our business needs, prior to the delivery of goods or performance of services. It is not possible to predict the maximum potential amount of future payments under these agreements due to the conditional nature of our obligations and the unique facts and circumstances involved in each particular agreement.

As of December 31, 2023, we did not have any off-balance sheet arrangements that were material or reasonably likely to become material to our financial condition or results of operations.

98

Item 7A. Quantitative and Qualitative Disclosures about Market Risk
Interest Rate Risk

As of December 31, 2023 and 2022, we had cash, cash equivalents, restricted cash, and investments in marketable securities of $13.3 billion and $18.2 billion, respectively. Our investment portfolio comprises money market funds and marketable debt securities (including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities, and commercial paper), which are classified as available-for-sale securities. Our primary investment objectives are the preservation of capital and the maintenance of liquidity, and our investment policy defines allowable investments based on quality of the institutions and financial instruments designed to minimize risk exposure. Our exposure to interest rate sensitivity is affected by changes in the general level of U.S. interest rates.

Our marketable securities are subject to interest rate risk and will fall in value if market interest rates increase. Due to the short-term maturities and low risk profiles of our investments, we do not anticipate a significant exposure to interest rate risk. If market interest rates were to increase immediately and uniformly by one percentage point from levels at December 31, 2023, the net fair value of our marketable securities would decrease by approximately $83 million.

Foreign Currency Risk

We transact business in various foreign currencies and have international sales and expenses denominated in foreign currencies. Therefore, we are exposed to certain risks arising from both our business operations and economic conditions. For the year ended December 31, 2023, our revenue generating activities and operations continued to be primarily denominated in U.S. dollars. However, we maintained a significant exposure to foreign currency risk, particularly in the Euro, Japanese Yen and Swiss Franc markets, Our significant foreign currency revenue exposure was the equivalent of $1.4 billion in Japanese Yen and $518 million in Euros for 2023. As we pursue our international expansion strategy, our results of operations and cash flows remain subject to fluctuations in foreign currency exchange rates. To manage the exposure to foreign currency exchange rate fluctuations, we have implemented cash flow hedging and balance sheet hedging programs.

Cash Flow Hedging Activities

We mitigate the foreign exchange risk arising from the fluctuations in foreign currency denominated product sales in Euro and Japanese Yen through a foreign currency cash flow hedging program, using forward contracts and foreign currency options that do not exceed 15 months in duration. We hedge these cash flow exposures to reduce the risk that our earnings and cash flows will be adversely affected by changes in exchange rates. To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be highly effective in offsetting changes to future cash flows on hedged transactions. The derivative assets or liabilities associated with our hedging activities are recorded at fair value in prepaid expenses and other current assets or other current liabilities, respectively, in our consolidated balance sheets. The gains or losses resulting from changes in the fair value of these hedges are initially recorded as a component of accumulated other comprehensive (loss) income (AOCI) in stockholders’ equity and subsequently reclassified to product sales in the period during which the hedged transaction affects earnings. In the event the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, within the defined hedge period, we reclassify the gains or losses on the related cash flow hedge from AOCI to other expense, net, in our consolidated statements of operations. We evaluate hedge effectiveness at the inception of the hedge prospectively, and on an on-going basis both retrospectively and prospectively. If we do not elect hedge accounting, or the contract does not qualify for hedge accounting treatment, the changes in fair value from period to period are recorded as a component of other expense, net, in our consolidated statements of operations. We had no outstanding foreign currency forward contracts or foreign currency options as of December 31, 2023. Foreign currency hedging activities were immaterial during 2023.

Balance Sheet Hedging Activities

We enter into foreign currency forward contracts to hedge fluctuations associated with foreign currency denominated monetary assets and liabilities, primarily cash, accounts receivable, accounts payable and lease liabilities in Euro, Swiss Franc and Japanese Yen, that are not designated for hedge accounting treatment. Therefore, these forward contracts are accounted for as derivatives whereby the fair value of the contracts are reported as prepaid expenses and other current assets or other current liabilities in our consolidated balance sheets, and gains and losses resulting from changes in the fair value are recorded as a component of other expense, net, in our consolidated statements of operations. The gains and losses on these foreign currency forward contracts generally offset the gains and losses in the underlying foreign currency denominated assets and liabilities, which are also recorded to other expense, net, in our consolidated statements of operations. As of December 31, 2023, our outstanding balance sheet hedging derivatives, carried at fair value, had maturities of less than three months.

We enter into these foreign exchange contracts to hedge our forecasted revenue and monetary assets and liabilities denominated in foreign currency in the normal course of business and accordingly, they are not speculative in nature. We believe the counterparties to
99

our foreign currency forward contracts are creditworthy multinational commercial banks. While we believe the risk of counterparty nonperformance is not material, a sustained decline in the financial stability of financial institutions as a result of disruption in the financial markets could affect our ability to secure creditworthy counterparties for our foreign currency hedging programs.

Notwithstanding our efforts to mitigate some foreign currency exchange risks, there can be no assurance that our hedging activities will adequately protect us against the risks associated with foreign currency fluctuations. As of December 31, 2023, a hypothetical adverse movement of 10 percent in foreign currency exchange rates compared to the U.S. dollars across all maturities would have resulted in potential declines in the fair value on our foreign currency forward contracts used in balance sheet hedging of approximately $23 million. We expect that any increase or decrease in the fair value of the portfolio would be substantially offset by increases or decreases in the underlying exposures being hedged.
100

Item 8. Financial Statements and Supplementary Data
MODERNA, INC.
 
101

Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of Moderna, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Moderna, Inc. (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 23, 2024, expressed an unqualified opinion thereon.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Reserves for returns on product revenue
Description of the Matter
During the year ended December 31, 2023, the Company’s net product revenues for Spikevax were $6.7 billion. As explained in Note 2 of the consolidated financial statements, revenue from product sales includes estimates of variable consideration for which reserves are established, including reserves for product returns.

Auditing the Company’s measurement of reserves for product returns under its contracts with wholesalers, distributors and retail customers (collectively, “Customers”) was especially challenging because (1) it involves management assumptions about inventory remaining in the distribution channel as of the balance sheet date that could be subject to return in future periods and projected market demand, and (2) the Company has limited returns history on which to base its assumptions.

102

How We Addressed the Matter in Our Audit
We obtained an understanding, evaluated the design and tested the operating effectiveness of internal controls over the Company’s process to determine reserves for returns on product revenue. For example, we tested controls over management’s review of the completeness and accuracy of the data used in the process and the assumptions about the amount of inventory in the distribution channel that could be subject to return in future periods.

To test the Company’s reserves for returns on product revenue, our audit procedures included, among other procedures, testing the accuracy and completeness of the underlying data used in the calculations and evaluating the assumptions used by management to estimate its reserves. To test management’s assumptions, we inspected agreements with significant Customers to validate the rights of return, made inquiries of members of the commercial function regarding any changes to the terms and conditions of commercial contracts. We also examined credit memos issued during and after year end for unusual items or trends not consistent with the Company’s analysis of product returns and performed revenue cutoff testing at period end to assess whether there were unusual trends that should have been considered in the Company analysis of product returns. In addition, we reviewed inventory on hand-reporting from significant Customers at the balance sheet date and subsequent to the balance sheet date and inspected vaccination data from third-party sources through the report date. We also performed sensitivity analyses over the Company’s return rate to assess the effect of changes in assumptions.

Raw Material Inventory Write-downs
Description of the Matter
As of December 31, 2023, the Company had $0.4 billion of inventory. As disclosed in Note 2, inventory is recorded at the lower of cost or net realizable value. The Company periodically reviews the composition of inventory in order to identify excess, obsolete, slow-moving or otherwise unsaleable items. For the year ended December 31, 2023, inventory write-downs were $2.2 billion, which included $903 million in raw material inventory write-downs resulting from the Company’s long-range financial planning process in the third quarter of 2023.

Auditing management's estimates for raw material inventory write-downs involved especially subjective auditor judgment because the estimates rely on a number of factors that are affected by market and economic conditions outside the Company’s control. In particular, raw material inventory write-downs are sensitive to significant assumptions, including the expected demand for the Company’s products and the expiration dates of the raw materials.

How We Addressed the Matter in Our Audit
We obtained an understanding, evaluated the design, and tested the operating effectiveness of internal controls over the Company's raw material inventory write-down process including management’s review of the significant assumptions described above and controls over the completeness and accuracy of the information used to develop the estimates.

To test the Company’s raw material inventory write-downs, our audit procedures included, among other procedures, testing the accuracy and completeness of the underlying data used in the calculations and evaluating the assumptions used by management in its estimates. Our testing of the data used in the Company’s estimates included the accuracy of the raw material expiration dates used, materials required in the Company’s products, and any alternate uses. We evaluated the Company’s forecast of future demand, including testing of the significant assumptions within its forecast, and evaluating the consistency of the forecast with that used by management for other purposes. We also performed sensitivity analyses to assess the impact of changes in significant assumptions to the raw material inventory write-downs and evaluated any contrary evidence identified.

/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2014.
Boston, Massachusetts
February 23, 2024
103

MODERNA, INC.
CONSOLIDATED BALANCE SHEETS
(In millions, except per share data)
December 31,
20232022
Assets
Current assets:
Cash and cash equivalents$2,907 $3,205 
Investments5,697 6,697 
Accounts receivable, net892 1,385 
Inventory202 949 
Prepaid expenses and other current assets627 1,195 
Total current assets10,325 13,431 
Investments, non-current4,677 8,318 
Property, plant and equipment, net1,945 2,018 
Right-of-use assets, operating leases713 121 
Deferred tax assets81 982 
Other non-current assets685 988 
Total assets$18,426 $25,858 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$520 $487 
Accrued liabilities1,798 2,101 
Deferred revenue568 2,038 
Income taxes payable63 48 
Other current liabilities66 249 
Total current liabilities3,015 4,923 
Deferred revenue, non-current83 673 
Operating lease liabilities, non-current643 92 
Financing lease liabilities, non-current575 912 
Other non-current liabilities256 135 
Total liabilities4,572 6,735 
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $0.0001; 162 shares authorized as of December 31, 2023 and 2022; no shares issued or outstanding at December 31, 2023 and 2022
— — 
Common stock, par value $0.0001; 1,600 shares authorized as of December 31, 2023 and 2022; 382 and 385 shares issued and outstanding as of December 31, 2023 and 2022, respectively
— — 
Additional paid-in capital371 1,173 
Accumulated other comprehensive loss(123)(370)
Retained earnings13,606 18,320 
Total stockholders’ equity13,854 19,123 
Total liabilities and stockholders’ equity$18,426 $25,858 
The accompanying notes are an integral part of these consolidated financial statements.
104

MODERNA, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In millions, except per share data)
Years Ended December 31,
202320222021
Revenue:
Net product sales$6,671 $18,435 $17,675 
Other revenue177 828 796 
Total revenue
6,848 19,263 18,471 
Operating expenses:
Cost of sales4,693 5,416 2,617 
Research and development4,845 3,295 1,991 
Selling, general and administrative1,549 1,132 567 
Total operating expenses11,087 9,843 5,175 
(Loss) income from operations(4,239)9,420 13,296 
Interest income421 200 18 
Other expense, net(124)(45)(29)
(Loss) income before income taxes(3,942)9,575 13,285 
Provision for income taxes772 1,213 1,083 
Net (loss) income$(4,714)$8,362 $12,202 
(Loss) earnings per share:
Basic$(12.33)$21.26 $30.31 
Diluted$(12.33)$20.12 $28.29 
Weighted average common shares used in calculation of (loss) earnings per share:
Basic382 394 403 
Diluted382 416 431 

The accompanying notes are an integral part of these consolidated financial statements.
105

MODERNA, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(In millions)
Years Ended December 31,
202320222021
Net (loss) income$(4,714)$8,362 $12,202 
Other comprehensive income (loss), net of tax:    
Available-for-sale securities:
Unrealized gains (losses) on available-for-sale debt securities210 (348)(42)
Less: net realized losses (gains) on available-for-sale securities reclassified in net (loss) income38 26 (1)
Net increase (decrease) from available-for-sale debt securities248 (322)(43)
Cash flow hedges:
Unrealized gains on derivative instruments— 130 74 
Less: net realized losses (gains) on derivative instruments reclassified in net (loss) income8 (154)(58)
Net increase (decrease) from derivatives designated as hedging instruments8 (24)16 
Pension and postretirement benefit plans:
Pension and postretirement obligation adjustments
(9)— — 
Total other comprehensive income (loss)    247 (346)(27)
Comprehensive (loss) income$(4,467)$8,016 $12,175 

The accompanying notes are an integral part of these consolidated financial statements.
106

MODERNA, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(In millions)
Common StockAdditional
Paid-In
Capital		Accumulated
Other
Comprehensive
(Loss) Income		Retained Earnings (Accumulated
Deficit)
Total
Stockholders’
Equity
SharesAmount
Balance at December 31, 2020399 $— $4,802 $3 $(2,244)$2,561 
Exercise of options to purchase common stock7 — 112 — — 112 
Issuance of common stock under employee stock purchase plan— — 12 — — 12 
Stock-based compensation— — 142 — — 142 
Other comprehensive loss, net of tax— — — (27)— (27)
Repurchase of common stock(3)— (857)— — (857)
Net income— — — — 12,202 12,202 
Balance at December 31, 2021403 $— $4,211 $(24)$9,958 $14,145 
Common StockAdditional
Paid-In
Capital		Accumulated
Other
Comprehensive
Loss		Retained Earnings
Total
Stockholders’
Equity
SharesAmount
Balance at December 31, 2021403 $— $4,211 $(24)$9,958 $14,145 
Vesting of restricted common stock1 — — — — — 
Exercise of options to purchase common stock4 — 50 — — 50 
Issuance of common stock under employee stock purchase plan— — 15 — — 15 
Stock-based compensation— — 226 — — 226 
Other comprehensive loss, net of tax— — — (346)— (346)
Repurchase of common stock(23)— (3,329)— — (3,329)
Net income— — — — 8,362 8,362 
Balance at December 31, 2022385 $— $1,173 $(370)$18,320 $19,123 
107

Common StockAdditional
Paid-In
Capital		Accumulated
Other
Comprehensive
(Loss) Income		Retained Earnings
Total
Stockholders’
Equity
SharesAmount
Balance at December 31, 2022385 $— $1,173 $(370)$18,320 $19,123 
Vesting of restricted common stock1 — — — — — 
Exercise of options to purchase common stock4 — 25 — — 25 
Issuance of common stock under employee stock purchase plan— — 21 — — 21 
Stock-based compensation— — 305 — — 305 
Other comprehensive income, net of tax— — — 247 — 247 
Repurchase of common stock, including excise tax(8)— (1,153)— — (1,153)
Net loss— — — — (4,714)(4,714)
Balance at December 31, 2023382 $— $371 $(123)$13,606 $13,854 

The accompanying notes are an integral part of these consolidated financial statements.
108

MODERNA, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
Years Ended December 31,
202320222021
Operating activities
Net (loss) income$(4,714)$8,362 $12,202 
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Stock-based compensation305 226 142 
Depreciation and amortization621 348 232 
Amortization/accretion of investments(61)31 54 
Loss on equity investments, net35 — — 
Deferred income taxes828 (559)(318)
Other non-cash items7 28 — 
Changes in assets and liabilities, net of acquisition of business:
Accounts receivable, net493 1,790 (1,784)
Prepaid expenses and other assets974 (1,699)(489)
Inventory747 492 (1,394)
Right-of-use assets, operating leases(605)21 (58)
Accounts payable13 240 204 
Accrued liabilities(340)612 989 
Deferred revenue(2,060)(4,157)2,824 
Income taxes payable15 (828)876 
Operating lease liabilities551 (14)17 
Other liabilities73 88 123 
Net cash (used in) provided by operating activities(3,118)4,981 13,620 
Investing activities
Purchases of marketable securities(3,760)(11,435)(12,652)
Proceeds from maturities of marketable securities5,575 3,151 1,338 
Proceeds from sales of marketable securities3,206 3,548 3,105 
Purchases of property, plant and equipment(707)(400)(284)
Acquisition of business, net of cash acquired(85)— — 
Investment in convertible notes and equity securities(23)(40)(30)
Net cash provided by (used in) investing activities4,206 (5,176)(8,523)
Financing activities
Proceeds from issuance of common stock through equity plans46 65 124 
Repurchase of common stock, including excise tax(1,153)(3,329)(857)
Changes in financing lease liabilities(270)(184)(140)
Net cash used in financing activities(1,377)(3,448)(873)
Net (decrease) increase in cash, cash equivalents and restricted cash(289)(3,643)4,224 
Cash, cash equivalents and restricted cash, beginning of year3,217 6,860 2,636 
Cash, cash equivalents and restricted cash, end of year
$2,928 $3,217 $6,860 
Supplemental cash flow information
Cash (received) paid for income taxes$(357)$2,729 $480 
Cash paid for interest$39 $25 $14 
Non-cash investing and financing activities
Purchases of property, plant and equipment included in accounts payable and accrued liabilities$130 $72 $111 

The accompanying notes are an integral part of these consolidated financial statements.
109

MODERNA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. Description of the Business

Moderna, Inc. (collectively, with its consolidated subsidiaries, any of Moderna, we, us, our or the Company) is a biotechnology company advancing a new class of medicines made of messenger RNA (mRNA). mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates. We are developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with our strategic collaborators.

Our COVID-19 vaccine is our first commercial product and is marketed, where approved, under the name Spikevax®. Our original vaccine, mRNA-1273, targeted the SARS-CoV-2 ancestral strain, and we have leveraged our mRNA platform to rapidly adapt our vaccine to emerging SARS-CoV-2 strains to provide protection as the virus evolves and regulatory guidance is updated.

We have a diverse and extensive development pipeline of 42 development candidates across our 45 development programs, of which 40 are in clinical studies currently.

2. Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).

The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

Other revenue in the consolidated statements of operations comprises grant revenue and collaboration revenue that were previously presented as separate line items in our consolidated statements of operations in our 2022 Form 10-K. The associated prior period amounts in the consolidated financial statements, as well as in the notes thereto, have been reclassified to conform to the current presentation.

Use of Estimates

We have made estimates and judgments affecting the amounts reported in our consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods that are not readily apparent from other sources. Changes in our estimates are recorded in the financial results of the period in which the new information becomes available. The actual results that we experience may differ materially from our estimates.

Segment Information

We have determined that our chief executive officer is the chief operating decision maker (CODM). The CODM reviews financial information presented on a consolidated basis. Resource allocation decisions are made by the CODM based on consolidated results. There are no segment managers who are held accountable by the CODM for operations, operating results, and planning for levels or components below the consolidated unit level. As such, we have concluded that we operate as one segment.

110

Revenue Recognition

To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following five steps (the five-step model): (i) identify the contract(s) with our customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as each performance obligation is satisfied.

Net Product Sales

Prior to the third quarter of 2023, we sold our COVID-19 vaccine to the U.S. Government, foreign governments and organizations. The agreements and related amendments with these entities generally do not include variable consideration, such as discounts, rebates or returns. Certain of these agreements entitle us to upfront deposits for our COVID-19 vaccine supply, initially recorded as deferred revenue. In the third quarter of 2023, we commenced sales of our latest COVID-19 vaccine to the U.S. commercial market, in addition to continuing sales to international governments and organizations. In the U.S., our COVID-19 vaccine is sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Wholesalers and distributors typically do not make upfront payments to us.

We recognize net product sales when control of the product transfers to the customer, typically upon delivery. Payment terms generally range from 30 to 60 days, in line with customary practices in each country. Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns, and other related deductions. These provisions are recorded based on contractual terms and our estimate of returns for product sold during the period, using the expected value method or the most likely amount method. We update our estimates quarterly and record necessary adjustments in the period when we identify the adjustments. Product sales, net of provisions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable when the uncertainty associated with the provisions is subsequently resolved. Shipping and handling activities are considered fulfillment activities and not a separate performance obligation. Taxes assessed by governmental authorities that are imposed on and collected from our product sales are excluded from net product sales.

Wholesaler chargebacks, discounts and fees

We contract with retailers, healthcare providers, and group purchasing organizations (GPO) to broaden our customer reach and offer contractual discounts. The chargeback represents the difference between the invoice price billed to the wholesaler and the negotiated price charged to the retailers, healthcare providers and GPO members. For distribution and related services, such as stocking and cold chain storage, we provide compensation to our wholesalers and distributors. We typically offer our customers invoice discounts on product sales for prompt payments and pre-orders. The estimation of these discounts and fees is based on contractual terms and our expectations regarding future customer payment behaviors. Wholesaler fees and invoice discounts are deducted from our gross product sales and accounts receivable at the time such product sales are recognized.

Product returns

We typically offer customers in the U.S. the right to return products, up to a certain limit as stipulated in our contracts. Estimated returns for our COVID-19 vaccine are determined considering available return rates for similar products, estimated levels of inventory in the distribution channel, and projected market demand. The estimated amount for product returns is presented within accrued liabilities on our consolidated balance sheets and is deducted from our gross product sales in the period the related product sales are recognized.

Other fees

Fees payable to third party payers and healthcare providers, along with fees to our direct customers that are settled via cash payments, including certain patient assistance programs, are recorded as accrued liabilities on our consolidated balance sheets.

Determining the amount of variable consideration to recognize necessitates substantial judgment, especially when assessing factors outside our direct control such as lack of pertinent historical data and limited third-party information. Among all variables, estimating returns presents the most significant judgment due to the broad range of potential outcomes and the current lack of return history with our customers. As we receive more historical data on our product returns, we will integrate this information to refine our estimates and enhance the precision of our financial projections. The actual results could differ from our estimates, and such differences could have a material impact to our financial statements.

111

Other Revenue

Other revenue consists primarily of grant revenue and collaboration revenue.

Grant revenue

We have contracts with government-sponsored and private organizations for research and development related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs as well as a related profit margin. We recognize grant revenue from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized when incurred as research and development expense. Grant revenue and related expenses are presented gross in the consolidated statements of operations as we have determined we are the primary obligor under the arrangements relative to the research and development services we perform as lead technical expert.

Collaboration Revenue

We have entered into strategic collaborations and other similar arrangements with third parties for research and other licenses, development and commercialization of certain products and product candidates. Such arrangements provide for various types of payments to us, including upfront fees, funding of research and development services and preclinical and clinical material, technical, development, regulatory, and commercial milestone payments, licensing fees, option exercise fees, and royalty and earnout payments on product sales. Such payments are often not commensurate with the timing of revenue recognition and therefore result in deferral of revenue recognition. We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer.

Cash and Cash Equivalents

We consider all highly liquid investments with an original maturity of 90 days or less from the date of purchase to be cash equivalents.

Restricted Cash

Restricted cash is composed of amounts held on deposit related to our lease arrangements and funds held in an escrow account related to a business acquisition in 2023. The funds are maintained in money market accounts and are recorded at fair value. Restricted cash is classified as either current or non-current based on the terms of the underlying arrangement and is included in either prepaid expenses and other current assets or other non-current assets in our consolidated balance sheets.

Cash, Cash Equivalents and Restricted Cash shown in the Consolidated Statements of Cash Flows

The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):
December 31,
202320222021
Cash and cash equivalents $2,907 $3,205 $6,848 
Restricted cash(1)
17 — — 
Restricted cash, non-current(2)
4 12 12 
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows$2,928 $3,217 $6,860 
_______
(1)Included in prepaid expenses and other current assets in the consolidated balance sheets.
(2)Included in other non-current assets in the consolidated balance sheets.

Investments

We invest our excess cash balances in marketable debt securities. We classify our investments in marketable debt securities as available-for-sale. We report our available-for-sale securities at fair value at each balance sheet date, and include any unrealized holding gains and losses (the adjustment to fair value) in accumulated other comprehensive income (loss), a component of stockholders’ equity. Realized gains and losses are determined using the specific-identification method, and are included in other expense, net in our consolidated statements of operations. We classify our available-for-sale securities as current or non-current based on each instrument’s underlying effective maturity date and for which we have the intent and ability to hold the investment for a
112

period of greater than 12 months. Available-for-sale securities with maturities of less than 12 months are classified as current and are included in investments in the consolidated balance sheets. Available-for-sale securities with maturities greater than 12 months for which we have the intent and ability to hold the investment for greater than 12 months are classified as non-current and are included in investments, non-current in the consolidated balance sheets.

We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit- related is recognized in other comprehensive income (loss), net of applicable taxes.

Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in other expense, net, in our consolidated statements of operations. Investments in equity securities without readily determinable fair values are recorded at cost minus impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in other expense, net, in our consolidated statements of operations.

Accounts Receivable, net

Accounts receivable, net represent amounts due from customers less wholesalers chargebacks, discounts and fees (please refer to our “Revenue Recognition” policy within Note 2 for product sales provision) and allowance for expected credit losses. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. To estimate the allowance for credit losses, we determine the allowance based on ongoing credit evaluation, historical experience and the aging of such receivables, among other factors. There was no allowance for doubtful accounts at December 31, 2023 or 2022. Additionally, bad debt expenses were immaterial for the years ended December 31, 2023, 2022 and 2021.

Concentrations of Credit Risk

Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, marketable debt securities, and accounts receivable, net. Our investment portfolio comprises money market funds and marketable debt securities, including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities and commercial paper. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations. We invest in a variety of financial instruments and limit the amount of credit exposure with any individual financial institution. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. Our primary operating accounts significantly exceed the FDIC limits.

We are also subject to credit risk from our accounts receivable, net related to our net product sales and strategic alliances. We sell our products primarily to wholesalers and distributors and other governments and organizations. We do not require collateral or other security to support accounts receivable. To date, we have not experienced material losses with respect to the collection of our accounts receivable.

Significant Customers

Our accounts receivable, net are generally unsecured and are from customers in different countries. We generated revenue from product sales to wholesalers and distributors and other governments and organizations, and to a lesser extent, grants made by government-sponsored and private organizations, and collaboration revenue from our strategic alliances.
113


A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented:
Percentage of Revenue
Years Ended December 31,
Percentage of 
Accounts Receivable
December 31,
20232022202120232022
FFF Enterprises***39 %*
European Commission*28 %32 %*29 %
U.S. Government (excluding BARDA)*23 %29 %**
Takeda Pharmaceutical Company*10 %***
Ministry of Health, Labor, and Welfare of Japan21 %***30 %
UK Health Security Agency***35 %11 %
________
* - Represents an amount of less than 10%

Fair Value Measurements

Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. ASC 820 (Fair Value Measurement) establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from our independent sources. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities: 

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
•Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or
•Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Our cash equivalents and marketable debt securities are reported at fair value determined using Level 1 and Level 2 inputs (Note 6). The fair value of our foreign currency forward contracts is calculated using Level 2 inputs, which include currency spot rates, forward rates, interest rate curve and credit or non-performance risk. We do not have any non-financial assets or liabilities that should be recognized or disclosed at fair value on a recurring basis at December 31, 2023 and 2022.

114

Inventory

Inventory is recorded at the lower of cost or net realizable value, with cost determined using first-in, first-out and average cost methods for different components of inventory. We periodically review the composition of inventory in order to identify excess, obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, we will record a write-down to net realizable value in the period that the decline in value is first recognized through a charge to cost of sales. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. We also assess whether we have any excess firm, non-cancelable, purchase commitment liabilities, resulting from our supply agreements with third-party vendors, on a quarterly basis. The determination of net realizable value and firm purchase commitment liabilities requires judgment, including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions, potential product obsolescence, expiration and utilization of raw materials under firm purchase commitments and contractual minimums, among others. We hold raw materials beyond our one year forecasted production plan, which were classified as non-current and included in other non-current assets in our consolidated balance sheets.

Pre-launch Inventory

Costs relating to raw materials and production of inventory in preparation for product launch prior to regulatory approval are capitalized when future commercialization is considered probable, the future economic benefit is expected to be realized, and we believe that material uncertainties related to the ultimate regulatory approval have been significantly reduced. For pre-launch inventory that is capitalized, we consider a number of factors based on the information available at the time, including the product candidate’s current status in the drug development and regulatory approval process, results from the related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential impediments to the approval process such as product safety or efficacy, historical experience, viability of commercialization and market trends. As of December 31, 2023, we did not have any capitalized pre-launch inventory on our consolidated balance sheets.

Property, Plant and Equipment

Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of property, plant and equipment are described below:
Estimated Useful Life
Land and land improvementsNot depreciated
Manufacturing and laboratory equipment5 years
Leasehold improvements
Lesser of estimated useful life of improvement
or remaining life of related lease
Computer equipment and software
3 to 5 years
Furniture and fixtures5 years
Right-of-use asset, financingLease term

Construction in progress includes direct costs related to the construction of various property, plant and equipment, including leasehold improvements, and is stated at original cost. Once the asset is placed into service, these capitalized costs will be allocated to certain property, plant and equipment categories and will be depreciated over the estimated useful life of the underlying assets.

Acquisitions

We account for acquisitions either as business combinations or asset acquisitions, based on whether the set of assets acquired meets the definition of a business. When an acquisition is determined to be a business combination, we apply the acquisition method of accounting. This method requires that the assets acquired and liabilities assumed be recorded at their fair values as of the acquisition date on our consolidated balance sheets. Any excess of the consideration transferred over the fair value of the net identifiable assets acquired is recognized as goodwill. The process of determining the fair value of assets and liabilities involves significant estimates and assumptions. During the measurement period, which may extend up to one year from the acquisition date, we may record adjustments to these fair values. Any such adjustments are recorded with a corresponding change to goodwill. Transaction costs incurred in connection with business combinations are expensed as incurred.

On January 31, 2023, we completed a business combination by acquiring all outstanding shares of OriCiro Genomics K.K. for a cash consideration of $86 million. As a result of this acquisition, we recognized $52 million in goodwill and an intangible asset related to acquired technology valued at $48 million, which are included within other non-current assets in our consolidated balance sheets. This acquisition provided us with tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA
115

manufacturing. OriCiro’s technology strategically complements our manufacturing process and further accelerates our research and development efforts.

Goodwill and Intangible Assets

Goodwill represents the excess of purchase price over the fair value of net assets acquired and is carried at cost. Goodwill is tested at least annually for impairment by assessing qualitative factors in determining whether it is more likely than not that the fair value of net assets is below their carrying amounts. To date, an impairment of goodwill has not been recorded.

The fair value of acquired intangible assets is determined by applying the income-based approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. To estimate the expected cash flows attributable to an intangible asset, it requires the use of Level 3 fair value measurements and inputs. Finite-lived intangible assets are amortized on a straight-line basis over their estimated useful lives.

Impairment of Long-Lived Assets, including Intangibles and Lease Right-of-Use Assets

We evaluate our long-lived assets, which consist of property, plant and equipment, intangibles and right-of-use assets to determine if facts and circumstances indicate that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, we assess the recoverability of the long-lived assets by comparing the projected future undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. If such review indicates that such cash flows are not expected to be sufficient to recover the recorded value of the assets, the assets are written down to their estimated fair values based on the expected discounted future cash flows attributable to the assets or based on appraisals. Impairment expenses for the years ended December 31, 2023, 2022 and 2021 were immaterial.

Leases

Leases are classified at their commencement date, which is defined as the date on which the lessor makes the underlying asset available for use by the lessee, as either operating or finance leases based on the economic substance of the agreement. We recognize lease right-of-use assets and related liabilities in our consolidated balance sheets for both operating and finance leases. Lease liabilities are measured at the lease commencement date as the present value of the future lease payments using the interest rate implicit in the lease. If the rate implicit is not readily determinable, we will utilize our incremental borrowing rate as of the lease commencement date. Lease right-of-use assets are measured as the lease liability plus initial direct costs and prepaid lease payments less lease incentives. The lease term is the non-cancelable period of the lease and includes options to extend or terminate the lease when it is reasonably certain that an option will be exercised.

We recognize operating lease cost in operating expenses in our consolidated statements of operations, inclusive of rent escalation provisions and rent holidays, on a straight-line basis over the respective lease term. For our finance leases, we recognize depreciation expense associated with the leased asset acquired and recognize interest expense related to the portion of the financing in our consolidated statements of operations.

We do not separate non-lease components from lease components for all classes of underlying assets. We do not recognize right-of-use assets and lease liabilities for leases with a lease term of 12 months or less. Instead, these lease payments are recognized in the statements of operations on a straight-line basis over the lease term.

Collaboration Arrangements

We analyze our collaboration arrangements to assess whether they are within the scope of ASC 808 (Collaborative Arrangements) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, we assess whether aspects of the arrangement between us and our collaboration partner are within the scope of other accounting literature. If we conclude that some or all aspects of the arrangement represent a transaction with a customer, we account for those aspects of the arrangement within the scope of ASC 606 (Revenue from Contracts with Customers). Please refer to our "Revenue Recognition" policy within Note 2 for additional discussion of revenue recognition under these types of arrangements. If we conclude that some or all aspects of the arrangement are within the scope of ASC 808 and do not represent a transaction with a customer, we recognize our allocation of the shared costs incurred with respect to the jointly conducted activities as a component of the related expense in the period incurred. Additionally, for any payments related to capital expenditures that are partially reimbursed by a collaboration partner, to the extent the underlying capital costs qualify for capitalization, any reimbursements received will offset the capitalized cost of the asset.

116

Research and Development Costs

Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, overhead costs, contract services, and other outside costs. The value of goods and services received from contract research organizations and contract manufacturing organizations in the reporting period are estimated based on the level of services performed, and progress in the period in cases when we have not received an invoice from the supplier. Research and development costs also include costs and shared cost associated with third-party collaboration arrangements, including upfront fees and milestones paid to third-parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use.

Assets that are acquired or constructed for research and development activities and that have alternative future uses, in research and development projects or otherwise, are capitalized and depreciated over their useful lives. However, the costs of equipment or facilities that are acquired or constructed and intangibles that are purchased from others for a particular research and development project, and that have no alternative future uses and therefore no separate economic values, are considered research and development costs and expensed when incurred.

Advertising Costs

Costs associated with advertising are expensed as incurred and are included in selling, general and administrative expense in the consolidated statements of operations. Advertising expenses were $204 million in 2023, $121 million in 2022, and immaterial in 2021.

Stock-Based Compensation

We issue stock-based awards to employees and non-employees, generally in the form of stock options, restricted stock units (RSUs), and performance stock units (PSUs). We account for our stock-based compensation awards in accordance with ASC 718 (Compensation—Stock Compensation). Most of our stock-based awards have been made to employees. We measure compensation cost for equity awards at their grant-date fair value and recognize compensation expense over the requisite service period, which is generally the vesting period, on a straight-line basis. The grant date fair value of stock options is estimated using the Black-Scholes option pricing model, which requires management to make assumptions with respect to the fair value of our common stock on the grant date, including the expected term of the award, the expected volatility of our stock, calculated based on a period of time generally commensurate with the expected term of the award, risk-free interest rates and expected dividend yields of our stock. We estimate the expected term of our stock options granted to employees and non-employees using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. We utilize this method as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term, and because significant changes in our business over the past few years have rendered historical experience less relevant. The expected volatility is based on a blended average of average historical stock volatilities of selected guideline companies over the expected term of the stock options, historical volatility of our stock price, and implied stock price volatility derived from the price of exchange traded options on our stock. Given the transformative changes in our business, we believe that a blended volatility rate is more indicative of future volatility than our historical volatility alone. We will continue to apply this process until a sufficient amount of historical information regarding the expected term and historical volatility of our own stock price becomes available, and until we believe that historical experience is relevant to our expectations for current grants. The grant date fair value of RSUs is estimated based on the fair value of our underlying common stock. For performance-based stock awards, we recognize stock-based compensation expense over the requisite service period using the accelerated attribution method when achievement is probable. We classify stock-based compensation expense in our consolidated statements of operations in the same manner in which the award recipient’s salary and related costs are classified or in which the award recipient’s service payments are classified. We made an accounting policy election to recognize forfeitures of stock-based awards as they occur.

Income Taxes

We account for income taxes based on an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a “more likely than not” criterion. We periodically reassess the need for valuation allowances on our deferred tax assets, considering both positive and negative evidence to evaluate whether it is more likely than not that all or a portion of such assets will not be realized. We make estimates and judgments about our future taxable income that are based on assumptions that are consistent with our plans and estimates. Should the actual amounts differ from our estimates, the amount of our valuation allowance could be materially impacted. Changes in these estimates may result in significant increases or decreases to our tax provision in a period in which such estimates are changed, which in turn would affect net income or loss. We recognize tax benefits from uncertain tax positions if we believe the position is more likely than not to be sustained on examination by the taxing authorities based on the technical merits of the position. We make adjustments
117

to these tax reserves when facts and circumstances change, such as the closing of a tax audit or the refinement of an estimate. The provision for income taxes includes the effects of any reserves for uncertain tax positions, as well as the related net interest and penalties.

Earnings (Loss) per Share

We calculate diluted net earnings (loss) per share attributable to common stockholders by dividing net earnings (loss) by the weighted average number of common shares outstanding after giving consideration to the dilutive effect of restricted common stock and stock options that are outstanding during the period. For periods in which we have generated a net loss, the basic and diluted net loss per share attributable to common stockholders are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.

Comprehensive Income (Loss)

Comprehensive income (loss) includes net income (loss) and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains and losses on our investments and derivatives designated as hedging instruments. Total comprehensive income (loss) for all periods presented has been disclosed in the consolidated statements of comprehensive income (loss).

The components of accumulated other comprehensive loss for the years ended December 31, 2023 and 2022 were as follows (in millions): 
Unrealized (Loss) Gain on Available-for-Sale Securities
Net Unrealized Gain (Loss) on Derivatives Designated As Hedging Instruments
Pension and Postretirement Benefits
Total
Accumulated other comprehensive loss, balance at December 31, 2021$(40)$16 $— $(24)
Other comprehensive loss(322)(24)— (346)
Accumulated other comprehensive loss, balance at December 31, 2022(362)(8)— (370)
Other comprehensive income (loss)248 8 (9)247 
Accumulated other comprehensive loss, balance at December 31, 2023$(114)$— $(9)$(123)

Share Repurchases

Shares of our common stock repurchased pursuant to our repurchase programs are retired. The purchase price of such repurchased shares of common stock is recorded as a reduction to additional paid-in-capital. If the balance in additional paid-in-capital is exhausted, the excess is recorded as a reduction to retained earnings.

Recently Issued Accounting Standards Not Yet Adopted

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Except as noted below, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU broadens the disclosure requirements by requiring disclosures of significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit or loss. The standard also requires entities to disclose, on an interim and annual basis, the amount and description, including the nature and type, of the other segment items. Additionally, entities are required to disclose the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. These enhanced disclosure obligations apply to entities that operate with one reportable segment as well. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. Early adoption is permitted. We are currently assessing the impact that this new accounting standard will have on our consolidated financial statements and disclosures.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. The standard requires entities to disclose federal, state, and foreign income taxes in their rate reconciliation tables
118

and elaborate on reconciling items that exceed a quantitative threshold. Additionally, it requires an annual disclosure of income taxes paid, net of refunds, categorized by jurisdiction based on a quantitative threshold. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in our consolidated financial statements, once adopted.

3. Net Product Sales

Net product sales by customer geographic location were as follows for the periods presented (in millions):
Years Ended December 31,
202320222021
United States$1,720 $4,405 $5,393 
Europe1,353 6,732 6,834 
Rest of world
3,598 7,298 5,448 
Total $6,671 $18,435 $17,675 

As of December 31, 2023, 2022 and 2021, our COVID-19 vaccine was our only commercial product authorized for use.

Prior to the third quarter of 2023, we sold our COVID-19 vaccine to the U.S. Government, foreign governments and organizations. The agreements and related amendments with these entities generally do not include variable consideration, such as discounts, rebates or returns. Certain of these agreements entitle us to upfront deposits for our COVID-19 vaccine supply, initially recorded as deferred revenue.

As of December 31, 2023 and 2022, we had deferred revenue of $613 million and $2.6 billion, respectively, related to customer deposits. We expect $554 million of our deferred revenue related to customer deposits as of December 31, 2023 to be realized in less than one year. Timing of product delivery and manufacturing, and receipt of marketing approval for the applicable COVID-19 vaccine will determine the period in which net product sales are recognized.

In the third quarter of 2023, we commenced sales of our latest COVID-19 vaccine to the U.S. commercial market, in addition to continuing sales to foreign governments and organizations. In the U.S., our COVID-19 vaccine is sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Wholesalers and distributors typically do not make upfront payments to us.

Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns, and other related deductions.

The following table summarizes product sales provision for the periods presented (in millions):
Years Ended December 31,
202320222021
Gross product sales $8,203 $18,435 $17,675 
Product sales provision:
Wholesaler chargebacks, discounts and fees
(976)— — 
Returns and other fees(556)— — 
Total product sales provision
$(1,532)$— $— 
Net product sales $6,671 $18,435 $17,675 

The following table summarizes the activities related to product sales provision recorded as accrued liabilities for the year ended December 31, 2023 (in millions):
Returns and other fees
Balance at December 31, 2022$— 
Provision related to sales made in current period(556)
Balance at December 31, 2023$(556)

119

4. Other Revenue

The following table summarizes other revenue for the periods presented (in millions):
Years Ended December 31,
202320222021
Grant revenue$94 $388 $735 
Collaboration revenue83 440 61 
Total other revenue$177 $828 $796 

Grant Revenue

In April 2020, we entered into an agreement with Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for an award of up to $483 million to accelerate development of mRNA-1273, our original vaccine candidate against COVID-19. The agreement has been subsequently amended to provide for additional commitments to support various late-stage clinical development efforts of mRNA-1273, including a 30,000 participant Phase 3 study, pediatric clinical trials, adolescent clinical trials and pharmacovigilance studies. The maximum award from BARDA, inclusive of all amendments, was approximately $1.8 billion. All contract options have been exercised. As of December 31, 2023, the remaining available funding, net of revenue earned was $97 million.
The following table summarizes grant revenue for the periods presented (in millions):
Years Ended December 31,
202320222021
BARDA$88 $372 $713 
Other grant revenue6 16 22 
Total grant revenue$94 $388 $735 

Collaboration Revenue

We have entered into collaboration agreements with strategic collaborators to accelerate the discovery and advancement of potential mRNA medicines across therapeutic areas. As of December 31, 2023, 2022 and 2021, we had collaboration agreements with Merck & Co., Inc (Merck), Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, Vertex), AstraZeneca plc (AstraZeneca) and others. Please refer to Note 5 to for further description of these collaboration agreements.

The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):
Years Ended December 31,
Collaboration Revenue by Strategic Collaborator:202320222021
Vertex$82 $48 $26 
Merck— 309 23 
AstraZeneca— 80 7 
Other1 3 5 
Total collaboration revenue$83 $440 $61 

120

5. Collaboration Agreements

Merck – Personalized mRNA Cancer Vaccines (Individualized Neoantigen Therapy)

In June 2016, we entered into a Collaboration and License Agreement for the development and commercialization of personalized mRNA cancer vaccines (also known as individualized neoantigen therapy (INT)) with Merck, to develop and commercialize INTs for individual patients using our mRNA and formulation technology. This agreement was subsequently amended and restated in 2018 (INT Agreement). Our role in this strategic alliance involves identifying genetic mutations in a particular patient’s tumor cells, synthesizing mRNA for these mutations, encapsulating the mRNA in one of our proprietary lipid nanoparticles (LNPs), and administering a unique mRNA INT to each patient. Each INT is designed to specifically activate the patient’s immune system against her or his own cancer cells.

Pursuant to the INT Agreement, we received an upfront payment of $200 million from Merck and we were responsible for designing and researching INTs, providing manufacturing capacity and manufacturing INTs and conducting Phase 1 and Phase 2 clinical trials for INTs, alone and in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, all in accordance with an agreed upon development plan and budget. We concluded that the collaboration arrangement was governed by the revenue recognition standard ASC 606.

In September 2022, Merck exercised its option for INT, including mRNA-4157, pursuant to the terms of the agreement and in October 2022 paid us an option exercise fee of $250 million. Pursuant to the agreement, we and Merck have agreed to collaborate on further development and commercialization of INT, with costs and any profits or losses to be shared equally on a worldwide basis. We concluded that the collaboration arrangement under the Merck Participation Term is within the scope of ASC 808. For the years ended December 31, 2023 and 2022, we recognized expense of $184 million and $6 million, net of Merck's reimbursements, related to the INT collaboration under the Merck Participation Term. Additionally, the net cost recovery for capital expenditures during the same periods were $102 million and $3 million, respectively, which were applied to reduce the capitalized cost of the asset.

Vertex – Strategic Alliance in Cystic Fibrosis

2016 Strategic Alliance in Cystic Fibrosis

In July 2016, we entered into a Strategic Collaboration and License Agreement (Vertex Agreement), with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited, together, Vertex. The Vertex Agreement, which was amended in July 2019 (2019 Vertex Amendment), is aimed at the discovery and development of potential mRNA medicines for the treatment of cystic fibrosis (CF) by enabling cells in the lungs of people with CF to produce functional cystic fibrosis transmembrane conductance regulator (CFTR) proteins. Pursuant to the Vertex Agreement, we lead discovery efforts during an initial research period, leveraging our platform technology and mRNA delivery expertise along with Vertex’s scientific experience in CF biology and the functional understanding of CFTR. Vertex is responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Subject to customary “back-up” supply rights granted to Vertex, we exclusively manufacture (or have manufactured) mRNA for preclinical, clinical and commercialization purposes. This collaboration arrangement is accounted for under ASC 606 and currently ongoing.

2020 Strategic Alliance in Cystic Fibrosis

In September 2020, we entered into a Strategic Collaboration and License Agreement with Vertex (Vertex 2020 Agreement). The Vertex 2020 Agreement was aimed at the discovery and development of potential medicines to treat CF by delivering gene-editing therapies to lung cells to facilitate production of functional CFTR proteins. The three-year research period of the Vertex 2020 Agreement was initially focus on the identification and optimization of novel LNPs and mRNAs that can deliver gene-editing therapies to cells in the lungs. Following the initial three-year period, Vertex was responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Vertex was also obligated to pay us for research services in connection with our performance of certain activities in accordance with a jointly agreed research plan. This collaboration was concluded and terminated in the fourth quarter of 2023 in accordance with the terms of the Vertex 2020 Agreement.

AstraZeneca – Strategic Alliances in Cardiovascular and Oncology

We entered into collaboration agreements with AstraZeneca in 2013 and 2016, aimed at developing mRNA medicines for treatments in cardiovascular, cardiometabolic diseases, and cancer. These agreements provided AstraZeneca with exclusive development and commercialization rights for specific programs, including the VEGF-A product AZD8601 and an immuno-oncology program for IL-12, with upfront payments to us totaling $240 million.

121

In the third quarter of 2022, AstraZeneca terminated our collaborations with them, including the development of VEGF-A and IL-12 programs, for which termination became effective on November 21, 2022. All rights to these two programs reverted to us. As a result of the termination, we recognized the remaining deferred revenue of $76 million as collaboration revenue in the period.

Immatics – Strategic Multi-Platform Collaboration to Develop Oncology Therapeutics

In September 2023, we entered into a strategic research and development collaboration agreement with Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies. We will lead the clinical development and commercialization of cancer vaccines and TCER® therapeutics resulting from the collaboration. Immatics will be responsible for conducting the preclinical studies and a potential Phase 1 clinical trial investigating IMA203 TCR-T in combination with the PRAME mRNA vaccine to further enhance IMA203 T cell responses. Each party will retain full ownership of its investigational PRAME compound, and the parties will fund the clinical study on a cost sharing basis.

Upon effectiveness of the agreement in October 2023, we made an upfront payment of $120 million to Immatics. The payment was recognized as research and development expense in the same period. Immatics will also receive research funding and is eligible to receive development, regulatory, and commercial milestone payments. Immatics is also eligible to receive tiered royalties on global net sales of TCER® products and certain vaccine products that are commercialized under the agreement. Under the agreement, Immatics has an option to enter into a global profit and loss share arrangement for the most advanced TCER®.

In addition to the collaborative arrangements mentioned above, we have other collaborative and licensing arrangements that we do not consider to be individually significant to our business at this time. Pursuant to these agreements, we may be required to make upfront payments and payments upon achievement of various development, regulatory and commercial milestones, which in the aggregate could be significant. Future milestone payments, if any, will be reflected in our consolidated financial statements when the corresponding events become probable. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized.

122

6. Financial Instruments and Fair Value Measurements
Cash and Cash Equivalents and Investments

The following tables summarize our cash and available-for-sale securities by significant investment category at December 31, 2023 and 2022 (in millions):
December 31, 2023
Amortized
Cost
Unrealized
Gains
Unrealized
Losses
Fair Value
Cash and
Cash
Equivalents
Current
Marketable
Securities
Non-
Current
Marketable
Securities
Cash and cash equivalents$2,907 $— $— $2,907 $2,907 $— $— 
Available-for-sale:
Certificates of deposit27 — — 27 — 27 — 
U.S. treasury bills807 — — 807 — 807 — 
U.S. treasury notes4,407 3 (67)4,343 — 2,664 1,679 
Corporate debt securities5,067 3 (81)4,989 — 2,082 2,907 
Government debt securities211 — (3)208 — 117 91 
Total$13,426 $6 $(151)$13,281 $2,907 $5,697 $4,677 
December 31, 2022
Amortized
Cost
Unrealized
Gains
Unrealized
Losses
Fair Value
Cash and
Cash
Equivalents
Current
Marketable
Securities
Non-
Current
Marketable
Securities
Cash and cash equivalents$3,205 $— $— $3,205 $3,205 $— $— 
Available-for-sale:
Certificates of deposit188 — — 188 — 188 — 
U.S. treasury bills767 — — 767 — 767 — 
U.S. treasury notes7,781 — (229)7,552 — 4,182 3,370 
Corporate debt securities6,595 — (226)6,369 — 1,560 4,809 
Government debt securities148 — (9)139 — — 139 
Total$18,684 $— $(464)$18,220 $3,205 $6,697 $8,318 
123


The amortized cost and estimated fair value of available-for-sale securities, by contractual maturity at December 31, 2023 and 2022 were as follows (in millions):
December 31, 2023
Amortized
Cost
Estimated
Fair Value
Due in one year or less
$5,751 $5,697 
Due after one year through five years
4,768 4,677 
Total$10,519 $10,374 
December 31, 2022
Amortized
Cost
Estimated
Fair Value
Due in one year or less$6,792 $6,697 
Due after one year through five years8,687 8,318 
Total$15,479 $15,015 

In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for impairment at the end of each reporting period. We did not record any impairment charges related to our available-for-sale securities during the years ended December 31, 2023, 2022, and 2021. We did not recognize any credit-related allowance to available-for-sale securities as of December 31, 2023 and 2022.

The following table summarizes the amount of gross unrealized losses and the estimated fair value for our available-for-sale securities in an unrealized loss position by length of time the securities have been in an unrealized loss position at December 31, 2023 and 2022 (in millions):
Less than 12 Months12 Months or MoreTotal
Gross Unrealized LossesEstimated Fair ValueGross Unrealized LossesEstimated Fair ValueGross Unrealized LossesEstimated Fair Value
As of December 31, 2023:
U.S. treasury bills$— $25 $— $— $— $25 
U.S. treasury notes(3)774 (64)2,983 (67)3,757 
Corporate debt securities(1)562 (79)3,518 (80)4,080 
Government debt securities— 8 (4)143 (4)151 
Total$(4)$1,369 $(147)$6,644 $(151)$8,013 
As of December 31, 2022:
U.S. treasury securities$— $128 $— $— $— $128 
U.S. treasury notes(101)3,956 (128)3,541 (229)7,497 
Corporate debt securities(138)3,505 (88)1,890 (226)5,395 
Government debt securities(2)46 (7)93 (9)139 
Total$(241)$7,635 $(223)$5,524 $(464)$13,159 

At December 31, 2023 and 2022, we held 392 and 582 available-for-sale securities, respectively, out of our total investment portfolio that were in a continuous unrealized loss position. We neither intend to sell these investments nor conclude that we are more-likely-than-not that we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.
124


Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following tables summarize our financial assets measured at fair value on a recurring basis as of December 31, 2023 and 2022 (in millions):
Fair value at December 31, 2023Fair Value Measurement Using
Level 1Level 2
Assets:
Money market funds$1,572 $1,572 $— 
Certificates of deposit27 — 27 
U.S. treasury bills1,246 — 1,246 
U.S. treasury notes4,343 — 4,343 
Corporate debt securities5,480 — 5,480 
Government debt securities208 — 208 
Equity investments(1)
24 24 — 
Derivative instruments4 — 4 
Total$12,904 $1,596 $11,308 
Liabilities:
Derivative instruments
$9 $— $9 
Fair value at December 31, 2022Fair Value Measurement Using
Level 1Level 2
Assets:
Money market funds$1,079 $1,079 $— 
Certificates of deposit188 — 188 
U.S. treasury bills767 — 767 
U.S. treasury notes7,552 — 7,552 
Corporate debt securities6,369 — 6,369 
Government debt securities139 — 139 
Derivative instruments
6 — 6 
Total$16,100 $1,079 $15,021 
Liabilities:
Derivative instruments
$32 $— $32 
_______
(1)Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in other expense net, in our consolidated statements of operations.

As of December 31, 2023 and 2022, we did not have non-financial assets or liabilities measured at fair value on a recurring basis.

For the year ended December 31, 2023, we recognized net losses of $35 million on equity investments from changes in fair value of the securities. We did not have equity investments in publicly traded securities with readily determinable fair values during 2022 and 2021.

In addition, as of December 31, 2023 and 2022, we had $42 million, at each balance sheet date, in equity investments without readily determinable fair values, which are recorded within other non-current assets in our consolidated balance sheets and excluded from the fair value measurement tables above.

125

7. Inventory

Inventory, as of December 31, 2023 and 2022 consisted of the following (in millions):
December 31,
20232022
Raw materials$163 $575 
Work in progress 15 205 
Finished goods24 169 
Total inventory$202 $949 
Inventory, non-current(1)
$170 $910 
_______
(1)Consisted of raw materials with an anticipated consumption beyond one year. Inventory, non-current is included in other non-current assets in the consolidated balance sheets.

Inventory write-downs as a result of excess, obsolescence, scrap or other reasons, and losses on firm purchase commitments are recorded as a component of cost of sales in our consolidated statements of operations. For the years ended December 31, 2023 and 2022, inventory write-downs were $2.2 billion and $1.3 billion, respectively. Inventory write-downs were immaterial for the year ended December 31, 2021. For the years ended December 31, 2023 and 2022, losses on firm purchase commitments were $141 million and $617 million, respectively. There were no such charges in 2021. Inventory write-downs were mainly related to obsolete inventory due to shelf-life expiration and inventory in excess of expected demand. Losses on firm purchase commitments were primarily related to excess raw material purchase commitments that will expire before the anticipated consumption of those raw materials. These charges in 2023 were primarily driven by a continued shift in product demand to the latest variant-targeted COVID-19 vaccine and a decline in customer demand as the COVID-19 vaccine market continues to transition to an endemic seasonal market in 2023.

In the third quarter of 2023, we completed our long-range financial planning process, incorporating revised forecasts of vaccination rates. This resulted in the reassessment of future demand for our COVID-19 vaccine, leading to a strategic initiative to resize our manufacturing cost structure. This initiative, launched in the same quarter, involved reassessing our inventory levels and renegotiating with our suppliers to reduce our purchase commitments related to raw materials which were not expected to be consumed before expiration. This initiative resulted in a raw materials write-down of $903 million, included in the total inventory write-down amount for the quarter.

As of December 31, 2023 and December 31, 2022, the accrued liability for losses on firm future purchase commitments in our consolidated balance sheets was $79 million and $268 million, respectively. As of December 31, 2023 and December 31, 2022, we had inventory on hand of $372 million and $1.9 billion, respectively. Our raw materials and work-in-progress inventory had variable shelf lives. We expect that the majority of this inventory will be consumed over the next three years. The shelf life of our COVID-19 vaccine product ranges from nine to twelve months.

126

8. Property, Plant and Equipment, Net

Property, plant and equipment, net as of December 31, 2023 and 2022 consisted of the following (in millions):
December 31,
20232022
Land and land improvements$22 $11 
Manufacturing and laboratory equipment345 284 
Leasehold improvements522 460 
Furniture and fixtures26 21 
Computer equipment and software
74 38 
Construction in progress
860 281 
Right-of-use assets, financing (Note 10)
529 1,581 
Total
2,378 2,676 
Less: Accumulated depreciation
(433)(658)
Property, plant and equipment, net$1,945 $2,018 

Depreciation and amortization expense for the years ended December 31, 2023, 2022, and 2021 was $617 million, $348 million, and $232 million, respectively.

9. Other Balance Sheet Components

Accounts Receivable, Net

Accounts receivable, net, as of December 31, 2023 and December 31, 2022 consisted of the following (in millions):
December 31,
20232022
Accounts receivable$1,584 $1,385 
Less: Wholesalers chargebacks, discounts and fees
(692)— 
Accounts receivable, net$892 $1,385 

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets, as of December 31, 2023 and 2022 consisted of the following (in millions):
December 31,
20232022
Prepaid services$182 $216 
Down payments to manufacturing vendors100 229 
Down payments for materials and supplies68 219 
Collaboration receivable61 11 
Interest receivable59 61 
Value added tax receivable50 140 
Income tax receivable19 10 
Tenant improvement allowance receivable— 42 
Prepaid income taxes— 187 
Convertible note receivable— 36 
Other current assets88 44 
Prepaid expenses and other current assets
$627 $1,195 

127

Other Non-Current Assets

Other non-current assets, as of December 31, 2023 and 2022 consisted of the following (in millions):
December 31,
20232022
Down payments and prepayments, non-current
$342 $— 
Inventory, non-current(1)
170 910 
Equity investments66 42 
Goodwill
52 — 
Finite-lived intangible asset
44 — 
Restricted cash4 12 
Other7 24 
Other non-current assets$685 $988 
_______
(1)Consisted of raw materials with an anticipated consumption beyond one year.

Accrued Liabilities

Accrued liabilities, as of December 31, 2023 and 2022 consisted of the following (in millions):
December 31,
20232022
Provisions related to product sales (Note 3)
$556 $— 
Compensation-related245 190 
Clinical trials175 319 
Manufacturing167 400 
Development operations140 88 
Other external goods and services137 264 
Royalties122 203 
Property, plant and equipment94 5 
Loss on future firm purchase commitments(1)
79 268 
Commercial56 48 
Raw materials27 316 
Accrued liabilities$1,798 $2,101 
______
(1)Related to losses that are expected to arise from firm, non-cancellable, commitments for future raw material purchases (Note 7).

Other Current Liabilities

Other current liabilities, as of December 31, 2023 and 2022 consisted of the following (in millions):
December 31,
20232022
Lease liabilities - financing (Note 10)
$— $161 
Lease liabilities - operating (Note 10)
25 35 
Other41 53 
Other current liabilities$66 $249 
128


Deferred Revenue

The following table summarizes the activities in deferred revenue during the year ended December 31, 2023 (in millions):
December 31, 2022AdditionsDeductionsDecember 31, 2023
Net product sales
$2,626 $515 $(2,528)$613 
Grant revenue4 2 (2)4 
Collaboration revenue81 31 (78)34 
Total deferred revenue$2,711 $548 $(2,608)$651 

10. Leases

We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2042. Certain of these arrangements have free rent periods or escalating rent payment provisions. We recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have two main campuses in Massachusetts, our Cambridge campus and our Moderna Technology Center (MTC), located in Norwood. We also lease various parcels of land, office and lab spaces across the globe for our business operations.

Cambridge Campus

We occupy a multi-building campus at Technology Square in Cambridge, Massachusetts with a mix of offices and research laboratory space totaling approximately 292,000 square feet.

In September 2021, we entered into a lease agreement for a building space, approximately 462,000 square feet, in Cambridge, Massachusetts. This space is designated to be the Moderna Science Center (MSC), housing a blend of office space and laboratories. Following an approximately two-year building project, the lease term is 15 years, with options for two additional seven-year extensions. During the third quarter of 2023, we commenced the lease and recognized the related right-of-use asset and lease liability on our consolidated balance sheets. Following the commencement of the MSC lease, we amended the expiration dates of our existing leases at Technology Square in the fourth quarter of 2023. Originally scheduled to expire ranging from 2024 to 2029, these leases have been adjusted to conclude in early 2025. All our Cambridge leases are classified as operating leases.

Moderna Technology Center

We have an industrial technology center in Norwood, Massachusetts, our Moderna Technology Center (MTC), comprised of three buildings, MTC South, MTC North, and MTC East, totaling approximately 686,000 square feet. Our MTC leases expire in 2042 and we have the option to extend the term for three extension periods of five years each. All of our MTC leases are classified as finance leases.

Embedded Leases

We have entered into multiple contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. In the third quarter of 2023, as part of our strategic initiative to optimize our manufacturing footprint, we amended a contract manufacturing service agreement, resulting in decreases of $262 million in each of the right-of-use assets and lease liabilities. Additionally, it resulted in accelerated depreciation of the right-of-use assets of $323 million for the year ended December 31, 2023. As of December 31, 2023, we had no remaining right-of-use assets or lease liabilities due to embedded leases. As of December 31, 2022, we had right-of-use assets of $639 million and lease liabilities of $440 million related to embedded leases. All of our embedded leases were classified as finance leases.

129

Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2023 and 2022 were as follows (in millions):
December 31,
20232022
Assets:
Right-of-use assets, operating, net(1) (2)
$713 $121 
Right-of-use assets, financing, net(3) (4)
436 1,150 
Total$1,149 $1,271 
Liabilities:
Current:
Operating lease liabilities(5)
$25 $35 
Financing lease liabilities(5)
— 161 
Total current lease liabilities 25 196 
Non-current:
Operating lease liabilities, non-current643 92 
Financing lease liabilities, non-current575 912 
Total non-current lease liabilities1,218 1,004 
Total$1,243 $1,200 
_______
(1) These assets are real estate related assets, which include land, office and laboratory spaces.
(2) Net of accumulated amortization.
(3) These assets are real estate assets related to the MTC leases as well as assets related to contract manufacturing service agreements.
(4) Included in property, plant and equipment in the consolidated balance sheets, net of accumulated depreciation.
(5) Included in other current liabilities in the consolidated balance sheets.

The components of the lease costs were as follows for the periods presented (in millions):
Years ended December 31,
202320222021
Operating lease costs$88 $48 $24 
Financing lease costs:
   Amortization of right-of-use assets, financing leases500 280 189 
   Interest expense for financing lease liabilities38 29 17 
Total financing lease costs$538 $309 $206 
Short term lease costs$2 $— $49 
Variable lease costs$113 $165 $100 

130

Supplemental cash flow information relating to our leases was as follows for the periods presented (in millions):
December 31,
202320222021
Cash paid for amounts included in measurement of lease liabilities:
Operating cash flows used in operating leases$(93)$(57)$(19)
Operating cash flows used in financing leases(39)(25)(14)
Financing cash flows used in financing leases
(292)(184)(140)
Operating lease non-cash items:
Changes in right-of-use assets related to lease modifications and reassessments$67 $— $(7)
Right-of-use assets obtained in exchange for operating lease liabilities714 20 72 
Finance lease non-cash items:
Changes in right-of-use assets related to lease modifications and reassessments$213 $— $674 
Right-of-use assets obtained in exchange for financing lease liabilities— 777 126 
Changes in financing lease liabilities3 4 3 

Weighted average remaining lease terms and discount rates as of December 31, 2023 and 2022 were as follows:
December 31,
20232022
Remaining lease term:
Operating leases14 years6 years
Finance leases33 years22 years
Discount rate:
Operating leases7.5 %7.5 %
Finance leases4.2 %3.6 %

Future minimum lease payments under non-cancelable lease agreements as of December 31, 2023, were as follows (in millions):
Fiscal YearOperating Leases
Financing Leases(1)
2024$72 $20 
202567 22 
202667 22 
202770 23 
202872 23 
Thereafter785 1,074 
Total minimum lease payments1,133 1,184 
Less amounts representing interest(465)(609)
Present value of lease liabilities$668 $575 
______
(1) Include certain optional lease term extensions, predominantly related to the MTC leases, which represent a total of $668 million of undiscounted future lease payments.
131

11. Commitments and Contingencies

Legal Proceedings

We are involved in various claims and legal proceedings of a nature considered ordinary course in our business. The outcome of any such proceedings, regardless of the merits, is inherently uncertain; therefore, assessing the likelihood of loss and any estimated damages is difficult and subject to considerable judgment. We are not currently a party to any legal proceedings for which a material loss is probable, or for which a loss is reasonably estimable at this time.

Indemnification Obligations

As permitted under Delaware law, we indemnify our officers, directors, and employees for certain events, occurrences while the officer, or director is, or was, serving at our request in such capacity. The term of the indemnification is for the officer’s or director’s lifetime.

We have standard indemnification arrangements in our leases for laboratory and office space that require us to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under our leases.

We enter into indemnification provisions under our agreements with counterparties in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited.

Through December 31, 2023 and 2022, we had not experienced any significant losses related to these indemnification obligations, and no material claims were outstanding. We do not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.

Purchase Commitments and Purchase Orders

We enter into agreements in the normal course of business with vendors and contract manufacturing organizations (CMOs) for raw materials and manufacturing services and with vendors for preclinical research studies, clinical trials and other goods or services. As of December 31, 2023, we had $1.8 billion of non-cancelable purchase commitments related to raw materials and manufacturing agreements, which are expected to be paid through 2029. As of December 31, 2023, $79 million of the purchase commitments related to raw materials was recorded as an accrued liability for loss on future firm purchase commitments. As of December 31, 2023, we had $261 million of non-cancelable purchase commitments related to clinical services and other goods and services which are expected to be paid through 2039. These amounts represent our minimum contractual obligations, including termination fees.

In addition to purchase commitments, we have agreements with third parties for various services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or wind down costs. Under such agreements, we are contractually obligated to make certain payments to vendors, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation. At December 31, 2023, we had cancelable open purchase orders of $3.0 billion in total under such agreements for our significant clinical operations and support and contract manufacturing. These amounts represent only our estimate of those items for which we had a contractual commitment to pay at December 31, 2023, assuming we would not cancel these agreements. The actual amounts we pay in the future to the vendors under such agreements may differ from the purchase order amounts.

Licenses to Patented Technology

In 2017, we entered into sublicense agreements with Cellscript, LLC and its affiliate, mRNA RiboTherapeutics, Inc. to sublicense certain patent rights. Pursuant to each agreement, we are required to pay certain license fees, annual maintenance fees, minimum royalties on future net sales and milestone payments contingent on achievement of certain development, regulatory and commercial milestones for specified products, on a product-by-product basis. Commercial milestone payments and royalties based on annual net sales of licensed products for therapeutic and prophylactic products are accounted for as additional expense of the related net product sales in the period in which the corresponding sales occur.

In December 2022, we entered into a non-exclusive patent license agreement with the National Institute of Allergy and Infectious Diseases (NIAID), an Institute or Center of the National Institutes of Health (NIH) to license certain patent rights concerning
132

stabilizing prefusion coronavirus spike proteins and the resulting stabilized proteins for use in COVID-19 vaccine products. Pursuant to the agreement, we have agreed to pay low single-digit royalties on future net sales, a minimum annual royalty payment, and certain contingent development, regulatory and commercial milestone payments on a licensed product-by-licensed product basis. In addition, in December 2022, we made a catch-up royalty payment of $400 million to NIAID, which was recorded to cost of sales in our consolidated statements of operations.

In 2023, 2022, and 2021 we recognized $301 million, $1.1 billion, and $641 million, respectively, of royalties and commercial milestone payments associated with our net product sales, which was recorded to cost of sales in our consolidated statements of operations.

Additionally, we have other in-license agreements with third parties which require us to make future development, regulatory and commercial milestone payments for specified products associated with the agreements. The achievement of these milestones have not yet occurred as of December 31, 2023.

12. Stock-Based Compensation and Share Repurchase Programs

Equity Plans

In connection with our initial public offering (IPO), we adopted the 2018 Stock Option and Incentive Plan (the 2018 Equity Plan) in November 2018. The 2018 Equity Plan became effective on the date immediately prior to the effective date of the IPO and replaced our 2016 Stock Option and Incentive Plan (the 2016 Equity Plan). The 2018 Equity Plan provides flexibility to our compensation committee to use various equity-based incentive awards as compensation tools to motivate our workforce. The shares of common stock underlying any awards that are forfeited, canceled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2018 Equity Plan and the 2016 Equity Plan will be added back to the shares of common stock available for issuance under the 2018 Equity Plan.

The Board of Directors may grant to employees, nonemployee directors, consultants and independent advisors equity-based awards during their period of service, generally in the form of stock options, restricted stock units, and performance stock units. The terms and conditions of stock-based awards are defined at the sole discretion of our Board of Directors. We issue service-based awards, vesting over a defined period of service, and performance-based awards, vesting upon achievement of defined conditions. Service based awards generally vest over a four-year period, with the first 25% of such awards vesting following twelve months of continued employment or service. The remaining awards vest in twelve quarterly installments over the following twelve quarters. Stock options granted under the 2018 Equity Plan and the 2016 Equity Plan expire ten years from the date of grant and the exercise price must be at least equal to the fair market value of common stock on the grant date.

As of December 31, 2023, we had a total of 47 million shares reserved for future issuance under our Equity Plans, of which 31 million shares were reserved for equity awards previously granted, and 16 million shares were available for future grants under the 2018 Equity Plan. No additional awards will be granted under the 2016 Equity Plan as it was replaced by the 2018 Equity Plan.
133


Options

We have granted options generally through the 2018 Equity Plan and 2016 Equity Plan. The following table summarizes our option activity during the year ended December 31, 2023:
Number of
Options
(in millions)		Weighted
Average
Exercise
Price per
Share		Weighted-
Average
Remaining
Contractual
Term
Aggregate
Intrinsic
Value(1)
(in millions)
Outstanding at December 31, 202224.93 $42.23 5.7 years$3,478 
Granted
4.36 113.03 
Exercised
(3.11)8.13 
Canceled/forfeited
(0.68)130.23 
Outstanding at December 31, 202325.50 56.14 5.6 years1,437 
Exercisable at December 31, 202318.98 33.34 4.5 years1,378 
Expected to vest at December 31, 20236.52 122.50 8.9 years59 
_______
(1)Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of December 31, 2023.

The total intrinsic value of options exercised was $413 million, $714 million, and $1.6 billion for the years ended December 31, 2023, 2022, and 2021, respectively. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period. The excess tax benefits realized from tax deductions from option exercises were $84 million, $144 million, and $325 million during the years ended December 31, 2023, 2022, and 2021 respectively. The total consideration recorded as a result of stock option exercises was approximately $25 million, $50 million, and $112 million for the years ended December 31, 2023, 2022, and 2021.

Restricted Common Stock Units (RSUs) and Performance Stock Units (PSUs)

We have granted RSUs and PSUs generally through the 2018 Equity Plan. The following table summarizes our RSU and PSU activity during the year ended December 31, 2023:
Number of Units
(in millions)
Weighted Average
Grant Date Fair Value per Unit
Outstanding, non-vested at December 31, 20222.90 $132.25 
Issued
3.71 107.23 
Vested
(1.01)98.68 
Canceled/forfeited
(0.42)130.01 
Outstanding, non-vested at December 31, 20235.18 121.02 

The total grant date fair value of RSUs and PSUs vested during the years ended December 31, 2023, 2022, and 2021, was $99 million, $55 million, and $18 million, respectively. The total intrinsic value of RSUs and PSUs vested during the years ended December 31, 2023, 2022, and 2021, was $120 million, $125 million and $141 million, respectively.

During 2023, 2022 and 2021, we granted an immaterial amount of PSUs, respectively, primarily to certain senior executives with vesting that is contingent upon the achievement of specified preestablished goals over the performance period, generally three years. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from 0% to 200%. The estimated fair value of PSUs is based on the grant date fair value.

134

Valuation and Stock-Based Compensation Expense

Stock-based compensation for options granted under our Equity Plans is determined using the Black-Scholes option pricing model. The weighted-average assumptions used to estimate the fair value of options granted for the years ended December 31, 2023, 2022, and 2021 were as follows:
Weighted Average
Years Ended December 31,
202320222021
Options:
    Risk-free interest rate
4.13 %2.46 %0.84 %
    Expected term
6.07 years6.13 years6.10 years
    Expected volatility
48 %50 %46 %
    Expected dividends
— %— %— %
    Weighted average fair value per share
$57.87 $76.02 $91.84 

Stock-Based Compensation Expense

The following table presents the components and classification of stock-based compensation expense for the years ended December 31, 2023, 2022, and 2021 (in millions):
Years Ended December 31,
202320222021
Options
$136 $123 $96 
RSUs and PSUs161 97 42 
Employee stock purchase plan
8 6 4 
Total
$305 $226 $142 
Cost of sales$37 $45 $22 
Research and development
157 93 68 
Selling, general and administrative111 88 52 
Total
$305 $226 $142 

For the years ended December 31, 2023, 2022, and 2021, we recognized stock-based compensation expense of $17 million, $18 million, and $16 million, respectively, related to performance-based awards, including awards with vesting or commencement contingent upon our IPO. Stock-based compensation expenses related to non-employee awards were immaterial for the years ended December 31, 2023, 2022, and 2021.

As of December 31, 2023, there were $835 million of total unrecognized compensation cost related to non-vested stock-based compensation with respect to options, RSUs and PSUs granted. That cost is expected to be recognized over a weighted-average period of 2.6 years at December 31, 2023.

Share Repurchase Programs

On August 2, 2021, our Board of Directors authorized a Share Repurchase Program (2021 Repurchase Program) of our common stock, with an expiration date no later than August 2, 2023. Pursuant to the 2021 Repurchase Program, we were authorized to repurchase up to $1.0 billion of our outstanding common stock. By the end of January 2022, we had repurchased the entire $1.0 billion of common stock that was authorized under the 2021 Repurchase Program. On February 22, 2022, our Board of Directors authorized an additional share repurchase program of our common stock, with no expiration date, for up to $3.0 billion. On August 1, 2022, our Board of Directors authorized an increase of $3.0 billion under the repurchase program for our common stock, with no expiration date (collectively with the February 22, 2022 authorization, the 2022 Repurchase Programs).

As of December 31, 2023, $1.7 billion of our Board of Directors’ authorization for repurchases of our common stock remains outstanding (the 2022 Repurchase Programs), with no expiration date. The timing and actual number of shares repurchased under the 2022 Repurchase Programs will depend on a variety of factors, including price, general business and market conditions, and other investment opportunities, and shares may be repurchased through open market purchases through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
135


The following table summarizes activity related to our share repurchase programs (in millions, except per share data):
Years Ended December 31,
202320222021
Number of shares repurchased8233
Average price per share(1)
$143.26 $142.83 $245.76 
Aggregate purchase price$1,153 $3,329 $857 
Remaining authorization at end of period$1,667 $2,814 $143 
_______
(1)Average price paid per share includes related expenses and excise tax, applicable beginning January 1, 2023.

13. Income Taxes

(Loss) income before income taxes for the years ended December 31, 2023, 2022, and 2021 consisted of the following (in millions):
Years Ended December 31,
202320222021
United States
$(4,056)$9,433 $13,108 
Foreign
114 142 177 
(Loss) income before income taxes$(3,942)$9,575 $13,285 

The provision for income taxes for the years ended December 31, 2023, 2022, and 2021 consisted of the following components (in millions):
Years Ended December 31,
202320222021
Current:
Federal$(225)$1,687 $1,304 
State72 47 35 
Foreign24 57 40 
Total current$(129)$1,791 $1,379 
Deferred:
Federal$888 $(569)$(288)
State8 (7)(6)
Foreign5 (2)(2)
Total deferred901 (578)(296)
Total provision for income taxes$772 $1,213 $1,083 

The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31, 2023, 2022, and 2021 was as follows:
Years Ended December 31,
202320222021
Federal statutory tax rate21.0 %21.0 %21.0 %
Change in valuation allowance
(52.6)%— %(5.4)%
Foreign-derived intangible income0.2 %(7.4)%(4.8)%
Stock-based compensation windfall2.4 %(1.6)%(2.6)%
Federal research and development credits
4.6 %(0.5)%(0.7)%
State taxes, net of federal benefits5.7 %0.4 %0.5 %
Non-deductible items(0.4)%— %— %
Other
(0.5)%0.8 %0.1 %
Effective tax rate
(19.6)%12.7 %8.1 %

136

Our effective tax rate for the year ended December 31, 2023 was (19.6)% and was higher than the federal statutory tax rate, primarily due to an increase in valuation allowance against deferred tax assets. The effective tax rates for the year ended December 31, 2023 also include tax benefits from research and development credits and stock-based compensation. Our effective tax rate for the year ended December 31, 2022 was lower than the federal statutory tax rate, primarily due to the tax benefit of the foreign-derived intangible income deduction (FDII) and excess tax benefit related to stock-based compensation. Our effective tax rate for the year ended December 31, 2021 was lower than the federal statutory tax rate, primarily due to the tax benefits related to the release of the valuation allowance on most of our deferred tax assets, FDII and stock-based compensation.

As of January 1, 2022, pursuant to the Tax Cuts and Jobs Act of 2017 (“TCJA”), research and development costs in the current period are required to be amortized over five or fifteen years, depending on where the research is conducted. The new capitalization requirement significantly increased our deferred tax assets and cash tax liabilities, but also decreased our effective tax rate by increasing the foreign-derived intangible income deduction.

The President signed into law the Inflation Reduction Act (the “IRA”) on August 16, 2022. The Act includes a new 15% corporate minimum tax and a 1% excise tax on the value of corporate stock repurchases, net of new share issuances, after December 31, 2022. We do not expect these provisions to have a material impact on our consolidated financial position; however, we will continue to evaluate their impact as further information becomes available.

Deferred income taxes reflect the tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting and the amounts used for income tax purposes, tax credit carryforwards and the tax effect of net operating loss carryforwards. Significant components of our deferred tax assets and tax liabilities as of December 31, 2023 and 2022 were as follows (in millions):
December 31,
20232022
Deferred tax assets:
Net operating loss carryforwards$90 $59 
Stock-based compensation111 68 
Capitalized licenses, research and development and start-up costs1,449 704 
Tax credit carryforwards140 97 
Operating lease liabilities154 26 
Financing lease liabilities139 135 
Other comprehensive income34 106 
Inventory reserve and capitalization 250 86 
Wholesaler chargebacks, discounts and fees
92 — 
Returns and other fees
129 — 
Other90 85 
Total deferred tax assets2,678 1,366 
Less: valuation allowance
(2,224)(155)
Net deferred tax assets$454 $1,211 
Deferred tax liabilities:
Right-of-use assets, financing$(106)$(117)
Right-of-use assets, operating(160)(26)
Property, plant and equipment(107)(85)
Other(15)(1)
Total deferred tax liabilities
(388)(229)
Net deferred tax (liabilities) assets
$66 $982 

137

The table below summarizes changes in the valuation allowance for deferred tax assets for the periods presented (in millions):
Years Ended December 31,
202320222021
Valuation allowance at beginning of the period$155 $149 $823 
Decreases recorded as benefit to income tax provision— (12)(722)
Increases to valuation allowance2,069 18 48 
Valuation allowance at December 31$2,224 $155 $149 

We periodically reassess the need for valuation allowances on our deferred tax assets, considering both positive and negative evidence to evaluate whether it is more likely than not that all or a portion of such assets will not be realized. During 2023, following the completion of our long-range financial planning process, we reassessed the evidence and concluded that a valuation allowance was necessary due to the preponderance of negative evidence, including:

•A pre-tax loss for the full year 2023, serving as a significant source of objectively verifiable negative evidence in accordance with ASC 740 (Income Taxes).
•A projected three-year cumulative loss resulting from our long-range financial planning process. This projection is due to a significant decrease in expected sales of our COVID-19 vaccine as we transition to a seasonal market. Additionally, we anticipate substantial research and development expenses for our on-going Phase 3 clinical trials and to advance our product candidates into later-stage development. These factors contribute additional negative evidence with respect to the realizability of our deferred tax assets. The projections are based upon revenue from our currently approved drug product, which we believe can be reasonably estimated. In contrast, future taxable income projections from our investigational medicines are deemed inherently subjective and not objectively verifiable; they are insufficient to override negative evidence, and therefore, they are not assigned any weight in our valuation allowance analysis assessment.

Our evaluation also included whether there were other sources of taxable income that would allow us to realize our deferred tax assets, such as taxable income in carryback years, available tax planning strategies and the future reversals of taxable temporary differences. After assessing these strategies and all evidence, we determined it was more likely than not that we will not realize all of our deferred tax assets and therefore increased the valuation allowance by $2.1 billion during 2023.

In the first quarter of 2021, we reassessed the valuation allowance noting the increase in positive evidence, including significant revenue growth, expectations regarding future profitability, and successful supply chain and manufacturing capabilities to meet global product demand. After assessing both the positive evidence and negative evidence, we determined it was more likely than not that we would realize the majority of our deferred tax assets, and we released the valuation allowance on the majority of our deferred tax assets, accordingly. The release of the valuation allowance was based on the then-prevailing positive outlook, which has since shifted significantly by 2023 due to the factors outlined above, leading to the reinstatement of a full valuation allowance.

Significant management judgment is required in assessing the realizability of our deferred tax assets. In the event that actual results differ from our estimates, we adjust our estimates in future periods and we may need to modify our valuation allowance, which could materially impact our financial position and results of operations.

At December 31, 2023, we had $1.6 billion of state net operating loss carryforwards, which begin to expire in 2030. At December 31, 2023, we also had state research and development tax credit carryforwards of $178 million, the majority of which will begin to expire in 2030.

138

We recognize, in our financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. A reconciliation of the beginning and ending amounts of unrecognized tax benefits during the years ended December 31, 2023, 2022, and 2021 were as follows (in millions):
Years Ended December 31,
202320222021
Unrecognized tax benefits at beginning of the period$128 $68 $— 
Decrease due to prior positions:
Tax positions for prior years— (1)— 
Expiration of statutes— — — 
Settlements with tax authorities(27)— — 
Increase due to current year tax positions:
Additions based on tax positions for current year44 57 54 
Additions based on tax positions for prior years86 4 14 
Unrecognized tax benefits at end of the period $231 $128 $68 

As of December 31, 2023, we had $231 million of net unrecognized tax benefits, which would affect our tax rate if recognized. Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. We do not anticipate a material change to our unrecognized tax benefits over the next twelve months that would have an adverse effect on our consolidated operating results. We recognize interest and penalties, if applicable, related to uncertain tax positions as a component of income tax expense.

We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. All tax years since our date of incorporation remain open to examination by the major taxing jurisdictions, as carryforward attributes generated in past years may be adjusted upon examination by the Internal Revenue Service or the state authorities. There are no open tax examinations at this time.

14. (Loss) Earnings per Share

The computation of basic earnings (loss) per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and potential dilutive common shares outstanding during the period as determined by using the treasury stock method.

Basic and diluted EPS for the years ended December 31, 2023, 2022 and 2021 were calculated as follows (in millions, except per share data):
Years Ended December 31,
202320222021
Numerator:
Net (loss) income
$(4,714)$8,362 $12,202 
Denominator:
Basic weighted-average common shares outstanding382 394 403 
Effect of dilutive securities— 22 28 
Diluted weighted-average common shares outstanding382 416 431 
Basic EPS$(12.33)$21.26 $30.31 
Diluted EPS$(12.33)$20.12 $28.29 

139

The following common stock equivalents, presented based on amounts outstanding as of December 31, 2023, 2022 and 2021, were excluded from the calculation of diluted net (loss) income per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):
December 31,
202320222021
Options26 3 1 
RSUs and PSUs5 — — 
Total31 3 1 

15. Geographic Information

Geographic Revenue

We operate in one reporting segment that primarily focuses on the discovery, development and commercialization of mRNA medicines. Our chief executive officer manages our operations and evaluates our financial performance on a consolidated basis. Most of our principal operations, other than manufacturing, and our decision-making functions are located at our corporate headquarters in the United States.

Total revenue by geographic area of our customers and collaboration partners was as follows (in millions):
Years Ended December 31,
202320222021
United States$1,895 $5,150 $6,177 
Europe1,355 6,815 6,846 
Rest of world
3,598 7,298 5,448 
Total $6,848 $19,263 $18,471 

Our property, plant and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):
December 31,
20232022
United States$1,560 $1,267 
Europe126 714 
Rest of world259 37 
Total$1,945 $2,018 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.

140

Item 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2023. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2023, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is defined in Exchange Act Rule 13a-15(f)) to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Management assessed our internal control over financial reporting as of December 31, 2023. Management based its assessment on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework). Based on that evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2023.

The effectiveness of our internal control over financial reporting as of December 31, 2023 has been audited by Ernst & Young LLP, an independent registered public accounting firm, as stated in their report included in this Annual Report on Form 10-K.

Changes in Internal Controls over Financial Reporting

During the three months ended December 31, 2023, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act), which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on the Effectiveness of Controls

Our management, including our Chief Executive Officer and Chief Financial Officer, believe that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by the collusion of two or more people or by a management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
141


Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of Moderna, Inc.

Opinion on Internal Control Over Financial Reporting

We have audited Moderna, Inc.’s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Moderna, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2023, and the related notes and our report dated February 23, 2024 expressed an unqualified opinion thereon.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Ernst & Young LLP
Boston, Massachusetts
February 23, 2024



142

Item 9B. Other Information
10b5-1 Plans

On November 7, 2023, Noubar Afeyan, our Chairman, amended a trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Afeyan 10b5-1 Plan). The Afeyan 10b5-1 Plan was amended to increase certain price triggers under the plan. The Afeyan 10b5-1 Plan, as amended, is scheduled to commence on February 28, 2024, and will run through August 20, 2025. The aggregate maximum number of shares of common stock that may be sold pursuant to the Afeyan 10b5-1 Plan is 745,000, which represents the shares remaining under the original plan that have not been sold to date.

On November 6, 2023, Arpa Garay, our former Chief Commercial Officer, terminated a trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Garay 10b5-1 Plan). The Garay 10b5-1 Plan was entered into on August 24, 2023, and was scheduled to commence on November 27, 2023, with a termination date of August 30, 2024. The Garay 10b5-1 Plan provided for the potential sale of approximately 4,540 shares of common stock and for the potential exercise of vested stock options and the associated sale of up to 24,897 shares. No shares of common stock were sold, and no options to purchase shares of common stock were exercised, under the Garay 10b5-1 Plan prior to its termination.

Amended and Restated By-laws

On February 21, 2024, our Board of Directors approved and adopted the Company’s Second Amended and Restated By-laws (the “By-laws”), which became effective immediately. The By-laws supersede and replace in their entirety the Company's Amended and Restated By-laws in effect immediately prior to effectiveness of the By-laws.

The By-laws, among other things:

•implement a majority voting standard in uncontested director elections;
•implement a proxy access provision, which permits a stockholder, or a group of up to 20 stockholders, owning 3% of our outstanding common stock continuously for at least three years to nominate and include in our proxy materials director candidates constituting up to the greater of two nominees or 20% of the Board of Directors, subject to the terms and conditions set forth in the By-laws;
•update our advance notice provisions to take into account recent rules adopted by the SEC regarding usage of universal proxies;
•reflect recent amendments and updates to the Delaware General Corporation Law; and
•incorporate certain other administrative, technical, clarifying and conforming changes.

The foregoing description does not purport to be complete and is qualified in its entirety by reference to the full text of the By-laws, a copy of which is attached hereto as Exhibit 3.2 and is incorporated herein by reference.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

None Applicable.
143

PART III

Item 10. Directors, Executive Officers and Corporate Governance

The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2024 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.

Item 11. Executive Compensation

The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2024 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2024 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.

Item 13. Certain Relationships and Related Transactions, and Director Independence

The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2024 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.

Item 14. Principal Accounting Fees and Services

Our independent public accounting firm is Ernst & Young LLP, Boston, Massachusetts, PCAOB Auditor ID 00042.

The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2024 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.


144

PART IV

Item 15. Exhibits, Financial Statement Schedules

(a) Documents filed as part of this report.

(1)    Financial statements.

For a list of the consolidated financial statements included herein, see “Index to Consolidated Financial Statements” under Part II, Item 8 of this Annual Report on Form 10-K.

(2) Schedules.

No financial statement schedules have been submitted because they are not required or are not applicable or because the information required is included in the consolidated financial statements or the notes thereto.

(3) Exhibits.

Exhibit No.Exhibit Index
3.1
3.2*
4.1
4.2
10.1#
10.2#
10.3#
10.4†
10.5†
10.6†
10.7
10.8
10.9#
10.10#
10.11#
10.12#
10.13#
10.14#
10.15#*
10.16#
10.17#
10.18#
10.19#
145

10.20#
10.21#*
10.22#*
10.23#*
10.24#
10.25#
10.26#
21.1*
23.1*
31.1*
31.2*
32.1+
32.2+
97*
101.INS*XBRL Instance Document
101.SCH*XBRL Taxonomy Extension Schema Document
101.CAL*XBRL Taxonomy Extension Calculation Document
101.DEF*XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*XBRL Taxonomy Extension Labels Linkbase Document
101.PRE*XBRL Taxonomy Extension Presentation Link Document
104*Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)
___________
*Filed herewith.
†Pursuant to 17 C.F.R. §§230.406 and 230.83, the confidential portions of this exhibit have been omitted and are marked accordingly.
#Indicates a management contract or any compensatory plan, contract or arrangement.
+The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Annual Report on Form 10-K and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.
(1)Incorporated by reference to the Registration Statement on Form S-1 (File No. 333-228300) filed with the Securities and Exchange Commission on November 9, 2018.
(2)Incorporated by reference to the Current Report on Form 8-K (File No. 001-38753) filed with the Securities and Exchange Commission on December 14, 2018.
(3)
Incorporated by reference to the Quarterly Report on Form 10-Q (File No. 001-38753) filed with the Securities and Exchange Commission on May 6, 2021.
(4)
Incorporated by reference to the Annual Report on Form 10-K (File No. 001-38753) filed with the Securities and Exchange Commission on February 27, 2020.
(5)
Incorporated by reference to the Annual Report on Form 10-K (File No. 001-38753) filed with the Securities and Exchange Commission on February 25, 2022.
(6)Incorporated by reference to the Current Report on Form 8-K/A (File No. 001-38753) filed with the Securities and Exchange Commission on May 13, 2022.
(7)Incorporated by reference to the Current Report on Form 8-K/A (File No. 001-38753) filed with the Securities and Exchange Commission on June 1, 2022.
(8)Incorporated by reference to the Quarterly Report on Form 10-Q (File No. 001-38753) filed with the Securities and Exchange Commission on November 3, 2022.
(9)
Incorporated by reference to the Annual Report on Form 10-K (File No. 001-38753) filed with the Securities and Exchange Commission on February 24, 2023.
146

Item 16. Form 10-K Summary

Not applicable.
147



SIGNATURES
Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
                                
MODERNA, INC.
Date:By:/s/ Stéphane Bancel
February 23, 2024
Stéphane Bancel
Chief Executive Officer and Director

148

POWER OF ATTORNEY AND SIGNATURES
Each individual whose signature appears below hereby constitutes and appoints each of Stéphane Bancel and James M. Mock as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
SignatureTitleDate
/s/ Stéphane Bancel
Chief Executive Officer and Director (Principal Executive Officer)
February 23, 2024
Stéphane Bancel
/s/ James M. Mock
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
February 23, 2024
James M. Mock
/s/ Noubar B. Afeyan, Ph.D.Chairman and DirectorFebruary 23, 2024
Noubar B. Afeyan, Ph.D.
/s/ Stephen BerensonDirectorFebruary 23, 2024
Stephen Berenson
/s/ Sandra Horning, M.D.DirectorFebruary 23, 2024
Sandra Horning M.D.
/s/ Robert Langer, Sc.D.DirectorFebruary 23, 2024
Robert Langer, Sc.D.
/s/ Francois Nader, M.D.DirectorFebruary 23, 2024
Francois Nader M.D.
/s/ Elizabeth Nabel, M.D.DirectorFebruary 23, 2024
Elizabeth Nabel, M.D.
/s/ Paul SaganDirectorFebruary 23, 2024
Paul Sagan
/s/ Elizabeth TallettDirectorFebruary 23, 2024
Elizabeth Tallett

149
 EX-3.2 2 exhibit32secondamendedandr.htm EX-3.2 Document


Exhibit 3.2
SECOND AMENDED AND RESTATED
BY-LAWS
OF
MODERNA, INC.
(the “Corporation”)
ARTICLE I
Stockholders
SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by or in the manner determined by the Board of Directors of the Corporation (the “Board of Directors”) and stated in the notice of the meeting, which time, date and place may subsequently be changed at any time, before or after the notice for such meeting has been sent to the stockholders, by vote of the Board of Directors. The Board of Directors may, in its sole discretion, determine that a meeting of stockholders shall not be held at any place, but may instead be held solely by means of remote communication as authorized by Section 211(a)(2) of the General Corporation Law of the State of Delaware (the “DGCL”). In the absence of any such designation or determination, stockholders’ meetings shall be held at the Corporation’s principal executive office. If no Annual Meeting has been held for a period of thirteen (13) months after the Corporation’s last Annual Meeting, a special meeting in lieu thereof may be held, and such special meeting shall have, for the purposes of these By-laws or otherwise, all the force and effect of an Annual Meeting. Any and all references hereafter in these By-laws to an Annual Meeting or Annual Meetings also shall be deemed to refer to any special meeting(s) in lieu thereof.
SECTION 2. Notice of Stockholder Business and Nominations.
(a) Annual Meetings of Stockholders.
(1) Nominations of persons for election to the Board of Directors and the proposal of other business to be considered by the stockholders may be brought before an Annual Meeting (i) by or at the direction of the Board of Directors, (ii) by any stockholder of the Corporation who was a stockholder of record at the time of giving of notice of the Annual Meeting provided for in this By-law, who is entitled to vote at such Annual Meeting, who is present (in person or by proxy) at such Annual Meeting and who complies with the notice procedures set forth in this By-law as to such nomination or business, or (iii) by any Eligible Stockholder (as defined below) who has complied with the procedures set forth in Section 11(a)(1) of this Article I. For the avoidance of doubt, the foregoing clause (ii) shall be the exclusive means for a stockholder to bring nominations or business properly before an Annual Meeting (other than matters properly brought under Rule 14a-8 (or any successor rule) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), and such stockholder must comply with the notice and other procedures set forth in Article I, Section 2(a)(2), (3), (4) and (11) of this By-law to bring such nominations or business properly before an Annual Meeting. In addition to the other requirements set forth in this By-law, for any proposal of business to be considered at an Annual Meeting, it must be a proper subject for action by stockholders of the Corporation under Delaware law.

(2) For nominations or other business to be properly brought before an Annual Meeting by a stockholder pursuant to clause (ii) of Article I, Section 2(a)(1) of this By-law, the stockholder must (i) have given Timely Notice (as defined below) thereof in writing to the Secretary of the Corporation, (ii) have provided any updates or supplements to such notice at the times and in the forms required by this By-law and (iii) together with the beneficial owner(s), if any, on whose behalf the nomination or business proposal is made, have acted in accordance with the representations set forth in the Solicitation Statement (as defined below) required by this By-law. To be timely, a stockholder’s written notice shall be received by the Secretary at the principal executive offices of the Corporation not later than the close




of business on the ninetieth (90th) day nor earlier than the close of business on the one hundred twentieth (120th) day prior to the one-year anniversary of the preceding year’s Annual Meeting; provided, however, that in the event the Annual Meeting is first convened more than thirty (30) days before or more than sixty (60) days after such anniversary date, or if no Annual Meeting were held in the preceding year, notice by the stockholder to be timely must be received by the Secretary of the Corporation not later than the close of business on the later of the ninetieth (90th) day prior to the scheduled date of such Annual Meeting or the tenth (10th) day following the day on which public announcement of the date of such Annual Meeting is first made (such notice within such time periods shall be referred to as “Timely Notice”). Such stockholder’s Timely Notice shall set forth:

(A) as to each person whom the stockholder proposes to nominate for election or reelection as a director, (i) the name, age, business address and residence address of the nominee, (ii) the principal occupation or employment of the nominee, (iii) the class and number of shares of capital stock of the Corporation that are held of record or are beneficially owned by the nominee or its Affiliates or Associates (each as defined below) and any Synthetic Equity Interest (as defined below) held or beneficially owned by the nominee or its Affiliates or Associates, (iv) a description of all agreements, arrangements or understandings between or among the stockholder and each nominee and any other person or persons (naming such person or persons) pursuant to which the nominations are to be made by the stockholder or concerning the nominee’s potential service on the Board of Directors, (v) a questionnaire with respect to the background and qualifications of the nominee completed by the nominee in the form provided by the Corporation (which questionnaire shall be provided by the Secretary upon written request of any stockholder of record identified by name within five (5) business days of such written request), (vi) a representation and agreement in the form provided by the Corporation (which form shall be provided by the Secretary upon written request of any stockholder of record identified by name within five (5) business days of such written request) that: (a) such proposed nominee is not and will not become party to any agreement, arrangement or understanding with any person or entity as to how such proposed nominee, if elected as a director of the Corporation, will act or vote on any issue or question (a “Voting Commitment”) that has not been disclosed to the Corporation in the questionnaire described in clause (v) herein; (b) such proposed nominee is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the Corporation with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director that has not been disclosed to the Corporation in the questionnaire described in clause (v) herein; (c) such proposed nominee would, if elected as a director, comply with all applicable rules and regulations of the exchanges upon which shares of the Corporation’s capital stock trade, each of the Corporation’s corporate governance, ethics, conflict of interest, confidentiality, stock ownership and trading policies and guidelines applicable generally to the Corporation’s directors and, if elected as a director of the Corporation, such person currently would be in compliance with any such policies and guidelines that have been publicly disclosed; (d) such proposed nominee intends to serve as a director for the full term for which he or she is to stand for election; and (e) such proposed nominee will promptly provide to the Corporation such other information as it may reasonably request to determine the eligibility of such proposed nominee to serve on any committee or sub-committee of the Board of Directors under any applicable stock exchange listing requirements or applicable law, or that the Board of Directors reasonably determines could be material to a reasonable stockholder’s understanding of the background, qualifications, experience, independence, or lack thereof, of such proposed nominee; and (vii) any other information relating to such proposed nominee that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to Regulation 14A under the Exchange Act (including, without limitation, such person’s written consent to being named in the proxy statement as a nominee and to serving as a director if elected);

(B) as to any other business that the stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting, the text, if any, of any resolutions or By-law amendment proposed for adoption, and any material interest in such business of each Proposing Person (as defined below);

(C) (i) the name and address of the stockholder giving the notice, as they appear on the Corporation’s books, and the names and addresses of the other Proposing Persons (if any) and (ii) as to each Proposing Person, the following information: (a) the class or series and number of all shares of capital stock of the Corporation that are, directly or indirectly, owned beneficially or of record by such Proposing Person or any of its Affiliates or Associates, including any shares of any class or series of capital stock of the Corporation as to which such Proposing Person or any of its
2



Affiliates or Associates has a right to acquire beneficial ownership at any time in the future (whether or not such right is exercisable immediately or only after the passage of time or upon the satisfaction of any conditions or both) pursuant to any agreement, arrangement or understanding (whether or not in writing), (b) all Synthetic Equity Interests (as defined below) in which such Proposing Person or any of its Affiliates or Associates, directly or indirectly, holds an interest including a description of the material terms of each such Synthetic Equity Interest, including, without limitation, identification of the counterparty to each such Synthetic Equity Interest and disclosure, for each such Synthetic Equity Interest, as to (1) whether or not such Synthetic Equity Interest conveys any voting rights, directly or indirectly, in such shares to such Proposing Person or any of its Affiliates or Associates and (2) whether or not such Synthetic Equity Interest is required to be, or is capable of being, settled through delivery of such shares, (c) any proxy (other than a revocable proxy given in response to a public proxy solicitation made pursuant to, and in accordance with, the Exchange Act), agreement, arrangement, understanding or relationship pursuant to which such Proposing Person or any of its Affiliates or Associates has or shares a right to, directly or indirectly, vote any shares of any class or series of capital stock of the Corporation, (d) any rights to dividends or other distributions on the shares of any class or series of capital stock of the Corporation, directly or indirectly, owned beneficially by such Proposing Person or any of its Affiliates or Associates that are separated or separable from the underlying shares of the Corporation, (e) if such Proposing Person is not a natural person, the identity of the natural person or persons responsible for making voting and investment decisions (including director nominations and any other business that the stockholder proposes to bring before a meeting) on behalf of the Proposing Person (irrespective of whether such person or persons have “beneficial ownership” for purposes of Rule 13d-3 of the Exchange Act of any securities owned of record or beneficially by the Proposing Person) (such person or persons, the “Responsible Person”), (f) any pending or threatened litigation in which such Proposing Person or any of its Affiliates or Associates or any Responsible Person is a party involving the Corporation or any of its officers or directors, or any Affiliate of the Corporation, and (g) any other information relating to such Proposing Person or any of its Affiliates or Associates that would be required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies or consents by such Proposing Person in support of the business proposed to be brought before the meeting pursuant to Section 14(a) of the Exchange Act (the disclosures to be made pursuant to the foregoing clauses (a) through (g) are referred to, collectively, as “Material Ownership Interests”); provided, however, that the Material Ownership Interests shall not include any such disclosures with respect to the ordinary course business activities of any broker, dealer, commercial bank, trust company or other nominee who is a Proposing Person solely as a result of being the stockholder of record directed to prepare and submit the notice required by these By-laws on behalf of a beneficial owner;

(D) (i) a description of all agreements, arrangements or understandings to which any Proposing Person or any of its Affiliates or Associates is a party (whether the counterparty or counterparties are a Proposing Person or any Affiliate or Associate thereof, on the one hand, or one or more other third parties, on the other hand, (including any proposed nominee(s)) (a) pertaining to the nomination(s) or other business proposed to be brought before the meeting of stockholders or (b) entered into for the purpose of acquiring, holding, disposing or voting of any shares of any class or series of capital stock of the Corporation (which description shall identify the name of each other person who is party to such an agreement, arrangement or understanding) and (ii) identification of the names and addresses of other stockholders (including beneficial owners) known by any of the Proposing Persons to be providing financial support or meaningful assistance in furtherance of the nomination(s) or other business proposed to be brought before the meeting of stockholders and, to the extent known, the class and number of all shares of the Corporation’s capital stock owned beneficially or of record by such other stockholder(s) or other beneficial owner(s); and
(E) a statement (i) that the stockholder is a holder of record of capital stock of the Corporation entitled to vote at such meeting, a representation that such stockholder intends to appear in person or by proxy at the meeting to propose such business or nominees and an acknowledgement that, if such stockholder (or a qualified representative of such stockholder) does not appear to present such business or proposed nominees, as applicable, at such meeting, the Corporation need not present such business or proposed nominees for a vote at such meeting, notwithstanding that proxies in respect of such vote may have been received by the Corporation, (ii) whether or not the stockholder giving the notice and/or the other Proposing Person(s), if any, (a) will deliver a proxy statement and form of proxy to holders of, in the case of a business proposal, at least the percentage of voting power of all of the shares of capital stock of the Corporation required under applicable law to approve the proposal or, in the case of a nomination or nominations, at least 67 percent of the voting power of all of the shares of capital stock of the Corporation entitled to
3



vote on the election of directors or (b) otherwise solicit proxies or votes from stockholders in support of such proposal or nomination, as applicable, (iii) providing a representation as to whether or not such Proposing Person intends to solicit proxies in support of director nominees other than the Corporation’s director nominees in accordance with Rule 14a-19 promulgated under the Exchange Act and (iv) that the stockholder will provide any other information relating to such item of business that would be required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies in support of the business proposed to be brought before the meeting pursuant to Section 14(a) of the Exchange Act (such statement, the “Solicitation Statement”).
For purposes of this Article I of these By-laws, the term “Proposing Person” shall mean the following persons: (i) the stockholder of record providing the notice of nominations or business proposed to be brought before a stockholders’ meeting, and (ii) the beneficial owner(s), if different, on whose behalf the nominations or business proposed to be brought before a stockholders’ meeting is made. For purposes of this Section 2 of Article I of these By-laws, each of the terms “Affiliates” and “Associates” shall have the meaning attributed to such term in Rule 12b-2 under the Exchange Act. For purposes of this Section 2 of Article I of these By-laws, the term “Synthetic Equity Interest” shall mean any transaction, agreement or arrangement (or series of transactions, agreements or arrangements), including, without limitation, any derivative, swap, hedge, repurchase or so-called “stock borrowing” or securities lending agreement or arrangement, the purpose or effect of which is to, directly or indirectly: (a) give a person or entity economic benefit and/or risk similar to ownership of shares of any class or series of capital stock of the Corporation, in whole or in part, including due to the fact that such transaction, agreement or arrangement provides, directly or indirectly, the opportunity to profit, or share in any profit, or avoid a loss from any increase or decrease in the value of any shares of any class or series of capital stock of the Corporation, (b) mitigate loss to, reduce the economic risk of or manage the risk of share price changes for, any person or entity with respect to any shares of any class or series of capital stock of the Corporation, or (c) increase or decrease the voting power of any person or entity with respect to any shares of any class or series of capital stock of the Corporation.

(3) A stockholder providing Timely Notice of nominations or business proposed to be brought before an Annual Meeting shall further update and supplement such notice, if necessary, so that the information (including, without limitation, the Material Ownership Interests information) provided or required to be provided in such notice pursuant to this By-law shall be true and correct as of the record date for the meeting and as of the date that is ten (10) business days prior to such Annual Meeting, and such update and supplement shall be received by the Secretary at the principal executive offices of the Corporation not later than the close of business on the fifth (5th) business day after the record date for the Annual Meeting (in the case of the update and supplement required to be made as of the record date), and not later than the close of business on the eighth (8th) business day prior to the date of the Annual Meeting (in the case of the update and supplement required to be made as of ten (10) business days prior to the meeting). For the avoidance of doubt, the obligation to update as set forth in this Section 2(a)(3) shall not limit the Corporation’s rights with respect to any deficiencies in any notice provided by a stockholder, extend any applicable deadlines hereunder, or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend or update any proposal or nomination or to submit any new proposal, including by changing or adding nominees, matters, business and/or resolutions proposed to be brought before a meeting of the stockholders. Notwithstanding the foregoing, if a Proposing Person no longer plans to solicit proxies in accordance with its representation pursuant to Article I, Section 2(a)(2)(E), such Proposing Person shall inform the Corporation of this change by delivering a written notice to the Secretary at the principal executive offices of the Corporation no later than two (2) business days after making the determination not to proceed with a solicitation of proxies. A Proposing Person shall also update its notice so that the information required by Article I, Section 2(a)(2)(C) is current through the date of the meeting or any adjournment, postponement or rescheduling thereof, and such update shall be delivered in writing to the secretary at the principal executive offices of the Corporation no later than two (2) business days after the occurrence of any material change to the information previously disclosed pursuant to Article I, Section 2(a)(2)(C).
(4) Notwithstanding anything in the second sentence of Article I, Section 2(a)(2) of this By-law to the contrary, in the event that the number of directors to be elected to the Board of Directors is increased and there is no public announcement naming all of the nominees for director or specifying the size of the increased Board of Directors made by the Corporation at least ten (10) days before the last day a stockholder may deliver a notice of nomination in accordance with the second sentence of Article I, Section 2(a)(2), a stockholder’s notice required by this By-law
4



shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be received by the Secretary of the Corporation not later than the close of business on the tenth (10th) day following the day on which such public announcement is first made by the Corporation.
(b) General.
(1) Only such persons who are nominated in accordance with the provisions of Sections 2 or 11 of Article I of these By-laws shall be eligible for election and to serve as directors and only such business shall be conducted at an Annual Meeting as shall have been brought before the meeting in accordance with the provisions of this By-law or in accordance with Rule 14a-8 under the Exchange Act. The Board of Directors or a designated committee thereof shall have the power to determine whether a nomination or any business proposed to be brought before the meeting was made in accordance with the provisions of Sections 2 or 11 of Article I of these By-laws. If neither the Board of Directors nor such designated committee makes a determination as to whether any stockholder proposal or nomination was made in accordance with the provisions of Sections 2 or 11 of Article I of these By-laws, the chair of the meeting (as defined in Section 9 of this Article I) shall have the power and duty to determine whether the stockholder proposal or nomination was made in accordance with the provisions of Sections 2 or 11 of Article I of these By-laws. If the Board of Directors or a designated committee thereof or the chair of the meeting, as applicable, determines that any stockholder proposal or nomination was not made in accordance with the provisions of this By-law, such proposal or nomination shall be disregarded and shall not be presented for action at the Annual Meeting.
(2) Except as otherwise required by law or Section 11 of Article I of these By-laws, nothing in this Article I, Section 2 shall obligate the Corporation or the Board of Directors to include in any proxy statement or other stockholder communication distributed on behalf of the Corporation or the Board of Directors information with respect to any nominee for director or any other matter of business submitted by a stockholder.
(3) Notwithstanding the foregoing provisions of this Article I, Section 2, if the nominating or proposing stockholder (or a qualified representative of the stockholder) does not appear at the Annual Meeting to present a nomination or any business, such nomination or business shall be disregarded, notwithstanding that proxies in respect of such vote may have been received by the Corporation. For purposes of this Article I, Section 2, to be considered a qualified representative of the proposing stockholder, a person must be authorized by a written instrument executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such written instrument or electronic transmission, or a reliable reproduction of the written instrument or electronic transmission, to the chair of the meeting at the meeting of stockholders.
(4) For purposes of this By-law, “public announcement” shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Exchange Act.
(5) Notwithstanding the foregoing provisions of this By-law, a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder, including, but not limited to, Rule 14a-19 of the Exchange Act, with respect to the matters set forth in this Bylaw. If a stockholder fails to comply with any applicable requirements of the Exchange Act, including, but not limited to, Rule 14a-19 promulgated thereunder, such stockholder’s proposed nomination or proposed business shall be deemed to have not been made in compliance with this Bylaw and shall be disregarded.
(6) Further notwithstanding the foregoing provisions of this Bylaw, unless otherwise required by law, (i) no Proposing Person shall solicit proxies in support of director nominees other than the Corporation’s nominees unless such Proposing Person has complied with Rule 14a-19 promulgated under the Exchange Act in connection with the solicitation of such proxies, including the provision to the Corporation of notices required thereunder with timely notice and (ii) if any Proposing Person (A) provides notice pursuant to Rule 14a-19(b) promulgated under the Exchange Act, (B) subsequently fails to comply with the requirements of Rule 14a-19(a)(2) or Rule 14a-19(a)(3) promulgated under the Exchange Act, including the provision to the Corporation of notices required thereunder with timely notice and (C) no other Proposing Person has provided notice pursuant to, and in compliance with, Rule 14a-19 under the Exchange Act that it intends to solicit proxies in support of the election of such proposed nominee in accordance with Rule 14a-19(b) under the Exchange Act, then such proposed nominee shall be disqualified from
5



nomination, the Corporation shall disregard the nomination of such proposed nominee and no vote on the election of such proposed nominee shall occur. Upon request by the Corporation, if any Proposing Person provides notice pursuant to Rule 14a-19(b) promulgated under the Exchange Act, such Proposing Person shall deliver to the Corporation, no later than five (5) business days prior to the applicable meeting date, reasonable evidence that it has met the requirements of Rule 14a-19(a)(3) promulgated under the Exchange Act.
(7) The number of nominees a stockholder may nominate for election at the Annual Meeting (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the Annual Meeting on behalf of such beneficial owner) shall not exceed the number of directors to be elected at such Annual Meeting. A stockholder may not designate any substitute nominees unless the stockholder provides timely notice of such substitute nominee(s) in accordance with these By-laws (and such notice contains all of the information, representations, questionnaires and certifications with respect to such substitute nominee(s) that are required by the By-laws with respect to nominees for director).
If any amendment to, or repeal of, any provision of this Article I, Section 2 is submitted to the stockholders for approval at an Annual Meeting or a special meeting of stockholders, then the affirmative vote of not less than two thirds (2/3) of the voting power of the outstanding shares of capital stock entitled to vote thereon, and the affirmative vote of not less than two thirds (2/3) of the voting power of the outstanding shares of each class entitled to vote thereon as a class, shall be required to amend or repeal any provision of this Article I, Section 2; provided, however, that if the Board of Directors recommends that stockholders approve such amendment or repeal at such meeting of stockholders, such amendment or repeal shall only require the affirmative vote of a majority of the outstanding shares entitled to vote on such amendment or repeal, voting together as a single class.
SECTION 3. Special Meetings. Except as otherwise required by statute and subject to the rights, if any, of the holders of any series of Undesignated Preferred Stock, special meetings of the stockholders of the Corporation may be called only by the Board of Directors acting pursuant to a resolution approved by the affirmative vote of a majority of the Directors then in office. The Board of Directors may postpone or reschedule any previously scheduled special meeting of stockholders. Only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders of the Corporation. Nominations of persons for election to the Board of Directors of the Corporation and stockholder proposals of other business shall not be brought before a special meeting of stockholders to be considered by the stockholders unless such special meeting is held in lieu of an annual meeting of stockholders in accordance with Article I, Section 1 of these By-laws, in which case such special meeting in lieu thereof shall be deemed an Annual Meeting for purposes of these By-laws and the provisions of Article I, Section 2 of these By-laws shall govern such special meeting.
Notwithstanding anything herein to the contrary, the affirmative vote of not less than two thirds (2/3) of the outstanding shares of capital stock entitled to vote thereon, and the affirmative vote of not less than two thirds (2/3) of the outstanding shares of each class entitled to vote thereon as a class, shall be required to amend or repeal any provision of this Article I, Section 3; provided, however, that if the Board of Directors recommends that stockholders approve such amendment or repeal at such meeting of stockholders, such amendment or repeal shall only require the affirmative vote of a majority of the outstanding shares entitled to vote on such amendment or repeal, voting together as a single class.
SECTION 4. Notice of Meetings; Adjournments.
(a) A notice of each Annual Meeting stating the hour, date and place, if any, of such Annual Meeting, the means of remote communication, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, and the record date for determining the stockholders entitled to vote at the meeting, if such date is different from the record date for determining stockholders entitled to notice of the meeting, shall be given not less than ten (10) days nor more than sixty (60) days before the Annual Meeting, to each stockholder entitled to vote thereat by delivering such notice to such stockholder or by mailing it, postage prepaid, addressed to such stockholder at the address of such stockholder as it appears on the Corporation’s stock transfer books. Without limiting the manner by which notice may otherwise be given to stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section 232 of the DGCL.
6



(b) Unless otherwise required by the DGCL, notice of all special meetings of stockholders shall be given in the same manner as provided for Annual Meetings, except that the notice of all special meetings shall also state the purpose or purposes for which the meeting has been called.
(c) Notice of an Annual Meeting or special meeting of stockholders need not be given to a stockholder if a waiver of notice is executed, or waiver of notice by electronic transmission is provided, before or after such meeting by such stockholder or if such stockholder attends such meeting, unless such attendance is for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting was not lawfully called or convened.
(d) The Board of Directors may postpone, reschedule or cancel any previously scheduled Annual Meeting or special meeting of stockholders (for the avoidance of doubt, including any special meeting called by the stockholders in accordance with Section 3 of this Article I) and any record date with respect thereto, regardless of whether any notice or public disclosure with respect to any such meeting has been sent or made pursuant to Section 2 of this Article I of these By-laws or otherwise. In no event shall the public announcement of an adjournment, postponement or rescheduling of any previously scheduled meeting of stockholders commence a new time period for the giving of a stockholder’s notice under this Article I of these By-laws.
(e) When any meeting is convened, the chair of the meeting or the stockholders present or represented by proxy at such meeting may adjourn the meeting from time to time for any reason, regardless of whether a quorum is present, to reconvene at any other time and at any place at which a meeting of stockholders may be held under these By-laws. When any Annual Meeting or special meeting of stockholders is adjourned to another hour, date or place (including an adjournment taken to address a technical failure to convene or continue a meeting using remote communication), notice need not be given of the adjourned meeting if the time, place, if any, thereof and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are (i) announced at the meeting at which the adjournment is taken, (ii) displayed, during the time scheduled for the meeting, on the same electronic network used to enable stockholders and proxy holders to participate in the meeting by means of remote communication or (iii) set forth in the notice of meeting given in accordance with this Section 4; provided, however, that if the adjournment is for more than thirty (30) days from the meeting date, or if after the adjournment a new record date is fixed for the adjourned meeting, notice of the adjourned meeting and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting shall be given to each stockholder of record entitled to vote thereat and each stockholder who, by law or under the Certificate of Incorporation of the Corporation (as the same may hereafter be amended and/or restated, the “Certificate”) or these By-laws, is entitled to such notice.
SECTION 5. Quorum. Except as otherwise provided by law, the Certificate or these By-laws, at each meeting of stockholders, the presence in person or by remote communication, if applicable, or represented by proxy, of the holders of a majority in voting power of the outstanding shares of stock entitled to vote at the meeting shall be necessary and sufficient to constitute a quorum. If less than a quorum is present at a meeting, the chair of the meeting or the holders of voting stock, by the affirmative vote of a majority of the voting power present in person or by proxy and entitled to vote thereon, may adjourn the meeting from time to time, and the meeting may be held as adjourned without further notice, except as provided in Section 4 of this Article I. At such adjourned meeting at which a quorum is present, any business may be transacted which might have been transacted at the meeting as originally noticed. The stockholders present at a duly constituted meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum.
SECTION 6. Voting and Proxies.
(a) The stockholders entitled to vote at any meeting of stockholders shall be determined in accordance with the provisions of Article IV, Section 4 of these By-laws, subject to Section 217 (relating to voting rights of fiduciaries, pledgors and joint owners of stock) and Section 218 (relating to voting trusts and other voting agreements) of the DGCL. Stockholders shall have one vote for each share of stock entitled to vote owned by them of record according to the stock ledger of the Corporation as of the record date, unless otherwise provided by law or by the Certificate. Stockholders may vote either (i) in person, (ii) by written proxy or (iii) by a transmission permitted by Section
7



212(c) of the DGCL. Any copy, facsimile telecommunication or other reliable reproduction of the writing or transmission permitted by Section 212(c) of the DGCL may be substituted for or used in lieu of the original writing or transmission for any and all purposes for which the original writing or transmission could be used, provided that such copy, facsimile telecommunication or other reproduction shall be a complete reproduction of the entire original writing or transmission. Proxies shall be filed in accordance with the procedures established for the meeting of stockholders. A proxy with respect to stock held in the name of two or more persons shall be valid if executed by or on behalf of any one of them unless at or prior to the exercise of the proxy the Corporation receives a specific written notice to the contrary from any one of them. In the event the Corporation receives proxies for disqualified or withdrawn nominees for the Board of Directors, such votes for such disqualified or withdrawn nominees in the proxies will be treated as abstentions.
(b) Any stockholder directly or indirectly soliciting proxies from other stockholders must use a proxy card color other than white, which shall be reserved for the exclusive use by the Board of Directors.

SECTION 7. Action at Meeting. When a quorum is present at any meeting of stockholders, any matter before any such meeting shall be decided by a majority of the votes properly cast for and against such matter, except where a larger vote is required by law, by the Certificate or by these By-laws. When a quorum is present at any meeting, a nominee for director shall be elected to the Board of Directors if the number of votes cast for such nominee’s election exceed the number of votes cast against such nominee’s election; provided, however, that in a contested election, a nominee shall be elected by a plurality of the votes cast by the stockholders entitled to vote at the election on such election of directors. An election shall be considered contested if, as of the last date on which nominees for director may be submitted in accordance with these By-laws, the nominees for election to the Board of Directors exceeds the number of positions on the Board of Directors to be filled by election at that meeting. If an incumbent director is not re-elected, the director shall tender his or her resignation to the Board of Directors. The Nominating and Corporate Governance Committee of the Board of Directors (or any future committee the equivalent thereof) will make a recommendation to the Board of Directors on whether to accept or reject the resignation, or whether other action should be taken. The Board of Directors will act on the recommendation of such committee and will publicly disclose its decision within ninety (90) days from the date of the certification of the election results. A director who tenders his or her resignation may not participate in any meeting of the Board of Directors or any committee thereof until the Board of Directors has determined not to accept his or her resignation.
SECTION 8. Stockholder Lists. The Corporation shall prepare, no later than the tenth (10th) day before each Annual Meeting or special meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder; provided, however, that if the record date for determining the stockholders entitled to vote is less than ten (10) days before the meeting date, the list shall reflect the stockholders entitled to vote as of the tenth (10th) day before the meeting date. Such list shall be open to the examination of any stockholder for any purpose germane to the meeting for a period of ten (10) days ending on the day before the meeting date in the manner provided by law.
SECTION 9. Conduct of Meeting. The Board of Directors may adopt by resolution such rules, regulations and procedures for the conduct of any meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with rules, regulations and procedures adopted by the Board of Directors, the chair of the meeting shall have the right to prescribe such rules, regulations and procedures and to do all such acts, as, in the judgment of such chair, are necessary, appropriate or convenient for the proper conduct of the meeting. Such rules, regulations or procedures, whether adopted by the Board of Directors or the chair of the meeting, may include, without limitation, the following: (a) the establishment of an agenda for the meeting; (b) rules and procedures for maintaining order at the meeting and the safety of those present at the meeting; (c) limitations on attendance at or participation in the meeting to stockholders of record of the Corporation, their duly authorized and constituted proxies, or such other persons as the chair of the meeting shall determine; (d) restrictions on entry to the meeting after the time fixed for the commencement thereof; (e) the determination of the circumstances in which any person may make a statement or ask questions and limitations on the time allotted to questions or comments; (f) the determination of when the polls shall open and close for any given matter to be voted on at the meeting; (g) the exclusion or removal of any stockholders or any other individual who refuses to comply with meeting rules, regulations, or procedures; (h)
8



restrictions on the use of audio and video recording devices, cell phones and other electronic devices; (i) rules, regulations and procedures for compliance with any federal, state or local laws or regulations (including those concerning safety, health or security); (j) procedures (if any) requiring attendees to provide the Corporation advance notice of their intent to attend the meeting; and (k) rules, regulations or procedures regarding the participation by means of remote communication of stockholders and proxy holders not physically present at a meeting, whether such meeting is to be held at a designated place or solely by means of remote communication. The chair of the meeting shall be: (i) such person as the Board of Directors shall have designated to preside over all meetings of the stockholders; (ii) if the Board of Directors does not so designate such a chair of the meeting or if the chair of the meeting is unable to so preside or is absent, then the Chairman of the Board, if one is elected; (iii) if the Board of Directors does not so designate a chair of the meeting and there is no Chairman of the Board, or if the chair of the meeting or the Chairman of the Board is unable to so preside or is absent, then the Chief Executive Officer, if one is elected; or (iv) in the absence or inability to serve of any of the aforementioned persons, the President of the Corporation. Unless and to the extent determined by the Board of Directors or the chair of the meeting, the chair of the meeting shall not be obligated to adopt or follow any technical, formal or parliamentary rules or principles of procedure. In the absence of the Secretary of the Corporation, the secretary of the meeting shall be such person as the chair of the meeting appoints.
SECTION 10. Inspectors of Elections. The Corporation shall, in advance of any meeting of stockholders, appoint one or more inspectors to act at the meeting and make a written report thereof. The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the chair of the meeting shall appoint one or more inspectors to act at the meeting. Any inspector may, but need not, be an officer, employee or agent of the Corporation. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability. The inspectors shall perform such duties as are required by the DGCL, including the counting of all votes and ballots. The inspectors may appoint or retain other persons or entities to assist the inspectors in the performance of the duties of the inspectors. The chair of the meeting may review all determinations made by the inspectors, and in so doing the chair of the meeting shall be entitled to exercise his or her sole judgment and discretion and he or she shall not be bound by any determinations made by the inspectors. All determinations by the inspectors and, if applicable, the chair of the meeting, shall be subject to further review by any court of competent jurisdiction.
SECTION 11. Proxy Access Rights.
(a) Proxy Access Nomination.
(1) Whenever the Board of Directors solicits proxies with respect to the election of directors at Annual Meeting, nominations of individuals for election to the Board of Directors at such Annual Meeting may be made by a stockholder or group of no more than 20 stockholders that satisfies the requirements of this Section 11 (as further qualified by the provisions of this Section 11, any such individual or group, including as the context requires each member thereof, being hereinafter referred to as an “Eligible Stockholder”). The nomination provisions set forth in this Section 11 are separate from, and in addition to, the nomination provisions set forth in Section 2 of this Article I. Subject to the provisions of this Section 11 and to the extent permitted by applicable law, the Corporation shall include in its proxy materials for such Annual Meeting, in addition to any persons nominated for election by, or at the direction of, a majority of the Board of Directors, the name, together with the Required Information (as defined below), of any person nominated for election (each such person being hereinafter referred to as a “Stockholder Nominee”) to the Board of Directors by an Eligible Stockholder pursuant to this Section 11.
(2) For purposes of this Section 11, the “Required Information” that the Corporation will include in its proxy materials is (A) the information concerning the Stockholder Nominee and the Eligible Stockholder that is required to be disclosed in the Corporation’s proxy statement by the rules and regulations promulgated under the Exchange Act, by these By-Laws, by the Certificate and/or by the listing standards of each principal U.S. exchange upon which the common stock of the Corporation is listed; and (B) the written statement, if any, consisting of 500 words or fewer delivered by the Eligible Stockholder pursuant to Section 11(d)(4) in support of the Stockholder Nominee’s candidacy that is clearly and specifically identified as the written statement that the Eligible Stockholder requests the
9



Corporation to include in its proxy materials and does not include any references to any other statements or written materials in support of the Stockholder Nominee’s candidacy or any website or other locations where any such statements or written materials may be found (the “Statement”). If the Eligible Stockholder has not provided to the Secretary of the Corporation a Statement within the time period specified in this Section 11 for delivering the Notice of Proxy Access Nomination (as defined below), the Eligible Stockholder will be deemed to have not provided the Statement and the Required Information will not include the Statement. Notwithstanding anything to the contrary contained in this Section 11, the Corporation may omit from its proxy materials any information or Statement (or portion thereof) if the Corporation believes that (A) such information is not true in all material respects or omits a material statement necessary to make the statements made not misleading; (B) such information directly or indirectly impugns the character, integrity or personal reputation of, or directly or indirectly makes charges concerning improper, illegal or immoral conduct or associations, without factual foundation, with respect to, any person; or (C) the inclusion of such information in the proxy statement would otherwise violate the Securities and Exchange Commission proxy rules or any other applicable law, rule or regulation.
(b) Notice Requirements.
(1) In order to nominate a Stockholder Nominee pursuant to this Section 11, an Eligible Stockholder must, in addition to satisfying the other requirements of Section 11, provide to the Secretary of the Corporation, a written notice expressly nominating its Stockholder Nominee(s) and electing to have its Stockholder Nominee(s) included in the Corporation’s proxy materials pursuant to this Section 11 that complies with the requirements set forth in this Section 11 (a “Notice of Proxy Access Nomination”) within the time period set forth below. In order for an Eligible Stockholder to nominate a Stockholder Nominee pursuant to this Section 11, the Eligible Stockholder’s Notice of Proxy Access Nomination must be received by the Secretary of the Corporation at the principal executive office of the Corporation not earlier than the 120th day nor later than 5:00 p.m., Eastern Time, on the 90th day prior to the first anniversary of the date of the notice for the preceding year’s Annual Meeting; provided, however, that in the event that the date of the Annual Meeting is advanced or delayed by more than 30 days from the first anniversary of the date of the preceding year’s Annual Meeting, Notice of Proxy Access Nomination by the Eligible Stockholder to be timely must be so delivered not earlier than the 120th day prior to the date of such Annual Meeting and not later than 5:00 p.m., Eastern Time, on the later of the 90th day prior to the date of such Annual Meeting, as originally convened, or the tenth day following the day on which public announcement of the date of such meeting is first made. In no event shall an adjournment, postponement or rescheduling of any previously scheduled meeting of stockholders, or the public announcement thereof, commence a new time period for the giving of a Notice of Proxy Access Nomination under this Section 11. For purposes of this Section 11, “public announcement” shall have the meaning given to such term in Section 2(b)(4) of this Article I.
(2) In order to nominate a Stockholder Nominee pursuant to this Section 11, an Eligible Stockholder providing the Required Information within the time period specified in Section 11(b)(1) for delivering the Notice of Proxy Access Nomination must further update and supplement such Required Information, if necessary, so that all such information provided or required to be provided shall be true and correct as of the close of business on the record date for purposes of determining the stockholders entitled to vote at such Annual Meeting and as of the date that is ten business days prior to such Annual Meeting, and such update and supplement (or a written notice stating that there is no such update or supplement) must be delivered in writing to the Secretary of the Corporation at the principal executive office of the Corporation not later than 5:00 p.m., Eastern Time, on the fifth business day after the record date for purposes of determining the stockholders entitled to vote at the meeting (in the case of the update and supplement required to be made as of the record date), and not later than 5:00 p.m., Eastern Time, on the fifth business day prior to the date for the meeting (in the case of the update and supplement required to be made as of ten business days prior to the meeting).
(3) In the event that any of the information or communications provided by the Eligible Stockholder or the Stockholder Nominee to the Corporation or its stockholders ceases to be true and correct in all material respects or omits a material fact necessary in order to make the statements made, in light of the circumstances under which they were made, not misleading, each Eligible Stockholder or Stockholder Nominee, as the case may be, shall promptly notify the Secretary of the Corporation of any defect in such previously provided information or communications and of the information that is required to correct any such defect.
10



(c) Maximum Number of Stockholder Nominees.
(1) The maximum number of Stockholder Nominees nominated by all Eligible Stockholders that will be included in the Corporation’s proxy materials with respect to an Annual Meeting shall not exceed the greater of (i) two or (ii) 20% of the number of directors in office as of the last day on which a Notice of Proxy Access Nomination may be timely delivered pursuant to and in accordance with this Section 11 (the “Final Proxy Access Nomination Date”), or if such amount is not a whole number, the closest whole number below 20%; provided, that the maximum number of Stockholder Nominees that will be included in the Corporation’s proxy materials with respect to an Annual Meeting will be reduced by (i) the number of Stockholder Nominees whom the Board of Directors itself decides to nominate for election at such Annual Meeting; (ii) the number of individuals who will be included in the Corporation’s proxy materials as nominees recommended by the Board of Directors pursuant to an agreement, arrangement or other understanding with a stockholder or group of stockholders (other than any such agreement, arrangement or understanding entered into in connection with an acquisition of shares from the Corporation by such stockholder or group of stockholders) and (iii) the number of individuals that the Board of Directors decides to nominate for re-election who were previously elected to the Board of Directors with respect to any of the preceding two Annual Meetings based on a nomination by one or more stockholders pursuant to Section 2 of Article I or this Section 11.
(2) Any Eligible Stockholder submitting more than one Stockholder Nominee for inclusion in the Corporation’s proxy materials pursuant to this Section 11 shall rank such Stockholder Nominees based on the order that the Eligible Stockholder desires such Stockholder Nominees to be selected for inclusion in the Corporation’s proxy statement in the event that the total number of Stockholder Nominees submitted by Eligible Stockholders pursuant to this Section 11 exceeds the maximum number of Stockholder Nominees provided for in Section 11(c)(1) (including by operation of Section 11(c)(3)). In the event that the number of Stockholder Nominees submitted by Eligible Stockholders pursuant to this Section 11 for an Annual Meeting exceeds the maximum number of Stockholder Nominees provided for in Section 11(c)(1) (including by operation of Section 11(c)(3)), the highest ranking Stockholder Nominee who meets the requirements of this Section 11 from each Eligible Stockholder (with such determination and the determination of whether a stockholder or group of stockholders constitutes an Eligible Stockholder to be based on compliance with the provisions of this Section 11 as of the Final Proxy Access Nomination Date) will be selected for inclusion in the Corporation’s proxy materials until the maximum number is reached, going in order from the largest to the smallest of such Eligible Stockholders based on the number of shares of common stock of the Corporation each Eligible Stockholder disclosed as owned by such Eligible Stockholder in the Notice of Proxy Access Nomination submitted to the Corporation hereunder. If the maximum number of Stockholder Nominees provided for in this Section 11 is not reached after the highest ranking Stockholder Nominee who meets the requirements of this Section 11 from each Eligible Stockholder determined in the manner set forth above has been selected, this selection process will continue as many times as necessary, following the same order each time, until the maximum number of Stockholder Nominees provided for in this Section 11 is reached. The Stockholder Nominees initially selected in accordance with this Section 11(c)(2) will be the only Stockholder Nominees eligible to be nominated or included in the Corporation’s proxy materials pursuant to this Section 11. The Notices of Proxy Access Nomination and nominations of all of the remaining Stockholder Nominees not initially selected pursuant to this Section 11(c)(2) will be deemed to have been withdrawn by each of the applicable stockholders as of the Final Proxy Access Nomination Date, and, following such initial selection, if any one or more of the Stockholder Nominees so selected are (A) nominated by the Board of Directors or (B) not included in the Corporation’s proxy materials or are not submitted for election for any reason, including, without limitation, a subsequent failure to comply with this Section 11 by the Eligible Stockholder or the Eligible Stockholder’s withdrawal of the nomination, then, in each case, no additional Stockholder Nominees will be included in the Corporation’s proxy materials or otherwise submitted for stockholder election pursuant to this Section 11.
(3) If for any reason one or more vacancies occur on the Board of Directors after the Final Proxy Access Nomination Date but before the date of the applicable Annual Meeting and the Board of Directors resolves to reduce the size of the Board of Directors in connection therewith, the maximum number of Stockholder Nominees eligible to be nominated or included in the Corporation’s proxy materials pursuant to this Section 11 shall be calculated based on the number of directors in office as so reduced. The Notices of Proxy Access Nomination and nominations of any Stockholder Nominees who cease to be eligible to be nominated or included in the Corporation’s proxy materials
11



pursuant to this Section 11 as a result of the operation of this Section 11(c)(3) will be deemed to have been withdrawn by each of the applicable Eligible Stockholders as of the Final Proxy Access Nomination Date.
(d) Stockholder Eligibility.
(1) For purposes of this Section 11, an Eligible Stockholder shall be deemed to “own” only those outstanding shares of common stock of the Corporation as to which the Eligible Stockholder possesses both (A) the full voting and investment rights pertaining to the shares and (B) the full economic interest in (including the opportunity for profit from and risk of loss on) such shares; provided that the number of shares calculated in accordance with clauses (A) and (B) (x) shall not include any shares (I) borrowed by such Eligible Stockholder for any purposes or purchased by such Eligible Stockholder pursuant to an agreement to resell, (II) sold by such Eligible Stockholder or any of its affiliates in any transaction that has not been settled or closed or (III) subject to any option, warrant, forward contract, swap, contract of sale, other derivative or similar agreement entered into by such Eligible Stockholder or any of its affiliates, whether any such instrument or agreement is to be settled with shares or with cash based on the notional amount or value of shares of outstanding common stock of the Corporation, in any such case which instrument or agreement has, or is intended to have, the purpose or effect of (1) reducing in any manner, to any extent or at any time in the future, such Eligible Stockholder’s or its affiliates’ full right to vote or direct the voting of any such shares by such Eligible Stockholder or any of its affiliates and/or (2) hedging, offsetting or altering to any degree any gain or loss realized or realizable from maintaining the full economic ownership of such shares by such Eligible Stockholder or affiliate, and (y) shall be reduced by the notional amount of shares of common stock of the Corporation subject to any option, warrant, forward contract, swap, contract of sale, other derivative or similar agreement entered into by such Eligible Stockholder or any of its affiliates, whether or not any such instrument is to be settled with shares or with cash, to the extent the number of shares owned by the Eligible Stockholder was not already reduced by such amount pursuant to clause (x)(III) above, and a number of shares of common stock of the Corporation equal to the net “short” position in the common stock of the Corporation held by such Eligible Stockholder’s affiliates, whether through short sales, options, warrants, forward contracts, swaps, contracts of sale, other derivatives or similar agreements or any other agreement or arrangement. An Eligible Stockholder shall “own” shares held in the name of a nominee or other intermediary so long as the Eligible Stockholder retains the right to instruct how the shares are voted with respect to the election of directors and possesses the full economic interest in the shares. An Eligible Stockholder’s ownership of shares shall be deemed to continue during any period in which the Eligible Stockholder has delegated any voting power by means of a proxy, power of attorney or other instrument or arrangement which is unconditionally revocable at any time by the Eligible Stockholder. The terms “owned,” “owning” and other variations of the word “own” shall have correlative meanings. Whether outstanding shares of the common stock of the Corporation are “owned” for these purposes shall be determined by the Board of Directors or any committee thereof. For purposes of this Section 11, the term “affiliate” or “affiliates” shall have the meaning ascribed thereto under the General Rules and Regulations of the Exchange Act.
(2) In order to make a nomination pursuant to this Section 11, an Eligible Stockholder must have owned the Required Ownership Percentage (as defined below) of the Corporation’s outstanding common stock (the “Required Shares”) continuously for the Minimum Holding Period (as defined below) or longer as of both the date the Notice of Proxy Access Nomination is required to be received by the Corporation in accordance with this Section 11 and the close of business on the record date for determining stockholders entitled to vote at the applicable Annual Meeting, and must continue to own the Required Shares through the applicable meeting date (and any postponement or adjournment thereof); provided, that, up to, but not more than, 20 individual stockholders who otherwise meet all of the requirements to be an Eligible Stockholder may aggregate their stockholdings in order to meet the Required Ownership Percentage, but not the Minimum Holding Period, of the Required Shares. For purposes of this Section 11, the “Required Ownership Percentage” is 3% or more of the Corporation’s issued and outstanding common stock, and the “Minimum Holding Period” is three years.
(3) Whenever the Eligible Stockholder consists of a group of more than one stockholder, each provision in this Section 11 that requires the Eligible Stockholder to provide any written statements, representations, undertakings, agreements or other instruments or to meet any other conditions shall be deemed to require each stockholder that is a member of such group to provide such statements, representations, undertakings, agreements or other instruments and to meet such other conditions. In determining the aggregate number of stockholders in a group, a “group of
12



investment companies,” as such term is defined in Section 12(d)(1)(G)(ii) of the Investment Company Act of 1940, as amended, (a “Qualifying Fund Family”) shall be treated as one stockholder. Not later than the deadline for delivery of the Notice of Proxy Access Nomination pursuant to this Section 11, a Qualifying Fund Family whose stock ownership is counted for purposes of determining whether a stockholder or group of stockholders qualifies as an Eligible Stockholder shall provide to the Secretary of the Corporation such documentation as is reasonably satisfactory to the Board of Directors, in its sole discretion, that demonstrates that the funds comprising the Qualifying Fund Family satisfy the definition hereof. When an Eligible Stockholder is comprised of a group, a violation of any provision of these By-laws by any member of the group shall be deemed a violation by the entire Eligible Stockholder group. No person may be a member of more than one group of persons constituting an Eligible Stockholder with respect to any Annual Meeting.
(4) In addition to providing the Notice of Proxy Access Nomination in accordance with Section 11(b)(1) above, in order to nominate a Stockholder Nominee pursuant to this Section 11, an Eligible Stockholder or the Stockholder Nominee, as applicable, must provide the following information in writing to the Secretary of the Corporation within the time period specified in this Section 11 for delivering the Notice of Proxy Access Nomination:
(A) one or more written statements from the record holders of the Required Shares or from the intermediaries through which the Required Shares are or have been held during the Minimum Holding Period verifying that, as of a date within seven business days prior to the date the Notice of Proxy Access Nomination is received by the Secretary of the Corporation, the Eligible Stockholder owns, and has owned continuously for the Minimum Holding Period, the Required Shares, and the Eligible Stockholder’s agreement to provide the updates and supplements (or written notices stating that there are no such updates or supplements) described in Section 11(b)(2) within the time periods set forth therein;
(B) a copy of the Schedule 14N filed or to be filed with the Securities and Exchange Commission (and, if not included in such Schedule 14N, the details of any relationship that existed within the past three years and that would have been described pursuant to Item 6(e) of Schedule 14N (or any successor item) if it existed on the date of submission of the Schedule 14N);
(C) the Required Information (with the Statement, if any, clearly and specifically identified as such) and all other information, representations and agreements that are required to be set forth in a stockholder’s notice, or provided to the Corporation in order to nominate an individual for election as a director, pursuant to Section 2 of this Article I;
(D) the written consent of each Stockholder Nominee to being named in the proxy statement as a nominee and to serving as a director if elected;
(E) in the case of a Notice of Proxy Access Nomination that is submitted by an Eligible Stockholder that is comprised of a group of stockholders, the designation by all of such stockholders of one of such stockholders who is authorized to act on behalf of all of such stockholders with respect to all matters relating to the nomination or inclusion in the Corporation’s proxy materials of the Stockholder Nominee(s) nominated by such Eligible Stockholder, including, without limitation, the withdrawal of such nomination;
(F) an agreement by each Stockholder Nominee, upon such Stockholder Nominee’s election, to make such acknowledgements, enter into such agreements and provide such information as the Board of Directors requires of all directors at such time, including without limitation, agreeing to be bound by the Corporation’s code of ethics, insider trading policies and procedures and other similar policies and procedures;
(G) an irrevocable resignation of the Stockholder Nominee, which shall become effective upon a determination in good faith by the Board of Directors or any committee thereof that the information provided to the Corporation by such individual pursuant to this Section 11 was untrue in any material respect or omitted to state a material fact necessary in order to make the statements made, in light of the circumstances under which they were made, not misleading;
13



(H) a representation (in the form provided by the Secretary of the Corporation upon written request) that the Eligible Stockholder (I) acquired the Required Shares in the ordinary course of business and not with the intent to change or influence control at the Corporation, and that the Eligible Stockholder does not presently have such intent, (II) has not nominated and will not nominate for election to the Board of Directors at the Annual Meeting (or any postponement or adjournment thereof) any person other than the Stockholder Nominee(s) being nominated pursuant to this Section 11, (III) has not engaged and will not engage in, and has not and will not be a “participant” in, another person’s “solicitation” within the meaning of Rule 14a-1(l) under the Exchange Act in support of the election of any individual as a director at the Annual Meeting other than its Stockholder Nominee(s) or a nominee of the Board of Directors, (IV) will not distribute to any stockholder any form of proxy for the Annual Meeting other than the form of proxy distributed by the Corporation, (V) agrees to comply with all other laws and regulations applicable to any solicitation in connection with the Annual Meeting, including, without limitation, Rule 14a-9 promulgated under the Exchange Act, (VI) meets the requirements set forth in this Section 11, and (VII) has provided and will continue to provide facts, statements and other information in all communications with the Corporation and its stockholders in connection with the nomination hereunder that is or will be true and correct in all material respects and does not and will not omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which they were made, not misleading; and
(I) a written undertaking (in the form provided by the Secretary of the Corporation upon written request) that the Eligible Stockholder agrees to (I) assume all liability stemming from any legal or regulatory violation arising out of the communications with stockholders of the Corporation by the Eligible Stockholder, its affiliates and associates, or their respective agents or representatives, either before or after the furnishing of the Notice of Proxy Access Nomination, or out of the facts, statements or information that the Eligible Stockholder or its Stockholder Nominee(s) has provided or will provide to the Corporation or filed with the Securities and Exchange Commission, (II) indemnify and hold harmless the Corporation and each of its directors, officers, agents, employees, affiliates, control persons or other persons acting on behalf of the Corporation individually against any liability, loss or damages in connection with any threatened or pending action, suit or proceeding, whether legal, administrative or investigative, against the Corporation or any of its directors, officers, agents, employees, affiliates, control persons or other persons acting on behalf of the Corporation arising out of any nomination of a Stockholder Nominee submitted by the Eligible Stockholder pursuant to this Section 11, and (III) promptly provide to the Corporation such additional information as requested pursuant to this Section 11.
In connection with Section 11(d)(4)(A), if any intermediary that verifies the Eligible Stockholder’s ownership of the Required Shares for the Minimum Holding Period is not the record holder of such shares, a Depository Trust Company (“DTC”) participant or an affiliate of a DTC participant, then the Eligible Stockholder will also need to provide a written statement as required by Section 11(d)(4)(A) from the record holder of such shares, a DTC participant or an affiliate of a DTC participant that can verify the holdings of such intermediary.
(e) Stockholder Nominee Requirements.
(1) Notwithstanding anything in these By-laws to the contrary, the Corporation shall not be required to include, pursuant to this Section 11, any Stockholder Nominee in its proxy materials (and no such Stockholder Nominee may be nominated pursuant to this Section 11) for any Annual Meeting (A) for which the Secretary of the Corporation receives a notice that the Eligible Stockholder or any other stockholder of the Corporation has nominated one or more persons for election to the Board of Directors pursuant to the advance notice requirements for nominees for director set forth in Section 2 of this Article I, (B) if the Eligible Stockholder who has nominated such Stockholder Nominee has engaged in or is currently engaged in, or has been or is a “participant” in another person’s “solicitation” within the meaning of Rule 14a-1(l) under the Exchange Act, in support of the election of any individual as a director at the Annual Meeting other than its Stockholder Nominee(s) or a nominee of the Board of Directors, (C) if such Stockholder Nominee is or becomes a party to any compensatory, payment or other financial agreement, arrangement or understanding with any person or entity other than the Corporation, or is receiving or will receive any such compensation or other payment from any person or entity other than the Corporation, in each case, in connection with service as a director of the Corporation, (D) who is not independent under the listing standards of each principal U.S. exchange upon which the common stock of the Corporation is listed, any applicable rules of the Securities and Exchange Commission and any publicly disclosed standards used by the Board of
14



Directors in determining and disclosing independence of the Corporation’s directors, in each case, as determined by the Board of Directors or any committee thereof, (E) who does not meet the audit committee and compensation committee independence requirements under the rules of the primary stock exchange on which the shares of common stock of the Corporation are listed; (F) who is not a “non-employee director” for the purposes of Rule 16b-3 under the Exchange Act (or any successor rule), (G) whose election as a member of the Board of Directors would cause the Corporation to be in violation of these By-laws, the Certificate, the rules and listing standards of the principal U.S. exchanges upon which the common stock of the Corporation is listed or over-the-counter market on which any securities of the Corporation are traded, or any applicable state or federal law, rule or regulation, (H) who provides any information to the Corporation or its stockholders required or requested pursuant to any provision of these By-laws that is not accurate, truthful and complete in all material respects, or that otherwise contravenes any of the agreements, representations or undertakings made by the Stockholder Nominee in connection with the nomination, (I) who is or has been, within the past three years, an officer or director of a competitor, as defined in Section 8 of the Clayton Antitrust Act of 1914, (J) who is a defendant in or named subject of a pending criminal proceeding (excluding traffic violations) or has been convicted or has pleaded nolo contendere in such a criminal proceeding within the past ten (10) years, (K) is subject to any order of the type specified in Rule 506(d) of Regulation D promulgated under the Securities Act of 1933, as amended, (L) if such Stockholder Nominee or the applicable Eligible Stockholder shall have provided information to the Corporation in respect of such nomination that was untrue in any material respect or omitted to state a material fact necessary in order to make the statement made, in light of the circumstances under which they were made, not misleading, as determined by the Board of Directors or any committee thereof or (M) the Eligible Stockholder or applicable Stockholder Nominee fails to comply with its obligations pursuant to this Section 11.
(2) Any Stockholder Nominee who is included in the Corporation’s proxy materials for a particular Annual Meeting but either (A) withdraws from or becomes ineligible or unavailable for election to the Board of Directors at such Annual Meeting, or (B) does not receive a number of “for” votes equal to at least 20% of the number of shares present and entitled to vote for the election of directors, will be ineligible for nomination or inclusion in the Corporation’s proxy materials as a Stockholder Nominee pursuant to this Section 11 for the next two Annual Meetings.
(3) Notwithstanding anything to the contrary set forth herein, if the Board of Directors or a designated committee thereof determines that any stockholder nomination was not made in accordance with the terms of this Section 11 or that the information provided in a Notice of Proxy Access Nomination does not satisfy the informational requirements of this Section 11 in any material respect, then such nomination shall not be considered at the applicable Annual Meeting. If neither the Board of Directors nor such committee makes a determination as to whether a nomination was made in accordance with the provisions of this Section 11, the chair of the meeting shall determine whether a nomination was made in accordance with such provisions. If the chair of the meeting determines that any stockholder nomination was not made in accordance with the terms of this Section 11 or that the information provided in a stockholder’s notice does not satisfy the informational requirements of this Section 11 in any material respect, then such nomination shall not be considered at the applicable Annual Meeting. Additionally, such nomination will not be considered at the Annual Meeting in question if the Eligible Stockholder (or a qualified representative thereof) does not appear at the applicable Annual Meeting to present any nomination of the Stockholder Nominee(s) included in the Corporation’s proxy materials pursuant to this Section 11. For purposes of this Section 11, to be considered a qualified representative of a stockholder, a person must be duly authorized officer, manager or partner of such stockholder or must be authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as its proxy at the Annual Meeting and such person must produce such writing or electronic transmission, or a reliable reproduction thereof, at such Annual Meeting. If the Board of Directors, a designated committee thereof or the chair of the meeting determines that a nomination was made in accordance with the terms of this Section 11, the chair of the meeting shall so declare at the applicable Annual Meeting and ballots shall be provided for use at such meeting with respect to such Stockholder Nominee.
(f) This Section 11 provides the exclusive method for stockholders to include nominees for director in the Corporation’s proxy materials. A stockholder’s compliance with the procedures set forth in this Section 11 will not
15



also be deemed to constitute compliance with the procedures set forth in, or notice pursuant to, Section 2 of this Article I.
(g) For the avoidance of doubt, the Corporation may solicit against, and include in the proxy statement its own statement relating to, any Stockholder Nominee.
(h) For purposes of this Section 11, any determination to be made by the Board of Directors may be made by the Board of Directors, a committee of the Board of Directors or any officer of the Corporation designated by the Board of Directors or a committee of the Board of Directors, and any such determination shall be final and binding on the Corporation, any Eligible Holder, Stockholder Nominee and any other person so long as made in good faith (without any further requirements). The chair of any meeting of the stockholders, in addition to making any other determinations that may be appropriate to the conduct of the meeting, shall have the power and duty to determine whether a Stockholder Nominee has been nominated in accordance with the requirements of this Section 11 and, if not so nominated, shall direct and declare at such meeting that such Stockholder Nominee shall not be considered.

ARTICLE II
Directors
SECTION 1. Powers. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors except as otherwise provided by the Certificate or required by law.
SECTION 2. Number and Terms. The number of directors of the Corporation shall be fixed solely and exclusively by resolution duly adopted from time to time by the Board of Directors. The directors shall hold office in the manner provided in the Certificate.
SECTION 3. Qualification. No director need be a stockholder of the Corporation.
SECTION 4. Vacancies. Vacancies in the Board of Directors shall be filled in the manner provided in the Certificate.
SECTION 5. Removal. Directors may be removed from office only in the manner provided in the Certificate or by applicable law.
SECTION 6. Resignation. A director may resign at any time by electronic transmission or by giving written notice to the Chairman of the Board, if one is elected, the President or the Secretary. A resignation shall be effective upon receipt, unless the resignation otherwise provides.
SECTION 7. Regular Meetings. Regular Meetings of the Board of Directors may be held at such hour, date and place (if any) as the Board of Directors may from time to time determine and publicize by means of reasonable notice given to any director who is not present when such determination is made.
SECTION 8. Special Meetings. Special meetings of the Board of Directors may be called, orally or in writing, by or at the request of a majority of the directors, the Chairman of the Board, if one is elected, or the President. The person or persons calling any such special meeting of the Board of Directors may fix the hour, date and place (if any) thereof. Notice thereof shall be given to each director as provided in Section 9 of this Article II.
SECTION 9. Notice of Meetings. Notice of the hour, date and place (if any) of all special meetings of the Board of Directors shall be given to each director by the Secretary or an Assistant Secretary, or in case of the death, absence, incapacity or refusal of such persons, by the Chairman of the Board, if one is elected, the President or such other officer designated by the Chairman of the Board, if one is elected, or any one of the directors calling the meeting. Notice of any special meeting of the Board of Directors shall be given to each director in person, by telephone, or by facsimile, electronic mail or other form of electronic communication, sent to his or her business or home address, at least twenty-four (24) hours in advance of the meeting, or by written notice mailed to his or her business or home
16



address, at least forty-eight (48) hours in advance of the meeting, provided, however, that if the person or persons calling the meeting determine that it is otherwise necessary or advisable to hold the meeting sooner, then such person or persons may prescribe a shorter time period for notice to be given personally or by telephone, facsimile, electronic mail or other similar means of communication. Such notice shall be deemed to be delivered when hand-delivered to such address, read to such director by telephone, deposited in the mail so addressed, with postage thereon prepaid if mailed, or dispatched or transmitted if sent by facsimile transmission or by electronic mail or other form of electronic communications. A written waiver of notice signed or electronically transmitted before or after a meeting by a director and filed with the records of the meeting shall be deemed to be equivalent to notice of the meeting. The attendance of a director at a meeting shall constitute a waiver of notice of such meeting, except where a director attends a meeting for the express purpose of objecting at the beginning of the meeting to the transaction of any business because such meeting is not lawfully called or convened. Except as otherwise required by law, by the Certificate or by these By-laws, neither the business to be transacted at, nor the purpose of, any meeting of the Board of Directors need be specified in the notice or waiver of notice of such meeting.
SECTION 10. Quorum. At any meeting of the Board of Directors, a majority of the total number of directors shall constitute a quorum for the transaction of business, but if less than a quorum is present at a meeting, a majority of the directors present may adjourn the meeting from time to time, and the meeting may be held as adjourned without further notice. Any business which might have been transacted at the meeting as originally noticed may be transacted at such adjourned meeting at which a quorum is present. For purposes of this Article II, the total number of directors includes any unfilled vacancies on the Board of Directors.
SECTION 11. Action at Meeting. At any meeting of the Board of Directors at which a quorum is present, the affirmative vote of a majority of the directors present shall constitute action by the Board of Directors, unless otherwise required by law, by the Certificate or by these By-laws.
SECTION 12. Action by Consent. Any action required or permitted to be taken at any meeting of the Board of Directors may be taken without a meeting if all members of the Board of Directors consent thereto in writing or by electronic transmission. After such action is taken, the writing or writings or electronic transmission or transmissions shall be filed with the records of the meetings of the Board of Directors. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form. Such consent shall be treated as a resolution of the Board of Directors for all purposes.
SECTION 13. Manner of Participation. Directors may participate in meetings of the Board of Directors by means of video conference, conference telephone or other communications equipment by means of which all directors participating in the meeting can hear each other, and participation in a meeting in accordance herewith shall constitute presence in person at such meeting for purposes of these By-laws.
SECTION 14. Presiding Director. The Board of Directors shall designate a representative to preside over all meetings of the Board of Directors, provided that if the Board of Directors does not so designate such a presiding director or such designated presiding director is unable to so preside or is absent, then the Chairman of the Board, if one is elected, shall preside over all meetings of the Board of Directors. If both the designated presiding director, if one is so designated, and the Chairman of the Board, if one is elected, are unable to preside or are absent, the Board of Directors shall designate an alternate representative to preside over a meeting of the Board of Directors.

SECTION 15. Committees. The Board of Directors may designate one or more committees, including, without limitation, a Compensation and Talent Committee, a Nominating and Corporate Governance Committee and an Audit Committee, and may delegate thereto some or all of its powers to such committee(s) except those which by law, by the Certificate or by these By-laws may not be delegated. Except as the Board of Directors may otherwise determine, any such committee may make rules for the conduct of its business, but unless otherwise provided by the Board of Directors or in such rules, its business shall be conducted so far as possible in the same manner as is provided by these By-laws for the Board of Directors. All members of such committees shall hold such offices at the pleasure of the Board of Directors. The Board of Directors may abolish any such committee at any time. Any committee to which the Board of Directors delegates any of its powers or duties shall keep records of its meetings. The Corporation elects to be governed by the provisions of Section 141(c)(2) of the DGCL.
17



SECTION 16. Compensation of Directors. Directors shall receive such compensation for their services as shall be determined by the Board of Directors, or a designated committee thereof, provided that directors who are serving the Corporation as employees and who receive compensation for their services as such, shall not receive any salary or other compensation for their services as directors of the Corporation.
SECTION 17. Emergency By-laws. In the event of any emergency, disaster, catastrophe or other similar emergency condition of a type described in Section 110(a) of the DGCL (an “Emergency”), notwithstanding any different or conflicting provisions in the DGCL, the Certificate or these By-laws, during such Emergency:
(a) Notice. A meeting of the Board of Directors or a committee thereof may be called by any director, the Chairman of the Board, the Chief Executive Officer, the President or the Secretary by such means as, in the judgment of the person calling the meeting, may be feasible at the time, and notice of any such meeting of the Board of Directors or any committee may be given, in the judgment of the person calling the meeting, only to such directors as it may be feasible to reach at the time and by such means as may be feasible at the time. Such notice shall be given at such time in advance of the meeting as, in the judgment of the person calling the meeting, circumstances permit.

(b) Quorum. The director or directors in attendance at a meeting called in accordance with Section 17(a) of this Article II shall constitute a quorum.

(c) Liability. No officer, director or employee acting in accordance with this Section 17 shall be liable except for willful misconduct. No amendment, repeal or change to this Section 17 shall modify the prior sentence with regard to actions taken prior to the time of such amendment, repeal or change.
ARTICLE III
Officers
SECTION 1. Enumeration. The officers of the Corporation shall consist of a President, a Treasurer, a Secretary and such other officers, including, without limitation, a Chairman of the Board of Directors, a Chief Executive Officer and one or more Vice Presidents (including Executive Vice Presidents or Senior Vice Presidents), Assistant Vice Presidents, Assistant Treasurers and Assistant Secretaries, as the Board of Directors may determine.
SECTION 2. Election. The Board of Directors shall elect the President, the Treasurer and the Secretary. Other officers may be elected by the Board of Directors or by such officers delegated such authority by the Board of Directors.
SECTION 3. Qualification. No officer need be a stockholder or a director. Any person may occupy more than one office of the Corporation at any time.
SECTION 4. Tenure. Except as otherwise provided by the Certificate or by these By-laws, each of the officers of the Corporation shall hold office until his or her successor is elected and qualified or until his or her earlier death, resignation or removal.
SECTION 5. Resignation. Any officer may resign by delivering his or her written or electronically transmitted resignation to the Corporation addressed to the President or the Secretary, and such resignation shall be effective upon receipt, unless the resignation otherwise provides.

SECTION 6. Removal. Except as otherwise provided by law or by resolution of the Board of Directors, the Board of Directors may remove any officer.
SECTION 7. Absence or Disability. In the event of the absence or disability of any officer, the Board of Directors may designate another officer to act temporarily in place of such absent or disabled officer.
18



SECTION 8. Vacancies. Any vacancy in any office may be filled for the unexpired portion of the term by the Board of Directors.
SECTION 9. President. The President shall, subject to the direction of the Board of Directors, have such powers and shall perform such duties as the Board of Directors may from time to time designate.
SECTION 10. Chairman of the Board. The Chairman of the Board, if one is elected, shall have such powers and shall perform such duties as the Board of Directors may from time to time designate.
SECTION 11. Chief Executive Officer. The Chief Executive Officer, if one is elected, shall have such powers and shall perform such duties as the Board of Directors may from time to time designate.
SECTION 12. Vice Presidents and Assistant Vice Presidents. Any Vice President (including any Executive Vice President or Senior Vice President) and any Assistant Vice President shall have such powers and shall perform such duties as the Board of Directors or the Chief Executive Officer may from time to time designate.
SECTION 13. Treasurer and Assistant Treasurers. The Treasurer shall, subject to the direction of the Board of Directors and except as the Board of Directors or the Chief Executive Officer may otherwise provide, have general charge of the financial affairs of the Corporation and shall cause to be kept accurate books of account. The Treasurer shall have custody of all funds, securities, and valuable documents of the Corporation. He or she shall have such other duties and powers as may be designated from time to time by the Board of Directors or the Chief Executive Officer. Any Assistant Treasurer shall have such powers and perform such duties as the Board of Directors or the Chief Executive Officer may from time to time designate.
SECTION 14. Secretary and Assistant Secretaries. The Secretary shall record all the proceedings of the meetings of the stockholders and the Board of Directors (including committees of the Board of Directors) in books kept for that purpose. In his or her absence from any such meeting, a temporary secretary chosen at the meeting shall record the proceedings thereof. The Secretary shall have charge of the stock ledger (which may, however, be kept by any transfer or other agent of the Corporation). The Secretary shall have custody of the seal of the Corporation, and the Secretary, or an Assistant Secretary shall have authority to affix it to any instrument requiring it, and, when so affixed, the seal may be attested by his or her signature or that of an Assistant Secretary. The Secretary shall have such other duties and powers as may be designated from time to time by the Board of Directors or the Chief Executive Officer. In the absence of the Secretary, any Assistant Secretary may perform his or her duties and responsibilities. Any Assistant Secretary shall have such powers and perform such duties as the Board of Directors or the Chief Executive Officer may from time to time designate.
SECTION 15. Other Powers and Duties. Subject to these By-laws and to such limitations as the Board of Directors may from time to time prescribe, the officers of the Corporation shall each have such powers and duties as generally pertain to their respective offices, as well as such powers and duties as from time to time may be conferred by the Board of Directors or the Chief Executive Officer.
ARTICLE IV
Capital Stock
SECTION 1. Certificates of Stock. Each stockholder shall be entitled to a certificate of the capital stock of the Corporation in such form as may from time to time be prescribed by the Board of Directors. Such certificate shall be signed by any two authorized officers of the Corporation. The Corporation seal and the signatures by the Corporation’s officers, the transfer agent or the registrar may be facsimiles. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed on such certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he or she were such officer, transfer agent or registrar at the time of its issue. Every certificate for shares of stock which are subject to any restriction on transfer and every certificate issued when the Corporation is
19



authorized to issue more than one class or series of stock shall contain such legend with respect thereto as is required by law. Notwithstanding anything to the contrary provided in these By-laws, the Board of Directors may provide by resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares (except that the foregoing shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation), and by the approval and adoption of these By-laws the Board of Directors has determined that all classes or series of the Corporation’s stock may be uncertificated, whether upon original issuance, re-issuance, or subsequent transfer.
SECTION 2. Transfers. Subject to any restrictions on transfer and unless otherwise provided by the Board of Directors, shares of stock that are represented by a certificate may be transferred on the books of the Corporation by the surrender to the Corporation or its transfer agent of the certificate therefor properly endorsed or accompanied by a written assignment or power of attorney properly executed, with transfer stamps (if necessary) affixed, and with such proof of the authenticity of signature as the Corporation or its transfer agent may reasonably require. Shares of stock that are not represented by a certificate may be transferred on the books of the Corporation by submitting to the Corporation or its transfer agent such evidence of transfer and following such other procedures as the Corporation or its transfer agent may require.

SECTION 3. Record Holders. Except as may otherwise be required by law, by the Certificate or by these By-laws, the Corporation shall be entitled to treat the record holder of stock as shown on its books as the owner of such stock for all purposes, including the payment of dividends and the right to vote with respect thereto, regardless of any transfer, pledge or other disposition of such stock, until the shares have been transferred on the books of the Corporation in accordance with the requirements of these By-laws.
SECTION 4. Record Date. In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date: (a) in the case of determination of stockholders entitled to vote at any meeting of stockholders, shall, unless otherwise required by law, not be more than sixty (60) nor less than ten (10) days before the date of such meeting and (b) in the case of any other action, shall not be more than sixty (60) days prior to such other action. If no record date is fixed: (i) the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held; and (ii) the record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.
SECTION 5. Replacement of Certificates. In case of the alleged loss, destruction or mutilation of a certificate of stock of the Corporation, a duplicate certificate may be issued in place thereof, upon such terms as the Board of Directors may prescribe.
ARTICLE V
Indemnification
SECTION 1. Definitions. For purposes of this Article V:
(a) “Corporate Status” describes the status of a person who is serving or has served (i) as a Director of the Corporation, (ii) as an Officer of the Corporation, (iii) as a Non-Officer Employee of the Corporation, or (iv) as a director, partner, trustee, officer, employee or agent of any other corporation, partnership, limited liability company, joint venture, trust, employee benefit plan, foundation, association, organization or other legal entity which such person is or was serving at the request of the Corporation. For purposes of this Section 1(a), a Director, Officer or Non-Officer Employee of the Corporation who is serving or has served as a director, partner, trustee, officer,
20



employee or agent of a Subsidiary shall be deemed to be serving at the request of the Corporation. Notwithstanding the foregoing, “Corporate Status” shall not include the status of a person who is serving or has served as a director, officer, employee or agent of a constituent corporation absorbed in a merger or consolidation transaction with the Corporation with respect to such person’s activities prior to said transaction, unless specifically authorized by the Board of Directors or the stockholders of the Corporation;

(b) “Director” means any person who serves or has served the Corporation as a director on the Board of Directors;
(c) “Disinterested Director” means, with respect to each Proceeding in respect of which indemnification is sought hereunder, a Director of the Corporation who is not and was not a party to such Proceeding;
(d) “Expenses” means all attorneys’ fees, retainers, court costs, transcript costs, fees of expert witnesses, private investigators and professional advisors (including, without limitation, accountants and investment bankers), travel expenses, duplicating costs, printing and binding costs, costs of preparation of demonstrative evidence and other courtroom presentation aids and devices, costs incurred in connection with document review, organization, imaging and computerization, telephone charges, postage, delivery service fees, and all other disbursements, costs or expenses of the type customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, settling or otherwise participating in, a Proceeding;
(e) “Liabilities” means judgments, damages, liabilities, losses, penalties, excise taxes, fines and amounts paid in settlement;
(f) “Non-Officer Employee” means any person who serves or has served as an employee or agent of the Corporation, but who is not or was not a Director or Officer;
(g) “Officer” means any person who serves or has served the Corporation as an officer of the Corporation appointed by the Board of Directors;
(h) “Proceeding” means any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, inquiry, investigation, administrative hearing or other proceeding, whether civil, criminal, administrative, arbitrative or investigative; and
(i) “Subsidiary” shall mean any corporation, partnership, limited liability company, joint venture, trust or other entity of which the Corporation owns (either directly or through or together with another Subsidiary of the Corporation) either (i) a general partner, managing member or other similar interest or (ii) (A) fifty percent (50%) or more of the voting power of the voting capital equity interests of such corporation, partnership, limited liability company, joint venture or other entity, or (B) fifty percent (50%) or more of the outstanding voting capital stock or other voting equity interests of such corporation, partnership, limited liability company, joint venture or other entity.

SECTION 2. Indemnification of Directors and Officers.
(a) Subject to the operation of Section 4 of this Article V of these By-laws, each Director and Officer shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment), and to the extent authorized in this Section 2.
(1) Actions, Suits and Proceedings Other than By or In the Right of the Corporation. Each Director and Officer shall be indemnified and held harmless by the Corporation against any and all Expenses and Liabilities that are incurred or paid by such Director or Officer or on such Director’s or Officer’s behalf in connection with any Proceeding or any claim, issue or matter therein (other than an action by or in the right of the Corporation), which such Director or Officer is, or is threatened to be made, a party to or participant in by reason of such Director’s or Officer’s Corporate Status, if such Director or Officer acted in good faith and in a manner such Director or Officer reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful.
(2) Actions, Suits and Proceedings By or In the Right of the Corporation. Each Director and Officer shall be indemnified and held harmless by the Corporation against any and all Expenses that are incurred by such Director or
21



Officer or on such Director’s or Officer’s behalf in connection with any Proceeding or any claim, issue or matter therein by or in the right of the Corporation, which such Director or Officer is, or is threatened to be made, a party to or participant in by reason of such Director’s or Officer’s Corporate Status, if such Director or Officer acted in good faith and in a manner such Director or Officer reasonably believed to be in or not opposed to the best interests of the Corporation; provided, however, that no indemnification shall be made under this Section 2(a)(2) in respect of any claim, issue or matter as to which such Director or Officer shall have been finally adjudged by a court of competent jurisdiction to be liable to the Corporation, unless, and only to the extent that, the Court of Chancery of the State of Delaware or another court in which such Proceeding was brought shall determine upon application that, despite adjudication of liability, but in view of all the circumstances of the case, such Director or Officer is fairly and reasonably entitled to indemnification for such Expenses that such court deems proper.
(3) Survival of Rights. The rights of indemnification provided by this Section 2 shall continue as to a Director or Officer after he or she has ceased to be a Director or Officer and shall inure to the benefit of his or her heirs, executors, administrators and personal representatives.
(4) Actions by Directors or Officers. Notwithstanding the foregoing, the Corporation shall indemnify and hold harmless any Director or Officer seeking indemnification in connection with a Proceeding initiated by such Director or Officer only if such Proceeding (including any parts of such Proceeding not initiated by such Director or Officer) was authorized in advance by the Board of Directors, unless such Proceeding was brought to enforce such Officer’s or Director’s rights to indemnification or, in the case of Directors, advancement of Expenses under these By-laws in accordance with the provisions set forth herein.

SECTION 3. Indemnification of Non-Officer Employees. Subject to the operation of Section 4 of this Article V of these By-laws, each Non-Officer Employee may, in the discretion of the Board of Directors, be indemnified by the Corporation to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended, against any or all Expenses and Liabilities that are incurred by such Non-Officer Employee or on such Non-Officer Employee’s behalf in connection with any threatened, pending or completed Proceeding, or any claim, issue or matter therein, which such Non-Officer Employee is, or is threatened to be made, a party to or participant in by reason of such Non-Officer Employee’s Corporate Status, if such Non-Officer Employee acted in good faith and in a manner such Non-Officer Employee reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. The rights of indemnification provided by this Section 3 shall exist as to a Non-Officer Employee after he or she has ceased to be a Non-Officer Employee and shall inure to the benefit of his or her heirs, personal representatives, executors and administrators. Notwithstanding the foregoing, the Corporation may indemnify any Non-Officer Employee seeking indemnification in connection with a Proceeding initiated by such Non-Officer Employee only if such Proceeding was authorized in advance by the Board of Directors.
SECTION 4. Determination. Unless ordered by a court, no indemnification shall be provided pursuant to this Article V to a Director, to an Officer or to a Non-Officer Employee unless a determination shall have been made that such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal Proceeding, such person had no reasonable cause to believe his or her conduct was unlawful. Such determination shall be made by (a) a majority vote of the Disinterested Directors, even though less than a quorum of the Board of Directors, (b) a committee comprised of Disinterested Directors, such committee having been designated by a majority vote of the Disinterested Directors (even though less than a quorum), (c) if there are no such Disinterested Directors, or if a majority of Disinterested Directors so directs, by independent legal counsel in a written opinion, or (d) by the stockholders of the Corporation.
SECTION 5. Advancement of Expenses to Directors Prior to Final Disposition.
(a) The Corporation shall advance all Expenses incurred by or on behalf of any Director in connection with any Proceeding in which such Director is involved by reason of such Director’s Corporate Status within thirty (30) days after the receipt by the Corporation of a written statement from such Director requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Director and shall be preceded or accompanied by an undertaking by or on behalf of such Director to repay any Expenses so advanced if it shall ultimately be determined
22



that such Director is not entitled to be indemnified against such Expenses. Notwithstanding the foregoing, the Corporation shall advance all Expenses incurred by or on behalf of any Director seeking advancement of expenses hereunder in connection with a Proceeding initiated by such Director only if such Proceeding (including any parts of such Proceeding not initiated by such Director) was (i) authorized by the Board of Directors, or (ii) brought to enforce such Director’s rights to indemnification or advancement of Expenses under these By-laws.
(b) If a claim for advancement of Expenses hereunder by a Director is not paid in full by the Corporation within thirty (30) days after receipt by the Corporation of documentation of Expenses and the required undertaking, such Director may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim and if successful in whole or in part, such Director shall also be entitled to be paid the expenses of prosecuting such claim. The failure of the Corporation (including its Board of Directors or any committee thereof, independent legal counsel, or stockholders) to make a determination concerning the permissibility of such advancement of Expenses under this Article V shall not be a defense to an action brought by a Director for recovery of the unpaid amount of an advancement claim and shall not create a presumption that such advancement is not permissible. The burden of proving that a Director is not entitled to an advancement of expenses shall be on the Corporation.
(c) In any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that the Director has not met any applicable standard for indemnification set forth in the DGCL.
SECTION 6. Advancement of Expenses to Officers and Non-Officer Employees Prior to Final Disposition.
(a) The Corporation may, at the discretion of the Board of Directors, advance any or all Expenses incurred by or on behalf of any Officer or any Non-Officer Employee in connection with any Proceeding in which such person is involved by reason of his or her Corporate Status as an Officer or Non-Officer Employee upon the receipt by the Corporation of a statement or statements from such Officer or Non-Officer Employee requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Officer or Non-Officer Employee and shall be preceded or accompanied by an undertaking by or on behalf of such person to repay any Expenses so advanced if it shall ultimately be determined that such Officer or Non-Officer Employee is not entitled to be indemnified against such Expenses.
(b) In any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that the Officer or Non-Officer Employee has not met any applicable standard for indemnification set forth in the DGCL.

SECTION 7. Contractual Nature of Rights.
(a) The provisions of this Article V shall be deemed to be a contract between the Corporation and each Director and Officer entitled to the benefits hereof at any time while this Article V is in effect, in consideration of such person’s past or current and any future performance of services for the Corporation. Neither amendment, repeal or modification of any provision of this Article V nor the adoption of any provision of the Certificate inconsistent with this Article V shall eliminate or reduce any right conferred by this Article V in respect of any act or omission occurring, or any cause of action or claim that accrues or arises or any state of facts existing, at the time of or before such amendment, repeal, modification or adoption of an inconsistent provision (even in the case of a proceeding based on such a state of facts that is commenced after such time), and all rights to indemnification and advancement of Expenses granted herein or arising out of any act or omission shall vest at the time of the act or omission in question, regardless of when or if any proceeding with respect to such act or omission is commenced. The rights to indemnification and to advancement of expenses provided by, or granted pursuant to, this Article V shall continue notwithstanding that the person has ceased to be a Director or Officer of the Corporation and shall inure to the benefit of the estate, heirs, executors, administrators, legatees and distributees of such person.
(b) If a claim for indemnification hereunder by a Director or Officer is not paid in full by the Corporation within sixty (60) days after receipt by the Corporation of a written claim for indemnification, such Director or Officer may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim, and if successful in whole or in part, such Director or Officer shall also be entitled to be paid the expenses of prosecuting such claim.
23



The failure of the Corporation (including its Board of Directors or any committee thereof, independent legal counsel, or stockholders) to make a determination concerning the permissibility of such indemnification under this Article V shall not be a defense to an action brought by a Director or Officer for recovery of the unpaid amount of an indemnification claim and shall not create a presumption that such indemnification is not permissible. The burden of proving that a Director or Officer is not entitled to indemnification shall be on the Corporation.
(c) In any suit brought by a Director or Officer to enforce a right to indemnification hereunder, it shall be a defense that such Director or Officer has not met any applicable standard for indemnification set forth in the DGCL.
SECTION 8. Non-Exclusivity of Rights. The rights to indemnification and to advancement of Expenses set forth in this Article V shall not be exclusive of any other right which any Director, Officer, or Non-Officer Employee may have or hereafter acquire under any statute, provision of the Certificate or these By-laws, agreement, vote of stockholders or Disinterested Directors or otherwise.
SECTION 9. Insurance. The Corporation may maintain insurance, at its expense, to protect itself and any Director, Officer or Non-Officer Employee against any liability of any character asserted against or incurred by the Corporation or any such Director, Officer or Non-Officer Employee, or arising out of any such person’s Corporate Status, whether or not the Corporation would have the power to indemnify such person against such liability under the DGCL or the provisions of this Article V.

SECTION 10. Other Indemnification. The Corporation’s obligation, if any, to indemnify or provide advancement of Expenses to any person under this Article V as a result of such person serving, at the request of the Corporation, as a director, partner, trustee, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount such person may collect as indemnification or advancement of Expenses from such other corporation, partnership, joint venture, trust, employee benefit plan or enterprise (the “Primary Indemnitor”). Any indemnification or advancement of Expenses under this Article V owed by the Corporation as a result of a person serving, at the request of the Corporation, as a director, partner, trustee, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall only be in excess of, and shall be secondary to, the indemnification or advancement of Expenses available from the applicable Primary Indemnitor(s) and any applicable insurance policies.

SECTION 11.    Savings Clause. If this Article V or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Corporation shall nevertheless indemnify each indemnitee as to any expenses (including, without limitation, attorneys’ fees), liabilities, losses, judgments, fines (including, without limitation, excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974, as amended) and amounts paid in settlement in connection with any action, suit, proceeding or investigation, whether civil, criminal or administrative, including, without limitation, an action by or in the right of the Corporation, to the fullest extent permitted by any applicable portion of this Article V that shall not have been invalidated and to the fullest extent permitted by applicable law.

ARTICLE VI
Miscellaneous Provisions
SECTION 1. Fiscal Year. The fiscal year of the Corporation shall be determined by the Board of Directors.
SECTION 2. Seal. The Board of Directors shall have power to adopt and alter the seal of the Corporation.
SECTION 3. Execution of Instruments. All deeds, leases, transfers, contracts, bonds, notes and other obligations to be entered into by the Corporation in the ordinary course of its business without director action may be executed on behalf of the Corporation by the Chairman of the Board, if one is elected, the President or the Treasurer or any other
24



officer, employee or agent of the Corporation as the Board of Directors or an executive committee of the Board may authorize or determine.
SECTION 4. Voting of Securities. Unless the Board of Directors otherwise provides, the Chairman of the Board, if one is elected, the President or the Treasurer may waive notice of and act on behalf of the Corporation (including with regard to voting and actions by written consent), or appoint another person or persons to act as proxy or attorney in fact for the Corporation with or without discretionary power and/or power of substitution, at any meeting of stockholders or shareholders of any other corporation or organization, any of whose securities are held by the Corporation.
SECTION 5. Resident Agent. The Board of Directors may appoint a resident agent upon whom legal process may be served in any action or proceeding against the Corporation.
SECTION 6. Corporate Records. The original or attested copies of the Certificate, By-laws and records of all meetings of the incorporators, stockholders and the Board of Directors and the stock transfer books, which shall contain the names of all stockholders, their record addresses and the amount of stock held by each, may be kept outside the State of Delaware and shall be kept at the principal office of the Corporation, at an office of its counsel, at an office of its transfer agent or in such manner as may be permitted by law.

SECTION 7. Certificate. All references in these By-laws to the Certificate shall be deemed to refer to the Amended and Restated Certificate of Incorporation of the Corporation, as amended and/or restated and in effect from time to time.

SECTION 8. Exclusive Jurisdiction of Delaware Courts and the United States District Court for the District of Massachusetts for Certain Claims. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for state law claims for (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim of breach of or based on a fiduciary duty owed by any current or former director, officer or other employee of the Corporation to the Corporation or the Corporation’s stockholders, (iii) any action asserting a claim against the Corporation or any current or former director, officer or other employee or stockholder of the Corporation arising pursuant to any provision of the DGCL or the Certificate or these By-laws, or (iv) any action asserting a claim against the Corporation or any current or former director or officer or other employee of the Corporation governed by the internal affairs doctrine. Unless the Corporation consents in writing to the selection of an alternative forum, the United States District Court for the District of Massachusetts shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Section 8.
SECTION 9. Amendment of By-laws.
(a) Amendment by Directors. Except as otherwise required by law, these By-laws may be amended or repealed by the Board of Directors.
(b) Amendment by Stockholders. Except as otherwise required by these By-laws or by law, these By-laws may be amended or repealed at any Annual Meeting, or at any special meeting of stockholders called for such purpose in accordance with these By-Laws, by the affirmative vote of the holders of a majority of the voting power of the outstanding shares entitled to vote on such amendment or repeal, voting together as a single class. Notwithstanding the foregoing, stockholder approval shall not be required unless mandated by the Certificate, these By-laws, or other applicable law.
SECTION 10. Notices. If mailed, notice to stockholders shall be deemed given when deposited in the mail, postage prepaid, directed to the stockholder at such stockholder’s address as it appears on the records of the Corporation. Without limiting the manner by which notice otherwise may be given to stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section 232 of the DGCL.
25



SECTION 11. Waivers. A written waiver of any notice, signed by a stockholder or director, or waiver by electronic transmission by such person, whether given before or after the time of the event for which notice is to be given, shall be deemed equivalent to the notice required to be given to such person. Neither the business to be transacted at, nor the purpose of, any meeting need be specified in such a waiver.
Effective as of February 21, 2024.
26
 EX-10.15 3 exhibit1015redactedgarayar.htm EX-10.15 Document
image_0.jpg
Exhibit 10.15

Personal and Confidential
December 8, 2023 (As revised on December 30, 2023)

VIA ELECTRONIC MAIL [***]
Arpa Garay
[***]
[***]

Re:    Executive Separation and Transitional Services Agreement
(Please sign and return page 9 by January 4, 2024; sign and return Exhibit A by the later of the Separation Date or January 4, 2024)
Dear Arpa,
In accordance with the Amended and Restated Executive Severance Plan (the “Severance Plan”) of Moderna Inc. (individually, and together with any direct and indirect parents, subsidiaries, and affiliates, the “Company”), this executive separation and transitional services agreement (the “Agreement”) sets forth the terms of your continued employment with the Company through the earliest of (i) the close of business on June 28, 2024 (the “Anticipated Separation Date”) or (ii) such earlier date when your employment is terminated (a) by the Company with Cause, (b) due to your death or Disability, (c) pursuant to Section 1(c) below, or (d) by you (such actual last day of employment, the “Separation Date”)1. For purposes of this Agreement, the time period between December 29, 2023 and the Separation Date will be referred to as the “Transition Period.”
Regardless of whether you enter into the Agreement, including Exhibit A (as defined in Section 2), the following bulleted terms (the “Accrued Benefits”) will apply:

•You will continue to participate in the Company’s Severance Plan and will be entitled to any benefits and payments thereunder in the event of a Qualified Termination Event (as defined and set forth in Section 5 of the Severance Plan), subject to the terms and conditions of the Severance Plan.
•On the Separation Date, the Company will pay you all earned compensation to which you are entitled.
•Your eligibility to participate in the Company’s health, dental, and vision plans, and the Company’s other employee benefit plans and programs ends on the last day of the month in which the Separation Date occurs. You may elect to continue such benefits under the federal law known as COBRA. You will be notified in a separate notice of your election rights under COBRA. If you are participating in the Company’s 401(k) plan, deductions end with your final regular paycheck.
1     “Cause” and “Disability” are defined by the Company’s Amended and Restated Executive Severance Plan effective as of June 13, 2018 and amended and restated as of November 4, 2018 and as of February 23, 2023 (the “Severance Plan”).
Page 1 of 16

•If you remain employed on the date of payment in March 2024, you will be eligible to receive a discretionary bonus under the Senior Executive Cash Incentive Bonus Plan (the “Incentive Plan”), reflecting your performance during fiscal year 2023, which, per the terms of the Incentive Plan, will be paid in a lump sum at the same time as other US-based Incentive Plan participants. For the avoidance of doubt, the value of the discretionary bonus payment will reflect both corporate and individual performance factors, which will be approved by Moderna’s Compensation and Talent Committee.
•You are not eligible to receive any bonus or other forms of incentive compensation with respect to your work for the Company during fiscal year 2024 or thereafter.
•You have the right to retain any and all vested restricted stock units and to exercise any and all vested options that you hold to purchase Company equity, and any such exercise will be subject to the terms of any and all applicable unit option and grant plans, equity incentive plans other equity award plans, and all related agreements (collectively the “Equity Documents”). Under the terms of the Equity Documents, all unvested restricted stock units and stock options you may hold will expire as of the Separation Date. If you have any questions about your equity interests, please contact [***].
You are obligated, to the maximum extent permitted by applicable law, to comply with your obligations outlined in the Employee Confidentiality, Assignment, Nonsolicitation and Noncompetition Agreement you signed on March 30, 2023 (the “Restrictive Covenants Agreement”), a copy of which is being provided to you with this Agreement. For purpose of this Agreement, the Company confirms that the Restrictions on Customer Solicitation contained in Section 6b of the Restrictive Covenants Agreement are intended to apply to Competitive Business or Competitive Activities as those terms are defined in Section 6d of the Restrictive Covenants Agreement.
Except as noted above, the Accrued Benefits will not be affected by whether or not you agree to the terms set forth below.
In addition to the above-described non-contingent Accrued Benefits, you will be entitled to the Severance Benefits (as defined in Section 3) if you meet the Conditions (as defined in Section 2).
With those understandings, you and the Company agree as follows:
1.Matters Relating to the Transition Period.
(a)If you enter into, do not revoke, and comply with this Agreement (including, without limitation the Conditions set forth in Section 2 below), your employment with the Company will end on the Anticipated Separation Date, unless your employment is terminated on an earlier date in accordance with this Agreement (a) by the Company, with Cause, (b) due to your death or Disability, or (c) by you. During the Transition Period, you will not report to the Company’s offices or perform any duties for or on behalf of the Company unless specifically requested by the Company’s CEO or President. Notwithstanding the foregoing, you will make yourself available to answer any questions from the CEO, President or any other Company executive related to the Company or to transitioning matters to other employees. Any change to your duties as set forth herein will not (a) constitute Good Reason as defined in and for purposes of the

Page 2 of 16

Severance Plan, and you hereby waive the application of Good Reason to your employment from the date of this Agreement to the Separation Date, or (b) alter any of your obligations under the Restrictive Covenants Agreement. On the earliest of (i) the Separation Date or (ii) a request by the Company, you will be deemed to have resigned from all officer positions that you hold with the Company or any of its respective subsidiaries and affiliates. You will execute any documents in reasonable form as may be requested by the Company to confirm or effectuate any such resignations.
(b)With respect to compensation, you will continue to receive your current annual base salary and you will be eligible for employee benefits throughout the Transition Period (subject to your continued eligibility under the Company’s benefits plans); provided, however, you will not be entitled to any other compensation, incentive compensation, or bonuses during the Transition Period or with respect to any period prior to the Transition Period, except as set forth in Section 3 below and provided you meet the Conditions set forth in Section 2. In addition, you will continue to vest in your restricted stock units and stock options pursuant to the Equity Documents during the Transition Period. You may exercise any vested options consistent with the terms of the Equity Documents. All unvested restricted stock units and stock options will expire on the Separation Date and be of no further effect, except as otherwise set forth in Section 3 below and provided you meet the Conditions set forth in Section 2.
(c)In the event that you accept a Third-Party Engagement (as defined below) during the Transition Period, your employment with the Company will end as of the date you accept such Third-Party Engagement, without any further notice by the Company to you being required. In such event, the Separation Date will be the date as of which you commence the Third-Party Engagement. The Company will provide the Severance Benefits set forth in Section 3 below provided you have satisfied each of the Conditions set forth in Section 2 as of the newly accelerated Separation Date and provided that you have notified the Company’s Chief Legal Officer of the Third-Party Engagement at least five (5) business days prior to its commencement. If the Transition Period ends earlier than the Anticipated Separation Date in accordance with this Section 1(c), as set forth in Section 4 below, you will not be entitled to any additional compensation for the period between the Separation Date under Section 1(c) and the Anticipated Separation Date set forth in this Agreement. “Third Party Engagement” means employment with any third party or engagement by any third party to provide services to such third party (whether as a principal, owner, partner, shareholder, member, director, manager, officer, consultant, agent, co-venturer or in any other capacity).
(d)Notwithstanding the foregoing clause (c), the Company agrees that during the Transition Period you will be permitted to accept one (1) Third-Party Engagement as a member of a board of directors, provided that: (i) you comply at all times with the terms and conditions of this Agreement and the Restrictive Covenants Agreement; (ii) you satisfy each of the Conditions (as defined below), including, but not limited to, working cooperatively and in good faith with the Company during the Transition Period and performing the duties described in this Section 1 to the Company’s satisfaction; and (iii) such Third-Party Engagement as a member of a board of directors will be subject to the prior written consent of the Company’s Chief Legal Officer.

Page 3 of 16

2.Conditions. Subject to the terms of this Agreement, you will be entitled to continue to be employed at the Company during the Transition Period and receive the Severance Benefits provided you satisfy each of the following (collectively, the “Conditions”): (i)  you sign this Agreement during the Agreement Consideration Period (defined in Section 19), do not revoke it, and comply with it; (ii) you sign Exhibit A to the Agreement (the “Supplemental Release” or “Exhibit A”) during the Consideration Period (as defined in Section 3(i) of Exhibit A), do not revoke it, and comply with it; (ii) your employment is not terminated by the Company for Cause, or as a result of your voluntary resignation prior to the Anticipated Separation Date; (iv) you work cooperatively and in good faith with the Company during the Transition Period and perform the duties described in Section 1 above to the Company’s satisfaction; (v) you comply with the Restrictive Covenants Agreement; and (vi) you provide a monthly written confirmation to the Company’s Chief Legal Officer, on the first day of each month of the Transition Period that, in the preceding calendar month, you have not accepted a Third Party Engagement.
3.Severance Benefits. If you satisfy each of the Conditions, the Company will provide you with the following post-employment benefits (the “Severance Benefits”).
(a)Separation Pay. In accordance with the Severance Plan, the Company will pay you $1,615,000.00, which amount equals 12 months of your current annual base rate of pay plus your annual target bonus in effect immediately prior to the Separation Date, less applicable deductions and withholdings (together, the “Separation Pay”). The Company will pay you the Separation Pay in biweekly payments, beginning on the second regular payroll date following the Effective Date (as defined in Section 3(j) of Exhibit A).
(b)Limited Acceleration of Unvested Equity. Despite any language in the Equity Documents to the contrary, in connection with your involuntary separation, fifteen percent (15%) of your unvested equity units (stock options and restricted stock units) will be accelerated and will vest no later than 40 days after the Effective Date.
(c)Extension of Equity Exercise Window. Despite any language in the Equity Documents to the contrary, you will have an extended window of up to twelve (12) months from the Separation Date or the grant expiration date, whichever is earlier, to exercise any and all vested options that you hold to purchase Company equity.
(d)COBRA Premium Assistance. After the Effective Date, if you are eligible for and timely elect medical benefit continuation under COBRA, the Company will directly pay 100% of the COBRA premium and all associated administrative fees until the earliest of (i) the last day of the 12th calendar month after the Separation Date; (ii) the date you start other employment with equivalent benefits coverage; or (iii) the date your COBRA continuation coverage terminates under COBRA’s provisions. Once the Company subsidy period ends, medical insurance coverage will be continued only to the extent required by COBRA and only to the extent you timely and pay the full premium and associated administrative fees.
You understand and agree that the Severance Benefits are being provided in exchange for your promises in this Agreement and that you are otherwise not entitled to any of the Severance Benefits. You also

Page 4 of 16

acknowledge that the Severance Benefits are sufficient to ensure your non-competition obligations under the Restrictive Covenants Agreement.

4.Early Separation. If, prior to the Anticipated Separation Date, the Company terminates your employment for Cause, you resign, your employment ends due to death or Disability or your employment ends pursuant to Section 1(c) above, you will (a) be paid only through the Separation Date, even if that date occurs prior to the Anticipated Separation Date, (b) receive the Accrued Benefits through the Separation Date, (c) cease vesting in your stock options and restricted stock units as of the Separation Date, and (d) not be eligible for any of the Severance Benefits or any other benefits, other than as is stated in this Agreement. For purposes of clarity, termination for Cause, resignation, death or Disability, or termination pursuant to Section 1(c) of this Agreement are the only reasons your employment can end before the Anticipated Separation Date. In the event that the Company should seek to terminate your employment for Cause following the date of this Agreement, it will promptly notify you in writing. Any such termination for Cause will become effective within ten (10) business days of delivery of the notice, unless the circumstances giving rise to the “for Cause” termination are cured within such ten (10) business days. For the avoidance of doubt, as of the date set forth at the top of this Agreement, the Company characterizes your termination as a termination without Cause.
5.General Release of Claims. You release the Company, its affiliated and related entities (including, without limitation, direct and indirect parent companies (including, without limitation, Moderna, Inc.), and direct and indirect subsidiaries and direct and indirect affiliates), its and their respective predecessors, successors, and assigns, its and their respective employee benefit plans and fiduciaries of such plans, and the past, present and future officers, directors, stockholders, members, managers, employees, attorneys, accountants, agents, and representatives of each of the foregoing in their official and personal capacities (collectively referred to as the “Releasees”) from all claims of any type to date, known or unknown, suspected or unsuspected, to the fullest extent allowed by law, including but not limited to any such claims arising from, or having anything to do with, your employment with or separation from the Company. This means you give up, except as provided in clause (h) of this section, all claims and rights related to:
(a)pay, compensation, or benefits including bonuses, commissions, equity, expenses, incentives, insurance, paid/unpaid leave, profit sharing, carry participation, or separation pay/benefits;
(b)compensatory, emotional, or mental distress damages, punitive or liquidated damages, attorney fees, costs, interest, or penalties;
(c)violation of express or implied employment contracts, covenants, promises or duties, intellectual property, or other proprietary rights;
(d)unlawful or tortious conduct such as assault or battery; background check violations; defamation; detrimental reliance; fiduciary breach; fraud; indemnification; intentional or negligent infliction of emotional distress; interference with contractual or other legal rights; invasion of privacy; loss of consortium; misrepresentation; negligence (including negligent hiring, retention, or supervision); personal injury; promissory estoppel; public policy violation; retaliatory discharge; safety violations; posting

Page 5 of 16

or records-related violations; wrongful discharge; or other federal, state or local statutory or common law matters;
(e)discrimination, harassment or retaliation based on age (including the Age Discrimination in Employment Act), benefit entitlement, citizenship, color, concerted activity, disability, ethnicity, gender, gender identity and expression, genetic information, immigration status, income source, jury duty, leave rights, military status, national origin, parental status, protected off-duty conduct, race, religion, retaliation, sexual orientation, union activity, veteran status, whistleblower claims in court (including under Sarbanes-Oxley, Dodd-Frank, and the False Claims Act claims), other legally protected status or activity; or any allegation that payment under this Agreement was affected by any such discrimination, harassment or retaliation; and
(f)any participation in any class or collective action against any Releasee.
(g)State Law Release. You further waive all claims or rights arising under applicable state law, including but not limited to the Massachusetts Payment of Wages Law (M.G.L. c. 149) and/or the Massachusetts Minimum Fair Wage Law (M.G.L. c. 151) including claims regarding entitlement to, or timely payment of, any wages, overtime, accrued vacation, paid time off, sick time, bonuses, commissions, equity, expenses, incentives, stock/stock options, and/or other compensation. 
(h)Release Exclusions and Other Exceptions. This General Release of Claims excludes: claims arising after the Revocation Period; claims for breach of this Agreement; claims to be covered under the Officer Indemnification Agreement between you and the Company dated May 24, 2022 (the “Indemnification Agreement”) and under applicable directors and officers liability insurance for acts or omissions while serving as an officer of the Company; claims for vested benefits under any Company Employee Retirement Income Security Act plan or other Company employee welfare benefit plan; and claims that cannot be waived as a matter of law, such as for unemployment, worker’s compensation and COBRA benefits. Nothing in this Agreement limits your rights: (i) to file a complaint with any administrative agency, such as the U.S. Equal Employment Opportunity Commission, a state fair employment practices agency, the Securities and Exchange Commission, or another state or federal regulatory authority; (ii) to communicate directly with such agency or participate in an agency proceeding; (iii) to communicate with law enforcement; or (iv) to communicate with your attorney. You nonetheless give up all rights to any money or other individual relief based on any agency or judicial decision, including in class or collective action rulings, except for compensation properly awarded by the Securities and Exchange Commission in return for providing actionable information.
(i)The Company affirms that it is not currently aware of any claims it or the other Releasees have against you.
6.Agreement Not to Sue. An “agreement not to sue” means you agree not to sue any Releasee in court. This is different from the General Release of Claims. Besides releasing claims covered by the General Release of Claims, you agree not to sue any Releasee for any reason covered by the General Release of Claims. Despite this provision, you may file suit to enforce this Agreement or to challenge its validity. If you sue a Releasee in violation of this provision, (i) you will be required to pay that Releasee’s reasonable

Page 6 of 16

attorney fees and costs incurred in its or their defense and/or (ii) the Company can require you to return all but $1,000.00 of the Severance Benefits and it will be excused from any remaining obligations that exist because of this Agreement.
7.Return of Company Property. On or before the Separation Date, you will return to the Company all Company property, including, without limitation, computer equipment, electronic devices, iPads or other tablets, iPhones or other mobile devices, software, keys and access cards, credit cards, files, and any documents (including computerized data and any copies made of any computerized data or software containing information concerning the Company, its business or business relationships (in the latter two cases, actual or prospective)(all collectively referred to as “Company Property”). After returning all Company Property, you must delete and purge any duplicates of files or documents that may contain Company information from any non-Company computer or other devices that remain your property. If you discover that you continue to retain any such property, you agree to immediately notify the Company and, based on the Company’s direction, either return it to the Company or, in the case of computerized data and software already in the possession of the Company, destroy it. For the avoidance of doubt, you may maintain copies of your employment records.
8.Confidentiality and Non-Disparagement.
(a)You understand and agree that you have been employed in a position of confidence and trust and have had access to information concerning the Company that the Company treats as confidential and the disclosure of which could negatively affect the Company’s interests (collectively, the “Confidential Information”). You acknowledge that this section does not prohibit the disclosure of information related to civil or administrative claims regarding sexual harassment, sex discrimination, sexual assault, or related retaliation, or good faith allegations of securities law violations. You represent that as of the Separation Date, neither you (nor anyone acting on your behalf) has filed any civil or administrative action against the Company or any of the Released Parties, or if such action has been filed, that it has been disclosed to the Company.
(b)You agree not to knowingly make any false, disparaging, or defamatory statements concerning the Company’s or any of its affiliates’ products or services; business affairs or financial condition; or current or former officers, directors, stockholders, employees, or agents, but only to the extent that you know or should reasonably know that such individuals are associated with the Company. You further agree not to conduct yourself in any way that would reasonably be expected to damage the Company’s reputation or goodwill; its products or services; or its current or former officers, directors, stockholders, members, employees, or agents, but only to the extent you know that such individuals are associated with the Company. This non-disparagement obligation will not in any way affect your obligation or intent to testify truthfully in any legal proceeding or to make truthful disclosures regarding alleged sexual harassment or assault.
(c)Nothing in this Agreement, including its confidentiality and non-disparagement provisions, is intended to limit your rights to engage in protected, concerted activity under Section 7 of the National Labor Relations Act or to file a charge with, participate in any investigation by or testify in any

Page 7 of 16

proceeding before the National Labor Relations Board. In doing so, you agree to take all reasonable measures to prevent any unauthorized use or disclosure of any information that may constitute Company confidential information under the Restricted Covenants Agreement. However, by entering into this Agreement, including the release of claims, you waive any right to monetary or other relief, including reinstatement, which may be ordered by the National Labor Relations Board because of or in connection with such charge, investigation, or proceeding.
(d)Defend Trade Secrets Act Disclosure. Nothing in this Agreement is intended to conflict with 18 U.S.C. § 1833(b), which provides that: “An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding if such filing is made under seal.”
9.Future Cooperation. You agree to make yourself available to assist the Company with transitioning your duties as noted in Section 1 of this Agreement as well as to make yourself available to reasonably assist the Company with any investigations legal claims, or other matters concerning anything related to your employment. You specifically agree to make yourself reasonably available to the Company upon reasonable notice for interviews and fact investigations, to testify without requiring service of a subpoena or other legal process, and to voluntarily provide the Company any employment-related documents you possess or control. “Cooperation” does not mean you must provide information favorable to the Company; it means only that you will provide information or documents upon the Company’s request. The Company agrees that such reasonable assistance and cooperation will occur, if practicable, at mutually agreeable times and places. If the Company requests your cooperation, it will reimburse you for reasonable time and expenses, provided you submit appropriate documentation. The Company will not utilize this Section to require you to make yourself available to an extent that would unreasonably interfere with your search for employment or any subsequent professional responsibilities that you may have.
10.Communications Regarding Separation. You agree that you will not (without the prior written approval of the Company) communicate about your transition or separation with anyone until after the Company has made a formal written announcement about your transition and separation (the “Company Announcement”); provided that you may communicate with your tax advisors, attorneys, and family members about your transition and separation before the Company Announcement; provided further that you first advise such persons not to reveal information about your transition and separation and each such person agrees. Once the Company has announced your transition and separation, you agree to limit any communications regarding your transition and separation departure to statements that are consistent with the Company Announcement.
11.Section 409A.
(a)Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), you are a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to

Page 8 of 16

the extent any payment or benefit that you become entitled to under this Agreement on account of your separation from service would be considered deferred compensation otherwise subject to the twenty percent (20%) additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment will not be payable and such benefit will not be provided until the date that is the earlier of (A) six months and one day after your separation from service, or (B) your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment will include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments will be payable in accordance with their original schedule.
(b)All in-kind benefits provided and expenses eligible for reimbursement under this Agreement will be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements will be paid as soon as administratively practicable, but in no event will any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year will not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.
(c)To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon your termination of employment, then such payments or benefits will be payable only upon your “separation from service.” The determination of whether and when a separation from service has occurred will be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h).
(d)The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision will be read in such a manner so that all payments hereunder comply with, or are exempt from, Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with, or be exempt from, Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.
(e)The Company makes no representation or warranty and will have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.

Page 9 of 16

12.Tax Treatment. The Company may make deductions, withholdings, and tax reports concerning payments and benefits under this Agreement to the extent that the Company, in good faith, determines that it is required to do so. Payments under this Agreement are in gross amounts and will be paid in amounts net of any deductions or withholdings. Nothing in this Agreement will be construed to require the Company to make any payments to compensate you for any tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit.
13.Legally Binding. Once effective, this Agreement is a legally binding document, and your signature will commit you to its terms. You acknowledge that you were advised in writing, by getting a copy of this Agreement, to consult with an attorney before signing this Agreement. You acknowledge that you have carefully read and fully understand all the provisions of this Agreement, and that you are voluntarily entering into this Agreement. If the General Release of Claims and/or the Supplemental Release in Exhibit A are found to be invalid or unenforceable in whole or in part, the invalid or unenforceable portion may be modified, revised, or severed and the Company may enforce the rest of the Agreement.
14.Non-admission. This Agreement will not be construed as an admission of any liability by the Company or you of any act of wrongdoing. Each of the Company and you specifically disclaim that the Company or any of its representatives has engaged in any wrongdoing or has taken any action that would be the basis for any finding of liability.
15.Enforceability. Except for the General Release of Claims and Exhibit A, if any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement or of the Restrictive Covenants Agreement) will to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, will not be affected, and each portion and provision of this Agreement will be valid and enforceable to the fullest extent permitted by law.
16.Waiver; Amendment. No waiver of any provision of this Agreement or of Exhibit A will be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, will not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. This Agreement may not be modified except in a writing signed by both you and an authorized Company executive.
17.Forum; Equitable Relief; Governing Law.
(a)This Agreement will be construed and governed under the laws of the Commonwealth of Massachusetts, without giving effect to any choice or conflict of law provisions. You acknowledge that this Agreement will not be construed more strictly against either you or the Company because it was prepared by the Company. You and the Company agree that the Superior Court of the Commonwealth of Massachusetts and the United States District Court for the District of Massachusetts has the exclusive authority to consider any matters related to this Agreement, including without limitation any claim for violation of this Agreement. You agree to (i) submit to the jurisdiction of such courts, (ii) consent

Page 10 of 16

to service of process, and (iii) waive any other requirement (whether imposed by statute, rule of court, or otherwise) concerning personal jurisdiction or venue.
(b)You agree that it may be difficult to measure any harm caused to the Company that might result from any breach by you of your promises in this Agreement and that in any event, monetary damages may be an inadequate remedy for any such breach. Accordingly, you agree that if you materially breach, or propose to breach, any material portion of your obligations under this Agreement, the Company will be entitled, in addition to all other remedies it may have, to seek an injunction or other appropriate equitable relief to restrain any such breach, without showing or proving any actual damage to the Company and without the necessity of posting a bond.
(c)If you fail to comply with any of your material obligations under this Agreement (including the obligations under the Restrictive Covenants Agreement), in addition to any other legal or equitable remedies it may have for breach, including for damages and equitable relief, the Company will have the right to (i) if you are still employed by the Company, end your employment for Cause in accordance with the terms set forth in Section 4 of this Agreement; (ii) terminate or suspend the Severance Benefits and/or (iii) seek recovery of any payments made to you or for your benefit under this Agreement, in each case with no effect on the General Release of Claims, the Supplemental Release in Exhibit A or your continuing obligations under this Agreement and under the Restrictive Covenants Agreement.
18.Entire Agreement. This Agreement constitutes the entire agreement between you and the Company and supersedes any previous agreements or understandings between you and the Company, provided however that the Severance Plan, the Indemnification Agreement, the Restrictive Covenants Agreement and the Equity Documents remain in full force and effect. You understand that by entering into this Agreement, the Company is not admitting in any way that it violated any legal obligation to you or to any other person or entity. This Agreement may be executed in two counterparts, each of which will be considered an original and all of which will constitute one agreement. Your signature may be delivered by scanned image (e.g., .pdf file) and such scanned signature will have the same effect as an original inked signature.
19.Time for Consideration/Revocation. You acknowledge that you have been given at least 21 calendar days from your receipt of this Agreement to consider it before signing (the “Agreement Consideration Period”). To accept this Agreement, you must return a signed, unmodified PDF copy of this Agreement before the expiration of the Agreement Consideration Period. Any changes to this Agreement do not restart the Agreement Consideration Period. By signing this Agreement, you acknowledge that you have voluntarily entered into this Agreement without any undue influence by the Company. If you sign this Agreement before the end of the Agreement Consideration Period, you acknowledge that such decision was voluntary, that you had the opportunity to consider this Agreement for the entire Agreement Consideration Period, and that you had the opportunity to consult with counsel of your choosing while doing so. You have up to seven (7) business days following your execution of this Agreement to revoke it by providing written notice to me (such period, the “Agreement Revocation Period”). The Consideration Period and Revocation Period that apply to Exhibit A are set forth in Section 3(i) of Exhibit A.

Page 11 of 16

20.If you die after the Anticipated Separation Date but before all Severance Benefits have been paid in accordance with the terms and conditions of this Agreement, the remaining Severance Benefits will continue as set forth in Section 14 of the Severance Plan.
If you wish to accept this agreement, please sign and return this letter to me within the timeframe specified on the first page of this letter. Thank you again for your contributions to Moderna’s mission.
Very truly yours,
/s/ Shannon Thyme Klinger    
Shannon Thyme Klinger
Chief Legal Officer




Page 12 of 16

Accepted by:

Arpa Garay
         
/s/ Arpa Garay                         Date: 01/02/2024


Page 13 of 16

EXHIBIT A:
SUPPLEMENTAL RELEASE OF CLAIMS

I, Arpa Garay, acknowledge that in connection with the ending of my employment with Moderna, I entered into a letter agreement dated December 8, 2023 (the “Agreement”).

I understand that this is the “Supplemental Release of Claims” and the “Exhibit A” referenced in the Agreement. I further understand that I may not sign this Supplemental Release of Claims until the Separation Date (as defined in the Agreement).
Release and Related Terms
1.I acknowledge that Company has paid me all compensation and benefits (other than the Severance Benefits pursuant to the Agreement) through my last day of my employment.
2.I understand that, regardless of whether I sign this Supplemental Release of Claims, the Agreement will remain in full force and effect, except that I will not receive the Severance Benefits.
3.General Release of Claims. I release the Company, its affiliated and related entities (including, without limitation, direct and indirect parent companies (including, without limitation, Moderna, Inc.), and direct and indirect subsidiaries and direct and indirect affiliates), its and their respective predecessors, successors and assigns, its and their respective employee benefit plans and fiduciaries of such plans, and the past, present and future officers, directors, stockholders, members, managers, employees, attorneys, accountants, agents and representatives of each of the foregoing in their official and personal capacities (collectively referred to as the “Releasees”) from all claims of any type to date, known or unknown, suspected or unsuspected, to the fullest extent allowed by law, including but not limited any such claims arising from, or having anything to do with, my employment or the end of my employment. This means I give up, except as provided in the Release Exclusions and Other Exceptions Section in the Agreement, all claims and rights related to:
(a)pay, compensation, or benefits including bonuses, commissions, equity, expenses, incentives, insurance, paid/unpaid leave, profit sharing, carry participation, or separation pay/benefits;
(b)compensatory, emotional, or mental distress damages, punitive or liquidated damages, attorney fees, costs, interest, or penalties;
(c)violation of express or implied employment contracts, covenants, promises or duties, intellectual property, or other proprietary rights;
(d)unlawful or tortious conduct such as assault or battery; background check violations; defamation; detrimental reliance; fiduciary breach; fraud; indemnification; intentional or negligent infliction of emotional distress; interference with contractual or other legal rights; invasion of privacy; loss of consortium; misrepresentation; negligence (including negligent hiring, retention, or supervision); personal injury; promissory estoppel; public policy violation; retaliatory discharge; safety violations; posting or records-related violations; wrongful discharge; or other federal, state or local statutory or common law matters;
(e)discrimination, harassment, or retaliation based on age (the Age Discrimination in Employment Act, as amended by the Older Workers Benefit Protection Act), benefit entitlement,
Page 14 of 16

citizenship, color, concerted activity, disability, ethnicity, gender, gender identity and expression, genetic information, immigration status, income source, jury duty, leave rights, military status, national origin, parental status, protected off-duty conduct, race, religion, retaliation, sexual orientation, union activity, veteran status, whistleblower claims in court (including under Sarbanes-Oxley, Dodd-Frank, and the False Claims Act claims), other legally protected status or activity; or any allegation that payment under this Agreement was affected by any such discrimination, harassment or retaliation; and
(f)any participation in any class or collective action against any Releasee.
(g)Release Exclusions and Other Exceptions. This Supplemental Release of Claims excludes: claims arising after the Revocation Period; claims for breach of this Agreement; claims to be covered under the Officer Indemnification Agreement and under applicable directors and officers liability insurance for acts or omissions while serving as an officer of the Company; claims for vested benefits under any Company Employee Retirement Income Security Act plan or any other Company employee welfare benefit plan; and claims that cannot be waived as a matter of law, such as for unemployment, worker’s compensation or COBRA benefits. Nothing in this Agreement limits your rights: (i) to file a complaint with any administrative agency, such as the U.S. Equal Employment Opportunity Commission, a state fair employment practices agency, the Securities and Exchange Commission, or another state or federal regulatory authority; (ii) to communicate directly with such agency or participate in an agency proceeding; (iii) to communicate with law enforcement; or (iv) to communicate with your attorney. You nonetheless give up all rights to any money or other individual relief based on any agency or judicial decision, including in class or collective action rulings, except for compensation properly awarded by the Securities and Exchange Commission in return for providing actionable information.
(h)State Law Release. I further waive all claims or rights arising under applicable state law, including but not limited to the Massachusetts Payment of Wages Law (M.G.L. c. 149) and/or the Massachusetts Minimum Fair Wage Law (M.G.L. c. 151) including claims regarding entitlement to, or timely payment of, any wages, overtime, accrued vacation, paid time off, sick time, bonuses, commissions, equity, expenses, incentives, stock/stock options, and/or other compensation, and including but not limited to Title 20 of the State Government Article of the Maryland Annotated Code. 
(i)I represent that I have not filed any claim against the Releasees in any forum. Notwithstanding the foregoing, this Supplemental Release of Claims does not release: (i) claims that arise after the Revocation Period (as defined in clause (i) below); (ii) my rights to vested benefits under the Company’s ERISA welfare and pension plans; and (iii) my rights under the Agreement.
(j)I acknowledge that I received this Exhibit A with the Agreement, that I may not sign Exhibit A prior to the Separation Date and that I have been given the opportunity to consider this Exhibit A for at least 21 calendar days from the date on the first page of the Agreement (the “Consideration Period”) before signing it. I understand that, to receive the Severance Benefits, I must return a signed, unmodified original or PDF copy of this Exhibit A so that it is received by the Human Resources Department of the Company on or before the expiration of the Consideration Period. I acknowledge that my release of claims is knowing and voluntary, including without implication of limitation my release of claims of age discrimination under the Age Discrimination in Employment Act, 29 U.S.C. § 621 et seq., as amended. I understand that for the period of seven (7) business days from the date when I sign this Exhibit A (the “Revocation Period”), I have the right to revoke this Supplemental Release of Claims by written notice to the Company signatory on the Agreement. This Exhibit A will not become effective or enforceable until the first business day after the Revocation Period expires (the “Effective Date”).

Page 15 of 16

(k)Nothing in any part of this Agreement limits my rights to make truthful disclosures regarding alleged unlawful workplace health and safety practices or hazards related to a public health emergency.
I HAVE READ THIS SUPPLEMENTAL RELEASE OF CLAIMS THOROUGHLY, UNDERSTAND ITS TERMS AND HAVE SIGNED IT KNOWINGLY AND VOLUNTARILY. I UNDERSTAND THAT THIS IS A LEGAL DOCUMENT. I ACKNOWLEDGE THAT I HAVE BEEN ADVISED BY THE COMPANY TO DISCUSS ALL ASPECTS OF THIS RELEASE WITH COUNSEL OF MY CHOOSING.

Arpa Garay

________________________________        ________________________________
Signature                    Date


Page 16 of 16
 EX-10.21 4 exhibit10212018employeesto.htm EX-10.21 Document
Exhibit 10.21
MODERNA, INC.
2018 EMPLOYEE STOCK PURCHASE PLAN
The purpose of the Moderna, Inc. 2018 Employee Stock Purchase Plan (“the Plan”) is to provide eligible employees of Moderna, Inc. (the “Company”) and each Designated Company (as defined in Section 11) with opportunities to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). An aggregate of 810,000 shares of Common Stock have been approved and reserved for this purpose, plus on January 1, 2020 and each January 1 thereafter, the number of shares of Common Stock reserved and available for issuance under the Plan shall be cumulatively increased by the lesser of (i) 3,240,000 shares of Common Stock, (ii) one percent of the number of shares of Common Stock of the Company issued and outstanding on the immediately preceding December 31 or (iii) such lesser number of shares of Common Stock as determined by the Administrator.
The Plan includes two components: a Code Section 423 Component (the “423 Component”) and a non-Code Section 423 Component (the “Non-423 Component”). It is intended for the 423 Component to constitute an “employee stock purchase plan” within the meaning of Section 423(b) of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and the 423 Component shall be interpreted in accordance with that intent (although the Company makes no undertaking or representation to maintain such qualification). In addition, this Plan authorizes the grant of options under the Non-423 Component that does not qualify as an “employee stock purchase plan” under Section 423 of the Code. Except as otherwise provided herein, the Non-423 Component will operate and be administered in the same manner as the 423 Component.

1. Administration. The Plan will be administered by the person or persons (the “Administrator”) appointed by the Company’s Board of Directors (the “Board”) for such purpose. The Administrator has authority at any time to: (i) adopt, alter and repeal such rules, subplans, guidelines and practices for the administration and operation of the Plan and for its own acts and proceedings as it shall deem advisable, including to accommodate the specific requirements of local laws, regulations and procedures for jurisdictions outside of the United States; (ii) interpret the terms and provisions of the Plan; (iii) make all determinations it deems advisable for the administration of the Plan; (iv) decide all disputes arising in connection with the Plan; and (v) otherwise supervise the administration of the Plan. All interpretations and decisions of the Administrator shall be binding on all persons, including the Company and the Participants. No member of the Board or individual exercising administrative authority with respect to the Plan shall be liable for any action or determination made in good faith with respect to the Plan or any option granted hereunder.
2. Offerings. The Company will make one or more offerings to eligible employees to purchase Common Stock under the Plan (“Offerings”). Unless otherwise determined by the Administrator, an Offering will begin on the first business day occurring on or after each June 1st and December 1 and will end on the last business day occurring on or before the following November 30th and May 30, respectively. The Administrator may, in its discretion, designate a different period for any Offering, provided that no Offering shall exceed 27 months in duration or overlap any other Offering.

3. Eligibility. All individuals classified as employees on the payroll records of the Company and each Designated Company are eligible to participate in any one or more of the Offerings under the Plan, provided that as of the first day of the applicable Offering (the “Offering Date”) they are customarily employed by the Company or a Designated Company for 20 hours or more a week, unless the exclusion of employees who do not meet this requirement is not permissible under applicable law, and have completed at least 30 days of employment. Notwithstanding any other provision herein, individuals who are not contemporaneously classified as employees of the Company or a Designated Company for purposes of the Company’s or applicable Designated Company’s payroll system are not considered to be eligible employees of the Company or any Designated Company and shall not be eligible to participate in the Plan. In the event any such individuals are reclassified as employees of the Company or a Designated Company for any purpose, including, without limitation, common law or statutory employees, by any action of any third party, including, without limitation, any government agency, or as a result of any private lawsuit, action or administrative proceeding, such individuals shall, notwithstanding such reclassification, remain ineligible for participation. Notwithstanding the foregoing, the exclusive means for individuals who are not


contemporaneously classified as employees of the Company or a Designated Company on the Company’s or Designated Company’s payroll system to become eligible to participate in a plan which is equivalent to this Plan is through the adoption of a subplan, which specifically renders such individuals eligible to participate therein.

4. Participation.
(a) Participants. An eligible employee who is not a Participant in any prior Offering may participate in a subsequent Offering by submitting (either in electronic or written form, according to procedures established by the Company) an enrollment form to his or her appropriate payroll location at least 15 business days before the Offering Date (or by such other deadline as shall be established by the Administrator for the Offering).
(b) Enrollment. The enrollment form will (a) state a whole percentage to be contributed from an eligible employee’s Compensation (as defined in Section 11) per pay period, (b) authorize the purchase of Common Stock in each Offering in accordance with the terms of the Plan and (c) specify the exact name or names in which shares of Common Stock purchased for such individual are to be issued or transferred pursuant to Section 10. An employee who does not enroll in accordance with these procedures will be deemed to have waived the right to participate. Unless a Participant submits (either in electronic or written form, according to procedures established by the Company) a new enrollment form or withdraws from the Plan, such Participant’s contributions and purchases will continue at the same percentage of Compensation for future Offerings, provided he or she remains eligible.
(c) Notwithstanding the foregoing, participation in the Plan will neither be permitted nor be denied contrary to the requirements of the Code and any applicable law.
5. Employee Contributions. Each eligible employee may authorize payroll deductions at a minimum of 1 percent up to a maximum of 15 percent of such employee’s Compensation for each pay period; provided, however, that if payroll deductions are not permitted or problematic under applicable law or for administrative reasons, the Company, in its discretion, may allow eligible employees to contribute to the Plan by other means. The Company will maintain book accounts showing the amount of payroll deductions or other contributions made by each Participant for each Offering. No interest will accrue or be paid on payroll deductions or other contributions, unless required under applicable law.

6. Contribution Changes. Except as may be determined by the Administrator in advance of an Offering, a Participant may not increase his or her contributions during any Offering and may only decrease his or her contributions once during any Offering. However, during an Offering, a Participant may increase or decrease his or her contributions with respect to the next Offering (subject to the limitations of Section 5) by submitting (either in electronic or written form, according to procedures established by the Company) a new enrollment form at least 15 business days before the next Offering Date (or by such other deadline as shall be established by the Administrator for the Offering). The Administrator may, in advance of any Offering, establish rules permitting a Participant to increase, decrease or terminate his or her contributions during an Offering.
7. Withdrawal. A Participant may withdraw from participation in the Plan by submitting a notice of withdrawal to his or her appropriate payroll location (either in electronic or written form, according to procedures established by the Company). The Participant’s withdrawal will be effective as of the next business day. Following a Participant’s withdrawal, the Company will promptly refund such individual’s entire account balance under the Plan to him or her (after payment for any Common Stock purchased before the effective date of withdrawal). Partial withdrawals are not permitted. Such an employee may not begin participation again during the remainder of the Offering, but may enroll in a subsequent Offering in accordance with Section 4.

8. Grant of Options. On each Offering Date, the Company will grant to each eligible employee who is then a Participant in the Plan an option (“Option”) to purchase on the last day of such Offering (the “Exercise Date”), at the Option Price hereinafter provided for, the lowest of (a) a number of shares of Common Stock determined by dividing such Participant’s accumulated contributions on such Exercise Date by the lower of (i) 85 percent of the Fair Market Value of the Common Stock on the Offering Date, or (ii) 85 percent of the Fair Market Value of the Common Stock on the Exercise Date, (b) 3,000 shares; or (c) such other lesser maximum number of shares as shall have been established by the Administrator in advance of the Offering; provided, however, that such Option shall be subject to the limitations set forth below. Each Participant’s Option shall be exercisable only to the extent of such


Participant’s accumulated payroll deductions and/or other contributions on the Exercise Date. The purchase price for each share purchased under each Option (the “Option Price”) will be 85 percent of the Fair Market Value of the Common Stock on the Offering Date or the Exercise Date, whichever is less.
Notwithstanding the foregoing, no Participant may be granted an Option hereunder if such Participant, immediately after the Option was granted, would be treated as owning stock possessing 5 percent or more of the total combined voting power or value of all classes of stock of the Company or any Parent or Subsidiary (as defined in Section 11). For purposes of the preceding sentence, the attribution rules of Section 424(d) of the Code shall apply in determining the stock ownership of a Participant, and all stock which the Participant has a contractual right to purchase shall be treated as stock owned by the Participant. In addition, no Participant may be granted an Option which permits his or her rights to purchase stock under the Plan, and any other employee stock purchase plan of the Company and its Parents and Subsidiaries, to accrue at a rate which exceeds $25,000 of the fair market value of such stock (determined on the Option grant date or dates) for each calendar year in which the Option is outstanding at any time. The purpose of the limitation in the preceding sentence is to comply with Section 423(b)(8) of the Code and shall be applied taking Options into account in the order in which they were granted.

9. Exercise of Option and Purchase of Shares. Each employee who continues to be a Participant in the Plan on the Exercise Date shall be deemed to have exercised his or her Option on such date and shall acquire from the Company such number of whole shares of Common Stock reserved for the purpose of the Plan as his or her accumulated contributions on such date will purchase at the Option Price, subject to any other limitations contained in the Plan. Any amount remaining in a Participant’s account at the end of an Offering solely by reason of the inability to purchase a fractional share will be carried forward to the next Offering; any other balance remaining in a Participant’s account at the end of an Offering will be refunded to the Participant promptly.
If a Participant has more than one Option outstanding under the Plan, unless he or she otherwise indicates in agreements or notices delivered hereunder: (i) each agreement or notice delivered by that Participant shall be deemed to apply to all of his or her Options under the Plan; and (ii) an Option with a lower Option Price (or an earlier granted Option, if different Options have identical Option Prices) shall be exercised to the fullest possible extent before an Option with a higher Option Price (or a later granted Option if different Options have identical Option Prices) shall be exercised.
10. Issuance of Certificates. Certificates, or book entries for uncertificated shares, representing shares of Common Stock purchased under the Plan may be issued only in the name of the employee or, if permitted by the Administrator, in the name of the employee and another person of legal age as joint tenants with rights of survivorship, or in the name of a broker authorized by the employee to be his, her or their, nominee for such purpose.

11. Definitions.
The term “Affiliate” means any entity that is directly or indirectly controlled by the Company which does not meet the definition of a Subsidiary below, as determined by the Administrator, whether new or hereafter existing.
The term “Compensation” means the amount of base pay, prior to salary reduction pursuant to Sections 125, 132(f) or 401(k) of the Code or comparable reductions under laws outside the United States, but excluding overtime, commissions, incentive or bonus awards, allowances and reimbursements for expenses such as relocation allowances or travel expenses, income or gains on the exercise, vesting or settlement of Company equity incentive awards, and similar items. The Administrator shall have the discretion to determine the application of this definition to Participants outside of the United States.
The term “Designated Company” means any present or future Affiliate or Subsidiary (as defined below) that has been designated by the Administrator to participate in the Plan. The Administrator may so designate any Affiliate or Subsidiary, or revoke any such designation, at any time and from time to time, either before or after the Plan is approved by the stockholders and may further designate such companies as participating in the 423 Component or


the Non-423 Component. For purposes of the 423 Component, only Subsidiaries may be Designated Companies. The current list of Designated Companies is attached hereto as Appendix A.

The term “Fair Market Value of the Common Stock” on any given date means the fair market value of the Common Stock determined in good faith by the Administrator; provided, however, that if the Common Stock is admitted to quotation on the Nasdaq Global Market or another national securities exchange, the determination shall be made by reference to the closing price on such date. If there is no closing price for such date, the determination shall be made by reference to the last date preceding such date for which there is a closing price.
The term “Initial Public Offering” means the first day when trading prices for the Common Stock are reported on Nasdaq Global Market or another national securities exchange, pursuant to an effective registration statement under the U.S. Securities Act of 1933, as amended, covering the offer and sale by the Company of its Common Stock.
The term “Parent” means a “parent corporation” with respect to the Company, as defined in Section 424(e) of the Code.
The term “Participant” means an individual who is eligible as determined in Section 3 and who has complied with the provisions of Section 4.
The term “Subsidiary” means a “subsidiary corporation” with respect to the Company, as defined in Section 424(f) of the Code.
12. Rights on Termination of Employment. Unless otherwise required by applicable law, if a Participant’s employment terminates for any reason before the Exercise Date for any Offering, no contributions will be taken from any pay due and owing to the Participant and the balance in the Participant’s account will be paid to such Participant or, in the case of such Participant’s death, if permitted by the Administrator, to his or her designated beneficiary as if such Participant had withdrawn from the Plan under Section 7. An employee will be deemed to have terminated employment, for this purpose, if the corporation that employs him or her, having been a Designated Company, ceases to be an Affiliate or a Subsidiary, as applicable, or if the employee is transferred to any corporation other than the Company or a Designated Company. An employee will not be deemed to have terminated employment for this purpose, if the employee is on an approved leave of absence for military service or sickness or for any other purpose approved by the Company, if the employee’s right to reemployment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise provides in writing.
13. Special Rules. Notwithstanding anything herein to the contrary, the Administrator may adopt special rules applicable to the employees of a particular Designated Company, whenever the Administrator determines that such rules are necessary or appropriate for the implementation of the Plan in a jurisdiction where such Designated Company has employees; provided that if such rules are inconsistent with the requirements of Section 423(b) of the Code, these employees will participate in the Non-423 Component. Any special rules established pursuant to this Section 13 shall, to the extent possible, result in the employees subject to such rules having substantially the same rights as other Participants in the Plan.
14. Optionees Not Stockholders. Neither the granting of an Option to a Participant nor the deductions from his or her pay or other contributions shall deem such Participant to be a holder of the shares of Common Stock covered by an Option under the Plan until such shares have been purchased by and issued or transferred to him or her.
15. Rights Not Transferable. Rights under the Plan are not transferable by a Participant other than by will or the laws of descent and distribution, and are exercisable during the Participant’s lifetime only by the Participant.

16. Application of Funds. All funds received or held by the Company under the Plan may be combined with other corporate funds and may be used for any corporate purpose; unless otherwise required under applicable law.
17. Adjustment in Case of Changes Affecting Common Stock. In the event of a subdivision of outstanding shares of Common Stock, the payment of a dividend in Common Stock or any other change affecting the Common Stock, the


number of shares approved for the Plan and the share limitation set forth in Section 8 shall be equitably or proportionately adjusted to give proper effect to such event.
18. Amendment of the Plan. The Board may at any time and from time to time amend the Plan in any respect, except that without the approval within 12 months of such Board action by the stockholders, no amendment shall be made increasing the number of shares approved for the Plan or making any other change that would require stockholder approval in order for the 423 Component of the Plan, as amended, to qualify as an “employee stock purchase plan” under Section 423(b) of the Code.
19. Insufficient Shares. If the total number of shares of Common Stock that would otherwise be purchased on any Exercise Date plus the number of shares purchased under previous Offerings under the Plan exceeds the maximum number of shares issuable under the Plan, the shares then available shall be apportioned among Participants in proportion to the amount of payroll deductions accumulated on behalf of each Participant that would otherwise be used to purchase Common Stock on such Exercise Date.

20. Termination of the Plan. The Plan may be terminated at any time by the Board. Upon termination of the Plan, all amounts in the accounts of Participants shall be promptly refunded. The Plan shall automatically terminate on the ten year anniversary of the date of the Company’s Initial Public Offering.
21. Compliance with Law. The Company’s obligation to sell and deliver Common Stock under the Plan is subject to completion of any registration or qualification of the Common Stock under any U.S. or non-U.S. local, state or federal securities or exchange control law or under rulings or regulations of the U.S. Securities and Exchange Commission (“SEC”) or of any other governmental regulatory body, and to obtaining any approval or other clearance from any U.S. and non-U.S. local, state or federal governmental agency, which registration, qualification or approval the Company shall, in its absolute discretion, deem necessary or advisable. The Company is under no obligation to register or qualify the Common Stock with the SEC or any other U.S. or non-U.S. securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of such stock.
22. Governing Law. This Plan and all Options and actions taken thereunder shall be governed by, and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, applied without regard to conflict of law principles.
23. Issuance of Shares. Shares may be issued upon exercise of an Option from authorized but unissued Common Stock, from shares held in the treasury of the Company, or from any other proper source.
24. Tax Withholding. Participation in the Plan is subject to any minimum required tax withholding on income of the Participant in connection with the Plan. Each Participant agrees, by participating in the Plan, that the Company and its Affiliates and Subsidiaries shall have the right to deduct any Tax Liability from any payment of any kind otherwise due to the Participant, including shares of Common Stock issuable under the Plan. Where a Tax Liability arises in connection with the Plan, the Company and/or a Designated Company may require that, as a condition of exercise of an Option and purchase of shares of Common Stock, a Participant must either:
(a) make a payment to the Company, or otherwise as the Company directs, of an amount equal to the Company’s estimate of the amount of the Tax Liability; or
(b) enter into arrangements acceptable to the Company to secure that such payment is made (whether by surrender of shares of Common Stock, net share issuance, the sale of shares of Common Stock or otherwise).
For these purposes, “Tax Liability” shall mean any amount of U.S. or non-U.S. federal, state or local income tax, social security (or similar) contributions, payroll tax, fringe benefits tax, payment on account and/or other tax-related items related to the participation in the Plan and legally applicable to the Participant, which the Company and/or an Affiliate or Subsidiary become liable to pay on the Participant’s behalf to the relevant authorities in any jurisdiction.
25. Notification Upon Sale of Shares. Each Participant who is subject to tax in the United States with respect to his or her participation in the Plan agrees, by entering the Plan, to give the Company prompt notice of any disposition of shares purchased under the Plan where such disposition occurs within two years after the date of grant of the Option pursuant to which such shares were purchased or within one year after the date such shares were purchased.


26. Effective Date and Approval of Shareholders. The Plan shall take effect on the date immediately preceding the date of the Company’s Initial Public Offering, subject to approval by the holders of a majority of the votes cast at a meeting of stockholders at which a quorum is present or by written consent of the stockholders.





APPENDIX A
Designated Companies


EX-10.22 5 exhibit1022formofemployeer.htm EX-10.22 Document
Exhibit 10.22
RESTRICTED STOCK UNIT AWARD AGREEMENT
FOR COMPANY EMPLOYEES
UNDER THE MODERNA, INC.
2018 STOCK OPTION AND INCENTIVE PLAN
Name of Grantee: [Participant Name]
No. of Restricted Stock Units: [Number of Shares Granted]
Grant Date: [Grant date]
Pursuant to the Moderna, Inc. 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Moderna, Inc. (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award”) to the Grantee named above. Each Restricted Stock Unit shall relate to one share of Common Stock, par value $0.0001 per share (the “Stock”) of the Company.
1.Restrictions on Transfer of Award. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i) the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii) shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement.
2.Vesting of Restricted Stock Units. The restrictions and conditions of Paragraph 1 of this Agreement shall lapse on the Vesting Date or Dates specified in the vesting schedule attached as Appendix A to this Agreement so long as the Grantee continues to have a Service Relationship with the Company or a Subsidiary on such Dates. If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph 1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date.
The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2.
If, at the time of a Sale Event, the Grantee does not participate in the Company’s Amended and Restated Executive Severance Plan, as amended from time to time (the “Severance Plan”), then notwithstanding anything herein to the contrary, in the event (and only in the event) that this Award is assumed, continued or substituted by the Company or its successor entity in the sole discretion of the parties to a Sale Event and thereafter remains in effect following such Sale Event, 100% of the then-unvested Restricted Stock Units shall be deemed vested in full upon the date on which the Grantee’s Service Relationship with the Company and its Subsidiaries or successor entity terminates if (A) such termination occurs in connection with and effective as of the date of, or within 12 months following the date of, such Sale Event and (B) such termination is either by the Company other than due to Cause, death or disability or by the


Grantee for Good Reason. If, at the time of a Sale Event, the Grantee participates in the Severance Plan, then the Award shall be subject to the acceleration of vesting provisions as provided in such plan.
For purposes of this Agreement,
“Cause” shall mean, unless otherwise provided in an employment or other service agreement between the Company and the Grantee, a determination by the Administrator that the Grantee shall be dismissed as a result of (i) any material breach by the Grantee of any agreement between the Grantee and the Company; (ii) the conviction of, indictment for or plea of nolo contendere by the Grantee to a felony or a crime involving moral turpitude; or (iii) any material misconduct or willful and deliberate non-performance (other than by reason of disability) by the Grantee of the Grantee’s duties to the Company.
“Good Reason” shall mean, unless otherwise provided in an employment or other service agreement between the Company and the Grantee, (i) a diminution of at least 20% in the Grantee’s annual base salary except for across-the-board reductions in annual base salary similarly affecting all or substantially all similarly situated employees of the Company, (ii) a change of more than 50 miles in the geographic location at which the Grantee provides services to the Company, so long as the Grantee provides at least 90 days’ notice to the Company following the initial occurrence of any such event and the Company fails to cure such event within 30 days thereafter, or (iii) any material diminution in the Grantee’s position, responsibilities, authority or duties.
3.Termination of Service Relationship. If the Grantee’s Service Relationship with the Company or a Subsidiary terminates for any reason (other than death or permanent disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units.
(a)Termination Due to Death. If the Grantee’s Service Relationship with the Company or a Subsidiary terminates by reason of the Grantee’s death, then any Restricted Stock Units that have not vested as of the Grantee’s death shall immediately vest in full as of the date of death.
(b)Termination Due to Permanent Disability. If the Grantee’s Service Relationship with the Company or a Subsidiary terminates by reason of the Grantee’s permanent disability (as defined below), then any Restricted Stock Units under this Award that have not vested as of the last date of the Grantee’s Service Relationship shall immediately vest in full as of such date. For purposes of this Award, “permanent disability” shall mean the inability of the Grantee to continue in his or her position for the Company (or an Affiliate) by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months, as determined by the Company in its sole discretion.


4.Issuance of Shares of Stock. As soon as practicable following each Vesting Date (but in no event later than two and one-half months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have vested pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares.
5.Incorporation of Plan. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.
6.Tax Withholding. In connection with the settlement of vested Restricted Stock Units, the Company shall issue the shares of Stock referred to in Paragraph 4 to a broker designated by the Company and acting on behalf and for the account of the Grantee with instructions to (i) sell a number of shares of such Stock sufficient to satisfy the applicable withholding taxes which arise in connection with such settlement; provided, that the amount sold does not exceed the maximum statutory tax rate or such lesser amount as is necessary to avoid liability accounting treatment, along with any applicable third-party commission, and (ii) remit the proceeds of such sale to the Company. In the event the sale proceeds are insufficient to fully satisfy the applicable withholding taxes, the Grantee authorizes withholding from payroll and any other amounts payable to the Grantee, in the same calendar year, and otherwise agrees to make adequate provision through the submission of cash, a check or its equivalent for any sums required to satisfy the applicable withholding taxes. It is the intent of the parties that this Paragraph 6 comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act, and the Agreement will be interpreted to comply with the requirements of Rule 10b5-1(c) under the Exchange Act. Unless the withholding tax obligations of the Company and/or any Affiliate thereof are satisfied, the Company shall have no obligation to issue any shares of Stock on the Grantee’s behalf pursuant to the vesting of the Restricted Stock Units.
7.Section 409A of the Code. This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section 409A of the Code as “short-term deferrals” as described in Section 409A of the Code.
8.No Obligation to Continue Service Relationship. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee’s Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Grantee’s Service Relationship with the Company or a Subsidiary at any time.
9.Integration. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter.
10.Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and


certain agents thereof (together, the “Relevant Companies”) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the “Relevant Information”). By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.
11.Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.
Moderna, Inc.
By:


Name:
Title:


The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company’s instructions to the Grantee (including through an online acceptance process) is acceptable.
[Signed Electronically]
Acceptance Date: [Acceptance Date]

Appendix A: Vesting Schedule

[Vesting Schedule]



 EX-10.23 6 exhibit1023formofemployeen.htm EX-10.23 Document
Exhibit 10.23

NON-QUALIFIED STOCK OPTION AGREEMENT
FOR COMPANY EMPLOYEES
UNDER THE MODERNA, INC.
2018 STOCK OPTION AND INCENTIVE PLAN
Name of Optionee: [Participant Name]
No. of Option Shares: [Number of Shares Granted]
Option Exercise Price per Share: $[Grant Price]
Grant Date: [Grant date]
Expiration Date: [Expiration Date]
Pursuant to the Moderna, Inc. 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Moderna, Inc. (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.0001 per share (the “Stock”) of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended.
1.Exercisability Schedule. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as set forth below in Appendix A, and subject to the discretion of the Administrator (as defined in Section 2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of Option Shares on the dates indicated on Appendix A to this Agreement so long as the Optionee continues to have a Service Relationship with the Company or a Subsidiary on such dates.
Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan.
If, at the time of a Sale Event, the Optionee does not participate in the Company’s Amended and Restated Executive Severance Plan, as amended from time to time (the “Severance Plan”), then notwithstanding anything herein to the contrary, in the event (and only in the event) that this Stock Option or the Option Shares are assumed, continued or substituted by the Company or its successor entity in the sole discretion of the parties to a Sale Event and thereafter remains in effect following such Sale Event, 100% of the then-unvested Stock Option shall be deemed vested in full upon the date on which the Optionee’s Service Relationship with the Company and its Subsidiaries or successor entity terminates if (A) such termination occurs in


connection with and effective as of the date of, or within 12 months following the date of, such Sale Event and (B) such termination is either by the Company other than due to Cause, death or disability or by the Optionee for Good Reason. If, at the time of a Sale Event, the Optionee participates in the Severance Plan, then the Stock Option shall be subject to the acceleration of vesting provisions as provided in such plan.
For purposes of this Agreement,
“Cause” shall mean, unless otherwise provided in an employment or other service agreement between the Company and the Optionee, a determination by the Administrator that the Optionee shall be dismissed as a result of (i) any material breach by the Optionee of any agreement between the Optionee and the Company; (ii) the conviction of, indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii) any material misconduct or willful and deliberate non-performance (other than by reason of disability) by the Optionee of the Optionee’s duties to the Company.
“Good Reason” shall mean, unless otherwise provided in an employment or other service agreement between the Company and the Optionee, (i) a diminution of at least 20% in the Optionee’s annual base salary except for across-the-board reductions in annual base salary similarly affecting all or substantially all similarly situated employees of the Company, (ii) a change of more than 50 miles in the geographic location at which the Optionee provides services to the Company, so long as the Optionee provides at least 90 days’ notice to the Company following the initial occurrence of any such event and the Company fails to cure such event within 30 days thereafter, or (iii) any material diminution in the Optionee’s position, responsibilities, authority or duties.
2.Manner of Exercise.
(a)The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be purchased.
Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i) in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii) if permitted by the Administrator, through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii) by the Optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such


payment procedure; (iv) if permitted by the Administrator, by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; or (v) a combination of (i), (ii), (iii) and (iv) above. Payment instruments will be received subject to collection.
The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i) the Company’s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii) the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and (iii) the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to.
(b)The shares of Stock purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have transferred the shares to the Optionee, and the Optionee’s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect to such shares of Stock.
(c)The minimum number of shares with respect to which this Stock Option may be exercised at any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time.
(d)Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date hereof.
3.Termination of Service Relationship. If the Optionee’s Service Relationship with the Company or a Subsidiary (as defined in the Plan) is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below.
(a)Termination Due to Death. If the Optionee’s Service Relationship with the Company or a Subsidiary terminates by reason of the Optionee’s death, then any portion of this Stock Option that has not vested as of the Optionee’s death shall immediately vest in full as of the date of death. Following any termination due to death, this Stock Option may thereafter be


exercised by the Optionee’s legal representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier.
(b)Termination Due to Permanent Disability. If the Optionee’s Service Relationship with the Company or a Subsidiary terminates by reason of the Optionee’s permanent disability (as defined below), then any portion of this Stock Option that has not vested as of the last date of the Optionee’s Service Relationship (the “Accelerated Vesting Date”) shall immediately vest in full as of the Accelerated Vesting Date. Following any termination due to disability, this Stock Option may thereafter be exercised by the Optionee for a period of 12 months from the Accelerated Vesting Date or until the Expiration Date, if earlier. For purposes of this Stock Option, “permanent disability” shall mean the inability of the Optionee to continue in his or her position for the Company (or an Affiliate) by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months, as determined by the Company in its sole discretion.
(c)Termination for Cause. If the Optionee’s Service Relationship with the Company or a Subsidiary terminates for Cause, any portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect.
(d)Other Termination. If the Optionee’s Service Relationship with the Company or a Subsidiary terminates for any reason other than the Optionee’s death, the Optionee’s permanent disability or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date of termination, for a period of three months from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of termination shall terminate immediately and be of no further force or effect.
The Administrator’s determination of the reason for termination of the Optionee’s Service Relationship with the Company or a Subsidiary shall be conclusive and binding on the Optionee and his or her representatives or legatees.
4.Incorporation of Plan. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.
5.Transferability. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee’s lifetime, only by the Optionee, and thereafter, only by the Optionee’s legal representative or legatee.
6.Tax Withholding. The Optionee shall, not later than the date as of which the exercise of this Stock Option becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and


local taxes required by law to be withheld on account of such taxable event. The Company shall have the authority to cause the minimum required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to the Optionee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the minimum withholding amount due.
7.No Obligation to Continue Service Relationship. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Optionee’s Service Relationship with the Company or a Subsidiary at any time.
8.Integration. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter.
9.Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the “Relevant Companies”) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the “Relevant Information”). By entering into this Agreement, the Optionee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.
10.Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.
Moderna, Inc.
By:
Name:
Title:



The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company’s instructions to the Optionee (including through an online acceptance process) is acceptable.

Acceptance Date: [Acceptance Date]








Appendix A: Vesting Schedule

[Vesting Schedule]



 EX-21.1 7 exhibit211subsidiaries2023.htm EX-21.1 Document
Exhibit 21.1

SUBSIDIARIES
Moderna, Inc.’s principal affiliates as of December 31, 2023, are listed below. All other affiliates, if considered in the aggregate as a single affiliate, would not constitute a significant subsidiary.
SubsidiaryJurisdiction of Incorporation
Moderna Australia Pty LtdAustralia
Moderna Biopharma Canada CorporationCanada
Moderna Biotech Distributor UK Ltd.United Kingdom
Moderna Biotech Kenya Manufacturing Ltd.Kenya
Moderna Biotech Manufacturing UK Ltd.United Kingdom
Moderna Biotech Securities, Inc.Massachusetts
Moderna Biotech Singapore Pte. Ltd.Singapore
Moderna Biotech Spain, S.L.U.Spain
Moderna Biotech UK LimitedUnited Kingdom
Moderna Charitable Foundation, Inc.Delaware
Moderna Denmark ApSDenmark
Moderna Enzymatics Co., Ltd.Japan
Moderna FranceFrance
Moderna Germany GmbHGermany
Moderna Hong Kong LimitedHong Kong
Moderna Italy S.r.l.Italy
Moderna Japan Co., Ltd.Japan
Moderna Korea LimitedSouth Korea
Moderna Manufacturing Australia Pty Ltd.
Australia
Moderna Manufacturing Canada Corp.Canada
Moderna Netherlands B.V.Netherlands
Moderna Norway ASNorway
Moderna Poland sp. z o.o.Poland
Moderna Services, Inc.Delaware
Moderna Sweden ABSweden
Moderna Switzerland GmbHSwitzerland
ModernaTX, Inc.Delaware
Moderna Taiwan Co., LtdTaiwan
Moderna US, Inc.Delaware

 EX-23.1 8 exhibit23112312023.htm EX-23.1 Document



Exhibit 23.1

Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1)Registration Statement (Form S-8 No. 333-228718) pertaining to the Moderna Therapeutics, Inc. 2016 Stock Option and Grant Plan and the Moderna, Inc. 2018 Employee Stock Purchase Plan,
(2)Registration Statement (Form S-8 No. 333-230245) pertaining to the Moderna, Inc. 2018 Stock Option and Incentive Plan,
(3)Registration Statement (Form S-8 No. 333-236713) pertaining to the Moderna, Inc. 2018 Stock Option and Incentive Plan and the Moderna, Inc. 2018 Employee Stock Purchase Plan, and
(4)Registration Statement (Form S-3 No. 333-271667) of Moderna, Inc.;
of our reports dated February 23, 2024, with respect to the consolidated financial statements of Moderna, Inc. and the effectiveness of internal control over financial reporting of Moderna, Inc. included in this Annual Report (Form 10-K) of Moderna, Inc. for the year ended December 31, 2023.

/s/ Ernst & Young LLP
Boston, Massachusetts
February 23, 2024



EX-31.1 9 exhibit31112312023.htm EX-31.1 Document

EX-31.1 Section 302 Certification of CEO

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
CERTIFICATIONS
I, Stéphane Bancel, certify that:
1. I have reviewed this Annual Report on Form 10-K of Moderna, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: February 23, 2024
By:  /s/ Stéphane Bancel
Stéphane Bancel
Chief Executive Officer
(Principal Executive Officer)

 EX-31.2 10 exhibit31212312023.htm EX-31.2 Document

EX-31.2 Section 302 Certification of CFO

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
CERTIFICATIONS
I, James M. Mock, certify that:
1. I have reviewed this Annual Report on Form 10-K of Moderna, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
  

Date: February 23, 2024

By:
  /s/ James M. Mock
James M. Mock
Chief Financial Officer
(Principal Financial Officer)

 EX-32.1 11 exhibit32112312023.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

I, Stéphane Bancel, Chief Executive Officer of Moderna, Inc. (Company), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
•
the Annual Report on Form 10-K of the Company for the year ended December 31, 2023 (Annual Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
•the information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: February 23, 2024


By:
  /s/ Stéphane Bancel
Stéphane Bancel
Chief Executive Officer
(Principal Executive Officer)


 EX-32.2 12 exhibit32212312023.htm EX-32.2 Document

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

I, James M. Mock, Chief Financial Officer of Moderna, Inc. (Company), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
•
the Annual Report on Form 10-K of the Company for the year ended December 31, 2023 (Annual Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
•the information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: February 23, 2024


By:
/s/ James M. Mock
James M. Mock
Chief Financial Officer
(Principal Financial Officer)


 EX-97 13 exhibit97modernaincpolicyf.htm EX-97 Document
Exhibit 97


Moderna, Inc.
Policy for Recoupment of Executive Incentive Compensation


Definitions
As used herein, the following terms have the following meanings:
“Board” means the Board of Directors of the Company.
“Clawback Period” means the three completed fiscal years immediately preceding the date that the Company is required to prepare a Financial Restatement.
“Company” means Moderna, Inc.
“Compensation Committee” means the Compensation and Talent Committee of the Board.
“Covered Officer” means (i) any officer or employee of the Company subject to the reporting requirements of Section 16 of the Securities Exchange Act of 1934, as amended (a “Section 16 Officer”) or (ii) any officer who is not a Section 16 Officer but who reports directly to the chief executive officer of the Company. This Policy shall apply to persons who were Covered Officers during the relevant period but may no longer be service providers of the Company at the time the determination to recoup compensation is made.
“Detrimental Conduct” means improper conduct (including, without limitation, unethical conduct, falsification of the Company’s records or knowing violation of Company policy, including the Company’s Code of Business Conduct and Ethics) that causes material financial, operational or reputational harm to the Company or its affiliates.
“Detrimental Conduct Clawback Period” means the three completed fiscal years immediately preceding the discovery of the Detrimental Conduct, or such other longer period as may be determined by the Board or Compensation Committee in its reasonable discretion.
“Excess Compensation” means that part of the Incentive Compensation received (without regard to any taxes paid) by a Covered Officer during the Clawback Period in excess of the amount that such Covered Officer would have received had such Incentive Compensation been calculated based on the financial results reported in the Financial Restatement. For any Incentive Compensation based on stock price or total shareholder return, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in an accounting restatement: (i) the amount will be based on a reasonable estimate, as determined by the Board or the Compensation Committee, of the effect of the accounting restatement on stock price or total shareholder return upon which the Incentive Compensation was received; and (ii) the Company will maintain documentation of the determination of such estimate and provide such documentation to Nasdaq.


“Financial Restatement” means any material restatement, whether required by law or regulation or determined by the Board or the Compensation Committee to be in the best interests of the Company, of financial statement(s), whether in part or in their entirety, included in a filing by the Company with the Securities and Exchange Commission, because of noncompliance with financial reporting requirements under federal securities laws.
“Incentive Compensation” means any cash or equity-based compensation if the payment, grant or vesting of such compensation is predicated on the achievement of financial or non-financial performance goals or metrics. Incentive Compensation is deemed “received” in the Company’s fiscal period during which the goal or metric specified in the Incentive Compensation award is attained, even if the payment or grant of the Incentive Compensation occurs after the end of that period.
“Nasdaq” means the Nasdaq Stock Market LLC.
“Policy” means this Policy for Recoupment of Executive Incentive Compensation.
Policy
It is the policy of the Company in connection with any Financial Restatement to recover reasonably promptly from any Covered Officer any Excess Compensation received by the Covered Officer during any Clawback Period. The Company will recover such Excess Compensation in all circumstances except to the extent the Compensation Committee, in its sole discretion, makes a determination that recovery would be impracticable and the conditions set forth in Nasdaq Listing Rule 5608 are met.
Additionally, for any Covered Officer who engages in Detrimental Conduct, as determined by the Board or the Compensation Committee, in its sole discretion, based on relevant facts and circumstances, the Covered Officer may be required to repay to the Company any Incentive Compensation received by the Covered Officer during the Detrimental Conduct Clawback Period that the Board or the Compensation Committee determines is due to a Covered Officer’s Detrimental Conduct.
Alternatively, the Board or the Compensation Committee, in its sole discretion, may reduce the amount of future compensation, in accordance with applicable law, including, without limitation, any bonus or severance, or the future grant or vesting of any equity award, payable to any Covered Officer by an amount equal to the Excess Compensation received by the Covered Officer during the Clawback Period or an amount equal to the Incentive Compensation received by the Covered Officer during the Detrimental Conduct Clawback Period, as applicable. Any repayment or reduction in future compensation pursuant to this Policy is in addition to, and not in lieu of, any other relief available to the Company. The Board or the Compensation Committee shall have full discretion and authority to administer and interpret this Policy and the Board or the Compensation Committee may take into account any factors it deems reasonable in determining whether to seek recoupment of previously paid Incentive Compensation (other than Excess Compensation, which shall be recouped in accordance with this Policy) and how much Incentive Compensation to recoup from individual Covered Officers (which need not be the same
2


amount or proportion for every Covered Officer), including any conclusion that a Covered Officer engaged in Detrimental Conduct.
This Policy shall be effective May 3, 2023, and shall apply to Incentive Compensation that is received on or after that date.
No Indemnification
Notwithstanding the provisions of the Company’s Certificate of Incorporation, By-Laws or any indemnification agreement, the Company shall not indemnify any current or former Covered Officer against the loss of any incorrectly awarded Incentive Compensation for which the Board or the Compensation Committee in its sole discretion has determined to seek recoupment.

Adopted by the Board of Directors on May 3, 2023
3

 EX-101.SCH 14 mrna-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Description of the Business link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Net Product Sales link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Other Revenue link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Collaboration Agreements link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Financial Instruments and Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Property, Plant and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Other Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Stock-Based Compensation and Share Repurchase Programs link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - (Loss) Earnings per Share link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Geographic Information link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Net Product Sales (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Other Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Financial Instruments and Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Property, Plant and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Other Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Stock-Based Compensation and Share Repurchase Programs (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - (Loss) Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Geographic Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Description of the Business (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Summary of Significant Accounting Policies - Significant Customers (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment and Software Capitalization (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Summary of Significant Accounting Policies - Components of Accumulated Other Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Net Product Sales - Net Product Sales by Customer Geographic Areas (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Net Product Sales - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Net Product Sales - Product Sales (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Net Product Sales - Product Sales Provision Recorded as Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Other Revenue - Schedule of Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Other Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Collaboration Agreements - Merck – Personalized mRNA Cancer Vaccines (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Collaboration Agreements - Vertex – 2020 Strategic Alliance in Cystic Fibrosis (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Collaboration Agreements - Immatics – Strategic Multi-Platform Collaboration to Develop Oncology Therapeutics (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Financial Instruments and Fair Value Measurements - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Financial Instruments and Fair Value Measurements - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Financial Instruments and Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Financial Instruments and Fair Value Measurements - Unrealized Loss Position (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Financial Instruments and Fair Value Measurements - Financial Assets Measured At Fair Value On a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Inventory - Schedule of Inventory, Current (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Inventory - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Property, Plant and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Other Balance Sheet Components - Accounts, Notes, Loans and Financing Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Other Balance Sheet Components - Other Non-Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Other Balance Sheet Components - Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Other Balance Sheet Components - Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Other Balance Sheet Components - Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Leases - Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - Leases - Lease Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - Leases - Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - Leases - Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - Commitments and Contingencies - Indemnification Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - Commitments and Contingencies - Licenses to Patented Technology (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Restricted Common Stock and Common Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details) link:presentationLink link:calculationLink link:definitionLink 9954525 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954526 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Share Repurchase Program (Details) link:presentationLink link:calculationLink link:definitionLink 9954527 - Disclosure - Income Taxes - (Loss) Income Before Provision For (Benefit From) Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954528 - Disclosure - Income Taxes - Provision For (Benefit From) Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954529 - Disclosure - Income Taxes - Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 9954530 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954531 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Tax Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954532 - Disclosure - Income Taxes- Valuation Allowance (Details) link:presentationLink link:calculationLink link:definitionLink 9954533 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward (Details) link:presentationLink link:calculationLink link:definitionLink 9954534 - Disclosure - (Loss) Earnings per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 9954535 - Disclosure - (Loss) Earnings per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Income (Loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954536 - Disclosure - Geographic Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 15 mrna-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 16 mrna-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 17 mrna-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Clinical Services Clinical Services [Member] Clinical Services Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Vertex Vertex [Member] Vertex [Member] Proceeds from sales of marketable securities Proceeds from Sale of Debt Securities, Available-for-Sale Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Accrued liabilities Accrued liabilities Accrued Liabilities, Current Research and development Research and Development Expense Changes in assets and liabilities, net of acquisition of business: Increase (Decrease) in Operating Capital [Abstract] 2018 Equity Plan Stock Option And Incentive Plan 2018 [Member] Stock Option And Incentive Plan 2018 [Member] Expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period OriCiro Genomics KK OriCiro Genomics KK [Member] OriCiro Genomics KK Rest of world Rest Of World [Member] Rest Of World Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Amortization/accretion of investments Investment Income, Net, Amortization of Discount and Premium Payment to acquire business Payments to Acquire Businesses, Gross Description of payment terms Revenue, Performance Obligation, Description of Payment Terms Arpa Garay [Member] Arpa Garay Foreign-derived intangible income and other Effective Income Tax Rate Reconciliation, FDII, Percent Insider Trading Policies and Procedures [Line Items] Number of options, exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Payout percentage Share Based Compensation Arrangement By Share Based Payment Award Payout Percentage Share Based Compensation Arrangement By Share Based Payment Award Payout Percentage Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] 2026 Finance Lease, Liability, to be Paid, Rolling Year Three Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Aggregate intrinsic value expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Inventory write-down Inventory Write-down Proceeds from issuance of common stock through equity plans Proceeds from Stock Plans Returns and other fees Contract with Customer, Liability, Provision For Refunds and Other Fees Contract with Customer, Liability, Provision For Refunds and Other Fees Expected dividends Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Non- Current Marketable Securities Noncurrent Marketable Securities [Member] Noncurrent Marketable Securities [Member] Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) Consideration paid Payments to Acquire in Process Research and Development Preferred stock, $0.0001; 162 shares authorized as of December 31, 2023 and 2022; no shares issued or outstanding at December 31, 2023 and 2022 Preferred Stock, Value, Issued Investment in convertible notes and equity securities Payments to Acquire Notes Receivable Diluted (in usd per share) Diluted EPS (in usd per share) Earnings Per Share, Diluted Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Less: net realized losses (gains) on derivative instruments reclassified in net (loss) income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Net increase (decrease) from derivatives designated as hedging instruments Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Land and land improvements Land and Land Improvements [Member] Collaboration Agreements Research, Development, and Computer Software Disclosure [Text Block] Trading Symbol Trading Symbol Granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price AstraZeneca AstraZeneca [Member] AstraZeneca [Member] Schedule of Reconciliation of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Employee stock purchase plan Employee Stock [Member] Prepaid income taxes Prepaid Taxes Financial Instruments and Fair Value Measurements Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Other Other Assets, Miscellaneous, Noncurrent Schedule of Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Deferred revenue Beginning balance Ending balance Contract with Customer, Liability Schedule of Basic and Diluted Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Derivative Liability, Statement of Financial Position [Extensible Enumeration] Derivative Liability, Statement of Financial Position [Extensible Enumeration] Executive Category: Executive Category [Axis] Number of Shares/Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Exercised (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Level 1 Fair Value, Inputs, Level 1 [Member] Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Schedule of Estimated Useful Lives of Property and Equipment Schedule of Property, Plant and Equipment, Net Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Research and Development Research Tax Credit Carryforward [Member] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Accrued liabilities Increase (Decrease) in Accrued Liabilities Certificates of deposit Certificates of Deposit [Member] Shares available for future grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Cambridge Leases Cambridge, Massachusetts [Member] Cambridge, Massachusetts [Member] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Entity Small Business Entity Small Business Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Collaboration receivable Collaboration Receivable, Current Collaboration Receivable, Current Percentage of Accounts Receivable Accounts Receivable [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] RSUs and PSUs Restricted Stock Units (RSUs) [Member] 2026 Lessee, Operating Lease, Liability, to be Paid, Rolling Year Three Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Depreciation Depreciation Federal research and development credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Audit Information [Abstract] Audit Information Schedule of Common Stock Equivalents Excluded from Calculation of Diluted Net Income (Loss) Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount 2025 Lessee, Operating Lease, Liability, to be Paid, Rolling Year Two Research and development Research and Development Expense [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Anti-dilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Selling, general and administrative General and Administrative Expense [Member] Right-of-use assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Less amounts representing interest Undiscounted future lease payments Lessee, Operating Lease, Liability, Undiscounted Excess Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Leases Lessee, Finance Leases [Text Block] Schedule of Provision For (Benefit From) Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Losses related to indemnification obligations Loss Contingency, Loss in Period Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Lease liabilities - operating (Note 10) Operating lease liabilities Operating Lease, Liability, Current Interest expense for financing lease liabilities Finance Lease, Interest Expense Finite-lived intangible asset Finite-Lived Intangible Assets, Net Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recently Issued Accounting Standards Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Average price per share Shares Acquired, Average Cost Per Share Ministry of Health, Labor, and Welfare of Japan Ministry Of Health, Labor, And Welfare Of Japan [Member] Ministry Of Health, Labor, And Welfare Of Japan Counterparty Name [Domain] Counterparty Name [Domain] Accounts receivable Accounts Receivable, before Allowance for Credit Loss Schedule of (Loss) Income Before Provision For (Benefit From) Income Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Deferred revenue Contract with Customer, Liability, Current Schedule of Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Convertible note receivable Financing Receivable, after Allowance for Credit Loss, Current Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Repurchase of common stock, including excise tax (in shares) Stock Repurchased During Period, Including Excise Tax, Shares Stock Repurchased During Period, Including Excise Tax, Shares 2013 AZ Agreements 2013 Option Agreement And Services And Collaboration Agreement [Member] 2013 Option Agreement And Services And Collaboration Agreement [Member] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Schedule of Options Activity Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block] Vesting percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Options Options Employee Stock Option [Member] Interest receivable Interest Receivable, Current Change In Contract With Customer, Liability [Line Items] Change in Contract With Customer Liability [Line Items] Change in Contract With Customer Liability Total operating expenses Costs and Expenses Maximum Maximum [Member] Total unrecognized compensation cost related to non-vested stock-based compensation Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Inventory Inventory, Policy [Policy Text Block] Right-of-use assets, financing Deferred Tax Liabilities, Finance Lease Right Of Use Asset Deferred Tax Liabilities, Finance Lease Right Of Use Asset Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock-Based Compensation and Share Repurchase Programs Share-Based Payment Arrangement [Text Block] Federal Current Federal Tax Expense (Benefit) Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other non-cash items Other Noncash Income (Expense) Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Business Acquisition [Axis] Business Acquisition [Axis] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Right-of-use assets, financing Financing, Right-Of-Use Asset [Member] Financing, Right-Of-Use Asset [Member] Customer Concentration Risk Customer Concentration Risk [Member] Restricted cash, non-current Restricted Cash, Noncurrent State Deferred State and Local Income Tax Expense (Benefit) Inventory [Line Items] Inventory [Line Items] Raw materials Inventory, Raw Materials, Net of Reserves Cancelled/forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Value added tax receivable Value Added Tax Receivable, Current Title of 12(b) Security Title of 12(b) Security Purchase Commitment, Excluding Long-term Commitment [Line Items] Purchase Commitment, Excluding Long-Term Commitment [Line Items] Changes in right-of-use assets related to lease modifications and reassessments Right-Of-Use Assets Reduced Through Lease Modifications And Reassessments Right-Of-Use Assets Reduced Through Lease Modifications And Reassessments Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Share Repurchases Stockholders' Equity, Policy [Policy Text Block] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Outstanding, non-vested at beginning of period (in usd per share) Outstanding, non-vested at end of period (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value 2024 Lessee, Operating Lease, Liability, to be Paid, Next Rolling 12 Months Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Norwood Leases Norwood, Massachusetts [Member] Norwood, Massachusetts Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract] Schedule of Accounts, Notes, Loans and Financing Receivable Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Wholesaler chargebacks, discounts and fees Contract with Customer, Liability, Provision For Chargebacks, Discounts and Fees Contract with Customer, Liability, Provision For Chargebacks, Discounts and Fees Inventory reserve and capitalization Deferred Tax Assets, Inventory Statistical Measurement [Axis] Statistical Measurement [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Goodwill and Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Down payments to manufacturing vendors Other Prepaid Expense, Manufacturing Other Prepaid Expense, Manufacturing Cost recovery Recovery Of Costs, Capital Expenditures Recovery Of Costs, Capital Expenditures Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Advertising expenses Advertising Expense 2028 Lessee, Operating Lease, Liability, to be Paid, Rolling Year Five Schedule of Significant Components of Deferred Tax Assets and Tax Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Operating cash flows used in operating leases Operating Lease, Payments Common stock, shares, outstanding (in shares) Balance at beginning of period (in shares) Balance at end of period (in shares) Common Stock, Shares, Outstanding Indemnifications Indemnification Agreement [Member] PEO PEO [Member] Down payments and prepayments, non-current Downpayments And Prepayments, Noncurrent Downpayments And Prepayments, Noncurrent Concentrations of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Auditor Location Auditor Location 2016 Equity Plan Stock Option And Grant Plan 2016 [Member] Stock Option And Grant Plan 2016 [Member] Initial research period Research And Development Arrangement, Contract To Perform For Others, Research Period Research And Development Arrangement, Contract To Perform For Others, Research Period Purchase Commitment, Excluding Long-term Commitment [Table] Purchase Commitment, Excluding Long-Term Commitment [Table] Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Number of AFS securities in loss positions Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Total liabilities Liabilities Total current Current Income Tax Expense (Benefit) Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Restricted Common Stock Units And Performance Stock Units Restricted Common Stock Units And Performance Stock Units [Member] Restricted Common Stock Units And Performance Stock Units Gross Unrealized Losses, Total Debt Securities, Available-for-Sale, Unrealized Loss Position Measurement Frequency [Domain] Measurement Frequency [Domain] Property, Plant and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Amount committed for funding Revenue From Grants, Current Funding Capacity Revenue From Grants, Current Funding Capacity BARDA Biomedical Advanced Research And Development Authority [Member] Biomedical Advanced Research And Development Authority [Member] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Investments Marketable Securities, Policy [Policy Text Block] Government debt securities US Government Debt Securities [Member] Gross unrealized losses, less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Selling, general and administrative General and Administrative Expense Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] State Current State and Local Tax Expense (Benefit) Segment Information Segment Reporting, Policy [Policy Text Block] Total current assets Assets, Current National Institute of Allergy and Infectious Diseases member National Institute of Allergy and Infectious Diseases member [Member] National Institute of Allergy and Infectious Diseases member Impairment expenses Asset Impairment Charges Equity investments Equity Securities [Member] Schedule of Entities that Accounted for More than 10% of Total Revenue and Accounts Receivable Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Supplemental cash flow information Supplemental Cash Flow Information [Abstract] Earnings (Loss) per Share Earnings Per Share, Policy [Policy Text Block] Repurchase of common stock (in shares) Stock Repurchased During Period, Shares Concentration risk, percentage Concentration Risk, Percentage Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Schedule of Components of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] State taxes, net of federal benefits Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Issued (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Accounts Receivable, net Accounts Receivable [Policy Text Block] Net cash (used in) provided by operating activities Net Cash Provided by (Used in) Operating Activities Aggregate intrinsic value, exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Changes in right-of-use assets related to lease modifications and reassessments Right-of-use assets obtained through finance lease modifications and reassessments Right-of-use assets obtained through finance lease modifications and reassessments Depreciation and amortization Depreciation, Depletion and Amortization Total Operating And Finance Lease, Liability Operating And Finance Lease, Liability Significant Customers Major Customers, Policy [Policy Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Lease Contractual Term [Domain] Lease Contractual Term [Domain] Less: valuation allowance Valuation allowance at beginning of the period Valuation allowance at December 31 Deferred Tax Assets, Valuation Allowance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Revenue recognized Contract with Customer, Liability, Revenue Recognized Other grant revenue Other Grant Revenue [Member] Other Grant Revenue Net Unrealized Gain (Loss) on Derivatives Designated As Hedging Instruments Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Equity securities without readily determinable fair value, amount Equity Securities without Readily Determinable Fair Value, Amount Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Entity Emerging Growth Company Entity Emerging Growth Company Estimated Fair Value Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract] Total deferred tax assets Deferred Tax Assets, Gross Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Raw materials Raw Materials, Accounts Payable Raw Materials, Accounts Payable Title Trading Arrangement, Individual Title Common Stock Common Stock [Member] Change In Contract With Customer, Liability [Roll Forward] Change In Contract with Customer Liability, Current [Roll Forward] Change In Contract with Customer Liability, Current Investments, non-current Debt Securities, Available-for-Sale, Noncurrent Individual: Individual [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Expiration of statutes Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Income Statement Location [Domain] Income Statement Location [Domain] Investments, All Other Investments [Abstract] Minimum Minimum [Member] Weighted average common shares used in calculation of (loss) earnings per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Area of office space (in sqft) Area of Real Estate Property Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Operating lease liabilities Decrease in operating lease liabilities Increase (Decrease) in Operating Lease Liability Other Deferred Tax Assets, Other U.S. treasury securities US Treasury Securities [Member] Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Deferred tax assets Deferred Income Tax Assets, Net Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Retained Earnings (Accumulated Deficit) Retained Earnings [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Arpa Garay, Stock Options [Member] Arpa Garay, Stock Options Number of participants Number Of Participants Number Of Participants Basic (in usd per share) Basic EPS (in usd per share) Earnings Per Share, Basic Issuance of common stock under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Accounting Policies [Abstract] Accounting Policies [Abstract] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Net deferred tax (liabilities) assets Deferred Tax Assets, Net Total intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Schedule of Reconciliation of Restricted Cash Restrictions on Cash and Cash Equivalents [Table Text Block] Pension and postretirement obligation adjustments Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax Restricted stock unit Restricted Stock or Unit Expense Principles of Consolidation Consolidation, Policy [Policy Text Block] Purchase Commitment, Excluding Long-term Commitment [Domain] Purchase Commitment, Excluding Long-Term Commitment [Domain] Operating lease, liability, current, statement of financial position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Manufacturing Accrued Manufacturing Accrued Manufacturing Technology Technology-Based Intangible Assets [Member] Accounts payable Increase (Decrease) in Accounts Payable Depreciation and amortization Other Depreciation and Amortization Entity Public Float Entity Public Float Property, Plant and Equipment [Abstract] Increase in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount All Trading Arrangements All Trading Arrangements [Member] Due in one year or less Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Less: Accumulated depreciation Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization All Adjustments to Compensation All Adjustments to Compensation [Member] Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Compensation Amount Outstanding Recovery Compensation Amount Total non-current lease liabilities Operating And Finance Lease, Liability, Noncurrent Operating And Finance Lease, Liability, Noncurrent Bad debt expense Accounts Receivable, Credit Loss Expense (Reversal) Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Arpa Garay, Common Stock [Member] Arpa Garay, Common Stock Derivative instruments, assets Derivative Asset Cancelled/forfeited (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Total deferred Deferred Income Tax Expense (Benefit) Consideration for options exercised Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Collaboration Arrangements Collaborative Arrangement, Accounting Policy [Policy Text Block] Present value of lease liabilities Finance Lease, Liability Cancelled/forfeited (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Additional authorized amount for share repurchase program Stock Repurchase Program, Additional Authorized Amount Stock Repurchase Program, Additional Authorized Amount Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Decreases recorded as benefit to income tax provision Valuation Allowance, Deferred Tax Asset, Decrease , Amount Valuation Allowance, Deferred Tax Asset, Decrease , Amount Cancelled/forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Weighted average fair value per share (in usd per share) Share Price Provision related to sales made in current period Contract with Customer, Liability, Provision Related To Sales Contract with Customer, Liability, Provision Related To Sales Financing lease liabilities Deferred Tax Assets, Financing Lease, Liability Deferred Tax Assets, Financing Lease, Liability Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Document Period End Date Document Period End Date Adoption Date Trading Arrangement Adoption Date Percentage of Revenue Revenue from Contract with Customer Benchmark [Member] Finance leases, discount rate Finance Lease, Weighted Average Discount Rate, Percent Financing lease liabilities, non-current Finance Lease, Liability, Noncurrent UK Health Security Agency UK Health Security Agency [Member] UK Health Security Agency Reserves established Loss Contingency Accrual PCV Agreement Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp And Dohme Corp [Member] Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp And Dohme Corp [Member] MRNA Vertex 2020 Agreement Member MRNA Vertex 2020 Agreement Member [Member] MRNA Vertex 2020 Agreement Member Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Provision for income taxes Total provision for income taxes Income Tax Expense (Benefit) Right-of-use assets, financing, net Finance Lease, Right-of-Use Asset, after Accumulated Amortization Vesting [Axis] Vesting [Axis] Number of operating segments Number of Operating Segments Net product sales Net product sales Product Sales [Member] Product Sales Estimated fair value, 12 months or more Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Inventory Inventory Disclosure [Text Block] Less: net realized losses (gains) on available-for-sale securities reclassified in net (loss) income Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Operating leases, remaining lease term Operating Lease, Weighted Average Remaining Lease Term Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Merck Merck [Member] Merck [Member] Money market funds Money Market Funds [Member] Tax credit carry-forwards Tax Credit Carryforward, Amount Operating Leases Lessee, Operating Lease, Liability, to be Paid, Rolling Maturity [Abstract] Estimated fair value, less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Acquisition of business, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Number of shares repurchased (in shares) Treasury Stock, Shares, Acquired Estimated Useful Life Property, Plant and Equipment, Useful Life Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Cash and Cash Equivalents Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block] Schedule of Summary of Valuation Allowance Summary of Valuation Allowance [Table Text Block] Schedule of Changes in Balances of Receivables and Contract Liabilities Schedule of Deferred Revenue Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Right-of-use assets obtained in exchange for financing lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Less amounts representing interest Finance Lease, Liability, Undiscounted Excess Amount Net Product Sales Other Revenue Geographic Information Revenue from Contract with Customer [Text Block] Settlements with tax authorities Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Additional Paid-In Capital Additional Paid-in Capital [Member] Unrealized gains on derivative instruments Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Document Annual Report Document Annual Report Net losses Equity Securities, FV-NI, Realized Gain (Loss) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Cover [Abstract] Prepaid services Other Prepaid Expense, Current United States UNITED STATES Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Fair value recurring Fair Value, Recurring [Member] Grant revenue Grant [Member] Schedule of Other Current Liabilities Other Current Liabilities [Table Text Block] Other non-current liabilities Other Liabilities, Noncurrent Total minimum lease payments Lessee, Operating Lease, Liability, to be Paid Remaining performance obligations Revenue, Remaining Performance Obligation, Amount Embedded Leases Embedded Leases [Member] Embedded Leases Number of development programs Number Of Development Programs Number Of Development Programs Amortization of right-of-use assets, financing leases Finance Lease, Right-of-Use Asset, Amortization Net (decrease) increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Extension term Lessee, Operating Lease, Renewal Term Equity Component [Domain] Equity Component [Domain] Lease liabilities - financing (Note 10) Financing lease liabilities Finance Lease, Liability, Current State State and Local Jurisdiction [Member] Work in progress Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Other Deferred Tax Liabilities, Other Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] (Loss) income from operations Operating Income (Loss) Cash and cash equivalents Cash and Cash Equivalents Cash and Cash Equivalents [Member] Total deferred tax liabilities Deferred Tax Liabilities, Gross RSUs and PSUs Restricted Stock Units (RSU) And Performance Stock Unit (PSU) [Member] Restricted Stock Units (RSU) And Performance Stock Unit (PSU) Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Outstanding and Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Twelve Months of Continued Employment or Service Share-Based Payment Arrangement, Tranche One [Member] Pay vs Performance Disclosure [Line Items] Entity Voluntary Filers Entity Voluntary Filers Number of installments Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Installments Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Installments Statistical Measurement [Domain] Statistical Measurement [Domain] Number of development candidates Number Of Development Candidates Number Of Development Candidates Underlying Security Market Price Change Underlying Security Market Price Change, Percent Royalties Accrued Royalties, Current Current Marketable Securities Current Marketable Securities [Member] Current Marketable Securities [Member] Wholesaler chargebacks, discounts and fees Deferred Tax Assets, Wholesaler Chargebacks, Discounts And Fees Deferred Tax Assets, Wholesaler Chargebacks, Discounts And Fees Outstanding, non-vested at beginning of period (in shares) Outstanding, non-vested at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Rest of world Rest Of The World [Member] Rest Of The World Other comprehensive income Deferred Tax Assets, Other Comprehensive Loss Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Schedule of Cash and Available-for-Sale Securities by Significant Investment Category Cash, Cash Equivalents and Investments [Table Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Performance-based Awards Performance Shares [Member] Accounts payable Accounts Payable, Current Weighted- average remaining contractual term, exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Computer equipment and software Computer equipment and software Computer Equipment [Member] Research and Development [Abstract] Research and Development [Abstract] Restatement Determination Date: Restatement Determination Date [Axis] Corporate debt securities Corporate Debt Securities [Member] Federal statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Number of claims outstanding Loss Contingency, Pending Claims, Number Commitments and contingencies (Note 11) Commitments and Contingencies Geographical [Axis] Geographical [Axis] Award requisite service period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Income Taxes Income Tax Disclosure [Text Block] Deferred revenue Increase (Decrease) in Contract with Customer, Liability Concentration Risk [Line Items] Concentration Risk [Line Items] Property and equipment, gross Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Leases Lessee, Leases [Policy Text Block] Preferred stock par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Weighted-Average Grant Date per Share/Unit Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] License agreement License and Service [Member] PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Weighted- average expected to vest (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Exercise of options to purchase common stock Stock Issued During Period, Value, Stock Options Exercised Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Net (loss) income Net (loss) income Net (loss) income Net Income (Loss) Total current liabilities Liabilities, Current Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Due after one year through five years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five Leases Lessee, Operating Leases [Text Block] Number of extension Lessee, Operating Lease, Number Of Extensions Lessee, Operating Lease, Number Of Extension Property, plant and equipment, net Property, plant and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Repurchase of common stock Stock repurchased Stock Repurchased During Period, Value Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Exercise of options to purchase common stock (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period United States Income (Loss) from Continuing Operations before Income Taxes, Domestic Inventory, gross Inventory, Gross Cost of sales Cost of Goods and Services Sold Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period 2025 Finance Lease, Liability, to be Paid, Rolling Year Two Comprehensive Income (Loss) Comprehensive Income, Policy [Policy Text Block] Capitalized licenses, research and development and start-up costs Deferred Tax Assets, Capitalized Licenses, Research And Development, And Start-Up Costs Deferred Tax Assets, Capitalized Licenses, Research And Development, And Start-Up Costs Name Measure Name Name Forgone Recovery, Individual Name Goodwill Goodwill Additions based on tax positions for prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Underlying Securities Award Underlying Securities Amount Collaboration revenue Collaboration Arrangement [Member] Collaboration Arrangement [Member] Right-of-use assets, operating Deferred Tax Liabilities, Operating Lease Right Of Use Asset Deferred Tax Liabilities, Operating Lease Right Of Use Asset Accounts receivable, net Increase (Decrease) in Accounts Receivable 2021 Repurchase Program 2021 Repurchase Program [Member] 2021 Repurchase Program Stock-based compensation windfall Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent Unrealized gains (losses) on available-for-sale debt securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Operating lease liabilities, non-current Operating Lease, Liability, Noncurrent Schedule of Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity Investments Classified by Contractual Maturity Date [Table Text Block] Total financing lease costs Finance Lease, Cost Finance Lease, Cost Income Statement Location [Axis] Income Statement Location [Axis] Purchase Commitment, Excluding Long-term Commitment [Axis] Purchase Commitment, Excluding Long-Term Commitment [Axis] Schedule of Operating Lease Maturity Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Effect of dilutive securities (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Property, plant and equipment Accrued Property And Equipment, Current Accrued Property And Equipment, Current Europe Europe [Member] 2024 Finance Lease, Liability, to be Paid, Next Rolling 12 Months Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Schedule of Lease, Cost Lease, Cost [Table Text Block] Inventory Increase (Decrease) in Inventories Net increase (decrease) from available-for-sale debt securities Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Plan Name [Domain] Plan Name [Domain] Income tax receivable Income Taxes Receivable, Current Purchases of property, plant and equipment included in accounts payable and accrued liabilities Capital Expenditures Incurred but Not yet Paid Returns and other fees Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Returns and Allowances Aggregate number of shares authorized for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Gross product sales Revenue From Contract With Customer, Excluding Assessed Tax , Gross Revenue From Contract With Customer, Excluding Assessed Tax , Gross Finite-lived intangible assets acquired Finite-Lived Intangible Assets Acquired Weighted- average remaining contractual term, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Trading Arrangement: Trading Arrangement [Axis] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Use of Estimates Use of Estimates, Policy [Policy Text Block] Raw Materials Raw Materials [Member] Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Unrealized (Loss) Gain on Available-for-Sale Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Credit losses related allowance Debt Securities, Available-for-Sale, Allowance for Credit Loss Tax positions for prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Auditor Firm ID Auditor Firm ID Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Right-of-use assets, operating leases Increase (Decrease) In Operating Leases, Right Of Use Assets Increase (Decrease) In Operating Leases, Right Of Use Assets U.S. Government (excluding BARDA) US Goverment [Member] US Goverment Restatement Determination Date Restatement Determination Date Commercial Accrued Commercial Accrued Commercial Income taxes payable Increase (Decrease) in Income Taxes Payable Additions based on tax positions for current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Other liabilities Increase (Decrease) in Other Operating Liabilities Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash, cash equivalents and restricted cash, beginning of year Cash, cash equivalents and restricted cash, end of year Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Variable lease costs Variable Lease, Cost Operating lease costs Operating Lease, Cost Impairment of Long-Lived Assets, including Intangibles and Lease Right-of-Use Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Gross unrealized losses, 12 months or more Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Common stock, shares issued (in shares) Common Stock, Shares, Issued Schedule of Restricted Common Stock Units Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Thereafter Lessee, Operating Lease, Liability, to be Paid, after Rolling Year Five Less: Wholesalers chargebacks, discounts and fees Accounts Receivable, Chargebacks, Discounts And Fees Accounts Receivable, Chargebacks, Discounts And Fees Total Assets, Fair Value Disclosure Estimated Fair Value, Total Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Weighted-average period of cost expected to be recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Comprehensive (loss) income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Intrinsic value of RSUs and PSUs vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Short term lease costs Short-Term Lease, Cost Entity Address, Address Line One Entity Address, Address Line One Tenant improvement allowance receivable Tenant Improvement Allowance Receivable, Current Tenant Improvement Allowance Receivable, Current Clinical Operations and Support Commitments Clinical Operations And Support Commitment [Member] Clinical Operations And Support Commitment [Member] Purchase commitments Purchase Commitment, Remaining Minimum Amount Committed Changes in financing lease liabilities Finance Lease, Principal Payments, Net Of Adjustments Finance Lease, Principal Payments, Net Of Adjustments Collaboration revenue Collaboration Arrangement Including Arrangements With Affiliate [Member] Collaboration Arrangement Including Arrangements With Affiliate [Member] Weighted Average Exercise Price per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Income taxes payable Taxes Payable, Current Net operating losses Operating Loss Carryforwards Financing Leases Finance Lease, Liability, to be Paid, Rolling Maturity [Abstract] Other current liabilities Other current liabilities Other Liabilities, Current Income Statement [Abstract] Income Statement [Abstract] U.S. treasury notes US Treasury Notes Securities [Member] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Derivative instruments, liabilities Derivative Liability Other Other Collaborative Parties [Member] Other Collaborative Parties Other current assets Other Assets, Current Denominator: Earnings Per Share, Diluted [Abstract] Equity investments Equity Method Investments Inventory Total inventory Inventory, Net Inventory, non-current Inventory, Noncurrent Financial Instrument [Axis] Financial Instrument [Axis] Advertising Costs Advertising Cost [Policy Text Block] Pension and postretirement benefit plans: Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax [Abstract] Total Shareholder Return Amount Total Shareholder Return Amount Repurchase of common stock, including excise tax Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Aggregate purchase price Treasury Stock, Retired, Cost Method, Amount Foreign Deferred Foreign Income Tax Expense (Benefit) Non-cash investing and financing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Inventory Disclosure [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Revenue Recognition and Deferred Revenue [Abstract] Retained earnings Retained Earnings (Accumulated Deficit) Vesting of restricted common stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Number of development programs under clinical studies Number Of Development Programs Under Clinical Studies Number Of Development Programs Under Clinical Studies Current assets: Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Deferred tax assets: Components of Deferred Tax Assets [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Total minimum lease payments Finance Lease, Liability, to be Paid Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Loss on future firm purchase commitments Legal Contingency, Future Firm Purchase Commitments Legal Contingency, Future Firm Purchase Commitments Proceeds from maturities of marketable securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent U.S. treasury bills US Treasury Bill Securities [Member] Customer [Domain] Customer [Domain] Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Number of Options (in millions) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Name of Property [Domain] Name of Property [Domain] Schedule of Assets And Liabilities, Lessee Current Assets And Liabilities, Lessee [Table Text Block] Current Assets And Liabilities, Lessee [Table Text Block] Effective tax rate Effective income tax rate reconciliation, percent Effective Income Tax Rate Reconciliation, Percent Present value of lease liabilities Operating Lease, Liability Other external goods and services Accrued Other External Goods And Services Current Accrued Other External Goods And Services Current Description of the Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Vesting [Domain] Vesting [Domain] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive (Loss) Income Total AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount All Executive Categories All Executive Categories [Member] Deferred revenue, non-current Contract with Customer, Liability, Noncurrent Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Pension and Postretirement Benefits Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Plan Name [Axis] Plan Name [Axis] Change in Contract with Customer, Liability Refund [Roll Forward] Change in Contract with Customer, Liability Refund [Roll Forward] Change in Contract with Customer, Liability Refund (Loss) earnings per share: Earnings Per Share [Abstract] Common stock, par value $0.0001; 1,600 shares authorized as of December 31, 2023 and 2022; 382 and 385 shares issued and outstanding as of December 31, 2023 and 2022, respectively Common Stock, Value, Issued Due after one year through five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Total Operating And Finance Lease, Right-Of-Use Asset Operating And Finance Lease, Right-Of-Use Asset Available-for-sale securities: Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract] Repurchase of common stock, including excise tax Stock Repurchased During Period, Including Excise Tax, Value Stock Repurchased During Period, Including Excise Tax, Value Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Financing cash flows used in financing leases Finance Lease, Principal Payments Schedule of Finance Lease Maturity Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Restricted cash Restricted Cash Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Total Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value Finance lease, right-of-use asset, statement of financial position [Extensible List] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other expense, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Summary of Share Repurchase Program Class of Treasury Stock [Table Text Block] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Authorized amount for share repurchase program Stock Repurchase Program, Authorized Amount Schedule of Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Unrecognized tax benefits at beginning of the period Unrecognized tax benefits at end of the period Unrecognized Tax Benefits Income Tax Authority [Axis] Income Tax Authority [Axis] PEO Name PEO Name Other Other Sundry Liabilities, Current Cash flow hedges: Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments, before Tax [Abstract] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Restricted cash Restricted Cash, Current Total current liabilities Operating And Finance Lease, Liability, Current Operating And Finance Lease, Liability, Current Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Tax credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards Takeda Pharmaceutical Company Takeda Pharmaceutical Company [Member] Takeda Pharmaceutical Company Schedule of Prepaid Expenses and Other Current Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost 2027 Lessee, Operating Lease, Liability, to be Paid, Rolling Year Four Investments Debt Securities, Available-for-Sale, Current Deductions Contract With Customer, Liability, Deductions During Period Contract With Customer, Liability, Deductions During Period Service-based Awards Service-Based Awards [Member] Service-Based Awards [Member] Development operations Accrued Development Operation Accrued Development Operation Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total stockholders’ equity Balance at beginning of period Balance at end of period Equity, Attributable to Parent Tax benefit realized from option exercised Share-Based Payment Arrangement, Exercise of Option, Tax Benefit Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Expected term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Noubar Afeyan [Member] Noubar Afeyan (Loss) income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Immatics Immatics [Member] Immatics Level 2 Fair Value, Inputs, Level 2 [Member] Proceeds From Option Exercise Fee Proceeds From Option Exercise Fee Proceeds From Option Exercise Fee Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Outstanding at beginning of period (in usd per share) Outstanding at end of period (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Weighted Average Weighted Average [Member] Schedule of Revenue from External Customers by Geographic Areas Revenue from External Customers by Geographic Areas [Table Text Block] City Area Code City Area Code (Loss) Earnings per Share Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] 2028 Finance Lease, Liability, to be Paid, Rolling Year Five Changes in financing lease liabilities Lessee, Finance Lease, Expense Lessee, Finance Lease, Expense Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Lease term Lessee, Operating Lease, Term of Contract Inventory [Domain] Inventory [Domain] Deferred Tax, Valuation Allowance [Roll Forward] Deferred Tax, Valuation Allowance [Roll Forward] Deferred Tax, Valuation Allowance Share Repurchase Program [Domain] Share Repurchase Program [Domain] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Other revenue Total other revenue Product and Service, Other [Member] Cash (received) paid for income taxes Income Taxes Paid, Net Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Total liabilities and stockholders’ equity Liabilities and Equity Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Other non-current assets Other non-current assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Right-of-use assets, operating leases Right-of-use assets, operating, net Operating Lease, Right-of-Use Asset Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Foreign Current Foreign Tax Expense (Benefit) Finance lease, liability, current, statement of financial position [Extensible List] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Arrangement Duration Trading Arrangement Duration Schedule of Other Assets, Noncurrent Schedule of Other Assets, Noncurrent [Table Text Block] Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Inventory, Current [Table] Inventory, Current [Table] Weighted- average remaining contractual term expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Other Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Loss on equity investments, net Income (Loss) from Equity Method Investments, Net of Dividends or Distributions Remaining authorized at end of period Stock Repurchase Program, Remaining Authorized Repurchase Amount Termination Date Trading Arrangement Termination Date Common stock, shares authorized (in shares) Common Stock, Shares Authorized Fair Value Debt Securities, Available-for-Sale Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Award Timing Disclosures [Line Items] Additional paid-in capital Additional Paid in Capital FFF Enterprises FFF Enterprises [Member] FFF Enterprises Inventory [Axis] Inventory [Axis] Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] 2027 Finance Lease, Liability, to be Paid, Rolling Year Four European Commission European Commission [Member] European Commission Number of years Lessee, Operating Lease, Building Project, Years Lessee, Operating Lease, Building Project, Years Decrease in the right of use of the asset Increase (Decrease) in Operating Lease, Right-of-Use Asset Increase (Decrease) in Operating Lease, Right-of-Use Asset Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Income Taxes Income Tax, Policy [Policy Text Block] Prepaid expenses and other current assets Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Insider Trading Arrangements [Line Items] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Balance at December 31, 2022 Balance at December 31, 2023 Provisions related to product sales (Note 3) Contract with Customer, Refund Liability Aggregate intrinsic value, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Impairment charges Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Following Twelve Quarters Share-Based Payment Arrangement, Tranche Two [Member] Cost of sales Cost of Sales [Member] Deferred tax liabilities: Components of Deferred Tax Liabilities [Abstract] Lease Contractual Term [Axis] Lease Contractual Term [Axis] Unrecognized tax benefits, net Unrecognized Tax Benefits, Net Unrecognized Tax Benefits, Net Change in Contract With Customer Liability [Table] Change In Contract With Customer, Liability [Table] Change In Contract With Customer, Liability Auditor Name Auditor Name Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Schedule of Financial Assets Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Weighted- average exercise price per share, exercisable (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Deferred income taxes Deferred Income Tax Expense (Benefit), Net Deferred Income Tax Expense (Benefit), Net MTC South, MTC North and MTC East MTC South, MTC North and MTC East [Member] MTC South, MTC North and MTC East Entity Central Index Key Entity Central Index Key Compensation costs Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Finished goods Inventory, Finished Goods, Net of Reserves Non-deductible items Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent Income Tax Authority [Domain] Income Tax Authority [Domain] Compensation-related Employee-related Liabilities, Current Upfront payment Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product Name Trading Arrangement, Individual Name Total other comprehensive income (loss) Other comprehensive (loss) income, net of tax Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Finance lease, number of properties Finance Lease, Number Of Properties Finance Lease, Number Of Properties Total revenue Net product sales Revenue from Contract with Customer, Excluding Assessed Tax Amendment Flag Amendment Flag Operating leases, discount rate Operating Lease, Weighted Average Discount Rate, Percent Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Total product sales provision Contract with Customer, Liability, Provision Contract with Customer, Liability, Provision Due in one year or less Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Acquisitions Business Combinations Policy [Policy Text Block] Number of campuses Operating Lease, Number Of Properties Operating Lease, Number Of Properties Finance leases, remaining lease term Finance Lease, Weighted Average Remaining Lease Term Leasehold improvements Leasehold Improvements [Member] Diluted (in shares) Diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Award amount Revenue From Grants, Maximum Award Revenue From Grants, Maximum Award Operating expenses: Operating Expenses [Abstract] Operating lease liabilities Deferred Tax Assets, Operating Lease, Liability Deferred Tax Assets, Operating Lease, Liability Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additions Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Share Repurchase Program [Axis] Share Repurchase Program [Axis] Manufacturing and laboratory equipment Manufacturing and laboratory equipment Equipment [Member] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Operating cash flows used in financing leases Finance Lease, Interest Payment on Liability Vested (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Construction in progress Construction in Progress [Member] Thereafter Finance Lease, Liability, to be Paid, after Rolling Year Five 2022 Repurchase Program 2022 Repurchase Program [Member] 2022 Repurchase Program Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Clinical trials Accrued Clinical Trials Accrued Clinical Trials Non-PEO NEO Non-PEO NEO [Member] Supply and Manufacturing Agreements Supply And Manufacturing Agreements [Member] Supply And Manufacturing Agreements Adjustment to Compensation: Adjustment to Compensation [Axis] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Basic (in shares) Basic weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Property, plant and equipment Deferred Tax Liabilities, Property, Plant and Equipment Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Furniture and fixtures Furniture and fixtures Property, Plant and Equipment, Other Types [Member] Revenue: Revenues [Abstract] Inventory, firm purchase commitment, loss Inventory, Firm Purchase Commitment, Loss Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Concentration Risk [Table] Concentration Risk [Table] Expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Name of Property [Axis] Name of Property [Axis] Down payments for materials and supplies Other Prepaid Expense, Materials And Supplies Other Prepaid Expense, Materials And Supplies Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] EX-101.PRE 18 mrna-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 19 image_0.jpg begin 644 image_0.jpg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end GRAPHIC 20 mrna-20231231_g1.jpg begin 644 mrna-20231231_g1.jpg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�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end GRAPHIC 22 mrna-20231231_g3.jpg begin 644 mrna-20231231_g3.jpg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�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n =!1M'I110 ; M1C%(% XI:* # ZXHP,YHHH ,#THHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH *"!110 4$9HHH 0**-H]*6B@ MHZT44 ! -)M'4TM% "!0*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K(\>^,]&^' M?@S4O'/B!W6STNS>XN/+7+%5'0#U/2M>L#XI:AX*TOX>:Q>_$9%;0EL7&JAX MV<>2>&R%Y/7MS0!YC\+_ -J[QO\ $#4]$NM4_9YU_3?#WB215TGQ!YTA_#3]KKX@>'_BS\5-:\%KXDN8;_1=6L[I8;>]B&_Y M'=E(R-_R\@ A@><"@#WGX5?M1Z%\2O#_ (DFO/">H:'X@\)V\DFM^'-34+-% MM0L"/56QP?<>HKBO#7[=?BO7?",?Q*/[,?BA_#+*SR:M8S13!(U)W/L!W8&# MGBJ_@[1_@$-<\>>)/AY\9K_Q;XDN/!MPFK7$MTLZ"%8BJ;G10NX8 R3@5F_ MLE?M"_!;XOC'QSI:3:?;7 NM,>X5IG)9B(_+ZDMG&,=Z /6/$7[3/A MB+X7:/\ $SX<>']2\6+XAG$&CZ?I,6999/FW!L_&_ MA=JVM:]H,RQ6=C82*S7N5W,_/$:*",LQ[@=32I^UMXPNO#6EM8?LX>*I/$VJ M75Q"GAV2,1M$L.T/,\CX"1Y=0&; )/7IGG?V:;>W;]M3XS79B7S%FM463'(4 M@9'Z"NI_:B^.7BKX=^*?!_PS\$7.GZ7?>,+YH)/$>J1[H;")<9(7(#.2> 2 M/QR #1^"W[4-K\3]5\0>"O$?@/5/#_B?PS%YNI:%,!-(T9 PT93[^<@>^Y>H M->;> /VU_C1XP^(WB;2;+]G;7-0L=-U9;*.UM-BR:=M)#>?G^,GD@< #'N<_ M]FM[;1_V^/B!9:A\15UZ9O#-K'_:]Q+$&NI=MKN50F%^4Y4*,D!> MI$>0TKGA<@@_0C/45>^"?[3&D?%6[U MCPOXC\*WWA;Q%X=19-8T75\*\49&1*#_ !)CG/H0>A!KY_U-M!\"?MG>*[SX ME?$[6/">F^,+&WO/#_B#3[A8H+J/ /EL[*0 ,X[8*\]179Z3X&^"?B_Q'XQC M^%WQRU#Q9XVU;X?W^G"62^6=(XW3:A9T4*&#E<9.<$T :FH_MA^*?B-I&M7O MP;_9^U[Q'X;M8KBWE\0+<101RX4AFB5R#(![9-6_^":K%_V6[%RNW.M7QVGM M^]-8G[,?QY^#OAC]EZW^'/B;Q;I^@Z[HNFW%EJ>DZE,()EN!OR=K8SN/<5M_ M\$V)$;]EVS96R#K5]@C_ *[&@#4_X*$?\FF>*#CM:_\ I1'7*:1^V5XL^'?@ M30_$GCC]G+Q)IWA(6=M;MX@D>,LHVA1(T(.Y5/;=C.1CJ*ZK_@H.0?V3/%&/ M2U_]*(ZY/X\?'WX/7/[(-QX/TWQ9I^L:MK/AN'3M-TFPF6::2Y9%481]!7<$'H2 <>^!W%7)O MV@]-F_:'7]GK0-!FOKJWTO[;K&H1R@1V (RJ,.I8@H?HXKQGXU?!/7=!_8K\ M(^+;JX6Q\6?#>QM]3MYI6VLN,&2W)]<;>/[T8 ZUUG[ OP_U_P#X0W5/V@OB M$/,\2>/[UKV5F3!BM02(U'H&Y-6U.UT;2[C6+^39#:P--,WHJC M)_05X?X%_;'\7^/9=/\ $FD?LZ^(G\(ZIJ2VEGXBAFCDQF7RO->)3N6,-U8C M QUKVKQ!=:98:'?7VN#=9PVLCW2[=V8PIW<=^,U\;W?C+PE^SGKNC^//V5OC M5!KGAOQ!K<<-Y\/GF\UE\UOF:!?O1D>A (/4GI0![G\6/VI=<\ _%^+X->#_ M (0:EXGU2721J&VPNHX\1YP?OXZ<=^]:/P@_:B\/?$OQI<_"_P 1>$=6\*^* MK6W\]M#UR$*TL7]^-APXQSQVY&<''G/C+QIX4\$?\%&+'5O&'B&TTRVE\!-# M'<7LPC0R-)D+D]S@_E57Q'XS\._'#]N?PCJ'PHG74K7P9H]Q)XBUJQ7=%M?) M6#>/O$'ICC,A Y!P ;NN?MS:[H6C?\+(NOV>/$B>!A:])^*G[0WP\^$_PLM_BQKMW+<6-\L0TN&V7,MX\J[HT1?4CG MV /I7R[\7/C)XN_:"_9B\;?$77/B+9Z#I5K>?8M+\$V:QB:;9/$!Y[M\S'!S MM0 97TXKH/CQ*MG\$/@G\5C!_:6@^%+VTD\00VJ^;Y:M#'B1@/[I4CURX]: M/6OAC^TM\2_&/C32_#WC']FKQ)X=L=:WBSU:[PT<96)I )@!F,D+@ X.3BH? MB!^UU=Z;\0]0^%WP>^$>L>-M4T=5.M/IK*D%F3T1G;C=UX[D$#.#77>&OVF/ M@-XRO]-T?PM\4=)O;S5FV6-G;W :9VP6QLZK@ YR!C%?,_PS'AOX(Y=3TV>&[2WMM0MY"2IWNA&Y1@#)&0>.AH ]T\+?MD?#W7? MA%XD^*6KZ3J&ES>$6,7B'0;N+%U:S;MJQX_VF.T'CG.>E1?"G]ISQ]X\U_1; M;Q+^SSK^B:3XDC\W2==::.>#88S(AEV?ZKM<9X/T[]C_ $6Q^(/B M&X^*=UXJL=2LK=/&EY.9O@%\=?"/ MPG^$?QEA\<^"/%DSQPZ3YXGN-&7C#AQTC&<]N%;@$ D ^OE)(YI:1:6@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BO;.UU&UDL;ZV MCFAE4K)%*@967T(/45+10!RWA?X)?"/P3K+>(_"'PTT/3=0;.Z\LM-CCD.>O MS 9J]XR^&_@'XAVJ6/CSP;IFL0QMF./4K))@A]MP.*VZ* .)UWX;^"? GPM\ M1:7X \%Z;I<2V!A1S7E?[$OP%^&.H_ 'PWXC\9?"C29-.:Z^B@#-TSP=X5 MT;6;[Q%I/AZSMK_4B#J%Y!;JLEP1T+L!EL>]0^,OA]X(^(FGQZ3X[\)Z?K%K M%)YD<&HVB3*K?W@&!P:V** .7T[X)_"+1]=M_$^D_#71+;4;6,1VU]#IL:R1 MJ.@# 9 IWB?X,_"?QKK,?B+Q?\.=%U._AQY5Y?:;')(N.GS,,UTU% &+XK^' M/@/QUI<>B>,_!^FZI9Q8\JWO[-)43Z!@<4WP;\,_A]\/('MO G@G2]'CD^^N MFV*0[OKM K:;'(Y^I(S6KX9\(^& M/!>DKH7A+0;33;.-V=;6QMUCC#$Y)VJ ,DUHT4 5=7T72M?T^32=;TV"\M9E MVS6]S$'C<>A!X- =/;2O!'A33] M)MF;)@T^T2%2?7"@5KX&$]/L]+8$-I]O:(L)!Z_(!CFM>B@#D_#GP)^ M#/@_7!XE\*_"[0=/U ,6%Y9Z7''(">IW 9[FKGC/X5?#;XC+&OC[P)I.L>3_ M *K^TK%)MOTW XKH** ,/1/AK\/O#>A3>%] \$Z79Z;<+B:QM[%%BD'HR@8/ MXU5\(?!CX3> =2DUGP5\-]%TJ\FR)+FPTV.)V!Z\J :Z:B@ QT%%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%&:,]Z "BBB@ HHHH **,T4 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%9?C;QMX1^&WA#4_B!X_\ $=GH^AZ+8R7FK:KJ$XB@M+>-2SRR M.>%55!))X % &I17@NI_\%2/^"=&D? RX_:6O?VTOAU_P@EOJ#6#>)8?$T$M MO+>*H8VT6QBTTP4AO+C#/CG&*W_V5/V\?V._VX?"]YXP_9/_ &B/#/CBRTUU M75%TB^_?V);.WSX) LL(;!VET4-M.,X- 'K=%?,6K_\ !:+_ ()3Z%\:!^S[ MJO[>?PYA\5?;/LC6?]N*UO'<;MODO=@&V20-\I1I P;@C/%?3<,\-Q$L]O*L MD;J&1T;(8'H0: /R1UO_ (/)O^"96A:S>:'>_"GXM--974D$C1Z#9;2R,5./ M]+Z9%>^?L+?\''G_ 3&_;V\?V/PA^'_ ,2]4\+^+=4D\O2]!\;:;]C:\D[1 MQ2AGB=SV4/DXX'2ORQ_X-$/A-\+/BS^VW^T1I_Q3^&OA_P 2V]GH$,EK!X@T M:"\2%SJ4@+()E8*2.,CG%=!_P=\?L1_L:_LHV?PC_:4_9H\%^'_AS\0]<\27 M5I>:3X.LX].34+:")9AJ A@"JDL,WE(95 +?:%R25& #^B#:37PK\4O^#A+] M@[X*?\%!Y/\ @G/\63XFT'Q/#JT&G3>)KZQ@71HIYH5DB#S>=O56+JFXI@,W M.!S7T]^Q3XT\:?$?]C_X7>/OB-"T?B#6OA_I%[K2/G<+J6SB>7.>^XFOYF?^ M"N_[(WCW]NS_ (.0/B-^RS\+]3M;3Q%XGNC_ &/)>-MB>XM]#^U)$S?P[S#L MW=%W9/ H _JRBEBFC66&165E!5E.0P/0CVIMW<):6DMW*"5BC9VV^@&:_&/_ M (-P_P#@M/X]\0>(&_X)+?\ !0FXN](^*G@F232O"&IZ]NCN=2CMLJVG7)?]>LG_H)H ^1?^"='_!;+]EG_@IC\=/'7P"^ M!7A#QAI^L?#^U>?6)O$6GP0P2*MU]F(B:.9R3OYY XK[&S7\\_\ P:&_\I-O MVGO^P+?XES]SV%[:ZE8PZC8W"S07$2R0RQME75AD,#Z$&O MY,/%/[-?Q^_X. /CU^UU_P %#/!\MY_9?P_TIM4\.PO;DB]2-BMIIR9 Y%C; M32$#+*0@(^<9_;'_ (-?/^"@]S^VS_P3;T7X?^.M<-UXU^$1C\,:PTTFZ:YL M8T_T"X;)W$^0!$S'DM"6)RU 'Z1T444 %%%% !1110 45ROQ%^-OPH^$DMK! M\2?'5CH[7BLUJMXQ7S .I& >E9W@_P#:<^ 7C_Q!!X5\&?%/2]1U&YSY%I;R M$N^!DXX]* .[HILVT>=T6?7C!_ G!ZU+XC\5>'O".G?VOXEU6*SM? M,5/.F.%W'H*Y_K6%]C*KSQY5>[NK*SL[O96>C[/15 M!)(^@4G\*TJ5J-.*HKI/A?XQ:6US(VV.&^ M$EFTC>B_:$3(HQX@ELS=QZ M;Y;[FA'5\XVX_'- &]10#D9HH **** "BBB@ HHHH **** "B@G S6%JGQ+\ M#:+XVT_X<:IX@CAUO5+=Y]/T]HW+31KGI% &[1110 4444 %%([K M&N]SA0,D^E<5X*_:-^"GQ'\<7GPY\#>/K75-8L(VDNK:UAE*JJL%8B3;Y;8+ M ':QH [:B@'/2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHKF/$'QE^&?A;XB:/\ "?7_ !7#;>(M>B>32-,: M)R]RJABQ!"E1@(W4CI2O5IRG"#<8I.32;23=DV^B;:2OUT.FHKEOBI\:OA?\$M(L]=^*7BZ'1[3 M4-0CLK.::&1_,G?.U,(K$< DDC R2!73QR)*BR1L&5AE2.XHYHWM<)8?$4Z M,:TH-0E=1;3L[6O9[.UU>VUU<=14-_?VFF6'E7C!N$6DY6?*F[V3>R;L[)[V=MCJ**,U#J6HV6D:=<:MJ4XBM[ M6%IKB5@<(B@ECQZ &F914I.R)J*Y_P"&?Q3\ _&+PK%XW^&OB./5=*FD>.*\ MAC=59E.&&' /!]JB^*GQ@^&_P2\-?\)C\4O%,.CZ;YZP_:YHW9?,;HN$5CSC MTJ>:/+S7T[G2L#C98SZJJ4O:WY>3E?-S=N6U[^5KG2T4W>*Y7X?_ !S^%'Q4 M\1Z]X2\ >,H-2U'PQ=+;:Y;10R*;:1BP RR@.,HPW(6&1UIN44TF]S.GAL16 MI3JTX-Q@DY-)M13=DY/9)MI*^[=MSK**:TB*NYCQ_*O)?'_[>/[(OPQUU_#7 MC#XWZ7'?1-LFAL89[SRF_NN;>-PI'<$@CO2E4ITU>32]3HP.6YEFE1T\'1G5 MDM;0C*3MZ139ZY17+_#/XT_"CXRZ0=<^%OC_ $O7+=?]8;&Z#/%[.GWD/LP! MKJ V>E.,HR5T<]?#XC"UG2K0<9+=--->J>J"BN9^(7QB^&WPIN='L_B#XJAT MV37M16PT=98W;[3<,0!&-JG!.1UP/>NFSQFCF5[!/#UZ=*-2<&HRORMII.SL M[/9V>CMLPHKF;'XR?#34OB=>?!JR\5PR>)M/M%NKS21&^^*%E5E8MMV\AE/! MSS4OQ%^+'PV^$>@MXF^)GC;3=#L5X6;4+I8_,/\ =13\SM_LJ"?:ES1LW@5[B-%8GV)KV"*6.>-9H7#*RY5EZ$>HI0J4ZFL6GZ&F.RO M,\KJ*&-H3I-[*<91;]%)(=17*^+OC=\*_ GCS0OACXM\8V]GKWB8R?V+ISQR M,UQLQGE5*H.<#>5W$$#)!QU(8'H:I2C*Z3V.>IA\11IPG4@XJ:O%M-*2NU=- M[JZ:NNJ:W0M%%%,Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ KY_P#^"K?_ "C/^/7_ &2?7/\ TBEKZ KY_P#^"K?_ "C/^/7_ &2?7/\ MTBEH _&__@UO_P""0O[''[:O[(^L?M$?M;>$;KQ]_9WC"\TK0?".M7TG]DZ: M!%"TEPL", TTA*@L>@117CG[_P#!PEX:_8=_9,^(OB3X9_#_ M ...D:7!K5GX3U-XI8--OGEBN[-6).8V>U=E!SM#C'2OT%_X,U!G_@EOKP_Z MJAJ'_HBVKY__ ."N@Q_P=E?LR@?]"_X=_P#2W4Z /9O^"R7_ ;S_P#!-7X5 M?\$L?B)\0OV=_@;:^#_%WPS\*2:]I?B:WO)I;F]6T DFBN6=F\[S(ED7) (< MJV>"#] ?\&P?Q]\<_M!_\$?OA_JWQ$UBXO\ 4/#M[J&@1WEP^YWMK6X9( 22 M2=L6Q>?[M>T?\%K!_P :D?VCC_U1_7/_ $D>OE__ (-$/^4.FB?]CSKG_I10 M!^(/_!(;X%?\%6OCG^TE\7=._P""4_QI7P;X@TVW:?Q5,VNI8&\M#>2"*(,\ M;ACYF3@[0.YKM/V:/AA_PL?_ (+(Z/\ !/\ X.(OB?\ $2'7M.O(;728=5>?^ M#UJT'_4R3?\ J,S5]S?\&RG_ 5OG_;Y_93_ .&=OC?KF[XN?"BUCL-6-W)B M?6=,4[(+T@\F10!#+W+J'XWX'PS'G_B-:L\_]#)-_P"HS-0!]7?\''__ 1' MU?\ :2T1/^"BG[$6DS:3\;/ 8CO]5AT',-QXAM[?#I-&4Y^VP;048?,ZKLY( M3'H?_! /_@MMI7_!3/\ 9YO?@Q\==4@L?C=X'TAX_$5I)B-M=M478-0C3 P^ M<+*@'ROSP& 'Z8X'I7X*_P#!P;_P28^,7[%/QV7_ (+6_P#!,Z"ZT6^T74O[ M4^(NCZ#'M^P2'Y9=26)3\]M*&*W,8!7#L[#:9& !R/\ P:&G_C9M^T]_V!;C M_P!/5?:?_!V!^WY/^R7_ ,$X+KX%^"-::U\6_&:[.A0O#)MDMM(4![^3_@:; M;?Z7#D$%:^#O^#+OQ+J'C/\ ;H^/7C'54C6ZU;P/'>7*PJ0@DEU-'8*"3@98 MXY-:W[0^CVW_ 7T_P"#E^S^ &%UCX.? V22V\1M&WF6MU::=+F\7<."+F]* MVH(/*9=<@&@#HO\ @AM_P6^_X(X?\$SO^">N@_L]^/?'?B8^,-5NKC6/'K6O M@>YFCEOY\*8MX&)$CA2*('H0F>YKYV_X)&_\%%?V5?V*_P#@O=X@B_9I\=7S M?L\_&SQ VDV9U+3Y+,Z4]ZPELU>*3&U+>\D-MYA)_<-YAY! _>(?\$2/^"1; M#G_@G/\ "3_PC;?_ .)K\\/^#E+_ ((=_LR^"/V"9OVIOV%OV:_#7@?Q#\+M M235?$,/@[1TM6OM)8A)I&$8^8VYV39_A193VH _;/=S@4M?(?_!#;]O&#_@H M;_P3C\"?&O5-6%UXFTVS_L+QGN?,@U.U54=W]Y$V2^_F9[U]>4 %%%% !111 M0!\G_M[W?@RQ_:$^$][\0S;_ -AQWDC:I]L3=%Y/F)NW#N*]"^%'C/\ 8>U3 MQU9V7PB'AG^WGW?8_P"S[/;+]T[L''IFN._;+TK2]<_:G^#.D:UIT%W:W&K, MEQ:W,(DCE4R)E64\$>QKWW1/A#\*?#6I1ZSX<^&F@:?>19\JZL]'ABD3/HRJ M"* /,?@]\2?@3X!\%?$CQKX$TG7(K+P_X@O;CQ,MVWF22W*$F0PAG.5X.,D5 M)/\ MX_!Y?[)GL/#_B>^M=4$0DOK#1C+!9/)C;'*X;[_ ",JFXC/->/_ ^ M/[.7[1N1_P S!J__ +/7T!^R3HFDV'[,_@VSM-/A2-]%AE=0@^:0_,6/J2>< M]: ,WQ]^V=\.O _C>^\ V7@_Q3X@O-)C1M8?P[I(GCL=P# 2%G4YP>0H..G7 MBLG]H']M?PO\+?AQHGBWPKH=_J5UXD,3:=&UA(JQ1,WS-)D !\!@L>=S,/0$ MCE_C%X/U+P;X^\5_M&?LQ?%W2;75M.1CXX\+ZA<*;>Y,*?-O5CF-RHX/&3R& M&XYQ_P!I_P"*=K\6?V1/ /Q3.E#38;GQEIT]W"?N6^WS0YS_ '<]#[T >]?! M#X[Z+\<-.OKW1O"/B'2?[/DC25?$&F?9FE+@G*#<=P&.3VR*Z#X@>+K3P/X. MU#Q3>D!;.W9U']YNBC\20*FT3Q/X;UH+::1K]C=3+;I*T=M=([+&>C$ D@'U MKRS]HJ34_B7XQT7X#^'+SRFN6^VZK-MW"*-0=NX>G5L=SMKQ>(IDV"IX[,(4ZCM!7E-]HQUD_NT7FT<9X+TS7_A'J?A MKXU^([J3R_$UU*NN*_2%)FS&Q_#YCGITKT;]KLY^#K-G_F*6W_H1K%\3?LX_ M%7Q%X;DT#5/C+)?6RQ_N[.:U 0LH^4>W-9>LZQK7Q._94N+(PO)JWARXCBU" MW(RY\A@"3[[.3_NFOS2-+%Y7D^-RN="<(U*,IPYG%N4XQ2JVY92^+2=N[E96 M/N)5,/C\RPN/C5C-PJQC+E32492;IWYDMM8W[*)[OH/_ " K+_KUC_\ 017E M?C1?^,N_!P'_ $#+K_T1/75_#OXQ?#WQ-X0L]0MO%NGPM':HMS;W-TDM>C7/ MP8^%=W9?8)_ 6FF+;C"VP4_F.:\UT77H?V??C7KEAXQW6^A^*)%N;'4F4F-) M 6^4GMC>0?3Y3T-=!\:--^#WQ"T&/7M:^)4-N+.WD:S:PUJ%5F8C@=]W('2O M.RVI@89?BJN(I0J8M3G[2-1QB[2E:"I\KC96:VU.['0QA>$O"^D>#-!A\.Z%$T=I;Y$,;2%MH)SC)^M:5> M:_LE3S7'P0TV6>5G8W%Q\S-D_P"N:O2J^UR7%4L;D^'Q%*')&<(R45M%-)I; M+;;9'RV:8>IAN_J%%%%>H< 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<_\5O'$/PU M^&VM^/IX1(-)TV6Y6-C@.RK\J_0M@5T%<]\6? \?Q+^&FN> 99?+_M;39;=9 M#T1F7Y2?8-@T >!?L@?L[:#\4_#$?[2OQZM5\2>(O$\DES;+J2B2&SM][*BJ MA^7D#(XP 0 !S7L'BK]E[X!^,8HTU;X6Z/')%(KPSV-FMO(C Y!!C KQO]D/ M]I+PU\)_#2?LS_'_ %2'POXA\+S26L,VK2"&"Y@WED(E;"]#@$D!EVD$UZUX MV_:X_9T\!VGVC5?BUHMS*V!%9Z7?)=3.2>!LB+$9]3@>] $WQJ_:.^'/P!AL M=-\1K?7^IZA\FF:'H]OYUW?\% ;/QK\5;F&STO6O!\=O MX:U74"%M[>8-\\>]OE1CSR2/O@9YJ#]MKQMX ^)&O_#_ .'/PVU>SU?QA_PF M%M=VLFES+,]G;*&\PNZ$[0Q*':3R$R>@H ]<^-/[3G@7X+:Q8^$KO2M4USQ! MJ4>^QT'0K437#IDC>Q#P+,IEM+A9%#9Z M94D9H [?XF?ME?#[P#XSF^''AOPMKWB[7+-,?L0>+_!GP MS\6_$7X<_%#6;/2_&+>+Y[F:35)EA>[M2J[-K/C< =[X':0$<PW6F:+X5DM_%&J6+!K>YD;A(]X^5V#;#P?\ EF?[IH Z>S_; MY\!^(+;43X(^%?C36[K2M0FM;ZSL=+C9HECQF4L)"NPDD*,[B5.5 P3V7AC] MJ/X3>*O@M>?'>SU.>'1=-C.[RVOY9&*) CS M;%;(^YABF#V(!Z"@#U3X7_M>Z#\2O$VG^'9?A3XPT2/65+:/J6K::BV]RH7= M]Y';:2.1D<^M>N[CZ5\J?#'QMXZ_9N^+OA/X'3_%#3O'G@WQ073P[-'<)+>Z MJ_[#%O!%\6 M/CDD4*JJ_$6Y555<87S[GCZ4 >D^#/VI/A?XW^#M]\:]/EO8=-TOS$U*UGM? M])MI4QF(HI.6Y&,$YR*P/!O[:G@WQ%XWTOP/XG^'/BKPO+KT@30;KQ!IZ1Q7 MK'HH*NQ5CD8!'?&:\S^ 7Q T;X1>"OCEX[U?1_MMKI/CFZG6Q51MD?@*/0?- MCGM63\9=7^+/B_Q'\#OB'\2?$>C"WUCQ_IEQIF@Z/:_+:QO+$X9YF):1MI . M,+[4 ?0WQO\ VE/A]\#)+'2=>@U#4]8U5B-,T'1;;SKJX]PN0 ON2/;->&Q? M%F3XL?MT> +^Y^'VO^&YK/0;N*2S\06JQN^=[!TVLP9<=^.>U;7B_5O#_P . MO^"B=EXP^*5Y;VFEZMX+:U\-ZE?.$@ANPZ;AO;Y4)42+UZR#UJQ\0_$.@>(O MV^/AQ/H.MV=]''X;O%DDL[E) IR_!*DX- '"M7_ &AV\ ZMJ'B26^LU MN=*L9%U&U=BT>R6Z0\JA V*>F2 <-CUG]G'P#X \,?&'Q9XCT+X^1^,M>U:S MA?7H[6"V6.(AL([?9@(U<\C& >22.UZAJ%GI5C-J>HW,<-O;QM)--(VU M40#)8GL *\)O_P#@H+\._-N-0\+_ P\9ZYH=G(R7'B+3-)5K7@_,REG!91W M.!7:?M<:#XH\3_LV^,=#\')(U_-H[^5'#R\B*RM)& .I:,.N.^<5S'[-OQV_ M9]M/V;]%N(O&VAZ;:Z5I"1:G8W5Y'');R*N'5HR=Q)()'!W9XSF@"#]H?]IW MPE>_LJZIX]^&HU/5[?Q!I=U8V=]I-KN^P2-"RF2?6?!RUDNOV0_ MCIXPT?3Y+3PUK5YJMQX9M74JJ6^V3[H] "J\<94CM7T9^R8H_P"&;/!?_8"A M_E0!Z&OW:6CI10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 5\F_M)+G_ (*=?!'_ + ]]_Z+N:^LJ^0_V^-2F^#' M[4WPB_:BUVPFD\-Z-/-INK7$,9;[-Y@D^8@?[$CD>NPBN7&:44^SB_Q1]MP# M&57.ZE"/Q5*&(A%=Y2HS48KS;T7=GUY7RK^PM_R=)^T%GMXVD_\ 1LM>NZC^ MV5^RUI?A!O&\_P >O"\EB(?,40:Q$\S\9V"$-YA?_9VYSU%?-W[+/Q5'@'X; M?'3]N#7=,FL=%\0>(+B\\.PW2[6N09E"I1E%U?8TH:HZT6H*]KNR;:6W4A_:B\':[^WO^U3JWP/ M\-:D\>@?#7PS<2331-\KZM,OR*3TY943GH(Y"*]P_P"">_QMU#XO?L]V6F^* MW8>)/"0^6SZL')4/R?F(]YQ49>TO*=HM_!&USU3_@H[\5=5\&? ^+ MX:^#9-WB;Q_J":+H]O&V'VN1YTG'. I"D]C(M>;_ +)OA*[_ &)OVJ[K]F'5 M-4EFT'QIH-OJ/A^ZN.CWT40%PGH&+"0X_NA*QO&?P]\>?MZ_MC>(=;\#?$BZ M\,Z)\+HX]-TG7+.'>WVXN3)Y?(^;(?CTV6_P!^ MOW(K*L'E.#R6EPYB<7"%3$P;J0<9N7M:G+*A[RBXQY$H73DOCG?='WD.E8/Q M4Y^&'B0?]0&\_P#1#US?@+]I/X:>-/!W@_Q.VOQ6LGC&S273;5LL?,P Z$@8 M&U_ER<9-=EXLT9O$?A;4O#RS>6;_ $^:V\S'W=Z%<_AFO4OS0NNI^*QIU,#F M"IUURN$K23Z.+LU\K'S]_P $HA_QAOHY _YB=Y_Z,K&_X+ C/[**_P#8Q6O_ M +-7/_\ !.#]H'X;?!_X;WW[-'QF\5Z?X5\4^&M2?)"@_X$=QQR M%5CVKX_^!OP^\7_L/_%+X8_&/Q?JDSZ?\3M/>P\9-.WRVU]/*9HBWMAHQ]8W M.><5WW[:.A^)?VP_VGO#O[)'@SQ VG:?X;L7USQ+JD<7F+:RE<0Y&1EAN4 9 M_P"6I/:JWQF_X)S?M">-/AU?:=K7[7GB+Q1]C@:ZT_1=2MV:.:>-2449D.TD M\ @<9HQ'M:M9SA%OEVVWW?\ E]X^&89+D>1TL'F&*A2>-3E5C*,W)TI1<*-G M&+46FW55VOLWTU.X_P""C/Q-\>VNE^#?V>/A?K+:?JOQ(UY--GU"%BKP6I9% M;!'W0Q<9(YVJ?6O0?A3^QA^SA\'O!L'AJP^&NCZ@T<.+S4]8L8YYKAL?,[-( M#C)[# %?+?COQ;\0OVB/V8_AI^UMX)T^;5/%GPIUA#XHT^-2TLWD,ADEVCDY M"*[ #[KO_=-?17A[]K/]DW]IGX2WFE7WQBTG28=6TUH-4TW4M9BL;RU###C$ MI'3^^,K[U=.I2J5Y3EU2Y;]K=/GN>9FF5YUE?#N&P6$YHQIU*D<2Z:;:J*=H MN?+9M>SLZ=VD];:G9?#_ /9^^ OP\\>7/C_X:>$=-TK5;RS-O=?V6X5)8]P; MF-3MSD#D"O04SCFO@[]C_P -?!OP1_P45U#PG\ /'LOB#PW#X"F;[8VK"\0W M!FAW@2* K8XZ9'/6OM;PC\0_!_CBZU&P\+:W'>2Z3=?9]01%8&*3GCD#/0\C MC(/I73A:D:E-M)+5[;'R7&66U\KS*G"K7G6YZ<)J52+C-*5[1<7*35DMKGS? M_P %,E_XJGX(\_\ -3K7_P!#BKZL[8KY9_X*F:-X@L_A_P""_C#HVER7EOX% M\96VIZC#&N2(@R_,?;S_ ]+,,#C,PX-RNIA:)?VI MOCDAUG1;#6I=/\%>'[AB;6"!#GS&7^(D;>.A;<3GC&C^R-XA3]H7]NOXD?M+ M^#+6;_A$XM,M])T[4)82JW.HT<1A\"FL?3PF$ARQ_B1BH_OXQMJI*\.9+WN7F\SZ/\ &/[,/[+W MB?2SX?\ %'PB\++$T>%6/3X;>0+TR&0*WXYKM/!V@^'_ )X(TOPIX>/EZ7H MNEPV=CNF+[;>&,(F6/7"J,GO7R#_ ,%%;/\ 9 ^)O@;4/C*OQXT^X\6V/AU+ M/P[8:+XN@=;C;,[K^YC+,YS*^6R!C'I5OQ-\<-1^$W_!,3P;8Z#/))XD\7:# M;:+H2)EI#+,"'D'?Y4W8/]XKZUT?6*=.I+W5HKW3W\CY7_5?-5_%#P;\1/VN/%?Q._;+\'7]S%#\/KV"V M\"B,Y$XLY/-E8#T"_/Z$RGKBONC]GOXO:/\ '?X.^'_BMHI55U;3TDNH5/\ MJ+@#;+%_P%PP]P,]Z^;?AG_P3A^/W@KX?V?A70?VR?$&A6;6^^XT73[_8+LM;_9A^-WBW]B?QAK37D<<:ZYX7O7CV"ZA=5$NT9.# MG&1D\JQK'#^UHUDYQ:YM]M]U_E]Q]!Q9_8O$&1U:67XF%5X.SI1C&::H)1IS M3;V/KJBBBO4/Q4**** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "L'XG_#;P7\8_AUKGPH^(^B+J6@>(]+FT[6=/D8JMQ;2H4DC) M4@@%21P5_LD_L7?LU?L+?#6?X0_LL_#.W\*^'KC4I+^;3[6>216N' M559\R,QR0J]\<5@_%3_@G+^QQ\:_VH/#G[9OQ,^#%GJGQ)\)P6\/A_Q-)=3+ M):1P/(\0"JX0[6ED/(/WJ]RHH YGXQ?"7P!\>OA7X@^"WQ7\/1ZMX9\4:3-I MNN:9-(RK=6LJ%9(R5((!4D<$&N;_ &5/V2?V?OV*/A/#\#OV9?AY;^%_"]O? M37<.EV\TDBK-*VZ1LR,QY/O7I77J*/PH \#_ &1?^"8_[$7["OC7Q!\0OV6? M@;9>%=8\4VZP:]>6MU-(UU&)#(%(D=@/G)/ %>]L<#K2_A10!\X?"?\ X)-? ML!? G]I.Z_:Z^#O[/]CX<\?:A>75S>:UI-[/")7N23,#$'\O8Q8G9MV@X( P M*T_^'8_[$(_;"3]O8? VS_X6PEPTZ^+?M4WFB0VYMB=F_9_JF*_=Z'UKWRB@ M '%5=;T72/$6CW6@Z]IL-Y8WUN\%Y:W$8>.:)U*LC*>"""00>U6J* /GS]D[ M_@EM^PM^P[XO\1>//V5_@-I_@_5/%-B;/6KK3;J;]] 9/,V ,Y" -R-H&.U6 MOV/_ /@F;^Q)^P=XA\0>+?V5_@98^%]4\41QQZ]J$-S--+=JC,Z@M*['[S,3 MC&2>:]YHH *S?%_A3P[X]\*:GX%\8:-#J&D:UI\UCJEAAK2HH \7_8U_X)^_LD_L :!K7A3]DKX4P^$=-\17D5WJUE:WL\L(/"]CX6B2Q\47$LVN6_F M-_I3R9WD\\9R>F*Z#POX9T7P=X>L_"WAVR6WL;&W6&UMU)(C0=!S6A10!YEX M]_8__9X^)?BF3QEXN^'-K<:A-)ONKA)'C\]O5PI )KK=9^%GP\\0>!/^%9:M MX2LYM!\A85TSRL1HB_=V@=".H(YS70?A10!PWPH^ /P=^ _VI_AQX8ATQ]0* MI<3-,S-+S\JY8^IX%=#I_@CPQI_BFZ\9VNEJNIWD/E7%TS$L4R/EYZ#@=/2O MS;_X.AK]*O"5Q< M7?AC3;NZE:2273X7DD;JS% 2?SK*I1HUI12.F>3]:V:/PISH MT:DXSG%-QU3:U5U9V[76GH$:E2$7&+:3W7?KKWUU.%UG]G3X.:[?MJ=[X,MU MD9MS_9V:-6/K@'%=-X7\'>&/!>G#2?"VBV]E;[LLD*8W'U)ZD_6M3WQ17'A\ MIRO"5W6H4(0F]W&*3?S2N=%;,,?B**I5:LI16RWO+=N3#<1[AGU'H?<5R-O^S+\%(+K[4/!<+W MA4(OKP/6K@Z5^7/_ 6E\;^,_#__ 4O_99TG0O%>I6=J^I([VUK>O'&S/J, M*,2JD DJ ISU'%?J,.E=T8QIQ48JR6R6R.64I3DY2=VPHHHJB0HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** .4^)/P0^$OQ=2-/B-X"T_56C7;%-<0_O$'H'&&Q[9Q6!X/\ V0OV;? V MH)JWA_X2:4MU&VZ.:XC,Q0]B Y('Y5Z5FCWH P?'_P ,? 'Q3T7_ (1WX@^$ M[/5+,-N2&ZBSL;U4]5/T(K'^&7[.WP6^#EW)J/P\^'NGZ;=2KM>\2,M+M] [ M$D#V&,]Z[;O10!S_ ,0?A5\.?BMIJ:1\1?!UCJ]O&VZ);R')C/K'JQ^I-;V:* ,3P+\./!'PSL+O2_ GAV'3;>^U"2]NXH"V) M;APH:0Y)Y(5?;BJ5A\%?A5IFBZSX=L_ UB+'Q!=/H7<3M_#FN^HHH Q M/"WPY\$>"M7U;7O"WAV&SO-=N%GU:>(MNN9%SAFR3R-QZ8ZTGA'X:^!O >I: MOK'A'PW!8W.O7S7FL30ELW4[,S&1LD\DLQXQUK2.,,SAB>H],5RH_8U_9K.GP::?AA:F.WF$ELS3R[X6!R M C;LJ,]A@9KU"B@#F_$OPC^&GC/PG;^"/%?@JQU#2[556UL[J'>(<# VD\J< M<9!S6)X(_9:_9_\ AOXBA\6^!_AAI^FZE;JPANX&DW(",'JQ'2N_HH XSXH? ML_\ P=^,DT-Q\2/ 5CJ<]NNV&XD4K*JYZ;E(./8\5=^&GP:^%_P?L)-/^&W@ MFQTE)\&X:WC^>7'3ET4 9-]X)\):KX/F\ 7OAZU_L6>S-I)IL<>R(PD8 M* +C QQQBK'AOPYHGA#0K7PQX:TZ.SL+&$16MK'G;&@Z 9J]10 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M,EN(8"HED5=[87)]'MM0L;N/9=6=Y")(Y5]&5L@ MU^:/_!P?X[\:^"OC%^S5)X1\5ZAII;QI-*WV&\>,.ZSV05B%.#@,W7LQ]:_3 MOGO05&4JVFM?V]%\"])\X/N6-C(T8;UV%MOX8Q7 M?>./@M\+/B3X.MOA]XU\$6-[HEG+'):Z7L,<$31@A,*A4 *"<#H/2NHQ[45G M&C2BFE%:^1Z5?/,ZQ52%2MB:DI0^%N"ZTTSEE:WF'1U*D$'@=^U=- M15N,9*S1PT<1B,/65:E-QFMFFTU?S6ISOPX^$WPY^$6E7.B?#?PG;:3:WEX] MW=1V^X^;.V-TC%B26.!W[5MZCIFGZOI]QI.IV<=Q;74+0W$$J[EDC8892.X( M)!J>BA1C&-D@JXC$5ZSK5)N4V[N3;;;[W>MSR]_V7OAUIG_"+:%X'\.V>C:- MX;U*2]2WM][2,QY\I2Q.$9OF;GJH ')(]0HQ[44)**LB:U:MB*LJM63E*3NV MVVVWNVWJV>?_ !9_9<^ 'QNNEU+XG?"[2]4O%4*M])&4FP.@+H02/J34WPD_ M9L^!?P/>2X^%OPTTS2;B5=LEW##NF9?3>Q+ >P.*[JBH]G3YN;E5^]CN_MC- MG@_JCQ$_9?R<\N7_ ,!O;\#G/#/PD^''@[QAK'C_ ,->$K:UUKQ RMK.HIN, MET5^[N))X'H,"NBV+Z4M%6DH['%6KU\1/GJR^ O"-KI@%<1XU_8;_91\?ZQ M)K_B3X*:.UY,Y>::WC:'S&[DB,@?I7K=%1*E3E&SBK>AVT,YSC"XB5>CB*D9 MRLG)3DI-+1)M.[26USC?AE\!/@S\&D9?A?\ #?2=%:1=LD]I:CS77T,ARQ'M MG%.^&OPKM/ /B#Q)XFB$*W'B+4%FEAME(CC1-VT<]6)=F)P.6]LGL**N,8Q5 MDK')B,5B<96=6O-SD]W)MM^K=V1W5I:WUM)9WMM'-#-&R30RJ&5U(P5(/!!' M&*\?U3]@/]C_ %C7&UZ]^!NC^36=\2/A/\ #;XM:*- ^)7@C3=:M5;,<5_;!_+/JIZH?<$5 MT5%/EBXV:T.>&*Q5/$>WA-J=[\R;4K][[W\SQWP]^P'^R#X;U)=7T[X&Z.TJ MMN3[4KS*I_W78J?Q!KM_$GP.^$GB[4]!UCQ%X"T^YG\+S"7P_F,JEBX((,:* M0HY5>W85U=%3&C2BK**^X[<1GF=8JJJM;$U)22:33E2DXMIIV;5TU9IVZ-:-;-;DT,\4Q;RI5;: MQ#;6S@^E25^9'_!N-XZ\:>+)_P!H+3_%'BO4-2AM?'-I-:QWUV\HBDE-X)&7 M<3@L(X\^NP5^F],R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** /RS_ .#I-@OP)^%!8_\ ,Y7?_I**^[O!_P"V7^R5!X2T MN";]I3P0KIIT"LK>)K;((C7(^_63^W/_ ,$]?@/_ ,%"?"FA>#OCQ?\ B""T M\/:A)>V#>']0CMW,CQ["'+Q29&.P YKYI_XAH?\ @G=G/_"1?$K_ ,*6V_\ MD2@#Z^_X;0_9&_Z.7\#_ /A36W_Q='_#:'[(W_1R_@?_ ,*:V_\ BZ^0O^(: M'_@G=_T,/Q*_\*6V_P#D2C_B&A_X)W?]##\2O_"EMO\ Y$H ^O?^&T/V1O\ MHY?P/_X4UM_\71_PVA^R-_TC>(8+/5+>. MZFT?48[A87.IQ$*Q0G!(YP:_7L'-?"?PQ_X-XOV#/A-\1M#^*'A?7OB$VI>' M]4@U"Q6[\0V[Q&:)PZAE%J"5R!D CCO7W90 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4&IVG]H:= M/8?:)(?.A:/S8FPR9!&0?4=JGIKLB(7D8!5Y)/:@#Y!_:$_8Z^%GP'^%^J?& M#P5\4=>TGQ5I,8N;;4[K6"9+R;."2Y.!CN>$]2_:)L_&E]8:QX:T^* M6&SEF1K*98GR!L*Y$AW$ Y()V@CG->T?L]>,M5^(/P0\+^-- M#?A_I#:]XX\366DV:M@W-_<+&N?3)/)]J\)_X*4_\DH\-_\ 8Z6?\GKE?VB5 M\0>.OVZ=#\#:CX*L?$EEIOALW6C>']8U7[):W$QR7DSL<.PP?EQSLZX&" ?2 MO@/XL?#3XH6'? M"&B3:;<6'B?3M)UP7$=_$Z-L)C$48W!L \'(^E9'[)GP=^%.M_%SXK6VK_#W M2+F/2?%B1Z:DUBC"U7#'"9'RC('2@#UOQ/\ M;_ KPA\31\+M>\>Z?:WD=FT M]]=7-XD<%LE7&G?\(?#=?8YK-&C M\YB,R;2,;CW/6J/[0ND7&M_MC>#_ (46_P /M,UC1=)\-M/H'A?4-2^PV4TH M#9Z(X8JJ\)CD)Z @@'TQX!^+?PS^*4$ES\._'.FZPL)Q-]ANED,?^\!R/QJK MJGQU^#6BV&H:IJOQ-T6&WTF_:QU*234$_P!&N02#"_/#@@_+UXKQGPC\"/BM MIO[1OA[XM:)\)?#W@K3[>WEM/$5OH^O^"/B+X%^)6EG6_ /BRQU>U M5MK3V%PLBJWH<=#['FO$_P!I#]EJ_?2O!VN_ 7PKI,W_ @MS<2V_A&_CS:W ML-H/$">%_A>/!OB.WO(T\6:#Y6PI.H(# MC (QD;L GOVH ]=U35=-T2PFU76+^&UM;>,O-<7$@5(U'4DG@"N:\$?'CX- M?$G5I-"\!_$O1]6O(@2]K9WJN^!U(&>1[C(IGQX_X5FOPLU2X^,#+_PCL,:R MZC&S'$BJP(3 Y.3@;1USBOE_QSJ]A?\ QY^#7C/P9\$I/!FG77B.&WL;R01P M3W]NQ08,,?*H5;C< ^-_!7A; MQW_P4BT_2?&&B6^H6L/@LW"V]U'NC,BGY6*]#C/?(SSV%7/^$8T'X=_\%$M' ML?!.E0Z9;ZQX&EEU*ULXQ'%-(LK@.5'&["KS[4 >U>//CA\(?AC=1V'Q!^(F MDZ3--S'#>WBH[#UVYSCWKQ?]AKQ%:>*/C-\;=8TK65OK&X\6126-Q%-YD;1L M]T0R'I@C'2J?[&G@'PA\4-?\??%+XFZ':ZOXC?QA=64HU*$2FQA0X6%5;.T8 MX]P!Z5:_89TK3M#^-GQQT?2+&*UM;;Q?%';V\$85(T$EV H Z "@#Z.U'4K# M2+";5-4O([>WMXVDGGF;:L: 9+$GH *XR^_:9_9]TW[%]M^,?AZ,:BNZR;^U M(R)5SC((/3/&>E7_ (WC/P=\4G_J7[O_ -%-7@?P"^"/PHU?]@QM7U'P)ILU M[?\ AF]N;F^DMPTS3*LNU]YR05VC&.!B@#Z@&HV)LO[2^V1_9_+\SS_,&S9C M.[/3&.]<;IG[2OP!UGQ"/"FE_%_0)M09]BVL>I)N9O[HYP3[ U\FZYXR\43? M\$^/ASX>EUZXMM/UKQ,NF:QJ"R'DV*L%-U?7"QIN/09/4^U>?_L1^+O%/CC]F#PKK_C":2:]:UEA^ MT39W3QQ3/'&YSR245>3UQGO6?^V3\#/%_P 8- T'6_ 1LKG5O"VJ&_MM'U1= MUKJ P 8W&1SP,?4CC.: /1?!7Q9^&GQ&TN?6O OCC3=4M;49N9K.Z5Q%QGYL M'Y>!WK&T[]IS]G;5KV/3M,^-OAB>>5ML<4>LPEF/H/FKS?\ 9\^(?P^\86_C M+2$^$$?@?QM8:64\3:.D(02*(VV2+C 9>>#C.".2,$\[^Q/\#_A!\1_V2-/E M\=>!=+NVNFNUN+V>U7S5 D8;@^,@@=#GB@#Z2\1^,_"7A#0F\3^*?$ECI^G( MH+7UYGS$XK-\ ?_%2.:3X=>.]-UC[/C[0MC=*[1YZ;AU'XBOEG MX >-_AF/V89I_P!H".X\0:/X7\=SV/A2UDC:9[U@J&*(1_\ +4@R-@'(&0.P MK0\!3WMK_P %!/#]Y;?"L^"X=6\*71FTL31[[F-4D*O*D?RHV5'RY/W0 M*K'4]/Y'VRSN5DC&.H)!X(]Z^;/V??!?@_XW_M1?%;Q1\7=,@U;4M"UI;'1] M/U)1(EI:AI%!5&XZ(HSCC)/5JZ3]LSP]I7P2_92\3Q?"'P_#HL.J7ULFIG3E M\I8XY9421P!PFX80D#^/UH ]2TS]HWX$ZSXF_P"$-TKXLZ#<:HTGEK9QZBA= MG_NCG!/L.:TO'WQ9^&GPMM8KSXB>.--T>.X;$'VZZ5#(?]D'D_A7S+JW[-OB M[QW\#[/PCX*_9G\'Z6[V,$NE>);3Q8&N(Y,*PGS]G#,3W^;O[5O?&7X%?'![ MGP+\/Y>))8CP-Y)8CWP>1D$ ^B_"7C/PG MX\T:/Q%X+\16>J6,C$1W5C<+)&2.HR.X]*TZ\K_9)\0:]H)CV-:7VQ ^5X'("\@ '!X!S7JE !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 ?E7_P<@7EKI_Q3_9OO[ZX2&&'Q5=R332-M5%$]B2Q M/8 .E>^T %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !2%L&EKXI_X*4?M&?M"W_P"TQ\*_^"?/ M[-/Q%C\!:M\2+:YU#7/'DEJ)9K*RB+*(;520#*Q20GD$80 C<2 #[5+$=J6O MFO\ 9$_8I_:!_9C^)M]X@\;?MS>,/B9X:OM),*:#XLMAOMKO>I\]) [ C:"N MW:,9ZGMZE\"/VGOA+^T?>>+K'X5ZK>7C>"?$LN@Z])<6+PHE]&JL\:%AB0 , MOS#CF@#T*BJ&N>)_#WABV6]\2Z]8Z?"S;5FOKI(5+>F6(&:GT_4[#5K./4-* MOH;JWD7,<]O*'1QZ@C@B@"Q14,=Y;S3R6T%Q&\D.T31JX+1Y&1D=LCUK@?V8 M_P!J+X2_M>?"Z/XQ?!+5+J^T&2_GLXKJ\L7MVDDA;:Y"N 2N>C=#0!Z)11SW MK-U/QCX2T34(=)UGQ3IUG=7# 6]K=7T<$[J?1Q]K1+CSMNU'C0D%B&8'@'I5C]A;Q-XVO?V'?A MEXZ^-?C.34-[MI5S%<6TPD1QZAE)!I]S>6UE%YUY*O#>H>%]2=UM]2L9;6X:,X8)(A1L>^#5Z@\C% 'SC_P . M^+;5!;^'O&O[0/C36O#-K,LD/AV]U F'"_=7DG '; X[8KZ%T?2M.T+2K?1= M'M%M[6TA6&WAC'RHBC 4?0"K.,C!HH X/]H#X#:-^T#X9T_PSK>NW6GQZ?JT M5_'):QJS.R9PIW=CFJ/Q^_9C\&?'MM.UF]U6_P!%U[1WW:3X@TF;R[BWYSMS MW&>1W!Z8R<^E44 >1?#/]F#7?"?C2S\<^//CUXK\67&F[SI]KJ5WMMXF9"A8 MQCAFP3R>:S/%_P"QJ=1^(VK?$+X;_&CQ-X0;Q"RMKMIHLX5;EP/O ]5/)Y[9 M..IKW#&!BB@#Q_XL_LEVWC[QIIOQ-\(_$_7/"_B.QTM=/FU;3) 7NX%_YZ9Z MMR>>_&>@IOC[]CGPK\1/ V@Z#X@\=Z])X@\-EFTSQE]L/]H!RYQ8H"@<@4 >/_ X_9;U_PSXPL?&?Q ^/WBWQ5+I;E]/LM2O-MNCE2N\H M.&;!/)YKJ/A!\#M'^#^M^+MZCN(U46\DC,Q1<=5&[OS7< M$ ]:* //?C3\"M0^*.JZ7XG\,_%'7/"NK:3'+%!=Z/, LL>* M9\!OV=](^"M &.!0!R_ MQD^%>@?&KX=ZE\-_$TDT=IJ,85IK-@0RL/H0*\OUS]CGQ+XF/A6_U[]H# M6;B_\'WD[KQ3 M>7&I6WA\:4UN\2".48&920,AB><#CFK6K? W2-6^/6F_'N77+E;W3=%?38[! M8U\IT9F;>3US\WTKN** /'_&?[(>EZIXZU#XB?#;XI>(_!6HZP5;6!H-P!%> M,.CLC<;O?W/J:U/V>?V;++X ZAXDUA/'>I:_>^*+R*YU"[U2- YD3S,ME>I8 MR$G/I7IE% &;XP\.0>,/"FI>%+JX>&/4K&6VDEC +(KJ5)&>XS7.> O@II/@ M'X(1_ ^RUJXN+./2Y[$7TJ*)"L@8%L#C(W_I7:T4 >8>&?V4_AUI'[/L?[.G MB)YM9T=%?]_=*J2AFD,@=2OW65CP1_(D5Q"_L%2:E90^#_%O[0_C+5O"MNR^ M7X=GO,1LBGY8V;J5&.!V[8KZ&H Z4 4_#^@:/X5T*S\->'M.CM+&PMD@L[6 M%<+%&HPJCZ 5Q_QO^"-]4\3>)->TUTU#6M5*[_ "TC.V-57A0, M#\ , 5X=^R#^S=XL^*O[..GRK^T#XFT?0]2FN([[0+!D\IE$A!56(W*&[@' M!S7V5>6D%_:R65TFZ.:-DD7U4C!'Y5C?#GX;>#OA/X4@\$^ ])^PZ;;.S0V_ MFL^TLW[)_B.Y^+>C_&G4?CIJUQKFEVK6TDK:;;A9(F!!15"X7(9N>3W MKVJC SF@#QOXL?L?Z#XX^(;?%OP'X^UKP9XEFC$=]J&AS;1=J #(O0G /8 MX&1GFM_P3^SW:Z3\.]9^'OQ'\=ZQXSAUYF_M&XUZ;>VTJ!L3GY%&,C'0\BO1 M<#O10!\]Z7^PQKWAZR_X13PY^U#XYL?#:L1'HMK?;?*C/6-7!RJ^PQU-=-XQ M_98N;Q]%N_AE\8_$OA.?1=$@TF,V%P)$N+>%0J>:C##N!_$1G/I7KVT9SB@# M% '"? /X#>'O@+X;O-(TK5[S4[[5+]KW5]6U!@TUW,1C<<= .![GUKNZ,#. M:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&) M'2EJ.]G%K:273*2(XV^!F@!V^G Y&:_-#]GKP[^V;_P %;X/%O[13?MS^ M(OA3X5T_Q5>:1X.\'^";-=UNMNV!-=L9%+.'[ M'^C^*OVQ_C3?>)I-!$.GZQXO72W>XU.XEE81OY*%F!(P#R<;>2>M 'N]%0P7 ML<]E'?X:-)(A)^^7:4!&?F!Z8[YZ5!HOB+0/$ELU[X=URSU"%9"C365RLJAA MU4E21GVH NT5X]X1_;:^#OB[]I'QM^S(EQ<6&K^ [6RFUC4M2DBALY'N@3%# M&[/EI,*QQ@< XS7K\;B1=ZG*GE2.] #J*:6(-9^I^,/"FAZA#I.M^)]/L[JY M.+>VNKR..27M\JL06Y]* -*BJ.M>)/#_ (;ACN?$.NV=A'))LCDO;I(E=O[H M+$9/M5Q9 ZAU8$$9!'>@!Q.*123SBO&?V^/C_IW[/G[(WQ*\?V7C*UTWQ!IO M@74[CP^K7:)/]M^SNMNR*2&;$Q0\>E-_8)\6^-M6_8@^'/CKXU>,9-0UO4/" M=O?:UK6IS!6E:0%][L>!\K#VH ]IHJMIFK:;K5C%JFCZA;W=K,,PW%K,LD;C M.,AE)!Y]*DN;NWLH_/O+B.&/(&^1@JY)P!D^IXH EHJ&]U"STRTDU#4KN&WM MXEW3332!41?4D\ 4S2=8TG7K"/5-#U2WO+:3_5W%K,LD;?1E)!H LT444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %? M-/\ P4D_X)^P?ML^#="\1^!/&L_A'XE>!;N2^\">+K21D:VF;:6AD*_-Y;E$ M.1DJ5R,@L&^ECGL*^0?VF?AA_P % @J&,*L2AVR*0R_*^*\=_X)2? [X!?LK? M\$_]9_X*B7_P^D_X2^UTS7K_ $^2;5)FCCL?,9(8=A?9DJJ@O@M@GGFOHC]F M_P#X)M?&?P_\//C?XW_:/^,FGZI\8/COX?N]-UO7M"MF6RT>)[-[:WCA#!2X MB#*?NKP@49QN.+^R3^Q+^VO;?LN:I^PE^UD/AW8_#6W^']YX>TN^\(37,^I7 MUU+,ICNY3* @1$\S*@*69ER.. #QW3/V./!WQC_X)Z>,/^"F'[?EYJ'Q ^(' MB#X;:EXI\/VNHZMDZ7%I6C>)%-\;W6-/CE3R[68B-A BQ#:6$98[ M%3D%GKVG7O\ @G7\1]7^/'[+_BZ'Q+X?7PE\!?#,EIJ5F]Q/]JN[XVL40E@3 MR=A3?!$Q+NAQGY(/$)4C9BD8V,F=H&2!G.!7M?\ P4&_9J\5_M=_ ML>>-OV=_!'B>WTG5?$6GQI8WE[N\@R1S1RB.3:"P1C'M) )&.O$NO7LL\U^A$C21J M)0 @<< AB0!N)Z5Z?_P4)_8QTW]NC]G#4/@M)XG;0]62ZAU#P[K@C+BROH6W M1LP!!*GE3@Y .1G&#P_[.^G?\%=[CQCX=\,_M-WWPAM_"FCL5\1ZWX;:[FU+ M7T6)E0(DBB*'<^UG;:AQD*%SB@#YW_9&_9L\%_\ !7?XH?%S]K#]L=+_ ,1> M'M-\87G@[X<>%?[6G@M]&M[9$,ES&D;J!(WFQX)ZLKE@?EQYM\ O^"@?QN_9 MJ_X)4^(- \*>)9M>\2:?\7)OA[\--?U23SUA@=CLEW-\KK#&K[ 20"T8^Z,5 M[GIG["W_ 4K_99U#XC?!C]B3XB?#T?#GXE>(KG6;/5_$S7,>J>%I[I52X,2 MQJ5D.U5VGYN4#80DY[SQ+_P1N^%%[_P3ITW]A;PSXVN;'4M%OH]6J %\94G'4],>E?$3X;6W[;/ M_!1#0?\ @G_X[U.__P"%1?!7X:9KFK>*]!U*Z2\U:*T M)^5X73;N8')PJ@L!T&:]+_:0_9 _:X\ _MF2_MR?L*7_ (-O-7\0>&8]#\9> M$_&TDT5O=+$ (+F.2'D,H"J5)'"CKDT >0?LH:C;?L3?\%#OVCOV3_A!>W<' MPQT+X6_\)KIVD27LEQ!HNH(EOOCB+EBF\3OE2*/VI/VG_&GB+5K$^'?%/B;PGX?M]8GM;70Y(3<_P"F>7$P%Q3N4$+DD &Q_P24\0>.?%/\ P3G^%.N_$359 MKW4IO#*C[3<.6D>%9'2+<3R2(U4?0"OHRN&_9E^$0#7#2US/QH\)^,O'GPA\4>"?AWXT_P"$;U[6/#]Y9:-X M@^SF4Z;_%3X8W$AVVIDD >\MAT'+'YAAD! .Y,[:7_!6SX._L^?ME?$+]ES MQCH^D7%]J/Q>\3:/9?;EU&>/_BFVQ=2XC#; QCG<[\;N@SQ73^-OV1_^"V'[ M1OP\E_91_:&^.OPM@\"ZELMO$OC'1K69]4U"Q# M&J&-5WL!SE4R>K'OZ'^U MM^P9^T'IWC?]G_XJ_L3GPK>3? G39M+T[PKXTNIH[6YMFM%M4DWQ<[TC''(Y MP><8(!Y;^V5\+=&T/XW? K_@C+^SK=ZAX1\ ^+OMFO\ C9;'4YC!@OD^#OAK_@GI_P5>^'WPO_ &,=!ET[1?B1\.M3;7O! M+:S/)9S7=HCFVN7\QG:(LRA"_0?,1U(/IG[1W[$_[9_Q*\0_"']M#P)XM\#V MOQ\^'%G<6VM:;-'.NA:M:W!DWVR/S*FQ974$_>\QB64@$[G[+7['?QVTC]HK MQ%_P4$_;V\:^';SQQ)H)TWP_H7A<2'3?#&EIN=T5Y1N=SEB3SC+'B\::Y;_$N;P_;Z[:SW%@L$EM'LE:W2&15 M5@JJ6W'$8R22V?;/^"(/Q%^($O@[XL_LS>*_%MYXBT?X0_$6;0_"6N7TGF2- MI^&VVYD_C$9CR,DD+*J\*% ^=/\ @F/HO_!4_P")'[+.M:I^S);_ S\,^'? MB5XQU75KKQQXDGNI-4MFFF(E:.&/[FCW):7=T)&\\CI\D4,K#/&X+FN;_ &=_ M^"-W[*W@.PT?X@_';P[J'Q"^)RW5MJFL>-/$GB"\FG?4499=R*LH0(L@& 0< MA0"2.*]2_P""@_[&>B_MU_LUZA\$;WQ ='U2.^@U3PSK@B\S^S]2@)\J4KD; ME(9XV'7;(V.<5P?[-VF?\%\/R7DVI:[&B% M4")(/+B+':SL0I/;'(H ^=OV3?@+\/O^"O?Q:^+W[5'[6UO>>(?"VE>)KSPO M\-?#4FJ7%O:Z19P\&Y"1NG[Y@48L?XF/HN.,^ ?[='QM_9U_X)8>+M \(>(I M]4\2:/\ '*\^&?PQUG5Y/.V0L8C!*SMPXB624+G*_(HZ#%>PV'["?_!1W]E7 M7OB1\*?V&/&_P[7X=_$K7KC4[/4?%1N$U#PG)<\3")(P5E"@X0D-]U<@$$GT M'7O^"0WP[O/^">%C^Q%H'CRXL=5TN^CUNQ\:M;[I3KROYAO&3=G#.2I&[(0\ M'B@#Y1_X*>_\$V_V>_V6/^"=VJ?%3Q@VK>./B]XBUK2;2^^(GB36[F>ZEO)K MA'G,:&3RU0QQRH RL0K=>!CT+Q?\.=0_;._X*"^%?^";OC_5;Z/X3?!'X5Z? MJ?BGPY9WTMO'KM^L5M#'',R,&=5,J8&< )(0KZWXHT'4+N.ZU6WMI,,6A=-N\Q-)P$0%B.@S7IW[2?[& M7[6W@/\ ;7D_;V_81UCP=>:YX@\+#0/&GA'QPTT=M=1JT9CN(I(>=P,4>02I M&S@L'*@ \T_9'C\-_L._\%)?CU^S'\+KV\M_A7I/@&U\7KX=DOI+B'0[G[.D MDPC+EF3>N3@G)79UP#7BW[&W[!/P_P#C+_P2NU[]I;]K#QIXBUZ&72])?B-\4- M#USX\?'?P_>V&L>(/WL.F:6DULUO#;1,(VD\J)&^\$!^1%"@+N/"O$>@P^*&\ G0?[4GN)ET\329\V0.(6DV_,^/W>3QP.P!\>?&/P M3^TM\;?^"-?[.?C[6O#VN^.M \/7-IJOQ0\+Z1?2I?:WH44L@C&4/F28@";B M,L,[^Q(^MO\ @EAX(_85N/!NN?'S]@R[U'3_ _XM6U@UKP?=:E-)'H]];^9 MN!@F=V@E82@-@E6"(5)%3>(_@/\ M[_ 7X1?"GPK^QKXV\!W2^ O!\.B>(_! M_BZWN%L]8*10HL\5Q'AXV3RVV@JH(+OBAXL?7=6T?PG&ZZ9I>F_P!HVRYD MM?/A>+S5&1EEW;AR.1110!R?[(G[-/AC]D#]GCPW^SOX0UJYU*Q\.6LD4>H7 MD:I+<,\KR%V"\ Y?''8"O2:** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D! end GRAPHIC 23 mrna-20231231_g4.jpg begin 644 mrna-20231231_g4.jpg M_]C_X 02D9)1@ ! 0$ D "0 #_X0!:17AI9@ 34T *@ @ !0,! 4 M ! 2@,# $ ! %$0 $ ! 0 %$1 0 ! 7$5$2 M 0 ! 7$0 8:@ "QC__; $, @$! @$! @(" @(" @(#!0,# M P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP, M#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,# P,# P,# P,# P, M# P,# P,# P,# P,# P,# P,# P,# P,#/_ !$( 7L#SP,!(@ "$0$#$0'_ MQ ? !!0$! 0$! 0 0(#! 4&!P@)"@O_Q "U$ " 0,# @0# M!04$! 7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*" M"0H6%Q@9&B4F)R@I*C0U-C+CY.7FY^CIZO'R\_3U]O?X^?K_Q ? 0 # 0$! M 0$! 0$! 0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$! ! G< M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B7J" M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(RKR\_3U]O?X^?K_V@ , P$ A$#$0 _ /WLHHHK M0S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH *?;_P"N6F4^W_URT ,HHHH *5%W.!ZG%)2HVUU/H?C%-X;L_"O@;2[2V\677AB3[?X\M;?5Y!;SM$T\5@RB63(! M957[W(!XKV#P+^W[\&?B5KTNF:'\0M!O+N&QN=38$R0Q_9[;/VF02.H4^5@E MP#E!R0*\?_9Z_P""/M';2?$5S<6>FO&DTDUQ-; M@FX0PJAE0Q 9DW*-@()QD9\KOOV!_B;XM\(Z2VO_ !8T.X\2>#=3TC4_"S6G MA2*'3;:33HI8E>Y0N9IFF25@P$@6,@% ,_"K_@I+\- M?&'PS^'^L>)-38&8X%/^ M)/\ P45\!>$OC=X5^'NAZA:^)_$VN>+8_"FHVUNTBKH\C022N[2;/+=H]B*T M:MN'FC/0UXK<_P#!&Z9M+\'63>,-%U.WTSPMIGA37$U'2KAH[J*QNI;A)X(X M;F-=[^&?B;H[6?CS2_^$ T#XCR_$BTTJ31B M=1:ZG259;9[D2;3&K3.5.S<0P!.%&7J&A]:$8-%!.XGZT4R0HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //?VB/VGO"O[+V M@Z;J7BN6_BM=5N6M;?[+;&=BX0N<@=!@=:\G_P"'MWP=_P"?KQ%_X*G_ ,:X MC_@M;_R2#P-_V&Y?_2=J^-/!G[-=]\0/AKI>O:?J6G6YNIM1^UC49Q;6UE;V M8MRTQDY_Y[Y(QT7C)XK]BX5X-R+%9-3S'-*DH.4I1T:2TO;H[:(_FGQ \3N* M_$7_@J?_&OBF']AO5#X2$;:IITGB^77+K2QIZ72?9[6&VA6::XD?!9 MAY;*X" D*R<$M@8]FX C!ZK MU)Q6 W[(WC!-46T/]C[IKO[)#(MYNBN^%GA30=8U;[#]G\10I-:QP3 MF60!T#KN^7;DJ1]UFP>#@UW]E^Q%J-GH33:KK6G1ZE&UXL]C8S)(5:M+#QPU M-2BHMIP:MS?#O/KTZGVU_P /;_@[_P _7B+_ ,%3_P"-'_#V[X._\_?B+_P5 M/_C7P2_[&7C6+Q'H^E,NCBZUBP?4PPNBT5I B([M(X0@X$B?ZO?R<=0:IK^R M7XO.G^))MNE";PO=-:7=J;O]\Y79EX^-A3$BG)8'&>.#5?ZA\'/;$RZ?;75V M7V>^@I>+WB,M\'#K_P NY=%S/[?;4_0+_A[?\'?^?KQ%_P""I_\ &@_\%;O@ MZ/\ EZ\1?^"I_P#&OA6[_89\=6?CF;0671?M%K9?;;FX6Z6JLVS)9 MGX7:"IY.< D,=;U32[.SA.J:+JEOI-[9/-^^@EFE:(.0 1Y:NN M&<'C(X.:=/@'A"I!SAB9-))OWUHF[)_#W_K5&=;QB\0Z52-*IA(*4FTDZ_O;7_AC]%/\ A[=\'<_\??B+_P %3_XT?\/;_@[_ ,_7B+_P5/\ XU\" MV'['OC#6?"]AK.GMH>HV-]>"SWV]]G[/GS<2R$J%$6V&1BP)PJ\@=*HV_P"S M/K5W8ZM>0ZWX+DTW3"J1WPUN,6NHRM$TRPV[D?-(8T8[6V],=2*F/ ?![O;$ MRTT?OK36UOA[_P">QI+Q?\1(VYL)#577N/56O=>_M9?IOH?H1_P]N^#O_/UX MB_\ !4_^-'_#V[X._P#/WXB_\%3_ .-?"5U^QIX@NCYFFZAHK02)&EO'>WJV M]Q>7#627;0Q)@[F\MSCG^$YQQF*T_8C\?75SH,/V/3H9=?4E4ENMK67[@W $ MPV\%H@6 3>3T^]Q4+@?@VUWB9+KK-7M:^W+Y?H:2\6O$>]E@X/5+2G)K5I+7 MGZM_KL?>7_#V_P"#O_/WXB_\%;_XU]+6MRMY:Q3)]R9%D7Z$9'\Z_"_QMX1N M_ ?BR_T:^:%KS3I/*E,+%D)P#P2 >A'! ([@5^Y'A[_D7]/_ .O6+_T 5\5X MA<*9=D\<-4RZ4I1JJ3NVGHN6UM%W/U+P=\0^)(->CLX;YELM)>YB\J7=L.\'&?E/ M':O-/^(BK]FG_H)^,_\ PGY?\:_/#_@XR_Y24WG_ &+.F?REKX3K],RKA' X MC!TZ]1RO))NS7^1^:YIQ9C&8_&OCW0=%FU"UTB'6M2MK"2_N3B& MR6658S,_^R@;%?'/QSU;X;^#_AS\3/!9\+>,Y?#5UXPO;AM M6L;NWAM)9G::!EC$=PZPM.OEMY2Q-ER%7=58KAG*L/-1J.>U]U9)==ORNS/# M<3YK7BY4U#>VSU?W_G8_2K_B(K_9I_Z"?C/_ ,)^7_&C_B(K_9I_Z"GC+_PG MY?\ &OS5N/\ @D+#:^+M:TJ7XF6Z>7?V^FZ%*FBM,NIRW&A2:U#YQ24K"OD1 M.C,ID&[&W<#D<]X#_P""7R^/M?\ ">A6_CQH?$&J:/;>(==BE\/3I8:58SZ6 M^IH8+TL+>>80(5,;M%ESE245W'+')\A:NJDN_P M_P"4Z7G6>)\KIQOZ+O;^ M8_4O_B(K_9I_Z"?C/_PGY?\ &C_B(K_9I_Z"?C/_ ,)^7_&OR2_::_8$M?V8 M/AKXD\0:IXXAU22R\1Q^'=#MK'3MZZL[V%O?^;-()2MN%AG*D#S,O'P2K!JZ M#P5_P2ZN/&.C^"=:7QHG_"/?$1K0Z#=6VE-<3W:_8I[K4BT0D&S[$8#'(S-L M#.I9D&<:_P"K^2*FJOM)HR:O ='N["RTZ^BTZ"]C-O>?-%=H%N$!4%6 MRI)0(58Q_8>1M)QJ2=_^!UY;=2_[=SI.TH17R7_R7D?J#_Q$5_LT_P#03\9_ M^$_+_C1_Q$5_LT_]!3QE_P"$_+_C7YQ2_P#!&AKGQSJVFZ;\3K&_T_P?J^K: M-XJO)=(^QM8S:?;PW+_9EEF5)PR3H-SR1*&#7^(O_!*+4_A]\)?B3X@ M3QE9Z]J7P]N[K_B6Z99J_P!JL8%A=[MBTRNJ[)LGRDE$9B<.R_+E0R7(9-)5 M9=.O=Z?9*EG6>1BY.G'3R[;]3]1?^(BK]FG_ *"?C/\ \)^7_&E_XB*OV:?^ M@GXT_P#">E_QK\ Z*]?_ %(R_O+[U_D>3_KMF':/W/\ S/ZV<#@'K@UQ?_#:/PM_Z'#3O^^)/_B: M^;Q&:8.A/V=>K&+[.23_ !9Z$\12@^6O\ST_-&:\P_P"&T?A;_P!#AI__ 'S)_P#$T@_;2^%I_P"9 MPT[_ +YD_P#B:/[>RW_H(A_X$O\ ,?UW#_SK[U_F>H9HKR__ (;1^%O_ $.& MG?\ ?,G_ ,35_P ,?M6?#SQGXBL])TOQ18WFHZA((K>!%?=*YYP,KCM51SO+ MI248UX-O9*ELO ^K6L,/AZZO)KI3/ M>+,,R0AD0%D4X6-F8 5^A=C^RY\/--&G"W\(Z/$NDG4VL@L9_P!&.I,6O]O/ M_+_CWH.I>+O$4?B#P7IGPKT6?QVVF2K-:6-W?/-$ MFLVVT895G5 [)A2C[@, 8Y#]H+_@H-X_\,_LR_L_:?H7CG5+/QI:>!H/B+XE MN_L\MW-XC\M4$.G2F-6V_:V\\EG"J!$.>:^X?B+\)/@G^R/\"_$WB34O!VEZ M=X1T?PL-"U1+>T>Z9M'1W*VGEY):,-,Y"CIN.*[?X-? +P#\)+1K[P;X7TO0 MTU;2K+3V:",AI+*WC*VL!W$X2-'8!1P-QHU#0^8[_P#X*"ZMXF\2?%/X@>"X M+KQ-X;\"^"?#\FC>'A,(8=4O=687$EPVW+2-#"8E4+R2LZ %B#4>@_MY^(?B M-X0^$OCC[5I]G-'\2T\">(](TF6X6VO8;VW*H\UO=11SP31R&&14<$JHPZ3_P3M^'/A_Q-J\-CH.DQ^!?$?AR#0-4\*/;%[.#],UOP*N@6=IX>\/>#/$4_BR;3+>$R-J^J-;O!#/+,[%R8 MQ(['=DL0G(VBGJ&A[.R[&*^G%)113)"BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH ^,_^"T&G7&H_"+P0MM;W%PRZW*2(HV< M@?9VZX!KX9TCQYXTT/P.WAVVM[Y-):.[A,1TYF;;=>7YPW%<_-Y2?3''6OVP M>-9/O*K?[PS2?9HL8\J'_O@5^E\.^(4,MRV&75<+&JHRW*]5>US\- MXS\&ZF>9W4SFACI4'.*BU&-]$DM7S*Z=KV/QK'QZ^(_]NKJ3+=27!N[F\D5M M*/ES-<6\=O,K+MY5XHT4CCID8/-,U3XX>/\ 6].U*UO+&.X34)I+A3)H*,UB M\D:Q/]G.S]UN1%4[?3/WB37[+_9X_P#GE%_WP*/L\0_Y8P_]\"O3CXG8%-26 M6T[KS7K_ "'S\O ?,G%P>, ,#U(!X(%/L/VC/B5IUQ>21PNS76U-I))(0GSNT M!V[CZ ]>:_8O[-&?^647_? I?L\>/]5%_P!\"M/^(H8/E4/[.A97:5_YM_L] M>OY$D8CD\U N#N0 ?+M'&<9R::_[2?Q-FTB^LI(=\-_)/_GE#_P!\"D-O$?\ EC#_ -\"L_\ B)67IW_LRG]Z M[W_D[ZF__$#.U>S-G_8N+1T: M59CF/;C/F*&&,!>@ !(/)^%OB%XZ\%^*]8US3AJ<&J:_!/;7T_\ 9Y/FI,47_? H^SQ_P#/.+_O@5I1\4,'2BX4\M@E)6:3 M6JWU]SN8UO 3,:TXU*VQCL[W84M! MX]_Y>Y4O ?,VDGG-3167NO1;6^/:Q^,)^,GQ!DU#2KIDO#/ MHL_VFT)TPX23[*MKD_+S^Y15P>XSUK2_X:/^)DK:4T\4ET^E !7N-%$DEUB$ M0KYS%,L5C 4$$$8!!W/\ YY1?]\"C[/'_ ,\HO^^!3J>)V!E;FRV# MLK;K9]/A\V*GX#YG3OR9S55VF_=>K5K/X^EE]Q^(/Q'UKQ5\5O%]YK^N6>I7 M>I7VP2R"R=1A$5% 7H%4#UXY)/-?MIX?&WP_IX/:VB'3_8%6A;QC_EE%_WP M*=7RO%W&"SN%"G&@J4:2:23NK.WDK6L?H'ASX;2X6JXJM4Q3KRKM-MQL[J]V MW=W;O?4****^)/U(**** "BBB@ HHK(^('CO2_A=X#UKQ-KETMCHOAVPGU*_ MN6&1!!"ADD?'?"J3B@#7HKY^\'_\%!M#_LK4M0\>:#>_#C3[>SL=0M'OM0M= M0N+J&];;;H]M:O)/%<-E28C&0 XPQY UY_\ @HE\&8K@QQ^-[>\;%EM-GI]Y M=+(UY$9K6-&CB8/)+&"RHI+8!R!0%CVJBOG'QY_P5"^&6@>$+36O#^H?\)5I M\\\T$UQ%OLH++9I<^I))(TR*3')# <.@89;V('877[>7PFTR_P!;L[[QA:V= MYX;@>;4TDM;G9;['@C=$?R]DSJ]S I2(LV95XYH#4]>HKG?!'Q1TCXK_ VM M_%/A"ZA\2:7J$$DU@\#^4MVR%E\O+@&-MZE"' *D'(S/'_P %9-/T_P , M^(]5UCP#J6EVOA[4K_2$D&LVMQ%K%U96,MW=1V$>"O\ @I%\)?$_@VQU34/$T&@7$VA1Z[>6EW%*_P#9J-9) M>O \R(8FN([=UD:)6,FWYMN.:T)O^"A7P=MA(9O&D4 ALS?R&73;R/RXQ;FZ MVMF'B;[./.\D_O3'\^W;S0%CV>BO%?$_[?\ \,?"'C#4-/OO$EA'8Z3 YO;Y M/-E\JX6YM[<6ZQ)&6D)>ZB&Y-R[F"]>EK4?V^_@_I&DK>W7C:QMH76Z*K+:W M*2L;:]CL)T\LQ[MZ74L<)3&XLW (R0!J>P45E^!_&VE_$GP?INOZ'=B^TC5X M%N;2X$;Q^;&W0[7 9?HP!%:E 'X#_P#!QE_RDIO/^Q9TS^4M?"=?I+_P7R_9 MB^)7Q8_X*$7>K^%_A]XS\2:2WAW3X5O=,T>>ZMRZB3,/#+HP:00Y0[U$:*C.TC MLQ81(X"N,K7B_P#PPO\ &W_HD'Q,_P#"&?@M MXLOK>_U*TUE4U/PKJ$GV6]MEE2&=#&8R<+,X*/N1@>5-:9I6C4P[6'E%SZ7< M=-K[W6US'+:,H5TZ\9O;:W4XCX*Q?&S]HVZ\?7VG?$35H[[X;Z5)XKO MY-3UAH);@PK]A!C:0C][Y,[1@N1B-BO5E!]"^-/[+W[2GP8\>^&_!FB^+/%7 MB#PSX/N99?"6H0Z[%:V>F-!917D\A0SD67E0S D3E<(W VOM.7_8O[24GQ<^ M)GB^X^!/B*ZF^+EC=6J5N>]/V=K;.V]EUNMG?Y,[J-.ERVJ^TO?=7VOVL^EOFCR?X@?LD?M(^-- M-U";QA9ZM-:W/B>47+:]XCLH5N-7\J*.27]].N]O),7[U H[J\_9Q\0:A\0['Q58ZYI>H7?A'4)[+2DL]+ M-C!-$&D,AO%.T[G+(P&2"WW'A$/PL_:PU32RXO/'SQ?%2U@L[V-M?02ZK"MC)LI]*\-Z19OJZWE]'I^LP-+%) M:V[3*K1O$B@QLZN00/NHVWI;;XU_M>1WW@R\F^#/BBZOO!@A1+B;PMJ>-5CB ML9+%([F(2"''D2,"8DC8L V<]8[;XK?M3V>IVLT7[/\ J$<&FW&A76FVB^#- M1\G2WT:&6WLC%\^[B&5XV#EMP.>#S4RJ8EJR5)/NFO3J_P"7J.-&@G=NH_6_ MKV[]#SK1OA/^U"_B30=:TG4O%AU3Q/KKZUH\@\06\.I7MY/'+&-0>W,WFIYL M-O(#)(NQD3J003YK\4_B-\7?A5-XF\!^)/&'B2&'Q!<#4]=TY-=%Y;:E-,HD M\V5HY'1V<$;ANY(PPR,#WQ?$W[2TMSX7O[K]G6XO?$'A..UMK?7I?!&H+JLU MK:B46]LTZ.K(B"8@-#Y>!_:4^$G[1?[4_P 3V\6>)/@SXVM]2^PV M^GA-/\*WD2-' FU6=F#22RGDM)(S.Q/)P !VX6K)U?WZI\MNEKW3TZO]#DQ- M%>S?L/:$HY;3C)6>OYL^?_\ @I5_R;I%_P!A:W_D M]?!,$/VBXCC'#2.J GH"3C^M?>W_ 4I_P"3)/VFM?VNBW0LJPR-%((W90Q#;59ER.!DG !JUJG[0VN>--;U#_B7Z?]HU^/4++8&;:IOY8W?;DX!# M(H&>,=:L>*OVEKZZ^(-E?WF@Z&L^C:Q=:E/:-*TD M,@"O"EA\E<92BY[JSZ=;_9Z*S[Z>9RRA@G=IRWT_JW_!T,L?LT^,O[+N+@Z6 MHDM[^'3A;">-III)8C*K( V"FP [@<'=QD XS?#_ ,#_ !=XKAMY-/T*\NH[ MJ%;B)E9%#QL[QJ>2/O/&R@=21CJ173O^UMJ)UQM0_LG25NEN[*]B8S2MY3VT M3P#.3E@\+LC9[G<.:BE_:DO(1I\-CHFCZ?9:4]G]EMTEED6,6UU)=1J68DG+ M2$$GL.,45,-DM[JI.WIJW?37ELM/T\PE2P-[J4K?GY[&''^S_P"-)M;&GKX? MO/M9MA=[2Z!1&6* E]VW.\%-N=VX;<9XJ.P^!GBW48[-H]$N%%])+% )9(XF M9HBPER&8%0A1@Q. ".M;ME^U%>?V?'8WVC:/JFE1@NUI)))&K3?:Y;N.7U:[\5:9K-_INEZE<:?;7]O\ -OC\S[7*\KNK*"5O>?\ 37EZ_P# Z\SXO^%FJ^!- M!M;W5(UM9KB^N+![-P1-;R0A"V[M@AQC!KH?V2?^3G/ _P#V%$_]!:LWXJ?& MO4?BV!]NM;.WQ?S:A^Y+ (P1WY-:7[)/_)SG@?_ +"B?^@M66#6 M&6;T%A&W#GA:^[U5_P 3.G[+ZY!4?AO'?U1^F@Z44#I17]8'Z@%%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %/M_\ 7+3*?;_ZY: &4444 M %%%5]4U6WT6S:XNIEAA4A=Q!/). !R23P * +%1W%S'9Q>9-)'"F0-SL%& M3TY--TS4;?6K"&ZM)DN+>X4/'(G*N/45Y#^U1\=/#OA[P'K&CV?BBQA\61P, M]M9VL/\ :$X=1\RO$B2%05)SD A22".M '._\%9./^";_P 8?^P _P#Z,CKW M#P5.D/@'1Y)&6.-=-MV9F.%4>4O))KX;_P""B7[;GA'Q-_P3Z\>>%+>QUZ.^ MU7PVMM:S2I";>5LQY(;SFDQP?O+N]J]$UC]O31/%WP(L['PW#KUAK'V>SM[> M\FLHIX1*NS<%C1Y))#@' \L@\5-RN4^M4D66-65@RL P(.00>]+7$_!3XE^$ M?&/AVWTWPUXDM=:DTZ/RY8GG_P!,0@_,7C;#KACC[H Z=L5UVHZI;Z3;^;<2 M+$G."<\\$\?@"?PJB2Q14=M6K%^0#0![=537]!LO%>@WVEZE:P7VFZE;R6M MW;3+NCN(G4JZ,.ZLI((]Z^5?AU_P5AT+7O#,U]K7A/Q!]K6"VN$L?#]NVJ3! M'TJ'4IF;/EC9%%+]X9W!?4A:VO%O_!4WP+:>(K[1?#>G:YXFU6TATW4+86\" MM!K%C=W=I;>=:,C,SLOVR(JCK&7)P.,D*Z'RLMWO_!*OX4ZQ82PZBWB_5IEL MK/3;"ZO]:>YN-(M;28S6\,#.#A58XS('8KA22 !7/?\ "NOV??@6TOA]KK7; M6;P/XR\/2R1-<7$TB:O]BBM=//3,B&%TWD97<26((-?1'P;^+>F?''X8Z7XJ MTNWU*QL-4$H%OJ4 M[JV>*5X9(Y4R0K+)&ZD D<<$U\D_M0?!CX#7GQ^\3>* M/%/C?P[9^/+CQ#HNM17']EB[U#1(K".,M;*ZG/ER+$SN?$U(P7>32_,IZ%X<_94^-?PHMK>UNO%TVBRS:-X>M8 MW^VPW-R^H:9+IUBL:LH9@]K<2@N/E#(Q)!0X]_\ B'_P3W^&?Q.T*?3=8T_5 M)H)9KRX&W4'#0S74MM+)(AZ!@]I"5Z@888(8BO$_V3_V2?AFGQ*^$NO:/\0K MC5M0^%GAW^PSIEU8#3SXADB6;[)?M&[;B;>.\NE4+O4>>=^%_@9X;^"'[-MWX'TG^W8?#=CI=Y$ MSVUR[:F4E$CS/'(N'\XEV*E<$';MQ@5\JVWP\_9CUKP9\,_ LOB?QYKV@ZSI M]F?"-K)49HS<9$IW IO/0FON;5=7M- TR>^O[FWL[ M*U0R33W$@CBB4=2S-P!]:_.O4/@M\(_ _A_4+7PC\:IK/Q%,K1IWVYI)7]+[GH7B3X1?LW?#']I3PCX5E7QYH^J>#_$%C;Z+;VZ7C>'-( MU"[F%_962RA&AA#R_,D091^\V'*[5'TS\>_V7O!G[3%DMKXRTV35+5--U#2O M)\XHAAO4C28X'\8\I"C]4901@UY-^S3\!OA]\1OB;J7Q#U;Q7X9^+'CBY.G7 MGV]-.6R.FS6D!@2XCM?,;RRQ4LK$94YVL>M?358RIR@^6::?9G52KTZL54I2 M4HOJG=?>CYE\:_\ !/;X-_"_X::UJ&H0>+D\)Z'I$MY>Z;;ZG<3P%H--6R>^ M$"Y:2[^QQ"/<,DXR%W')S[C MW,5O=RQ[?+$[:;;S)@G 51E0Q!/T-\1_BKX7^&6FJ_BC5K'3;>\_=!)V):8- M\I^106VG.,XQS7P#X;^&?@[X!^%])T+X?_$K7X/$&A^,9_$&GZW/X8@OX4B- MG)I\&GK;RW,6Z*VM'"*X/(0-RE*2[I.WWGF8_B++,#+DQE> M$'V$/A+8VGC*PU;P5<0>'-*E>*^;3_ +89HM=2 MW>\*F)[AVB67#-DJ"OM7I?B3_@F3\,/%6MZ]?70\4*=?^VA[9-7?[+9_;+Z* M_NQ%$05"RW4*2.KAU;+*1M.*S?V4?V?? /BOXD:[\3KS7-&^(_CRZO[:YEU) M]*^P3:+=1:?%:MLMB[>2[H&;.,@2LH)'-?2U<=2C.G)PJ*S71[H].AB:5>FJ MM"2E%[---/YHY;X)_!W1/V?OA5HO@WPW'=QZ'H$!@M%NKAKB4*79SN=N3\S' MCH!@ =3114F@Y9&4<,P^AH\YO[S?G3:* '>:W]YOSH\UO[S?G3:* '>Y'3FO+?A)INB:Q\1=-M?$4ZV^D2L_FL\IA1 MW",8T=P"41I JLW8$FO7M&\%?#$75(-$6ZFFTFWO[*+5G>UTQYGF6[\F4 M/EQ&HB;)9@I/4CBO&R&.,5%O#U(03EKS;Z+\CGR_VZ@W2E%:]=]BA>_M3:;8 M&_AT:UN;&S:W L8Q8P?Z/-_:#S[^_P#R[L$[X.1TYI-;^/O@?48+VXAT_4K6 M[:SO=/M+5+"'R3'-?BY20MORK*@*[0#CUQ46E^!/AV^B>&?MLI1 MV_2_E_7>Q5U3]I[P_K>O37+V^H679K?:7!J\LNFV8EO&B=TN%)S+Y'E,J%\%G;C/R MUSGQ.^''A'PU\,M:UJULY(+Z/5KGPU:VSRO@3PW3M]J7/WA]F"H03C<3TXSS M9EA\QJ8:4JTZ;BKMV796ZK?7U\]#+$T\3.FW.4;;_=\M_P 3QG->B?LD_P#) MSG@?_L*)_P"@M7G=>B?LD_\ )SG@?_L*)_Z"U?+9)_R,:'^.'_I2/(P/^\4_ M\2_,_31>E?'_ .VY_P %.]5_9*^.)\(V?@[3=N>]?8 Z5^3_P#P65_Y//;_ + %E_.6OZ[D?T]X6Y'@(/^B:Z+_X.9?\ MXU1_P_5\0?\ 1-=%_P#!S+_\:KR;PY_P3]T^_DLIK_QR+/3]<07NB7"Z>I_M M:S-O!)YP+2K'$PEG$.)'52R-AB<"M+3_ /@GMI>H>'-%CN-?U;1M:M_[7N=> M-S9Q[4M[.Z%NGDJTJJ)"S1DJSXVNS;OE -'<7;V-^]O:Z:-]_)IV MO9V3/1_^'ZVO_P#1-=%_\',O_P :I?\ A^KX@_Z)KHO_ (.9?_C5>0:A^P7I M/A31;JX\0>/I+.>SBU"\<6FBM=0O:V=Y#;NZMYBGS&$\95",!L@L ,U/XH_8 M5TWPK;K%J6O7%K:Z&=SFM(X?*MMX&\_:02-P &[)/%+ED M:?V'X?-I1H-W;2_BZV3;M=Z[6TN[M'J__#];Q!_T371?_!S+_P#&J/\ A^MX M@_Z)KHO_ (.9?_C5?$GC?PZGA#QCJFE1SS74>GW3VZ336KVLDH4\,T4@#QDC MJK#(K+I79]52\+^%*D%4AA59I->]/9_]O'[#?\$_OVWK_P#;3TCQ1=7WAVS\ M.MX=N+>!%M[MK@3B5'8DEE7&-N.,]:^AJ^!_^"%'_(I_$O\ Z_['_P!%2U]\ M51_+G'F68;+\^Q&#P<>6G%JRNW;W4]W=[^84444'R 4444 %%%% !1110 4^ MW_URTRGV_P#KEH 91110 5S_ ,4/$>@^$_ M_J'B6Z2UT>W4>9(2V_<>$$>W MYC(6("A?F+8QS63\5?'FM?#RZL]0M]+NM4T.-\:@EM )'ABVG,I;=N&UL' 0 M@KGD5\V^(O$M]^W+\:/)M+J\L_ N@_O(WB_=L8GR!*#U$]P-VPXS% -PPT@- M)L:1C^"_$?Q&^.>A-X5\-WUYIGA#3)YH3=SN8"(]YVQ3RQ'?(X4_ZB!P%Z22 MY^4>G^ /V)?"/ANQC34H9O$,V0["Z_L^#_!UC MX7T:STW3K6WT_3;&,1001*$C@0= !^I)Y/6O!_@C^UYXI^*7Q-N-0_LBQ3X9 M7VMRZ%H\L5O(U[C^$?\ @G'\ M9&TW1]+TU5\.N_\ HMG'""?-BY^4#GWKUC0O@_X<\:?#W0&U3P_HVH>;I%J" M\]E&[X,"$@-C<,^QKS+_ (*ZVVK>)OV(_B!X7T&\AL]0O=)$LP8(_P!JB\S/ MV;#]_ [P_J&D? _P &VNJ7_P#:VI6^AV<=S>>2L0N7 M$"9;8H 7Z =J /$?B'^P_I-T\=YX7OKGP_?VIW6\4LDDUK&>P1MPF@QT!B< M?W2"0>.3XL:]H/C[0/#/QDFU1M"T=I;E+A"&DF^55$TDR ?:;=5+AG15E0,? M,4C+5]=W>FJ!TKB/BS\)]+^*/AB33=3CD"JXGM;F$A;BPG'W9HF_A9?R(R#D M$B@#TG2GM9-*M6L7ADL6A0VSPL&C>+:-A4C@KMQ@^E6*^2/V>?C=JO[-_B[4 M/AWXFM[S4[>-S_9$5C -WG-N=%A7=_J+A0[(H_U2 =Q88XR=$0SJ****!!1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%.\MO2FX([4 5]6UFST"P>ZO[NUL;6,J'FN)5BC4L0 MHRS$ 9) 'J2!65_PM'PO_P!#+X>_\&4/_P 55+XP^ IOB/X7L=/A:U7[-K>E MZG(+@$H\=K?0W#KC!^8K&0 >,D9QUK?/A_3\_P#(/T__ ,!D_P * /,OVG=( M\,?M%? 'Q1X'_P"$R\,Z=_PDEG]D-Q)>0S)&-ZL^!_&EYKVNZ3'<6NJ"W2U@TZUU0W,*W"_:%\Z&WM1';[$PS* MF1SQ7Z0?\(]I_P#T#]/_ / 9/\*/^$>T_P#Z!^G_ /@,G^% SX9\(_\ !.W2 M?"?BGPMJ'_"UO >H)H;VETQN8PT]BUM)=R?V=9O]HQ%I2WND$5U$=IVNKJ@ M4YSC;V-5-7^+WP[T'QS:^&KK4O#Z:Y=2B!;185=HW;[H;1+"XN7:_MX[! M+)'DV/YRQQ6\(CPA^<$A@P)KOOA5^RK\!?%>O2>-?!_AW1I+[4GAO7FM+F:/ MR<307,8^S[P(09;:&39L4%H\X.3GY ^-'Q$U#5+W6-4FT>^,T>J/J=NYE@:: M7&_RTE"G8_F0D*&#$8;G!45B?\$Z?VNK^Y_;9&A:?INAZ<_BJ"'36M=0FE+0 MQ0/))*EN\*,/.$>T@2*L9$>-RX7/Z#BN!%3RJ6.A-N44FU;1]UY67778_&79OO=Z6LM_)GT)^U]\7-'^&-V/A3H,KT;)'7'MO[9/BKQ!X4_:/\>--H[>(-)CN459%&&VKDEESGFOE;XH?##4/&BW5KJMSJW@[5+Z:2_U#Q%<2-]A>&*' MS4MU1=B87"@EN5,1QUQ7Z1PG@*6%RFFZ:7O14G9J[>[[6]'?H?A_B!FU?,.( MJ\<1)_NY2A%-.T4FTNZ?RM?4]2T@^(-2L=8L].VR6^@V,%GI]I.$^UJ\NURV MY3M\P;6;@G!QQ7Z'_L=_M#WGQJ\.W^GZXUJ_B'1&1GEMT*I>6KC]W.PQM1RP MD1D4G!C)X!%?EUX--QKW@Y?%'ARQ\^'4+ C4(KN\:1-5D60&2]28,I5D8,!P M,!BSTOK9-.S=[ZO;S/8\(\]KX+B"G@*P>(O$GBZ[78([R#8RH2NU$Y\H)SP03@\ MGI6S\;1YOPWL8].N+_\ MZU\1']Q=G-RUREP99$(ZA5(PVX\!>[ZOY[[_>?G_$V9XG,$/''C#X>_ M%33;KS]"WC5KR^\N:Z,+/O0)R%W"1N&.00N>E?87P$AO(?V%O&]UIEE M-I]O?>(T>X^3.$"VR3,@7).)!M. ""&Z 5\EQYEF&Q-&A6JI*?/&+>WNR;NG M^:[:GZ%X1Y]C\#BL5A\/)RI.E.:CJUSP2LUV[/NK7VT\9^/?QXUWQ_XNU'6; M[R+?5KQRCK;R%XX(5+^5;@[5)"(2,X&YMS=Z\LU'XPZ;I?B:SL9;R:WFNE:: M&W%?&=K=Z? M)]EODC607=J3OAE&-I9^F.@8-D=J_4+X1?$JS^+OPYTKQ!8LICOX%:1 P)AD M ^=#@G!!['D9&<=*_(7PO9+!JZ36@NH8;JYE\U(O]0TP(!SG)"G VCCD'K7Z M3_\ !/:VN(_@SJ4MQ(K&;5G 11A8F2&%)%QZ[U8GKR3S7Y9XL9706'IXQ64T M[>J?^1^^?1[S_%O'5LMDW*G*/-K>R:ZKU7W_ "/=Z***_"C^M HHHH ***YG MXP_%S0O@1\-=4\6>)+J2TT?2$1IFCB::61W=8XXHT4%GDDD=$5!RS, .M '3 M45XH/V__ (=Z/JNB6'BB?6OA_?:_=WEC;0^*]/;2@LULL#.K/(?+PPN(MC*S M*Y) .5(KM=2_:6^'6CP>))+KQYX1MX_!S1IKK/JT*C2&D;:@G^;]V6;Y0#U; MCKQ0.S.VHKR_2_VT?A=J5[K<3>-=!L8]!E$7<<%MI7XF:WTZ_P!0A@O)EBDFC9EB M+;B-T$H!'78>X(KJ/A)\6?#_ ,=?AIHOC#PIJ5OK'AWQ!;+=V%Y"?EFC/\B" M""#R"".U '1445Y/^U!^VIX"_8]M+:?QQ>:E9Q76FWFJHUI8277^CVKVZ3,= MG0@W46!U()QT- 'K%%>%^,O^"AO@'PG;1W-O9^,/$6GS:O;Z%%>Z)HSWMM+> MW$=O);PJZG#&5;F+81PAYV*RG#8B?M*RN_5GQ*?\ M@EKXH(_Y&C0/^_,O^%(/^"6?B8#'_"3^'\?]<9?\*^VZ*\W_ (AOD?\ S[?_ M ($_\SG_ -7\%_+^+/B0?\$M/$X.?^$H\/YZ?ZF7_"@?\$L_$ZCCQ1X?XZ?N M9?\ "OMNBC_B&^1?\^W_ .!/_,7^K^!_E_%GQCHG_!-?QQX9FDDTWQOINGR2 MKL=K8W$)=?0[<9%1W?\ P3.\::A:P07'C32KB&UW&&.3SW2+<'O$5UXAT6ZM]'O%N9(HHI \@ (P"1C//>OK.BGA_#[): M-6-:G!\T6FO>>ZU0Z>18.$E.,=5KNPZ5^3__ 65_P"3SV_[ %E_.6OU@K\G M_P#@LK_R>>W_ & ++^"; M6;PK:_VOI-IK-K+>7=C%K,<-N841&DDG DVQKM=,E\!MP'/2O']GF?* 69N M ,DG_/:O=8_VX_B%HRV=LND:7;VGAVTF@NK,Z?9$N(T("-& MH;D#FB-NI_2G$7% MPZ6^OQ,\=UY;/<;0LI+2B,$R 9('+#D5>\$?!=S/XC\,^%YK5=8WV M=]?6@NKC1Y[N""]\FW9I&**\*1,"P9E' 937.I^U5X[LM%\26,FGP^3XMO+O M7"SVEQ$UG)<+MGFMRKK\A7'+[U&T'US7N^9\M1IYK.A^XI8=J^FS3UN[.^MD MVW?N_GK?$']FKXM>&-7US34OKSQ!9Z1'(EQ<6VJ*T=SYL2WUQ&BL^^1L 2.@ M!8E58CE*M8TO5-*U:WLK:W74A)=)]NMS,\CLDA:( MLD<1*.H+!E/:M;2/VHOBK\3[FY\.Z;X9M+B\\22QV^;73KFVD2\-NMM]HW+( MJK*\0BW%_D&Q&VCOR_QR^.'C+Q)X7U+PGKVAZ#9JNIVXU'4=/L&634KVRB:V M0M.&,@:5*-'L](N;SG9%.L\,DCW-J)02/X6A29"IX.>%42X#D!5NKEE<7!R0LV, 9E^;%?.7P9_;A\0_%3XI7%V_O:-9MTRJZ1(&=E%K<6P#1@L.B3QS@*6) (X5=HH ]HEML]F(']:R=2L<;EQ[$>E? M_P"UK8^./VYO^"EUK\,]!UO5-!\(_#S0I]7+VEQY<=Y-=--X6N8UM5N2[2164\?F11$O\Q\IUFC M.6"HF3DX !2_;A^'QN?"=CXHM7:TO_#\Z12W*G:T4$DB[9">WDSB&4'G&UP M6K7^G7$*%AN".8VVM_P%L'ZBO'_V(?B%XXU/X1PQZ)H-C<>';?5I MVDF>Y'VJ&*01S;8HS@.[-)(V7."7YZ541,^K**KZ6]Q)IENUXD<=TT8,R1G* MJW< U8JB HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH 5?O#/3/-?GWXQ^/WCZ32?BPO\ PFGQ4TSXO:=:^*1%X5L="\[1M)LX0ZZ7 M=1.T&T9B2&2.02.9999%((&%^U?BQK.IV#>&;'2K_P#LR;7M96PEN1 D[11_ M9KB8[5?*Y)A49(. 3WK"\2ZX_@V2./5OC!:Z;)+N$<=Q;:?&[[,;MJE(=(\7>)M:G\76K?#_1M-N/[% M^Q)Y.NOH]ZD&KO&WE;G-]&+AE &X;5V#D$_;'[&VJ^+/%/P#TWQ%XTN+YM:\ M67-UKD=G=1>4^D6=S.\EI9;2JLOE6YB4AQO#;@22*Z*'PAXFNH4DC^(5])&X M#(R:59,K#L00F,5A^.[GQ5\-Y_#MX?%DVK0ZAK]CIEQ;7&F6T:R13RB-B&10 MP8 Y!!ZCO4(TT>QZ)JFJVNAZ7@K;^,=E8 M_$CX2^+/#,.MZ/:W'B#1[S2XYIKA&2%YH'B#,N3?64VP;WV7"-M'M?%3PSX;O-3M]0 M\0:/8S:+%;SZA'/=(C64=PYC@:0$_*)'4JI/WB"!6#:_M3_#.]\1W^CP^/O" M,FJ:7<1VEW:KJD1D@F>40JC#=U,Q$?LY"G#<5X+^TY^PK#^T+\6_&OBJ'X@V M^D/X@TW0+*PM(-6EAM@VGWLMQ*;R*-PEPK*ZB,,#L8$]ZY/3O^"?&K:IK'Q( MT_4O&G@W2?"OC#3=3A@M=,OIIHCJ4]^+ZUU%+:]:->3_ M +'?PK'P'^"^G^']8\2Z/XE\8:A=W.L>(M4LV6-=6U.ZE:>YF2,L652S85?X M54#@# \=O_\ @HEKX\=>)?!;6G@G0/$O@.77I_%-]J]Q<#3-&TZT6%M/O'V? M/B[6Y@8+D\+, =R[:9)]=4Z+_6+GIGFOB#_AY3\4/AI\.M'UCXA?#WP_I=[X M\T2^NO!=I:S7,;ZKJ"74$5C:3K(,P-'=%NY[RTTR>^N;[5SIYN7O;]++R]/B\MSP2^^V.#XGT]'-]N0".;[&9\8Z1&0]!7T M3^P[;_%G5?C7XCTWQ]-XIAT/X1VL_A33[O4 R0^-)IKMYX]3!S^^\NR6TBW- MDB1ICG+,!YS8?\%5/'7QF^ GQ&U7PIX?\&^']>\*Z%'XB@N#JSZS#!:F\N;5 MX+B)8XS%>_Z,76)B5VRJQ/^./_!1/XC^!OVC?B1X9M[_2=-TO1KNWT?2U M:RM[AM*BD33'FUB[#2B58(TO)V#LH@8Q;"RLI)11]^45XW^R!\?[[XE_LF:; MXX\:7MA%)#+J4=SJD<8M[6]MK6]GMXKU5!*A9HHHY1M)4^8-N017>>%_C;X/ M\;75K;Z1XHT/4+F]7=!##>(TLG&=H7.=P )*D;@ 3C@UI&G.2YHIV1SU,12A M-0G))O9-J[]$=117"_'_ .-$/P4\$"^5;.XU2\F%O86EQ,8UN&ZN25#$*B L M3C X'>OE7_AZ3KWB+5CY-GH^A+9W,>ZSE0S/>*"5D3>[JP#%7*D1J0 IY!-> MSE?#N/S"//A875[7NEK:]E<^9S_C?)\FJ>RQ]7EE9.R3=DW:[MM\S[DH );C MKVKSO]FS]H[2_P!I+P?>:E8VLNFW6FWCV=W8S3+))"0 R/D=4=2"#@.E?H;^P9\5=4^-'[)WA'7]! MZU^C<=9)[#+\'CJ4KPY5'\+IV\U?\#\2\)N*%B6ISNIMHM>64;^3 MM96[GS=_P4$_9P\&_#'X+^*+/2M6\0R>)I+!M2T/2Q'NM[4+<*0NZ)%8C_6* M@=B!U/ R,G_@EO)\(_AUXS\-[O"6J>%_B?XHT9K*>]UC4OM1FO(FQ<00*6(3 MS=AD4K]Y48<8&[Z+_:__ &%[7]IP76I6/BC6?"_B"2P-B'C(FLKE!NVB6(\@ M?,03&RG![XKB/^"?_P"P#JGP/OKCQ3\3(_#.M>,X;@MHL]A-/<#28F0I( S[ M4)?@@J@*AF&>37*LZP57(94<3B)RJ?R7:U>B\G!65[W=[]SN?"V9X?BV&)P. M#I0H.WOV3]U.[\XU'=I-65DEL;'[;_[-6HZY)IYCU&WMV\N[ MXR#^N0.*\'_ &S]1\&_"SPE#K5]X1T74];\07L&E_:6TY9)%C>0 M&61V4;LJBL5.=V[X3XRQ6'4, Z?M%M'6S79.^Z78GQ%\,;:NGM>UMF[6;U[]SXETKX:W%]J.FZ7#<'6[&_L(A<6EM:YNIEB5@$A2+[B, M?O C!+G!&>/O3]BW]GZZ_9W^%EW87T>FV]YK&H/J3VUG'\MBC(BI 9#\TK*$ MR6.!EB *]"\%?#7PY\/K../P_H>E:3'Y>Q3:VRQL4)W8+ ;B,G.">M;E>9 MQ-QE6S2FL/&/+33O;>[Z-]-CW> _#'#9!7>.J3]I6:LG:RBGNE>[=_/[CX:_ M;8_9!O/ 'Q,UCXA>&+&TFTW7?])N@\32+I5Y@F25@N"L,N Q;.%?.KS>-+:&9=7M)/[.N%G#6<4"X69%R N\XY)[<=J_:3/^%>'^)/# MOPF_X:CT?PG<>!O"MYXIU/3Y=:-V;&$FV\HA4!7'WF#.1[*20'RH1&I"B>XE4@LJ@_*FX-+MXXS M7ZE?"KX0Z3\)?A/IW@^Q6273K&U-M)(_$EVSY\V5R/XG9F8X[MQT%=%I.D6F MA6$=K8VMM8VL(PD-O$L4:?15 _*K%?-<3<5U\WFKQY(1VBGU[ON_N/N^!?# MO!\.4I-2]I5GI*;5M/Y4NB[ZL_,_]H?]EJZ^#_BF/^U[&\ATV&3[/'K A(M; MQ2<0C>I*HQR!L;!![]#7CM[\/6EU.2Z:QC^TPX;SP@4V\*@@+T)"X(Z]P2:_ M7CXBZSHOAWP'JU]XB2WET.SMGGO4GA\Z-HU!)!3!W=.F#7AG[+OP=^&_[07P MOL_'DW@NS@_M^2Y5;"2YGFM$@2=XXP8&Y+XEXBC@>?&T7 M)1:CS)JS;3=G?K9.]K]-#\AXH\#L)B,V5#*\2H2J)SY))W44TFTTG=)M632U MOJ?(?[/_ .S_ *M\5O&UOI6DW$:B^8NDD*Y@LHE.7DD&&4E5.%&?F8@"OTM^ M''P_T_X6>"M/T'3?M#6NG1[!)1^"KO3O%FE007<4C113MK,$6YVFBMXK>Y1R65FQ^O>'WAS@^&*$E3E[2K+>35M.R6NE]?^&/ MM>CI7P=I^N_M>:-K6EZA#>:YK7G:A9LVDZCH5E!9[+BWU-94EE15D6*![?3S MN# AKEF)(("^Z?\ !._Q!\7/$7P1QF*-I481X6 M1%G,JQN$7,84?/C>WR1^B6L>H^//COX,^%U_=VWB3Q-H^B3V&D2Z]<)>3B+R M;"*18Y+EL\;%D=%SZL!U-8/AW]L7X6^*_B>/!=AXYT&;Q8S"-=+:4Q7+2&)9 MA&%<#]YY;*^S[VTYQP:\G_;2_P"">%Y^UA\/K7XN:K\1K'QEH!\5:EXKN MO$T6DWOVR?P_933:-%8QW44 8;;V&='99L'=#*R$9P0P/H;Q)^U_\+_"/@#4 M?%&H>.O#T/A_2=6ET&ZO$N/-6*_C8K);80%FD0@Y50< $] 2+'Q=^&GAC]L# MX!W&B2:J]SX=\316M_9:KH]RC,K12QW-ME0Z1X;\9>']8T3?9:K/%J]M<:;?1:S#;36LM_:W=@8G@ED22-VDV MNTK1D294U]A?L[_#K5OA%\!_!_A?7=9C\1:UX?TFWL+W4TMQ;K?2QH%:01KP MN3_]?F@>AY)XU_X)X6_Q?T*2/QY\1/%GB[69]+US2I-0N8+6%8(]5MH;:3[/ M J;(5B6!6C S\[N26SQS&F?\$GO#7A[6=8U;2?'&NVFK3:FFHZ#>RP6UU_85 MQ]J:YD38X,=PCSLYV.HV@\?-\U=S^T/^QQJ7QE_:$\+^,=-\4'1]*L;0Q^(- M(>-I(==FM2\NE.V"-JP7$LCN 1YBD*_ETV^M;[^RTDFM;6&6\ACB>-DNDDMB\>&V@3N"RL"-;]I7_@FCX7 M\.>$O&%]IWCJ^M_B)\6+%/!7VS63&MKK$DMK L-K)'#"4APUGYRLD:X)93E" M%KL[C_@DUX;O-6;5+CQOKTFJZS=7)\2W(LK)$UN*>[ANVMTC$>RT;S;>$!X0 M'V[AU(*\I;_\$N?&L-Y,W_":>'%N%\2KK#:RD%ZNK:[#OU!_]/;S?+>5/MD< M:E4QL@&6P%49?C;_ ((]:UJ7A:STO1/&5CI^GPW5G<3:;ONH[66=-*@LY[W* ML9!=":%IHV!!_>MEE;Y@K >L2_\ !+SP1=:[+>2:WKDLRWFDW3(1 QC.GZK> M:I&F2I*B22]=&[E$3ODU[7\ _A0OP*^#OASP7'J;:O#X0_LF?L8>(OVF7WA[Q>'>*PCBEEN MVG:X:7SY9YB9!A6*>7O=.Z^6H"5S/[0__!.'7/C9\?=?\<:?XTC\-WVJ7VGO M8WMNLWV[2;6'2;ZRN(HF5@ 9);F"; P#Y W8'![V4 M8QTVN_MCYFL?^"0OC.U^%VD:%_PFGAPR6S7D;QS?;YK727N([-!J=B!(GEWT M9M7=?E5-US(D'C+39-2L[&R%YJFG">WUB\EM=.U.S2*.61BFW%Y;LAD^ MZT//&TCSGX9?\$MOB=\6O!\=QKD>F_#8V>I6K)X?#RQ6D@33HK>6[00SRLDZ MRJ[*^\;V9V&S(8H#],7D6,-N>-?+72[C;4#)J\-]:B9U8Y$,4;Q[2K(2Y&PJS _2W[-'PR MU7X+_L_^$/">N:K:ZYJWA_3(K*ZOK:U%K#GO1MYQWH **<8V':FT M %?D_P#\%E?^3SV_[ %E_.6OU@K\G_\ @LK_ ,GGM_V ++^?"O[=FB>"M-\26-Q8>,/$5Q?I$!J>N202W^IE+:2$V]WT'D@N& ;S2/F!!) M!7SG]F#Q-H.E>$_'-CJTWAJTOKR/3;FPFU?\0_!'XG_&/6=8UAO"\5YJ%[KK0R^?*EE>.+N VD]P6? 9X3.5((5CG(R%% M7"]KIG[-Q54P5;'SCC<)4J*,4N:%];6FM--+MIN_37R\?^.7[2.G?%?X6LTFL6&I^9*ZE EOI$5@R\_MQ>&/B'J.FR7FD^)\M MH&JZ'J%V)(A*J7MM'"ICBW>26C*9RJQ!@0-H()->W?X+77BS0M-L;+PA9Z;< M/J]Y=WVIW-S.Z%)I%LK1G#HBAH]I5V7!^7=GH>M\1_#CX):;X=N=_N7OC%'IMN\$5@%.UI$NI3E7&0"1R :<5+=,\W'5LE4:.&K8*NK MB/[?;+8VUL ML#[2 Q#0,V#\OS"K7@[]OW1-#\':183^'_$?B#4K+4[35KB*^N5N8Y[B*YDE MFE#,68-(LAQA!M*X);)(A\6^'?@/?ZCHMCH]UX=MH[[2KY([^:_E$<$YTY1; M&\'+1R+>9.X@=2"I4"MKPKXJ^%_A>*/2=-UKP?9V>A^)#=F]BNIX;JZADT1( MC)!*"&9/MGF*PR, ].:KWMVSCJ4B\]!["OIG3]+^#<.M^%7;_A KKP_-;1AHC?W<.L>=]A_?->LP M,* 762BD -\O( (/C/[0UCX9T[XS:Y#X/NK*\\.^8C6CV:.MNN44NB;V8D*V M1G)!/(XP!G*_4^RX2E@*>*J4\)AZE.4XIR%Y0I.-VU27_XW7PF.K?[Q_G16=V>U'AO+FKN MG^+_ ,S[L_X?G:__ -$XT7_P;R__ !NC_A^;K_\ T3C1?_!O+_\ &Z^:_P!E M'P-I/C^3X@6NK6]O-Y/A9Y+220 O:3-?67_XW7!W M?[ /A_2=+\>7G]I:U-#X7NK]M,NC+"]O=QVGV=_+GC5"59Q,5R73.,JK &M+ MXT_L4^"+B;Q-KEKK4VA>=KEQ;P);1*VE:0B7D%L(90JG;N21I QD7'R@(P): MGJ8_5_P"B<:+_ .#>7_XW1_P_-U__ *)QHO\ X-Y? M_C=>$_MC_!K0O@OX5\%V&CZ3J^FW!O-:@NI=6,+7U\L-S$D4K&(!3&RY:/CA M6ZGK7A-+4]'#9#E=>FJD*>C\W_F?=4O_ 70\01QLW_"M]$^4$_\A>7_ .-U M^@'PG\82?$/X<>&_$$ENMK)KNEVVH/ C;EA,L2R%0>X&[&>^*_!*X_X]Y/\ M=-?NK^S%_P F[_#W_L6]._\ 26.G$^>XHRO#82G3>'C:[=]6=E1145]/);6, MTD,+7$L:%DB!P9& .!GWJCXT^8/VX+R30/VC?A;J\D;&QLF#9QCS93>V\2H# MZA9V?'HI->^:3A/ES]W@5\]_MI>%/&WCWP&VJ:MI^DV.D^%Y3B]MII%N)([A M1%)($()1$+QL3][$+X^\#7JOP,^(B_$GX<:3K)Q'<7$.R[B'_+"Y3Y)D('<2 M*WZ=>M0S1$_[4FH>,$^!>M:?X#T&ZU[Q-KD+:=:".>&&.Q$H*O<2-(RC:BDX M W$MCC'(S?A]^RG:_#+]F;PEX-M8X[S4/"J+=%E95%W=.KBXPS#^/S90"P&1 M@$C)->H:?)YFU0?O'''O7@?PB_;PU#XI?$RZCM_#=O%X#;79-!TW6!.[SW[Q MA%>3RP,*@=XR.N5?U5\(#E/^"@GA+7]>_8/^-&I>(K-K2ZD\+S0B,R!Q(_[M M=RA6( "*#@@$-+( !R6U?#^J:Q^S_I'A6^TO2;S5I+G1(VL(4R8YX;F"$S1E MC\H:"Y5)BN0Q@>0)G9LKHO\ @IEXGV?LA>/M$@1)9K[1)/.4J3,;[7+: MUT:WNIAAKFULS*WGXP"JS7$]Q( 1]W81@$*OB6JP77[$?[;=]JTUA?-X#\<) M.[W5O:M,MK'+)YTA.U20;>Z9W*YRT5R6&XIA?M2>[_/U/>LS4+S:I7=WSU_* M@#COB7XGMM'^'FK:PS>=9VNF3WN4_P"6D8A9\CZK_.N#_P"":^CW&C?L_P!Y M#=+\T6KR6\; ?))''!"BLI[CJ,CN#6?^V_\ $*'PU\*I-+,C>?XAE\E@C%9% MMH\2SLN.V44'K_7UHJR HHHH ***^,_VO?VO_&'P:_; M>\(>';'QMI.F^%+JXT:UN]$CM;:;4)S=W31RR203JL\T!CQ^^LY2+?RV,J-T MH ^S**_->W_X*:?%+XBWOCG3=-DU;06\8:UIMU\+[I_#L=J;G26U6&PN([>6 M[7[/=N\,D-R)22BB[QN^48Q/%'_!1OXN>#/A]X7U/5OB5HEC+97.L#5=,DTR MPC\2O]EU*."."ZM'407%PB;DDM;&5)OWB2*7!!)@5MSPX,KJ1@@CS>01QB@9\LP_\%3? M%GB72?#<5CX-A\-ZAXET?PRT=UXEM)+6SCO-6OA:O=1A9"9K*,99.49R5!89 MKNM1_P""C5O\*9/[%\4)I'B_5]&,DOB+6?!\JG2](MCJ9TZ*1HIY/-DG$H(E MMX3(T91ADY7=Z5K7P/UOQ'HDFFW^A_!^]T^;3DTA[:?0IWB-FAW);[2^/*5N M53HI&0 :S8_V8;B*'P[&OA/X)K'X18R:(H\.2XTMBVXM#\_R$L Y(ZL W49J M=1G+_LB?MH^)OVDOB]J'A&\T71]/O/A]8W=KX\-N9'%EK"WTEO:V\!8\));P MO;_M&_M0Z#^S)8^'I-:T M_P 0:K<>*-0;3=.M-'LUN9YIEB>8Y#.@ "1L!M=N3)86T!;3]5$MDT.V19=S+A;@D%3D,@( M(H%YF)X,_P""GWPS^(GBSP]HNA0^+M6OO$-E:WRI!I!W627#3I&LJLX?.ZWD M#-&KHF 6900:ZCP!^W-X#^)NFPW6CR:U<0R>#F\<2%M/93:V"R-%LE&?DN"\ M=SWQ6M3#UJ:4JD6D]KIHYL/CL+6FZ=&I&36K M2:=EMT*^F_\ !3;X/:YX?^'^J:=XB?5+/XC:G;Z/9/91"X_LNZFMTN$CO@I/ MV8A'0,6X4MSP":Y2S_X+$?"'5/!.F^([*W\;W^AZ@NI3R7EOHF^.PMM/O([. MYNI_G^6$2RQX89W*V0*Y;XK_ /!+7X8^"_A/K3:UXI\5VNFR:)9:-NLVAANB M]KI*:9;M 0!^_81K(!T,G'WLKI,/B/ M3K1],BN;VZ@O)(UCY(>,P[8VV[#AQDMMSK1P&)JTW5I0;C'=I:(PQ6;X'#UH MX>O5C&KOHM/4]E\=_M^?#F7PG::@MEKFI:G:W6M?9K V8ANM.GTK_1[ MN6777Q-L(;#4-/DN66S ML@H7SI+=5QLDG:.%G8'=0U[X?ZM:*L MMQ.XOY]/OC&\2IMD.]UX63)S@KRQX6ONO#_'8>C4J4)/EJS^&35U=+1;[WUM MUL?DOC!E&,Q%*CBTG/#T_CBFT]7J[K965F^E[V/T3_9^^'%I\(O@;X1\,V-Q M'>6FB:3;VL=Q&^Z.XVH,R*ZACF:"1;FV+_ M /+"=.8Y![JV"*_-?_@GC^U_K7PE^%_Q6^'=C:7L:^ 5CU?3-2U"1KRTTRV: M:WMS:LC$%6;+R(FX+G?G;M.?8/!W[5GQ.TWXD>']/M_$5KXTN-:OU@&G75K; MV\B_9MMMNU].:Z[77=H]S+?$ MK*?JF#]R4?;)))*_+KRV;W=FNB?<['5_B=\#_A5K-OX7U/P'X=U"ZT40V6KZ MLOAZT^QP2+MBFD,CKNDV2%=XQD;\\X./;]+^ OPQUO3X;NQ\%?#^]M+A=\4] MOHUG)'*/565,$>XKXD_X*:?#B/P)\8)H;"ZFN-!\8(FKZIIL<8E:UN"TBM<. M6^;RY)(X2%4\&.7@# KHOV!?VV-'^"G[)2P^(K7Q!J7]FZA?3S306D4?EJUP M[, A<,V%^"/_!#:_P#QNL3Q;^S)X?G, MW_".^'_"FA?;-*O=,NOL^F16_P!H6<1A0_EH-R#8<@Y'-4OB#^V9X7^'FNZ? M9R6>L:LE]IT6I/-ID<=P+5)N80Z[P?G4.0RY'R\]1F;PQ^VE\//&6AZI<:?K M+R7VD:=-J5QI,MNT&H%(8C+(J1N )&4#!V%@#WKY/^R\7[+VWLISM]Y^B M1X@RWV[PWMX<_P#+S*_?1=?D="G[.'P[55'_ @'@?@=M!M?_C=4]=^"GPJ\ M+:?]KU3PA\.M-M=PC\Z[TFRACW'HNYD R>P[UY[\._\ @H5X=\5?&5O!>L:3 M>:#>7<4MUIMR)#=07$$,3RRO,RH! 51"<$LIR!NZ9^9?VR/BY9?'V^UJ^FU: M9_#ML/,TZPN#\L'EMM2XB25!LE?8^X$%AN R*]K+.$\9B<:L'63IZ)MM='M; MU_1GR^>^(F6X+*WF6%DJVKBDG;WEO?M;3IU7<^V-8_9N\)'4/#^H>'_"_@_2 M+[2=5M]16[M=*@AE,29W*CQH""P;'7!&>UQ7JVDFZ&"YFCC*E8).0&.$8>H./E/_ ((^>)_'%Q^U9X@\ M/Q^(-8F\"Z=HTFJ7=C*RR1?:Y&BBA+;OF4D(Y&S _=XP!7VO\2?V,O OQ BN M[I=/DT?7)))+F#5;6YE62UG9]Y:Y534'*_NU&];::-=WI=V]#1\+?LW?"^[\->&YM+ M\*^'KS2]'U)/$VA2^7YZ6EX8]J7D#,25DV' 8'H:Y;]M+PU\,?!WAZ'XL?$+ M3+[5+CP!&LVG00:E-#]KE69)HH5MQ(L4\AF1"JN#RH["O$_V7_VGM=\)_''0 M?A[8W5MXA\/ZE?SV,<,<.U($C\QFNK9B=ZQ':7*2%AM.%P<9\A_X*@^%=7\! M_M46/B#XE?VEXN\ ZM(D?A.:>/\ XDOA._="GES6^\"4-M!:0XQD#&>:ZJ'" MLHYC#!XJ:C&:4D^LHO:W9M='^)P8KQ!C/)*N98"FY3IR<)+I":W;>THI]5^! MW7@?]K34/A<=#T/X;_!W0_#_ ,*5N6^VSZIJ*37FIPLDC<*I=I-\DD1C9F<[ M4<;?NBNL_98_X*3:/\;?CKXB\(>/O"/@GPWJ+!]'AUV/5+=[;7HU)!LU28": M4 OC8-R[F;@=_F?XP:MI^HP^#[6SDM[AM)OPR2177E_94,;(VP1G@*#A?3"@ M'DUB>,?'2^/M-N/#-UX(\5^)-,.D]I(I5T:/:9-Y! M(*L.A K]"QG >!6$XO-*\)^(=+:T2VM%\BWD>-F+Q?* "HB6,; 1L M'(&&-?*_CCQK<7-Q9R6%XUCJ%C<>?9S)(4>&4*V&3!!+CDC!!X/O7UUIO[-7 MQ%^*7_!-;3]!\0:GJ.O_ !$O([77;5?$4J?;=.EW1RM:/.%7]X%\Q"Y5?OE6 MXSG\Y_BS>:MX'UV^TG6M,OK+4-/O&LIH9(6;R[A25V*1D,W7&TG(^M>IX;O+ M:F"J86;ASTVT_P"\OYM;76MCP_&N.=TLSHYA3C4=*K%2CO[DNL+JZ3T4NF_< M^P/VNOCEJ7Q2^"?PIO&2&5+KP\EPVLF!V274)$\N>))@W#1M$2\3 [CMR.,U M\[ZSX[6QLH5D<-Y:K'N"\#MG'8?RKZ:^'O["_P 8-;_X)\OX,NET[1_$$GBD M>(H=/O+W+;Y96V5]M'9V/F?%S!Y MW/$X;'8N$U[:E!N\;(M7NK74) M/#K:!,-1G@3]WYL,B-"ASA7D)D=47<#F0]LBOJYO^"DO@6RURVM-0L]9TV"X MG6,W<_D^5!&<#S7VN2%4GY@,[5!;D5\)Z+\2[J7]C7X?(GA'5=%T70[[4HM0 MU&[M9/LFJ7DLD$D-TCD;=S!F0;AP4VHV!BO)_'WQ7CF5)'DS]GEWH0V 6 X0 MGWSTKSZW!N#XBQ-?,\2^35QLI+3D]U-]+NR=NUCV<'XD9GP;@L-D6!7M?=C- MN47K[2TG&-];)MQOO>[/T^_:\_9"^$?CSP%XI\8:]IT%GJEY8M)#K,4\S+%< MNH6"Y$2R*DDF[R^OW@-I.#7@?_!+CP)\9OV8?VB_$WPYUKP/>-$CAFAE)PZRJJC8 6!8G/!KT[Q!\-!#^Q]\$?AO>7NJ:I=>(]1LM MTEVKVURL(W74H*9.SRD81J&)V@+W''UI86@L+&"W6269;>-8P\C;G<* ,L>Y M.,D^M?D.(S2MALNE@9S]I"HY)*5[14&E&4==+ZZ;:']%X'(\/CL[CF=.DJ$Z M,8.3A:\I5$Y3A/2TK+EUW=]S%^*6J7FB?#/Q#>Z>T*WUGIMQ- TK;41UC8@D MX/3&>E??BO#TCEMFE>4]'UM&.NO;WD?56E//;J3M"EJKZ7G/2Z[V@[&M7B_Q> M7_A8G[5WPZ\,IN>V\,Q7'BG4,9VJRCR;<$CCEV8X(_AKV:69;>)I)&5(XP69 MFZ*!R2:\;_90CD^(.M>,OB7<1E?^$NO_ +)I6]?F33K4F.+'L[;WX.#D&C+O MW4:F*?V59?XI*R^YO+/H@K MP?X7Z)9_$;]MGXA>*/LMO-!X1M+30;2?RT;%V5:6=U;[P8*ZH<]B17IWQL^* M=G\%?A7K7B:]RT>F6Y>*,?>N)C\L<:CN68X_P" Y"X_V:];!WH82K7ZS]Q?>G)_)))_XCYG,HK%YGA\ M)NJ7[V7E9.,%ZN3QXS^VWX@N]7\%Z1\.]'D9-<^)E\NDAD/S6UD/GNY^.RQ KVY; MK7KWAOPU8^#M L]+TVWCM;&PA6"&-!@*JC _'N3W->+_ +,]E-\;OB=KGQ@U M&.1;&^C;1O"4$JX,.G(WSW&#T:=QGUV@5[M7KYD_8PA@5]B[E_C=KK_MU)1] M4^Y\SD,?K=:KF\MJEHP_Z]QO9_\ ;[;EZ.-]@KEOC=XJN? ?PB\3:]8F!+_2 M=-FN('E7.&5<@#CEB1P.[8%=2.37YI_M[?M9:QK?Q5\1:7)<:EI^B:/@_%36K6'7/%6O,]W M97=U$&_LN,,T6(5Z*258[B-PSU(Y/V!6G%DLO^ORIY=!QC'1^BEJXQ:5DWU?7YVZ'E7[9OQ%OOA?\#+C4].O-1LKB2^M M;4O86DES9!]QE)537ZJ?M*?&D? #X.:IXF5;>2ZM MVBM[5)V*QO-*X1=V.2!DM@8SMQD9S7QWXB^(^HZW\'?&+3>(FN%NI+34KZYG MN5MVGE-PB&.&,#:=R/M\I0% "'[WS5XV!QTL--R45*ZLU)77])GV&,P4<3%1 ME)QL[IQ=G_5CHO\ @F?\?M7@C\(_#>3QLGQ#%I9S?VAJETS&YN)0KS3W"/)B M1X_/D$:!QN*$-A0,#[>KXB_8*\+Z3>_'A;RRVMJ,%G-J$SB&%&BA8^444J@. MUG9_.+B9E2;RX;?@S QEEX8$L&"@D5X9%_P5H^(?B_XO>%M$TGX<:?: M:/9WBS>*[T7G@\=AJ5"5*M04YN_+* M[5KJVJ6CMNO,YJ^'JSJ*4*CBNJTU_P O,^Z;C]ISPY8?![3_ !I=1ZG!IVI3 MM:Q6XM_,N#,C2JR8!V\>3(=V0"%X/(%>(^#_ /@KWX#UCQ%X\T?5=#\1:7JG M@^\>&SMXK,E&+P#->^(GP;UK1?#+:,NM:BD<4#:J7^RH/,4L6V*QR%!V\$9QGB MORR^./P'\::=#XLEU2U\(RN=1>.4V>N1WLTE[)A2%3RVVN0N-V0H*;&PW3JP M-/#SJN>F#CCK[XYK&O&G&;C2=UT=K7^7 M0UHRJ."=16?5;_B=A113D7HWS&<&2*,V@^T*4C4"YCVOP"WF7B7_ (+5^,M" M_8TOO'MUI7AO3?&>IZP-/L-%DT^\>WT&U@A@DGN[QN')NED\VV1A&#'-%\S% M7-%QV/TLS7S3_P %,?A9\0OBM\.-%M?A[!K$^H01:T)QI]]]D<&71KR&WR=Z MYS2^&_^"H'BK5?C''8R77@K_A&=7UNS2',#PW.@6+ZY-IC0 MW;-)@3R11+<*SK'L#XV,.:^X8O%.GWOAV35K&XCU2PCB>9)+!A="8("2(]F= M[9!&!R3Q2YE:XGH?//Q:\1?%#Q_\"EAT;P!JW$Z-#O21IU2-"5QA.'C_ &ROB+\+O#VE^(]/\9:] MXD%VJ_VM93RK?F3Y,EK>.1,18DQN7@[68#!48^\/V5OC-=?M!? +P[XNO;2U ML;S5HY?/@MB[0QO',\1VEQGG9G'."2,G&:^6X?XNP6;U)4L/=2CJTUTO;=-G MG8'-J.*;C3O==SB?^"A'PI\7?%[X2Z#I_@NUNKO4[37ENYA!=K;,D(LKR/=N M9EX\R2+@$G)![9&#X&?XN:E^R_X.\-Q^ Y+&70M M]'\66?B'5?LVIZTB6*1 MR#2[JTN&59FD5U$L[H 65LCDCZ6 R:^(?BW^U[XY\1>(-7TN^U+_ (0JWTR^ M>SEL-,_=7B,C'"RW#98[EV,/*V@J1RP-=G$'$6%R>BJ^*NU)V22O=[^B^9KC MLPI82'/5OKHK(\OT_P#9"^.<7B?P+)IWAOQ+8^%]!UG4I]#L+K4H5DTUIM2L MIH;B\B6Y*VRQVXO%7R'F/[M R$3NI^SOV-?%GC[QSX&UK4O'L]O)P+\7_$>@2:E?S2:EI$> MHVD<]]+=>:8*&-I*RE M?1[JSL5@L9'$T56BMPKY!_;9_P""8NI_M:?&]O%UKXNT_1(3I\%C]FFLGF;, M9?+;@P'.[]*^OJ\%_P""B?QQ\7? ;X)Z#J'@CS_[>USQ?H^@(EM9P75U+%=W M'END$=PZ0F8CA?,=5SC) KV#Z3(L^QN48GZW@)IS0-&8B(0Z.0F&?YBF0 W$Z'V7 M_$6^*/\ H(7_ (#'_(YO_AQ9KA/_ "432/\ P62?_%TYO^"&GB![=86^)&EF M%&++&=.EVJQQD@;\ G R>^*](T3_ (*KW7BT^!]2TCPCYQ^(D>FV>GZ)=:O% M#_9US>:G=V:M=3+"[QS(+<>; %;8Q*Y+ D_2G[+WQUA_::_9[\)^/K?39M'C M\46*WOV&683-:G"" MWC,DC,P!/"@]JYD=6_WC_.O?OV:?@U\3O );QUXZ4A5I9+R M&21+-FB158-*K2AQ&W!09/!Q69^KXJNJ5"Z:3MI?N8)_8H\4R^(]'T^WU+0+ MJ/Q#>P6FF7<<[B&\6>R-[#,,J&5&A'1@&#<$5T4_[!5YX@?PVV@^)='MD\0: M/IUS%'K5PT,MS?7-FUV\$01"-BJA^9L8QR>15+1?C7\>-&N-6UZVM]:5)-0A MM+J9O#\;6]A=0+]FCAB4Q[;A>*+-/ \,# MPR3:'M&G1QVK6\;/E.@@9AENQR>>:9YSEBV_XD%_GUOIZ$>G_L.^)-3O+5(? M$7A?[#K3V=OH=ZUU*L.OW-W$TL%O"-FY7*HV3(JJO&3S5.7]B_Q-#X,T_5FU M3P^K7QTYY;!IY?M%G'?3R6\$LHV%<>;%(I"EF 7.,8SK:/XK^/GPTNM+TN#2 M?%.GSW=K%I6EVT^A!F_T1&V/;AXSLN(D=CYJXD"GKBLK2/B7\9?"TUO!9P^( M+6XL&@TZ(#2_WR/I;/2:UXJ\(Z7I=J;)$U&[FN%CG-TTL<2JGEF0'?"ZD,HP!GI7GWQ>^!&O? MV33X?$2V]K>ZC)=HEJK$RHEO.UN96XQM>1'V\Y(0D@<9]3^,>B_&37;!]!\9 M6DU\KZAIEL="T[3A#->AX[BY@$+PQ;%VK+., Y!)^5@AQRO[1,?Q#^-_Q!UC MQ)JO@GQ!IL6@VD&G36QM99!I4$$"[5D=E!+;#YC,1SYF>F*1>%Q%;FC[2<6M M;VMY6MZM^GS/(+C_ (]Y/]TU^ZO[,7_)N_P]_P"Q;T[_ -)8Z_"JX.;>3_=- M?NK^S%_R;O\ #W_L6]._])8ZJ)X?&O\ "I>K_)'944451^>E?5]*MM?TJZL; MZ&.ZL[Z%[>XAD&5EC=2K*1Z$$C\:^/O!FHWG[&'QCU'PQX@EG;PIJKB>WU"1 M2R(@VQQ79.>F-D5QTVNLX#M!((V59"IV$C@-CC/XUXWXA_9)A^*5 MC?7'B[6-6NM:D"_V=+?&W[%VI MPZ#XFT_^UO"9D,=A-!)MB121A;:5SM7O_HT[*5Z1NRX%>X?#OX]^&?B.@72] M6MY+Q1F2QG_T>\A]FADPXY/7&,]Z@HX'X]:9K/C?]G'XB:MKVG7FFW3:))#Y M-RFTN_RQAE7GY0@+ \8:XD&!\V?>/ ,XMOA_H*?W=-M>_P#TQ2N%_:,G:_\ M@1XLMV# RZ>RD$>ZUTGAG43#X1TP?-MBL8 3C[N(UZF@#H;F^4#]/PKFO&_C M33_!^@7FJ:E=1V.GV,9EGGD/"*/YGL .22 .37#?$S]J?PG\/1<1/J*ZKJ4" MDM8:WW &XGQP+AE$4>,+7P[)"NFZA:&.WDFO%DF@N)P(;QE2UR/*.T,X#$9%?; ;: M>*^=_C9\:/@C\%;>'P3XDT!9K/PA=6^J6>FVNCM>V]G=2%WB953(CD+/(?GV MCYF/W=_^S[^U)X=_:2N= M8CT&UU:V;1;/2KV?[;$B934;&.^@"[6;YA%*H8'&&R!DHZ'X5N/%]_JWC&Y>UMH[-)U@,$,J#,626,DS92)=F4;?QS/[" M/QL^$EY\0O$G@GX>^!H_ ET\,6I$1F)EU>.-5BW%D9B&B#*@1CP@&.!@>L_M M+?#/X8^+/![>(/B=X;T'7-+\+1O<)-J%A]K:W4E=R*H!9@[*F8\$,57() K; M&9?BL+6^K8B#C/31K77;0Y\MSS 8_#?7<'5C.EK[R>FF^OEU/&/B3_P4>T6P M\,ZX?"W@BZU:[\(&^>WEN(8FTW48])GMEU>.R>-C)O@BE+1L\<<K*"^U'X=(NM4FDN8;=5D6*YABN6^RWB)(!)<:13JD@W*' . M2*],ZUY=XM\5>&?V6?@_I]KX9T_2]/M[I\:/I:[HXIFD/F.0 "P 4LQ/3.!D M9%?.'QA_;"^)%IHMY/%KVFZ;;B5I$BL=.$V<= MQ@MY33J), 9)VYSP 37Q/H'_ 4E\0>%QJ>@ZAH^L^(->VMXS'I?R M(#%<26OVS6M2WN9[Q1]J\V3.\Y4;MYRW M"8'7M7NX+@+&U*TJ.(:A:UGO>_7=:?U8^3S+Q@RREAH8C!1=2][KX>6VEGH[ MN_1=.I^C&@>(M/\ %6EQWVEWUKJ-G(2%FMI5DC)'49'<=QU%9/Q$^+'AWX3V M=K<>(M4ATN&\#_ VR M2ZYXH6>VN[5Y4L[&2Y>(G[2\1^1I(@-Y &Y_+8 \XKJ_VC]+UKP=JM]_;7VB M'Q+()7SJ4OVA=2B;EVCVLH*X"X*8VE0".H.W^H8+!UJJM)*22MS-/R_74 MY/\ B+L:V32S+"X=MQDXR;^"+5KZJU]]M'Y]_KZ/]LGX5OJRV3>.M!CF8LJM M+*8H7V]=LK (WL0QSVS@U1^+/[7GAOP%874.EW5IK&M*T$5I!O<6MV\N6 69 M%8':BLS =/ESC-?F3/INM>+O%FCV[(K:]JY@T[1XYYUB1IY^!(YSM3 P,D9& M3CL#[]\;OV8?&7[)G[/D"3&QUPV%MYL>HZ;:R1P:?=;VX)?E&Z0@* M.,^UC. \KP>)H4*F(;E4VB[*_P ]DGMW;V9\QEGBWQ!F6!Q6*HX2,:='>:N^ M7Y-ZM+WKK1+=6/=O#W_!3WPU=>-5TG6?#^J:/"\,A%Q',MX3,G6,(@!PW(5L MY)&-HX->L? ?X\>%_CGX:\1:UX22:*&QOWANWO8C;"6X$*/O;.2%VE03@$;3 MQ7X\VWQ$U+3M1\1>*OML4UC()["47$YDN)9?W;A@<8 SM'' P!P*_1__@GA M\"?A_P#L^_"NQ\86_B:[U#6O'VE07E]-J%P88O+D)FC06VYD1D#A"V2S!>?2 ML>-.$,LRG"*K2O=Z==]K^)WGB95T:36;IK-[R^DGN@]O'L@C\V1G(@'40G/R]"4VYYKJ_^ M"7?[2NGS?&CQ9\/KJ^O&N]8C75M)MV+2PJL*[9PISB+AD^7;@X)W$\#SG_@I M!I-C\&GN==\/>(+*_P##^O7L[+I]O:%/['2?OKCQ!XVU[;2>237H9YCLOJ M<-1M%RG5TBEO%PM>^G3;S/)X3R?.*/&TU*2A2H)N;;NIJI>R5GN]7KMU5STG M]OW7Y-)\">&;??&MG>:R&NE8X9A'!*Z8/M($R!U'MFOEWQ+XKL;W1;A6,9DB M4SPLQQY,J?,D@/\ "RL P;L0#7T-^TUXILOVE/A=<:':Z+XDM;J.076GW\=I MN$%PH(7((Y1LE6&0=I.".M?!O[*ZW7[17Q)O-)NI-UGH"+<:E;)*(WN\2[#" M&8C:A*D,?O;>F"<@X'G@J>3UIXE\KI.\EW3VMZ[:B\4Z.:5N)UR_DEE MU>&UEEL[GS9$,MZVTGSU?HEU9<_X)V_%'21^S!\>M2CM]+F\>2:C:VFHWLT M&Z2YTVX=((]P8%,+ON,!>"W++ZY^M^,O$'@CX@:#IG@36+CP]KFJ/%X:L[FW MB221(IY8DP RGIL5LCD!3R,FKWP9_8=TGX!^&O%4FG>-O$FKZMKD*M+-:Z,\ M5O-Y#^=$GD>81)\XQER>&. ,UY1K_@_Q1\=/BEX?T?1]-\2:?-?7$<\E\--F MC_L]4Q([AF55WIC@9^]@=:_0LIK99BJF88ES7+*[]]?W=%9[I-.R['X[Q)@\ M[P%+*,"J4E."4?W;V?/[SYHZ1;BTF_F?3O\ P6*\4Z;H&O\ A.WDNI_[>M=) ME:<")?)DA=]H._._?YD;<'Y0N>A//S+_ ,$Y_P!GGQ9^TY\8_MFL275C\(8? M,359KN4QVVI>6V?LEN2>':1\N5 &P2#.XU]!_ME_LV6OQD\ W&HW6E>+H_$$ M0@T_3+ZXU%6D9Y9U1(3%MVR!FD/!P =QPHQSTGP,_99\)#XGZ)X^U;XF:7J M_AMK+[39:9!;2P3W(N+=D(E=F#*H$A( 4$]#BN=_; ^ .OZ99Z'XJT_P:+S3 MM,NU'B&PT@M=3WEF/F,CQL=[E-N#L.=F5[@CV#X9:1(M&AT&WTW5 M%9H3=Z&]M)<5B_#?XH?$;4- M1O/.U>PU!M(LIYSYZKIC@31(I&3SFOH7X8_ OQ1H7BGQE--J&GV=M?Z MJD]BZZ= S2I]FB5V&%RJ^8K +Q@[CSFN>_; _9%USXS_ NM[.SU!M4UVWU2 MQ:TE*)$+"/[5"9Y<5E>?/"YDL7.3E=).[OLEU_KJ>_GW!Z MQV2O+Z5-0:-M1_M;4/$WC:)$:*TC M\RR@LD=G@V,H)9GW%R2> 0,<$GZ8N?VIM/OHI+=/#OB"X6=3&52 _,""#VKG MV^#TV%C'B;7$MH_ECBCE\N-%[ !< #CBG)\%;7^/5]=;/7_ $V09_6O$S;' MK,,7/&8AMRD[^G9?):'U/#^3_P!D9=2RS")*%-6]>[>^K=W\SY1^#/[.]W\, M/VUH]:AN?%L^B^#;6+5-(L19^5=LL_G0K!<2=&C5489509.,X(.?H[]ICQQJ M'QX^!'BCPI/\-[C54U>PDAB@N'VH92/D)Y7 W8S\P&,YXR*HZ/\ L^:/J'QJ MUG4EDFO-,72+736E^V"1EO(KBY>6)AG(*I+$>?[V.H-=A'\!?#2GYK)G'_71 MA_6NC,,VJXC$0Q&*DY3@HI7[+;:W^;.3)^'!@H4ZDI-I.Z;E=-J] M^EK+9=C\?_&?P]^(,.IVOAI_!NM>'_$N@K"MP;8HL *21*$61F"R*S3Q=,X\ MSGH37U/_ ,$S]*\2>&OC!XD^(5QX7AB6ZT^"TTZ;6+R)%29=ZRR0!CE?E.S< MC $%C@[J^N?'GP ^'^K:YH%KJ5O);ZA<2R1Z<([@J\A3R[B0=^/W"$_E_%70 M^&/@%X3\(>'K/2[+28OLEA$(81*?,8*/5CR:^GSCC[$8W!/"UJ:2FET:VTNM M>O\ P'<^$X;\),%E>91Q^'K.4J;>C:>LDG9Z7TNFOO5KD4O[1WBI 2Z>$(?K MJ2'^IKX[_:%^$'BGXM?MP>$O'&K^*/"&I:']NCFATJZN!-#9"VC$KPK&1L*R MM&6+=<\MNP*^W(?AAX>@^[H]B/?RZYWQ%\.+4_%SPC-#I,3Z7#;:BMP5C'EP MS,D7E,Q[$J)E'^\:^2RW,/JE1SH*S<9+H]&O/KZ'Z-GF3K,*,:6*?,HSC)*[ M6J>E[6NO)D8_:3\42MN_MOP;">O,N_\ DM?%_P >/V(?"?B3X]^$]?M]4\'Z M;H^LZM]GU71K5+C[/EC:KZ8B6L/XG^(M*^&'@+4MAMG7#^$KSHYCC&KX=N:=NR:MKTU MNDNIX;_PN+Q!X[_:+_M.7Q!:LG@FQ:UMI_LDWE_:+@9D 3.Y8P!DCO7H/\ MPOKQ1_T-UG]/L$__ ,:K=^ /PM;P%\-[>/5889->U61]3U5]H.;B8[F7Z*,+ MC_9KM&L;.WA9Y(H(XT4L[LH 11R2?8"L\RQ%&5;V5)7C!**\[;O;J[OYG1D> M#KPPKQ%>7+.JW.6^E]D]?LQ27R/FGXR?%W7OB'XU\'^&[KQ%:WEK'>_VW<_Z M%+LC6WYCW Q@G,A'3TKTB3X[^) O'C.U9O3^S)QG_P ATW]GS2X_'WB#Q)\0 MKBW58_$$PL='1D^YI\!*JP_ZZ/N;\!7I&O7NF>&-#N]2U#[/:V-C$T\\K@!4 M11DG_/>MLRE",H8.$;N"L]OB;N^FZT7R.?):D(JT7OLTG M+_MX^?\ XX?M!>+-;T&+PI:^*H)+OQ639R&*SE5K:V_Y;2G,8X"_+QSEJZKP MQ\5]<\'>'+'2=.\3:?;Z?IMNEM;Q+83XC1 H_U7H*TO@1X6F\8ZKJ'Q"UJR M6WO/$""'2K21,'3M.4YC&.SR'YV(]17IATJU;K;P_P#? J,PK4J4(X."7NZR MVUD]^G39?-K:[670\P'Q^\4 ?\ (U6' MXV-Q_P#&ZDC_ &@_$K'GQ1I?_ K*X'_M.O2_['M2?^/:#_O@5YG\;_%TEQJU MMX%\(Q6O_"7:Y&6DN3"'CT.T/#W,GHV,A%ZD\^EEDENWIL MCT,RQ3P5!UJDV^B2O>4GM%:[M_YO0\U\3?&/6?CY\4[.QO/$&AS>&_ ]VE\[ M212K;ZCJ ^XGW#I/\ >21?YK70?#_X0Z#\ M-_!ECH>GZ?;M:V4>TR2QAI)W/+R,3U9FR3]:U3X2TL]=/L_PB4?TK;'8RA4D MJ=*/N05H[?-OSD]?PZ'/D^5XJC"5;$3_ 'U1\TK-Z=%%>45HOF]V<6W[2OBB M(_\ (6\'R_[LX7'YK7F'QB_:!\2?M!:G)\.XKW08]'&R?Q#=PW:I')$&!%D' MQP\F/F Y"_C7S-R\KGU)[=A@5U894<'36+J1]]_ M NW]]^GV>[UV6OG8[ZQFE:6749_NHZ59*]G_ -.T^[^W;9:;O1-&^/7B+0], MM;.RT[PT71W_ .N>HPD?^C*N MR?"OP[*?FT>Q^H2HI/@]X;E'_(*MQ]!BO%E.BW=K?^NY]1&GB(I1C*RV_K0E MLOVDO$=P-T?A..YY_P"6%_$Y_)6-? O_ 4D_98UOQS?V_B/X<_#WQLVJZQ< MW$NL6-K,+JR7(,AF7=\Z.[DC"DJ?FX!QGZ ^.W@E?BA\1(?A[\.VAL;RR N? M$VHIN\O3H#]VW\P9VS2?W0,@#DCI7LB?L^>&+:&.&&UDCCB4(F'.0 ,#^5?2 M8'$U O#.I>%?$4UQX>T"RL9IDM60,Z0JI^4C*G/8 MUW,7[6.EM_K-#UR'ZP,?_9:YN/X#:/;,6M[G5+=C_P \KIE_E0WP5B'^KUS7 MHF[$7CDC]:^=J.C.3F]V[GVE&.(I4XTH;122V>RL8?[7?C?PO^TM^SGXD\%M M=:CH>H:M K6-Y<69V6MU&XDB8]]NY0&QSM9L7L7Q7KC+G M $DFX?KFJ>K_ C\03:1=V]GXKDCFF@DBC>:V278S*0&.1V)!_"L_9T>C_/_ M "-HXC$KXE=>B_S/F_\ X)*_&?2SX]\1W6I:@L%NNC10[G'R*QF# 9]2 3CT M&:^\K3XP>%[X?NM=T]_82=*^??!/[-^I>!/".EZ7:W'AT_8+2&WD(TB!5G=( MU0N?DW'.#R3G%7+[X/ZU*/\ CQ\)S-_LV9C_ ),*4:%-K614L963^#0\?_X* M5^%O%@_: \,>-_ ]G<^*-+U;3TT;4(=,D$L]E/'(YB8IU".LK#?T!7G YKYU M^,_Q;U3P/^T1_P (QK-Q,U_X7TRRL)3)+O5I#'Y[&,Y(V;IBHP<$HQX!P/N" M;X2ZK$GS>&]#9O[]M=3PL?P#5YS\5OV0K/XB^*]"U+4?AS8WDUO=$ZA=B_S< M36ZP2B./7)F)02(%,",/[VYE9E_V2#QD"O(_"G[4<>@_LXQZA+,D5A9^);Y+ MN5H,)YQMX&A1I<+Y+<)A46ZT MF15('0#&['TQ6G8?M%^)E5MOB#PM<%>UP)(2WT+HH_6AX.8+,J;W3_#_ #.G M_P""@?Q8OO@G^R?XD\0Z==-97$,MG:M.N=\<<]S'#)M(^ZVUR W;.:^"?$GQ MQTN'P-Y-I]DMH9K:".WA1" &:ZA/;Y=A5)!S_'M/7FOLOQQ\3[[XP?#O6?#/ MB#1?#'B30]D_#7PG MJ&G+H.KMK.H7-_JGVR2Z@6WD7!ER<+'DD X')/7FLWAJB-H8RE)VU^X[;]G+ M5=,\8^)M.6;R/+L\2O J*?,!#(A;N%4YP?7IWK[H\#:=.EA#(]4M((_$NHWVDQ22:E$SJJ6,TH M +93+-O+!04^4YJWJ/[8'@+6/C-<>'8_#.@ZAH/B.^AT/5+M[1&DOF1S!"TB M[<2QK(550V2%)(P.*_/#XX?'%?%'AC4I+FZF*W44C/(Q(DD9B6+DCDLS$MGJ M2U>7)\;;@Z8L5O<36=Q)M2%T!/"S7&H M7)O+\7.G6]P?$*02>0ES.#&-SHP ?<5#+ACR!W?Q(^&;:5^SMXE\+> =+TS M1+B;2+NVTFRLH8K2VBFD1L * $4%F.>!U)R.M? 7[!GQ:D\.?&OP?':_:KZY MO+F+1S\Y9I8)B%E9\ [MH D)P,&/J 2:_3CI]/>OT[A//'G.7RJ5M))N+MVW M5OD_O/H\KQKQE!REO=K^ODS\5_B]-XW^$/F:;XG\.ZQHL,&[$R*(S'\YA4L2" 0 M222<\Y)I?@I\MWY(RRG+:6'_M02_";XC>'_%5JTD MUUH-['<-''=M;"\@/$\+X.UE>,MA7RH8(W\-?KE\'OBEIOQN^%N@^+M'6XCT MSQ%9I>VZ7"A98U;^%@I(W @@X)''!(YKY:_91_X(V>"?@V]CK'CR\/Q"\36I M61(I$,.D6K#'"V^29<'^*4GM\HK[&MK:.RMHX8(XX885"1QQJ%2-1P . . MPKYK@'A_,,MM::?I>H1PM&(M8TR M*SD9(SL=$=AM<1D;2%8@8XXYKS+]N_4;;PY\6]+NE:%;BZT0^>H3]XVRW5T[;::?-'ZK6NBZ7<*ES!9Z;(LC^>DT<$9WMDMO# =(_\$XO#F:9^/YIA(X7&5<+"?.H2<>:UKV=KV$V MGT/Y4AYO^/?AA^T&? ?QF^(%CXP^(6FVMCJ/B6RLM(@U?4+J_U6 Z@$LF MM+,H$M5AC4O'+ S/(I P 37HW@/Q5\3].^!OQB3P1IOQ2\2>#;R*[3PKJOB^ M]N+3Q%I1_LEVEFMTN$^U7$8O BQ*^V0.7P=H6E%=6^)&ES>'_%/A_3/&>GWGAR[T^YU?>(?M+S27$:R-;I^\,C)\CLWS-A M<'["/6F*U@JEXE_Y%K4O^O2;_P!%M5VFRQK-$R,JLK@JRD9# ]0:!QERR3/Y M^Q,F6^9?O'O[UZ[H'[7=QX?^%]GX=CT6$W%KH3Z!_: U&12T!U"*^5A'C"NK M1[,@_,K^V#^N/_#,GPWS_P B#X/_ /!1!_\ $T?\,R?#?_H0?!W_ (*(?_B: MGE/N:G%F%JQ4:E)NWGU/R[US_@HUJ^O:;>0OH%E!)<:C=7BO#J#*OE7%Y'=R M02#9F0;X\;MRC!R5)4&J/AW]O.31I?%EQ-X5T^ZU#Q=?:E)YO"?A^&]\/ZYJ=W=W4] M]?2^=J2SV2VFY$D4BVPHW;=K@GMCBN2NOV]IM3CO?MOA>SO+AKC4)M/N)=5D MWV*WEC%9.K80"4K'"A5CMP>9=%)>Q?KS:_F?EE:_P#!0&ZM=4O;K_A%K!VU@P?V MHIU2;_25339=/D$9QF'?'+N!!)1EXSFLS2/VSK7P[X)UWP_8^#;/^R-8C9(K M6\UB6]B@8VJVXF;S%+M,NW>'1H^RX*C%?K!_PS)\-_\ H0?!W_@H@_\ B:/^ M&9/AO_T(/@[_ ,%$'_Q-*Q7^L&7VM[!]/M=MNI^%LTBI:LN]3A",D]>*_=C] MF(Y_9V^'O_8M:=_Z2QU"?V8_ANPP? '@['?_ (E,/_Q-=KH^GP:1:V]I:PPV MUK:QB*&&) L<2*,*J@< # [4)'#GN>PS"$(QBX\K;U\Q]%%%4?-A1110!R MWQIMK[4_AUJ&GZ?;6=Q/JJFSS=Q&:"W#JW[UT"MOVD# QR2*\@O?^"=7A37? M"6FQQWNK:+J4-NOFE"EU LI'S,L4RL(V&2%,93;R0 3FOHC.**+ ?%/[17[( M7BSX0? KQ%JUI\1=0DTW2;-G_LVS:[M?.7P%=-X6_8(\0> M-_"VDS:]\2+V^M;BVAN%22*>YFM]R*VU'>)/!-] M;RF1=H$L;QMM>-U.0P/3\P0>XQ6MHUK'8Z/:0PKMBBA14'L *"N8\ U[]A;P MYX%\!F30X;O5->L[B":WFO46:"#;*K-MM441*@^;HC.%)49'%?06FW#W>GP2 M2*JNR D*I51] >1]#TJ:B@FX4444 %%%&.: "OSK_P""@<&G> OVBO$$,+K] MKUBU@U6;-QYSE6++EQ]Z/#*P52?NE=O P/T4QQ7QE_P6#M?"6B_!JRUB32Y& M\3W6H1P6VI6*Q@ !&!2Z?.639N" Y(8<8 -?;>'N,6'SRBI)M3?+IY]?D?EO MC)EDL9PKB'"2BZ:YTWY7NOG>Q\B?L"_$&&W_ ."D/@%A=36<.H37UK$8H1+Y MHDMY"L+ G*JP )<9*E!ZFOOK_@I3=7^F_##P]>6]U-#;1ZL(I8E?:KR,H,;. M>A4!)%P>?WH(!( K\R?^"<'[2R_ ;]MS1-0DTN'6+'7"^@3Y \VQ69U)GB.# M@ILY P67<,BOU>\;?'KP[\2_#=YH>#?"^L6+[!)J4E]_:3C[TWS,QAV%@OEGMD\YXN?\$KOB MKXDG^,VM267BF_TFQL])\N^A^S37/VPLP6,X3]WO0 %_F*YQT./N,5F-.GD M,\=@W9RBVK[IO1?#?57NM=UJ?E.79+7K<54\JS-7C"24N5632U>D^71VLW;9 M^[N?IC\1OV3QXF^'F@VEKJUQ=>)/#.F1Z79W^HL3#H /!P?J^75=4\ M1X\V\\;:F6;(VJEK'M]LEN?IBOC3]J_]DWQ]XX^(/B32]#\ ^()-!T_3!K=H MXQ*EU*FW%L"-HD8_,-B_/A1U')^#X!S2-"M4IXVK[J3<;V2NWZW6][?,_6_% MSAV>*H4:V5T'S.2C*UV^5+1M6:=DK7OV1ZW^P#X_\%^/%^+6@^(-4OM)N+B[ MTV[$D%PJ^;'$SE5"8Y^<8?/RLI5>,<\7^VUXSTGX+>,[&XTF;7-4\-_:H+B* M_N5&(I=IWQAP,#&TG&!P^/4UVG[!G[(7CFSUG7OB=XGT_0?!>K^,[>*"WT.V MTWRETRW3&O?M&?L*6?[47PY7P]XB\4:K;BWF6XLKB MVB3_ $&0<%E3A&RI93D=&]:JIQ10PO$%3%)WI2MS1O=)\J3M;=JUK[;D4> < M3F'"%'!2ARUZ=W"5N64ES.23OLI7O:U]KL\+_P""='A_1?$?A_4/B!J'@F'Q M5?PZ\)?#VI3(\;Z5Y VD)*2 P9R3QGN&R1QUW_!2WXI^(/$?P^L]4O8;.SL] M-\V"2VM[N.4PF4#$K;267[NTDG W#H37MGPG_8^\'_"'X>Z/X:T^&ZGL-'@6 M&,S2!]:\2:]X5CTNQFO-)AA^WVL\0=9(;A,J<' M[RD94^XQZ5X+XC;P@Y*,KVULH[6UV6O;=GU\>"8PX9CP[4J*FZD5&ZM> M4_BN[)'U9@D.@V(U90@DF6WG@\OROE _>8+#&[ M@[0?L\> OA(ZR>%_!GAO09DB\A9K2P1)A'@#9YF"^WY1QG' KL5.P@K\ MI7ICC%3G?%SQN94\?3A;V?+9/6UG?\7YE\+>':RO)*V45JG,ZW/S25T_>5O* M]EW]#\F_@S^Q]XVUOQY\+-/USX?ZC=>$M<1=5U S1/;PS-Y<48K-)QG7LN56LKVWWMM?S/7X3X#P&0TJE+"MOG?,V[7V6E[7MIH MNA\A_MS_ +#/C[]I#X9Z7I?AN^\)V%U:ZB)YX&A%I%+&RE,^8JECLR6VG[V, M=<5[UH'P@UR+0;2#4_%-X+A8$6Y6P_#XM&L[B\N-:\16MK.L7> '=(GN6 Q@=0#ZUZ8Q!/R_=[<8XKDQ5;%?4J*G M;D]YQTUW2=_NT/1R_"X!YIB71YO:I04]=-FXV\[-W.*'P-L;EE^TZAK%\P(P MLUTS+G\Z\Y_9Y_89^%OPSUG7/$_AB&_U#_A*)769[N\\^&/9,^Y(EVC:HD## MOPHYQU]E\?:G'H?@+7+R2YDLX[73[B4W">XEN)+ZW.HL9'+%#.3)M!/89''J34T958X"I651J\HQY5M)6;=_2R^\,5&A M/.*.&E14N6$I\SWB[QBK>MW?T.UM/AKH-@O[G2K1?;9G-1_\*YTN3Q5::O'; M+#<65I-9)&BA8F25XG8LO=@85 /8%O6N@ILTZ6D,DTC^7'"ID=S_ *!DG\ M,_A7EQE-OE3W/H)0IQ7-)*RU^XR?"7B72O%2WYTV2&?^RKZ73K@HH^2:/&Y> M/3(K::9F7!9B/3->,_L.^%8]*^#UQKB&Y4^+]4NM5"2S^<-C3.L; ^K(!N/< M@5[)77F>'IX?%3H4I747:_IO^)YN0XRMC,OI8O$14935[+L]OO5GY,BN[&'4 M(U2XBCF1)%E574,%="&5AGNI (/8BN ^,'QO7X:;Q9J;03E8R MWDP*A&1V!,C)SV4,:]$KR?2V;XC_ +75]>*S/IOP[TO[ AZH;^ZPTGMN6(*. MQ&16N5T:4ISJ5U>$(R?;6UH_^3-'/Q%B*\*5*AA9:?0>9Y/^V#XQUSPK\)H]/\,_+XB\67 M\.BV+++LD0R$[F3W"@\_PYSVKU'3WD&FV_G)Y^#WKR;P,Q M^/'QZN?%IR_ACP1YNE:&?X;R\;BYN1ZJH_=J?K7L'6O6S'EHT:>$LN=7E)]; MRM:+]$EZ-L^9R24\5BZ^9"O M!=TEUKZQGYG[9P*QRW#QJU.:KI".LGY+IZO9>;.S/,?/#X? MV=#6K4]V"_O/J_**]YOHEWL7OV//AWJOP^^"MK_;ES)<:IKUQ)K=T)!^\BEN M,.RL>YQM/L21Z5ZI0>3_ /6KD_C1\4X_A)X(EU!(?MNJW3K9Z58K_K+Z[?B. M,#N,\GT -36J5LPQCFE[TWLMM?T7Y!A:.&R;+8TVWR4H[O5NR_-O\6>?:EX< MC^+?[:MK?1W5W]C^&.G+YACEQ$;Z=MW\ MVVUZF/#F!G1H3Q-:/+5KR=22[7^&/_;L4D_-,=6;XR\7V'@#PGJ.MZI-Y&GZ M7 UQ._?:O8>Y. !ZD5I*-]>/:FO_ TU\3ELDS)X!\'78DNWQ^[US4$^[$I_ MBBB/)[%N*RR_"QK3YZKM3CK)^79>;V7W[)G1G&83PU-4L.KU:GNP7GU;_NQ6 MK^[=HT_V;/!MZ-(U#QEX@MQ'XF\;3C4)4<9:PM@-MO; ]ML9R<=V->G4%BQY MHK'&8J6)K.K+2^R[+9)>25D=&5Y?#!8:.'@[VW?63>LI/S;;8 9KRN[9?CM\ M:8[=?WOA/P#<"6=NJ:AJ>/E3W6$')[;C6M\9?'E_'F!D*.YKIOA_X&L?AKX/LM%TU66ULTQN8Y>9SR\C'NS,22:[*'^R M4?K$OCFFH^2ZR_-+YOHCS,5_PHXGZI'^%3:>$;&]U?79%N_%GB.07.I3#!$ M/]RV3_IG&.!ZG)HP,50A]^M1K[,'T_Q M3V797?8Z[1])M]"TJUL+.%;>ULXE@@B7I&B@!1^0KRW6Y?\ AI+Q\='MV\SP M'X9N0^I3HWR:S>(=QQ_LC/X=]X3\):?X$\.6NDZ3:QV=A8H$BC7]23W8GDD]2:TBW MA(>WJ?Q9;?W4_M/S?3MOV.>HEF4_JM+_ '>F[2:VFU]A?W5]I]?A[F@JA%"J M JKP !@"BBO/_B5\8+JTUL>%_!]M#K/BZ?'F!CFUT=#_ ,M;EATQV3J:\[#8 M6IB)\D/5M[)=V^B/:QV.HX.E[2KZ)+5M]%%=7Y(F^+WQ=D\'7%KH.@VJZQXS MU@$6%@#\D"][B<_P1+UYY8C [U<^$/PHC^&6DW,EU=-JWB'6)/M.KZG(/WEY M+Z#^[&O15' %+\*_A):_#6WNKJ:ZFUCQ#JS>9J>K7 _?7;>@_N1C^%!P !76 MUUXC$TX4_JN%V^U+K)_I%=%U>KZ)>?@L#6K5OK^/TDO@AT@GOZS:W>R6BTNV M=:\Y^+7QCOM.\1Q>#O!MO#JGC2]3=(7YM=$A/_+Q<'MCJJ=6./;.?XK^+&K? M%'6;KPS\.98C) 1'J?B1UWV>F ]4B[33=>!PO?I79?#'X5:3\)]#DL]-262> MZ?S;R^N&\RZOY3UDE<\L<]!T':M:>'IX-*MBE>?V8?DY=EV6[\EOSUL96S*3 MP^7OEIK251?C&GW?1RVCTN]J_P (_A)9_";1;B..XFU+6-3D^TZKJMP/](U& M8]68]E'14'"C\3764B@YJ'4]4M=$TZ>\O;B"SL[5#)-/,XCCB4=2S'@"O-K5 MJM>KSS;*Y_ M'PY>.3Q!MQJ^MD;K7PU$>I)Z/<$?=0=#R?:G?>//$?[3LLVF^"9KGP[X)R\- M]XGDCVW-^!P8[%#R 1_RU/&#Q7IGPY^&VB_"?PI;Z+H-BEE8P21C MR[GN37K4Z-+ ?O,2N:KTANH^<_/M'_P+L_G*F*KYP_8X%N&'VE4V.5PSF>\O)VWW.H3M]^:5NK,Q_ #@<5U5%%> M/6K3K5'5J.\GJV?387"T<-1CA\/%1A%6271!THI44NP"@L3T %?//QI_:XUC MQ;\0+CX7_!&WL?$WCQ0R:OKI5?$0I*\_NZOR1A?M^?&GQQXKU.R^"?P1U.VA^*'B6$W.L7B\'PKI.WY MKEY\*7T=M=W?B#Q5XBG^W>)/$VH?-?Z_=GK)(W\*#)"1CY M5'ODUZA6^)K0Y51I?"NO5OOZ=D8X:C/F=6J_>?3HET7KW8444J(7;:H)/H*X MCL$KQ&W_ &Q[/Q3^W$OP9\/V;7DV@Z7<:KXGU&52L5D0J>3;1'^*0M*C,?X5 MXZDD<_\ &;]K37_B;XTU'X8_ :.SUWQG;%8=:\43#S-#\&(W!=Y!Q/= ?=A3 M.#RW0BO1/V9?V6/#?[+G@-=+TGSM6UB\FDOM8U_4,2:EKEY+@S7$TG7YB!A0 M<*H ]SZ$:,*--RKKWFM%U5^K_1=3SY5YUJBC0?NI^\^FG1>O7L>E;C0PW#GG MZT45YYZ!$]C#(/FAA;ZH*P_&K^%_!OAG4-:\0?V3I>D:7"US>7MV%2*WC499 MF8^GYGMFM'Q7XLTOP'X9O=:US4K+1]'TV)I[J]O)A#!;H!DEF/';IU/;-?*> ML#7O^"I6K0V,,&J>&/V;;:19[JXG1K74OB.Z-E8HU/S0Z>& )8X:3'';'7A< M.YOGF[06[_1=V^B./%5HP]R*O-[+]7V2ZGKG[.'B[P3^UK\);?QSH_AUK70= M5O+F+2YKI LM_;0RF);G9_ '97PI^8 #."<#I=?_ &WE$4S+E'4JV,=#@FNI\(>#M)^'WANUT;0=-LM'TBP4I;65I$(H+=22=JJ. M,DG\:N2.=_6LZE;WVZ=TNB-*>'7(E42;ZNQQ=O\ NWTRSB@L=,75NDH(]P5Y_&NXBD);%24E6F5+#P9Y== M_!_6LOF'PO?*XY\S3UC;\#'@C\ZYSQI\!;SQ3X7U#2+SPW9_9]0@:WEFTW49 MK:9D88..6P:]TK'\>>/=+^&OAJ;5M8NA:V<. .-SS.>B(O5F/8"LZ^,C"E)U MVE&SO?16ZW,:F%I)7;LCXA^)G_!+OPGXI$,1_P"%C:"S,6(AO[6^$K 9P$>) M20.N 1P*\N\1_P#!)""%,Z9X]U2SN(P#LU3PVS*S@YSNAE.!TX*_X5]]_";P MCXBUWQ_=>./$DDUK]NMF@TK1I"&;2H&*D%NPD91R!R-Q!)Z5Z5)"LJ[6567T M(R*^+P_"N1XZE[6I@E!-Z6;BVEL]'I?MO:USSJ>54:L>;EMVTZ?*VY\!?LN_ MLY^,OV'=+L](FU[7HI(;::RNTD-HG1YB 2!M4G&XC)QZ5O?%OQAI/AB6WT MBUT>WU[Q1J@_T'2T09(_YZRGI'&O4L?3BJ/@3]FG1](T^:YUR.'5-?U)O-O+ ME%V1H>T42_PQKT'<]371@\MP>%A+*LK3C%N\Y7OR)K5)_P SMHNF[Z)W3P]2 MG^XPSLNNNWW]39^%?Q9T[X-^"]/T-?".NV-KIT"QO.(3(UP>2TKL!@EF+,3G M^*NOT_\ :K\'W>!-=W%FQ/W9HB,?C7'?\*-TVUD\RQOM5T]E^Z8;EAC]:JZE M\+=4M+9I%\42-#;@OF_B2:.(=R2X)QZ]*^LIX?"TJ:IT_=C%:=++\3NC4Q%. M/*MOE_P#T_5OV@?!^D>&K[5)->L5MK&!IVRWS, .BKP6)X ZYKE/V1-'UTZ M#K7B3Q)J"W6I>,[F/4T@=AYUE%M*QQ,HX7";3@<#)[\GP2Q^&^L?'+4AJ%O8 MZ)<>%]-N6,#_ &7[*-;D'!?"X)A4]#D9-=9/X)U+2V<_\(_JUGWW:=JI*JWK MM<$8_&O&PV'6.Q2QD9-4X74/[S>CE;32VD>^KVL8QQE2=15)1T5[;_?V]#ZN MQQ17RO:^-M9\.NOEZ]XLTU5& M[8BX13Z95NGT6MK2/VAO$]LR+'K_AO4W]3ET9W1S&'VD?1V**\9TG]I/Q 8XS<>%_MT9SF33[A) M\XZ@!2<5JV7[67A_*KJ-GJFDLW3SX#C'MG!/Y5D\/470VCC*+Z_H<9^TE^P5 M!\=/%VJ>);/Q1J&E:U>+"(898Q)9(8T\LAE&'8,O09PC%F .XBOSM_;._9W^ M(?[+]G8W'C&UTJWTK79I+&UO+.^^T(95P?F&%905)89'\)Z&OT&_;%_;-?P7 M\)K6U^',UKJ7C+Q7>KI&FHS 26C.I+3A#PQ102,G:IP3QP?5M=^$O@_XV^$? M#EKXPTG0_%[Z*8;NW^WHEUY=TL85I #U8Y;/8^E8R@UNC]CX5\0+Z*]EK=-IZ;WW_ (9^&U\&_#;P[HZW"WBZ7IEM:"<+M$VR M)5WX[9QG'O6W1MV#&,*. .E0ZE>_P!FZ;<7'DS7'V>)I?*A7=)+M&=JCNQQ M@#N<4C\KJ3=2HYO=O\QM[K=GI=S;17-[:VLUY((+=)9UC:9\$A$!.6; )P.< M UXWJO\ P4!\#Z9;SW!M_$UQ!$T@26&R1A,$S\R_O,@':<;@OX9KY!^+_BW2 M_''Q"USQ%J>F6]K>>(''F6LSF5H% 4>46;GT;%D5% MQM4#HM+F/WGAWP=IUZ4:V85':23LK*S>^MY7/U8\.>);7QAX=L-6L)C<6.J6 MT=U;R?WXY%#*?Q!'%7*\>_8(TQM,_90\)XDMYK>ZBENK:6+):6*25G5I">LA MR2Q''->PTS\/S/"QPV,JX:+NH2E&_>S:"BBB@X0HHHH *^6?V@/VT/B)H7[4 MNM>!/AWH'PWN-*^&^AZ9XE\9WOC'Q!)I#W-M?SSQQP6#*C(K*MM(S3S9C#,B M8!.1]35Y=\;/V)_A)^TCX_\ #_BKQY\/?"_BSQ%X7"IIE_J-F)9;=%F6=8SV MDC69%D".&4,,@9S0"W/C+1?^"LOQL\F_"O^W;FVL-0M M=>A:]MM)U"YMI VMO+';P>:?MCQB0JZIN.!7V MRWPB^%.D^";_ .#+:/X;@T/QA;ZE<77A4\1ZG%>32S7KF/.6666:9G]2[55U MC]FKX-_'+2-8M[KPSX1\36>H6VFZ9J 0K.K1Z;,\UA&Q5LJ;>5W>,C#*6)!Y MI%N+2O8]6888CWHHZT4R I]O_KEIE/M_]7L8^Z_*?Y5 MB>(?CUX3\+$_:-8MG=?X(CO/T]*\R\&_M1K#>ZYIFC:!JVIBUO6FBD=-B".4 M;@2<8 SNZD5I&C-[(PEBJ4=Y?J>^4'A=QX7N3VKYZU_]HSQ1<$JU]X+9/WFJ^*];9@VU;2W%K"1V^9B3C\#71'!R^T[ M?U]QS2S&'V4W_7WGTQJWC;1] #&\U2RM]O4/*,C\.M(L2?\^F:\;T[X8:I?N&C\.Z?#G&)=2NI+IQZG;E5Y],5TFF_";6/+VS MZ\+&-B2T6FVZ6Z\]<%0"?QJOJ]*.LG_7RN9O&5Y?#&W]>=CI=2_::U.XB9], M\*7HBQN$UZX@CQZY;:/UKE-:_:&\47$KI)K?AS2.1B.V+74JY_ZYJW3W-:EK M\#-#619+K[9J,R_QW,S/_,UO:9X)TC1U"VVG6D6.F(QQ[U7[F.RO_7F0XXB7 MQ2M_7E_F>677B;5O%)_>ZMXOUC+8VVUNMK$R^H+$GGZ"O//VEOV2]=_:.^$E MQH>FV+Z/J*W"7UK=W^H-*'E0,%CD 7"H0QR0I(X(STKZJ11&/E4+ZX&*';"G MO71ALQJ8>K&M0TE%W3\U^!QX[)Z.-P\\+BO>A--->3W/SE_9M_X(O>,/#'Q5 ML_$'C'Q3I>FVVDSI?6L>A3O+<27*.&&YWC78@QSC+'/\/4_^"M0TQ+JYTVYN(R;:[MY#'+:S#E'4CGAL9] M1D5QGP.\>Z]I>KS>"/'4_F^*K-#/:7P4+#K=M_STC( RR]&4\CK7K8[,,;FL M'BJU1.4/LI6:CW7=7WZK?8^>RG*,MX?JQR_#T91A4VFW=.72+[.R]W2SVWWO M^(?V9?!/BFSM[75/#ECJMO:W"7<<5T"Z"500K%E^%=&U^S6F^AM02)+"KQE6CD 92O1@>AIV<5YM^SUXKU"VAU M+P3XBG:?Q%X0*Q"=^#J5DW^HN1ZDCY6]&7WKTDUAC,,\/6=)ZKH^Z>J:]4=> M68Z.,PT:\5:^C3W4EI*+\TTT!.31344J.:=7(=X5XZ?"D/A_]NJ/5.5;Q'X6 MD.\RG+R02HA4+TVA&7CU7->Q5YG\1],\O]I?X::CN"J;?5++KR280X'Z5Z^3 MU&IU*:?Q0FONBY?FCYOB6C&5.A5:NX5J;7E>2B_PD>F4445Y!](%%%% 'E7Q M=B3Q7^T=\,-'\M)AI+7OB"8;L-%Y<0BB;Z;W_2O56(QG M_/RH[>D$H+[^5OT9YI^UOJ*YDT/3PI^;?.=K,.1]U-QR.F!7H@ MY->6Z*O_ MO]HNZU3_6:'\/8WL+(_PSZA*!YS^_EIA/J:65PBJOUB?PTUS/ MS:^%?-V^5RN(*DWA_J=+XZSY%Y)_%+_MV-WZV[GH7A3PS;^"_"^FZ/9@+:Z7 M:QVL0']U%"Y_'&?QK0HH5=QKSJE1SDYRW=VSVJ5*-*$:<%9122]$<[\6/B-; M_"CX?ZCKEPAF:U3;;0#[US.QVQ1CU+,1^&:S/@!\.I_AM\.88-082ZYJDKZG MJTO_ #TNICN%'^[6!!&OQZ^,BW3?O?"7@.7\L?E>[\VET/ P'^VXV68/X(7A3\]N>?S:Y5 MY)OJ%>8_&[Q;J'BG6H/AYX9G:'6-9BWZK?1G_D"V)X=S_P!-''RH.O.?2M_X MN_$R7P)IUK9:7:KJGBC66,.E6&?OM_%*_I$@Y8^V*7X0_"U?AIHMP]U<#4O$ M&L2_:]7U$K\UW,>P]$7HJ] *6#A'#0^N55=_87=_S/R7XO3N/,JD\;5>6X=V MC_R\DNB?V$_YI+_P&.N[1M^%/!^G^!_"^GZ-I4"VNGZ;"L$$8[*.Y]23R3W) M-:8H#9-<#\5?BC?6FL1^$_"4<5]XNODWLSAZ3%Y=K9KRS?ZR M>0\O(Y[NQY)-4/A1\*K+X5:%);P22WVH7TAN-1U&?FXU"8]78^G7"] *WM=U MZR\,:/<:AJ%U#9V-JA>::5MJ(/\ /;J:Z<57C**PF$NXW[:SEWMVZ)=/5G%@ M<).,Y9EF%E4:T5_=IQWLGM?K)K=^20SQ-XFL/!OA^\U35+J.ST^QC,L\S]$4 M?S)Z #J:\Y^%GAR^^*WC2/XA^(;>:UMXT:/PSI4Z\V,#=;EQ_P ]I!^*K^%. MTC0KS]H+Q!:ZWKEK-9^#]-E6?2=*G7:^I2#[MU.O]T=4C/U->I$Y-:3E'!0= M*#_>2TD_Y4]XKS?VGVT[F-.G+-*T<155J$'>*?VY+:;7\J^RNK]Y] HV[N.I MH(+=*\S\0^.=4^*VMW7AOP=<&UL[9O*U;Q"HW):^L-O_ 'ICTW#A?K7#A<)* ML][16K;V2_K9=6>KC\PIX6"O[TI:1BMY/R_5O1+5D?Q#\47WQ;\07'@CPK>/ M:P0_+XAUF'I81GK;1'H9W'!Q]T5W_A+PEIW@3PW9Z/I-LMGI]A&(H8E/0>I/ MW_ #/S[+HOG?FRW+YPF\9B[.M+1VVBOY8WZ=WO)Z[62*Y7XH_$M? = MC;VUG;_VEXBU5O)TS3E/SW#_ -]O[L:]68^E-^)'Q1B\$26VG6-JVL>)-2XL M=-B/S-_TTD/\$8[L?2H_AQ\-)/#E]<:YK5TNJ^*M20+/W=NG:"$?PQC\S MU-5A\/"G!8C$;?9CUE_E'N^NR\HQ>,JUZCP6"?O?:ET@OUGV73=^;OA/\,7\ M!VMY?:E>?VKXEUMA-J=^1_K&_AC0?PQIT ]LUL^-?&>F^ /#=SJNJW*VUG;# MD]6D8_=1!U9FZ #K4/C_ .(6F?#7P^VH:I,RIN$<$,8W374A^['&O5F/Z5R6 M@>"[SQAK$/C#QPL5HNG@S:=I$CC[/I"_\]92>&FQU)X7H*TC3EB)/%XM^[MI MO+^[%?AV2^XPJ58X.FLORY+G2OKJHKK*;ZWU=MY/RNP^'?@K4/&_BJ/QOXHM MVAOMA31-+:P\/S7&D>$\[+K6@"L^HC^*.U!Z*>AD/X5WO MA7PII_@G0H=-TNUCL[.W&$C0=?5F/5F/4D\FNK$5U2E[2LESK2,.D%TOY^7? M678X<'A98BFZ&%DU2;O.I]JH^O+Y=.;9+2.FJ@\!>!=-^&_AJ'2M)@\FWARS MLQW23R'[TCMU9R>I-:TTRV\+R2,L<<:EG=V"J@'4DGH!ZUSOQ#^*>D_#6UC. MH3227ES\MK86R^;=7C=@B#GGU/ KE8_A]KWQIFCNO&F[2= 5A);^'+:7F8=5 M-W(/O'_87@5QPPLZO^TXF7+%O=ZN7HNOY+N>I4QU/#VP6 AS32LHK117]Y[1 M7EN^B(]2^(VM?&B[FTOP+)_9^C1MLO?$\D>4QT:.T4_ZQ_\ ;/RBNR^'?PVT M?X6:%_9^D6[1K(YEN)Y6\R>[D/)DD<\LQ_(=JV[*P@TZRBMK6&*WM[= D<42 MA4C4=@!P!7 ^)/C@U_K,FA^"[ >)]:B;;-*K[=/TX^LTW0D?W5R>*U3J8F/U M?"QY::W_ ,YRV_1=%WY73H8&2QF85.>L]%9?^2TXJ[]7N]VSK?&7CC2?A]H4 MFI:U?0:?9Q\;Y#RY[*HZLQ[ B_[Q^;Z5Z 6 MWR_PI_F_DEN5]3Q.9:XW]W2_D3UE_C:Z?W4_5O8H^ M&_#>G^#]"MM+TNSAL=/LTV0P0KM5!_4GJ2>2:O=:YWXB_%CP_P#"G3TGUS4( M[5ICB"V0&2YNF_NQQ+\S'Z#%<,UQ\0OCD<0I-\./"\AYED DUJ]3_97[MN#Z MG+5E1P-6LO;UIKV@O5KR.C^) MWQ[T?X=7ZZ3;QW7B'Q1<#_1M$TT>9=2'L7[1+ZLV/QKG-/\ @?K7Q=U.'5OB M=U=+6W]H4\,N3 II]9OXO^W5M%>GO>?0YED]?&R53-6G% M;4X_ O\ $]'-^J4?[O4;%"EO#''&B1QPJ$1$4*J = .@'I3J.]8_C[XB:#\ M*?#$VM>)M9TW0=)MQ\]W?3B&,>P)Y8^PR?:O)492=EJSZ/W81[)?@C8KD_C% M\<_"/[/WA&37/&.NV6AZ>N1&96W373]DAB7+RN>@503FO)+C]IKX@?M%?Z+\ M%_"JV6BR_*WC?Q7 ]O8 ?WK2UXEN#U(8A5Z5T/PC_8G\/>"/&,?C'Q5J&H_$ MGXA8S_;^O8D^Q_[-I;_ZNW4=MHS[UV+"PIZXA_);_/HOGKY'+]8G4TH+_MY[ M?+O^7F<5R#D6,+>I_>%3^7NOPB^# M?A?X"^!K;PWX/T6TT+1K4EQ! /FFD/WI9'/S22-U+,2373LQ8\DM[^M(JESA M02QZ 5G6Q3G'DBK1[+]>[]2Z.%4'SRUEW?Z=D%%>9_&C]K[P#\"KY=-U?6OM MWB*;B#0='A.H:K.>P$$>2,Y'+[1R*X.2[^.W[3 9;6&#X$>$9ND\^S4?$]Y& M?1/]3:Y]]S"G3P6P<$UZ?\"_V2?!/[/MY/J6CZ?-J7B: M^YOO$>L3&^UB^8]2\[Y*@_W4VK[5Z6:T6(I4?X*N_P"9_HMEZNYFZ%2M_'=E M_*OU>[]%8Y_X6_"GPW\$?!%GX;\(Z+8>']#L!MAM+2/:H/=F/5W/=F)8]S70 M4VYGCL[62XFDCAAA7=)+(P5(QZLQX ]S7AOB_P#;W\,R:_-X?^'>DZU\7/%$ M)VO9^&T#V5L3WGO6_<1J,3:3?=_YM_J;RJTJ,;/3LO\ )'N@ M4L> 37A_Q>_;FT#PGXJD\(>!]-OOBG\0N5_L+0")([$_WKRY_P!5;H#UR2W! MXK#G_9T^*G[2JLWQ9\8KX3\+W ^;P=X+G:$RJ?X+O4"/,D]UC"J>?05[-\)_ M@WX5^!/A&+0?!^@:;X=TF/GR;.+9YK?WI&^](Q_O,2:VY:%+6;YWV6WS?7Y? M>8\U>KI!S#.-TGR\< U](11K!$D<:I''&H1$5=JHH& !P !P .U.IKOL%8 MUL1.J_>V6R6R]$;T[>[]6.J-XV9ZD'S#-(Q"J6;A5ZDG@5SM]6;" M*@6G 9KA=;^/VD1:DVFZ#!>>+-64[3;Z6OF1Q'_II-]Q!^)JB_PZ\5?%)<^+ M]571]*;KHNBRE?,'I-;Z+@5Y53-H2ER82+J2\OA7K+9?*[\CGEB$WRTUS M/RV^;+GBKXZ6\.KR:+X7LI/%GB%>&AM7Q:V?O/-]U![#)IG@_P"#4\OB*+Q) MXPO8]>\11C_1XU3;8:5ST@C/\7J[['W.37.^,OC=I/AK5#I-C'<^(?$#<+ING+YLB'_IHWW8QZECQZ5RUJ,(V MQ&:5$[/2*^%/I9;SEVO\DC.44O?Q#^73[NK.R=PB,[LJJH+,S' 4=R37F^K_ M !>U'Q]J4VC^ 88;R2)O+N]0\?A_392(3CI]HE',A]5&%KT/3-+MM$T^&TL[>&UM;=0D<,*!$0#L .*UY ML7C-%>E3[_;EZ+[*]=?)%?O*O]V/XOT[?F<[\./A;I_PWAFE6:XU+6K_ )O] M4NSNN;MO<_PJ.RC@>]=3FHV@WMQ]3Q7$^*/C=;PZK)HOABSD\5>($^5H+5O] M%LSZSS?=0#T!)^E=4JF%R^BH+W5T2U;?DEJV^O5FCE3HQMLNW];G5^*/%.G> M"M%FU+5KR"PL;?[\TK87/8#N2>P')KSF+2M8_:.N(;C4H+O0_ :-OCTZ0F.\ MUS!X:;',O[N,_>8?WV MR:] SDUQ_5Z^.UQ*Y*72'67^*VR_NKYOH956SUR,UGWWA#2]37$ M^GVLF?6,5I57N782\_A51;Z"E%/H:;8V<3S3/=2^9!#&HRQ8-D;0 2]LC#YWZ,>!FJ]M-: M7/1RW):>*DZE7W*4-9R[+LN\I;175^2;./\ @S\,==^//BV3XGW5GI=YHWE2 M:=X7MKVV%N9+3=\]Z5CVE7E/W2>0@';%>C3>#-2T1MS:#J]FP&/,TS4BP)[- MMD!_+=7L\%O'9VL<-O''##"@CBCC7:D:@8"@#@ #@"EA#*OS-G\:J-=I6.?. M*T<;7YX+EA%*,8[\L5LO7JWU;;ZGD&G_ !*UOPV=L/B?7+':O$>IZ>77/=0R M%OSVUT^A_M'>*(?NOX;UY5(4>1=+#*<_[+[3^?Y5W$UM%XT#X^^ M)K^]TN72+C7I_P"T(XI9-V8W"@E> I=6R!WY)).:\Q^%5HWQN^,^@>%4OK2 MS&K7@2:6XF,:)"@,DOS*"0WEJV..N.G6OKK]L']F/1OBQ\4OASX!THS6=]JT MEYJE_=IEY-+TZ"+:SC/&))GC4*3RP'UK6^#/_!.72?V>KN[OM'DT_P 0:M>* M8Y+S5[BZ+;):6<,<_F>7&HPH)))) M]2>2_&*GTWXGZYX6*K!X MFU2S*@@0ZM8,RDYZ;TW#IWQ6WU._P2O_ %Y7/YPEFDI2$)#=/8FNDT_]JW18G6/6+'5-%FP"?M$! MV\_7%9RPU1=#:.-I2ZV]3U&BN?T'XJ^'?$R!K/6+*3(SM:0*V/H:Z!#YB[E( M8>H.:Q<6MSHC*,E>+"N:^,'Q7TGX(?#;5O%&MR,NGZ3%YC(A'F3N2 D:9(&Y MF( SQSGH#72]*_.__@NE\4HO#FJ_#S2)_$MA_9-J+G5M5\.;W,]ULVK;S,JJ M?D9M\(W$',K%0V#B&>EE>#^M8J%!O1O7T,7Q?\9+CX[Z]>Z]JC?9M2U!0;![ M=WA:*%I(H0RE"IP(IP .CKDG[Q ]B_X)3^((]-8@%/W%B3.6R,#\^]5^+.IKX>\W4YI+G4[QK.TN)KAG7RUFF=I0C M#Y=RLB_=/R?*N % KZZ_X)"_'SP_HWQQ\6> [>2[F/B2UM+G3;F8EFNY+:VW MS9_NJPD9US_<89Z9A;GZ)Q!A80RR<*,596^23Z>A^B5%%%:'Y6%/M_\ 7+3* M?;_ZY: &5'=7<5E$7FDCA5>I=@H_6OGSQ/\ M!^*;PM')?Z)X<4Y'E(_VJZ' MMMCW'/UQ7+O;ZAXTG#M%XF\1,QR&NI?L5MU_NC,:Y.__ &GKK4DW:'X9O9X^@N;L^1#S MP#N; Q^-<5H/PFUQ"K*VD:"O&?L=L))_^_C[FS^-;=M\#M+EE634[B^U>8?Q M7,S.OY$U2IT8[Z_U\C+VV(GMI_7GK^!AZY\>O$>KR;)O$FF::K?\L=,A:\FQ MSW4;<_\ CVK#_LC4/%LFYK'Q+K;,/OW]U]EA//]Q%--T1 MK M8V\..X09K0Z57MHQ^!$_5IR_B2_7_@'E^C_"37%.Y5T/0UP1_HUJ)9@#_P!- M'W-GW!K)\1_"2UT3XJZ'>:SJ6I:I;ZXCZ?,TTY"B8?-'QG SR.*]FS7+_&/P MG-XP^'M];VGRZA:@7=DPZK/&=ZX^N,?C4RK3>II#"P1?TCX>:)H(46VFVL97 MN4!-:\<*PKA%51Z 8K&^&_C6'XB>!=-UB'C[9"#*G>.4<.A^C BMNLW)OHQ<2V-P.C# MU4]&7N*ZJBML/7G1J*K3=FCGQ>%I8FC*A65XRW_KHUT?1G&_![XE7'CFQO-- MUFV&G>*=#<6^J6F>&/\ #/'ZQR#D'MTKL$CV'-<)\7/!5XU_:>+O#:I_PDVB M*08L<:I:_P =NWJ<Q^M=3X*\96/C_ ,,6FK:>[-;W:YVN,/$PX9&'9E/! M%=F,I0E%8J@K1>Z_E?;T>Z\M.AYN6XBK3F\#BG><=8R_GCM?_$MI>=GU.'^/ MNC7'AB]TOX@:7"TFH>%B4OXD'S7NG.0)D/J4^^/3!KT;3=1M]8TZWO+659K6 MZC6:&1>CHPRI_$$4Z5([F-XI%62.12CHPRK C!!KSSX(&3P'K6L>!+IB5T=C M>Z0S'_6V$K$A1_US;*G\*N_UC"6?Q4_QBW_[:_P?D99?PZ^_E42T_\ M"BK>J7<]'HH8[!S2*VZO*/?%KS'XXQ/_ ,+:^$TBE@JZ[,&(/K;GC\:].KSW MXS1J_P 0?AH?XEUYB/;]PV:]/*)6Q*])_P#I#/"XDCS8!K^]#\*D&>A4445Y MA[H5F^,?%,/@?PEJ6L7)Q#I=L]RWOM&0/Q.!^-:5>=_'*(^,]3\.^#8V;;K5 MT+O4,?PVM=F!HJK7C&?P[OT6K_ \W-L5+#X68?R!4?A7:W-S'96\DTSK'#"I>1CT M50,DGZ 4_C/RK@= !VK@?CU?3ZOH]AX3L9"M_P"+9_LKLO6&T7YIY/;Y?ESZ MM6BYL;B^:6G,[OR6[^Y&,N7+,N4(:\D4EYRV7_@4K%7]G>"36+#6O%]U&RW7 MC"^:YB##F.TC_=P+]-H+?C7I%0Z=IMOI&GV]K:QK%;VL2PPH/X$4 ?@!4D\ M\=K \LKK'%&I=W8X5% R2?8"L<96^L5W.*T>B7DM$ODK(WRS"+"82-*3U2O) M]V]9/YMMG)_&;QW<>"O":Q::HF\0:S*-/TJ#^_._&_\ W4&6)]A6A\,O 5O\ M,_ ]AHUNQF-JA:>=OO7,S?-)(?=F)/TQ7+_#6U;XH>-9O'-Y&ZV,*/8^'X'' MW8W_;M_O;./+8O%5WF,MFN6"_NWUE M_P!O-)_X4NXC-M%<%\8/%U]?7-OX/\.R[=?UR,F:X4_\@FTZ/.WHQ&0H[GZ5 MN?$KQ_#X!T2-EC:\U2^?[/IUDG+WPJO\+?AY)X.LKJ^U.:._P#$ MFL/Y^I7@'WF[1)Z1H. /QHP<(T8?6JJO_*N[[OR7XO3N/,*D\5/^S\.VK_') M?9B^B_O2Z=EKV-;P=X0L? /A>QT?38O)LM/C$<8[MW+,>[$Y)/J:S_B7\2K? MX=:5$?(DU#5K]_)T[3H>9;R4] /11W;H!3OB)\1[?P!9PQK#)J.KZ@WEZ?IT M/,UT_P#[*H[L> *S_AW\-[C2]2F\0>()H]0\47R;7D7F+3XS_P L(1V4=VZL M?:BG35OK>+NT]4NLG_EW?R6H5Z[367Y?9.*2;MI3CT]9=E\WIO'\+/AA<^'] M0NO$7B&XCU'Q=JR@7,R_ZJQB[6\/HB]S_$:[;K39)5@B:1V6..,%F9CA5 ZD MGL/>O.]2\5ZI\9;F;3?"\TFFZ OR7FO!<--V:.U!ZGL9.@YQ4\M7&5'5J-)+ M=O9+LOT2*YJ&64(T*,7*3O:.\I/JV_-ZN3T7X%CQG\2+[6?$4GA?P>L=QK"K M_IVHN-UKHR'NW9I?1/7K6Y\-OAII_P ,M&DM[1IKF\O)//OKZ<[KB^E/5W;^ M0Z"KW@[P;IW@+0XM-TNV6VM8_F)ZO*QZN[=68]236;X\^)UKX/GAL+>&75M> MO!_HNFVY_>/_ +3G^!!W8U;J.JOJN$3Y>O=^NIE&C&@_K^923GT7 M2-].6*W;>S=KOR6AH>-/&VF_#WP_-J>JW"V]K#P,#<\K'HB+U9CV KB=(\#Z ME\8MBVK";2_#[G.6_AGNO[S]PG1:U/"/PNNKS7H_$7BR>'5-<5 M?]&MT'^AZ4/[L2GJ_JYY/:NX)W<]:'7IX6/)AW>;TB.E5]6UBTT'3)KV^N(;6TMU+RS2MM5 /?^E8OC;XF M6/@V>*S6.;4M8N?^/?3K4;YY?<]D7U9JQ=+^&-_XTU*'5?&LD-R\+>9::-"V MZRLCV+_\]7]SP*QI81>'_ 6Q&^YP8[W6E[J@ZQQ'^\>2*]!T#0+'PMH\&GZ;:PV= MC;+MBAB7:JC^I]2>35P< # & .@Q537->LO#.ERWVH74-G:0C+RRMM4>WN M?8%P-/#7Q.(ES3:UD]++LEM&*[?-MLMX) MZM5)-0U[XT QV M/VKPWX7D&&O&&R_U)?\ IDI_U2'^\>3VKK-)T;0_A=X8\JW2UTG2[4%Y'=@B MY[N['EF/J>36T*-/#M>U7-/I'=+_ !6W?DOGV.:IB:V,C^X;ITNLWHVO[M]E M_>?R74H_#SX86O@1)KJ2:75-=U WVIW'^MN&]!_=0=E'%5_'_Q4@\+WZZ3I MMN^M^);E3Y&G0'E?]N5ND:#KD\GM6/?>/-8^)L4J^&V_L/P_&#]I\07B;-Z] M_LZ-_P"AM@5E^#IU@AFT[X>V'VAIWS?>)=1R\74S"%.FL+E_NQ?VDKN7?D6\GWG+W;ZW9.UA8_#74( M_$WC:_&M>++SY;&T@C,@ML](;6+K[&0\GU%7;?P%K'Q;O([WQ@IL-%5A);>' MXGSO]#=./OMGG8.!6]X-^&.G^";F;5;NXDU/6I 3BYJOK%2I*^&5VE9S=DHKM&^D5Y[ M^@OJE&C!+'/EBW=4TW*4WWG;6;\E[JZWL=E>7MEX:TAIKB:UT^QM$ +.PCBA M4=O0?2N!D^).O?%*5K;P3:BSTW.V3Q!J$1$)'?[/$<&0^C'Y>AJ]IGP8;7M0 MAU+QEJ'_ D=]&0\5IM\O3[0_P"Q%_$1_>?)XZ5I>,?B[H?@69+&262\U(C; M#INGQ^?<-V V+PH_WL"N6C3IQGRT5[6??[*_S]79>3._$U*TZ?-B9_5Z79-< M[\K[1](WEYH;X ^$&E^ KN6^#7&K:Y=#_2=4OF\RYF)[ ]$7_97 IOCOXS:/ MX'OEL/\ 2-6UN;B+2[!/.N7/;B\G+;Y1^]"PWMG3]EEU/V-/^:2U?FHO5OSFUZ,XW_A7_ (H^+C>9 MXOO/[#T-N5T+3)B))AZ7$XY/NJ8':N^\/>&]/\):1%I^EV=OI]E ,)# @11[ M^Y/J>37*^)/V@= T?4FT[3VNO$NL#C[#I,7VAU/^VX^1/Q-9K:-\0OB:/^)A M?6_@/29!S;:>1D8KR37H=-\0/BYX=^&$*?VSJ44-Q-Q#:1*9KJ<^BQ+EC M^6/>N3;6_B#\6QMTNS7P!HDG_+[?H)]4F7_IG#]V//JY)%=1X"^#7ASX;2O- MIM@K:A-_K;^Z8W%Y,?4R-D_@,"NH)S_.N;ZUAJ'^[QYI?S26GRCM]]_0[/J. M.Q?^^5/9P_DIO7_MZ>C_ / 5'U9QGP]^!.@_#R\:_BCGU37)A^^U;4I/M%Y* M>^&;A![* *[.H=1U"WT:PDN[RXM[.UA&9)IY%CC0>[,0!7D6M?MK>&M0U*32 M_ ^FZY\2]9C)4PZ#;[K2-O\ II=/B)1TR03P?PKGG+$XJ?/-N3[OI^B1Z6'H M83!4_944H+LMW^K?GJSV,(M/TF23_4VK/YEW)-,^&.AR_>TWPV!>:K(OH]W(-L9(Q_JUSR M176?"7]E+P'\&+YM0TG15N]E.-EW?^7^=CAV^,WQ8^/2A?A[X0C\#:%+@KXC\91$3RH?XH+!3 MNR>QE('M6IX&_8A\,V/B2'Q)XVO]4^*'BR,ADU#Q&PFM[1O^G>T'[F(?\!)P M!S7L6J:E;Z1927=]<6]G;1\O/<2B*-?JS$#]:\DUS]M[P6-1;3?"J:U\1-84 M[?LGAFQ:\13QP\_$2\'.=W0&M(U*LE;#QY5Y=O-_\&QE*G2B[UY8@=CP M*\<\WX\?%_[L?ACX0Z3+WDQK6LE?H,01MU'.<9'6KGAC]A;P7!K46L>+)=:^ M)6OQD.+[Q1=F\1&&#F.WXA3D XVGJ>N:S]A3AK5G\EK^.WXLU]M4EI2C\WHO MNW_!%&^_;BL?&EY+8?"WPGXB^*%]&2AN[*+[%H\)&1\]Y, A''\ ;.1C.:JR M? ?XL_'9?^+C>/E\(:+-]_P[X'+0M(IX*37[@R,#S]P#KUXKWJQLHK"RCM;6 M&*WMH5VQPPQA(XP.@"@8 ^EQOP<_9U\$?L_:>\/@_P - MZ?H\LW^ONU4RWET>YDG?,CD^[5VBAF/RY)]J\1_X:I\7?$KY/AO\+?$&J0-] MS6/$K?V+IQ]PK9F<9R.%'0>M0S?LZ_$OXL@GX@?%"ZTVPDSOT7P7!_9T+*?X M7NGS,W0'C;SGUHGAYM\V(E;U=W]RO^@0K12Y:$;^FB^]V_4[OXK_ +3'@/X& MKM\5>*=+TVZ;_5V0D\Z\F/'"01[I">1_#WKSY/VC/B=\:DV?#7X:W&BZ;,/E M\0^.&-A!M/\ ''9IF:3KWVC*X-=]\)OV7/A_\#I&F\-^%M,L[YSF34)E-U?3 M'GEIY2SD\GO7?M(TC;F)8GJ34^TH4_@CS/N_\E^K97LZ]3XY^)$RMYBZ/&3I>@P-G/%K$09!T'[QCG'([5[5X4\(Z1\/? M#\&E:#I>GZ+I=N-L5I8VZV\*#V50!^-:=!3?VK.IB)U-)/3MLONV-:6'IT]8 MK7ON_O9&LASVP:DK!\4_$;P_X'S_ &KK%C9OVC:0-*3[(N6[^E<^?C#JOB=< M>%?"6J:@C?=O-1Q86H]_F^=N?0?C7DU\TPU.7)S7EV7O/[E<[[;O\ M#O@-Q&/6L3QA\1M!\!0;]8U6SL3_ QN^Z5_H@RQ_ 5S,4_XJ#Q5_ M9MJ^=UEH4?DY'/!F;+]#V Y%;/@_X.>&_!,_G:?I,'VQN6NI\W%PYZY+OD]S MTQ6'UG&5?X-/D7>>_P#X"OU:)]I5E\*LO/\ R7_ ,-/BMXA\:_+X3\*W(MV^ M[J6M$V=N1ZK'_K&[^G;UI/\ A1MUXP?S?&OB*^UY<[O[/MLV>GK[%%.Y\?[1 M]*Z/Q?\ %;P_X(;;J>K6\=PW"V\9\ZX<^@C7+9_"L _$+Q9XT^7PWX9_LZU; M[NH:ZQA7'8K OSGMUQUKSJT<,Y'K6]\6ZHA MP8=-3=#$?]N8_(H_$]*B7X%?\)+*LWC#6]0\2NN&%KG[+8H1Z1)][_@1-=OI M&CVF@Z?':V-K;V=K&,+%#&(T7\!7=".-J14:<51A\G+Y)>ZOO?H:KVLE:*45 M][^[;\S@CX \6?$=<^*-870]-D.?[*T20J[CTEN#\Q^BX%=CX2\$:3X#TS[' MH^GVVGV_\0B7YI#ZLW5C[DFK6N>(+'PS8M=:E>6MC;J.9+B41K^O6N)D^.,O MBAVA\':#J'B)NGVR4&TL%/J9&Y8?[HK/EP."GS5)B2%:C2= MWK+[V>@5Q?BCXZ:/HVI-IFFK=>)-;!P+#2U\YD/^V_W(Q[DU0/PGUWQX WC' MQ%*]JW72=(S:VI'H\G^L?\P*[/PSX3TSP7IBV>DV%KI]NO\ !!&%W>Y/5C[G M-;>TQN(_A1]E'O+67RBM%\WZHKFJS^%D1V&DV-MI]G'TBA3:#[D]2?1=.A&+YMWW84445W&P44F#N]J6@ JIKVN6/AC M1KK4M3NK6PT^QC,MQE<9\8OVC=!^#UU;Z9(MYKGBC4.+#0- M+3S[^[)[E>D:=][X'UKD=$^ GB+XWZW:^(/BY+:M:VDHGT[P;92E]-L6'W7N M6_Y>9>G!^0'L:5^Q[F#R=*FL5CY>SI=/YI_X(]?\3M%=WL9=Q>ZY^VY=QPV/ M]H^&_@ZI_P!)NB&M]0\7X/W(A]Z*U/=CAG'3V]TT#0+'PIHEKINEV=OI^GV, M0AM[:! D<*#@*H%6T18HU1%6..-0J*HVJ@' Z =,4M,QS'-'B(QH4H\E*/ MPQ7YR?VI/J_DDEH%%%-FFCMH))99(XXHE+N[L%5%')8D\ #U-!Y,5=V0V^OH M-,LI;BZFAMK>!2\DLKB..-1U+,> !ZFN?^&GQ;T'XPZ=?7WAN\_M33;&Z:S^ MVQH1;W$B@%Q$Q^^%R 6'&>A/->1ZMXNU+]MC4+O0?"UQ=:3\+;65K;6?$"#; M+XC*GYK2RSTA/1Y>XX'6O9/AU\.=)^$_@S3_ ]H%JMAH^F*RP0+SM#,6.3W M.6/)YI'O8W+:&"PW)B6_K#:]U;1C_>_O/I'HM7KH/M_A_I%M\0KKQ5':[=>O M=/BTJ:Z\QCOMHY'D2/;G:,/(YR!DYY) %:4MO\V5&[-3T4SQ*E24VN=WLK?) M;(9 K(G/Y>E17^GPWT++)#%+GLR@U8HHNR+7.7U#X1:#K*[IM-ACE[/'\I'Y M5EW/P?FTR!ETO7]2M8EZ0S-Y\/M\K9&!]*[RD==Z;3T-:*M-=3&6'IOH>0:A M\+]61V,FD:)JF,D26X:SG/.P>P MRNUO;.#]:]?8BUF^5?Q-6%VW$7S*&W=01FMOK'=&+PB3O%V/EW]IC]O7QC\* M]-TW1]-UW3FFU1)+AM4M[;]_!%$5&Q5E3:'8N,DAL*K=R"/A3]HJ'7/VQ_VE MM,US1=)L[3Q?X@M@FKW!U!GL;J>VC"QZ@49O: MOHNJ?%(ZA:Z-IGB2T;3](6)O.EN%2<^=*X.52/T.:QN+?0/"%I]L6 MR4A)IHKPFXE(/)\QY'8D\DY)KT7_ ((Y?!WQU\'OBMX/\57?@.3Q1X8^(6B3 MV]IXHL;\-#X9A#;F2:-ONL6A1-HP?F^4GYP/F']HS6=)^-_Q0\5:A;ZE#=27 MVH7!MM06V"": 2,J!D&/W90#"C&.HYKZB_X)A?&:^\ >!+CP';ZY=:3_ &'N MOK)TB:XM9HI''F>8!\R-YC%LX(PX&<@U$::G4Y5\CTLTEB,+D<7),I2ZV]3T:GV_P#KEJAI/B"QUZ(265Y; M72MT\N0-^G6K\'$RUAL=2=]CR#1?A]HOAX?Z'IMK$?79D_K6PH"K@# ]!117 M2Y-[G#&*2LD%%%%(H**:LJLV W-.H * <&BB@#RKP1=?\*D^.^I^%9OW>C>+ M0^KZ,3]V. ^M>JUP?[0OPWNOB1X +:1(L'B70IEU/1IQU2XCY" M$^CC*D>]:'P3^+%I\:?AS8Z[;+Y$TF8+VV;[]E=(=LL3#L0P_(B@KH=9111W MH)"BBL'7?B;H/A:"ZFU35;'3;6SP)9[F98TW'/RKDY8\'H#0!O45Y7X0_;)\ M%>//'<&AZ5)JEPMQD)J)M#'8[P<;"[$-DG&#MVG(YKU0\&@ HQD8HHH CCA\ MML[NG->>:Q"/@GX^?6(_W?A7Q),$U)!PNG79X6X'HK]&[9YKT61BHS535-*M M_$6E7-A>PK<6EY&8ID(^\IZ_CZ'UKLPF)5.3C/6,M&O+_-;I_H>=F&"=>"E3 M=JD7>+\^S\GL_(L^3SG=D=1CO7#_ !LL7T"32?&5I&6N?#4W^E*O6:RDPLJG M_=X8?0U-\+]4N?#U[=>$=4FDFO-*026-P_6]M.BG/]Y/NGZ5V5Y9Q:C936]Q M&LD%Q&TL?SB_\ -?<85$LQP;2]V?XQG'5?<_P]0BFC MOK6.6%UDAF4.CJ>'4\@_B,&G(FP5QWP7GFTK2+WPW=.6NO#,YMD8_P#+2W/S M0M_WSQ_P&NSZ5SXJC[*HX7NNGFNGX';@<5]8H1JO1O==FM&OD] K@?BW;M7JTTC >@@//X5WU<;XNF\WXR>#H-N5CBO9S['RPH/ZUT9;)QK.2Z M1E_Z2SDSN*GAE3?6=/\ ]+C_ )'94445YYZP'\O4GM7 _">/_A,?%^O>,)%W M1W3_ -F:82/NVL).YA_OR9/OBM+XP:U<6_AR/2;!BNJ>(I186Y'6)6_UDG_ M4S^)%=!X>T.W\,:%9Z;:+MMK&%88Q[ 8S]3U_&O0A^YPSE]J>B]%N_F]/DSQ MZD?K..C#[-+WG_B:LE\E=^K1;=UC1F9E55!8L>B@=37!_"^ ^./%FI^-+B,^ M3< Z?HZM_!:H?FD'H9&Y^@JW\5;N?Q%-:^$]/D:.ZUD;[R53S:V8/SM]6^Z/ MJ:ZS3M/ATG3X;6VC6&WM8UBB11PJ@8 HB_88=O[4_P (_P#!?X+S"2^M8Q+[ M%)W]9]/_ %._JUU1-WKS_X@SR_$_P 3?\(?9R.FG0[9M>N(S]V/JML#_>?' M/H*W/B'XPN-!M[?3]+C$^O:J3'9QXW+%_>F?_84<^Y'UJWX%\%V_@705LXF\ M^>1C-=7+#]Y=3-]YV^O;T&*>'M0A]9E\3^'_ .2^73N_06,OBZGU./P+XW^4 M/G]KLO4U;:VCLK>.&%%CAA0)&BC"HH& !]!6;XR\:6/@;0I+^]9F52$BBC&Z M2XD/W8T'=B:F\4^)K/PCH\EY?2%(U^5549>5ST1!U+'T%<_X2\)7FOZ]'XB\ M01JMY&"-/L/O)IR'N?64]SVZ"LZ%&+_?5[\OXM]E^KZ&^*Q$T_JV%^/\(KN_ MT77T&_#_ ,&WUUK,GBCQ&B?VY=1F.WM1\T>E0'_EFO\ MG^)N_2KGCWXB?\ M",SPZ;IMM_:OB"^_X]K)6^Z/^>DA_A0>IZU!XD\=76H:L^B>&TCNM2QBXNVY MMM-'JQ_B?T4?C6CX(\!VO@JUE97DO-0NCNN[Z;YIKEO<]E'91P*Z:DE?V^)7 M3W8>72_9?B_Q."C%\KPN!?7WJCUU>]N\OPC^!2\"_#G_ (1[4)M8U2X&J>([ MY0L]V1\L*_\ /*(?PH/S/>M?Q5XNT_P5I+7FHW"P0CY44#=)*W947JS'T%9? MB/XB>3J3:3HEM_;&L?Q1JV(+3_:E?H,>@Y-1^&/AS]DU<:MK5Q_;&N$?+*RX MAM/]F%.BCW/)J:D7-^VQ;]$MVNEET7]),UHU%"/U7+HWMO)ZI/JV]Y2\OO:, MD>&=6^,$ZW&O1S:3X<5@\.D*^V:]'8W##HO^P/QKNHHK?1M.6-%AM;2U3 Q M''"@_0 5D^+OB%8^%)4MRLU]J4W$-E;#?-(?*I%CL M1AH]&MG/D^WG..9#[=*J?-5BI57R4ULO\EU?F_OZ$4^3#SE&@O:UG\4GT]7M M%+I%?=U(+SQ]JGQ"N)+'PBJQ6:-LN-;G3,,?8B!?^6CCUZ"MWP)\/=/\"03- M;"2XOKHAKN^G;S+BZ;U9CV]AP*V%B@TVR"JL-O;VZ8 ")&H_0"N7N_B5-KE MPUKX7L?[6E4[6O)"8[*'ZMU8CT6H4ZE6+I4%RPZ^?^)_I^!;ITJ$U7QDN>KT M25[>48ZOY[]W8Z75]9L_#^GR7=]<0VMK%RTDK;5'^?05R$WB;7OB2NSP_')H MNDMPVK74?[Z8?],(S_Z$U7-+^&$=QJ,>H^(;MM>U&,YC$J[;6V_W(^G'J9KN>?P'%;8&:YWQ+\3=.\/WGV*%9M5U5A\EE9+YDF M?]H]%'N:RV\(ZYX_&[Q%=?V5IC8QX8CU.3UXK:N/ \.EZ'&/%6J6.AZ-'RFD:W/L[??E/TJ] MI'BJ\O-/2Q\%>&X[73T&$O;U#:VP]U3[[GW.,UM1C2HK_9U?O)NR_P# OTC] M[.>O*OB9)8N5NT4KOY05_OG?_"AP^&<_B!1J'C;4H;JWMOG33H6\G3;0#INR M1YF/5N*?+\75U0_8/!VDR:\\/[OSHQ]GT^V^LF,''HH-5-:\%:3I@34/'GB! M=4D4[D@N'$%FA]$@'WNW7/:K4'Q"U'7;9;?PCX;D:T4;4O+Y?L=F@]53[S?@ M!FN>2]HN9KF2[^[!?DW^#]3HIR]B^2/[MO>W[RK+[KJ/XI>0V/X1WGBZ3[5X MSU9M5C0[QIMMFWT^'_>&=TF/5C4U[\7=#T&1=(\/VVT'>_XGUIVD_%&SALEL? _A:^U M:%>%>& 65DO7DR,!NZ=0#UJO9NJKRO-+M[M-?/3\EZDJM'#NT;4F]W+]Y5?R M3=OFVEV)F\)^,/'_ #K>J1^&].;K8:2VZXD'I).>GT05=B3P7\ M,8>9INB> M=]YI'W7-P?<\NYY_6JC^$/&GC+_D,>(;?P_:-_RZ:*F92/1IWY]/NCUK4\)_ M!GPWX,N?M%KIL2K4T_E@K+YM[^OO'3A\ M+7E/VM"E[W\]5WE\HK9>7NF+_P +9U[QJFWPCX8N9(&^[J6L$V=L/=4_UC_@ M!33\$+[QDP?QIXDOM8CSN_LZQS96*^Q53N?M]XUWFM:W9^';(W.I7EK86Z\F M6YF6)!^+$"O-]3_:W\*SW+6GAJ'6O'&H9VB'0K)YXP>?O3'$:\C'4X-8T\74 M2MA(*/GN_P#P)[?*QVRRNG)WQ]5U/[NT?_ %O_V]S'H7ASPOIO@_3%L])T^T MTVU7@1V\0C7\<=?QS5R:1+:!I962&%.6D=@JK]2>!7E(U;XP_$%_]$TSPS\/ M+!NDNH2'5-0V\'_5IB-202.2<$5''^R%I/B,+=>//$/B3QY-']Y=2O#;V"G& M.+>(J@]>2>17+*";YJT[ORU?^7XGI4Y*$5"A3LE\E]W_ "YXI_; \#Z%J+: M?IM[>>+M8'2P\.VK:A+G&>63Y%_%N.]9;>(_C1\4B5TO0M!^&>FL<"ZUJ7^T MM2QZB"/$:GC^(G@^U;%U\_&/C8+_ ,(?\--9:&3&+_Q'.NEVXR2"?+^:1L8S@#.*UC3LKPA\Y?TE M^9G*=W:<_E'^F_R*UC^Q=X?UZ^CO_'FL>(/B1J49W+_;5R191G_8M8\1CH.N M>E>D:AK/AOX1^'$2ZNM#\,:3 H"([Q6<*#H,+P/;@5Y[)\*OB?X_7_BI/B%! MX]_M*XT7^W]24EVU#7KE M]0F!)!SF4E5Y&>!QD\U,Y*6E6=_);?HBH1:UI0MYO?\ 5F7 MYQ"C8(]<$5U7BS]H[X?_ R'V.^\3:+;20@[;&S83S#!Y"Q1 D'/; KGW_:4 MUSQ7N7P7\-?%>MKR$O-3"Z39MC&.9?G((Z':#[548M*\*=O.7_!LOP)E)-VJ M5+^2_P"!=_B5]._8D\)ZI?17WC2_\0_$?4H_F\WQ!?-);*W!)6V3;$HR,XP? MQKU73=+TSP/H2V]G;Z=HNEVX"A(HTM;= .@P,**\P?PI\9/'1;^T/%7A?P-: M,?\ 5:)9-?W8&01^^FPH/8X7\*+;]BSPCJ5X+KQ5=^(O'EX.=^NZG)-#][<, M0J5C&/3&,=JFI)2_BU+^2U_R1=./+_"I_-Z?YLM>*/VS?AWX>U V-GK4GB;5 M"<)8Z!;/J4S$@D#]T"HSCNW'>LM_BY\6?B&F/"GPWM?#-K(N8]0\7WXC;! ( M86L.7Z9&&88/I7JWA?PCI/@G3UM-%TO3M)ME&!%9VR0+Z_P@5H=\UE[6E'X( M7]?^!8OV-67QS^[_ #?_ #Q>;]F'Q7\1&W>/_BEXBU"VDX?2?#J+HUB1D_* M67,K@J<'+#/K78?#/]FGP#\'G\SP[X5TBQN\?->/#]HNY#QRTTFYR3@=^U=E M?7D6GQ&2XEB@C49+2N$4#UR:YG4OC?X:T^4PQZA_:5T,CR;")KIR1V^0$<_6 MN;$YI&FK5:BBNVB_ /9T*;O*U^[U?XG6L[.V69F)ZDGK25Q7_"P/$FO?\@?P MC=0QMC;<:K<+;+@CKL&6_"D_X1+QEXA&=1\36NDQ-]Z#2;0;@.X\R3)_$"O- M_M)3TH0E/Y67WRLON+]NG\";_KN['97EY#IMN9KF:&WA4$EY7"+QUY-'4N%FOX;S7KK@^;J=R]SD MCC.TG;^E;MYK.A> =/V37.EZ/;HO";DA&!_LC!./I45*F,:YIN-->?O/]$OQ M%*53=VBOO_R.<;Q;XV\1C&E^&;31H6X%QK%UE^HP1%'D\CU--/PDUCQ&/^*C M\7:K=QL,-:::HL;?OQEG4UY[^K5/CE.L^ROR_A:/WLQ?)+ M=N7Y?A9?>:WA7X4^&_!1,FFZ/9038^:=T\R8^Y=LG]:C\3_&+PUX3F,5YJ]N MUUSBWMR;B9L?[*9.>>^*R_\ A2@UIE;Q%XAUS7L\6<^)?% M=XT#?>L=(3[' 1Z%^7;N.HS6YXG^)6@^$6/]HZQ8V\G:,RAI#[!%RV?PK%_X M7'=:ZNWPYX7UK5\]+BX465L>,@[I.2#]*YZRPJERXJLZC_E7_P C#?YW,Y>S MO:I+F?9?Y(WO"'PTT#P(G_$ITJUM9#]Z;;OF<^I=LL3QZUJZIJEKHUJUQ>W5 MO:0KR9)I!&OYFN.&@^._$Q_T[6]+\.6[=8=,@^T3]?\ GK)P..#@=JDT[X!^ M'8;I+K48[SQ#>K@^?JMPUR0<8R%/RC\JZ*-:KR\F$HD:PE*U MJ4++ST_ ANOC]I-Y=M:^'[/5/%5VO&W3KT^('C3_67& ME>#;-OX8!]NO<<_Q'"*>G3."*[NVMX[*!8H8XX8EX"1J%4?@.*?6GU&M5UQ- M5^D?=7WWYOQ0_8RE\A_ 7P_IU^M]?QW7B+4E.?M6JS&Y93_ +*G MY%_ <5VBCRT55"JJC 4# 7Z"BBNS#X.C05J,4O3KZO=FD*4(?"@HHHKH- HH MI54N<*"3Z"@!*C5&#UPWQ-_:2\&_#"[%C?:L+S6&.(M*TQ#>WTS=@(H\D9Z9 M; YKF&U?XM?&A=FGV-K\+-!DX^UWX6]UJ5?5(1^[A)_VR2*1[&'R/$3@JU:U M*G_-/1?)?%+Y)GH'Q.^,'AGX-Z0+SQ)K%IIL@VDWPO\)3<'5=0B$FMWL9[PV_W8 1T9_F]JZGX9?LR^%_AGK!U MCR;KQ!XFDYFUS69?ME\Y_P!EFXC'L@%>A$[NM&^YT+&8'!?[G#VD_P">:5E_ MAAM\Y-_X4<;\(_@-X:^"EG-_8MG(^HWIW7VJWDAN-0OV[F29OF.>?E& /2NR MH8;A13/'Q6*K8BHZU>3E)]7J_P"O(**%&XUY+X]_:DCE\07'A?X=Z6WCWQ?" M=DR6\FW3-*/]ZZN?NKCGY%)8XQQ0;8'+<1C)N%"-[;MZ)+NV]$O5G>?$KXGZ M#\'_ E<:YXDU.WTO3;<8+RGYI6[)&H^9W/95!->11^#O%/[8EU#=^*K>_\ M!_PQ202V_AXL8]1\2+U62\*G,4)X(B!R>]=%\._V97_X2V'QA\0M47QIXRB^ M:V+Q[=+T3/\ #:0'@?\ 71@6.,\5ZRQW,2>2>I/>D>O]PL;>"RL[.,106\""..%!T55' JS1M&[.. M?6C%,^M(\@1@I_BH 5D#]0#2T51\3>)M.\%^'KS5M7OK;3=+T^,RW% MU<.$CA4=R3^@ZD]*!QBV[(GU/5+71M/FNKZXM[2TA0M--<2+'$B8YW%N,8SU MKSKQ9+R#D-@\P6N<$9^9^/P]J\&>$--^'_A' M3]#T>UCL],TN!;>VA3HBC^9)R2>Y)H2;.^I3AAHJ\OWET[;I>O=^73J?FS\# M/^"37Q(3]H33=$\;V,$?@6Q N=0UC3-0_*QUE6>EMEHGYM=SF=<^$'A_7'\QK%;>;.1) ?+93ZC M%8FJ?"'5(X/+LM8%];@86VU.%;E ,8P"PR./0BO0J&.TF^EC MQ:]\'ZAX:F,LFBZAI[ _\?&BW1*CG_GD^??@$?2NM^$7Q6UIO&5EIS>(X[ZU MD\P-;ZA;-!%<)IP?7^MBK([B4!5^7OQ4E%%8'4%%0S3LDF!Q2VTS2[MW M\/?% #XX%B)*]Z=1WHZT %!YHH'- #(XA 2V[WY[5X)XYU6/]EOXU_\ "96\ MBGX>^.+F.T\2*G*:1J!^6&]QV1_N.>G>O?NM% MK/4+5A\LL;\'Z>H/8@&@:T-R35 EUL7RW3KO#?>Z=^G<8]W.*^>?V:/&]Y\(OB-*=2\1:EH9U"\N+QW6&>=VMER=QVQYQ@LQ)4Y7)Z"O7KZPC MU&+9(#ZAAU6JOAF6& 7%O;1^7%:2_(0#9';*HY#-CY>IKME\7Z M&+C5;*WU+3<+K6BL9[5O^>PQ\\1]G'ZUJ^&_$MOXGT&UU"WW>7=)G:?O1MT9 M3[@Y%: .#7)6\(\">.FC"[=)\02%T_NV]UCD?1Q^M=U-^VI>R>\=5Z=5^J^9 MY=6/U?$>W7PSLI>3V4OT?R[#/%,8\+?$K2-:7"V^JK_95X>V3\T+'Z'(_&NP M/!K(\>:!_P )-X3O;-(+C>66W@M[0+_=."Y_4TL*[*YK&C3=2:BCIQ-=4:;J/Y+N^B^93\&*?&OC.^\1R?-9VH;3]+!Z;0?WLH]V; MCZ"ND\2>(;?PIH=Q?W38AMUS@?>D;LH]R>!4FF:3;Z)I$-G;JL=O:QB-/91W M/\S7.:=!_P +#\1)?RY[4KJI)XBM\/;OV2_ MK0KE=""PF&^)[M]+[R?FWMW?D.\#^$)M-GN-8U1A-KFI >:*/%5KX2T[[1<,SNYVPP1C=+PP^Z^*3V5]V^\GV'Z'X=GN+O_A(O$SPI=0 O;VS-^XTQ/7T, MGJQZ=!4* M3DO_ &*_7^MSF5.*ARRO&$M?[\WY]4OQMV183^Q?A=X=CA7R=/LH_N@G+2, M>_J['\366QUKXB#Y?/T#1'/WONWMVO\ [34C\:MVW@^ST>7^UM:O%OKZ,9^T MW)"QP^T:]%_G0?%>H>)6,>AV>(>AO[M2L0_W%ZM_*LXV32LN[+L-OHOPST#:OV?3;-#DDGYI6]3W9C^)K*DU/7? M'0VZ$M/T&7^TM6N_MUZO_+U>,-L?LB]% M_#F@^,[K6F*:+8277;[5X_B;\!1'?GA[SZREHOQ_7[BI_"J=3W(](1 M^)KSMMZ+[RUX;\'Z;X(M)'MXPLCC=/=SONEE]2SG_P"L*S[GXB?VC.UOH-G) MK%PO#2YV6L7^](>OT6I4\ MJ\HFUR\DU1E.1 !Y=LG_ !][ZFMFXNK/PY8;I MI+:QMHQ@;B(U7Z5FY0 M)+XZCM.Y;*$&.TC/NO5_JU=/;6T=E;+##&D4,8PJ(NU5'L!7.'X@3ZVYCT'2 M[C4O^GF4>1;#_@1Y;\!6%X@GMMQ_X2CQ UT>^F:;E8_QV_,?Q(%:_5ZU5\M1 MV72*_2*V^=CE^M8;#)RH*[ZR;LGZR>_HKF_J_P 3-.L[PVEBL^LZAG'V>R7S M-I_VF^ZOXFL^^T?6_$EH\WB#4HO#^E_Q6MG*%=E]))CT^BU@Q?$B*QCZ 1P^=*??:OR@^[-VK*U'2Y+N\$GB'5HUN#RL+-]NN1[+"O[M?Q![5WT M<%[/;W?767R6R_%GDXC-G66MYKLO=A\V]9?@GV.AB^(.@^"=+:W\-:;'-&#A M[ICY%L6]7E;ES],UCR'Q!\3E/F+<7UFW)1"UCIJ?[SG]Y*/I@&KUMI/]GJMU M#I,-OMZ:CXBG&5]TA[?3CK3;F\M/$#,;N[UKQ8R_\LK=?L>GQ_5N!CCN3^-= M$:<(/F@KO^9ZO_)?>CAJ3JU(J%:5H_RQ]U?E=_=+U*J:9H=B%L+V^F\031GY M='T2'9:J?]H+][ZNU= (->;2UC']D^!=%C& 5DN,?HBG\S6''XZDLU^Q6=U MI.AP\ 6NC6QOKHC..2!L![<\\5)9>$-0UN=;B/P[/>3=1>>)+O=CW$"\#D9P M?6BI%[U6EZV_!.T?_2GZE4)17NT$V_[MU\FU>;_\E7H2:3+X,,'C>W0_P"Z MM:D7PVU;5X%CU7Q'>+;XQ]DTF(6<*CCC(RW%5+EOA[\)7::ZN-#L;I06,D\P MFN6(Z]2SD_3FN2>)H7OK)_?]S>B^46>E2P&+:M94X^O*OFHMR?SFC"T Z6EU M]I\-^$M6\27S<_VGJA\M/KOEYZ'/RJ*Z(^&O&7BD_P#$TUZUT*W;_EWTF+=+ M]#,_\P/6JC_M Q:VS)X;\-^)O$;#*K+':?9;;(&1^\EP,'UQ^%17ES\2]?A9 MY#X4\$V?.9)W-]<*"."3\L88=.:PJ8JHW=12?>3YG^/Z([J.54HQY93;7517 M)'YVLW\Y,W-!^"?AW1+K[7]A;4KT'+7>H2&ZESSW;@=>P%)XP^.7@_P ?*U3 MQ#IEO,O MXY?.FX.,"-,MD'C&*\R\0VO@M[CR_%OQ'USQ==9?-A:7++$V.JB M&V'KR,FM?PCJ]GHB!? OPGO4#$8O+N"+3U8,/O%Y,R$>M<]2,ZCYJK*OE\)^ _$6J*3@7FI;=,M.#@\OESC@\+ MR*;_ ,(5\4?&RDZQXLTCPG9R8W6^@6GG3C.01Y\W /0@@5;;2OBGXL&ZXU7P MSX5B8 E+*V?4+A<'D;Y,)R/8XK#\1?"KPEI_S>.O'NJ:RQRK1:AK(M83SG'D MQ%>1Z&ICR)^[;Y+F?^1K+G?Q7MYOE7^9DZSX!^#?P\O_ +9XMUNW\2:NA:1G MUK4FU*LF." M#G(7\*S_ U\1_AOX1^3P;X5NM5G*&13H^B,Y?L097 _GBMZ3Q]\1/$;[=+\ M$V>EP[@!/KFI@-M(X81Q9/'<9JY1;^)-_P")V7W$Q:7PM+_"K_B4WTSXN>,B MWG:EX4\$VK9 6T@;4[L#M\S[8P>H/'X5'>?LL:+J8:Z\:>(?$WBS8I9AJFI& MWLU7J?W4>Q-H/// JV?AS\0O$T?_ !./'T.DJR@-%H.FK&5.>HDD);GV I8/ MV5_"<\XFUE=8\43[F;=K&HRW"\]1LR$Q[8J/:VT4DO\ "OU=OS+]FY?9;]7^ MB*MK\4OA+\%C]ATFY\.6=P&\L6VC6HN+AF;G'[E68YX[]:>W[0.O>*$5O"_P MY\4:E'( 4NM4*:7;D9P?ODOQ[+S7>^&O!>C^#K98=(TG3M-C&,"VMDCZ=.0, MG\:EU/Q1IVD?->:A9V^3C]Y,H.?SKEJ8BC'WI_?)_P!?F;>SFEK))>2_S_R/ M.CH/Q?\ %^?M6O>$O!L# _)IMF^H7*\\?/(0G3KQ^%-;]DO1_$3^9XL\0^+_ M !DQW Q7^IO#;8."1Y4.U<9KJF^,.BS/LLVOM4D8D*MG:/)R/? %-/C3Q#JJ MC^S_ K<1*R[EDU"Y2%0?0JN6KD>=4]J;_\ 4W^*3,W&B])-R^]_P# +O@W MX4^&/AW'MT'P_H^D\EM]M:(KY(P3NQNYQZUT#%F&6W>F?2N2;2O&6K-^^U;2 M-)3<#LM;8S.!W&Y^/QQ2?\*BCU#!U;6M?U;J"LET88V![;4QP/K6$\97F[QI MOUDTO\W^!K&36D(6^Y&WK'C+2/#RG[=JEA:8P"))U##\.M8+?&G2[P[=+M-7 MUN0@[19V;%&(ZC>V!_.GQZ%X)\#,K-'H=G+TWS,C2''J6RY@".NR//(],TU?!/BC65']I^+)+5<?N6-IYCX]-\GIZ MXK%\M3?VE3_R5?\ MJ_,G26_-+\%^@EM\#/#BR>=>6MQJTV2?,U&X>XY/7@G M;^E7KOQ?X9\!P^6U]H^FJO'EQ,BMD#IM7G(K//P9L]1YU;4]>UIBN&$]XR1L M?7:F!5B'2_!WP_.X1Z#IK;L[G*;\_4Y.:N%.5)^FZ'H*L/OW=P M;J13G^Z@ Y'N:DD^-^ARLL=A_:&K..V< 4W_A-?$VKKG3?";?HOZ_,8_P +=2UQ676O%FL7 M4K^B?"#PWX?F\Z'1[62?.3<7 \^0D\'YGS5,Z%XTUB M3_2M>TO28MQ)2PL_,?:>V^0]1ZXIJ_!2QU#G6-4UW7&V@,+F\98R0>NQ,#^= M.&'C?FIX>[[S:_5R?X#4%>\8??\ TS5UOXE^'?"\>V\UC3K?:"!$LH9N." J MY/'IBL@?&5=6?9HGA_Q!K#9QY@MOL\/(R#ODQP?7%;VA^ M#\,'=I^D:?:-_ M>2!=WYG)_6M8L2!_L]/:NY4<9+XIQBO[JN_O;_0U4:KTNE_7F<7YGC[Q!C;# MH/AN%L$EV:]G [C PN::?@U)K04^(/$NO:QR&:%)OLEOG_!_9NCZ?:R#'[P1!I#CH=S9;/ MOFMIY-HY_"EILB;^^*[:-"G37+3BDO)6-HQ45:.@JMN%+4:/M&*DS6KW*"BC M%$C"&%I'94C499F.U5'J32!:NR"BN"\8?M/^ _ ]RUO=>(K.[OESBSTX&^N& M(&TO1U(RJW%PJR/U^ZG MWCT(X%<*?@Y\0/'N#XL^(DVFVK8XY!^5>1FFO\#O&WQ04 MGQYXZN+2QDY;1?"RFQ@Q_=>X;,K_ (8'%>O%MP [ 8 ]*&;:.:JP?VU&CI@: M4:?]Y^]+[WHO^W4F/WDL<>Z>;_?D;+M^)KIJ1 M7#4CR;*#R<1B*M>;J5I.4GU;NQU'>HY;N.VMI)II(X88QEY)&"H@]23P/QKR MOQ%^UWH+ZK)I/@VQU7XB:XAVFWT./?;0G_IK6XK%RM0@Y M6W?1>K>B^;/657?X6?$GXT#=XU\31^#=#DX;0O"\I-Q.O]V:\8;N>XC 'O7H/PS^$'AG MX-Z0UCX9T6STF&0YE>)=TUP?621LNY]V)HU/2^JY?A/]YG[6?\L'[OSGU](I M_P"(\R'PF^(7[066\>ZH?!?A>;G_ (1G0KG-Y=)_=NKL= >Z1\=>:]:\#> - M$^&7AN'1_#^EV>CZ;;_<@MH]JY_O'NS'NS$D^M:]%!QXW.*^)@J.D*:VA%6C MZ]V_.3;\PHHHH/+ 4SRF\W=N_"GT4 -EB$JTD4(BSW)I] .: "DVC?N[TN:* M &)"$)ZM^TAKWQCU*ZT M7X2V-O?10N8;OQ;J$9&DV/8^0.MS(.P7Y<]2:#HP^&G5=X[+=O9?/^F=U\9O MC]X?^"%C;_VF]U?:OJ)V:=HUA'YVH:D^;I?@NWD,EC8'.5ENVZ7$^.Q^53TKK/@K^SOH_PKOKG7)KB\\2 M>,=2'^G^(-3/F7U5UA5>BU>IIB5C]T5=SSFM2BVZ3(;<5Z U/IL/E(W7D]ZG 8 M2=%\NG4VQA0PW#!HH)J0&QQ+%]T5H>&S_P 3VW^K?^@M63%2 M6UBUW?>^;/\ WR:F?PE1W13!S03@4B@#D?QV:HDF>%9,9[5+8 M0K]JB7;\K. 1Z\U!;(R)\W\7./2I4=HW5E.&4Y!]#0!\'_L9?$3XJ_&[XLZE M?ZMK7QXU31=,^(&I:9Y^FQZ5_P (O#:6]TRI#<%R+G:JX5]BDX(P3S7;>!_^ M"H&H:GHFE^(O$7P]_LGPGKV@^(=9L+FSU=;F[=M&#O<1O$R*%$B)F,ACR?FQ M7K>@?L$?"/PKX\7Q/I?@Z/3]=74FU@7,&IWJJ;QI#(TQB\[RR2Y)(*D'TQ6? MKW@3X _!B+0O#VN7'P_\._V#9W\&F:=J^LQV[0VVH!DNU$6TWQ,CU76=,UO3+K6Q#IVG M_P!EI&\\D5UY9,OF":+RQL&"QWX"FNJT']BKX Z;H.L>$++PYX;E358+;5KR MV.JR3WRV\.?LMPDAE,T4,>2(V1E49.#R:75_V7?V?Y_AAX1L;S3/"L7AM;Y[ MGP_=G6GA-]&.Z$P>X:< ;AO;S !P0!@U!$M.U_Q'?O,XO;K[9=2P(MM'#"Z22J(V=O,,:E4PI+$"NG\4?MF> M-/B1\3_ ?_".Z/\ V#\/KCXK-X*N=2.H*UYK'V>&X$\,UL4(CA>105(?)909X8IF!4R M!@K'&><59O/V2?A!9?'"T\5S^'=)M_&VI:B^M6;-?RQM/>QIB6ZBMO,$;2!& M&]E0G!!:CWM@O'L=!\??V>-#_:$^'LF@7WFZ=<03+>Z3J5G^[NM'O4YCN8F' M\0/4=&&0?;YF^%O[;WCSQM\1=2\&ZKJV@Z7K7@.#[/>2V\2S+XN?SQ"M[;!A M_J^0SHO*_-ZC'U7\8- \2>+/ ]UIOA?5-/T:_OE,,E[=1R.T$;##&,)_'V!/ M3GO7E_Q%_8+\,^)O@9I'AW2YKC2O$WA.3^TM"\1P*JWUK?\ #-(QZ-'(0%:, M\;<>F:'Y"C;J>J:EXR:Z\(:;=VL$RS:S!')!#)B&3+H&V'=]PC/)/W0&/:N3 MUCX@Z]>_#?5'\"V>C77B*QUZM<6A.!OD4JKQ'PEX@DM8=/L[99 Z1>6?WEQO59%4*!A%++-N)/RB/=W%',/EMH?+'B3Q MS^T?\6?&MMX;U3Q3X)^$JZ@OF116MPKWDD1;&^(O$GC&,K87NHKN\N!Y=I,,@+/&E^TGR11>&Y&EO\ 5IIWFNKN4MELR$X)9QLX ^42]017T+UKPSX; M>)=2^%&@+:Q+X?UJXN+]FO%LI[BYNKT.[K$R2+'Y 81QL74OA&5\GD$^C^(/ MCCX6\+:@+6^U3R9Q$DTH6VED%HK@%3,45A'D$<,<]^G-:TZ-Y]O8R1IM_=A9B9%&Y\;@ 2 N.,UU4L!B*JO3@W\C/VD; MV;/>*S_%.@)XGT.>S<[6<;HG[QR#E6'T-<'\(OVC=/\ &<]CH>L++I/BB2$ M13LC0ZFP7YFMY4^1^A)3Y6']W%>EJVX5E*%2A47,K-$5(PJP<'JF9G@W6I-; MT17G&R\MV,%RG]V1>#^?7\:I>#HO['UC6-,_@CG^U0C_ &).3CZ,#4MQ%_8/ MBV.Y7 MM4 AF'991]UOQ'%/U"+[%XRT^Z PMU$]K)[D?,N?UKIT;DEM)77DU M_31Y_O1Y'+XH.S\T]+_/1^ILCDUS_P /T^T6^I7Q.[[??RNI(P0J_*/Y5JZ[ M??V;HUU/WCB./KCC]<4SPSIW]D^'K.W_ (HXAGOR>3^IKGB^6BVNK7X:O]#I MJ1Y\3'^ZF_F]%^I8N98;&"2>9A'%$I9V/0#O6'X+TY]0O;C7;I"MQ?@);HPY M@@'W1]6ZG\*FU=#XIU==.7_CRMF#WC#^-NJQ_P!34FL:E-?7)TW36"38'G3@ M?+;)[?[7H.U:P@XPY5N]WV7_ 3&I4C*I[26JB]%WE_P/SOV*>NSR>,=1DTB MUDDCLX_^/^X0XR/^>*GU/<]A6Q>7EGX7T@,^VWM;=0B*H_ *H[D^E0@V7@S2 M4B52JKPB ;I)F/7'JQ-44M]DZZKK3K&RG_1K;.5@_#^)_P"5/2245\*^]O\ MK[B5S0;DW>H]WTBO^!^+U#2=&N-?U./5-4C\ORN;.T;I /[[>KG]*75?$\^H M7$EKH^R21.)KM_\ 4VW_ ,4WMVJIJ^K3:PXCF\^WMY!\MK#_ ,?-S_O?W%J& M:".9$M;I?W:_ZO2[+D?]M&%;QIW?--;;+HO\_P N[.6591BX4KZ[OJW^GW7M ML@T5MDL\.@JUY>3-B[U2XY7/?'][']T<5-:-8^&KV3[.L^N:Y(/WD@^9A[%N MB+["G743) L=_=1Z;:XPEE:']XP]"1S^ J2*\DL+,1V=O;Z/9_\ /6X_UC>X M3J3]:N36WHMD_[TG<;>Z+)J$7VCQ%>11VJ_,+.)]D M(_WCU<_I4L.N76HPK;Z'8+':J-JSSKY<*C_97JU5[6RCN+A9H;6XU>Y[7%V= MD2G_ &0?Z"K\^D75W%OU/4?)A[Q0'RD_%NIK.36BF_1=/DE^IM3C+>'S?5^L MGHEY).W0S;C3]+TR]6;5KR36-0ZI&1O"'_8C' _&KTMYK6MKBVMXM*M^@DN! MOE(]D' _&HX-?T?059=/@\]QU,";LGW<\?K61J_Q.D!\M9K.Q[;5_P!)FZ^@ M^454:=6H](_?^B7_ 3&6(H4%[TTO*.[]9-W?X&[:>"K*UD^U7TDFH7"\^== MMN5/HOW13KSQ]8)-Y%H)M2N%X$5I'Y@7ZM]T?G7!W^MRZB=[VES>?]-=1FV1 M#MD1C ZXJE?:UW''D6*")!^/ _&NRGEDYO]Z[_ -=E_P \^IG MD*2_V>*CY]_F[?J=;K?C2_6/_2K[3_#\7]U2+JZ;Z < ]?RKG5\0V4]X7T_2 MKS7;T=+K4"9 ON$' 'Y5B6=_8B?;8V)NI2<9$;7#$_HO\_K6S;>'_$NOPKMT MV2.# .;J41QXZ'Y%P/YUW1PM.BO>LEYNW_!?S9Y<\=7Q+]V\GY)R_2R^2&ZK MJ&L:_(T.I:LELG3[):@NP'/&R/\ ]F-5UTW3]&'S6T0.,EM1FVYXSQ!%DGJ? MO&KMSX272H2NL^*M-TU!P8;8@'.>.!@_I26%IX1MBOV33]>\0R;B@*0.L1/I MD[5_6I^N48KEB_E%:??I^II'*\75ES2C\YN[^[7]"G>>+;1\@6\& M+"W/_ $R[=>^.E7-(M=>NEVZ1I;:="Q/S6T"VP;T)EDRY!SV%67^(TFAQ[;' M2/#>@[N%:]OD,BMW!2(%NGN*JGQGK?B:4*NMZO/N^;+_/FN M6>.Z4X?>[_@M#TJ>2RWK5=?[JM^+U-&U^#U](QN-0O+&T;/,K@WP^'Q)&OBSPOH)4!_)T+35EF0]\.>) MK>$MJ6O^"?",>W=L\W[?<#GTR%_(&J,UEINO2,S6_P 0/%KK^]03.]O 0>N/ MN#'MBM31O">I:: MUH[>6WX+]3F9WTCQ4[+=:Q\0_'#$[&BLX7M;7:W(^[L7'IDUM>&O!^KZ<=WA MWX;^'?#[-N;[3JER)IU;IG"!FY'O74'PKXRU9&6Y\4V>G1Y&V/3M/'R+W7W7E_*7%S>K( M,]ONH,?@*[S3M$^'_A!R;6QT1)H3G*0^=)S[X)_6MJ+QU#L6&QTW5+A0,HL5 MKY:?AG %K7XLY71M=UJPC:/PO\-8-)BW*5EO9H;)2, MM:ANSADM2BY],MBH;#63:B-=+\)W4:L-R.R1VX4_S%6A?>*K\+Y= MCI-GS\WG7#3-^ 4#^=TD]G]R(EU[Q1J.W[/H5I8JP^]> M78)4_P"Z@I/^$?\ %&J#_2-E^1:U# MX?Z:J2/K6NZE=< 2"XO_ "4&/]EES3+AF\J$W,A]^A_ MG4,,O@N!Y&M]+DU*51ABMG+<%O?+<5L6?BBXB*#3?"FH*K+A7=8[91]>^*RC M[.]XJ%_)2FR5RWTM^8#XCF=&73= UJ[&W-_P 6Q_*A]6\6W^[[/H^F M:>K*"KW=V9&_%4%2?VCXNOE7R]/T>QYPWGW+3''T4 ?K37\.^)KX/Y_B&VM1 MG*BTLAQ^+'-;IUI;.?RBH_GJ7[S[_@O^"-;PQXFU/=]I\116:L!\MC9 ,I]- MS$G%5[[X:Z0@9M9UC4[SD2,+O4#&H(_V5P,59D^&*7I;[=K6O7JR?>0W7EKG MUPH%2VGPI\/6LF\Z7;SR8VE[@F9B/?<31]3G+>FG_BDW^"NA^S;WC][,>WU+ MX?\ A:8_9QHWGY\S$$7VB0D=P0&/ZUH)\5([E573-#UZ^5E+(8[3R8V/IER! M^.*Z*QTJUTM5%M:V]OL&%\N,+@?@*L$[NM=%/"UDK1<8K^['_-_H7&G);67H MCE/[>\7:GC[/H&GZ>K+G?>WNYE/NJ"D/ASQ9JJG[5XBL]/5UP5L+(%D/LSDG M\:ZRAFQ6GU'F_B3D_G;\K#]C?XFW_7D&.,D?[ M*8%:6F?#'P[H[[K?1=/5R0=[1"1LCOELFMI#FG54EV,UT6QVRJXS M2N=U'+<755Z=*37HST2BO-4^.7B#7XU;0?AOXHNEF0M'/J3Q:?$".S;F+4// M\7/$BMY9>W5O9QX+;IY5C&!U^\1TKSJ3X(>)O$6YM=^)7B216*L(=)ABTZ- M".HR 6P?J*GTS]E'P'97 N+G1Y-;N%8N)M6NY+Y@3UX=BOZ4]1_5,!3_ (M9 MR\H1;_&7+^0NN?M3_#_1+AH5\0V^J7*XS!I<3WTG/3B,$?K5(_';Q1XE#+X9 M^&GB*XSN"W&LS1Z9"&'3(8E\'Z"O1-"\.:=X7MEATS3['3XE78%MH$B 7T^4 M#BK4[-M[Y]:-0^M9?3_AT'+_ !R=ONCR_FSS%_#7Q:\9%OMWB3PQX/M6./+T MFR:^N0I':27"A@>X6FQ_LFZ'K,ZS>*M8\4>-)\AF74]1=;!@9(&2?55K5*DN:I)M]V[O\1",B@<"L MGQ7X]T/P):M-K6LZ7I,:@DF[N4BZ#)P"*#@J?*CP@/4$,30?V5AXNF67QQX MR\5>,.YM/M']GZ?U./W,.,C!(^9CD4K]CL_LJA2UQ>(C'RC[[_#W?OD:WC'] MISP/X"U#['<:Y#J&J9VKIVEHU_=LW3&R+..W4CK6"_Q)^*/Q0^7PQX+M?!^G M2=-3\4RYN,'M#TO1H<8(M;=8V; MH.6^\>@ZGM6YG)H#Z]@*#_V>CSOO4=__ "567WN1Y#;?LDV_BV9+KXB>)=;\ M?7 .[[)._P!CTN,^BVT1 (Y.-Q/'TKU+0/#]AX4TJ.QTNQL]-L8?N6]K"L,: M_15 %7,TC-M%,X\9FF*Q*Y:T_=6T5I%>D59+[A:*;&^\=*=0>>%%%-D?8F<9 MH =138G\Q]+%"(AQ^M'0 DD$?7O2J MJCIWYI)BB1-)(56.,;F9CA5'J3VKRWQ1^UKH,>LR:+X/L]0^(7B).#::(HDM M[<_]-KD_NHP.IY)]J#:CAZE5V@O\OFSU);8O-N!9N>E>7_$/]JO1] UZ3P[X M5L;WQ]XO'R_V9I!#QVI];B?_ %<2CODD^U9?&\B3XA>(O^$=T60Y_X M1KPS,8Q(O]VXO/OOZ$)@5Z=X$^'NA_"_P_'I7AW2;'1]/C_Y8VT83>?5CU9O M=B32U.A4\/1^-\\NRV^;Z_+[SRVS_9U\0_&B[CU'XN:M#>6:N)8/"6DR-'I, M!ZCSWX>Y8>YV\=Z]BL-*M=*TZ&SM;6WM;2V4)#!#&(XXE]%48 'TJQVHIV,: M^*J5=);+9+9?+^F"C:,4444'.([A%R:9'<*YQT-+/%YJTR.V96!.W\*9.MR: MBBBD4%%%% !5[PU_R';?ZM_Z":HU>\-?\AVW^K?^@FIEL5'=&79!EMUW?>]/ M2IJ*;(Q5"0,FJ)'9J2U -Q&&V[2P!S4,;EUR5VT[M0!^>^AZ%\5O%5]H,EY\ M0/C19KXGD\=?VC!;W28!;>\"%F^ZQ+,@91P:_3$ MS2$GYFYQGGKCI^5#3R2?>=FYW/-(^('PETWQ@6^& MGP@T==.T[6;.6WFU^T\RXM]0TR?JCD/&I PRFL_7/@=\2?VLO@I\ M*? OACP?)):_"7X;V=V)-8OIM#%AXANHPUO/%NC/G36L% :4AF' K]2' MN))#EI'8YW,EC\3>$?'= MQX$\+V]@UGI4TNHZ/;^=*+YU@&)@&NH[D.T0+A/+=0Q"FKOP[\8^-/%7PK^# M=WJEOXH;Q-IOQFAL=(O]9N9KN34K%[67[4T,ES#%%--E\;1^)&LX3X@ALFTU;_GSQ;&02&+/==ZAL'H13=;\':7XE\3Z/K6H6-O M>:MX?,S:;=2@M)9&9!'*4/8L@VD]<>E'*+F1IOC<=OW>U)139I/+C)[U1!Y_ M^TE^S+X9_:C\#QZ1X@CN+:\L)/M6D:Q9/Y6H:)?L2?E;&3G[U M?727+!OFY'?%4?%WA#1OB7X5OM#U_2['6M&U",Q75E>0B:&=3QRI[^AZCJ"* M'$I,H^*-,TCQUX1ET^22'4M.UVV* PR*\<\4G(9",H>Q#4ZMR%8D!CQ@'BINNH^731GL8W?$[Q, ML<)=;&XA>) O"VNGLVR20+P5FNBI12,[858_Q<^4VGBDZ9H-Y&BFWDNM4OI+ ME!PVX7#HJ'_=157'8(!5OXH:GJ7@%YO#-OJ6L+JM[=V:W;:3=1VUO8VKRQQ+ M)A5,L6V)0BQEQNW,V".3Y]\5="@^%^ISRZ2VW0[F\V2VLLK.]M,[8\Q&8DLK MMRP8YR20>2*^PX9PDDW6FM'L<6,DOA0W6+VQ@NI;B&SLX9I,[Y$B5&?ZD $_ MC7*ZWXHSNY_6LW6_$N[=\UU ME7YED0_PLI&>*_0;X4:W?>)?A;X;U+4EVZEJ&EVUS=#;MQ*\2LW';DGBOR[U MW6!>Q%?I=^S;XBU+Q;^S]X-U+5H_+U"\TF!Y?]L 85_\ @2A6 M_P"!5\GQ3'W827=^IV826K1UFMZ=_:NERP]&8;D/]UAR#^=9]_.=1T&SN\+Y MMO,CL3_ 0<-6U61=6WE07\'1782J/J1G]17R=&73M_PP8B&[[JWW:H?XC47S M6MESBXF#/C^XO)_I5C6=0>VB6*W^:ZN/EB7'3U8^PJN2OVJ6\DSB-1#$/[WK MC\:AMXI+V227S/+\P8DF)^XO]Q?ZFM%':_3\R)2=W;>7Y$*^991_V;IS;I=I/4^['L.U7%>'P[:K:VL?G7#9;9GYB>[.>WUJI7V-HD/^JA]E'?\*K*9KVX\UFDEF'_ "TP"R_3^%![]:;LCA&9&CC/3,C? MR457NO$6GVR_O+B2<*,A$ 1?UKJC3?V=6<-2LK>^TEZEU1'#$R^9PWWT@/+_ M ._(>OX4ZT>Z>/RK6(V\)/*P+MS]9&K#E^(21$+:VL6>@8J9&_#M6=J7BW4] M35E=I@,'AW6(#GT)S^E:_59O65EZLP^O4D^6G>3_ +J_7<[);>#2RS27EM9G M'S>5^\F/U8\_E5.?Q=H^EONAMVNINGF3-DD_CD_I7$[+BO_ =ON.BU M#XCW\JG;_H\9[A0G_CS?X5S=[XP6ZF.^\BEEZX0-=2>G':K$'AV(S_)IMFS% M<[KB5[A@?ITK0M=-U7R%\J1[>/[KK:VHB'X' _G5+%86DO_P#(R#!J.KH?+TO5;J,?Q73^1$ >^.!BE;2[ZW5EFU+0M'4@@K"?.D / M3[N<_G6M)X+N)W_TB2XE;'R-/#(8/O/I\>[[X+R2Y^F, UC4S MJ,5I9?C^>GX&U/A^G>]23?X?EK^)A3:?H\+M)>:EK&I2*02L,8@0YZ\L MTGTRS=O[/\.VL\D9R'N97NG<'OA1CCZUT$6@6D,;M]J9>@_<6**?S;-3M:V8 MVL[:G>6I_X"M<%7/(O1U/N_X!VT1:JH_4BN"6;4D[Q3/044E9,XZP\-JH< MVD.K2-PI%AI,=O\ B'DRV/>M1_ =YJ1E+Z#<7.[#!]5U=F7/^XG%;4NM7$TG MS7EPR]_W\<>?P&:KAXYWD5F29?\ ;N99#_XZ,5A+.+[1^\?*B&V\$W^GAMMQ MX7T-7 /^C6*O(A'HSFGW6E6.2;?_ -]G'Z5L65PVFPK]@\-Q6:K\OSF.':/PYJ$Z7>7,@\RVU23'&9+\ M*/R44D7A.8R,S:;I_P W>6Y>4FLY8G%3W;_KY,:YNB_#_@$MUXCU+:WF76AV M0_A+3&4CUZ55?7FGF42>).HY2SM,@_0X-7+7PI>1!E5=%MUSD;+3>1^)JTF@ M:@4VR:LT?]WR+=$VBL_9UY=_O_X*'RS>YA^1;WJ?,OBC4FC.<$M&K?RJ2+0X MX]IA\*+^\(RUW<#(_,DUL/X3:Y3;<:IJLV#G_7;/Y"D;P)ILBCS%N+C:WC;U6,"MEA*O5_B_T ML5[*7]?TCC9;K3;J)_,U;Q%J0D/*PJR@?DH%+'INFO+&T?AG5K[C >X) _'< MV*[A?E''%&:/[/[M?=?\VP]B_P"E_F/TITFN6,) MP]]9*1QAKA!C]:S[WXE>'=.G,<^N:3'(O53>6>5>XU&&/\P-U%RO[+Q'VK+UE%?J=I2#-<8=7^(5U=L$T+PS9V M^/E:;4'E;\0JTV/2OB'=O)YVM>%[&-ON&"PDF9?Q9@/TH'_9[M[]2"^=_P K MG;4H1FZ*37"Q_#CQ7?P.M]X^OD);*FQT^&' ]"3D_K22? J/48X_[2\4^,-0 M:,GDZCY*GVP@'\ZF[*^J89?%77RC)_FD=S)(L(.]E3;R=Q Q6+JOQ+\.:)&S M7FO:/;JIP=UVG&/;.:PD_9Q\'M>>?<:7-?3;0I:[O)I]WUW,:UM*^$/A70PR MV?AO18=YRW^B(V3_ ,"!IZC]G@([RG+Y)?JS)N?VD/!-M.,85 M8XPJJ/8 <5,TC/U8M]33U#V^!C\-*4O67^27YGGZ_$/QOJDR+8?#^2VCD7_6 M:EJT4/EGME4#&F"'XJ:Q%S+X)T%E?LDUXS+^.%S7H6:,4#_M&$?X=&"^3E_Z M5)GGLWPG\7:UYRZE\1M5CCF_@TRPAM?+]E8[FQ^--_X9FT&^N/.U;4/%&NR, MFQQ?:O*4?W*H5%>B 9IWEM_=;\J5D']LXM:4Y*/^%*/Y),X_P_\ 3P3X8:- MK+POHLASR177BK089(OO)]K1F'X G]*>AG+Z]B7K MSS^]G5,V317G$_[6'@D6XDM+S5-64G'^@:7<3?KM _6GO\>=1OIVBTOX>^-K MUMI:.2>WCLXGXSR9&&*5S6.28[>5-Q_Q-1_-H]$(R*15V"O.!XT^*&LK"UGX M'T#258D2?VGK7F.GH0L:_P!33)/"GQ6UQ'^T>,/"^A_O,J-/TAKAMOH6E;KU M_AHN/^R6OXM6G'_MZ_\ Z2F>F*I8\9;Z"JVJ:O9Z) 9+Z\M+.)3@O<3+$H/U M8@5YW=?L[W6M+(-<^(7CG5(Y&#^5#=)8QH?81+T]LBI]/_92^'UO,\T_AV+5 M)Y""\NI7$MXS,.^9&/-/4KZKE\/XE=R_PP_637Y$^O?M1_#WP].89/%6G75P MK^68;+==R!O3$8:LM/VD+CQ&RCPY\/\ QOK18LGFSVJZ? I'3+2D<'Z5Z%H_ MA32_#L+1Z=IFG:>K8+"VM4B!QTSM S5N0,&Y9FXQR:%*/ MB5XJU"%]P>UTL1Z7 RMV^0%SCMEJ]1C/%.I$*?I%7^^5W^)P/A M;]EWP#X2O%NH/#-C>7P(8W>H;KZ^,"N\MXEM+=8856&)1M5$4* MJCV XIQ.**9Y^)QV(Q$N:O-R?FVPHJ.4L&X_"I!]V@Y1-X#8I::4!;-.H *A MD5B_0U-10 V%2JTZC%% !12A21G'RCJ?2N&\;?M)>!?A[/Y.I>)M-:\.-EG: M/]KN9">@$<6XY.#0:4Z,ZCM!-^AW% &3Q7DA_:"\5^-UV^"OASK%Q%(,Q:AX MAE&EVK @$,$.96!YZ =J'^#/Q"^(;M_PEWQ";2[&0$-IGA2W^QAAS\K7+YD/ M&.0!R*5SI^I\O\:2C^+^Y7_&QV_Q#^,?A7X3VOF^(_$&FZ23]R*64&>0^BQK MEV/'85P;?'OQA\34,?P^\#7GV63A=;\2DZ?9_P"\D7,LGMP >,UU7P__ &<_ M!/PQNC=:5H%F=28[GU"[S=WDAZY,LA9L]>F.M=L3N///UI:C]IAJ?PQT M7W)_F_D>,R?LM:A\0'CN/B7XMU+Q;@[O[)LLZ?H\9]/*0[Y!U^^W/Z5ZCX/\ M*Z=X*T=-/T?3K/2=/A&$M[2%88Q^"BM6BJ,:V*JU%RR>G9:+[EH%%%%!SA11 M10 4444 %%%% >E1VYD(._\*DHH ***B@>1F;>N/3B@"6KWAK_D.V_U;_T$ MU1J]X:_Y#MO]6_\ 034RV*CNBC1115$A39)A%]:=4#7EFD?MXZ;J!FCFT/[6(=273DFT:^.J6VI9N;.W M:6SD6%3;^WM-U/5+D7KR:=JDELMO<^=;3F>%!E8 MI&EM(&8J,,5)()9LFH].I77]L7X;QZ=]N;6KE;".'S)[MM/G\BTE\MY?LLK; M?W=SLCD;RF^;"'U&;,'[7'@1X+.5M0O[:"ZB25YIM.F2&R#O)'$)Y-NR,RO% M(L?)#E>#@@F"S_8Y\#Z<56WCUVW@SYTEO%JLJ0W-WY;Q?;I%'WKK9(X\S.,G M.TX&*MG^Q-X#TS3?LL,.M_9)3OO;8ZDP@U602R3)+<1J C/')-(Z;0@4MT( M%&H] L?VYOAM>6MY<2:IJEA;V-N]S+)?:14R3N&FF=V+,[E0HR23T & *.5]0TZ'RKXV^+?@CP% MX[UJPM=:TNUTV"ZMCIWF73&)U6S@1 LCD^9M*,,%F(*\]!7%>-OB]X7\2V%Q M:WFM:;-#<'+@7(#9SD$$'(((!SZBON_6M*M?$NFR6>I6MOJ%G,,/!0<8X>K:-E9/H<%6BU[R/F^:QT/Q#9S-I^K7]RBDIYL5\7\ML9^F>_-+O$DFB3O%?1W-G-&P3?+J5T%GW@A885^:5G[ MA0H()]QWQ7ZA>';BTT6336TVT73M#UZ-UAL.%&DWT/$]L!_=8*S@#O&[#AAC MY=_X)J_!/6%U"X^)$E]#9Z3>Q3Z9'8H \M_M;:7E/\"HP.T=2?0=?IJ[$D%A MJ"Q,BK'XQT\Q@0+\@EMX?-P<9R^Y]S=?F(K\_P"(\9[7$J$7I'3YO<]+!P]Q MW.N5MPK+U^_@T\[I9%CWKC)[\UI1KL6H;[3(-0V^=&K[>F1TKPXRY7Y6>6-2,?)&>*Z6?3/(.)&9/4L67_$5&FC>8OR_:&7J3&XD_E7/+B#$ M7LHV^1O#AO#-:S;_ *\F*NS^')HV^>&1?P-5TTR(!MRH>PR^,_GB MN66;SO[W-^"_0[(Y+0M[L_N7^1-]A6/G?IX'H6) I\%NN,?;M-C_ ''Z54' MAM)MQ:U+*#C*KO\ Y-4,GAVTMN9+18TSC]Y'*N?YUD\TIM7ES?>;+):7\[-E M+=94Q_;%JOIB3'^%.?2K69!OUBU;_MJ/\:X;QQXC\-^ +*WN-22W6.ZD,:>6 MKR-D#/( R.*YMOC?\.F3_4[F]6LY*\/&<99!A*KH8NLHS5KJ4E?75=3UL+P1 MBL335:A3G*+ZJ-T>P1:'I^U0VI6[8SR'7_&K$'ARQ[WRLO\ UT6O&4^,WPUX M+1PMQT.G3?T-.3XT?#1OO6UCM]/L=PI_D:RAQ[PN]L3#_P "7^9I+@',%_RX MJ?\ @/\ P3V:30=,'WKM?^_RTX:;I.WFXC;ZW'7]:\1D^,?PO\S']FJP_O)' M./YBAOB]\*6_Y<;],]=@EK2/'W"W_073^\II_P" K_,]P6'18P5: M2U8?[4V?ZTY9=#A/^LTT?5U->'_\+,^$,I^;^VT^B2XJ]!\5/A- /W.KZ]#_ M +J7'^%=4>.>&7K'&4O_ )$RX*QL?\ F'J_^ ?Y-GK[^(M%LGXN+%?]T#^@ MI1XYT6,_\?UN#[*?\*\?;XN?#,GY/$WB9/8)-_\ $TK?&;X?1IB/Q?XE3MS; MR-_[)6JXYX<6V-I?^!Q_S!<&XWKAZO\ X!_P#V'_ (3W26'_ !_*?HCG^E0W M'Q$TJW_Y:7$G^Y;NW]*\A_X75X,'*>._$D?TLY/\*)/CMX51,1^/->9O]NQF M_H*?^OG#O_0;2_\ U_F5_J;CO\ H'J?^ R_^1/7$^(^FRC]W'J3_2S?_"E' MCN CWA\?\SUJC?6RN/\ "FS_ !^T.-/W?C*_D;_:@NE_ MI1_KYP[_ -!M+_P-?YE_ZFX__H&J?^ R_P CV ?$%G?:NAZ\>V!_.I3X MOOF_U?AW5V_WO+7_ -FKQ,?M!:/_ !>*-0/KM-P/_9#3)_VC-#B VZYK*1?M(>'=O[S6/%.?^F<[8_5*]#;1]4VJPC\:.K M,I6_C/!_"O6RO/LNS'F^H5XU.7?E:=K[7L<&.R.I@K/%TO9WVYHR5_O9TL.I M>+)7Q_8NCQ+ZM>L/HS_LNK8_ M(U#''"K_ +R]^(*^N5;C\J]8X%"DMN7_ ,!;_4ZA+#Q=-&P;4-#@8]"EI(^/ MS:HX?#7BPD^=XFM<=O*TU./S-<[=/I-ICSM>\:0Y_OB5?_9:(;KP[,!GQ1XF MC/\ MSRK^?RT#]U;-?\ @N_YG07/@37+I@3XPU./':*UB0&G3_#*:[3;/XE\ M2R''.VX6//Y+6"\GA=3AO&>L*?1M1D7^E6(-,\,7'3Q;J,F3G+:P5S^M O;2 M5OWGW02-*#X.6'D-'<:AXBO%;_GKJ4@_1<"B'X%>&XY?,:QNKAN_G74L@/ZU M4;PMX8E^]XDO6S_U'#S_ ./4Y_@]X:U#YFOM2F')!_M9SU_&@/K,OM5I+TB_ M\S1A^"OA:!]R^'M/W9ZM$6_F36C;^ M%LF#1Z+I<)7H1:(I'Z5SB? SPRK[O M,U%_9M4D(_G5Q?@AX=8?\>-Q(/>[F;/_ (]08U*T'O6F_E_]L=&EK:6RC$=F M@7IA5&*5]7MT^7[=;+Z_OU']:YUO@7X7(^;15;_>FE/_ +-5?_A07@UGW'P_ M9EL]2S__ !5!ERX1_'4E]R_^2.FFUVQMUW27]DJ^K7"?XU1G^(?A^V'[S7-) MC_WKM!_6J\'PD\+P+M7P]I&/]JU5OYBI%^%_AI/N^']%'_;FG^%!,5@ENY_< ME^K(Y/BOX7B7/^GQ/\:SI/V@O!<3[3XCT\L.R[F_D*Z"Q\'Z/I:D6^ MDZ; #UV6R#^E65TBS4[EL[-3ZB!!_2@?-@4]5-_.*_1G*R?'_P (I"9%U;[0 M ,XAM9G/_H-5;7]HWPY?Y^SP^(9\''R:1,?Z5W<2+ ,1JL8]%&VGF1@?O-^= M _:X)?\ +J3]9_Y1.#O/CO#"R_9_"OC2[#=TTME _P"^B*DG^+&LM'NM? /B MB;CCS&@B_P#9S7;-*?6C.12']:PJ^&@GZRD_RL<+#X_\::E:,UOX!:UD!QMO M=7B3/X**;;ZY\2=061?^$=\*Z>8K[\LM-MO 7CZ<,MY\0+= QZVFBQ*0/JQKOZ M*+%?VI47P0@O^W(_JF>>Q?!#5KFW:/4?B)XRO QS^Y>*VP/3Y5)I!^S-X?N; M)8=1U#Q5JV"3NN]:G/7V4@?I7H=%/E!YUC;:3MZ)+\DCA;;]F7P%;>7N\,V% MRT0P'NB\[GZEF.:Z+2?A[X?T%]UCH.CV;=,PV4:'\PM;%%%D<]3,L7/2=63^ M;" ?95VQ*(E_NH-H_(49S0S;134DR:#CZM5V]=TRC'ZUBZA\6O"NDO(MUXF\/V[1 MG#*]_$&4_3=FBY<:]%ROJ0#:-)T0-+&? M9I6/'O39OV9?[?+-X@\=>/-:\Z/RY8EU$64+_P# (57'YF@/J])?%47R3?\ MDCT'7?%.E^%X'EU/4M/TZ./EC2,/G6O5"=W7-%%@^M1C_#II>MW^>GX'DX_9+T_P 0R+)XO\5>,?&4F!NB MN]0-M:D@Y!\F':/;!)XKN/!/PG\+_#:#R] \.Z/I*]-UM:JKGG/+?>//J:Z" MBCE1G4Q=::M*3MVV7W(;(GFR;F)S]>M.HHIG.5C+)YQ'-6:** "BBB@ HHIL MLGEIF@!U%1P3^:2"*DH *"<"B@C<* &I(L@^4YIU-2,1]*=0 5&!(9^OR5)1 M0 4444 %7O#7_(=M_JW_ *":HU>\-?\ (=M_JW_H)J9;%1W11HHILLGE1LWH M,U1(.^S'R[OI3CQ5$WLBJ65MWM3ED+CGK5?&SXK:?=7VB_VA_I5C>HE M_<:?X7E1].L8YK-A?JQ9ED6X62=/+7)54)'*/4\Q7*SZ9\0>'=.\7Z<]GJ^G MV.JVD@(:&\@69&R,'A@<<$C(YYKY#\?_ /!*Z]OO%LTGAGQ9I]CH4TF]+>_M MI'GM%)^XI3Y7"CIG:< ^M6)OVLOC)?6NL7'_")+#-I<\SP1)9RXMIA#?[+6 M1$.95_=6[Y8Y)<&M47Q8&NM0TS6;G3H[JTTN2$7T*A'CF M\I=^W(X(/!!(/!KEJU)5&Y2>KU-*=HOR&GQY-?6UQ?V=O:S6-A:Q MWUY"TQ6^2%BRR.D6TAA$RD,-P.4<==N[HT=9(U9&5T8!E8'(8'D$5SWA&V\O MQ[H-YYLTMQK6LWGVK?9M;ADEM7:1!&>53=#$VXYRP)SEJD^%TKR_#W2]YR8T M>)?DV81)71 !V 55'T%9IN]F5**M=&ZZ[Q2+%M;-.HJB /(JI=:%:W3;FB"M M_>C.QA^56Z#S6M9M]+;VS[ MM4TA[8#DW-KED!]5_3 M1_AI]Z9@:=9+?P>9I.MS-'T"LPF4?4'D4LT^M66!/866IQKWA;8_UVMQ4FK> M"]/U>?SXUDL;P=+BV;RY![G'!_$5GS:CX@\(?\?$']OZ>O6:!=EU&/4IT?'M MS7FU8SH+]\I17\T&Y+YQ=[?)->9WTW&M_#:;[2T?RDK7^]#7\0^'Y9A'J%K) MI<['I<1&(9_WAQ6K#H$(IYS',)4;\\BGZ%XFTOQQI[-:30WD:_+) M$Z_-&?1T/(/UJC>?#*P,IFT^2[T:X_OV$-#BU.ZL]0M?MSF&>.(Q3;O+/#KTZ=QZ5\]L=J$^E?QG MXQ._%%6T91]V&DMU[JZW=_+78_I_PSTR"FW)/WIZK;XGY+\@HKKM2^!GB6SD MU)K?3Y;ZUTMF66>/:H)6-)' 5B&.U7!.!TYZ5-XE_9]\5>&+FZCDT]+B.S2! MIIH)T:-3,H9$ZY+'., 9.#CCFOAI7W;K1ZG%YKVCX/_ 1\,^,OA/;ZKJBS+>7$]_YLT6HF.:W@MXT??#;;&\]A MNY7*\8K@Q\#/%AU>2Q71;AKB.%9SMDC*,C$A=K[MK$E6 4$DD$8XK2\(>"O' M"GP^UO+J6CV8GEN--N&;:MG(T;%GVCYD,@B(!88;;WP:]OAO U<)BW+'8.56 M+7+9QV?-%-ZJVBNK]WNMUY.?8REB<*EA,7&FT[W4NG*VEIKJ[.W9/1[%C1OV M;M0UK2]%NDU6S@CUJXC@43V\D;0;X))U9H5=0W?*Y*XR%.?45J:I#\1(I]-L[?5M2U&/R[2 M6U,,@"Q236K2QQC.#N6(R#/3&1TJI=^"/&TWAR+1;6XNM4T>'3K?5?LL,P$< M*2HTRH%8@LP^9MJY&IB\LR_DG"G@:O,HM7[3LK.RD[K1MVN>3ALRQOM( M2JXVGRN2=O[EW=7Y59NZ2O;J;_PN_9UL?$%BLFI7B75]>6VG7=O9PO)"L$=U M%R5)'6L[3/V8=4\16FFW&GZEI\T>J3^450.RV(_>'$K#HP$9X M(!;C&>:3P]IOQ,M]9\-^%X=2U+2VU0QMID$EXJQH@Q*KX!)"C[RY[Y ':I-: M\+?$G0/"FEW4=]JEWI\3)<1K:3!C:2K.T2# ^9L2$X(RH,F.]=E/"Y94PJY\ MOJVIJTFDD^:Z;N[W>C[:)K1'//%9E#$MQQ].]1WBF[JWO)6TLKM='K9J[8S0 M_P!F#4O$6ISVUKJU@X6-)(9O*?RY6:)Y/+8CB-P(V&TDGH0".:9!^S)JEW%I M,MOJEC=6NIPO.UQ#&SPVZK!YY!8<%MO&T[6R,XQS4L4/Q8T_5-3*W.N07"PQ MW5[(+F)4\L!HE;=G;Q\R?*R7]GU[W=__ E9;]KI^;WZFGUS-&[_ %^C:W=?RZO; MO9^G2VAQ?C?PE)X&\476ER75K>M;[")[=MT<@9 P^AP<$=B"*R:ZO7OASXQU M3^UM8U+3=2F>SF9+^>?&]73:&XSDJH9& M:&96B7#1N&!X'<5^>YZ5]7/X4L;-89+SX=ZM9,J*@N-$O-P((!+X1E/Z5^Y> M!>:5<%+%RA%23Y+WYM/BZQA)+YV/R?Q;R^GBEAE.337-:W*^W1RB_NN>Q;MI M]*=N;U->,66MZ+82QQV?C[Q1X?D7O>$ M?%,*ID;T,$DA/3+1E@/R%?TAA^+85-/9.7^"4)_@I*7_ )*?B-?AV4%?VB7^ M)2C^+3C^)Z%N-(:X.7XE^*-"9EU3P-J$BQ[ =!N'W2:+ILC>I@6H)/ACXO^['M_E6^1DT 5MQTF)3_LR.O\ )J=+\(=#>/:D-[ O_3.^F7'_ (]73$XHI#]O4_F9QX^" MVD!_ENM>C_W=2DJPGPLM[>+;!K7B:'W&HL?YBNHHH']8J=SCQ\*;Q'ROC#Q2 M/8SJW\Q4T?PZU.$_)XQU_P#X&D+?S6NJHH#ZQ/\ I(X^[\!^)2P^S^-KY%]) M+"%_Y 46_@OQ9;C_ )'3SO\ KII<9_DPKL** ^L3\ON7^1R8\.>,H_N^*--? M_?TH?T>J]SHGQ !_<^(O#I'?S-,8?R)KM**!_6'V7W(X:+1OB-$V6USPK(O] MW[!(O\C5M(?'B#_CX\)/]8KA?ZUUP.:* =>_V5]QQTDGQ"0_+'X/D]>;A:C> MY^(P'%KX-/\ VUGKM:*+![9?RK[CA?MWQ*'33_!K>A^TSU'+J7Q/5_ETGP8R M^OVR8?TKO2P!I:"OK"_DC]W_ 3S]M4^*7;1_!?_ ('3?X4U=4^*3/\ \@?P M6J^OVV8X_#%>A5'(QW>E"COR7+?UJM>Z/\3Y M_P#4:WX)M3[6$\G\S7?T4K"6(L[\J^X\]L_#WQ09C]H\6>$T';R='=L_FPJ9 M_!?Q N%^;QUIT)_Z8Z$G]7KN!"=U24[#^M2O=)??6?[*GP\L9BZ^%K&5F.29WDFS_WTQK;TCX)^#=!G:2S\*^'[>1A M@LMC'D_F*Z:BG9$RQ5>6\W][*FG:-8:46^QV-C9LWWO(MTCW?7:!FK,TC ?> M./K2A=II3S08RDWJR&-?,;G-3 8%'2B@DB>4[O2GQMN6AHPQIP&!0 4444 % M%%% $=R[)'Q4=O,S28R<58(W"FK&J=% I@.!HHHSBD 4444 %&:** (?M7SX MQQG%3$;AS3?(7?NIU #5C6/[JX-.I&<(N6XH5PZY7D4 +1110 44%MHYH!S0 M 4444 %%%% !5[PU_P AVW^K?^@FJ-7O#7_(=M_JW_H)J9;%1W11ILD8E0J> M].HJB2.&TCMQPOYU5N-LDG3Y?:KS#<,56^PD'[PQ5(".UA"3*5SC/0G@5=ID M4*Q#CKZT^DQ(*:RL9 0W'<>M.HI#&RQ+*N&% A4(%[#I3J;,S(GRKN- !)(( MQS3^;TJ5D#]12>4N_=CYJ=0 5R7Q MT\7ZSX#^%6JZMH%B=0U2U\D(OD-H^)/$,-Q)XET&T-G:6UL/"EU!]K#6]ZYOK6(R^8JA MHH-\9R'W9#(&6HO!'[0WQ@\;ZQ96"6L=A)-?MIO]JRZ%.]FL/G$BZ$'FA"QC MP-PE6NB6*VMG;P6ENC,RQ0H$4%F+,<#N6))/G4 %%%% !0PW#%%% #5B"TX'!HHH YSQ9\-K/Q'>+?6\TVD:Q'_ *N_ MM?ED^CCHZ^QK*TKXGW7AC6H-%\80PV-U<,([/48N++42>@S_ ,LY/]D_A7<5 M1\2>&=/\8:+-INJ6L5Y8W P\4@X/H1Z$=B.17A8S*JD)O$Y=)0J;M/X)^4ET M?]Y:KK=:'L8;,82BJ&-7-#H_M1\XOJO[KT?2SU/(_P!M[1;S6/!>A1V=I=7D MD>H.SK#$TA4>4>2 .*^;3X$UQE(_L75O_ 23_"OK3P]K^H?!;Q';>']=O);S MP]J#^3HVK3-\\#]K6=O7^ZYZ]*])$S-T8_G7Y!GWACA.+,SJ9I5Q$J-5;\ZQ_&7@;2?B#IGV/6+&&^A!RA?B2$_W MD.KG2]-MY/#MRS:>J1M)]FGVSI&CI&-GW5VASR!DX'OGVIAXN^#'S0R7 MGC3PO%]Z)VSJM@O^R>DRCT/S8%==X%^)>D?$FPFN='OOM4=NP292&22%B,X9 M3R#U_(UQ8/@'$8FN\-B2W]UK2<>MT]-;I7:.K%<5X>A25:A@ M(5**VDI2LGM:2>L7Y-:V6KLCYAT3XI>+=&D5V\(-=20+9_9VDM;@>2]M;-;* M^!C=NC9L@\9Y[5+X;^+WC#PW%M7P@9I%M+>S64VLZOLAA:$!BN-P*L3@\!N< M5]:^:W]YOSH\UO[S?G7MP\(\;%IK-*FG]R/7<\F7B%@G>^7PUM]J70^'=3^( M&M6/Q9TWQ)=::MOJM@UJT-O-"Z))Y$:1J,'!Y51G!ZFNATOXD>,/#]Q'-IGA MF>S$=BEC;8M)I!#&MVMTI!;[QW*!D]17UCXB\,Z;XOT]K75;&UU&W88,<\8< M#Z=Q]1BN+/P?UCP*?,\$^(KBQA!W?V3J9:ZL7]E).^/\":^;K^$.;X*M.I1Q MDZD)-R;@HJHF]W9M*5_*2?D?04O$;+<73C3JX6$)Q2BE)R<++976JM?JGZG@ M7CKXC>,/'5C?6DWAFZAM;Y(5:/[/<2[#'-YQ.7SD,QP1T 'O6_+\:-:\1C4 M(]:\#W3V4FEWEE;VEO;SK&7N&A9E8YRL?[K@)]W@ &O7H/C[)X5F6U\;:1>> M&;@\+=H3SUW0X-3M+Z&73[F,21S^8 A4^YZ'M@]# MQ7I97P#];K3='-YNH[W9GRQKWQI\=>(_#>I:9<>';CR[XR)"T=M<)]CB=40QA1PX"Q MH%+Y(YZYINJ?%7Q/JDK9\$^3!,E^+F*.WN<3M>0I%,V3DJ<1@@#@FTYP2<=O2I/-;'WF_.O2EX0XR6LLTJ/1+6$7L[K[G_5 MCACXB82*M'+X+?[4NJ2>WE_GO<^.]7\<>)/$-E>0ZCX,^W--.UU;/):7 ^Q2 MM!' [* 0&RL:D!NC<^U9_P 7?&WB/XCV&FG4O#UQI\.DHRB46\S,V[&.-'C^634[,[AC'F!@0?TKEQ7@ MKB*]"=">93:GO>$=;.ZO9INSVU.K#^)]&E6A5A@8WAM:G KA?$'PB\-^,;F2^T M.Y31=%_V&_&VFZ7JU]K/BCR[./2K MS0S/:ZC\]];JZ[H@9%Q&7RZ!L7PIBZN'JIU(U4OWD;6,>HQ-'<01W",- MA66,."#VP?7TKEM6^!/A;5+CSO['CL;C(;SK)VM9 1T/R$#]*^)/C%\*_P!I M/X27VF:-H_B?Q%K%G_PCVNZEJL&G:I=ZA-8ZE^$_B#XDU+XW:5X1T>W^)R6;_$"QU^TN+^ROA9MX8&CKE9;N4;?] M?P\$C;S+G*YYK]6Q>6X/%:8BE&7JD_N=C\]P^,Q5!WH5''T;/H+_ (59KV@@ M?V'XSU-57&VWU2);V+&).'L-F<,HPN*G"7+-I*]TX\K??5G7Q0_";QKJHM[G3X?#>M94>5-&^DW(88P 1M4\D=#S72+ M\']'?'6M01D;DAU)4U"!LGKN;#8Q[FNS\1^&--\6V36NJ6%GJ,#<%+ MB(2#\,\C\*XF7X'W'@XM-X)UZ\T%@<_V=GR'TV,=R#ME3Q7N5^'JN'DZ MD\/"HOYJ+=&I]R:C+_P)/R/*HYS2KI0C6E#^[4M4A][3Z8@;-5M&A0Y M.!B090Y/?-6?A9XV\1:QV[#(D@E$BD'IR,U8'2N M&U3]G;PS=7;76FPW?AN^;G[1I%PUJ2?=1\A_$=S58:5\1? __'GJ&E^-+-?^ M6-\GV*\Q[2+\C?B!TKM_M;,,-ICL,VOYJ3YU_P" NTU\E+U./^SL%7UPE=)_ MRU%ROY23<7\W'T/0C2+FN$TK]H/25OTL?$%KJ'A'4'.%BU2/9$Y_V9A\A_,5 MW4,RW,"2QLLD<@W*Z'E.HH **** &RQ M"9,&E1/+3:.U+10 4444 %%%% !5[PU_R';?ZM_Z":HU>\-?\AVW^K?^@FIE ML5'=%&BBBJ)(YH6D8$-MQVJ2BB@ H'6BB@"N?,#_ ,7]*L!MW0YID\7FKZ4D M$/E ^] B2C-!.!4=O.92V5QB@9)12,VU2?05 M[E^>%Z46 L4UI K <\^U.4 M[A10 4444 %%%% !1110 4444 (S;?QI2NZBB@ Z4444 %%%% !1110 4444 M &ZBHS$=]24 8OC_ ,*:=X\\+W.AZE*L4.IKY:X=5DW#D%-W5@?2J7PJT^3P MEX+L]%OM4LM0N]-$D7G),-TL:L2&89R&"D;L]"#7S9^V7^RKXO\ BG\4_'5Y MIO@O3?&B>./"^GZ%X;U>ZU2.T;X?WD$LKRW.&_>*CL\SW5WW.[Z[6^J_4[^YS,,-4UWQ,OB$ZAJRRI,;34?)C DL/L#;5V MD<0X(SG#@-[5RXC!T*TX5*D%*4'>+:U3[I]/D;T<54I1E"$FHR5FD]&O/N?\ !5GP78>+K70IO#GB2/5K[QU:>!;>!VB7[0]RN5OD)/S6Z,"C ?,&&.]> MJ_ K]JWPY^T%X^\?>'=&@U"WNO .H_89)KE D6K1Y>,W=L>KP":*:'=TWQ'U M%<5K7_!,SX8ZYXWL?$)(M:TZX6[@NH=2"M'(M\E^C+_!G@72;=+_Q#-:,MJS@V_RW43R,4D<)M$:L2@*A MP,=Z]NM9Q<1AE965AE6!R"/7-&HZC#I-C+P_Q/IWKCJ8*A*LL M1*",65C:6D#DQ0Q;'<1N?*)EY8'(KZPT'XKZIXV M\&Z?J!N) M^]W'4XKR>(LZEE-&-?V3FG=.VR[7^9[.1Y/',:CIN:BUJO/O;T1].>+OBGX4 M\(:8NJ7EQ-XA:4L(7CE683D<'82VW [D<"O$_BC^U[IZ^/-.O+"S:VL[=H5+ M?Q1_-EL)_$>V.,\^U?,^F6,FI[;:QFCALXHI-TDDK;KESM+["!G^'O@#&.:C M\+^(9-$\=6^J:A8G5-+L;F1(DGD53(1_JW8#GC(.<8ROUK\QS#C;$YA6A2O& MG3O%OJU9ZOT\K;?,_0<%PMA\)3E.SG.S2Z+5::?K<^Z==^(4CZE)>30VK1LV M\K$GE/'[J1W]C^=>A_##XJ-?7=O:3W7VRWN3LM[DG]XC_P!QSWSTR>0:^:= M\=Q>+-$MKZ!I&@N%WH).70@X*MZD&NM^%>J33ZG,JAA'Y\)!'!+YYQ^&*_>( MNG5HJK3=U))I]T];GY7B*'))PDK-:>A]1:[XDL?">E/>:E?6VFV43#=-<2B. M-3VY/?K[U\W?$?\ ;4U?Q)K5_;^%;F/3=%L9U6*\9&6]OG4QN7"2Q[$B() & M"7'=06)MZHQ_A#8V[QRN<\] M#^>/QO/C/X+"^C\0:#K.DK8JZ_:C [VK[0,E)E&PK@C#9QS[$#\!\8.)^(\M MC3H913:IR5W4BFVG?X?[O1W>Y^E>&O#^28YRJYE43J1>D&[)JV_GKI8A\6_$ MVZ\)>,M6M;UK=+>ZN)M2M'MU9;>.!V+LOS,Q&QBV=S$D<]*Z#X)>([ZT^)7A MS79+5A9Z/*NJ6Q%UYSOH?W5R@8J48?>*G MJ1W![U_+*Q&(P^(AFM)7JJ7,[])7O>R\^^GY']"RH4:U"6 F[4VN56_EVM=^ M1^F'PG_:>TKXG>(;'17L+[3]8NH))!O"FTF>+'F+$^X.W7*[D4LH)QP:UOVE M?&7B/X=_L\^-M>\'Z:-8\5:/HUQ=Z59&(R_:)U7*C8O+XY;:/O;<=Z^,/V?? M!WCCXM7.@ZUHWAN;4-!T_68?^)K+/%%Y3PSQK,X4-GA&?[O/48(Z_>GCC4KS M1O".M7NF1?:-0L[*XN+2/;N\R58V:-<9&VDCLV?RT(6[@)B)"%LR M*1#9_MQ^/M3B\/WUG\0-='BR?PYX=OM!\&7FBVJ2>-Y[F]GAO/,B2-G&8$$F M^&1% 4/@ D5Z?>?M2>)/&5G'8ZEKUM'IJ0QW$5SH4+:;-JA& MIY/@XCQPX=I5G2O-I=;6U[6;3\O^ >Q1\*<[J4O:-13[7Z=[I?,T_C/^V?XZ M_9B\.?%&\UJX\.^)=8TGQ=%INAVGV26UL4MCI:WGV=&!W-(=K /(_P SM\JG MY4/U3X%\1MXS\"Z%K30_96UK3;;4##NW>29H4DV9P,[=V,X'3I7RC!^U3XF^ M'R37%C?0^)+:2%M\&NRM*EHZ_,)E*CS'8\IM+@#<",8(/UQHEW-?Z'8W%Q%' M;W%Q;1RRQ(^]8G9064-_$ 20#WQ7VG"''&6\14YSR]N\;VUUK;N?+< M2<*X[))QCC$O>O9I[VM?31]>J':MI5KKVGR6M];6]Y:RC#Q3QB1&'T-<+:8G"KDI2]U[Q>L7ZQ=TSB_A?XZ\0Z[=75CXF\.SZ+>P-F">(%[. MZ7OM?G##DX/4'U!KM*?"GG3*G]\A)\D*NS//?N?V3_C'J'[0?[.7A/QIJVG M6>DZEX@MI)KFRM)6F@MG2>6(JCMRP_=]3U)-=]SDY6CT*BBB@04444 %%%% M!1110 4444 %%%% !1110 44U P;D\4Z@ HHHH **:R,6X-.H **** "BBB@ M HHHH *1UWJ1ZTM% $4-MY39S4M%% $:=&GEKM%.H9MHYH CG@\X4 MZ*/RDQ3E8,.** "BBB@ HHHH **** "BBB@ HHHH **** "BBF+<([;0W/\ M.@!]%%% !1110 5>\-?\AVW^K?\ H)JC5[PU_P AVW^K?^@FIEL5'=%&HY[? MSR/F*U)15$@HPN**** "FB/$A;<>>WI3J* "D=MJYI:#S0!5EG:7"A?(!/BS/8:WYB[8YH_F=%^Y<)_$"/7^5>3^&I%TKP7H]L9HV:VL88S)$I/8#DU7\,:>VB>%["U MF.UK6V1')[$#G\JX/QOX^M4L[O7=0D:/1]*1I(4[R8_CQW9NBCL#[FN#17E+ M1+.=^-/Q?USQWH-]9QVC6 =0?3)I))([<[8;@JP2=>H*D^W5 MRVU\[GT#X<^+ ML,*SVFJZDVQID6R>Z+'(8'Y=QX.&R >O(!YQ6JOBJYT>ZDDMY%6-L9BQ\LGK M],^HKY!U/XKB6%E,IV,,$ \5[E\!?$5_\5_A]:W;1-\LCV[3LI6.0+@;^>Y[ M@?Q ]*^A\/\ BJICJ?U#%1]Z$='_ #)::^:_(\_BW(J>%E]9HOW9/5=GY'UY M\ /%G]KV5Q:!LP+&MS;@]45NJ_3/-2_%KQ*HU-;1Y/+M;!!?5B,<_4"O$_C]KDFE: MA<7%XS&.^8&%@=RHJJJE2<<8))[_ 'O<@=QJ6NX&TLTG&"#W7U^HK@_BIX7F M\=PP?8I(Y+IE:!$DD^5MW0CK\V[&?4?05\_QME%3,,IG0H1(_'$.E^)[::&:2559CMC4,1N!&T*?NDY.>X!.. MM2ZO%_V/=,\<^$['3-;T:QB\/V,0BMK>X@#RJF, M?)GE21_%UK\XP?ASB:E!5*TU"32T:N[WO9]M.WW'U6+XVP]*JXTX\ROOLK6W M7<^;/V(Q+'/?>3CTKT'P7\.-$^'FF0V>CZ?;V<-O&(H]J#=:*MS.]@/(KQ/_@HPFJ7? M[%OCJUTK2[[5IKJS594M940VT*N'DG?<1N1%4DASN?C_ / B M%KS4+%8/M%U=7B[(+>*)I9KD@;L(B DMC)P!DCZ5]V?LB_LPZ+K?@ZZUCQAX M-TRX:36O[2TF+5=/(NK21(5A>1ED17"L1\L;@@8+#[PQ[/X6_9_\">!?$:ZQ MHG@_PWH^J1EF2YLK!(9$9L[F&T !CD@MUP2,XKK9[E(!NDD1/4NP&/SK\CX% M\'Z628V688NK[6;325O=L[6NGNU;T/TGBWQ*JYMA5@\-3]G'1MW]ZZ[6TM^) M4(T_PGH_[N&WL;*W^['!$$123T55'4D]!U)JG)KU](JM'I\$,+=3>3A=RGKE M!GMV)I=:UG1;^PD@O+VT:%L$@3#(P>",'.0:Y^2'02-W]N7TB]MOS?KLK]JI MTXQ5K'YE&S;<[W/S5^-VNZA\(/BCXGT2ZLVTZ#1[Z?R(X]SQK:;BT31G&YH0 MA&&/0#!QBN8M?CRMI(LTDWR0?O&!/7;SC],5^GGBWPOX+\>>&-1T36&U;4-/ MU:TDL;I<2(TD+C#*'4 J#UX[\U\X>+_^"6/PDU;1K.VT^Z\=0WD-SYD]TUV@ M^U1$_-$P*;5&.C*H;KSS7\P\1> 5>IC)8C+JBE&;E)J7NVN[I*UT_73T/WO) M?%NE##QHXRFTXI)6UO96N]FNG?U/$/@KX!\8?'CQ18Z.-(UG3=)GDC.K:C/9 MF&.QMVY8KYF SD<*HR><]*_1:3QIJB#Y)K$XX ^SG_XJN>TK3X- T>ST^U4Q MV>GP);01EBVR-%"J.>> !S4D-Q;K^[N>V,'UK]LX$X M!P?#&%G1P[-2M%*,$U%+SZ^KM^1MIX_U: M-OF73Y!W_=NO]:GM_BG)#_Q]Z>OE]6>WEW%1Z[2!G\#6&=2\/[1NTW5@>^V< MM_[/4MM<^%II!YEMK"KU*R%V4_7!K[AQ78^1Y5V/08M1A?3UNUD'D>7YPD[; M<9S^5>%W?P:^&,?B77=>T_X7^'I-4\0#=?7+1^7+?XD6;H,[-TJ(YV[=S*"V M37K,'Q"\/S6IA-TL,*ILV2PM&NW&,=.F*\-_:K\#77B[P5:Z3X%\5Z2^J37\ M;_V;_;,-E?31*C$QQR,Z]"58AL$J#SV/D9MC'@\'5Q,8.R7=VZ'R]X5_P""P&J?!OXB:PUU\&_"^BQZYJSWWB)- M.N9X=0GO/N32GS!L,X55!! !V]> MP9MW(89R0P)W @_Q5[9_P3E_:-\-_!_3K[P#K_V7P_)?WTNHVVK7-UM@OI7V M((&W#;&P15"G.UMIZ'@_AGA[XDXO%9M++\XJ=JR#=^76KI&*\/G M2.1LLJLPZ$CD5B?\ 'KJ%PJC_ )9R'S4_)L_H:_HATNQ^.2H/H>R4 M5YWI?QKN(2%O[&.9?^>ENVUO^^6X_(UU6A?$31_$#+'#>1QS'_EE/^[?\CU_ M"LW!HQE3DC:HH/!HJ20HHHH **;Y@W8IU !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% ",VUU24 %%%)\8SD*3V.-3_A>7@O[;J%M_PEGAYI]+M_M=XBWJ M,;:+Y?G;!/'SIP,GYTX^89 LSJ:*\W\,_M<_#WQA)IL6G^)-/FNM4N)H(;9I MXXYT2)IE>=T9@5A_<2$/SD8.,9QK6O[1'@&^M]-EA\9^&Y(]9G-M8D7R?Z5( M&"%%]PS*.<ZDB\QRQ>+:S*./E7.0!@+T]#ZUY/$.3SS++:F%I.TG9KU7?R/>X=Q MT<%C88B:T5[^C1\_^-2LDC0Q_NY9%+"0 93GEL_4]/>O.?%.DK;OY;S-/+"O ME^43L7/L.*\EUCX1 MZ]=>(6L8-)NKEIIBD%W",P.HR0Q;.(\+R0<8SQGBOQ'-.!,WR]1J.'.F_LW; M3?1_Y['ZU@N*LNQ3E'FY;7^*RO\ U]YZ)^S7X]A^(T$6@SQ26%]H=I$ A<,U M\BD)N0=1CY<@]-PK[/\ A3\(O[+,.JZLN;S[\%N>EOGH6_VO;M]:\^_8C_9' ML_@]X9@UW5K6"3Q)?1[VE906B!YV@_W1QCU^\>HQ]"5^ZY/+&+ TX8YKVEE> MWX+U74_&\XJ8>>+F\)?DOI?\_1G-?%#5FL]!6U1B)-0?RB1VC'+_ )\#\:\& M^-\$GC_09-)@FCMXX7$ENS#]W).G9O\ 9(+*,=SGL*]7_:!U%](@M+A/O1P3 M%#CHWR?_ *_PKPS6-6^S0-&T@D53PS');)[^_O7K?5*>(HRHU=8R33]&<^#J M2I356&\7=>J/G?6/B=)IUPUO,X6:'Y73?DJ1P0>_!!'/<5QWQ#\O4/VF_ DGC[P6JW%VH!4Q;^" M3R",G'RXKS+]F+]ES6?B_P".+^W\5:=KVFV.G!8C;",P27EPQ!$8+#. I#$@ M'((&17X)F'A[B\/F$L;>[MA8Z;91".VTZ,XV*.F\_KCJ23FNI^$_P:M? MC;S7,,3:A'&J1HH_ M=V:@8"H/4 9_*NYK]FR[+:&"I*%&*YK)-VU=D?DN8YG6Q9.Z//C?='RCK M/P^:&[:.2\FC"M\RRQ[9$/MT_P ^M=#X!^%DV,DC2'Y[B7H@]2V./ MPKZ=FTVSU$K+);6UP64$.\2L2.W)%3V\$=M$(XXTBC7HJ*%4?@*VE7;6I?M+ MG)_#_P"#^G^"T6:95O=0QS,XRL?^X/Z]:ZXG)JEK>OV>@P[KJZAM_16;YF^@ MZFN6UCXP",;;"S:1O^>EP?+7\%'S']*Q]Z6I"C*1VP&:IZEXBT_1Q_I=]:V_ MM)*%/Y=:\D\0^/\ 5-5!^T:A)'$W6.']RGZH4< ?6J/@7X60^!KP:IJE]#]I5&15!VPQAASR>6X^E/N4\ M,02MY2[=-S@M^IK:B\46=A_QXZ#;QYYW3,N[/O@$_K4=YXZU2ZCVAK.V5 MA@B.+<1^+''Z5JO0T5]K%%&5%_=JBKVV@8IKS[74!9)'8A55!EG)Z "J\;"& M)8USM08&::\K!E99&CDC8.KH<,K#H13-=3:@\(:S=KG[)# .WG3@'\ES4J?# MW5G^\VGK_P!M'/\ 2H+;XE:K;KMD^QW&/XFC*L?K@XK2\.?$N34=6CM;RUBC M^T/LCDB8D!L><'D5FY31@_:+4I2?#?5?X9K!O^!./Z5$?ASK0_AT\_\ M;9O_ (FMCQ+\3H-#U"2TAM9+J:$A9"6$:(<9QGDD].@K%F^,&H9_=Z?98_VI M7_PJ4YL$ZC([CX?:U$,BUM9F]$N!_4"J<_@S6HEW?V9*W'/ER(Q_G5Y/C%J" M-\VGV)'^S,X_I4Z_&J1%^;2U;']VY_Q6JO,K]YV,"71=2MRIGTW4(H\_,?)+ M8'<\9KY7L]/\.^.M$U+7KB'3;C5=>O#-?'[/&6:8X$<2@#=\J*A .3G+'KQ] MH0?'"U!7S-/O8V_V&1L?J*\Z^(GPY\$^-=2TS4-%^R^#=6TU[B0RPZ%'Y-_Y MR@,LX3:S<@, !SZU^9^*'">/X@R^-#"2MR/FY?YGHEKLK:O4^UX'XCH93B MY5,3#222NM;+6^G5/0^-/B1\+K2ST^262VALH8B9)I(H ">,^N M *Y+X!?!3P_X^_:#TG1]S*N7:39)*Q:1CM!)XQ&O'6O M2_\ AGGPHVI7.I:;9PZ??WO$]W:JA>?G)W-@ELD G)ZU^8\$^"N,PE>CF&9U M4I1FI.#7->*OHW>UV[/JK7ZGW'$WBEA:].I@\'3;4HV4MK-]4M[)=[?<<"K+ M#&J+]U!M '8"FO<8!KK]2^"&H0#=9WUK=?[,JF)C^(R*YC6?".KZ""UUI]TB M#_EHB^:GYKG]:_IR+6Q^+>TB^II:=\-]6UK2([VU^PW$<@W!%N/F'L>,9]JR M=:\.7^AJ1?:?<0IG[S1[HS_P(9%4=.UJXTJX\ZQNIK67N87V_F.A_$5UFB_' M?4K!1'?6\.H1XP67]U)_\2?R%/WB??Z&1X=^(>J>&]OV6\:2W'_+&8^9&?IW M'X&O1?!'Q;LO%=Q':3)]AOGX5&;*2G_9;U]CS6"\W@GXA-]XZ/?R< X\DD_^ M@-5:/]G^^6_C(U2U^SJZN)%1A)@$'@=,^^:RERO\-?\AVW^K?^@FJ-7O#7_(= MM_JW_H)J9;%1W11HHHJB2.Y=DB^6JTM-$:KT51^%4@'44#@45( M!113991$N30 D\7G)C.*2WM_)S\V7-I;: M??\ V_,"*S2,(98@/FZ8\W<".046NXHH \&\+_L%Z7X.NYKBS\4:P]S.;21Y M9K>-WDEAELY7D,O^QS;Z=J/A_4]'\3 MWNEZYX7MYX-/O'T^"Y4>?<7)IT-NDF);%T9(E)5"J6$*8R=Q9F)S@#W*:VWON6 MHS:OFJM$7,SRO]HGX+>&-5@DU;_A%?#\EU=/*)Y381;G=_F#%MN22V>3WKPO MR;#P_8-:Z;9V^GVL;LPA@B$*(Q/)"@#!S7V7?:=#JEA);7,:S0S+M=6[_P"? M6O(O&G[,;7UTTME]EO%.2%F)CD^A(X;ZG%=%"HEHS6G44=SP>QL[CQ')=W$?_$JT\A41AQ<. ,#W ZG\JM>$OV9;L2( MNH/;Z?9J@SZ\U[%I&DV^@Z;#9VD2PV]NNU$'8?X^_>BI6OL%2I MOK>H;S3[?48?+N((;B/^[(@8?K6U.LX%QFXGR7X-^'DD M]]#';6\NH:AN.PJ"5CSZ ],>I]:^B?A5\+(_!%H+F[VS:K*/F;JMN#_"O]37 M3"*P\-V4DBQVMC;J,N40(/T_E61>ZQ>:M%N5FTNQ;[LC#_2)Q_LC^$'WY^E. M524R]9&IJOB.TT9Q'+)NF;[L,0WR-_P$?S/%8U[XCU"]&$\O3(3W;$DY'T^Z MOZU3B>.Q5A:Q>2&Y>1OFDD/J6-1%BQ))Y/?O3C374TC12W(%MUO[XK##<:I> M+]YG;?Y?U)^5?YUKV_@>>[3.H7$<,&/GBA/4>C.>WT'XU5TG7[W1]+CL[>UL MD\O@S%F.\_WBN,Y/N:SM6O6OIPEY<37TS?=@5?E_"-?YG-%I,/>]$=+J'CZQ ML%\JT5KUHQM AXC7';>>/RS7,ZUXUU*]4[[I+&'NEO\ *?Q<\_EBKECX+U+5 M1NE":;;@?Q_/)C_=' _$T](O#OAZ1XG5!O/"Y8@9 XSUKY:^&WP9\=>&OAQ M::?HMKXD\*ZE';L;ZZ2TTS3YKB6/3Y! JO \OF*+H)EGPQ!YX9JJ\MC2TGOH M?6MI-H.@MNTO1VOIUX^T7.VU9K*]M8HQ9O>VKE-,7.(Y_(C.XOW5P#N*U@O9 M?&#X@Q:]H=Q-XDFN[5$M+J.XNK5=/-K)9LP1MF&>\+M 2ZG:&W\XR*2LN@*F MD?5[PQM+ODW32?WY29&/XFE:?C^E?*OB&S^/]_JFO/;/XBLK&ZD$]M&M]:S2 MQ2":Y_=(X*E(C&;?E%VCY?E8"3.U!X+^,5PCZGA"BK53LC0^C&FW#_"GZ9IUYKTC"QM9+D*<&3.R)?\ M@1X_+->#_ /0/'VA:G967B6+Q!Y<=J\0\NZM%T>WA$";!Y2#S&N#/YN2N %* MDDCBOI6R^)XL;*.&/19(EA0*H$ZA!@=N/Z4G)VND3-R2]TCM/AAJ%P/W]Y:V MOM&AD;\S@5>M_A-;J3YVHWTN>RJD>/QP:S;GXM:@R-Y=C8PGMOF9^/P JA=? M%/6I#\DEC#ZA8"W\S46FS&U1G3Q_"C2T;YI-0D]FN#_0"KVD>!-+T2\6YAMV M,R<(TDC/L^F> :X)OB?KF.;V$?[MNM1M\3=<#<7P/U@3_"CEEW#VUX?\ +:S/UMA_C1RS6S#DJ=#J;CX,63K^[U"_C/J=C?\ LM4; MWX*./^/75=QQ]V:'K^*G^E8__"Y=<43XP:X6W+)9)]+?/\ MS5*,P4:A0\2:#>^%M06WO(U5G7?&Z'*2KTR#]>QK-:3\:DUOQ)>^(KM9KZXD MN9%7:F0%5!UP .!5!YO>M5%VU-XWMJ32R*X^8*WU%-@NI+%]UO)+;L.ABQ7J^A?"GPQXBT&&:UDN;E9%&9UN"&![Y'0'V(J92Y=R9RY=SB M]-^*VO:00JZ@URB\;;A!)D?7@_K72:-^T&ORKJ6GLOK):ON'_?+<_D:76/V> MU(9M/U)E/9+F/H/&>T5R-Z_P#? M0Y_,&O*X-2DT^^2:&9K:XA.5=6VNI_SVKW+X0^-YO'/AAI;E1]IM9?)DD486 M7@$,/Z^]1*\=4R)1E#5'DWB;P'K'A<,;RPD,/_/:(>9&?Q'3\0*B\+_$;5/" M#C[#>,T/\5O(?,B/X=OPQ7J>H?M >'=.U&:U:2ZD:%S&\D<.Y,@X.#GD4^S7 MP/\ $2?=''I=U<-_"5\F8_AP35<[^TA^TT]Y&Q\/_&@N/UY_$&HC#FV,XP MYMC0MOVA/$HO"SM8LN>83;X"^V3)B;ZKV/N,&O6O!?Q4L/%FV"3_0;YO^6,A^60_P"PW?Z=:SE3 M:,Y4VCJ**"=HYXI%6\Y^3]:?=H7A..QS]:J ;C@=ZI M78)/-CW4^FQC:@IU2P"BBB@ HHHH **** "BBB@ HHHH *O>&O\ D.V_U;_T M$U1J]X:_Y#MO]6_]!-3+X65'=%&BF13K*3M[4^J)&O<)&V"W-.!S4,EF)')W M8W=>*F VB@ HHH')8=UZC/3ZT %1W$'GKUP1TJ3'%% %>WMF63W,399 ML\4 2T444 %%%% !1110 4444 %%%% !1110 4444 !.T4V.591\M.(W"D5 M@XH 6BBB@ HHHH **I:OKL.D!596FN)/]7"@R\G^ ]SQ6/JOB+5-+'G2?855 M5WM;@%F4>A?/7Z"JC%LI1;U*7B'6?.\23-.T:PZ7(%BC<_*6P"7([]<#Z>M/ MM-,U#Q0_GLS6ENW/G2K\[#_80]![G\C73FQM[J9;B2WA:; PS("P_&H?$NE2 M:SHTUO&VV1BI^;(5\$$J?8]*KVFR1?M-.4Y'5+33V*PZ?Y]S<1N"]\TK%4P> M0O9B>G P*!.9[GR8(I+B;ND8R5^IZ#\36QI_@J:!! W7_>;CCV& M*=/XCATW_0=%M(YI%X)48A0^YZL?I^=::O).P@C5DW\)#"N6;\N31RM[E$2-0MJC?QW+?- M_P!\CG\\5F_%GX0:]J?@*2W\/:SJ%OK,UW:IYUHL,3Q6YN(_M#)Y@8;A#YF, MYYQ@$UZ/J^NVN@P>9=3+'G[J]7?Z#J:XOQ#X\O-<#0VX:QM6&"0?WT@^O\(] MAS[U*E*6Q*E.3T/DC6?A]\9KKQ1<6^J:EK^K6.D:R7189;*.*4#[7'&T;;\R M1".2#S%=5R?3O[/GT]?+7RK9"0 M_G;=Q;+*/E;!Y6O>@BQKM4;57H/2HR,5:@=)\V:'H7QIT&ZOKKR;YKCQ!!;- M.8[FT;[->*FGJ\T@+85?+CNT_=Y^8Y"G<&KJ?"WA?XG:+XC\-WEUKFN:E#YU MG)JUM=W%H;<*[W@NT"(@.U$%F4PVH[X_"CE2ZB,0Q[5_/']:?,B?:(YUY.:KM<,)#N*A?K73-KG MABR4>3H-Y=,O0SS?>_4T+X_LX95^Q>&M+5CTW_,P/Y4]C/22,G M_>IC2-W#_@A/]*7PY^V)H?B]M+_L.\\.S+K$MW!:>5 Q\R6T;;$M,N+S4+_2+.WM8'N'/E!F$:??8("68+WP#BCF8]U^,+?X5M'XY:P\\T*:EI[30/YW-$'QXU::Y>&/4=/FN(U5WB"(653T8@'(![$\&B[#FEV.=D\Q6VM' M*OL8V_PJ&:X$9PQVGT;BNP7XXZZC?,MBWL8,?R-.'QQOG7_2-,TNY]?D(_QI MW?8.:78XDS[AG6+ M-SOB)X/_ %OZ4N?R#G?5'!L]3:3KM]X>N_M%C=36DW# MM9YL_$$UFS=$GP0/^^@/YU'<_ J^FCWZ?J6GZ@G4#=M/]11[1;,/:1V9)H/[ M1%]:;4U.RBO%'!D@/ER?]\G@_I7::%\9?#^N,JB^^R3-_!2ZQ\ M.M;T3<;C3;H(O5T7S%_-:Q&M][%6Z]P?\*ETXLCV<&?1]UH.EZ]MFFL["\[B M1HE?/XU9LK&WT^W6&"&*&%1@)&H51^ KYPTC4K[09-]C>75HW_3*0J/RZ5V& MA_'76].VK>1V^H1^K+Y^:!\;]&U<*EQYVG2-QB89C_[Z''YU)XD^$NA> M-8CAJE4:T94:K6DCROPC\8]>\)[(S/_ &A:KQY-R2V! M[-U'ZUZ-8>,_"_QAM5L]0A2&\(^6*XPLBG_IG(.O^>*XGQ/\'M6\,[I!"+ZU M7GS;<9*CW7J/PS7,_8]XZ;L?I1RJ6J*Y(RUB=GXO^ M[H_F3:4[:A;+UA;Y9 MT'\F_G6%X5\6ZMX,G*V=Q)$JMA[:5=T>>X*G[I^F*VO!?Q:U/PJ8X+@MJ%DO M&R1OWL8_V6_H:[NXTOP_\7-/^T1,%NU&#(@V3Q'T8=_QR/>CF:^(.9QTF>8^ M)M=D\6:RU]):VUI*Z*CK!G#D?Q'/?M^%5#$JJ-^WKQD]ZZ#Q)X"OO"'\)_2G>$M1_X1G6UNFA6ZA93'+&5!)1L9QGN,?C5W5M"E)6 M]TU/!WQ/NM+C6UU$R7EIQMF',T(]_P"\OZ_6O1M*GAO[5+BWECGAE&4=#D$5 MQ^J_#NSURU_M#07C59/F,&?W;^H']UO;I]*Q?#^K7GA+4)/)5T8-_I%I)QN_ MP;T(ZUE*/-L92BI:K<]4HJOI.JPZUI\=S;L3'(.AZJ>X([$58K$P"BBB@ HH MHH ***1VVJ: %S1FJXN6SV_*K .138!10S;1D\4U)ED^ZP-(!U%%% $<\WDK MZYIL%UYK;2N/3%/FA\Y?2FP6ODMG=N/:GH!+1112 1\[#CK53!R>#N[5 M_I7R1-IFM_ #X97/B:'P1JND^._"6ES3ZYXCN+Y!!XQN5NXI/LBX+M>&]PX2 M21%-L74+C)6OK:FSDK%P2".X- 'RKJWA/XU^'=2U::&\\;7MUJD45X9=/-JT M7]I'38%@C DX2RCN1.DR@9P(R=V2:L0O\5%9*S,GDB06N]PP#(1E5;S<_3UA_Q[_B:FI6'S'EO[+'A_Q5X2^&VI+X MRM1;>(M2UZ]U"Y =6CG:II8U>)MPZ M=*KV0S(?8570GJ6J***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH 1B M0IQUQQ4%O)(TPW9QWJQ10 4444 !Z5'"K@G=4E% !1110 4444 %9^M:W]A* MP6ZB:\D'RK_"@_O-[>W>KTC;8V(]#7,:*[3:9)<,=T\Q)=SU/.*N$;LN$;L> M-ND"61I#+=2@J31=!;466ZO RPJ=\<3<;\<[G]NX'XFH;*%;KQ!9 MPR*'C*O(5/0LH!'Y9J[XUF;[/:1;F$=Q-MD XWC&<&KEV1K)Z\J(M5\12ZBS M1V#/.,UT?,FDM,!4,C%LN,YP3[8S[UEZB=EOA? MEW.J'''!.,5UT,*6L"QQJJ1QKA5 X'6B5HJQ,[15C'\>7%Q!I"B'>L;OMG=> MJI@_D">":Y\ZY&L*VU@AC7&,1#=(_P"7:N\'(IL4:Q9VJJ_08J8SLK6)C4LC MC]-\%WFID-/_ *#">>?FE/X=!^/Y5TVD:#:Z%$5MHMK-]YV^:1_J:N45,I-D MRDV0WSQP1&::18HXQ\S,< "N7UWXA23EH]-78O0SR#D_[J_U/Y5G^*[R6_\ M$=Q%,[216[ 1H?NK^'K[]:SF^]6M.GI=FD*:W9%)NEF:61GDF?[TCG+-_GTJ M.0*K!?XFX"@9)^@IU_(T4!9>&KLFL8?#GA"2\LXTANB@/FXW-S[MFKE*QI*5 MCG;/P9?7,7FS"+3[<=9+EMI_[Y_QQ5'6K?3K(QQV=]+?39/G-LVQ@=L>^?K5 M6XOYM59);F62>1B_NC:BW-Q M=+ O C$IVC\*FT^);B\2-QN1NH-=''I=O:!?+A1>/3-)R"3.0ATN6Y):.$R9 M_B"\_C5A?#-U)][;'ZASG^5=4ZAA4>T,.:7M&+F.=7PEM^_-M]E'%21>'((I M59_,DVD'@[Y@ MELVDMK^^\])(;DKO!3Y$$4@!RZJIR"O,J?L1WOV/4$GUCPY/<:TKO>74NCO+ M/:2^9=.JVC-)F*(_:2&SECLX/S''O=S?2B:1=W"]/E'%4'U.X\UE\QL4N5#/ M"=(_8@U3PCK-SJ6E>)K-M1CNI9+26^MKBY$T4QNO-%R/- W[;IMK1@8,8)R& M(KH_@K^S)??"/QXVIG7+.^TW^RH].:TCM&5[F5(K>,3.SLVP@0'B/:&W_,"5 M!/IL]W*P)\Q^GK4?VF0Q[O,;=CKFJY +36BI_"JCT(XJ)K).IC ^@%5FN9 5 M_>/^=->9Q_&WYT 22VJG^%6_#!%5WLT;^$?B*>&+)DEOSI+>9I7"LVY:I7 K M/IZC^$K].GY4D$GV,-P'#"YC0K(0.WXUEQH)!\PS4<@V2;1 MTSTJ4E<5D0K:9'_UZNCPA?OI*7RVDTEG)G$J#>!@X.0.1^-,>-4' [5K>#/$ M5]HNLVZ6MQ)$EQ*%D4G?%7POIZ^'Y+Y;6*.[7'[Q!M)SZXX/XUYD!D4HRYD*,N8]7\ ?$B M'Q>/(F5;;4$&2@/RRC^\I_IVJ;Q1\,]+\4;I&B^RW3?\MX1M8GW'0_C7D]E, MUI>PS1LTAXQXG^'-_P"%BS2)]HM>T\0^ M4?[PZK^/%9E@]QIETEQ;2R03Q\JZ'!'^(]J]Z=0T1R,@\$'H17E/Q"TNWTGQ M5-#;Q+#&4#[5Z GKBKA/FT9I"=]&=)X0^)T.M1"SU9(X9I!L\PC]S/['T)]. ME1^)_AG]E+7&FKNCY9[;/3W0_P#LOY5PJHKM@J"*]$^$6HSWNCW41SFAWUUHEQY]G)MW']Y&P^23'9AZ^_45U:V^G_$*U M61E:UOX1\Q7'F1__ !2_YXJGX^M([?6K.2-%5KI6\TC^/'3/O[UEB=[*:.:% MC'+'*H##T) (^E4]5S(?Q+F1TUF;7P#:?9Y)IKB2X=HH DHHHH **@M)6>=@QR/\ Z]3T %13 M1NTBE3\HZ\U+10 4444 %%%% :IO;213J5PRYSTJY10 4444 %7O#7_ "'; @?ZM_Z":H.<(WTJ?P1*SZY#EB<%L?]\M2E\+*C\2/_]D! end GRAPHIC 24 mrna-20231231_g5.jpg begin 644 mrna-20231231_g5.jpg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�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end GRAPHIC 25 mrna-20231231_g6.jpg begin 644 mrna-20231231_g6.jpg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htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover Page - USD ($)
$ in Billions
 12 Months Ended
Dec. 31, 2023
Feb. 16, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2023    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-38753    
Entity Registrant Name Moderna, Inc.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 81-3467528    
Entity Address, Address Line One 200 Technology Square    
Entity Address, City or Town Cambridge    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02139    
City Area Code 617    
Local Phone Number 714-6500    
Title of 12(b) Security Common stock, par value $0.0001 per share    
Trading Symbol MRNA    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 40.2
Entity Common Stock, Shares Outstanding   382,073,208  
Documents Incorporated by Reference
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s Definitive Proxy Statement relating to its 2024 Annual Meeting of Stockholders to be filed hereafter are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. 		   
Amendment Flag false    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001682852    

XML 27 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Audit Information
 12 Months Ended
Dec. 31, 2023
Audit Information [Abstract]  
Auditor Name Ernst & Young LLP
Auditor Location Boston, Massachusetts
Auditor Firm ID 42
XML 28 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 2,907 $ 3,205
Investments 5,697 6,697
Accounts receivable, net 892 1,385
Inventory 202 949
Prepaid expenses and other current assets 627 1,195
Total current assets 10,325 13,431
Investments, non-current 4,677 8,318
Property, plant and equipment, net 1,945 2,018
Right-of-use assets, operating leases 713 121
Deferred tax assets 81 982
Other non-current assets 685 988
Total assets 18,426 25,858
Current liabilities:    
Accounts payable 520 487
Accrued liabilities 1,798 2,101
Deferred revenue 568 2,038
Income taxes payable 63 48
Other current liabilities 66 249
Total current liabilities 3,015 4,923
Deferred revenue, non-current 83 673
Operating lease liabilities, non-current 643 92
Financing lease liabilities, non-current 575 912
Other non-current liabilities 256 135
Total liabilities 4,572 6,735
Commitments and contingencies (Note 11)
Stockholders’ equity:    
Preferred stock, $0.0001; 162 shares authorized as of December 31, 2023 and 2022; no shares issued or outstanding at December 31, 2023 and 2022 0 0
Common stock, par value $0.0001; 1,600 shares authorized as of December 31, 2023 and 2022; 382 and 385 shares issued and outstanding as of December 31, 2023 and 2022, respectively 0 0
Additional paid-in capital 371 1,173
Accumulated other comprehensive loss (123) (370)
Retained earnings 13,606 18,320
Total stockholders’ equity 13,854 19,123
Total liabilities and stockholders’ equity $ 18,426 $ 25,858
XML 29 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock par value (in usd per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 162,000,000 162,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in usd per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 1,600,000,000 1,600,000,000
Common stock, shares issued (in shares) 382,000,000 385,000,000
Common stock, shares, outstanding (in shares) 382,000,000 385,000,000
XML 30 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue:      
Total revenue $ 6,848 $ 19,263 $ 18,471
Operating expenses:      
Cost of sales 4,693 5,416 2,617
Research and development 4,845 3,295 1,991
Selling, general and administrative 1,549 1,132 567
Total operating expenses 11,087 9,843 5,175
(Loss) income from operations (4,239) 9,420 13,296
Interest income 421 200 18
Other expense, net (124) (45) (29)
(Loss) income before income taxes (3,942) 9,575 13,285
Provision for income taxes 772 1,213 1,083
Net (loss) income $ (4,714) $ 8,362 $ 12,202
(Loss) earnings per share:      
Basic (in usd per share) $ (12.33) $ 21.26 $ 30.31
Diluted (in usd per share) $ (12.33) $ 20.12 $ 28.29
Weighted average common shares used in calculation of (loss) earnings per share:      
Basic (in shares) 382 394 403
Diluted (in shares) 382 416 431
Net product sales      
Revenue:      
Total revenue $ 6,671 $ 18,435 $ 17,675
Other revenue      
Revenue:      
Total revenue $ 177 $ 828 $ 796
XML 31 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Statement of Comprehensive Income [Abstract]      
Net (loss) income $ (4,714) $ 8,362 $ 12,202
Available-for-sale securities:      
Unrealized gains (losses) on available-for-sale debt securities 210 (348) (42)
Less: net realized losses (gains) on available-for-sale securities reclassified in net (loss) income 38 26 (1)
Net increase (decrease) from available-for-sale debt securities 248 (322) (43)
Cash flow hedges:      
Unrealized gains on derivative instruments 0 130 74
Less: net realized losses (gains) on derivative instruments reclassified in net (loss) income 8 (154) (58)
Net increase (decrease) from derivatives designated as hedging instruments 8 (24) 16
Pension and postretirement benefit plans:      
Pension and postretirement obligation adjustments (9) 0 0
Total other comprehensive income (loss) 247 (346) (27)
Comprehensive (loss) income $ (4,467) $ 8,016 $ 12,175
XML 32 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
shares in Thousands, $ in Millions
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive (Loss) Income
Retained Earnings (Accumulated Deficit)
Balance at beginning of period (in shares) at Dec. 31, 2020   399,000      
Balance at beginning of period at Dec. 31, 2020 $ 2,561 $ 0 $ 4,802 $ 3 $ (2,244)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of options to purchase common stock (in shares)   7,000      
Exercise of options to purchase common stock 112   112    
Issuance of common stock under employee stock purchase plan 12   12    
Stock-based compensation 142   142    
Other comprehensive (loss) income, net of tax (27)     (27)  
Repurchase of common stock (in shares)   (3,000)      
Repurchase of common stock (857)   (857)    
Net (loss) income 12,202       12,202
Balance at end of period (in shares) at Dec. 31, 2021   403,000      
Balance at end of period at Dec. 31, 2021 14,145 $ 0 4,211 (24) 9,958
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of options to purchase common stock (in shares)   4,000      
Exercise of options to purchase common stock 50   50    
Vesting of restricted common stock (in shares)   1,000      
Issuance of common stock under employee stock purchase plan 15   15    
Stock-based compensation 226   226    
Other comprehensive (loss) income, net of tax (346)     (346)  
Repurchase of common stock (in shares)   (23,000)      
Repurchase of common stock (3,329)   (3,329)    
Net (loss) income $ 8,362       8,362
Balance at end of period (in shares) at Dec. 31, 2022 385,000 385,000      
Balance at end of period at Dec. 31, 2022 $ 19,123 $ 0 1,173 (370) 18,320
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of options to purchase common stock (in shares) 3,110 4,000      
Exercise of options to purchase common stock $ 25   25    
Vesting of restricted common stock (in shares)   1,000      
Issuance of common stock under employee stock purchase plan 21   21    
Stock-based compensation 305   305    
Other comprehensive (loss) income, net of tax 247     247  
Repurchase of common stock, including excise tax (in shares)   (8,000)      
Repurchase of common stock, including excise tax (1,153)   (1,153)    
Net (loss) income $ (4,714)       (4,714)
Balance at end of period (in shares) at Dec. 31, 2023 382,000 382,000      
Balance at end of period at Dec. 31, 2023 $ 13,854 $ 0 $ 371 $ (123) $ 13,606
XML 33 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Operating activities      
Net (loss) income $ (4,714) $ 8,362 $ 12,202
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:      
Stock-based compensation 305 226 142
Depreciation and amortization 621 348 232
Amortization/accretion of investments (61) 31 54
Loss on equity investments, net 35 0 0
Deferred income taxes 828 (559) (318)
Other non-cash items 7 28 0
Changes in assets and liabilities, net of acquisition of business:      
Accounts receivable, net 493 1,790 (1,784)
Prepaid expenses and other assets 974 (1,699) (489)
Inventory 747 492 (1,394)
Right-of-use assets, operating leases (605) 21 (58)
Accounts payable 13 240 204
Accrued liabilities (340) 612 989
Deferred revenue (2,060) (4,157) 2,824
Income taxes payable 15 (828) 876
Operating lease liabilities 551 (14) 17
Other liabilities 73 88 123
Net cash (used in) provided by operating activities (3,118) 4,981 13,620
Investing activities      
Purchases of marketable securities (3,760) (11,435) (12,652)
Proceeds from maturities of marketable securities 5,575 3,151 1,338
Proceeds from sales of marketable securities 3,206 3,548 3,105
Purchases of property, plant and equipment (707) (400) (284)
Acquisition of business, net of cash acquired (85) 0 0
Investment in convertible notes and equity securities (23) (40) (30)
Net cash provided by (used in) investing activities 4,206 (5,176) (8,523)
Financing activities      
Proceeds from issuance of common stock through equity plans 46 65 124
Repurchase of common stock, including excise tax (1,153) (3,329) (857)
Changes in financing lease liabilities (270) (184) (140)
Net cash used in financing activities (1,377) (3,448) (873)
Net (decrease) increase in cash, cash equivalents and restricted cash (289) (3,643) 4,224
Cash, cash equivalents and restricted cash, beginning of year 3,217 6,860 2,636
Cash, cash equivalents and restricted cash, end of year 2,928 3,217 6,860
Supplemental cash flow information      
Cash (received) paid for income taxes (357) 2,729 480
Cash paid for interest 39 25 14
Non-cash investing and financing activities      
Purchases of property, plant and equipment included in accounts payable and accrued liabilities $ 130 $ 72 $ 111
XML 34 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
Description of the Business
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of the Business
1. Description of the Business

Moderna, Inc. (collectively, with its consolidated subsidiaries, any of Moderna, we, us, our or the Company) is a biotechnology company advancing a new class of medicines made of messenger RNA (mRNA). mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates. We are developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with our strategic collaborators.

Our COVID-19 vaccine is our first commercial product and is marketed, where approved, under the name Spikevax®. Our original vaccine, mRNA-1273, targeted the SARS-CoV-2 ancestral strain, and we have leveraged our mRNA platform to rapidly adapt our vaccine to emerging SARS-CoV-2 strains to provide protection as the virus evolves and regulatory guidance is updated.

We have a diverse and extensive development pipeline of 42 development candidates across our 45 development programs, of which 40 are in clinical studies currently.
XML 35 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
2. Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).

The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

Other revenue in the consolidated statements of operations comprises grant revenue and collaboration revenue that were previously presented as separate line items in our consolidated statements of operations in our 2022 Form 10-K. The associated prior period amounts in the consolidated financial statements, as well as in the notes thereto, have been reclassified to conform to the current presentation.

Use of Estimates

We have made estimates and judgments affecting the amounts reported in our consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods that are not readily apparent from other sources. Changes in our estimates are recorded in the financial results of the period in which the new information becomes available. The actual results that we experience may differ materially from our estimates.

Segment Information

We have determined that our chief executive officer is the chief operating decision maker (CODM). The CODM reviews financial information presented on a consolidated basis. Resource allocation decisions are made by the CODM based on consolidated results. There are no segment managers who are held accountable by the CODM for operations, operating results, and planning for levels or components below the consolidated unit level. As such, we have concluded that we operate as one segment.
Revenue Recognition

To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following five steps (the five-step model): (i) identify the contract(s) with our customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as each performance obligation is satisfied.

Net Product Sales

Prior to the third quarter of 2023, we sold our COVID-19 vaccine to the U.S. Government, foreign governments and organizations. The agreements and related amendments with these entities generally do not include variable consideration, such as discounts, rebates or returns. Certain of these agreements entitle us to upfront deposits for our COVID-19 vaccine supply, initially recorded as deferred revenue. In the third quarter of 2023, we commenced sales of our latest COVID-19 vaccine to the U.S. commercial market, in addition to continuing sales to international governments and organizations. In the U.S., our COVID-19 vaccine is sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Wholesalers and distributors typically do not make upfront payments to us.

We recognize net product sales when control of the product transfers to the customer, typically upon delivery. Payment terms generally range from 30 to 60 days, in line with customary practices in each country. Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns, and other related deductions. These provisions are recorded based on contractual terms and our estimate of returns for product sold during the period, using the expected value method or the most likely amount method. We update our estimates quarterly and record necessary adjustments in the period when we identify the adjustments. Product sales, net of provisions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable when the uncertainty associated with the provisions is subsequently resolved. Shipping and handling activities are considered fulfillment activities and not a separate performance obligation. Taxes assessed by governmental authorities that are imposed on and collected from our product sales are excluded from net product sales.

Wholesaler chargebacks, discounts and fees

We contract with retailers, healthcare providers, and group purchasing organizations (GPO) to broaden our customer reach and offer contractual discounts. The chargeback represents the difference between the invoice price billed to the wholesaler and the negotiated price charged to the retailers, healthcare providers and GPO members. For distribution and related services, such as stocking and cold chain storage, we provide compensation to our wholesalers and distributors. We typically offer our customers invoice discounts on product sales for prompt payments and pre-orders. The estimation of these discounts and fees is based on contractual terms and our expectations regarding future customer payment behaviors. Wholesaler fees and invoice discounts are deducted from our gross product sales and accounts receivable at the time such product sales are recognized.

Product returns

We typically offer customers in the U.S. the right to return products, up to a certain limit as stipulated in our contracts. Estimated returns for our COVID-19 vaccine are determined considering available return rates for similar products, estimated levels of inventory in the distribution channel, and projected market demand. The estimated amount for product returns is presented within accrued liabilities on our consolidated balance sheets and is deducted from our gross product sales in the period the related product sales are recognized.

Other fees

Fees payable to third party payers and healthcare providers, along with fees to our direct customers that are settled via cash payments, including certain patient assistance programs, are recorded as accrued liabilities on our consolidated balance sheets.

Determining the amount of variable consideration to recognize necessitates substantial judgment, especially when assessing factors outside our direct control such as lack of pertinent historical data and limited third-party information. Among all variables, estimating returns presents the most significant judgment due to the broad range of potential outcomes and the current lack of return history with our customers. As we receive more historical data on our product returns, we will integrate this information to refine our estimates and enhance the precision of our financial projections. The actual results could differ from our estimates, and such differences could have a material impact to our financial statements.
Other Revenue

Other revenue consists primarily of grant revenue and collaboration revenue.

Grant revenue

We have contracts with government-sponsored and private organizations for research and development related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs as well as a related profit margin. We recognize grant revenue from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized when incurred as research and development expense. Grant revenue and related expenses are presented gross in the consolidated statements of operations as we have determined we are the primary obligor under the arrangements relative to the research and development services we perform as lead technical expert.

Collaboration Revenue

We have entered into strategic collaborations and other similar arrangements with third parties for research and other licenses, development and commercialization of certain products and product candidates. Such arrangements provide for various types of payments to us, including upfront fees, funding of research and development services and preclinical and clinical material, technical, development, regulatory, and commercial milestone payments, licensing fees, option exercise fees, and royalty and earnout payments on product sales. Such payments are often not commensurate with the timing of revenue recognition and therefore result in deferral of revenue recognition. We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer.

Cash and Cash Equivalents

We consider all highly liquid investments with an original maturity of 90 days or less from the date of purchase to be cash equivalents.

Restricted Cash

Restricted cash is composed of amounts held on deposit related to our lease arrangements and funds held in an escrow account related to a business acquisition in 2023. The funds are maintained in money market accounts and are recorded at fair value. Restricted cash is classified as either current or non-current based on the terms of the underlying arrangement and is included in either prepaid expenses and other current assets or other non-current assets in our consolidated balance sheets.

Cash, Cash Equivalents and Restricted Cash shown in the Consolidated Statements of Cash Flows

The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):
December 31,
202320222021
Cash and cash equivalents $2,907 $3,205 $6,848 
Restricted cash(1)
17 — — 
Restricted cash, non-current(2)
4 12 12 
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows$2,928 $3,217 $6,860 
_______
(1)Included in prepaid expenses and other current assets in the consolidated balance sheets.
(2)Included in other non-current assets in the consolidated balance sheets.

Investments

We invest our excess cash balances in marketable debt securities. We classify our investments in marketable debt securities as available-for-sale. We report our available-for-sale securities at fair value at each balance sheet date, and include any unrealized holding gains and losses (the adjustment to fair value) in accumulated other comprehensive income (loss), a component of stockholders’ equity. Realized gains and losses are determined using the specific-identification method, and are included in other expense, net in our consolidated statements of operations. We classify our available-for-sale securities as current or non-current based on each instrument’s underlying effective maturity date and for which we have the intent and ability to hold the investment for a
period of greater than 12 months. Available-for-sale securities with maturities of less than 12 months are classified as current and are included in investments in the consolidated balance sheets. Available-for-sale securities with maturities greater than 12 months for which we have the intent and ability to hold the investment for greater than 12 months are classified as non-current and are included in investments, non-current in the consolidated balance sheets.

We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit- related is recognized in other comprehensive income (loss), net of applicable taxes.

Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in other expense, net, in our consolidated statements of operations. Investments in equity securities without readily determinable fair values are recorded at cost minus impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in other expense, net, in our consolidated statements of operations.

Accounts Receivable, net

Accounts receivable, net represent amounts due from customers less wholesalers chargebacks, discounts and fees (please refer to our “Revenue Recognition” policy within Note 2 for product sales provision) and allowance for expected credit losses. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. To estimate the allowance for credit losses, we determine the allowance based on ongoing credit evaluation, historical experience and the aging of such receivables, among other factors. There was no allowance for doubtful accounts at December 31, 2023 or 2022. Additionally, bad debt expenses were immaterial for the years ended December 31, 2023, 2022 and 2021.

Concentrations of Credit Risk

Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, marketable debt securities, and accounts receivable, net. Our investment portfolio comprises money market funds and marketable debt securities, including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities and commercial paper. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations. We invest in a variety of financial instruments and limit the amount of credit exposure with any individual financial institution. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. Our primary operating accounts significantly exceed the FDIC limits.

We are also subject to credit risk from our accounts receivable, net related to our net product sales and strategic alliances. We sell our products primarily to wholesalers and distributors and other governments and organizations. We do not require collateral or other security to support accounts receivable. To date, we have not experienced material losses with respect to the collection of our accounts receivable.

Significant Customers

Our accounts receivable, net are generally unsecured and are from customers in different countries. We generated revenue from product sales to wholesalers and distributors and other governments and organizations, and to a lesser extent, grants made by government-sponsored and private organizations, and collaboration revenue from our strategic alliances.
A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented:
Percentage of Revenue
Years Ended December 31,
Percentage of 
Accounts Receivable
December 31,
20232022202120232022
FFF Enterprises***39 %*
European Commission*28 %32 %*29 %
U.S. Government (excluding BARDA)*23 %29 %**
Takeda Pharmaceutical Company*10 %***
Ministry of Health, Labor, and Welfare of Japan21 %***30 %
UK Health Security Agency***35 %11 %
________
* - Represents an amount of less than 10%

Fair Value Measurements

Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. ASC 820 (Fair Value Measurement) establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from our independent sources. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities: 

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
•Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or
•Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Our cash equivalents and marketable debt securities are reported at fair value determined using Level 1 and Level 2 inputs (Note 6). The fair value of our foreign currency forward contracts is calculated using Level 2 inputs, which include currency spot rates, forward rates, interest rate curve and credit or non-performance risk. We do not have any non-financial assets or liabilities that should be recognized or disclosed at fair value on a recurring basis at December 31, 2023 and 2022.
Inventory

Inventory is recorded at the lower of cost or net realizable value, with cost determined using first-in, first-out and average cost methods for different components of inventory. We periodically review the composition of inventory in order to identify excess, obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, we will record a write-down to net realizable value in the period that the decline in value is first recognized through a charge to cost of sales. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. We also assess whether we have any excess firm, non-cancelable, purchase commitment liabilities, resulting from our supply agreements with third-party vendors, on a quarterly basis. The determination of net realizable value and firm purchase commitment liabilities requires judgment, including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions, potential product obsolescence, expiration and utilization of raw materials under firm purchase commitments and contractual minimums, among others. We hold raw materials beyond our one year forecasted production plan, which were classified as non-current and included in other non-current assets in our consolidated balance sheets.

Pre-launch Inventory

Costs relating to raw materials and production of inventory in preparation for product launch prior to regulatory approval are capitalized when future commercialization is considered probable, the future economic benefit is expected to be realized, and we believe that material uncertainties related to the ultimate regulatory approval have been significantly reduced. For pre-launch inventory that is capitalized, we consider a number of factors based on the information available at the time, including the product candidate’s current status in the drug development and regulatory approval process, results from the related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential impediments to the approval process such as product safety or efficacy, historical experience, viability of commercialization and market trends. As of December 31, 2023, we did not have any capitalized pre-launch inventory on our consolidated balance sheets.

Property, Plant and Equipment

Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of property, plant and equipment are described below:
Estimated Useful Life
Land and land improvementsNot depreciated
Manufacturing and laboratory equipment5 years
Leasehold improvements
Lesser of estimated useful life of improvement
or remaining life of related lease
Computer equipment and software
3 to 5 years
Furniture and fixtures5 years
Right-of-use asset, financingLease term

Construction in progress includes direct costs related to the construction of various property, plant and equipment, including leasehold improvements, and is stated at original cost. Once the asset is placed into service, these capitalized costs will be allocated to certain property, plant and equipment categories and will be depreciated over the estimated useful life of the underlying assets.

Acquisitions

We account for acquisitions either as business combinations or asset acquisitions, based on whether the set of assets acquired meets the definition of a business. When an acquisition is determined to be a business combination, we apply the acquisition method of accounting. This method requires that the assets acquired and liabilities assumed be recorded at their fair values as of the acquisition date on our consolidated balance sheets. Any excess of the consideration transferred over the fair value of the net identifiable assets acquired is recognized as goodwill. The process of determining the fair value of assets and liabilities involves significant estimates and assumptions. During the measurement period, which may extend up to one year from the acquisition date, we may record adjustments to these fair values. Any such adjustments are recorded with a corresponding change to goodwill. Transaction costs incurred in connection with business combinations are expensed as incurred.

On January 31, 2023, we completed a business combination by acquiring all outstanding shares of OriCiro Genomics K.K. for a cash consideration of $86 million. As a result of this acquisition, we recognized $52 million in goodwill and an intangible asset related to acquired technology valued at $48 million, which are included within other non-current assets in our consolidated balance sheets. This acquisition provided us with tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA
manufacturing. OriCiro’s technology strategically complements our manufacturing process and further accelerates our research and development efforts.

Goodwill and Intangible Assets

Goodwill represents the excess of purchase price over the fair value of net assets acquired and is carried at cost. Goodwill is tested at least annually for impairment by assessing qualitative factors in determining whether it is more likely than not that the fair value of net assets is below their carrying amounts. To date, an impairment of goodwill has not been recorded.

The fair value of acquired intangible assets is determined by applying the income-based approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. To estimate the expected cash flows attributable to an intangible asset, it requires the use of Level 3 fair value measurements and inputs. Finite-lived intangible assets are amortized on a straight-line basis over their estimated useful lives.

Impairment of Long-Lived Assets, including Intangibles and Lease Right-of-Use Assets

We evaluate our long-lived assets, which consist of property, plant and equipment, intangibles and right-of-use assets to determine if facts and circumstances indicate that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, we assess the recoverability of the long-lived assets by comparing the projected future undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. If such review indicates that such cash flows are not expected to be sufficient to recover the recorded value of the assets, the assets are written down to their estimated fair values based on the expected discounted future cash flows attributable to the assets or based on appraisals. Impairment expenses for the years ended December 31, 2023, 2022 and 2021 were immaterial.

Leases

Leases are classified at their commencement date, which is defined as the date on which the lessor makes the underlying asset available for use by the lessee, as either operating or finance leases based on the economic substance of the agreement. We recognize lease right-of-use assets and related liabilities in our consolidated balance sheets for both operating and finance leases. Lease liabilities are measured at the lease commencement date as the present value of the future lease payments using the interest rate implicit in the lease. If the rate implicit is not readily determinable, we will utilize our incremental borrowing rate as of the lease commencement date. Lease right-of-use assets are measured as the lease liability plus initial direct costs and prepaid lease payments less lease incentives. The lease term is the non-cancelable period of the lease and includes options to extend or terminate the lease when it is reasonably certain that an option will be exercised.

We recognize operating lease cost in operating expenses in our consolidated statements of operations, inclusive of rent escalation provisions and rent holidays, on a straight-line basis over the respective lease term. For our finance leases, we recognize depreciation expense associated with the leased asset acquired and recognize interest expense related to the portion of the financing in our consolidated statements of operations.

We do not separate non-lease components from lease components for all classes of underlying assets. We do not recognize right-of-use assets and lease liabilities for leases with a lease term of 12 months or less. Instead, these lease payments are recognized in the statements of operations on a straight-line basis over the lease term.

Collaboration Arrangements

We analyze our collaboration arrangements to assess whether they are within the scope of ASC 808 (Collaborative Arrangements) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, we assess whether aspects of the arrangement between us and our collaboration partner are within the scope of other accounting literature. If we conclude that some or all aspects of the arrangement represent a transaction with a customer, we account for those aspects of the arrangement within the scope of ASC 606 (Revenue from Contracts with Customers). Please refer to our "Revenue Recognition" policy within Note 2 for additional discussion of revenue recognition under these types of arrangements. If we conclude that some or all aspects of the arrangement are within the scope of ASC 808 and do not represent a transaction with a customer, we recognize our allocation of the shared costs incurred with respect to the jointly conducted activities as a component of the related expense in the period incurred. Additionally, for any payments related to capital expenditures that are partially reimbursed by a collaboration partner, to the extent the underlying capital costs qualify for capitalization, any reimbursements received will offset the capitalized cost of the asset.
Research and Development Costs

Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, overhead costs, contract services, and other outside costs. The value of goods and services received from contract research organizations and contract manufacturing organizations in the reporting period are estimated based on the level of services performed, and progress in the period in cases when we have not received an invoice from the supplier. Research and development costs also include costs and shared cost associated with third-party collaboration arrangements, including upfront fees and milestones paid to third-parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use.

Assets that are acquired or constructed for research and development activities and that have alternative future uses, in research and development projects or otherwise, are capitalized and depreciated over their useful lives. However, the costs of equipment or facilities that are acquired or constructed and intangibles that are purchased from others for a particular research and development project, and that have no alternative future uses and therefore no separate economic values, are considered research and development costs and expensed when incurred.

Advertising Costs

Costs associated with advertising are expensed as incurred and are included in selling, general and administrative expense in the consolidated statements of operations. Advertising expenses were $204 million in 2023, $121 million in 2022, and immaterial in 2021.

Stock-Based Compensation

We issue stock-based awards to employees and non-employees, generally in the form of stock options, restricted stock units (RSUs), and performance stock units (PSUs). We account for our stock-based compensation awards in accordance with ASC 718 (Compensation—Stock Compensation). Most of our stock-based awards have been made to employees. We measure compensation cost for equity awards at their grant-date fair value and recognize compensation expense over the requisite service period, which is generally the vesting period, on a straight-line basis. The grant date fair value of stock options is estimated using the Black-Scholes option pricing model, which requires management to make assumptions with respect to the fair value of our common stock on the grant date, including the expected term of the award, the expected volatility of our stock, calculated based on a period of time generally commensurate with the expected term of the award, risk-free interest rates and expected dividend yields of our stock. We estimate the expected term of our stock options granted to employees and non-employees using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. We utilize this method as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term, and because significant changes in our business over the past few years have rendered historical experience less relevant. The expected volatility is based on a blended average of average historical stock volatilities of selected guideline companies over the expected term of the stock options, historical volatility of our stock price, and implied stock price volatility derived from the price of exchange traded options on our stock. Given the transformative changes in our business, we believe that a blended volatility rate is more indicative of future volatility than our historical volatility alone. We will continue to apply this process until a sufficient amount of historical information regarding the expected term and historical volatility of our own stock price becomes available, and until we believe that historical experience is relevant to our expectations for current grants. The grant date fair value of RSUs is estimated based on the fair value of our underlying common stock. For performance-based stock awards, we recognize stock-based compensation expense over the requisite service period using the accelerated attribution method when achievement is probable. We classify stock-based compensation expense in our consolidated statements of operations in the same manner in which the award recipient’s salary and related costs are classified or in which the award recipient’s service payments are classified. We made an accounting policy election to recognize forfeitures of stock-based awards as they occur.

Income Taxes

We account for income taxes based on an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a “more likely than not” criterion. We periodically reassess the need for valuation allowances on our deferred tax assets, considering both positive and negative evidence to evaluate whether it is more likely than not that all or a portion of such assets will not be realized. We make estimates and judgments about our future taxable income that are based on assumptions that are consistent with our plans and estimates. Should the actual amounts differ from our estimates, the amount of our valuation allowance could be materially impacted. Changes in these estimates may result in significant increases or decreases to our tax provision in a period in which such estimates are changed, which in turn would affect net income or loss. We recognize tax benefits from uncertain tax positions if we believe the position is more likely than not to be sustained on examination by the taxing authorities based on the technical merits of the position. We make adjustments
to these tax reserves when facts and circumstances change, such as the closing of a tax audit or the refinement of an estimate. The provision for income taxes includes the effects of any reserves for uncertain tax positions, as well as the related net interest and penalties.

Earnings (Loss) per Share

We calculate diluted net earnings (loss) per share attributable to common stockholders by dividing net earnings (loss) by the weighted average number of common shares outstanding after giving consideration to the dilutive effect of restricted common stock and stock options that are outstanding during the period. For periods in which we have generated a net loss, the basic and diluted net loss per share attributable to common stockholders are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.

Comprehensive Income (Loss)

Comprehensive income (loss) includes net income (loss) and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains and losses on our investments and derivatives designated as hedging instruments. Total comprehensive income (loss) for all periods presented has been disclosed in the consolidated statements of comprehensive income (loss).

The components of accumulated other comprehensive loss for the years ended December 31, 2023 and 2022 were as follows (in millions): 
Unrealized (Loss) Gain on Available-for-Sale Securities
Net Unrealized Gain (Loss) on Derivatives Designated As Hedging Instruments
Pension and Postretirement Benefits
Total
Accumulated other comprehensive loss, balance at December 31, 2021$(40)$16 $— $(24)
Other comprehensive loss(322)(24)— (346)
Accumulated other comprehensive loss, balance at December 31, 2022(362)(8)— (370)
Other comprehensive income (loss)248 8 (9)247 
Accumulated other comprehensive loss, balance at December 31, 2023$(114)$— $(9)$(123)

Share Repurchases

Shares of our common stock repurchased pursuant to our repurchase programs are retired. The purchase price of such repurchased shares of common stock is recorded as a reduction to additional paid-in-capital. If the balance in additional paid-in-capital is exhausted, the excess is recorded as a reduction to retained earnings.

Recently Issued Accounting Standards Not Yet Adopted

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Except as noted below, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU broadens the disclosure requirements by requiring disclosures of significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit or loss. The standard also requires entities to disclose, on an interim and annual basis, the amount and description, including the nature and type, of the other segment items. Additionally, entities are required to disclose the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. These enhanced disclosure obligations apply to entities that operate with one reportable segment as well. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. Early adoption is permitted. We are currently assessing the impact that this new accounting standard will have on our consolidated financial statements and disclosures.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. The standard requires entities to disclose federal, state, and foreign income taxes in their rate reconciliation tables
and elaborate on reconciling items that exceed a quantitative threshold. Additionally, it requires an annual disclosure of income taxes paid, net of refunds, categorized by jurisdiction based on a quantitative threshold. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in our consolidated financial statements, once adopted.
XML 36 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
Net Product Sales
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Net Product Sales
3. Net Product Sales

Net product sales by customer geographic location were as follows for the periods presented (in millions):
Years Ended December 31,
202320222021
United States$1,720 $4,405 $5,393 
Europe1,353 6,732 6,834 
Rest of world
3,598 7,298 5,448 
Total $6,671 $18,435 $17,675 

As of December 31, 2023, 2022 and 2021, our COVID-19 vaccine was our only commercial product authorized for use.

Prior to the third quarter of 2023, we sold our COVID-19 vaccine to the U.S. Government, foreign governments and organizations. The agreements and related amendments with these entities generally do not include variable consideration, such as discounts, rebates or returns. Certain of these agreements entitle us to upfront deposits for our COVID-19 vaccine supply, initially recorded as deferred revenue.

As of December 31, 2023 and 2022, we had deferred revenue of $613 million and $2.6 billion, respectively, related to customer deposits. We expect $554 million of our deferred revenue related to customer deposits as of December 31, 2023 to be realized in less than one year. Timing of product delivery and manufacturing, and receipt of marketing approval for the applicable COVID-19 vaccine will determine the period in which net product sales are recognized.

In the third quarter of 2023, we commenced sales of our latest COVID-19 vaccine to the U.S. commercial market, in addition to continuing sales to foreign governments and organizations. In the U.S., our COVID-19 vaccine is sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Wholesalers and distributors typically do not make upfront payments to us.

Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns, and other related deductions.

The following table summarizes product sales provision for the periods presented (in millions):
Years Ended December 31,
202320222021
Gross product sales $8,203 $18,435 $17,675 
Product sales provision:
Wholesaler chargebacks, discounts and fees
(976)— — 
Returns and other fees(556)— — 
Total product sales provision
$(1,532)$— $— 
Net product sales $6,671 $18,435 $17,675 

The following table summarizes the activities related to product sales provision recorded as accrued liabilities for the year ended December 31, 2023 (in millions):
Returns and other fees
Balance at December 31, 2022$— 
Provision related to sales made in current period(556)
Balance at December 31, 2023$(556)
4. Other Revenue

The following table summarizes other revenue for the periods presented (in millions):
Years Ended December 31,
202320222021
Grant revenue$94 $388 $735 
Collaboration revenue83 440 61 
Total other revenue$177 $828 $796 

Grant Revenue

In April 2020, we entered into an agreement with Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for an award of up to $483 million to accelerate development of mRNA-1273, our original vaccine candidate against COVID-19. The agreement has been subsequently amended to provide for additional commitments to support various late-stage clinical development efforts of mRNA-1273, including a 30,000 participant Phase 3 study, pediatric clinical trials, adolescent clinical trials and pharmacovigilance studies. The maximum award from BARDA, inclusive of all amendments, was approximately $1.8 billion. All contract options have been exercised. As of December 31, 2023, the remaining available funding, net of revenue earned was $97 million.
The following table summarizes grant revenue for the periods presented (in millions):
Years Ended December 31,
202320222021
BARDA$88 $372 $713 
Other grant revenue6 16 22 
Total grant revenue$94 $388 $735 

Collaboration Revenue

We have entered into collaboration agreements with strategic collaborators to accelerate the discovery and advancement of potential mRNA medicines across therapeutic areas. As of December 31, 2023, 2022 and 2021, we had collaboration agreements with Merck & Co., Inc (Merck), Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, Vertex), AstraZeneca plc (AstraZeneca) and others. Please refer to Note 5 to for further description of these collaboration agreements.

The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):
Years Ended December 31,
Collaboration Revenue by Strategic Collaborator:202320222021
Vertex$82 $48 $26 
Merck— 309 23 
AstraZeneca— 80 7 
Other1 3 5 
Total collaboration revenue$83 $440 $61 
15. Geographic Information

Geographic Revenue

We operate in one reporting segment that primarily focuses on the discovery, development and commercialization of mRNA medicines. Our chief executive officer manages our operations and evaluates our financial performance on a consolidated basis. Most of our principal operations, other than manufacturing, and our decision-making functions are located at our corporate headquarters in the United States.

Total revenue by geographic area of our customers and collaboration partners was as follows (in millions):
Years Ended December 31,
202320222021
United States$1,895 $5,150 $6,177 
Europe1,355 6,815 6,846 
Rest of world
3,598 7,298 5,448 
Total $6,848 $19,263 $18,471 

Our property, plant and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):
December 31,
20232022
United States$1,560 $1,267 
Europe126 714 
Rest of world259 37 
Total$1,945 $2,018 
XML 37 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
Other Revenue
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Other Revenue
3. Net Product Sales

Net product sales by customer geographic location were as follows for the periods presented (in millions):
Years Ended December 31,
202320222021
United States$1,720 $4,405 $5,393 
Europe1,353 6,732 6,834 
Rest of world
3,598 7,298 5,448 
Total $6,671 $18,435 $17,675 

As of December 31, 2023, 2022 and 2021, our COVID-19 vaccine was our only commercial product authorized for use.

Prior to the third quarter of 2023, we sold our COVID-19 vaccine to the U.S. Government, foreign governments and organizations. The agreements and related amendments with these entities generally do not include variable consideration, such as discounts, rebates or returns. Certain of these agreements entitle us to upfront deposits for our COVID-19 vaccine supply, initially recorded as deferred revenue.

As of December 31, 2023 and 2022, we had deferred revenue of $613 million and $2.6 billion, respectively, related to customer deposits. We expect $554 million of our deferred revenue related to customer deposits as of December 31, 2023 to be realized in less than one year. Timing of product delivery and manufacturing, and receipt of marketing approval for the applicable COVID-19 vaccine will determine the period in which net product sales are recognized.

In the third quarter of 2023, we commenced sales of our latest COVID-19 vaccine to the U.S. commercial market, in addition to continuing sales to foreign governments and organizations. In the U.S., our COVID-19 vaccine is sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Wholesalers and distributors typically do not make upfront payments to us.

Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns, and other related deductions.

The following table summarizes product sales provision for the periods presented (in millions):
Years Ended December 31,
202320222021
Gross product sales $8,203 $18,435 $17,675 
Product sales provision:
Wholesaler chargebacks, discounts and fees
(976)— — 
Returns and other fees(556)— — 
Total product sales provision
$(1,532)$— $— 
Net product sales $6,671 $18,435 $17,675 

The following table summarizes the activities related to product sales provision recorded as accrued liabilities for the year ended December 31, 2023 (in millions):
Returns and other fees
Balance at December 31, 2022$— 
Provision related to sales made in current period(556)
Balance at December 31, 2023$(556)
4. Other Revenue

The following table summarizes other revenue for the periods presented (in millions):
Years Ended December 31,
202320222021
Grant revenue$94 $388 $735 
Collaboration revenue83 440 61 
Total other revenue$177 $828 $796 

Grant Revenue

In April 2020, we entered into an agreement with Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for an award of up to $483 million to accelerate development of mRNA-1273, our original vaccine candidate against COVID-19. The agreement has been subsequently amended to provide for additional commitments to support various late-stage clinical development efforts of mRNA-1273, including a 30,000 participant Phase 3 study, pediatric clinical trials, adolescent clinical trials and pharmacovigilance studies. The maximum award from BARDA, inclusive of all amendments, was approximately $1.8 billion. All contract options have been exercised. As of December 31, 2023, the remaining available funding, net of revenue earned was $97 million.
The following table summarizes grant revenue for the periods presented (in millions):
Years Ended December 31,
202320222021
BARDA$88 $372 $713 
Other grant revenue6 16 22 
Total grant revenue$94 $388 $735 

Collaboration Revenue

We have entered into collaboration agreements with strategic collaborators to accelerate the discovery and advancement of potential mRNA medicines across therapeutic areas. As of December 31, 2023, 2022 and 2021, we had collaboration agreements with Merck & Co., Inc (Merck), Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, Vertex), AstraZeneca plc (AstraZeneca) and others. Please refer to Note 5 to for further description of these collaboration agreements.

The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):
Years Ended December 31,
Collaboration Revenue by Strategic Collaborator:202320222021
Vertex$82 $48 $26 
Merck— 309 23 
AstraZeneca— 80 7 
Other1 3 5 
Total collaboration revenue$83 $440 $61 
15. Geographic Information

Geographic Revenue

We operate in one reporting segment that primarily focuses on the discovery, development and commercialization of mRNA medicines. Our chief executive officer manages our operations and evaluates our financial performance on a consolidated basis. Most of our principal operations, other than manufacturing, and our decision-making functions are located at our corporate headquarters in the United States.

Total revenue by geographic area of our customers and collaboration partners was as follows (in millions):
Years Ended December 31,
202320222021
United States$1,895 $5,150 $6,177 
Europe1,355 6,815 6,846 
Rest of world
3,598 7,298 5,448 
Total $6,848 $19,263 $18,471 

Our property, plant and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):
December 31,
20232022
United States$1,560 $1,267 
Europe126 714 
Rest of world259 37 
Total$1,945 $2,018 
XML 38 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaboration Agreements
 12 Months Ended
Dec. 31, 2023
Research and Development [Abstract]  
Collaboration Agreements
5. Collaboration Agreements

Merck – Personalized mRNA Cancer Vaccines (Individualized Neoantigen Therapy)

In June 2016, we entered into a Collaboration and License Agreement for the development and commercialization of personalized mRNA cancer vaccines (also known as individualized neoantigen therapy (INT)) with Merck, to develop and commercialize INTs for individual patients using our mRNA and formulation technology. This agreement was subsequently amended and restated in 2018 (INT Agreement). Our role in this strategic alliance involves identifying genetic mutations in a particular patient’s tumor cells, synthesizing mRNA for these mutations, encapsulating the mRNA in one of our proprietary lipid nanoparticles (LNPs), and administering a unique mRNA INT to each patient. Each INT is designed to specifically activate the patient’s immune system against her or his own cancer cells.

Pursuant to the INT Agreement, we received an upfront payment of $200 million from Merck and we were responsible for designing and researching INTs, providing manufacturing capacity and manufacturing INTs and conducting Phase 1 and Phase 2 clinical trials for INTs, alone and in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, all in accordance with an agreed upon development plan and budget. We concluded that the collaboration arrangement was governed by the revenue recognition standard ASC 606.

In September 2022, Merck exercised its option for INT, including mRNA-4157, pursuant to the terms of the agreement and in October 2022 paid us an option exercise fee of $250 million. Pursuant to the agreement, we and Merck have agreed to collaborate on further development and commercialization of INT, with costs and any profits or losses to be shared equally on a worldwide basis. We concluded that the collaboration arrangement under the Merck Participation Term is within the scope of ASC 808. For the years ended December 31, 2023 and 2022, we recognized expense of $184 million and $6 million, net of Merck's reimbursements, related to the INT collaboration under the Merck Participation Term. Additionally, the net cost recovery for capital expenditures during the same periods were $102 million and $3 million, respectively, which were applied to reduce the capitalized cost of the asset.

Vertex – Strategic Alliance in Cystic Fibrosis

2016 Strategic Alliance in Cystic Fibrosis

In July 2016, we entered into a Strategic Collaboration and License Agreement (Vertex Agreement), with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited, together, Vertex. The Vertex Agreement, which was amended in July 2019 (2019 Vertex Amendment), is aimed at the discovery and development of potential mRNA medicines for the treatment of cystic fibrosis (CF) by enabling cells in the lungs of people with CF to produce functional cystic fibrosis transmembrane conductance regulator (CFTR) proteins. Pursuant to the Vertex Agreement, we lead discovery efforts during an initial research period, leveraging our platform technology and mRNA delivery expertise along with Vertex’s scientific experience in CF biology and the functional understanding of CFTR. Vertex is responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Subject to customary “back-up” supply rights granted to Vertex, we exclusively manufacture (or have manufactured) mRNA for preclinical, clinical and commercialization purposes. This collaboration arrangement is accounted for under ASC 606 and currently ongoing.

2020 Strategic Alliance in Cystic Fibrosis

In September 2020, we entered into a Strategic Collaboration and License Agreement with Vertex (Vertex 2020 Agreement). The Vertex 2020 Agreement was aimed at the discovery and development of potential medicines to treat CF by delivering gene-editing therapies to lung cells to facilitate production of functional CFTR proteins. The three-year research period of the Vertex 2020 Agreement was initially focus on the identification and optimization of novel LNPs and mRNAs that can deliver gene-editing therapies to cells in the lungs. Following the initial three-year period, Vertex was responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Vertex was also obligated to pay us for research services in connection with our performance of certain activities in accordance with a jointly agreed research plan. This collaboration was concluded and terminated in the fourth quarter of 2023 in accordance with the terms of the Vertex 2020 Agreement.

AstraZeneca – Strategic Alliances in Cardiovascular and Oncology

We entered into collaboration agreements with AstraZeneca in 2013 and 2016, aimed at developing mRNA medicines for treatments in cardiovascular, cardiometabolic diseases, and cancer. These agreements provided AstraZeneca with exclusive development and commercialization rights for specific programs, including the VEGF-A product AZD8601 and an immuno-oncology program for IL-12, with upfront payments to us totaling $240 million.
In the third quarter of 2022, AstraZeneca terminated our collaborations with them, including the development of VEGF-A and IL-12 programs, for which termination became effective on November 21, 2022. All rights to these two programs reverted to us. As a result of the termination, we recognized the remaining deferred revenue of $76 million as collaboration revenue in the period.

Immatics – Strategic Multi-Platform Collaboration to Develop Oncology Therapeutics

In September 2023, we entered into a strategic research and development collaboration agreement with Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies. We will lead the clinical development and commercialization of cancer vaccines and TCER® therapeutics resulting from the collaboration. Immatics will be responsible for conducting the preclinical studies and a potential Phase 1 clinical trial investigating IMA203 TCR-T in combination with the PRAME mRNA vaccine to further enhance IMA203 T cell responses. Each party will retain full ownership of its investigational PRAME compound, and the parties will fund the clinical study on a cost sharing basis.

Upon effectiveness of the agreement in October 2023, we made an upfront payment of $120 million to Immatics. The payment was recognized as research and development expense in the same period. Immatics will also receive research funding and is eligible to receive development, regulatory, and commercial milestone payments. Immatics is also eligible to receive tiered royalties on global net sales of TCER® products and certain vaccine products that are commercialized under the agreement. Under the agreement, Immatics has an option to enter into a global profit and loss share arrangement for the most advanced TCER®.
In addition to the collaborative arrangements mentioned above, we have other collaborative and licensing arrangements that we do not consider to be individually significant to our business at this time. Pursuant to these agreements, we may be required to make upfront payments and payments upon achievement of various development, regulatory and commercial milestones, which in the aggregate could be significant. Future milestone payments, if any, will be reflected in our consolidated financial statements when the corresponding events become probable. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized.
XML 39 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
Financial Instruments and Fair Value Measurements
 12 Months Ended
Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]  
Financial Instruments and Fair Value Measurements
6. Financial Instruments and Fair Value Measurements
Cash and Cash Equivalents and Investments

The following tables summarize our cash and available-for-sale securities by significant investment category at December 31, 2023 and 2022 (in millions):
December 31, 2023
Amortized
Cost
Unrealized
Gains
Unrealized
Losses
Fair Value
Cash and
Cash
Equivalents
Current
Marketable
Securities
Non-
Current
Marketable
Securities
Cash and cash equivalents$2,907 $— $— $2,907 $2,907 $— $— 
Available-for-sale:
Certificates of deposit27 — — 27 — 27 — 
U.S. treasury bills807 — — 807 — 807 — 
U.S. treasury notes4,407 3 (67)4,343 — 2,664 1,679 
Corporate debt securities5,067 3 (81)4,989 — 2,082 2,907 
Government debt securities211 — (3)208 — 117 91 
Total$13,426 $6 $(151)$13,281 $2,907 $5,697 $4,677 
December 31, 2022
Amortized
Cost
Unrealized
Gains
Unrealized
Losses
Fair Value
Cash and
Cash
Equivalents
Current
Marketable
Securities
Non-
Current
Marketable
Securities
Cash and cash equivalents$3,205 $— $— $3,205 $3,205 $— $— 
Available-for-sale:
Certificates of deposit188 — — 188 — 188 — 
U.S. treasury bills767 — — 767 — 767 — 
U.S. treasury notes7,781 — (229)7,552 — 4,182 3,370 
Corporate debt securities6,595 — (226)6,369 — 1,560 4,809 
Government debt securities148 — (9)139 — — 139 
Total$18,684 $— $(464)$18,220 $3,205 $6,697 $8,318 
The amortized cost and estimated fair value of available-for-sale securities, by contractual maturity at December 31, 2023 and 2022 were as follows (in millions):
December 31, 2023
Amortized
Cost
Estimated
Fair Value
Due in one year or less
$5,751 $5,697 
Due after one year through five years
4,768 4,677 
Total$10,519 $10,374 
December 31, 2022
Amortized
Cost
Estimated
Fair Value
Due in one year or less$6,792 $6,697 
Due after one year through five years8,687 8,318 
Total$15,479 $15,015 

In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for impairment at the end of each reporting period. We did not record any impairment charges related to our available-for-sale securities during the years ended December 31, 2023, 2022, and 2021. We did not recognize any credit-related allowance to available-for-sale securities as of December 31, 2023 and 2022.

The following table summarizes the amount of gross unrealized losses and the estimated fair value for our available-for-sale securities in an unrealized loss position by length of time the securities have been in an unrealized loss position at December 31, 2023 and 2022 (in millions):
Less than 12 Months12 Months or MoreTotal
Gross Unrealized LossesEstimated Fair ValueGross Unrealized LossesEstimated Fair ValueGross Unrealized LossesEstimated Fair Value
As of December 31, 2023:
U.S. treasury bills$— $25 $— $— $— $25 
U.S. treasury notes(3)774 (64)2,983 (67)3,757 
Corporate debt securities(1)562 (79)3,518 (80)4,080 
Government debt securities— 8 (4)143 (4)151 
Total$(4)$1,369 $(147)$6,644 $(151)$8,013 
As of December 31, 2022:
U.S. treasury securities$— $128 $— $— $— $128 
U.S. treasury notes(101)3,956 (128)3,541 (229)7,497 
Corporate debt securities(138)3,505 (88)1,890 (226)5,395 
Government debt securities(2)46 (7)93 (9)139 
Total$(241)$7,635 $(223)$5,524 $(464)$13,159 

At December 31, 2023 and 2022, we held 392 and 582 available-for-sale securities, respectively, out of our total investment portfolio that were in a continuous unrealized loss position. We neither intend to sell these investments nor conclude that we are more-likely-than-not that we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following tables summarize our financial assets measured at fair value on a recurring basis as of December 31, 2023 and 2022 (in millions):
Fair value at December 31, 2023Fair Value Measurement Using
Level 1Level 2
Assets:
Money market funds$1,572 $1,572 $— 
Certificates of deposit27 — 27 
U.S. treasury bills1,246 — 1,246 
U.S. treasury notes4,343 — 4,343 
Corporate debt securities5,480 — 5,480 
Government debt securities208 — 208 
Equity investments(1)
24 24 — 
Derivative instruments4 — 4 
Total$12,904 $1,596 $11,308 
Liabilities:
Derivative instruments
$9 $— $9 
Fair value at December 31, 2022Fair Value Measurement Using
Level 1Level 2
Assets:
Money market funds$1,079 $1,079 $— 
Certificates of deposit188 — 188 
U.S. treasury bills767 — 767 
U.S. treasury notes7,552 — 7,552 
Corporate debt securities6,369 — 6,369 
Government debt securities139 — 139 
Derivative instruments
6 — 6 
Total$16,100 $1,079 $15,021 
Liabilities:
Derivative instruments
$32 $— $32 
_______
(1)Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in other expense net, in our consolidated statements of operations.

As of December 31, 2023 and 2022, we did not have non-financial assets or liabilities measured at fair value on a recurring basis.

For the year ended December 31, 2023, we recognized net losses of $35 million on equity investments from changes in fair value of the securities. We did not have equity investments in publicly traded securities with readily determinable fair values during 2022 and 2021.

In addition, as of December 31, 2023 and 2022, we had $42 million, at each balance sheet date, in equity investments without readily determinable fair values, which are recorded within other non-current assets in our consolidated balance sheets and excluded from the fair value measurement tables above.
XML 40 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
Inventory
 12 Months Ended
Dec. 31, 2023
Inventory Disclosure [Abstract]  
Inventory
7. Inventory

Inventory, as of December 31, 2023 and 2022 consisted of the following (in millions):
December 31,
20232022
Raw materials$163 $575 
Work in progress 15 205 
Finished goods24 169 
Total inventory$202 $949 
Inventory, non-current(1)
$170 $910 
_______
(1)Consisted of raw materials with an anticipated consumption beyond one year. Inventory, non-current is included in other non-current assets in the consolidated balance sheets.

Inventory write-downs as a result of excess, obsolescence, scrap or other reasons, and losses on firm purchase commitments are recorded as a component of cost of sales in our consolidated statements of operations. For the years ended December 31, 2023 and 2022, inventory write-downs were $2.2 billion and $1.3 billion, respectively. Inventory write-downs were immaterial for the year ended December 31, 2021. For the years ended December 31, 2023 and 2022, losses on firm purchase commitments were $141 million and $617 million, respectively. There were no such charges in 2021. Inventory write-downs were mainly related to obsolete inventory due to shelf-life expiration and inventory in excess of expected demand. Losses on firm purchase commitments were primarily related to excess raw material purchase commitments that will expire before the anticipated consumption of those raw materials. These charges in 2023 were primarily driven by a continued shift in product demand to the latest variant-targeted COVID-19 vaccine and a decline in customer demand as the COVID-19 vaccine market continues to transition to an endemic seasonal market in 2023.

In the third quarter of 2023, we completed our long-range financial planning process, incorporating revised forecasts of vaccination rates. This resulted in the reassessment of future demand for our COVID-19 vaccine, leading to a strategic initiative to resize our manufacturing cost structure. This initiative, launched in the same quarter, involved reassessing our inventory levels and renegotiating with our suppliers to reduce our purchase commitments related to raw materials which were not expected to be consumed before expiration. This initiative resulted in a raw materials write-down of $903 million, included in the total inventory write-down amount for the quarter.

As of December 31, 2023 and December 31, 2022, the accrued liability for losses on firm future purchase commitments in our consolidated balance sheets was $79 million and $268 million, respectively. As of December 31, 2023 and December 31, 2022, we had inventory on hand of $372 million and $1.9 billion, respectively. Our raw materials and work-in-progress inventory had variable shelf lives. We expect that the majority of this inventory will be consumed over the next three years. The shelf life of our COVID-19 vaccine product ranges from nine to twelve months.
XML 41 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
Property, Plant and Equipment, Net
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment, Net
8. Property, Plant and Equipment, Net

Property, plant and equipment, net as of December 31, 2023 and 2022 consisted of the following (in millions):
December 31,
20232022
Land and land improvements$22 $11 
Manufacturing and laboratory equipment345 284 
Leasehold improvements522 460 
Furniture and fixtures26 21 
Computer equipment and software
74 38 
Construction in progress
860 281 
Right-of-use assets, financing (Note 10)
529 1,581 
Total
2,378 2,676 
Less: Accumulated depreciation
(433)(658)
Property, plant and equipment, net$1,945 $2,018 

Depreciation and amortization expense for the years ended December 31, 2023, 2022, and 2021 was $617 million, $348 million, and $232 million, respectively.
XML 42 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
Other Balance Sheet Components
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Other Balance Sheet Components
9. Other Balance Sheet Components

Accounts Receivable, Net

Accounts receivable, net, as of December 31, 2023 and December 31, 2022 consisted of the following (in millions):
December 31,
20232022
Accounts receivable$1,584 $1,385 
Less: Wholesalers chargebacks, discounts and fees
(692)— 
Accounts receivable, net$892 $1,385 

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets, as of December 31, 2023 and 2022 consisted of the following (in millions):
December 31,
20232022
Prepaid services$182 $216 
Down payments to manufacturing vendors100 229 
Down payments for materials and supplies68 219 
Collaboration receivable61 11 
Interest receivable59 61 
Value added tax receivable50 140 
Income tax receivable19 10 
Tenant improvement allowance receivable— 42 
Prepaid income taxes— 187 
Convertible note receivable— 36 
Other current assets88 44 
Prepaid expenses and other current assets
$627 $1,195 
Other Non-Current Assets

Other non-current assets, as of December 31, 2023 and 2022 consisted of the following (in millions):
December 31,
20232022
Down payments and prepayments, non-current
$342 $— 
Inventory, non-current(1)
170 910 
Equity investments66 42 
Goodwill
52 — 
Finite-lived intangible asset
44 — 
Restricted cash4 12 
Other7 24 
Other non-current assets$685 $988 
_______
(1)Consisted of raw materials with an anticipated consumption beyond one year.

Accrued Liabilities

Accrued liabilities, as of December 31, 2023 and 2022 consisted of the following (in millions):
December 31,
20232022
Provisions related to product sales (Note 3)
$556 $— 
Compensation-related245 190 
Clinical trials175 319 
Manufacturing167 400 
Development operations140 88 
Other external goods and services137 264 
Royalties122 203 
Property, plant and equipment94 5 
Loss on future firm purchase commitments(1)
79 268 
Commercial56 48 
Raw materials27 316 
Accrued liabilities$1,798 $2,101 
______
(1)Related to losses that are expected to arise from firm, non-cancellable, commitments for future raw material purchases (Note 7).

Other Current Liabilities

Other current liabilities, as of December 31, 2023 and 2022 consisted of the following (in millions):
December 31,
20232022
Lease liabilities - financing (Note 10)
$— $161 
Lease liabilities - operating (Note 10)
25 35 
Other41 53 
Other current liabilities$66 $249 
Deferred Revenue

The following table summarizes the activities in deferred revenue during the year ended December 31, 2023 (in millions):
December 31, 2022AdditionsDeductionsDecember 31, 2023
Net product sales
$2,626 $515 $(2,528)$613 
Grant revenue4 2 (2)4 
Collaboration revenue81 31 (78)34 
Total deferred revenue$2,711 $548 $(2,608)$651 
XML 43 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases
 12 Months Ended
Dec. 31, 2023
Leases [Abstract]  
Leases
10. Leases

We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2042. Certain of these arrangements have free rent periods or escalating rent payment provisions. We recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have two main campuses in Massachusetts, our Cambridge campus and our Moderna Technology Center (MTC), located in Norwood. We also lease various parcels of land, office and lab spaces across the globe for our business operations.

Cambridge Campus

We occupy a multi-building campus at Technology Square in Cambridge, Massachusetts with a mix of offices and research laboratory space totaling approximately 292,000 square feet.

In September 2021, we entered into a lease agreement for a building space, approximately 462,000 square feet, in Cambridge, Massachusetts. This space is designated to be the Moderna Science Center (MSC), housing a blend of office space and laboratories. Following an approximately two-year building project, the lease term is 15 years, with options for two additional seven-year extensions. During the third quarter of 2023, we commenced the lease and recognized the related right-of-use asset and lease liability on our consolidated balance sheets. Following the commencement of the MSC lease, we amended the expiration dates of our existing leases at Technology Square in the fourth quarter of 2023. Originally scheduled to expire ranging from 2024 to 2029, these leases have been adjusted to conclude in early 2025. All our Cambridge leases are classified as operating leases.

Moderna Technology Center

We have an industrial technology center in Norwood, Massachusetts, our Moderna Technology Center (MTC), comprised of three buildings, MTC South, MTC North, and MTC East, totaling approximately 686,000 square feet. Our MTC leases expire in 2042 and we have the option to extend the term for three extension periods of five years each. All of our MTC leases are classified as finance leases.

Embedded Leases

We have entered into multiple contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. In the third quarter of 2023, as part of our strategic initiative to optimize our manufacturing footprint, we amended a contract manufacturing service agreement, resulting in decreases of $262 million in each of the right-of-use assets and lease liabilities. Additionally, it resulted in accelerated depreciation of the right-of-use assets of $323 million for the year ended December 31, 2023. As of December 31, 2023, we had no remaining right-of-use assets or lease liabilities due to embedded leases. As of December 31, 2022, we had right-of-use assets of $639 million and lease liabilities of $440 million related to embedded leases. All of our embedded leases were classified as finance leases.
Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2023 and 2022 were as follows (in millions):
December 31,
20232022
Assets:
Right-of-use assets, operating, net(1) (2)
$713 $121 
Right-of-use assets, financing, net(3) (4)
436 1,150 
Total$1,149 $1,271 
Liabilities:
Current:
Operating lease liabilities(5)
$25 $35 
Financing lease liabilities(5)
— 161 
Total current lease liabilities 25 196 
Non-current:
Operating lease liabilities, non-current643 92 
Financing lease liabilities, non-current575 912 
Total non-current lease liabilities1,218 1,004 
Total$1,243 $1,200 
_______
(1) These assets are real estate related assets, which include land, office and laboratory spaces.
(2) Net of accumulated amortization.
(3) These assets are real estate assets related to the MTC leases as well as assets related to contract manufacturing service agreements.
(4) Included in property, plant and equipment in the consolidated balance sheets, net of accumulated depreciation.
(5) Included in other current liabilities in the consolidated balance sheets.

The components of the lease costs were as follows for the periods presented (in millions):
Years ended December 31,
202320222021
Operating lease costs$88 $48 $24 
Financing lease costs:
   Amortization of right-of-use assets, financing leases500 280 189 
   Interest expense for financing lease liabilities38 29 17 
Total financing lease costs$538 $309 $206 
Short term lease costs$2 $— $49 
Variable lease costs$113 $165 $100 
Supplemental cash flow information relating to our leases was as follows for the periods presented (in millions):
December 31,
202320222021
Cash paid for amounts included in measurement of lease liabilities:
Operating cash flows used in operating leases$(93)$(57)$(19)
Operating cash flows used in financing leases(39)(25)(14)
Financing cash flows used in financing leases
(292)(184)(140)
Operating lease non-cash items:
Changes in right-of-use assets related to lease modifications and reassessments$67 $— $(7)
Right-of-use assets obtained in exchange for operating lease liabilities714 20 72 
Finance lease non-cash items:
Changes in right-of-use assets related to lease modifications and reassessments$213 $— $674 
Right-of-use assets obtained in exchange for financing lease liabilities— 777 126 
Changes in financing lease liabilities3 4 3 

Weighted average remaining lease terms and discount rates as of December 31, 2023 and 2022 were as follows:
December 31,
20232022
Remaining lease term:
Operating leases14 years6 years
Finance leases33 years22 years
Discount rate:
Operating leases7.5 %7.5 %
Finance leases4.2 %3.6 %

Future minimum lease payments under non-cancelable lease agreements as of December 31, 2023, were as follows (in millions):
Fiscal YearOperating Leases
Financing Leases(1)
2024$72 $20 
202567 22 
202667 22 
202770 23 
202872 23 
Thereafter785 1,074 
Total minimum lease payments1,133 1,184 
Less amounts representing interest(465)(609)
Present value of lease liabilities$668 $575 
______
(1) Include certain optional lease term extensions, predominantly related to the MTC leases, which represent a total of $668 million of undiscounted future lease payments.
Leases
10. Leases

We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2042. Certain of these arrangements have free rent periods or escalating rent payment provisions. We recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have two main campuses in Massachusetts, our Cambridge campus and our Moderna Technology Center (MTC), located in Norwood. We also lease various parcels of land, office and lab spaces across the globe for our business operations.

Cambridge Campus

We occupy a multi-building campus at Technology Square in Cambridge, Massachusetts with a mix of offices and research laboratory space totaling approximately 292,000 square feet.

In September 2021, we entered into a lease agreement for a building space, approximately 462,000 square feet, in Cambridge, Massachusetts. This space is designated to be the Moderna Science Center (MSC), housing a blend of office space and laboratories. Following an approximately two-year building project, the lease term is 15 years, with options for two additional seven-year extensions. During the third quarter of 2023, we commenced the lease and recognized the related right-of-use asset and lease liability on our consolidated balance sheets. Following the commencement of the MSC lease, we amended the expiration dates of our existing leases at Technology Square in the fourth quarter of 2023. Originally scheduled to expire ranging from 2024 to 2029, these leases have been adjusted to conclude in early 2025. All our Cambridge leases are classified as operating leases.

Moderna Technology Center

We have an industrial technology center in Norwood, Massachusetts, our Moderna Technology Center (MTC), comprised of three buildings, MTC South, MTC North, and MTC East, totaling approximately 686,000 square feet. Our MTC leases expire in 2042 and we have the option to extend the term for three extension periods of five years each. All of our MTC leases are classified as finance leases.

Embedded Leases

We have entered into multiple contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. In the third quarter of 2023, as part of our strategic initiative to optimize our manufacturing footprint, we amended a contract manufacturing service agreement, resulting in decreases of $262 million in each of the right-of-use assets and lease liabilities. Additionally, it resulted in accelerated depreciation of the right-of-use assets of $323 million for the year ended December 31, 2023. As of December 31, 2023, we had no remaining right-of-use assets or lease liabilities due to embedded leases. As of December 31, 2022, we had right-of-use assets of $639 million and lease liabilities of $440 million related to embedded leases. All of our embedded leases were classified as finance leases.
Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2023 and 2022 were as follows (in millions):
December 31,
20232022
Assets:
Right-of-use assets, operating, net(1) (2)
$713 $121 
Right-of-use assets, financing, net(3) (4)
436 1,150 
Total$1,149 $1,271 
Liabilities:
Current:
Operating lease liabilities(5)
$25 $35 
Financing lease liabilities(5)
— 161 
Total current lease liabilities 25 196 
Non-current:
Operating lease liabilities, non-current643 92 
Financing lease liabilities, non-current575 912 
Total non-current lease liabilities1,218 1,004 
Total$1,243 $1,200 
_______
(1) These assets are real estate related assets, which include land, office and laboratory spaces.
(2) Net of accumulated amortization.
(3) These assets are real estate assets related to the MTC leases as well as assets related to contract manufacturing service agreements.
(4) Included in property, plant and equipment in the consolidated balance sheets, net of accumulated depreciation.
(5) Included in other current liabilities in the consolidated balance sheets.

The components of the lease costs were as follows for the periods presented (in millions):
Years ended December 31,
202320222021
Operating lease costs$88 $48 $24 
Financing lease costs:
   Amortization of right-of-use assets, financing leases500 280 189 
   Interest expense for financing lease liabilities38 29 17 
Total financing lease costs$538 $309 $206 
Short term lease costs$2 $— $49 
Variable lease costs$113 $165 $100 
Supplemental cash flow information relating to our leases was as follows for the periods presented (in millions):
December 31,
202320222021
Cash paid for amounts included in measurement of lease liabilities:
Operating cash flows used in operating leases$(93)$(57)$(19)
Operating cash flows used in financing leases(39)(25)(14)
Financing cash flows used in financing leases
(292)(184)(140)
Operating lease non-cash items:
Changes in right-of-use assets related to lease modifications and reassessments$67 $— $(7)
Right-of-use assets obtained in exchange for operating lease liabilities714 20 72 
Finance lease non-cash items:
Changes in right-of-use assets related to lease modifications and reassessments$213 $— $674 
Right-of-use assets obtained in exchange for financing lease liabilities— 777 126 
Changes in financing lease liabilities3 4 3 

Weighted average remaining lease terms and discount rates as of December 31, 2023 and 2022 were as follows:
December 31,
20232022
Remaining lease term:
Operating leases14 years6 years
Finance leases33 years22 years
Discount rate:
Operating leases7.5 %7.5 %
Finance leases4.2 %3.6 %

Future minimum lease payments under non-cancelable lease agreements as of December 31, 2023, were as follows (in millions):
Fiscal YearOperating Leases
Financing Leases(1)
2024$72 $20 
202567 22 
202667 22 
202770 23 
202872 23 
Thereafter785 1,074 
Total minimum lease payments1,133 1,184 
Less amounts representing interest(465)(609)
Present value of lease liabilities$668 $575 
______
(1) Include certain optional lease term extensions, predominantly related to the MTC leases, which represent a total of $668 million of undiscounted future lease payments.
XML 44 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
11. Commitments and Contingencies

Legal Proceedings

We are involved in various claims and legal proceedings of a nature considered ordinary course in our business. The outcome of any such proceedings, regardless of the merits, is inherently uncertain; therefore, assessing the likelihood of loss and any estimated damages is difficult and subject to considerable judgment. We are not currently a party to any legal proceedings for which a material loss is probable, or for which a loss is reasonably estimable at this time.

Indemnification Obligations

As permitted under Delaware law, we indemnify our officers, directors, and employees for certain events, occurrences while the officer, or director is, or was, serving at our request in such capacity. The term of the indemnification is for the officer’s or director’s lifetime.

We have standard indemnification arrangements in our leases for laboratory and office space that require us to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under our leases.

We enter into indemnification provisions under our agreements with counterparties in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited.

Through December 31, 2023 and 2022, we had not experienced any significant losses related to these indemnification obligations, and no material claims were outstanding. We do not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.

Purchase Commitments and Purchase Orders

We enter into agreements in the normal course of business with vendors and contract manufacturing organizations (CMOs) for raw materials and manufacturing services and with vendors for preclinical research studies, clinical trials and other goods or services. As of December 31, 2023, we had $1.8 billion of non-cancelable purchase commitments related to raw materials and manufacturing agreements, which are expected to be paid through 2029. As of December 31, 2023, $79 million of the purchase commitments related to raw materials was recorded as an accrued liability for loss on future firm purchase commitments. As of December 31, 2023, we had $261 million of non-cancelable purchase commitments related to clinical services and other goods and services which are expected to be paid through 2039. These amounts represent our minimum contractual obligations, including termination fees.

In addition to purchase commitments, we have agreements with third parties for various services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or wind down costs. Under such agreements, we are contractually obligated to make certain payments to vendors, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation. At December 31, 2023, we had cancelable open purchase orders of $3.0 billion in total under such agreements for our significant clinical operations and support and contract manufacturing. These amounts represent only our estimate of those items for which we had a contractual commitment to pay at December 31, 2023, assuming we would not cancel these agreements. The actual amounts we pay in the future to the vendors under such agreements may differ from the purchase order amounts.

Licenses to Patented Technology

In 2017, we entered into sublicense agreements with Cellscript, LLC and its affiliate, mRNA RiboTherapeutics, Inc. to sublicense certain patent rights. Pursuant to each agreement, we are required to pay certain license fees, annual maintenance fees, minimum royalties on future net sales and milestone payments contingent on achievement of certain development, regulatory and commercial milestones for specified products, on a product-by-product basis. Commercial milestone payments and royalties based on annual net sales of licensed products for therapeutic and prophylactic products are accounted for as additional expense of the related net product sales in the period in which the corresponding sales occur.

In December 2022, we entered into a non-exclusive patent license agreement with the National Institute of Allergy and Infectious Diseases (NIAID), an Institute or Center of the National Institutes of Health (NIH) to license certain patent rights concerning
stabilizing prefusion coronavirus spike proteins and the resulting stabilized proteins for use in COVID-19 vaccine products. Pursuant to the agreement, we have agreed to pay low single-digit royalties on future net sales, a minimum annual royalty payment, and certain contingent development, regulatory and commercial milestone payments on a licensed product-by-licensed product basis. In addition, in December 2022, we made a catch-up royalty payment of $400 million to NIAID, which was recorded to cost of sales in our consolidated statements of operations.

In 2023, 2022, and 2021 we recognized $301 million, $1.1 billion, and $641 million, respectively, of royalties and commercial milestone payments associated with our net product sales, which was recorded to cost of sales in our consolidated statements of operations.
Additionally, we have other in-license agreements with third parties which require us to make future development, regulatory and commercial milestone payments for specified products associated with the agreements. The achievement of these milestones have not yet occurred as of December 31, 2023.
XML 45 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation and Share Repurchase Programs
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation and Share Repurchase Programs
12. Stock-Based Compensation and Share Repurchase Programs

Equity Plans

In connection with our initial public offering (IPO), we adopted the 2018 Stock Option and Incentive Plan (the 2018 Equity Plan) in November 2018. The 2018 Equity Plan became effective on the date immediately prior to the effective date of the IPO and replaced our 2016 Stock Option and Incentive Plan (the 2016 Equity Plan). The 2018 Equity Plan provides flexibility to our compensation committee to use various equity-based incentive awards as compensation tools to motivate our workforce. The shares of common stock underlying any awards that are forfeited, canceled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2018 Equity Plan and the 2016 Equity Plan will be added back to the shares of common stock available for issuance under the 2018 Equity Plan.

The Board of Directors may grant to employees, nonemployee directors, consultants and independent advisors equity-based awards during their period of service, generally in the form of stock options, restricted stock units, and performance stock units. The terms and conditions of stock-based awards are defined at the sole discretion of our Board of Directors. We issue service-based awards, vesting over a defined period of service, and performance-based awards, vesting upon achievement of defined conditions. Service based awards generally vest over a four-year period, with the first 25% of such awards vesting following twelve months of continued employment or service. The remaining awards vest in twelve quarterly installments over the following twelve quarters. Stock options granted under the 2018 Equity Plan and the 2016 Equity Plan expire ten years from the date of grant and the exercise price must be at least equal to the fair market value of common stock on the grant date.

As of December 31, 2023, we had a total of 47 million shares reserved for future issuance under our Equity Plans, of which 31 million shares were reserved for equity awards previously granted, and 16 million shares were available for future grants under the 2018 Equity Plan. No additional awards will be granted under the 2016 Equity Plan as it was replaced by the 2018 Equity Plan.
Options

We have granted options generally through the 2018 Equity Plan and 2016 Equity Plan. The following table summarizes our option activity during the year ended December 31, 2023:
Number of
Options
(in millions)		Weighted
Average
Exercise
Price per
Share		Weighted-
Average
Remaining
Contractual
Term
Aggregate
Intrinsic
Value(1)
(in millions)
Outstanding at December 31, 202224.93 $42.23 5.7 years$3,478 
Granted
4.36 113.03 
Exercised
(3.11)8.13 
Canceled/forfeited
(0.68)130.23 
Outstanding at December 31, 202325.50 56.14 5.6 years1,437 
Exercisable at December 31, 202318.98 33.34 4.5 years1,378 
Expected to vest at December 31, 20236.52 122.50 8.9 years59 
_______
(1)Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of December 31, 2023.

The total intrinsic value of options exercised was $413 million, $714 million, and $1.6 billion for the years ended December 31, 2023, 2022, and 2021, respectively. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period. The excess tax benefits realized from tax deductions from option exercises were $84 million, $144 million, and $325 million during the years ended December 31, 2023, 2022, and 2021 respectively. The total consideration recorded as a result of stock option exercises was approximately $25 million, $50 million, and $112 million for the years ended December 31, 2023, 2022, and 2021.

Restricted Common Stock Units (RSUs) and Performance Stock Units (PSUs)

We have granted RSUs and PSUs generally through the 2018 Equity Plan. The following table summarizes our RSU and PSU activity during the year ended December 31, 2023:
Number of Units
(in millions)
Weighted Average
Grant Date Fair Value per Unit
Outstanding, non-vested at December 31, 20222.90 $132.25 
Issued
3.71 107.23 
Vested
(1.01)98.68 
Canceled/forfeited
(0.42)130.01 
Outstanding, non-vested at December 31, 20235.18 121.02 

The total grant date fair value of RSUs and PSUs vested during the years ended December 31, 2023, 2022, and 2021, was $99 million, $55 million, and $18 million, respectively. The total intrinsic value of RSUs and PSUs vested during the years ended December 31, 2023, 2022, and 2021, was $120 million, $125 million and $141 million, respectively.

During 2023, 2022 and 2021, we granted an immaterial amount of PSUs, respectively, primarily to certain senior executives with vesting that is contingent upon the achievement of specified preestablished goals over the performance period, generally three years. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from 0% to 200%. The estimated fair value of PSUs is based on the grant date fair value.
Valuation and Stock-Based Compensation Expense

Stock-based compensation for options granted under our Equity Plans is determined using the Black-Scholes option pricing model. The weighted-average assumptions used to estimate the fair value of options granted for the years ended December 31, 2023, 2022, and 2021 were as follows:
Weighted Average
Years Ended December 31,
202320222021
Options:
    Risk-free interest rate
4.13 %2.46 %0.84 %
    Expected term
6.07 years6.13 years6.10 years
    Expected volatility
48 %50 %46 %
    Expected dividends
— %— %— %
    Weighted average fair value per share
$57.87 $76.02 $91.84 

Stock-Based Compensation Expense

The following table presents the components and classification of stock-based compensation expense for the years ended December 31, 2023, 2022, and 2021 (in millions):
Years Ended December 31,
202320222021
Options
$136 $123 $96 
RSUs and PSUs161 97 42 
Employee stock purchase plan
8 6 4 
Total
$305 $226 $142 
Cost of sales$37 $45 $22 
Research and development
157 93 68 
Selling, general and administrative111 88 52 
Total
$305 $226 $142 

For the years ended December 31, 2023, 2022, and 2021, we recognized stock-based compensation expense of $17 million, $18 million, and $16 million, respectively, related to performance-based awards, including awards with vesting or commencement contingent upon our IPO. Stock-based compensation expenses related to non-employee awards were immaterial for the years ended December 31, 2023, 2022, and 2021.

As of December 31, 2023, there were $835 million of total unrecognized compensation cost related to non-vested stock-based compensation with respect to options, RSUs and PSUs granted. That cost is expected to be recognized over a weighted-average period of 2.6 years at December 31, 2023.

Share Repurchase Programs

On August 2, 2021, our Board of Directors authorized a Share Repurchase Program (2021 Repurchase Program) of our common stock, with an expiration date no later than August 2, 2023. Pursuant to the 2021 Repurchase Program, we were authorized to repurchase up to $1.0 billion of our outstanding common stock. By the end of January 2022, we had repurchased the entire $1.0 billion of common stock that was authorized under the 2021 Repurchase Program. On February 22, 2022, our Board of Directors authorized an additional share repurchase program of our common stock, with no expiration date, for up to $3.0 billion. On August 1, 2022, our Board of Directors authorized an increase of $3.0 billion under the repurchase program for our common stock, with no expiration date (collectively with the February 22, 2022 authorization, the 2022 Repurchase Programs).

As of December 31, 2023, $1.7 billion of our Board of Directors’ authorization for repurchases of our common stock remains outstanding (the 2022 Repurchase Programs), with no expiration date. The timing and actual number of shares repurchased under the 2022 Repurchase Programs will depend on a variety of factors, including price, general business and market conditions, and other investment opportunities, and shares may be repurchased through open market purchases through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
The following table summarizes activity related to our share repurchase programs (in millions, except per share data):
Years Ended December 31,
202320222021
Number of shares repurchased8233
Average price per share(1)
$143.26 $142.83 $245.76 
Aggregate purchase price$1,153 $3,329 $857 
Remaining authorization at end of period$1,667 $2,814 $143 
_______
(1)Average price paid per share includes related expenses and excise tax, applicable beginning January 1, 2023.
XML 46 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes
13. Income Taxes

(Loss) income before income taxes for the years ended December 31, 2023, 2022, and 2021 consisted of the following (in millions):
Years Ended December 31,
202320222021
United States
$(4,056)$9,433 $13,108 
Foreign
114 142 177 
(Loss) income before income taxes$(3,942)$9,575 $13,285 

The provision for income taxes for the years ended December 31, 2023, 2022, and 2021 consisted of the following components (in millions):
Years Ended December 31,
202320222021
Current:
Federal$(225)$1,687 $1,304 
State72 47 35 
Foreign24 57 40 
Total current$(129)$1,791 $1,379 
Deferred:
Federal$888 $(569)$(288)
State8 (7)(6)
Foreign5 (2)(2)
Total deferred901 (578)(296)
Total provision for income taxes$772 $1,213 $1,083 

The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31, 2023, 2022, and 2021 was as follows:
Years Ended December 31,
202320222021
Federal statutory tax rate21.0 %21.0 %21.0 %
Change in valuation allowance
(52.6)%— %(5.4)%
Foreign-derived intangible income0.2 %(7.4)%(4.8)%
Stock-based compensation windfall2.4 %(1.6)%(2.6)%
Federal research and development credits
4.6 %(0.5)%(0.7)%
State taxes, net of federal benefits5.7 %0.4 %0.5 %
Non-deductible items(0.4)%— %— %
Other
(0.5)%0.8 %0.1 %
Effective tax rate
(19.6)%12.7 %8.1 %
Our effective tax rate for the year ended December 31, 2023 was (19.6)% and was higher than the federal statutory tax rate, primarily due to an increase in valuation allowance against deferred tax assets. The effective tax rates for the year ended December 31, 2023 also include tax benefits from research and development credits and stock-based compensation. Our effective tax rate for the year ended December 31, 2022 was lower than the federal statutory tax rate, primarily due to the tax benefit of the foreign-derived intangible income deduction (FDII) and excess tax benefit related to stock-based compensation. Our effective tax rate for the year ended December 31, 2021 was lower than the federal statutory tax rate, primarily due to the tax benefits related to the release of the valuation allowance on most of our deferred tax assets, FDII and stock-based compensation.

As of January 1, 2022, pursuant to the Tax Cuts and Jobs Act of 2017 (“TCJA”), research and development costs in the current period are required to be amortized over five or fifteen years, depending on where the research is conducted. The new capitalization requirement significantly increased our deferred tax assets and cash tax liabilities, but also decreased our effective tax rate by increasing the foreign-derived intangible income deduction.

The President signed into law the Inflation Reduction Act (the “IRA”) on August 16, 2022. The Act includes a new 15% corporate minimum tax and a 1% excise tax on the value of corporate stock repurchases, net of new share issuances, after December 31, 2022. We do not expect these provisions to have a material impact on our consolidated financial position; however, we will continue to evaluate their impact as further information becomes available.

Deferred income taxes reflect the tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting and the amounts used for income tax purposes, tax credit carryforwards and the tax effect of net operating loss carryforwards. Significant components of our deferred tax assets and tax liabilities as of December 31, 2023 and 2022 were as follows (in millions):
December 31,
20232022
Deferred tax assets:
Net operating loss carryforwards$90 $59 
Stock-based compensation111 68 
Capitalized licenses, research and development and start-up costs1,449 704 
Tax credit carryforwards140 97 
Operating lease liabilities154 26 
Financing lease liabilities139 135 
Other comprehensive income34 106 
Inventory reserve and capitalization 250 86 
Wholesaler chargebacks, discounts and fees
92 — 
Returns and other fees
129 — 
Other90 85 
Total deferred tax assets2,678 1,366 
Less: valuation allowance
(2,224)(155)
Net deferred tax assets$454 $1,211 
Deferred tax liabilities:
Right-of-use assets, financing$(106)$(117)
Right-of-use assets, operating(160)(26)
Property, plant and equipment(107)(85)
Other(15)(1)
Total deferred tax liabilities
(388)(229)
Net deferred tax (liabilities) assets
$66 $982 
The table below summarizes changes in the valuation allowance for deferred tax assets for the periods presented (in millions):
Years Ended December 31,
202320222021
Valuation allowance at beginning of the period$155 $149 $823 
Decreases recorded as benefit to income tax provision— (12)(722)
Increases to valuation allowance2,069 18 48 
Valuation allowance at December 31$2,224 $155 $149 

We periodically reassess the need for valuation allowances on our deferred tax assets, considering both positive and negative evidence to evaluate whether it is more likely than not that all or a portion of such assets will not be realized. During 2023, following the completion of our long-range financial planning process, we reassessed the evidence and concluded that a valuation allowance was necessary due to the preponderance of negative evidence, including:

•A pre-tax loss for the full year 2023, serving as a significant source of objectively verifiable negative evidence in accordance with ASC 740 (Income Taxes).
•A projected three-year cumulative loss resulting from our long-range financial planning process. This projection is due to a significant decrease in expected sales of our COVID-19 vaccine as we transition to a seasonal market. Additionally, we anticipate substantial research and development expenses for our on-going Phase 3 clinical trials and to advance our product candidates into later-stage development. These factors contribute additional negative evidence with respect to the realizability of our deferred tax assets. The projections are based upon revenue from our currently approved drug product, which we believe can be reasonably estimated. In contrast, future taxable income projections from our investigational medicines are deemed inherently subjective and not objectively verifiable; they are insufficient to override negative evidence, and therefore, they are not assigned any weight in our valuation allowance analysis assessment.

Our evaluation also included whether there were other sources of taxable income that would allow us to realize our deferred tax assets, such as taxable income in carryback years, available tax planning strategies and the future reversals of taxable temporary differences. After assessing these strategies and all evidence, we determined it was more likely than not that we will not realize all of our deferred tax assets and therefore increased the valuation allowance by $2.1 billion during 2023.

In the first quarter of 2021, we reassessed the valuation allowance noting the increase in positive evidence, including significant revenue growth, expectations regarding future profitability, and successful supply chain and manufacturing capabilities to meet global product demand. After assessing both the positive evidence and negative evidence, we determined it was more likely than not that we would realize the majority of our deferred tax assets, and we released the valuation allowance on the majority of our deferred tax assets, accordingly. The release of the valuation allowance was based on the then-prevailing positive outlook, which has since shifted significantly by 2023 due to the factors outlined above, leading to the reinstatement of a full valuation allowance.

Significant management judgment is required in assessing the realizability of our deferred tax assets. In the event that actual results differ from our estimates, we adjust our estimates in future periods and we may need to modify our valuation allowance, which could materially impact our financial position and results of operations.

At December 31, 2023, we had $1.6 billion of state net operating loss carryforwards, which begin to expire in 2030. At December 31, 2023, we also had state research and development tax credit carryforwards of $178 million, the majority of which will begin to expire in 2030.
We recognize, in our financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. A reconciliation of the beginning and ending amounts of unrecognized tax benefits during the years ended December 31, 2023, 2022, and 2021 were as follows (in millions):
Years Ended December 31,
202320222021
Unrecognized tax benefits at beginning of the period$128 $68 $— 
Decrease due to prior positions:
Tax positions for prior years— (1)— 
Expiration of statutes— — — 
Settlements with tax authorities(27)— — 
Increase due to current year tax positions:
Additions based on tax positions for current year44 57 54 
Additions based on tax positions for prior years86 4 14 
Unrecognized tax benefits at end of the period $231 $128 $68 

As of December 31, 2023, we had $231 million of net unrecognized tax benefits, which would affect our tax rate if recognized. Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. We do not anticipate a material change to our unrecognized tax benefits over the next twelve months that would have an adverse effect on our consolidated operating results. We recognize interest and penalties, if applicable, related to uncertain tax positions as a component of income tax expense.

We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. All tax years since our date of incorporation remain open to examination by the major taxing jurisdictions, as carryforward attributes generated in past years may be adjusted upon examination by the Internal Revenue Service or the state authorities. There are no open tax examinations at this time.
XML 47 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
(Loss) Earnings per Share
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
(Loss) Earnings per Share
14. (Loss) Earnings per Share

The computation of basic earnings (loss) per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and potential dilutive common shares outstanding during the period as determined by using the treasury stock method.

Basic and diluted EPS for the years ended December 31, 2023, 2022 and 2021 were calculated as follows (in millions, except per share data):
Years Ended December 31,
202320222021
Numerator:
Net (loss) income
$(4,714)$8,362 $12,202 
Denominator:
Basic weighted-average common shares outstanding382 394 403 
Effect of dilutive securities— 22 28 
Diluted weighted-average common shares outstanding382 416 431 
Basic EPS$(12.33)$21.26 $30.31 
Diluted EPS$(12.33)$20.12 $28.29 
The following common stock equivalents, presented based on amounts outstanding as of December 31, 2023, 2022 and 2021, were excluded from the calculation of diluted net (loss) income per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):
December 31,
202320222021
Options26 3 1 
RSUs and PSUs5 — — 
Total31 3 1 
XML 48 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
Geographic Information
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Geographic Information
3. Net Product Sales

Net product sales by customer geographic location were as follows for the periods presented (in millions):
Years Ended December 31,
202320222021
United States$1,720 $4,405 $5,393 
Europe1,353 6,732 6,834 
Rest of world
3,598 7,298 5,448 
Total $6,671 $18,435 $17,675 

As of December 31, 2023, 2022 and 2021, our COVID-19 vaccine was our only commercial product authorized for use.

Prior to the third quarter of 2023, we sold our COVID-19 vaccine to the U.S. Government, foreign governments and organizations. The agreements and related amendments with these entities generally do not include variable consideration, such as discounts, rebates or returns. Certain of these agreements entitle us to upfront deposits for our COVID-19 vaccine supply, initially recorded as deferred revenue.

As of December 31, 2023 and 2022, we had deferred revenue of $613 million and $2.6 billion, respectively, related to customer deposits. We expect $554 million of our deferred revenue related to customer deposits as of December 31, 2023 to be realized in less than one year. Timing of product delivery and manufacturing, and receipt of marketing approval for the applicable COVID-19 vaccine will determine the period in which net product sales are recognized.

In the third quarter of 2023, we commenced sales of our latest COVID-19 vaccine to the U.S. commercial market, in addition to continuing sales to foreign governments and organizations. In the U.S., our COVID-19 vaccine is sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Wholesalers and distributors typically do not make upfront payments to us.

Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns, and other related deductions.

The following table summarizes product sales provision for the periods presented (in millions):
Years Ended December 31,
202320222021
Gross product sales $8,203 $18,435 $17,675 
Product sales provision:
Wholesaler chargebacks, discounts and fees
(976)— — 
Returns and other fees(556)— — 
Total product sales provision
$(1,532)$— $— 
Net product sales $6,671 $18,435 $17,675 

The following table summarizes the activities related to product sales provision recorded as accrued liabilities for the year ended December 31, 2023 (in millions):
Returns and other fees
Balance at December 31, 2022$— 
Provision related to sales made in current period(556)
Balance at December 31, 2023$(556)
4. Other Revenue

The following table summarizes other revenue for the periods presented (in millions):
Years Ended December 31,
202320222021
Grant revenue$94 $388 $735 
Collaboration revenue83 440 61 
Total other revenue$177 $828 $796 

Grant Revenue

In April 2020, we entered into an agreement with Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for an award of up to $483 million to accelerate development of mRNA-1273, our original vaccine candidate against COVID-19. The agreement has been subsequently amended to provide for additional commitments to support various late-stage clinical development efforts of mRNA-1273, including a 30,000 participant Phase 3 study, pediatric clinical trials, adolescent clinical trials and pharmacovigilance studies. The maximum award from BARDA, inclusive of all amendments, was approximately $1.8 billion. All contract options have been exercised. As of December 31, 2023, the remaining available funding, net of revenue earned was $97 million.
The following table summarizes grant revenue for the periods presented (in millions):
Years Ended December 31,
202320222021
BARDA$88 $372 $713 
Other grant revenue6 16 22 
Total grant revenue$94 $388 $735 

Collaboration Revenue

We have entered into collaboration agreements with strategic collaborators to accelerate the discovery and advancement of potential mRNA medicines across therapeutic areas. As of December 31, 2023, 2022 and 2021, we had collaboration agreements with Merck & Co., Inc (Merck), Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, Vertex), AstraZeneca plc (AstraZeneca) and others. Please refer to Note 5 to for further description of these collaboration agreements.

The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):
Years Ended December 31,
Collaboration Revenue by Strategic Collaborator:202320222021
Vertex$82 $48 $26 
Merck— 309 23 
AstraZeneca— 80 7 
Other1 3 5 
Total collaboration revenue$83 $440 $61 
15. Geographic Information

Geographic Revenue

We operate in one reporting segment that primarily focuses on the discovery, development and commercialization of mRNA medicines. Our chief executive officer manages our operations and evaluates our financial performance on a consolidated basis. Most of our principal operations, other than manufacturing, and our decision-making functions are located at our corporate headquarters in the United States.

Total revenue by geographic area of our customers and collaboration partners was as follows (in millions):
Years Ended December 31,
202320222021
United States$1,895 $5,150 $6,177 
Europe1,355 6,815 6,846 
Rest of world
3,598 7,298 5,448 
Total $6,848 $19,263 $18,471 

Our property, plant and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):
December 31,
20232022
United States$1,560 $1,267 
Europe126 714 
Rest of world259 37 
Total$1,945 $2,018 
XML 49 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
Pay vs Performance Disclosure - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Pay vs Performance Disclosure      
Net (loss) income $ (4,714) $ 8,362 $ 12,202
XML 50 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
Insider Trading Arrangements
 3 Months Ended 12 Months Ended
Dec. 31, 2023
shares
Dec. 31, 2023
shares
Trading Arrangements, by Individual    
Non-Rule 10b5-1 Arrangement Adopted false  
Non-Rule 10b5-1 Arrangement Terminated false  
Noubar Afeyan [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement  
On November 7, 2023, Noubar Afeyan, our Chairman, amended a trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Afeyan 10b5-1 Plan). The Afeyan 10b5-1 Plan was amended to increase certain price triggers under the plan. The Afeyan 10b5-1 Plan, as amended, is scheduled to commence on February 28, 2024, and will run through August 20, 2025. The aggregate maximum number of shares of common stock that may be sold pursuant to the Afeyan 10b5-1 Plan is 745,000, which represents the shares remaining under the original plan that have not been sold to date.
Name Noubar Afeyan  
Title Chairman  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date November 7, 2023  
Arrangement Duration 539 days  
Aggregate Available 745,000 745,000
Arpa Garay [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement  
On November 6, 2023, Arpa Garay, our former Chief Commercial Officer, terminated a trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Garay 10b5-1 Plan). The Garay 10b5-1 Plan was entered into on August 24, 2023, and was scheduled to commence on November 27, 2023, with a termination date of August 30, 2024. The Garay 10b5-1 Plan provided for the potential sale of approximately 4,540 shares of common stock and for the potential exercise of vested stock options and the associated sale of up to 24,897 shares. No shares of common stock were sold, and no options to purchase shares of common stock were exercised, under the Garay 10b5-1 Plan prior to its termination.
Name Arpa Garay  
Title former Chief Commercial Officer  
Adoption Date August 24, 2023  
Rule 10b5-1 Arrangement Terminated true  
Termination Date November 6, 2023  
Arrangement Duration 74 days  
Arpa Garay, Common Stock [Member] | Arpa Garay [Member]    
Trading Arrangements, by Individual    
Aggregate Available 4,540 4,540
Arpa Garay, Stock Options [Member] | Arpa Garay [Member]    
Trading Arrangements, by Individual    
Aggregate Available 24,897 24,897
XML 51 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation
Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).
The consolidated financial statements include the Company and its subsidiaries.
Principles of Consolidation All intercompany transactions and balances have been eliminated in consolidation.
Reclassifications
Other revenue in the consolidated statements of operations comprises grant revenue and collaboration revenue that were previously presented as separate line items in our consolidated statements of operations in our 2022 Form 10-K. The associated prior period amounts in the consolidated financial statements, as well as in the notes thereto, have been reclassified to conform to the current presentation.
Use of Estimates
We have made estimates and judgments affecting the amounts reported in our consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods that are not readily apparent from other sources. Changes in our estimates are recorded in the financial results of the period in which the new information becomes available. The actual results that we experience may differ materially from our estimates.
Segment Information We have determined that our chief executive officer is the chief operating decision maker (CODM). The CODM reviews financial information presented on a consolidated basis. Resource allocation decisions are made by the CODM based on consolidated results. There are no segment managers who are held accountable by the CODM for operations, operating results, and planning for levels or components below the consolidated unit level. As such, we have concluded that we operate as one segment.
Revenue Recognition
To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following five steps (the five-step model): (i) identify the contract(s) with our customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as each performance obligation is satisfied.

Net Product Sales

Prior to the third quarter of 2023, we sold our COVID-19 vaccine to the U.S. Government, foreign governments and organizations. The agreements and related amendments with these entities generally do not include variable consideration, such as discounts, rebates or returns. Certain of these agreements entitle us to upfront deposits for our COVID-19 vaccine supply, initially recorded as deferred revenue. In the third quarter of 2023, we commenced sales of our latest COVID-19 vaccine to the U.S. commercial market, in addition to continuing sales to international governments and organizations. In the U.S., our COVID-19 vaccine is sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Wholesalers and distributors typically do not make upfront payments to us.

We recognize net product sales when control of the product transfers to the customer, typically upon delivery. Payment terms generally range from 30 to 60 days, in line with customary practices in each country. Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns, and other related deductions. These provisions are recorded based on contractual terms and our estimate of returns for product sold during the period, using the expected value method or the most likely amount method. We update our estimates quarterly and record necessary adjustments in the period when we identify the adjustments. Product sales, net of provisions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable when the uncertainty associated with the provisions is subsequently resolved. Shipping and handling activities are considered fulfillment activities and not a separate performance obligation. Taxes assessed by governmental authorities that are imposed on and collected from our product sales are excluded from net product sales.

Wholesaler chargebacks, discounts and fees

We contract with retailers, healthcare providers, and group purchasing organizations (GPO) to broaden our customer reach and offer contractual discounts. The chargeback represents the difference between the invoice price billed to the wholesaler and the negotiated price charged to the retailers, healthcare providers and GPO members. For distribution and related services, such as stocking and cold chain storage, we provide compensation to our wholesalers and distributors. We typically offer our customers invoice discounts on product sales for prompt payments and pre-orders. The estimation of these discounts and fees is based on contractual terms and our expectations regarding future customer payment behaviors. Wholesaler fees and invoice discounts are deducted from our gross product sales and accounts receivable at the time such product sales are recognized.

Product returns

We typically offer customers in the U.S. the right to return products, up to a certain limit as stipulated in our contracts. Estimated returns for our COVID-19 vaccine are determined considering available return rates for similar products, estimated levels of inventory in the distribution channel, and projected market demand. The estimated amount for product returns is presented within accrued liabilities on our consolidated balance sheets and is deducted from our gross product sales in the period the related product sales are recognized.

Other fees

Fees payable to third party payers and healthcare providers, along with fees to our direct customers that are settled via cash payments, including certain patient assistance programs, are recorded as accrued liabilities on our consolidated balance sheets.

Determining the amount of variable consideration to recognize necessitates substantial judgment, especially when assessing factors outside our direct control such as lack of pertinent historical data and limited third-party information. Among all variables, estimating returns presents the most significant judgment due to the broad range of potential outcomes and the current lack of return history with our customers. As we receive more historical data on our product returns, we will integrate this information to refine our estimates and enhance the precision of our financial projections. The actual results could differ from our estimates, and such differences could have a material impact to our financial statements.
Other Revenue

Other revenue consists primarily of grant revenue and collaboration revenue.

Grant revenue

We have contracts with government-sponsored and private organizations for research and development related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs as well as a related profit margin. We recognize grant revenue from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized when incurred as research and development expense. Grant revenue and related expenses are presented gross in the consolidated statements of operations as we have determined we are the primary obligor under the arrangements relative to the research and development services we perform as lead technical expert.

Collaboration Revenue
We have entered into strategic collaborations and other similar arrangements with third parties for research and other licenses, development and commercialization of certain products and product candidates. Such arrangements provide for various types of payments to us, including upfront fees, funding of research and development services and preclinical and clinical material, technical, development, regulatory, and commercial milestone payments, licensing fees, option exercise fees, and royalty and earnout payments on product sales. Such payments are often not commensurate with the timing of revenue recognition and therefore result in deferral of revenue recognition. We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer.
Cash and Cash Equivalents
We consider all highly liquid investments with an original maturity of 90 days or less from the date of purchase to be cash equivalents.
Restricted Cash Restricted cash is composed of amounts held on deposit related to our lease arrangements and funds held in an escrow account related to a business acquisition in 2023. The funds are maintained in money market accounts and are recorded at fair value. Restricted cash is classified as either current or non-current based on the terms of the underlying arrangement and is included in either prepaid expenses and other current assets or other non-current assets in our consolidated balance sheets.
Investments
We invest our excess cash balances in marketable debt securities. We classify our investments in marketable debt securities as available-for-sale. We report our available-for-sale securities at fair value at each balance sheet date, and include any unrealized holding gains and losses (the adjustment to fair value) in accumulated other comprehensive income (loss), a component of stockholders’ equity. Realized gains and losses are determined using the specific-identification method, and are included in other expense, net in our consolidated statements of operations. We classify our available-for-sale securities as current or non-current based on each instrument’s underlying effective maturity date and for which we have the intent and ability to hold the investment for a
period of greater than 12 months. Available-for-sale securities with maturities of less than 12 months are classified as current and are included in investments in the consolidated balance sheets. Available-for-sale securities with maturities greater than 12 months for which we have the intent and ability to hold the investment for greater than 12 months are classified as non-current and are included in investments, non-current in the consolidated balance sheets.

We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit- related is recognized in other comprehensive income (loss), net of applicable taxes.

Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in other expense, net, in our consolidated statements of operations. Investments in equity securities without readily determinable fair values are recorded at cost minus impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in other expense, net, in our consolidated statements of operations.
Accounts Receivable, net Accounts receivable, net represent amounts due from customers less wholesalers chargebacks, discounts and fees (please refer to our “Revenue Recognition” policy within Note 2 for product sales provision) and allowance for expected credit losses. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. To estimate the allowance for credit losses, we determine the allowance based on ongoing credit evaluation, historical experience and the aging of such receivables, among other factors.
Concentrations of Credit Risk
Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, marketable debt securities, and accounts receivable, net. Our investment portfolio comprises money market funds and marketable debt securities, including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities and commercial paper. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations. We invest in a variety of financial instruments and limit the amount of credit exposure with any individual financial institution. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. Our primary operating accounts significantly exceed the FDIC limits.

We are also subject to credit risk from our accounts receivable, net related to our net product sales and strategic alliances. We sell our products primarily to wholesalers and distributors and other governments and organizations. We do not require collateral or other security to support accounts receivable. To date, we have not experienced material losses with respect to the collection of our accounts receivable.
Significant Customers Our accounts receivable, net are generally unsecured and are from customers in different countries. We generated revenue from product sales to wholesalers and distributors and other governments and organizations, and to a lesser extent, grants made by government-sponsored and private organizations, and collaboration revenue from our strategic alliances.
Fair Value Measurements
Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. ASC 820 (Fair Value Measurement) establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from our independent sources. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities: 

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
•Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or
•Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Our cash equivalents and marketable debt securities are reported at fair value determined using Level 1 and Level 2 inputs (Note 6). The fair value of our foreign currency forward contracts is calculated using Level 2 inputs, which include currency spot rates, forward rates, interest rate curve and credit or non-performance risk. We do not have any non-financial assets or liabilities that should be recognized or disclosed at fair value on a recurring basis at December 31, 2023 and 2022.
Inventory
Inventory is recorded at the lower of cost or net realizable value, with cost determined using first-in, first-out and average cost methods for different components of inventory. We periodically review the composition of inventory in order to identify excess, obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, we will record a write-down to net realizable value in the period that the decline in value is first recognized through a charge to cost of sales. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. We also assess whether we have any excess firm, non-cancelable, purchase commitment liabilities, resulting from our supply agreements with third-party vendors, on a quarterly basis. The determination of net realizable value and firm purchase commitment liabilities requires judgment, including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions, potential product obsolescence, expiration and utilization of raw materials under firm purchase commitments and contractual minimums, among others. We hold raw materials beyond our one year forecasted production plan, which were classified as non-current and included in other non-current assets in our consolidated balance sheets.

Pre-launch Inventory
Costs relating to raw materials and production of inventory in preparation for product launch prior to regulatory approval are capitalized when future commercialization is considered probable, the future economic benefit is expected to be realized, and we believe that material uncertainties related to the ultimate regulatory approval have been significantly reduced. For pre-launch inventory that is capitalized, we consider a number of factors based on the information available at the time, including the product candidate’s current status in the drug development and regulatory approval process, results from the related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential impediments to the approval process such as product safety or efficacy, historical experience, viability of commercialization and market trends. As of December 31, 2023, we did not have any capitalized pre-launch inventory on our consolidated balance sheets.
Property, Plant and Equipment
Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of property, plant and equipment are described below:
Estimated Useful Life
Land and land improvementsNot depreciated
Manufacturing and laboratory equipment5 years
Leasehold improvements
Lesser of estimated useful life of improvement
or remaining life of related lease
Computer equipment and software
3 to 5 years
Furniture and fixtures5 years
Right-of-use asset, financingLease term
Construction in progress includes direct costs related to the construction of various property, plant and equipment, including leasehold improvements, and is stated at original cost. Once the asset is placed into service, these capitalized costs will be allocated to certain property, plant and equipment categories and will be depreciated over the estimated useful life of the underlying assets.
Acquisitions
We account for acquisitions either as business combinations or asset acquisitions, based on whether the set of assets acquired meets the definition of a business. When an acquisition is determined to be a business combination, we apply the acquisition method of accounting. This method requires that the assets acquired and liabilities assumed be recorded at their fair values as of the acquisition date on our consolidated balance sheets. Any excess of the consideration transferred over the fair value of the net identifiable assets acquired is recognized as goodwill. The process of determining the fair value of assets and liabilities involves significant estimates and assumptions. During the measurement period, which may extend up to one year from the acquisition date, we may record adjustments to these fair values. Any such adjustments are recorded with a corresponding change to goodwill. Transaction costs incurred in connection with business combinations are expensed as incurred.
Goodwill and Intangible Assets
Goodwill represents the excess of purchase price over the fair value of net assets acquired and is carried at cost. Goodwill is tested at least annually for impairment by assessing qualitative factors in determining whether it is more likely than not that the fair value of net assets is below their carrying amounts. To date, an impairment of goodwill has not been recorded.
The fair value of acquired intangible assets is determined by applying the income-based approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. To estimate the expected cash flows attributable to an intangible asset, it requires the use of Level 3 fair value measurements and inputs. Finite-lived intangible assets are amortized on a straight-line basis over their estimated useful lives.
Impairment of Long-Lived Assets, including Intangibles and Lease Right-of-Use Assets We evaluate our long-lived assets, which consist of property, plant and equipment, intangibles and right-of-use assets to determine if facts and circumstances indicate that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, we assess the recoverability of the long-lived assets by comparing the projected future undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. If such review indicates that such cash flows are not expected to be sufficient to recover the recorded value of the assets, the assets are written down to their estimated fair values based on the expected discounted future cash flows attributable to the assets or based on appraisals.
Leases
Leases are classified at their commencement date, which is defined as the date on which the lessor makes the underlying asset available for use by the lessee, as either operating or finance leases based on the economic substance of the agreement. We recognize lease right-of-use assets and related liabilities in our consolidated balance sheets for both operating and finance leases. Lease liabilities are measured at the lease commencement date as the present value of the future lease payments using the interest rate implicit in the lease. If the rate implicit is not readily determinable, we will utilize our incremental borrowing rate as of the lease commencement date. Lease right-of-use assets are measured as the lease liability plus initial direct costs and prepaid lease payments less lease incentives. The lease term is the non-cancelable period of the lease and includes options to extend or terminate the lease when it is reasonably certain that an option will be exercised.

We recognize operating lease cost in operating expenses in our consolidated statements of operations, inclusive of rent escalation provisions and rent holidays, on a straight-line basis over the respective lease term. For our finance leases, we recognize depreciation expense associated with the leased asset acquired and recognize interest expense related to the portion of the financing in our consolidated statements of operations.

We do not separate non-lease components from lease components for all classes of underlying assets. We do not recognize right-of-use assets and lease liabilities for leases with a lease term of 12 months or less. Instead, these lease payments are recognized in the statements of operations on a straight-line basis over the lease term.
Collaboration Arrangements
We analyze our collaboration arrangements to assess whether they are within the scope of ASC 808 (Collaborative Arrangements) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, we assess whether aspects of the arrangement between us and our collaboration partner are within the scope of other accounting literature. If we conclude that some or all aspects of the arrangement represent a transaction with a customer, we account for those aspects of the arrangement within the scope of ASC 606 (Revenue from Contracts with Customers). Please refer to our "Revenue Recognition" policy within Note 2 for additional discussion of revenue recognition under these types of arrangements. If we conclude that some or all aspects of the arrangement are within the scope of ASC 808 and do not represent a transaction with a customer, we recognize our allocation of the shared costs incurred with respect to the jointly conducted activities as a component of the related expense in the period incurred. Additionally, for any payments related to capital expenditures that are partially reimbursed by a collaboration partner, to the extent the underlying capital costs qualify for capitalization, any reimbursements received will offset the capitalized cost of the asset.
Research and Development Costs
Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, overhead costs, contract services, and other outside costs. The value of goods and services received from contract research organizations and contract manufacturing organizations in the reporting period are estimated based on the level of services performed, and progress in the period in cases when we have not received an invoice from the supplier. Research and development costs also include costs and shared cost associated with third-party collaboration arrangements, including upfront fees and milestones paid to third-parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use.
Assets that are acquired or constructed for research and development activities and that have alternative future uses, in research and development projects or otherwise, are capitalized and depreciated over their useful lives. However, the costs of equipment or facilities that are acquired or constructed and intangibles that are purchased from others for a particular research and development project, and that have no alternative future uses and therefore no separate economic values, are considered research and development costs and expensed when incurred.
Advertising Costs Costs associated with advertising are expensed as incurred and are included in selling, general and administrative expense in the consolidated statements of operations
Stock-Based Compensation
We issue stock-based awards to employees and non-employees, generally in the form of stock options, restricted stock units (RSUs), and performance stock units (PSUs). We account for our stock-based compensation awards in accordance with ASC 718 (Compensation—Stock Compensation). Most of our stock-based awards have been made to employees. We measure compensation cost for equity awards at their grant-date fair value and recognize compensation expense over the requisite service period, which is generally the vesting period, on a straight-line basis. The grant date fair value of stock options is estimated using the Black-Scholes option pricing model, which requires management to make assumptions with respect to the fair value of our common stock on the grant date, including the expected term of the award, the expected volatility of our stock, calculated based on a period of time generally commensurate with the expected term of the award, risk-free interest rates and expected dividend yields of our stock. We estimate the expected term of our stock options granted to employees and non-employees using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. We utilize this method as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term, and because significant changes in our business over the past few years have rendered historical experience less relevant. The expected volatility is based on a blended average of average historical stock volatilities of selected guideline companies over the expected term of the stock options, historical volatility of our stock price, and implied stock price volatility derived from the price of exchange traded options on our stock. Given the transformative changes in our business, we believe that a blended volatility rate is more indicative of future volatility than our historical volatility alone. We will continue to apply this process until a sufficient amount of historical information regarding the expected term and historical volatility of our own stock price becomes available, and until we believe that historical experience is relevant to our expectations for current grants. The grant date fair value of RSUs is estimated based on the fair value of our underlying common stock. For performance-based stock awards, we recognize stock-based compensation expense over the requisite service period using the accelerated attribution method when achievement is probable. We classify stock-based compensation expense in our consolidated statements of operations in the same manner in which the award recipient’s salary and related costs are classified or in which the award recipient’s service payments are classified. We made an accounting policy election to recognize forfeitures of stock-based awards as they occur.
Income Taxes
We account for income taxes based on an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a “more likely than not” criterion. We periodically reassess the need for valuation allowances on our deferred tax assets, considering both positive and negative evidence to evaluate whether it is more likely than not that all or a portion of such assets will not be realized. We make estimates and judgments about our future taxable income that are based on assumptions that are consistent with our plans and estimates. Should the actual amounts differ from our estimates, the amount of our valuation allowance could be materially impacted. Changes in these estimates may result in significant increases or decreases to our tax provision in a period in which such estimates are changed, which in turn would affect net income or loss. We recognize tax benefits from uncertain tax positions if we believe the position is more likely than not to be sustained on examination by the taxing authorities based on the technical merits of the position. We make adjustments
to these tax reserves when facts and circumstances change, such as the closing of a tax audit or the refinement of an estimate. The provision for income taxes includes the effects of any reserves for uncertain tax positions, as well as the related net interest and penalties.
Earnings (Loss) per Share
We calculate diluted net earnings (loss) per share attributable to common stockholders by dividing net earnings (loss) by the weighted average number of common shares outstanding after giving consideration to the dilutive effect of restricted common stock and stock options that are outstanding during the period. For periods in which we have generated a net loss, the basic and diluted net loss per share attributable to common stockholders are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.
Comprehensive Income (Loss)
Comprehensive income (loss) includes net income (loss) and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains and losses on our investments and derivatives designated as hedging instruments. Total comprehensive income (loss) for all periods presented has been disclosed in the consolidated statements of comprehensive income (loss).
Share Repurchases
Shares of our common stock repurchased pursuant to our repurchase programs are retired. The purchase price of such repurchased shares of common stock is recorded as a reduction to additional paid-in-capital. If the balance in additional paid-in-capital is exhausted, the excess is recorded as a reduction to retained earnings.
Recently Issued Accounting Standards Not Yet Adopted
From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Except as noted below, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU broadens the disclosure requirements by requiring disclosures of significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit or loss. The standard also requires entities to disclose, on an interim and annual basis, the amount and description, including the nature and type, of the other segment items. Additionally, entities are required to disclose the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. These enhanced disclosure obligations apply to entities that operate with one reportable segment as well. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. Early adoption is permitted. We are currently assessing the impact that this new accounting standard will have on our consolidated financial statements and disclosures.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. The standard requires entities to disclose federal, state, and foreign income taxes in their rate reconciliation tables
and elaborate on reconciling items that exceed a quantitative threshold. Additionally, it requires an annual disclosure of income taxes paid, net of refunds, categorized by jurisdiction based on a quantitative threshold. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in our consolidated financial statements, once adopted.
XML 52 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Schedule of Reconciliation of Cash and Cash Equivalents
The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):
December 31,
202320222021
Cash and cash equivalents $2,907 $3,205 $6,848 
Restricted cash(1)
17 — — 
Restricted cash, non-current(2)
4 12 12 
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows$2,928 $3,217 $6,860 
_______
(1)Included in prepaid expenses and other current assets in the consolidated balance sheets.
(2)Included in other non-current assets in the consolidated balance sheets.
Schedule of Reconciliation of Restricted Cash
The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):
December 31,
202320222021
Cash and cash equivalents $2,907 $3,205 $6,848 
Restricted cash(1)
17 — — 
Restricted cash, non-current(2)
4 12 12 
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows$2,928 $3,217 $6,860 
_______
(1)Included in prepaid expenses and other current assets in the consolidated balance sheets.
(2)Included in other non-current assets in the consolidated balance sheets.
Schedule of Entities that Accounted for More than 10% of Total Revenue and Accounts Receivable
A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented:
Percentage of Revenue
Years Ended December 31,
Percentage of 
Accounts Receivable
December 31,
20232022202120232022
FFF Enterprises***39 %*
European Commission*28 %32 %*29 %
U.S. Government (excluding BARDA)*23 %29 %**
Takeda Pharmaceutical Company*10 %***
Ministry of Health, Labor, and Welfare of Japan21 %***30 %
UK Health Security Agency***35 %11 %
________
* - Represents an amount of less than 10%
Schedule of Estimated Useful Lives of Property and Equipment The estimated useful lives of property, plant and equipment are described below:
Estimated Useful Life
Land and land improvementsNot depreciated
Manufacturing and laboratory equipment5 years
Leasehold improvements
Lesser of estimated useful life of improvement
or remaining life of related lease
Computer equipment and software
3 to 5 years
Furniture and fixtures5 years
Right-of-use asset, financingLease term
Property, plant and equipment, net as of December 31, 2023 and 2022 consisted of the following (in millions):
December 31,
20232022
Land and land improvements$22 $11 
Manufacturing and laboratory equipment345 284 
Leasehold improvements522 460 
Furniture and fixtures26 21 
Computer equipment and software
74 38 
Construction in progress
860 281 
Right-of-use assets, financing (Note 10)
529 1,581 
Total
2,378 2,676 
Less: Accumulated depreciation
(433)(658)
Property, plant and equipment, net$1,945 $2,018 
Schedule of Components of Accumulated Other Comprehensive Income (Loss)
The components of accumulated other comprehensive loss for the years ended December 31, 2023 and 2022 were as follows (in millions): 
Unrealized (Loss) Gain on Available-for-Sale Securities
Net Unrealized Gain (Loss) on Derivatives Designated As Hedging Instruments
Pension and Postretirement Benefits
Total
Accumulated other comprehensive loss, balance at December 31, 2021$(40)$16 $— $(24)
Other comprehensive loss(322)(24)— (346)
Accumulated other comprehensive loss, balance at December 31, 2022(362)(8)— (370)
Other comprehensive income (loss)248 8 (9)247 
Accumulated other comprehensive loss, balance at December 31, 2023$(114)$— $(9)$(123)
XML 53 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
Net Product Sales (Tables)
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Revenue from External Customers by Geographic Areas
Net product sales by customer geographic location were as follows for the periods presented (in millions):
Years Ended December 31,
202320222021
United States$1,720 $4,405 $5,393 
Europe1,353 6,732 6,834 
Rest of world
3,598 7,298 5,448 
Total $6,671 $18,435 $17,675 
Total revenue by geographic area of our customers and collaboration partners was as follows (in millions):
Years Ended December 31,
202320222021
United States$1,895 $5,150 $6,177 
Europe1,355 6,815 6,846 
Rest of world
3,598 7,298 5,448 
Total $6,848 $19,263 $18,471 

Our property, plant and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):
December 31,
20232022
United States$1,560 $1,267 
Europe126 714 
Rest of world259 37 
Total$1,945 $2,018 
Schedule of Disaggregation of Revenue
The following table summarizes product sales provision for the periods presented (in millions):
Years Ended December 31,
202320222021
Gross product sales $8,203 $18,435 $17,675 
Product sales provision:
Wholesaler chargebacks, discounts and fees
(976)— — 
Returns and other fees(556)— — 
Total product sales provision
$(1,532)$— $— 
Net product sales $6,671 $18,435 $17,675 
The following table summarizes other revenue for the periods presented (in millions):
Years Ended December 31,
202320222021
Grant revenue$94 $388 $735 
Collaboration revenue83 440 61 
Total other revenue$177 $828 $796 
The following table summarizes grant revenue for the periods presented (in millions):
Years Ended December 31,
202320222021
BARDA$88 $372 $713 
Other grant revenue6 16 22 
Total grant revenue$94 $388 $735 
The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):
Years Ended December 31,
Collaboration Revenue by Strategic Collaborator:202320222021
Vertex$82 $48 $26 
Merck— 309 23 
AstraZeneca— 80 7 
Other1 3 5 
Total collaboration revenue$83 $440 $61 
Schedule of Changes in Balances of Receivables and Contract Liabilities
The following table summarizes the activities related to product sales provision recorded as accrued liabilities for the year ended December 31, 2023 (in millions):
Returns and other fees
Balance at December 31, 2022$— 
Provision related to sales made in current period(556)
Balance at December 31, 2023$(556)
The following table summarizes the activities in deferred revenue during the year ended December 31, 2023 (in millions):
December 31, 2022AdditionsDeductionsDecember 31, 2023
Net product sales
$2,626 $515 $(2,528)$613 
Grant revenue4 2 (2)4 
Collaboration revenue81 31 (78)34 
Total deferred revenue$2,711 $548 $(2,608)$651 
XML 54 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
Other Revenue (Tables)
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table summarizes product sales provision for the periods presented (in millions):
Years Ended December 31,
202320222021
Gross product sales $8,203 $18,435 $17,675 
Product sales provision:
Wholesaler chargebacks, discounts and fees
(976)— — 
Returns and other fees(556)— — 
Total product sales provision
$(1,532)$— $— 
Net product sales $6,671 $18,435 $17,675 
The following table summarizes other revenue for the periods presented (in millions):
Years Ended December 31,
202320222021
Grant revenue$94 $388 $735 
Collaboration revenue83 440 61 
Total other revenue$177 $828 $796 
The following table summarizes grant revenue for the periods presented (in millions):
Years Ended December 31,
202320222021
BARDA$88 $372 $713 
Other grant revenue6 16 22 
Total grant revenue$94 $388 $735 
The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):
Years Ended December 31,
Collaboration Revenue by Strategic Collaborator:202320222021
Vertex$82 $48 $26 
Merck— 309 23 
AstraZeneca— 80 7 
Other1 3 5 
Total collaboration revenue$83 $440 $61 
XML 55 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
Financial Instruments and Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]  
Schedule of Cash and Available-for-Sale Securities by Significant Investment Category
The following tables summarize our cash and available-for-sale securities by significant investment category at December 31, 2023 and 2022 (in millions):
December 31, 2023
Amortized
Cost
Unrealized
Gains
Unrealized
Losses
Fair Value
Cash and
Cash
Equivalents
Current
Marketable
Securities
Non-
Current
Marketable
Securities
Cash and cash equivalents$2,907 $— $— $2,907 $2,907 $— $— 
Available-for-sale:
Certificates of deposit27 — — 27 — 27 — 
U.S. treasury bills807 — — 807 — 807 — 
U.S. treasury notes4,407 3 (67)4,343 — 2,664 1,679 
Corporate debt securities5,067 3 (81)4,989 — 2,082 2,907 
Government debt securities211 — (3)208 — 117 91 
Total$13,426 $6 $(151)$13,281 $2,907 $5,697 $4,677 
December 31, 2022
Amortized
Cost
Unrealized
Gains
Unrealized
Losses
Fair Value
Cash and
Cash
Equivalents
Current
Marketable
Securities
Non-
Current
Marketable
Securities
Cash and cash equivalents$3,205 $— $— $3,205 $3,205 $— $— 
Available-for-sale:
Certificates of deposit188 — — 188 — 188 — 
U.S. treasury bills767 — — 767 — 767 — 
U.S. treasury notes7,781 — (229)7,552 — 4,182 3,370 
Corporate debt securities6,595 — (226)6,369 — 1,560 4,809 
Government debt securities148 — (9)139 — — 139 
Total$18,684 $— $(464)$18,220 $3,205 $6,697 $8,318 
Schedule of Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity
The amortized cost and estimated fair value of available-for-sale securities, by contractual maturity at December 31, 2023 and 2022 were as follows (in millions):
December 31, 2023
Amortized
Cost
Estimated
Fair Value
Due in one year or less
$5,751 $5,697 
Due after one year through five years
4,768 4,677 
Total$10,519 $10,374 
December 31, 2022
Amortized
Cost
Estimated
Fair Value
Due in one year or less$6,792 $6,697 
Due after one year through five years8,687 8,318 
Total$15,479 $15,015 
Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value
The following table summarizes the amount of gross unrealized losses and the estimated fair value for our available-for-sale securities in an unrealized loss position by length of time the securities have been in an unrealized loss position at December 31, 2023 and 2022 (in millions):
Less than 12 Months12 Months or MoreTotal
Gross Unrealized LossesEstimated Fair ValueGross Unrealized LossesEstimated Fair ValueGross Unrealized LossesEstimated Fair Value
As of December 31, 2023:
U.S. treasury bills$— $25 $— $— $— $25 
U.S. treasury notes(3)774 (64)2,983 (67)3,757 
Corporate debt securities(1)562 (79)3,518 (80)4,080 
Government debt securities— 8 (4)143 (4)151 
Total$(4)$1,369 $(147)$6,644 $(151)$8,013 
As of December 31, 2022:
U.S. treasury securities$— $128 $— $— $— $128 
U.S. treasury notes(101)3,956 (128)3,541 (229)7,497 
Corporate debt securities(138)3,505 (88)1,890 (226)5,395 
Government debt securities(2)46 (7)93 (9)139 
Total$(241)$7,635 $(223)$5,524 $(464)$13,159 
Schedule of Financial Assets Measured at Fair Value on Recurring Basis
The following tables summarize our financial assets measured at fair value on a recurring basis as of December 31, 2023 and 2022 (in millions):
Fair value at December 31, 2023Fair Value Measurement Using
Level 1Level 2
Assets:
Money market funds$1,572 $1,572 $— 
Certificates of deposit27 — 27 
U.S. treasury bills1,246 — 1,246 
U.S. treasury notes4,343 — 4,343 
Corporate debt securities5,480 — 5,480 
Government debt securities208 — 208 
Equity investments(1)
24 24 — 
Derivative instruments4 — 4 
Total$12,904 $1,596 $11,308 
Liabilities:
Derivative instruments
$9 $— $9 
Fair value at December 31, 2022Fair Value Measurement Using
Level 1Level 2
Assets:
Money market funds$1,079 $1,079 $— 
Certificates of deposit188 — 188 
U.S. treasury bills767 — 767 
U.S. treasury notes7,552 — 7,552 
Corporate debt securities6,369 — 6,369 
Government debt securities139 — 139 
Derivative instruments
6 — 6 
Total$16,100 $1,079 $15,021 
Liabilities:
Derivative instruments
$32 $— $32 
_______
(1)Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in other expense net, in our consolidated statements of operations.
XML 56 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
Inventory (Tables)
 12 Months Ended
Dec. 31, 2023
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current
Inventory, as of December 31, 2023 and 2022 consisted of the following (in millions):
December 31,
20232022
Raw materials$163 $575 
Work in progress 15 205 
Finished goods24 169 
Total inventory$202 $949 
Inventory, non-current(1)
$170 $910 
_______
(1)Consisted of raw materials with an anticipated consumption beyond one year. Inventory, non-current is included in other non-current assets in the consolidated balance sheets.
XML 57 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
Property, Plant and Equipment, Net (Tables)
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Schedule of Property, Plant and Equipment, Net The estimated useful lives of property, plant and equipment are described below:
Estimated Useful Life
Land and land improvementsNot depreciated
Manufacturing and laboratory equipment5 years
Leasehold improvements
Lesser of estimated useful life of improvement
or remaining life of related lease
Computer equipment and software
3 to 5 years
Furniture and fixtures5 years
Right-of-use asset, financingLease term
Property, plant and equipment, net as of December 31, 2023 and 2022 consisted of the following (in millions):
December 31,
20232022
Land and land improvements$22 $11 
Manufacturing and laboratory equipment345 284 
Leasehold improvements522 460 
Furniture and fixtures26 21 
Computer equipment and software
74 38 
Construction in progress
860 281 
Right-of-use assets, financing (Note 10)
529 1,581 
Total
2,378 2,676 
Less: Accumulated depreciation
(433)(658)
Property, plant and equipment, net$1,945 $2,018 
XML 58 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
Other Balance Sheet Components (Tables)
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Accounts, Notes, Loans and Financing Receivable
Accounts receivable, net, as of December 31, 2023 and December 31, 2022 consisted of the following (in millions):
December 31,
20232022
Accounts receivable$1,584 $1,385 
Less: Wholesalers chargebacks, discounts and fees
(692)— 
Accounts receivable, net$892 $1,385 
Schedule of Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets, as of December 31, 2023 and 2022 consisted of the following (in millions):
December 31,
20232022
Prepaid services$182 $216 
Down payments to manufacturing vendors100 229 
Down payments for materials and supplies68 219 
Collaboration receivable61 11 
Interest receivable59 61 
Value added tax receivable50 140 
Income tax receivable19 10 
Tenant improvement allowance receivable— 42 
Prepaid income taxes— 187 
Convertible note receivable— 36 
Other current assets88 44 
Prepaid expenses and other current assets
$627 $1,195 
Schedule of Other Assets, Noncurrent
Other non-current assets, as of December 31, 2023 and 2022 consisted of the following (in millions):
December 31,
20232022
Down payments and prepayments, non-current
$342 $— 
Inventory, non-current(1)
170 910 
Equity investments66 42 
Goodwill
52 — 
Finite-lived intangible asset
44 — 
Restricted cash4 12 
Other7 24 
Other non-current assets$685 $988 
_______
(1)Consisted of raw materials with an anticipated consumption beyond one year.
Schedule of Accrued Liabilities
Accrued liabilities, as of December 31, 2023 and 2022 consisted of the following (in millions):
December 31,
20232022
Provisions related to product sales (Note 3)
$556 $— 
Compensation-related245 190 
Clinical trials175 319 
Manufacturing167 400 
Development operations140 88 
Other external goods and services137 264 
Royalties122 203 
Property, plant and equipment94 5 
Loss on future firm purchase commitments(1)
79 268 
Commercial56 48 
Raw materials27 316 
Accrued liabilities$1,798 $2,101 
______
(1)Related to losses that are expected to arise from firm, non-cancellable, commitments for future raw material purchases (Note 7).
Schedule of Other Current Liabilities
Other current liabilities, as of December 31, 2023 and 2022 consisted of the following (in millions):
December 31,
20232022
Lease liabilities - financing (Note 10)
$— $161 
Lease liabilities - operating (Note 10)
25 35 
Other41 53 
Other current liabilities$66 $249 
Schedule of Deferred Revenue
The following table summarizes the activities related to product sales provision recorded as accrued liabilities for the year ended December 31, 2023 (in millions):
Returns and other fees
Balance at December 31, 2022$— 
Provision related to sales made in current period(556)
Balance at December 31, 2023$(556)
The following table summarizes the activities in deferred revenue during the year ended December 31, 2023 (in millions):
December 31, 2022AdditionsDeductionsDecember 31, 2023
Net product sales
$2,626 $515 $(2,528)$613 
Grant revenue4 2 (2)4 
Collaboration revenue81 31 (78)34 
Total deferred revenue$2,711 $548 $(2,608)$651 
XML 59 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases (Tables)
 12 Months Ended
Dec. 31, 2023
Leases [Abstract]  
Schedule of Assets And Liabilities, Lessee
Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2023 and 2022 were as follows (in millions):
December 31,
20232022
Assets:
Right-of-use assets, operating, net(1) (2)
$713 $121 
Right-of-use assets, financing, net(3) (4)
436 1,150 
Total$1,149 $1,271 
Liabilities:
Current:
Operating lease liabilities(5)
$25 $35 
Financing lease liabilities(5)
— 161 
Total current lease liabilities 25 196 
Non-current:
Operating lease liabilities, non-current643 92 
Financing lease liabilities, non-current575 912 
Total non-current lease liabilities1,218 1,004 
Total$1,243 $1,200 
_______
(1) These assets are real estate related assets, which include land, office and laboratory spaces.
(2) Net of accumulated amortization.
(3) These assets are real estate assets related to the MTC leases as well as assets related to contract manufacturing service agreements.
(4) Included in property, plant and equipment in the consolidated balance sheets, net of accumulated depreciation.
(5) Included in other current liabilities in the consolidated balance sheets.
Schedule of Lease, Cost
The components of the lease costs were as follows for the periods presented (in millions):
Years ended December 31,
202320222021
Operating lease costs$88 $48 $24 
Financing lease costs:
   Amortization of right-of-use assets, financing leases500 280 189 
   Interest expense for financing lease liabilities38 29 17 
Total financing lease costs$538 $309 $206 
Short term lease costs$2 $— $49 
Variable lease costs$113 $165 $100 
Supplemental cash flow information relating to our leases was as follows for the periods presented (in millions):
December 31,
202320222021
Cash paid for amounts included in measurement of lease liabilities:
Operating cash flows used in operating leases$(93)$(57)$(19)
Operating cash flows used in financing leases(39)(25)(14)
Financing cash flows used in financing leases
(292)(184)(140)
Operating lease non-cash items:
Changes in right-of-use assets related to lease modifications and reassessments$67 $— $(7)
Right-of-use assets obtained in exchange for operating lease liabilities714 20 72 
Finance lease non-cash items:
Changes in right-of-use assets related to lease modifications and reassessments$213 $— $674 
Right-of-use assets obtained in exchange for financing lease liabilities— 777 126 
Changes in financing lease liabilities3 4 3 

Weighted average remaining lease terms and discount rates as of December 31, 2023 and 2022 were as follows:
December 31,
20232022
Remaining lease term:
Operating leases14 years6 years
Finance leases33 years22 years
Discount rate:
Operating leases7.5 %7.5 %
Finance leases4.2 %3.6 %
Schedule of Finance Lease Maturity
Future minimum lease payments under non-cancelable lease agreements as of December 31, 2023, were as follows (in millions):
Fiscal YearOperating Leases
Financing Leases(1)
2024$72 $20 
202567 22 
202667 22 
202770 23 
202872 23 
Thereafter785 1,074 
Total minimum lease payments1,133 1,184 
Less amounts representing interest(465)(609)
Present value of lease liabilities$668 $575 
______
(1) Include certain optional lease term extensions, predominantly related to the MTC leases, which represent a total of $668 million of undiscounted future lease payments.
Schedule of Operating Lease Maturity
Future minimum lease payments under non-cancelable lease agreements as of December 31, 2023, were as follows (in millions):
Fiscal YearOperating Leases
Financing Leases(1)
2024$72 $20 
202567 22 
202667 22 
202770 23 
202872 23 
Thereafter785 1,074 
Total minimum lease payments1,133 1,184 
Less amounts representing interest(465)(609)
Present value of lease liabilities$668 $575 
______
(1) Include certain optional lease term extensions, predominantly related to the MTC leases, which represent a total of $668 million of undiscounted future lease payments.
XML 60 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation and Share Repurchase Programs (Tables)
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Options Activity The following table summarizes our option activity during the year ended December 31, 2023:
Number of
Options
(in millions)		Weighted
Average
Exercise
Price per
Share		Weighted-
Average
Remaining
Contractual
Term
Aggregate
Intrinsic
Value(1)
(in millions)
Outstanding at December 31, 202224.93 $42.23 5.7 years$3,478 
Granted
4.36 113.03 
Exercised
(3.11)8.13 
Canceled/forfeited
(0.68)130.23 
Outstanding at December 31, 202325.50 56.14 5.6 years1,437 
Exercisable at December 31, 202318.98 33.34 4.5 years1,378 
Expected to vest at December 31, 20236.52 122.50 8.9 years59 
_______
(1)Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of December 31, 2023.
Schedule of Restricted Common Stock Units Activity The following table summarizes our RSU and PSU activity during the year ended December 31, 2023:
Number of Units
(in millions)
Weighted Average
Grant Date Fair Value per Unit
Outstanding, non-vested at December 31, 20222.90 $132.25 
Issued
3.71 107.23 
Vested
(1.01)98.68 
Canceled/forfeited
(0.42)130.01 
Outstanding, non-vested at December 31, 20235.18 121.02 
Schedule of Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted The weighted-average assumptions used to estimate the fair value of options granted for the years ended December 31, 2023, 2022, and 2021 were as follows:
Weighted Average
Years Ended December 31,
202320222021
Options:
    Risk-free interest rate
4.13 %2.46 %0.84 %
    Expected term
6.07 years6.13 years6.10 years
    Expected volatility
48 %50 %46 %
    Expected dividends
— %— %— %
    Weighted average fair value per share
$57.87 $76.02 $91.84 
Schedule of Stock-Based Compensation Expense
The following table presents the components and classification of stock-based compensation expense for the years ended December 31, 2023, 2022, and 2021 (in millions):
Years Ended December 31,
202320222021
Options
$136 $123 $96 
RSUs and PSUs161 97 42 
Employee stock purchase plan
8 6 4 
Total
$305 $226 $142 
Cost of sales$37 $45 $22 
Research and development
157 93 68 
Selling, general and administrative111 88 52 
Total
$305 $226 $142 
Summary of Share Repurchase Program
The following table summarizes activity related to our share repurchase programs (in millions, except per share data):
Years Ended December 31,
202320222021
Number of shares repurchased8233
Average price per share(1)
$143.26 $142.83 $245.76 
Aggregate purchase price$1,153 $3,329 $857 
Remaining authorization at end of period$1,667 $2,814 $143 
_______
(1)Average price paid per share includes related expenses and excise tax, applicable beginning January 1, 2023.
XML 61 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of (Loss) Income Before Provision For (Benefit From) Income Taxes
(Loss) income before income taxes for the years ended December 31, 2023, 2022, and 2021 consisted of the following (in millions):
Years Ended December 31,
202320222021
United States
$(4,056)$9,433 $13,108 
Foreign
114 142 177 
(Loss) income before income taxes$(3,942)$9,575 $13,285 
Schedule of Provision For (Benefit From) Income Taxes
The provision for income taxes for the years ended December 31, 2023, 2022, and 2021 consisted of the following components (in millions):
Years Ended December 31,
202320222021
Current:
Federal$(225)$1,687 $1,304 
State72 47 35 
Foreign24 57 40 
Total current$(129)$1,791 $1,379 
Deferred:
Federal$888 $(569)$(288)
State8 (7)(6)
Foreign5 (2)(2)
Total deferred901 (578)(296)
Total provision for income taxes$772 $1,213 $1,083 
Schedule of Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate
The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31, 2023, 2022, and 2021 was as follows:
Years Ended December 31,
202320222021
Federal statutory tax rate21.0 %21.0 %21.0 %
Change in valuation allowance
(52.6)%— %(5.4)%
Foreign-derived intangible income0.2 %(7.4)%(4.8)%
Stock-based compensation windfall2.4 %(1.6)%(2.6)%
Federal research and development credits
4.6 %(0.5)%(0.7)%
State taxes, net of federal benefits5.7 %0.4 %0.5 %
Non-deductible items(0.4)%— %— %
Other
(0.5)%0.8 %0.1 %
Effective tax rate
(19.6)%12.7 %8.1 %
Schedule of Significant Components of Deferred Tax Assets and Tax Liabilities Significant components of our deferred tax assets and tax liabilities as of December 31, 2023 and 2022 were as follows (in millions):
December 31,
20232022
Deferred tax assets:
Net operating loss carryforwards$90 $59 
Stock-based compensation111 68 
Capitalized licenses, research and development and start-up costs1,449 704 
Tax credit carryforwards140 97 
Operating lease liabilities154 26 
Financing lease liabilities139 135 
Other comprehensive income34 106 
Inventory reserve and capitalization 250 86 
Wholesaler chargebacks, discounts and fees
92 — 
Returns and other fees
129 — 
Other90 85 
Total deferred tax assets2,678 1,366 
Less: valuation allowance
(2,224)(155)
Net deferred tax assets$454 $1,211 
Deferred tax liabilities:
Right-of-use assets, financing$(106)$(117)
Right-of-use assets, operating(160)(26)
Property, plant and equipment(107)(85)
Other(15)(1)
Total deferred tax liabilities
(388)(229)
Net deferred tax (liabilities) assets
$66 $982 
Schedule of Summary of Valuation Allowance
The table below summarizes changes in the valuation allowance for deferred tax assets for the periods presented (in millions):
Years Ended December 31,
202320222021
Valuation allowance at beginning of the period$155 $149 $823 
Decreases recorded as benefit to income tax provision— (12)(722)
Increases to valuation allowance2,069 18 48 
Valuation allowance at December 31$2,224 $155 $149 
Schedule of Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward A reconciliation of the beginning and ending amounts of unrecognized tax benefits during the years ended December 31, 2023, 2022, and 2021 were as follows (in millions):
Years Ended December 31,
202320222021
Unrecognized tax benefits at beginning of the period$128 $68 $— 
Decrease due to prior positions:
Tax positions for prior years— (1)— 
Expiration of statutes— — — 
Settlements with tax authorities(27)— — 
Increase due to current year tax positions:
Additions based on tax positions for current year44 57 54 
Additions based on tax positions for prior years86 4 14 
Unrecognized tax benefits at end of the period $231 $128 $68 
XML 62 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
(Loss) Earnings per Share (Tables)
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Earnings Per Share
Basic and diluted EPS for the years ended December 31, 2023, 2022 and 2021 were calculated as follows (in millions, except per share data):
Years Ended December 31,
202320222021
Numerator:
Net (loss) income
$(4,714)$8,362 $12,202 
Denominator:
Basic weighted-average common shares outstanding382 394 403 
Effect of dilutive securities— 22 28 
Diluted weighted-average common shares outstanding382 416 431 
Basic EPS$(12.33)$21.26 $30.31 
Diluted EPS$(12.33)$20.12 $28.29 
Schedule of Common Stock Equivalents Excluded from Calculation of Diluted Net Income (Loss) Per Share
The following common stock equivalents, presented based on amounts outstanding as of December 31, 2023, 2022 and 2021, were excluded from the calculation of diluted net (loss) income per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):
December 31,
202320222021
Options26 3 1 
RSUs and PSUs5 — — 
Total31 3 1 
XML 63 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
Geographic Information (Tables)
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Revenue from External Customers by Geographic Areas
Net product sales by customer geographic location were as follows for the periods presented (in millions):
Years Ended December 31,
202320222021
United States$1,720 $4,405 $5,393 
Europe1,353 6,732 6,834 
Rest of world
3,598 7,298 5,448 
Total $6,671 $18,435 $17,675 
Total revenue by geographic area of our customers and collaboration partners was as follows (in millions):
Years Ended December 31,
202320222021
United States$1,895 $5,150 $6,177 
Europe1,355 6,815 6,846 
Rest of world
3,598 7,298 5,448 
Total $6,848 $19,263 $18,471 

Our property, plant and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):
December 31,
20232022
United States$1,560 $1,267 
Europe126 714 
Rest of world259 37 
Total$1,945 $2,018 
XML 64 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
Description of the Business (Details)
Dec. 31, 2023
developmentProgram
candidate
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of development candidates | candidate 42
Number of development programs 45
Number of development programs under clinical studies 40
XML 65 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies - Narrative (Details)
 12 Months Ended
Jan. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
segment
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Number of operating segments | segment   1    
Description of payment terms   Payment terms generally range from 30 to 60 days    
Allowance for doubtful accounts   $ 0 $ 0  
Bad debt expense   0 0 $ 0
Goodwill   52,000,000 0  
Impairment expenses   0 0 0
Advertising expenses   $ 204,000,000 $ 121,000,000 $ 0
OriCiro Genomics KK        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Payment to acquire business $ 86,000,000      
Goodwill 52,000,000      
OriCiro Genomics KK | Technology        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Finite-lived intangible assets acquired $ 48,000,000      
XML 66 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Accounting Policies [Abstract]        
Cash and cash equivalents $ 2,907 $ 3,205 $ 6,848  
Restricted cash 17 0 0  
Restricted cash, non-current 4 12 12  
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows $ 2,928 $ 3,217 $ 6,860 $ 2,636
XML 67 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies - Significant Customers (Details) - Customer Concentration Risk
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Percentage of Revenue | European Commission      
Concentration Risk [Line Items]      
Concentration risk, percentage   28.00% 32.00%
Percentage of Revenue | U.S. Government (excluding BARDA)      
Concentration Risk [Line Items]      
Concentration risk, percentage   23.00% 29.00%
Percentage of Revenue | Takeda Pharmaceutical Company      
Concentration Risk [Line Items]      
Concentration risk, percentage   10.00%  
Percentage of Revenue | Ministry of Health, Labor, and Welfare of Japan      
Concentration Risk [Line Items]      
Concentration risk, percentage 21.00%    
Percentage of Accounts Receivable | FFF Enterprises      
Concentration Risk [Line Items]      
Concentration risk, percentage 39.00%    
Percentage of Accounts Receivable | European Commission      
Concentration Risk [Line Items]      
Concentration risk, percentage   29.00%  
Percentage of Accounts Receivable | Ministry of Health, Labor, and Welfare of Japan      
Concentration Risk [Line Items]      
Concentration risk, percentage   30.00%  
Percentage of Accounts Receivable | UK Health Security Agency      
Concentration Risk [Line Items]      
Concentration risk, percentage 35.00% 11.00%  
XML 68 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies - Property and Equipment and Software Capitalization (Details)
Dec. 31, 2023
Manufacturing and laboratory equipment  
Property, Plant and Equipment [Line Items]  
Estimated Useful Life 5 years
Computer equipment and software | Minimum  
Property, Plant and Equipment [Line Items]  
Estimated Useful Life 3 years
Computer equipment and software | Maximum  
Property, Plant and Equipment [Line Items]  
Estimated Useful Life 5 years
Furniture and fixtures  
Property, Plant and Equipment [Line Items]  
Estimated Useful Life 5 years
XML 69 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies - Components of Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Balance at beginning of period $ 19,123 $ 14,145 $ 2,561
Other comprehensive income (loss) 247 (346) (27)
Balance at end of period 13,854 19,123 14,145
Total      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Balance at beginning of period (370) (24) 3
Other comprehensive income (loss) 247 (346) (27)
Balance at end of period (123) (370) (24)
Unrealized (Loss) Gain on Available-for-Sale Securities      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Balance at beginning of period (362) (40)  
Other comprehensive income (loss) 248 (322)  
Balance at end of period (114) (362) (40)
Net Unrealized Gain (Loss) on Derivatives Designated As Hedging Instruments      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Balance at beginning of period (8) 16  
Other comprehensive income (loss) 8 (24)  
Balance at end of period 0 (8) 16
Pension and Postretirement Benefits      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Balance at beginning of period 0 0  
Other comprehensive income (loss) (9) 0  
Balance at end of period $ (9) $ 0 $ 0
XML 70 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
Net Product Sales - Net Product Sales by Customer Geographic Areas (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]      
Total revenue $ 6,848 $ 19,263 $ 18,471
Net product sales      
Disaggregation of Revenue [Line Items]      
Total revenue 6,671 18,435 17,675
United States      
Disaggregation of Revenue [Line Items]      
Total revenue 1,895 5,150 6,177
United States | Net product sales      
Disaggregation of Revenue [Line Items]      
Total revenue 1,720 4,405 5,393
Europe      
Disaggregation of Revenue [Line Items]      
Total revenue 1,355 6,815 6,846
Europe | Net product sales      
Disaggregation of Revenue [Line Items]      
Total revenue 1,353 6,732 6,834
Rest of world | Net product sales      
Disaggregation of Revenue [Line Items]      
Total revenue $ 3,598 $ 7,298 $ 5,448
XML 71 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
Net Product Sales - Narrative (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Disaggregation of Revenue [Line Items]    
Deferred revenue $ 651.0 $ 2,711.0
Net product sales    
Disaggregation of Revenue [Line Items]    
Deferred revenue 613.0 $ 2,626.0
Remaining performance obligations $ 554.0  
XML 72 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
Net Product Sales - Product Sales (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]      
Net product sales $ 6,848 $ 19,263 $ 18,471
Net product sales      
Disaggregation of Revenue [Line Items]      
Gross product sales 8,203 18,435 17,675
Wholesaler chargebacks, discounts and fees (976) 0 0
Returns and other fees (556) 0 0
Total product sales provision (1,532) 0 0
Net product sales $ 6,671 $ 18,435 $ 17,675
XML 73 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
Net Product Sales - Product Sales Provision Recorded as Accrued Liabilities (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2023
USD ($)
Change in Contract with Customer, Liability Refund [Roll Forward]  
Balance at December 31, 2022 $ 0
Balance at December 31, 2023 (556)
Net product sales  
Change in Contract with Customer, Liability Refund [Roll Forward]  
Balance at December 31, 2022 0
Provision related to sales made in current period (556)
Balance at December 31, 2023 $ (556)
XML 74 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
Other Revenue - Schedule of Disaggregation of Revenue (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]      
Total revenue $ 6,848 $ 19,263 $ 18,471
Grant revenue      
Disaggregation of Revenue [Line Items]      
Total revenue 94 388 735
Grant revenue | BARDA      
Disaggregation of Revenue [Line Items]      
Total revenue 88 372 713
Grant revenue | Other grant revenue      
Disaggregation of Revenue [Line Items]      
Total revenue 6 16 22
Collaboration revenue      
Disaggregation of Revenue [Line Items]      
Total revenue 83 440 61
Collaboration revenue | Vertex      
Disaggregation of Revenue [Line Items]      
Total revenue 82 48 26
Collaboration revenue | Merck      
Disaggregation of Revenue [Line Items]      
Total revenue 0 309 23
Collaboration revenue | AstraZeneca      
Disaggregation of Revenue [Line Items]      
Total revenue 0 80 7
Collaboration revenue | Other      
Disaggregation of Revenue [Line Items]      
Total revenue 1 3 5
Total other revenue      
Disaggregation of Revenue [Line Items]      
Total revenue $ 177 $ 828 $ 796
XML 75 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
Other Revenue - Narrative (Details)
$ in Millions
 1 Months Ended 44 Months Ended
Apr. 30, 2020
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2020
participant
Disaggregation of Revenue [Line Items]      
Number of participants | participant     30,000
BARDA      
Disaggregation of Revenue [Line Items]      
Award amount $ 483 $ 1,800  
Amount committed for funding   $ 97  
XML 76 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaboration Agreements - Merck – Personalized mRNA Cancer Vaccines (Details) - USD ($)
 1 Months Ended 12 Months Ended
Jun. 30, 2016
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Oct. 31, 2022
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Additions   $ 548,000,000      
Research and development   4,845,000,000 $ 3,295,000,000 $ 1,991,000,000  
Merck | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Proceeds From Option Exercise Fee         $ 250,000,000
Research and development   184,000,000 6,000,000    
Cost recovery   $ 102,000,000 $ 3,000,000    
PCV Agreement          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Additions $ 200,000,000        
XML 77 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaboration Agreements - Vertex – 2020 Strategic Alliance in Cystic Fibrosis (Details)
 1 Months Ended
Sep. 30, 2020
MRNA Vertex 2020 Agreement Member  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Initial research period 3 years
XML 78 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2013
Sep. 30, 2022
Dec. 31, 2023
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Additions     $ 548
Revenue recognized   $ 76  
2013 AZ Agreements      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Additions $ 240    
XML 79 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaboration Agreements - Immatics – Strategic Multi-Platform Collaboration to Develop Oncology Therapeutics (Details)
$ in Millions
Oct. 31, 2023
USD ($)
Immatics | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Upfront payment $ 120
XML 80 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
Financial Instruments and Fair Value Measurements - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost $ 10,519 $ 15,479
Level 2    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 13,426 18,684
Unrealized Gains 6 0
Unrealized Losses (151) (464)
Fair Value 13,281 18,220
Cash and Cash Equivalents | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 2,907 3,205
Current Marketable Securities | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 5,697 6,697
Non- Current Marketable Securities | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 4,677 8,318
Cash and Cash Equivalents | Level 1    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 2,907 3,205
Fair Value 2,907 3,205
Cash and Cash Equivalents | Cash and Cash Equivalents | Level 1    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 2,907 3,205
Certificates of deposit | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 27 188
Unrealized Gains 0 0
Unrealized Losses 0 0
Fair Value 27 188
Certificates of deposit | Cash and Cash Equivalents | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 0 0
Certificates of deposit | Current Marketable Securities | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 27 188
Certificates of deposit | Non- Current Marketable Securities | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 0 0
U.S. treasury bills | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 807 767
Unrealized Gains 0 0
Unrealized Losses 0 0
Fair Value 807 767
U.S. treasury bills | Cash and Cash Equivalents | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 0 0
U.S. treasury bills | Current Marketable Securities | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 807 767
U.S. treasury bills | Non- Current Marketable Securities | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 0 0
U.S. treasury notes | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 4,407 7,781
Unrealized Gains 3 0
Unrealized Losses (67) (229)
Fair Value 4,343 7,552
U.S. treasury notes | Cash and Cash Equivalents | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 0 0
U.S. treasury notes | Current Marketable Securities | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 2,664 4,182
U.S. treasury notes | Non- Current Marketable Securities | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 1,679 3,370
Corporate debt securities | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 5,067 6,595
Unrealized Gains 3 0
Unrealized Losses (81) (226)
Fair Value 4,989 6,369
Corporate debt securities | Cash and Cash Equivalents | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 0 0
Corporate debt securities | Current Marketable Securities | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 2,082 1,560
Corporate debt securities | Non- Current Marketable Securities | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 2,907 4,809
Government debt securities | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 211 148
Unrealized Gains 0 0
Unrealized Losses (3) (9)
Fair Value 208 139
Government debt securities | Cash and Cash Equivalents | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 0 0
Government debt securities | Current Marketable Securities | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 117 0
Government debt securities | Non- Current Marketable Securities | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value $ 91 $ 139
XML 81 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
Financial Instruments and Fair Value Measurements - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Amortized Cost    
Due in one year or less $ 5,751 $ 6,792
Due after one year through five years 4,768 8,687
Amortized Cost 10,519 15,479
Estimated Fair Value    
Due in one year or less 5,697 6,697
Due after one year through five years 4,677 8,318
Total $ 10,374 $ 15,015
XML 82 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
Financial Instruments and Fair Value Measurements - Narrative (Details)
 12 Months Ended
Dec. 31, 2023
USD ($)
security
Dec. 31, 2022
USD ($)
security
Dec. 31, 2021
USD ($)
Investments, Debt and Equity Securities [Abstract]      
Impairment charges $ 0 $ 0 $ 0
Credit losses related allowance $ 0 $ 0  
Number of AFS securities in loss positions | security 392 582  
Net losses $ 35,000,000    
Equity securities without readily determinable fair value, amount $ 42,000,000 $ 42,000,000  
XML 83 R58.htm IDEA: XBRL DOCUMENT v3.24.0.1
Financial Instruments and Fair Value Measurements - Unrealized Loss Position (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]    
Gross unrealized losses, less than 12 months $ (4) $ (241)
Estimated fair value, less than 12 months 1,369 7,635
Gross unrealized losses, 12 months or more (147) (223)
Estimated fair value, 12 months or more 6,644 5,524
Gross Unrealized Losses, Total (151) (464)
Estimated Fair Value, Total 8,013 13,159
U.S. treasury bills    
Debt Securities, Available-for-sale [Line Items]    
Gross unrealized losses, less than 12 months 0  
Estimated fair value, less than 12 months 25  
Gross unrealized losses, 12 months or more 0  
Estimated fair value, 12 months or more 0  
Gross Unrealized Losses, Total 0  
Estimated Fair Value, Total 25  
U.S. treasury securities    
Debt Securities, Available-for-sale [Line Items]    
Gross unrealized losses, less than 12 months   0
Estimated fair value, less than 12 months   128
Gross unrealized losses, 12 months or more   0
Estimated fair value, 12 months or more   0
Gross Unrealized Losses, Total   0
Estimated Fair Value, Total   128
U.S. treasury notes    
Debt Securities, Available-for-sale [Line Items]    
Gross unrealized losses, less than 12 months (3) (101)
Estimated fair value, less than 12 months 774 3,956
Gross unrealized losses, 12 months or more (64) (128)
Estimated fair value, 12 months or more 2,983 3,541
Gross Unrealized Losses, Total (67) (229)
Estimated Fair Value, Total 3,757 7,497
Corporate debt securities    
Debt Securities, Available-for-sale [Line Items]    
Gross unrealized losses, less than 12 months (1) (138)
Estimated fair value, less than 12 months 562 3,505
Gross unrealized losses, 12 months or more (79) (88)
Estimated fair value, 12 months or more 3,518 1,890
Gross Unrealized Losses, Total (80) (226)
Estimated Fair Value, Total 4,080 5,395
Government debt securities    
Debt Securities, Available-for-sale [Line Items]    
Gross unrealized losses, less than 12 months 0 (2)
Estimated fair value, less than 12 months 8 46
Gross unrealized losses, 12 months or more (4) (7)
Estimated fair value, 12 months or more 143 93
Gross Unrealized Losses, Total (4) (9)
Estimated Fair Value, Total $ 151 $ 139
XML 84 R59.htm IDEA: XBRL DOCUMENT v3.24.0.1
Financial Instruments and Fair Value Measurements - Financial Assets Measured At Fair Value On a Recurring Basis (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]    
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other current liabilities Other current liabilities
Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value $ 13,281 $ 18,220
Certificates of deposit | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 27 188
U.S. treasury bills | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 807 767
U.S. treasury notes | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 4,343 7,552
Corporate debt securities | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 4,989 6,369
Government debt securities | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 208 139
Fair value recurring    
Debt Securities, Available-for-sale [Line Items]    
Derivative instruments, assets 4 6
Total 12,904 16,100
Derivative instruments, liabilities 9 32
Fair value recurring | Level 1    
Debt Securities, Available-for-sale [Line Items]    
Derivative instruments, assets 0 0
Total 1,596 1,079
Derivative instruments, liabilities 0 0
Fair value recurring | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Derivative instruments, assets 4 6
Total 11,308 15,021
Derivative instruments, liabilities 9 32
Fair value recurring | Money market funds    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 1,572 1,079
Fair value recurring | Money market funds | Level 1    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 1,572 1,079
Fair value recurring | Money market funds | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 0 0
Fair value recurring | Certificates of deposit    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 27 188
Fair value recurring | Certificates of deposit | Level 1    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 0 0
Fair value recurring | Certificates of deposit | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 27 188
Fair value recurring | U.S. treasury bills    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 1,246 767
Fair value recurring | U.S. treasury bills | Level 1    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 0 0
Fair value recurring | U.S. treasury bills | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 1,246 767
Fair value recurring | U.S. treasury notes    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 4,343 7,552
Fair value recurring | U.S. treasury notes | Level 1    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 0 0
Fair value recurring | U.S. treasury notes | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 4,343 7,552
Fair value recurring | Corporate debt securities    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 5,480 6,369
Fair value recurring | Corporate debt securities | Level 1    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 0 0
Fair value recurring | Corporate debt securities | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 5,480 6,369
Fair value recurring | Government debt securities    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 208 139
Fair value recurring | Government debt securities | Level 1    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 0 0
Fair value recurring | Government debt securities | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 208 $ 139
Fair value recurring | Equity investments    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 24  
Fair value recurring | Equity investments | Level 1    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 24  
Fair value recurring | Equity investments | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Fair Value $ 0  
XML 85 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
Inventory - Schedule of Inventory, Current (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Raw materials $ 163 $ 575
Work in progress 15 205
Finished goods 24 169
Total inventory 202 949
Inventory, non-current $ 170 $ 910
XML 86 R61.htm IDEA: XBRL DOCUMENT v3.24.0.1
Inventory - Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Inventory [Line Items]      
Inventory write-down $ 2,200,000,000 $ 1,300,000,000 $ 0
Inventory, firm purchase commitment, loss 141,000,000 617,000,000 $ 0
Loss on future firm purchase commitments 79,000,000 268,000,000  
Inventory, gross 372,000,000 $ 1,900,000,000  
Raw Materials      
Inventory [Line Items]      
Inventory write-down $ 903,000,000    
XML 87 R62.htm IDEA: XBRL DOCUMENT v3.24.0.1
Property, Plant and Equipment, Net (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 2,378 $ 2,676
Less: Accumulated depreciation (433) (658)
Property, plant and equipment, net 1,945 2,018
Depreciation and amortization 617  
Land and land improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 22 11
Manufacturing and laboratory equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 345 284
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 522 460
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 26 21
Computer equipment and software    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 74 38
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 860 281
Right-of-use assets, financing    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 529 $ 1,581
XML 88 R63.htm IDEA: XBRL DOCUMENT v3.24.0.1
Other Balance Sheet Components - Accounts, Notes, Loans and Financing Receivable (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accounts receivable $ 1,584 $ 1,385
Less: Wholesalers chargebacks, discounts and fees (692) 0
Accounts receivable, net $ 892 $ 1,385
XML 89 R64.htm IDEA: XBRL DOCUMENT v3.24.0.1
Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Prepaid services $ 182 $ 216
Down payments to manufacturing vendors 100 229
Down payments for materials and supplies 68 219
Collaboration receivable 61 11
Interest receivable 59 61
Value added tax receivable 50 140
Income tax receivable 19 10
Tenant improvement allowance receivable 0 42
Prepaid income taxes 0 187
Convertible note receivable 0 36
Other current assets 88 44
Prepaid expenses and other current assets $ 627 $ 1,195
XML 90 R65.htm IDEA: XBRL DOCUMENT v3.24.0.1
Other Balance Sheet Components - Other Non-Current Assets (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Down payments and prepayments, non-current $ 342 $ 0
Inventory, non-current 170 910
Equity investments 66 42
Goodwill 52 0
Finite-lived intangible asset 44 0
Restricted cash 4 12
Other 7 24
Other non-current assets $ 685 $ 988
XML 91 R66.htm IDEA: XBRL DOCUMENT v3.24.0.1
Other Balance Sheet Components - Accrued Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Provisions related to product sales (Note 3) $ 556 $ 0
Compensation-related 245 190
Clinical trials 175 319
Manufacturing 167 400
Development operations 140 88
Other external goods and services 137 264
Royalties 122 203
Property, plant and equipment 94 5
Loss on future firm purchase commitments 79 268
Commercial 56 48
Raw materials 27 316
Accrued liabilities $ 1,798 $ 2,101
XML 92 R67.htm IDEA: XBRL DOCUMENT v3.24.0.1
Other Balance Sheet Components - Other Current Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Lease liabilities - financing (Note 10) $ 0 $ 161
Lease liabilities - operating (Note 10) 25 35
Other 41 53
Other current liabilities $ 66 $ 249
XML 93 R68.htm IDEA: XBRL DOCUMENT v3.24.0.1
Other Balance Sheet Components - Deferred Revenue (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2023
USD ($)
Change In Contract With Customer, Liability [Roll Forward]  
Beginning balance $ 2,711
Additions 548
Deductions (2,608)
Ending balance 651
Net product sales  
Change In Contract With Customer, Liability [Roll Forward]  
Beginning balance 2,626
Additions 515
Deductions (2,528)
Ending balance 613
Grant revenue  
Change In Contract With Customer, Liability [Roll Forward]  
Beginning balance 4
Additions 2
Deductions (2)
Ending balance 4
Collaboration revenue  
Change In Contract With Customer, Liability [Roll Forward]  
Beginning balance 81
Additions 31
Deductions (78)
Ending balance $ 34
XML 94 R69.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases - Narrative (Details)
ft² in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Sep. 30, 2021
ft²
numberOfExtensionPeriod
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
ft²
numberOfExtensionPeriod
numberOfBuilding
campus
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Lessee, Lease, Description [Line Items]          
Number of campuses | campus     2    
Decrease in operating lease liabilities     $ (551,000,000) $ 14,000,000 $ (17,000,000)
Right-of-use assets, operating leases     713,000,000 121,000,000  
Present value of lease liabilities     668,000,000    
Embedded Leases          
Lessee, Lease, Description [Line Items]          
Decrease in the right of use of the asset   $ 262,000,000      
Decrease in operating lease liabilities   $ 262,000,000      
Depreciation     323,000,000    
Right-of-use assets, operating leases     0 639,000,000  
Present value of lease liabilities     $ 0 $ 440,000,000  
MTC South, MTC North and MTC East          
Lessee, Lease, Description [Line Items]          
Area of office space (in sqft) | ft²     686    
Number of extension | numberOfExtensionPeriod     3    
Extension term     5 years    
Finance lease, number of properties | numberOfBuilding     3    
Cambridge Leases          
Lessee, Lease, Description [Line Items]          
Area of office space (in sqft) | ft² 462   292    
Number of years 2 years        
Lease term 15 years        
Number of extension | numberOfExtensionPeriod 2        
Extension term 7 years        
XML 95 R70.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases - Balance Sheet Information (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Leases [Abstract]    
Right-of-use assets, operating, net $ 713 $ 121
Right-of-use assets, financing, net 436 1,150
Total 1,149 1,271
Operating lease liabilities 25 35
Financing lease liabilities 0 161
Total current liabilities 25 196
Operating lease liabilities, non-current 643 92
Financing lease liabilities, non-current 575 912
Total non-current lease liabilities 1,218 1,004
Total $ 1,243 $ 1,200
Finance lease, right-of-use asset, statement of financial position [Extensible List] Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization
Operating lease, liability, current, statement of financial position [Extensible List] Other Liabilities, Current Other Liabilities, Current
Finance lease, liability, current, statement of financial position [Extensible List] Other Liabilities, Current Other Liabilities, Current
XML 96 R71.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases - Lease Costs (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Leases [Abstract]      
Operating lease costs $ 88 $ 48 $ 24
Amortization of right-of-use assets, financing leases 500 280 189
Interest expense for financing lease liabilities 38 29 17
Total financing lease costs 538 309 206
Short term lease costs 2 0 49
Variable lease costs 113 165 100
Operating cash flows used in operating leases (93) (57) (19)
Operating cash flows used in financing leases (39) (25) (14)
Financing cash flows used in financing leases (292) (184) (140)
Changes in right-of-use assets related to lease modifications and reassessments 67 0 (7)
Right-of-use assets obtained in exchange for operating lease liabilities 714 20 72
Changes in right-of-use assets related to lease modifications and reassessments 213 0 674
Right-of-use assets obtained in exchange for financing lease liabilities 0 777 126
Changes in financing lease liabilities $ 3 $ 4 $ 3
Operating leases, remaining lease term 14 years 6 years  
Finance leases, remaining lease term 33 years 22 years  
Operating leases, discount rate 7.50% 7.50%  
Finance leases, discount rate 4.20% 3.60%  
XML 97 R72.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases - Minimum Lease Payments (Details)
$ in Millions
Dec. 31, 2023
USD ($)
Operating Leases  
2024 $ 72
2025 67
2026 67
2027 70
2028 72
Thereafter 785
Total minimum lease payments 1,133
Less amounts representing interest (465)
Present value of lease liabilities 668
Financing Leases  
2024 20
2025 22
2026 22
2027 23
2028 23
Thereafter 1,074
Total minimum lease payments 1,184
Less amounts representing interest (609)
Present value of lease liabilities 575
Lessee, Lease, Description [Line Items]  
Undiscounted future lease payments 465
MTC South, MTC North and MTC East | Norwood Leases  
Operating Leases  
Less amounts representing interest (668)
Lessee, Lease, Description [Line Items]  
Undiscounted future lease payments $ 668
XML 98 R73.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies - Indemnification Obligations (Details) - Indemnifications
 12 Months Ended
Dec. 31, 2023
USD ($)
claim
Dec. 31, 2022
USD ($)
claim
Loss Contingencies [Line Items]    
Losses related to indemnification obligations $ 0 $ 0
Number of claims outstanding | claim 0 0
Reserves established $ 0 $ 0
XML 99 R74.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Purchase Commitment, Excluding Long-term Commitment [Line Items]    
Loss on future firm purchase commitments $ 79 $ 268
Supply and Manufacturing Agreements    
Purchase Commitment, Excluding Long-term Commitment [Line Items]    
Purchase commitments 1,800  
Clinical Services    
Purchase Commitment, Excluding Long-term Commitment [Line Items]    
Purchase commitments 261  
Clinical Operations and Support Commitments    
Purchase Commitment, Excluding Long-term Commitment [Line Items]    
Purchase commitments $ 3,000  
XML 100 R75.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies - Licenses to Patented Technology (Details) - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]        
Consideration paid   $ 301 $ 1,100 $ 641
Purchase Commitment, Excluding Long-term Commitment [Line Items]        
Cost of sales   4,693 5,416 2,617
Consideration paid   $ 301 $ 1,100 $ 641
National Institute of Allergy and Infectious Diseases member | License agreement        
Purchase Commitment, Excluding Long-term Commitment [Line Items]        
Cost of sales $ 400      
XML 101 R76.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation and Share Repurchase Programs - Narrative (Details)
 1 Months Ended 12 Months Ended
Jan. 31, 2022
USD ($)
Dec. 31, 2023
USD ($)
installment
shares
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Aug. 01, 2022
USD ($)
Feb. 22, 2022
USD ($)
Aug. 02, 2021
USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Aggregate number of shares authorized for issuance (in shares) | shares   47,000,000          
Total intrinsic value of options exercised   $ 413,000,000 $ 714,000,000 $ 1,600,000,000      
Tax benefit realized from option exercised   84,000,000 144,000,000 325,000,000      
Consideration for options exercised   25,000,000 50,000,000 112,000,000      
Restricted stock unit   99,000,000 55,000,000 18,000,000      
Compensation costs   305,000,000 226,000,000 142,000,000      
Total unrecognized compensation cost related to non-vested stock-based compensation   $ 835,000,000          
Weighted-average period of cost expected to be recognized   2 years 7 months 6 days          
Stock repurchased     3,329,000,000 857,000,000      
2021 Repurchase Program              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Authorized amount for share repurchase program             $ 1,000,000,000
Stock repurchased $ 1,000,000,000            
2022 Repurchase Program              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Authorized amount for share repurchase program   $ 1,700,000,000       $ 3,000,000,000  
Additional authorized amount for share repurchase program         $ 3,000,000,000    
Service-based Awards              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting period   4 years          
Service-based Awards | Twelve Months of Continued Employment or Service              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting period   12 months          
Vesting percentage   25.00%          
Service-based Awards | Following Twelve Quarters              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of installments | installment   12          
Options              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Aggregate number of shares authorized for issuance (in shares) | shares   31,000,000          
Compensation costs   $ 136,000,000 123,000,000 96,000,000      
Restricted Common Stock Units And Performance Stock Units              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Intrinsic value of RSUs and PSUs vested   120,000,000 $ 125,000,000 $ 141,000,000      
Performance-based Awards              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Award requisite service period     3 years 3 years      
Compensation costs   $ 17,000,000 $ 18,000,000 $ 16,000,000      
Performance-based Awards | Minimum              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Payout percentage     0.00% 0.00%      
Performance-based Awards | Maximum              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Payout percentage     200.00% 200.00%      
2016 Equity Plan | Options              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Expiration period   10 years          
2018 Equity Plan              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Shares available for future grant (in shares) | shares   16,000,000          
XML 102 R77.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation and Share Repurchase Programs - Options Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Number of Options (in millions)    
Outstanding at beginning of period (in shares) 24,930  
Granted (in shares) 4,360  
Exercised (in shares) (3,110)  
Cancelled/forfeited (in shares) (680)  
Outstanding at end of period (in shares) 25,500 24,930
Weighted Average Exercise Price per Share    
Outstanding at beginning of period (in usd per share) $ 42.23  
Granted (in usd per share) 113.03  
Exercised (in usd per share) 8.13  
Cancelled/forfeited (in usd per share) 130.23  
Outstanding at end of period (in usd per share) $ 56.14 $ 42.23
Outstanding and Exercisable    
Number of options, exercisable (in shares) 18,980  
Weighted- average exercise price per share, exercisable (in usd per share) $ 33.34  
Weighted- average remaining contractual term, outstanding 5 years 7 months 6 days 5 years 8 months 12 days
Weighted- average remaining contractual term, exercisable 4 years 6 months  
Aggregate intrinsic value, outstanding $ 1,437 $ 3,478
Aggregate intrinsic value, exercisable $ 1,378  
Vested and expected to vest    
Expected to vest (in shares) 6,520  
Weighted- average expected to vest (in usd per share) $ 122.50  
Weighted- average remaining contractual term expected to vest 8 years 10 months 24 days  
Aggregate intrinsic value expected to vest $ 59  
XML 103 R78.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation and Share Repurchase Programs - Restricted Common Stock and Common Stock Units Activity (Details) - Restricted Common Stock Units And Performance Stock Units
shares in Thousands
 12 Months Ended
Dec. 31, 2023
$ / shares
shares
Number of Shares/Units  
Outstanding, non-vested at beginning of period (in shares) | shares 2,900
Issued (in shares) | shares 3,710
Vested (in shares) | shares (1,010)
Cancelled/forfeited (in shares) | shares (420)
Outstanding, non-vested at end of period (in shares) | shares 5,180
Weighted-Average Grant Date per Share/Unit  
Outstanding, non-vested at beginning of period (in usd per share) | $ / shares $ 132.25
Issued (in usd per share) | $ / shares 107.23
Vested (in usd per share) | $ / shares 98.68
Cancelled/forfeited (in usd per share) | $ / shares 130.01
Outstanding, non-vested at end of period (in usd per share) | $ / shares $ 121.02
XML 104 R79.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation and Share Repurchase Programs - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details) - Options - $ / shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Risk-free interest rate 4.13% 2.46% 0.84%
Expected term 6 years 25 days 6 years 1 month 17 days 6 years 1 month 6 days
Expected volatility 48.00% 50.00% 46.00%
Expected dividends 0.00% 0.00% 0.00%
Weighted Average      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted average fair value per share (in usd per share) $ 57.87 $ 76.02 $ 91.84
XML 105 R80.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation and Share Repurchase Programs - Stock-Based Compensation Expense (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Compensation costs $ 305 $ 226 $ 142
Cost of sales      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Compensation costs 37 45 22
Research and development      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Compensation costs 157 93 68
Selling, general and administrative      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Compensation costs 111 88 52
Options      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Compensation costs 136 123 96
RSUs and PSUs      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Compensation costs 161 97 42
Employee stock purchase plan      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Compensation costs $ 8 $ 6 $ 4
XML 106 R81.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation and Share Repurchase Programs - Share Repurchase Program (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]      
Number of shares repurchased (in shares) 8 23 3
Average price per share $ 143.26 $ 142.83 $ 245.76
Aggregate purchase price $ 1,153 $ 3,329 $ 857
Remaining authorized at end of period $ 1,667 $ 2,814 $ 143
XML 107 R82.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - (Loss) Income Before Provision For (Benefit From) Income Taxes (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]      
United States $ (4,056) $ 9,433 $ 13,108
Foreign 114 142 177
(Loss) income before income taxes $ (3,942) $ 9,575 $ 13,285
XML 108 R83.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Provision For (Benefit From) Income Taxes (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Current:      
Federal $ (225) $ 1,687 $ 1,304
State 72 47 35
Foreign 24 57 40
Total current (129) 1,791 1,379
Deferred:      
Federal 888 (569) (288)
State 8 (7) (6)
Foreign 5 (2) (2)
Total deferred 901 (578) (296)
Total provision for income taxes $ 772 $ 1,213 $ 1,083
XML 109 R84.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate (Details)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]      
Federal statutory tax rate 21.00% 21.00% 21.00%
Change in valuation allowance (52.60%) 0.00% (5.40%)
Foreign-derived intangible income and other 0.20% (7.40%) (4.80%)
Stock-based compensation windfall 2.40% (1.60%) (2.60%)
Federal research and development credits 4.60% (0.50%) (0.70%)
State taxes, net of federal benefits 5.70% 0.40% 0.50%
Non-deductible items (0.40%) 0.00% 0.00%
Other (0.50%) 0.80% 0.10%
Effective tax rate (19.60%) 12.70% 8.10%
XML 110 R85.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Operating Loss Carryforwards [Line Items]      
Effective income tax rate reconciliation, percent (19.60%) 12.70% 8.10%
Increase in valuation allowance $ 2,069 $ 18 $ 48
Unrecognized tax benefits, net 231    
State      
Operating Loss Carryforwards [Line Items]      
Increase in valuation allowance 2,100    
Net operating losses 1,600    
State | Research and Development      
Operating Loss Carryforwards [Line Items]      
Tax credit carry-forwards $ 178    
XML 111 R86.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Significant Components of Deferred Tax Assets and Tax Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Deferred tax assets:        
Net operating loss carryforwards $ 90 $ 59    
Stock-based compensation 111 68    
Capitalized licenses, research and development and start-up costs 1,449 704    
Tax credit carryforwards 140 97    
Operating lease liabilities 154 26    
Financing lease liabilities 139 135    
Other comprehensive income 34 106    
Inventory reserve and capitalization 250 86    
Wholesaler chargebacks, discounts and fees 92 0    
Returns and other fees 129 0    
Other 90 85    
Total deferred tax assets 2,678 1,366    
Less: valuation allowance (2,224) (155) $ (149) $ (823)
Net deferred tax assets 454 1,211    
Deferred tax liabilities:        
Right-of-use assets, financing (106) (117)    
Right-of-use assets, operating (160) (26)    
Property, plant and equipment (107) (85)    
Other (15) (1)    
Total deferred tax liabilities (388) (229)    
Net deferred tax (liabilities) assets $ 66 $ 982    
XML 112 R87.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes- Valuation Allowance (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Deferred Tax, Valuation Allowance [Roll Forward]      
Valuation allowance at beginning of the period $ 155 $ 149 $ 823
Decreases recorded as benefit to income tax provision 0 (12) (722)
Increase in valuation allowance 2,069 18 48
Valuation allowance at December 31 $ 2,224 $ 155 $ 149
XML 113 R88.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Unrecognized tax benefits at beginning of the period $ 128 $ 68 $ 0
Tax positions for prior years 0 (1) 0
Expiration of statutes 0 0 0
Settlements with tax authorities (27) 0 0
Additions based on tax positions for current year 44 57 54
Additions based on tax positions for prior years 86 4 14
Unrecognized tax benefits at end of the period $ 231 $ 128 $ 68
XML 114 R89.htm IDEA: XBRL DOCUMENT v3.24.0.1
(Loss) Earnings per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Numerator:      
Net (loss) income $ (4,714) $ 8,362 $ 12,202
Denominator:      
Basic weighted-average common shares outstanding (in shares) 382 394 403
Effect of dilutive securities (in shares) 0 22 28
Diluted weighted-average common shares outstanding (in shares) 382 416 431
Basic EPS (in usd per share) $ (12.33) $ 21.26 $ 30.31
Diluted EPS (in usd per share) $ (12.33) $ 20.12 $ 28.29
XML 115 R90.htm IDEA: XBRL DOCUMENT v3.24.0.1
(Loss) Earnings per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Income (Loss) Per Share (Details) - shares
shares in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Anti-dilutive securities (in shares) 31 3 1
Options      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Anti-dilutive securities (in shares) 26 3 1
RSUs and PSUs      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Anti-dilutive securities (in shares) 5 0 0
XML 116 R91.htm IDEA: XBRL DOCUMENT v3.24.0.1
Geographic Information (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2023
USD ($)
segment
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Revenue from Contract with Customer [Abstract]      
Number of operating segments | segment 1    
Disaggregation of Revenue [Line Items]      
Total revenue $ 6,848 $ 19,263 $ 18,471
Property, plant and equipment, net 1,945 2,018  
United States      
Disaggregation of Revenue [Line Items]      
Total revenue 1,895 5,150 6,177
Property, plant and equipment, net 1,560 1,267  
Europe      
Disaggregation of Revenue [Line Items]      
Total revenue 1,355 6,815 6,846
Property, plant and equipment, net 126 714  
Rest of world      
Disaggregation of Revenue [Line Items]      
Total revenue 3,598 7,298 $ 5,448
Property, plant and equipment, net $ 259 $ 37  
EXCEL 118 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 120 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 122 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 338 493 1 false 97 0 false 15 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.modernatx.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.modernatx.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 3 false false R4.htm 0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 4 false false R5.htm 0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS CONSOLIDATED STATEMENTS OF OPERATIONS Statements 5 false false R6.htm 0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statements 6 false false R7.htm 0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY Sheet http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY Statements 7 false false R8.htm 0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 0000009 - Disclosure - Description of the Business Sheet http://www.modernatx.com/role/DescriptionoftheBusiness Description of the Business Notes 9 false false R10.htm 0000010 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.modernatx.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 0000011 - Disclosure - Net Product Sales Sheet http://www.modernatx.com/role/NetProductSales Net Product Sales Notes 11 false false R12.htm 0000012 - Disclosure - Other Revenue Sheet http://www.modernatx.com/role/OtherRevenue Other Revenue Notes 12 false false R13.htm 0000013 - Disclosure - Collaboration Agreements Sheet http://www.modernatx.com/role/CollaborationAgreements Collaboration Agreements Notes 13 false false R14.htm 0000014 - Disclosure - Financial Instruments and Fair Value Measurements Sheet http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurements Financial Instruments and Fair Value Measurements Notes 14 false false R15.htm 0000015 - Disclosure - Inventory Sheet http://www.modernatx.com/role/Inventory Inventory Notes 15 false false R16.htm 0000016 - Disclosure - Property, Plant and Equipment, Net Sheet http://www.modernatx.com/role/PropertyPlantandEquipmentNet Property, Plant and Equipment, Net Notes 16 false false R17.htm 0000017 - Disclosure - Other Balance Sheet Components Sheet http://www.modernatx.com/role/OtherBalanceSheetComponents Other Balance Sheet Components Notes 17 false false R18.htm 0000018 - Disclosure - Leases Sheet http://www.modernatx.com/role/Leases Leases Notes 18 false false R19.htm 0000019 - Disclosure - Commitments and Contingencies Sheet http://www.modernatx.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 19 false false R20.htm 0000020 - Disclosure - Stock-Based Compensation and Share Repurchase Programs Sheet http://www.modernatx.com/role/StockBasedCompensationandShareRepurchasePrograms Stock-Based Compensation and Share Repurchase Programs Notes 20 false false R21.htm 0000021 - Disclosure - Income Taxes Sheet http://www.modernatx.com/role/IncomeTaxes Income Taxes Notes 21 false false R22.htm 0000022 - Disclosure - (Loss) Earnings per Share Sheet http://www.modernatx.com/role/LossEarningsperShare (Loss) Earnings per Share Notes 22 false false R23.htm 0000023 - Disclosure - Geographic Information Sheet http://www.modernatx.com/role/GeographicInformation Geographic Information Notes 23 false false R24.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 24 false false R25.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 25 false false R26.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.modernatx.com/role/SummaryofSignificantAccountingPolicies 26 false false R27.htm 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.modernatx.com/role/SummaryofSignificantAccountingPolicies 27 false false R28.htm 9954473 - Disclosure - Net Product Sales (Tables) Sheet http://www.modernatx.com/role/NetProductSalesTables Net Product Sales (Tables) Tables http://www.modernatx.com/role/NetProductSales 28 false false R29.htm 9954474 - Disclosure - Other Revenue (Tables) Sheet http://www.modernatx.com/role/OtherRevenueTables Other Revenue (Tables) Tables http://www.modernatx.com/role/OtherRevenue 29 false false R30.htm 9954475 - Disclosure - Financial Instruments and Fair Value Measurements (Tables) Sheet http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables Financial Instruments and Fair Value Measurements (Tables) Tables http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurements 30 false false R31.htm 9954476 - Disclosure - Inventory (Tables) Sheet http://www.modernatx.com/role/InventoryTables Inventory (Tables) Tables http://www.modernatx.com/role/Inventory 31 false false R32.htm 9954477 - Disclosure - Property, Plant and Equipment, Net (Tables) Sheet http://www.modernatx.com/role/PropertyPlantandEquipmentNetTables Property, Plant and Equipment, Net (Tables) Tables http://www.modernatx.com/role/PropertyPlantandEquipmentNet 32 false false R33.htm 9954478 - Disclosure - Other Balance Sheet Components (Tables) Sheet http://www.modernatx.com/role/OtherBalanceSheetComponentsTables Other Balance Sheet Components (Tables) Tables http://www.modernatx.com/role/OtherBalanceSheetComponents 33 false false R34.htm 9954479 - Disclosure - Leases (Tables) Sheet http://www.modernatx.com/role/LeasesTables Leases (Tables) Tables http://www.modernatx.com/role/Leases 34 false false R35.htm 9954480 - Disclosure - Stock-Based Compensation and Share Repurchase Programs (Tables) Sheet http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsTables Stock-Based Compensation and Share Repurchase Programs (Tables) Tables http://www.modernatx.com/role/StockBasedCompensationandShareRepurchasePrograms 35 false false R36.htm 9954481 - Disclosure - Income Taxes (Tables) Sheet http://www.modernatx.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.modernatx.com/role/IncomeTaxes 36 false false R37.htm 9954482 - Disclosure - (Loss) Earnings per Share (Tables) Sheet http://www.modernatx.com/role/LossEarningsperShareTables (Loss) Earnings per Share (Tables) Tables http://www.modernatx.com/role/LossEarningsperShare 37 false false R38.htm 9954483 - Disclosure - Geographic Information (Tables) Sheet http://www.modernatx.com/role/GeographicInformationTables Geographic Information (Tables) Tables http://www.modernatx.com/role/GeographicInformation 38 false false R39.htm 9954484 - Disclosure - Description of the Business (Details) Sheet http://www.modernatx.com/role/DescriptionoftheBusinessDetails Description of the Business (Details) Details http://www.modernatx.com/role/DescriptionoftheBusiness 39 false false R40.htm 9954485 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 40 false false R41.htm 9954486 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) Details 41 false false R42.htm 9954487 - Disclosure - Summary of Significant Accounting Policies - Significant Customers (Details) Sheet http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails Summary of Significant Accounting Policies - Significant Customers (Details) Details 42 false false R43.htm 9954488 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment and Software Capitalization (Details) Sheet http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails Summary of Significant Accounting Policies - Property and Equipment and Software Capitalization (Details) Details 43 false false R44.htm 9954489 - Disclosure - Summary of Significant Accounting Policies - Components of Accumulated Other Comprehensive Loss (Details) Sheet http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails Summary of Significant Accounting Policies - Components of Accumulated Other Comprehensive Loss (Details) Details 44 false false R45.htm 9954490 - Disclosure - Net Product Sales - Net Product Sales by Customer Geographic Areas (Details) Sheet http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails Net Product Sales - Net Product Sales by Customer Geographic Areas (Details) Details 45 false false R46.htm 9954491 - Disclosure - Net Product Sales - Narrative (Details) Sheet http://www.modernatx.com/role/NetProductSalesNarrativeDetails Net Product Sales - Narrative (Details) Details 46 false false R47.htm 9954492 - Disclosure - Net Product Sales - Product Sales (Details) Sheet http://www.modernatx.com/role/NetProductSalesProductSalesDetails Net Product Sales - Product Sales (Details) Details 47 false false R48.htm 9954493 - Disclosure - Net Product Sales - Product Sales Provision Recorded as Accrued Liabilities (Details) Sheet http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails Net Product Sales - Product Sales Provision Recorded as Accrued Liabilities (Details) Details 48 false false R49.htm 9954494 - Disclosure - Other Revenue - Schedule of Disaggregation of Revenue (Details) Sheet http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails Other Revenue - Schedule of Disaggregation of Revenue (Details) Details 49 false false R50.htm 9954495 - Disclosure - Other Revenue - Narrative (Details) Sheet http://www.modernatx.com/role/OtherRevenueNarrativeDetails Other Revenue - Narrative (Details) Details 50 false false R51.htm 9954496 - Disclosure - Collaboration Agreements - Merck ??? Personalized mRNA Cancer Vaccines (Details) Sheet http://www.modernatx.com/role/CollaborationAgreementsMerckPersonalizedmRNACancerVaccinesDetails Collaboration Agreements - Merck ??? Personalized mRNA Cancer Vaccines (Details) Details 51 false false R52.htm 9954497 - Disclosure - Collaboration Agreements - Vertex ??? 2020 Strategic Alliance in Cystic Fibrosis (Details) Sheet http://www.modernatx.com/role/CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails Collaboration Agreements - Vertex ??? 2020 Strategic Alliance in Cystic Fibrosis (Details) Details 52 false false R53.htm 9954498 - Disclosure - Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details) Sheet http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details) Details 53 false false R54.htm 9954499 - Disclosure - Collaboration Agreements - Immatics ??? Strategic Multi-Platform Collaboration to Develop Oncology Therapeutics (Details) Sheet http://www.modernatx.com/role/CollaborationAgreementsImmaticsStrategicMultiPlatformCollaborationtoDevelopOncologyTherapeuticsDetails Collaboration Agreements - Immatics ??? Strategic Multi-Platform Collaboration to Develop Oncology Therapeutics (Details) Details 54 false false R55.htm 9954500 - Disclosure - Financial Instruments and Fair Value Measurements - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details) Sheet http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails Financial Instruments and Fair Value Measurements - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details) Details 55 false false R56.htm 9954501 - Disclosure - Financial Instruments and Fair Value Measurements - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details) Sheet http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails Financial Instruments and Fair Value Measurements - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details) Details 56 false false R57.htm 9954502 - Disclosure - Financial Instruments and Fair Value Measurements - Narrative (Details) Sheet http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails Financial Instruments and Fair Value Measurements - Narrative (Details) Details http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables 57 false false R58.htm 9954503 - Disclosure - Financial Instruments and Fair Value Measurements - Unrealized Loss Position (Details) Sheet http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails Financial Instruments and Fair Value Measurements - Unrealized Loss Position (Details) Details 58 false false R59.htm 9954504 - Disclosure - Financial Instruments and Fair Value Measurements - Financial Assets Measured At Fair Value On a Recurring Basis (Details) Sheet http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails Financial Instruments and Fair Value Measurements - Financial Assets Measured At Fair Value On a Recurring Basis (Details) Details 59 false false R60.htm 9954505 - Disclosure - Inventory - Schedule of Inventory, Current (Details) Sheet http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails Inventory - Schedule of Inventory, Current (Details) Details 60 false false R61.htm 9954506 - Disclosure - Inventory - Narrative (Details) Sheet http://www.modernatx.com/role/InventoryNarrativeDetails Inventory - Narrative (Details) Details 61 false false R62.htm 9954507 - Disclosure - Property, Plant and Equipment, Net (Details) Sheet http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails Property, Plant and Equipment, Net (Details) Details http://www.modernatx.com/role/PropertyPlantandEquipmentNetTables 62 false false R63.htm 9954508 - Disclosure - Other Balance Sheet Components - Accounts, Notes, Loans and Financing Receivable (Details) Notes http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails Other Balance Sheet Components - Accounts, Notes, Loans and Financing Receivable (Details) Details 63 false false R64.htm 9954509 - Disclosure - Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) Sheet http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) Details 64 false false R65.htm 9954510 - Disclosure - Other Balance Sheet Components - Other Non-Current Assets (Details) Sheet http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails Other Balance Sheet Components - Other Non-Current Assets (Details) Details 65 false false R66.htm 9954511 - Disclosure - Other Balance Sheet Components - Accrued Liabilities (Details) Sheet http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails Other Balance Sheet Components - Accrued Liabilities (Details) Details 66 false false R67.htm 9954512 - Disclosure - Other Balance Sheet Components - Other Current Liabilities (Details) Sheet http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails Other Balance Sheet Components - Other Current Liabilities (Details) Details 67 false false R68.htm 9954513 - Disclosure - Other Balance Sheet Components - Deferred Revenue (Details) Sheet http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails Other Balance Sheet Components - Deferred Revenue (Details) Details 68 false false R69.htm 9954514 - Disclosure - Leases - Narrative (Details) Sheet http://www.modernatx.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 69 false false R70.htm 9954515 - Disclosure - Leases - Balance Sheet Information (Details) Sheet http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails Leases - Balance Sheet Information (Details) Details 70 false false R71.htm 9954516 - Disclosure - Leases - Lease Costs (Details) Sheet http://www.modernatx.com/role/LeasesLeaseCostsDetails Leases - Lease Costs (Details) Details 71 false false R72.htm 9954517 - Disclosure - Leases - Minimum Lease Payments (Details) Sheet http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails Leases - Minimum Lease Payments (Details) Details 72 false false R73.htm 9954518 - Disclosure - Commitments and Contingencies - Indemnification Obligations (Details) Sheet http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails Commitments and Contingencies - Indemnification Obligations (Details) Details 73 false false R74.htm 9954519 - Disclosure - Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details) Sheet http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details) Details 74 false false R75.htm 9954520 - Disclosure - Commitments and Contingencies - Licenses to Patented Technology (Details) Sheet http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails Commitments and Contingencies - Licenses to Patented Technology (Details) Details 75 false false R76.htm 9954521 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Narrative (Details) Sheet http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails Stock-Based Compensation and Share Repurchase Programs - Narrative (Details) Details http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsTables 76 false false R77.htm 9954522 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Options Activity (Details) Sheet http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails Stock-Based Compensation and Share Repurchase Programs - Options Activity (Details) Details 77 false false R78.htm 9954523 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Restricted Common Stock and Common Stock Units Activity (Details) Sheet http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails Stock-Based Compensation and Share Repurchase Programs - Restricted Common Stock and Common Stock Units Activity (Details) Details 78 false false R79.htm 9954524 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details) Sheet http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails Stock-Based Compensation and Share Repurchase Programs - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details) Details 79 false false R80.htm 9954525 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Stock-Based Compensation Expense (Details) Sheet http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails Stock-Based Compensation and Share Repurchase Programs - Stock-Based Compensation Expense (Details) Details 80 false false R81.htm 9954526 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Share Repurchase Program (Details) Sheet http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsShareRepurchaseProgramDetails Stock-Based Compensation and Share Repurchase Programs - Share Repurchase Program (Details) Details 81 false false R82.htm 9954527 - Disclosure - Income Taxes - (Loss) Income Before Provision For (Benefit From) Income Taxes (Details) Sheet http://www.modernatx.com/role/IncomeTaxesLossIncomeBeforeProvisionForBenefitFromIncomeTaxesDetails Income Taxes - (Loss) Income Before Provision For (Benefit From) Income Taxes (Details) Details http://www.modernatx.com/role/IncomeTaxesTables 82 false false R83.htm 9954528 - Disclosure - Income Taxes - Provision For (Benefit From) Income Taxes (Details) Sheet http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails Income Taxes - Provision For (Benefit From) Income Taxes (Details) Details 83 false false R84.htm 9954529 - Disclosure - Income Taxes - Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate (Details) Sheet http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails Income Taxes - Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate (Details) Details 84 false false R85.htm 9954530 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.modernatx.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 85 false false R86.htm 9954531 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Tax Liabilities (Details) Sheet http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails Income Taxes - Significant Components of Deferred Tax Assets and Tax Liabilities (Details) Details 86 false false R87.htm 9954532 - Disclosure - Income Taxes- Valuation Allowance (Details) Sheet http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails Income Taxes- Valuation Allowance (Details) Details 87 false false R88.htm 9954533 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward (Details) Sheet http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward (Details) Details 88 false false R89.htm 9954534 - Disclosure - (Loss) Earnings per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) Sheet http://www.modernatx.com/role/LossEarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails (Loss) Earnings per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) Details 89 false false R90.htm 9954535 - Disclosure - (Loss) Earnings per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Income (Loss) Per Share (Details) Sheet http://www.modernatx.com/role/LossEarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails (Loss) Earnings per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Income (Loss) Per Share (Details) Details 90 false false R91.htm 9954536 - Disclosure - Geographic Information (Details) Sheet http://www.modernatx.com/role/GeographicInformationDetails Geographic Information (Details) Details http://www.modernatx.com/role/GeographicInformationTables 91 false false All Reports Book All Reports mrna-20231231.htm mrna-20231231.xsd mrna-20231231_cal.xml mrna-20231231_def.xml mrna-20231231_lab.xml mrna-20231231_pre.xml mrna-20231231_g1.jpg mrna-20231231_g2.jpg mrna-20231231_g3.jpg mrna-20231231_g4.jpg mrna-20231231_g5.jpg mrna-20231231_g6.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 125 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "mrna-20231231.htm": { "nsprefix": "mrna", "nsuri": "http://www.modernatx.com/20231231", "dts": { "inline": { "local": [ "mrna-20231231.htm" ] }, "schema": { "local": [ "mrna-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "mrna-20231231_cal.xml" ] }, "definitionLink": { "local": [ "mrna-20231231_def.xml" ] }, "labelLink": { "local": [ "mrna-20231231_lab.xml" ] }, "presentationLink": { "local": [ "mrna-20231231_pre.xml" ] } }, "keyStandard": 433, "keyCustom": 60, "axisStandard": 32, "axisCustom": 0, "memberStandard": 51, "memberCustom": 44, "hidden": { "total": 14, "http://xbrl.sec.gov/dei/2023": 4, "http://fasb.org/us-gaap/2023": 8, "http://xbrl.sec.gov/ecd/2023": 2 }, "contextCount": 338, "entityCount": 1, "segmentCount": 97, "elementCount": 820, "unitCount": 15, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1253, "http://xbrl.sec.gov/dei/2023": 38, "http://xbrl.sec.gov/ecd/2023": 18 }, "report": { "R1": { "role": "http://www.modernatx.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.modernatx.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS", "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R4": { "role": "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals", "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R6": { "role": "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R7": { "role": "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R9": { "role": "http://www.modernatx.com/role/DescriptionoftheBusiness", "longName": "0000009 - Disclosure - Description of the Business", "shortName": "Description of the Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPolicies", "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.modernatx.com/role/NetProductSales", "longName": "0000011 - Disclosure - Net Product Sales", "shortName": "Net Product Sales", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": null }, "R12": { "role": "http://www.modernatx.com/role/OtherRevenue", "longName": "0000012 - Disclosure - Other Revenue", "shortName": "Other Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": null }, "R13": { "role": "http://www.modernatx.com/role/CollaborationAgreements", "longName": "0000013 - Disclosure - Collaboration Agreements", "shortName": "Collaboration Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurements", "longName": "0000014 - Disclosure - Financial Instruments and Fair Value Measurements", "shortName": "Financial Instruments and Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.modernatx.com/role/Inventory", "longName": "0000015 - Disclosure - Inventory", "shortName": "Inventory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.modernatx.com/role/PropertyPlantandEquipmentNet", "longName": "0000016 - Disclosure - Property, Plant and Equipment, Net", "shortName": "Property, Plant and Equipment, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.modernatx.com/role/OtherBalanceSheetComponents", "longName": "0000017 - Disclosure - Other Balance Sheet Components", "shortName": "Other Balance Sheet Components", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.modernatx.com/role/Leases", "longName": "0000018 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.modernatx.com/role/CommitmentsandContingencies", "longName": "0000019 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchasePrograms", "longName": "0000020 - Disclosure - Stock-Based Compensation and Share Repurchase Programs", "shortName": "Stock-Based Compensation and Share Repurchase Programs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.modernatx.com/role/IncomeTaxes", "longName": "0000021 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.modernatx.com/role/LossEarningsperShare", "longName": "0000022 - Disclosure - (Loss) Earnings per Share", "shortName": "(Loss) Earnings per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.modernatx.com/role/GeographicInformation", "longName": "0000023 - Disclosure - Geographic Information", "shortName": "Geographic Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": null }, "R25": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-331", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-331", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables", "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.modernatx.com/role/NetProductSalesTables", "longName": "9954473 - Disclosure - Net Product Sales (Tables)", "shortName": "Net Product Sales (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": null }, "R29": { "role": "http://www.modernatx.com/role/OtherRevenueTables", "longName": "9954474 - Disclosure - Other Revenue (Tables)", "shortName": "Other Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": null }, "R30": { "role": "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables", "longName": "9954475 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)", "shortName": "Financial Instruments and Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.modernatx.com/role/InventoryTables", "longName": "9954476 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.modernatx.com/role/PropertyPlantandEquipmentNetTables", "longName": "9954477 - Disclosure - Property, Plant and Equipment, Net (Tables)", "shortName": "Property, Plant and Equipment, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": null }, "R33": { "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables", "longName": "9954478 - Disclosure - Other Balance Sheet Components (Tables)", "shortName": "Other Balance Sheet Components (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.modernatx.com/role/LeasesTables", "longName": "9954479 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "mrna:CurrentAssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mrna:CurrentAssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsTables", "longName": "9954480 - Disclosure - Stock-Based Compensation and Share Repurchase Programs (Tables)", "shortName": "Stock-Based Compensation and Share Repurchase Programs (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.modernatx.com/role/IncomeTaxesTables", "longName": "9954481 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.modernatx.com/role/LossEarningsperShareTables", "longName": "9954482 - Disclosure - (Loss) Earnings per Share (Tables)", "shortName": "(Loss) Earnings per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.modernatx.com/role/GeographicInformationTables", "longName": "9954483 - Disclosure - Geographic Information (Tables)", "shortName": "Geographic Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": null }, "R39": { "role": "http://www.modernatx.com/role/DescriptionoftheBusinessDetails", "longName": "9954484 - Disclosure - Description of the Business (Details)", "shortName": "Description of the Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-4", "name": "mrna:NumberOfDevelopmentCandidates", "unitRef": "candidate", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "mrna:NumberOfDevelopmentCandidates", "unitRef": "candidate", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "longName": "9954485 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R41": { "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails", "longName": "9954486 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)", "shortName": "Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-27", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R42": { "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails", "longName": "9954487 - Disclosure - Summary of Significant Accounting Policies - Significant Customers (Details)", "shortName": "Summary of Significant Accounting Policies - Significant Customers (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-45", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-45", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails", "longName": "9954488 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment and Software Capitalization (Details)", "shortName": "Summary of Significant Accounting Policies - Property and Equipment and Software Capitalization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-55", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-55", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails", "longName": "9954489 - Disclosure - Summary of Significant Accounting Policies - Components of Accumulated Other Comprehensive Loss (Details)", "shortName": "Summary of Significant Accounting Policies - Components of Accumulated Other Comprehensive Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-71", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R45": { "role": "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails", "longName": "9954490 - Disclosure - Net Product Sales - Net Product Sales by Customer Geographic Areas (Details)", "shortName": "Net Product Sales - Net Product Sales by Customer Geographic Areas (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-77", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R46": { "role": "http://www.modernatx.com/role/NetProductSalesNarrativeDetails", "longName": "9954491 - Disclosure - Net Product Sales - Narrative (Details)", "shortName": "Net Product Sales - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-86", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R47": { "role": "http://www.modernatx.com/role/NetProductSalesProductSalesDetails", "longName": "9954492 - Disclosure - Net Product Sales - Product Sales (Details)", "shortName": "Net Product Sales - Product Sales (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "mrna:RevenueFromContractWithCustomerExcludingAssessedTaxGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R48": { "role": "http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails", "longName": "9954493 - Disclosure - Net Product Sales - Product Sales Provision Recorded as Accrued Liabilities (Details)", "shortName": "Net Product Sales - Product Sales Provision Recorded as Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ContractWithCustomerRefundLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-87", "name": "us-gaap:ContractWithCustomerRefundLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R49": { "role": "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails", "longName": "9954494 - Disclosure - Other Revenue - Schedule of Disaggregation of Revenue (Details)", "shortName": "Other Revenue - Schedule of Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-88", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R50": { "role": "http://www.modernatx.com/role/OtherRevenueNarrativeDetails", "longName": "9954495 - Disclosure - Other Revenue - Narrative (Details)", "shortName": "Other Revenue - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-18", "name": "mrna:NumberOfParticipants", "unitRef": "participant", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-18", "name": "mrna:NumberOfParticipants", "unitRef": "participant", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.modernatx.com/role/CollaborationAgreementsMerckPersonalizedmRNACancerVaccinesDetails", "longName": "9954496 - Disclosure - Collaboration Agreements - Merck \u2013 Personalized mRNA Cancer Vaccines (Details)", "shortName": "Collaboration Agreements - Merck \u2013 Personalized mRNA Cancer Vaccines (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-116", "name": "mrna:ProceedsFromOptionExerciseFee", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R52": { "role": "http://www.modernatx.com/role/CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails", "longName": "9954497 - Disclosure - Collaboration Agreements - Vertex \u2013 2020 Strategic Alliance in Cystic Fibrosis (Details)", "shortName": "Collaboration Agreements - Vertex \u2013 2020 Strategic Alliance in Cystic Fibrosis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-119", "name": "mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-119", "name": "mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails", "longName": "9954498 - Disclosure - Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details)", "shortName": "Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-121", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R54": { "role": "http://www.modernatx.com/role/CollaborationAgreementsImmaticsStrategicMultiPlatformCollaborationtoDevelopOncologyTherapeuticsDetails", "longName": "9954499 - Disclosure - Collaboration Agreements - Immatics \u2013 Strategic Multi-Platform Collaboration to Develop Oncology Therapeutics (Details)", "shortName": "Collaboration Agreements - Immatics \u2013 Strategic Multi-Platform Collaboration to Develop Oncology Therapeutics (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-122", "name": "mrna:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-122", "name": "mrna:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails", "longName": "9954500 - Disclosure - Financial Instruments and Fair Value Measurements - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)", "shortName": "Financial Instruments and Fair Value Measurements - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-145", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R56": { "role": "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails", "longName": "9954501 - Disclosure - Financial Instruments and Fair Value Measurements - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)", "shortName": "Financial Instruments and Fair Value Measurements - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails", "longName": "9954502 - Disclosure - Financial Instruments and Fair Value Measurements - Narrative (Details)", "shortName": "Financial Instruments and Fair Value Measurements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails", "longName": "9954503 - Disclosure - Financial Instruments and Fair Value Measurements - Unrealized Loss Position (Details)", "shortName": "Financial Instruments and Fair Value Measurements - Unrealized Loss Position (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails", "longName": "9954504 - Disclosure - Financial Instruments and Fair Value Measurements - Financial Assets Measured At Fair Value On a Recurring Basis (Details)", "shortName": "Financial Instruments and Fair Value Measurements - Financial Assets Measured At Fair Value On a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-145", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-204", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R60": { "role": "http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails", "longName": "9954505 - Disclosure - Inventory - Schedule of Inventory, Current (Details)", "shortName": "Inventory - Schedule of Inventory, Current (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.modernatx.com/role/InventoryNarrativeDetails", "longName": "9954506 - Disclosure - Inventory - Narrative (Details)", "shortName": "Inventory - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryWriteDown", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryWriteDown", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails", "longName": "9954507 - Disclosure - Property, Plant and Equipment, Net (Details)", "shortName": "Property, Plant and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails", "longName": "9954508 - Disclosure - Other Balance Sheet Components - Accounts, Notes, Loans and Financing Receivable (Details)", "shortName": "Other Balance Sheet Components - Accounts, Notes, Loans and Financing Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AccountsReceivableGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AccountsReceivableGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails", "longName": "9954509 - Disclosure - Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)", "shortName": "Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:OtherPrepaidExpenseCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:OtherPrepaidExpenseCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails", "longName": "9954510 - Disclosure - Other Balance Sheet Components - Other Non-Current Assets (Details)", "shortName": "Other Balance Sheet Components - Other Non-Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-4", "name": "mrna:DownpaymentsAndPrepaymentsNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "mrna:DownpaymentsAndPrepaymentsNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails", "longName": "9954511 - Disclosure - Other Balance Sheet Components - Accrued Liabilities (Details)", "shortName": "Other Balance Sheet Components - Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ContractWithCustomerRefundLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R67": { "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails", "longName": "9954512 - Disclosure - Other Balance Sheet Components - Other Current Liabilities (Details)", "shortName": "Other Balance Sheet Components - Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FinanceLeaseLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:OtherSundryLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R68": { "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails", "longName": "9954513 - Disclosure - Other Balance Sheet Components - Deferred Revenue (Details)", "shortName": "Other Balance Sheet Components - Deferred Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R69": { "role": "http://www.modernatx.com/role/LeasesNarrativeDetails", "longName": "9954514 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-4", "name": "mrna:OperatingLeaseNumberOfProperties", "unitRef": "campus", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:LesseeFinanceLeasesTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "mrna:OperatingLeaseNumberOfProperties", "unitRef": "campus", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:LesseeFinanceLeasesTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails", "longName": "9954515 - Disclosure - Leases - Balance Sheet Information (Details)", "shortName": "Leases - Balance Sheet Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "mrna:CurrentAssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R71": { "role": "http://www.modernatx.com/role/LeasesLeaseCostsDetails", "longName": "9954516 - Disclosure - Leases - Lease Costs (Details)", "shortName": "Leases - Lease Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails", "longName": "9954517 - Disclosure - Leases - Minimum Lease Payments (Details)", "shortName": "Leases - Minimum Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails", "longName": "9954518 - Disclosure - Commitments and Contingencies - Indemnification Obligations (Details)", "shortName": "Commitments and Contingencies - Indemnification Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-255", "name": "us-gaap:LossContingencyLossInPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-255", "name": "us-gaap:LossContingencyLossInPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails", "longName": "9954519 - Disclosure - Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)", "shortName": "Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-4", "name": "mrna:LegalContingencyFutureFirmPurchaseCommitments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-259", "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R75": { "role": "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails", "longName": "9954520 - Disclosure - Commitments and Contingencies - Licenses to Patented Technology (Details)", "shortName": "Commitments and Contingencies - Licenses to Patented Technology (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-262", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R76": { "role": "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails", "longName": "9954521 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Narrative (Details)", "shortName": "Stock-Based Compensation and Share Repurchase Programs - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails", "longName": "9954522 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Options Activity (Details)", "shortName": "Stock-Based Compensation and Share Repurchase Programs - Options Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-4", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-4", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R78": { "role": "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails", "longName": "9954523 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Restricted Common Stock and Common Stock Units Activity (Details)", "shortName": "Stock-Based Compensation and Share Repurchase Programs - Restricted Common Stock and Common Stock Units Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-269", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-4", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-269", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-4", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails", "longName": "9954524 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details)", "shortName": "Stock-Based Compensation and Share Repurchase Programs - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-280", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-280", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails", "longName": "9954525 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Stock-Based Compensation Expense (Details)", "shortName": "Stock-Based Compensation and Share Repurchase Programs - Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-292", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R81": { "role": "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsShareRepurchaseProgramDetails", "longName": "9954526 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Share Repurchase Program (Details)", "shortName": "Stock-Based Compensation and Share Repurchase Programs - Share Repurchase Program (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.modernatx.com/role/IncomeTaxesLossIncomeBeforeProvisionForBenefitFromIncomeTaxesDetails", "longName": "9954527 - Disclosure - Income Taxes - (Loss) Income Before Provision For (Benefit From) Income Taxes (Details)", "shortName": "Income Taxes - (Loss) Income Before Provision For (Benefit From) Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R83": { "role": "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails", "longName": "9954528 - Disclosure - Income Taxes - Provision For (Benefit From) Income Taxes (Details)", "shortName": "Income Taxes - Provision For (Benefit From) Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails", "longName": "9954529 - Disclosure - Income Taxes - Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate (Details)", "shortName": "Income Taxes - Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails", "longName": "9954530 - Disclosure - Income Taxes - Narrative (Details)", "shortName": "Income Taxes - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "mrna:UnrecognizedTaxBenefitsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R86": { "role": "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails", "longName": "9954531 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Tax Liabilities (Details)", "shortName": "Income Taxes - Significant Components of Deferred Tax Assets and Tax Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails", "longName": "9954532 - Disclosure - Income Taxes- Valuation Allowance (Details)", "shortName": "Income Taxes- Valuation Allowance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mrna:ValuationAllowanceDeferredTaxAssetDecreaseAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R88": { "role": "http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails", "longName": "9954533 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward (Details)", "shortName": "Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-18", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R89": { "role": "http://www.modernatx.com/role/LossEarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails", "longName": "9954534 - Disclosure - (Loss) Earnings per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)", "shortName": "(Loss) Earnings per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } }, "R90": { "role": "http://www.modernatx.com/role/LossEarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails", "longName": "9954535 - Disclosure - (Loss) Earnings per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Income (Loss) Per Share (Details)", "shortName": "(Loss) Earnings per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Income (Loss) Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true, "unique": true } }, "R91": { "role": "http://www.modernatx.com/role/GeographicInformationDetails", "longName": "9954536 - Disclosure - Geographic Information (Details)", "shortName": "Geographic Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-325", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrna-20231231.htm", "unique": true } } }, "tag": { "mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "A2013OptionAgreementAndServicesAndCollaborationAgreementMember", "presentation": [ "http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2013 AZ Agreements", "label": "2013 Option Agreement And Services And Collaboration Agreement [Member]", "documentation": "2013 Option Agreement And Services And Collaboration Agreement [Member]" } } }, "auth_ref": [] }, "mrna_A2021RepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "A2021RepurchaseProgramMember", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2021 Repurchase Program", "label": "2021 Repurchase Program [Member]", "documentation": "2021 Repurchase Program" } } }, "auth_ref": [] }, "mrna_A2022RepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "A2022RepurchaseProgramMember", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Repurchase Program", "label": "2022 Repurchase Program [Member]", "documentation": "2022 Repurchase Program" } } }, "auth_ref": [] }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r24", "r783" ] }, "mrna_AccountsReceivableChargebacksDiscountsAndFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "AccountsReceivableChargebacksDiscountsAndFees", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails": { "parentTag": "us-gaap_AccountsReceivableNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Wholesalers chargebacks, discounts and fees", "label": "Accounts Receivable, Chargebacks, Discounts And Fees", "documentation": "Accounts Receivable, Chargebacks, Discounts And Fees" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableGross", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails": { "parentTag": "us-gaap_AccountsReceivableNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, before Allowance for Credit Loss", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r190", "r283", "r1013" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of Accounts Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r722" ] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNet", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r667", "r721", "r789", "r1013" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r283", "r284" ] }, "mrna_AccruedClinicalTrials": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "AccruedClinicalTrials", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical trials", "label": "Accrued Clinical Trials", "documentation": "Accrued Clinical Trials" } } }, "auth_ref": [] }, "mrna_AccruedCommercial": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "AccruedCommercial", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial", "label": "Accrued Commercial", "documentation": "Accrued Commercial" } } }, "auth_ref": [] }, "mrna_AccruedDevelopmentOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "AccruedDevelopmentOperation", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Development operations", "label": "Accrued Development Operation", "documentation": "Accrued Development Operation" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 }, "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "totalLabel": "Accrued liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r27" ] }, "mrna_AccruedManufacturing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "AccruedManufacturing", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Manufacturing", "label": "Accrued Manufacturing", "documentation": "Accrued Manufacturing" } } }, "auth_ref": [] }, "mrna_AccruedOtherExternalGoodsAndServicesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "AccruedOtherExternalGoodsAndServicesCurrent", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other external goods and services", "label": "Accrued Other External Goods And Services Current", "documentation": "Accrued Other External Goods And Services Current" } } }, "auth_ref": [] }, "mrna_AccruedPropertyAndEquipmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "AccruedPropertyAndEquipmentCurrent", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Accrued Property And Equipment, Current", "documentation": "Accrued Property And Equipment, Current" } } }, "auth_ref": [] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalties", "label": "Accrued Royalties, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r27", "r742" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and Postretirement Benefits", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r4", "r16", "r34", "r910", "r911", "r912" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Unrealized Gain (Loss) on Derivatives Designated As Hedging Instruments", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r204", "r214", "r215", "r506", "r749", "r910" ] }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized\u00a0(Loss) Gain on Available-for-Sale Securities", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r200", "r201", "r202", "r204", "r214", "r215", "r910" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r213", "r214", "r530", "r531", "r532", "r533", "r534", "r535" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r33", "r34", "r106", "r191", "r606", "r628", "r629" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r213", "r214", "r530", "r531", "r532", "r533", "r534", "r535" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive (Loss) Income", "verboseLabel": "Total", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r3", "r16", "r34", "r511", "r514", "r555", "r624", "r625", "r910", "r911", "r912", "r917", "r918", "r919" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r840" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r97", "r783", "r1019" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r454", "r455", "r456", "r638", "r917", "r918", "r919", "r993", "r1020" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r846" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r846" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r846" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r846" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r71", "r72", "r417" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising Costs", "label": "Advertising Cost [Policy Text Block]", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r163" ] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising expenses", "label": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": [ "r462" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r810", "r822", "r832", "r858" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r813", "r825", "r835", "r861" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r846" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r853" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r817", "r826", "r836", "r853", "r862", "r866", "r874" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r872" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails", "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation costs", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r449", "r461" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r192", "r287", "r330" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.modernatx.com/role/LossEarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive securities (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r253" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.modernatx.com/role/LossEarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r46" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.modernatx.com/role/LossEarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.modernatx.com/role/LossEarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r46" ] }, "us-gaap_AreaOfRealEstateProperty": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AreaOfRealEstateProperty", "presentation": [ "http://www.modernatx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Area of office space (in sqft)", "label": "Area of Real Estate Property", "documentation": "Area of a real estate property." } } }, "auth_ref": [] }, "mrna_ArpaGarayCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "ArpaGarayCommonStockMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arpa Garay, Common Stock [Member]", "documentation": "Arpa Garay, Common Stock" } } }, "auth_ref": [] }, "mrna_ArpaGarayMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "ArpaGarayMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arpa Garay [Member]", "documentation": "Arpa Garay" } } }, "auth_ref": [] }, "mrna_ArpaGarayStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "ArpaGarayStockOptionsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arpa Garay, Stock Options [Member]", "documentation": "Arpa Garay, Stock Options" } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.modernatx.com/role/CollaborationAgreementsImmaticsStrategicMultiPlatformCollaborationtoDevelopOncologyTherapeuticsDetails", "http://www.modernatx.com/role/CollaborationAgreementsMerckPersonalizedmRNACancerVaccinesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r503" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment expenses", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r9", "r60" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r143", "r189", "r227", "r258", "r273", "r277", "r327", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r504", "r507", "r529", "r602", "r672", "r783", "r799", "r950", "r951", "r1000" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r182", "r196", "r227", "r327", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r504", "r507", "r529", "r783", "r950", "r951", "r1000" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r83" ] }, "mrna_AstraZenecaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "AstraZenecaMember", "presentation": [ "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AstraZeneca", "label": "AstraZeneca [Member]", "documentation": "AstraZeneca [Member]" } } }, "auth_ref": [] }, "mrna_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "label": "Audit Information [Abstract]", "documentation": "Audit Information" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.modernatx.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r804", "r805", "r818" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.modernatx.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r804", "r805", "r818" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.modernatx.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r804", "r805", "r818" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r297" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r298" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r294", "r337", "r601" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after one year through five years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r927" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after one year through five years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r302", "r600" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value", "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date." } } }, "auth_ref": [ "r924", "r925", "r1011" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due in one year or less", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r926" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due in one year or less", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r301", "r599" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 }, "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair\u00a0Value", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r295", "r337", "r594", "r922" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r291", "r337" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Investments, non-current", "label": "Debt Securities, Available-for-Sale, Noncurrent", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r186", "r291", "r337" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r869" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r870" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r865" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r865" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r865" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r865" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r865" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r865" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails", "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails", "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails", "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r420", "r421", "r422", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r444", "r445", "r446", "r447", "r448" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r868" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r867" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r866" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r866" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r81", "r82" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "BiomedicalAdvancedResearchAndDevelopmentAuthorityMember", "presentation": [ "http://www.modernatx.com/role/OtherRevenueNarrativeDetails", "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BARDA", "label": "Biomedical Advanced Research And Development Authority [Member]", "documentation": "Biomedical Advanced Research And Development Authority [Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r501", "r775", "r776" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r78", "r79", "r501", "r775", "r776" ] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r77" ] }, "mrna_CambridgeMassachusettsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "CambridgeMassachusettsMember", "presentation": [ "http://www.modernatx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cambridge Leases", "label": "Cambridge, Massachusetts [Member]", "documentation": "Cambridge, Massachusetts [Member]" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases of property, plant and equipment included in accounts payable and accrued liabilities", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r43", "r44", "r45" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 }, "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r40", "r185", "r739" ] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsMember", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r41", "r142" ] }, "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances." } } }, "auth_ref": [ "r41" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year", "totalLabel": "Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r40", "r118", "r225" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r118" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash investing and financing activities", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CertificatesOfDepositMember", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Certificates of deposit", "label": "Certificates of Deposit [Member]", "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured." } } }, "auth_ref": [ "r13", "r790", "r791", "r792", "r793" ] }, "mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "ChangeInContractWithCustomerLiabilityCurrentRollForward", "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Change In Contract With Customer, Liability [Roll Forward]", "label": "Change In Contract with Customer Liability, Current [Roll Forward]", "documentation": "Change In Contract with Customer Liability, Current" } } }, "auth_ref": [] }, "mrna_ChangeInContractWithCustomerLiabilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "ChangeInContractWithCustomerLiabilityLineItems", "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change In Contract With Customer, Liability [Line Items]", "label": "Change in Contract With Customer Liability [Line Items]", "documentation": "Change in Contract With Customer Liability" } } }, "auth_ref": [] }, "mrna_ChangeInContractWithCustomerLiabilityRefundRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "ChangeInContractWithCustomerLiabilityRefundRollForward", "presentation": [ "http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Contract with Customer, Liability Refund [Roll Forward]", "label": "Change in Contract with Customer, Liability Refund [Roll Forward]", "documentation": "Change in Contract with Customer, Liability Refund" } } }, "auth_ref": [] }, "mrna_ChangeInContractWithCustomerLiabilityTable": { "xbrltype": "stringItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "ChangeInContractWithCustomerLiabilityTable", "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Contract With Customer Liability [Table]", "label": "Change In Contract With Customer, Liability [Table]", "documentation": "Change In Contract With Customer, Liability" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r844" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "mrna_ClinicalOperationsAndSupportCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "ClinicalOperationsAndSupportCommitmentMember", "presentation": [ "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical Operations and Support Commitments", "label": "Clinical Operations And Support Commitment [Member]", "documentation": "Clinical Operations And Support Commitment [Member]" } } }, "auth_ref": [] }, "mrna_ClinicalServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "ClinicalServicesMember", "presentation": [ "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical Services", "label": "Clinical Services [Member]", "documentation": "Clinical Services" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r845" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r845" ] }, "mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "CollaborationArrangementIncludingArrangementsWithAffiliateMember", "presentation": [ "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Collaboration revenue", "label": "Collaboration Arrangement Including Arrangements With Affiliate [Member]", "documentation": "Collaboration Arrangement Including Arrangements With Affiliate [Member]" } } }, "auth_ref": [] }, "mrna_CollaborationArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "CollaborationArrangementMember", "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration revenue", "label": "Collaboration Arrangement [Member]", "documentation": "Collaboration Arrangement [Member]" } } }, "auth_ref": [] }, "mrna_CollaborationReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "CollaborationReceivableCurrent", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration receivable", "label": "Collaboration Receivable, Current", "documentation": "Collaboration Receivable, Current" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementAccountingPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementAccountingPolicy", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration Arrangements", "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for collaborative arrangements." } } }, "auth_ref": [ "r166" ] }, "mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/CollaborationAgreementsImmaticsStrategicMultiPlatformCollaborationtoDevelopOncologyTherapeuticsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment", "label": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product", "documentation": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember", "presentation": [ "http://www.modernatx.com/role/CollaborationAgreementsImmaticsStrategicMultiPlatformCollaborationtoDevelopOncologyTherapeuticsDetails", "http://www.modernatx.com/role/CollaborationAgreementsMerckPersonalizedmRNACancerVaccinesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement", "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]", "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement." } } }, "auth_ref": [ "r992" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 11)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r30", "r87", "r603", "r658" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.modernatx.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r129", "r360", "r361", "r723", "r943" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r786", "r787", "r788", "r790", "r791", "r792", "r793", "r917", "r918", "r993", "r1017", "r1020" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in usd per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r96" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r96", "r659" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r96" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals", "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares, outstanding (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)", "periodEndLabel": "Balance at end of period (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r17", "r96", "r659", "r678", "r1020", "r1021" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value $0.0001; 1,600 shares authorized as of December 31, 2023 and 2022; 382 and 385 shares issued and outstanding as of December 31, 2023 and 2022, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r96", "r605", "r783" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r850" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r849" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r851" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r848" ] }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComponentsOfDeferredTaxAssetsAbstract", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets:", "label": "Components of Deferred Tax Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities:", "label": "Components of Deferred Tax Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive (loss) income", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r35", "r209", "r211", "r216", "r596", "r613" ] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive Income (Loss)", "label": "Comprehensive Income, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment and software", "verboseLabel": "Computer equipment and software", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r49", "r51", "r84", "r85", "r282", "r722" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r49", "r51", "r84", "r85", "r282", "r630", "r722" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r49", "r51", "r84", "r85", "r282", "r722", "r886" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentrations of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r89", "r167" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r722" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk, percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r49", "r51", "r84", "r85", "r282" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r48", "r49", "r51", "r52", "r84", "r140", "r722" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r49", "r51", "r84", "r85", "r282", "r722" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r80", "r750" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://www.modernatx.com/role/NetProductSalesTables", "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Balances of Receivables and Contract Liabilities", "verboseLabel": "Schedule of Deferred Revenue", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r953" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/NetProductSalesNarrativeDetails", "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r384", "r385", "r404" ] }, "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails", "http://www.modernatx.com/role/CollaborationAgreementsMerckPersonalizedmRNACancerVaccinesDetails", "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress", "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r764" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r384", "r385", "r404" ] }, "mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "ContractWithCustomerLiabilityDeductionsDuringPeriod", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deductions", "label": "Contract With Customer, Liability, Deductions During Period", "documentation": "Contract With Customer, Liability, Deductions During Period" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue, non-current", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r384", "r385", "r404" ] }, "mrna_ContractWithCustomerLiabilityProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "ContractWithCustomerLiabilityProvision", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/NetProductSalesProductSalesDetails": { "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/NetProductSalesProductSalesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total product sales provision", "label": "Contract with Customer, Liability, Provision", "documentation": "Contract with Customer, Liability, Provision" } } }, "auth_ref": [] }, "mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/NetProductSalesProductSalesDetails": { "parentTag": "mrna_ContractWithCustomerLiabilityProvision", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/NetProductSalesProductSalesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Wholesaler chargebacks, discounts and fees", "label": "Contract with Customer, Liability, Provision For Chargebacks, Discounts and Fees", "documentation": "Contract with Customer, Liability, Provision For Chargebacks, Discounts and Fees" } } }, "auth_ref": [] }, "mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/NetProductSalesProductSalesDetails": { "parentTag": "mrna_ContractWithCustomerLiabilityProvision", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/NetProductSalesProductSalesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Returns and other fees", "label": "Contract with Customer, Liability, Provision For Refunds and Other Fees", "documentation": "Contract with Customer, Liability, Provision For Refunds and Other Fees" } } }, "auth_ref": [] }, "mrna_ContractWithCustomerLiabilityProvisionRelatedToSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "ContractWithCustomerLiabilityProvisionRelatedToSales", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Provision related to sales made in current period", "label": "Contract with Customer, Liability, Provision Related To Sales", "documentation": "Contract with Customer, Liability, Provision Related To Sales" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r405" ] }, "us-gaap_ContractWithCustomerRefundLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerRefundLiability", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails", "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedPeriodStartLabel": "Balance at December 31, 2022", "negatedPeriodEndLabel": "Balance at December 31, 2023", "verboseLabel": "Provisions related to product sales (Note 3)", "label": "Contract with Customer, Refund Liability", "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer." } } }, "auth_ref": [ "r955" ] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate debt securities", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r772", "r774", "r1016" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r111", "r590" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r110" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.modernatx.com/role/CollaborationAgreementsImmaticsStrategicMultiPlatformCollaborationtoDevelopOncologyTherapeuticsDetails", "http://www.modernatx.com/role/CollaborationAgreementsMerckPersonalizedmRNACancerVaccinesDetails", "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails", "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r230", "r231", "r377", "r381", "r556", "r746", "r748" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "CurrentAssetsAndLiabilitiesLesseeTableTextBlock", "presentation": [ "http://www.modernatx.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets And Liabilities, Lessee", "label": "Current Assets And Liabilities, Lessee [Table Text Block]", "documentation": "Current Assets And Liabilities, Lessee [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Current Federal Tax Expense (Benefit)", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r891", "r916", "r990" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Current Foreign Tax Expense (Benefit)", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r891", "r916" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r137", "r489", "r495", "r916" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current:", "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "mrna_CurrentMarketableSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "CurrentMarketableSecuritiesMember", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current Marketable Securities", "label": "Current Marketable Securities [Member]", "documentation": "Current Marketable Securities [Member]" } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Current State and Local Tax Expense (Benefit)", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r891", "r916", "r990" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r50", "r282" ] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit losses related allowance", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r296", "r337", "r345", "r347" ] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment charges", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded", "documentation": "Amount of expense for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), for which no credit loss was previously recorded." } } }, "auth_ref": [ "r346" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Gross unrealized losses, 12 months or more", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r159", "r342", "r758" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Estimated fair value, 12 months or more", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r159", "r342" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross unrealized losses, less than 12 months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r159", "r342", "r758" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated fair value, less than 12 months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r159", "r342" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Gross Unrealized Losses, Total", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss." } } }, "auth_ref": [ "r156", "r339", "r758" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Estimated Fair Value, Total", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r157", "r340" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r155", "r758", "r935" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of AFS securities in loss positions", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions", "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r158", "r341" ] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r916", "r989", "r990" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Deferred Foreign Income Tax Expense (Benefit)", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r137", "r916", "r989" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r470", "r471" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r9", "r137", "r176", "r494", "r495", "r916" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred:", "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "mrna_DeferredIncomeTaxExpenseBenefitNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "DeferredIncomeTaxExpenseBenefitNet", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Expense (Benefit), Net", "documentation": "Deferred Income Tax Expense (Benefit), Net" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total deferred tax liabilities", "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r93", "r94", "r144", "r483" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r916", "r989", "r990" ] }, "mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized licenses, research and development and start-up costs", "label": "Deferred Tax Assets, Capitalized Licenses, Research And Development, And Start-Up Costs", "documentation": "Deferred Tax Assets, Capitalized Licenses, Research And Development, And Start-Up Costs" } } }, "auth_ref": [] }, "mrna_DeferredTaxAssetsFinancingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "DeferredTaxAssetsFinancingLeaseLiability", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing lease liabilities", "label": "Deferred Tax Assets, Financing Lease, Liability", "documentation": "Deferred Tax Assets, Financing Lease, Liability" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r484" ] }, "us-gaap_DeferredTaxAssetsInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInventory", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory reserve and capitalization", "label": "Deferred Tax Assets, Inventory", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory." } } }, "auth_ref": [ "r76", "r988" ] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax (liabilities) assets", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r987" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax assets", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r987" ] }, "mrna_DeferredTaxAssetsOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "DeferredTaxAssetsOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Deferred Tax Assets, Operating Lease, Liability", "documentation": "Deferred Tax Assets, Operating Lease, Liability" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss carryforwards", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r76", "r988" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Deferred Tax Assets, Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r76", "r988" ] }, "us-gaap_DeferredTaxAssetsOtherComprehensiveLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOtherComprehensiveLoss", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income", "label": "Deferred Tax Assets, Other Comprehensive Loss", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses in other comprehensive income." } } }, "auth_ref": [ "r76", "r988" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax credit carryforwards", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards." } } }, "auth_ref": [ "r75", "r76", "r988" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r76", "r988" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Returns and other fees", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Returns and Allowances", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated returns and sales allowances." } } }, "auth_ref": [ "r76", "r988" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails", "http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: valuation allowance", "periodStartLabel": "Valuation allowance at beginning of the period", "periodEndLabel": "Valuation allowance at December 31", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r485" ] }, "mrna_DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wholesaler chargebacks, discounts and fees", "label": "Deferred Tax Assets, Wholesaler Chargebacks, Discounts And Fees", "documentation": "Deferred Tax Assets, Wholesaler Chargebacks, Discounts And Fees" } } }, "auth_ref": [] }, "mrna_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Right-of-use assets, financing", "label": "Deferred Tax Liabilities, Finance Lease Right Of Use Asset", "documentation": "Deferred Tax Liabilities, Finance Lease Right Of Use Asset" } } }, "auth_ref": [] }, "mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Right-of-use assets, operating", "label": "Deferred Tax Liabilities, Operating Lease Right Of Use Asset", "documentation": "Deferred Tax Liabilities, Operating Lease Right Of Use Asset" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Deferred Tax Liabilities, Other", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": [ "r76", "r988" ] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Property, plant and equipment", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r76", "r988" ] }, "mrna_DeferredTaxValuationAllowanceRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "DeferredTaxValuationAllowanceRollForward", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax, Valuation Allowance [Roll Forward]", "label": "Deferred Tax, Valuation Allowance [Roll Forward]", "documentation": "Deferred Tax, Valuation Allowance" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r9", "r61" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r9", "r262" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssets", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative instruments, assets", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r197", "r198", "r528", "r640", "r641", "r642", "r643", "r644", "r646", "r647", "r648", "r649", "r650", "r665", "r666", "r709", "r712", "r713", "r714", "r715", "r716", "r748", "r788", "r1018" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative instruments, liabilities", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r197", "r198", "r528", "r640", "r641", "r642", "r643", "r646", "r647", "r648", "r649", "r650", "r673", "r675", "r676", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r748", "r1018" ] }, "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative liability." } } }, "auth_ref": [ "r509" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.modernatx.com/role/GeographicInformationDetails", "http://www.modernatx.com/role/NetProductSalesNarrativeDetails", "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails", "http://www.modernatx.com/role/NetProductSalesProductSalesDetails", "http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails", "http://www.modernatx.com/role/OtherRevenueNarrativeDetails", "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r403", "r765", "r766", "r767", "r768", "r769", "r770", "r771" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.modernatx.com/role/GeographicInformationDetails", "http://www.modernatx.com/role/NetProductSalesNarrativeDetails", "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails", "http://www.modernatx.com/role/NetProductSalesProductSalesDetails", "http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails", "http://www.modernatx.com/role/OtherRevenueNarrativeDetails", "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r403", "r765", "r766", "r767", "r768", "r769", "r770", "r771" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.modernatx.com/role/NetProductSalesTables", "http://www.modernatx.com/role/OtherRevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r954" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchasePrograms" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation and Share Repurchase Programs", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r415", "r419", "r450", "r451", "r453", "r778" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r804", "r805", "r818" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r804", "r805", "r818", "r854" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r839" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r802" ] }, "mrna_DownpaymentsAndPrepaymentsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "DownpaymentsAndPrepaymentsNoncurrent", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Down payments and prepayments, non-current", "label": "Downpayments And Prepayments, Noncurrent", "documentation": "Downpayments And Prepayments, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "(Loss) earnings per share:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.modernatx.com/role/LossEarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in usd per share)", "verboseLabel": "Basic EPS (in usd per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r217", "r237", "r238", "r239", "r240", "r241", "r246", "r248", "r250", "r251", "r252", "r256", "r518", "r519", "r597", "r614", "r753" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.modernatx.com/role/LossEarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in usd per share)", "verboseLabel": "Diluted EPS (in usd per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r217", "r237", "r238", "r239", "r240", "r241", "r248", "r250", "r251", "r252", "r256", "r518", "r519", "r597", "r614", "r753" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://www.modernatx.com/role/LossEarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings (Loss) per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r46", "r47" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.modernatx.com/role/LossEarningsperShare" ], "lang": { "en-us": { "role": { "terseLabel": "(Loss) Earnings per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r245", "r253", "r254", "r255" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails", "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Effective tax rate", "terseLabel": "Effective income tax rate reconciliation, percent", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r473" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal statutory tax rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r229", "r473", "r497" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in valuation allowance", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r985", "r991" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationFdiiPercent", "calculation": { "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign-derived intangible income and other", "label": "Effective Income Tax Rate Reconciliation, FDII, Percent", "documentation": "Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII)." } } }, "auth_ref": [ "r985" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "calculation": { "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-deductible items", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r985", "r991" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r985", "r991" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "calculation": { "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation windfall", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r882", "r985" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State taxes, net of federal benefits", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r985", "r991" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "calculation": { "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Federal research and development credits", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r985", "r991" ] }, "mrna_EmbeddedLeasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "EmbeddedLeasesMember", "presentation": [ "http://www.modernatx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Embedded Leases", "label": "Embedded Leases [Member]", "documentation": "Embedded Leases" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation-related", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r27" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total unrecognized compensation cost related to non-vested stock-based compensation", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r452" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average period of cost expected to be recognized", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r452" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax benefit realized from option exercised", "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit", "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r172" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockMember", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Employee stock purchase plan", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.modernatx.com/role/LossEarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails", "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails", "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails", "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Options", "verboseLabel": "Options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r801" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r801" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r801" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r879" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r801" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r801" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r801" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r801" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r880" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquipmentMember", "presentation": [ "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Manufacturing and laboratory equipment", "verboseLabel": "Manufacturing and laboratory equipment", "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r17", "r180", "r213", "r214", "r215", "r232", "r233", "r234", "r236", "r242", "r244", "r257", "r328", "r329", "r383", "r454", "r455", "r456", "r490", "r491", "r510", "r511", "r512", "r513", "r514", "r515", "r517", "r530", "r531", "r532", "r533", "r534", "r535", "r555", "r624", "r625", "r626", "r638", "r698" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity investments", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r264", "r326", "r902", "r933" ] }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiRealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Net losses", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r615", "r932" ] }, "us-gaap_EquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesMember", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity investments", "label": "Equity Securities [Member]", "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants." } } }, "auth_ref": [ "r56", "r794", "r795", "r796", "r1023" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities without readily determinable fair value, amount", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r325" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r847" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r810", "r822", "r832", "r858" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r807", "r819", "r829", "r855" ] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EuropeMember", "presentation": [ "http://www.modernatx.com/role/GeographicInformationDetails", "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Europe", "label": "Europe [Member]" } } }, "auth_ref": [ "r1022", "r1024", "r1025", "r1026" ] }, "mrna_EuropeanCommissionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "EuropeanCommissionMember", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "European Commission", "label": "European Commission [Member]", "documentation": "European Commission" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r853" ] }, "mrna_FFFEnterprisesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "FFFEnterprisesMember", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FFF Enterprises", "label": "FFF Enterprises [Member]", "documentation": "FFF Enterprises" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r378", "r408", "r409", "r410", "r411", "r412", "r413", "r522", "r560", "r561", "r562", "r761", "r762", "r772", "r773", "r774" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r521", "r522", "r523", "r524", "r525" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Level 1", "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r378", "r408", "r413", "r522", "r560", "r772", "r773", "r774" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r378", "r408", "r413", "r522", "r561", "r761", "r762", "r772", "r773", "r774" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r378", "r408", "r409", "r410", "r411", "r412", "r413", "r560", "r561", "r562", "r761", "r762", "r772", "r773", "r774" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r520", "r525" ] }, "mrna_FinanceLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "FinanceLeaseCost", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/LeasesLeaseCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total financing lease costs", "label": "Finance Lease, Cost", "documentation": "Finance Lease, Cost" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/LeasesLeaseCostsDetails": { "parentTag": "mrna_FinanceLeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense for financing lease liabilities", "label": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r540", "r546", "r782" ] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Operating cash flows used in financing leases", "label": "Finance Lease, Interest Payment on Liability", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": [ "r542", "r550" ] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract", "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Leases", "label": "Finance Lease, Liability, to be Paid, Rolling Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Present value of lease liabilities", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r538", "r554" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": { "parentTag": "mrna_OperatingAndFinanceLeaseLiabilityCurrent", "weight": 1.0, "order": 2.0 }, "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails", "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Lease liabilities - financing (Note 10)", "terseLabel": "Financing lease liabilities", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r538" ] }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Finance lease, liability, current, statement of financial position [Extensible List]", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current finance lease liability." } } }, "auth_ref": [ "r539" ] }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.modernatx.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finance Lease Maturity", "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r999" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": { "parentTag": "mrna_OperatingAndFinanceLeaseLiabilityNoncurrent", "weight": 1.0, "order": 2.0 }, "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing lease liabilities, non-current", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r538" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total minimum lease payments", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r554" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finance Lease, Liability, to be Paid, Next Rolling 12 Months", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease due in next rolling 12 months following current statement of financial position date. For interim and annual periods when interim period is reported on rolling approach." } } }, "auth_ref": [ "r999" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finance Lease, Liability, to be Paid, after Rolling Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r999" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueInRollingYearFive", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finance Lease, Liability, to be Paid, Rolling Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r999" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueInRollingYearFour", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finance Lease, Liability, to be Paid, Rolling Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r999" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueInRollingYearThree", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finance Lease, Liability, to be Paid, Rolling Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r999" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueInRollingYearTwo", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Rolling Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r999" ] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less amounts representing interest", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r554" ] }, "mrna_FinanceLeaseNumberOfProperties": { "xbrltype": "integerItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "FinanceLeaseNumberOfProperties", "presentation": [ "http://www.modernatx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease, number of properties", "label": "Finance Lease, Number Of Properties", "documentation": "Finance Lease, Number Of Properties" } } }, "auth_ref": [] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Financing cash flows used in financing leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r541", "r550" ] }, "mrna_FinanceLeasePrincipalPaymentsNetOfAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "FinanceLeasePrincipalPaymentsNetOfAdjustments", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Changes in financing lease liabilities", "label": "Finance Lease, Principal Payments, Net Of Adjustments", "documentation": "Finance Lease, Principal Payments, Net Of Adjustments" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": { "parentTag": "mrna_OperatingAndFinanceLeaseRightOfUseAsset", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets, financing, net", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r537" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/LeasesLeaseCostsDetails": { "parentTag": "mrna_FinanceLeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of right-of-use assets, financing leases", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r540", "r546", "r782" ] }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Finance lease, right-of-use asset, statement of financial position [Extensible List]", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset." } } }, "auth_ref": [ "r539" ] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.modernatx.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance leases, discount rate", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": [ "r553", "r782" ] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.modernatx.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance leases, remaining lease term", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r552", "r782" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r331", "r332", "r334", "r335", "r336", "r338", "r343", "r344", "r379", "r382", "r516", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r612", "r758", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r928", "r929", "r930", "r931" ] }, "mrna_FinancingRightOfUseAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "FinancingRightOfUseAssetMember", "presentation": [ "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets, financing", "label": "Financing, Right-Of-Use Asset [Member]", "documentation": "Financing, Right-Of-Use Asset [Member]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r353", "r355", "r356", "r357", "r591", "r592" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r58", "r59" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible asset", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r125", "r591" ] }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinitelivedIntangibleAssetsAcquired1", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible assets acquired", "label": "Finite-Lived Intangible Assets Acquired", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition." } } }, "auth_ref": [ "r354" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r814", "r826", "r836", "r862" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r814", "r826", "r836", "r862" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r814", "r826", "r836", "r862" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r814", "r826", "r836", "r862" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r814", "r826", "r836", "r862" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r113", "r682" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r109" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r187", "r352", "r593", "r760", "r783", "r937", "r938" ] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r12", "r57" ] }, "us-gaap_GrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrantMember", "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails", "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grant revenue", "label": "Grant [Member]", "documentation": "Award of money not required to be repaid." } } }, "auth_ref": [ "r956" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r804", "r805", "r818" ] }, "mrna_ImmaticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "ImmaticsMember", "presentation": [ "http://www.modernatx.com/role/CollaborationAgreementsImmaticsStrategicMultiPlatformCollaborationtoDevelopOncologyTherapeuticsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Immatics", "label": "Immatics [Member]", "documentation": "Immatics" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of Long-Lived Assets, including Intangibles and Lease Right-of-Use Assets", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r128" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesLossIncomeBeforeProvisionForBenefitFromIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesLossIncomeBeforeProvisionForBenefitFromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r228", "r496" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.modernatx.com/role/IncomeTaxesLossIncomeBeforeProvisionForBenefitFromIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.modernatx.com/role/IncomeTaxesLossIncomeBeforeProvisionForBenefitFromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "(Loss) income before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r107", "r147", "r258", "r272", "r276", "r278", "r598", "r610", "r755" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/IncomeTaxesLossIncomeBeforeProvisionForBenefitFromIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/IncomeTaxesLossIncomeBeforeProvisionForBenefitFromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r228", "r496" ] }, "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on equity investments, net", "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions", "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r358", "r359", "r683" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r359", "r683" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Axis]", "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r14" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Domain]", "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.modernatx.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r229", "r466", "r474", "r480", "r487", "r492", "r498", "r499", "r500", "r637" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "totalLabel": "Total provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r160", "r177", "r243", "r244", "r263", "r472", "r493", "r616" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r212", "r468", "r469", "r480", "r481", "r486", "r488", "r634" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash (received) paid for income taxes", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r42" ] }, "us-gaap_IncomeTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesReceivable", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax receivable", "label": "Income Taxes Receivable, Current", "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes." } } }, "auth_ref": [ "r86", "r905" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Increase (Decrease) in Income Taxes Payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r588", "r913" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in assets and liabilities, net of acquisition of business:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.modernatx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "negatedTerseLabel": "Decrease in operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r889", "r913" ] }, "mrna_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in the right of use of the asset", "label": "Increase (Decrease) in Operating Lease, Right-of-Use Asset", "documentation": "Increase (Decrease) in Operating Lease, Right-of-Use Asset" } } }, "auth_ref": [] }, "mrna_IncreaseDecreaseInOperatingLeasesRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "IncreaseDecreaseInOperatingLeasesRightOfUseAssets", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Right-of-use assets, operating leases", "label": "Increase (Decrease) In Operating Leases, Right Of Use Assets", "documentation": "Increase (Decrease) In Operating Leases, Right Of Use Assets" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IndemnificationGuaranteeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndemnificationGuaranteeMember", "presentation": [ "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indemnifications", "label": "Indemnification Agreement [Member]", "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor." } } }, "auth_ref": [ "r949" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r817", "r826", "r836", "r853", "r862", "r866", "r874" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r872" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r806", "r878" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r806", "r878" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r806", "r878" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r221", "r223", "r224" ] }, "us-gaap_InterestReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestReceivableCurrent", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest receivable", "label": "Interest Receivable, Current", "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r905" ] }, "us-gaap_InventoryCurrentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryCurrentTable", "presentation": [ "http://www.modernatx.com/role/InventoryNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, Current [Table]", "label": "Inventory, Current [Table]", "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.modernatx.com/role/Inventory" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r348" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r124", "r743" ] }, "us-gaap_InventoryFirmPurchaseCommitmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFirmPurchaseCommitmentLoss", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/InventoryNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, firm purchase commitment, loss", "label": "Inventory, Firm Purchase Commitment, Loss", "documentation": "Amount of loss recognized on firm purchase commitment for inventory." } } }, "auth_ref": [ "r173" ] }, "us-gaap_InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryGross", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/InventoryNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, gross", "label": "Inventory, Gross", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r907" ] }, "us-gaap_InventoryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryLineItems", "presentation": [ "http://www.modernatx.com/role/InventoryNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory [Line Items]", "label": "Inventory [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "totalLabel": "Total inventory", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r194", "r740", "r783" ] }, "us-gaap_InventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNoncurrent", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails", "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, non-current", "label": "Inventory, Noncurrent", "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth_ref": [ "r903" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r162", "r184", "r193", "r348", "r349", "r351", "r589", "r751" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r124", "r745" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in progress", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r124", "r744" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWriteDown", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/InventoryNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory write-down", "label": "Inventory Write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r350" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r114", "r261" ] }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amortization/accretion of investments", "label": "Investment Income, Net, Amortization of Discount and Premium", "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities." } } }, "auth_ref": [ "r115" ] }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsAllOtherInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Investments, All Other Investments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments." } } }, "auth_ref": [] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Investments, Debt and Equity Securities [Abstract]", "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments and Fair Value Measurements", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r141", "r149", "r150", "r179", "r289", "r292", "r526", "r527" ] }, "us-gaap_LandAndLandImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandAndLandImprovementsMember", "presentation": [ "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land and land improvements", "label": "Land and Land Improvements [Member]", "documentation": "Real estate held and assets that are an addition or improvement to real estate held." } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermAxis", "presentation": [ "http://www.modernatx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Contractual Term [Axis]", "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r887" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermDomain", "presentation": [ "http://www.modernatx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Contractual Term [Domain]", "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r887" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.modernatx.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease, Cost", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r998" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r127" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "mrna_LegalContingencyFutureFirmPurchaseCommitments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "LegalContingencyFutureFirmPurchaseCommitments", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails", "http://www.modernatx.com/role/InventoryNarrativeDetails", "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on future firm purchase commitments", "label": "Legal Contingency, Future Firm Purchase Commitments", "documentation": "Legal Contingency, Future Firm Purchase Commitments" } } }, "auth_ref": [] }, "mrna_LesseeFinanceLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "LesseeFinanceLeaseExpense", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in financing lease liabilities", "label": "Lessee, Finance Lease, Expense", "documentation": "Lessee, Finance Lease, Expense" } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeFinanceLeasesTextBlock", "presentation": [ "http://www.modernatx.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Finance Leases [Text Block]", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": [ "r536" ] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails", "http://www.modernatx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r545" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails", "http://www.modernatx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r545" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r544" ] }, "mrna_LesseeOperatingLeaseBuildingProjectYears": { "xbrltype": "durationItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "LesseeOperatingLeaseBuildingProjectYears", "presentation": [ "http://www.modernatx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of years", "label": "Lessee, Operating Lease, Building Project, Years", "documentation": "Lessee, Operating Lease, Building Project, Years" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.modernatx.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Lease Maturity", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r999" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total minimum lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r554" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Rolling Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r999" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r999" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r999" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r999" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r999" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Next Rolling 12 Months", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r999" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less amounts representing interest", "terseLabel": "Undiscounted future lease payments", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r554" ] }, "mrna_LesseeOperatingLeaseNumberOfExtensions": { "xbrltype": "integerItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "LesseeOperatingLeaseNumberOfExtensions", "presentation": [ "http://www.modernatx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of extension", "label": "Lessee, Operating Lease, Number Of Extensions", "documentation": "Lessee, Operating Lease, Number Of Extension" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.modernatx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Extension term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r997" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.modernatx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease term", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r997" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.modernatx.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r536" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r26", "r227", "r327", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r505", "r507", "r508", "r529", "r657", "r754", "r799", "r950", "r1000", "r1001" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r101", "r146", "r608", "r783", "r915", "r934", "r994" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Stockholders\u2019 Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r28", "r183", "r227", "r327", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r505", "r507", "r508", "r529", "r783", "r950", "r1000", "r1001" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LicenseAndServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicenseAndServiceMember", "presentation": [ "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License agreement", "label": "License and Service [Member]", "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark." } } }, "auth_ref": [ "r956" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [ "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Nature [Axis]", "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r362", "r363", "r364", "r367", "r945", "r946" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r362", "r363", "r364", "r367", "r945", "r946" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r362", "r363", "r364", "r367", "r945", "r946" ] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reserves established", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r362", "r881" ] }, "us-gaap_LossContingencyLossInPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyLossInPeriod", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Losses related to indemnification obligations", "label": "Loss Contingency, Loss in Period", "documentation": "The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates." } } }, "auth_ref": [ "r944" ] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyNatureDomain", "presentation": [ "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Nature [Domain]", "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r362", "r363", "r364", "r367", "r945", "r946" ] }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyPendingClaimsNumber", "presentation": [ "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of claims outstanding", "label": "Loss Contingency, Pending Claims, Number", "documentation": "Number of pending claims pertaining to a loss contingency." } } }, "auth_ref": [ "r945", "r946" ] }, "mrna_MRNAVertex2020AgreementMemberMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "MRNAVertex2020AgreementMemberMember", "presentation": [ "http://www.modernatx.com/role/CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MRNA Vertex 2020 Agreement Member", "label": "MRNA Vertex 2020 Agreement Member [Member]", "documentation": "MRNA Vertex 2020 Agreement Member" } } }, "auth_ref": [] }, "mrna_MTCSouthMTCNorthAndMTCEastMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "MTCSouthMTCNorthAndMTCEastMember", "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails", "http://www.modernatx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MTC South, MTC North and MTC East", "label": "MTC South, MTC North and MTC East [Member]", "documentation": "MTC South, MTC North and MTC East" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.modernatx.com/role/OtherRevenueNarrativeDetails", "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r282", "r767", "r954", "r1014", "r1015" ] }, "us-gaap_MajorCustomersPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MajorCustomersPolicyPolicyTextBlock", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Customers", "label": "Major Customers, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity." } } }, "auth_ref": [ "r48", "r49", "r51", "r122" ] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesPolicy", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Marketable Securities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": [ "r88" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r363", "r364", "r365", "r366", "r414", "r587", "r623", "r649", "r650", "r702", "r704", "r706", "r707", "r717", "r734", "r735", "r757", "r763", "r777", "r785", "r952", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r845" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r845" ] }, "mrna_MerckMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "MerckMember", "presentation": [ "http://www.modernatx.com/role/CollaborationAgreementsMerckPersonalizedmRNACancerVaccinesDetails", "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Merck", "label": "Merck [Member]", "documentation": "Merck [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r363", "r364", "r365", "r366", "r414", "r587", "r623", "r649", "r650", "r702", "r704", "r706", "r707", "r717", "r734", "r735", "r757", "r763", "r777", "r785", "r952", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007" ] }, "mrna_MinistryOfHealthLaborAndWelfareOfJapanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "MinistryOfHealthLaborAndWelfareOfJapanMember", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ministry of Health, Labor, and Welfare of Japan", "label": "Ministry Of Health, Labor, And Welfare Of Japan [Member]", "documentation": "Ministry Of Health, Labor, And Welfare Of Japan" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r865" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r957" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r873" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.modernatx.com/role/OtherRevenueNarrativeDetails", "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r282", "r767", "r954", "r1014", "r1015" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r846" ] }, "mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember", "presentation": [ "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "National Institute of Allergy and Infectious Diseases member", "label": "National Institute of Allergy and Infectious Diseases member [Member]", "documentation": "National Institute of Allergy and Infectious Diseases member" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r222" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r222" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r118", "r119", "r120" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 }, "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.modernatx.com/role/LossEarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net (loss) income", "terseLabel": "Net (loss) income", "verboseLabel": "Net (loss) income", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r108", "r120", "r148", "r181", "r207", "r210", "r215", "r227", "r235", "r237", "r238", "r239", "r240", "r243", "r244", "r249", "r258", "r272", "r276", "r278", "r327", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r519", "r529", "r611", "r680", "r696", "r697", "r755", "r797", "r950" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://www.modernatx.com/role/LossEarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Numerator:", "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Issued Accounting Standards Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r845" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r814", "r826", "r836", "r853", "r862" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r843" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r842" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r853" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r873" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r873" ] }, "mrna_NoncurrentMarketableSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "NoncurrentMarketableSecuritiesMember", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non- Current Marketable Securities", "label": "Noncurrent Marketable Securities [Member]", "documentation": "Noncurrent Marketable Securities [Member]" } } }, "auth_ref": [] }, "mrna_NorwoodMassachusettsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "NorwoodMassachusettsMember", "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Norwood Leases", "label": "Norwood, Massachusetts [Member]", "documentation": "Norwood, Massachusetts" } } }, "auth_ref": [] }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesAndLoansReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible note receivable", "label": "Financing Receivable, after Allowance for Credit Loss, Current", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease." } } }, "auth_ref": [ "r283", "r284", "r595" ] }, "mrna_NoubarAfeyanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "NoubarAfeyanMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Noubar Afeyan [Member]", "documentation": "Noubar Afeyan" } } }, "auth_ref": [] }, "mrna_NumberOfDevelopmentCandidates": { "xbrltype": "integerItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "NumberOfDevelopmentCandidates", "presentation": [ "http://www.modernatx.com/role/DescriptionoftheBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of development candidates", "label": "Number Of Development Candidates", "documentation": "Number Of Development Candidates" } } }, "auth_ref": [] }, "mrna_NumberOfDevelopmentPrograms": { "xbrltype": "integerItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "NumberOfDevelopmentPrograms", "presentation": [ "http://www.modernatx.com/role/DescriptionoftheBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of development programs", "label": "Number Of Development Programs", "documentation": "Number Of Development Programs" } } }, "auth_ref": [] }, "mrna_NumberOfDevelopmentProgramsUnderClinicalStudies": { "xbrltype": "integerItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "NumberOfDevelopmentProgramsUnderClinicalStudies", "presentation": [ "http://www.modernatx.com/role/DescriptionoftheBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of development programs under clinical studies", "label": "Number Of Development Programs Under Clinical Studies", "documentation": "Number Of Development Programs Under Clinical Studies" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.modernatx.com/role/GeographicInformationDetails", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r921" ] }, "mrna_NumberOfParticipants": { "xbrltype": "integerItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "NumberOfParticipants", "presentation": [ "http://www.modernatx.com/role/OtherRevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of participants", "label": "Number Of Participants", "documentation": "Number Of Participants" } } }, "auth_ref": [] }, "mrna_OperatingAndFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "OperatingAndFinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Operating And Finance Lease, Liability", "documentation": "Operating And Finance Lease, Liability" } } }, "auth_ref": [] }, "mrna_OperatingAndFinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "OperatingAndFinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": { "parentTag": "mrna_OperatingAndFinanceLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Operating And Finance Lease, Liability, Current", "documentation": "Operating And Finance Lease, Liability, Current" } } }, "auth_ref": [] }, "mrna_OperatingAndFinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "OperatingAndFinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": { "parentTag": "mrna_OperatingAndFinanceLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current lease liabilities", "label": "Operating And Finance Lease, Liability, Noncurrent", "documentation": "Operating And Finance Lease, Liability, Noncurrent" } } }, "auth_ref": [] }, "mrna_OperatingAndFinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "OperatingAndFinanceLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Operating And Finance Lease, Right-Of-Use Asset", "documentation": "Operating And Finance Lease, Right-Of-Use Asset" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "(Loss) income from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r258", "r272", "r276", "r278", "r755" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease costs", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r547", "r782" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract", "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails", "http://www.modernatx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Present value of lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r538" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": { "parentTag": "mrna_OperatingAndFinanceLeaseLiabilityCurrent", "weight": 1.0, "order": 1.0 }, "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails", "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Lease liabilities - operating (Note 10)", "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r538" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease, liability, current, statement of financial position [Extensible List]", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r539" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": { "parentTag": "mrna_OperatingAndFinanceLeaseLiabilityNoncurrent", "weight": 1.0, "order": 1.0 }, "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, non-current", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r538" ] }, "mrna_OperatingLeaseNumberOfProperties": { "xbrltype": "integerItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "OperatingLeaseNumberOfProperties", "presentation": [ "http://www.modernatx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of campuses", "label": "Operating Lease, Number Of Properties", "documentation": "Operating Lease, Number Of Properties" } } }, "auth_ref": [] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Operating cash flows used in operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r543", "r550" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": { "parentTag": "mrna_OperatingAndFinanceLeaseRightOfUseAsset", "weight": 1.0, "order": 2.0 }, "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails", "http://www.modernatx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets, operating leases", "verboseLabel": "Right-of-use assets, operating, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r537" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.modernatx.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases, discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r553", "r782" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.modernatx.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases, remaining lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r552", "r782" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating losses", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r75" ] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards [Line Items]", "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards [Table]", "label": "Operating Loss Carryforwards [Table]", "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization." } } }, "auth_ref": [ "r74" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.modernatx.com/role/DescriptionoftheBusiness" ], "lang": { "en-us": { "role": { "terseLabel": "Description of the Business", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r91", "r138", "r631", "r632" ] }, "mrna_OriCiroGenomicsKKMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "OriCiroGenomicsKKMember", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OriCiro Genomics KK", "label": "OriCiro Genomics KK [Member]", "documentation": "OriCiro Genomics KK" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r195", "r783" ] }, "us-gaap_OtherAssetsMiscellaneousNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsMiscellaneousNoncurrent", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Assets, Miscellaneous, Noncurrent", "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "totalLabel": "Other non-current assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r188" ] }, "mrna_OtherCollaborativePartiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "OtherCollaborativePartiesMember", "presentation": [ "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Collaborative Parties [Member]", "documentation": "Other Collaborative Parties" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) from available-for-sale debt securities", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r7", "r15", "r139" ] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale securities:", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) from derivatives designated as hedging instruments", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r203" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains on derivative instruments", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r199", "r203" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: net realized losses (gains) on derivative instruments reclassified in net (loss) income", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r203", "r205" ] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flow hedges:", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments, before Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income (loss)", "verboseLabel": "Other comprehensive (loss) income, net of tax", "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r7", "r15", "r139", "r208", "r211" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net of tax:", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: net realized losses (gains) on available-for-sale securities reclassified in net (loss) income", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax", "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities." } } }, "auth_ref": [ "r6", "r106", "r206", "r324" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and postretirement obligation adjustments", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax", "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net periodic benefit cost (credit) of defined benefit plan." } } }, "auth_ref": [ "r6", "r106", "r131", "r206" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTaxAbstract", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and postretirement benefit plans:", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains (losses) on available-for-sale debt securities", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r200", "r203", "r324" ] }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Current Liabilities", "label": "Other Current Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Other Depreciation and Amortization", "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other." } } }, "auth_ref": [ "r9", "r61", "r112" ] }, "mrna_OtherGrantRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "OtherGrantRevenueMember", "presentation": [ "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other grant revenue", "label": "Other Grant Revenue [Member]", "documentation": "Other Grant Revenue" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "totalLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r27", "r783" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r29" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other non-cash items", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r120" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r116" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r845" ] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid services", "label": "Other Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r908", "r936" ] }, "mrna_OtherPrepaidExpenseManufacturing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "OtherPrepaidExpenseManufacturing", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Down payments to manufacturing vendors", "label": "Other Prepaid Expense, Manufacturing", "documentation": "Other Prepaid Expense, Manufacturing" } } }, "auth_ref": [] }, "mrna_OtherPrepaidExpenseMaterialsAndSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "OtherPrepaidExpenseMaterialsAndSupplies", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Down payments for materials and supplies", "label": "Other Prepaid Expense, Materials And Supplies", "documentation": "Other Prepaid Expense, Materials And Supplies" } } }, "auth_ref": [] }, "us-gaap_OtherSundryLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherSundryLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Sundry Liabilities, Current", "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date." } } }, "auth_ref": [ "r27", "r62" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r812", "r824", "r834", "r860" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r815", "r827", "r837", "r863" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r815", "r827", "r837", "r863" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r841" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common stock, including excise tax", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r39" ] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of marketable securities", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r37", "r219", "r290" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment to acquire business", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r38", "r502" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of business, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r38" ] }, "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInProcessResearchAndDevelopment", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration paid", "label": "Payments to Acquire in Process Research and Development", "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination." } } }, "auth_ref": [ "r38" ] }, "us-gaap_PaymentsToAcquireNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireNotesReceivable", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Investment in convertible notes and equity securities", "label": "Payments to Acquire Notes Receivable", "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics." } } }, "auth_ref": [ "r37" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of property, plant and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r117" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r844" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r844" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r843" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r853" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r846" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r842" ] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceSharesMember", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Performance-based Awards", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember", "presentation": [ "http://www.modernatx.com/role/CollaborationAgreementsMerckPersonalizedmRNACancerVaccinesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PCV Agreement", "label": "Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp\u00a0And Dohme Corp [Member]", "documentation": "Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp\u00a0And Dohme Corp [Member]" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock par value (in usd per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r95", "r380" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r95", "r659" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r95", "r380" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r95", "r659", "r678", "r1020", "r1021" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.0001; 162\u00a0shares authorized as of December 31, 2023 and 2022; no shares issued or outstanding at December 31, 2023 and 2022", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r95", "r604", "r783" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r909" ] }, "us-gaap_PrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidTaxes", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid income taxes", "label": "Prepaid Taxes", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r741", "r759", "r936" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassifications", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r899" ] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from maturities of marketable securities", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r219", "r220", "r923" ] }, "mrna_ProceedsFromOptionExerciseFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "ProceedsFromOptionExerciseFee", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/CollaborationAgreementsMerckPersonalizedmRNACancerVaccinesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds From Option Exercise Fee", "label": "Proceeds From Option Exercise Fee", "documentation": "Proceeds From Option Exercise Fee" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales of marketable securities", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r36", "r219", "r290", "r323" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration for options exercised", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r5", "r19" ] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockPlans", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock through equity plans", "label": "Proceeds from Stock Plans", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ProductAndServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductAndServiceOtherMember", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other revenue", "verboseLabel": "Total other revenue", "label": "Product and Service, Other [Member]", "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other." } } }, "auth_ref": [ "r956" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails", "http://www.modernatx.com/role/NetProductSalesNarrativeDetails", "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails", "http://www.modernatx.com/role/NetProductSalesProductSalesDetails", "http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails", "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails", "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r279", "r590", "r617", "r618", "r619", "r620", "r621", "r622", "r737", "r765", "r784", "r890", "r947", "r948", "r954", "r1014" ] }, "mrna_ProductSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "ProductSalesMember", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.modernatx.com/role/NetProductSalesNarrativeDetails", "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails", "http://www.modernatx.com/role/NetProductSalesProductSalesDetails", "http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails", "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net product sales", "verboseLabel": "Net product sales", "label": "Product Sales [Member]", "documentation": "Product Sales" } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails", "http://www.modernatx.com/role/NetProductSalesNarrativeDetails", "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails", "http://www.modernatx.com/role/NetProductSalesProductSalesDetails", "http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails", "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails", "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r279", "r590", "r617", "r618", "r619", "r620", "r621", "r622", "r737", "r765", "r784", "r890", "r947", "r948", "r954", "r1014" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Accumulated depreciation", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease." } } }, "auth_ref": [ "r884", "r888", "r941" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.modernatx.com/role/GeographicInformationDetails", "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r888", "r939" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, gross", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r883", "r904", "r940" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r10" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.modernatx.com/role/PropertyPlantandEquipmentNet" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Net", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r126", "r168", "r174", "r175" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentOtherTypesMember", "presentation": [ "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures", "verboseLabel": "Furniture and fixtures", "label": "Property, Plant and Equipment, Other Types [Member]", "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r10", "r168", "r174", "r609" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.modernatx.com/role/PropertyPlantandEquipmentNetTables", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Useful Lives of Property and Equipment", "verboseLabel": "Schedule of Property, Plant and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r10" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r127" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Estimated\u00a0Useful\u00a0Life", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bad debt expense", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r218", "r333" ] }, "us-gaap_PublicUtilitiesInventoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PublicUtilitiesInventoryAxis", "presentation": [ "http://www.modernatx.com/role/InventoryNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory [Axis]", "label": "Inventory [Axis]", "documentation": "Information by type of inventory held." } } }, "auth_ref": [ "r906" ] }, "us-gaap_PublicUtilitiesInventoryRawMaterialsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PublicUtilitiesInventoryRawMaterialsMember", "presentation": [ "http://www.modernatx.com/role/InventoryNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw Materials", "label": "Raw Materials [Member]", "documentation": "Basic goods that are to be consumed directly or indirectly in the production of finished goods or services." } } }, "auth_ref": [ "r102" ] }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PublicUtilitiesInventoryTypeDomain", "presentation": [ "http://www.modernatx.com/role/InventoryNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory [Domain]", "label": "Inventory [Domain]", "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale." } } }, "auth_ref": [ "r906" ] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis", "presentation": [ "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Axis]", "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]", "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers." } } }, "auth_ref": [ "r92", "r145" ] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain", "presentation": [ "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Domain]", "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]", "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate." } } }, "auth_ref": [ "r92", "r145" ] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseCommitmentExcludingLongtermCommitmentLineItems", "presentation": [ "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails", "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Line Items]", "label": "Purchase Commitment, Excluding Long-Term Commitment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseCommitmentExcludingLongtermCommitmentTable", "presentation": [ "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails", "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Table]", "label": "Purchase Commitment, Excluding Long-Term Commitment [Table]", "documentation": "Summarization of information required or determined to be disclosed about arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers. Such disclosure may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing for failing to reach minimum quantities required to be purchased (such as penalties), cancellation rights, and termination provisions." } } }, "auth_ref": [ "r92", "r145" ] }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase commitments", "label": "Purchase Commitment, Remaining Minimum Amount Committed", "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations." } } }, "auth_ref": [ "r92", "r145" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r841" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r841" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails", "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r363", "r364", "r365", "r366", "r407", "r414", "r445", "r446", "r447", "r563", "r587", "r623", "r649", "r650", "r702", "r704", "r706", "r707", "r717", "r734", "r735", "r757", "r763", "r777", "r785", "r788", "r942", "r952", "r1003", "r1004", "r1005", "r1006", "r1007" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails", "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r363", "r364", "r365", "r366", "r407", "r414", "r445", "r446", "r447", "r563", "r587", "r623", "r649", "r650", "r702", "r704", "r706", "r707", "r717", "r734", "r735", "r757", "r763", "r777", "r785", "r788", "r942", "r952", "r1003", "r1004", "r1005", "r1006", "r1007" ] }, "mrna_RawMaterialsAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "RawMaterialsAccountsPayable", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Raw Materials, Accounts Payable", "documentation": "Raw Materials, Accounts Payable" } } }, "auth_ref": [] }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails", "http://www.modernatx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Axis]", "label": "Name of Property [Axis]" } } }, "auth_ref": [ "r733", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034" ] }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "presentation": [ "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails", "http://www.modernatx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Domain]", "label": "Name of Property [Domain]" } } }, "auth_ref": [ "r733", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034" ] }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "mrna_RecoveryOfCostsCapitalExpenditures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "RecoveryOfCostsCapitalExpenditures", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/CollaborationAgreementsMerckPersonalizedmRNACancerVaccinesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost recovery", "label": "Recovery Of Costs, Capital Expenditures", "documentation": "Recovery Of Costs, Capital Expenditures" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r807", "r819", "r829", "r855" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.modernatx.com/role/CollaborationAgreementsImmaticsStrategicMultiPlatformCollaborationtoDevelopOncologyTherapeuticsDetails", "http://www.modernatx.com/role/CollaborationAgreementsMerckPersonalizedmRNACancerVaccinesDetails", "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails", "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r230", "r231", "r377", "r381", "r556", "r747", "r748" ] }, "us-gaap_ResearchAndDevelopmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Research and Development [Abstract]", "label": "Research and Development [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "presentation": [ "http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails", "http://www.modernatx.com/role/CollaborationAgreementsMerckPersonalizedmRNACancerVaccinesDetails", "http://www.modernatx.com/role/CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "documentation": "Information by form of arrangement related to research and development." } } }, "auth_ref": [ "r465", "r984" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "presentation": [ "http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails", "http://www.modernatx.com/role/CollaborationAgreementsImmaticsStrategicMultiPlatformCollaborationtoDevelopOncologyTherapeuticsDetails", "http://www.modernatx.com/role/CollaborationAgreementsMerckPersonalizedmRNACancerVaccinesDetails", "http://www.modernatx.com/role/CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r465", "r984" ] }, "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod", "presentation": [ "http://www.modernatx.com/role/CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial research period", "label": "Research And Development Arrangement, Contract To Perform For Others, Research Period", "documentation": "Research And Development Arrangement, Contract To Perform For Others, Research Period" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "presentation": [ "http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails", "http://www.modernatx.com/role/CollaborationAgreementsMerckPersonalizedmRNACancerVaccinesDetails", "http://www.modernatx.com/role/CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r465", "r984" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.modernatx.com/role/CollaborationAgreementsMerckPersonalizedmRNACancerVaccinesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r90", "r464", "r1008" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Costs", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r463" ] }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "presentation": [ "http://www.modernatx.com/role/CollaborationAgreements" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration Agreements", "label": "Research, Development, and Computer Software Disclosure [Text Block]", "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period." } } }, "auth_ref": [ "r151", "r465" ] }, "us-gaap_ResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchMember", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research Tax Credit Carryforward [Member]", "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes." } } }, "auth_ref": [ "r74" ] }, "mrna_RestOfTheWorldMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "RestOfTheWorldMember", "presentation": [ "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rest of world", "label": "Rest Of The World [Member]", "documentation": "Rest Of The World" } } }, "auth_ref": [] }, "mrna_RestOfWorldMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "RestOfWorldMember", "presentation": [ "http://www.modernatx.com/role/GeographicInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rest of world", "label": "Rest Of World [Member]", "documentation": "Rest Of World" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r808", "r820", "r830", "r856" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r809", "r821", "r831", "r857" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r816", "r828", "r838", "r864" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r901", "r914", "r1009", "r1012" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r901", "r914" ] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted cash, non-current", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r161", "r903", "r914" ] }, "mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "RestrictedCommonStockUnitsAndPerformanceStockUnitsMember", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails", "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Common Stock Units And Performance Stock Units", "label": "Restricted Common Stock Units And Performance Stock Units [Member]", "documentation": "Restricted Common Stock Units And Performance Stock Units" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockExpense", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock unit", "label": "Restricted Stock or Unit Expense", "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement." } } }, "auth_ref": [ "r9" ] }, "mrna_RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs and PSUs", "label": "Restricted Stock Units (RSU) And Performance Stock Unit (PSU) [Member]", "documentation": "Restricted Stock Units (RSU) And Performance Stock Unit (PSU)" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.modernatx.com/role/LossEarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs and PSUs", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r98", "r130", "r607", "r627", "r629", "r636", "r660", "r783" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings (Accumulated Deficit)", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r180", "r232", "r233", "r234", "r236", "r242", "r244", "r328", "r329", "r454", "r455", "r456", "r490", "r491", "r510", "r512", "r513", "r515", "r517", "r624", "r626", "r638", "r1020" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.modernatx.com/role/NetProductSalesProductSalesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.modernatx.com/role/GeographicInformationDetails", "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails", "http://www.modernatx.com/role/NetProductSalesProductSalesDetails", "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total revenue", "totalLabel": "Net product sales", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r259", "r260", "r271", "r274", "r275", "r279", "r280", "r282", "r402", "r403", "r590" ] }, "mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "RevenueFromContractWithCustomerExcludingAssessedTaxGross", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/NetProductSalesProductSalesDetails": { "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/NetProductSalesProductSalesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross product sales", "label": "Revenue From Contract With Customer, Excluding Assessed Tax , Gross", "documentation": "Revenue From Contract With Customer, Excluding Assessed Tax , Gross" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerMember", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of Revenue", "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r282", "r885" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r178", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r736" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.modernatx.com/role/GeographicInformation", "http://www.modernatx.com/role/NetProductSales", "http://www.modernatx.com/role/OtherRevenue" ], "lang": { "en-us": { "role": { "verboseLabel": "Net Product Sales", "terseLabel": "Other Revenue", "netLabel": "Geographic Information", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r178", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r406" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://www.modernatx.com/role/GeographicInformationTables", "http://www.modernatx.com/role/NetProductSalesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenue from External Customers by Geographic Areas", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r20" ] }, "mrna_RevenueFromGrantsCurrentFundingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "RevenueFromGrantsCurrentFundingCapacity", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/OtherRevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount committed for funding", "label": "Revenue From Grants, Current Funding Capacity", "documentation": "Revenue From Grants, Current Funding Capacity" } } }, "auth_ref": [] }, "mrna_RevenueFromGrantsMaximumAward": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "RevenueFromGrantsMaximumAward", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/OtherRevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award amount", "label": "Revenue From Grants, Maximum Award", "documentation": "Revenue From Grants, Maximum Award" } } }, "auth_ref": [] }, "us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuePerformanceObligationDescriptionOfPaymentTerms", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Description of payment terms", "label": "Revenue, Performance Obligation, Description of Payment Terms", "documentation": "Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration." } } }, "auth_ref": [ "r388" ] }, "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionAndDeferredRevenueAbstract", "lang": { "en-us": { "role": { "label": "Revenue Recognition and Deferred Revenue [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/NetProductSalesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining performance obligations", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r171" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets obtained in exchange for financing lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": [ "r551", "r782" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r551", "r782" ] }, "mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in right-of-use assets related to lease modifications and reassessments", "label": "Right-of-use assets obtained through finance lease modifications and reassessments", "documentation": "Right-of-use assets obtained through finance lease modifications and reassessments" } } }, "auth_ref": [] }, "mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in right-of-use assets related to lease modifications and reassessments", "label": "Right-Of-Use Assets Reduced Through Lease Modifications And Reassessments", "documentation": "Right-Of-Use Assets Reduced Through Lease Modifications And Reassessments" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r873" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r873" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r32" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Accumulated Other Comprehensive Income (Loss)", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r34", "r995", "r996" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.modernatx.com/role/LossEarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r46" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.modernatx.com/role/LossEarningsperShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Common Stock Equivalents Excluded from Calculation of Diluted Net Income (Loss) Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r46" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304" ] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Cash and Cash Equivalents", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Available-for-Sale Securities by Significant Investment Category", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Provision For (Benefit From) Income Taxes", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r136" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Significant Components of Deferred Tax Assets and Tax Liabilities", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r135" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.modernatx.com/role/LossEarningsperShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Basic and Diluted Earnings Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r920" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r134" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r70" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r70" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Assets Measured at Fair Value on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r521", "r522" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of (Loss) Income Before Provision For (Benefit From) Income Taxes", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r916" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.modernatx.com/role/InventoryTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory, Current", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r23", "r103", "r104", "r105" ] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Common Stock Units Activity", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": [ "r69" ] }, "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock", "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Assets, Noncurrent", "label": "Schedule of Other Assets, Noncurrent [Table Text Block]", "documentation": "Tabular disclosure of noncurrent assets." } } }, "auth_ref": [ "r903" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "presentation": [ "http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails", "http://www.modernatx.com/role/CollaborationAgreementsImmaticsStrategicMultiPlatformCollaborationtoDevelopOncologyTherapeuticsDetails", "http://www.modernatx.com/role/CollaborationAgreementsMerckPersonalizedmRNACancerVaccinesDetails", "http://www.modernatx.com/role/CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements." } } }, "auth_ref": [ "r465", "r984" ] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Restricted Cash", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": [ "r21", "r142", "r1012" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails", "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails", "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r416", "r418", "r420", "r421", "r422", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r444", "r445", "r446", "r447", "r448" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r133" ] }, "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfTreasuryStockByClassTextBlock", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Share Repurchase Program", "label": "Class of Treasury Stock [Table Text Block]", "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": [ "r64", "r65", "r66", "r67" ] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r781", "r986" ] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Entities that Accounted for More than 10% of Total Revenue and Accounts Receivable", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r48", "r49", "r51", "r52", "r84", "r140" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r800" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r803" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.modernatx.com/role/GeographicInformationDetails", "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails", "http://www.modernatx.com/role/LeasesNarrativeDetails", "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r280", "r281", "r642", "r645", "r647", "r703", "r705", "r708", "r718", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r738", "r766", "r788", "r954", "r1014" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r265", "r266", "r267", "r268", "r269", "r270", "r280", "r756" ] }, "mrna_ServiceBasedAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "ServiceBasedAwardsMember", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Service-based Awards", "label": "Service-Based Awards [Member]", "documentation": "Service-Based Awards [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award requisite service period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r778" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r778" ] }, "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments": { "xbrltype": "integerItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of installments", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Installments", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Installments" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cancelled/forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r437" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cancelled/forfeited (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r437" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Issued (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r435" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Issued (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r435" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, non-vested at beginning of period (in shares)", "periodEndLabel": "Outstanding, non-vested at end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r432", "r433" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares/Units", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, non-vested at beginning of period (in usd per share)", "periodEndLabel": "Outstanding, non-vested at end of period (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r432", "r433" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Grant Date per Share/Unit", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r436" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r436" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividends", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r446" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r445" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r447" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails", "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails", "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r416", "r418", "r420", "r421", "r422", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r444", "r445", "r446", "r447", "r448" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate number of shares authorized for issuance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r780" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares available for future grant (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r68" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding and Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number\u00a0of options, exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r426" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- average exercise price per share, exercisable (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r426" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total intrinsic value of options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r439" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cancelled/forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r430" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r428" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value, outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r68" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of period (in shares)", "periodEndLabel": "Outstanding at end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r424", "r425" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number\u00a0of Options (in millions)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of period (in usd per share)", "periodEndLabel": "Outstanding at end of period (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r424", "r425" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price per Share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r440" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Options Activity", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]", "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r18" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r440" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- average expected to vest (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r440" ] }, "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payout percentage", "label": "Share Based Compensation Arrangement By Share Based Payment Award Payout Percentage", "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Payout Percentage" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails", "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails", "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails", "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r420", "r421", "r422", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r444", "r445", "r446", "r447", "r448" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r429" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cancelled/forfeited (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r430" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r428" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Twelve Months of Continued Employment or Service", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Following Twelve Quarters", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r415", "r423", "r442", "r443", "r444", "r445", "r448", "r457", "r458", "r459", "r460" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average fair value per share (in usd per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [] }, "us-gaap_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of the share repurchase program." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r958" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic value of RSUs and PSUs vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r779" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r444" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value, exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r68" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- average remaining contractual term, exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r68" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- average remaining contractual term, outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r132" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- average remaining contractual term expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r440" ] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short term lease costs", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r548", "r782" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r121", "r226" ] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "State and Local Jurisdiction [Member]", "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r17", "r31", "r180", "r213", "r214", "r215", "r232", "r233", "r234", "r236", "r242", "r244", "r257", "r328", "r329", "r383", "r454", "r455", "r456", "r490", "r491", "r510", "r511", "r512", "r513", "r514", "r515", "r517", "r530", "r531", "r532", "r533", "r534", "r535", "r555", "r624", "r625", "r626", "r638", "r698" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.modernatx.com/role/GeographicInformationDetails", "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails", "http://www.modernatx.com/role/LeasesNarrativeDetails", "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r280", "r281", "r642", "r645", "r647", "r703", "r705", "r708", "r718", "r720", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r738", "r766", "r788", "r954", "r1014" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r232", "r233", "r234", "r257", "r590", "r633", "r639", "r651", "r652", "r653", "r654", "r655", "r656", "r659", "r662", "r663", "r664", "r665", "r666", "r668", "r669", "r670", "r671", "r673", "r674", "r675", "r676", "r677", "r679", "r681", "r682", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r698", "r789" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r232", "r233", "r234", "r257", "r590", "r633", "r639", "r651", "r652", "r653", "r654", "r655", "r656", "r659", "r662", "r663", "r664", "r665", "r666", "r668", "r669", "r670", "r671", "r673", "r674", "r675", "r676", "r677", "r679", "r681", "r682", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r698", "r789" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r811", "r823", "r833", "r859" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted common stock (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r17", "r130" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of options to purchase common stock (in shares)", "negatedTerseLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r17", "r95", "r96", "r130", "r429" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under employee stock purchase plan", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r17", "r95", "r96", "r130" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of options to purchase common stock", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r17", "r31", "r130" ] }, "mrna_StockOptionAndGrantPlan2016Member": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "StockOptionAndGrantPlan2016Member", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2016 Equity Plan", "label": "Stock Option And Grant Plan 2016 [Member]", "documentation": "Stock Option And Grant Plan 2016 [Member]" } } }, "auth_ref": [] }, "mrna_StockOptionAndIncentivePlan2018Member": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "StockOptionAndIncentivePlan2018Member", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2018 Equity Plan", "label": "Stock Option And Incentive Plan 2018 [Member]", "documentation": "Stock Option And Incentive Plan 2018 [Member]" } } }, "auth_ref": [] }, "mrna_StockRepurchaseProgramAdditionalAuthorizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "StockRepurchaseProgramAdditionalAuthorizedAmount", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional authorized amount for share repurchase program", "label": "Stock Repurchase Program, Additional Authorized Amount", "documentation": "Stock Repurchase Program, Additional Authorized Amount" } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Authorized amount for share repurchase program", "label": "Stock Repurchase Program, Authorized Amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsShareRepurchaseProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining authorized at end of period", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "documentation": "Amount remaining of a stock repurchase plan authorized." } } }, "auth_ref": [] }, "mrna_StockRepurchasedDuringPeriodIncludingExciseTaxShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "StockRepurchasedDuringPeriodIncludingExciseTaxShares", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Repurchase of common stock, including excise tax (in shares)", "label": "Stock Repurchased During Period, Including Excise Tax, Shares", "documentation": "Stock Repurchased During Period, Including Excise Tax, Shares" } } }, "auth_ref": [] }, "mrna_StockRepurchasedDuringPeriodIncludingExciseTaxValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "StockRepurchasedDuringPeriodIncludingExciseTaxValue", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Repurchase of common stock, including excise tax", "label": "Stock Repurchased During Period, Including Excise Tax, Value", "documentation": "Stock Repurchased During Period, Including Excise Tax, Value" } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common stock (in shares)", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r17", "r95", "r96", "r130", "r635", "r698", "r719" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common stock", "terseLabel": "Stock repurchased", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r17", "r95", "r96", "r130", "r638", "r698", "r719", "r798" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r96", "r99", "r100", "r123", "r661", "r678", "r699", "r700", "r783", "r799", "r915", "r934", "r994", "r1020" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityPolicyTextBlock", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchases", "label": "Stockholders' Equity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income." } } }, "auth_ref": [ "r11", "r701" ] }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SummaryOfValuationAllowanceTextBlock", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Summary of Valuation Allowance", "label": "Summary of Valuation Allowance [Table Text Block]", "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance." } } }, "auth_ref": [ "r73" ] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponents" ], "lang": { "en-us": { "role": { "terseLabel": "Other Balance Sheet Components", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r900" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "mrna_SupplyAndManufacturingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "SupplyAndManufacturingAgreementsMember", "presentation": [ "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supply and Manufacturing Agreements", "label": "Supply And Manufacturing Agreements [Member]", "documentation": "Supply And Manufacturing Agreements" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r852" ] }, "mrna_TakedaPharmaceuticalCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "TakedaPharmaceuticalCompanyMember", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Takeda Pharmaceutical Company", "label": "Takeda Pharmaceutical Company [Member]", "documentation": "Takeda Pharmaceutical Company" } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax credit carry-forwards", "label": "Tax Credit Carryforward, Amount", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r75" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward [Axis]", "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r74" ] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward, Name [Domain]", "label": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r74" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25" ] }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technology", "label": "Technology-Based Intangible Assets [Member]", "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights." } } }, "auth_ref": [ "r22" ] }, "mrna_TenantImprovementAllowanceReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "TenantImprovementAllowanceReceivableCurrent", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tenant improvement allowance receivable", "label": "Tenant Improvement Allowance Receivable, Current", "documentation": "Tenant Improvement Allowance Receivable, Current" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r844" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r851" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, net", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r152", "r153", "r154", "r285", "r286", "r288" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r872" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r874" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.modernatx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r379", "r382", "r516", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r612", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r928", "r929", "r930", "r931" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r875" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r876" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r874" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r874" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r877" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r875" ] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsShareRepurchaseProgramDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Average price per share", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": [ "r64" ] }, "us-gaap_TreasuryStockRetiredCostMethodAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockRetiredCostMethodAmount", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsShareRepurchaseProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate purchase price", "label": "Treasury Stock, Retired, Cost Method, Amount", "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method." } } }, "auth_ref": [ "r17", "r63", "r96" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsShareRepurchaseProgramDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of shares repurchased (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r17", "r96", "r130" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.modernatx.com/role/CollaborationAgreementsImmaticsStrategicMultiPlatformCollaborationtoDevelopOncologyTherapeuticsDetails", "http://www.modernatx.com/role/CollaborationAgreementsMerckPersonalizedmRNACancerVaccinesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r503" ] }, "mrna_UKHealthSecurityAgencyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "UKHealthSecurityAgencyMember", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "UK Health Security Agency", "label": "UK Health Security Agency [Member]", "documentation": "UK Health Security Agency" } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.modernatx.com/role/GeographicInformationDetails", "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "mrna_USGovermentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "USGovermentMember", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Government (excluding BARDA)", "label": "US Goverment [Member]", "documentation": "US Goverment" } } }, "auth_ref": [] }, "us-gaap_USGovernmentDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentDebtSecuritiesMember", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government debt securities", "label": "US Government Debt Securities [Member]", "documentation": "Debt securities issued by the United States government." } } }, "auth_ref": [ "r1010" ] }, "us-gaap_USTreasuryBillSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasuryBillSecuritiesMember", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. treasury bills", "label": "US Treasury Bill Securities [Member]", "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government." } } }, "auth_ref": [ "r1010" ] }, "us-gaap_USTreasuryNotesSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasuryNotesSecuritiesMember", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails", "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. treasury notes", "label": "US Treasury Notes Securities [Member]", "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government." } } }, "auth_ref": [ "r1010" ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. treasury securities", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r752", "r772", "r774", "r1010" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r871" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Unrecognized tax benefits at beginning of the period", "periodEndLabel": "Unrecognized tax benefits at end of the period", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r467", "r475" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax positions for prior years", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r476" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlements with tax authorities", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities." } } }, "auth_ref": [ "r478" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions based on tax positions for current year", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r477" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions based on tax positions for prior years", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r476" ] }, "mrna_UnrecognizedTaxBenefitsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "UnrecognizedTaxBenefitsNet", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits, net", "label": "Unrecognized Tax Benefits, Net", "documentation": "Unrecognized Tax Benefits, Net" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Expiration of statutes", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations." } } }, "auth_ref": [ "r479" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r53", "r54", "r55", "r164", "r165", "r169", "r170" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails", "http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in valuation allowance", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r482" ] }, "mrna_ValuationAllowanceDeferredTaxAssetDecreaseAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "ValuationAllowanceDeferredTaxAssetDecreaseAmount", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decreases recorded as benefit to income tax provision", "label": "Valuation Allowance, Deferred Tax Asset, Decrease , Amount", "documentation": "Valuation Allowance, Deferred Tax Asset, Decrease , Amount" } } }, "auth_ref": [] }, "us-gaap_ValueAddedTaxReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValueAddedTaxReceivableCurrent", "crdr": "debit", "calculation": { "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value added tax receivable", "label": "Value Added Tax Receivable, Current", "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r905" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": [ "http://www.modernatx.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease costs", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r549", "r782" ] }, "mrna_VertexMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modernatx.com/20231231", "localname": "VertexMember", "presentation": [ "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vertex", "label": "Vertex [Member]", "documentation": "Vertex [Member]" } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Axis]", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Domain]", "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983" ] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "WeightedAverageMember", "presentation": [ "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average", "label": "Weighted Average [Member]" } } }, "auth_ref": [ "r734", "r735", "r1002", "r1004", "r1007" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.modernatx.com/role/LossEarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.modernatx.com/role/LossEarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r920" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.modernatx.com/role/LossEarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.modernatx.com/role/LossEarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted-average common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r247", "r252" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares used in calculation of (loss) earnings per share:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.modernatx.com/role/LossEarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.modernatx.com/role/LossEarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Basic weighted-average common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r246", "r252" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i),(j),(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "a", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-13" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-10" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-3" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)-(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//940-320/tableOfContent" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//942-320/tableOfContent" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//946-320/tableOfContent" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "985", "SubTopic": "730", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//985-730/tableOfContent" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "SubTopic": "10", "Topic": "330", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-5" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "(b)", "Publisher": "SEC" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r881": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "SubTopic": "740", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//210/tableOfContent" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-27" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" } } } ZIP 126 0001682852-24-000015-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001682852-24-000015-xbrl.zip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

MVNRW_L402>TJ3 MS3<46BG(X^J@7SNDKIE*3:SI.;G#^R.=5>.=9*3YD$@S;%9])^'UH6& MP9(%\'JVG&63:=-LQ+5\"=-K\]Y?5B#;D/0[S6 YEPRTX JT%(9T]2EM@>+# MU7J;P@&- 3ZDM+%Z'?+L7WS*L%TR@0(/ERK$9+$98PP_./X*A97@RUNG%=6 M37 ;3XIJRH4$=)V9E,/36,G<@>F!**+8!1A4KM&D>QM9SI%R_821Q(L^$8Q. MZCA1WM"0P$H ;,1%V6US476B;6\V3?:1XEQ[[]\X5]ZSR[9:T)K:*%2HF3G( M$OVT+Q_;Y7PQ6@D8@0[&!>-P\%^\7J-SFG]9GY7*4S*MQFR= RM,)VA4%J?5 M5.WUZW;6 ,L<,H$XLC$2)L_J"UK6B M >D\P0EQ[=KR3@#A()@$FB>C?6FN-RL$6]OFM>RZ+A,KV*;'H9P%TC( M;G*BU)24M:"W,E!):[1(E9:CDGX^MOG?;*HPJ0$JE]_P*$,T-CZA)CUHK[W' M=-P0T]%OP'R/Z;@=@9XU?U/,B+='!T(XX&\+]0..:C+Z%J"RHWT]H*NH593;4609>6DL(UN\9@AHU/Z' MT(<8CMU1ZP]G._%[83"@AWR_#=UFPS-#3T>MJHFT$GW 07_PI= E^(ODTLK) MDE.LHZ:EEPC96#>O/I9I::(J62UOMT?(C2+?\LQ6[WXZ>KFS]]Q7'?.ULYL= MH[2FB-K8V20A.8 _C"0V;!J7,OW5V8T*6)' MUDAT]1G^[.Y1U)6<68%F>J?2P^DM"X11HA$&!IS^#;MSNMKI_PUV?W47*LZ& MS__K"%3T0?(JI!MN>T(N8%,VI%Y%>D-60+]5CCU$T\_(_N!0[(K M/C?9=6HIZ8F!SINJ!\!4%ASFD^ <+)JA%#&J+'V@0W\J2?#*99TVC9?/N-8A M;'J!IDFF%=^.$Z[OM2,7O>AXG!L:SUF@#:\XO3Y\^>CYX^W-O?GY3/]YZ.GC]]^C^/GWVU\3C^@0QPP]KF^Q_?'+S- M#@^.CSX<_'"'B:NU\)6)&MOF4P4OG93+XQRI[\ER.MWA(&,Y([VP*B6:0S=G MS$[WB;Z9]V02;9B'TD?AX>X7I4NG22*YS!$.W(?G]!F#&V;S$IKH C96+-'G M&!JHW^FRC50K4T.T<)H5EM@"Y;X+)=>1D"S_2DPOE)&TJ,0)X8+3JNF5%_1J M;;N28;!22$OK^9&C L""Z8@1'BLXL:8%"$-KG6>/]O[-HA)QZ\X1J#L^WWU) M_N[+!B_B;-8;_L-_T_]E_[X LX'& CJZ96#NT( .9HUFIL,#\RO>__S?V-&> ME#-:$/_K:5F0HNO.JWFV)=[MI=0L08%V;K3%0AEL&5I<=EPH(;3],O=3NG^V MKQA#*M$/>R-Z]#BL$&RR =8,U/%V15(LV8-L#58QGW3>_+NRDW?+.S M]^5RXU"@^T]>?+ETUHMT;1[M/L9:Z#8:R(CVH:)KP CDVA((0.6LQMU8U*L= M9,!-,Z0'G]R2XL7]WOQ>>^,;5-W@((GB(N4+AVX5[B^R8\Z*,PD D>E_4:[N MM^B?<7P8S'RA,7ZV >_+COZ;KLGO0.H;R->AE2^:Z9*1=7G8KYTIMP_$ M-\5C)X.P!K$=6PSDKG.@+6IGYF)L+S0WP^B\LF':%E7'.+0A)@;U# Z3%6-: MP2;JL0VG*V:L:92I:'9X\/Y5SIU4P$8\+IF46U0^.NBI;F E,..A57V3D#M; M\/U3 /$+614SMP"&C"S50*1L5,K/Q MS#J .:2#'93;9>IN-M_9R6,P07#'HS5CQ?/JE-]Q8/F 85\BNB1M3IFOFIG] MPLVW52""25ZNI'-\.0+9OM"7;T@6.C!8;W5E*<0RVZSGU+AW_-?3$.H:('D1 MN1P(>]V+XJ\4Q9_!+<$<^E]<'-?N70B!MF@0\;.AK@?=8ZHN=J"HQT'" V>S MC'YG@H3!&!C)LBXGE8&X$N&7[)R\?^7].1+TQ;G6;+;5Z5():YL8')A6DY)7 M$+A*+1H><3+G7HO^CO>S^4%?7'+-6K/\DPD5MSVN)**PT-(8LN8LKT$:4=K6 MM89;5);FD*Q4T/C(&(U19.42:-(KQ6<:^ RIBZ* @FDI[1?'K'!G9=$A,HU/ M.%-%*V"!+)513D4#++[AK1ARMQJ=?S][5B)D MV#F)O986P>*X8"+-B,3KG0%.3-N_^7/:-ORXR_-$],OQ+ M)L#I2F!53G([:R#V$ DV#T[+Q27:=*X;Z(SX@QJ'X<$(N#1"*AB@:J[X(E5PX,PEX#;YR8L<[LK$@KB"Q=E]"O)UY]VOS,;E47Y ? ML^I30),=@XWEV -2=WP.-75 MZ.;3*BY?MT#?YV8>(\U6@@HF;?Y0:/.WWI_\V&VO1PVKR+DB:30L "GJ7X3< MCKUZ_B*P0O&*E;V1<9+_WC8%F%RJLTJS#X9*[.^'\<<"HX/J>OK*5SPD5KY3 M8,F;RYIV_2M@LQ$-$!N4A*@+4A04),@):XE0=48E*U9$;-# D0..1!0TJF6[ MPZ@>@,&:N]#D_:O_>@LXZ[HKVV+ZP&*5S(K O-&,C<6&2R$C#"5IA3VJIBKF M]>#3>/5[A0VQNI\NO_9,P_>]B@;TACS(NAF. [G/IY(A31"*KQ7R>D0&H"1# M3^;<"C9M>@.,U))A]->\F#87O^(_&C@_<= Q;>F[48^K2+05<+U^ZMHL35US M.EYGS1T1B_Y!7AYSTV3I>,EL#IS&_$40VCVP8-Z/ M#6/1G!(>T:K_4M;XZC\=:?J9C'8GS,9>?DGX*YEU9\4O@%C2P?A("[S4G.ZB MF=L.MDD[[U"!S&TDH+]PZ@*CP)3C3@H/NUW+_6W5T$"^\'K'9>8"2]52=2D8 MC+CDE=2+TCH^RK[%K7&,_#HKAI_A@.,C>2Q7(84%'E$RE_]5EK_ZQ+#2A/RX_\0NQ MTSL89A*K&0(=F?E3T#58CYMV!_[)M&)&WXA,:B8+NC5)10OC%9="2SK[DU2X M0+^.SIE(CWV@%L[0T/N4.?BN*%"%$+&=H/"[.*W%LJW9;FB59%[,%25PS\8E M@K9:'1W3V_B**EY:)N8\0N2NJ>MRNFY]*2PH!$'XWW4GFA6)%,3L8 #HQE* M".E;IUJ&;>I!%YXLJ(XC>L!CI]C.0.K,VAX&%0J8 6%W4*@P:0!'8#KW^$=R"EHEA@D/6AI%7E2 MWB$>HH4%3%EE276V-,;%"J8/FOLA),$:+PPI[XMG$\F">3 ]=-H&()-@ .A^ MI,=P'NL,]F*&F:A590ES'U#*I$RS-_2C MIG9I8@U6+2RQ9WSWTU.%3G7$O:_"]G)H M6.EX\0J^,$PX=,,UZ\Z:#WYW;+46Z5>YJ']1E8/I\%MJ4NC!NUW#W=C,"3=: M>U;4ROX3+M739CK./=\W;$FR#OCZE!@C4GE3VCWK\LN!0 D[<*'YG"YNBTJQ M":!9[$LC)4+ B/-4#UZ XFQ$#@__Y]X+?1;#RO9?J,"1+.>9>D*AEV??"78& MLA5(M<6\&ELLPE5/3FJ:=M2@2D=I+"U?F;#OH(?@( MC3-AH;#-_GM#DA1=41V1G-#=U M+KA1(SSFB/;2ZFAO#ZW$32U;S]^L>>7&%^5:61Q39TALEXP< 9P6M<1#822D+VJ;:1E.).E95+$8GH31R:5K?MHV MI\M.:;J JAL[Q%0L=I8&,[I.\VI>L@',] \D74-S, .PG]CI9U7UC))*(;\A MR*JV*I:JV\M"B3-F9&Q7Y.DW8<;OW+T[=$/1Q_^ M[V^Z +XD38;9+D 12>MUKIVM1#L",E0"ARY1V3.&_*!2JJ'/L8\*7H=M*1Z3 M10=2XS.&32*S3^$R'%RI-64[!%DE37IN'9Z\WPX]9^36B(#G;J!&VPS<6(+8 M":NA1])QE*+1[N\&.Q%6"GHA^77%K&1,%&>X.D$43N!!XE*0TM0"">IOG'6- M.R.^/90FYII<8R6L%<9,YI[FZ-WP=K/C*5,K! )P3!-L:=FKD^^R]Q(GCP2' M:O2]3Y9.C;W#L,#S9HK&N9W9A)TVR+0+JCPE]5J:=88XRBF"06 _@8%Y>;D[ M$TMN\6F7)O=UNE-?AYWT/7D]Z> M)TBY*W AD#ZQUO+J4(G!M97JW*;7@596H[H:VN^"-"[(SF0I9R%C MC/V:3%TCI?\DUR\FS<+L^X[34NF56^QD@<>_-HU(]= MB:4"JXHD5\8R"ZS6;O:],>DQ#?8HD4O'=-?9^T*T24DG0V6(ZU[BKP/VH%QD M"FLBKV".NA$W?K8_A!6)LOOSIF%93D)("I)>!Y*<[AUA"5WP=94>=_=!P:$^ M\AHKY0 5 G>YUV6E$5<,07Z&?.C!J[@?7.".]T^04&*,K,28"M]46$UNF0(% M (]9].'W"_@)V@\GODY6(KRM8%PD MMP,F>RZ"1LM/2%9 >&"],4UZ>!Q35&J2'0WK:H%3F=JYXX)UZ-694:<5TX O M7!,Z9!_8 1,K8@846L EA(5/< NLT-A&D(QDJS@:>V0Y 9/:B)PO1]FC D:& M>\M552<'[T]V#IN?=O99XQ8U]^61@B0-O$U)]XN!G,M;%%)+4UF[Q3JP]:F: M.J?_,TW1AHX$6:)%&?M']*0QVBYJ+6"2ZVHU ,]0HFIF91*AYMJ3#/-YX<8X M;5G-3I''%7;:1BJXS(;2WAU:G^!>/&JZ15#G02X.IDTN[2T]98! &U$8EW7FS$ IIG9?N MLMVA_JECY?;^Y"=>%YOH;THP??%SR&W-:48]S7PI M67D)=TBF47&"CW+U20>-$E9H$$'WS%X;IJ8SHFXYR:(J>4F_FQ:?FA/R1\__ M)G>GUNRJO 3[JTBV)(X=BD3&OPC^1!W&E$M];]3A *65B[N]?T>U3B.&#(35 MG8.EZS=8,:4+9ASYHC0XQ=\2LQEGGZUAG%2Y]2HHRB7HD)&P+2\D$X^W"J)_ M-SLI8W2FZCYFKT4S:VP&ZJ)G@NG/+:?B9OD3Y[+N:L#H3LN#.-)\:'P/6K5W [[=;"T7 MM;3@D1P@X14'7*(<:/9BB:+X8 4;96;[\0KKT=X"!K%4", Z!,%^DF?? E'N M&T%&;FO4G[P31\Q>=5+4S:3*^UI#E#-=-3\5H[MRMC>C @Z3SMEWV^;[N8Q% M6AMHV8=OE2AF[A(0EUL197:1^'97K/R[#4KEF+&Y'R+ M>+[8V<-(8O%*JN3ZCK;0\ YXV,%K-N/-WW7+!7YM\ E4@Z% B9YP>/!^YT.Z M#-R-G4WI9EII<7[UCR7]<[$DIQA("JA'.[[RA!%"%?$Q/+=H&G4(D[!UUP^X MF#6IO2M\',/L*QCI>,F;)$#"$"\-Y.1)?CYMHLF=,]Q>!,12U\YN)VZ M+\$9)!5(]Y7=O4TZFHFM<6C*/! VC$I5B7HO2M>J:2!+H'1D*%B]VM'!GSIO M3ZRW230+*$3X+4W]NX&0;IAU?7J+LZ[?O?OIU?NW;UZ]_9"]?_7=CS\4#""6@FN^ !@^&=$PG(]9=!'2ZX*Q(:0[ M T#Q%'2""ZFDXYCH\E2YWZ3-,1>61%,VMFE7O<'0C1@]U7W[7!C$+3M;W"6% MDZG,!%8%DBUK'^=V^4\*>3@:.'4BZZ]?'H03T?$J^1:MK^5$XB8G&7U)G\HU M<]AT,S:,#VCYMEZ_/#S8EN.YX*3%E(/LPK5UMIPZ *JM?O(2^KD,YEC2J]J! M\439XOD=Q]^?'&R'/%+5;GS-;O8M?$*92?I*@5JD'>FUWG.3YA&BA:AEXEM> M%]44FD#N/-3S2=H]MF5FN=/>TI+@*M3'0&.JL?$?ET-R: 4?>70ZK00$'79# M/5+X%&%#F]92L[0Q77+!J?>_+\=2,4.B-(IY:N"?[0_J&6G$*561A;4W5[D) MR3[N=2GX?-4KH>6>+H?^T%IIDB)J1IK%*;(1R2N?QW,NI5BBP]Y4B07VW_YP@.GC2A3% M',4DVWK[$B<=P1O4W_.JT0KI3Y*_T3?S<"[THN4B26MV6)Y)N;I>L_^$CD]? M_'8[IJ-@!ZA;T G_W$KL.W.)?:N65)2_#?U&=?5E:C,"K0#X:27#]/CZ$: M(@#Y(U;_YGPERIR(#JB(15>+MOE2@[[!$-G@K:N9VS!<55T7N]6$0B, :\;" M)2O]*K>N'0&^3+5,B@V>%(4H!5\FT>CP)]E/>#0Y']WB@@PGMH_"<]G=:=!O M%_7HC96[N>^'MQ0@NP'9C&(O6[2W?3U,22 M;?.BZLK09KS+=3Z<)<$Z2Y=$8Y:(KWOX .7KG6;%C,DNU*$K@;&SN!NY-4-U=GM]=N'\V(./33;L+$]D,@'=' M2AD<_<5(@HZM%C%,<5>F&/IG(80VD MXDO;GMZT006#3+L=,_245<]WA\>)4MS->ENDM'FL>T%JQ>\%*JJAI49N=4&Z MJ ^B2T)!#6MEIA'7>:>23<9]TRG^8E2.Q=LP72Z,E18#+3]9-RNR^IGF)%)I M%BA+6G 9#!/K,4T+_=-XEL(38^!'KR^+_^QFK\#T8)/3+KLU.X4=U!U<#UJE ML7BBJBOCU\UNCQ&C876J6H+\7ZDV!O(X%Y:)WIFW)TK420-2WBV )HOY/?K% M>XE/?8N2[&SKZ/VWVY'"PF4"N6C)0$_]MUK1>-QUZS;D6*1:CEHSX)K.;35> M0E8B&8EVJUM_N@@43L.,<;=6\N'ZC5=U8$GD^Z,V@I-QX%T4DX"FIP$)69). M3Q7NSU+9T:2ALU;'V7HJT%^B[>GD54ST&A+9Z896"3[V5.EE%J"QU]W,8ZV4 M<+:Y0S)D'?26)SU'B2VP+E]"D\II5V45\Q)GH/9)*\(KZ"?K^KY86DC! ^WH MN(ZD?ESQQ:5B)!*##C=?&)AR2X=D2/]>7ANUEK^'BG;$9]?BGUKKI$?@QKG2-=;NPGL4(O.U&#>=\MJS/4!LD[O MK6KBB&\:!E"6"GLEJ7^)\J"&M.>2C*%LZ^W1]^X!0".G]X8854C6@P6G[KBV M4G8P<$(Y?RRJ3V%77HEMYU71:=6HKK7V*25II&\/$8+4T&#Z@_@U/JQ&H\#) M+Y:^,@(8M*+,.B#:I*'G5S6M)UR'!,LP"TO!"HRYJ\++=[.?SZNIF%WI0K%N M:FH.@-1C<4LE#Z#CD,XO4546,@@Q *UX+4%@6.=&O&BR##P(GS<-EV 9P'R8 M\G#O!1Z2_WQ9=4GT=F#.QKY7@6&-XZ3,![+YG/WU8!1/[V$4=TS5OJ;C2'(3 M @9]FU:=0KZNP/^AU26S,LT_2.O#^5SN6GM87PL,!TE?PDEG]QC4X'$XAE8> M'I!$XN+UB:O32%LF&@BNQ):0AP%0D0SE.J,_3QQ5N/?::\>8627J1Z._PU=M MWZ^)C.VIA\-;UY9@D&*K";8>"HHC\@T[@@MI6LS_9'TMO_ F#;=Q.<;B9WMK MAF7<0'6U4>+1(X8?]J(5BDA*&:$>%/^96YW&-,F?)-MV6G6SW%"ZD@?5/!X9 M42@7EHA1KZ:+H0-B_ESC[?_).O[<8AG:OX$,72D;:@"S XG\R40"=W-.27X- MR4($8L8A'&A,B6L 64-Z=JL37]Q%$Q*10%S9W3KPBA*8BG&3F21^K 18ZY@7 MFO&J+@0H'MTS9G=EY@. 9 (S3?#H>**=%UCQ[;FQE;"754;GCPZ_9"0RP6L_ M/Q-@-)6[?NZ%^X\2[H=F3G\)RP1IE@!D)6 ME\@D,W-WX]F(I'398NM6_'EE%!2'11H#*X'H$C%V_$7EE*YJT.4IDUW,)W$8 M0WOF:,3H:\AT;+Z!.J)K7I^RRX$X>4RG%C,Y9781#E5H\F):@+ZB/MLL[9MD M^ZXGE#]8=L,J=-6NA)XA3\V@-2*BC] -9@?JT"+A:3JQ_#2?,G=GY(WF)).U M2S$-Z.EA!H%\"@QR&-^E%$07C)78A,6[=:NJ->[]$&6U*!6LU$DY=)O)MU5';H1F/KM&3+&H3B@ E?F_;>L\D);]'Z^$4+Q.AU-10ZQ;T#/VK %^L[0 L)'COT ME?/PH'7D^8RKH?\T^%M&4BQ]:\A(!->513-I%:3R&4VP-&**&SGA%!XDBQB( MC6NLJPY!-2EZA[V /9NG61[C05=(O8.C]H1&(E)Y]K%N+FLAUV&%K>='0]U8 M.N9S%9X9#<@I2;R\7E5BUT_[RE2/&+W&EL?!@5Z?X1W'( F(E),WBL:Z(]/9%&TQ>*5F2%S: M0^U<:Y4P,#,?\HAMR@?HJ;Q1'S-R MM@C6MB?&?\&:C6(4B=QD!Q(I6@-OF.Y%KE20H$74>-R8H^;5XER2)FWB:@9H M#0?. -_$00W^T4*(XOAA0=V*RLE!J!E\9<8/(0=[4&.AE*LPH!LW/QT?]YZ< M& .[Z!-L ;-8;V#3SJ/I&CV2#J>FP+_++ M1=5-BI$_*PPS88%*KL@H4>M%"Z%:(FPB'%->1 DE_CF@G%<#''FUQ*;QI\^. MIS1H5D09.[715B5#8UXFFY >0_J7T ->&,Y,1:'Y5GSD.B5:+,IAUR?8Z&^ZDY1;N.#55?"1U,A9./= ^%H]FIW7#]V=PE$0D(O]6\*MVHDF,HHXIP 9:@VR MM?&XB65:C"^J3OH[6EX140JVE^S#SA7UY&OY3+T/&>^%L6KD 'SN(;LVR 07(;76^0[&9'X0Z4+>SMW.44 M5 MJOID-*7;?M-'Z(Q. *5U*'1+Q5'.?J-SC-/C2V+=PP\NA6M:Q$Q0#%)O0WY MW.,Z=()#3@B5PNB'[+ ^F^&?]S&HE^E1G M=>.1=Q+$*.) V5UKNH4#MQIU"%U5_>*[B$L?'(+H(GKI8C4O7? Y72!#'T)5 M2;-FMDG \]CUSNP]Z\=-X2K/[N$JMU*)'4W8^U#/08@ENB%M%9.&TBR[K SN M.JE:.I^)BVB7_N#YBDJ@DK?QA>_>E2=GFHYK:=6DJ/5UEX6BL2_8AU=H1(D* MCJ Z3 GCMK>R5BY]6)SW78$8?0@94'Y)Y'F=E>["E8L8:%3I3QVC@HQ7,6;< M:"_08)&G1:D5^EDAA\F1QZH=+6O;.R)MAL3O@XTSFBIX(P-U-KNA(P M9=6T9JGK,OU*/77+#(17="N,>;7Z;%XQ8,G=$N_(+*_/9$GS$0E\35C,I'=: M(\ZP>O*AD:&NSUIMI%LBCMK$U*)C(0=\6YI1)F>0];!5^RZX(&Z5?@/A<2!. M&'7J:=7FD$3$IO3=[E>[4LWW>O"ED&^?VW73O.G,].C#8.J8<55R(5'[L!E" M-WPGN:-9N9#?TM#K$@[KM]?,NS_(SU[\&PW1HQR"1U4B[2%-45V3'6CF12$X ML6K&.DXX \'^$RVBA9&BH?IUX_X$!9JR YPUDMZ"=D'G/XL1UNK\A!B$0>NK M3TCH+,ZU-<_4^/MZ9O$5DB+V<;IHPI5L*7%\E<-*B(ZZB9N_Z^,R:=:_B.2J MJ.POSNJ&^W5 TW*!@0:U!G;GKM"H; A;A*LDY,OI'B%1.V-(#GN_0Z>:KJ-J M0&:YWG-2[@"O2#^H$UKPP-XG[DC,VK&,T5,0%)]R)2R$4[KC=#RU.W(9#H).L0(Z,2 A+?,%2/!KQ"XJ'& H)!42$[A.N=0O!8 M:-2FTQVFU@ 0;"S@C!@)Z<=[.10R7L* U)[ 22P&F#!VUE0/OP*FVM45'RKD9EC$%U)JB+](J*NW@J17+ MWAI.?(/H!.7S(6R(V[;&B1;BV=*_,68^GW(^AI4O.E5I*X>PF"[IGW P;S))\OL[8 MSL:-E&C0A7)67A6SOB.2L\'10_\29.&S'TDD#A)XS]:K'P^V[\CL-CMX)^6H ME49OL:P2 O ]5S\J6UJ7;7W__(@F"#!DZF\ ;L,6-?_+ M^1[TH*L,[,AC#?#/(E!OUTVPN?*0 5;4?#"K2>"X22BB=PQUH=E''&1\IML5 M Q/(,>1+>+JRR'OZ\_!$S0\7K)]W\ 7_9H[C,5H$C_&10Z.7XTYIG$PD4YKW M-3$;4E<23'0?V?;'J^6+ )EJZ8M8TPG.5*-K;BX*'(VSCG<+M^?HE,E.LH B MSEX]W16]^[G4DLKF^)[[V\%[ACA%-7W&KM-4N M;XTC8+6@*5#RHVE1S8Q51 @$4ORV0&H?NBN -Q/?(3( (">:9<\BGK;;T658+/S1X"/!K M9^@4P.B>,%!E#HPTK8+QE^NV(S U*&>;JO))_ MAQXSZ<]]^YDD]ZC:BK=#\I"#CU6E% /8X5NQ]=MKT;'PK$)79W4K#*JSKNGA MX1L$@NS ::&["@W,6A"(21'2M3,RBYX\/'"2)](:Y#]T(%/*@\O8>M7S+Z,92 "TLO'AR*@O#>AD!SE. MEL?<&3;+3S^7W.\(QH706[(7/E A=M<@2AM()4GD"T0C/'[DZOH@R13_GR7!7/5P?Z#1-JOL# K"2/D"J(:9 MH1":^>DFT"6A$E2>E=.PE@N*@]68D*9@K47:]+,R/2;%.^(Q/@,W>F M"HOAN+F4?JY**DM@E5T6%5N%Z$O=MD+06]61\/B: K(A ;G'.O2P#L_OL0ZW MTLJ-"N1;0"Z/D[97HA,.Z4H:M^0"\7U1K/EQ/E$2#]X #J$8CSN?!>-$H;;Y M Y3VOV&+. MBD>2B@2:I>:.87.D:I +SR'[V6@/3/FA4+5J%>+% M3,B!9%!B*-96L$9YY3@6>=AS^_D3'X618#;#11.;RZK1LB1<$ @Z._;Z6E?. MDOM2B#IHZU!_ IXD(4?FVC2./ W4-.&P.+ X_8^'C@?.>L_"$Q.G:_T:'8+= MN)%O6-EW5S3L#0ORYU.TQ[2./R$[TT34?)>E#)#>9I5P'G>M>I56Q[RIK)(M M.Y'&G*MLZ_VK-R?;+L4:(K)&W-DWKLE\Y^G(B\$[@D)%/"9MHZ$Q=W[=&9CJ MT*/"3C_C^Y>U?>,&KFFM M='0-@%X!62PU4DQ0$U)G_3YA*3YD$M\J/8K<#=>Y_D9D_Y"=@SKL5?^*E^C M6A5F7 FE(#7 QH!59>7 BJNQLF I$8:RP$4RY^6+2_)3?J M,0CQ\1YC)*BT8.%[&6--@FY,PK,4BM1H.9(2Q: DI1W375$G5[2)\$*6(W#CJCVYF[VK=1(Z:=?:3XOT^[$/ M1-W\R0C0E7 :W)NGOAJ(5R1\:]W5GOL"G?+3O!J25]FB'T^./[S+U2.'XG>] MR$/0Q?.3)PT(^@/#+3U\L)E[($C 7=']&TO9@LU@JZ'0X*3 37,RG6*BTOP/ MQUT Q '\!O&;@*/IU:0M5G,MO?+5:4Z]P-\AHU_7_8I[AX24#8U@[9I^=L\5 M0N#PX"N>QL!+.Q(@8D[BQ&G'1S6!Z#-X9FNA"41:!";FL;]1GC4 ^%867&(O M :>=_#4Z5KVT%H 9])B1AMV'*J>O#+.+WNSPC+UGVBV)6XT,!MNW3 DDAL"V MSUXG,.P[?1P.T!?CM&7C/,'G%XMSH+HGSF?Q4$(/G4<'!2'1HS^(:XK$FD0$ M6(E"(^660=#6H&.YW+E2::!3+[.#,YPMB-"WP7<:-BV.Z)*\2*R)_0X.(J$3$^43H M\0)3#_VS9E6-Z$HUT2]R5-/59U:UJAJ8''0?F8]A(XH8/O Q M!.NA/U(XM,@H1:J:#;Q71WYK!>X1EE#K+ 9VLR\E&T;AY^I;CK*B,^9"@9S0 M1XIP+CQ!H3&DJ;$X.%%<=&<(9(60&;TW]TRIG>L&QSQ;2C"[X*,G)D&D,LC7 MQ[QYH55M&\Y1XFT=2[DH)Q*A2@$\TG!*AG M/R9[CR4P)?[HP3V6X%;>KKY?!5>%,=QYI%3LZQ:X5Y(#UVC0IMY8N_(82O>O M"2!SZLZNE5QM.&5KFNO.&#K#,9^7PAOD&Q\*-'W9-O,2J'"R^!M 40_HB&1; MKU[=\3J2-U(3[8TV*T#M%8#05!TU$$P/NC@@8"()^T^S-R43L2M!CO[]U8]\ MS;T%52Y9"4*2E-TJ?.37)JX9F6;8N/_;#QKZ6W(U/0^O(%(10!UW(=';^ MNZB7P-N@^%+&$_J[?)!<^_L(E=AZV^QFCQ\^^7K_P=ZC[8RA[MR\AP1RA@U6 M:&X+H(16M+B21=8@$3[(==4,AK5X_AI?HE22P8AP^QD+0#/M/^:(YF1ADKW+ M(T%E/2J=&1X7D $W:\)]L+A>H]Z1+7'M+S9UO'1\39\%Y1Z M+:*O$8X9Y\S7=&.*U 2Z$!(=/JS:CC0%268K?2F[^ M!Y=E\2V.QJDM9V&L=NXFEZX+=_M;UZKD<^459?@6]W-@E-2FQR80^K+BJ*6V MBLO@)I'H\0%GG(G_0[C+E&YVZ*.>H;*<=M;J M0A:06"[L(OC^0DNJ!]3#UL&'-\?H1ZJ46>M?R04X@B*H.!2-(@NZQ)42*!O/ MJ%000I_%,> 60AGGUO='/WU]1IHL*E73VUFU%$,U5P4X&IBA!'_2[E]A8 MI5&X"R-T4RDR_\L-:)$F,RJ0\LV+3?*F=T=W/UOS9AY=9!0PM@]L$&H M-A\2V,S&@!.XRZ/A;._%!!U?>BJL/L:(2DCM)1*N40XH.>63UM*2%(LIA5*I M=O5"*K@V'0[2QZ>K&%/O[+1*BRRV>7M\=L8;)L\W8(R2]R'4B<1277)[91WA M"R6>GBVY6!Q D;-:UKD_F(&A]#Q?J*JZM.DYIFLGKG%L#!@4#YJ_**8YD%\* M>0(-1/=;TU1_'--2P#HFI+^I#/8P_=$RXCIL=MC*<^3J+LJ46-G1$FYD^U^_ M_L^+BU+9+$IIXCE%H2CHNU$LA1]%I%F*AVFY&^$WV5:U':"2.\9>8WZZAC M:Z_E] H6.#D%6]7%ML>.\C"2.E%KJS";L0E7FI7$CCDN6,5YJ$376&4.0W=.QR;H'4)OQ;V4K +G59PTG:\275>Y0=!J@/^*N MB4T!E'=G#>6[P\MI4NFD$(" D<+H_5BQ6"H2W*-0A&U\Y3-E5^S)N6?:NN+$ M:Z2&OHI*!3[S#*PU!.BF']YM0SPX0OTT :WT0I!Y=V1^5UOJ/^8LH%PQ,;.6C9%07D+W?]G$[ZNZ ML['\IL#(/D)=]V,$^&!)K:#?RSYUH8I$9 U[LG&") MC WK'$II5#CI%[ 6ZF;#('JIW1"0EG3%,/!I7>)D_L-;],7/^@='77^V+-AT M"]2) >2@EZ5UNXA8AU<_.@3.FDNNU0>GI22B@QI9L^5"=]"(&8)A=S.-\2>Y M3 9HRH4.^<^!Z=W0%X,[J/4;'9#+($8REPDNULO1(E68>?4A-A'9VI4(-W-)(P MKITX,2VN0KB*J>/Y^+$?L:S[GD1OUHG%+:PA&E1)>JNUY6+9LINAU ;\PTC9 M*;%^2RZBBLR])[=R$_'EP7Y)1X2N:CB(4M,ER(WK5SODQ>X1$0$1L7>/ MB+B5VLK9MUN-U <7)NY"H99B: .'3Y$D7YVO+?%(:PR^O9L-)+ZU2DHB6M(5 MII*X9+-!>T[62^6A#3W:=N_!FCD\@#W5ZS0R&ZTQS)AM%>SFCA6 MG\X*ZG73HAH9HH$8 RWK@CR":.NNV;7)LEX5)&.@@8N4B<^\:<72IAW#*T8+ M(=$LA&Y'C41I-0H%Z]4WU=0.T-'TLOK_'N[1G8'P7>T-V^9RY<62">/MOJRZ MP58>&C%;7!^9L=FNOY[MSU" ;!/=E.GP$OP"XW.!LU\_ JEPX6 CP/*\;AM' M<%<-MKU]+7TOT/YS)KY[N7Q^^W%:1CR?OI5+_(33D%C2O&;@CUFLDK M\5@\!&7O#;*$4O.9!N7%SH-N;0P@T#G#U[=DX[:A5B*6O%2*'_1R]I"@& 1M M^H^3+Y,V81RYE?)/)!,E!<@&Z?7OTD;;L,O8-%Y$9FZ[*@-*.19.:SX7O5*E M'JHN4X(2^X;OJ>A?ZU:3\WW])>7SJ2&N!=TOW41*9M-U<@2C"/.%]&;1*_@- M#/3L%>BKZ(XXPZCH::%O;]W4L0ZY3YL0*9KQU0GG8T,1X[__R[.'3QZ]V'^P M^R C.9]J)=>C?PL,J'6-[-W9M#GE)!YY%\L([Z--QHV,*XDM&60)!=8-EZ[M M+Q=V%B7K..W5!3RGEB.,B .&-C#6O_KO8A&)0'3+6(+V ;C,PWX MPU;3XN<(#PS9UKZ&<3&2G(2O_$C>&NX/GB*N$DUP*CQBK;AS7,R*,R:K!)*- MXX:(.+I*;ET@S'TW>YM2-DB5-Z](K,66[$_(4X&4@K/T@NYKYF$.)I^.1>C+ M)RK#I?7CWZR/ EW,C1#4+X(&0H*"O@$27JZXH7^S?MO]$/\C'&#Z[[YB1,G. M_H.]9[1GS+>BWTL#C>E-0A-T>!#2/.47+4(Z6I+HO]B9YM>772J0*27 MKG9*\3%W]_*PP+F@LB;<=< T53>@JNB ,L: ^4)XX:P7'26G:5?<6K.\OJP_L(Z&YO\]4N@A;!_:])P]? M[#W=?;RNF"^;=CJ^Q"JI0NZI7Z!L2/O>$0MXV#I\XYL;1R11$,([,KEA^Z\' M23^@^WGG;]7H(P;&R/2E"/!Y=2K7P6 36A" +#N@\$]+$L 0%!'68JQ;I*IJ M8W\LOE()[UXF1HU936]&I MED83Q\5JYGDK9L6X["T&/6E#/TT-S1H(@<:15CQ($Z?P!JW9#ZAU;-:4+#C2 MCV](ZS;,V5"0H50ZIAHW$/.#D_WLK*M',P&QIKV$36BM0. ?<5&8<\H#D$J MU9SA9>%*DEZ1&-BY]+ 36)694_3S2*9'VTGM' M%-XF^'07?!Z^O9R3?T7(TG-B(,6*6G&.2ZY7@Y"&B M)?5WS(Q'">W'@HEW;PMLU^F&Y/S:&^,OS)E72AGZ,N4>] MRJJ$M#-&,-MRJ@A'%ZDI5HWXOF%E&%?*Q$IM4"6CIN,Z?@D+:,&[OBN\'RA' MM]3!04B/#9^8Z"#0! 29.=+):4LY8]KD!%*AE'[R'Y5B8-A(:CF8H-- (0*N MP9$0H#@J984I%]R7TK6E\#=G1#BOKY#KDJ(1%<635ERHV\JO]6\)=9^[OE$) M('WQQ$\6(D)67K:&''E<"19E)/U5C;IH!M4B!]RMYZ]LA?'72T+OWR>AOV3, M:KA?5=UDR[KBSJCSAJ[=E9B/FQ1V2@NB7;[DFEP_LMI+][8!TG@UQ(C-74NU M*R:=4EZ'?"GWX?*A%LM.KJ\%XX\8SKTC,5ZC=8=>GX9X?:9D6V)F2]GQLDN@ M_(U 9N2I<$"5^CV65^996M -U_21T@8,O&*G=/5CKR+0>^YW#MU M$\E2;(A"Z+H^X96+UG&*+YN MAF)\A=W'MS2(X?QT.=6KSUJVZF>;LF(W.R%L((%(LZW(JL:RJ(V )MZ([/6;&0_838;A'$F80;03GY1-U@]P M-K'#HBSPSG*>E8$I/3 JCQWPQ1T5EZ4?5V.1V8:K%Y7XCDDLJ^#51\1=(X]8 MMM<_(]12A\VLNFAZKNLH*!B;,?L[;+HD,"%6%0%"S$9J)]R)@LWUWP4',(=_ M%BM/]<;&EJ9V-JI+82UW1(!!L=")YY&"F:L:(8K@F[0CR0&60! >70IZ9FV_ M^629#2>$X$Q3'-.Y5UY=PTM_R[RHX1OK+<.]63=Q8HY-UQYHZ90IL\>*7P9K M\K*6F&A;GO*1#I)-7_5)@G4/0,Y2HI6X6<:*"^FU!2!$XU, IG.X4EG(2V35 MV>?1E#%2?JUP8=>B785UOK0M8>[V='#Z 0RU2//G>&O0T'BI,"5:9U7 MH#EQ[8H&Z<2+Z8@+^55@,,80^>179K&]RJS$5$*?CKA^T3DI5/RZ8LJUUY46 M-9\B+,3_2,\W2RT(Y#/C2-NW,Q=Z%P%L)]F:CG3WK2HSPVZ("+M ME./>E0LVE_4E2L@@L<+X9"2!E=DVEV5 2QHS;%^S]6^J*;C:E5&N1Z%-OR#G M#?@2KBQEJ+*%YVE9A%YP4\,E8Y61(R5"IC4-H7.-:S')UGIZ!H(JO@N2DIQH M.R)(Y=)-%55'2 )=/?9 MCN/6]L,9IPBHE]L^)!-\X(3O\F[5+<"H;Z93S_L14]0Z)H3#T5WQWL!I0\L8 MN#=Z5D(;5C!VLN8-%OND*[.TSMTW-DD[MJU3.172**((7Z?]7^L767"$#79( M,6 5\)R7;2O76"P>$62LDMKXW3%M#@F#Y17;H5?:B]M55CCX)F^T%O;2/A1C M475X!.^+%#YPZPAFP=-_&\U65%B)Y3T)Z\07X;0(U8$#(_!%UV80:C7:NJN' MYP419P5>V$T7Q]3V=MNW$;M"*XE]5[#3,RDNFE9I6/KR&"2GY1,@Y].4<^K- M>CLO^[X"<;?XAGE\Z[0@>_?/XI) M,VTZ"#N6],U(6:I=$RQ-N26A!H0;*VE+QW#2W=N[WWLO[DCJ=C@!)USYSLZ& MHW9'9C0<:O\^\5=AM+2^MUSH';0NN!$RG*3 ^DFFP:S7H-^9RYU%-^Q*X+XS MV(-T"P;(18HFTOO+-:)4;KI0]QVC)0=P-?P5YY 9;+L )S:3^I,RZ-])6RPE M1%2<(MX4TVH]$?"N2<6]O38&9#O]A7*/)+GQ[IM?EP*;P[:OSW:FY83V]1EM M/.>J*@:M?K.SMU[.\$>)%Q_Z)R^^D&*G(;Q(U^;1[F.LQ8=-"+K(#O,1$D&^ M\)2;J<9.)HSXA"8&C2.8Q$3O0W3%[^E8'2]RE3+#LM43HM[4.D!"8\7UC@4/%D-*'N4F8OG;A$=!&CO4)6)2WS46@8Y9'< M)-#<G\PG2W["[^53==%4TL9Z7%KSA5PIJ$;T\T1H5( M"E]9,-6&&V_E=7?H_LS\RC,CYA+=[N;('S?MPMO_!R/VZ.U/H?W<\R>@VCP^ M .]N[V@9&HUSS'R(II7]_@8BG]X^Y2<&M+%$=N2)HY0%HK4@J9Q;N9Y\J71? MH3^.2S-W5E[4K20^J.=X/-.D1BYML:==-5FQX$:I52$F><3/EG.F<-(S@?/M MSQ';;_(9PH#IH=I8A#?Y=T7_K^Z,.KP^^W X=4U5H&DQE= MK%^S9.:#89X>ON&CE82JFSI@#\(-%=]XBNN%>;HM1K->%\NG9"3G-!2MTC3B M_0=O?RR8$X[2A;!R6*8KI/.O!W][> ]_NU=0O]GR/;801RSQ.5G6W3E01VP ME[7$WQ"3=_AA!:3X$E.^]R<3=/O&QAWBJH&NVCHXC-=](&L..?&K4NI2VF,Q MQS7$DSW# 0\"V@!7N18.:2GV] K;,-L2LK8=_8W6KXBSB J4[3A@6R>'+O9E MH(#].%!W4B1%%@;0=E"+YTTWKQ;%5 NU]>':[MIZ^*D*5&,;O@-36K3W]_3O M> Q>KTM#'Z@AY5*)!"MD;1COP=G$3R$]8: +[HX7@!8.9@&QKZ6OP( LWSLN MO_M>!V*$>:J_EO6DJ*QR3PI(_=Z?MDTQ9A#2F6RZQ%B1#2T]3H)CI?$_!<)D M;!( (Y+."V/XL^WO%P[F#V_\ ;F6S1E0/.Q%K<6TA\+7,08GOP%.=N>CA4JY M;4N,7'2)H&BPC^6%$YOD8C;STJI)182*=CQ5Z #[CG>F!]QP9BM%+-F-9DLW M#C@;66IP>(BNN](]&'("3K K2C Q\"M^/C9 ^K5*SI%![MJ46YTOIC"(,78SR#Y0%)6P?9%G6L#F'X(-MVKHJ8,N* MXNEQUE62G!K,!<#[/-E9<%Y01 KP!\YHE^ M'!^3%!G+TD@Y 7:-._IJ\BU.29J=6-M<5:G<9T-B)$NEVQ6FF72YUHEFL/ F MGWX566E;N6=PI#,$)&G98.$&B9O'-G&2C(/N'RE=@/"*>M8E+I(6R,.:?!SK M2K^7E1;1.'X?#>A%TWQ4Z!&6T5K@[>7H@O!X<) MJ!;$M@:$1)!L&%0/=#)KZ,152EN#9?51,O1984'D4[.D%T!X_I>)5'\\07U M^+7.>V@H/Y]7T[+?!X_76K"9,<0BRL8=9S[J$9%5?L)Q=[T2Y9,,2(1!><$* MY*I3A@;'$/I8+S]>!I<"OPS4 79'\ 41>RZR%HN(SGG!=!52CR"X1%J=&N<% MEYJ,HEL,H\^3V,6 \7#K[Y= _19O4<_W9>T0 ]!/4LM=K#H0H8ZM)H&X&RN@ MQ!28;7A97U1M4]N3U^#$GWM-WT)NO0UUU;H K P%#KV.I0Y(Y(WT [=&8(; M!XDE\G=2W]TXU,0SL9,[2/Y?-D#@/<=%;U,Z+F6;Y$+@>&? M?+4"0SF 4M>>-0>'!Y+P#D:/]B7K(@>+WJ=V!->;*91BVJMCJP%4L:5KMZUZ.0R5++()Q<29Z=0#KQ%)V1K<9LTSX MW!Y$\PA_(QDF(V2L$9PIAX"&*FK8HE)5%1+^QXBWO=1T#5E/UCTL-V[!20EK MS]I5]R)I M6EG^A-DW7GA;!#",P?U8!)2C=+RG5V,U,'XM>067')']/6"Q)G=@$RBGG_(WI,OIN M07^R\A;%2N(YES8-Z#C.UQ+7>")-)3@2?#F8U58XYQ,*HAQR97KG]I<="6SH M$ZK==S+T9*SF\5.^%G*L-WU'"1UI0H_ JQZ,^I,P^N-BM7/0[?S?9KGS7>.$ M[ &[U]6,)WPJ$J-2%.ZC-6;4FRQL;N9M5_YCR2H[&FGY-<(4](,=<:O]I-UH M%W&RC\DX8&)C^YY[QRY6_>'S%Q^B\=T+I?7TO9.[#8(_B#&=+,5]#!\R;7MA M\AWJB!1(KF5"UY9Q.+!>^LL!XJ5,RVXF+2_U2"F@Y-=XBY#9K17_<+$U0PI/ M10$OF=#NKM]&!\LSE,*1?.Q+*..HGBC_]GO;6">I^]G6T?N#;5;1JCA,)X@> MI4^C"K;6J7TCDB56"@.2^P9RC>(YKJAC,H,NQ>FDC^& $M __[K/36^:Y6*G MF>S,FQ&Z(I"V28D=AJPQ#7"5PM;@-:)Q%DH;<*RU[-@ E>34T*!-!&)9Z6AKX1A M=T5RPVWM[^[!9L?9!R?9(]8.2/*E$L@#*]D)HL50VYJ/J.^"EWF)4^*9R.'T8[G7*X4QIB M(9N/4D]H=[DJ69D'YD#MGRPRJA?<>36G-5I=]>?9.T\>%C:Y78D07#US4/(QQRS<38M0UC.T^B(?&[:H5WYR3*2:X$<'L$ M&+@#E\>6L7I1KS_)7?> DB/F*Y*:3JN[3%<\O\=X18S7HWN,UZU4D)Y+,VMZ ME>A&+>K@D^QP@&JI6BS-Z;,+-ZES/VTE59>4G\BU#3,)1<]"%=(VE]+[VNL- M>$P^EL,DCP/YR '\$]=<2X[!&?8Z"SZ\5^&T'*&8W;9\EX?XELOH)/C1@9HY M,2I0:U/-V7*NKR@]H-G=E:MV0RN?F&RX(_,8/A$_EYQ.8;*@\"MUQ;CJBD$NQWGS;XBS5VKI&$Z=Z&%)F+4@>97 M:B[%SXU_S5Z1KR,6VF+//Q,3HWQI;BWH6XH>9W^(&^[E\JM7X/[^J MGH^?[3^>%/N/G^\_>S1Y_NSYZ.G#O?W]2?E\[^GH^=.G__/TP5>WX3!N2.2] M>W_\[OW!AU?9T=O7[]Z_.?AP].[M75%@MU&Y=,N1=+9BF];L6WBR#3V]+K(??CA$OV_K;1#= M>>-"@?G^&:/A<-K>PUW_ @Z(W&@T'V(?1=*'1_5H%X,+#[?5D M(RA-6S)JLA].]I[) Y#D>CTMSMB'.0:^F N4V*L(\1U\&<>:X_]CU@TU^CIR MC'+SX-S0]0_O. 1G9)QAA*@.ABM GO2T&?&0"[SW@2^-.?G'LD#RZ+"8D;\V M/J-_OCG('NSO/7PNNA'#6I33T^WLZ=ZCG2>/'SRXLSD@ MY'FP8O+\I0<&M1J7U[NSF21%Y]V22S[%^41IXM)J-Z;NPKLDGB+^'&E MGW?I8UZX[3FE#5A_T=?Z7SOX.&[!22Q4X]@4F8A:D838["D<%KHC%XMY]\W7 M7V]X^=?Q(3L[_@E?C\M)0=?9;M'-/[U(\I+T:JX_DH1XP=):E]/N&S"KE*=- M\U'F.]'_\E-8T+/^CWR\N 0C7NL__1]\C+G\4-4?R_&1+MR4_ZNJ^:NJ#_P# MU2/N\69&XF^/%A(VVF5BY<0H8C0X_&^8U"NL']1:[$(3_LYAT:H3SZ&#(F6Y MD;T97*^,^Y E0":-=P,HM9R/Y7S2SQ'W['V3T\Q*=]8C],$&Z=O5VA(VO%"H M8>&\X5%IE"W1:Z)>@5[#[>*;7Q_[_'6>#NT@;1]80N>I*_!4>HB3'-E<$R>&0=(,((2 MP%,R>I76F0/;3OH5H'S89T:!6[=P;N-Y!)NG+A<9R]<6+@FZ M(Z!KZ<;:):]AVR!3^AN=-I.O?5JMH3YCS72^08=&AW3I:[JXA6!K,&"(1T]D MHJ8@8;B/68:8Y>/[F.7OYV;N/WCZ_!8[FD> ,.X=[&:>ON[6!^3X5=^@^+(: MW6"__V^S1"H$\0R$'H5@ L4*E3E\D=5=J0JYDLP(SX51MCD36!:K#6[(LZ:) MKC=?A,%+KSZ\BWDCF,<-M9QP M[JSRT)5)T+:(LK'G[V)O%E64]*8FO#2Z!NXIOJ.:T<>[8D-NZ%+'CESM[S[.+ M8A2;B,2F#0Z[$F5)Q<>RWNDO8@37R.NM^9NV%5=$FB J+A7%#E;TMH)K-);V MBK ,LE59#-6W3 MKKL(X".2TGRXE<6$F\R/$:W/?:>R*_9=WF[H3\72256B,,+Q+Q6N8&BI(%>\ ME>-E&UCK"GM[#! 4 EF8D,<_8TZO4%K%N' 0QW>=(7HM< F>@5: I-IN/NO$ M70J8^7+&./.(DA^CX69U*ME+SBN*/2T-D[6='*0'9 MU+.YY21\843$6# WF=)Z!; 7<.3B__\-L7)AI1H MGF1*VQ+0[$X& ;HVXQ=H01WURR"]]#[:("\%%@KEEOJ98Q%N;K M+A3DV5@DDFL PY>@H'7'N.:6 B<:KK/ M6,J!T>Z]BDFPUHRK'NVF4J!8^2\:3UP$8C\9'"U)()-E%M[L'Q)*46#I0\Y. MI(<$0/5?-%<1X0JBA4EA!L)U"2&3B5]-U'B)FGY=I9NV<(35:0<16ARHNHAP M'FZU67ZJK(!\5BT<&R\W :^LKUA;7(:05%BG!4YJ;TZ^+26:C;WKMK5?GMH. M*&)C&3'E/F EY*&B*IU3_(J_$V1B_2E: MPZR!_'H?)+_" T&+7VR0 /&[)4R0.Z')TPHB/7#*H M=POI%[@XMP__+E%E!@%7LBJRJ8V>$M:@HCC+I#.M*N669:+L) 0[+IG;F,RZ M@-)FWE4(G[2UE+,N1W>0X?^+YP'2PX85X2YZ%K.'BI>ICH4>W&S'5N$UO! F M^+I8RHDAJQFOMW&B/[&=9N<4:@II6^-.TUC2C?CN1I:&?4FUTCAG![T5^]A5 M4H%&(BRZ';?3?&Z:Y:;"+=D+UHLF>DNI# T*]K:OZ/69J\]GY-EI UM5PC, P-.W M\$FD/&U7Q\E7"_%.-"R(@'!4#[G0,R M6-2+T&HQ[:LY:AHXED7D 4Z'Y; $6KG&RII?.AFP+F,@0F+-&/E(6Z^Z( 5G MQ[I 5= EH:;353*(-9_62'5F)6V]AQ4*A&I0!@:;N?Q1LOTGO'?8EC9,FX:I MDAB/&%9&0!&W-]C=IVAC(!W,FL22#>Q#DE#WLI]ICVGE4F(=X3\&21 4N3AI M\,2B$M!\*WP_;55RYR^O9!/\$G="_F565.+;">_NIFQRN,+R;&-1/7RI>]59US>ROLQ>W_R4UAW7=%01M[ST]GP-;GP MUK1SPV.SK&6MJ-')%+P!MLV+P=T&'H7?G8J@Z[KY6) 'PV^ M$(BYT 20K8\X[#6^S,ZD-)&/7G 6&%X MP3!I4#@TO5CK.*QKJ$IBL9 (1AT[9W*U)>O81"T&OA>VE0(KX5%JL:@7D*%K M)XSF2LCMG"MWU;35>],X!BC%8%P)/G!,RS%MYF2\0"@19(][F6Z=EV';.:MK MR-RP>MDN:0 G_>$3OI%[%$Y X3SYXU X W-G4K\KR.5NZX7]F784\H9K=7&6 M/^365*P[0Q$]NF#UXA[R69D84.L)Y1!!BB<0KL$"$1A7'-P%3.["0/-WWDSZ M_#46>D"-H^YF;Z2_K%(6T :,"K&&T'Y)ZS&1"?4%270NZE$H)9O!SM9RJ+-SM<]$*2+K.220KJ?I)4VLV!PWA=_STU" MI-QN47;2IBOVK$XC$Y+RZ8%IUMN'WN_X[[WC@03*<0=R<^I0E&@P%/ +26$7 MDRWRQG<"HP@[S=4C][OV3]^UI+NIVH>J1>7:L*8BFOQK$]7?Y9P%,F)O(;D1 M?(8J?']IW.V+]>=2P@AZAR:,F_V<[E!\4DP9[30OI@R<0C'/S:PQ=VL5DMZ= MW7+JCD9$ V*K9M @LLMW7?@85VCX-#"F JVC_<\+SL !;'0K0H6W:J^#=2D+ MA*TB3ZKB&X@5VJ2$R\J@'_DNT]UER&9+6Q(N#D6XUQQQ=D;-:3L-=H_4;1;J M S,M#-^,D*" MWM%+X=KW(O/S^A,+=3WP[TJ6)%0X,(4\2*CC$*)#/2&L55+ MC5.7&F.&DBX9=R'J6\FA\BRQJCQ,!>-JE*>C=9V" :800;"+,YLE,MSA,,2+2[ Q4KSWK*M6,<+<90/"?] M)J9:06)JEK)I97DJ7+$Z$>FM6$V70F2K(9K-D:J;)(;N.%<78&- ^3%.DA6Z M5^0BC^L&3#&E_1NO>H:,M*U1G*5!*Q7AA05K+3BQ7RTH:TP6(\TA'&9U!#1JOL9!JPWB6@F$!"(K.O4*BC683F2\J M<5.IDG3*-A6:"N%'(0D-6BFZNVG@,F3D5QOGWD>=&-"$^X4KOCF-VG*<$)+G M'Z3=M<)<];.F]?8(UV(+6:.(4(QUU^5980&8J$(2.O&[;?!)>#NY$BQ4R[49 MPGD:B$XG 8"PSI@:]LK6-6W4)WE.F,"C75<:>36NQ#33JE] M@B%3:^.D-"S-;#:XR!TI:PJ8H?U@//0,B7E&$@;K@5G=^:19XW9FZ^M4)8;Q M3%\8V@-E8>ZEPSPI.N*S1R>J8M?0Z]D]FPXE^DL0"\EY2 M1,$024A=&8Y3ZL! J,XQK(*G:3%MT3U^Q;]>AGN#9!1E'@M-A-3>^#@%C6*I20D&&!L7)31H MW24>^5!@I0^NDM207HVW_N3_.N19_^8R/(? WYGHX2IXBG)VA5[VP:53Q(IQ MX!R\/]DY;'[:V0="?*GI(Z.1\/UU!E]D_F7_;1P1M7?=^@VZ&N7:#2Y4<*D= M-%\B_U V5>Q))-^.!2R1QY2Y*A3\+!@<.=?2+0NUIVF!@BQ:@;7N+J@@% M,>:NV#.1),5ZJMCL<,,Y,CW=R@=#,Y;@ MA:V6T\.P-OT8#PNR$L7L2_H<)N*W>%G2--O- _G]YWE@%/6I0.4<7 MHT$*3 A0\29<]QOWI_$>*.+676J6(R7!AGI; E3ALQ91-G1GJ>L FU7B.\ 6W#ALXX@8>Z=)7' MFOI9PGM?BA).V^AU0U>\K;3@;@J?I.:("]Z"2]U>\"6/"];D5AX5"TX&L[:- MI2QBZS",8B.FG[T#V>V*B;QOO?7S*X 5ON3&HG^]D#%?[P(],DRY]'UPQTF< M-U;B=/G[5NSFW^4"G]I!6GUE),2!""C6]_<#8;=^T:_%57SF$N.>+8219'!! MC$M0;X1\GB#W.U?+O R-=']#6P[FX,NM,.?*.!_Q/[8P'-I;*;$XK%1?L MQ:?OZ6*G1)4! Q041?0YNLCHC:C?#OE^60_(O8C.6=N%RW")?SY@X'^\#&#@ MY11]BE/D&F)475>+5PY9*P^(("XPHZ=9ENW8*2&[X\%G204;J+*Q3V.DF.N- M_\[6[5GQ1$F0@%&*+@.K/]5';2$D=7Q;DQC? !=!UF/W*JE31IM)VU4@ XAQ M^)VM\-F>3)";!$4"GGO#LBFO+8K])8 91\L4_X;S.R6CBQ/!F,_2H4PHRJ;T M@-F8%;+>WI==@TS%S'Q*)7IM+IONI33SXSX,P&U\V2IGMU5RC<_-;=A\.+05 M*FS=5FLJ3>7]UYY- $!Q0K_8XB09@"O?XKQL@4^_!;1;K=@ZW@C8CYYTB2]+ M\C2G$C+Y^ >!"V#'AN# *L:GA6I"-AVI^&"5(BJ#,KDJ#][(*;PLX],L8SPV MH;DAQ;,3DZ$P6PZ#,?PR#1F\MR??+EF\2 ?:QSVLTIWJFW-7JUSW@8L;_G?]KY7;\+\C3;VZGWW9W2^90"E=8T'\ M >@U(JZD=+CCI.O @%3$!M<(*LXZY\5,CTFP2&.#$N$KH-"H&6I=X30S ;QA M-.-MBH<(\;YH@F6N,)3WVKBWQETZ'GB9=O;V*-Q.M):SD(%BA0-@%5:XMC37 MQ0-!Z;\KI9E:,RJGVR"C!&(W*BN^+:"Z;2\X MY>645V!BV*FTQ,KS1"10&B.*@GAY%N?Z6:/99.2';)K>V4KR :9CT% 5QDRK MCN"6 G SR'>"PBX86Q[7KP;:X!V&,.RI:.C@#9K':-+> 5+AZUG:N&??T1E\ MZ\3V:SN/A?=0^(E]\,SNIUF[+YB%3Q_/B846U>9JSZ1WTN@K1!:[8*5L&&UD M +*S#@Q0%>27&(JI29+ ;]X57#*N)\BX9/P56 SC8)R."-4O3!%/=$+CD8JG8VNLBHZ_O>SC+_DY,PZJ@=".TF60<5(Q#TK* M2,Z#!F(;[N&K2F!H_GI*V!&[G<'/(12.&9$,T\S!1B>U$'N[LA[#RXX>,X)@8!N6 MD"J<\J^8KJ%$3*HJ@9.,(#U_I#0MAC$.5,,SE)@%5:S]*_$F86JX:VM+PE7=QRV%%PLWY:/"(CP'#SC9M/-P"ZU+V[%+LN@F0F1[BG0->&@2=8'^CV:5H MB][RN>2F)WH(H-,L*7R]<.2*-@(VUH'4W6B M8I$ HYW02]L956WR6S#0=0,E:):"DK[:ID65#;1%5^;S/-\S+(:#MX=\^ M0S="+B[&6,_*+S,JVLL$R&1&&(?V2=ND/%)RV0,I.P4;7*2Y7KU/^,.]%^2B MX"10B>'%V(.=.!BT>2-[\2?9$Y#A==6-Q 1H@"!R[&;=.Y;[EW M/"<8>O#Y8E^O-Z7S;=F:EOL6N2)ZOJOEEV#BQVQE*-L6LA?<&OKDJ(+#,0;6 MH,!E("TA\CX@&CL15)Z^(3_&-".,5B15:&_7,CP55AVBH:*)4%3E^EG^(HH=DV#0 MR>^QN2F3*A4'9O+#>,P@;E"R3!GZ MX[+SLQNXM%RTB%\ASBK,&-(LM=[!1H8P*>UDX2C\7G:,JV<75_GV\=M'?HW+E?...?A?!5DJ74EWD9U-%!G?]\&8,Z9V9'?\6@J>Q(S54AB)GHR#EQG"5S M*O/E]]!UK:O +!@/FI<*:G?0STB[R!PA5(>7SV\"7*/M!@A-N!G$YE]I5?W; M]3P:H$A[Q](QC2< )>.))":SG@O*%?!'$DZ>>DIDHQ-N,LRB>[VWCI;S>7MI MDPE_(X*K8(]B"(7Z&LK8Q2\U^E\N9X*K&&/F#IX2T +M%7 FU>W-<6XKRRP" MC$G+'"\3P=;EH2>BXR[L.@PKCS1[N2%MZ(!BT]5UN*8RI7_50K'21@.E9(-] MBJ/%']?G.LLL$Z,+1/*#[[0QGH2$5E$\M>17$*?@^E$R9:N8KEUEK#LU,3/L M'*5G4I4#[XK@E*J+\7"-7$SX'H\8BQ!G8M.N;L8R9N]#X$1DD=M*NJH0;LGP M"(H.3.Z'?H5JTP?@9R5](7XECM/,,P B^UY#.NU.%#<%S+QL\X9P'9'"(:S_ M%NH'5&1=L#Y:;D=B-/ 7.]%45XKQF%5A'1[#L!+)-P+!;A2C8[E=CQL/4Z88 M;(&("JK2QKS_+ASQMNBE&_5!7.91-9A;%0(7JVQP'K_'G3BZ$NH0)56\#?:( ME*<3^QJ_%ZPC@*?;!)9PEVD99;X5VTTAM>6Q4V\XH[2C4JUI!?N$2\7;$$,G MQ!OQHEBNN(_WLBKCX1./;8?1LW+D-K3U9PQ(ZN*+^9A;6$-L'5RM"*!7WDUI MK ","F6E+9^A-5KE^R"YCT? )/0R4]&GQ"#$VT"NL'3R7A+/;".CLRQX#2F<6#UT5[L_])7QD M#/\N&B,Y8O[9 5&)0R/'5"0OP37"05CF'K$+2_7\D[R<1-6'<6F]-!^,(=*\(B8XDB$2M-H27XB6O5U\GA)X4 M&PYAPE'%Q=1\22@&@2H2P54'YG?MF:A<+\-NRSO2[[[_Y@H-/S8$VA9G:5N& MJ!T@_(7>\6=_^>N[S^,I_*7BD)JE7*Y7/_$O8T5FYN?OV^X#./[7MV$/]9P8 MW[])>5[A!;YN4>6M7WWV^LWKSWTFI'XXWB]W/!JXZ>CJU\CW"*RN\4O^.]-] MKG4]N[%4>09T[:-K86F&,D9MQV&ZUE3E2I!^5 7#DX>)%A>'A4-7&%XC@QK=31_7 DI5CGH<5?_06SLL?7\;ZET,AW889JS+87,; MI]]OQV&3E(DGOUKHD^%>3#<3 M_@ ,,.])9E(JLSMN0'DKG$'$$ZW+I=+K&N %<4.37FP5K5K9P5:H07A>"]W+ M)KJQEXP[7;-G)_=8F*I6R-_T?2DJAS61?S_Y-GW2SK_-37_5,7(UDNCQS MX4VKZ._T>IK1*]\BL2F0HADF_$W;#W-1"T.(H)B_F7I6B.TI@#>!"%4_ZP[,)AESKJ?@FXN$HVYB7EO7"UUU=P1R>YC!";@ M&)G$3 FP/S"_P3X7XHA$AK<@J'I^L%DI@;J41[\A!_8"^*R2Y,+Y&(6Z@05B MYCCXLV:*7R9X3LCUU"$B/3]5_7G1 -B%@B(,Y;/YH&VGW M0UQQ 8D_!6>$+%^Q^LZ$Q>**_(")VNKKMNRV,0+\[H>OJ1<;G7^U$>W>(03S M5\Q4_?? NZT=?1.\=4K&2$R15R6,"';Z-Q1TBIL'Y<"(60\I(ZLA7'#E3S!( M?X+WN@N@JL+F2VAE\1\+$[Z>T;U6P8Z9-=5>E_X-!:?+C54&,]W3SU[_\+:_ M3'4_X5@)Y\I]/*2!@N1!H_DTBR.C3N4\7P[D/03G7D=5TE"-=@3#.R^+^S1$ M)R=CN6W1ICC9&Z9&X< IK*\<3?U"=L6 M?T4P7/$%R<\A7;E2E5_VS9,YB"005[D]4QVS^!H@3:&$>!)$7T*S1>XQB[=Y MIUW6[M.O';5K4/3(V?:E1& WR'S[W11>% M'&/4< !1/]-^(59E5@1B>V':QGG!Z+)9GL#[9RO/U((+_0@)!_O;]EXH*]I. MF2RTR&)U3A+ HS$<8(T!2/6=U@\3:@*8S-D2OBG34)&R,N@\S??^0;DK=VKM MC"\R[!3]&J(-UO$FVF8UU^R2VM*%[MM0A']Z&2C"BZWXK6W%O LIK(IMC2#V M#GT)HZ9UV>,,1?Q^7UBE#A#^?4499,IZ2R7TGJ=3 65V$QIBGN*H\Z_?OY," M6$6<4]$G-:+7./\=I,%&A<]M4$YDZ%^A0XK'G*=;'/:XP2^3]TNUD^&UMC8E MR)4_]R[X82X^[ D(M5,4.^O:G8X-^3_C8KM3+^@_]H>^E9*'O[?H0.Q;K='^S=R MBO(?\6????N7J[HZ5-O+#GL**C57Y4A/O!WX9$]I[[9=PT@$M=2GI9#+XCV1 MVTJ)Z*CT*-&E!+5X1H^"3W8 )PP^][+:0*FI?H>NA-KR;@@Y7FSDJ7QNR],P M#W6$N%>LDW9W-*,FTI'<.@:OF,/\H@-KXYO$*#;>Y;8K[Q_Q/3]F+Y&TM)SB M^YH#%&+-]K(WG[)=(R*@,+M4&L0'T9Q=BCN];6M$^>85-$EOYEHUQ0H:/LO] MGG[LB7/.-SZ!/#$4LIUQ42%I\\4(,\;GB8%*C*/ M9T5@P9BJ7$LJ#,%%\6^PD2 M&:K9(G.HT \SF;<7/E]8>N$;!C:0F.VPMA13QJZ?@67% M[>9Y3WUU2=BSC*5!I=?A/F ;;=O-:$2(6%(&/#1&'1CVH'&R62::6? AT&?O M?WA]@1L\X0YT70/;@)0UQZ"RYWS(.YJDG,].1V,&F_JDB2+T2(KSY2DP8\7, MOF051YCYE:'$PMA6C+XN?D:N2DVU2RSR)!4^JKD\7&/A 8#_>L7__8?$J?9(CM:KC;=%D,7.Z[$;.P5LC TQY)9-3];+1\3P+QB 'Y!Z#>/8*X0BG M8.,L2R C/1*>E#$ /F+I;Q]]#;)B(N21 $PZ];HA];[5#1#!KK8LM+J$2'_5 M'!DK434>U2T_)O[)54*XB[$T7>+AY*2"A?+KNP7#^;+7>$)XP;@63%""#8]) MRI(.D>&)_L-7[2$T5ZA\B?_PQ5=35 %YEW4KO+Q"IX? -RO"K4"E(QFWDD]6 M$'Q#A"&$:AG7V)P/*1L;HD B/)I:!$[@=4OS[H*VHUG_Z)3T4?*"[R+$;W9; M9!>F.GA;U_%.0G-7=6UC4^UZ2X0:,_!O6[MI_U-;-IO^3VJ'.*HI\PO0D6% M$\Y1X&I3K,^+3:=]"*JM05!4/=[Y[D]X+3^R"#*!GP@^=GD$10)@F "C^S$! M9AS_DB%*X@\RZJNU#K9N6]>I!%I&XH(8>RB;Q:T*2,H&B39 MG_^/)V<"Y;0+KG(X9D*=HMU$:DP)5=P+5?2N0A7OHR M'LU>;H#KIF75Y:QF/,:\ K =](I@@?/;\C)!R0@MDS6XDKM1^G2.[@Z&.U+2 M!O@S(KM'FG^U$8$9J#=XI1:)0MJSWRFG9^5XF'87D.)$D>MS!0E/?0G^V^$' M(*XO0'MWCTL2%QU?&+?U8U2P*V$JCH>T,?-4<,$4RD(-.YD9]?L-JW4 :$!< M=P<6XX$MBT.R"U8'OX+6X=ZR8Z;P$RYW'D;+N+:@VP+6BAY1N;6ATM,Y6A>J M\UG=C_&B6Z2P'Z"841-0S#E-@V MQ'\97GI:\%/<$D.%=E%@R][:EG*D<.5PQP 7-FDJN1U'VTQI]8-^+6?.Y8LK M7VZZ>HYAVDE4'8!8.O3&SB.C&R?N%EEU=$:4MN$1KDT)2,:U<93+&$ ")_8( ML;WTK:V)B],MN.=')*#>37+5Q?NP-U4^LZ0JW)X4D>9>-$W(RM.A87$J=:9C M 'QH-@U,&X:D]VZ![+%A>+PW5BXR$9DN^%D*\),/U\&T=85KK M(J]2*.U%ZO$6X+F8 [B1CA@OH 7"ZKX/1)+,HS=9,;P1O$^3Q19**OH%L3%H MDOI0$\.6RS^LSH]V,Y$E0+]WXCDW8]=)YL69B[)$?)Q9^J>%=__;'UX&O/O, M_,8KZFYQ))5&8L-MO+.;VX50'4DKYPP!G GJA5#LA5$YT-+% ]&%Q!&!+;W. M).#0KL9 9-?657L%+PNG_=$S&>F+BW[P?UHK!,,4HNFG9(=)VZT<.!P/:+1= M51[94.)WB)6>O0P:CES6\WZ>0-]$9QR)/GPSQ;1Z19SFJ4>0D.HH00]P>:V2=4EUO6$XV^X(2G-0WX@^- M!W1%H6%X=#O&1]WB?Q!1?_0:T=(!22@5+;9A!YY'RU53O!:+WC)'8Z!4"D>, M2E2 071^H*UF_>LAKG,G8?3]+553X2;E-BQOD,**2Z9*+M!BS:@_C 1DX\LS M&*TO=(!)Q5*IL2C1D3*60@Y&DW3&)$_:NQF'(G:J5N06P 'B#Q;IPRCE.[[5 M;)B!65TG4[HZ@T<\]?0[KBX\TW?E]XX1C"]^3I2!JZA;1 Q-PI M$#="QB6_@W3]8]=]J7'\B*;+UVB4T-I3RKTI_2"8O^ M 'B/W@M'2P L)&AP*UAMH.] PW_4.0[51/'O5VLI#RRD+F*(66Y,P28E>GD, M9W1?],G(%$+PG' .XXX"]J7J:,HX7[5N8OR_(-]#_2X*Z+-4-GX#>@T0L'_V MZMUWGR>SPUN@*39;Y=;"'T> ERM43)Q'";1G/96=T$%CC2$?^<.&JAP@%LSQ\Z+4.^2U MNPNWU:8.2>KTU^_??4Z01R#.M)]%_O*XP;:D D;O[X8:OY3KM%< 6FZZB$(3C/O8?UZMOA#.XLL M/1NP20JB)BB\ MM-SLR:A@\G$QC%,E,NY ZTHT[!N''2 !+FYHL8D+2BV'S!#S7 M1ZH73/4P+R2G3S!# /&U8_80?#]KAOJ,[8+.?P(.*6*2EM(E8^IX;19FV"_K M\A2L%7\/6>W+F?O+"GSZ%8@9XDW%L1+$G-#D4C7B[&1$E_N_(Q@N\,0.^@"- M5@S\9B^F&M[BSYW#PNBLK4._X5G+F.=5)8A<>\&ERS[X]/L@6KU?8*&XY'!7 M5K6KC\V1;^ NF9(I^ZSBLG!/,"63+Q4!L@F\YHC1DSK< QX1*-,FU)%8+"1:R88BN<76,=?&O,Q:W-$:%M"! EWBA5VB:X M+.-AO3XPC;YM53GKGJ 9+J._L$(_Y;R]DWGC19=!?$(30:*/)76JM%N'VBN* M"HQD,DBCH&'\%60-$[[HP[C&EM:QD%XX:#J-*-#W."5>&ZG9ML3U1UUG^8S@ MV>R^\:!=-M>3\#$Z#\0= @)<50W^AUO)"=O+!:GH#) M0@)'T/PCVH&"QU&1+K"8H*'.OBW]D?UZA(\@ML2W2F%:L1_7,$B6NK53LML( MIG#0KJ:% T)VL M>*ED'YHIC:T!3XEAO7&TS3 M% DO7.'!]AF<*UZLY!U9UE?W;5<#DAY4EHWL M%2N7,A3M;C89Z-ILQCW\>E#M3X&NQZU;$(1K!W )KF#C/V#[+^1$W#C*BC7P M?B;*:V[:.4U=>$G[-L$D]]S%QOB5J)_B3INVN).)"AS$%N8'&FT;;V+*19BE M/_D-\N&/!]YY[]*BM1"8D:OF],M@L%O R5\\?U5@HE+)G"(?:)=%(.HA)5M;$@C M&="OM)<8ZH=C3>A=R1+TJ,.=,@R4>YQ%((!.%PZCH_>C5[JS&7"9([]>O0AM/[ ME$9?AYF,DT0'TV<@QHO$DB3_'H.I0Q<&,DV8ZLW=$N%A256W]X"@:GLP2():FQASR&&UVZK[("9$H=D2QRH.8:@*2)'#"+(X@YMD'\IKX2L&;>NUROC2P MW2-6SN.XHC<^MJR%Z=2%F*WJ)V*^'9 9B03V=/;4J$_0ZJ'X7EEO1BJ#Z;BF M#U[]X\6@J^UD&)^']1]DFG&$$X6AT1T+Q72(C8<$S$ZY]$P%'QUUP8O>6&_G M,P2AT DE_GE?]1PD8MJ#TR!,^) 24B1B(;R0Q3SVVN =R0<2#OQ^HJ_,E ;( MZ+5#>9#F.*.M<$$8?OH:948\G&OFDM)AKK[A9XUP?-DJU9GM BXW< ?1O\EH(+.M<*61'7UW:DG**TTQ)83KNSRGR-%@3M!I5@H02$)004A)HP4L._ M\E6?,[OHXXT>R@ZCCH5)%-+ATUF4.9]\ MGB//3WVB5_W,8EU/R@\'!O\[;!'W6DRH/4J(Q7%62C6J]1Z8=@2MWC*M9N&) M;VR+]9MNC#^)L;8-8S4[+GNN';7"%!*8YR5+])),_H$9Q1YIK+"X8/5U24\= M8<1ESS^-T4ZD:QPHE" $-+3-7! XFDZ!/0IA$W]2IWS@/*:'&P&GVOML'IWX MP7&Q,370$>43RCS:J2PYOU6)'?M/(U5:I)ZQ!H#I!JZ9RR#T5WJMR[;[]-LN MS=XA6T1VVHQ/5?6;=JO-7]Z\<\I,,\2A&#MRBP%#!ZW1H]I75KCL@5T:B%CF MKH(ED$E[1\@HL.A2#JB0"1B+RW;Y]-A!I$GOG9/X0"V4 TP(,]=SLJ<*T]+! M(BIVXUA:)]M+M#.(!HLY/1^P(+Y'/&^S+IOB*89/J@TOJ_7J,L1L/M&(S M3CO!4@3%W;-(/H-["B*2Y.!#KR\&0^W>T^,S>SUQ>4XU="Z+_S1@.^)O5@[8 M>27&:1@MH^.>R*D+0"E)7"])%N"+U:@EBQ[%-X #4>Q9X<1DT+FCIY?6&H;5 MX#A>*K)ZMON2Z7$KFZ1^G?_FN)6D7.*P-NSQ4)\T!4HX;O]I"X8*+"Q=FERM M)Q+.^-I\CCNA%+0<10$X)Y,3QRJS0']Y.5B?_F!Q+$8$1JCQG0&3E*B^E+A- M"W&,K^"NGJEGSK6!&>-5,$XEL=2%,H&YNU'QW9-@Q$(5Q(&GZCB'H"9E;<3_>D8]E!R;7>] M)#>(-VJ5.@V3B.PHM4CL5'U)EG0"II!G%\"S]-;EX#Y!:R=>N@XW56\KR#L# M-\^A['LB^/C;]?OK8J6:D<"*"4B7&VA0-WO!G"G-UK3VGAGU3,+ZY+3!/Q]: M_9?!V*-YSDZWW;T)&'S@C-(+"9#>XB%()H=-'L4 MT>HX0/1L0^WB=0=ZB!=%W!7^XJ9$[,G84^!S;^$#>M(0(^HMK^0I43@+O@6K MA\(5+$O-3(=ZX=TL%)#:%0!:]HH7^U!":PGZ[=S:/?L]\4A^ZZ;-F!P=@X'# MB>.*,Z=K?)?U$4\)["+"(D-&HQM!ZDQP?=;>@$!X&,+^(/WJ>.9)$J$CED[^ MST1KD5!Z%6*K %2CZ!=N6B)=N_XJ_)7VWW1?VY1I@4CY?-4=5)[N$F2>V,+8 MBTKE39+7TMN-H*:6Z+D47D^0)/AX>F&*]IO/P&?/G/XBTGA[*FK[-WBMB#BK M8X8 :HKK0*DC%'1KDK^:H$WRT1'*[SW8 M-R/6X7:EANB)&H[O[R5&(V'AUT0)/5RX8@9J5,DDXT3,U$[> ##N/5%3&EB: MM,VP"5C=M0,E)UG!04;,'I[THFWIM#>#38DMW[&\EV+6EI*_;;'5-3;#_8,!\*&93;LQ'F^4-<2?QD*Q]/M%4F,R M'40FQI[\'[$QSQ=HB7XDP7+-L:*(2LPHZ1#%-WN34EF[.J-,2WS[YA4MOXP% M.9B6A;#X&K.+Y27<613#>HQ. _&D1!Y/ _@'I^K0SK#>VP]#:7]2P62J61S! M$0,D=A=I[,S23@FWQVC!(EKT<<(S=W6H]I58Z*&4@4._LH-*E\U]9WJ5RV M3O"Q,',2S=E\:=P>4J*C^&;F?+#P5#:H(:<"9F/CPT1?4O6W> ]QB\97$3\" M8MI@BGFXXBW^,VS@'SWY]SMYE,_>_OCN\T(T"<%2OL:"!][7U\S4WZ^^C5Y^ MM$FS'Z)U*KL8:G[V^NMO?_B_ZBOZ=7V#H*]X^IUS%9CIA4"0]"!,![N"WP*VGZ\ M%1R>0E/RMT*'8K(W;UO-B*?_/C%11SGX)D&NDP.[$N0L^'66JW77EI![@<+H M#=PK*8N5>/<0PVSY@8ZK-WI-6YQ7/[YYUW\NUR:U2B(TI!1"A:_F-S(^LCRJ MNJ%B]JG!N1U1-!N>WJPS ZT0AB;_S,*V%;E$>B00_NR_PFWCYXK^OS+:K4)H MDYW."3EC?.CX -_$)8+I_E-W^8L'J!H*6'KCH.:3A06GKS M-_-*%B_;1[[*\:#LMO)0;S9@9TDXF%+AZLUU,(A MQ*.)0#H%RX"*7AU/)N#J?8E)9D&-OT" US5G2>4P@>JG;@"?$XHGV%$ C0JX M6RE^Q5^DZ?H.:I4=Z-('WF^,C3R]A)G@4Z:Y]\*OA_X($WWQFV! MP:M[O):1$YV?\^686A1*?+T$A1EF6_X*-N =EY)3B,FG]Z*3S*(:/YDAYC[S MGM&=JJ= H<6,%-22D#T\(-^9CS#C_0Q7>E5^]L+);C'#%ZCX4 R+A;#[\ U M!]9&D!-F[520.*""'2D!;!]F]P"K45 DM)%(J)?G!BN-5TC0&HN[#ED0X@W) M!![FYEJ^R>Y0UP '5#GZS<93R3=VF:[-DK+%BS3T,%!YWW8?8 /'50&PE^#P M(43R$5LM&J5Y@I(:1V?1\Q0H2WJ($XF!$PU$<"65'F+L5F]SNWN4H 8614<% M/O'0RV+-8/YM@GA===>>I][(ZQ^^>__N!V8>3]]CVF\C2;-:+#/8>FO8#4[, M*_Z?FF >9%81'HQY=,S]WDT:YCY]@E 59J- 5>V& &PZ65@LVJ02MF&!3[ 0W"2" Y@I=DY83I;M'LJCTKS#-155 MVNO5UQC8M-+BMK:Z0FN7+0"?^F2K,V;"M^?X^%#_C6L!W @$ ,D0OB_QP'M MI&*<^A> .?G(]ABE6G$I29P>5HYX#CIF32&2<9WL+BS[FL-$)YGDV! )>9MN MHD)?\CKY#?\A_*69 E*FQW[NBW':S4XF==*GTUX-:_>B<\IR-MC0.1?IM-*0 M%>W!P'?A-D23K'UOC\SRQ)2;K/V]$<.>4@OE8 M@$CLQWY $K&&/A%OM\,4%5>4IZ@3A" MY !'-E 6I5<"JZ4ZF+N7E*GV/$1&GQGF<+KW3:RQA5)68PNR8^CW2;_( MD5?HT6.P((8?V#->FF=OH#!^@M'W+(LG2!67<(8[/"R6K&J)7P5?PT?=9H&2 M@T-X2'>FV.A)!&Q\G-!!:RA'H>";&AS0R.N1?E*9!JD2[@IPQ'G(UIM,!!B' M/NTPS#6_9OM[%$XE6 =!#Q!*]]0E"7VG^B$%Q=C2I"^X.D2)D')ZSKRBY#7& M9.B19MO*+L@='+@?>?3A/F67TY:% R:'N@](^L[=%[FI[**(1(2K&J/Z7%B+ M&$!\JR\\(DD2?X;_;[AH9N0^,_N]6*U;"$?F\#7X@A&$4(#3@YV,KKK 6;0K M[#'L%1,C9) ,R"B!;0DH7HR%'?CJ,4= I?L2_EXQ3=-4])?<]/$0BE4FANJP MM<.6WMH9BTI>2N(9>O";NR#J^;@ MY/G)Y; M ]!7 2" PD6?022=FM+ J %",N!<3:Z>=1)7%&;BWUZVE?/'@RL+TY/!QPUQ M8&]> R18XGCW$BE:X%YZB6@*\,DCVK$>(,EDD(ZGFN=92Z"?TR>93>MFF+CG M?D.F'0 U[CP686*PMTT%$AP,EJE>@0=PO4HQP@O/@36O;-#Y*"@3U^CUL[R-2[666IM;56US97.HSLZ6U!;$/!+F3,V+LF"5@HF)+ M@23)Q$R_+Y2& )V3F9RL7@CE6W?WLEI=R$XF/I+3H>0^LJ!(91R<@(W"D%5[/RVA8HD1F& M=TD96%I<02H"'V5.B9_!_U90F2("5[F](9W5X[IUT(W4M#P8%HU U=.DY7W9 M=4CR0*2+"9G\>0(2HAG#=!"")7HV?GQ@6I[.QL!RREG@HKN'K6O172=F"O?& M_J&C)\09RSH[DZ,E8VG6B\*KW\ 2T1!.ODB]6U4$J)*HR\SG[D.GOU-H/\W8 M1W8(Q%8##RX3.&.K]3B$^>?V_Q0HJX8M]G4Y1D#&@+DU6*\>)YGG;8.*] M <>.>.;;E=\]*!(#/);EFC %>4@ 3S'/PE*OJ08UA@*N_S"W:51!V= MR@M0^9T,=$'A8^93S=%HI'PN#]CV$)B04%.,QZ/[ MP#>?54MI@6C;8"(K;\^'E@Y#;V4=_@\>'"2EI[)O7-22_.O)T5?$3PJ:X#/P.!QI&ZZN\A M62,&X#UG,TG5^$"+%/AGJMWQ+&,X(@>E ;LP90*4(1M9GV=MT*%-"<=I\*]R M#F?YBF7//^>[.U^E,(B2GW57$3\#CXC@7B^[H4%@$7;H>" %.@ A2%>P3TT? MPVA<^>LLWS4T(^-9QT!!@6)^P,*'%=&^\]]M:-W0C#:?#A-[T2VH_DGWK$(6 M2_WO:1*EN6$E8YW\;KR/.L]EU'$82E5;;-Y'YU^_D)(0XSYANJT@GS.0XA=" M;V*JW@K'@3)=8ZCFR\NH$#C60;:C 1\QOTB!3R0G"(7]@D0!*:HQ&A(?W+IA MI2D.M"[OI\C1A>&X=I#H"S>8Q%LPQ%OM72'+$ ;(1MI7VK:C$#(!%CUVENQE MITD_!9YBX>3!I0=.]],E 5B38?C 8@7V,\ V7'WQY7_\$7%2.]J&8.=)M"?P M@-1# K^[&(:V]_"3HDN,1;J)3CU6IP0AO'5WCGO=M3"SYZ#X5%: #?3YBB)YC^LY786$\:B[9$:3,1E68]:11#F&F+(22MJZO0Y>^.6NXR M2LC42'&[ 9K?)3GP5*Y%/ \ZE.[+PB1CFOTNL"!D++H):#NB^"* M.@P#;T8!'QF3&PZFM;6>>;(GT9KU(7R@*:2?QV8CO78>#-Y4=Q71YG;5GA@C M0OR_ P_.QGR)^!UWHO;3@XX(H72)B7@)S,U%\Y+IAX)]&0.I>6GOPD,'V#"6 M<$NXMR$A3Y)?0DGAOQON 25&X;%1.@&W,PPV/D("6S))'$Y [,C9AP M@EM)E!.3B@-4NGB\5F\>CC^GI$184C4(T$)> MEN/=7O:#36AB(X&GH>I2#L^$P!.Z>,Y68-=6L/6)!'KVVH]'9-(.]3/&>_. M^;FS#%H+R;*X[)O7I1A!.&DHO^PX9@JL2RJ<,_B3SE/I M,7S/7BS>_&<_?/OF_>=3G3*P5OW8+0W'&,FEFW_AD,A0X#KFRP-77I.*CG]( MF?&!C>@&'2'-(^'=XM0__%!=&3>$!%\>\K&C$7_*W#AFEU&O@N09]V,CESW4 M9>,GR6A2"*P0_#D 0M!-#-!EI&[(=C/YL?[8#V'?2V)"MM,B=Q:R9CGJ&MIY M6H*_DZ*DL7Z2O#U\&2;NC@>TZ1+F5]$;Q*_:6!RE1]PKT%BL1@$0C<6@Z"H) M0QIM*<7)G%2= D,PT,(0U!(@;XA-]T-@_IN,UB['7%(@T+-G<)(&KH+/FGH4 M.S#QD"9EP-0A,1'XL[[(:]KW,'BISP01NJL&"B!*8S#O:R7DGWA4\5".4"3 M'8K1AU6"X,!O/T^#?5O5VRXT\[41XJ5VDPX]N/)/H/'>,(=%4 M7[%,9^GV7HK[FF_>_H 6V>E^#BB'[B-*82=*P&5&!#\-QL_]A?R*_K8?F5AZ M;/07:QEQI0GNR?@YDI/R%#;\-\Q1P*PV\V5I]JKY^=@EP^]I@@L>.=IK&&E MLC:XQX";Z@#'%5P M3.WPYW4Y;&X#0IF%&"QZ]?@8X/YI"(-;] 5- 7 MD!E>7E/SB)C<@%"K%69%BKKL!SUA"6DN,12ZV'-!F8.^5.6U%FX:6 "I"E7, M.,OK!06*JD?:T8=OR88&X&;BJ.II=F MU=<<,<']+8IBL^A,,L*\3DCED%MQ M$PC,N14_?5J* 82:OOB/K])2'_O'G:&?V'F+5D7?G\OVI)#0 UUE166 >,B5TT,GLAPLNA-21\PD0[G MAIG]G(ANRF:&&5\W#$]()EL3HW!LE#GA4)WHS&HSDY]E!IJNXI8O+N,NF?&)Q!1E+ZO%#HYI2JP3'01,2PV771+70C;896I'O$C3/_JL\&R+A'#Q/C MMA<>=7_7D/@0BU6)H@N?$N0QC+Y^#T%CC!0U+ 3Y'#AB/.G* 9\_=2E8DURH MKQW1V&U<@'K*,'*<]F;B!F%$*'MH9TDP,EV-![J[5<\=K)U] 9X0_UB8F-(D M&7 Q0I',U97I0*],V2UQ!XO6R RB .XCK\_/ &ME4XNJ.0):5SD9JS K/Y0T M/;10& O1"4Y:5UF<)1.\B6656$I>E8/M\E8I7,Z!5GSV70)1;3QP^"O3B@>Q M9JG$U,R+OU[EY8*<7(/A(JU4[.S!A $-+1L\"/='Z_8>B^QE0]@18,Q,G"1& MCVZDA-D[(0GAT!.:Q31S@ZIPDU, )RYN-[CRT&X^4<GLY W%A(]-I"U_U% MVYB?1+D,NI%X]M&;C_LUH<S.2>X3-?V.+L\E'M&UBR( MLU5(6B(O@@:N$2_S^H>W/1UA,]\3_],)"_BU+]"Z\&LBNGO(#0DN:!3A5YR35([$5A/P&0 MB#X<%JQ@T.Z].+?LO4HC7SLZA'$,\,1*Y@PN'U>#?B]_%E/TYL37!:[A>1-GWV(+A' >_ @TB M^99^AVQ=Z_'.KO=Q@OL->S68?PGLY*8\])KB3MLB7%X[,D\V2GX*Q('[4#ZH MP\##PY[D#QX](EC/+!$5ZE10 0%>0CB7T5AEE*Z&$-7]5S(94=+Z+4J:'O%> N$S\Y^WWYDDYSB3V@" M$E&'.\Y8A6N.V@K%."(A4:L.* ^CL!S9ZMS.H0!>$#OL]G9)M7K&@%1""L&Y M P-?.4;U5(VN[I 5=)C,!$]'0O/(]3= N4.34=/%0I1H8MJXER;4+65#!'[3 M5I*!7,Y^+SS*ALVP;F8]6Y]PV$2,K'BL:[!:KQ,>7@1+G*#5 M.M%04-HY4J3FHFVJ-E3X;925[CWUB8>$#$[-FI(EQH&DSAL>&7>9D8%Z* "K M^AIHC_#9A*%G(YV:GTT9][.D9.Z7FC"@F%!6R2.,MH$5LE2"VZ[]/$W-$\=\ MZ[&JMT1@<"-#9/FC\Q&^J=LU37Q-)\;FE9+TXO@NZ(A2P7!62/8LT\27;4]^ M;-V$".LBQ\!QNLYIO\2*;MB1QB@3 ]-_!<>%&D1D[!V/3C&@!(&C8N31];I0+M%8%8K8W\P#U@G)L9GA_AS MAI1&S_"$VJP(FRR*SE^V!TKX#+GS7'"-8RXZTX_D#/#S4S+>L"9E%.*Q;AOJ MQ\%E3+N\'_=@EGJAG!'I5$GOM0KYG;0#8092Y*J-#[<9-W6H-C'.K;8.J2B/ MTULD.+/-G XKW&F@F1MQK'W(*D*<'45G]8WE;/-@YDDQ:N,= J65T5_%/Z#& M% N$E))+(<>B#WN+1 HVNBZH.^6N#JAO>9P#&V[+.&MT4;6K:!!!H ;V[ORT MS CXT,I.%M8/CN:9Q6+5!K#*7(.?Y**T!MHCTZH@S T3GHDY&+5-\%^+?NX M$4MS#Q*5?%E?5TAA?KRE11E@B..AL#3YSQ%!IDKN6^O!&QN?ZK MR\)^\H5E(R/%;3#";HY)2_]V(/TBVZ&UJ3Y'3#HV+EI(B$!;7TC*!_769?,! M[FFCH!GY=6)@2'_[*[BCRT;YY!O%$[3CLIC7<7YO6>#$*?QQ&TM'.)D)1.;J M4_)YV#K=*K$_._:?'L/&S9>Q2_!!+SNB>XM/4U:F'5^IO+ MMR]J[E2%'2J8!CHMX4;,_*?*FNNQ_F!<6@B9RDN7F'G7Y<8A*OU]"9V5ZL/0 MLTTE8G $"E]+VBP41*35CU.VZ>O5#_-G92+@RH$/2&H.+(?DGA[CT[;GD5OF MCA&327/:)!CP<@DI,UZM7R[^I#[T\ M0>9K8)?P[TFC!+<0>%K=ID;RO<)@Q' DJ&=P"> ^_=*4=V55.Y#Q%.(@?<7+ M:GSZU9#"!CM,ZN#T_=B!#[\LP*=? $7_P%G U0#< FN0-Z&^K,&G7P,$ZU'4 M2FAN))ZIH287H\Y-2&DQ,3% 23V8S2XITD"Q0Z+AUE(PP76 #;:MMY>T[VG6 M,H;''S#:+Y%P;K4;D17O92=6P'?#HY92J9-$,)9=950P9_^B/A(Q MQ6@&ATC09X4\A&2<-J=#"NTX5*)_%1"F MK(DPBPVM3DL$[AA00<[M;2SDXQB;%130JWA$TDP$4?[WZVR&^\RW39J;, M#?S&BYE16AJ_W0WWI9#CW0<;YRJ@B8*H"!2>I30]J;-"]2CT12;KR*-%25D" MA\.3I[H;:Z \7/O3AXOQ\L]69E/FWKNS,@_1]/J*AE7$M9R1TM>7PQ#? 'Z[ MW)"SZ,MU"R$K%$_;<<#A,9$-EM]NZ0<9JQ^8L\V*]]+VYGK,_"T+B\ "\*P* MLQCXI.YB@)[Y\5B/=Z>'U%/)$>6JT&UBH3E]< M7PT\<)R2N/IRV<='$@N4RSR#!KAUTTR-6,^@G;[C*,^1X4 ,;19R2 M2H"AMHBVMT[L_'EE>H>T@Q-&'(V8GE3$3$U35J]@L"9NH+)8O2Z;T;NXY,C$Z7'\+M"MU57R0-/R#JA<;^I#B7"U0@%)HE0Y3O@;1L[FW*27:5-1NN7'\",(VX2<0"^,C) M;9$',$S!6>PCF\ :?: X:V/5DJ*T!@"X7377E \<+#KEO M"/UXX?K9O^J5@Y0R>'E$@WL&JFCGM[6H:U0N"E VA!I")X/#52E#M9L\Q$1H MCYK#ROLXX(^1F<2?(DZ5 X@#7Z_>&U7'+C6YBT\6'1MH$H/3*<3_D:1$-)$T M/5<1"#-&=C $,[=5NFS0.:.5>. >Q!=FB#T%@4,8S1*_0EYLCLAO7NYAZHVA MBVH46VC#0EV("]?06P2U7!A!)\F3F1M5?21@2D3&Q+&'U^68]FIF5DR[KQJ*H'B!@ MR@DLX-"V6*JXB^_"Z.4IZ.<[=M"DLS<+_W 5+55+U4 01D=[K'O'?P29'Z3: M3DDR'G$J3A:4\GQW&:?1=@X(ELP\+*C,&.V49F\$45[]I6VWJS?)+;U#/OQX MICX#/H'/4Z57S^R.WL>]+]OZ1A#%O.Z-:,/]SKE^ 3*M?N!QQQKLM=N )C]@ MS1G!<0L(6&'"UI-A6MB$"+9"+=VVVUH+"!DB,N8F3)/A&$A;J% Z')[#9ET* M_'?8C\H: H3X24E4L&G"NT&E2=]F(IF8Y5A>A!2V-+UKD,28W,1'04X++!:* M)=,RG+%]:;JNS4>8MK6"ZJ0K'/)A]^0D6QL?P953O:GKU;NV5706MFG@/;O, MR1X0. ?%G8B)D!_6(JJR$\X/%K-A5OJRA)J,&+?NH)?2)"[)**D*4 M%>\_IFV8/H0P.7 M^(+[>8).+@#2F&NR2J6B9P_2I;O^Z=>$[1Z7*G,Z\)8X[*$GWX)/:K1PA5M\]HY4]PS8[\V.K/D4A0'4.*8 L(>\76: MXEP6]BG&2FSM)KSLEP5XV@6(B4['_[.449]."++*Y-^'\D-@?DW\#O9Z[]IJ MNYJ+&?F@NE8?V$\4#(&^\993V,6XDELM"#&_(/^>RFM"WXSZZK9!K!30^3G@ MEUU/61C#827$VG-C'F!J2@[#% ^P\F-R1FE7;N,%RB&LM#NN9>' .&;"); *>#F2'/ S)$:?_Q"GIO?5<+EU:VFY&"'VY2TD%%Y?A]R MVT'=*[/4.VGEH_WC#F%K;0E:3K@[W96(@0>(\DAI'J9]]25\U0DGNB(TV9>/J%X#JFBL@2Z)ATEE@M1CANA7 MF.4!JUG$H$"?=/\DS-,OVPPN2LA-6X!I[5CT@YDM(R32P68!7&V>+^SMV\FU M2RF.<"AVK95(UVV;95O%TF6J*LXZI7J].6M5N#M;T.514]BNJ4MIHJBT-W5@ M%?BO1%[=V]*DG'Z]^C9&6M#'G9.WC^^C&"H$ M,=FCO7[SME>2:7DC?IK6'L0I-#SX3B>:TO,O.1.?W=Q&?QL0'[,Z:L9G4BWY5M-\Z D MLB'5G.$6;C$G[,O83:=;F!T8?.K 8:_)WQATJ^^MX"% MU"TJS%>T:7(7NCD_LH#ZQ;/!)URCNJRX5\Q$6U><,N1:ZQH2=-AD,][&8+0ZC\))4'LF= MHQ1:)A084&F;4:+"ABM.:O[%%T*JYW';AL#(^8<2832T5 R4!&QS-PA:%?ZG M:TB^[!/VHW1FX=F_?>.YNDX$ )("I"#L^);WE5/E0P+M7O2>ZG98DGZ"5;X) MY,YTSJAKAW8#3'7];7LOJ^,LGMOZP-L%D"I+17 3I< V0;F*"M)MM:Y,#UV1 M143FCS?;P?\3BNWX67[ZOR-;%M)R0[#[J'Y:NLL0*$_%FOC?:F,&)KCL4\6I MPO%2Q-#)G+-IOOE\+^OFPI/XV1I9'>(Z9TB)C]?T*%V@K IE_<\+E/57O+;4 M"4YTYI*=F>S9;(^*)W_]]G^^^^;JBS\9[ZQV00A63!O&T M*&@#%99,,M7_Z3$%CTR:POWF'R[=%!-6KG0HK)T3>Z<@65@W?='3N>!%W. K MC;?J8Q+#NR157A7&OE"-&0)CG1L.U72T#C@+PTTTBPC:71_1X\LTG99 <=#N M['?MKY@#^.[['Y>PZ&-3_>\8ZL0$47T!N1A@ A8BZ+%GN2+0!Y))HE^6NC4$ M4C_!]IOLG[-_XP_S[J(\(H\1IR_74& MD^4+8(P9CS!>'CL&8K:2I*G&D;!0YO M]#$AKO6JCPXMFK_XC"]P:OO9/)$WKX@"_ 88:G\LAY/@"O9]M:GWUN&)7O$^G%#,F8(VV!"1SJHV(06)A6C3;^8 MA2=8.M3O-1Q(/BYH]3 /["B[JM>D @T+9B=$\KY+\AA;>_RERY(^/1MIKII[ M68-/OP9.Q=@.T4[5LI%_? L]R0OJ^7EH8KM)Z=4K1I/6]A7$2X#EW*]K)J\R M"1RH'@KFF41R*$;:4HO0E_EEVIWDASE:H7[<%ND#\N+/Q6@^_=9PD^5,KY#5 M;.)+K>ZJ[8@(KKQ*3TN[I,?@AFF5K,J!)B_K^P3K.Z)8[FZL5<\AK7YSTT;5 MP&?CU\MQ?,*JF\<3:T,!1+7YR GGB*P6A;((4/*)L3/ !*= MVR%0$B\/QQ??2D(T L@Y#TQ-&L/"&N9PN,>4.ALW_MUVW HR>F 1$X[O?0MU M.&0< D 2^:+OV^Z^;;?%ZDUTZL *12], E"6#\B) M!(DQI0M FM <&S$O+2-HV"V?8VE=*?'&C-@,'W(P#UV+[PM5YU+T0]Y5SM3$ M$?7)]#3O<*KBC]@X94CPL\ZF,,E@"D2D@O9P/(3S5/1F-$@X0&TN%:IF$#0A M+97+DH;F&0M=Y60M6Y/C;,?.M5436L>VN6EI%RJ/X_7J/4#ZV#FX%VA[VZZS M=A4H^0U?[+4G["G]^47;UND4)GZ=2O/N,'"TXV M5NP'_&]X[9\;G9-Q"M'R%#"]T"Y!#J!(+"C."1#(J:);]F8N.7[4%4GTT.");%9Y$=EL6(]53<^45U(8RX 3QZXIJZZDU29&.32CWOH;CRS MQ[YR-%39+]V$IMV#3+!\4%S&Q'D:B'@6;V'8)6+XG7GT>'5%M"A-5AU^*5B; M3@'WVWA&6^3VHT?AI@0.OR5(0@-9*5]@]H<-_&<]! MF6NEX8)MN_)>Z-&FH.I>JA9!1=O^3(<''6:RL3ASA8W"Q%PYW'!H[\MNV]ND M3,KN[-V )W3>0RAQ@'"0D(1BNPE)1J&,H28*7?!BDLDX:]$ ,WCV;[ >4@,EW9B4BF MJ)F?^Z/^.MK(;3@$S$6Q;$P%2F[+VH KF+7>A3UN='^66\Z([6S?>S_ 9[UX M%.'DN;_WA[(P>L.__>M=@NC.O.B)I0R/>_7 P[ Q*IVUZI+W)6.]# M/'>W)5-T.0X,.&\PR\O"*")[2\./1Y?/;3"9O&^[#Q+_Q"-)XTL,@EDZXJER MD>@D3:;_O(*Z,D<70'8-]%*7P274X?/&CP!N23GK]'+/E"X%4L=$"YH$/X:40,@9. JXJ^+A7!Q"#1.Y=;[R M@N$\^^COXZ-N&D+DKA,4U0NNSOO\G<9=8-2%/F&S>7'-*E+'8GBC2U$4][:L M@>3$]1ZC?\"AWLROJ_"#MD"+5"].C6#>O [;LU_51W56_!HN+U V2PFQ!'Z; M^;2VQ4(%A_]>B$IJ@<8+RQ0CD=Y$!Q+-0-QW,3:7T3QF1Q$KLVL]25Z1GYD4) 6?JD( MM"8%%'[7<_>%(_HX);]JQOT:1FYWDX#M,N_T!$W[!^B2I+9%)!Z.O'1_HF.)SJGP@=S$71.38KUF,DL3KX*0^)PC@:NC(/TM^13T3R MM=4:\\0VETF06FB1,U\L/+R.W[>;D9++N[*J,>9C\S:K)XM/O(648W!&#<&! M0:@?PT!Q5<5L*)?%2?P673-Z%:1I9$[ M2CCHHS'>-FRJGG.I)D <6('8Y?8,%S0^T/KHZ">2$7)I OI5_1P5U X3Y$>, M<];1;D&3>:8I35E[*-G$-/AG[ FG*WLYK9_^M#Y0I;&.(Y3:EN+W43E/(;/E MVB$6#;T!*'NM(D)!2B;/*B)I>:C\0N@"HU@274.J-U(=OQU"&M\^Y,XN.^S3 M[[!RP>_3!J">M^0;1N\530?6XDFUW3%'YM7%/=%5 J-9XCZR/"><^B4.ICPW MZ&5G?/J=$=< $UHB(:3QC_G@P=?_D4#2C\K2/C'M=JI@'H &2&J85 ,>.VI M)%8AB:,3BV.VQN2A0=8STZ$!@O*R \[0QP3/?H\EOS8C/0E 'P#NJF8V8>$F M**"%:W+DQ!@7N,2-OI"R6U=#IZ)S1]-1OY>2%-18KVCN1@X-9(JH&78Y'<\; M1PMVQ1^#"E3]]J5(C#.0ZAXF8WJ"^=X!(M_M U*?P_7^.;0'D+O\>R!^W)@Q M#)T &V5WQ429 M\6^C/U]^GU%> O&^A PQOA'!2KN>GFVRTAWI=S$34E( M030+/[?Q:C \CP:&^@8(SF(SM@D=R6_0KT#_L0XWC#;G-B/BA@D5:0.DW CX M6X,3.N^'EP]>?7N"%)BQ6#4I[PCT2[6CH9N!"6I\,V^ 3S#+?E(9I] M>XV'LA\0@0!+FZRI70CF)O17M@FS*P]U)@-.-AJ!.6VN,>1J\O%=1@/6-B%& M)&777 &;0M<>RWI ,%Z[JX95?PL("*>4 .VF&[C0H3SN%;SKL^C\%Q=!-5)Q MQ-R<==.J7CI:H)#%M PP 2?T^$12+('JA1 T?D$I?,<9;D._Z:IU?&NA[@.A M"VA/Q2,.B/_5G[G)5@I^-,T:GK/GDF[T,[31T>O!$ JI9)R[TD79NA 7$$K.68%'VT!\P33I%&]L#\/KS"P-L'9 3A,0G31, M)?H1PFJY <4=6X-+2O/=4(%P M?CP+WO55/&;E0U)(178X6$93=IZ(3\W1I>(:](.\41P\5FCV%# J4RF)1!Z\">PG(,CW?$38\/N9V8\' 50NDA(VF9O/G YX.F6;0;U%#GNPU*&Q&U024.77AK^&?B[B5)GT%)K3 M\D39-$(MW/5.!G:=W (ZYDU["(K1*9D"U,%Y--LN)N*NOE'B.>B>!2QZEHX& MS2R2'CU8Y+(7+91F -SC-.#L+<''5SI$O32=V=&B( EC'RX>T5,LB'&^8FT]*:V;3()TLNH M+LG$PJF#:4HE6-Z&A/>H+=*W2YD25$F8N1"4LX%K)37O7RJIDV M:;-INZWI^H$;Y1S +2P5(*#6*4.K)-![O7H3G30\C,TC\_$6S@5O!/[RUW?] ML];YX>9!D]U>RP'V0J5C(/1JL/L83TE\,R8 "9MBAIEIQNC.FE>[20;.3YH-M6W\R/2, MIE:ZX/X+IK>#VML)K7%79:V/;'0S8G8JIS5"H(?/R0(FQ$BHTKD!>(F5XB*? M,R1.C'C\6A 9?K5A&P#A#,;^2#'7GXY#A"ID.Q.)X(K,499PSSGS8<)!R)G* MO"-+@D/S)@O+E"P-$W+.O4U@3[\CHN89,'KB!N%I9[U@W%%_?NP3<-8JP]F4?\Z*C-M53J%E*X/9"X4M"IE'.Z=*A?W_>R7:?I MY@MJOWX\]][LH/^Y/^:OZS*O?:.8CS#F8H ^WR ])]O)@>4\)2]") CS/AF- M]1Q#@@P905$;6./('@W.3.5.&#F$.Z F[@&8]])EMQ' 1-Z1FU,8B: #M9:4 ME1KE[?AQ@'V(/F#+KUJZ!PI$O=?2 M=T625 DELZP-^]6]7EO;8&$HB8Q\@" MEJRC@+K5ZT.#(@9W=UBZ@,]Q%7ALXC7)Z9.@,IT@^)R73Y^;:[A>";>OY&)_ MNWY_K?=-#IFOTJ4;)?[LP'4Y^GA/$-TBBTT4QP!,_-O92V-SRO=+[Q!'Q_.5 M6-M"$?'I-Z7_@GPS 4-CU.S#]XN<'>[3ADV:NY0D]LS)4A&C%*=%^:4RIW@8 MUW8AF+UR)U-H 525'2#L@"@D'Q1O)&Z)FWCWMQ6?80G2[")TYW-W/8^DN"$N"!)%D'QQ M09#\BM=VRFX(,^3L/D7)$+!)4]4'0\;08ME5GY69+T MTDC:)8@C#DO9.+0X-,8BE;V_ M MNU"& 9"F#VX>GOR&*82^S3,7!I7][?V[']\J P!SJ MT*GE([:7Z:&B]^/A9070$M'LR%(_XW<+H#^ 8(XTC M_H/B8AV&%(XV%3B'07\E&Z44;EI#5*A9DVD9FX4AMS\1,:5 P7I@<#W<+Z7. M%*EB"7#@;@9)V\72O&Q[\B-2QTE+0VC+>?.AH1UZA7[RK!GIPH[$#'33E3AR M9 <;PRU, FCY,5Z"SBE4)W$[C7&9H_W@$C;4%XC,[GKUGL"FL#?@-H =:T]4 MXTC.201YXM@2G:L2K-R6R9P3'+0%S0G3R4C,)PMY;/+(E N3P$!OH%!Z/U+9 M@>T^'EI)NQE6PV ABT VP+E*'UP?TQ.--"MCQTC8NKR'S!7POG]&BC[6$((K MO@*HYZ:,L?H=OO972,R"$.!M AD6DD"3CX2?6ZP%Z< ;_S$T);53^#)2!I*3 M5&[CT8U?I'+UP)(M69$P>^M)O8MP<3*>WVF'U^42:JM_1JD^9&",FVH'&TE9 MUAE-ORWW)0YY/YH(>/6V@:C_9RI-WC&9W&[Q+8N^L:]72>N4WPEE=%=#>T4[ M#SN>]H\8%?7'?@A[B:>R@,EV;+QI3.]*)Q& G^I7LM'*O2ML8 [3M"*Q1G,\ MJ6REM!7B_\?'=-DH(A,1'^]>@MT+%J=D)]G]*,Z9BC8K&\<;;H%/AVC69Z$K MRS5F_54N_&"' S"L\>'8>H#WZ.KM/3Y,&^WXD4,0Z4U+/W8/+H2B)3V66/_I MR7A11!R]87N/]P97ZK4#A!40R ).F8 IO MQVC)S7S2]3&8>='>)6D;0JF:&L8?FO:>\V4QZT8ZG6^%:9PJ$1)4G;;#K5O/ MU"/ BHHFE@6$'(IR&0 W-%6UL:3"0&F:RRQU<5$T 5U_TITH\%&N;N/C).5Y M!??K@@J*P(P^E&&<(IW7 0$C)_7"[*[B'4"N!N:U;A%%X>#7E!C)>070T4U# MB:I])GC2<.N%QKW:'H.JP==#:0/$"8TU.PC_&MQ;T.*-.RR3YR_EX%,-C">( M\8&X%0<&0+UJ?71D._AU,SZ9I2= MS!L*IK?/("?$_^=989_-I4^EZV9XF$\ M%%8$=;1;:*/7;7*S3V7B,5\87;D5S M,!_FA+8:UJ:MDPHQF:R@H-$(1B*".-]9_%F_, ; M+-1^^8O5G[ZT:V:MM^<$[_& ;QT+BYPN5O6?_Z-X_G5 MEP#9#\ LSQ(WKR@P:(/Z^1MH@FAMGW.%[]Y9)34O_Z$SN@=.-S/WE,:#"YP; MF4].TMG;C8_$?OS-S3-BBSEN%N$[>6B<6.?E@"UE'0+G'Z27T^YRAC1&#C&Y MGL1#%5BE6U$ I3(0514;JQ$$+0M0)8;++^;8T70!D5-3LCZB5;2="P^?OM!U M&.YA!^\AE*6_D3?Q\%]DN8F_@E/21_4D;'F3495U6KS,CL*ILJTUGM)7G!#2 M^.:MG%>\:USF"R/&(_$,7U[P#/^ VE3>PH&-?:)[NUA9C7_X@)T>.'"]-$3@ MLUC/H7.&YYV.ITI&2R6%YJE:H53C!J.*S]JYP0H#UR&/&6@W%UB<)<#(S3 ' M&2K&Z/-]JW'^]?MW3O;R.7;ZVT/Z>I"^#FT;OB$<.1*&CIY6%QTZ0>4D,D_H M/Z1DP4 ,KV\N,H?>L$D-AJ[(>^';$8"A\76\H_WRE@SB9]^^>_MYX5H.QILU MM8+]*4@:WFG;#;NVKMKKLXQL(8O ;;TA(54BI>AYENG(/!P!)P>J?C"Q36Q7 ML5+?(.'M,6;'O12)(3ZJL8>+%Z \?ZQQ/4K$"&UGJ8U[AZ2TC#&!\*&CA^30 ML!O#Q@2C^^!"OL2_Y=T2)(W+0?9)X&Y!>3I:0B#V'5L<:V9(:3LI[WIH"35I MG.W28.*G11RAU0MI)TL[NC5E7RDY9MK3^)>Q0WL%5>KKU;/]X)HX;-W5<,Y^30V8-KKO&XJ4TPZ^W!X&X1,_@AN/>\S6J>.# MZ'Y5HEOY]1FL'99CSZ 4,3;I06W*KFOOF[ \# MSPV"(!E]4M>-7X^O+%ZO7E$>E*:PZ#K2/)>S6OBQZ-,0< ![#.RI[VG3ABE6 MPAAI6MAD$!ZAR= 8"_<= MXGHHA)),<4F-U'+.WI&0$D[W'>@K?U?$C#;L5W\L5DC"_(>O_HK$PN_,Z%SC M'[[X"DR44U)%HH^DTYX68PB3(_J$S)R&/=&FX7:>@Q02G;$S==(N=H /%V#@ M%+=].@DJSG['??QP%HK-SSLZXB4ODETAD(Y$@68:B;E!-YB9S:1V!/]W'T3N M&[GT_8(;19M0$Q;)WU41@31_"8A!9.HJ[8[ =)"T\U04#U.+,H#Q[-?Z(:"5 MX?3G8//SH#G6<.;V=NNUX,'0C+5@ZP1FD'#F$7V0!R HZ,!M"#QX/7W6?S43 M ^-$>Y8&I9U]YZ5EN$J@J#PQEK1?IK^70$KZ[. 0 M#P&4%-1;)Z-TJ@\B "Z++ZSC/;-FV,!&!"KWI4>2L:<&-;QFGT;1>++4*F?E MZ64Z.'_W"[I]6+YLHR\8:R)N #SM5A@P%G^#,DK,%_6RU1!3LAU%."IBX:7; M^)'=NW:0++4YJ,# +69 ::5#^P$3/JIAK^MV\R$'A*5SX@F_X]B % /"SV48 MI=3&E\T^>I9P!XVG.;/D2:(=BT8IP1Q6O_U29R1%Z:&UNM4N/WR=/]%C'WR% M*?[F6JPWO/7R<'S;VY>F5FEL+7HH7;N&_@>H$ M$9$DH;.;KT4S7C!.K>;S3L80R3L%$C<(7?%F&"^$DV;FHJV3YY^CQM&AL"W%2?3/Z4BT%8 M*C.T3$Z%=/^4EC='H]*46N3#-Y)YPP;9 !;$W!/H![@ M8#.]'OXFI,94(U'Z"X6[NEB!?X[A?#F>5G!0%H"*%<*-F#3^T_D,@:CIGD^& M*[T;$\21*Y;G%0?>F:DKG*4:)<(I%-I%W!+Y:A:>)]T/_G1Z,:\PF%ZQ'WN% M%YINC:>KRJKYOB:5R@QS.%K7BB'&+^C9A)/J)BSA1.MN8'Z-[]XI,&.WZ^-K M U^Z!X@-?+M:T#;&M??QWOUM2YO#&)P1"(Y )OP5ZW]P(*@D+L3WFKX^FZ_S M75P<*TEZ"[HJ:$34XA@Z4>2 TI?V.SKG,SF]5&[]T3K)(6R57?RW+6FW;<,^ MOOFCJ\/[%?=P-V!,X<,%Z:X MZG2R/?^;!?$M14\!'EJR=PP)P9O(+-,Z<1F47+F?H_" ?7XZ#64$\IPNK]X[ MFY3;5A<)BHD8E(B=PUI@Z9V6%]"=>@L8K4 C/"'KH +B;+_=T\3/WD#^222" M%*5BG B'D6JEJL&],X7L+? M1S%3X083.@5%>M(=![5* K\TE/.3#(0IE#XOS(139LSF"/HR+QV#K]Q:6+LN MJ6GO +J\'#<5T9G*$K7):D:7(:1N-BI/X&3(CF0N)LGJ6) :0 6T ,(ZA8P9 M.$DAO%,R.58:X@"^8(.P&CB[3? X9C"-QF&T^6UR41OL=GO-> $\:U52_=2- M:XWT9)!GAP+NK<\'$[N1])$_0ID\)?P>^.2N4*M>>11=]ND08D8/TC:FGQ2C@>O43%TJSE1A(X]A>73&Y MM3ULO&0@#S!6F:\FQJV-U0@I# .2^#1\G@5T> M@A]Z; CCP*?9#;<*4P+A' MJBL%N?/)H;*?-,:F<]V6>2P*#L$L/"#"J\[U.7O_@UOYM3Q9$#X-30OH=A[6 M/5-IGA4+9;A63.GU)2$=FFH +#W+N9O.CW=R+I?W],D8?<7EN4FQANX-TTJH M'H-L'5Q7 EGRID76 =9_PEWDVZ8U--:KTYM3.NI0;3;7HCWCFC MB=@#;LV)R/\^V 5^\J]>F^)4W.PUQ\!^<)%.\3ET.]KY7H;MB:5F4PX"O(DO MLSQ4L(PTA^"^J>!/2;5DAH&&*KO$14MZ"5R)DLJFHY6N(6XC*4Z7;.9K21N* M?*(*[8^1)!Z_F;8@NWT;D#SQ ,((N8K)!A%,J.8:5I?YRB M(9K6TDZ=/^V^]&F>#S5=%D,QU$NY6I?-!SA1FZ/(D-%I<<5E(>[&V,CK^)I/ MBZ^6]A-5L\4M+M!WJ0MS+(_N*60C?_LL^D'UDG#"J:**+C9[H* MC,K8(4FPDF7F5GG5:F?67[BG">W-K>]H^FWC6M#2Z9,?UKHK Q&2X0J7D)]T M[=\(DA+[T5W5"TD1/$0\YLFFI.%/800I!@_5W M)P;0&3&$?QZZ0*3>5[*_R(%\=5G"3[Z$][>!O,EL%X1;W1KT4#ZH9]!6-SF% M!LYHT3ESE5:\6W6SR&E$_K(SE9T-0PE;@;0S M,$W4'$3E"3JNY>6-NY1FB>>S7+#1=24#CDY20Z<4V[Z4_0!R+B..3C0%N12A M@L/$]N23D[J6J ?Q+QU*E^23?"E=N'M5:MA[R<9W;?(N45XW8?:U\R_I_Y3I M#ZIG/99U3F(X7>(-V7D_0J7Y[/?EK]94F8SW&.)X@6,K);M*9/EPD]]W;7,C M,AO$56=D68DRAF?ES4=S='0QN9-'_ (,)@+A8<)[9K!%Q!SK%5] $?JA>B4] M"2Q)#'FV(XA8 =P(X;]@9J"Z%E\4/S# &8&0$!H@55)%SD;/ "B;3IYI-R;G MQ_10#?B:U_*5/URO_HSN'!"%+!E5S-3:$EH\/=V_"T M\LD?Q1*5('@K:T\Q$A9N;=\V]#"*A&6_@;5_5?I.<$B'>+< 7ZJ7>FK".IRT M?*47JDL^/R:MH_S^WB=@&0=_FQWX6:/.'FJ:*;C=<$GNGL7]CC8 _/KFEJ7!9G&-/_RW\OF.;4>I%=]@!8 M8]5,7#IA*!NWP[ &DAI."-DUYVV>JL?WTX*Y!EW+>:,$&/4%5,[^S;1+G#L>#!ZE\E=?"T<8>$' \$&X63 M;I#[%M.'\$2J69U_,>0C@Y+73,J?JRA2&K?O.&HB?Z<$0_=[/OQ M /I,J]"]E:G $X;=5OD#"9("O /\>6, T2H"PF%[*X0 M7=0H T<_DIJ4OSOA4-DF[)%[P^X;_B3'O@DI<0'0]+8_!Q\ @NC< M"!7J7="4ZIDRAGT3A,J*!41(G9D!++@%7K<-PD0)3[,+6Z@D>C&1031=&'$# M B#.4. %2:O,^/RD9$>2%_"J4Y)65'BAT@)^CG;'PH(!8ZF+1C.F7<5$34G> MK'I!H-4YZ:;K:9AU9@;K-]!H]H;:*@@\<08P8*50?-GF^\^L_:IH(.9PL^C" M'?Z Z#XBZ3Z:OE3\[FVUKGA 294(C2=:Y'WL1=+T$H&NF<(>@6AEP[W..4++ M"2M%4&T=' B=J BY\0M<3+>0;L"5U2:B%>9)NL " <_@J>>^(X'EM>8 MV3/4%\F&Z6AZ$45K9G2;62S [CENKI[&/;/'QY@3K]8'XB*G!DS;#XVMP8E.I:4C$#^3TS5!9$@45 MJ3!1)6.JXI/$A_)W5\=P'^53C6U#0D"ZI?3Q1EH(]Q7 9#..B'KASI-3)#(,?#=9PPMDNS*1.Z!==XU-!F( 3!^ MG"C3G48D]5 8A!C_D^)OIKAW#YEKG,H%81,!6E$V-M]!U]ZU'W)N1.-#Y-*7 M,75@3UDFKL '<)T+1V6CZQ@K%U;Q>&W0.-%Q=XFX+9#300YP7X+$GO#D%)XR M(R'(V(<2 LG=6%^O$@THOR"+NB432FCV:]" HBYT0N[@C83=!90RXK_$)S'D MB^MYBVLPDH*7;4E?*5*]QG5ICLZ!*U?"6/=8$U#@ T8K?EBF3+(YE42%LU_7 MA-4FQ4<_8)5)1"7R,8Z-2B5)XHO;AGVU*:9F%P):&!$'OQN-\P&OORLWD$^0 MQD/V%'0'!Y@18 UNJ!I5:\6OEQ,I%'*D8%27U%VR]T>SX,ZNN]G)G(;4%)]5 MZ!DVF?MGUU@5Q+R_E<(/0]HJ,.!EC[Y?3F1N\E7<:@M4S55_FZ:]"1%&8F\= M_L.!]0T&4N'LW\9O *-TFO)S9+FWEU_3W\\&G4[,#18POU6W(W6A,V0ES"5G.1,, 4#1P+&PLW;6_S M"I:#H&+XA;/?B"?]TFLV=O2&T7+T*WY"7\'R9I-5A\5\3O1C;?3-+O3UJQ^^ M>85?_>;5#^]>J8E(]S-NI.^_>_7=-W+18+*OO.9=V-4$;_.KHNPJ/MY,]HY8 MY#T;T%0 /6#.F-CPZPU&JN(2TB>]=#>,ZM#>BMQ+U_&D9X :ZMCAWZD M$:<.6U)]9T*%0C4:P%90=:!I^3\N8/A/OU*F_[YOM]7NN'1TIW,/1)OA1VD' M+:6BFI@QGS-B#::%+VOZZ=>4R"BGS6_'IU6YK'WLD!V*+QXDI9JPX>LO5 MD[@HH;J#Q8)&GH8K*K*#G':675'-<]=U?6#\N%@XPF[2^%BA9_[ M8 ,J/ZS+[J$3OD6M(1&:$"H64>UPX=3RXOWS01K_[65 &B^GZS %J43058Z^:@1E2:2;@M*XK_ZKN[M,1S_) MREN;9B;YMPY!0B D[./E@1K7GEX7"@GEWCOGA MJ$-'YU(Z=)C,6'M8*L34C=Q51NC8XO0R431[ 3L8#0-;G3$?4J\>22&$C)YN MT!#N_C:YQY1,U9U7[^;+WU MF]N1YQ6O_S[7*EYT2Z-*3E,42LA]FEUE!S3&:D"JO/UY[ ?'JAS76K55,XA# MS]$4%J/H'VQ<&(HE)TH;E^7^K9;[@#QRPA0136P&OZ5#:&+[-@6 %L5[@\4"Q/M=D,&A>:NZEH!*BW\\LN.WOX\ M=I"P% M$S#/$,-C1=NUP!.GE$42#%_\ MZ3__L/HL^>?/48^]9$!>,7MAQ3@: %R,@NLZ3,%3X21X*FDSIA)TM*.BM6GZ M74"RK_CAK@MW+4E<(O3X'N9>',YQ[(._'0%^)%BXP]A!6#DS&Y0_\S0O8=5 MBDC)_KD;1GPEQL=N!AS )HW]MT?%,A*)7I*[;20\-LCF$?#<,"H@6A<47__7 MZK/J@UQQPXF_"^64T*/'GOHJ7B=?QE3$ZI8F^"5#*!.#I)O=P M&V)^=HOB-.4NQ#ML0MCV7\$_Q*L]_G+3MA9=?U3-6!FN&XAMJ1U_.\/&-P+48TT-W1,73N(IS9V!X$3%#70D- 48#A\9H-9JR M?B07,?%PVK#A*@+JIPR7@FAB@C56\7/&'8 MM,YH'\41[I(7S>,-4['WLE-5 5G7BS8_=^V.=+AR3V"WDN!6N52*+!P.S"7* M,',C6F!!!F%39/*XFFE'ZQUMHWXU?:#9GNTD+AC,4VBK% "$^IMUE[O\$I]* M7!10Q!^F>\M.Y\.,)K_C3-$'3AJ^U5VN? 5*F M(FJ'9+[]@.2G'])-VK';%M;(F?IHSH5"3B0^?'I\H>UVD0)F@^S?K?:WV)EA MF.=)7BOH.Y#O6;F[N@!29CK%8&![[ZK@!T@X]/5 5U3QRJN_[ZUZ<: M"%*J-7E,%)1W4K?@4]J72D2*0_^>GXQ8&+Z/NJZA4>F43G5>TJSH0-'?">T7 M,2A0S$IT="$L%ILYDL*,22!7#468O#A-M-3$Z*,P\FU9GEMK8&$V\C ?/'Q? MTG?[XZ/];VH_/X OZ9_/(S:PUL6/?1J4-XE=UM+ M!OP/Z'_MSYZ9LR/M:N/.PDY4;FK4,$)_AR[Q_=D_3DLLV(+B+O/16PU%SG/) M;+J:1S31MDFJO*_GIUR2_)(+8M"0PS*!)3?X+79S=;P[^KL.G"Z(1UGJS39S M\6+GV@7-*::3&#K;H//TALJ^J'E=(MZNIDQ/Z<1(*1E59P1KB6#[%E9Q]?G$ M9PB^ G +9\Q2G 2_:3S^]7![_6.P>[.!,%L0:$:_'WTF&[2' X/><382#H H MF+O!LC4]VMFAH8P>"OS-$EL7X>=$7CH(9HR5+(/A&3]8.'21LB/O P4LE?EV M8-UY3L$7GW6S*:*@:QR6X;3E](HW/ 9)232O/U7O>O?64+18CA0=+$%*AAK* MR@-)U*6DG'E^MM=Q__UPL$_N<+#_GI [VC1F&$.-#8CS: N'7> X"R?-YFZ5 M7[_."8ML+\[+C-.1Q?,MT+]TFWYAK?W3W,T#PB+ZOR=TT)1G#9=#-DQ)L6-( MBJ]S;E/GY\SS@-/9PU5T/<\Q?6&_\JP(FBIM-DMCQ_C)0BCDNYY9I^B'N[UX TVPB\2? M9J*UO-NT/>;#\HZ_]3F\<-]-8K^C(*5OD=3E=Q,>))[!1FG-?)4/X0(.6 #5 M)VTT?9]AF6.^DKO5< .K81-132Q/R[QU[TL0:@7]E[MYN &["FZQRS>FWV2V MC9+8OI[81$95Y/$F7/^A2([>Z*1JCCE^O)OB&^A[+8KWCK@RYL=D[Y6KX[[M MI E]NT-[-U&??Z*.^[+BR)&9Y%#ZR?RTF?R#$?F-]VF:XE2*K;LNRYLZT>92 MZ@?<9,\0A\(*ON&FSNINCS3Q$8@.E>% %4]_(+P<,I.J2^\%-X MU[;Z!7)H=#$M/G'-IV)A!6X8,B9L< (;KV8$=7)GZ=GN\]9^ E$E!4$MO;<2 M)^=US92-&O$(VPQP&9RI7U9\))"1&6",%;00T#*,!D43%O-/6WM^,=]$?AI' M0YE7%YTI8G(>!8V>GFIUGAOG//UQ_EY!>*"E'I,HF P*@]#($)R?H.(KWM72HWK+40]O+L'@7#'K B'1];*W:?;TG_@N MU_'Y=ZCG+R0Q!GI& 4I.DC4>%Q=-X(Y$6(Z%Q># C &I:+3FB\J_9 +:LHM( MJ>DG5IIL%5 !;.81BLD MK;_# I?JM_];>(0@=GU\@2;VC4@96'V:M9CH*:*XCQ"RCM[)AU*,'2)OCYM) M3/MFXG6DJ!^+]P9DG&@Y0A^X40X/I18'&KQ6X/"L 8P7$#5L04D.8&0V+4#B M,BZ9.=')C!4MC1L.85V!":V_IS2.':Y8A>P&&P:9YL66OVIH")&IX/X6!;?( M'(?VV^ZSBW)NM>_3FYT1>+.7\OH[>$;_X;\%4E!UA8AV8!C+;G8HI] [G>^: M:W_=>>-[S1/X9VW?D,;* #-.[* _']G#/.EF+HPI:;XX4X0] %C MJE+U 2$L9L4PA-*]962[54F772@G1NQ9T0OO_"!?A1BFEPH-$-\<9(I7 QQM M(6F*#P CD:GXHEB_@V_VOS&PWVX20S#F^:,68^;.=;S>)/%A6<9 M"#YZEE5D\PZRN@+OXC4=H#=M(0F(""$$(I:5%CWO_F QIZB@/RAK^+KAN=9YN9#VM$RO%'2 (?8IPEC/)@QYG,/76Q!VY9' M[^"I%P=) ?F1^Z3N<2.Z:?RR]9@$Y<^T<$B6H%%M77%QI$X19T2BZ+[;I+A* M9C&)3/V"#3"4(EV+\1Y9O(U")>.&5Q:.;.; 0ZKP4A:6IY^W?2DWV+3LPZ,L MNBQ]P4Q"$*<-'(",'*:( )3'6$;QIQQ0:RA T146^07'NZ&A,@DKXIYR[T6_+>25K@\W33$ML!I M)ZD=OX&V77G*S+D"OC"77+WBIT)T5EVM"_,]Y+3VI9)L=E*BJUX:V/VV7)4= M2+.RT&02SJL&-="^5F2)_3TU+<;W:V(G9SC<5PT"=@:^\RH(7]$FUM.+#O"R M2\;#1_Z:R4@_^E/3GC?- @_Q.F\KBMY9!)5&9+7N=21>DR.3ST_IQXW3P.4& M8(R,7BU=LWMP%W?!@]V@B!% J(1G5S0PS6*E*]'C_6- MWXU3F9QA='B-D0GV(%&R<\6OF %6M*/I&>(,-B$E4?K3&$LC5Z&K7S6;PJO7 M392ACPL6%97F&NGGGVBEBI72O-^<-JU!?&#':;)4O)--F7Y@,S!VK$H=[B"6 M7J\-EUL[N:9NS8JJ>5NR^Y#(GGI//+(1DL]?M/Q9=ZF!^ME)#NU-HU'!"<#! M63Z7'X+H>Z8GMS5/LD2K0X,+BCM+#TRO?F88#J6L&",XMLY*,G96KS-USS!N MUOE%SF.Y$%'O'$P&?%$-7+P+472L4E]VIR+5&Q^S/Z8E6N:MQ1HPX+KJR$-L MVUP%<1/(91 C!2.0P]9>]:(A"<5,"S)[Q0?R6KOW Z%,)1 +$9J'B=#(._ M1XG9+GG\[4)ZC#?D19D[66\)G\+6W2J$R+427S2;S!#);/!CZ%1$NIK@R^T6 M\>57BB6(VKJQ=S2UIQ-[-L5= 2=^P>POJLZ>KNZ$]2(ZZN[.9)^9>D(Z$-F, M"@-GIR91>?L@Q0@6%1Z4S#XLKC;&B>-&VK_KM3V98ZR@3=JSBWM,&Q:8]KNV MA,^_NI"=HT.HH?73*;.ZCQ/"P78)RC*1]I:%=X<&NZ&YXQ;@,%FBM%7%[@.O MG1WS8,>%Y1DXN7TQ ^V1$_N]F[O//W><3R]:I#@9/8*6/=%7TFP7]F2RLZ)X MM9SC,*%SYK% @*]E*ME_ZRJ?%W?S>%-M70H+";(A,E474::R5=\O_&;=L,=G MI -<6.GARE7*7D'^5V16U6K:W7S> BZ#C68!3DN)S9!D9"+CL&%,&2&>"2+ MG""Q*ECHUPO3T9[:RG=3>@.JOZ=ATAA!AF ;;)%*%(+H3QGS,C_"B9WUR&JL?%:OPG,5-W[;D (O3_"[0E M/CAX\J#09><%U8[V/((=">66*W2I-+= M2KD)OH5 H/SJ+4^);>!I7ZTV:#J%W(4*IG@V6:;&/>/J$WSP/6%O#IK(=Q-Z M UN_I0G=J\"IP!HA0J]55V/9D W4R: M/NNZ906]XJ10C#5T9$O[T)#AM-%N2^?N;G*:@.7= KVALTG.!]2N7+7"[ UY M)[. #QBHK%0!U(>/<;V<5B>;HKM^L)OJ8/:8)9T+MY7"J2&,A= "$+J0]O87 M(+70-Z2DC@SE2M>?<0_41HV:#@BSM.T=<^\#RF".SC_UK6$D7^J7GC5MVZ\W MY%I;0H5E+.Z]?/;V\+Z*-OQU]H->=*@%:EZ-+&OVZO(OD MUM6O&W HE=XMD$:$N3RJLKCG@5!7$#BTP5?[=%P8LP$#,,)MUUP9XM/%=10% M=G=3()RM68(@GP.;A5KDHBCGC:=&LNLPN/J0:SX3R*)X-X MLHMF'EMJ,&CV?0\M:HM U%_$Z6U RT]WHN&UQA[K9*47B \B//^U'L\2N*5E M3'=_L/9'&2AENN6A4T*/_7:N[O'0R MOTH5G /(&&0]&&MG0A3B2 AG:1=*CET12;JU\#Y1=5?P74>3&P-9'4!60,%V ML.(0?W[I)9=HZ/*N$QP:9_)#%4G[KRY,[J1+>A=#ZY57O$0#N)"^<33K6Y^D M=REPE'+'W7GA :*R@D'(N_5-SWFWT?T#!A3)TI3O(\*R)I7]9%K4#=>?41H% M1QIW6?4*Z(IPR4%1'"X5#8-7(TV&80*7<-E+.<2?"-RBX-TVY_30L2 FM6"' M!_;E7T#5;OW!0./% )"3/E?=^HW((V36M!=,2 ;[ 22F-#GZ:,E"9-@A83# MJCDN9A-D^F0C+SMS_ :.8 L[A!2)JE9[?_::OL7F(]/&2J#=D+3U+8BR^J8? M>.M"B?I)+N)T+Q/H%U7;4K1&NG5HON*%#D!(3VLR2'5"Z[+E/LAX#M%O+\S2 M9XGZ P\YL 9.\D&TMS$2IL@=P@\M-_OP8U$\%"S>72 !R\1H.2$NP0ID6N72P20Y-(@P#($02Y+M9L*:LHJF$]O9S?9]P) MM_0Z3S'%/PI$QV\%RJ-;1=&>$.MOF1L,WO[F";OQM5A!/J M[=5[8)4V+6 *C?>_'N[7UM2AEM"L?;D/1R_1[K?_=. M6$@18!"-!EW17#1$-D(#AC1K#%J82Y(KS,V@!&%X(H0O,J#[<\(8T ,VW)XA MWEP%'[]D>RP3M)2=GN@X38?-;NGSMRH-CP-_>HTYPVOI,]-S4UP?I.$&+85# M37J'[&#G9)YW2#:"!"@JJRCL2OLT#8U%A]C1#J9'_O#?2<,/:'%8T*R9]SJ^ M/$YG97$>!)44"QEZ8 7OICG)(;,%1S]#?X]_SXY%+-AYFV=LQ;AT27Y' M__.9\UODG^SD! (M2JO5][8,)P:]-DGGC []I)#J;737Q_;*#HVT,VM=; *>ZY0^*[KS1^T$"F_+9H/& M4B^E%-M_.0BD;]:P'XAV0@>D9B[+#H]I#08V6F+I-6G+S>;E('V5S\F/9#A5 M6=.!LNDUC[P$7Q(MBG+1<]HOR:6!T)?UD>DT?1F=THF1"Z\P,ASQD+.>2HV* M1PWUXMUJ;T-R@FWI!1E03EAAP86%3BE998GEN/FW@7=@86+'G%^C M59V9R/&JR+'FS@M-*U]@5DTN4I,4N A>0*)XVCNGY9IV KJS&-LO>]>ZBA.9 M:IGO@"ZGX3Y#62:E&]&X#'0H(G?D/0SK@\E\%C1SS'O3',X-ZDTTF-+UO6B0 MRT'(HN/!0R@/:"-"!D)IVIO:-Y^YMN[K45 M'TT2RD&'(:.QS&+U@0EG1,A<&O8YH\1A%EC:FNB\B.F+^E!L)C;@D^#%8>\_ MT;>KNU-F*E9LE%I/&JSCT5/49V7;!.5;0.N2T\CL]+CV]2Q?';?E@J6'DT;N MVVT$AE)@!JAW+DZ6YJ>=O^.7BC,*<1MS%2!\EM..1;76E;,23>E$IF?0(Y:> MN6JUAZ6-Z7UCB6SM\0?543PDM;$LF);C"UU_^ILV-M%C$?/URXUGJ W2L^[@ M5H(\J8C0+\K6M+J#S])WJ9E!%/&=T=GUM M7]/I%[EBK=HD^;C(SB%8=NE^U!H7%P(%7TF.G;:9\7$B4V,>38^8&]6A(68CX^70::(,U$:MZ?!CW7E76V /LTLX> M1<%N&X[#^L*[UJAQM\JE9+,EN\)1";MTH5+'ZC*_)"/H0F-SMF,0HG&TYP]9 M]VW7&_VK52DY8[[[>^D3,A,N(;5BU+5E:K5<;XPU-#VKL@N0"HBL+]-F.%DV M4E\[%\P%GSEU)PX18 ^((0.^(HM=[X!B:$Q('5ZG^9*"?49^=KW M/YSO-L(@> ]!:2/:[VOC06#%6+5T- ^ "",8CYTHM'R MHH$KX'@6;4N?[E;98)%N3EE\AY=HWFJRO@*M<\^^:^3)XOI$BPVGIC%-S83K M\:/2(_..1-4_;!7'-AL^XNHOV$PI0Y:-I6C!+G76)V9&,L'CD?^8@6_:0".% M*\2'B^-)_X7WN*9M:]>E+[VG^8GELTB9HO+'(%]T(@(![:13L)=O-K3[0E[/ M/[B+QB[9"L>@IVJ0)"VX-:TH0MBA/*]%7@L-GK@0 M<#9:+%"O!RTC4]1&F!9LD68)R02V]MDDYDJ1@UE84,V0DPY<9IPLP2#Z-0HJ M'YNT,)^S_"3G3"Q'L^'LO2G#>8=;";B5IW>XE4\8-CL SHM6DVB6[L]#;H)S M_'(,:^C*J_22'93)K_BP-;?.DQ]9$U$>?$!7OS1W9M+_4RCE-A<0]]5T7SY, MX*IS26:>P@URQ5?FYEF1>_9.HC^@;U MV'VN"/C9GPMZBU,R?;; W]*N];[CH4"D[5?<,$6SGO(3571 M(0W/Y8#U>B?N.&6.0M\HGP+>TZ:N9UPO;EIRC&?/..Y>T>7?ZC4.&1W"IR$K M",7F)/<5^^0[M%%+"Q@^PFU@,?(2-#EG7MG"\7^5Y'&1QE0<1@9@ =*$.$69 MVW$^9W6PK41]QL+G&[66S;PW$FUTR1AR%5L]N/YQ/.C]DCA,//7EDN9$ $G\ MO1#Y_-PHM%Q#+BW3>G^AG8JZD]VG!NL2%R=+?)QL[.0,PW($A=*\&M<^!9,A M/I9>** C3-AIN/65&31X)%NVO)\\!_%3#$2DT9!N0\ZV2XX[V6IAMM7OT?63#J38*>VAT0N"%[N.[E)0[Z+17C'E M+/UE66Z0=V\IXCAM)$2_]=2P[+AAIJ D9JDQ.<= M0\Q+KQG 9+Z.WY^#III)&(O7_?6E<:7]U'S:L[*13%+^C(O3;9' M&3%QM:9WHJ'R_-19$Z8L)MN.QB'M%X:J&Z+92D[NK2=V6*++Z35J( M7#,\I\0#Q*Y7-6#B3VH@58@ +',33PV).8L.V^09C+'^P1?3Q+*4Q(>T2W_K MR^XTH(:41$9G9432G/I;\;,Y-*'TY-&*9,N<1KVPA8@T0^Z>GEX>>,7,<: $ M5%+;7.3,83IX5H0 Y43U!,%EKHCWF7=!U,C>7.GP^?!!ZQ?LHN"-4 M)4O^'@?4@ P[),-P/O&[V/H=';5!==RUF2=-7HK^&9BC"-C1B1.F@+QL;X%' M=7F@+=C$*L$[F28'^RA@C96QSQR_=#KJT: E6KI@*_'Z<>Q@HP1CA/>AP]22 MEIE%/&ON#BCJ,I%.[WY^]0D"R!)6@^YX_**+,D8?Y1.S\E#L; MC$\X.^PT+/6&,XG6$"XZOH$V0+D'\D^732><"HX->?1%E$".% EZL 0HFI2G(4L@^IY\+_<*B MZ$"DX\L[Q?[L=?RA[518,#0H@(! 1]<-:CYQPPLQV>%3;#!HT9$GY5YTCVZ] MR#45>]94G"QLPST@RVU1PS9^#%DP#4MP#_=-FJ !$J7+W'O350H0L]BHA!60 M#!N,.3-("/0$MVH-%.@FI63RU8<'7FL<-ZFB6-M" M1DN:N@0G:,LD)"@V-%OO<.N)LINL"['%"U$CBQU9QOXW$B=3A/FX%?EZS \T MQ[9,ZIK>0]/6<_5LV]7 ]N%2TZ!&-"M;=!D^'RRL)<*D T2RN4[@O6'= 4?% M,G+JUDR&F-1![^3'/M&N?_O@#@_PN_@2;]5DQA(BESWZDL^;B'SQ[>L2$TJ> MV9]!=@6S8M(?<562^/9G%]&\]H%YR!8^?Q$'%)CL06X_:>!0ZH"IIHW8S3BT MMEOHO,:]D?NS\1QK'4\+=%*9X>K[GON#J_7QH;R2C*+PSDIV^1CYE8U?*&P1 MZ3,""!8'9)Y+#IIS;6T\]CIAI\C@W\S;\A@_&'N9?>J2S+/N%Y<\C_&LO"!-S,Y2S+SYP7_,. M0F)K(7-YN9@970Q*[((086QEF/<,AY)6F2V=2,\!'%OL<1G$4\M"8E\:3DX6 MV 0)Y@WS.BH9;=G*MWY[*N4)YS67^;R8V)^ZT%-.0$BND=^M6R^W91T($X)K MDKD5L2AR(6[C)1-R^:\[!$9H+B? MY$GZ7H_SO*T%D\.J5_S%4U%X4<=>G^>2&!$92,4%&%?=O#EMG'XA)SYHD;VO MF_.J6)R@/*J@&_*]Z! MD(55=LD4!9H'$,J2'Y8I]X3:5,;"S2C7JSM:&VS M!(@@Y?RYU>$=67:.0.[(#RIZ[K3/5+8.\C3JV8T62@#7B%5ATR'[- H10X5P MRP(;=MS3/N&0,D%?A&;!1#-1DGXB4LDC BN06>)9,[&2)%,3GY;H+*FS+(!@*U5];04>1&DKCLV@"DU'Z^Q19N? M2RMS:.Q'7(6T5^'(PSE081^\*F+S):V%4IX>82M7@YI^0R85E8#!1,4RSZ(P MB14Z )5\<3#^NOE'*19EZXV%N$"'QTP3>21HET(>^_$WG.>*#P#+O$KG.4N"TG9]4W,DG8OV=)6W M9(]^[1%'9ZVX]L]F,A5!RY$<0Q3G BLVAE8S&>,D56<-VJ&: MRT;JI%6ZW;B$)(]NT4]\U\U0G%Q%X M9BI1J@N-RZ)Y!,[=+CV5#][D8Z[HOI.FB;B^GA"LJZ0HML9!;(<-))MA1@A!]^.Z+T"DHW M(P D:8H3:IA17DNKZ!MN;-$B#BJ5SF'6CTR"^:3SJRM0WV4'P1$#:C342A4C MS)W=V5/B=O-F72B>GNY3?)CK\8/5W4Q-PU5C.,QA;4&Z6"#[A@J8J,07POF^(B/!"CA=@@,I7VJ MDURI;\8/_,P3#Q5:$9S7(I0H<1-FOM\C+KB8(W6-OV,]Y_W9W\KWQ3GZ#KD\ M,GZ&[E0OQ*[9T-:*;=>_F>P@;L5T^1!1X.,ZX-N/"RMG"&VBRMTEB5>V;[2- MW9*V9E2S'?$I0Q)C:&>+2,,XE31:Y@*86MXS1S_-[A]5PB >/= MK5D_035?V,^3](>=BM'MBEFCCZ"%GDS]._"1MXD[;V"NF:)]J;ATBOK+KHK! MA07@K.TVIHD7T35_YD-+@.FR-I!)9CA$KGI@FO)(#T9.$<"9Q8X8*X8%2G;] M&+J4&YY!-D[GB+Z9\&;GY^-C##YR1P%'+2)JXR$;"4Z;R]#F:QXR":H66T>4 M-QD&+3+',K0W94V,5>DOV8*4Y%5I,-[,-PUC^Q\^>/A Y5^>'TIYK#L%*G6) M=NRVKTP^0?,XM%8"SL4O2U?:U!RQU,[PBS^)2;,6/<3Y6.IRHAO^% M?&P.8NE1'\5'#2F*EXS,6>0A,.8SA#EP.,X0)35[+*SR/=QAH?&>FM7X<-:@ M)F%?Q3N[JFQ]7WSRXJV_^+H?G MGV,-*FRA,UZKW';CRO;IFD4+G-3X@\9B8(F;:!@VKO[Z(^GZY81VS\.N4E#: MYJ?J.V&3H'MC0&U_K&Z]Z0VRIPG\A )JUPPIAHT92%6>#9D$OR2J,P MQTVM+(+0;,D]84V'&B"66$B#ZI)TUTE#CTB2Y+HE^&!$]QE.'*7@,("-&/UA M-+>LH*DH:?&\K@'M=NP3L<*,NJT49[4=;$T7/N5,YZ"NZO1^]40[?'8HNT76 MO[+V.E5.KK#QCO*ORR)QI239R:DE\WV:XM2DYBWTVAB;(N6FC(KH;7$L/NRY M%'-6"= L]JR^QJ%-]WS.0-UW^!;7RWFP.7=2#PG8]&84MVJF74]Y>2]Y)QK/MW2U MV?/0QP>L>>>RAG6/EEQ>O$'!KB#['Z(WN[M=^4A+:=\\>O"#7>3MGX\.I\3_ M7M%",^%8HY/6GESRNQY:-9-9E.0 'K:#%JB[QK>D0)C@=@)Q!(Y MK/=LZ<1;&RFHT*_/R/<3(![GCSNFO*&PFE^RVI1LVAW_P\B<@^H\GBF1[KM6 MX:.*ES&Z;BC:AO/&-+R!QO<'O1B\RX??_Q@=U:BON_=,$>O2L0;GRMU3#87S M"/>5$OA66W(?:#&*#VM0C)=$5[D'5A(74FS+3U82=>TPX.//4N*DV+A>;B=P&"@H(OTM-VSJ)K;&,;G"K,O/Z ]=Z(5<%;SSR\[ZQ VD MJ3GD)@C.ROEOM>S)?,T@T; E2R6>J>0#X2O_VK=EMU!Q^NVJDOORW^BA11>X M';#_:H*&1R!UI[AP H'&M45)5? ,Q2UG;TS\Z)*-I-)-RCLI5X?,B/>_>B%Z M 54%;\Y81IN^DW82'A>X$[W+_LR=^\EQ!J*G\,JBUZRQIS$X1B=7GT.P' OQ MH9OVA.;WGWE(#8_&CZU!.61JNN0:%C%8N!$-DS5;FT XRJ8K^/$VM1PR#;K MWB>MF8%;J@1PV2-62$@,RGF8FW)US*%Y6(T#W$V$2]YN _'*>' D6H6;(FT& MTN>K+:12PM8P(LEOHBC5)9&49.!EO\D!!#A:?Z PPK,_I '8X<1+\LKV@V\$T0-)VQ(%G&, MP;M/WNO"/2VBGHQKNPS1Q$1O3ME&QW$7JMN9:6\;KYX!XKJP4X(M$-@A,#>6 M#I_DQWWG!)F7Y+,45KSEWPY0YR)B#JX- M;%O^G4%&N,K!0$X!$'% +[Q>H5J,0,^#"P-1V;\T3S=EMO\\T=R0*2,BJQIM MRRE>C4%BEJT+=#.6*S0H,GF$?JT%;77!&]).U.1,WNZ'[<\./:V%]A..'@\P MO+[;-#@N:)ZUMV5XV9&C=4Q&AKLDE#<+*:3!NHK&9AA-N&.I=-W=0J1=<]1J M(CX6)R>E_X2P(S2UE"+^%)U?\]$00!E%&G><6+^%,*P8Z&[TSG$H7[G.R#:S M9 )+_X%\.&B>)NT[/FT4V*Y-%2;5@*/I86(:?BF7T\^" =9NH:!T)KU X?[* M8^:)*4K4$^YU][/(3Z/3/ OB2VF:6:8J9B;<(&?>\"AI-1].9SJ?DI.SABB! MG6$U9+/WY?S]L3)&%]5R;T&CDG)%\V*1AP&D)YX!4TO%_%CI(Y!NBE-R6C:? M;Q"[WV4(+5U87>QS7K0\$\BC&].->VF.'M0Q=E3LI*3KM;*H^K&16!MAH-_RHP MJR_]L;!FP,'"\MMN+^_/7G!1!SR2DUM&_ WM.(H7O(,-!-C PSO8P"<,V\ Z M)&>QRU7P8691U8 SET(]%QHZD94,Y$7TL'L6EZ XNR3A<\MJ($W+U32[& MTLP1@!XSNZ^6 P9VG,RA+?6L;"I!!%X,K(&"?2SX\[Z7:Y(-!L(G+FFH+2J- MM5?0#CO9#4$+)44'QT2L[,&9\!3C3#YI6MGG&4ZWLA.3DZ5LI>R190[KBB&) M95-%YHW#'29^+!:#EF1M?O-M#49K;#ER,H)D+ZN5 N=#3!X[LCU#O??A8N)A M6M =_@%:LJ#\MQ0].6";!P!?4ZQS7.E>J*/6Q RX*U)Q# 6333=@_9H#@Z%%3'1#'9V7/:>[P5,%J#T MH,0H$4VRVH?%7HRL]5C?[NR*!L^>:)+F"'4KN8%;\CR,5Y#GR77S.?$E8]+V'#QX< M_.F[;_[TXIDG?K^_D_&4SC8*9^,5R395N/YXU88Z ]<"#7$]\2TV'UKI0C"M M20"1UG;BZBHZ"7"9T)GQ5N&U0.=[30N1A2]I+Q7SOB[1:+0VLQNA.%)":T6_P9@_M:K].YV+7C/?-0"T+T%-Q5U/FC M,NPF3K6L2W8.-IQV84\HP '%@MQN._[6&L57^:(86.LR+%F'+-<.%SLQ)8]$,T[>3&P8AJ]KI[8:SG"I MX!:8Z'0VXS7"FZLP:GXMY"T+))@ XXDE6!7]+&9;9!S5HW#2=L/1L 2:0Q\: MO!.;.IPWP=J+XQ30;?-F403RZO"0^EOH'@ACR'B%CA_E960B\?'\9OR$P\,@ M"0283"0SW Z+))5(5!3C^;'KV^-?*@HIWA%4'<@2<0H1=?>I M7&H\#K1!!,HDDJ96$0[> *D,C5%&+$?S.IR_,/XA2 R3(QZUL)5^3>W";]T8 M0D@HRB.U*79+2!\GRT/9[$7?6IYO%:/V%$DC)[+OWVS!7LFK8$IX"+R]@Z6" M1YR<]\GU4M9A<:7/(F!<.= ;34+C232UWK!;G]D'FR[T'L1<-4,C^!V4+F'<.Z#&T!Y ?CM02DY/!/F*K[0F*?I$ M8@B5UM%-)RF,#/^N7\UTQXY&& /KM&FVCJU?#[=ZH_T\)4!E*V*#<(.##9=_ M@;J?B:TG="5*H&2+$H,+=KQCB>/@RRT%.;]]E=+#"1\5!8G,E2(UKZQV/ZK,KKDYZ-N.?GXR>SVC+-1<.T8]Y=P8U-^^!Y M";^=QN;%B\.!4P>002EZOF#=VMBL+^Q;U46TDO+QE7C=23[.OP__(;*^P6(4 M'VR?Q&%-QC1X-R\$+SZA?8:*75Q_S*?=5T4@Q-JZAN3\-#243^3P>(0N!X%? MU/S'-A!/@K3E2T:_6IXSE@"MLGD3%F)!?=V=C(N'BB.#TUBY?%<(N>3$C";: M.>:;L *$=*TYLVAK@ 9 BV88[5&U/!(7!2 MJR8IL"%#))S?JA\H1<"D*\&5XO_AV!ZO@R%T)0_IMNNL"T$T:)WD$'Z78?8M/-C$XLD-,):V8\%-/'&H$8V8$+TSES M&3_."@GGM2-SHBBH.-6UX]R-Z%]8+PP@I8"ORX6#%4+==ZDD+.893KIH3CN5 MG. 5@RIC^]G$\\(SPGT,KLK,^*N"3:EZTN[>VSPZ)T((D*AZ6;Y4UTI?!/B* MS*!J]DH.#M]Y/PR0PK8?6G%#KXN#UVK##?IRN=)>F=RY]@;$CM\0 #!KU#,Z M*ENEDQ-L]5!= : 7 \'%_BUPBOY_I,!FB1BG9^@):5 IZR=CO)KZ5):J--) M*Y8""NX2$X47]AX7]*R;-,1*1*C0)@J7U\&F* HT"RXNEFV%^+Y8]"6&F[;. MBUS0HK%K9IS,"%Y@+,!SM6:3C $R9=KCS:7I0JR3MR5JTSWO]S*VZC12!=UBE[@9^> M.VQ,P,9\-^81ABTYK&731TK)^Q!1LZ-A#_TI2TQL:)6SI>=ZVFB@'I$:[ M3)8Q-QA0)F,.]RD'U+F=#I0R2C1F^AKS M>R]^N3_[J=F?/?[FR9\>/CAXI(KBR3?<%^X'!_G%ZT/PT-#,E=KN10]S\<]"'Y%W)D+?%-^:U/IE Z3,Y^8M M8U;2X. \XS__[/Y\GUG$&PLLV. $<+MS_T.,D(Y.OH*RVLW>(I1*89C";@\>6N LRL'HJG0EX3$]Y[8NE MM_=Z#$93RRM&/C\Z^_M.27+OFUO4Z0L$"Q@JNV^%!* M5S\[3IHV"0&8FV-I=Q2D0JRW#"L[EP3HTTR:.[!URK3U/YQ!4*RWLKDH2EV0M[F7;S;2[>53ZK*Y^-^'KPR 2PX^[5\0<"D6A+?J MD%H*-B,XQ*G:JS@A8&I'XRI[*&7'@R='YX8V. I82U@5SH*7:$^F#ZIW:413 MCI\K\#"[8&-ZV'P^4#DS2H4Z=LF@Q:A>TDQBFU+,N-BI9F!?WL55;Q0^TID_ M2(>8LM,&0U*$W*$6&52))TY)'$C?X3Z1KN!Z'R/]@_*%R"4Z7\'LV#+O-A+T MH/X89&SH+9NU,X[.02&3%E!^M#YVWDF_/C0G1*YC/=^ZW.(;BE<:]/F3'_A9)WNB]7YDE,& M&"99R]@5$=(%.SE!Y!M^R>$:3:&WN\B,%SX^21/*6#2 >R'^''CS&ON7HK&F MA=O,LZMMA'T2.EU6MZZPNM)C^R,$+G?^3+B*XY#B?DC;#Y,8TY0PCF:!7.#S MP#R,KK75NJD+%=RRRH?4<3E7"? \6CT$=<]ZYB)R_LK1M^FQ0 MB$:/O_F/MB D"FG[=8 #2F"A_$T'XL8ULP%IQ!B"6.ED#>F.QQN*C\IR845(UJ:B39Z9K[G,:-D(S:PX3\ M+J(,MU&\8#520--#.)3 6G-/V+>!D(;$L"B)!=2 M>_Z1$X(^)[JWG!HV88C]M2GKC;_*[=ZO":I I5SSV4G5'#."17/\K [%0HS2 M"@)G-W&B-X)DD4'GU;FF(?GW)38%:;86RIGKL,$W)>X8E$"Y"X0 M.PLGVD@IV*RYY=1TM+: ''7;L__NF6 L9(Q)@K 'O?*Y(_@RC%WB37 JUW:_ M]'0.MK MAB,OZI/\1) -/:_]:6JIV6ZBR&4V8H+.&5\ OU*"C/+P20]Q):67"..PHRG M3;4P/KIQY^VB.-X(FRYCDK2R! #OUZ1,#)@ ST%QY0S(R>X'W@?O(H&JB3)< M1S2GFR .T$95CVSVZJU:C"Q-MS8QT5#8*068JN>-39F5Y!6X03YBKH:YA?_: M"D%8"_1VKRJ6-"S?T;BA7LY27/7FO_;X-U\(*P#@ZI/O=S"0^#X=M$?[CWF0 MHK6*W+E)L_H\[TZ3+3FFOKF;E=][5LA\ 6MI :IGBJ!-Z$Z?9#LSEIV9Q93[ M'*(.&P,$A.("5XP8=@;485U4=Q/Z^2=4RJ:7RR@/R!_XQ MU#/,U!FH>9/01 M3=QMRAN:0ZM^O"\NX@:2RF0B/* )CR3"5'E'_FK ER2'XMTD?OY)C#7UH5)$ M:BU!O8*$BH0VUO^?>\=FV.UA3+K:64W1EGQ903+E>$-;:_14(#$50G_/?[E; M)I]]F?#F+6NW?0.&3,F"%;PW-Y%8[!1A[RUT;FP2[XWB"'&S4Y.)73+JFY2&]MN?^*#V3-:OE2S.PRQ;?& M[^1LQW8^,W+-1!5 595TI229/>3X9K B/[@5?@ MB@F1RNS*7T M(SS.?5+SISJ'Z;J3Z;/B:P1_&J&V(>0@>H%MGWR?06SRF("8=)+R1A5%;S

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

C$= ;U(\!E1OHC-""O5,6+1:Y/[LCA$_>P%PI(9,#1)YP=54>KB HT3\_( M9A421>?5!.+#1TPL&S:\512!J7HOMU1N44;.0)TM6]D^;K&C=R%]AL -RKV) MT8Q >;G!OAFV-@9%_^%@ =WS;'H&W0]>7:YG0]5#M0<+?R)Q"\-OL $*6]ZL6G]#6WVE^EE M>C+WY%UNYA=.+FU6#',>MNX2?69AY;!U$7-9207M\ Z*?RG6T-(,@3E!N5\ M%@2+8#<-,$R_AJ\N&CZ@2B)93;#^'F1]A]G)_*&5PYS"OF/X[UF[:W0 J6*1 M86M8U3TN^@#&*G=8:C C:V(4:?0EC!80"CQG#WU.+">TX$8*8>5NMCS2.JRO MB.&E+CG0+)[4"\"-5IFTDU>EM+]\1 /*L+;V*1^>Z$G/0H"46^$EKL&"Z3@Q MAE!ER@ ^IRV7&&7^LZEN$KVZ,ZM!=\+0^BJ&Z47TMWZ'@=,:&V0N]!?P!DEX MJ8>@DKZX?DCV]Q=$7_O-D;U9VNIR.UX\=F1_0%3K7BGU.#.\&L*X2/_K<[T8 MO5LZD)ZD2(YPAEW/*'8]^QVP0]N0RRXZH2F5V_Q*EJJ188JMM$YJ-5;^DGQG M07TH)GS:EYF3+A'!J>YYB8G#2MG.8Q/H@Q@WRX8)WJ"4'5%]+?KDI.QMAM11 MAA3S&582$V.WC31! [X8SXI=J5]@Y)OTSY:T'!=%U-!E%U\ ' O 2DG606^' M5F_^V._]]:$/^E_F9CWP7_DB75;N%L^=6OQ:Y(J."8V'Q?Z_S5J]T ;\VC;R MYOVOPTSBRY^GV5^_7=QW\8=-!Q[#X-BHC^Y@J=%;/5@$*@1.C\EVP,]OL1 +22AH; $A7 :ACWV4-YVB?;\T7!PU>.>!N>T_O<[%HDA;UI# MN*G[%J:7U,AY*CP#N;9!S?[=C"*[*:7FE-TMS39=AZ;H* +5A)_=ES"4$]'R M' PYZ%U@\!>[OMG<$%&X94,5L7V2/-M=)Q8+'[U3N?/3CE+]921VD#2?#S0F MO?FCI(4;I<*XH%@GI<@GH%7N;4VUTQYIXD5R MXOUQPJR2YETE@T-NI04^5U/9?T:R>'[N9@8^7&9,5"+RG:MOJL@1L^@[+P Q M)@0B#">275?[?&!EFI@S56YEP1B.4G]4S2K _!;8[?;/G]L&>!/R0=O,[US1 M\8N"^@I\W@ILG/3Z 9OZXSI/?M(/94P/5]=*0]00#S]A= =(<.YMF.><5#): MA'\L+Q'+8#)!WCI)?F[)/AB4['_/YR\U=8+;]W&8P[ F%MDWRVG-VH?B)0C% M.0C;A914[8E2I[L\Z>=J2N)]_V*O->FWZ^N4F*,+ $>H0-1+?%2LD@OT[S!. MC-'U9Y^#GT1G+UJ3)6DXX5;I779+@(=U?CQB'7[C O S5(!YI3?+N=R5]4LZ MDO[8A/%1G:1R]_@@P]7TN\+RCXG %KWT<.U2:REY4-0"5>A#9\*^-#X'SF\ M\=1(NP"89 9F;NX:3KOWZ]YTYI2C6KE[=-7T3YM;EPHG)-V0:) K4J&-);OB M<.1,@GMQ8U-S&]UNC<2+FM,K'[UK_,4^.H;FJ*HD7A:Z"@N^(5<$C- 3]+ZK M\\#2Y2U+S"*S)),)PS)#%]?)QK";[O?B N;?FRY-:+H'59+="_74$:'216%E MMG==9.]'[2[6-%JV1)/_TV1WDO^UQL;=7ZU .]XL!0UR 1#HW&Q, DGV?BU MV7\#'![D?^;121IKO8M7[HG*#?L;=M@_*A^/@/&!7#BGZ^:%03T*_T'@:CG# M(VCO9J$]KHA4NT/I7R1>4HB"V':8@]DXZ(,\9?+R5=CKZJK$T6I[LQ[3QSHT6=%XZ-]PXDXS.+$D M.>B2[ M% */]:(J=B[3+1<9LA\$*JV"H"Q$JBJA'.U_-DIY0E_!FK-.VU@WS9K2.-GX MNZF!2@#]LR@-.-P_;;&*<\OE3W$FYYQ\A^NG&A.-L,[BR;_$(M-K>5A M2X/3$?-/*#*;-1< (T,WCJ]34T(ZXV;\_WC\%D,;!G8H4[D[%IUT3U8LVQ8< M+P!7>PM?#!;7IY6)J<_;XD&*QP^WZ@:6N#5T>-%:?'6)%-#NG24^"J3T2'G4 MSI(U/0W*.D:E,AMBZ7\C)A]_*[]))?6&C,WM,4,!P[)6WBO-6M^.^LH97QLN MO-TJV]*MJ84?NKFOO"&!HB\ J2[<32I/0+4KMPEJ+&!H!R'MQ$?NAORSA:8J7EEK^=_!SGAKR7-8I$?@EM^'D!Z!L>/5^8LXA\QY=Q%[T!"VC?/&P1U237VUGV M9B](H6=%8TD7 -'ME51'MD9#5 NJD@+WWZFE96[05E*XA5A9'HYM,UQ*'0V% MA0 Q7*_1\0[8\FF5D;JMS.6(DV3ZC*@:S\^HSFQ_1GX:;O)$L$?5DS23J),X MY9M [+H\UW!Z>H9"Q:K)]:5A1%:0 M/Z9!>UIS'KNQ@GFL,TKJ04P!Y0H# M'X)8-MWDI7]D'5JK:$&+)I9$L =AMA4YT4'\.W^&&\O4@"-2>;;MG6D]B*W>6+7T[-^Q+7W!IR@L-0!J'.T,LQ>:=;#W+!1B M9T!T,9Z)'9RAAY%1).WJSA:_:;X(P.JF 1=D':I^R9 8+A$%X?E:&\\%O.UP MCA5ADB"&:84G^Y ?HUYXEI>X<9#BZ0K+!6K]S@5*1#M\>_LO ,<.QE,ZXX=V M!Y;/Z20L#;(\(:-WU).#X:VN.Z,?TU]^K*K#5-T>.#50H\*GX MHT<,.45OJE5-$/>^@*Z&<2,% ;. 5QG$K,2>JKN<;)QE:@KW3*9+Y1]DM9PC MR+<"60\/!UQ^+C)*N2.Q,H12,AWFG;)JMFS729OP>ZPU[_#=[ M_5#07&*9ZYC9D<*GE=?7T/<"/Q_1\LEM=EE"./ :[[7FD)BR4.=*8J9^>>7F MB3#_I] V1HT'Q8DMJT.DTRKSI6:CJ/D]H@C]RQQMD2WCJ?.RA=B)OPBBZ^(!0HWI@;LF1EA)UWF]3LRE00U6Z7*1V6B-_0JXZD&HC MIA_>82K[-Z/:C[T*%!B9U9V)G2G@H='X;I^3_I,8JL5!K.L\NZD/'/A3/YGV M5AF_QK\<;/JXQMBQE;(#$JYK3C.-+*P7HPC!?DUST\$)O&ILB9V4FVC/W,5H MBZL_(UPHCY%R)&%):\):="56I-2-Z;72/O5FZ]^GJ MVJ9;FE6Y*?%_OU'E;6AFHA/F+:$T1_(9"R\(1K48-^ =DE?W]KL*;(BE=67_ M>0LK3X8T EM-O7GFC<$N1%*X\>ZI3Z"V99%7N%927O6JOCJ.,1;QR:" M3DXVC\:_PQVET%A,H#QHL&P^%#C&=IJ);JIRM;3T(5<;BO?2>R-D8C+L[S.7 M4]JO@AQ%=D[%#IQL&IM;W\A^1@FZ-$MIKMYQ\>JA!H0.L@^) U6M^NN(;KZR MPZS1I!#_%5)AS_!FO^3L;F[?HG#K>+U>%.6.CX>[W_-,QN\%*G[?SQ?AZ(8? MA E%%DYNV=>-^A*QS-5I\$BO:SY*H_2LCF+-0_L3H4F;4[@14XTI__(;,R : MDG2$5JQ/:MKQ._>O<3X!&C1OPURQ?U"\6WN4=!PWE5JB]S7WQQ:KSXK_+LO- MJ:2V-L\WA0X=A]')&4=99N7>4-G,S72PA"2_:7\WX9>M[!7X.4]"=K7W9YHC M-Y;Z!%I;4YC:3-$^?$*_?7Z] 80+P^DQ;_6D#/DE$V>[,91E,V"&=&5^*!<> M'%%PX'%(RS-OJ'8ZKL'_)6G!=WEMP[@*6_-1PQ_$9JT5R>=N5*#:]C-#VO!! M*)"1LCMR8)(LJBJN[:4+;365?C53-2-F+C8H*S2GA[65\4."[AR*/'QN.Q/@ M-N6NGWVJ$OZ:HT1%H MBNJU@@RCQ'&$7>2D:)O&OQ%TZQ97/6JPST*"LY(:)EZC.IV21;N.NH3] 1."F7?XCV$^O-8A M/1P)"W7K)FF/NO9LK#^\O@ T?TBA,%P F%PCR'Q6B)K;C6]KZ^8&PS*&6154 M6M=[#[K3&NQT]PY#C*WHRSE^3SP.5@ZI5J6$IF*=^6Q6ZA?\==FM@+@,!UT+05%&$HO @!@2IC/*D M2PU%@A\Q^MX_68=EJ]U&T80ONX6)ZKPT9K-O\)EC.1GRMF2!/FC\G#L>^K#D M42W6&JWH"+0A5N1O[T%*; =>NJ<.A8FH+1>4C/3([*:*[+67#M6MC.[JK1;LE#^B@E\[+2<]//%8=' M_K\L:>Z9T]?)"Q&J:B/=3> &JQ3^94H J0+D (M&DH.X8D.!B D:F*OKS'%I M*^V0"#9!0O/\8;B%A7,7D&Y]KWE!?7QR@#KD.;][PJE[YHQ:IO]K'Y*4]03S M>9OM_.[K=[_\;G1\DLF]A8IY\C /Y>K///WCW]]K3&-SXX-/=/YU)A0<,EW[ M]C4VLW\*=6]=A8667%CEPJ*HW\2(Z8WB:10"?:G273LNP;_(L*N9J$(T%1@. M\:0[2/]U#QBLDGRYYL^%9#6VR7XHO3[Z_$?KI(H\),(VWE*5",;%%F;0:*H4 M$%P(_RG*K(JHC1)\NV/FK51NXBM\-/ ML-TUA85OF VKE;J:S/#S..Y,MGV'B#0'F8B'3^TQC+5NZGW@$22PK$Y!!2#) MZO85]\?L8G7C;VQ*7'$'EI0>CDYK=@28_H=;TTRQ;#01%9RL6D:]T;/ACJ%\ M/0)./F&Z ,2:#PTR@ GI8LNB3>=&)-!?40YF BVJU*?Q-X>57IB0LEP "X(G[4?EL8NJ$-WV) !4$?T3QK*L ZLVD ME%FUQWCU 2P- ^R+;]Z&)X<-#+L["V9Q[ED$E_J^OZDRP6-L,?E(.[,@*VRV MA?2\HP+.3#Q1PPN4ZU2Z*=BD<'S0:FEZT7S[^W\^WNO7W<+AQ\WX^6)% M2Z*M+D$HOBI\AE5S/#M7B)T]HS-WM$J'5?%)DZ[DG::2<8] 1/K\(4GO==$0 MHP0+A9F=_Y *W5I\#ENB3P0M=:GAV\,?+X\(3GKJYD-R%TOW\SNI)NYT_X$Y MVN$VTFRY($,]-D]V/53^DN'%1W+DWW+]O_A6'9)>DA-&M\N8$#TX/N"#\SW\ M"?248UZ<7*Q$ORBBMAW(L:P069I=7NSR;NK$'2->^W@)::B IB%I$?,):BOX MO@\[HO/M;7W0;8\<%@%9)$3_2MSW/\^>PC8/K M3:RE?WQ6[@J*L*Z0,]GT/9-JZ]\M>G).HN*>P<)EG9K8AB0MRRS4ZK3'.FE7 M?\X10)/"O.CV:G4O YC2RJQ'@R !%U9QKZQ-NVG>'+4)ZF2;;\63F697F 3 MV.U6%P>9^2FSKU3: M!MH[L^=2&^A$DWI&Q'5S;^P*[G_NVU)OI7AJ>FM+\1J,\AS6/./E@M;[ 9)5 M@3:'964*@:O)]M&,6O>-$\2;,A*8-4N5RX="#&D1HC;Y\<"R% <.B M!B=JM$J*Q[UHQS2VGN^M/WMC6@QAQ.Y&X=N["!LVW&/N?F$JH%,'#S:=MHD8JU]WW_'PV/$0^$5-CQ\>--V$&=C;,AIT&8&^A766$FY!#EX0P_'I.H1P M<"3\AI3_>/V.TXAE$.)<3P*WH#\N-)=/YM>0+4M0ZRVX+9$Y.J5"':I%KD#= M"GV(%XM4 O*GM=^$Y$#]9/M:Z,LO:KW8Y6G@B-_K:O+6N(#TG&VC.MGZ#P' M<% Y)/3WC,=$;GV:QEN&0?WCQQ$NRMX;F@^:DHJ(/K =/%KZ4Z/2@\[M0DUY=Z%&8 M7_ICSM7EP!X#0N!'*7 TE!GUYX@LVF?Q%W'CMZF)Z9?HO&P]KM*]]>"$W!BN MEZ_R]3F@12D>Z,AXIC MA[1I#7%K/2)O=__,N>ZLG3[HH'\L?#>/Z?:5A/>![-69_F+3?+BI;>TRC&L[ MP-^,9+R8[O!X@1ZQE3UF^9]/EUX3K#&,(9%\9$W_:Y3X(*JK/1HE4H.OCD;L MW0V5)T9[>[G;=J'X:]WD\[Y'?#*U6U% WC?[PD9X#REMWE2QEG*NB5]@;'U5 MTVGM[GD?\D6,QJVXSCWY:2MSYGJI.I^BG0FH9_3K#*1@(Y-V^5W1O':EX9GV M5RX9K-=Z"0RC;MSWYKUQ>PQ'3N$B:U:7S%G:S^;*'4PFIB'%GQO1%E\^Q*4M MR/RJQB/ZV6/'WIW?__A2UA:8_1ZHL&[Z#A4T8.A6#]XVU Z.'(\K.OS6L-<6 M1CYF6^/_$L2+ZHKT2M9!9_[=]G;@1S')FK75?-BT_.R^C???G<7;?UY7"?IQ:N7?0( M\\:JB]]]X?'[TK4:YC/KQ&B;) Y-B$E]X[$][F SO0"$/S"Y MO)D.$%Z%_=,*A!8[W;6H]\^=_/<1Q)>F)_OV6W\L0UBABO?F Q M[1L;':$":FR%;YA(9ZON_#"KI+B5)Z8)].F9J'26)[>[INV_PDG?Z0:U;27V MYB%CM*?YTW_ODWY%"PKMBIVPGF7^U70[)/5_S<8@TY>?H1R_PJ:;?3W3^>>L M<@)2)LYKMA6->R"ABJX-#36G4[1IT_!O.=MK2'29U=;/?\]%MO$Q;;;E0$I[ M4T674CJ[^J#P]^\^(V%DMW=_OU)$VD&V^_("G^.5^9I)2NFG:?,$#T_4G]_( M]'\S_*#-O&.#!7S9H%-;XX%Y09K=!4#D"8W8.%$_Y*AH.X$A@T-N]%7_PH"Z M:3.!!>[>WMJ8[)5__\Y56W1SO@XYV[S+L!:)&K,IG&3H8A3+Z H[?+]_ =CK M#Z8P;6DV0TCE9O&M_/L_1>?(;UV[TG%WGS^;F>G)"8_)X,3OF,^DQ_HKZYA; M%U%11_E_I@N[.;IA038!FYL'U]%7&^JE92]?^ER[]AM6ND/10] SC$\@@'E5Z8@+\.CY MV+]\SQ3#).^.IVF#T#:]+;U_?VR[L\F@Z@E;LU[MEU*56Q< :G#C.H+^\\E^ MZ2PED7V728BBM("UPNS%L6PZH/8?.FY]I/47*N8NZ^;A_CRZ[]+@WN/;C#-M M? /-%GXVI3,9^FF_( 1"V:JL+/D,I:8ZG7QLPI)\PGK-+,8Y=^;',[DK[U+#0$113C;SIS *"E)4MZ7!R) ME&#H]0DB-'O/4(<"3&N/_B0#S^_<$5@MK' U?'BU0OSSG;7JQ[XQ.6-A$L.S MYZ"NAKH!]OZ0#)N-.1ZB08(*XH]ZKH4:)W(F(YA^SNP'?+C."%'Y;69D)GO$ MU.6N39 K;%'8BMFWOXU;KX5R95;S8>=X8-S_[&?)5^"HG>'J+,]COMX5!LLN MURIEV1>^?6.U8#O9/4IVN:45"Z=F=HCTW]&\%QW L>:)G^/N&3;*O%TT)S9/ M]Y&;CW"N@2Q_4C^]05HM![&4Y1_Q-@ID&>H27ATR&9J\6JI0DBGCFE$K?S'W MD(7C5< %X'.0Q+^32DT\]VJ!HUCNG-5N%_6D?X#CZ'ETCX=VI96.T'"0U]#" M":$/WN%4'I40F&2>['A)\ZOF]!0%<3-M.=3?\[[!SQZMC+#BR%EO;!BM%14E MWKZ:EV%]Q.7$POC[X@7@':3=M,6$D^.!P)WJY5B]A@;-%%=5ZF_M?H41_7JX MWDI+30A4W=I0FEZB4NR3V.]*12:/4#[LZ\9K?I8[AM:-!T()6L@+ MP((SL-#=W$HFZQ8YHLO;O(S4+I_ G8]?S5.P7OD=\;MADK^//9GT@/354!TK M'Q@1M1^Y<@W M56@<%E2<\3R'?U->6_%5Q*&=> !3J^0A2!-K:=\?6 MGU\'R5&,V\?"ASVX.%[.C:XXGO(;%K5\$^IJ[OG=4D2X^KER\A[B.=6ZKJL, MT9]YPM(38>VZ]9TTI0Y3M>897X<]>B9N?*2@A],Y:[@ &$XRD7ZSH3C>>0^M MRL"YAN.+Q4>K7,3[VU[/5<&R7;BDV4CBVLOQ>1^SB/\3K?Q2#O35\ MK0K7^O1N3+^H:6AQW<9V_JE#TR430#RU\%!= 7<_ M&G<80]W'M.8$(+ A;+.[;(_Y,]()3E2'N;#IW7GR"['L"X!P-N*!AF>,CE<- M28Y@3:)#SJN@GED^\! M1XJVJ\OLTGNL0_.%3@L")5[\C&A+E=D/O"-NUES=W4[W+JG.QFU&N;GT%R;@ MN\.L? 4_^7LHSU1.6&^Z].'LL[26ULRP!>O?;I8OB6I8Z]L2TT2P>E30$.P' MW]L+0$=X<0DYYS_%09]3@;,ZP;7C+W@=Q& 73POM7.)@[ N!QE$ROJ@,N4-- M2_*!.1)->S,+:N[^)_C-SO3D]C+LT9['XS?C6+.=Q0_SB,I$9 E4J(1'6=BN0GP="N%O7ZI\X-QE0< M;Z)P136L$D0A54?H@/22!$7.:BK/*4X?M,.F2?1[@]*U/7N=L587*D0(0*R) M%A(XC1/DVR->_8R<&CHV4F M/ZYD!J8M8,"#J5]@[CCTU^5\"E/^*?\(J.L"<$6)$1L97]$J]J./WS9 $WFW M'[2HEPSCV*S8L1_/,]O!1LY+KR?=B]?\0_=(D6P_^O(-TC0MH*+KGHY"KQ[Y M4-VW&=EG>VW==X!Y*J:>[6WLGM#,WV]0 'PL)]+G[%A@:Q34EFTDH\.\QDA! M\]QDP6EK#QN9&'I3P@OG=,YVJ(Z*V_NR-2%DPHC0DE(& MFWWJL$.R S)5%DB0!@[G_[W17V#\3WB$.E[E@9LPC3D1^'3,./HNS&7+QJ$X MCX;C F#T*J43SHSHAM5#NCK/@'L2^7IC'-B&,Y;4YB,*ARAH.ZT]UN0[;.=R M/]]XF/.MS(R0=G:KLLSU.)C_NO;6D+;790*FT8V:]4?^>MRG7/@H#'1L2P\"2PZ H^TFA+Q_V-TWOSDL^VT-1U"] GJ7:ZSK\;,T[9Q>5O M?C8@7H3WO=JADO9\^JO)R5-\(,\*9C942F)R%")ON)RH"Q%SWJ9? -A"]=O7 MS\ ?2-RW8RHX=G$Z+[%T088ES" X.EEO>LN&H&^'2XRV>31Q/^S7CE\-3SJ5 M<,#I%=^$:=8\K38^P85X"^QK1[G6A!6[#9%MQ#G(5U-)V,^ YK9?2N4R]#3N+SX MQT4W;E-1578]D.E*2D_0?7)NJ^F2_^QB=91"3[?A[9X22*1!XW=^T3F^ M"5JG=@4NCG:+??9'/O,0[7VJYI+#A#QGLQL=G!++H&=;OM)?Z%N\&=K> MFYR(HZS >OO !/HEX"ZDL*<73%X#6)-_'.7, R+"_+?T%P!ETE23>+&MA$N[D+Z@( MUV\9QBQ'5;VJ97$_VDA S#(V'HRBT_*/O[G";EO!3^IM?6!9ISR20MN(DM"G MD%T5 2+2D.!)M[>=]7CC3,EY?% -I3JUAP05!B=&D(2+(<*:.B#-\8K#;!6& MC\CZ3W9QT%O")C'Y'/_*$*R/<[+38G*SC88IL\ZROU/^%-JP\G64>DC-I%CF=6M.&\C_8[_.TML!2H; MJJ?WX0)P2[J::<"->SE8X?DJNRATF!.<*1?N$M#0?W=ZA\*^OY$NJY6O=M2F:6K>5,=TL5]V>SUW-60'E/]LB%^]^_[7=,D#ZP. MJ,^&,TMKDL6IMAGRUILK4D:$J53"+HJ/G@/N=:-*J/L"4&L;T6J,PVC;@'=V M9(TF1=6W!HI=DRU%VD:S/>1SF-C-"EP\[CD]>M*C=2_-/3-1M]"?7 /E["L. M:T*4I_Y, $J$-(RO[8L([,_;U@[.P@)]:^4Y!\%9-\(TW'^=6T$8%NM2$33G M[T1_:-FXU&_\/\;>.ZJ)[VWWCJ*B"")*+T9Z!^F=R!=I(B @O42D$WKO$9#> M! 24WGM >N\E]%XD]-"DAQX@"8?O[SGKG.>\[UGO>O^XYI]9L^>>O6;FOCY[ M[WLFGN;U$9/3DXV%*@'.7@;XP#.=H, G@6,78BCI-"V[]3F[U;%TYA;]LF*B MD96D8[\F.:#WGEF,Y/ ZJX3J(XYY7,\RWI3@2E7WL_H+)=6;!=/B-T%:WY69 M!KA[;.X+P)DFQ>T>D];_ R"UD;H/O]A"VWE!O)Q8BDMT#?XLM Y7@:TIA(=J M-=C_B?[[)"XW@XH,GZN*??T['X[)TV65^,!A;0G8XR\\)@&Y$BCY<+W5IFM.?_+ ]0\/+"9]RX@O?,9V]=U3QH0M.[;N MAS\#6\[(>CT7D)?!&&43)X@7S+I:UM%YU?#K_*C, ]K Q_C2.6U'LS6EX!<[ M57J[VG77P6G=Q ^'O^@N[,+BP *XB96J].UOW%-:*.Z,W"+K8?B!]P=GJKQJ MROYX(K@+ZP/*$\5^SCXYOR3-#)D^4>^ZZ,2$OXY:.7,ML:E;E>,864L!Z^M: M[" [^U:O+WC(UG(G S-'7&PM'O)SM$W3R'9]5$_>_%6STNJ-CCKRZ(52CNHQ M6,'%4M"2F&Q:Y4'X7>)T)%XSG"VM(,JO-_/1F94?,1+X;MEYA+?LZX2NS_$T M[A09*C9ZF.E);Q+L;ZUW$TSPF'71H]<_V],=.267H&(G/.%Z0&P4IILK:):*3BD3MZ>QX2_ LI9YR[W2O^@B "QDL1\,\(S!T2 M'6?,O7#4\FZAWM_!;],?C5QF79DD*O2$K<55;C MR=PAG/8=6WD;E/ ?BDT+L.T,*^KTT=^#G9"1#]74->?1O'U;P/E/NYSOJV_B M;P$"B3=:QXQ#E7$>T)>$DTIV)4N'VEZF&GPG\I[E27X"_:)QOZ24R<''9-16 MRU\P[5;FNQ_LF7!:8SRO>XP'A:]HND-0(Q#A6T %B_,**O;]">YL2?BP05:; M&\--:":@X+AHFH@G5([XQ#$,!7.<[1G>#)6R>\^ MMVF:0RL1%-*>G0@,6;-Z+]12.%Z]3L9=%T#=A$/.Z[I9^+<;<^SC:%.$K];B MH'A:4Q_"'BT6^1"V"5PA&\U31W&7(JOMLE5BW$]]JF^2KU[Z!9MN^V?@9W]Y M6]AIWP!?J/ES=V/ =[3P0R;M>F'*;**#Y;> C1G"#+J:NBUEN6B!V&4%CNVK M637!@IG-DDNLO'Z#!8F>E>M\=9KD-<(C8XW(:^"M& MU,I7+MBA$%.][F$>7V%2!:,9X0F@']E8AUY![21@5;?.(6*PG/1 M<^<6[X.WK'GN#5-@&HIO 5]O 9U2*2KX'X#>!]"CDZF0U+R#+:3P]:(;%M)C MAH:CVH?A%S:_<2<*HK@O(>A65'[[9A]68.YS4DTLT+$>^W#J9M 0_V?%5>B_ MC56<2G6:3)@^U%?6!AZH9.ZIZKF*JEV/"/H9J7A",5QCW_@S4V_LI,-Y.,Z M9-(OWX)<2O?^K2Y-!JX9J:]G4'G#J93O GPW%%A9>0OXZ=V.QK\2]KY!1\I5 M^?-PZ6#'05GYK\0F3$''6'OBJDQ4!= A,I-PX$I2!6EV\43D%O#R_0I5&U#^ M9VPOCEEU<:%_Y8;9IF$[E/P/ HRFA0Y3/%KW7MN]!:P"4<0FMX!OETIW6^"@ M?]CV]2<1((E@*?3*VHGU)NEP9;(E%$>A$X3/OM[^0N&L.@'#EK!>'ZS.!XP5 MVG*XV+? !69>7W6WG]'SKU$2J>R81>]$[!< M*QAVA9A51F=="+\?UTK*\1C:>!D(/)6RB3ZO:KC+K[9W =2(3EWZ\[?'M2," M=Z#YP+WM9[> <3M>#!'T%W37'H0+*(&N\M\"&/_@]Y![()I>M7C!,3Z?H>(_ MT&U7[3-H#QV'RY;:6\!\:0_\X&'N+8 B0@AOKV:1&/M]BA6;*RCZ=:$AH3>WX:"OTKG(Q[%'GGMIUNR@1O 2BJC*E;P!/[FDD[,,$*L3SD9T>A M$LPS%M2$PM9)7"7O81]ZYH%K0D/=<:>ZQZK0G;2#V!G.\06%&>'2QQBKW0[^ MQ/8H%)3@O*KEAF?8JRW;6$C,8],:<6,,?R3!6!Q8W3MYX;&0PJ]S,S_97>Q9 MI0._X(E]<5V[1^O_3S@\ZLZ905$Q/6W?!M'8ARX5^2J$;T=$8G-!^TUU(,:/ M<%J..U/6B@YL:]1>/ZG07?V85[=YAWL&6-5L+DDC05N:C^.KIN/Y>;&Q(R6B MOD+(+K5T),30_:1F>OU4:'1).L$Z5L+X.$\,ATZ$7NC3-Z'V.RQ[7[%$W0+J M)4NO,#7$2P9"MX# HZOTAV,!0D,%#]#=FK%T.;7A]PK54(.0F@50N*\R/5S" MGEP2IZS+RQH\O=9B6<9^9BMPM5>L")+KR $&&-/$@/G*[,MIVM/=N+[B:M5;N-?" M_2_#>0U Y[22MX#UZ6VTU!I,=@MR\-YD /]&;PS<]_5ZN&W&FE>Q_530!,VY M9@5T1ONH+67 2!RV5*P6T$_EJCY/_&TR9/8FL8I0V#%$^A*B!MN.!-2A%C-, MC%:9 M[.(9*;>.RWR)@8BK(9YV.DE/(:4D?^\WIUX1_.7R!>;NV,BU)11T$!LE]8/R M]8P81E0WJZLU=U_+8-F P@^E/JV,ZQ@P;A3XEC,=;%^@(&Z(( 7]$[3:),RIQ.;K>(K2'\+2 !A&U9AMOZLBW35N]($ MU?CHW)J,+VV8JBF[EH?K.]W&V=0 MB65&+TI6N['>ZAP8EL'?0NARDQRQ@#>UJ6&-OS^R=I/*'*H^+:E5^CFAZ4@_ M[?Q" W_'.%1.^J/7K#!"=3F<=X QN [[R_>AW>8A:B1XZ-V;5W];#OWS?VXU M<;.N'86>42R99OV]L)MZ,R\?>OK4@%3=S&5ZN-)ETLT,9_L::&Y4R18.;0JR MP@13C1 NR DQ#62M.SMHBT>P90&B(@ ==X A$'&O/SN'O_P1E(.A)DZ,;241 M0/J)WT9X/-!X=\;]?(D_RK\VLLA7'U4>?\(]%]X"LI](XV_%R/S BEA$)E.[ M)'?]&EJ-%FI4G'+#G>CM(0^X&:6:5MJ]&I:!?JH)ZM) M;P&RX]NO@:4/@3#.7/.@\O,-:-S.#YW46T#7\3%YMFMI 8;OV&R\/R#>9SZK M2D/M"U4XV9-CD=X#BP5A'!G*/FRA??-&.W[C8,Q0OF'G2&[P.FVN9_(<@AE3 MW7E/DIK%NF-LRONUC1T2_[X^ S3AFNH%0 BF/Q>LS+1(C'UU-M]N 3XX&4$2 MTWF>ZI_FGFR&NY&8/[U[A=%KP;>LB$LGP61R)RJW@'@I?*-CU>0USU=&:AI3 M9W_7-Z-'!N5J? X9&HPL+QK1?GF+@L_WNG6;='2'J55JDL<2IK#Z<;&.-G84 M%QIHCQS5:MY@UYN] &"2Q?339<7NQ7Y=RT6"PYITZK%N%)>^7WI^E$WV_86N M2L)G09OWHQ5P(\"MY,7VX5,P&KS,]U=YMO<:\QW_^$F3TSQ-5%O\>@/(0I>[\""# MLP&EU@5]BA$.&AJ7E,C=X9QRJRTIS7 9\EL?*RX/C!!33_]@9%WZ7G6I#NQ, MP^!59?_%Y7Q/-2?"4DQWB#5-0<@BXE\ _E>V55[6*0 W,MJ75WF!'.\!;*SW M(QXOLMTK9NB7UDQQ$V(D.2O\>$\]@#ZS8D#CWT&*.QFCYC"A=CC87=I.R=5I MN4L!]/\I@6,I,""CFY"/8*\:V)0?^2OP25%B'S[4O*,JJ?72AZ'8W&YY>O-[ MPS9,AXU_DXQ0X!;PU-]-2/&U%$?JD\0F(?TXO>/:NEN OIO$US^1E#C[FEUY MQR#NWGL!I%\5HLWV5.&4.2%VN2D (*M(*]D>U,L1^F=G]6]:75$!("(CLBW MHIRW=X_XA>_'8_=8:)%?9I<_XW3>%%=%+4USF)NRXG["0$VL*DG8!WD/0A8] M$4P48 0$SZ21YK2^U$'P7H1>:T7O,F/[,M>\U,_V*+>J3?S+])+D&O18U;B= MM3[JI\1F675OVO**;:@$72F54%/[9K8N_3TW33VYF&_6*DM91L7\[Y8KX M[L6)>K^W<$0^PAKBJU?XYZ^F4BOWT4&>UP%I9D.^M Z!N*5U!^!Z)KP=PAN5 M/-O4"\Y]7I\/B5 6RQ10'ZI MQB?W&*!?HDQ5T?BH=C546ZK@W,?YPWC(KZ\OC#YLN_2_734[P\L"N,S6"M'Q M;]UHSIRE>E&9S^V_\)-,1I3Z6&W)Q1:^^A*7D)8H#U]B*;CS?(-S.+]S,(9" M[1;0HR7E85 SRS6AY99J$,9L$ GY>38PM/ ^E&/5MO/PL>1S14GJS5(-+9H? M&16:[]TC3ZA]O83.:WNQZ:UEL\+DE2O&_TR1M2GJ5O7OD$]2OAN4)>K8I'5; M:,Y5T&/4EM>1OY<8T/_9ZX&.U!J- R^\B6@[5;">>K;:ZP)V86=/Q5SK'O? M,E%EO&6/^FY+1\WM_'FH!9?0*CBP^Y:!H+C-DY5TQ!MYK% MCN,"X#_B7NVW;UX)N4WT-[5[@*06T]67!9^M992C^K[P]%T&_^]5/?OC) M;&B,2->:!T@%)Q527P;7@>8@3AHVRT^GSKTPZ%EEFLY)Y'Q+(WXC'/^8+%,X M%TG\& KO 2Y<>Y^G/)QWHSQGGS@^&/&J-15_>CFH#AYYM-'FY%$_(+3E,>4$ MPPBG'G #!]_/W8S/'1.';OY4*-(?R!^%Y_?(TV=>AI*5/@N@+:K2W=4)*TR# MOTFD.>TO_&O,,HEQ*JS65R':@)P,O*P8H3ISE0PZ+Q'))"PC++"35FZE7K^Y M<$X$]Q(/0J_/Y-.5.K7RCZ.G#XL.W\*KA<+ M\43RJ30/28J?[2QZZXS9NF=+)V(LUU^VDVK5F /=J97=#LOK/4[F3*^AW5+\ M!'8#(&]O6!OK1OOKG*8#Y57+<-N-Z905M:3K.64+/_%PT0XJ4='U%+2UXX5% M0D*V!"_K]N4^;GW7---\TIKC>&[$RV\!]JJ0(N4B-N@6\,!78)WWV\5U>5$U M]V;/)C=VP[*E+3OR3!]EQ>%\3[VY(03^$K/GNSJ2_W,,(@67DNUF>^?J+1$2)OQ M/PY[&$+CX$M]@7; TWD2Z0S_O*G-[3P/MQPA72Y!<)9>^L#F$C)-V;\X%IOP M.15,M4XW.=SN'\Q+O>J-IKFPGQ:"\"8-- F_?;8;U"TQ1T7'DKP1* MVHF$,DS8V?/4JKRB$U_1NN$2N$?+SB$X&* ;."QM@6BD&NCU_ME2S;N1QKYJ M<\I6ZS]555V5T#11#\E0I>'ONU%\7RZH;\++O]*4(UIFOJ9@CM M"F28D65602]*5U_\$]O2>/0=WR9!'U7?DX[7E6(T[8'(7\Y\R=P#L7YC:LTQ M.O&ZXRKUQ0E;3?:'E][2")8:!/>WUP8Y+?E" MWU1ME4"4BT8O<6\TZ-/TX.+>=T,NOB7C?IXOGTXZK!+K+1V _+Z%C-]MZ+-\ M-2E2C(H2]%X8O+UTESUP^A8A^/1EI=V"<\ENGE@_X3W*LB1\UBKP_/F1!Q3S M1,\!L7/5>IWBYR)H?PL YT(\P$.E"ZV9A1D:6KU61N+/ ME8>^K[8HG3S MH>(R3U=F$"@5H>RG5T)T,[Y>C4!6_%BWDAN%L;/!%E07%OSJ%.**?%ESP"+&RT YWG&CX[$G7Z^^3D7CN@M;H&S&) M/UU;AID-1@2NOVM9?/SZ!5I>\UKGT/CA5J*C1N\@B89:_.76%'*/4HDW/78 M8S"T@TRB4E41&H$XMRW1YN#V,GJ;K<\*[1TTC?G,87_K7L#I,F-;U->N*)S+ MJ'M\OM]D\CG%]C6I\&_WK5B^L/:^_.:K25 @?_9&B5Z*?R()[X0,2Q^*_/-I M:EX,&O@QO%FJ.=\VI0J\UE"@Z>>;;15U*4?9@*^5+:V%TQV<;_+KZN-:]9E-KR-" MU(BM3V)3NGK;?K.B-5W57EJW,=?KN1[\TX<3I@FH3S=;GPO2"4- %O+UTW5/ M)^/C#]/GEF/Y\S@FD[G?(6\D"DR7//%E&OPFK9ILHW<_ZP>JA4C3-@"%(PLK M;BH/<%IM\BH %_WP3RF[N-/DA-7VX$T[N%*XV@V_^"V I5 9%2KK>9$G\IL7 M*]#VR^D.U74^J++E@1PTKW[!8P,1;Z%)>\:QV*7W[W]G/N4^0"X\JD5:^?7E MP*\B=MFRH+K%B^OPKM0>WXHH20VIJ-V5X4\3&/'I-1!KE-LM $W]S\H(I"3G MZW7/+2 O1OJHPY^92WIL';(!5N*BAVX\),<]/3;_]S]?4Z.W@/(40\NK-^5= M$7A[+T]NDJ]H?Z*VHW)OVMBFP%@L&U2AY%*_],32@\#+2^WJ5V'K$&A;EU;$7T^FC!6\""WEYM3B1^'7BP;3WXQJ,G>TH- M!?$&UHRI#Q7[JNE$6<(*/TJ^H6+ 0Q? 9!ZOWPSWR"42 LQ0G"H>W@$#'G2)? M-?LF:* .;IGGF;7_U+%H!<8;30<]@'66(U\H"EYSFT@J7#)>0CM%?X;VA"=O M.>#U[IT8UI^7S#6!>JYN =,0_R>UTK,O!S C'F<:OY,81C&EAY(78]TKI%2Q M"$F]-4&ZEG2Z!5 JP2\,Q?']-7\'.NOQS&O3;-9S[\,'K&Y*JMW7TQ6NR8NQ MXO5HO?78&OM,I-OI.^\\?;DFDC-6(>:53BG+CV/IQXQ]RLT5"1MR=\B252&3 MDQAZ/EC?ENE\"V <8\!F,&9,9$_[FJ^/*!G<("HCSSYR2(#FP5UUDX=)#B^- MCP-YA)I#B,Z["+42=]7_;6(%1Z,4KI&ZF@RRGJA4GI M)V@1F?2\:E1%Z,&&2>"0Z2NU+Y$LMC,Y/O)_51 *2I-*U"$P*:O>.)M 5Y 3H1 Q-O_S'C> M4=Y]8*TO&D[5^T%^;42DW^BF>!HP$VUZ4QJDFF?YN-&>3>=9H[$<@/L_39(C MQ+)HQ^_)D7[\C_X[V!7-_.\EZL5)O0JNZ@4#E(D$&6>['.&,(9,23ETX-^UU MVWC7*[^24Z)N,H-])F +WZ>O,;//$]@-UZ6>K&HAS#Z6R<:TU5Q_4&0O*S-[ M($('AXE'R-)P*7.L!=\G>TSQ>T>U8'@X_*1\_>V#^,=PP458C]E'T]-UHVX( ME,/5Z7$HZ3U:JTKERS:']XG?0>I*FSS8/U=WUZ/#?#S5>SWV%4=FTU07\,6- M2&-NX'&;K*%?ALBO%P9!+[Y/AN5:?N_+(W\2,-M4KX(]5L5_]%4:#(W^]Z?' M(D7HA)XWBTI(HT?C\P@# V("(YF+W[.7Y0ZP+_Q7$=DY0;Z6])=F_(_T(SN! M-2)]Q#1[Y-I/('3?$L!UJ=A2GF")^3)I)X:_,EO?N$P[%FF+\5_'15RG^KQ, MRQQ-3$\M?8F>Y$SMOV*Y!5P4H[,A:_-"135U.(2=QFS?S3O<8$.3L/9>8:=C MVSN#9&(GKBEANIG?$26Z!<3MOL_G>&JM6HSLA*;G9IM X15<7!;)1U[T7[[W M-J-;BLV3:*]E@_J%_ACLS%ZDE%U.R!!ZS"G&J3B&D2LEBI!JVY=1^)A*B5#; M)^?K_TWBA%@Z/,QO$N#O)7CP42^2K^-0-U[-6:E Z3-(DEH@ M"9\Y6O13;/ MIEZ\1T1?:SG3DM% R52HMX>8N;=,XW/U@DE@62C O).6^ .=E'07-Z=:?6T] MF.>I[BSEG!BB!( GA::SL;&MLMU1X,D>R?_Z/K]NJK@2T^WA[?9?4^]O%OGD M2 $S8=RBM-1L6<]<>C.)RC *GO6SIRIY$));0&E[[979M>C?O7T(YWMTIMM: MM T11=_S;E,WQRX)*7D>KMH7WH2W@"$QT#PHV(-,H2>#:@ICDC-2L)M4::R[ M2"BI\8PX^]4W=\8X8W(!CN(G+:I&S 2I-;@G5TJNT&7]\GK]5WTT?-]RBDQU M!,5!M4#1MM*;"H7),2;)7ZAM?12M2 MU0*$^C1 E6X.F <)&,X]-6+(=6BG \F")]2H)>FT&Q%T)2X,$_!%@2!Z"W,W MY=YG%4HO!5Q-K^8VJ"Y#1%6YAGY&HY][E>:3HY*3GX:>H7U%AA&5G7 MAQ6>K9I\+907LFX>%&@V'&@^F("E>.=N/&T/-^9O:8>$H(;74B#%E1=B#2+D MQ;;K*,7.5QLS=#[(T5J_XOF%14]G!$VWEV61TH/?BOY+W"W&&@DT[N8=KSW( M+CQ^KBP[C%9BS%?M6)'/?EU(?>FC^2LS2(%45+N,@P_G>0?)2W0N]D[$=V]I M."^QR^EA9A!3RO/75*L8A0[Y$C='DBCW%K/#-M6Y.0,C[TS^O14*24VD*\1. MN>.NNZ;>%U[3CAOQAS/&*S%^;_.@*]!Y8/G@U?1\FX#G[K;RE-T&ZF!(.*.8 M1NG"^F(T+C?/U'+)*'OLM=FJSS;BIV?S*GR$,#E#$-4"]F:UW:U[BAO8X8^5 M/?VL8[0*#O=6Z$E]4N[J?(/1?S*$D0)#IN:,LAWCRG3(5O[JZ%5])E>(P+Q7J/*1U]ICV)CMDZ_ MF7&+[B4R.=+5FFRAB\B-Z:GEA7O\[*H7KYWM["":T =GWXM8=^3H6471I.G,MD&@7NWBDK.X4W^W@^XN M25M]B&!QX27CG,M :@R.FZ=F'A10?C7VJ_]'G=V4[M(I;SG??40USSR M&[AS0,*TSJPT VHT%8F5@KD9T!C)+X40NO31$A4+-=\_(R\+R2Q#KF245JQ=HSAT"8^ ^GA.(G(BRK.24LE^YV[.!!I2N@ MC'*/;3V%JN#NFLF37K9\5M:GW(FS)7.[F<6KQN+HZ'5B.MT5?96UU"([AW@R M*]R8$T\W[;*3F.^& "W). "_U6'H.%?_F'*:<;:%V/5"P]HC2?LBZ>*TS/R0 MFMS<-*T,VK3*NK0*@,QEH6]8@RT,P#36%!E4#9+[SXT\W&:%UQ+*]WGI@ -:^9HEVV3ZW7I#Y<;&> ME%@VIY#%C3YV8GL=725JXZ3%_[>HX,J<:J"TIBZ^R2ZO:7GIUTE?ZW$AW)@1 MM9Q?8.CIOC[4QL_$35?;Y1?#^DF64KW[:V66QA5C1F/!;B:9KUK)^WF46L*# M 7^>+S'+VR]K-]A)1Q+B"TD" :O.G'O,34HD3'JY5INOY8=><[)XVXEULM*U MTWX]&]0^A,#"4Z_%M$C3.:&S?=E)>Q#-YN M'8LYA])Z)O0(ZWS?E2:\<5&1,#*03$K&V]>H(>G8SWI.PTG]G2;7Y4#O%D#A M:X<$A5U06T^W2#D5=N?ELOTP&!Y>J$QKWOA&N:;4,; QAZ"@*+6D^"4X1&B* M3K^('9YU@\<(>N+TA"0$&DQ???XL@^5,)ELM9VA],IYA+ES8ND9G>UAAD5J] MH%E*C/2CULK6IJ1=)* M[-42IT/22+C$3!YE&BKR\ZS\_*#;31+]?L--9' ME14D"E;IR\!@J39IIN$[$V)IDX MP+$RIV+>5LX=\/#N5P2G>GZVVDM,.E2OQT*)'T2W#*65>U7,5'K9$Y,5,/PP MWTVX28\=_U=P"2/2*NI7S1JF.1Z$N;&?[Q$)P#!1;I*-:,]TBL48S MP(U1H&V3F5XFC1^=R(WSW;BJ,G[;:$P!B'F3MZ =O9+R> MJ@U1$2U=.PJ>JM-X]YIH('HAZ#G92\9GOJF"LV."'W(FWLTGTX49$=<(U%0PPF&%YX>X@G=73DX&^Z)XDN67%[,$Q#C8&[: M9/D/1OV/N /E3Z'+4W>2[&I7*)W9G, X M)RJXIX80Z$89\REX;3MC1TTJ)DKYW?R9FN],9G"&\#%YI8M7(;I4 M-E5IVB0NY4DN#8PGE\Y==(QQ_$2&SA'RNZ4V\F.]E3U##))\-S[+#12 ;.6J MB^&OH_OBO/_I"CP/>UIK-X5F:;,W&N6R^R#$41XB_,T!,YUO=C3CJPYE"CN# MZ8_UD$O#*3(4^&C2W#DIU@S5>C\3]_04[(E6?[%COB^(29GHL&_'IS$IN-SI.[6-Y9Y!%$YLW4C5C0.Z_N/PHOC9 MK;(>E9RJ_L]5D-:QO,UGA?_N(4EAR\++*F@[6BO\G]-'C,(3RBJNIP\!'&UK MRBKO_K!/ _ZM@OT_]6#UCD*$S+0EJ>\\I*;9#P55;<)&4D#48@R[=<7K*)?W ML%9GMGO65![GUY,3_XN)_A51/-_KSNSG\LTZ^>+_%8QMY9.$1XDOAU1R:[G_ M]SG^OZIN2:UR(G(4MX+S/LO:P6WB(]@ 66YW#97[WCF@7BQ'A]W2,^N$WJV* M?*;G5V]OQAG>"\B(DM&U;&G,&WX)B%=7'*E5.B.[O[QYM>:M_IE+4_]M&;[D MC>:/P_^)5O]-]P7L,-;O#^\:%_]_=H)]3BX?W3DSX OZ%M"5XA$KR>N2O:M1 M]G$7LEE.IZW2_5W30QM_LMB78VH#E1RX?V9PH#'TL7GJ79S7P)LE+IN>$).T M$ +Y_;/7#]4N0M( )*BG'S*D#SJASG>*YW7?L'K[4:[WV*F6@#+LMP M57"/TEQ&Q(S1+AR <>9JG@G=NE:Z M:LY=]PJ&Z/%(6![?#KU)2=5SZ*O=FU%CY,OK(HL[=1VIFQ:5YK[:M M]%SB)FUQMFYTMLF/I_X*:- IZ?&F+$Z)MK)AL.F-N4,VK68I_!9@OA )?(06 MT=)KHBG/5;;09Q=.^) M^9>MMJ)N 2^$UXR#?_4R6WPP<*CUC3U>O[A &]S08=30/^NE7\ZMS4GBY^N" M%V\!EDUYQ@P& V3OU /=K^(<=+Z@1<6H*F#,*DN<73C16T"GN#2M_X3QFQFA ME9>\8:K9I5S%?#73OC\[XKOWB6K=XWI$&<6ZOR[/#(5UCL-$/Q4_9)=9YH9I M'F:JQ;72:KU7_T'/DLMLD3!1(;W-Z74+>*B',@J-A+FRMX@A%<\A1W3ZGN3+ M^%;)!\3.C08;3)C9OQVY]TX?41X9EZ(X+V"H[8.'ZT= 3P_YH(_U3:AGN1=4 M+(UOXVPF-M=%W.&E'2P15AZN*R3G9+T0,.K#6(CX=O2^KP*#9SPW1+7!H($G M>SJPQIG[!)SK_.U^]6M %%W44$+:3'O02M5 M/I+?^0.B>%+69] E/\_ZHE3448>(*]1AQ(BO,3WASZ6S>X1E6MX<'\SSY/1] MS6G^Y+LW24]_59#0L-:]L6D-[2VE&HPL*JC6O@4D_7HA=POPXU4K)BLI.'#V M,HHI_31Y<-XJ#I'H9VBJ;3"JZF8X5*(8CS@&(2XO+*$T_@,9O"C+ -=4U_9C MPMFHNK+5!4R]NF24AL*3&OFR]_>S.^#>%WMZO3TFB8F)(5H!_8QS@C;B4>(J M4?4BSQA#R!;W?8B/I=/W8@H(OI5ROL2$=M#4F*8D/WWN#_G;H8PRCZS>,#:8:TP8U+,C;A&A19F+J:^U4.E M%+OA-]3,1.M:9P71,_MW^ M[+PF!2'UELH\<**>>S!Y=)O DR;\9@FN&7'B&2F>I"DOA$U(\5!=X)F[RAA5 M2(#S%>TT%M66G!XYO/,30QY%^).B0GXVY6_V+--;*S\V%M,V$:.E^U:W^&S# MD;,'QX:;:_)&GZJV_*Z&0"3<@Y6AI%!A@R<8A3K1,>F94^E?IBR%=8@^J[7J M"'81)298T^;HY,UC*MPK-![E5BZJ/2-+88B4O06$8C?!))>N/XYMB.FSLMG$HJAN9"S9:0*BY70SY M)%0M;V0N,]X"G,9\SP8VJ*\*WQXO&G--<%=D65,_#5X.5#5Z+,JQG$>]YT^V MFZ!6/%Q"J;#=)4/[XFH;&,)Y&=;D9E52LS0=;WVI9I"9B&1S5NIZ/V+]UT^N M'!T/[_+67+;1F478_?@@HN+$%B,DU2AU?3,WLD)RQZXJX)Z4&6Q[L+WIE*L! MU'@EP^OOCYXX+@YU;BH_%U''L7N7BMI0=X MS"SJO\L?=UO2WCP'W3L."D?'+4\D)%P\834?8%4)#;UKIEK=WC*E1.*48 MY])?GU3SC+_;#Y0Z;)TN6EAB0N&T."?C^+9JGDI-(?1TB M08S'9+K=3H$NO\M9=:'J$ZZI,(./6A% H<]<)R7B_??@K-94?6^<%::J4-N] MG*DL$"FEC-%KX))AUI=\2C]D83%=YQ%XB),DK!M)GS*I4Y(_?#2IT[K?6NP7W:?,-%TI2IE M<'E%OCQ\MN3<'*?,QDI+/8O-]S5'@D*AU6/1M4?X.[FZQ]JQN89&.]KRC+P( M5JW!Z,BA]22$],6B1T44R'(%WW,=.3,:!+-:IDG]..Z*M0"B4X8DU;W4"(_+ M1DF%/>6AS6/J@>+8G?7H]Z?RJ)A:GP*YB^A_1@>1R$FIYI8!;6&K.2JJ(0!? MW%Q1Q0'Q,]%4H9&3QB_5WCPO(B<0@TZU4\KG!F>@I(8%^J&3Q2Y1W[H*<8B6 M3\/@134T=QK]3&T!U"O23HSQ1S9J/\7IR!54*P_\Z2;[NH4QKRTNV!)@16A_S?_ M?-J>X,=SE3>6820M(LN4 $!APBI2TG$-H97..9(_.SM7FZHVA+NWKXXJE"A6 M1@B1WH +??)/!7$"N'F<./9GB]BQ_*E^ ^HHW"V:M7?"NHFN<)ZYME+9-!^V M/3\1L#A)5X;7?PL0J!\LW)0]5POPE5\60/$$PP1!YG80E;II0HEZ+Q8K#95? M':-+?T;Q51-/HH"U:N%M0*8YA_&H2^.Z3+GD(2;#MKQ !8? M]ST&&5HENX#_NHM0D"@X.#G9T5;UQ+9^+*HU-6P'^\4P\?K?6%]! &K (V+W&'Y^GL(WZ3ZV=G+ MI*HH2&ZV#F"KT+F-$&6!_:$XO6 M:%KID0)U08D=7"7"',9"SG)A*J^JG83J\I(X$OHZ.,N^57*3W'_Q4=A#>]Z= MO)PZ,%>_M&@.$:^T,#JKNF#K'C]H\BLC*I;Q%QS!DQ6YOZ(^4_&BC^K0-G/XBC&#*L\SDXEC?TSJ)G,> MM/XJ^T8&-VK\\K@ 5JBW(YX)?"=AROA*PET49!*EFW8]@^]^*F_..VU.6 \@1 MU?^8'U&6([U'.^Y5*+:53NT%J=$LLD"(93W>#AHE_9M[DD"Z^;G[?RU(^[_I MRR)CW?B=>1,'^)'^_UN#EINQ,L:XQ:FA_DF1K0OY;T IC#W!]:]\O#6+[H); ML-E*"AH!:"6Y)Q-0+"+3"7Y_=R,3SY+MR"]TTN40KHUN#\G+.LM[\[3FLROI M)Z>"15HV6J6"-=K^\TPO[GKM>__N0K"3GFE#MIX*SI( M$!IV+*&$FE9YEE]LL'/!ML82-\#-F;E*D%6)UX8O"C=]KQ&E([@4O]0:Y[HS MZ+P9T4R/KCZN6^A((4R.@._O(D%\5.1*X9)7/F&4>/%^^'2E@Q;82LQ+X6RB MUNBS=ON6Y 'EZ']F$K7:6SPA@^L M]GO-&J%-9ISP01TFO-''JSICTF+-NDGO+ BJ2A]^\22*$0#_M%BF'PTQ0Z') MJ*:T=>9T9L=.?-Q 2H-HCO0/+V"1+1;G5ZY-6.*Z6C#E8M^(I$B\4H,].$W0 M+M/^Y[5V:( TUY@)["JR3BSW*IWBT)#U^+X4--$+%))GQ-GI+569(@R!4)KR MOW,A_1DM+_-7!D[6O+I 5>ZF5OLPP?9SSK/4^08 3; Y^S'1JTU$$^?1"5_ M\1HW>,R[O]80M27V7;'P3U1$K,8T["R2BL<^3S<[S/SGWUC ME4'QN_;G <3 3(&U$B]SL %$@[Z>X3H\7_I'/E9A,BXO6&(@=AWN;A\A@7<( M"9+S4GY7+V:B,FI8*1\:+OG>C4@8LJ1A,>5J]:GRF_"KCX_\G4%G)/#9%EXX ML$9LUDUT;K/4[&3Y%'+Q8]\3_Z\5LSQ4NXU-$$EKUP MVR5(.)AQ=IIL9UF/X7&."!X7TXU>\?N6D7XHL37^UJ\2]H15= M^;/R9&#O;*RHXKL;* *IJ_>AT)3P.3'9(?B>KQST&+QV#EMXM\(5:S]5E1CS MMH'FZM G //VK"(;=<>2):;%6%DRH#?)Q"V 7Q^RUE.Y$)/JO2'9 4H M+=_)G.4YIO3L<:]X:&__ ,4LS"\P5YMBKXW#(B*,$BVW/A,%!'^_L,0@2 M;ZT?W-N[SA=S%1 5$R,+ M@[>.%]_X12AN-)E;D3 E;-HM/=X[M>_S4QC7&3NN4]=\,VCYSS?#@A1KUAG0 M2>,YK4!L"#$==2)=;HD=K-QW FBEJ!E58!1BWNY,MMX"UJ#[UJ;FYEXB8;DA MD+TME:_RU,J?&\>2L#),Y_ U\'M/\(74E*3+F@2=@,%$V1<4-NH?3HA/&-Y@ M<93OKTTE8.]LNV@GVB6\6.833.B)8(W-X65KIIV$'WSF"WJ!^'UIM.@IYU%5 M;;W16"KH"Y_3\A.;1"Q(SNU>^;&;_/Z!&EE)9/:+'7%"CY7II%N5NDC\(69H4<,1O$G) M7]DW6"\UXE1NFREHJM9*Y#9_)SQ>&AKOL2B_(:>A:%A'##@UGE>)%TH25M!R M==3ZEP)7 R6"=O0L*,$P$QN3BJ$Q"IJ+ILHDXI?GON\X$1B8A$=U(_H6@&(@ M;YGFTB:N,3(RYNGG1H;GIVP$-#\.>\(=E78O7CKQTG(_\N;-WZ:5H/+:6$I/ MD0\-UD(5!]PLW#IJ#+N3[X)-O*C,Y!S+%(9H A\])6[AV\>18S,Q3U;!).65 M.9Z@;F_I8BH+Y53.!R'O+$:W:-[>BU'DGGL0A6R:/]2XUZ1$(J7\FQ*S=R+] M$.6?I!2=9!)9>F QI62P5%U;GG%@,(YEC?1]7YIJHDU,I#8/EU_"[I7/3JZ$ M?XP&=7F##M?J*ZOJ;RH[G[_34)/3HE.2PM>P24LY/XN OTTO4:-![ M\Y&/.TNR_JRKP]'>N1M%N4&]OA,HP>EQLGD4N.(Q<[U<@ MBJ>BM,K\S6F$%X]<3G76W9N+?%^C1&._I*:, MLFX^O<-,O&&OE1?G+[)O.04/2\JMDGG_'/C"OQNAGOHC);D9TIP'<\6ZGH%\ M!GP-\@DEK=;9:Y#QVK,7VLWSY>E8M>=HSE4@I:_GL5Q,C&"TI7[%4BJX25V?B.!H/.-6"WD[LG]UH M\L0TY0=+E?C$89NP\:FX\B +J8ZL# M1/'QNRGU)KKKQ::M!]JYXT]TH+.1I\96Y9G^RDOE<3D-DQ2S7= JJQGW+[['.0 M5H\;TU@P1.M;X_^R*^,XYZ1WUSSOK&AP,HJ-VS2*E8E4#SX[;];#C]N\ZE)= M<$K#::UY0!^U4<*11A[&4S@*M+>*9@^>V_F0PN80-)S2YNZH,^OJD"SFZH33N>D6=SIW;3G777R6LK%L(X M8%.QU42)9Q,PEQ:; W(O!TAL0:-;7NA6]^]F:"":LMD2G)$ M1(J$VX(]?AY7G7PZ3/#(7OKN"#D90X*Z=VI&C"\5INTPZ3XJ<;T'I;$IK,N= MJ1[T()U M0#U1Y6^YCX42!M9_/4$AGCY(55ZR5&7>40[G0A^7O+P4;\Z\I#:;I=A9T>Z M-S6.3RF2.^M@_MH(2&FUPZ;#KVN' L]8M=GV]=D3A+,7HHIH)5F_29ZS>UMQ MP[:J],U?Q0VM$8E>1$;X+>!54W!7T2T@R1DH!&(9^PNYII_<]Q?C(,[>_Z&3 MO@.E/J2G=]@W_07=SF^V<[C9;,!$N^E3]*@ >P@KN[UH78!7YJ##E1,I*,%( M9RZ59KQP41;*JICI/]\5*+@*([T MFNV^*#T?,:J8@\15^6Q=M+CH'E!"=;FU^'<2YZGFWW\-.^M_':PA8:?AE*+/ M=J]2S&WC2ZH$/^N@P(B2'$"87^_18>M.7X3\36$M0#UI>S0NV6DO]GU2'_$/ M/KL%SY*LLGB[A:0#N/Y$((CCC51CR6?I"/92AO8EL5[%9_^:^%)C\E^9/4F[ M.GC<8YB');#_[M]_V0[&_,V5(]5Z\1^W+.P$UV?+>J#2Z6]KB4CZ%P!"/N=F ML)/-P ==WC[]=]P\Y8XZ&)J2ASZ*#8@5]N#,3(J-R&5.";'6;SO^3PJ)B!%T MHE_T-YYAOC/AAIF]8]'>^!T'(+GF8](YX8NFBVI(MH$2Z2,M@]003HI?L4W! M(4]=HB( >VP5 E/MD(K[N_YYS3YC>.UO:BEX5C[=]R^YB% [F=*GYG2 MG[>-9Y4&>FY[^H]+XXE+V(!0OSRMK/=\!:=<':8&*/#S?*IC?HD!>>Z)=8S< MLW";UGF8A9L&$6-DU@YD-6-[O:5JV^(<9^MW7!PK1\Q?IRC^T_^+R=XSDW+T MGX0_ZYHXBN1 W$*1 ;1+;VTK4[G^Q@C)O1#@E-01"0 MWFL4!*07*=)!>@TM-(%(KZ%#-/3>!$--("%=>(H3+V M4L)ZTO#$(1XAN?.*V4-X8,AT-B[3W?,.$Z ? MBIR[ZL%)ZF>+J_15KG^>(3BGP'3;&-.'=O=$TTJ34M_&FK2+7"GJHX8]B[G9 M1WEOF'D)18=^1B\Q,&'[S+6 C)[6.(2O5YU.W0RO_J.3X-UH#P_O/P=@YGRX M_V"6?P6 Y)B"9+0-S=Y[Q &".\3VG]QHI-2*27YP.,/[YQP0#+F.JAZ4JBAK M;";B8)E))QNP,X3#//3@[Z^88Z4:@NSB-[%9Z-0-&15_]N/$!*8O[!Y!9Z/= ML@%[6T*'G ';7P?N58HN1MMAC4SG X],-+L/PK]Y+ZWADE=:DTEGS&B_UY.I MPW(PW;<<$\!^#H](EW- UI6]BYV>OYH)&;$<,T^5]EITYOPA>#;SM=#J'& 9 MV"\TLUZ),#C+=K\[]J"V0;.%C9[AV<8\]SD @4-03XDYUCP?K0U4T.D0ZON0 M228?;?MK9SZ*+)J<$M: *+HN;*DF3!HZWG7?BLDXB@D;L\'<H MQK51HJ[2#3L;>W9"V#J68FZ90(>;-!.:?34'HR^UF<'W>GR.:+&./^.]B&UH M\0A'6^Q1WK8@.[2\"_M1MPL5J/D@,MVO 2%\]@WU#FV]= Z(%M@AZ17:8>VC MTYE 'T""*MY.G73WGHI\S!-ZP!9X32'@QC6V>_N!$>GO;L=/?TJU]2M M 'H2"Q+'%]6,$>S$?G8N40R'>%IEF_/0O@8PDTH;$;^K_]2%4,4'WZNPXYA% M>BBM-$9;P^Z*KQW^L'$S8+:SOQ_5[-3!TL-@RTAWC?'Y']Z/A%E<>?,[^^,! M0[^3R]K2O+)P8Y[):[,6")6>#C;0AM*FM=M%I?+M6\\ #[[]M$MW, &#E"H%PT MQG9GCVZ*"RN/ 3.73+_(JEG$M+=FI&G43*@.<"*1;>^N2G>6*>_T,JI6=UG ."3N&!HU8I^OC7/2+/^GO("^06NPIN MKF([G[/,()KMTB+[,\:T-[IF^)QJ/7\MGT,3NL .%:%SR^F M$HZ;OI1:6.P5H3G:*N>Z06K#W@3\T33^I D0F_\PKL1ZW\M(PS8>E+M\0N7:3.KAYJ MRCJ-#$9*!TT[ICXTZW,V0CL7[L[,J=5K#-T,**C[OJ>0$4KRVA#?6\\8%]X= M;KT$*5?R7B[7WI+-*=M)#+D>S=<9\-3Y5+]T9-3,CD$K\2[>-KRE[E.XW3!R M@B)>Z2VCWC6CO@U R5YE"&>4*_+:-1L$[S5](Q9)D/G6AE-_1PX#VET\&Q=2 MX]%(Y!"DF7-; /:Y:A=VS!J1#VRVSP'V;.< U<#I)?U2AQ^6Q/O=D+!4Q=TBO@N0G.&I#IM2*?$7G# MS41UICA+8^)1#$1H7\W<4\:JU:!FG"2]7$ZOC:EX..X@9N*#0_L%##-;?5M0 MNO-1PJ^HZ+FDY ![LW\.9<_-UP:#XW\M'(^968%%""E"&&Z]#2PV48N65R * M!+G;B^UR"'?D**W,G_1?>;HH7N-RY=JM6-=MLQ1"3KL7^<' LOP-7A>P@]F: M#V=%/[9%$[D0 ,I)6%K5H;_%$=\T-0#;G)2EC0)S^/'7UHRO)*F]_Y#S)84K M_K'+QO5U1_7&APQ6 "K6%NVV:M 3B<="8F[^K0NJVQKOF>+L;AB'UJ;?A MF(5UJH7BJPN-6KW/$$VMK &#K?03,FK.Q81Q/1PJHN#]K>5(?(#T3 M>1)SE< ;V6Z0^\W*73O!*F\!([:$R/5$3M=LE0<4SCA+A!M"#[?,<6[3VE$) M=37^VG-]GO4S3CP#U+81^-?V (_+J?A[UYK.U!9"<@"SUOYV[N3!DK<6A,CP M-;&LZUNGU_G<"V,L9RKKOZ*^N1#*M#CK]KVTG,*MT6W3)&,UX;O<>\SG"WYDT.40@,>;F6R3A_# MNN-GX /,,2G,IY[ 3P@%G%+7#P'&&24;8?^0$X*N5;\J_+>CF07:O'GN!N'S MO-<&?M^)1B9>D_QQ$@KY33YQ7 ;I(HE230UQ6I^_766G5">N52?SS@P9(_QI M=7)%M0S3%RNM_@F)=@ZS_[:R'Q>4AF13:BF(J\@T =P9>M=HG.>R_L/VUA:< MJ05DKXR^EK_)NP\_/9+]/P:OQ(#Q^OM"+7E_+.!Q2=V!\H%KNN=R/C3[^(&D4B61&Y0<1+VYVE$6A((60>_!?84KGQ24*1ATWB6\ M;!0%?.U:YQ()5_.%%8RY0OQ>_++LQ + MW&Y5P393@.CDPSVFB(*>1>+]EYL>@Y4V=.TCY<7UD":;0,ES@#)(LJ>OGL=_ M*9QJS3H2]N#N MB= F4(#FWG]O&QQ.CR'1#\@UC;N7:AAT0I.*YAY,T+^>X(8]YK-,_"RQ5\T_ M1*=Y_#GJT\CW2+8Z=YUCKIHI_J,?.["NNQ@LYLL.> #NE>HFOLG%6>5F&::B MRY-TNT#8D\F*^]F5F8*Z.6)2KC@BM?2E\> ^"LN]4!\B9L@QB5IDQ)&2#30? M9^J\85KW/ EBFHY7L_XZURS05XD["X)NUGF<^I,9[=179 MC)]=N3)#4[A?:GKG+,6A\TM3T/3FL:W+VT_-?<"]#9%MM"]37-[TAM0'<8^X MI^+'V\C;'L#EOW/AB8A*W6*7'M7'WQO5U8%?,FG-6+S1^1TJR#:SV0:_'UX+.N/ >49/(K'U(_ \VUUA0J M]&9:2XUM=4Q*4WD#I!TU@5%_5(F;38A_ZE$GOB6\>OO!&231TG3[;FHM+#%- MKM]S3%%#_C/^@(@G4;$*5ZX0M5^DS57D_;/1F78N7WS*<4(BXH[*"__M* M%*.C/*KF0E$/(RY5=CB7F K,6=N3S2:R$N$9=M,$=M_:H1QG-D&+]7#Z"1^1 MS'DYPJ0)MUG+Z&'#GYV=#U\'%@:-H@_.EAJ&-!O+=J!'B,(;WLYBAVB\N=X) M_#KF)'W41A#?0C>VQ0ZNJC3C&84>Y;(^#_V"N5^?"7F*$2GWPFBWZ+1N/GVS MFW0.>$(R/CAY6V%($-">5-Q\85.W <.\Q9;U;V3R8V_34/QY5G&_Q9N?691V^F?3 MDD9DJA5*L,=9]YBR$)QM"C?J6CEP%?GW?[!NY]6.BYY4<,9HQCXOP,E M2=*7H:6SR9_2X5,W?_N9$X*86G)F-)94*G:T^/AS&YJ0)C+8/JM!NKHWF;@? MS]6*L:SP9[UY94V7"^*.?#M8U5HUQE7.3E3B8I9LH &0?+_2)59(#/ZTH/EX M>(F7E[7XZO%H^5'96->#U'6\\D*QS&'HC;^[OE=Y7J/S]/ MHTP(&K0+@J3%-UQ2C5=>:DVL)F0^_9 ;(LNDG,1 E?TJYQJE R2?F]LN3WTF M'J^\ [YG>_<*'I]4USJ:$X<2^6103J:'%8,]1YT:N-"C"ML7J(<%\?4QZNVKR:['3LZELS(G8.N&33"FH0,7ZQ-R/8EGKW\?KV+_*C&MCBM6_S^WM%M$1; M6O* L:^?/N;U.:!G%D6^P@?$U2,7SP%\9<-3O^!1;#4PP97BD2T',+61%/GO M:U3D:4;4.:!ZDG4^,!JRC-&;<<9;A2*6"D_U(21^$VFWOH;C*2H;X[2R_#LWG")1Z@''?VQ$\LCV6HX M=B:W/OIAA*C@:(PSL+6DT+WO!%C0HTR;0VIY3,Q)U.6-]5: SXGB^U]ZR0\6NKEEHI4PLAE*U*S_V_ M%"G*YK,XL'IYT&W.&%IMV#]?KUQBQ.X[I\,G.(S[T\7TU8(6WX\]X;=^\KT:ST M/GLFN:+S!W-Q3'3";;HSHVN5LP?EA:G/-Y6%2P)L_L8/1C+S#*M546IX#N^3BM MCCLQ$/UO>N M?1=<^S5T42-U9SDRJ@(WI0VKU[]IM%XF6DLN_8#?"!B!.E3HRZHRC5LYR S^ M_4R6-=AC#+-?AE/YJ6JQMQ06) ?,W"P:8LC"]X#(5Z_C2\"/":S^>0K'Y?QR MI49T#10]J925;)#%821,RT?DE6$+>VA-FXSGZ[(X*176R-*:^=>S:R>HU/LR_X%W+D9/MZ/D"03JC[W[>;EJ>*KD4L."9\ESDT!-<=F)TP\6ME3N:O\C9I;. ML9P#8G=0DZA#>MW_&,L[,;#X3LE-ZWL*P_83:5^=K3 6_ U6\WK1!=?7?58< M+IX6GJ8\YN+_B'M_ZGLSZQ-Y>#IR26M&;AUA3#>6U\/PFL+7U\I(0@)WB"]E MT-*H_'< X]*FGKD*TYNV'K_)DL< OEI7#15&\N:U,(L#"]YM]?IZ(7&CFBZ MVO][&UX#7HUJ1.LE^-4N25 I/ \*!T#_V49<%$\2HJ(CCT)?/W5)\\@I>Z"/ M?&5FS_ 4\06I\=1[S#]8S\ 7]M$HP>?NL%EV223LB4*+JNG#*;^_=]3':^UH MDA\8YKKN)_WD[/V+N;*YK5D[+D;+ ,D1G5V5\OH.90TGQG4I,/LO53X=/!@,-!*D7_ 6!* M2<99=>V2B?8JHH)AY44AWCFK4(ZT5;Z&X/CS(,I( A?;WFA%:A1UJ6\T;K'L M$U/)0W$3M8_5LDX]0E^Q,A"6>:"F<:;J=*H4]K+]13H=YP'B@:NA;76N:=B^6LXL^SP*6_ MB_GL;@^[M<)7(K$W4X\^!_A%PV7T';NR/K,<%RX\X2/)EFTQG0YB/(K7H4^% M9/37EB"UPMZ?0A9I4R+7T\WI36-*M^N:J-G?30RP!VP=>9[2%#2@;A/V#XQO MW6JP8]6_QP&<5P:CVF5#P4<\VDF=Q:\TY5>BK!?QW78(!F/85FH2JM1PDZ7/ MS?!==?23YT1CYUI[E/!+4#RMD(D!-[?#@H(;^WT@0[,@UL+$B/#]LUW5_6#]ME6[N<"G=DC%2=.@L5P0HRVERH%5:(Z? MS8@#HJ(Y;:UA[RH36C)Z;;05[55<6(I^P!=LQB]=>S878!%;Z&2[Y<>W" _# M"GPA27B[5]BE)H#=TU.1R-FNG'JJOU[\(X\>2&M1I*B+NQBN5O_T%8E"YA00 MI'6G>[B07J:^:Y_%D=@H MJF.^BH0-J2HPV4K=6QP7D9>9]CT0%8OXL)@9T+9;S&1[.'PA"$MGF MY':D04F^OX950-QG6Q;*LQWDZYJ'^;CUG; <0DLMZH_T,,U@4V>]$]3[M= ! M9ZU]O5"\,S+7X?J'.\K=+KR:G?.U@W-WQOD%Q&Z>/1J:FZ)L<%V]]H;%__CZ M#:N;\X"E:"NVL3]6',)]>/,&Q[RG\'R.I'H O*<%LWP3'FP/C(9V#(L^*;;9 M$:5=[?]25?/RU] 4<^^S='O2#6)]M 4@MDI\1#O39-XF"NN6E-[9"DN_: @+%?D^@V\G>NFAH-> =D< M,^!CHFC^=TQCX_'L*W@Q8R#&0L-*;.8 M,G;?\2=UG3X6)O$RZRHM<8-V76N&1-6:*GL:D%^X=6/BUK3F M$8.O0@VMS?T4KB#B2S.HO<:K?MXN-N8'8.,L?-\".1'[WHS9#U(A7-1*Y$"3 M[O*N9@T7;INJE?E)31UJ="]K-%UO,;D[:(:VHRO'5^EOSP!QQ6Y+O<=.UJ-X M*$TRPC[53OKFT))BF!DDRJBZJGY\9^K>P_![NN8 M[N_G#_M?Y.YOFH2$[F%@XW7E*QZGGP/*6HVSOBT?%KO-O^#4.!0B<_K=1^&B M2!CQJC[/_-[5R1$'KTN2V([IJ891IC^"IX'2!JWO@:R']L8\QMY8MZAN+N88 M\BE;@#MW&/C.AJG8EYGIS\C45PI=%52H1M.08ET[15U;9%X,+RZF6]:WW1*-?!H.WTP/0IPL-631 MD]@GFT6:Y*ZW(DW]IIWCJ27RISK2C2/U%7)/N\,W\7B\^ M-P7Q13+=+64-S(6QW+.JQHQ!IZ&J&T7;UYQ6X'3# ?/!ND(\1?/U"&;9[>P] M[H^(9F[NTQ:IJRYX!F%&*JA54UDY6HVU"? M)+F8\.X^C1QCSQ:*YL_1@-G.+8IEO:]K@M9XQRU*/&RZ<*S*#U)JZJ7V^FN? M@>(M7ZMI&JS#2S*@^T?%CW>^FF5)G45-9]] ]ZMJ"&'6=M= A,]4/3*UJUA[+V,R/%_JO?0DH32,UJVMX0U\[;.OX9U7"JI M0H,T8@(4H-\__@L;NAH4_7,:LRE'%1@ ]+768V5>VG_1F)WNV4:^&.)J22,S MHV/[" ?T[ ?/P44//P)-J+N@'QU=W8UL?PH^!IU_A@+TB'.9Y,3]EUBK>MR5 MQ<3AL!R<8FD>X6\[U'A\.Q/4T"I'&>F@O_L$W-O CPG!T]Q1H=.HFBAD,0BZZX%HSK)+&)_/(&\_4 M'N^^W!3^E'Z];S;>ME-@;TCZ["V?-H15(Q]N4_L5G==CS;BGD6RJJZ\ZV+<2 M1E&!I[[RD%G/40*B:0CO02W9VNH#A591U3VA)+U%@1!L/*%_ N85H8U!N-^, MO0^5$*ZNSEM#L8E$3"B03K/3G %7&7N>,8X]TUG0#,*SH0PX, M<=NHXU%H9&FO[N'3;+H3JPK"E!51-@_V3B\1FM-L MVU5& MX:^6_1JQ\S).+ZU2%<*?]0P..@$JS$P(P1RKN>,&;P]%>B4ANX@C2*(UH6(? M=M&RS2B(U,;!*NERB*4$'^)1V1IQLES*QR3U1>ILG$J34:H1\TH*^3#:!4WV MYY&\7$I!YEIXS,R]\02S+_J:R93E!U=5:$?F[?C](=&0C6RP@X0$>">U4;4[ M/C':8[@M&2/D77.]EN@\I9:$A?_-VNO2FBH_W :Q>7B.S6M\71='5WV:9C\Y MG81%G"#U51S>Q7O?2T_^L+PA1=N>2^P;+J=K.6)90TXS[E'2PFTLV=Q;Q6.8JAT70NYVU9G6B2 M'I#-:WTW7H(54?GV'6+SL"9)^AE$J*=E9EZ5*\[3J06LU?7:_]4R^MT!*T/C MZ^$;8Y"WMW3:I=!#^?E>J6CDO=W\^#'8MEU$G*@.*T+4.$;T%M$AS4[Q&K5Y M>LBC)D@@JH83WPYA%R]P'Y#>D2#RR$J6@VK?^:9H\WIU#@VA*S]=6I+-J2?] M3+QZ^@'O4LD]&)")!&(MA78/6#VDUDIC;VJ\+R;QY(Y$\W!5ORH0!'_4LVJ, M93Q;)KMA4GKVZM>?WU&S+23HH:CI].;0K 2EI2>+$5PJCD/Q-]>G%I<#23#\05IYR72 M:8#EKW%(JK_S,OE.<)P2S[)LVU)Z[?-#R3V;'N 0XCW+Y#D@N,)O@#7LH62? M\9K$*4+>-&//H/W4AQ"@MHH,ET;V_+UMSPUN6""+K3VWU(YLC,WEMY@D7=I[ M!+P;\^@=S%[NFNJ5_7Y(<^&I1W&S%FY8;4]QDT6@>E:"5/_9_JU_CSP!\_6W M^E1R)9I5U.7E5N_/?1H%WY^25S:--%Q:J"T;34,CO;(6+QJ9X C1L.,(T_%. ML!89MX6*84PQQ[.\&S.&J7'0]_0WL=&10=B6S0E1)= #G-R&@K=F)Q__O,J> M[LAT9V7W:_#DQHWM\ ;--$6;&_.*;IFW"1DTR-LUD_'/K&(_'%P_&R3WC&2] M2@2&D9G/$I#=J3]R5S.G965'S@%_4(E.)>$[@=GAAYJ?H9'X)MD)5]5]ON8? MH!G76HL"VW>[6V'QSOBXH?>>&"AG3Y8UUVP//J[RA*/'BKWU3,'=SK&0] )I MQ R=(M,=,/:D ,\!#*CU\,+E;>6=HU))D()^D_Z!,EG&;1C5\BYLKO_]6G"D M2P_/QXZ1V.NG>K(&PL#.QKAQHS0S -8_4Z6@(7YQ$/74[_CJ@AN;?FM&L7P) M+,P\5CF#MB3KA31+VU[3.:!S;>"L: 88X*HG(\L+\XK_I=BET+T:2Q,-Z!TF M3/G5&X#BM];?*##H6[UY_F$4FU,/;+8%I$;7:CVG*Z\.VM;64@ (>S5O'$]0 M!'1#FM$G>M^=3\8MY1Z1.D1_?J#W'LC,1'**BUY'/>Z2BOUO5VG$.(S FVC) MUAVEJW;L'N& ^'_J6>"8OO*+E6W%(; M]RK?:2#]L#3A?QC9)=DN,5:(>UEVNB+YU@D&Q ]H)[?WQW3&G/_^7U!+ P04 M " !@@%=8,1:OD9&@!0 U]P@ % &UR;F$M,C R,S$R,S%?9S4N:G!G M[+QY/)3]WS=\R#)D&6M"F;*D+,F6BHQR(DFT6"*F0DA(R&#,6+*'Y$36"4F% M)ON2C%TB^Q)BC+&O,Y8QS';/>3WW<]_7^?M=O^NYKOMUW<]]7<]S'N;[Q[SF M>WR/S_K^O#_?XS@P?S*G <&K1B9& !L;&W"/]0'D MYN3DX. \" )Q0[RLB94"@('V-C9#W"P_R$UZ]=@UN\ AQ"G M\'&U2UPB-^Z#9+Q%U4.3YV>D9?_MN!=X?L/'\O**RJKJFMJZYI;6MO:.[YU?A\8'!H> M&?TY-HZ?(V=\B[E+W]/_1B ]C9_N_C7]1+B*77 0X.=@[0 M'WJQ'?#_8X(0!^=Q-2[A2S= ][U%9-1#N44O)^66-O'(:MPDBCUXVG_PD)PF M7I[TAVK_I-F_3;&P_R7-_H=B_U.O<8"/G8WE/'8A KLC;;J'1^^!1L:]M-I MN^%W$K@^#%.PP>" 4EA?>4Z4,(%+IC@:-XI4O'R2W9@A;&;'"$O#4@29 ,'X3XN5OW_# M#Z&8:'GM'W1@ M,&3" >0GSU"+O!!-%%YN&+MX*H@)A((9 MFJAFDR)4W\U=)G 0G._$/N7"'^)\)<(?XGPEPC_1T381S3:C-&>#LEQPQA3\47N5,(4R)IRS:[&"D*474"Y3,1JB(K@D^&')] MB&;MGC]YZ;$?/_1ZRE#%$2-TN^SE)="QITI*-OU^8/"C6V[[ M)1$]Z2BV"9626171TBP7OF(V2/0;'NB_8KZ'*WCC^%6$GM8*&@0/PQFHQ406 MGDZ[,!'@Y 3-N.4YN))E_6F)I?U"Q%L*B(CK\/>OF\:2Q&.,DH+Y,^267P:\ M^G#FLNS4P .UT-HRD^8<3@!N_N=B^F?3!BJTJ8;?!XY&:+M_M&\3 M4AQ M?L;)XOO#Q7+A%BDYFA[O#L5#Y%\39F\:"9S_Y-\&$T#-<,+Z4+/G"U&CW:A]P3?\:'%*^.W$MHR!$P7P]]6#(44Z(:#7O_R* M_T8!__XPB: W 5L8S:.?[9B7C?R95 M>EPRW5M[Q7$6SK'PII/VP]MRVNJU)XEF?%5F MNIBD#G?SWM_G\A MPDA45+W!QP;L.Z5'_B_>+1^[E/T->F[W4V %0IL)R!Y*8P*P&ZC%!R'@?[8C M\J%> 6]FW>$@-UC!+]"'6]Y_WLSK_F0YQS$GW$=(=4?(H).,D$C/O73E=*\"P>:/T&GAY0 >#SE<2NUBEI2A@"C"K0 MU3LE?F,,Y5)<^D7B[42I09'8^:GZ\(3 (9B@GC0\"N\2ZUE_?B;^W%+@C[)\ MT\?."7=!%M\-C+H+CR4\W_?#]',2/>-)XH2T,";@>B57B'(7[D"PQ2Y:JJI8 M=QW\T7=&0(T).,S7=Y 3*/:_&Z M9^35]]V#BTZ-IV-7?SIVWG7)&C[JTX0K'PW1TUJ"<*O2>(K=_6/\W)V#9SYH MQ>3Y>)]N!^QRN2TV+!^OU%E2^4#B_RX5?PM+6@6$<* M$_!'J^DQI@Y+IY!5(Q$B>;3S(U!WE #\61<5:O2Y[[BINY?6W$_^M\5&"P\= MNT0Z+S[*2ZOELFNT6FVDV,) W/Q'TQFC)[=OJW<\5W_ M_9C$XDEV_(8XW-R2J!KC!P&OI&+O#V_O71,_RWA@,E>SK'U<$77 7:9AF[00 M@F CK1 4.L 'QRFWJ$HS7.A'HQD.;^OB6W\$^8@\=)Q+%?I$?&"?>5V]%6(N M0$DA%K9 N9G 0QS(O-A-SZ6U]]#U\3!3E>Z/9$EX>_\<%T_JGMY^\A86>K(1 MU/O[#4- ]-\P@B#A*"=P'%I05\EQQHR]6<&BWRM??>+7IWS72$.^V]F))^]_ MS^'&*(YL7S1H":R<2OLX9E[XZ.RKPX65M2_>)IU;EC _-CH)(28C+A)AJZ/4 MB^Z,"XEM(F;OS+S]"SKP5:$&UY(]97R.\U='4)]+5R9.:U$\J%<*VU7CF(#P M-D])\7;7A%+T3%E=YH^$R5M>KP[4%6F&:=YL%;!94QH"$ :&P3?>4VPN<37)I@Y3U M1M#ND$3P? S>FOH!70A)\FS6G4EHIAYZ[F1 OPT=7X$W=9D'R;VP '4.6?]" MLA$35Q<(Z'$1AI@31,#OBEZ+UH\\=_45?P6J$5RH-4[Y4E1JH>-G)V>YC[/ ME8_CYDVXL!PABO$,$Y""][:,^IOD4[ W!U14BM?7M7_)O$HE0J;>-R?75!D< MS2J=%03'N&(^OB6J-J-"H5P(WAGP$!^=&2_[ M\;$K4#7O68R!'D,L.OF?]HZ&?9R+9I<+?:7_T7(<(?F)[=;7 NXQ/KT5Z99-QZ2'C1!+O>ZU=QI5B:7')C*!MP_J@\BW MAC"ZSD0P(>UY9:W3D*Y6X2+H5D4L?ET#Y1:0N_5>9DO?DQ1\ (LTAJIC1 MR[A(9*1\7+:-#">[JYQN'KQ5GX11Z4WV>MKF\3/TA,G3PCGV)^N<-O1L72'5 M5G"PE=TE=T6VM6Z$61%2?C$&Z3+PZX\J^:15[\LV!?^, MU^C:D[#M.$ZL$R1, ZYA=T&Y[H5_Z:^R\18UOSL\-ZBM'C6_ @ZOW,8Z8V*E MCQ&QJU02H4-M,G-#Q.!BP< 4+O'BBW5[Q,AD=K>V2*\W[-BRM-+(C@?$?$"U M,O[R[M7!ZN#8]IFEV; )[ZX [^1*#9RK1+XYR:'Z[>)X9))C\:-#@==SJ]=2 M#^V:'Q'7"8"IGWG6H.,)$F7;76BDVW;9TI.80$7Q+&EX!/O>?51<3Q:-?U/- M^.D>F3)FJX]3;[_5!?T"L'B"Z6WI*DSY]E;T./=9$+8.6YC&[J(21,XHP_ 2IH[UK 87P]\W;V&ED@;BYM(O&Q)3?" M?\8N6,%\8(8D4'0HO? N;Y>2W-??#3S.R<4XFDW9(\@\ F8CR@L&M M68BR=K_8+3DX\T9I7_$GE7> R)$XISD;]O9+P-:2@\];2IHE";?:0H3:D@[E M^Y0LDVA&E:%>&V_5>\M[,L,6DOL$S/4OM!*SPV-*A"[>ECP_?'UCU-%PK>.%?5GQH M%WAU(I[=PYHCN08(T.T#+?K:,0%\(:OBIQ)G)B Q17EV$/Z])M-PLN46@L7M M3J_N741):\ 4$)?2R%%>$8%I- 6#-APQHI+FXF/6K1G#J9M&=;_>**(UJU9# -!%SCLDZU;4 M(?CR.4>20JP61M"8;5)XN>[YJ(S&[F@=KVPF<'!W86S7/X!& MF-#:R\RC72.A(BL"*N)EVP*G4@K,OG27E@T]C 3UVG\K%EUH,#1C KPN'9") MCKLL9MK5"IDPPJVZW&0,H=?TC'SF C)W'_?J^"0^ N8]4809V&[OUOL/)LHF M"G(#?T)#D#D!O,=.@3*:0*S 67?/KJQ,W5^6@ELC!B^TQ[U4;YWF0PSXJ'=.E[8R@)3)2&.5\T99ZSC#ZJ-(P;T+>4$ MC7Q>N,C&#.S@.!=AGZU#*EDUS'.E+95WAC>4*\4#,>(N]\X4G3YWHT;QTU;H MT-I1=5=V_$>E-8P@LD./=PCUR /28NLT6F<>IEJOJVOF[3Z??B+R6'>DZ+-? M3VQ4Y4J!:H585&,O&-F#@^@ZSQP%7Z?ZSF^:?)J]61Q<8I\M$ M<6E+W!35.,4WQJ)9,XI*:^9AL/*-%JPXH^?LU(E*8O!H*UKD4(W] WYM.W=3 M^IEX!BS):U?N'/<36G;K>U3M#60/$RA+2,<@A,RCQ:7M44KG[#XN6\]ZAI+N"KM55PA32*N&2G37_&E%VRS0KKP M:U%\])3OOL=W3GF.[]U'KWB>5YA3T)TV9@(<.TP@.:>/":Q\9S5 OVD!"(*? MATK*T,C6ZKBN,Y@3/_R,MS M/4^O= Q@)2N\(I#GZ'GUH&G,8 M"G-8I?[6=&.KXWL2S1@4<19Q:3HQG'65WVG&))'F!OXZ8FJE<]&$S??D1VGB M>=V:+R,WN\X(GS+N[?X2*O=,E&U32XR,7M.BZE'8&[$@_ @-/)WY]9;I*R7K M"E(/^E/ED.>=*NSX&Z\4MFDE([7:$'FURJ]@E?!9=FZ5[J+YB%E:HW>"S2L M& 6N)Y(E:/9C]9+-IPJ)5[< MWE=J(K^>W9*Y\S91@N^EN/!GV:2(\VL9N50CA!SD %)MQ4&LNC9H0LDJ(4@G MIL\+[J2_?-A7SNG#N2;%ZUS>,"-&5UUA/$,&8>"5P.+E"!,5]',:Y+XR_P=3 M8;N.)U\DD+VBWHH?+& *[/)5&#DB&^D4IPG'O=BK4Z3=Z.,DKX1ZPT]V=G&F MP:8W:NIC 6!SQ$0BC+3(?Z_O[UBA/30,1<"U8LG'I.W(CQ9 M.#Q?_[%AB')?->P8/9R0W,$$B"]1]POCQM(80OG<=5O/W>7R>]"1!K MN/U ;K(2 !+>LCJ/;>M1G& ]F&A,]H;QP@W:&'S#"+<9>U/S2"9@.8(?+J@X MI'1*=E<(TW7\9O'ESXM<-@OLM4/8A^CP*B90^59:X%6;LN:I>C7IW'>+6\L^ M;=+YB($SW(/EFG$I$N-9M%KV,&Y0DZCUSWW4:GX^98/\/KSI%=SX-L4OSW8) M,EX7F78B3Y4/;W>?*C=[M+^\C+_[Z9F]@\@;XQ0"6:N?9DC<;?=/11WT4XVP M_13E(;^>YJ\0G3_L."RL]5"MZW!*][7OV)9&A8TC]T(06G@HSXKT!1)_:L0; MMZU'=5\)JV$#DT_7]>7H /#*'#A@QF(!HE@7=#2::,3]\.,NU0:WER M(G9&AM(S0-+A?'Q _P$/0,C]!&UQ4!ZA27U N;I*]N3FPE;5@C%F=:^F[*,D M[+]=:FHD7"Q:A1URK;/$K&IC;! 72?J4)&=ZN73NS-'+*]W5.8VI!J_7LCP/ MWC&RJ3[_3$)BG(TD+WI#G_-OA^]^%"W9#,1HWD]DQ)1]>E 7;, P>1?.!.X' MLZ#YMS$+D)I#/+&+[$^))\6.N&.X*59;EN71:^Y5\+5IY0L?.Y44RP6FA8V, M D>S3_,"U[D"M':JUY8^V%.,-AI1X(KS;\N)8HE1)>O*:QX_B[6O]^ +$$_6 M-D]U]BJ;6YT']K9FK)LPDC3(D$PY*2K*2]-$GN5VN5P'B>#+5R.2HM?9A75& MQ1TB\$S@$'QTQAD;T2#>.6/7Z:L4?_VP$B(M1#&=3HSC):[PF MN&,8O.)"/4G3B"*7E1$GEK3%]7B'ZT^.;]L^WDWFJGS9T,<1C?\F9=*B$4S( M(K$*1"B"EZI'LZ!8$] B!M/!/BVE%&G+'.M$NX#"X>,MHM:X32.GDY8IH*ZD MR#?@V/>88EH T;@1):(G0#M'PK;@!'Y,VVT(4N)US^NEZ^6K;.O,!@@YX11^ M-%T:=&T12M!PF,=]9@+A'HA+'G@V8KYM0[_M+V/M5AC%)"_![_4G_Y*T]+ W MT\'=.WLV3_6A9UTQ5=NH,1;EA3:CPW-.D,"M7Q4W[@PA+LX$34HXE>6X3E@T M5?[XOM9+XUCXYO2K<[KV'2$,,22K 3^H*_()OM*LC15"W"!(J7UH>9!1 M7.=7$%\*O =#NGL,/CT][ 3YDOB:O4E/BJ9(@K5-/@I6:+Z@F]&3R_G%WE3T MJ5R0S$VV!SW?+[P$>DQTV>_FG[)2;(P$<4CG-3324[>A46A!K)N9AZYL(3S. M@-A!DRW_/W(KM"/NF/+\M5)=SNVA"JSRX?([)E$\194)$X Z_*MX13M M$I&^$._IEWW33,.D;VUCMBSB@'A7I[++$^@7% R_%R '('!YKJ,Y,B./-4OT M(!4PG/G1RGJ=%/]OJV+6ROH2*5VLJ=*QN..G&Q>KL M(U^T3_KM):5?MPR=WL5\\E.-PO$F-Z'8D@$AG$]LQVW8C\XV(W;&3G7UB0]B-5:[NX D'*C MIB0EO$NLGB#EI:NTRD!""S%%.6J M"K@5^.<_(EY?64[2SL#E25);9J):LC7(;R@%Q(6V#-\#IC P)8-Z:51?*BK% M3;9+>L/0ZV0B%_0SZJT+[ HOO3='^6\X7M/.R[U[^]-#[IY6GP7+GGK?HG>[6P,]J03$!ZP7I45V1& M]2>DP]J!BT@?C?"0(_&7?NE?][(EW4,'?Z;_ZF97%^-&>EY2F1!E(W&*[:L4 M,EH=I(E^B9&^[N@(273KG8UCQB/UM\1C'#_;\4BQ/3\T;[EU>1-Y[UR'L@E[ M>A_*:2,2PK_>< 82?<;AT;[J<\_'JLH;>1DVZ](#M]4#=&X,WWD](_/S* ^G M1B.H:=MZS'V:!1%3XO3,[<38"]4M79/..ZQF>]S6C;0B?G;BC8;YG%RQW&.. M&)#2EH;B[$N3(L8Q>@)"_#UC:!P:6=&)\45SP.!P>,;,Z ]U,[Y+Z7PGUVJF M/SN8/&#S-&>IH")&WOAW]1Y*K%[3$1/)@%!*28.FQ(68552%;UR<72%<=TEF M+_6$LTZ^LR/^(Q30M7T+V6PTDQ)T*FJT/]-O[[CB+MCQU%CL#B*D&;B?B:\?Z= MQU>RSCQ^&6#!JC==C0S0"$,._JZE)>=H&:-_Q"L]=6KBQY7JE)L=\\\L(8K) MG4<5$[[FXN"PNT.:P=?!Y8_.B@O;_FKY"NM*.EQT>D[NB& 1RQUPX!B/0V. MPE8HK!(^PMFOU7PN)8E%3&Z73=TU41X,=Y4\^Z3;TD[@J2!;\F"!S]1IB@\Q MDR"'@^0-U*M^<&4H$\/MEUU:U9>]5"<*K--G;X'V*\P6;P,\BI>^9P![['84 MV(R7 %SV,@F9_RX8W5)'Z)1&!RRT3OD]F E##QUH-:62N@83VM)%&%T MH]B5M;SXM2-I%XN6WXWK% P7^.2_J6GK_O+Z@;F: 9TA@C1Z-IK-&(>PTY2( M&,/!T[JJQ/V5WTHS5N6K8SRTJK&EV-"\7^Q%),6;W1>^RVFC[HG]].RD6 **R:?5"/ MT);V9!$[7KT_$G\VB;-CO!Y=NO?ZQ+7''A1%[&GK0MLMW)\?XMU%"2!')#NB M4 _C87C10)?7:657/J] 'HU[K,WZ!1S?K#HZD9B^Y7GD"GPF=QCZR,/60QRO MN&1[;X"%ZSO22L&W?^T5^4L]9I-4"7^T9O;6\SS'-D8@+T0O>PC[^(=Z6[UA M"5P''YF&!TM3(D'A%B1EVQ?5$%2Z]&&)RZW=R,=A 4#V\#>:$KU I5Z>N+[; M**U)=$:WJG)U^9 G@J3B.LHS!GR&\]/%TGV2!T'SGD]:(8*LU<,IM51K.]IE MBA<>RDT):K)B@*J)(V]55^5*L6XI!Z*X(Y(*9 M>*GVG&,4G?P5J. V$U#RCQ:YE,><\MLS)M#<6IK0]9TQT$M&_I14&=M$!66/M8N\TY@JUX*.%U)- M&GBU:3(,&$TI]# 3>!F)JG@6 -ONVKVSB9V@3OVBB(FR[4!6F.VK M"X'_(([*\PDS/ZSJZ*+-X^4J&).4R9O]_1E[Z-:%T2S&,$H\L1T=7\?XPO?. M[ 2(*I"A%J*2)Z<$WDU88('2:-*_P"S_P9 N)+$3HF@*,! 20A&ABJ]"B3'T M?,8)B/N6WO!\%6IX54J-L>4RG@@@GC"!YU+3N$0:B!Y'QE&N_L#2KNF-SM'3 MOC]F D4__1?H+N)-ZF+C_RBLYYS&Q9 M1H_C4(?Z@/ 7&:6L)*Y!3U?UX"D0] .P52D;YM'54D??:5DQC6R;"SY M+"N=?7==]-5AH'A"?^+%&I"QQX@%Z%9$JV2%Y\A34S0#DG$SJQM3Q'U+M;\U MPXF-,6PKF7::*RGY!E-Y^U2].S?ZE[JI#Q'7"AY7AXC05$F0D+6*6^1@@[8T M/=E$*_?LPL=2&9CA8<=;Q M[5V3]YWWO5VCBIT)-^^<.^+D! @\4>NCY)-_F@LCC%CX\)K&X_7.>#JZ($:S MR]Y Z*Y2WIO;>M;K*9>)9VC>,-5^?6G"-'C^5_:L'&T M^Q@9I9+GT6#5@M6#V;=@*@,NB@(W#/]]PVHT#,%J*+A1+RI4@EB1Y\[HPH;M MKE+) 0UW8ZG^]P@ZWEE'7 H>].M#KBVBJPQ3$MN\8I J0RS?%Q7"9SH?G_9% MK45&=48;E=9LI1ZIF@;KOW4I\6G0I+];?4CQ>@\7P8^&*C..P(-NOS3Y>-B/ MQ^O3AEJ_9 #@@5[=Z@!";"#<>2$7(%$-BHF-4[K$W>AWGR6S LUHXNW=77,\ M]=4"XL\$-!)JH 8.<21W\@M4K#1O+7%_$3IV>:5U-T>^IH;JEMD=4":L\D6< M371M,CG+]ZA2N^N_^;;$/]V:N$[QH&HBKE&^Y'454KXA+<%*JR9$+6O4F!X6/C+1<:1F@&:V2&=+C%' MOH4(7)\[W-2C]&(4>8B";D'R]-7#WKOEJ0JXOUBZCSK:?;.X^'GD3:$NV0-@ M ;;I?4FZQ(@G!BE*P;:CA-?TA-Q^N"D+_U"(74?*G:\>GO:TM)(02Y/WKCP8 M<;A9.IVD^O/+;6)'>R(_)0IO')=KLQUTU @JYF;1=0(O;'QR"Z^L+W7V)?A: MC!Q4'YQ>N1'"T"5.?BG?ZO66 @P"O,O5GZ!>J!HQ MEMHQK; QU$QBHZO.GWA)UQ M^+A[;RB:CR$S94\3+R>.9,]P.Y75U]118G=_?-#,3>N-/75C]_/DE^Q/E_:G MV1=@X[QX&W7)R7<<^CA/1XWJ8,A+ABWG&3 ?W,K,[DI]]AJ^-F%]DLWOFT?36TY T6@><#FRJ235CF/7]6=U"X$N MD303_$2\JO70I&-9@HFLZ[K$ZY,\BJ4O-K^#?[0;><-LX,8LL(YAG&(T9DB' M3Z_4Y YY(BX]P8V5V1>4#LD*7[UVL*?)Y#"X(DM(8OM]@\P>&HR4I'%3W&8F M;^(L*3'W9X*"QNXE+*P)NU5%/N3EK>EU><&6AC.$U\?&/N=BG^7==&:Q:, 3OM)VGQ)%OD,IPINS5\?M>''B[KCR2/Z0 MV]0ULGG)!$1?1FU9",S][MB@M$+7=AAR8@)AN0YVE3LM=G%G*X0D!/K!/P^9 M*PN$^M-^,G8OND?0_N!F-;!EX27U>%OR^@CTJ\&N:=+M>APB: M <76![^G*%PG#K? "\UC"FL'3\LE3%WI?S97+GM2=N'FF>L&!]25UC9XC?,0 M3O1LAO@8Q1T_AVW=6.5U"F,"IN%M ZY/E])B/TJZQ#^!^(#NS:Y+E=7^,G-# M:%.BM..A'E(_URMT5$0L^^HA>MD:/]T-+$VJNJ1R-0)<_4]OL3\B8L.]F!A!* F%KP51- M8Z)+,PJ\$Z_1@OY)O.OV>7S%)[BF]\NM4[5I[E=:GV"^\V<%*[GCISX$%".; M45+SV+H,LM6HQ[RJ]_&G3FXE<7KF3P-S=I*IGJAO7X@ZC-8N+SJG*_M*._6.]L)#"!"50Y M)DI/C GT+GX!IQ?;T9U<_?' M'=:5)]!!O\49?NFK@&^[*7\ZW3 L-GLIJX%0>C 2W/?T8'C&4CV$Z@Y7Q4]A MBI<=Q"C'"Q>M W_4O\29>7VZTMT6+=O%SV.3?/Z$I@7/Q+<)F#RK AH@P/0/ M%:IA%U1^KX+Q:5*Q$C8MNF?@\5HFT^K*]6@]0>ZT(]XU;*'5;O/E];S4ZY<< MIS-[N5@,V!+="N/M1.RG5%94)]Z_6-!2ZN(Z'V]RT%1M'*!V9!VQCKBA?Q33 MACJRZ*!+XM#..4IT0$\'J_/Z52^3O'Z2+ MK;BVN=KS;/V!=P[]4,^-/CT;QZ?W.WQ9EZ$<'* MO @P2:^C'3(&F4 [1[HB.\CH\O4MV5/95,CA'N2&5CNEBV%$]V%@"YE ?[S- M-IO7S09&__#IC;,!2$3OV>X%SWD%B8V1AE 2="V8Q6H4UMBF>V.P+-J)9@A- MG&21D3(F4%$=G._ZN^<6(K=K3$Z.7R/?KWB+Q[WCQW*$D M-SF<;%YVO=3V6'CTD@V(:]"@%]&@Q32AH08)N!<^ MN/#YMFGF-\\9M4<#OX3*?GLFG*J_62[:OK:L?PS%CR"P>+WXC-=XETDF'AJM M*\8"IL@1:1YIF4VC(A_W#Z;>?)D'PAZ$_JYL&!9R14'VT_7#9DR WQF//>2V M+X<31HJXY>B2]!(]JZKV)QX]'9-P-*]1B!$LKCG?LRY@SGZBP3,O1&O'[&&O M%L%OP:?"AQ,-E_-"-.M-@@N7'8X-?=K. MUJ"*F^;,F*CX;EPLI&H:QMC0VO?0KHV_ L[]>-C_]P]9B0U2%!@7::R&\5X, M:MO)K]O:?!I-V26ITL/D69Y+Z@.I.;!'1_*$>4LL.BG!V-7E*TLXP6JCE-KOKE)"M2Z1B7L2I-C^KOK!ZB:Z7&CXR1 M9S5QR8GD+_T(PS>4 .0QA,I O=\,"MQ8M8_\HI[+<9OF"_<)^T9=GQ\H@!HU- M31U/+ATC.YREOZL(2HRZ@ U#2B-TRBC^;]U?%6=4)"VKXW[9R*"K_,INW-G^/ZM3L0ZVJOF<"BYF*\TJ%0]#9#%Z'%*M)R S*IX2QN/N_;'(7GK2O9UF: M2_U3T]DQG1B*E&8"#^B)#*& 3_*, 2H+X"KVBG\DJMX;B\=-/294_A&'._KT M6C52G!$)1SL.VQ0@=A(WR"@R9K\WJSI[/N"('_6+.75X#BW N(!J9B=6SVB' MHTKU6 '(\_Q)!QE7N8=RVNPZLLH*0O_=M(( 2U&V50-RW)=*"B\>$V4E>>L. MS#5PJ-6JVA;;RX_1UQ""3B"=Q,FE'\\"-];LIWLE)EFX<8MH:C"*\%.I M3M8KV\\BV5W'G^61[K=V.]>A4][8=/CPWL=88,>-<8$'ZY)&N:LI%GVVQB_I M0\'8>*U]@T5T[CG(E"K%^@8>/>YC6$?QR8-KSUBW9)I'UR'#[OAFYG\T*[2W M,T+-I;_2DO^=#SAWV++G62Q1\B3[HBJ ');T:L'&2Z(3*A*C;#W3[_L5-*0= M"B^8K*SWCCR)&'F:6,NX_N0C& 3,9FU$L Q84AV!E,;!0>U(WG)*Z'3GI_B= M!K0WG.QC>]TG-<'IYGZ.9T04('0KB2/I MT_2G1VW'QP=ONIC(QK^.1KJ6'5Z?OVR3G)S@_EU/!W&;!1##)',[4AH91M8F M)T73X]:D46EEY&37NU\>NTJR^B)S8<13O%"L<;>K=,),PFR%#]CA?^ MG[;PX+48#$*!Z-6J(JRB0;WL)=JI-22.=E<[JC=_VSG@\JJ7QGF#%YA3HQE[ MFRQ?]%)&VO^T/=[6;/\YA=R'RZ43UOK=#&@OL M:]]5U>6<145<4*)9VL'*$T4SEQ#9$V<#L$[MDQ/P'AJYYQPFE=59/J*84J\_ MTCL .^0V=:+?HSX8CQ:[XJD5K'#C]]:'654;YYT/7M4+Z $;RG*PVXLG0!_] M -VE2'VDG2'VMNAX@5Q'K;WM#50:2N2[C"S[)[IQTDLVO[?/M+"[=G3U_E$' M!Z#$$0M3\\2U=U? M]:%<;7PA45"1>@4OO*F=JZZ;[JWCY76N^,&P\_=BI)32CA#2#F.D6)GIZ$#9 MH%=3+U!\\# R))F>^*&3!2CNP1C_[)KOSP+LN'X%?/5'?QG,T?$208[;3NZV M@WG@3.!2OTR_Y[:*]$5)4Z4X3*5A@*"+:LWJY=SP[2-A;^8;O%E@7D%$K95, M8Z,"&\H_P*VG(]&Y]BMG-PV"M1IJ934.'4M4UI1_<&WV=;^^@I>L!QRSND-* M9HA"6UF4 N6$\@Q.ERW'^FI&=MP>B"OC#PORP@)B%P)/3;P$;GNE7Z;C*T:;-2U 4["*A36> M=RR2CB>^8@P,7AO9@7(NE9\N>+NXZV!?+-)U^$7CJS6/W+/TR5IV@* +%W\. M=6,"%$,_KQ?:6&)\:&VMD19T0J7?C77E(H7MX/LJ"8XDWC5M*=!JI-Y(J[<:Z_.[TR M85S ,(&#J&;H-@\3Z$S'4NJ O7>Q^W8,418^HQ9%F$"R!HKDBVI&$Q/I!U"; M#[T8IT/TW/(:4EG>@>(A^QQ,8+8;1[.'$ MILDQ 'TU+SV0"<6_ &:Z8 BS> MG&+,"(7N:;!$$S>FG6+1!";0I\ $3CQD C.+[/,92DM>E%L,(2;PQIQQ[0<3 M:.O_2Y[_4_)@L2[0,0B^L(UM1JC$31RZ"'79-/NZ_6&7-CFVEX"<&2UG BU? MD+Q_B'B+"31E80GZD.3;UBNJ-)WJ:2S]@!^4)M'%T$3]->FO2?^[)RVOHZEL M",F&5+*$K\YDE4^ 4-FR^@?GGYC48YM/%]#ZH$>U3$" 1%%B!?E% R; Y8,B MW6;;4S%$LLA.2SWR(&M!L,4?"^)HEA#B!B0,N\T^!"6ZL%)13!_R:LAZQ9RF MTS&-H0,[8)K$'ZEWXZ\%_^LL6$A))FM00,1U>>S(MDYHWD?--'7S8-^Y*TZ_ M=:1.$&T=PBI1U50T6YFHE,A2_N$Y[V[S>ZBLXI?(I#S>;J"&6 M<>_,K=LD2SR/5M#5&]YVL+DX]C<&7N(?.J+!>LJ8IXGYN,$+1>VK%++%1S27T M!-8,"1:(2W:P%#8F7[_/TFN+"30Z,RXQ/CLQ@6T)5E_/94SK_6&KM%W$$/-: M]6?-Z*6]'H%2/D+Q5HP.U#8?JS+$.S*!V#\+<(P)V*BC]OD*F$"X+,-EOD1L MWY)52ZK).JPY+HQK[I _3%Z$E410^[#?H"!^:$7X*-?V-":3O%1DB4_[>,']C.*=Y MR#882N."S4)6N,Q9Q/5W+-$)U4T;SL->Q?ZM4?[6:&4^X'T0FL&NN@G>"6>5 MWC??811UZ#SR43^L /8W]O@[>XV=CZ*S]S(!MK0]T'Y3,DM#9U6:!&0+JN6* M&<#\C9)_;X75K!9&Z (3".FBA?^'AD=O[Y\V<>^V(9,[B*QO%D.25RJEP.I3 M/^KCV!8>M3@WL!/F'J.G= M5>O5>__$^PW^A&/PWI>%?H?4?'%K_ 5[_Y]O1 MF'[LGW7Y4$(<)!M4WM)ZEUFUK-9P8FO')^K(A[G2T:.N_]"5N#__)X_1I=]0 M BBG^,M:=4.LPJ)Q(RN@6G5AF>!;TI6EY+@A,ACK_Y>;_TKN_TU>'_WS?OOH M(N3/E^W4@S"^2SYK&U36K:CUDMG:'2^=] RXOZ5])&+6IV/D'[LT4_0OE_Z% MU_\'O/[GMQRX?Z(6J0\'YS_WQ!R(67/G=5_=\UW'Q"2VE[*G;T,?# MR<^&3^,TK@#-'W1SAB?JMV?@7KF?*V9IE M$A%.6W?8EIH'A:&Q8%\)N8E!,H&.1?9/KW[3@&_ W2:4=*N.PTK0YG1NW M9XUE H1M5 LG@H<)Y$HQ <5=)D!#AD"/N6)&-RCW,*'0;5G4G,,?)R?V,P$^ M,:("X[D7K0C'!$C[P%_"_0O"N?]I0WZG^L^G['#NKFH0C4U*:[Y6$LU3_#RD MS$31XZ,=[N_EK_-1=$-'0O0L:UGZQ*!PT)Z\#__C!>_W0%[LR?^5P;Z$_5G- M<(%0?9C ^,[V)**3>H@)=!.8@">*ZM"0^>]ZJO(?#;YL<0;4#[M/9UU#S3+> MQWX0H?%VJ,N5&[$[9RJ+$+Q,/HLW.H05N0;,0_*0IV=(H3E MN(R.$'1>)[_(V->9]EI3(21&8_D9)QA]XPU%?"B![0FED3X]B$V<=896Y>4? M*G.-!C(]$I;\#EKICO4"[&&*Y2ND ZGI")$J!=(GD4T))^=>*5 M8!$?,Z3&=?@R/6Z>S\ S ?_O&L%O^@#_?2U;AHO;%=-W$<]U^-" MZ&:VDFVMV]"QR0Z/Q)''AC1?2ZH<&-"\TU9AH:BH6R2E.*/?6C5M?CS-!X^* MTSOOAJN<^DJ$=4!$2^H-"HVG3VFY\[N;]!6O?M+=K4V0JWTE\TKQ>\1;BW0U M]8_"M2="](8Q[,-0#U6V)<8Y/:E(JTJ]*L(.HG-M1M2J27O#QE[!.I MWU1F;PK%IAZ\LC=(#J3GZVG2[M/S\B@:)?!!@\^9^-7=IY1"AP&9RE28:,>1 M]TF&HF82-GID>;40ZZ3-LYS^'D3Q#FD)4GNB?%247[SUC?Z"P6.#E39:\#PB M;:3J2:>PUERY@U+,'7N;LO%K_67(MMKIV7OY-9$ MM+R-;A1SOM_$(7CIJ,^M$5 (0E&7?QH%IOC>S6PJL+GD3 [+U,6=/O.E:I9P MKD?=.^==]>(_3-\VE#MX3[XNC>X-HRM682**UM'C+0P33U;YOFO-BON2(OPC M.CJ,"AIJ]@O< MA3&%W4ZUI28W0S?98?N4&E:KU0OC9W1A-^WK663$"[9OJA+HJ[!79B 3"!V9X<)+)W1].._.FA2337<&3K[C#H M/3MS27+C&7?<*^_4AY;LM<<$*M("2U(BAK,KA^>^5K:M1BK9/$RQ7'A2/&DQ43=)MAAA>6F;D MDYZV[4_XEJ%Z.476N&QD%9\HVXU-B5_CW MCVFU*@7(>2C:I1TP,E24"-LY=LC"_%)-X' LB:[:_BS-=K05&NTM/J09+'XU M_A64P,[5/"/YS$+54IJABK! B7Q=4OM M.+:WD9/- ?AAGO$-):Y[ZC6/ ; ="1RMK*OT9EFRYP-TS'=2#U1;BW:$IDF> M>NCQD><<0&33"CY\Y>/WI\7J2O.]L=4-BJ33*:3^3[JF69*[\5SMC6@\S0U"NE(Y9[K.%?F=])/PM>Z?K\N8FKR! MT226[^4\N+>:)/O,*UGJA7Y(+CF!RA#)OH14-)7XFL@0DF,",3K&I4@S?0,R M1@.I+OY=Y\QU;;:I$!V=WD-NMJB8"ASXEWU 8$,!Q^C9*H8=6OU<+(_4$RDC MW=;IE]?A/?RN4U,&A6.]?D\8=P6-!KY1%!Z][SQW)(<3[@L]M/-#/1CBT%"; M0?AM2-/#OU6ID-?7F*K)_W@D5J!Q>N^ZS>R";^'YYE"4?;]NL':+O7GK+?BP MT_")@=FZ9 .J6-W2P7ET-5%A*4?T]*?VOTS8)+_"U M=0]L"/=^VPE_Q?5=]VG;83>AE^NNP[>CS'\_T@OG5CRHQCZ%]+H028L MFIV!O:W%!/: 9=C.F@(CS)5]Z]D"0T^>"2"8P(78@O_) =$WB V\M" MK;'Z,O?10;\MA54[5DN22&/TU// MHJ@.;I_D(\_-*QKH"G';9^A&/$R]B ]I X*;V8:NC+,O5S:<7PPU:1AK8 MAI0?"FM0KLH-.M9?CQ?KOG$RP5>V(O9JEIABHR2!!IFVYR5'CM0[SD @2V3& MJ<%M>N"6P0#MO['W)?!0M_W>?U$J260),;*6)=[WO.\Y?3[^ M/N9RS?5;KM]U7=_OM?T5WP1YYI@T.1X+;>W_#"Y/-S9.^>QU>R_QS4-F(9#& M-:O#RJ&K-" (S05FN35"TGZ,-^"Q&)SA&>8.H6H2= 6R-N2&S+4V7%J7^91- M/NAPY(IXA-PD@\8$)-:="8A&-C98^$KKEVJV ZD=*>^7I[33_.HXXB9/&#G; M65T1B=G^<)49?0TJ.@R#&'VA ?9#_(WJQ\-&B>4Q9'=\.\)<5]79QZ[O;:@1 M>G&@OO <,T5>XGU!,%NHU6[2B^T;<",W7IA\ U7:3Y]?T_QV_VJ%+!]0O^*= M;&MTXGFF2O/=LW1,Z23U8;7JN?RZ/ZE)*5 QM%O]J),@?P5&O?,-CMWQI;ZS M^P%#!8]+N/?!YRL-AA;WOCI<5$VT0MEW#>][(PMEO<'JUUEKNB"0N!FW2=+W<(0!]J;8W)A:77) M*]B/H_X\NE$YJ8MM\QZ2>X(.;D8-,P++*ME.:7T;;^0EFN02E-2):U5?K*KH5$"=5M@FI]GHP["S&ER:P9 MB3^CSW^I)QP]INNZ="^LU\CD14])9'""ET=03-LQ4R%UPTV$PFSHJV8/AH5> MXS")>.H)DOR81%"UP&@6H;;J!2QI(8L4HEU8\0Z6RF*?TJK4;:%?DL@9Q?3@ M"//NJX%FT(,PW&A.D^S!EC'(7D2]6#;)8[H::Q2?;S8X:.F47!<99UP59ZMG MH*@]\I(E-NC1\Q9)X&S]:^< H6ZRO,WZD(UA2??;ZE;\]H75F0,!MG$<"H.- MK)_GWS ;FC!\1"D3F1L->.8$I7O O'C+,_I=\ OB<:G]^7ZH/=4ANK&#+9SG M]MIJN8M47E9)5MPE[M)RS. LD;\Q0(Z :XA9)?8'X:$*]B;O&+L7751Y, MP",.X6:47%Z;#EFVY;6X:C-\8=ZYCXGY( M36.$$33D<+^@*YTUHB&84GSK[OSNZ$S M6Z\>NZ_[#:G/R!?!1.NP8Q*O1=*?'7";QA*I7_J-SBJM6[MNP*.?T7\F*%>I MC_,H[Y4I#&MLVY.0G0TY6J2A[8,Y$0A;7'0M!\E-L'P,&2EX*K'#KQW:B"WQ M=#)+:_ Z_#IY]#J?M4K#"+QF*ZG3AI"SOI=@$ S7Q;-Q.J5V/@#K>./;8!WQ M>!R[<[Y_]K3GWC[=TL@'!=WJ%E4,@3J26?X\?Q0:O_ 1/PPC MY MNM4\6X@0@^C;?(IO/R0;77RT3T4TW5;U([-0@E4FL7C=BV"\ P?5C_U+I% MLC>*,2E:_F9\+ZK_Q.F<>P;+BU?D2WU&JQ#?F8=PU:RY>K&KN-$!&*(794827B?V#RJ=@ M\!)^:1Z$AX37GL+ H=FDJ9:-@%/]);PE+)V'G"H_>Z<4%*DI8\\GGG-7VSMV M$W)7DBT)C*%S_.^D9FY[N&TQSH(V/B/(E@!,/&R;$7Z:$(ML,"!I9_57*[^% M[5_4:Q/PNU(1"<4IH.>ZB5:#K]?(X#OO0LK%Z:.O^@OZ0-M" YJ^["GE2OJ3",B_8/NG&CM?^Z^5 M[P-=N$4#1,L-:4"!% W(-NHCE :$PB]W+=0>,VW*<#*[7\B:/7[:32G]4ONR M+DMP]I.XU_()7S!T71K$86>H,%@GE0:8TF4I;D%8IRK Q?LD5<(7QX>CMTQE MOY"AL2K&ISOE]UK?=51Y?7QVX9P[^18%Y4 MN[P=0CTVZ4_^/G?U$4,BIHCVX#D?=NMP*PW-B(TM.H"*ROSQ,\7U MTW;;XB_;_I%M>24TX!NTWMB8+QBL?O+6[I9'M1;]3QG;M!OL?"?BK\A%T^'H M@:UW,Y_8H.9K/5Y8Y/>J() PEU02\0/ :OPK8^TCF@\LGR^X[&GF(AH(^S3%!?G_PMC_SA7Y_X%MB@:&E,=D,8?^6\)$ MCTT,RV&?)#./O1(L87,M 6H_%W'\?YA[?MGV3[/MQB@]T$2WVOMR8YJ:51;P MCV_H.T[N:A<2)5>TM,K%P>ZL_SP:7_N%-'[9]I=L:T;;X39/#M/-*$=1Q))K MQPGQY$ ,M?8D9-43\Q#&,L(6H2Y *FII5'-)B9ZJ*5X!5RQFE3ITD+X=/!?H M*[>$X9I1Y\:\BM&YR:>4*;0R=2;!ID5>M45V( 8N;J,EW]1<)E!U//M- M6;G;&L1AI#J-)V%BI<&&P]#3HPNGT5>3RN@94-'Q]RO7[KO*%NUMLD2,K]^G/UQK?MP, -5^P>]6G& MU*92DH@=VS?I5T2)2-EJ>4=A73=\7EZDV<==AVS.U1\#)^0R[A-]6PUH,G+U MTX#Z"Q *L ;9GI2EJNJ01:_O;*ZG_ZJUI@%CCQAB\^"2W5ZQRBU*URVLWEJ= M8H*6N :];"\R#YB3=%_6SID<^GBV(HO(W+!7T=+!V\W)# B M/BOZ\4+RB=%D<4G3=P/*#Q[R,W.5TH!]G#1@E;&7WOZ?H$D3($*"P(9D MV/X]DBGDXT@VMK"%$8-2)^0W_1-/"ZA],?7-T%/4#3R?3X$ 76,3.."'$9ZJ(2)7TMX3 >5Q&!OS>I91C2RGSM?Z3V;F71"LJ M[K[0='GS.N,X("GYNH4QZ2D-^$Y&Y@\: -B7A8C_-CG>\-$ C-C M)=2M&(-D(:%U=86+^V5L3&_BD_;H^46:3Z1R2SXPEJQ[Q&D+QL13F] K*C1@ M $G%H%Y-,[:MHB-PA];.>EZN)B(:G6)Q\BI=A7X4M'65[9 DN-SZM MQMC1BCW5" Q$?-)WQI\LSR;EW2""&I8XZ_#FE%O]EM>O]"DTY#IZ>TJ&;NL\ M+-84]>2\:?A1,H_)\E/C[9IST< *8Q8-C*L?AT-H0%@"?DY =H%. M?'%V_0I#YNW+\"&<;77X5%OS1#,-D'*=)U:IJ-2-><6'#JL5DE"C4%[2F>8 MP>[#5D6%)>\+,6!Y]9=7!WRJ3$6CJ3C^ZK&'-U:/8MYU:0CZ$Y;P7E-A9,T\ M$K(Q722E*5VZ=S2N;TG_#7; S%S[\TN.Q2G^)V%7:WCBR3+T M7J7^GBC M014LDP4+=]E#>2OR3M]I&%C1>'%3\&)O&;?^B[+$BT9"#[_6]1"@(27Q$;6' MN^&*&=_RP^.S!\3R\RL1^X]_^#BK.ZL[GJ@[WM_'R3")XZ[=;T8VZJT^ZRV. M\LJD ?:?NYS8L2^+9BL]'SN^%>^\. [#B\;=#3UXI#^E,3Y\F=2M#[K1K1A! MP$67J(JF7.XS8G#GV\=SYUW[/DFQL%[65EYSR6Q34TV!&DZ&T74H(]D\#VY$ M2(D'VXQM^ULO-<1X"=0F9$Y'&/1\ZF31GF=?%$]JG]AW/R'\\/[<]U'FH.!: M1<+SYYB(:A"1#Z=%N-%]Z8OID(/PDF$/A[9TE^D0Y87(><.6ML.:ZL#4*LA%OI#)'*]2 '65]\K!EN6ZY9KN.B U:W3$0R=LU M)WSI 2].+(1+0=$MV)<&Q, E7G\EI;5P.*4V47-?.^[4X"O,'') M/_#6AFWB4,=RZWBM[K&;S 5=&D>5&]#A$$*08[I4";5[VWM]O1SQUFT9C!99 MD*EJ:QZK959@K!1[XL+O[/TB@B*EB!>*45 D.!1 MMB*L9MC^0G/S)83DJ3UW+;\]*;P-9NC_!V^I\E1GIP$/DW?>8 #:EL?H6W2& M(L;%"A"8%NKGM9: ;E!)3AC$#KU[IO8$,;8V1SW)_XU6]I[N$=WT$Z(Z[B)Y M:N1 [6\#[RMOZ0.^-5S+83EDSA \I3\WST%_!!EUGRI7S"*&"LTFO$5CL<^D M67SZ"5*@H3#^XA/Q<>XFT!*>A4?#HI0H16@,9*]7&YH5UY*+=6SV-S"(''1< M3GN=F7[BUB.P7S!:95"UU7658=V.B] RO[:M35K<&,UI1$9LX#A7(;&I5^+Q M\J,L$/YI7Y?\H@&+*;=O%N;%YX:\$>R;/F=O>"#HZ&MA:,P@"L14[9X%UZA= M5ATB[_4!AT4,>IH.:DI.!D//3J*>UO-1N M'BQHGB>+;$MLWW)*+5$_ZG)IUH?CC+NW>[+)%TG)-RG^D;N"V@Y*!=. X(" M+L1ALA<*AOH XC\9.JQ27EA$/)DB,J!YI\>Q_.H+;.Y^X03^T[8C#[NY)"8R MV$I?OZS5*25.-;GM"\!A#0)+.R-/D2(^#!_[@BJMYM:0P/69_MK^5#?2++4"RLT M@)\&=%LCY$ET/"$2#5V;0<) M=9Z]:HJ)68CX/-3XC'(#Q6FLT:SC<>9,^=9,STG;\F0]?N6DL/M7/W,J#2Z< MU?>/!;L*OG25QU+-SWBM0)3SDFV.E_+V>-\O+:W!G"Y%]2Q^FXUSC:XY&)([ MJ.-$=,1X9/P8^)5BI=B7LWSO0H-.%)8FNCSM4'9AYJV;FS'\2@(U^F8O3#Q' M1JSI557)ETT.LYP0O,@&5@O[E,X&O23@=,U%5489? M+TE!=0@!-:-<,MD.J7&O.(N2[!U%*Z1B&R:8$]Y[K@F6I$)"2SO9==T%'V,I'MW; M0Y;*=^HO&OPZO;&1_"7BM+[;G67A.T#MQ2/\6B=49RKL\_4D@LE:K+'/QU.Y M7R5[%R1@!Q6?!:M^HXYFNC1PSS.;"3@Y?OL([>46+$DY'5*>*?>Z8,F(I/,& M9F/4IT#Q<;TCB#%(7!]VN".>*O7RS8-KY@[8S #>5FS6;YC3M9S]."VU[NFM M$(JFT*JWOPZB#;GVV4FH- MYJ;+8CE47C+ZJ]N>N;FLVM?WSEYT3'A3-G@;(EU,JZ/U?$SP?>H/: M %DY@QB(IPX:M[GKD*.E$ /HK1L&-2/0S>/O<.LT@)H@,OOF^$LT(R0_^*^ MR$*X" T04J0!J)AXRM&U4I/:G?&$#F\Q32W4.%\Z&*[H?.#;7XA'A:L?ZR\Y MH>1D9ED^T'=?:C.799]HS(&]FUV6\KVNK5-<#>3KI)H\!W5)PKU4QA;EB%LF M7@;LM1\:32PNEA'>M7X*[ 8W/A H:Q\0#CQ;$#TF1+S0AVM=1UXLLH@F2\ _CNU@!7SLN/.X(58%M'A15R_NE9,A?,9;Y M8H5?OE,?![\SC[.XAHI*<-C*\A5/>^DT+(T1 M*8^;'&W3,=$LBUKFFDCVL8[2X[ISDC+%%"9T6$.@E&NTEHU4X^9#%&EF\_ R M>=T&X3Y8?'PZ,"3T^EM?-'%>R1#*(#[UOP7K1 MA%6K_2LX.&W]SM"S):I,Q7:. D/7-2M[4.RJO^>H4KQ0#4:ZMO,@ZH#[9E?+ MJ\'\DH>BRY^JHJSC!J[%R47!ZIB^$)E;I'S@ F_FN(<%B6+H<&R'3CE1Y]N8 MGO5^@:+(1K2CR;+GI,(Q#?[B\LD,-O.7U>4--. P1HL "LRW:C,B&D>56O(- M3]Q1&$FT^/3R"/GC>*(C.[OWJ=U9[LF_[=&_K\Y&S,]Y<*R*'3OLF!K[*%AJ M2/[: QWW.Q-:0)V>U*Z#6IFGT^^V[ E4X_O;S8L_/2]0-*"5V9 >28Z0UF )Z%%KLNC,5Q\(YS1JX1:4#Q61ARH8V M:(+RPD&$.0/"JSC%IR6HHS.^-61]]P/"9U1":^]$M'NQTGM<7IMT!M0=0CR9 MWN-ND>CL([W2"=@LZAFA =$]U/VL_L33^D<1]=Q4!DMNF:N#YQ ] 5^+CC2: MD^N6;1<'RLL\FV![7FR+DZ]54>("I&"'2-?LB.)51 Y]CY8KSMOG3DKK3U2G M.WJ>K'ND<\8TQ/V!;1#TY8VKS"W(7718C^ )Z* JD%I&7!@;Y"S@QXGZ)=B. ML%RMLY5G8U<3?-QN"2L$GWMVLAE[\]R#9\4V;2CT;P@>6-7Z8<+!X'7[>OH0 M##_LYB?^?&*HOETHV?%!LL%IU7C;KHKQLB\760,MC*>S.1D(;)%HN_AHT"&( M76<@:-<:J_"Q0T6K9L5LS?!3D Z]MOZ?:,<+O'C:(!@N*2-R-=V_C M$CIPE-)Y ?#13B(P;DN,W<0U0DFFH$-NZE]L(82HH;G:VR'V& M2?S[ I$FY#ZX:2YUB+J;%.62[9-^L W?!U28FYHY +UA,.G)5( M&'HN9-RR6+9K0,]6($P:[D72(IJ/4E,(]LU)<,ZN)2%"Z(;[+&1W*>B064U6 MI,YC%TF+W=P+A9P"<5G'?ZLR:(=Z=6F F,@@RC.J*LG[(NG;*&*OHQG/_$8! M+.N;+A[';-+IEHLU;7>%^"Z[:)<;J'H\C549>I[IT$$#P@-XR8ZDF>U+\%.D M&.)A?&TLX:4L4'?OI*R+XA-%_IK[NB^7ZX^%WE;1E!X0M=:X?W0<@UW]^_$< M2>V'+NO+HN=P-, UWQG_AL)$FAO)6XI,92:+8.^4$:R&S=$I8CVGFY4,7*?$ M;J1'^WDUP==HP 'C,<36?A*"!NR2H %CBELY^R=A8.[]]XAN2'?*YY@S:W9(IAI;;F8MD#+E&Q"<)3)G&M./E-=6.%:K8\6>Q^642;17 M$UJ[10-MI*^M/ROPX UL%PT $R9S-I0'34G@:0-Z+I $/NGY6;AZLK=?^N5 IP( X$)"> MK.ZJC MY;T*;YMGUK^&YJ+]>-5DV]\IW1W0P),U$5FS(-82EB.*?IZOIS$\D>OYG'4% M'+J'WB:4M5=\4#UX@]A=PT,]@FJF :M01MAN..UT6L?Y?N4JIM+&PK+]@,?GO/V T1%Q^ZM?.Y:D5\)$ M#T<;J2TBLQPJ(\(5NS)-YRI=:\X.1MS8]O[VK77?$^SGQ<$'$?S-IP;96PO: M+E!2J-(PIZ&%U7A>4\>K%P>&I60,%[EN-Y\^U\B@PHAT:G'[BFHYH*M6$*@[ MGN1)UYRWP.M!FYBA1[J8Z%!?6NU2F_[:\/;T?7 5.(SO:G:02Y-IKIC]RRM; M0[-)YA[YBH/CBIV1"4Y\SKF]Q^+6W3C5<]T%4Y-:7#\6[OKTHGG>]8"&VQ/[ MC/9[WC3@$%PVG_5^GWCW51I0K^N99];Y5CSC8=O1)WMGUO^UUF^B2=9H.C'X M8DP?TTCL.QIE_N1K9U/K(J-$DQCSXO*99=6Q%**"Q;-W\,'^2JT03'NT0Z^5;WVLL9SO\6>^.YZB;/P7^**N?^8=C_C@]L1V_ !&:Q3) M!5.%2XRQ6,I?+:E\WR=2RETT2M7[MG[I0?/,).4+W)8Z;Q,^?O<@\J]$(]3B MX\+NH_J/+%?]9M,K?801Q;#$-3%IKD&,#+;/KR@N?3VN&R'/9DJ,B,@B(J+6 M7BL^R0DQ)9#+"L^]NRP6[LET423I.(_8X_>&;2VB[E<,^*?9YP[!7GBA$^A MIQC?*7SK)'UT>G+ 9V!\4PSM]_S;U*)K/NHO>,PIH#S)XS7%/D=6/]_99:(2 M\[D\A2B2A.PM3U'JU+7:(%659U8NIDJJP/K [YBTJ)AAEY M.K5-A+5H'3LZYNK3Z;MLMD&7\Q6!F28(J#R'X[OG);[LH0784>"?PDDY$_TKSA907H3?I<4L# M;A3CMG:GK*WLJ.P,^;K4[-UCI9V:'LK7[R:V8:$?/,"U#/'L.0@Q*_XI)!00 M;G:(%>HQ:JX]>I5%=FX2MIMKB080F@*4Z8:@(NA_"B.H\CH_1Q>EYC$-Z"1% M;&6GTQTDC48]'>'<.:_7P$7"48-K033@0Q3=:>V@G\I:7S>F 9!1T&RR'PW0 M**+6V@=>^_U(XD^Z_536P#/D+##^\1B0]N?._R?"_O;^,'V7S]Z M_#+U'YNZE;/.2P.>#E '$>NC[Z$_E8+ZC9)*Y9@#[5V3Y?PZQZ.D?'JHP>ZT M8DS5ZZL81F8/656NE4'-M!$Y4SLS!:=<76P;=?CRMB ;?G" \?F71NN[RP]$ MVN]O67'H$>TKKUW@(G51CO^E&;J8/YS9S'_3](=='5_V9 ^]->XO-K\2?/&V M=FSOJJ3V7G(L+/X##0A.+8@AX!I3>>+ 56GYVDI=A_*8:4"4!7N:WZV'+!W*"OOC1B?88[D 'RQX# ^)4D =O?@.EM*(=(BX^K[4SJ;\H[E)UFZ# MZYP729V[(\H0 T!GNILB8U5VFX4WOI6LA;!8)O,9'I@XM.4 MM<)%1O;D#Q_7?8\S-H-O$E:@O6 Y8GU'?T,[LM'!^-)U!9L%"%$Z^&!V+718 M1+8S[NE,NW--2B15D-1IWE>RQ#I(*M;%A%7W:+T:'&CQ<73GE-K'[RH:IQR5 M<&A^$7_&[/[G?8/JB5\YZ>YD+*"R>%B,]^X+X]!B7WQK6_ M!"$?U:K[KCL=9YR:6PI5BWT0P-H_U>75;CW9V6!4*?CB%0S1:#CC_;#ZMU.V MMN^#3QA[JOS6?3#2&!PR0!8D**0+I)GW%ZSZM?,MW7#(U/._;OF^#\7$ON>K M>++IQ 67[HOG&ILT;B7;]'2__OOSKZ^=:< R0R]Z#FM 8>K;^GX230.4]K]G MRF[*=)+A>M1-JA?7?WA"V1^T#7)4PKXFWJW@0,K.^\'?IZO7(BRS['-\MY2I M[ +RV^50$O_.];Y02,#W>P-XOONW#EE8S7[#%4U0+'N=<0!*.G^O00Y7T0>,;FE2)?1DHA\"S]T"JO.B=0_'O%_Z*O$+FI M&.S7$W>9O-/-1A=O+6]>*U,)\+D-WNI'_S%S/'UL::'2H064!FR?X\/^N>HH M-1)],.G4HCRC'ID55"5RQ>7F.MZ_KLDXX$!HD6DK*7JK6VK99?"Y :)L8/6( MH8\&?&?:]/=F81["12A%X&-$I^U&[%7"SKX _E$W-A,!PY6&])/=K&&;I,N^GO%..)]"\)%[ MNO=XT6F[+W97R$?'A((!YK>(/Q5_EC P)AM!%2>#NFO%3"F9EPC#+W+*7O'? MO!%G(G2UZ4&0Z:/?3D@459CB:RQJX NLS'!]TU!+._KZ[,[ZK*_":^%D3))ZN.LF$%$2'Y> -> M1T$A$]>3+FLR-KK>''A[5*7EXUSU8XZS-WZ_M:ILQ^X7\ M$51P@#RR/M%!_22Q &UG1\EY8TJ"Z"A/72H!1RT^J91VC(.)!@5K,-F[-2%+ M[4/O@8)2$4VQ_)>)$O%@F8!@$YYZ7[VAP4A"TWC"/DT.;?:-DK!SCULL]@.K MG7\_'D850%A(72IZG@:X$!.71ZFSM[=&+^ M4PH(0HF2*YHD3R:UR^%*$TA)^DM;=&QV4">&NFMG>SBK/@%##1(\00/0:$J/S@_%P&,N@'[_%GWT MU>I$I$)(^_Z"*$[$&U6HHS^=TK"SG:72 >F(! ;Z?2XZU;H.5Z0C8)UHQ!*= M%]W#M)9\,_>B""?!V]L9M* 0*3EC[FZ?E08*MRELY7Y>#UE^)=5_X95 M]Y';5^#@\HI>04NIQL])%CX)=Q[NXFF[T(#(\OI4CCJR=;.3Y.06CE[=2S2@ M4&C 8NHF=S2D[RBJI);>)4=&T!FH H)P> [U0RX(/K>6CP[Z19H@&_1@K70> M-SM.9Q<>M=W;#51A03\RW:0/!@7H'[+M<)-7)#K*THCGI $X''4&E>"02;GV M:5MOB8T4Z;.THD,#&-0K?\J62>5+PZ,HN\#7:0 "L?VJ]L++^#4=J079:LCH ML2ET.XC,M#7W0Y[X7Y;],RQS.H/"QN ;^XN%'=6/'VR]J7=1+E&EA(]VNVBHE9?O;P1Q,?RT'Z@WB%G+S.7JAA0:X2M5WD+P9 M MMFK8_GM/.;6RWKK:GGA9':E-J+?57 ES,_GG3&*OEJZP<'=6!Q7IF<7R_FK-UO:O$_-R =]0#C-2_'\\0(W#>:_"\>5 MFVM/%1% X8M>[=JJP\U]F8?YO0YTY;6^MA5*6"Y8^.PGF13275QM281H$0RB MP"=>S'I<+*\5J_33DY71O/HI+495]);N\< 'Y&ZA%E6 #_'WJ<6]=:)B#EDL M"C]A*DCZQK]AQVCKOK2WZGV'R6(S TC$-DX>]>?4A+E1EAM1SSQB< B6-(]V MI7XL3-V8'[9/F=QT,'>=%WC?+!\2?VDXW$!)%&[C$1*?#]C^*".K'"82MEJ,L%OQYLQ;V<,Q5W;(6FMOA9UVI]@_J,V?8R>RMNGC/G8RN MVIXL Z9N2R>TT_EMZ>CK;?&?1#R7!FG *?Q]S]Z;^<[7J*U=2TMDM/+\.UU( M2I7KPAMSWA;>)L#P3P7D@D50B/J;>'T>LV7U-DJV'>M4 AJ1,JF-*K^_Q_V9 M/:/*C%GO?Y*/_9<3PA\4R"Z &5R)O] K8#3E,="J[28.J4<,%*1_-P'YA7ER MX7]/,^IYT@ 0!PVH13R_H+&;\]I_Z 'I?W?(:&[2X+MK7O\I^V2M20@J9(T& M;.VLKV$/83Z""#<61*@<;*&( ZOHTD$3_ZI1P227]3R=;PIGNO'>F?=O/0OY M&@0U__Y[/=7Z(T.,S7Z47$]>Q9Z]TGPD+QLL7V1X\B+%X=FK< M=N0+\]3]E&U1TAZV 70CA#F?!I1GD&[EPB0A'+/I?/'0FD-.QB^G/K*=B8*W M; \0S)?8KDAU>O''+)'NNS7B#M( 1TM]1SPNLN%\=U;5PX[U_D(G[F%#UI:' MV7',C*F4Z] ])'^P"?6X)9L^]/!9U%=S,^X$RKN!Q:'QIX7HMJ&5.QWR'5)B MM8=([&2(?T9Y<+4:5F!M:CUL^,F]U^KM[AXFRDA1$"^)PIC-F6*P*4ZLRK29=*?E4YD59:8J67-2QBO(XE=Y#BZ?]3[_G MM8&>A?'468F2&+<%2="QB,#YK-Y[!H=)OC2@H?9LETT')FJR(AIW]:H:^'R8 M1(\ XQGCN9K.!MS^8=A3LHX[_KD@XE#-TYX!H\1Z\2KGZ\\^V$FAVU0AXO=7 MNI^_(K$TJ$%"#<*DP6>ROI(L7R1^G4[NE].QM4Y2MPW0N)IF[FGG'E(QE0\$ M>,'R6BJ'4V@ 4QT)0MBH6U^!D@9&+[P5/-IS9^%3!&Q8VSDD64CR$3\+QZXH MCXN,PK)!GC#,^BW*6S+(;Q05&DL(^3!\MD<&?&1]#F4V^ZXSU[R1N]^#P#!1 M%6JR_O"TY8#H%.A%/V(__'!.)WYS 2Z08:Z/[X65.![K'M'N86\6<(DT& P7 M.&=S=DZK27T?82/.1<8%KILQDRY45OI>KPWFI:>R:,C;%^D-=H#)2C_<5,,2RN?RC?92U*1L2YXI9- M@E$(&7CW.F_%6>SLJ5EL< M_:VK6Z!EZFZ+:U.;'&O8YA4Q2L*]M'99ZK['*%U/1[$'/%LZD;+S&0\3C;#7 M[W:QIS?Y"&:$#-?6$G/JT;OA%Q.[#;A)$$VBUK=G TJEKS1AOZF_MC4:(!FM M=239^&3K90^:FG>^:MM7EMAQ\?$+6/2"W".1W9>(Y4=:.!DV/X[E\USMIP$C ML0%'N;D[866^1DA_;R:?-O,+OBC9*X''I0U4]CN7$3%-2"9R (7>?NPJJ'QS M9HBHR>[#AGUK^^[E!4FL>Z5A7X8BW;;*I)6>#!S( 8(JC ;U; IP&[*Q:/D%^IHHC6D=3*+[0K1OUT<=1M1#1?W-[ M]/]KSW#E;=D"@=X!71Y# =EU9]+,9H0$,'WH"'] MZO*$NF #_H]'Y1W3A4TU>]=D+K0VGFY[OKP9=PDL\QAXAU5ZX,_^:N:^F6)& M:<_\2&&ID?VA@?.%&;>M/]]_S2@6);HAFMI:2O+&ZX$XVD:EW XXK%.%'A4F M&477BU7Y-[ ^/;>H*N"3P98>< P&TNX5H;RL-O"S$>@OMW/H7T^Z J]SX-<) M\0DSV/OY8+][\ W@RAXI='S#,(@41+1I5-.)79!1S+1Q=CP9\V+V4[%9FE', M1HHN8VR\Q#/;6"33ZQN\5P>W:EHB%-)>>ZG<[IY_%7-CE*HJTY6\-,Y.765? M(4?GK=@',FO>A!N,( ["L!W\!NPPA!YFX98+4?.-J8Y'0IG<8V-#AA9>3H85 M7/@]E]-C35!N@^ E?D,W-HL9[\I[SJI/CZ4S/H(.'>@T$94XDFK7 D# M'6G5^V2?K'(GPJWH,.9DHL#>H<5& ^O"I16-Q7K"D\TI7I1S-U@YBX3P7K=* ML7NU&"OL5CB097J^H^F,!MY;B?G.,Z]7B'K9E[&/7MK@;JQ=2_?7OC\%747 M9%6D>[><=B%>-HP(WUU-?%A9SA=::7X1;C,Y990ZW1*;[XZ4RSH-A.^Z:["X M;C.!>I'5XR+>*[.451JN-W /AG_O4)>HX)'=9\[+4":N,5=BG_'VA/H1DIK; M(?T"=&B),D:\,RVW+&W?>_@#@>Z%00^5\=4,MEU)^GWPZ^X$M%;%EU40!QU@ M'-IV3K,$-?IFE=TO]PXZ=+&)&^OU/#/^UMZQ"0YYP#UA&LVPL+1*N=Z$A<5K M]:Q*J8Z$#^A\*=5=VWMO.S:TG:,ZF?#623,T,NG8/K>J*J[IU)9@^)E1F?TR MAV]^N==NH!TJ%'^ENCC._-[>4X':GVZX")Q263"^9WGX"F'RZ9ZTK*]F,[Y> ME0OAW9^XPH\W>X9= !B0FAH\#G_G-DG)[T]M0+\_Z*[ L%GU!U!H^*\G.O[C M1RQZ$(5NY [(^A0-*)V;J=Q,6I>A=TLM5'K9ZS7^RO]AX/G'Y^BKIUYOM-XX MCPY<"1Z%E/M/51Y']#8-W%H((?7'KX>_IS-U/RCY((3L^F\L3RZP>E(#U]&D MHPC2$ C+-T5A6$ 0Z("6^"_$L42QM<:VT5Y48#X(HBA@_YX&L#_.W/=UK*@ 1EG451F$%59 MYSM]?J>NOS1@DR4]9BTK9%*JE>ZY1RK1"3: +)CEED<&B8IY7^*Z3\;+=8J. MS4WB"$%D;AJ A+ @\+;TP+7\-U>W"@K.[)-\V-B1:NC4Y2*37+6$&@F0;7ZZ M=@!U*HRO0M(K+=@[51_E>VG@K *Z'6E))\<$%LHV4DS=)YC2 1>)O7._[E+G? M9Z",B:!5 6,:L LQ"9H+9Z.&W8 0N*@Z&.B/AH%^3/A])>9?56B@W*VC-^ W M$=1=Z-:M.>HA2#!N90KO1I9&_DXDO__\^RP6M!'QQ0M*WD<#GB *CD"VN*[2 M:]!X$_27',")R"/%;QW,H]A 0;,/09"@WJ)6_$8#IF]JT0 &Z/C."M1>4)W;Y@JAG,IM M\#K60BW7&Z?<,3?Q>\SK#UU7[7E"/\F*O%/ M L!TAKJ'I+#E7ZSOB ]_U)C=1JKIBOG-7@H=LH#-^17(OP+YOZ+FZ5RCA'0M MSXG/*SDIVX$GQ7-P]_999+1=NBZ/,X=2A.A!^80>KN4+OM#Y 1H@5E6/6\,: M4 Z+N8^=MKC"PVI4V=SK*NI)=.;*W)HX9ZGV0.? MMYRIO*@Z]*K0#D#:FB/O+"(Y$]PH>Y70I!UO\*W/2BTO+=QIH ;3;0_2(W<. MTYV/I ;.($8J:$#"*(30'L!*]_\>.F!BQD#'=,CRT!#$M"8=8=6M84B8\FLZ MZV6WZ-%"=_:';'JXH,9IP"JS'@W8W4*.9_]1' 2?2N:GQR(KBLI6@&ZNJ8R& ME!:S;>U%4G?+TN,4L?/R.34HZ21D'!;_O:2=$P>8$=S6(1<$P=^+JKC0>XV2 M_P3QY3P-()Q /$'D;4(H#-WTO'08*-*(^%Y./.DV>@^]%D+H*#!D#D5$N;Z, M_X/1#13HSNL&#Z906>(W!46^EZ2 :% D*5-#^:%D>MN+]?/B1#C?!JVR0\C[ MH9/TFMZYN>T>FF"!:"6"?A"3^;WSG0=>9VZ;[[QF,(J>8/A[=!HO([88LVE M\!A5AQZVWXD"_>![JZ$+(.RW",K.1O5=*?26@=YYQZ* +)D'M S6^8<5?9S: M_QDR+8P@<:(__Q^M9"P),>+G%L%'+77!=[*:S\QXNCB+?J$!CFU"HF"\N6<> MZ%I07/K:[.,8NI]$DG-I@!4W$QNINIX\,\.8Z7'L=IKRBZ2)"K/H M,A#K7MT[O<*I,Y7&7R'_ .ZO=%K\-Z <_]%W.YK MC%1=:4F92_UIV?%[QOI'-7]?]?E.U>\KZV_K3M_I.OV]GK^O.WVO:^9W>OZ^ M[O1+A9]4R'5.P?8X5 ;ZBW\SGE^V"R.J\!NH+,_E_/>80CFR^G\$0&V1GK_'V,!J]K6LRSOJJUS]!J_#.Y-*,]IW?[J ]NW MO"BM?LL*A:<#"QI =^; MNUPQ9;<:9I/W?=4(?S]\:B]CP<4,-MEB2C787[91 (HO;9E?0&D1S\KP7.\F M0T"1=])9\H2OV*?/CYZ!V_#K/%T1>-_NCBS16;#S)SJO T39>++:UE+#680! MQN6>_Q4I&N, MO2*>S:Y[CYS_>,/9><2V.6RR900: M6Y;6V*93:6')]D8@1!-X0E6>"I>MJTET.R0]:#2L^+ *H/\&J(! M^2VF";0W0 QN'%&_4:D&ER2V9Z5T32^WBWKSW2X4YGS\\D)DSL,Q)O+(@^,L M85.!M?1ASW<0AE[G)Y370]AQ,P_)&H1*"XL9OD6D:*S;[@%]T6CE$F>)1[.S MJ&7;WTXQO?FR!]= [!\&W3\=!AZGI0Y*F T9H)Q(2M/MGB_N;)QV'*X=>$H MPU"4O;BVANY9^1D+>KZE%@A']3XB3R.2.4".%&-(9(M<*O&3/>)0GEHSCS$L M.7P^QAWP.?)0V#^O./ZIG=!O_B M/U$G1'NK,X8O &$)$"*#B;@/,E(&!._( M$E8[N[Y;?8K.,[_U*F"T]2(U/55-]S\["8#D.6"<#.N6<*OD !$"&YDSK6%+ MDJQ%3*ZB!RH'R>UJ?X'"61NCTX[KW5&\[$+E%RYVL=^PD317%8L2Q53/0(HZ MZREL8S=Q37F@ SZ@0ZZ?PUULML_-E+O%M[D-/KVL=5RNWF_M+1L'>1]F#3D MHN-/[EM5/<8-J9!PUQ+G&%.QAY8EW1<_OXT^].(R>Z(%R D@ZB/TB"T+=MOZ M\-\(I<@F66ZX"J&S(<^/_^Q)T%ZHS(OWZ(JP;,<"4^V9:Y<6Y!+WR 7GW'>& M2U23!K:M SK0!WC!<#B[\\%,?[LQ?T^=9]@YY1@7D0N'2NX]R+(CZ)49/V-/ M>'P6U8CZUC(&"J.JP'I&01]PAV$Z^NIJ[\I+,/?H*M;=/7^X/EQE<2&5ZT[K M(4*!TGCAL2(E(O00VAKWP PT7X4W"(;N@UOBJUA%=.)VN) M-(&2.-..67<<<3UP0W**OQSPZ8C?UH/1 #QBOGU; PKS:_9-B5MU.TA*9&.# M@9I]5Z.\O<_H"[?(R9]>>+\<$VXL%()TV->@Y(&ODZP M&55$-[CMA]WY.M" 1Y&,"Z'HKU-Q6K)/52I5W6ML1$/>EU\T&9\L@*M2TM1/ MD_+&= +)[L2&)D'VW@4R@SV8CRL^3*B"U=M=VEJYLM+Q\=V)&QROE<8/[*YK M9<;<^#M;$&#Q/]UH]_['I<2 SCK$LBR2A*,F'=Y$-G9N'MTYYT5'<)>>7+O MM=$R'O1/N++H/_18I6PKT8"/KH1RRGWZ('7^HY7CSTE6+C1 F*Q#$J,!6<4X M>BO9/$JGI7,+$,H)T NZ#Q#*(.Q?LL"D#+VLZH1LV(F]K]-%^]5[/$^F/=:HSTM4E#. MA4=ZSQ&SEOWII7+?OM\D+<\$QA@:*)V(8^ =48[F:E?!%EZR#Q\,.\&=5!5R%7B MV?XWA\[H96[.))49_HP&UNF1>F>BK2&2.DJA&K]P6DZV.3 M*.3JR\0]?/;)-U'B(:'S#(C>%WP<=/M\RP;;\T)>@J,C&"!O[0%7I!^N- M7"QA]< UL@\\-];"++WJJ;?4.A3F>JLR>E]G.X=V[.$+-$"Z+P0E%.B#"Z+* M6,U >6N/.V$[PQ9+O*/G&E+5\]W.UK\KYHAYTCVI?/7\E^1DQJJ)8Z+6=?M/ ML]E!H^EO^]YFV5GJ8/_6#\! 5U)O:I/AKQL?%;YY!$T(-TT <:P 2_ MZ?\6;EQ#BL]UY'MDI5I24FJN+V#+_O7"T>O:MZX+[2Z+X@I]QFV]4"87QAE? M!XK4)P3#XB-70XA.+K=*DU"<*?..\-(J*9 M3< )NG]MB1/2(,(<['KO:)J8UU[OCOUCR%BU6E10A,I(4D/8FWJ M<$=1M0+#I/W\2WO>>I@H/4E7P'8TONM0^5P+ W8.Q6]>IUM/3RU_-RL0&*N0T[P;V]LH]9; M7SQE+^8/CHF#(QJ116^L'(<9^R0(WH%4H;DMGO!\N"HB&]8\J/CLX_[@HH'! MTI).%I&GB(DH#NDGQRX%GV4_^BH#Q[M8;5U6!-=__21?@G7DY:Y2,3:Y-LM0Z[(\^8Z7! MMA6IX[E@AAXP0Y#I,) &X"9H -_'KGL#9V+UH(XN0H]K<1OIIPRV(N/=9_6= M$=8S-& %3^^D XS)QP$JEM['3U$Q5!H@2^JBE.;0@$X*BD*%$C.W>0QH )(% MNKV,QNNLGT32 '5N],8$HCZ0;2$?0D4L():6Z<0,]+U@2"$=MFP2Z"P.+47E M_"7ME[1_KS3&SH!3L/LMHU9/T@7Y^FJ?E=^]R(IK.QY_Y]U%=--]ZGWL][ M[KWGW'O./?X1!MDC>_[6G&NNN7YSU6HO"URLQ> ,Q)PC5JC YJ$2+$D:08%K MDV52(7VU>* C[5U-IH)KGV)H!E^Q,?A8'_]Y8EED_2?O)6,+U8=BI.7#)@'):H_ C M?!F/\#&@G/O;V#V]EVA"WHZFZ$)=0G"W)P,%I;<($8?&%,2/TJ8A8<*+7/-&593U^TL!JV*YOZOC=_#Y'7S^9[U]E;MU[G;6 MP$#3(5+PS0FVUX97RD?M8+.S3WZROZQ+_T!-AZ:H774%[X69R_$%C]AC!M;_ MW$A9!=O1DM*23E,N(0IM<@4YCYO]8]\!8]N@(_JG0M3W4[JMQ8J*@^@(ZT%" M-B?NIWZZ6$_+)]X\"^49_Y!V^QTE?D>)?Z$H43R*Z&NOQP5'W6%EDXZ87T4< MF'Y6RI/#RRR0[^&5%V'77C[[DR[%'61ITG8N68<4B9MGNOAE10"IO, W-#_,S>AI5\M1M'#YHZYG\XC?NT42&4A^F;\U9V%O$_&)GV^M'U5\OU MB69D$\OWGP8&;L^,_.=2'XFEL777_\69W6^T7Z+9],^LB=3V)RMH?S/O$Y/ 1=Y/ECNNOVW\.@<_ O3^LZG\ M&^U_'*T;_F#UWMX5(Y,/I<;+"RS\1@Q/GFYVU_\1J8 LGF':^#Q'/?Z](MI5 MMNVPVKFQ=C\%>$D1A$$%OH$T4>1 )P<(A I *& BV9Y2^PVDJH="QI ,M\._ M:12(V=Y $-)HMY#?5-I";)&Q8]IKW1 0? V[O@'61<]9P2DH*7#Q$Q4(A/66 M@622.:10/!78#?Q&^XWV'T63U[;NOBF@V7FBHD1T0 ?@E%XW^&#]1T@CH7O: MKZU8#0_4];([[=]Y"CNDT4FST?%W70_47NY%/%[;CZCYH%B9RDK(#\=86SIP M(CDMD=[D_NMN9^*T>6J7R=@\9/K;S M"UG=)=,^27Y63C%/%.EQS\V#YH'EV0)&KB*V5[Y?]Q;&!#QDR!A"\O H=AN; M*):LK2=^;D2Z2+YZ8RG[\B[[2^5K7#Q*+8!8Q5E2 EVZYUIW4O-$3?.[OLF4&D/E\<*"O7QB'W8C0H5Y2&U$+"[=DQ?1 M03:C]W,7TC1ZURYN$7+3)K8M+5(L1O:EA%HZNPQKX.W2W?:T0\7,9SMT2SF' MAS3M:'4%#^B%[CCLX1KR3GSQ^)ML(=TK#&+)KV:Z57C0ZI077BY9O1\5]=S= MC]1RV2@U'6<#&H4'ETE?'7)AFDN@SH];X(]\/Z$\4:%^H%H@)/E*=?;5A M'WL#AHO@^R&?;$:\D>B_2G(^ -)890P?+(OMK>?)N8M62+VFU-\P^X98M5UO M^I *L*6QFA*S:EUVDA636J1Y2/4G"$6E#\*O=Q?K2/:C7.\R\GGX12-MF'TS$VKIS[N(ZA(;A$D9D(P74P=B>* MF&._06"Y11[2A%?"!\]H4\I?EW1>LKU?ET5,!S_ 'LAX!-=H.+EC6'-42/KT M>Y(B7K<(PS3#CI(M(KT\2,G!=63I32H\/!":J)#LL2$A8O'Y2E\,!_?ANGY@ MB[<2Y%;C)A[0ZR4?'&-FJ)4U?5BJ]WS&U5K@UNW[^R*3G5V]QYYE(D=XRIEQ M+IQFI-OF1'3P2C3;<#Q/F3[EY4[>VPE*5C''@V^FTC/(UTZ#G!IQ:%!CXG"=C2ZXVC _@B=';'GXQ\ M?X*AS)K4,G:2N(9A*9QO=F1AU[?\K& MN8IW?A%P2$H('T6P?-VL>Z: R3%WZ"98S?"R[\IX]\3&R$N(]JVQ[%Q"FB#@E[6[Y9%@B# / M^FQ;!MN,1]NL<3-=>)Q?X5N?@EC/:C9DQ/9SN$,D?!3S40 =9DX7F14-I=0* MW:HZN?*GPY@*U+ZR77][.<:5:6H?FUM$5/'2:N+< .&- >EP_%0@E( #! *A M',;*:62UTZ'-YWY^1><^CN**$:ED&^&SJQMER]92[E>YL\B<'F,\HIHX6D53L]( MN5#Y$/F]TI+! NWX@X!0[TXGI59+?PG5-9?M#VKP+2TR,S$K2O(.?"X%K+K; MPVL>'"2*Y7A].70\-,%%ZE;L3I&[K?'Q02PT&ONWCI+.PQZ /!IPDCB>_N4K M4C2^?;I]T,'Z4$\QWU';+I3&M>WV^@\MNU4B1SV4!/=C. F+E5A.3\0:'T&\ MWB"(G75^RX5EQELQO*@3$6?4-IZ*LSXC-,R^[#Q;?'+\#)>?;SQ9BD0%LCR7 MU]S:*Z0=US2KS8U:HL4*W1U[8/9;DCI\3[V2>7UWP'"PLZ/@->S V>JUCVTH M/1G"YU26[CMZ(:>3+O=D?LTH23I&&*1?2O]X4ZF.=3?+>1SBL">ZQGPJ%#Z: MBBVD I5P^B8V8G3-]+,.&X[S-J:YSQ\VN4G$TSVPV24 D%\06#4+GI- /'8N M>NL"69442#PR\M';Y0'*A!E3/8L;-9.F*[IA4_NHA^D60XM:$>(8QXXSU;1O M&;[JH^;3?3LK#B:O81 !WNO5C.6*#EXV[B\=?/-3<@2\-(5B9@/TC 8'&&DP:%/G'S(P.]2Q3]+:P;I5"YGK R M^<,!'].TZ:0/6U>1P[RD9_DD5ARFRDPS-S= MO%G*"(JRR1G88O@?B@ZZTE[9<^.Q\TZ((#&B'!3GVK:$24PG2>\(8X8N013E M1&,J\ !]L=1AS(5U8$AG?K>^"Y>MU1N1L2,-EX9>[V(H\Y1>(WU9U. E7R#" MH]3$LSTE3$ANK@E)"Z'GV-0N.4Q=+&XW5E[ <7II295W5(5"$'O< .K(S8YIJU755*)30(BK(V1J$@":V79 M^CP[P:XN<5BR)%&?N,?[G###ZP0<8.]*VSL:[3RLM^'!H!JDEA]\5_.FKQ1)X!+Q MT3![(42'\LDFC%>/!M+GT(ZQ6"DY1X+HD;X$,DFG]*Z:5<-T@GL M\A6QT-PQ7<$=ZI;[5:6*6^*VG-+R5?N)S[$MHX=I&J\)/&1U)$T1MTZ2$*,@ M;]-5/)P%&WGGP]&UF?I3%141S7($\^WTIF.,/&=J;D9]>KM?4!$(L(H.UQ#S MO(0;CK9[Z5E=RR\=*+E@JBW44IRM9<<5RSU48&X,/-WARN(J,4$%0H4%.JX1 M%N>3\Y.9P/G&FW2/DOPBO/)V3RODBPQU'IVRK7^9OR3-"XDSJ'?AGL5R%#/# MJZ-?FO9JXEHYD&^D/CQ\8ZJ=8L?]^8&V(-:>XU/;@K%[[/$@QB4_;X8'%.D! MSV"\1^@*;Z=<7'I_Y8N*&/<]U>YSB3*#.I\PY;EH28%'^UIHA>]Y5%MT))LY M[4/TIY@YU;:]7DYL94LX(BHS=;?J8_Z)[&C3!3N3+. M:5]6%^ZV=K>T]!W6S^!8*MU^MSV%(H=OT%P?DF"N.E?20Y9L,IA[']VOY+ ^ MTI?CVW_9>'*H>3#IA$'AAH8IWQYW-@069@ZL-Y9?=;]'E-!I+TIQJ5J>Q@M, MK^KQOI=Z%?ZXW#]\]^&!XITC'_;(5EQ75[QM48,6*!=X,8S\MLI331D>*3>K MG _'P52>2GGFQO#2S%=O/*YC''5%5LLC:$GHZOYU/[E[ MDXXNJZ/\KJ[KK# M4EI7_O77\;TV);$3MJ_58>G3 M1!ILD-'*8F85MV^=H=E>(*-6:%9X HBWSQ20X#@7 <\>B[9R*9=7#@D>'KS> M@?UF_:(=I_(-K4T^\HD#!4I"LY@O:IHO/#':Q5U%^F=;3=OS.SZ75G1,Z8X^ M,2"*/#M2/BM7&%<";HH[B:#[[6,37;H^YF"?1 M2:4E34YR,5YGH\87&0_XLS+/@F_F/]2EYWJNUQ \X_2(+,&Y5@./G=54<8UR MD4K-[1;; H:3&1"C1RT11K M7=M.K(&O<'7 "1;B5$#4< W!1@6^7#H'<:R;:'(,%*N-I?M0FI#!](]3 ;HW MX)(6[+>0_QXA$S^=6*)9[H1G0M,-FB/YATNS^LTL*A6V8C+/S=Q/Y>+3>E30 M)!NE AZUH/#;5"%6U!W0) ,$2'3?9&6=[,UEX;FTHG#TC9"L?Q)LIBPK$@4LTE,SK$&51 M?D$%("JYU(%[);& (#E$,X)?5C-!G+K/_]TESRR#D]X4+FHEBV.^'R K([=@%K2)5EP4[ =^@9N./Q5EH#-"E^E J>^0AJ,D/W ET_@VRP.X#B6 M7$1R#-M*_+&XU><\]2C!>5"],\XN4HY&KT8?@_2[ Q77A7("WOD930F6PRXA M*.8H>2V?II\*^[-1_U@/L!E;R)B:28@-:2H@I<'_O&+BI^+^;-%MF\_P:2LX M.9D*/&1=/?YM/K=9FIQ(!1+0S(:(6Q I_Z',/YJ44C )6SF*INA_6_C\]_&$ M_C+$O!!.#YEGV!IYAU2S;GW%]HN+J=)2NM5'^@WMI@AA3_&W>:S_ P7[[:*_ M7?1//2';!>Y@P-ALIV93SX],B$RT)VQ/BXMDZA%_99)]SRL&H-IUD&;L_YK@ MBA;X6K 7=_I0/]TL=]5]?\W1;2WSW_7[#U*__T(M_:>-@ C]'U]'VQ!SM(@M M'](=5.#A],KWE1EM_3R\\[G#>M MU'WI"KY.H,3CKQ:L2'0TOVPQ?&H>-E&>%.L@/:QN/0#7[)_.1;PA!5/\D^PH M3)!!Q\,TFO"PS=V0#E)0.6(EEBYMD0L#%D@L(<%QGZ.*9^*< M\8O'7Y><)"8MK]!,$4X.M7@UC-H\9*D*J_U.:OH/A?)3R/YUM1VB=?PMXO^+ M^&'/JL]W^8.Q06!><7=;9VWVU^E4%%D#+2*XT9J*(HZH8S6*:'H-3;'?)P_? MOWV!OHL[_(<,Y, *6^K>]\5-QBX<*?!ZC L[@EG5%,N8)_-K(QE-P MOI4*('LZ[OQG=Q]^-T(>_N/9'A9&/SVRWK_EXOME6&H[F2)(0E@2;,,S9S?K M\O!(=L/T4\?1E&NMS>TQP+N@0W>]0H8"$TTT1 M3*K-4/?$'B514G(TLQ%'XVY^1RT_&%_H K$<[*=CF;34,O7 MGE++TV]=B,=&I.XGZ>):V4@2HY:^_,EZ<9I$YC$=*!,/N9]Q(S0K_F%(;T " MW/.6QO02ND]QC.<=063-Z3T!$;6 Q=\GQ> BS9E/HG@7&O,L,?O$WZO MYZ+1@&S!CB8)BW5H[$)=Z?%ETAI+@=5YNX2L(.%<#CUE6F1%0^WL748N>4_2 M;6O\7NZ_G?(P2*D9\'UL:)F258NAG1&63Z[LKCA.V&X-?S9X\,O^KGW(E?[W MR>YOP6-7O92M&>271-%,Y?*$6B[B MQ;)$267Q93K+0P! !_BT:J&8/0@N)[:+X$B7J$V#FN1(S0MM*$;ZE$Q/#_W2 M3KL2?0VS^7Y=:6[V1WR*F#T?7TYKTEEJ$TKU M82H&!HCQ"O>>>,,KF-VW*R M:"AW.H/CQUN(*)4D&$=V-A?1X=9W7.9@3&/%VF.>PJ^ILW344('7K=4^L MF M2740 QRQ3;F2JB,J\\[]RILSGZ9=#3YGL/>&+;N0Q.'^*R[!&DK;Z609W !\ M;IM5EYC5)YF'ZDG\%&JSW^1>X?$K'M?T 9^"/ULI$T+I1BSI2V-G1Z &DH?$ MO=I*7'L#168'B*194X$M=R2"V62.S$L%#FQ0@4@J\%4&_H0,->*86NG-%>S* MRT N0P3*5^=O,:[WG_EP?P4+7<@)BTQ@CP-\Y5S\9/P/#R8F1Y:D:T!_Q*:> M.@4&E;N.E5(!TEU#C&2 1ZK21NI+]B_4 M!B,?ZR1QDG3Y3:+(IXCN/35ZK2RDD>I262'%2I4;66$WPCCCWRF*KQ<(LIC= M[)ZB[;Z3QIJ9C9$,KNEV&FL5\"R;N;;)&[@2DL=Q^5S$8TK/K4]@N$RR=4IG MET"K(/DT822PHVYSJ,2O0CB2;F(MP&G/B/.;(J6#E,X;,DVBCAZRNRX('C.> MUF'(G>&/S(RQ.CR]WDNQ1Y-@U%@HTVEYS!01C'=VO?-JES/!0"_65 M"-8.'R,J!!)S]+3:G%"P-(=+'V_8WXA=FW_1$7LE;>.^R.YV#LLUV=QW676ZUJWWL:-Q[\.3@NQ-C#A^!5DY=!UP MJ1$0(JO$OZA=;7YJR^C5ZSV_',16/JKH[-J*WGGM4UOGRD M "+KY>Y.&HC4J[.16+OJ.RTG)_U4OA:',_F<']!/6!N6.O-5 MV%1*V(CC4VCD7/9YTZ,3C;21U>J.GSNTG?;$Z1^HY7*T&K^UX]7]6%UU@!L? M0S:)))]\3@HVZEA):!?MD!\ZVW$QJK-XT)BGU9D]]E1]Z(4G L .M0*R:++U MOJX*L2&R>A?JI#PFN#9C\R9$DJID!(_[O%%*DM79V=F+TWS$Q=3^YDT])'J-83WXQ45O"3;N.4 MU+1QX.Z104_;5L.W76HFKCS#AU!%IW7PR]=D&SX+1,N<>B ZM<_$AP#B)[)J M+%)NZ_)7!.3/J,@\:,HF.4_KV]T6?!:FXM=R[6:&7YU909%0S;$TUK-_CSD' M#^&=)/ULSW7=\LZTKB*?(^W==TJ]Y"T2'O!>7?([Q=YZ_@,R&.-#XA2[#ZO6 M=T+IV4K+A;HG*V48Q\1<*-T]Y< 'C,9\30*(:!Y/Q 4"(D1:SNFB?-A:E__; M,X,9;+NNW//?!8^\;M)%X4R9(J[7I"!,7[^-JS6_I\F=JZ(FTWR;^:W Z82O M"D:A%QX\Y0SH>,KCF'JP&!&2RMY)!7#,1/F6LH1U9LG2;@7BD %+]=:7F)3, MT^HT1DHWW0_X:5S*\;8*7LM\X62WEGP/KJ$5/<]K\.;0DMN[ 0; 0W[U104: M+\1K3$J1][>8->\L4>"]>S^W6P%!1R0K@*M![=^SI0]:GQ2F*6S"CLH(MH^+UOG&9 M[+ M)P=2TD5OU]YYZ3XF)($W"2Z"L]@_A%>_,!7F">NR'L+W\V4ZO-9Y*!C3('J_ MLD6'X;/3:/($X1 1D>RR_=0%6TC.:Y[R2E:<$G K%=Y8R_>N>--9?%\\V.7. M_-FO-FWY*"^IP/:R[$LWV^4B @L^2C>JNPWNCOZVFB+ J)RX$(.?/R W^'0 M?4DA>7^A#KY4XC[-_2IR#<;2CB%*A8WUD3TF4\V+>&J]$F17X[-=TA:^O\9D MAKEJ^G'Y=$B;JC*MU(/IX]&/W"P3ZZ2.=.!, O<3;%-<"_5>6>N^'&K(0N^3 ML;BND4[KT>EV0OBPEK?TQZ%;3-)[%<*S!;\*[[M?]#Y>G<8M9&!&0'"M$6.@ MQ\RK38H<-0CJ<:$;1F=(&'B**H5-4D[;7JA^V_*%AK)VB':R3&)FF]6<%)CK M ++UU*F<*'I3VK80VV]29(K*/ )Z<-(L/Z,5G:B863:[9.E97[7)ZS]7(3!- MG.&G6WL:9R5K+DH,ZCDIS5988M(L 6)\@$=45PI!%[B_R;AF<[]!H M=N[AZ[1;>O >O*^D?+O7 V-/@*U-!A-:$=WE(IG[B07=^A]6[I:$2W:[VJC: M!#M4+8P!PL%;Y=+!"VJ:'F/2@@;XR*-"$B9Q5;P&HJX?"[S\ FLB:)1M6@RR MZ_?6 B@JH.5C!*L1NE2=A*F28FFP>!&5]:+OQ<*T4>J=*VS[K\D"XQ$VL8[U M_C=7T(R]I/YU[==="*/@FN/]#2A5AYWK"03Z#6Z;>!WV5-]I>!8 $VM#F#EL M3N2"O/EBKPF9V*P91?Z+FCZ>W<<$PN]Z7$C4,.>Y]'Z? @,AKC3 6H9HAC)* M'Y[ME_JZ?&?7:O#39N2U \6*DD\V3*697T=DCD5YKZ:QROV_!7-?L=]-&Z(: MOR?Q:3O"#OV7/WL0WU]UL(SNMUB#:$]0R!<4+),*N$"Q%TX%=E&!T-QR[6O MI;:M/D,YG_+A5]#P-5]B?36,=+X$>E,?/TDT65 MJ^*CYT98/)<-9&8J]B)W$/.?7WY9$850HK/=XR'6^CC6XTZ]#!78(X!KMEA3 MZO"E]0PWI?11/H>9O";R]V[(6ECQ78]5[H;)5"PF7)UEK_\)>2R1:>T P?@EWH7&$XUK24E#'2(J!LIGKY[,MK>&!=*MOKWXIO_< MPR+5^$I:-W%:5]I)^060\-@!MKQ.!1ZBR8>@AE0-Y2EH+/D!%*A/\)6@&5&L M6:1NE[W]I./5:\-'D]T2$<%Z]UU&;LT[]="H5<>/3KP3-!' ^$*)X !8S!"D M<0QT\8+WEC'7A6Y'KJD/>R3-#;ND3#*_'8I\S^+6:?+\#^9-IW RBU!\H6X- M,D(@@-H@WEM3[2%?(II8$=>K$>$JB54I-C5E*&^[$)OB]F>=!SI%(N]FA D] MJCZ&>*23\;J^J2BA]1E)>NW6%XH@I446M8^P.MC=CW3@-;_2Z7Q!3T)7Y6TL MKI-[3^VX[<=]=_$?:+\#A/U1<]HG)%I"%H7+I1++2&+:NK3ELD7?8 :EG#[H M.8KOWI1AZ[6!GLPQ4S@M%;"#DM)+&L=)61C(O\&;8)4;1LAEC@K8+&G4QHM\ M&II4?-*S>-4W?AK]"]M^F\0EB_%KD[>IP+@X%=@-QQUKAT\M4H']<-)?Q@9^ MY1C%6M_N_?LS2WX;>OB[0?\\M7Q2XZ YR0,OQS;M';E=H^+SF8/Q1O'%-T?[ M]L>XFNT:SWHV)C^))32!>^#35X@,V^1H*A!A,DU63!U=^BR:C1=X'^S;%+[O#^T,@.?EIY3\NHB^$I#ZWG%MYM0+4A7J8 F0PA\<1PD7XLF MW< &P5:.>090*-I4H$YBA@ITSV'**\9&X7AA.VP3C+QK@R=L:HL(6N?E]]?/G_WT<-#+C3M6[8V7?1_\[6S" MU8&T'/0/OFA(*;WA,['.0-;\O+X!=3[W80?:$%9@M13YVW1&0 UL?0E.D=$F MRXY4LV[N53M)!4 1*C#&!>;U(;Q\*JD V[(ZQ90*C&HW%)GT('Z4#G4)I81J M2A K&SC2 (6.6MCL79-AA"M8H]8*)L!)[-\N?NGY6?J/^)M#\>N)@S BZ_&1 MB6C*3E2XUK=#_'^4_5NWOY%NEST0;ZA M5*>K>?JMD_&Y8,G8]4X&&!+53_Y MJEC89JO!]F-?_D&'M?9F#+)1+D9")3=F5 9X"'>;O00)^W*=YY?*'@S'Y_> MWS"CR\212BFNC,9'O&=_D'>&>=@PUMS=(;WKDR>G]O4!SQP]!(^C;#)FJ#C^5=#22';L:.K( M/&N+G^IN"=Y?D$S'L-KORZ']71F^3;Z"?RB'X0_YS[>9P#]+5;Y-[?YS(O]P MG^J6N&K=?]5DB-87T4% DI@++Z" MS3C&A?&>/&?^L?GC0V+=J%&GQVJ5RAZ^9D%QCTF\I+-!5?D,X M??2M?TTWV&T+T%O(,*?&* M/&*?9_/9#;3MT!I\16F^S$78;O/#2'6/4.$EB-&RNB1%1Q$YHI0'Y\] M%V9X^A.>NN0NG',T.LB>^Z7L+._$H&CE!9J+)T32?VGD<10?P=>*U9"8LO ! MTXSW*C<2E!D.S4O@.A$J>D/$2'37VEL:[\AWDC5QE[$X[4&HRC&)U0RU)N! M[+! #U&ZKV>>_A1IJ%1I:!PO.)766NSQ*Y/N34)7#:E>["[B:XR4BY36*6_# MOB'G9KQNV6?I/*@0:"H3(;@P(],J[T.(KN.MX'Y+""$%%E9S6"3+)VZ)"IF> M,'%)Z+'V2!B1_F1Z0C :S[QLDO;G:>.M<$+IQ;8[5(!%#]?*IIDY6W8^D27F M8-?$_7?%'^YST4Q^?%/7MX?IL!F-U1S+J$Y^7&6%<)>5N"E\L3F M!!>)AM+PW5S:.U63FT[0>]E>TST8O1?]S]F:_AWD5]\?)WOY>V&7BUMY'63M MR_REALWRQ@$OE^V.^5_-)7,[JYNO"6D@=RT>%2EX4A/;GYM[X*X07Z*2J'?2 M2RW $:PRRF.^J&ZP]6T6[*S\KD2T ZA\>0\ 4Z85M)'3PT>Z,:B2NIJH!7AH")/RLJ?+I,.<,A5-^A/>0ITEWGX]0BSP^37- MZ_ZF2PR&$2;R/O@4Y.7.?=CRKL6%Q;R&8T,&MQ8EKPOZYYX_PZIF;,5%D^Z# MES*Y7**PGI0R,?3N2?Z>2X.JS^(+R\YQ1M:+2W5.YO:1>FI4W".,C9/6LI!V MG Q1PP*-'')7/'9P*="TPLUKG_O)'25KO9KA>3-@Y>B1J-#>XIP1A R^XQ5M MMDN._^0O(:[?/= MYUEM\ 6?XN3[I:91=4](V^5"!=6GM/=GK:.SR"HD!WPR@A.\@N3?&IKNO[/N MF.A_4,\_(/@4KRK-QR,GX,>^-@->EWWW)2V;%7SH'G_7_;Q$)D?+S;4V]:#R M4G7)?$Y$U%.[%^;$J8BC:E[X9DV+MR$6R8G"EKL''ACZ[=BGQ/<1L*.5G^:! M DHY.TY=L7J$D(!4R559R-OC49"/YG)R<>!$Q[P8E!UBN?MT=>R9NG2= 9T# M91_1I&;>%N_5O:A5VC%>HI-R2H/49>&Y+U9I;R47S3)>]6=1XL%^J2/+MB6O8\I_5#3SAN3W%DPGK2.#JA@+/B"TB*\MRY-P"W*QV0+ M/(AY5%=AZ9SSFFZGJU>C_'M8 /GX6.M.U+$V#$9>0#%Y/H@CDF,C@N7&"0M2 M^'S?_-/E,&"#,E8_+%X>&0NRSW2DG_["';MI3*]0-Z[L4N8JJR)HY*-86S89 M;B.5BLZ=X5&X-=[HXN0NZE9QAL5(A^% D8:(Y]VFJE3I#QV2]&DEA/GMX2RV MJ#L'3Q[IQ;TV&!843A?9N2Q' VKW%,-9!^7KXK.'OA:^F9/M:VF309Q[R<"% MP^N;6EM;15YAIGL'\_N::.\_],879J7:8 MOGJ1$>DZD=?E.QTQ-4[[>F^M1A/D(^>6I51@0/H7AP[H-2Q8V:)6FP+BOGC,7QA$EL4/)?<; M9%OI(T4G)T9C[UYW,##;'>=?OS7D&/G?>Y@SO70P1([_,MZ+H0+;SYB=C']\ M<@5E21H81?M18 7=9*_\>MR\V-JFNH+ NV<)IX\W\,5;-!GW'HO04^"RB3U$ M^^YYQ=UB*N ?Y-O2DR1M7ZZ M^] MIM]/(_EYQ3G2I2U]E$$P/C&*PHNZV%8.L7M&WT!< #Y<7Z]R:; "+6IY M*.PR>CULXXAW1,2H#?T[ESY-RFXFD+@U"D87J[OHMZ^ H;[<[?G%;IF57"_M M[MTL>*^I9K_$>XCOKA*+5V7#, !LW0HC8 +!(IM9V!N61"*ZSK7?K''[OEAQ MMF9FNJC(E5L7Y3VN'2\"F(0-S)='>J77*HDF\X=YP^5<0LSI@H-0-NGA^J<$ MU#48KT8YJ]/,*ZPY?=91).]8)"7] .=Q1 M+@ +6(T\LFS:GM5&Z3F:]OITK0AGXWZ=ZMB,>)T&P&_OF"CM#+_$>&LHHLBC M#L9%ODG,JAZY7\%'2'@A?O^FT\+J+!7@M;2D<9.;OA[6WK=?(G1WP++RP-. M4CXG)I?^>W54@ =K,P"&HYGN@,Q]R+9*M]LO'88EWKZ]=T^K9%FC/73\D(/E M8\*30\<^QM7M8NB\8])2P;Z=47XIQ[>V3!OJJ4B:SFIF^*WY@T?'"".!\[:W MW5R7O!P+,J^[^CW\['N-2V9J;SX"!Y_G(P;KD39PZ" $'UD>)Z&*Y;5?=MP\ M36%+FDAJ^D27RE3S^&D)C<"7^<%CBM?G@,5H)_NG>C M^ZTV;6#-J)W*2KIX2]?@I:_"TQ1O(JM<_6BA^1U"\=2N,H=^V5B3R=02?>2S M&2RA$\&)G;:E HU,"(J\-EF>MV9QDP^[=*J'"D2:Q!LB7+;C$J$>5PU.V$L% M8C:"-RN?@E]N(,A\TLOJ)A3^<+S']IZ1C?U(*E"7306"GI-2J("F(D7'G H0 M7RV].D1I;*("T\(PTAZP =Z]9XP2< 3*=QO!)_\^MO;:>:AIGB!0@8\VE).4 MUW:P%3X3*D"O1VXU^@D*CLNN$ >_-%.!6!XLV;'\51C\S2TJL,D03*&%+;&N M!BA1@;1/6)(L8M(;\SV4X8]FG;AL^$>M'X*Y?/7;]!!F92P4I;K [Z&B28[2 MH2,KQ\'Q0"B,\&../(^>>XJEW,=1 ;]ZHR7Y>^ P)IVUP%OU/ MHL=OA_VG==B7L92.$4ZQR#&08T&;SM3'?^ A.!_OY?2+L@N _2YXJ[SR"UIX M_8(SS]A]*V^Z A]A,S,&_W+6^]U,_ELK.K]I=*1>6H TB\\**DJY;;%U%WVP M6E5S34>DT?1IP*,3WEL]K3^M?)STLJ5/I2_'G6+,ULU\7M2V(=RMG6I;7&@I MI?+X5=31#,[SMQRR#M[I6K.;UN(R1/C!>D[^(UU65:QU"\&C9@:.&@27]804 MS7KF9[;C>6.K90OI[_.9H^CV+2P]2+Y'&S'N9EE:,Q+)01*I'69\_:8H:.ML MEYA)%X;%H'?^QIU2_Q,G >=4SZ#S9[KB9@!U\[#)_43]YJF:<"QK)1=X]76' M2/G[)P\7EFUC$K@N/;6Y*1M[S#M+I,(83:RO-,_,<[GJE'-V5Y1N'+)DY[_;5%V;@M8\_0ZP,>CTP>DBU)7]-)H":Q+OS9S%*TP/2F47-/ M'-V#PG!%"Q<5Y8,N4NE:^Q,=;A='7;YQG[O/,QQO&X#CRYU;E]T/]W!S4&H7_-P M(EUXKIFPX99ZB+;C$$:MW?>(0QFL&DOO:'T0FZ!_R:QC?ES'27+\7=G[QU68 M_5'#.^UN7H\K/I:VQMU%LJCM-XB4ZZYH6Z!T[=:Y%B^L&&9Z'> 4+%!B%? [ M>61F5\-8$M#[WW"&@8 U"_'&^GVRKDV>0ZUOE^.6?X-L_J[]\<'/=D;7?1#R M5;97<4K LD2."E@=L')LL4 ^P6/M]KW=QTUW[)7L^5I 6'DO1OBYG[J!/JDM M2S?=@X29E M!+*)N<8'%Z'BA9B#C1OQ;(@5K.LGIU)9)%H.I;$4XCVBQTDQ^-LYZK%?B;GL [7 HT^? MPI0&I^B219>CSXY/_]N7.&DD?Y=W]WQ&?W>U*G#H>=A_^5,+Q7TR"&5PJ]^V M1A3MQR2!H^DP5G>74)"E@O^K.2)8NMQ@M^?66?2%PH(WL=,'T\P2S Y>OA3R M\>9Q87HOM9[VX>_N8BT^ 1/I(TM7P F7D!B>1IS>,UROKU NSR:NH]/F&B9%7MJ_0CYYC9E4C=L_ZL)&!>RMR>=B)YNTHL^^Y6R^ M[N*4W!RV+SG"PBAJ0L"5L95[,U@+0+%O'273O=U^C'(BUN,R-.@KWG84(_F* M75@\NX44S *;"0/(@T2# M:E@(16,[E K8+?HEN007-],OU\SOL3[8Z;QR+T XW,YYTGCK_*F0P;<1N%*EC MZV"9ZW),@+MA7Z"XN/RJ%!<-81*;ZSF[9K"=57&,E-J!\PBG'/2TP1_,BUQX MXH93E2X1L"#MMX_@W2?4=D:W]4D#K3/W.UH,B8%@4HMFPE[11U8E;4=@QH2T MSW1+.\LUN7,T)/+JR87O>- RM=%Y]?8R!YV/ U0Y.03M6N$#VZG@%3@=8M"3 MMJ:?"H3=2>%7,JFZRW^]_L*]H!C_]!JV83VE/.?U0P6LRQ*P0J/N) MXK66(>412O&%*%/BB7LT^8Z^'/>D63WO5M*JF%>*-+YC+XEX+S9I2_O2#OSR MBS/^:GZ\[=)G9,O 0;%_RF\A]]O=8*?6+&Y/#/37M#>0WI6([TZ+\V/N M(:^/]#_YU&9E0CX""D L)AG/2N9NI0(U$-'9C:Z#V(48*8 *T$%AD,B]CK" MF%UKP_8T.6<+SD<%-&Y O 7JS MC+"!H_D@Y4!T'D1RIL9]5V!]I-:-96DR'93[_Y7(7#XNK%0 +K*>1FFM UN? M@*/2Y"CCL!GL#Q"DRQ1%B"$IUL!($F@J$)(^ZPEN;, ^,*SY'J>@(')) U&- M(A.C?P/A)[/!_I^N\$(B>GD206*B B+QS\LP/X%0N.&1$&_5)S)0=D-1#7]H M/+F-CJ ":%F(DR(V!/.XNW[&(+PDNU"!4RXA<(()G JP:W=#D6QY M">[-.D>V(V\D4G9\FWJUS\_Y">-G>VN4!D-H,5M?0+LQ^-1G+(&7HBVAY8[X M">,G@Z^6P\GDZ.& OUF=JH%,*+OC.B]Q0E[]"KVX.WVAQA^5X-(,.V$UEZC M;[_X5_6+OV&=QE1PD?KE)8=9>[HN7R_H$ =8MR;_3=@F0ZO3X&XR4@XIZLO: MD[*7WMA*]M8N]5VJ#B._K?R[Y?R'Z_2GTQLLUW^TMPE(X/RH(0X!U['NL79, M%>PJ&M!*U4*&O^>[%L')Y,[_9ZTGFD0>O]SYX);&D]XIB?.\)"P/WG@'& MPQ=CSV9H-%%NC/MT?=M-^&X[ZA]H-R'OJL_1$8MVESNS11SF0U5K2\_X]D2] M,/4]W>-'YB;98$B).'383;*'DWQJGI=M!4_@Y$[=-;W3]NE/.1BD)?2.B13N MWTE 3B=!Y(:RU].E5O@HR6Q,H)7=0@_7NM7\^6X^KQJKQW,_-XN,0)V?O=#!\7;0XX%-]\LS3_^L""7S;:+<%R\ M1CWI1;$CE]KO]!4SW'\>W(0T.W!? MV @(BK%P./=I]*&G1K$6X,D01%;,1IT@LM:^+R4,K0?:=//J)Y]]URE%?BF> M.B18>ZNI+^%TQ#S\V(5D_[C[BOWE^E1@U^<1COI >7;\[9>\T=44W2U$GQKV M3<@NR@)Q+6*EDO[#9!A 2+' .>\0ZGYCY M514VW'!5'1U[<;1@S",.Q[P8T(&;Q(J'G'G8;_:%5^=1;]!2>3E3,];67MLR M-S",P.O19#T+,=D1\0?N&-;&43B'03:I]%11>)5QF7HE83B1>;7YZ2?NOALE ML=U>KN0=-N=>AM"/^JLN^F\R]T,9.%%HJ"LKR ?+(=G!;#='VW?1\@#T%M+#H4 M'(&W/'_I#([A$>NMR]G9?^T1V#_1Y:^PWH7:189P?ZM!!0,C;RE M!AN#LY)R!ZZTR*E?9&J54%?T.C\ \G=^(5MDD.(N]$C>F<446=DG^E=?B&YR M7[([5G_LW&L:K(><4WS#1L%3?X 6^WH2,DO=,RK@H_TM9&\'*V[3R[-NS< I M!^)J4B7;RT6X'R05]_1Q4#:957HWG+<6Q%QCQ#^QR-;S*=&^X\:)> I8)"61KO%XK*YQQ&VW@E"$?N[4A].U#C6 M+DG6RR#Y6GQ(JLA!NGG9N4PH+U_UJSGH]-')*M/SK2CG>S]7M\)?ZVLZK$2J M'I4.4N1Y[5E?1Q$D/%UW;'7A>9=CT2?W*8/^T$%W21H14>]NJ*=3DW;!T>(; M4;H96K@;X:TJ8R.G)1]X09T9_&[SNS'E6L#L.\G:WUG1O[[>E[]+;IMGL[5& MQ6@HJH1BG7B;;LY :.NFW0 M?4V6H^K5VU4RT\P.,TDO$H(SAV94X@?Y?=$. MG(.60T-G"[3V.#(=?U] 0M'2R;VC_*_ M6'+ZT'_V\=+(NY!Q7@%>!7&H"8_-BBT:$^O [ MLJZU%^T\B5WDO]B \KGB&0K(\S)FI$X_5%C CM&;$* MA38@5_=5D=;'=3>N/;;*BTL]=KO=3_)7UM9+\PP_2S0.=\BU3TI)+<@8RDIV M ;,&10GGT,.Z;/%7ZR\X1@?X[O.TP"ND:#S#P3D:PK'(:Z_!LX7D*J;T M=^(*EWMM]JO56=5\'IR*;$H](G)Z0$ _<&NN[Z])0]Z2.A M=)Z&@*U7F5,1#Z*(>FK7\'^NC#"_FYC?/SBH\<6LI"X6BG-Q]S_2^ZE$_](D MAVC%?^$+YF% XR\"3_=S/UGP%[&B.#MMSZ]KY-^%7Y8.+>O"5K_=U^,NI6V2 MU-+-R+2=V.A0X; _@FX/,#.FK$[GA2;+HP.P4UB(EB\V0]R=VPKQT_*1-I++ M@ S]1<6P%D^ DQM6>'XNA_>,#Q($V M[V JO-2*J4>Z16 M"KD/LNSE'[X;+4EQ@7\I(A1#V%G5*?948%2\!T'H]F6A JF4XU0 JP"2C6 _ M/D"%:\%FHDSZ$9Z_-?LSS:RR*%W"',5O.X4FB;="%]2ZEG!%C<+F1RVD>HYX MNT48M9*0< :P%81RZ9%D..5(A=;SZ%5MB7GIN3E+X6^M'%D> MJ0/7)R$6&);^PW=,C'WZMN&G+;U%5E*(U^(RU+AH-+[M%"PD>)#7B>CMC4*H MB63_^"!GW!Q*(B_?JFC?JJ8<$+Y';H/R5(-\+"Z7+$0%U,F0V7UO0FWW%?RG M)QL\8? N08A905UM2' J%9"#4LA9S ^Z1/_6[6^@VRM53/_[*D[S9O[6,8[/ M@2?LG60:%I?O8&+_C9<+.ZB 8^NN_J]K7\J'CYE$'3PE$M1AOX^FSD()RK7_ MX57]WUR-_QRZO?).G#?$2904'I8.3VY\:V;Q.:C#CX;/4M'Z'K&[PO!?VSB_ M=?O;Z39'82>MZY/>Y\[VF&L\PYC7V[DX<$5ZOQ:-,,O:AWH61*\>+5;!@7D% M7D5OI&#GZZF LT15"\F#QJ]IYMJAK&8!"^LEO56-G$!2DT)SH;>2VKGTQJ/( M?@7O,_J^AS8U*>Q0_S^M# 6]$4.06 ;'":$I 4GH[55>*B"0]TIB*7V]@_?? M^=$AVM^_^/4O&@DE 7)E*J^[W??6HY7Z(X65GM1YG=\&^>SCM0%NDZQT*FHM@Q#B;I HZ%+RD=> M?.&@IW%?Y7;TDP&_>R?]!XEQM:E'VLFLN$B3&I6AGMXBGZ/=>DU-:*GQI6>1 M>JI.)TQ'=[C2:/@7B_P?]MX[K*ENVQ<.@B+2!*27H" H5:E2)"A=1!"EERA% M.A$%"1((2N\""@A"E"(=1 @U$CI*$:1*)Z%)3Z@!0O+%?9[GW%??L\\^]YY[ M[K?O/>\?R^>1-=<88XXQYB@K<\U?@D.LS2V3L&N[;QG@!!V*\[]=R*-T/UID M0/L/,B#D"?R R16^-P@F>B+R"!4WAE1UBGXH5-MZEN1TT%17D:SB+SY@LE.) M&!L/@>SIM2NU:[GUG9#^=W5YVU5 N6^[C-N9=*:N81-Y9#N&7>_L[7RQ7ZYN MSZ: JS>#I ,9KJG4?&62W^&_SBAJ6-=0E]2)K(I\GWR3#7F&M8,Z*8CY!J#G M5^GB?Q-^>2JXU **T!A QLK *Y?J0BM]GU2X.VR=2]#(]KAWLO/%0W4U9. _ M4N-8UO^](PHM%\,7##B-[$M<;QY'A;O)F8,NSI#6ZYZ^*_MY#KDQ&5#F MIF M4P>F_Q>>YEJW<<:ERE;M*$^NEQF:S+7A;T,H:AT8TY)99Z&XWG8!]J!E M'J:BDW1>_/TO6">MBH17-24YS[:FMGM92R)BD6AZ0C;6)SR\+;QAA&/ MEQY'EZ@!3R/?/!FNB%E[>PDKAWIACWTWZBV MEHY$.OO4YE@E,53Y>EV#,!B/ZW&912:M?ON@)/ID_>&3/MI$HB,N)585Z(/K MMH4>;+77R8_$5D:LS^*/9[SD-/JR&*93[:\K:%QKS*.H8\?[T.M#D9,KD!>) MYH*.M\U!LSLRZ0>\KUH&"-TLQ_6VI/<\F,*-5WUQJJT]/-[\N430AZ41SV[" M[=&3L*0(KN#/BY#O95R>$L=OQ,#L_3 ]VOR&-TB#F5^Y2A9BG]&TN;F=TM4] MKO^Y&&/Q_..ZTAB>LW%P$-ESQ[@/Y8%%4)>68CV,NUH&+$]*.YYBZU$+0)4P MA++?13&RN!_3N\<(\+M!U""DX^]8$Z[EFKN9H1G2K0>018C3M'V:OHD!4=AA MX<0QWA^OWVXI5DBGQ48L*)G>*[X*GU6,E2^C6U(3&$ I#Y>[D82&!;]Y2"-/ M6II+T@LG_C3'QKDK#F/U+V5?T@2YKJ?@X"UC K48?OU;5NF7,0$R*WH?D!;5 M[?=K+G'*Z#-C(X25#G?\ALQW2!S-$(ER\[/D7GNO MS#!M$<*RXM_>[1N7QW?;KO 3ZOW<.^-2TC)0Z"8GS[XZ!M.#YO MZ4 R]$V%C7S%OG$7=,^HYT5_T9JNIJ8(W1,)A1Z?0QE+:+ 5;JH$BQ8@=+0K M9O(-WA_<+EO36\5$33E_/WW3M.I#3DC075345_94<:G9C!+(C(.9@/"0?!D3 MM*MUB@9AYJ50!'FKYSR\UQ]Z=\M2IH,Z)^TU4S"!%?F?RI+?3(AW\#2L>F)LPF3CGCZHSZ#=M<"%A\'HX9A8 MY2WKZJA9*[5SX7>5GP5<'S Z2Y6I])WCP7DZB&P@&2"C?O@J:G K\*NR;!LRT%K8%SSOFH EM??PMO =E[N^\Q +.IR^\$]?Q])9X?+72^L*RJ#J>T[ MOGK#>&=[6?,Z/#0T\"F12$/FB0E7SH0?4[SU_1[M287?SR6'Z8L/&5XN/48E M7([*#0.>#J5:&2Y#4>5-$V9;IBXFNKW+=WZBF!90Z=HUK^HK2?6B9CRQ<5SD MDOK\1V:NA342[7AU[/;&Z>5,2;QBA.1VT2B245QSVU4UK&:B[#F9ZQ5? M0M),;LM]%*/=5V^>H?Y"!C@;1DR=)]S!CW6T3O'C6+]FX)IJG MNX&KQ_U2 +FH-<$8V.H[7W=3,:Z@/-.N&:E/ 3.<0]MK.BW?"%40]NJXRG%] M$S\Y^==9FVVU]]Y-*0D]>)!A!%30N! ?&S[FA!/(\,(? W)^.=_B>MG%^ ?V M6.>]2U_$;K263JQ/&2M MA-]AQ5>^"([(V%_4T+H[A/\.JIP5HRCM;@[XVEZ,\\*=&=E-&U/A@BOU9 M\-4UR_-XQ9@2ARO^*KPN"B4Q+15=T.856S="P+^VWUVW=A]#AP,X*1Z#0+/_/# M$EHY1+3W8]\MDN;R$XHYM]8XPU;[^4N7[N(G@ 4AK] MDQ=7YY9VZFJ7BR++ ME.U2N7;I7I5^@A>/@U,W2X7N,UT)_+FD,/E7^=!U,#MTO(5'--2'<5?2M4%P MR$?<08]ME>%D50B',54-[(6.FC7K3(&8V[>B2((5+KAEFG;5Q\V0^7QG2P&X M"RXZEB>3NA?PW;YW(DR>ROARX.34+#CMV/P5/SN:TF/XE)+1:N[C;&YYS%WG1C>F4R^^MRT;=4[.C7T8-!C M&\1+J&\.Y!O,371#,SFGF'X;D_VL][)-:/Q36]6N7:M5#Q>#/H!.. V^VHNY MRHDI"R/RYDPLCVFJ<=D6WB)O]-C24BB&LH_IL?; MACCA#3RS,K81M0ZCK'19W9K!CMV,7!1/\>/KH=WW2^Y'<0OYW(F?%"]B*N6= MZ^XCBN/!=_ODT&<0D9?)@.9K7@QFCZ"00YD1$LLFUXE+XB=C9_9O?5/,#+R/ M[A+:\QDBZ& 8R\)W]">M+/$GD+,9KNN#W]7>846J523U)N[K2F+":$Q5RUG6 M85(+]PII%9T.99>JGESZH=,>*(5H_""S;\N8MDMMEU!P_.Q6R#'\.QJJ>?DF M@^S[Q]4L 5N02#* 0TVX9981-.*J,3L*:*T(FBMB<\>7$[&\\"Q08EY,D -M=,4/]X\].\R"$DO8JNYUM_ MSB#5R^GF=J9Z'#/W+;B;#!N:/JCPZ\P PY&@,X:E7WP+SD],"57B573XRB/: MACZEC6D'^?EM=CO3<7]=?='H9<-1@MNX,4ST>4]XO]HC.1^7XI2NL-GT M6)A9:D=,3ZE*78F:8916" "47B(#^%$>>80'O6T]);!K>,Y(8=WU=103@E[^ M2F6RMEBOA\>5@6''A+NO]')JO!]P.S0U'G);/2VZ%Q,S$\.SJ0\<;6\>JCRD M(SIB>S2:QKS+NYPP]$7U\%6"ICO/A>[H8Y/Z/#(%+%TJ99U4Q]795RK_\2'Y M8%5XTS4U*9@Z 83K:/)%,R*M D1;+=$Q$G(>>T^^&3*4=R<%KK44>1AWOG9L M 3"=+'M'_!4/.X& P0'5"4]\*$0>2&L2R45IATIT[%[V5.$#4)7 M 7]=8Z^"C\=L6--,?YA^)D( 8:.;ZC'73[LM:61V%S^.? MQX0F66/816F(DXVTW:#R]60RX+3:.=AC0D8N@5.+<#7+A01$-.UETO3GWCFW MS'(A8?U\[-E8SJ"[I[-%?:U98;*[OOCV^D,Q4L^E2;<13DK)3M<@Y*D M\F7DM#')9#?MT%W0'4#C28)+U0=5*?G0"CV>6\CW M8_JGOD^N&1<]^FPG(7KJ(9>:\ORM6X^+0?:4P#(>V+V$DUF#[,!I=3S.HWQY M0A+D5]W[58MDZMH+A75@132-C9^%E #[489Q8-P[^$QBX)EA#\_ WE)7RV/. M8Q86"E=J,C+T"U929[>$9P]?+8)P!M-1".8&=M*W:C0]BGE6%&\6@K)Y.SK5 MXB7YJ:TFV*HZG/,V39J^!Q\R4T[?:HO,'3PQL$ ML+BU\R[G':M*1=G9N;2YD]=\8S;K3P'\>59(LC"JG]N\#LM.V"Z/I"4G%4)U M+**M^W?XS^EF9RHED2S*$Q5/B.S[2BF-H?#J['*(L71,8"V^< ,C&1])) ,B M%,*N*<0?(;SK%706%#=BK@N%*&&.ZD:"W&SI<7LAH)E\6YJD:WV5/:P&ADUI MK]:V7(:]QM/KPU[O&5S4XIW8>_!%#;F+]&LOP8FJ#P>J.H,Y'M0/IK0^54M0 MB(6X\95':X=I2W0O&]7"DI[S,;L"<(9CXS.VL?C"V;:G*2V44-L;IW;I^ZC( MJZ)Q0C-^(V? /?.B@/SS\6[G$D_]^]F^FK12^H_D/.8F\!!N, MI+\1[AI>*[<]HQB:9QFG_\5;Q3S/>;W[.HVDN$J*>=6%L=2O[2W2$W!.M!WH M.-$2OS,=@\%SQL".8Z]>'W7?L>H][B9JJ%PL!KA;R\MU!4#53@=PNL*U4Q:* MIB?*XYP:T\R"44+OWR>]=4E(G:DVE7BD]^")W:/N;GT.U41GZJUJ$EUOJ?,6 M\?115@,?\<+0W#!*L_H@MC?\^(_$R45DXN2]RAH_2WD3B4XZH/@Q)1/V0=(7 M >Y!,L 1'4T&, 2RPVX23'#+ ZV6NPD^(L]F0?26M$.LYG9.-5&[?IR/E;3O MV#-SM2U@=M-,H7FU^,KG!'0GB6R8 Q-I?=O&(% M,N!%41?*&GM7[OU' M]H?]=JR6QZ^['(.4RN(;3J9C04T0'NB3;U&NG'76S9U:*_S]!5"^AWX6)ER^ MV 8[O%-$*=I%A5\6&QY^LU>Z!<*\U" \L(;YO(74(];7UYM:'VV4-W_8&E@K M 7N:4>/\9^)#&TX0P,9]JM(>PLI/WA5,+E?DS)N_]A26ZKSTUOTV\HS]V=O7 MA#?550^U")'W_;'2T2".>S*N4T#<0B3$/B_:CYJN7_Q.OK7, M3M#GA]CPENG016QI 9[Z\($;K\FP//CD^W3G-'W+TP)6_A8<9[V%-44=XF7# M';G5>>F7T71J]%"G&71+*\[T&4W_#WW)[@:3+3J+D'[9CP( ,>I5:CZQ_,62 MQ\GP"L]TR"Z_\FP;26P0Q7U?XM$807ES>;+R1RLE'X^V'ELP?U&(57+RWE<7 M4V\#0-$=_#H= I?[R "7JGK\R^2ID[BO\5"IXF#2-[8VR5<,#P[WAG#8$-G7'"3F\?C5C>L)%LK):4_(VKN?ANU<;4%^C]0_*!M MWIZDX4/35VO<@R1^6JD):M([0X4YT"Z?!0.(-P@=1TC![I628KI KQ=K\\E3.Q#F?HN4G%<#_YY:O\#UP)\,S3]=CCI](5>HM & M2ZR:@;G544VW8_MU/QJ=YUXU3.&EZ!9XD)H P26?4$<:VS,=WH"9GE5N:Z_U MEK)=FK7@]%/1EOG(/G;IF0D[NWJ;$_-H?+/]3#;QTJ$G\BAB*SV\@;-FD+N; MY"7B@=[M??_DGE-,'VUF$WZVM4YR))QH6# Y84. F.(V(HFF:;J5<8H*3WH? M#)_,ZV(]L2G\0$E)4L7I[%VIO$B4(O[&[,QZ!78E/F))H=HK2]]?.@Q=4<*I M;G*)PUD(+KUV;ZTS,@T3-HOJJ-ZS'T%*ASV5*L#VT-J^%F9U'O-82(+8O5/K MW-T38;YL0+AM.7K 3G['LAE'!J(VV$&^H(R<'WQG(VLK9ZC#1?A'M* M"H5SG8XDQB-3@V:[W)ZG!UX_!:NDFN\CV@YY]]!B%)^YRX/8H/:WP-1+8U^S M2Z%6S6;*.RN06+NPJ4O)U9R4\7A064@G'VQ"H\&Q6>,?%2&\;$]BU M0HNE$Y.KJGIE!-N-Z^E&<28!WU!WFDZARBN='K=&A3K$S]])&T$3V-Y716/< M/'A;>19#=^",2U]ROJ\P(T5GDO-M7B72&>"JK03$ KC37$I(0/"T4SN M)('1Z9,[DOHV0_+TFSYU\/% (&>$V1 1RMZ [%X^^Z_OL*\^[^,$+4=O^H+VX7C4MPK M:NHG=U7WJ6Y-[QP]:FZ()TVDDX(.PH^V@&0 )_AJX!_ALW]0BQX^@AQ0+P/W MNN%$&^!X$KP/^'//#Z7\PJ[\; MJKTC V =/U$7CVH5CZAVF \70"2IOVTY6ON"_L&<#Y^F=%=X;[BG 1F@'J!! MVH\G Z+_9B U]UFRPA6 C^_S>EJ!1+D$!1^976?/Z("51C% M4JWU\]A%BM\D5UG^H#0RU)NEXKT?WY3QGKI"9"U1I!E,B_Z(>O5I;FH)_7IG MFBB[T1)_(%J'()WH^@G_]R=AP.?@S=_QZ",FVY^?\E!"YD]LVRI52I+12(D MX5Q /V.9#JEL$;C-+TT\!5Z .1U@6N#;8O$D:D-B?"DE*R,"^>#?KE+R,TX! M3-+-)G'O83J.V"8-*;(Y_D2*W&64ZID/=8T, M"-;[:0[0$'&6%)Q+J1[TB2U'#S'H _:?O]3GD71&X+A>-!/H1^8RG, K_1.+ MGM)*'.)F29'K>93A'\F 32U8)!E ;__S.R@E:# 9<"+I;_;ZT\2623]/ZN@G M QIS2?=)-0^GCT[]W'Y':3R%5M $I^EPX+:A#XC(F/(3T9(," L@4,9K[MVA M/# *WS_7H/EOR(UQATZ3PJ5/PV?ZX3_A9^$_SS!9@L]0$M(E,L#Z"H042A&X MT84,2/C?9 Z= _0;>)\W&G<1G@HOY:-XR?5\RN-RE#1XL/$G[8-^LT]9PN\B M_^YIV4?@KZ ?RF#"&70W:(2)EW+O+AS' Y\+\/VSYH&_&8>,:+1JTPVTJ7I)0.*6?.M(9LP9:XG^DM[$7WE_Y M)\._L"?DSEZQU#;D=/ORY$>M[T=UU17D-<(24U\[D_50PXD:DHAX49UC/RN*9>8 MC])G(=+!WS>Y8RZ1FN"K]MI).)-J,#]FE;=L']^X>%^]()XOPP:CPTL$B@I6;;,@7]?'X=XSJ4Z.D6[ MM+ -^,\./'Z:MB4K$2^;'5)@VB#Y]:+-^[F-O7J!*;TV)1'QR]D:="GM&7HJ M%R\TR?M,BJ^]VP$2A2D^TL?\<\NQ'1DP^Q+>K 4Z NR #A>D24I6=\T6\M;> M2_^#048G_AKQ[X]XE83Q>.IUQ+8?J8]DWCX[J MF___8+(#-! ME^)\;P4H_\#:R(".GR@N4? #JF7X7C>8^*@J_RT#^*\A_UQ#Q))KL70(K<$S M/^H2@R&"$UTRK2KN(]2_N7QT>GS"ZFN*K.VR8E76DBE0:GKQ04B]9N&I]DM,?>(3\F0 MWW>H;YLM9Y_4_1K_7A8#+\;B!+'4;^^>O;<_*W'RN-&S(+^.6\A9-'L@(P'1 MGBE'B(2_'VLL\,N!>AJ(616%ZI:6R:UI+^/?/JK/E%<*U7\I2">CZ'&N6HZ@ M:H-7P>8%(WO C0?ASRKC3^7.M_#;'GSU*_-\'_[Y;JCD@]23KVRUI86$' 3I MO@A2]\-<\-3-9 #C=OZ.(0V[=2&_$]WY$2VY.1 M^6!RPHF[\>L%:EYL1]Q.CZ@EKB.8*)P[9 A^<5'37\7Y M06AY1FGO!6N&[.&4MOAC*VE52$P\%U1OC;?-EL>OU50Y)):]ZIV+*QLFAY_1,?GJL2UR.= M'LL-*,@BN>T8$U)N.5/5+4:@3/!"6 7DS,8I-S>,I%!+N7K=\*?CQ;Z*O3XR M=,9C0P^T0Q4TC742-9..7"] K2[4;LHTBI?';3M\&.R$:Y$NK^\'X,6$.H0Z2 5<2O.NI>]R"2VSGA5O MVTH(IK.-M@S]/B?EW=)M;->'9^\,>GK,67A@Z=TD^MI.=18(@=*^3EF6MM$@ M =Y 1J)!:<]9_J+6YHXNZ5/P@0&JN.CGD7*@D0X&<<-R-XIL3 M#8;);G >F 66.0S(WR!$@)OI2S,ZFW(."YS97,.\T/=RY,O"$BO$(8P/><[? M>3D.R&>5NBH[GH<_85IKKL9 M=*0+@*;)8#6+]E. MQCS1F5JV0W%* F_8@6:$JNCCIRIF)L]!3DVZ<=)J5@[,)?OU+TR=GQAY4A%4 M[^AYALG+,@T<@;+!=6!UPF"BV QO:,P63I?7Q?$/L[V*&6T&S4BP[ZT=\!X__"PE MSUNT9.<,6]*J_\)PNX,AZ<)MH6271T]"J(*N\J/NVP-CDYHW<_J69>G#_Y./%;2O1#P7L& G1?VLTBU,0)\.:#,/2) M7DY*D!:'BZ3.*O#X-R$0,B:)(_2'(OP M9F'"^:+:PP)51ZPPKK[%Y[9UQG335:M6(,U.@,CZ^M1(A_+:H/+1T5QH;C6I M/\[\09Q(._TU8 (#@'G?D6M#G9UH@2QU(3>L7NS/;88@>7A\^:F2YN.IBH/]N5(7"-J4 T M'(LT=\^] .QRD2H5M' XU7GCNH/CA") E[:[06D:9DEHPJ68X0*3<,FS6D,0 M#CG4IR%DAIJ^B&:"3=N[N">)VAZI=^0>WE.8?:X@D*&Y94*.%9HM %9\I.,RN2MP MI:$E5E*Y!5UEMX;3;.-=[ 4'I4K/*$%AX:?L'#:G_5+L.CYL.+8]FKI,:+M? M#%/&'\5'RD%X84KH >)5OP*#4^G..]+E.08-V/8%NO?5,F7WSD_$&'W,=SQ/ M$L-MM'+4X#CCX>7;G^S;ZD[97BN /C9 76Z3+^DS6'*3&S?)BVEAXC&4!+,R MM'/95@DB&HR7NLS MH#(WM4HW1KJ;2KYL#?B^!=MSI]$6B$/$P-RPALRCWWO\V-\HO$UU"E%]]*FG MK=5H74BPX.%J4U01P,#;$M&QP60!5=08*?'P\;!=M*YUXU>\5EY)!D2^ZNGG M9&V:5S**98DSO)SCJ/F]+96!+0,';ZQ;#&T0AND,R>L#/WYW)0-&078I/;'$ M:9&VHLM(/A;2DM:U'%X&7 X%X8*34N.8W53V% M!/_'COFN;#<2K2;&)S0;/'O/ASSZG&\R:9YM#Q#8FP%%/9F2&]SP]N]A-L>E M1$I@K2(K#9Y>T21I7#9Y+?S/,H16B!:4+S M7G/F65QC7.-2,@NANEVQ;OV]R9R%J$2)_V,(@T,'TS%9)3$]L4O,J/\XB-1# M<&7XVD6,X2BDZ2DD"F8/*>C-F79]L72MLH;5*4J/94)W^2M:D*7JR;IGZAV; MC=^>AH+6NG#P-C W#(A;,<2]CY-_75G&M_3T$]' B^&TL/7X1I7?(ZHKF"#R]DA+(BXZ_4SD0\K:-JW'(! MNG<\T*OF\8O)E=I* @A+T=3S8##L9I(.$!>*#C+3BKZK>!JQ/5TE$7:9@PRX M!'NM4K6V]@9O2Y4?^ 5]QI,,L$=$3=&HG;& Z942-9.LRP?22'W1T6Q^$-$T MZZX/CBQ?A^]-V',+&M&:'5X-_-:@\HE0@!?%'.VU766>?9"43;A)>-[;?B"0 M[N9>-:(TOFO&L=I7;3/=&FAK:,*'6(4?^D('L#I-TGPNP-/2J/C(9#6^!CPP M?"=24C#4QTI.3SU!2).E0D/"/>=X$_6+&[5E1@3.0Q5"_:XO/J\=1.TLP!TU MB]&)\G@_["UY@WOMVRHD)[K+GXXEA_4,YHE"?^$9A_ET 9N 0VI"?=OT!T20 M-V>%&B=A?";=?U1N0VJ=PX6FXJ;#1[^$;G^1V([S5<_5W8]A@ZYN8!!K9P/> MD9J>&K8;\DV_+RC2P+0/EN8E"%5S^G([QA[+*BSP_1YT@>\#MD::(+JXQHD' M=5CN11&I\!]_&,Q&^_-*LRX]NEK)T:.0[G.*O_!%UD66"I%;=(QGC0,MYXE: MAQ(P(\*S0RD8@,"9[\)IR13*5_YE]M/U,5)/9OM)>F5U! IR>3+U].?2PMOZ M7@F6!]6KM[&]SQ \@3S$VP0(%L%'O#TD 1G1'5DEVI>-3W3*6;"'A'$+G\9S MJX3XQYD7 .[-4:\_W1<8Z4"PH\X?PEW4CHVH";9@@=30\.L-PVN55[S%_>4_ MG)P_%_UU?_YE;*V4M4/2YK.@J^%Z!*JC)'SA!E::*!$?H8APE@$2--=WIF6O M17O[J^D;2L<$8+8>3HRP8'M#&B0&R0"*CQPC:E;UHWII73)940-2.]*5FJKU M*:]>LW5)+_ ]5SJE\PGP,%.!\ Q?/9NW1H<7;T2<4O7*@RE\(_&/COGM^5KR M6<;4?3IJU38)C:EET02TS_&&6RNHVU*W3E>1 :W,[*2>Z1,[*XSZ>@2G0D)+ M*RO!MS7P=R2LIOIM-3710[5B-L_W"=Z(3;FX4TPL> 6'!< M("N!S8 0^XZH68%T6?.4S_=>DLNX?K+;39;NX?F(Y^:%&=VW9.H?3=D4![:@ M65#4N(X9UR;,)^"L.%1[Q6A056?FJOYM?3>#Z^OXZ$ACO?!DTFT[]"<:/H>+ M$\U!5_UW30@8O"$6_3Q0^D=RIB!NNM4 WFR9Y)+)CY]+7NC5&[;)GN QJ6) MUY_7]U.B46;80N&!%;1K+'B0Q5&1(P%<1#3N#Y0:M709,2:\RNX3^A87[$__ MTEDRCF6]3S]$^D/,)55C(O#H#4F)X*M+&,7"3[I83]#330_M:D.E1Z]CKTQF9#M_)0/" KF)+H2EPQNP2X1H/!NF@5+72@.: MO*6D/>13Y7D_/='+VFP^&_+@RC6)<6$[]2=\)OBF-((P34IBVT>T]N[S_=R"IT\&W$B]K<6^US'W['\#SM]_^?43$Y2= M#/AR9PB^RBA-BG^..O9SRN)D0&)>(:5EY $? 8]#N?>(42N4QOA@G=+#)JRS M$77&7M[6@JLBOK_[#P&O-+"0 2]XR("1M@Y2W-/?P88!CZ8K12.09 MC M/ MJ58O7XPW_^8!0MZFT1/-X&.H,&#B8SG\G*B[-0CYW 0828-Y$HY*"> .(',N MKCC!&GIC4G('S:DW7Y20.]F=G-Q-9WR7-EG_>8O+N//HE<\@C6GSE@+S"8N) M]O/5-;%9B0H_.AN?@X3 "H$]\(JX6LQT,$D:U]&*%ML\-(LD*O(*18*P^AYL MEJ,Q89X6#$FG;VG<>G0&![AJ.]*>4CW-3;R62U^SAI+']##1;42G-G^:;$V4 M6;=3E'[%P!LO:#?#RD3%MQ:^!LJ>[,AS32+HMSV%//<1#ZFNP&?LO*%[W[5P MR=SA@HCB92TA=GJ)#^?X._4!UZX@CI,8":4;,X8Q:7 MH:^]%24Q,D47E^\]5[K\YOF<5Y\9GCV^%1X!9I@CF!7 0"DZ_BOGO^V .*1R M'QP8CWO02>Q^*WX_G_&"-0%UDCVB:\8AR.CH';1(!G8CA-(KJ.J5 MN:@QH_##H=C0RIK,:1U49;C1A_JPR7M"'A-]K3@YK_9K%AKB&_M<"NJT*C/, M\4#GR\$,?K O0.3ML$TA(OXQ%Q M%.^+V6M0ZO,@BKMA#VW4^$54K#ZOGZ\ZK2-3]/D'?"0[=4X8]O:5B1-=30L9 MYLZZ^$CO 3=(F54;Y]BY:)U/^DH>=K69#A/Z7',!Y9>I>9V$[Q6X ME[$']@\G$=6&B==<," N2\+5RJ4<)+YZ]*R^S'O9CUZGT]3ZIC3%7[:4\&;!F=?:M7BH*??5,UV[Q:=^3EA,, MQ-!=TF:0 DH=VRQ2H1!E(Z['T^,E(HK3=7N=FFF-C M%96?;WZN?]W(&]GVE)FBG8AAX&G)C6%Q20VMH$HR6W!;;6FV/+C%=!^>03ECA;+TE@,B*,W:YEC M\SIU43O>UNJ:,L2%?6@>Z,--?R]X"5RQUZ*$$O+"&K* H?#;N#52)4Z#OQ2) M=9OT-;(RI]ZWP[JL.\6"816G7Y0;<3FF;@-VQ?Y9=D__#@YK>12W7>^A"ZVQ M[EB@.1283HUQZMV6WX83SXV!B0=DP)PV&< #&,[Z",=P]),!BR-DP#E%PC>* M#U:ED %JZ'T6='N0?'XQ@J!5B=[?H4PFEB0';Y;,)0-ZRTB:$/Q;1E=Q41*+ MAS0I +XI!(\%XJ)=X%N4:)[ 2W2FMHSZ0HGK5I2TA0 3(Z9G=?[B^T_(5^@W MF*&2PKEM$)-+_[1;U/ ^R]0:.*-&X*;.R&#:\"],U'D&30U_803Z(Y.^$TCV MI%\8Q?]Q+V79#A&!N#'#M)G.?+> M$Q7ZS<"D+Z1O<<.<(@-KDIRIEN9"0#5>KBG#6T-8!&YX3.>(;8-8 OJ)W=<' MA;.\,6[N5 K@^LKW=:VARA*FGUL'?.$5QA:&YR+H7VG]FG%+R_',6E>/..BY MY=314_>'"%P7@@W]PX)2ZAV"22HZ1)G%UHT##OAF($4S<2.^9 "C1P[\FQH9 MT#GP+TB%)97Q!Z+3^Y9PDCS88.>K*!GPUCR ,O5D(.-1>N/T-K_9.IR8CP%A M4M1$X7T59$#2+IKX))[@V!LYO2U!T?X1);+REVZ0>,9UR8"L #+@5=Z_H E: MN0"W#=&;E.:4G!A4>]E)%\HK\*2%D/#+5X%5(H M@HCXB4F(G"0#?J5#T8/V06Z4/.3\)^G7R8!?"!'EJQ+( ,U#,D#< M\"?:Y<$B&R6/2:A1/+R+^E#Q&?J'[LE3<49NH?#BE:DV!>G3I!,>,R^C$9,*]#]YL/5/X^ U_X MKZ1^][R QY%DP \.X%,*M6?_]3XLX \YE"/JUB5BSN$6%JJ3.E\$U'WW\'A7 M3JK(Y/+>^7F,YZ^>)PX:*])'IN''&P.=,R&7S0[OMS>5FT$.2OV,'V^LF<+_ M\IC_QSWFKZCW?]R'9<"CX5B'RZAX3$E^4 6P>OPA[1&R]/ W\YGP=ZPYYO30 M))0%*7 8OT-76<\*E1W\7:TDDP$5P-;Z(FA>=(M_5H)&=D##=P>6%_#AN[_I M"^Q &KU^VPV99+>@/ M)'^6F8$4S:DA]MDI>LL^\NX&)0*]T?M"AH0P/Q#QJ&BO@PQXH<;[C_RG88Y2 M#8$H*D,8$J,H"M,AGCW0(1[ Y\Q^EF C-UOVS^[]E)GY+[)_D?W_D^SSQ5T7 M0L*#^ZR$Q_?3KK'"\ZSXRFF>M6:V-ZS\RL!"F0P(]:YQZ']N.1NP+!Z(W^>U MFHK?&;A$T@V@-!1SP:2SF918 W(]PE/^QQP#_T^LN[]/]C^WGO^B^Q?=_R9T M/SGMVA#TL>CP:5:DWLZ1^"H+W.',Y&Y$SG[.ZU/,";U@$:_!?D?&FGKZ*&'?3$ VJKQFC*UE,,0X ML>(CI8[IC]>1FN&KD&@;:+]=<+N3:7E=87],?$OEE#@GZ?21$"D M"E.J9R MN/ EX-82&9 )KK-&O;'%O[]^\[4KE%M_TY8 XQEE_>_'6.37X'S"O]@GD++Q1#OU&V;:\,##%6;IV$=I*6]M\R] M5@@"(>5HB[@LEKQ(4CM/!L#( .6H?_M-^W_@^@6RW;9EMBS6EI/@6V;AG%:V M._2UQ,]]+\'B1Z; H+R+ZDL?[830'-95H^YLR3@#Z-X?7ZM/$$+ML91\/I:D M84B[DB85"FU@1,D:E/P8<+V-@GM6[YNNAW:XO.S=YM5G[_<7KG7&,E>FOONEV[GSI< 2?A=T: M1.E@RB($E&O2S6^7=KR'LJI\TM&.TN>:M+*ITZMZEZRM.\H]6)#08-R82%?F M08@M!H\2'0@Z]]W\'Q\OF9_*W:UW=G34^R;A(+YPX8JCV05M*(-9PP7J0;', ME&)SMX=="AD!'O SLE\\A),_%D$/04%]K!@ MMB4!QK[UG1)?8^2W[72MZ:MKJT5G;C]7Y[;S^B)(-?&"5J1&$K3[$G=\-]O1 MZ2JI*(MW*7GLZTJKFL"@=[I^@3E&* J[/'4EYPG(Q^2+>XR3?#0^916-JU>C MM'F0-8KCV:^ED,"(>$K\=O>[N,N_/_ND%[GOM]@]&N=E6X0M6S4DZ&S ,<*D M7E++*.G545'%ZO@CT#!DW^N-S^Y;!C0_T1#7VV+N/M[*DU"5N?-:8M7#8[X> MA7($?&SR.(7Z^.*D\#D%JH4"@N@L,(0DZ'IG* MZ?H^^D%=G-)-/T$(?;4PPY8U.,AV".V"B&PQ&R4#Z(Z-NF1K;3T/(W5L/IHR M?(1V4Q1XH+)O0>*!KW'O@JN(\H? %,JP/.+Y)\#O4V BS$_-E0QPMN?;A]L? M:A.)->.93_IHGB0\GP'P4QJ!7*@-+"?:02NX,,B"Z'!5C=A?7KR%7X*M=O/CX2/]#G8;JC]]4K^:[?DQE><6C;:5[_L*[#&TK MO@\EP&,P4UQU:QGR_;/"@*SU7LC8]DJ1GX>TAZ\3),-#)J?O8<\>O4]IEE%MR3YZ^=IW;[-M^KM7 MIB++BKI =:%K\E.1=-_\9<6'YBZ["7)[G+[&$EX:/,^[UU?530"L>E< =_&= M2=J)VBO"GM3B%S\+;@L>F(4%CHQ!XJ0:Z(B:B&MXSO#M:>8.C(W.6I5R7/#5 MR<'OU2_1*0]3RB7\;E+5B3;19#2N\5/"I1LSESGAP32)==)78WAT)F2,GU,K M_1:+R%?-3,?)CM2GCQ3L:8,S 9=VXL?L&RV92DK,;:U7WCI7(!ORX,RA.WJ5 MAXIWS;PDL5:\WJ>*B[L=FH._L!?-0N*F: F!DDSE)0KCZ>!JVH'54NEA<-0<$<7+(B9X(3IB%#U\,N>6KGSXZ/- M]%)*XIBEA*A?G:[)>5&[^M8FX M6\KH<97>*M9]6^\Y+P$X7,]"9)R\*A!&H',Q& MF"I[/ZV['M5VOC*A4^+;E]A$*4PP,M*FZXVG-1J,KXK$Q-JK]R/%,2=RRZR1 MF>FNY:A$:]WRRK*@MVLFFG8V'[*#="6H-H$L;CQJ!;A93&\[@G[IX_>E _Z7 M9BL.R4MLL:P+PIR7SO!1\05:8\P()7>I@WNDGSVM! LT2!'RL*LR.OX8?GEP M\Q1S1J!#IC!LF;,\,]3QM?'Y^T,>%=_RJ7]$B7^%^9?80FG;QS@C'WQ*(K'H MKZ5)%=%\1(CU6P@#'>J-H+<75#3.P5R082S$<4( M%TL(U2UD !O,*0?Z?.0S&WA90+BN)MQH2R1.(7YU?8&+?X_X?O2O[)\#KC:\ELN\*2TR'%!HY(4/0-OHMW M;'@F&N')PQM]Q#.F*>/'+'2"^?+8AYS$ OAV1#3D?FW=&B\F(Z4%P>Y2K0R. MW2'8?6)M48O&\C]9-#70"G''O#NT+A.6$:$/G L5KY$!OGI!78'3H1A< 9?\ MJ@SNX%K'O!M"#]I]4.NQZS;N3@;0?'-8]9IP&)Z'W<'=&FE%<*)NX\9:K/ ; M45E]"$Q 7%Z!N;GKUOB7 INK71?2]%]ZR5P"S&<[/MF_YO&V8 H/;Y7F@AHV M9XKB(.%Y>*:273#0$FH\1N)=\?-Q\Z=;]5B?M*_]E,#ROKN,X9'A6??/"-DK MW( #;-1^-J9G) IU'@]NX;%%8 PCE$7#Y1WJ#(RG.Z;$!G:,5&M\<]O*E5\- M#>,P+-G7YM?2O4P$>0YL?ZD6+L-^/4.74EW^^H<%9L)%PTB4%68Z%,P\BP-' M(:5IW93SXKPG%0_U;]9 4X4+KHQA=+?8'AK?_EA2Z6!$.R+?030GU&) ST@G M47AX+!*\"F8:17GU^NVZE"K(Q;&<^)SP9CZ5B3;0#;.FB$EIO4#)7P;P&6,8 MG/"2Q(C&%0=>1 V*#&(#+!RWB BQL;G6P.[0[Y=9"HG9D$]^B[$H/^PT#[Q) MON'L=T(2N!:O78)!"'1@#FVL3#VV)K2.'U6_?."U=;F+K_Q\Q+HS]499"!P9 MW@R/&[.M@,] N"U7/OS ^6R?IL%KQU7$C5IP0,(/6AF0,O M$"]_(H1C(*Q:183K;5("*T9Q4P[.FF*61M^4Z:A.*7J()YX4/*T=*'.4(HS7 M:3.,F@:2SA%OU'[;!DIBF99J5[6.I:7FN)NJ^-"$WJJR &7\YSJ M-O@*42@)?/02[9@AA-5&\$^5XWJQ3X+A[PAI;5S5N[9Y=5A>JT'^A)23+=]W MSA\'!#80>+' \ 9A*/ F/CS5U_N9@=[CB9PQ1:?O'?)KVEFI(5T MEE#MC^LET8%PAS?ZLM-6VC)E^S&XKPE.;FQ=JOW6*L59VP7,R6A[Q8/P"[;STCSPU1QBO&5*@:2=SHLQ5W>VWCV2_@EL*X6G^?] MPCWAD/KPQ 7JG7.HE&8R .G;C."!@0<#.9T#I<*-\5\S'UAER/"J/"]/10_' M@[HV(ZUG@A9?Z!AI@?2.WH*0#?(VQ)_OC2#X$[VK"]/@7 MWX7'B#HU6ZLH/$( WFG8P W_'IX/_['XEMF:T'-H"Q,\0O@420([2 J5?3Y6 MGUO++0(R_5]K.KS@'^::R$IDXO[ Q)P+@1[NAA"\3F8P_I?M"5'3O*ER^CA@GAG2(E59DQQ_%.:_1X ML"&/IK*W\1>5+YY"FZ%MS?4OJZMBJ42I-%+W,1;]Z\$X,J 1<8S$2CQ'X,<: MLCKOHMFFVN=5AYHC&1 FU]B3[\I:;R7YPF3BYLHE[0B/1:D3.N<^!C*21M"T ME%*)\>FA)HXS3F)GTK:'(=&"2[3JU0L^SM@'FC(79B72@S[WW@:GD0$LF!%5 M>ES*;@V.J=J7,QIFXU+BG)9'29$YY3'+IDG60GZ/KNV=A38)%MX/?$*K0@4I M(LDIADWOUATE\#:%#94Q5KTU6O(_J0SZWI%2#R&6'QZ"PC>P06IC?P_0N_7W MK9X!78<6\"]R#92V%7Y4ARP+*]H-I*>T4)1FY^>GPJF(;I((_#,VY>@I^.!N M<]2%L@:0\/]J"_3W+M --38RX(L$#G+TK)C"]+J9F75>,WS_?":EHOX@CR!% MW%A>V4_B).'O$ VW0+4R9,">,@@3/_<\ZD+I'=2%K"C OW>)<[8B5KSAE-AI M>'1\A1))]4C5.I3Y4OK*/EM*Q_\/'O]7,APC)!W).R24)&C;L9 M=P2UA/_H2@/\/8W_SQZ;>Y&HC2=EX-!->PWGA["U23[WT)]]=+@TZ@4%@T MKGW ]*BD@9.0U%9MNFD%C=?H6X6!LI'-,ND!3]H2-Q<<)<,ZQHW'9)X"*P3> M;E+M4D/[6TAL.;BTG'Y7IUL>QMKJ#=:7]K/DF7P=9*N.:FCL1+]P<4^7O2:Q M$+9N$PIFP%%H+M7S#_J7Q]I>E...BON"R( ?INZF(K2)6JLCKM?XZWQ5RR+4 M@,0KN,55,N ]3 -G9=F#%]&]5_,-99ET8M@GUJ(3.^6WM6"XJ'OSD56Y&+7, MJE&V,VT_&<"AZD,&G$)CXJ.(X%W@&FA54F;V]B$P?=Z/=-?]4''-HW8\9F;V M*J/W[N9^GXZ(PH;1]^W/99&!$C!YW&X)<,UKUD;_9MQA:YI/2'(R)Z=P9]6I M*2!RRW+2D*4^;.SK6UFQPJ1G43NZ,%$,.&J:7]7B+>S&AP]X[@%W=Q'<8MC. MH%6TD$,?Z6!7Q84J3@^V)6$@,NQP-_;1.](]9FM*S(E'5ZL)0>N;$?K.W>4)L?Y=H;P3L&PJUE3T-G96H)/_I=B4,B&G(&. M7JSG3;S5I-7YEAY[FI#J]>_<,^.)0EN9\F.GCZ^0 1AG9S>L6UE\BS$9$"6F M%!]FL$O4$$DK]\N$OC MCX-C9DO%YR]Z(]@(.JT"]$/NVY3E$QI:2-!H(PGZ@]"4\O+BN&'R%;J.GOFD M,T)"ZZU9*6 69&I,J4HCH1T1HW_,9W8@Q_[ZGN5]V\>7)GB+6 M'-*/CNJYM\SYJK38>((!D1$SS7*4O@H>._"I>K<+D>W>1'U/-DC_H&C_1/;9 M&V_V>C!;3_9*I@**((XI0C,0P.UJ[!11X$Y^]I@-3K?'2[MF>]@KK5_M]55> MUD'M-C_'7=N,?-THS-I0>WC)4$#DR'>HAPPA/R4^0P3Z[EH4M5? M&J(Y<3U1W\6S_.P=ZI-"#.7E@9Q/+E!/_[UX(/;K=LK_C[WWC&JJZQ9&-R(@ M(B!*;U% 46F*%*5%5$1$0$% :1'I("#2 @1"$9 N(* @18I(1WJ/=!#I/=2$ MWA-J@)0;WN\;WWE\WO/XGN_>,^XI[_FQ&8/LO>:::_:YUMQS0[(Y20#>VUGL M8#>:!"A*4.Q7_^'%:,U_*;5\1'%__5N:;*'VXZB?KX"=W*G3T*C&1JD7Z /; MA/ 1].,J%?W#[-I.2YSR]'HU5N9^ =Z@:#&)IPU:5#_N3/ M'/)/89(&#RNM"C:5&:YSW:'40.K$5(L6]'*OAZE*PLH,5OH+ MUL_O,$7L6Y* 3/56R8)L&#.6T5>D)0WE^6#&,)IKPVGB@6)"[#JV'%/^#=_] MX "LC,G[$F%,%1.6JQ/[+G\$Y7\L->(6E19FOB 36KB\DLD*7ZW>EQB+Z@A5 M8]?\[NY3X;A3D)\1:WRY?]?9.7J%J+QP(W3K6I[^V*,]8]Z$*3RD[]M68"!, MUP)](?9&4VSY[H)M9]B/U7A6[M,_/ ^'.MTUFKI]#BS"/]JGN?;B%0&R:1S, MHQ8P<-(%M=2U8OAJ-%>>#-;09[>F0?M&7V:^6RL;_$Q6+%5$&IS2W2^B,7C_ MISE$Z^1^[+<-HL68664S=_UKA(LGH@,Q[_3D\7"DDIMRS?^[SY?5O;&G7=*$ M%HF=E4ZL1I]V#'NHZLK2V %SUJ M]I'"\(*6JV')?741A^J5).#6&CEZIYPE 3,2%(DYL.N8NEHXFJY6]5[YP 4L M=2)K=/:%H26^JI+0GYH7PX(>4CI(GSOFNJE.+8YGQ"@W@!F=,P>W$V3W=W3* MI:P\98OBY3Y^0?WO\M9 O&;XY GBZ+*4; M/6)=-?KMH]W+-=@=-(^R3DEIC+KF_;SU?(%@::V]9X]8OK=<,QS^%8VT7U'H MH;8(KV/'V:#O2MD4++6@TCWJ=Z#!K:A06\*2ZMO*.V3O;U M8L!IH8@9"ID93R<,;,XJ[;I)>IIH5@V*_;Q)/^?Y95GE M,L9:'4N+=#LSTA MTX $I+@DDP"?33@V7J$_']XCJT$. /?!N$[@SHS8<4O(Z1*-53C3TCMKI#WR M7-6AY'=9V(C9LQ=VC-I.6KCGLV>NV+-"=56QK0&2$$8;%X1M[X[J,^$-D9K6 MB,X I2LKE2>,W]UO.W? ^2MPD-4P>)$GDP1,PY+QYMXWX5QD+B8WT7MH#.W< M';)U]J!3_E9>VRMWYZN5YEN>&*24C0I:-"-2G4ON:TX2)4X1!0[8B]M#\B9< M&I2DNEL]Z,PU%G;[ *4E>T8U(3!*1[N](?:[P*?7-HZ_9>916>Z?9<_S5YH M;35D>LJK-A*O].1O6^:7)#.K21PTY_;)YO5W<+:LOAXUR#ZW[^!;R2XW)!T" MMD!00I$V*CN&4OOK>:NZ#VURU,QWASRJE9;LG06N"QDJ=Y@)BM*:"Y@ER ?^ MGN=4U887?[2J!CXL*_&=4@]@*0ONN]30%$F%/'V)_22S"<^U)W)[1&EVHQ/-T>935)#H^#7XZ-_+\DP;92G4,LDYZ <.']4.;D63B:[ ML\]#K*;S>T-Y![I_JU",$A6$*"_6J6=Y,;M^GEE+O0NK2)>T FLV'1>YT_2Y M9]1[QTZG?[V:;:OEX]/L['4#)XW2>!N?\24G1\]H;(7U&Q>TU)!-N[JOX*[ M;(.=R(7@>Q%@Z=BG^6XM;OE^OVF2"\";;_L]0U=C]H&Y)U7H$)?[\M*&!-=+S2YI'=KJ(+?UN=9[1S)]-,SYN/,IZZ.#Y7_7E1H9*?AOL2S.(\<\@(,\S\[YW0R MCH9GY)-M8"FR\1TL/7[=RI!?X-CC^YJW!,Y0N;)$_TJIOS._>4JFOS<-1[70 MOR/"41GV[W$^[@4B^R8"G$@.$';?2$9CQ5"@-\2K3RUWC43[X*5K)6'J].8_ MP"6=C#&N#!NB#UN6];D2YEYF=9\;B.=I*10K[8R5$F[9$^7<^4X_V_R=T-O6 M@UGF<._CU>5L1=]+* \J]$M+O5 4C)FSWR3B:%PF M)HJ#YTP)[[U8.LB!J 'F#E1?@6UHQ[$ ,D).4@V]#K;;HCA@W=+N>.QG9"Y; MJ,GQX=3?D^?U%HP6(S?%5*K!D\B2AM7)RH"_F(+<<7/@G-!S8FH_T\;_@AIX M7=U"S>7S> D$P"@^X[GA_CI)/&^A%'EF13(2_9WB^YK7KT=<&V]/_/E4:NW' M*T5V]I7?FM ;\M*[)CB;=%#@E!EFA@]*80JA;SGP[V\UGC]U_:75@[:1Q3YJ M_F\L/; '.#!*+&3H@-M(N"_\BX2\.H^%6I1L5EYZ64V(@D$V5D;JWDS]#?GZ M[WF_5VUZZUDQXAF1TAUW.-@M7W4RD\;1HDHD6FC!2*/VJ7)/]QH#/X,K7 MDRG&M[AU)H97K3#FARB6P$:Z DJ]":B@1I)J@KR"1TZ00%G,Z,=)6;_S'VF% M1QO#&60 5"O!<;7@0'S\+Q-RK0]4N0 +KEX*6O3V4DO]?J:*8_ MW(QU\])4[FJE]'D&I@&;,OI- 7**'OE0NGI6=]9O+@&7Q;QZY7\&OYE-Y4B' MBZA0GK_*0)/A;O$/7'KI?P8M_/? P@W\=R_+]C)R&X@AA;O?;A,H#X7:$SH- M=0X)S&&8&3>H2T2"N3BC@-.-?*TUR"G$(ANFG 10ZR#P$9 4#-&5D. ? S*Y M/*DVX7[!_CO>+_0&Y- >=$IYR%B]YW%).2Y]8ZE@&B:IY-FQ6Q V:;#Z9, M/R$(43GMS]#4B*4D8$"X.X $O(63@,?;=60B"#8^T1U'6./("-]"^"-PXN1G M9MT5!C$=1!\X'1QC9D,"VK;A>? =NJO_,^Z_USADE6%WH[%SMGU_':=X0FY* MPJ.RDVP_(MX0ZG\LR&';[6ZT]QSJ-HH=4.%%2$!]3 $)X._]7S+42#Q/ @C* M?8=D-4NF?PQY3VK2@?D.\^*F;$!9* '9#J!@GP==?X\ZYM)"9O*%=.+"T,K-:G MU[CZBI"8.L!]/N(Y\LF)$Y3LBPYZR=981L*Q[6X\API9O'=P.VZ'#XH3\UQ& M"3S^F:NOMI5CD, M1PD/W.\OV1(;R;MS>4 R?:SHIZF;3:Z.M3!I[T;X/'_+R6$_Y6 O, I$V^1 M^0-A QW<)-O,M_!%MB_PZ1\:1.7<9#J#E9RTKR'J_1-R^_N>MY5N;B7+N='4 M>1 -+U$69LNH!V9:LF[J+[E[YB?8"_09U.B\RWW0US8W^\X?8+4P-[=+C]*X MF/4/Q(/-R?.L.F8M>-1*A[7*+*JZ3605]33MU+KAR!5O\9\_F_:$56:'J"(: M()162>()S4->IS [F<'SPF;#S_M25)?H3EVS:K"_R?/:+4_L5[E2&$2##JB6 MDG'BT4?N@&+/B*FG(&_G@ZB3H0R:WM+D2;#^_5%[$N#"1\#QGR&N:2N\Q&?3 M* 9GS&@$U)W&16:.C>"J&ZH$@U_:3OT,&-/K_UP3?K%%^DI;+D4K!XO-FA'9 MCZ08?23'K)?!^[Q_$FK RP]%3]/PN24DU0IY YKF4U=OQ<$'[B*V@45>W)#M87K7C/&R_=7*A0,+S'U#O M2^^JJ*2JH;H^EY6ST-/9@$DL2DOB6MN3MK>S9MJA5N\8&)J[%0V:IJCJ>,>A MV3--F[BSC>+0V!D%EZ(#^COS _[4_K\Q:"^J$0;VKT M46_EI/.A$*4AF"P0]J)/DEZ!8XV?*?0>*YNFG^7TEZU5DRLDT@6V>9<1_$MOT_Q>0)Y(D8!]8ANRL"1)] MK3/_]+CFL&CI5NHRQ7:GI-;JIFE^VOESMO(TD9V E_O_.4;IH MQ%9$1 X=*#"<*P5-QAR<&PX.1-\=OG>H7*0_*K$F_6B *G'N)^"6G>]E MF(E37!!&:+H8.JX/S5IOMRZ8K2N'ROGO'!9[]H4 M8F<>]L4M23@G]CV_6X==QS#B'WDJVW4Z'XLU/:ECHGY^%CU=/#33ZYGS&[6.%FI*.#=3PH*9H MQY;2=+'\$^@M;5UHWHROI/GY1[Y/-]B[E#O:%OCGDZF0N(5=M3Z\(MK&)I%1 MOU\TOQ6^H)-^9T_9VD])"_*/S+!,Z[1>&C12'D!ME@O+Y0T-[5]? M5>T4 _"E+=#J!AG7(*?J,%GMHN"#'\:! 69M"L0F%_Y(9*VKYC>Z)*%W@[:W MNEG642N..?(1T2[([TXP,]\J44,X7Q!.EH#K]#:XN2>=[ M.$HZW0]V9>\_2$IY9@KXT*GVW[ XQ/]L1?]BO1*B9!9#PXPTY,8 MR^??K-?U+HL-XXG$^4'FQY!S7J%'1SPL>2DXW2=8F66:AZ6']PO+/#J2)_E> M!GEMP9HL>/T$D44V@\1C)" +NT<(T86W/:)YKWO'>)H'KHG)6PBR+=GU/-.Y MJ^9BJG02.GWY>>=>X"WWX1K]":CC[3J<<6JYGX3LT'#)&*1L8API=-_5^W-< M(2Q*E3NZ->-91?_V-L8PV2\L+-1=NS5TH0\V'"+>RKM9WQN$?@CS"?.$E90"=3],IZHE*2Z.+2ZVQ6K=])TC-\/UPJ^MM]S]0C=OR46H8EBK M\ZQTJF(2(Q+,G-VKG,3W>_-7?,7/4OEPN_+S[GS,7=Q+ @W:E8SA8"%CSTYI M*55(#?'<4SQ'I*[SPRADV3ICXNX61]_NKVMUGF'/12+1E&*QH:B#;W/?]Z6Y M\36<6=E6,M+>VV!VW)?A1AF[2O/:XG0LOH4"7Z&83>V34\KY4 MIB_+F">G(QE_%-F2F &,\]^>MF-:9_*,_7Q+L. M2?@34N3D,Z#Q>ZUIBO:G# TRXGSFALNY?%R/!5U0$]CX?N\YIV+Y)V<^;X78 MU#J=;S@?8TPWVB+$N?-*H\Y R0QJBGH)HYBOYLJRVY&G&^/T?I=6NZ# M8.T1E0H68P2?M_QD\'[K;@TVUG]Z0A]5VQI2VGW&TNN4S<1M-2,(O>&RR^:' MF6\Q@^DR#F?=K+]? SN9B#2;61;B-K0PH*9DG&X?KK;F1D=F!^H;^F-FA';R M<:G//"5Q)&#I4M%=%CZ/J),_UI^\.7F+9L!)MZONY%&[%V'&-UYB$:BI)LC9 M2Q7.,H8%;T77D[4PZUG4'&OYZ16.KQ^G/]VKOPD6NG&\99DZLTDL8C@6 6Q[ M>BB6LT[>P#XIM-13^"@3:.-I9'Y-[O6E;M;U8HG$6Z?E 8]2EI^6[N04UT>! M&VD5ZSB!R]'NV^YEUK(>SK48$+R/$^\:>VO%_KJ)VV[))_AG!:XV+>)-+VYS M\$)E4=+039'<;T5N=@+&W"X)&A,??G8P]+Z/;' M\T\?\C@VR9CEU1S\1,86#=ITV*VV-YQD97)CE?<+;'5VG=]VD+OJ=-QW#(+B_$&]F2$ M.K8+WD).HP=+AK",C4^="#2//I[3#Q,T(/;4?1/;X]P<6\6FG@,+29Q59_[T M*<7BM"'^*=8B2++V=3=JSW<5IFCV>:+4?STSW\8VHUZR 3 -'KA0VOC@46)N M%Y_:Z*/.@.\T.;T0>=P*VB7R"S2YH>[J0 T5G#%8&'8!+:(^(2G;4I;4;.O5 ML1NB$R;=1+1A;DHI/':UO4+>$@?9]<6J9Z3@5)OC24#C"/[:=#=3NXG]J6'. MD>@GI5%KD>>N(T\<";M%2]"DY/:?ET/)5EJ#H^4<]J4)0) #W MMT^JKARU%[*\HZ_]=S\9/3XT\.J'8'Y,4O3@-4C B=+6$$1)Z9@GURIKG-'= MQDX5+G=81&U@G'>R*+IQGIEB74*W91=>'AB1@?/+P4M5$!)+%[T$,U*7W2&! M,UCZZ'IG4Y6?6Q.?E.U#32RW%$S*;^9?WWU+R"VH$_'ZSGL!2P("(88XBX*E M@[7\B*QFLZ\2KO$P[.3MZ%0-UB$S).%5Y7'?$HJ]"9;]F<.+,(U!YVX03+L0 MP]:4S W3Q-TT0=VK]&LB7K-*KRP=NDH;(!3T(JSK=.R83RAE>"A4;(0$[)9A M.R.^(YB@U]$NB"S5G)5)MD%RP$6)RR<2543%CEN)J]GN!LB&]JIP."V\XE@\ M9DJY(QI,)@J9-&OT'IAR(FU!*NPQEB''(=>FC,BU95(]*.@1E+]AZA(.K#<5 M1_.?$TCZN)TO3:3=FTD.,CJ."T%K^"'8\4I9T, F5Z1\7*B$?J?1KDV6'FVJ M4H6W7.A])H7!T=:?1>^N6E)N7+E4$-+7W>1%00)\HZ%P)5#!!>V&7,MJP^Z3^J'943\H M]FI9,*!5?>QU--L;LJ""D&R:V(4@9S GKKR^:C['[F)%5=+AWM#N5UB%-*SA M^CE9[=L1"2GY-D3:0[2-H4VK$4LY%M&4'.Y" L[.]J4/T 3@/;^J\ ;FIJ51 M1W5=II3X&ESO8WX\9IR: J#<#@B^E'+L7[D8F0BYB-EX"'P809S0&V[4WA/[ MN_.(49P846F+!'"1@+X7\.LXA+ VVQYV=)3^"\&G134QT3\V1]W%*VE\ M;5KJI&!FPZ6,9Z&"S;RG!LTC&A3.]N?BC=&6S]^]J>W?,#U]18%AB&DL9"PQ M$RQQC:F+'O#45W*31X2IM;:(<4$FK+^,-1C1]TP'+YQ!1.]F^1ET;5[:5PF? M$'E[0X!VC'W<,9 $T%.B)Z05B[%)U9AQ2[(;$GTFX'EKA4]-[\?0[6.&!B/[ M%&?DQ(O?5+@J";S_40CP+BG!T@[OP9YC02%RH,-;4#$-C($5:NH4SFN=_D[3 MGM[76VNBL7%,Z:QH5G$%L\8 4^U'N1PA+WE+<_":6/K6H$Q,IC=>R IMJ/N@ MK#SA2QMO:<,&^_?1(8@]SN9]K=4:#C?+I5F#<;LVZE)D4@00(GK4 .R51B]^210HM;.#T%#B& M%82@-DUZK8'\Q5+N\*#P!+3R0#H?%]W-/+X* MPLAC#3FYL\$,;N2G\;5S^I@9FF@J516[QM34]_2$7.&QJ#G6N73DM4)$&Z#@ MFUKGA1%K%M&ZBW/%I-5/,F%6%2YA;1?>Y#IS/*\=@!>OYN8.G8CN2G)@SI>^ MB0R.O/F"_1/5Q5HA5'>3302;X0JG:'D:O.$FNI:YD?#Y2UY/5:!IMM[EZ0]7 M/O)Y%ETRO_NR93IUYAW#Y%^)XR\?8AD\^+7'XRU0W!23A$D!U%ZG5/&0D"MW BQ\4YAK/UKPH J-$K;FKR1P^L;U]3D#_A-^;R'L"IQQ;?[(S?LX5 M^M\OO"Z1@.*NSX2(K[BTAOQ79=+PEZ60 ^.K7;VKZ5ZV1D0-'>OTQ=L&^3;* M-LNE8WT+/RW>%_:&"=M=B2CU%\QU^V27E'Q&+<\-TK;J1 *0>EU3')C MPF$ M,;+AXD3AGV$#IAJ)5P);)ADQQ$I4K4&%X3VAL>=ETHL:?+>X @0K5H;]V@]N M-VRM8N1\.&\'ZYN:"(_PT-0Z\')@S+]A(YI8B>>Q:SDC4*\N-:2%_VRW .^% M2I[N0\%MCE/%")J%3_*!S@X1E*N6S:\[9?H2 MDB77J-0RNCV,UGO#*A/4A+9 )6)A(G*V7V$T6 &D71Y5*:&LX/JSI7G[TOP7 MY>Q:3 SWW-I:=*/KFU_ O$SMO0_:P\SO_Y3*T%EPC:=)9J5X1+QKA//:@-4:NFRSVQSCO5]83W(0>7M"CTN/.,9+-73Y8PG-)Y($D[ MWCE\1(7OR_>UA>8H-D$.^2*;MCPVCHKV"1+P72Y>^[).2-8]N4+;4:-=71?= M%=N"@4,-W5;)IA7V^2JU!S@IM_P[VE4T]^RW&.N*5/ZQQ^SGS4T&Z M<$PDS*A?8E VKT3H7LU[EZV,_4>@5RE7#X9[.0?[E+C#5YF8S_S4 !AV-A=\ MUA.:V#@W@F9IO$IAF\W57WUH[_L< #:P^?*BABNJ;N!Z>/VW]L:GVI"KL>?S M+AID!;(\XS89'_0G%H^/$-1!,;2]NGH9C MAUUA)UH)<+H.)0%&%74]&P*("<=4)6XIQMD6N?=WWK./!;0>/DL?Q'L6V)2) M67A\Y;"=W-_ARSES_O .84D\^\1*_PW>F S,!JH=V[H;,S&91>W_>2DR2$Q2 MZ(TH__BK[.P3XTV[W2O>GII3WV6H$\AY1:.X%5N\QMOXO>9'BKQYHHGM8>^S M@I^.!"#933^_9/*;])9#Z.%Z9R"G%P7O#<@I.CAD%KV![O(5?UWM8K[N,?MI M[PO.=48Z3$XPE028+KEO[PY1GG]QK?7B=_]&&K(FVBD%(C4PW:O];KF6\;:#Q#RI M!(^LNQ=+2T,>),U?S16O>]DFU:1AP.M-9*98D$H^77/'Q(3JDU[T_NEE2FU% M 4=S.<0Z62H_X]G@_'HU6)UR&G^)3M'%$15' 9%7?>,,+O>"%8W#7\OR4BQP M=1S>;'7-@AIQ,;+H3XVN1(YWE3OH29VYY'V3KEJXZ>H^])SOS6; K1%V"\N% MRX+=1]:V#PV6TW5.75TKYY&:":MHN=%L-.PE@D,TQ9G^O8B"E,%[E]0S?-3OJK7/U M/R*J_9*@N?;!8%H[(CEHL3 (R1R0J%74;ZN,[5-]1BDVJ1M$-)7SO3[PB)HQ M5,ZM 'IP(-3I\=CS-C2Z([3HRA51QX:O)^6[Q*&Y)_\0*7TA 2^F]C_!U[I) M@,WP-[5IFWV%&\^@;:KVA(^,@19]G&0H0\$Q( CB4!>SOP%F\Y5[38=UNM5J\K MV,D,UDR+S-9<*QEN&=/\""%%STRC\8FT3M /3KY-Q8:ZIS0@L>.+EG6,V+V0 M.GZH8U.23 EF,L@*]35?+28N<(TWBT#<2D-P!/SQ S"COED;@B?HD8&KPJ&E%N<&"#XS.&'.H-B#LM)1O'KSW MI'8PW>:+CK'(8&,W7UBVPJ.^JX_<@%-1;GD1:S:@?7PY"4#D$"7@-D])0/<< M@D" 8%,8I%N3&>U@AC,;P/+T:-W'S]VPO:&]FR(2CJ/M@+9ANK2H.+M/Z,Z2 M07D D0MV%\/HZUQPBNQ'933UK,JQ:JB;I.!4P M3JBZ'E.VOM#4IR%P]:.9XS6.S3CK>\%TS^,;^DB ^50AL:\8II2L(\W+558: M/W,?L\0>WJA3V6 T>8ENZ'[:+7%USF==U/ADB]\1SNB.%4;W<> ,,[*I*C&W MCD*EJ](JA3TB@;5DV23*=LKUQ]C'8SM;&:XKP3O@OR070V-TQZ'*?G5G M1HQ9%:NYTLI[OF^F#@OMO]AOVH-V5>.UN>CJ3?6>44+YG/_>&;F6JAN]-\@BO15D M3$NBPD<'6?M/0DJV-RK"9L7.:?*9B38Z'CMY,/S7/'R+.YR&A];8VF>T>Z+I MKVL/&F/BWDK(5H^>M[D;M8S7=[MW(Q+R\O)LT:?B&Q1>^P+#*N@I?YFR6DQ@ M_21+>461VAWENAX[.X'(\;L=)JZV$O4G-%6$Z*C:. 0L[ 7<=?]ZXDZC*X3W MMGDP0[0J@1^EVV#/4U\ 4+H#@'M:;G M!=5X,0Q/02.8PG*2LR1$/4C8&$D"1F5>RC@7_V@JB>"IN25@G/AAC6.E75!@ MXX]<3CO4:R7"14C QO)1/Q']U.Q_JKN/_M2&N> \H4"!DOP_J.;ZM)ILXW"\ M[:<#QE")C=,&99G";POL:3[6:KU0,-A@/TXQ+*";O2B3& ^QR_9#NV9#ZI9=XM M9MGBN@!NG*S16=GEPHY/%>TUV0>LY$"=;)+XL?W0I+[I\>Y=TS+I1VI%]S:E M::6:&BGNMX.D'79;?R-$4PQPYN(3):96*@BBG=4A$CEO% M-[W5U EBY4NZ$WIVR_=JBBA;TK%#(NV* YH$C-@W3)W *\._W,%2-BPY.*;; M5,&B)&O8;"6B+DWVYB9IY60CVB.]OY_)@5C^AK8PBQRO1J(H-K.>T1MQHD8U M:[$(*MA0G-<=RE>$J%21%+LD'4U5=U[S49SMSTZN4[XUWM;SY+#^^!JFNV'J M+9A1SA5#]Z ?SX,6H7SVS/FILYK>P5-)>LG>*/1I@RZ=VYETWC0_FY*H/'U^ M<5N_TG[>76.U&(.X@QMTQ5JW-O(J-W$5GT]X2NRILAV;V1S;NZAU^L>I5TD$ M&\HFQ#%G@L5N*P;>_,%N>Q S'X%*R.-$#ZF8'JW[NA#?FTM:QTWC:)"U!;\L M$_1'\T4Y!PF"%$>T@.GPK["936"?NHN8\'B8L[&]5?X24<1W^JV@_RF'B3&) M*Z/OSJ,,;-M?W#&U/7HSLE["BT&LH8 :JM]:Q80MRT(=/C.1R1S+7ZT9O1CS MY:/O'?%0-L?066\:R1V-O^9YRQ0 ?YYGOPO';#3W3T^=7B*>P :^=5;1""B= MD&C/HN,1,32:1$+M>M*X T[=,F\TO7\_/P%5OKJ&A3;!)"$I"':8M!E6\*$&(_SEV%*.VW'O"909TUHL+4U'I6/B MAV690]T0 4:';).#@4AD")P8A@I4/>M_#NS?PL1#\6_C7&B42<&MJ7PZ\S_]OPP \ M%)I&A,-GBTC [!V"$EKL@)H$M*/(%^C:8XCZGZD0\2> Q!(ST-8A";@01P+X M0,MB3/ >::(&(_'^?G#P@2N1O5N#!*0>%0?YDHWPS#;\3]#^L/K3). Q-(3H M@]B$PC>5?S[1[4=@6MSA!&9]")Z-;#I :7\/+8]#&4\DHTK.P]L"#T*:(-OT M)""Z\:C;ZHO4ND02$'"]GP0LII+]Y70M'$< _0DBP?('>&&/J"I&O L>,.(C M 2GV^"00/G*+A65[ W\M*9D$*+&2UWGT7FKKXM^#6[GWF&R<$)O/X)OGB:E8 M-@(E?);L=&8C/GPMR(3_B4__"CP]\8A] AG;#A(0R?COS7LAT"AURZ;-XECK M+I;."A]C\CSS)Q=3.>,4V1%.AQYN9J#3:Y]2 M64\*LWTZ-4/P_&LJI/]]+X5R'_/"'CP3:DVR5,B*LUN]O%S45%NDZ(+!C)S3 MDG[RF!X<3TX^R"Y@CNP"\&),%S1+%G@2X!\)NGZ95YY:/YG/'=#TRF*SS(;\ M^BBXK(0$[), \MH0'43)+N>X?_"(!(5+< :AE$R0;D(!@7@4*-F0I2OY$'*( M)Z(+'C@7<3>/KSE&_Y.SDA-_+VQ,9(G^(\S&3$=2A%_KF$\4(%!,$&TVFT0 M&:C->+?MO.B#_/??"$E=(W.ZZ_K9OM?"?N++7$&VO\&8\1Q."'/LL %,N5- MB5O1T3AKS;E4':@]<,Z\LXF1O2PDEO*4B(F_!OLXH]&7\"S, CHY5(Y3@1L: M#J$#T:H=6T)&!-F*B:JGP4T!7473YTR-PE]/%A-2;U5_].4%=J=^1PUL 1N, M;EARZB0,UK=F5[(XA]UD[@N-NG^&$1>C:"Z'/R]TV/8!_YFHR6A$_>7SM#TW M%-3*V1H$HV7UR=?'^JW M5T0Q/(/>O-$V),>#_7&(FMCP_ER'L6Z]X&<5-&->5["B(GA"A+PJ\[_LO0>FJXZ 4*,YI8ZAC<+[%=#@Z6!]-1(VJ Z"$(M M4JC<^?M/6&(GY_*^0)]QDUVY\/U(T_J33Y@6010*](V8HG[]&O@IW/6&JO!O MXG+Q]KXE'_)L;5/#7D5RQ%Z:K7RN6OYAN4+T=JI/=P;\=TA0(:_$_9$>$7\4 M#< P->L_\>A?CP;5?[D]R./QK-"6\?&Q@Y%HVW/ 0\2$PC;%?O^_="QQ+"2' MO@V"6)-&SBX7?>OS)2'1/; I"0@.A_=WTOW?'XL;%L/2J4;K8&(VZR.=[5+G MJ8T^S\@&R./XL7F+VDY76K(7UU^C"['-CQ)I;05ZM]<_>H8Z&JHG9]FV2LXD M46)?0Q,:98RRW[Q8GQ P S4TP3IPW!$-U1[R6NSS"*TO>X5\S;@86R"O3 M1!KMHZ=">$$X#QM;!S2]FA,NGSO];LLFZSG3:;YHW$PMK/Q0$/\$,]4XML%Z ML3);-,GYIJU2&2[]^>'#T7;M\PZU7KLRP^TOOO:%7SS]/L]C2M^ICP0,92Y" M3ZGS?:'.>'I[76H.5KZ25S(TY;/G/)_U"3_89:T7X-BI63E8G&3#<*BYTNDI MSRT2X=]L4AF[0(4];!:W1##L2)3;;T_8.BL'3KL\89O1=)#X?:T&'\GX]2;XCAX+ M]N.^+B MH5YBRE$_SR]/Q"5<>B5"F9U?,//2Y $N8'J86P;4I56_!Z]D[ !'K;V0.!LB M12>G_J9(QM3;39YV>X\FWSXXZ40O3#;%$DF=D-ML_V4%8]W7ZV7M'.%*8P:O9X24)-E*NP_EO/;!S';=C8[&+5 M!. F%>&0BHNWU8>,W Q;Y^4BO07ZO60MAY&\[^+')X6_#91TF)5N.M$KMY54 M:[/KO+.CTA_X2O2&$B-0MC9-]XPSK-@./@;R6HRL)1E^7*JVO(&WK@V/^&JM MYUU8_*VRJD[@:ZDOJ]MKF; 4"WYJ;WFNHWZ:)?):BH,EC%QZR\B !&J$@)O;7\G=OQ9N;GEJ(U9+PS?$Y?8O@^ M4V[GH2T+H5PYB&WM+U'3>%3^'A$I6?L^MRA;BCV?HHL1='S]J>MJ5&ST8>'XMH,-Z:W%H6B2WMVA-8>+I4A/0=;4MD_EP2S6KDR MI#WG:&O-4!7TW_G@[-27WB>6-@A:?UI:'#06BODP#J4I!1A-.M("V").)*78U9D\: V^_3:R$$MKRIFP9_O;2L$@L/W@:?U!^O#*;"7"\DC !MGF^&L-R!E^ MMI*Q_?+9,\]J2,]S]-CD,GK]!CKA4I?4S1OVD<\JY)F3? M?X"8PR_8TJN@1 MO"?*3>XR\Y1%M*&A^B6E<;+7]U'^T(5X8!GQ+]QX_,L**Q,BSDY-X%8: M"JWTR@.^8+HR,@TG.KCCA)'^O1#!]MB>RR,8G_-;[ MC)LSNAA+S2.+AEQ]IL^6[=;T'W'HFL;S*(I%3GKF1W, MH/&P3N,M6<'Q"L:U6+:&E>_.B(HE@4$D*S M-5^"T:,(-$V/D,JY.+O#1Z5E-0-Y=HKZJC9^1;*E%$]5V2/1]+Y7PR$"HB=H M('\M<#]@+W")- V08^,K>287OWU5D9"2,8\^Y7M3DF[TDS)5U3<:NP7CV'KD MYP0:.Z$L6TTNR?Z9 <&RHIH:XU./)&;VHE]:6,X(')N](OOJ^AM!2FIOGK^< MB]F:LS0\JE!R9ZXV:OQA;$]"D,XU@?Q7D?D:PJW>:='(RJG3,".,V)L:92L4 MP;&ECJ>W=*468=&W0Z]S0O3+^*MJ/M=3H_)7;Z8PA/RU "1 &Q4AC&H%//;J MG,S'[L4]D78@Q%\-U>Y034P1$J*,KC_.&Z-?#S]=(X3E5XM^C(D+*H$S+V'; MC#UJ68E";3'?CV=!1[UO_$VB!_^:30MQZ&&?A)9D3& $!PZ&*[]!K.=,!]E/ MVX$KIN:=%C(?I&7@EM5DF^HN^35-GL,DYG]DR*0*C^;)6U(M$;..^F#7%.8C M>V8]._'%)8>!GM\Q*&)Z*HCW#"[,WA7\!O\X%9=*=Q.6\%'"]C97:6Q"P:R_H/N+DCPB'=NE/8,O;NJORIJ8D03R?1]9GRH]1>*?_YS&;9RL)P5 M:H,2B1S'11CURX%M75_'NFQ9QT6."?37N=SU'Z%VJ6\(5V>@ B!_SE-H&O_,OA*KXS*)V^Z#Q8HO9J>%UT$O39.N-G'.@"TCD"8:Y"R2 M>@$=ZV-B-4, =Y:&]PG1/^;S7=60NX$X"?ID%_ <_ MU84X";=9,VDVNHJU]\%[8'YLH5HCG'AH:^[%WXUOX@QEB[T3MN1PQIMA]9C4 M)XM\19;$0VGB9!*(D$JDQO6WLLJ =M41*%F;D+P[C6<@04^OW-V\VR$=6ZER MC*G:XL>/1AK@W5%QRU_9XII^E'TK0;8UN3@\!NNA6\3+V9?OY":9D*-3<:@\ M^N+6SYF?(]68TV3S>Z!+>Q=A'L35P5!?R*GV'7@0.@UX[/TE#3LA[."7G?8-D+,U*M/V M@>"3SJ!@F>0WV[@=\)ENAAR&!.K$LYD?LO/XRA//:R2\"/TT;1IP3(/-:QPI M4M "? 2QNB^V0%SV<"9\JF2 V$WBILM!*)#@W3('(7 @?* M?[D@H86(0'AI8!!1$,K8.J.,>^R$8(6Q>+(F9\' 5<.V:'J!4*D2USE8:I+1 MWD2):(L@5#G%,9<^%]Q,:_W%@OX/]E-7A-L8%,9A+ZD"2 C-KH0B\E#DY0[V[3-9C:CH2T"+4!_Y3AV&OQ$8. M*9IK]5WY5Y(EWL=/Y(FP]>8OH&H:U4+_NZ>:7SPJ!TD7(_ M C,:#R>OZT0F$,SG+]:,B 3,L6RPL.U/+=8_)V,(WK>"; MR@OPE6$F>(\&4861>/? ]<\#F.&-YN3X8UL]#XYYCL"_J'N1&K$#.3H# >]+ M(/;/'=4GAA!]X9OWX9N"_Y;IF>'9^\KX?1+03A;D=IJ#G2;(]ED2$'6'!$0J M'!V _#PZL4C4(P'3]7!<,^A7B 4?OJ81='^ %[J):F+$^^#A_*,SD&1\% @? MM+WQ9WI>^CMPL&8ET!]6KTBL=6 C'"G5G(')U9^)( M;##X5YB0:X^5#PK>P[N3\?$0_#MX@8$2"5 $[PN ]\\N3>%>=H*)08,%Q%-L M)"#T\=]#VP\.!@_"TH@P,KY_^_X5P1TM=D!+)N5Y$M"6?'0$\@N_(GZ%J/OS MR6-BSAQHBYP87(PC8PWZ]^/^8G?CLUR8]N>.7*DX>SLQ)%V&=RKBO4"ISRYE MB057Q V.[?SR0[:CO3(ZR.$F F6@_!V^+^AN3W ?A2_1E[I?\&)[&YRI]RJ\ M'?&3F%,_$&,@>27:U>XR0B<8,E(%Q^/(3)R*.;)^WYQ(P#[F:.];B,CB$KP@ M\^/W#P 9A)"CK4#_ L+^46S[!R1T+5-._K<8G)>UB'1?*C=].G:,[_4)?WB5 M9XY>]G+RYJEJ$I!/5IV4>*"SQ\F#IF=[WH;+W,260Z"A$GQI-X<$_ +&@BS& MLY1DGSE< CD \D[^%UG]?]S@5BQ#Y(LH*ZZ7>LGHJCZM$R ! M^FED,A[ %\5NL<'_. 4S_,42"=A"D;7,2Q=_98V90O6/XL9\<\^F"7")OUI,INUY,"0V M'VW4-@P3\05DK_P'-N:4/*(26S4$$V$B\(T?1R',+VRL5@(T_YG'ZH#?;(=P M2&A;%)6;;ZU3ZUT0#/KD?B3'O[ZO5?V7FF$PW,+XU@\EUIAHTKQIM:!9VJ=S M:*05P^G10."%R:#&1Q\4X[ Q$$D M*B(5^_2OFMS8GGY6[C-E0+AZH M,4:'L37$N@KSAR_H#? 5!ZN<7!_)$P+4*6[0W&"F*/UKNC*^(8J-00/1KD'; M; ,2T6G(^HRZ2.=3COFIP+!L!_K9-"L0DM;+J(,R5A0BI#>#&%\/-U M$4^^>10AOU:&M%TJ3$VL?J1VV-,H-'^GWU6R1@5;75]E.%^=,HIK;(S&]:L7 MQ\\0F;:R&H:#VYE>\8Z#/X8^3Z*A]I;]C0S..(%"XB4CZDD '72LI6HR#&7C MJ?6PN+JB>D"TKZOW8CS+Z^#-.J#]!E70]PU#+Q\TCU"SNWQ^7JJUCGM+C$N2 M6>UNLHS&\1_P(!Y:'=[I'DH2\)_#7OU_,W;*1KVK;'<&[G\K.ZY_7_%TP9Y& MJ>T@/9QX2R:.X*'R-T^.GZ@D 1%!\"EP5ZH.1Y]T'V#6 M[>OIQCZYU!(XP"C@1L"O)/V_BA152;> 5MFYUE:V-_-M*L8L.^NBTEP:^L?$VM M>Y&AHOTI6]5E8R_9]7;HU>VT>\F-S%';>E3,CY\ED/_B?G@+=)7 M'ENP%OM=B9@)Q:S@LO@JD91*\J2 ^"G Q:?_^',GI,/6 M!#/%MJ[O:HU9!MX:(Q\76JJ$J F>G&VF-!38TL\*>!ATHKW]^TV!62U?*=6VOO7O;&Q8=*1[T/BZ[?Z/J,Z!W7;097*^&W-X>VE?CS+8; MTY+:,LEJ5O5>5>3;6,2%$=X'WC>77],*;,*&_O QG27$2#G1 G3H2 *0.S2M M(8C (7A)>< 8&D0F%.IDO\8;>ZK28?R%85Z>K8Q#,T3[PAT'VNBY]I&GX=?# MKVL1FQ%;-TC 6#)QN.#+(N4<_9W&9 :8#39D%T[\/K"&]T3E<$@>K@@=)KH; M>BH,@WE"D%68LIC"%P:_O@*2J8V:'L.!3>R":C MCL@FZ[D%\4>O$WO@F,3M\,])3Q_1?+L;*E/Q7CFR2IS6-M,1?3$S"W:3D"9G MC%9S13/ZU%#99%GMNASP9LP4,+8[TR$%++K+RJJ)/65WX3?:-JBEKUJ.S5/. M'2"# 5Q9Z_=W*[S'<*Y6N0;Z*U[<0UZ"^6EF5HR!L[VYL5.K>XQE=,_L!.V+ MVX5?/Y2^RG 1?$GS^LH!V-^IC%!<\S@[X3YQE-%/HOQ>ZS$5T8TTMVO];N$" M:A,N897US1Z)S!18-K^7S@DY!?1+7FP?7Y9^*.D.DO$*_KZF:J%FQ+X6 Z_Z M>IMBD=E=UQ.5' 2BC*A?8_M._6/(\]Z)/)1]H,/1(1[.7OM]K,W#H"BSN+V MV>ECI^K,%=P/O((!I<,T7X72S?+5=HQ88Y(P3I4USS,+VD*7$V;R5(SWXXRM M=<.XB58E2(!USXKS%=C_GKK*;#1$^_$MT#F86']^#1=F:CHPPKB_H#2/KM'E MH"PAJ]&&.R[.97=/"R@/3I:(^H"DTAVKW%7E-RZT&14@9->Q&[E)3?)@M>/" M);/FGK[HP0N*6^O.?9A9")"ZR&+D*E?-=-7U:H%^JK>"1\W_P]Y[!S2U90OC M!Q%0*:%(+T%I2I>J4@(B B(B*KU$I8L0$9$@@:!(E2(@(*"$(@K25'J12 =I M2I4:>B\)-9#VQ7GS9KSWOIFYO_=^WWLSW[M_G#_./N>LO>I>:^VS]]HXYR>: MG$0_7-DGG.JU'N+9_>SLEYJ"@\J+5QEA[_-/IW6=G%'CTO:<:\4]YFV,?2EO M$@5Z%,#>BIU/4;H9"E.>2?5*].5S,Z^.'^I.OS9J[NYT:MUIS$"1ZQX M1A%%\QU^,G MT*H %6UXT7'+^/D[IJ.2Z.O?M, L1#$C*:J0Z<@'W&HE>F7=R0(+Y2D-XPTY MC;UOXN$>V5SFJD$OI;4NAYA]:1$-FRE4!<&JJ)PE2]O NZ@FK-'YIG3ZC+JB MIS,HLD3/\C[N),/*SOK]J-EVR;;-8+I(K0]BZMVIHU2[>J&NB!.9\,1K9.*! M(:ONG#K.&AGLVFGD%))YZ6-J9@I7I-G]T ZS_2+RJCC'8HL^_WV.J[P M2TL]C.O5%+/.Y&"8S*HLFRD2*;!S8-!S.FS<65+QT:=0\A\ MBTAV! /+)UJK)K=)?XG/JA*-^Z8;51R>HA+F8P>_U3K$3>D>NMMA2#^__NX$ MS;M#IDP^*F=.-[OV43W.T5]>/+6_J&>_84[D5-0IQJG60T.L-#-X4QJNX,-? M#]M&@9T(EFI&:5CY/M MX% R*P@$8JS#XI1-OUYXQ?V=;WF5&BY;KVX,E9V:*8*F%BE/#9JQ62'K5 -. MN216%R@M@R*,'9V/2H"=PVYS99B"[CA'D.YG!D+.HATQAQNP,5,M+13@(%&K M7QG*1K2RY;..DFKBV\D2ZQ@N"NV 5EGL5M;IF=2PS-,^49X*$,2K3L$8R0V: M!_&+V/IC)+3[Y)CQ!=R#E*<;MZO4XT>E6ANJZS7=QQ[DJ(?5H[[SG:#=(#22 MCP^J4Z.7@]LD%/DP7L4B-#) 0I" M4=Q4U>.D [(X=!)3*-DK0!&R/$ M;"=W04+?*D]KJE. YRB$ C5P!%VA -^ZH794S4'>N7H:JYDJ2>QA/)_*%5]5'%*!DQ#..\&9O:6"P$7 M7Q.)P+DL!\2,N5A*N!2X3;XC).U\I !QKE2F MV5$ @K<;E-E\ASP.-M8]U7@N/JU9=/%SH< M/SU+T$HTB[E7G$_UX,9)"U4G:* 2NI:&/(;>9T:9RWPR+4/# MX^-S9!KU>OC1X$:%CLCLYW3Q]_-5#RN,0+'%,I"/:Q"7R;<8I%,!P=7$.M5' M]9XKC6;WS-X-AU-]V@%$?[=E*GMFQLP_DR6P.Y\FF(6:ETXC_/TG4-RVGX81 M.5# TLIU MN"6RQ$!N:UEM1[^CI=-ZQ+$L1;\F6^^>SY-8;8:0;?30@_%IDP%UORFXND$V M/E1G0':U0U5($#N3M@Z4 CQCR:8.%#W(!?% B*H' 9U J*#?G5#$*8IX[K602)1N@69PR9.H"MN+W) M_*\\=BU]2M4C=[LI@+W>+S UTOV[SP=JHZ:8Y1K--HU?+YFEO&8U%LO_:-D5+^UUH4DT M*B(^U(S.TECX,3,TG<7Y9[1G"VM31+;_GC; MA[7-DSG^8J;K\7,1&Y+.GJ8*%P[3 E7S.>E,T/];7/I?_/BT!M>(155U7^(X MZ5:L4T='PWJ9ROS;3%"K6?G/@OXV"=X[[(;:QE& 8HW[?30=U#@'_Y3\^ ,% MP$!(4>!?J(BM\M$_7OCO>V&6K#28C=71RW5+J1_1AH%5;XE[\E73-?=?O:QO M\EGY"[+A MR8'%I! ;"VWA2@V94"E**(\21##3(O9AVW)R9%\2[L=/ZA_GUB2_1':_ M@]Y'[RG^GL\A?37HO?G=EA][]O#AR2W$_>Q=0PH0K_F= H1$8E$D$#5@F*A: M_G%4&C5=Y)V$[ M1(XHZ;^J SUL4OI!%,FRG &E(!/+'GL<_.O^7[KSC RE3 M741@\([ZK;(Y ]7BTN"VS?7IN#R&[H&&[=,R-FS%* ;4@LAAB$;+W5!YOOEJJ#$Y)T6 MHI+S$PJPX!=# >@&H42G7U/U1]__;_>=647*)(H.]!01Q1?E'86;J_Q;95;C MF1&6?QN%+$T>6W,;[%HJ\NWM7!+*RR/.>NT<*%&OO0CXL=B&@L* ML(XB-^<2>:G)I=$$-8^EHR83"Q]L$P(T[(Z\LJR[DZJW]8 K/V]RL3]QPX"T M,(?\Q8 <5<+WC*8JH: A_Z#?K: M=$=2@(%%Z#:.?!1 _H\[\/\G7W 8&7%CA\>MC+5U%"OKXV\2#9]- '9HRDG/8#-G*!!_>?SO7^8#XX7 MY%DLG+4=S\X='UD<]GYMI-$T.YIW5+XY2WIM1EJH1!R]9"(??,3YKL_VFX/%LG[=U?C!E4DKSKLJ'+P721_9.V-)\"1G^WCKOVG*Q4DN@ M^Q=I"BE^2F[_"#6&0%" '>4BSREFV5ZKXAZ)OH)C_44B<6YNAR5TT^#3(W-G M+UR>,QU/%K[AP;LD.=;4:/9@HUL]]R#;25^QV,?O3O"*QG\&?-)9?/YVVCK^ MOD^FU)K?;43J!4QZS=XRO:+\+JZ='S#M#V5ZS:HMP'J[Z;_$RW_"Y]>WW=5L M0B]5^D49B 7=9(DXXZC.UE,MV8%3)0;"D,NO@("[?SWX_GKYG[>-]EW_NY.@ M?Z^>^S9H)94""%/U UJ,7,A^!Q52AV3"0W<2L:-GY^NA>.NO>I/\+3%&!/$D MSQTS@F/%YH<<8W86AO?BM0/:A>55,8SS9AG6<-8]*Q]YF*.5J M>J+.K9E9>R'^Z#.)M=>)\HM';\NL%3+=73=EN.54!.]N0?($<"VG,=K>K#DV M5<#1*"3\\=L:3.F3PO+E5",.??I+]VPOB1_TN#(9[W:GX\[AD244>X#0".+" MUYL?_98+1*X45\5>V7H38PSZ6'08;"M5I4]ZK7"V?[I\![2O:R MQ7F IG0E0 4>.O4,F_@*NS-HV O;+F*QPF?N7AN1/.#R[D0%J,YW-IP >_.Z0AH%:I7ZR*/%X98_3]W1@WKR;CZLS=KZSGV:7TV>KQY9%:SQ6(ZM8+<(=+!!:.'?3JU':$*P\T_T M@DLZ1>KG.C/1 W<\9--(;TH-:KL.^K =:A6=@[TXX2!D_3*E#;O;@N%W"SB, ME6ML?Z6HUU/#,64XIME$U!"]VI[[N3Q>K,8UKHI&KFGJ3=Z9I-FSVT0 M(3/($*18U4HR?Y4'HH@N$*G&#\738#)01-WO!-NXRI>;#6W1G)RJ)3#^4J MO5#VM"& #8L)S5Y=9$5HAIY"Z [5C<4?(_4S*F<'"LHE78=][G^3,: MG^>!])SF,A6T[9#;G1*7!HC>V(>]YE@&HG0[5]_V@7%!@D8DV9.+_1D!YAC- M44+$* :U\"HWP_,L@R;!84HDOWH*P#*!OSL,;BCBOOV@EK>JK#A"-/'DUB*M M^@-%=6O;YQQE1HU"=]T6P4?Q#&1VF ! M;7 :(U0)3 MXYZ,%$?SO\<'34O[6II6;2MUX/65C%EO7QR+D6,[E$6Z8HD][ MJ?N7:=?NY)=1-8&J4Z!&(\/Z &L788K77Z\F]5XTIM1Z=8F,[5D4]&3(3PW M#M>=$4H?S#2/Z[RQ7H(!3A$ <+S:_3F2#&KFLBA7?*\T"WW,?3Z MS#3X_E>&[@%(22SP[OQO$1A# [?@3(JJTW[BT!Z8.:-,5V[X"_X\JY#\ @W9MG M%LN=NOW'\KX40FZ@(#L!N!;J>'>YC(J[T=0T<]IZF1-C%0W-4#H M=\=4^*^L3A^DK:, MYZZRUGBH,W&K$11['P8@A,K"V$VRF[+P(?@7B-7&[5Z M%!I[O[2>OZ/=#JXY [[O:[R2BGMJ@V9AR),2*F3W4*N&-MDOK[V8@TP&(<[D!;3PP3[#V-S (Y"AV(L[0B+6 M8'%#MRSI.+VS#7.J8YL7$S";LI.QU8$@52RR>9*@20'J3B*4I_".&Z461)6R MAT[RQB/BL5EA@0]796H(QXK.4KGM D^]A#^&"[+%RW!'WT?R+M:*?,LGFKRU M6^3&CND*I1\SK2USBDIE/_ ZN.O!.9YIY2U1S/NHP@\3>5GX,=F#A>:REC,8Q[AS'FN5.P6C@J,FN5^F( M$SC58.6<;>T<%SMP,-UVQ=6/PY>>E:@EU-%Z2M#>I9U3HEE107'5@'+@ S & M*WQWPZZF;.C=)*W0ZX^*>F^ON0],$NN"9V;A H.M<0A9[&!#$5[2)[BHA)^W MP(.H-ZEA:-HOGK+AEUA1J:"0U%$X0M]_A?-N.@!P;H^]K8?2+I*54YM5:IFP MI/*G;T8=!R=[)JQW1ZNMO3\;R\_"SWCH<38O8XHI/XK+:$_&1()'QHUW9(,\ M,Y'V_C$^K^:J55/G?8,\5.T]&EYZ'Z79%,/4?:+=^4HJJ%5;A+![*#/KZ&)% M^1XD3XZI8$S2AI3VG,M=16NN7[CB,%ZC>.!M!A.G)[A^3!8T;$T^G(% L<]6 MXFR[0U=+8<=QI?Q/W,+O1$X-6UJI7E/YRATZ>OB*OOBGH*G=%9\BJB\JK)Y> M#T%S>-;-3BJ=C+D!OI$K,'-F"17&90.%KHR MFT$\0WKI@->>7*XL*!GHD2VIRQE-3S2+\_84:\B1Y'W:VAFHM=H$('JI/IH= M ] C7<-8E[,FWG15YU?3H[&$UNVMV7 M"Z( M[M#K&!/:F2FP4\2^7:?./L'M#3/S2GA3/56/(FGN/9>]1<5Z+" MZ15"D(5]']$=0#MHR$U*@L62+"6.'D@$(7/3^O;8N( MB,@9'DU:4C31".N!HF % MX?L9@3B%0PQ])7]C&0 MOV@@0.FJT68N< M1NY?,IY#",?1/-C MZ0!ZN1AYS)J:G^3&DWJ)>;2?D1NTL/T53.L5AE,$ [C9;C/T -'Y[:*S1[%@ M$-0U_VS!;"4W5TO.HK1)RM[F5$L,+$!F28@='S\IU6:MAX=E?L>/P]W;'&I4 MG_AB!9B2C#3DY$_M%MH7%1\:/:0AU18 !'0]5/T,/; _"%OGNETQ?= WJL\P?%M6PF "=K_)>Z6@GJ>+R]W0 )4>=,U[$7P*5+ M\F:J[D:'0E1NJ8A$,F6 +W7J33DW%3'@Q2'AFF(?L>_PET\/7NFKD7.&W576 M.%OWWDK[H=,I8VE]GYI;!\V&OQ1]+3?'FN_X]Y#9B,W.JYXY*/2_7\VX=/2P:Z)O4L@Z&4X#F %Y2UGV+WH8R"(@H ME3$ZG#P\[NO-OYNJ'SUQ/%:RY="%%_''S$>SKQ]_9K/?/QB%<)^6X[T]SH45 MJ&()ATU^+XB_-NA-.%D*["K4BUF[N-]*H]UHQ*E=[)GPCC:%2+F)SM7*O2;$A"Y;WSY3ZP,5[O]MDV6E7! E].ZZ_1"@+>W,%.NNU M3 &P):5LN#JB[$ 9&OO4_Z4EL\X<1Q3T"\&D?+GD[=!=DN(S7XUB34$B#:KA M;'FCD5Z3D"2J.4GS=,BXC*Z'],#XZ8'3LV$M[%*L'^X\DWPKZMZN6,R5OXYW MRD/CK\;CY?%3!#*[Y39]7S8N:8AUK*3Y$NR[-7]M=Y@BJDJQ^R(PGX%?9$J3 MQJX_5>Z4TO&GM^5OW.^,_B 8Z[>@5'W&G4LE^M9\^+<4LV'@YDPD\^M2#*<; MAK>HEF,Y0"JMI3ZS?EXO908O*^47LWKHIHN!%"G3:2/MQNM7**?K,AN^@0'8 MW>'N.AD1"QPX>,T@6H/A_%=E$,LK[M8OQK#[,N;\N\P95T<\Y+W0.2WJ#W*Q MW%/T61-^:!K04R'SQ[,E[AH2Y#H&6Z[L!V%IA%6A:PCT,<\['SG)\A1 [AK M0N[A0H.H#OOIY[)Q6:SYHVTU-+W%[4$K3+3'8ZLZV$S+4=>C0@AF]<))_.85 MR>;&.'W.)22@J?&=:%.#DWU210T#U8WS\/='2O;+@];-YHVK0[R]!")H*X-W M=25+I-?,7=2^R^[*N&EPBR,Q]P&],Q=&L7O#@L=N7@ M0+OZ)5X+Q2S1+]=;)]:9=!^ 00B) KQ3USZ,#9^)/+ILOKFWV25,D'G-FH=V=A!J2FN2U"X8G\HI\J.F;IM&Y!4* ML/N9 O!ANX-J:?!ZYV8EZECOPVIT&&;D@,84D$("KO&UD=7KL^N18O_NE-G;ORV$N3Y]&+C.=' ML@_YT EOV6,*I:@=3Q;74%54"\9" 2:D,<2'M;UB]?.<[S<2H=<2!8:7W>^@ M#<').!6U$.SWUH;3V9W7$I3VK'<]5@<_=0V2>5,GBT@'?YQ'SH"'1YFIG5. /:H@%$NI[SKAW7Y4D."@$V?F])0\* MR?:^J4S4D-+VNDOX;@ [11L')ZU_LOW?P[(_T/\#_7\5]$TY!U>ZL2O6;3O^ MAHTA",1C@QLC*(2N#9*HXA-) 1:8)S%$NE0*$'-=%54F$0ES=WRT%0-ZUUIM M*%;R.>;M>LY^*!7-[G5B,O(9TNVN*HGVQPD/Q.Z<&O["Q0!.;&%"5F[%_?=E MAHY.5PQ,>0ZFG?F\51#S4_R3H\EK]\IK]A&^T?P/\A<#?^1COQDG[1#_+AIYBJ M1^X]:A$\4SC]YU>E4G&1+A\7+4QY42]!V8#ASTF5TL^)&6SO+XHA].>\3(OG MIVQ-[Z>D:H "_#EE,_E+6D;SZ _0_S.@E:/D609'TP\A_0CW^ _A_'OB9177O-R4>Z<9Q MAPA!1#>I>O*)XF];O0>GSI%OPF*U>83]!IV53NTI!*P&+)+9%BTTZ:+X=6^U MYB,&EC2" ;5_*EK^ /ZO _QVVH=I1L95V;GQ8ZK)QR<\KC!L%A;]N^M1;7R6 MN6#^^GC0[/X5AGFQOQ3[,?QI%OT__^/S"OFG_9-K"/^I(J$QQ,T>(O?$JG5# MB@#[@N(R-_?#N7#/W&(%&UWV3&GSQ+H+HJ)QUMEW,1]AQ,BR,E\]C'LXT +].EWY,:C>G,%XP*,$YT47G5Y>MLZVUY?%?G0M#'<<=O5( MO!:W+,2EB&T$?WRFG0(<6BTKBY?U7)W?'6H(>TZIZJE;::%7F,*;C@"\Q2 MZ S3"PM'FE3)[=37\*$M3-!9W<1/V(=+&'V#N:\(@\E."7U55LL+[Y9ZK8?R MSX];MHYXSN0)QCOD2D[8DE*)9WS CQ#&K^V&;G_ LQA==D,R+::)ENCW#:F0I37I@_>8W(N3F M7>,$C97&8.=A[5,7,F81K _.?Q>>&,RPSL^#L;[J,:A_)'(A^WK9&6%V?=[5 M^&WE38DZ=#!9M4]3]=-@C/L040W[I6,A#529\+0LIS='+J=2&'1*IB8U0'&3 MM\NW*-O;2+;=IM=C:_5B#[..<77XZIJ[;*;EK105.DM!'M8OVL*/Y;7366ZW M3S&,:,K<)A\FT'>OD+BZ+0@^KU"*W6ES@5?S+!]"]_; M!M3C?4S8?;?M7KE5\8^,#Q:B/V2--0@DLQR9MG_?)N"L+N06TT,!["$A#Y'- MS,:-2&Q^S<%:H7B]CZ7%[V.T2IGI9JZ-UA2'$5]%6(H%PA@\-[!W.=TR2 7J MRC[3H," X]]6MG)+*PO??KAVDZZRPC6+^STO0R+-:#4M1[,\"SR=):8>+:C. M.6W,_B8H>ZFX+$M)SM-%=FLYS\+[4#S_3'&*RX#::_[GB8]> I_G#_+-!S 2 M[WS")TS#PE*420FEV6^>%HXN[BLW5=P9U[YS+'JFUJ"]1>V9_N?AA5//F@L1 M5M]@1;7'B'R5']Y75)3W$O4\948'L,5B)1(&M5H]K/)AMEDV+YD[LG(Y6^ 0 M[0$$"*NGC[OJRA?5$G9'V9H"L(TM>@Z?^53Q>&/#U>,&Z[1OTI?4>RU];4=O M!:H28;@N"M! -4CUPQ.VJI?+JKYM&X:[*Q=<-%-;=?93>_K4PG[F0(>,@W.K MJ%132]>A1B%-?%:A'4*W_WXW&YY?%[L;[/WTZ<'B@1*I-[ZW0@XY.B5NP_KM MQ^;8JEMO5'0-+%XOK&&84L'#)HS9EU(<>O$#QKR+XQ+][B+AV7Y.%<^M#;B. MQ1G11_L*5MOM8 M1K^;_$U*L8DG>#2/O'104?M*3P&" E1NUPKC&!IRMP7%!14;[-2Q*S[[#T@8 ME]*^)^>F# TL7IYVX4V6?X?\-MMU[U3QE'%X2AB^=S(FE"Q47EJ9L"HV@-#V MOIM?_^6STVG3 ^\;BXUV#5H/,[UUG>;#<-6 ?:?E#HZ.++)G%X5).\28],CR M!T=O<(%8)01$6.T1W@8"/D6:I.=$\)385^_UL''U7GY]_*/IO#HD\DU;W+#M MZQLMSO9Q-,=/D^T_M[BF[0/93UD M[M!JS^FRH'V$@];MVLEBRU;%LH(:AR^UYRZ4*[!SJ;7V/PX1P8N:P5']8I[C M-;L-=EPX[J;U _C>IK.?$BC XQJCJ54^=[!AKS=? M)^X]Q-FRE.*RZL;!V+7@_+';W6)EGXZ,NJH,// :L\-D"E< MAB2H@PX^'ZXITHJA\8:$?D.!;C$%O/#;4BQ(I0#M!Q'IZ MCLY!]EI@*OFB\2&K)?3A(DT!.-H*VU6>N\@\(0-I&(0.I3@,EE>)=?@YN._$ M2EV^:EL';;\@.;!8J;47R%"&-Y]J"59WS%AZ6/8J3]HLQ<2Q+^EJB/7AK8V\ MFJL=*UNC(SKW+C[^?'[MXN,&80X;YYB";;EH-!/10PE,9^O:[/B1<+1JN[)W M#:$M6%/O4Q;'&^L8PD4S*02_BAAB^8I6A T1;Y7C9N=BLKX3U7"ZGA[+VRO:&(/C%9N_J# Z/R]V%PYN#V0B24S//R'2W!+&Q33>'RCR M-O(Q*^X5/:N>V*-H/?I1^8E)\Y-V4?7SKP_T>N8 MT^8,>SVS=&I9Q6LQB4N2(V!QHDI_)OPBHNZ5EE2KJ!=4$P'!TA>#F]8!# ;O ML>=>0@&.PN>P8S;?*PP=*ZIAQ>T5A:P7(T?XH[ZT' RR!O-K(W>!CUDZG^)O"7[YM>HUZE$V;*JJU1%[U%>2VGZHE/.(1>GK'>X/D(Z>PNV;X).SR9&%"-OX> MH1'[-J8D=YM1C?^D[&,KNF3'.%/=TY'T#:H_;=9"X\GST9%.SKTA2[)\,1YUNUEF@MN1G22TI%N!!B(_$45REW+NL0' M?LJVMBIS9ZY/)+D@/''NM*UCE-49MN=G]B[WL"BHF7&BZG_L+*13J<+=23M: M)208.CEE>G2KMDFKS#_HOKW7>Q4O-6V)OH&)U&07HL>! M=H+7&]MD[Y18;.4]4A^XL#-4\SWS<$53J<6:23GP$J<%UD><)+VIE6C &;8@ M&6M/NHQ3\],GZ'/8.ISNF^R)/0^H<9SL45U)8T(3(D'CPH6[IX)LRE)#2"/ZR**Y547OC8CKQ9_*+,8RTI1\&9\S50LPJ$_,P(!; M >UH&@^($Y@?X8EW!3TJ*E1:M6IVMVY(4PXU2KSI=1O'R7>G_)A*N,B-0T:? M/TA_GW5KY][1PQDQ$!VQ:?,Z0[2(WUSUMG]S%>&//>4L# MQA-.MZ(MCT:^:F2QU <(YI/059[]EI6@;*(S[J5*XCWD#8."VZR+.6V'O@L\ MC[+]'KD*'&B)'ZC9W6$DO4>8$B[J3G7R3W$]NCF)XEF8ZKT2TFW\V,(^]7)5 ML,-CHX^M*]8OXY^=.GZ7Q:V1> W;,@6)0=]"#A$FQ%,G5[VT:W!J.MSAWOR? MA"9:,H=&*A-J>Y]EJLJ*2/%_3!J*5DP92]WQQ]<1E .^H9@UI>S@];O3,@4C M>A.='LP<=8OV,M&)2Y?NE9AE[S9QO/MP*STJ3$&;!R#1%R658&*@G%M%(U;= MDY"(^^OT+1,D^XLU TJY6\C2]AQIME/ZC1OZ5^5G; M&"%1Y@%BM?A/I SLOHY$_ 04?\']UH:74#_8@WFN;'!O3V!KT* M-4&&!HB%ZO2]PH>J%R8@G$@=/H[#')')\J_WTE_K"WWJM2 ?Y#Y,;W*;%4U M9#B366)')V@:%KEULD;B6 \S,45L)"'VK>AKDV,W#F]:.W5$3NEJ;L^A2E Q MZH8,48@?NU[#4<7]Z\W&P8/O=56#"XDBF:_.3?$'\8OF/; R'CTM/>(4>5P-6Q[JG;Q>8SY1!!I-WM:^U53;Z3GVYKL+C?I@"&);&O MA*-,9DTV;^2>"A8SV#,0D> M8B=%4@ 79!2JQ&$8$N9=<&UB=!R4,O:VKP3% M-&YG6&3!9;YA9M$1I\?!=>7BAZ[1+746J9U[6.YHA 1!D^@:@9D4+\TA:O3# M#+!)]6CNI2+G *6=J^4FW)Y2Y_C/6(S$F5:VPVY#J E50SDN=!4Z8CZQ,LK+MS=^5!5VGKEM2!9_WEN%RV=*-LS."H24T)E"S/"#XNYV)LOLZT! MLJHT4%[5#H<,[2@:"A:4?-$!5,=LZA5TF,/E!!S\A#YE#N/C=?KNIRXT#ICO M]%AU\P,Z%Y9,0S734_;L=[SP7!D*I_EE^O)@*;,&@@,F.OD$?>-] MU$3(H@$P9Y#FVQ\XH\!J?##0G\Y]VJU39YJ. @3+I,<05 V_W>R3*[3D1Z(\ M%5^SY7DT'[#NZI W[@2+U(HG$ P19P9*EXTD>VV3.V>'WI?TH0RK8PRK*P\6 MQ3,3SLMDW_N<<_UYG#:M1,3F^N-Q$*XHIO804;M/W=)9]8FF,+S?PUUL,R%A ME[E<2KNPP<#BSW7/!9MJ@6S,&D2?%7$V!VEUJIRM[);U$U^T=Q MK@_5TG4)5S'/N;H%Q!"MQ%S>[YE =04@"&I!#\,:R$>QW8UH%KB;W0N$ 78G MV-=OQ\]=UB_V;6OBK:F33LB3&5&'[@_W/(L>TJY\9+(0((OOG(0!HZ[[ 1_\ M?+WRQS[+BO24V,HN7Z\]=5^1WTW_=<*MT5-SG(QIBFE23;7"<+!5!=9X]5;B M,">I3H7EBY4,E @*39O&#:67LRD__VK5(KJ0$70QYGV&8BNCU UY.E0H-4LK M*>)$7,5YO\-'2&&80WKNW$^('GW$.=/N,Z][[/ G@1+^B^U1^=5P^Z EG18^ M7EP#'+*Z3 $.'U^<-B504XN=:\>>=C!'O9WG:;YW>OJ@>5<:"!M0@#-O0@G! M9K !V1-AI5O?UI34.LUZ6Q/GYOI%Y>T47@9[)YZPOKG7;Z8Q:;'*0:IN1F)# M;! .0O3]+5$L[[M!P0<95C$W-VKK95Z )Q1 INB1#_ZI.LH7#B^],4(Z /J&# M3\\/I%X:G!]CXM!U*V267%@$W3OZ[D)*D,Z.@4#;DR-BHN7MC^])A0[6'G8; MV!VGPS8E- U5:Q["J:#\I\X'UU1L2S4X=*I5%?:[BBOJ,UPK?7]:J588'R^- M K;!H3BB..YZK30?[<+;^KSTR_>_CNLE!/<=\(]*%]2V-$R8$*< <8$:'#KX MR2R\\Z1X.)C&\0*.8J*F-W@=IM?$IIMX;!>\Q5-%0N+?029! M%10@O6F0JL)-5QB,=+T@V-!1Y-=;R]L48"J'&J-J3I.#N*%%%(!32U"9LX," MU(,]*8#VTZ)!"A"1168EQ.PSV0:@B:; _3YSJI\YY-]"HI=%0\F2?W3\S]@Q MS2]*C/5_7GC(5#Z8$NF&5*+G?9!X:7;/PU@34W '^7/?Z2PI$7/(G\&8_-Q[ MX-G;4LF_P%_OI^Z!Q9Q"YY^0!_],-=7=5Z)^1OY_=[^@TZ0=V9'AQAY]_"N#^AS1B0,!CVMUJ*&!\31RGP.A30$>5U( ? 0!VERN MHDEWOW; .[Q@142KQT[)8Y7+VJ6^T&+FV>GM0FLR=U(#:A^\AL8>6*< 8455 MK<67 AB8)>$VBKGQ&#%$2R4\!OJ9.@8B5&HXMWV(0V/ M(3_!L"(G"I'DXS'XZV15"I"AV@C&2Z%^8)V'GO1%4,.^##)5)(#L#\HAOVT9 M8)HF!SI2@,!V8A#)>!*]S]=" 0Z\)3M_@6!S?P3BYV!A$*PYY$_8_8HF\WX, MMJ96@-I$ ;RI(+B11%WP;UN6Z:DRTU*@ )\=R=KDMU@,B=F> CRZ1@$49\&_ M1CN+S F)H@ +1C@&\I%YJA)(+:WC[: LR 5D%14"(_H'J;^ZWPXZ354]7N0$ MM0]A"G -#R.'4 ?ZS[D4(/G_)TGH[=>]1'YE0F-YD<^0N40JRCH6%&""&OMV M[.G]&N43O]6Y_>I?*576K^])-[H@"_10/!.Z%=)'IF*$[(IJ;);_&%_%*[:@NIK\QBY\FAA"(B4/UG&G_=8*$8LT^31*:5VP!M0T*H M''$#$X^@]E#41[_&%_QKY8*:(^LW\%3B=$B#9,#VWXC\=4,^;PL):*< -$E[ M#/^MQM#VGG@*%]5PMFE2X]Z%R,EZUV+VMU^)-==1OR'CBBM&H!;LNVL'BW0J MH6(MDIW0IA"9=IEC;[__-XK\A^+^H;A_C.+_I,9P\B-""O?Z5'';)+,OVP5# ME>33M+@1J,6OA4-B'W&*X>MD^?BFJ\AC]CMEUG#\8^,GR A3Q6:+Y6)_R8U M"P7D/E,V!0@2(3M_^F9W^!\;-RG^!?*K.@7XDTSR>2$D^JM46XNEJM7X0M'! M?VR]Y+8.R((0\D_#SP 3BAQT$CG12E69]?OFCW^'9?Z5>JJ&&U-CR^=HK .R M8[=*JNX_L+/?MGST NTSH/YMZ B2H/+B"Q2O )GS&^.<0/T>LQHZ$TJB[?[S MR% 73WWH*$?D!6]JK$5@C?^1R:R\;" _FO^SCMUHHVJO0A*9*6;O]TA>;^?R M3:I!;_[9H'\I^4+G9N3R_:(?95*.;!3]JMN<)235Q7F4;]38*T]@-KD_5@I9 M;/->_%NL\.?X+R+SAQK^;U7#_ZKD!W]1WL'.]-=2-^4).(/0) ^@?"*=H@51 M,E\_5H[.1Q\:0D&__$VB4.?_T*?_K?KT/RKYM?^@OHCY*SALRCE(W;% .VMA M7*GR4U\A[8MT@E@];#AR=5,A4--4(GZXJIL)'V!K?%E1/$,Y9_/(2LSIA3/+ M-J;OM]_WS!0Q<']*<=O44)=59(X*R@W.Y6U2LY-1#A@T'[Q6\_P)42\N-=#W/WJE*-N6U1QR,ZR%ABP^;\Z-9Y9:FO5 M8JG ) 7].S/"UT7:TRRA_";.VF]",B4 M10_A_%?BZ92UA&Q;V66_IW-5\.Q*!XA4S:'WP:,LO?1C(MK M9"M;-W.+E/"<;RSPQ._,/"T@E#>)XG'15/HZ/8" %"Q6K<6(7[S-YSCJP[4: M71%[^%I,@>1S\1,'\& M[S7X@#5>9W87"N@:1]3#;+CV[(P5--[YNB\'WI-" MX4);8"%HD'?,2@PG0@?[-L0;*N-(8/E0,&)E_*&XM*920(6%A>5,$SS@ W:- M DQVKV F7;SG+&N@>?#>AOWN,(^C:^Q+JGR=K^-O[%X7O5 ;SL?2C\'3Z)#[ MT#P)@8YG(:%U!^_"/Z6#['J4GX)87..H;12L1I%?&Y M;'53D[H24X)+F9<5'FF)+>TJ+EBTDGE23N,Q415\O-+0A3,Y.UDBV?H65WRK MS=I0-=.;-B5"I$XSRMX\^:S M#-%;+J5(9K<46-C]9 .+]:V\BK7T>VEM 8U,<]T[S^0N*Z+0N/&Z552R.HOPY6X]>*CH.H0-832- M"A_@$QWGPV+"^7H&NKY,IKO*B95NQOGMR*LUCM^\'VYKVY#]\?VM;"/ KY-S MK@K9:(Z-_C2M(=7LT\;$9W/5K>QL9-@[\9X8N6?IC@4S8VP ^Y7/C8G/!H]) M1!*1N:J/U4_+H2<%< Q10@3SM*F-KC-B7[<6GMPI^R!^0+F50RL[>YS6MS/4 M]'HZR#>SUK^B O\4.S)=WH $V2*T4$UD$.YPGR95FHPG2CD3&?5BS?U+3HF< MO\P_&V5Y\49Q:'WWA",^')=5]R! _2,^'/+D,!.=&<\S0/FS8?55]7=( Z:>> MRV18RAG3*1I6V4Q_[ZZ"6[?RJE]SFBP^^"V>OL4JM*[7VH7-[>Q<07:=8&== MG*75BH!>3?3&1ST!9]"NCO #8-=*:@X%&.$,I^YCV+>E M8L*]X$CCKS4FN:[#@FD)KRWU[7AXW*V;4[@5A&'/I2](#!]62(0E<5B07F^C M^)'UU>_+:G 2007*18>'X7FF_0B)2:E7#U>46]HY\X_)>-@_<71T\K6_=^Y= MD>A[8+_YHS*(R]7*/*PDBGYNW:DH3WK#.]ZZSOJO^RG6+WM;\ MS U0"@+ AQ?@/VXV5LF^JQ7NE]X*\M@1$ATDROED&.7H2=8NC)^<"+:S&%:L MG-(]]U%O([?3\#5Z![5J.>7SPL&E%M1K7R;X@/1N#?=&I!?B$ BV#?IZA:'P MFQW#Q OR<>)MK%%1]$JMB W\3*FN7P'XW/N>_#7I6^72/^0VY3K[+(?>6-(" M$'T7:.XY1Q9$6.&#< R3ZPW,[$9.W9=PH1$C%JG7<0=5/G24)>[XR/ 7Y#L< M&K[J$&SRVNS*NZZV8SS"X/-+:=(]);9>Y[^M>]2\TK.*L\@_MC%6,Q>M*!7U MF;5"5V).Y/3G^8C!HA2J\P3AB^N1)<9U>3+0IDUXNVZBNY6%1ZF;M8OR"2?K MPSXG5;[I'HU5>-]\W.S_8L<%&"A". ?%/><3C& D'#+_/]-U''GFE MT&,D;94K?@(F"H]JUU_*ZH#/18J4$[)H.P?CV.SS/!CJI:;Q=H]HSO M+PVV>\XVJ%W\H#*E\JKS8!80I[)!?^&!U QC4*4@1??^U'^.)IM#4YJ/!=4 MXS=E03Z[=!8<231Z!P^8\S^WH0%N\'FH6]'C;7WPW-Y<\J?M40359^_ M;YAB3=W*J'.?34N;EP4E6L=>,\_1>_!)M:!6I6Y?N#FZJ,PY3]?0S?5VVN MEZB]6%4^5%,.%3I#8CF1%>$]8:;BU)M=*A M38/%B^9FQ8ME#[ 6'677QJ0' JX;'L]16:F6\&UC0'HKIW!BPK&U<:]*=;/+5;3S2KUF9[R<5F\>,=@)OH! MV$]JM)/K04BHQ'#EW1LHR(.*ISJ'V38FL11^>?+N63);><=WFPEG4=IBJ"2^ MH7%@7!9/"\MIFB+I-*M:0:*VP!@WJ]NN5:\BV]\-T;K['M [9'!=WXN0L_%1 M[J!@Y[8IX*7)1@&>)5;^*$=(4!PTLNE^@IP1*T0.MI [MJDYTQ7CIRA631#Q M%-9VO<'=#&. XRJ:9F3F]Q\KN=8@[26*J;Z[-'+]XQO+NY]I'Y^@7>)KP3E' MEH!H%KS<-,4'E3 L"]B/^54A!3Z"!36.+R1#XLX=9=>G>DNWR?_#WGN'-;EM M^\(O(D5I(DUJZ"!5Z1T$:2*B]%Y$:@1$0(($(B"]"0@(2%&Z"$B7(KV(2&\2 M:@)(AX0:("07]SG//GOMO?9:Y_N^<[][[KW[C_R3Y\T<[\CXC3;G'&-L*7>! MJN&X4::55E],1\[,C!4D0$$/%/,(]9HS0 0DW7?CEBLW=6_:Y;(UG7LM$HM>IUW#C=SZ3)5LHY[6RO9 M)C_AOGT[C%:!>7&+=\<(U1/MK4R]]NQE=/0LGW[8^K4G8KY-CXV>$/LI"@10 M(4E"L;H(8[12/%*7RP@UDIQ2HKA^PH7,J_4Z ^QOF :T:'28U)%"CBT+BW_9D; MX[2YLQCK>VATEF[7,%DF(HJC@5H.2VQS8-8WBV%:?\S)01?\"/NV ZA(F20NM_I*&V<6]&HPI0\;=)[A9I?&=$/CV+.M)QT3SU:3%5"R_#88[ M.U0RPR*[:B,]Y46Z5(JQ;IP(GY/^^O.?,MA>&=RRWR"6QA=9V+$3"JMVVVG? M(<3T8HT0H@S.4KZ?9G0\/-W9)[8076.W>&,O725*[B"(N6BME4,U+K#\.% 0 MPJ>/SN]Y*82US['"U/ZXF7TKQ"!H!PE<\%5A_FYYX=+75?6GYGI;NJ@62\RX M+RJEIQ,'ZV168\_0Q TV6&5P[3$?=7-0M[.@<+/@5LER(HQ_.PAE*'I!.V?5 MW#&2MW"A_\[A99L#)W7=V710.M2S T45A;U8'>!@&][M+ M;0DOI['Z+CY=8>Q&;-CPXZ9 E#@*K.RX@A6:I-O%<2^_?E; M3QMJ&3T1R5'$[I&JM(QOJJ> -EQ-QGC-&Q:F1(4A.[T"?@+K2X:;1$# I87RF'DJ'(^E51L"Q H!=QG M-7@^1ZN/;^TPT?(1O-78-'2J1Q:B/+KB+T+5&YIJ484QY^F)?[0HYB1<8YR] M$2+;,\#U3'"09?*K5J38D:JCRL)E99?T2! M0;IC_T;/$VIM$/S]K9_]THF]:6(:N^'">U<(3OB*UU.>BV1[P8IFV^SLW)AU M%,?'HED><,94B=\D4&%)A'R,)\*JH8>Q!H4]?*^/S(6Q)@F" M09GYBX[ 0IQX%GAY!R,@D; .JNI.1GQ5V#CSMT1+9;CE8P))H_' X^\\,V[9 MY%+O@(K'*"--Z&0F[BN];R##62TVH! 3C,H"+R(DANZ2[E 5:<@B+9H4Y*;D&3EZ["^.:2@]L$E+WJ:5= @ M^*>__K7BO0?7*J&M\6\H-02R8Y5DH+(8CP^:!9"Z'AP#JC:?6]6[:J(F RR; M+J9%>553WS#9[JT]^XG)=^6J^9#J7SU3VVXKR;BP,0WMSU.NW<0X:7M_&G'C MJ@DR"T[AE&F]K\V=%*==+G]6A*.%ZJ!:>CRB0*P^-F'9E($<6/D1[Q*9W%&H MH^YLGZE*T#93OU3UD]Z6[]Q?J2ZZ4:1<)-Q7UAW[>% J-WE_=#NGY5-#I%-= M0^TK;=KA3T16C-K_/@6C_VGV907M7$P' O;29Y[*5"0U9]U?UUB91H&Y^354@_W2:,NHEOH9P<#WBL]GH6P-?E MGG<+F=,4*6YUAKC?/EWQ9*O@;9$ M1D$LMS%EEQ3RWHV^D+RD;=CC]X)ZC3H^-(%'!ZE3*X+I-&YZK^U,I4F MF^O_HI\!5L^M9CM<]0LM#SDXG673M9Y7&RLMKYE7B()!!2 MZ)Q%CB:)S$ET ZF.U9C:N\7SQ+Y-$J@5#S9D83%Q0CN=.D--,[W;("W!/&[=ONGC*O"LXWAVF 80;5\;FSI.'=DR],9O",<2M?*RNS6.!7[HJFC47JT6,ZVJ\*]!:[FAN5C@H\[3&L"[)6 M48;;K5S?:7@_*E(J!'4K@@2,:._O4&*,]_329;BITWBHQ6>2'WZD36/MUE(D M(:Z'U0C(^=X_*NWWV)X"CV[)0]-FS\+O2/HY/-C=>VH][Z(]ZW-*EE&:H6/0 MY5-.N=[,U*#C9G.W::2,5:$K[' 6\#OO7$B^JLUL_'# M_\QHZO^NG^?QFSUX@*>EHV5[%K8F-'Z(!U[@@27B^8.IEE?E$]'\%UP1VZ</%5RRT"8NV<;(L)6[*H=", E<&FYJ5D+) KC7/-,ER0F**LLK'2" $$W6/:%, 25#4M&[>EKJ M%3JGB+LR4)L+5 ^R:%D%$SL0?:(44SFB^T(>[)RH_I7\75C QB)53#-H3$&W M$#NWC#@#77?;52-H=?O5@M->BKH[G-_T_R+ MZ[QVQB*H2X]AU7PE0K)?5 W59 XU?BX24C+C(F8I,8$#6^LH?DP86->1T,KH M] M6-\4& 0P>T*R::.)",R^&=BCRY)Z0)O)VET0FM:+?O\J%-(B/FE229L*6HG:O*R,8$F_*2G'>\CALJ8M'#+Z9=YR1 M>TLY _@3OT,.;N(!1F<<&ZY[?!M675HF JMQV_+] 3_6N+D\*!*H"1-?LF2= M!A4(ZIB/:IK[$&M4WK7.^U6W1XI;F#^4++.;A>;0$+ZE'O.]Q75.P4NI(X' M(\9 '4WTVDO=J<1,#7;1%[A$+VMO'2A2D'W7)^9YT]6S'W2D!['P!P>F)0#L(CS9"T^$C:O//"^ M^*]#MXO^7Y<2K8.FI'&W['$MYXG5L([U()H0$1>+9E*4T_G9^&G)01C^F3XTZ,G@,/CR^?:-!6UKD-%F88(*EMB2$32#NAMCSTC MV;!&XX%+QKEX0(6L''L>"D?D4)KH8&A+RUS2"Z.@7L@6MM[\[R*/A7WJ2]EK M@FV5S.Y*&4^LB8L:B9/ _2RO4%BAG=K\A;TZ1S&IMRO8F)1 M-NW9=#4MQ*YS7*-=RT**"G!1,% M#&)\4=EW,+X^):XW;5R?'[:45#O=GY1L3%"<_=;3V!>_;*2UJ+M3*S-\A<&^ M3DA['@T+7RS^Q;CIFLXEL<\ M_@P0:4'O_#KV_!OJ@'AG-M7C)EW4]F);DHTK_7.KKO2UW4%[F:CE'$"0_95H MWQ<"_6\$!'$CA1?=UYAT4X+RIES2W3X:RP6\ON[A!KX0&L<_K/J!GQ4 ,42 MAM\(3O-OJ;X0QW%!0:BC+D$\0#X'CGSJB#H[F9\.2/&ZDLIJEP':X' TG_:3BU>&STKT9WPKK]MDD+C)F#-R_%ZV2PY83QA M[-6WCJB,/R I4PHZ]!K="N1<99.?P-H@XQDPA;>UD55-$WRUIB/7[9WG;A(U M4:OF;%^LY&RDU?W>II+W^>SMYF*J?LUP$QBY0XZQ-T@WVU$0S[.:SD^J_FCN M(:(9M"T<4G53T$-"A9Y'-5%[J^4/041(UF5ST3O ]_3"HM:8CQ[1!A-%1<6H MCP>5SE4]BN++3+.)SLM1IG&=\@ZQK0+7[.H_D!SZ#YE^%OBA^,3?T_R/ 8M>8 'Z#U?H1+V(\2O?)=*;!Y1LY^R1\8^G+ M28?/1[SGR3#*.D-0M7*(DP&J+(TMMA 3HILX,U?S_OWU*(?T2^S)%GT:'$@9 MN_IGZ1M_S/D%4'@+Y6,'PF2+78+2KA_8>B M^PGOV0E#+R9Z*B.NCN_/PZ]ALB;&='+6<4Q,S][)-810]-?T)DX+F-)3IIIP M<=Q3J$@4$Q_" W_",0F#WZD\_",\MCE\$<8 T>M(?UVIZXOHO[H.E]?PNR3V M)L_?]W/MW'?3:+]<@DA; N[DT19'V*75%@JH[,*LP(KQB!VJO[/.G*W4R;L8 M5JC-];6S^U2J$FFBFLC%)4)8,NGTQ_:*Q3CV5';ML(6ZFHIU(U 4K1F--7@O MA#:; S/0]S&I"[DQ=[/7!?,;LK:FW#9Y&%G_AI]V5NW0JO6MWMM!G?5*HI@/>D@-ZR^3] O9@[[A+&XOZX M@J:7K^,H' P7+@CR*7#0'Q=V2U_HYKI,R 7+:^'X#,]XEI"4D0.E8()%2/3K M6: 'HQ6?5QUXXWV5!7*"H( M=__&Y_[_:G5CZ)PG]NZWDY#UUC4Q1&F4O(>?!7<8H4Y5>>/&0OL;>3KUN[B= M'K)H,[L)7$Y6F'#HV42_\O/G;X!^Q.7P7_N,J(EYR^[3B99]G@BOMPZ$%0/?I*E4LBA/10W) ML!EWM[6(-!XV-IU-D8R]L%U=_5*3W!9X:@CMM]ZS'/SG+H'M-SO*\NB.!:4@ M]*DV:BX3R=Q_9X""Q*H&353EDM@=&&P'Y M(G>'^RNE=J4BCF[G$FFW*4M[;MK\YK_YK8 MAT=+).1MF+OE?2J-G1L7J!,*XVQ_4D@0LEAFN+0BUW&HC**HVQS()A29P ,F M*.]G(Q8]GD7:--;=_5S?J@0_NKZ_[?OMTUUR\F#Q;.V_X_'!WX=05 *C>, > M1&2ZUD*R/R6I^_ST#L9&T-+YD,' HEI:?'$I?8GTEF_,;N-EP)]I R<.)3B/ MS[I/RXFMUR?34Y(^0#3-HBU'#E@YM7*S9)-P9A6)TL2\Q[XBLO FM)7T/Q>G M]_@*4UUK)J$9!OT.:I:^HV]#O7IR&R[YY>/3;F$FQFM5XL6JR[OW2)\HEKS[ M4QX(,<6G 2,[.G6B8^?J6I-Z4: >; $;M/50.#8MHLEC,9-89MQ]/W^M\7E_?U.R=G&=:YG!9 MX4>S6R/I*L/%*Q3/-?\@6D':=(A28*U1;*4+.W1K">M9H#'$KKNP:?+"%:/D ML,N5G\BO/24E;@I!4&W*+\2_G),>;;(0C8#:+W[QT*H#Z])[,&[PGGE#TIY5 MFA=TD4IAFT*"1NG^_E6Z1Y,A_% F44UJR'GJC^:-&RE,N-R2U''O MOO==KZ;U/CTV[:!3%U A:28HP-*M3__8ES'#GV6#\UP.:^FET&93 MYIV?;GE$;5 MA1D-]1+:NQ'&1YP4%1Q7!B_6QA4=.YVJ;FPJVYW>G7^X!]VI\@OOV[L9>_K< MO8=Q(VHDHWN.LV$X+$'JRP>=O)>F72%S6D-$^I?+4RS<"0@)66Q-1K+_GK(F M5JP\3'EELDL90\. ![A,1ONB*B/-OFW#L8IZ8?$$GN0T#RH;ZGI&Z][M6D&8B0B:\[TK;@YNX6L=]4 (_8/QPZU"U=NW.PF,DBU&BOTGTRZWY"PHV)1 MX/(CK94]B$_YQD7" ;\+S3EX(,P(U8,]P13B@0L/\<"2JS(B&7H3#R@U7\<# MK6]:CIE>0PKYX]O3\4"=I@@A\CI65RD;I+?6TG1<,-]MS5XUG*T58CGV;L3* MC*E=OI[^0NE14 SK9UG9Q;>CU1[,D/".VGAPW@8\*Q7,Q0!YO,,=RA@!)'YH MI7E!'%"RIH=QL"&'#99'P5"\HCB-7!RC20=H;P.9C;T4C0<2BI7X>^$NA64M MEW2"((G"$N,CE4>'5JD)N_UA^;[YU8M>OL8082YRC MRA6N47 2&U;HYU"DA)Q\=D3%4MJXX] VJ'C\LSGK/\%QF:7)ZV_825_H?[EA5NHJ@D9:J]DT2O]&B/DH3=V%]U([]]\AS[Y"6(^.,# MM![N8A<>^#INL_',9,[&$X2F$I]?CL==A.;^I7+IMT^-P3H$,/:X *@!'@BZ M"=N5!/WE5T]@G0J#L!1E#/5_BM88K'3*QB^@#0]SR4>I,[_A3-OI5 3ST(7/$A(5 M$!O[:>;V91]$RQ,_;(-1^=_!YLS]VVG?-A4F/&UG]U=]B]*#][]*KOY4T/$' MC8([HI^5D6Q.+7T@+.FQQJ]*L]]BL.AWUIG8+&]J7C@W1W[G<^0_J4$-WH%N^686(+!W&EM/H)> J!2."LPM/9'$^ MHO_ST/U_KM[^7\39N/'>H16JDX*!C;-NYD?G)#4KKN.(,'O@'P#J_G^7\OV+ MM_\ZWC[TG+M!N_*E<#9.MY)L#G?./89"[F-6V7U6]7_0H]G_3?7H_UP+\=^, M,S;UTW-P]7J@=D[K;$YT) -:_J,16W<3%8I/ ^./C%:^XC+!QI&R.Z1%[5ZH M$;\2FRM+=B$KSC_.TSH-D?ET1V\TYOZ:ES7?&XOO\3(#)"S7RP=DDFZ^2T,N M6E#.OM8?M["H.\FN?F*M&_UU]QA1$7E=MMYY)S?&9'5@MWZ>$*N(VND(X-VX MBYI(I4^R]_'W+.HG5X_PCUP2NX,';O+]=.1C!5H!@$CS#[-1&_Z 8[X7.!#$ M'Q$?MCBD()K?E;N*[I=L-V\W+4HT,S>C-$WJ:V3[S-C:"I@(%@0.*%-5!SR? M-*P9+C.(_->.Y4S/L!,[G0\Q(;4&3F M*I>9N55;ZG2I-MQHV,?BB\"^ZKV[O,@)TWSGO<$4TS*_;K]2T!\DS>]^'7,/ MABC1]WYH"=WGKRZ6? ":GG5(-/#^:AG^JE%JA=>,3/;X3:UI>C$>N$S5"D*= MVQ#+; J+;"*_,+4\1N[=/D;LKH[[[/>7M>)QGJ-1\#_+L(J/CB"I? M]WI:-6@K>CCW8VB=AY6,[J&AV_P-P2L.Q6Z]=@Q43K-H$[N6\__"):N^%M&,-E QUI()QRVW. M0&Q055CTB5OJ<5=I>WIZB=M*5.D)2B1IJ1!"8_I#"64NI/WQIL:_MVWZDUV7 MO[1^^H-]H;_T;_KGNVY_Z?WT_\-;&#M%MBP1GJ]ON2'^&P*&!_'4-E8N=5=Z MS@+"IT6"1BEFE/I>)S?5,* M6<8I;0K\_A7BNHRR;M5 @[?0+RC#P8]@FRO5'A2_BD=?BM\YM:H^4:^T[&-] M__V1;4G$\D.EV\ 22_F<.R2'*GU_D KFXMR0]>ZLL- \X.7U4YZQ4[[/,YX1 MJ:";K,=T"38/;%S@ULD?H/IU(_9AS#X-PS&OIO% 29R!C)C B5U5C[MFC5G3 M>,%DLQ(D6B^13+ZOE++;I9I"R7G8'EP;)RWTW/WATZ=ZU[YVBZN !#L8TQ_% M/F'\P3]X3]<-L]A6UTR %IX(+]+QD)S]K+KS^/MPYM=KMI](IT8_->^X'[WZ'6^DY?KH[[7YEH6RXGG;Q8IROM/D,VCBW: ;2@J28 M2Z!]'A_M;2$OLP\QITW4XO"A$-?X?)PAI">K2*(63( ^H#O Z&+Z1OFJ,!2 MI,XUMR8'WP*;LP:&('L7Q(.7+KF ;4)02%R>_:>]P?#)46S@R($')2;J#%;- M\27YMTCAO@!R@N498W[NCPD:B[C-/!S7-$D-WO_-WO[ V3 UV8#H; MJXMQ4R&Q51G$DDY^Q/+&W\$$+1/3T22V44FTH6X_2:O,I^3<'6 M_@L 1:L'T""4:< GY<%0HT6JRV;".[&BD@%UNBR<2"1\J."^QDN6F!=R+$&C MRXME3:/3G7*I[?Q-;G8>8/\;7U(LI&\Q:2M1YU*^:764U[;9N:I81+@4)0AO MY@3;7)7\5_-5S)88^)%K53[PJ-WA,QAFRAIKT&WQ;YR-N?G MU2)!^TB[EC>EFS',A7=Y+BIU98&%9>@'=*H+XGRK?&JU1 MWE*46]G*[_FQM3+K23PZ8=CSC]0MRT#JH%9U=M]1&),=@ M[A6:83A1F>1D[C;!&].CBIB+5UH)?WX3].V&QWWY@$E<7^GLE0.+U@U:9'@2 MHG)$[@LL+O>XMO];X]LBV*/Y8Z+XD[,,/* N'"!H(QGX-P64^Z(@2$=G^F2G MCFAX(&5#W7!Y7.991<):2BN52OWJ+6M[L&EXA^0.KW*.#WN W^7CVX+/];]ICFU/HJ) M94,>F:\WBV+&DE,CNP1K_J5'B3*+\(<"WZ9#*$ A.*EQJE"?,_GN(_2Y=G'Y2:84%VLS MM:;>$(C,:1+X4/1>QS=VVAG.HI7+_ 10E(LZSM##?%ETLU\8+^STV.*R R/+ MKSDOJE6<"MFL-O!TYX(?1TVIFJV$9AD+:=LH$$U7&V^-8'J0#.<9!@CR;!"I M%Z$ RG66OC))]]H/WB&D$_X+],MZQ$C/:-Q"JC MY181*S&B;@=3CB,#%;E@E 69BP@BSB@*R1SQ^O75[A&5Z45X&>]I9%UF>3Q# M>FTJ"MS]/"6T=!;C;S):79)QZJ;ZC9\G@>T:7$5JD"4AV:WQGHD,WT66*P1S M#ZP%T8)(MKH"C XB.;.LD2JL#&H7X%%HA4F!/(15>%2E0+L3J00'DI&F21 ! MIEN[%>V9H)>!G),+F*#%^(M@)8ZD[ONK-W_,6FRDTJ/4GBH-\Q*2C;Y]X*3'F>OY]ZDG>BD6#OX%YEZ;IWVU3>HNBQ MGTH/WX[#S1Q2LPC]CRJ*G%&[B@R'L9\:,;$Y&!H+%"P*"D)FNCFE# R:!8_G M0MY'YOE=/#RB46UU@QM99>KP+M]O39T-'*9_*GDP$;K00H^IZDB'[DY;0Z+5 MJX*V."%O\^8LG]Y+9>"X=H,7SGA+0'6;/0HX2!<TL&OL][Q*\EL+0*.+@MV">$! M5RMQJW$%(P?$#B&FK[,%%;6>M&8^VYWM\+C"7)N>[(;8#,=;.HY@%>ZDBPX$ M#B1Y:-$>70;M^ [/U>?N)8L!!IW&+7 FQV3$ZGN7G]7PO)E&/>X':E?F0KPK M>75"&17ND^0.6V9WG <6$Z KPCL3@L)JZN/54\84FNKC[TS+-O,<*-^U5W$) M7K^HS=P@+6^ZL)A>/R%:LP-7';T==O)S7ANU$@ZKWBZU34Z1SXCNG;NF,$1Y MC=-\YE4AEQAQMY$N\#R6#C''?/9A$^KYOKD&H1>>)8-6BO00>F7M2D]O')$R MHK'\2"5Q)B^5Z-G;LS3>%<&CMEL3X&PV!=$"C'3'',LS04*BP[:E#MU#E2)'H'+C9 MQAPO6B]"O3^U(X#&>!Q678:=%>;P5#Y1Y1-C+G1>HOS!\R*"/$O0IFN^QB>\ M8^M2#1Z@A2JB!T(0/0*U\)KQV!+-)]LJL>0N3TCNB M_3B8C_Q.J N].+-<<"OA:H-@;UF+<[0LT\F&*LHF&FJ&Z%?R7XT>-$2[#VVN0U1-IDK!3F/!AQ0M&_U360 M)I60N_'LOI[\U]HMCH:Z-'MC;HT\>/>T":.C?4PB>'SU+[<1TU#QV)NGPAA17;1>C-N!['[&ECXKOU3J MA;MH;4[Y2%:SR:4+4@.S_:.7G0G'5\M?"RLOY(&HMFMT+50]+F)UZM"Q;\R$ MH3RBH0ZXB3&$K<5 79 I;I-_-NTNU"NJ_2RGY7$!FF]3^P/6#*-69H5QQRG> M&[TGOOX;R2($3G$#<")2J#W@KO/'<_E*$!I=/.3U:-#\&V MU-_4&3+W^JXS/[7\W,NW3 @ 9[JT,Q35:O 89,Y$71M+B*;?LV&I)D1HZ.! M&ZJ>*-L_5=37?>X3T2O0\+6K]/U=VAE#:4;F(SL'5%D=&G:8=?8VD F"!SKF M:7(P7,56+J-6&W>:F6O'.1J7!+Z^7^Y)?*&Q2TZ3P-\K?XL=9/S YDI@MY(\ MY@QMWPJC53 1[625[TG1\5%*6/#/]-<(N5/])9%>8'(D6NM[,.>3"Q>FX!WL MNS?Q@",5G L96'5JW(=J,<'DYV&M*JM'R_+1@IHYFKFLQ(<,_$,6+%RS.:FD M-G;7;,]C_R^KYTIE=J*[FTVB,ALEM/)CB[.% M:% SVXC$*3]7^DH["GS=K^BN0@\%=V0$G?YMHBR57.>#AX#R[:*/+9?A\V80 M)ZVZL0.'R9IKI9PZF4:VID1+08#+2^<[.5XI\$)"&;KBWTR(8Y,]U8!D&Z \ MPK8E8]E6-I\G5S^X5K [?KB=9HC]2*IPDR7N8(\/*\G0N7/"V+*K.HD'8DV& MYO^^M&C#DBNH'?E$///Y@Z05U^WK^_'>,$5(>+H]RJQ4#F*^]])*8HM16W!/ MSX*W9NC !N,J&CF_+PY;"BW' TRY.*9HI.\9^?PQ!Q@/='_X6;^@2]BN1#W4 M9.)?>%8)/[H3)B-QD*Y;-2]7[^=H.W7;"*X:G!\'M)*#B?$ 8GH]E>E^352' M:HT-5=>'.6L]'XD*HEX#06QH$!-&J=E M_FL4\OA8$\'[#LI0']]#_R_B=U%MXR(9=^25JT%;^MRV]?<[/!^1F_D2Z=\@ M74Q&E67G0K71;)D%%)0@JHOBEE:Z^3-WVW4@2#&QEYE+G=DT\+:=_I M"+[E>6!GW\<\NZNI8[,R^GX]7+_9_U[>=07OXT)WHRT^7_]G#36S9?"I]!;4 MF U-RZHC'N@EL_DUJODW\C%2INA #$;0N,+O6C/7#97I#R"WVW='UI&:%)7B@O6749T.9?)5!;,YJ+HW!=(*[SGE1PX#I=L$Z M)X9:HDK*9 M'^QQCQ<:."993/FL^;,5XP$*=;0\+LP#^ZKFW\9D/X#>PP/OSK,<;F$89MS/ MB&[J+"D5#PPI**.NX8&$%3SPJP\FL1$>:$O$ ^+C,$11,Q]LJ!\/)-*W8%WC M?\M,N<#[^,VW+;B@<^_\HN=7)Z@!Y56QT0+]%B+71K_97L#/"\Y"0(/Y7^ZNWL"$'&RRCZ)ZBR9^A??<#/ZZW#P^L MLH$PY+"O?^DB&2* !Q9Z86EKSV#5X9T6C'R)5-2/_::]PS>E>OBR3<_ZS?\? M+;/^QX@V27Z@>7C/!@^HH/! J_VO'EI.H'U&$SQ K(,=-/H'4LJ_%6+3ARCE MRJ=XX(0D'$<(^M4][%=7SV\M&#&;G\_+?TOJP=])T6C9\,'?(N85[%]X^?^ ME_]B04>M'*9CDOT(.T0CI;L7R5OL:AE!+WV6]_](9&/",)?L2&/CM8M*W%-7 MR07.PGXL[L7E_PNO_\+K_W1!E_B=:D'5QYBX/)&B-SJGD\Z(?]CBJ"?3_P67 M?\'EOY6@/_3\ FH43F<<32_RR.HC'K"K7?*<[NNQLW;YUW_W+R7Y7R;HO$!B MZ'/T?*S2=6>X5%79695NO46\%*A2):-V^NO&GI!MC%A(VY:-'N8_QL=A0@[M MST4SCY@_J"HFV0?FVQ=-AHCNNOCF(I1\]-;IR.]%O MN+5/8@C1!FJ*Y(Y7U,#&7*'P*^S>B8?OA&(]42EZ6CLQ;H+VSS.N9 MK&9Z71ZW)O.H^#WZ+"2561N;%!."YELG&1XSR3+'C!R>+BI'2+SS9:T+:Y)] MUZ:(]KIFTO@Y4[/[)G_?PG4/*1;5Z;5M2;L(IY_)T96<]^ T0&=;I M/.?WAM%I(JG(5AF>6F/BNF6V-O=[P 2>%X,7OI=9U84^N%I5O-1PW MIH\XJ%0=\074\?PHKDF'+L\D];G[BY0%N.IIL+;$I(':97K^Z?N]/Z4N73:\ M"BAR1AT/MH) PI)4T7C@"G>3VU,* ?E2$@VYP'?,FF?Q?C+UJCRQT]21W+LF M4/^0- Y;,U/)YQA,1EYVE.Z"J,@JF%"'J2YS.;[J&K8]RQJ[TL\B-:*T1B)! M,#%L+0WJS*;"I")7PI>M-#L;7&KJ)DN1T5O4ZKES^6]K*RP'Q=QY8IXJ_7@3 M%%N5>,.PUB2JQ06LC0.! ]FK4=DQPE VN/>(.69Z\U5^F@'CE$R$[F%G-#=( MMG3\0NQIL%T1X9QS^554>?=KU& '*/10WZ5A)T[!H0SR? 0M\85;4W+I:RV: MLC6U6FPG&90E7J6DP_UE P&(\ZF$JR,AB'/FRL M3'@M%W[Y>\S'/&IN]]69+?N0%Y25_Y6%X5^86W$749M9%$UHI^B=G:WJUPWT M4A-P_7>?L]P:XT4NOR IM_9C<2IHPH!RP :0:Q +DZ:4Z4[AI[LS-B_/.CUM M$RI4CE^[DR1>8K&]3_(:UFY4>O9I%@\\MCDK^7HJG7U8.+^TR&:]N>*N')XO MDH'L]]*L2/G6838F]'B9N]?#S8?;LUF#TO *%=WV'$$%BJXT.S[\Y8&B-7*= M]<+V=1K#N!M5O/,'"73 "U)"29\M*#:2%*NK/E- MZNZ)VO?6G%>WC]\D3;I@P[D)OSW&JG]8:PCH#RTH] /;>>&:)YC#M?*_MLWD M(#X?E-5UVESSB;TWJ%HW4B9:35"PEN RDB&_8E.].< :'-ICT#:@"*X'4>V, M(E[.4>UQG?IB>?L>\O M]880X-ZLL(*=.F&5_?E9(1^DTGWRQSZRBPN/[UDP MZ[3G"E6\OYEP:85YE7!E6M=+_U/83T$WU?4YP13C3(ZT9 <'^=>?2'ZR[XH/ M#2O5%\VZML"]7!GTURTZLQ\G.KK4D=O5);V-H?2"?P%W9A/N-[J1M.OF6KLR MI!?4'J)+QZ)B;;?8Y8,;=D.U5J?X:I]X)BPJ7X;*H+#FS!8I*+TS32G MNMA2$4>#L-MD>Z*RRW'$RE$O9#)V6"#QAG'..PJW/ECUW#!*YON2T!$J>[^U M3D8A9E^2!,O#-'G8<]AR^ 4/');KU07D8W$9@3A?[\7R.T?9EW!]$\_#P[TS M8N]NB,^MWQ?" \ZCUE-N'SL 0ZW*&[[L5^ZU;>U8SF:WS9-C?-M/#@L76=4, MPJRX3-TD>O(C!N$,#RLW*9MH&I]I=Q/?3 =V6S ZDH-;)F-XH-:':HM//][O ML' O3:N-:"_QYK1DR<(."Q7QFA)'V%S/]S$?';T*3:A#SU2N_>EWD='$CIBE MAU\FVYH)42LO#G;HNEA_YOOGKK/12J.UWBO+F#??#ODDVIXL0YB4OI<=V4*F MH+R !PA7&[K3?#_,Z4(K/M&!+'>RQB181K^J;7;%7 M<&+#C:^8PSKBR2#V[5+I/7'E!Z;NDI>6PT9Z-$W[BB)KY>L]8]PW296M6]D" MP,A8QU8S,C?KDQG3':DLH[[RJ:,S/"!*LCP[?VWP>; P^'[PP/:(_,:;+0]2 MZ1M"WZ\^I;SE,\!,D@5>:Z$QI]K:$;TS(7)U9!ZQIT/7WZ")2V)*I+WA\UB0 M,"D&I"K83X,8#,**YZ[>Q#2:C>=,'&1X-\:X5'1/'"9HMTLTAEG4R]^#*/BR MLSW)$IKD&J%\W3"0TV!&I!LUJ\7>MA2;-GUB"$;J6DDDY(L4/V]PW,(##QDH M.6;?KC@^6U$X5_\U'5$ 8]\NQ]#90MYT4EU+II3)_*V4.NGJXYNOG@7A*N(@ MIY][) >G,:+J*)/H)H=W&"^S"?O&T7VRWG*'--OK?'W,FE>^.W&!63N)9+M) MQ5;++3VXJ7],BQ_*CM"M2D)9IY72Y_\]"KG]9F M"I5+FL!PG7N8IH5J\TG]TL)50"'N'V]Q/&>(;P(A=1F0/*F=>B3FTQO2'?=P M/>/[S!GQ51D;Z@GYD0NO8TL4[NW:V9!N" 9_57'=:YE2GU#D%O^D?OIXIJ(5 M#QC6[(=/E^*!E2:;HQ\Y5%(C6%\T0Y?YSS0/%Q1\HZU!_SO(H 7M_LZ!.TN+ M)?^CE#3-SC,%]X1%(T896(/GQVK8-2@-FB%B6A75U1.OP%SF*@ZF_K'F^VS( MU=QM9L6GG:@AA=\A:.G[NZ9Q'Q<6-\]@Q>BM"3RP-R=ZNOG@< -VO,-P=LA/ M^,W[W,.7(YTZA0F[K*\/*R.N##5).7X>\1:,?E/FL=*4PA=:)F).#[$WC-*F MLX_3EF;4$:=XIR=\J@N]A-;K$K;1#F^'1ZTUB$9\EV.(8W@VY3B< '_<[DM1 M^:B/6(7/8=IS-UCQ'/J_0WH@4 I"?]II33"T[T'ITLOW WKKG169:1JG::E; M#;/+(RY/PDNT=Y_%W9L![A$]E:98I IOJ2:)AZJ#4=.=2C>&);?$M8,G]M2: M1H:X4Y!+6F5U)I_.,PWS-QQ:"GO6:W\E=.K3@CV*QIW2$BSB0"A01" /9M0( M[1177=QTW>WL]0E]?.X/U^V&T"]-E7FIXOU>KAO+?5QJ@%&8VJ?;]W8M0\?0 MRNVDWAXAS8JHHS"0Y;AH32;G+BGGI(*Z?W'C]\/MB&*>S5T_VT09\I*9D\F" M@(9YG'\7'@B(4IKUP .*2#S0W 4\L18:DF14(NY[WX6PDN]J:#F\*Q69LT', M6YGE%I6CUR+PT/@X@Y''<(O\R244P\) ,HH/49N-"!"3][HA[%-D93[-4VEE MU4Q>2?J**-8K]/;]"YSO*6E-_'^'RR48 Y1L\3K4P.4#A""G)JF36B0<*1_V M5HVGM%R8[1W54>%+Q@,Y;5+U-(6(J..7@A3K5M+N;*6_0W"A3@H/4"MQ0[TQ;DC!)ES88#I^N"PL=QC/5]KGDQSXD<3Y^Y/CP6"!(S&9!6XD+RXQR:WDA MU,PR \E;NW.8+AVQY6,AX[V6,S.G9AWI8/$FT[ HZ5O8XU=FVK/5_BU_U9;< MOZ+I/LDK3/QM='D(CL.E6>G3$!?ZXZ0YK1QO8]Z:-+7Y#%>/H [+X<.?MV-3 MO4<%\Q+?32^_^F[B,H@)*L"J82I01_?#5MH]5SEJ^J^NW!M>^1*L>\NV;LRM ML#YE>40CZ-[7'Q\]&U'9D*J+-NY_Y?8_Q OL4858DTXT77^'O54W_KBY3ZH$ M&6OQH,I&$M1?E[9'LVRZ-2//0CUS&1V@?.@[J2"/& P]^9F+**D+I2 MR%U/^%YBK:1BBRQT2"G99#F_U 5[SXT(EGQ36A>C;R/9@-59X(%!2,M.A>;? MF KNL^QFQGX$<_Q52-1IQTE\N,=!8?"U+9]R&NN-AF!X*ZB/@4;/2\'U=/G- MR]"H%QU"/;G[*4QZ6PY(TX*O4Z$RKBQ*^U>A MZLG#;(IM45=O[LW2NDX(\6T98Q:&;FSY).,<7^C M9=#EA987-JCDOD6R+P8=@3PHG^9BQ&DVQ51+E(*]?]EZ+VO/R1%\(M^L_8JT;, ]@"Z9*#$)9_&[7]]^=)_FN4Q07[G8M'Z\6V-38 MAGQ6G5AP6A*M.TK>)_E=(/8=ME1-1ON4"F^*<$1K9D()$+%2\'6D80K=N,1I M\383([VTT'#8KAKU;F4]_!Z%-68E U>)&FWLFD[T6NWB&4P:C(=V3TRGO ^ M%DJ[JNY+'R8+UV:LM;L[W/9B.H[T1V#B[T)PAPZB:3S6+ ]AZ#2>R'*,+UA- M[\^<'7P3TI?B)W17L#JSYTFPM0J[VPHCX]X@*90';9R&JCOT&MZN+A>\C\H\ MJX:/*3M'G"70W&T*BEO 0+6%P+OTIU.KET"JOV_(()I!W)AXE$=;+0ZHQ'AY M(I/R!>'.SE+XE5C]TD8D60 M)\@!9F;MG9\,#$];(V(]^=5CM#E8&A_?MGS[EC/NA5'+7_&N0C-\__#8 MLU*S?W*L8;KR @Q7$/2D?1Y7;6UX?W2)WE:\ST3S/_S>BKQ>"$Y0#\,O>=39 M*^&)!T@M,$3>IC5JGI?P@.[IPZ_VU!Y[)+U)C>YS4X-T"TSAFQEHC9U#64SI M@AI"/;4S?:=36[*/5;9\B_1SA73*KE_^]T;B!RQ;CA3=-Q.) D//?I<;:#A* M]- 7[;NYLZ@7$T@\I"!.U],>3SNM^W'5_+7X=.Z/>6V&E,.K7%K'NLQQ M.FX77_P@Z@H,^R>TJ9&B4_;(\$ZJ*:\%DM8O:EH-0][\RW%ZK.OTDX>/#V^H MF(U,HB:1\1TP6LP*,J[8/K!!H\5I MD35P[N>#]U\_"@-/5)&10E.R;*Z==OQ$U)=Q=65?@IH5XV9Q1)A(MWR_+,I1 M!1Z_ JMU&^<(/U]103&^%)OOLA>?TL8_/P']7DR#4)X6[U"N%NWVB)P(9!K% M45MA,A8"4Q6\9M=JK84_C>2AA:((B[(TGWD'V8 :?I"Y";]Z1GM %9W%BFE# M9QSJ1+?+@8(V ^DAV=;IPC0/1IA-@]<50=IBUY83K]L]8$D+-?0#!]/]H'H# M!+[]/7NPJW<-RX,6#<8#CN@%FZ"3KO+@@S.F=N: J]L_X=>1WQUTA-[?]OF> M(^,D<&]%>**)KP-&CI/ >I_E*UV#JF,B4?,:F <,+VP;&!A2TK\SQ?;CX^/^^Q]SGN^:Y^]CW_,=>6^ M,[/*;]:L66LRF6D\=_Q$DDN\] E%1G?G%=!/IZ4XE!,T&,%.!APACZM/DX$G M+#TZGSU![&\RO2?YU"W"G1',MU4^,?-/77J;;G>S\0*5S[C[(9N 3O0!N':9W)CH/<^[F!>:#I:EF4>8ARV.PG0???L<6Y%I!!M)Q"/3=ATJ*VR5D M(!Z1@QCF F]FB$U=)41LIQ=7#L/9_9W?-$AF> GI/PG^3%_PY85V8X'VAX,D M]G4FHI@>)QGHS:60GZR&DD10=R87-W,F1;)ED8I?R< #T8V8,"[3K1(GPRS= M#C^Y8NC*-73,%,;9SX^N3FS%]W3?5+]KGNDTO_.5VVWWH][ONHO):S*,NS/( M@\)C*\.'-C2=HR1*3VWJI,)6M[5/1.M)VVJ>4CMK5;KM-;; M@W-B'Y3M*9Z7;LD<7=#-U,O6]5SW?S.2Y<-H0W45]8EQ\BRW.P Z];$(]^8Y M)LI(;U!)[I6NHP=43"G>J0+M+)-Y\DH$[?&KS(FI2AP7,"&^"&R^$H0,J!50 MD'V\@,*G@#&F,!0IR(("^J$!!$[.(/K Z2PY>U1=/6&I8%\K\=JHKO9 XE#. MNEBNZ1"\^EYYQ527!FXH[%73NXK@6D6W-Q"G8QU. V@G@167R=AC"T=#$PX& M5G@DG["OZCJGC7\NDOS;K3M-8"L3^QDI)\AF7^"3F]9.!SVL#G2[;>7N7YZ-GR_2]/-QQJ6M.2 MHN7UBTLK^JZ@%2$:]J]D)8BV&5]A8.W>LBA._9J+]P8ZV5NBL_GJUV1S3B;F MSRR\]Y1KE9>Y?U;1KAJ,OY4N108RC"E6V."))NJ"?D1FXH6YL-CZ#=,:HL57 MM(6^0?!T9$ P]56U MWM_$3;DBA P@XPB]"/MI\!S%O#E)F@H:GLB_87FR_E F,@ 6W'E)ZFE%]#Q' M3$H1HUW#YQ,P/1%"XIR->YWLYT]Z[D:#<:/>_WIJ+OQ8#=%8BD/L'Z4X4KHW M9&#*X=_M1W4?&4EA^]LUQ9#=XU_9^W^L1P:"'"G.&2^3+I#]QW& F R_[R<"OSODUU/Y?>G, M0O%J@JUD@&Y)K'+2=> ;I7[;SQFO_#*C7V;TW]^;;V)"E,4=CS+1+0FW"2-* MOK43Y7_.=_27%?VRHO_'WEQ"_$=74,"]"(IXL6934"O#X1V#7J]+RMW"51N2 MDGDST;)=I2]MGZMP"S'EL&\S/5J]&Z%Q9OT52*[2COI]85MEZ^LSUI,8H6&! M,:(A.+-6(=,PVNB6W-VI_>@B3Z^.H*XL':H:(GLR\< MA8&T?[KF S^]ES.)/D1BP!>L3>I%RNJ%&6851L(AVS7^M]8[/G?WE.1'RN2> M7K1Z?$$Z[?&,6Z\QCCVF&1$*H9_!&^? PV^ MO#>S+V)9XFJ/L(=V3MKL4_]DB7!C+8K$"LN^B86LB&6/.-HY(SE;C=75/8X1 M($3M_/P0X0]Z$ZU+&RL+Z4]XT G7<=Z-B-!TH>%2),T$;$D-IS9JK@?-G#!5 M?WO;HLGU/7/YJL-=&,_YZ1-Y&8D[Q$A>P2^DG^;?RGY81!.(&[\$P??X3;\X MC&XLKY^ MB<#8#+=*,'>Y=4G(LE4B$R*V? "LF!&SW-3=JCWN%Q>^)_:SE:8/M:H$17,+ M"[QHTZW@2;Q39X/I6H@<@W6WD4S7@_*KQ;%F?K7!%\;?]YR8B8PL,1\*D+* MGT)AQ4%T27IL\D_W](?)0-F]X$)FT92H^]5QT\ZWS^WSCE&^+A'_3.. ML_E&DQSY64W8C>9D2SZK=NU.. MJ_91$'C)L=@B?2[;9YM;J/_4XH?H_Z]+*W^-^N^[AXR_:V@/BUZDE55L, %#0#,MI=#SB_1*VG(>Z#<9 MI0FWDJX3TM=JGYS>.#[G?1M/D$VV9$E5ZW799,8,/5,]>LTV6FOFPYZ]GF,2 7R\'^2K+U=_3BL?/M<2T*UZ7^7,T3LW;%Z$ M TKNTC=+$=$/>D<<^IV564N&O58X3C*^>*?CCGOV&?%Y-^Y1F'SZ%2TBD]S, MICY-!J+QVV?P^PDF*9+(2F&4'T'STZ06JVN/%!^8/^UN-LZ^18*Z>8@GHFU2 MD4["SP 87[R[J*F_VZGD=OS@7?\>2P]+%PW -YDHQ;2,IAEQ&*4)F>Q=O5M5 M49.RJIB<:),D46D;5:EVM6#UND^/^:"R.#[_)3Z]S2@13I,]"@LT--A^8;1B MJ)517=+&# BR=JM>VJ@1J>T.![9XP9&^%M\2WFA,00Z;X!.,^B5.AQ MK@["(\2MF$4N]2PEF&_ 51BPWW8:<]^\5IN^0>KG9/ZHUK9^:+WQV/7SBZ:5 M>Z>H/X]-EZ^0 9Q@ZQH#HE&1#( 0$+1_#Z*&TE&W7,MP=D,[F!ZB0 HT>&7S MR7-,_.J48G:O&[>BL:BHTEQ"RL:[4]3O\?:X(T2ESVN2D.NZMS[N M]2T7Y//<"JUUB5RY3VO49NX--AC&+TW/6,I@3V-+ T )UXI"6[9OQ1CZ7#WC M::*0(A4*N]I4S,.O^SR>+1;I^3LP431-+>U=.DY67V:@B40*#@_ MSP(2PZ3I)(+=3#E2$3Q'RS^-E ZX#LRSD@'^=]70UJB+NKQ:@[41"EOH4E&(8R8;]5AQ#WAL62I :ZAD3:R!,98=D MDV#V <6YHD27O0BQPY9E+NX(>(7O*3YGMM8&]LX%3BIO?1J* M"SFBG+S?@5B;!6$#%Q#CR23237 (A'E96F7AY^NCVAH9; M4?@3DR@*&A9-U54OO$3-(Q?RE"/!E ?\S$ M.;>AL;GUQY+7WXZXJ!W9#J9>5"I;Y-0#1OZC[%-'(E$4&W"&$7;/N ML9NI!8>=X_!&."K2*;@8=CC2>J#^P]Y0*L?+:@3RFX]&[]F83Z-52Y$KH*M M+QEX M(AS:!VUF/PJINH51TR@#BC=]!I=*@&(R&FC^,(I,!17^5VH,,G<[]( MDM1Q<@F4]E#\&0G+)5>E)308<]5< 4Z:J39=SB3)IQX;@I\:'&[O&A"_?5B[YBN MW*;[]:1YB8DAGXP'YW38;*\]>OHQZ''NX9>,A-\!!?\%Y0+&L>WXOE>PE\-* M"E-2=)""?,?7EB.+O:K5#:N!_DF.-N&. @ZV]P696#M"K/(X&:*'IR#-NJ(8 MO<=>8#9G2[^1V^^F)OH.)HQ_7&8Y)6!X94'HP65]K4//;!YU 7H_,8E;L[7Y MEVH-9?6H+P9+:T>U:Q&R#T;&W-6LT_YKJ%@<8J/J(0-_>=;\W5Q[#?Y:(YVW MSCRSJ,A2?_GA)O2]7LG\ N&Z8>4Q'O_P&]*[TCX'71,^?17]E$TWN[$3!.VE M ?]$4F.* _.@!+O__FCP>Q5/-OU_:(O[U30AXEN\7==/)WX1N!;Y+^#8HW-R M'!\8J5*/.6#;)#I+B_.TRRSZ]#XU@17T+)]2]?^\$V;01\C O9@C<--ZG/Q3 M)? 4^C ^M6F(YD8M=BZB-/!.@(M;G,S)!X:O)^G?*T6?]3 B.NXDA/\^:9@TA$V:>L3MVRYCFHW,:^9>R_7$,QA MH.T*[&I9+EY&XGJ79T2#HY=]G@:;,;7[8>T#;4*!UO /+*H?%8[KT[Q!_-3. MC(/Q" J%N5"P@P^)L2)(R?8U[-&=RJJ*P;(H(5/'G2+UI@[JVL?:K ]4W/C[ M51M::8$MJ;\@?>IW^&LCIKU7D)-KCY5E*2^OZC'A:UHG!(+;"(:DIH9J592_ M3,]YUO'X16:FP=BS6D"!/V\CF$>);QKZ9!O-4OK53@JO+E+D?WG1^.C=VQDJ M$W?N-YW1SSW Y"5+5?@S8TD)Z$&4H1Z#'?6H\,FM_%PA-XIZ2WD[7"3MATY$ M'R"9ZXA=?60#37"F3AKUG3DZIWR0-.8+7J$I=.3PI6E<"]MSC7FG*9Y$.C6D MI!0[/VMP.][5T-[R*CL7C<0C%?ZO_R,'30+\ZJ L)+B<#(QZ]UKHOE$+']!T M"7ZZ>C_0=8K&4'&SRZ>'*#O7I+=W$)9 VES&8TC>F([J'C,!EL]N9\-^AEV?(XCPD<7/+/7Z?>2O[ M!UJ__:](!E1B6!#HMV#\%CQ9PQ^REYFXG3P!IR%>5MK9S:0DZ$A31--U M.,4&7FJ&@=<&043?&+QC3S!R\PA.='^/,GG$&'=X&I#>SOIG[83\:O7/VNK& M;=* )95)@>Y$B3'+Z"-PB^%>C?]U& M-9BU:'YZ7$]8:1VKQL!6JE]J#K?.1-NQ:X?$?4RX-HU&ZY4+U?>1B)DB&)14 MW4%) "TKI8E2R7>PB;FJBJTRSI8Y\KY5>GQSYS\U,07GGEKO=HO8\;T@U%,+ M_EG.-G^JL(UI0?"OA)ZO'EX@ S\+D*J/GOIKX>H_3QLQCN&F) _8F_6&1%(/ MF^J@Z]SYZY2 1=#BLX<\:%W9";*U"G[J2:7PWY;N_',W6JZG'>!0L(JW.1"P M;X,W:[IE6O[,OM)8QB[9]4Y0FRQY6,Q40,HED@1FI#\[$ M0>$ZGMM)EJ:/,Q(5.-RU&N,-J+AW7ZM&NP.2/V=B6ZM+&5^T=V$^MS3KY:_L MCZB,'/=KE%SU2%(L>JC9/B(8N?3SG-(0KH:S)YX(.(BC"5/NW%Y;3N4N#.CZ MYA, 30HJ7VT82[,^?WXS?]YFXZYFJ\*I\WN]ASE_AN>U/J+%?OYO=SPCEM.- MMR_+Q^]G?NI)G0MCE)^>'9O=2YLK%\M\R8CX6<*?JY"2E,L45CIV2A9:NL#: M()ML6C@:I]PI\'1]>CUTG+ #_G3>(FV+W=ET$%$LZT<@ U)=!'$6O=G5L1JG MI%:W5C<5;N1/8F]3;'0=!1/C(%D+YW:"U';B4X7T*_LDR'.>^J]?N%O=TNBG MLYS_L7GSW]7"<*A6,/O+@O>YYF):P6L%$('JT4\X!>)#*&+I!1!P?YPRBS>C MUI!S!CJN46#V"H]:[N.UD4KVV\,C1M35?C. R]L'OC>'3E5/$?3^-E&;T4 MZ-3Q+E7,(R?O\ CTFL[<$9W#TB&M*UF)U\>G3_ /4JVWM?8$>Z>S#A)I,5'* M='KL#I:GAE;7X%IPVT*=[+9")X$)N;+'WQPD; WSBN++IX3"ZKO#HL/'R_-! MX23N-AR3'K8[%:,7DG(I/>A@=7W@)-^#)7V7=H/OY2SB+:W4##M$X&4+74)A5_5E8D?_CAO\3Q+QLK./%B_42K( M]WK,-#2<)R8(#HN;@%WQAS0/+/!(OAP9V')1)[@NFXOW@>(Q4T%W;,)VK+0% M@SZN0M[W+-/LECE4KH^)J6,C04 MP -3;[8$5?=Z08_.IZ2'>+GO)//8?GM!/S1P?=7&QU+$,&]Y^781M[AVMRX M;\L@GL'KN1%,\3$-%RWC,A"I<=[MZ2P=T^^@[T\ZP&G#K_M MN-.!<7?VT-BS(K*BBAK^N1ADB#(KUM L.Z16*M/A-)3:3*W:#LGP/EK$JHMG MV2!(_-W5:%I@.]<4$;C))TJ06KXHDFJ_GWQO^P'(OC0:7*Q"4&CAH%GMW76; M-0:6+<^S4>&&EU,QX*-$_5Y/,"/QROOWN ,+$ZQ]-MBU8+E2DV73EOP;G3Y\ M>0_;A% .&X*.\B4";5R'U(EH/2)O&38I%;.OIX>]GB.9^?++HI'I:V6_'JBU MP J+F5D-TY;6"!7[<_TDC=%C F@<30.:"E;2M.<:F(\7;$KI#GGS4-RS2UV[ M(GUTD*KTR"O/,\^.PU^Z64@F9XTX^'J5([--&K*_F%T1>#PT)!Q]*I;^T$W] M P\5CP(X]&B-;LV0$B^&3HSAUK1:724N.NKXQ<0T-VV)DM3$YO#BS-9F_OL? M-F,Y2>4X$J7U)\:.A4_)$" MH=LO[&;[M1[+5H7(;5EF97YQIG.MV+ZUTPF]:-Y8(2W^^$+LK)!Y8+!1^YWV M2V?2LR:_4IO65M4,REZ2WUM=["@=F:LJC=86+K,;'UK]1.L0-I.QZ]%]BKJ% M"+)^BV^%A($.UEKGHB*69?.5/^<3KW.SX!L>B*R_JOIR(*+RVLGFMX=G'=+> ME>NX!3#@;E41KA =L'/!BU&8F;:;+'$<7 M'CQ0,$Z6WXXU&Y^XV.$A:W"F=OD=LTD[]UWVFZJ7GC(^?LB=[[ =<+)OK;3N MRE?74L(\_^@4K?)R7'6BK7(SB]C<%BXI-\\DYE&)DQXXVCKV]J)I($N)\A,V MUAPWHGOS9=Z0 YBTZ&/#?64&GJGLGY$W.&Y-&\%NC10>U)F358TXTCDMK'[N M6%6K]J5YZ@\K1!H,$PA^'V _LF_VAG-H.2FE+G,Y?C M/GHGTFJO$4PR;T_IWP!WS?#H=B=.5H$=G]5S+1DC1WCN]$FD3U]_,4=J"Y2) MV"I!/'MTT.7^Q]PXWAP-:BN#;5!4/2],<\HBDL-2"EL>,96KZ*/TQ66K[B)O M^S365V1ED+UNM]32W'Z<4E! ,]W6:NA%AQWQP?TU2M MG,X'?!A039#'Z?356&CH)OL _%*N4_)[S2SG4?JJNF&3UC5)QP$/M*; @6Y; MR;/T3W+TE\(FT0?PO%,[X?5"J.:O4CHXXW#9*/@:0SXN\ M71SDTO.B[2KX"8D#KXLUQD B/!DD97$I:+S=*)3-7#KA1DWTM]4AVNGT&=+Z M[8D++^#E(M+KF"N?VP9-DY]LZCK&E3'PZM4[K-@5JWLXQ;-7/#V5Q%QY_ KF MF,RF2V[L_3,Z2(8%A127@A=N62-ZV:.U,F:CVJY1;!)T8HWM3^YVI1+@.=> MIU,^O\C&5"RG_5VSTT%[@MON-4.%]4?QEM.6@_E>$2,G'H23NK_Y/4W_THZV MLY;%:0CES^R:O788K#I4U7U]+:*>F=(]AW.LD4L)U])$ZM-B4]$(.@ .62OEH-BGF7I] M+:FW9H QD6:D0%+G\,9,A-UP@GLN]$3:VPM3#Y5Y]Y,\7[C.366OT/C@_)HK M?'?:^&@TDC6,A$OEAXKG[:2%%#AP;3R/^5KUWA@+BCO/%1[ BS4C 80UFHYX M'\OW-"4Z; K!!,%[MU6+^XSBE(:9S1:/TFB&QK[>LWYI[[3O787WPYCUL()# M5Y7.9?9,<99<]'/JOWUYV,7)XQE]EO>NO>A,]X2O42EETK'7Q(9ALWX[X0)$ M5RICQL]CV^]9.HN9(?MF%& GGP&IB'QXY4G MG,D +URK++ IQ>5%E?X:;WO7???F0X:!=^ZJ&$AJ S8:6$DH#^D3N P9N :_ MB8VK/P;C;:NVS0[D_^JU9'&+>TL,]GBTVQ)0JK@?P=]_6*?&)FUZ\V(/1N^Q MYRX1?*DPL)3.L?9B#$>4T$7S(Z-WSS?E%]$28IO>7K.OE_4=G.K2-?U^'R-(_$;)$-_;">I^9(Z&="\ MY.]W>X>?L5>RUL!YRJ3TDCR4>72L++^^2/BUBS>]N'O?ZV;H#:'X&\>/]])\ M!)6!6V*"01R%2BY82 L98*G5QJH;]UI%DP&"R5K&@$O9LZQ''[0ZW%TQO%@L M,?+32\D':?#/;Q9 ? @'\(C4I'?()E-01"%1[J&N:*AG/N_-4NS.]OBM'?'R MM]?RZ!U/J(H]5>,+L[JQ(KC9V8H\"F?%"3A?@)M-KE"WR(S$NR!-^R=K'^' M(\)'"#N:6-'@6D7&?,9$RMQ[+<2X,G[),+K[XZFD;' \HI1K\:^G#)!GX\4SE M,<2/;Y:)G&1 8)<,1)&!!6GP<^(U,A#7(K6WB=K,"6(S@, #M-@,-(!_1&&? M1Y2L$9.D&,C L EX4VJ(FGI("ORY! M8\C [G$K,K"T MX_#7I%(8)0 (T^TF#3I_I;Q;PKA!B3DKSO%S/+Y_GYTQ=$ M^VX.8KB29-!+H_OWM*>4@Y0,,B=A?X"82_V7P\!N$C D?#I6BB:CD+\ $S3((WBE*Z-KYH!7G@[<%!\+E),W_-[5 L?\74 M:0Q,KD[T:EG?YM#SVSX7RW+,GL^:3TZOB!T 04YL':Y_^Z[Z0;)M9B/VB\G8 MB-IZ[0I?K0Y/:73+BW;J)#OAL$5MH5Z:"/A%G,M:,Q,M406?@!FS2S 8S-?PLS.4-TI=>':$]3M7RYU5G7.'FFP=LKK/ED>9JWRJ>79 MBOYA'1;M56VY.&?L6F.2LG!R\ZT)KKX5HNII:Y%\]B[\H:T>7(:2&ZFV5*H-L%]^<%YW;9C;_U (R/W^&1'TC'<65I M\ND"6%)RX6CCV%3@C>+H6<%[UF<*7E-'RYRBGD/1SX_:MH77BR,/3@I?1P;"+80N M,M=\#4UOL49_>_0U"".]T7W.D)*N[,=;:.K^U6>\WE S"AE( : MS%?K)IZ@LA1*^F?[%@9M]FT:VU_;7##MOAR:!A\#>Q^;?GTWRKH10C>%I_.9 M/NGE*D?K61Z+;^OJSI?KB^$UG5:VUK*AHC\XB?RZW-8)4==^,ZK[U@RM[4R? M7#Z/:W+O"Q1RF-5Y5RY#?>_:HV&''M7;AG!IK.?$B50+!*T#M$ 7J6#D(L_J MOLNEF#56.>/6L:#"?T@D]1W^S30F(,0M8UY9&$L&B">WA^6KP:%;VO=67-<. MG(@+ERA=4M3D;V1N^RAD!TP+]@50CZ$7]K(C2G'\(=GSMSP:&,IC,IP2%H\M M[/#2I@C[2&!N#P;2,HNHL:"]'XCUR<4C%ZW<1@OFJT5>8+ID&!2TWY?U;RYYC3%D/16C-XB<.QH.4"L_ M?BC9]U=67;Z[W.SZ[_L>54!I"O_?:LY-B1XB7(>T2_)B_R\[-G]I@K2V%U.( MSNW6$O/]8G-!+/AS@5_TQ-8:"(K3W*=V0:QED(&6X=#O[T_:N_7P K("GTEZ M5([:Z24#4_,$1#AXGI<2:?@SD22KG4Y1/__#FYCO*R^]>?6K^;]J\T>]JV7/ MUN18[1WIBTNK7IA'BME6@L[N;.7_@=+\'V]* ;X%H*=B]@Z/D@$T):"+R%PA MG2(#+UT*]S?!^.J%MY0\Y0]OE/]0NR E_!>!_PX"ZVB>^7.POH&KPZ65KM:5 M*LKMQ<7BC\SN=XH]OL"-";DZB\*D$,^1 ;5+A21Z5\2N ))@0@8ZP(.HI4C0 MGGXB3C@@L&GWNAA?4*(I5Y7A55T32/&PMB09>+1+P^5VF/I,6V.P&-71]?MZ M*>85.BE71QM-'?WWEOV+R #], :YQ[R"P%I3 I<.-D23'-Z>],0/0N0:)P/K M&G ]#7^%O:IGB-Y6Q"XEXA*!*^S-)9"!WI1DD@X9^!A3#OY!M!B\'8J>4B&& M8IN!O$B25F'8?.:^^2?PO#68F$H&$IBV>D3)0(:<%#&9#"2"[OW($H3M"N"F M5. ?)@.'%<#$. AKG^;W(H"6TO4H#)T@NU*4@$KY"QD(=L;V[!_91N&EJ\C M3/B/(M6+OHK9\CA+H1E)80 E70,/*R%)3P91ZQ#2C;\/!-#BMSMD0)TBUPR: M^ Q1X />I\U!S*"(;PG6).[")O"F(*5#)UOGR$#\J3\)A$\/!W_^U$0*IDC5 M@=JE2&*^CMAC-:0\(78-MMN(YR#!B'G-,C+0$-5#!H0,?A2)'7>)#9'[/&2? MWIZ"(&+]#JEJA@QLBF11V%$DS%SY$^J9/THE-N5+$%X6%"$6LIGV/ M#C(PKTOI1TKD/*LY]B?D-7\4S+AYTX!48 ?:E$:2*!-C1\A_LS'8.J)+VIZL M9E=KU0HS=%XA6%B2)H]TZU'O-%VZM'=S[9=I_3*M_T%^YO'.MANVK.YUL?9D M)XS96$1C4%(; O>9VS5N&?R/="D5!]M+'1T?:1$/8*BHO,+-(I_A3A? #R/= M_%.'_V^%]M0 68=TDO4>C89<4X>^45 MAA7,1/=S#-*K:#,+.IA+"7XC ]XH7^)B83;BSMHN/;Z$5$Y!$[*E:LS'WWR][UO_!WS@A?6]C8B@B:3RWK$(Y]C_,O>H/ M[M_[QR<)_P0$+'766'==:JZ7TP4BGU$Z+!F3FN_$=[X :4^/]7FR&OO0XU'< M3I WZY^72/6IE?_':_>_C\ [WY:Y4*$!5X[%U@E%=Y2B&/TCR@A)6 MIZHC P6>5+M-E-D-Q$+Q"(@7&H:_[WWZNU;+?U9H!L'?_\.P!LJW:(J."9!H MP,[I#$D2Y3)-'&GSEWR#4QJD7%E,7@=/#'$?4;Y:%&SGPP:E.G9:K24W;#\! M,<,!7MJ&[K.5+:".U?,N<4Y(#BA!)[]>&=#%N43E+FRHYESILO]G$K,*^B7HTUWCQV_.W>+/6=+'WT=R/Z@>VZES7+,I0(9F" M=",V,+/J6LEG@M\89;(CL=F12A3WRG )Q_%ME?0-\X=_>H:;$_DO>91N+>1 M;)AUCIF(\.-+;3,F+YLSV*R]:E<:K-/]2&R(T#+HPP#Y7KF:_8O04'YQY_PK MVWL3VH=2(&<-[KUM40C-T,K/9"A1O/NU0BA\F:0 OS@8( )7J._?=#'P!'&8 M/?+)6%)5]P_4CV1EJ\W9=;_ZON&C8J2'RO'L)B3;(IA#^0*LR;QTL" 3J_F$ M#F;WL9_;1&*+07,F?AOSX4.L!J&2]<+13N6SNKXBR=,V-;CM,HQ.#:0(8C*F MCG#XIMNX_7D]7P![MN-,M4SD)-=T.9*=BCH] M3H[OG(NW=!S?\1&R=_=+DGN.R\60@=!:VZR%"M+1(0FXXO0E2?=[96+MU]Z' M"A]0?/9"4YS>WC&^M"+U$4W]K M_>X1ZRB(D\!E3-]K^P_K=J)4AU<1S6"^6F\LP1+[(B12F=?$;!26;%+6E^\E M0=,L@3A4FJ ,[K^<%%LL__53S2/_!S]RF)>?.'Y<"N M+_*I7ZZN"NWAJHSB8TI_&>R5*)QH,[W,;K.D#DJO^C#,_K;^C$@BC M"VHBG2@>DEPNS;^^9)AL>*R=46E$PHH94#BK&U/UV':0NI+Z;0V^:*J'Q=EW M%MFT=N@+_G&G>HTSW5<]\Z$QGHW$UKY!>-OBQ/EX'UCVJY]!^SCOYD7"TE/VMW84(#JB2MOT0@, M-Z"8Z[F=TT]$?-BNY\(Q!9?EJ[F82'BM7)V^CKQ6^:*BF_U5>9KYE77.V-/, M,LEWJAX=LL=Q-DGQ]#A/HIE'\"'7/BL+X.^;YR5 1N4*D#FJ;A4]90*7U@[8 MGCQ]8H/[FEBE=E+[8]JEJ]@5*YE M]JF<8!]W\/U532YI1E[W"K4M/FS,:\OI6 M/$"LB;"-$V"1*.U_?L/&A?G]A_'NK(<7 \Y@(2U,X?Q4N-6$*=I:! M;V;A1U!8[G!=M5#NL7NO7PQ;"FP!;,P#^@[L-)*XDE6QXZ.%D4H: M?EYO1F$/G-LQMUTE^/IQV954GT\&O;*RN-EI>R!#_)"G,@T^,=H7UY6S'!G!O'@5U''%AK&0A?F;B )UROH+ZVT#%[-& MTPN#FQ :/,JB3V[?XT9Y/U''2;*TL\9";<_QDV0/72G+(0>]E*+ZH(&>$"Q' ;Z=/6-V19VXH<)5W*G^1C:B8#V AS M6 U!QZ*BK[[!T6OFFM)@7$5V.^&+#XQV?55<^8YE,@:T2^N,W,*1@9)+/M 5 M'RP(@M_'( \X3O#7#MR;ZX7?R88]GBV[8*/A!U/J6DQE7I^#?3C!6"7P4*F^ M9QN+VT0=\T($#X-*RNN8FC=++?1TL,2 D\4PR;RP"^E^):$KN$@7?OM/#^;D M6@/Z0&6).RV%7ZB;Z\'8I244_=8^V**L;^M\7MGAZ V]=,5V0T_MJ=%/-9 " MSA.QM^H?E^'IIHZ 77+1D1(^;Y#T79-EV*G1,!N"526GCOQZJKR/WY5SJ LD M_JVI"LA[=/2W_>1Z0;B"A5E3ICD.%)W:O)U\^!NB1+BH^K%+O$)5:L],8L M+;QI)R4JJ+EH^+BP$$IFO.(RG0IZ%"" M6]>01@F&P_72KUS)M'@+/:)\>:6 M1_IM4L96Z+VY7\7++'1/GNL]V/.9## B[*38X"?QB3A+$-W$_ (VMTT^'J*9 MV2D;-^Z8TAQJ>"N,0R!=/9)UX_'9EY*;QVKH;'R]5RNLC&GYKHRTLWRGV'ZHA[^($E5X47P41)*9S102BLKC_K M5$RHEUF4M44%%IW*-Y&C.*[K[2=8>I_F@7#:+#<45@]UG'@5*]H, M88'SX=NF)'2:E07K^Y9K[[R:<-HIL;C:J\LBT4PUZ'/6;(I=F/;!^*>^]^UB M[8<+G"@F>!U-3Y3 !V(WVA! :3ZX84*@5RXQ^6;(C<^%68'Z Q;H$TVV"HXP1''EPZ1FX:HT,=UG,"MV; MK_5@"92[K33]RS;:M:'W2CI84<@0XAZ"AF@2O*8+870@<5?W%4C8)*D^&- 6 ME"D^I19T]HKV??^WU"V(R0Q(62*JD9)CP97QUF_P4Q# B6E>:^I2B-/,JR7^;:MG";<&"7*X[TQ>!+H"-QMF@SPG2K'NB*M MEF0L%=^"G>Q 4G$\[]W'J3]\?&P"BXE"%K>U7"#)P3JG:!K]_1H^X.?48U2' M[\$=G960MF''-+^9UJH6FP"?7 _,V*RVCQ6](@,-YTG'G$!'B=08,,BA&#:U MT^CK[(AU( MP*IJ-:VG+VSFP#5?+<7GKV0\5.DN3VA_W<+M=:?T!*]%\&%GWDG1IJ_>-_8K MY:(X*=ISUY_&EV#FFE*]2!,)S1.GD]9YOYKLO!L)NGG91C5^,G@W4S R? L\ MHK,M6+G_S*5>TM(!]644$4I4]7N0SEOW^-OBJIB$4N1(T_WXE?$^U*P@WFX%=Q MNE];7UIAUX(]WUHC6102YSJK?4P^3#X-.G%B726Q*#)M%M&(P;$G);A,^9LU M@$?JCS[++<,,-BURE*^JZ(2M*+U\^^SD,_%/\]G"L!,Z6-3D_G!( /MB #O. M[E7U[+<\5\%!*0'1G;Z+/LSK*KM/:%G2I6-]M^2@M9R4P,:/@4];UT8^V^+M[]O%!1&R]QY9$NE8O7I>M]\2DQ,V?.R#C@8(\4T MMI2\!S_6@?#(<3K+4Z \#5W MH&XV\;"JHPNS7QM;2(\8*M;N9X.4;(@UE8(H]H"-QO0SV,+P,@F/1K<%GKR+ MC6I>#&+&U4F?Q'%7!%E;E-RN^FAH2)LJ1SQ9O%8Y]D[]X0V^NROZ%\N2H)%!YB+Q8]=E8FY!CK&2N(P@QDM2\SL M1UZ3DSHW0[CBS>M229BX)=3MRY_X$6^,@89*EDF%*EC*U0T49N(LZNJJQQ8R M&DVOQ'T,EJZU?<^G%9 W%CTX>1."OUDO#0W>N.*5?YYX.=GP8MSG[8YMV]B8 M$\1M#=CFERW%L6>5EB^<>_8X M2$"]O?M^T6.F;A4]%K@6SF+MH9R_3^W1.]C:/<_B#-( S:W;IN<(PR7KY0"5 M^(WK$ ="3?W5P<\!=*.6$WAGO; [,8U[T! OA@-^+LU7^\8EBB71R: 'G!U" MQ^,:.EH?9&$*PXVH^[6GW:=3.URWB#NXD-TI/>+6^PYF5?BM*-O9U%YMXZ9'[AI M=NK#VQ:?\C(".+\%^:1P%CO\I-8ZS_$B7WV$=S8^Z=A0?YZ3M-"Y9\(.SV]W MD 'Q]OOXDUH''X"/D'@T)WG]#6??SO#B91*!I3/ M(M '8O":F^A=7" )ST;%1!3VU2.2I/;7T1C-[SX;(1K!;RC\(D$['S)_J?-+ MG7\F=8ZC@[=RQ<163+Y5WNYWK+BB!3[;Z3$P?FOG.YZWZ[G[5R3+&"R$RZ,U MHEW>?WWS/3?,[=( 0$DN=* G! M2=J%8C._^YR#^@MN!M^C\_ DA52A-H54"T5A,^*I/SZ>@?Z.WG<8O3R"P(CU M(^9PB+4D,D#ID^\>4K_#[YP'[&JBBR];JH?@!+AAS2A=O;F MR$#D;[^*YTY)[7'!%P:_ND*C(PS89H.H./( 6# M&"EN9@E)DC;Z0>(82AC$0@9ZJS QQ(.4GHDQ^#>2 $4D7E(Z2>B_15!-H@T9 M&"=2D\Y"]_SPL63@!ZDT?Q";X@[ELL,0\^;8-M(!W7\_&:H4)[5/E\Y%!CYH MH_!;(!S%27E@F? -J(6U*?4_"07Z46Z*)QM*%Z:\\6@"X6D5R !_)HEGH!FU M*0FS)@-4(A2V@XA6O?V>#^!?8/X3@"E\'FR+9KFV+N9L2G^2D5I;%@]U"]5; M,OJ1KF[9_CLE76>A;D\]IJYO\BO%8]?4O# (OP]SF[F@/VLA@U@-H**,?H7] M2T0MQ(\^(9/$;=P,V3R+]R91 F,R@ M/_;/>/^I!"ILP:,*^!QEHI?B]/RO^HTE,BY+F)D&X0,0 MNCGD3S+]R9517/"/-O0GDXA$$I /$:T,9$ /P0+Z0:A3?Q+[S9^-Z!>8_UI@ M/E=8+IDZGVG/LQ,R<^9WB[$231+@;9I@J?&I>L5M0.9 MW A_A#4<-&+?['&YP O-U*R'51KF!IFK.5*FY!_!\&B:JRV]6UJ:QY*%Z'?Q!GX79^E\W97%K7K >M/7G"KV5C9/;&2^ M4,H.TF@*\C?!Q]DP*SD M.HX0^(O:+VK_=6IO77^;[%2,7,M>=E5.[GKHK1/2&L56F?X2(K/WX MU2DL3 M=(^-:1Z+=\DO4VF?#M3<^YKB'3,.PC')2,TFDP["(_[VS&X\!OEYQOS(Y_XZGG'&B&CY(LIOY[O9 M86YYLT83E[A?8G;%2DM=W/9*[_VT:1SXA9OU^0A03(;X);LJ6^>%$?3F):6* M0/>T;'9Z.QZ9N:@5'XCG )&[[+^TV (YZ]_Q:YGJ7TJ=6ZDMID:7)RU/"VL1 M\DGL,1@^][;K_=>,%>C8TJWE^VFGJ4''?T6ST+!-^SW??;%C+\3 MS!X?J/&^HJ]@)KR?+<[H9"(@\!"L6("8GH+L]&R\?6>&Q..3]S>(BV?^YN_6 M?ZWLA6Q3U(F]308*1U";AL-&!%-GT!V+2!):SM]#R*]8E[QAW,#"Z_C%R91Q_ #3;XGL+6FMMV%KY=& ]XG M[=7-),5>*]^@Y:8O:CIW\H052.(M=;.23Q[,3!7/ASM*:$A&L9:O*!&0 MS#I3;]]H=0TZ!7PE+G-Q8*Z%W/&,/0F<+2ALFSB.S\(981#A2I?> MX3T:>0YGN/'5+'393SGG?LF*$]7FMK,;>"4MR4J5:',![!WM50N:1/,X0]A> MX7JB7#SY&"W 6DC-]_V>#&K^&A;V*=RV*5MF>GU&S3K=R^]@2-VCL,RUU#-P$ MH>IZIV[OEC?FR'QY6$RX298,V*J]@++!M"5$C;/F+;+."0K\INA?O\SQ MIJ*BYXQS,B08Q0$7G#3K">%G0C8:X*W,.FVS8 F&556$!ZE.A/(K0Z>9DA4O MYS';$"Y;/7S]1I6>"@5JTS5N3@I@*\8B@ERVD.Q+O@P5H07B7@P&>G29/ M7NV5O'D\AD&)V+HU-1 >MNL E$._,%DF,PQ,P$^NP"DV^I='F[6'U,YW5'%R*3^M;@0&2 M''[X)BX[@L@\V1."71J *2[?'W=6/HEC+JJHVG'30N+- ^1.)!<;[<,\ M<\Y1*5AN XJ-= H&:N/1"Q7"]H0(?JY5\,O\,E]ML3R,+1O$%4<\7YTI#_I\ MX\YE1TZJ%V$>I5+&V+D//"%/E*QQ3+=J4X;,H,Q.#RK*(ZBE/;5*" M4O\?]MX[K*EM7Q2=B(!([TT(TI6F@J 0"(HTD:IT(2HB34"4*I$@"$@7$%!Z M!Z5$I$/H31&D2:\)2"\)-9"0W*S[G;)M3@'Q],V1R;:ZJ(D)NJM2XW&[ MT_I%@MJH6-CG+W&<]FH?O1]ZSC+Z"\_X%-T9!4/0#!S@J^A>MJ]Q.P8A&!NK MKR=;D"FOQ<:"T8^B[QS.:S&PV0$35EV>&>.J>K?;DMF/TH/F2 #OVG.!>H03 ML\.,V.O>O.D))\7!*=_'&R=#>-YRGWI[ W]3Z7[0ID PAFEN&6?3*-B4U#I# MBWDQ4R;_T%'@U)!0X,0$]X]79C7,K0?Z%FG58 MS+YY&U&+3\M:]R,F8FPM$;I]RM%@MMKK+ M -T@JSY @.2N5)G*,KY'6T4L9]:>L KQC-:58$\*]ZDN$RP,OZ"XL+&\OFB M<^RU$;\23V2A4PC67FURJ6-E6>M+VOVR5P)B),@[;/@+72L%RQ5$5"J'_>0L M'>?L=6;X>$[D!%]W\+/(N73:3$:=1HA/B HUA._KG,\]W%WBW3:+#//MO8N/ MUH%&!3&&".H1UKDIVANP=]6PA&F"/NZ5/[]#G=V"TJVCC9&LCQ..7OL*I9PZ MO(XG$HTU5>_,$-Y<")7*D0+/@$) K)6S)\<("EAVXIF(EI$!=5M?-(/2]K/" MU2HC%VHVAWOF&\EW#*/7P#7T^#NR= M'\*/JFO"9\8F*RZY*,?>G3V_15'%RN=LZPA,?,)]0.MQ=8SPRD8CS]U'X5^8 M&QPG?7#D_;9ZH;Z-[V;_%$W5RZPW[='S#K%,B?,^9[V?"7 ]FMNY,%* M+P5$!?D@K;10:;PJYGHO_*1BD:7V C>[W$[?B))]OWA5@M$(^MC%OAW$1!2! M:>OL&3##6U50T[JZ0XBA"]8/[>:9J'#"^D'7,+-ADZU4JM^R<)_'=/-G.J5[J!7%KH+S@2*I0,7S MM_FTQ0*D]+!%[3/\55B5F' PCYT=ND16(\FF;&CWA0NBI%+7 1=K^WX#'?M0 ME/;^[#.F_Z8U.5AW 5(Y#GE3UQ! M.]%,Y40_]9/CK,M?PA-E6C$TP;9C^\G)"VF MZOY<.+0*:?M01(!B;;*P;.V-+!BS0*F]E5UN%]':'WLNCA5KTCO"D/A:Z<5G M@GJ1)[*XW=X5?*OO07+A1<:6%9/%8@H)W#A)[US'_"L%6,B^L6K."U: ,D7] M41%[;X#NBWPU1GW&)RJCS:H,C9C*@RC9S9D)JP8_RW@C ]%W']NE4=7!Y@G< M9Z6'KIP\H4^;R22%:\!Z=_H+'J<78)E>>DA*ZNSI6NQ^G;TS*E+6,(BP<2LK M#/U:E?;((_73]*)@][F305WE^26>*!) R6\ #9GIWNPR4.0JL[)N^&'T6=.B MM0?;.4@1M'/IG(HVQ](^B,;3QY\91]G*Q65ZR=I1\$:(J@9E) BM4UW6F70[4>]+S@3OAM!QK9FRP M;21CS7@TQ[L; MODT"@BZ!F)UG6< 6%<=)=T;3NSOZL%;CFHFY,;;N_ ,"62^WXE=_767:@],B M7K=<.H;!U_O,P$;S!DP^ B,C2^W/]]^C\,[U;\NK4^X@H\?%TG8^B\@TRU4Q MLC]]\N1\QN^6YF]7$SCDU,NQBJW0$$O5+)[D-D-<6.[$74WN#PX+NJ_<8[]\ M$8]5 ]VR@CW%N?OFK/%6-K4ST1GD.0R>\E1>WBMZ%-CQM=EB2G7L*_C^Z_^Y MF+ZB,P-C-L?0UR%]HG.HZPB>XLR?:\J;K4$UEN[Q^M+=\]HU5#MO3EWIU+(\ M?/YMWP5G(4Y@[]YI)0&8 !\?'QNFT+"/I8'RRXW-HU G9EK+6;?$WK(8T>>$ M:5\$9]VG\"$B;3TVXD;EM&.!._+1(S>0;R>V\D5R)ZE$K[JP!C.LG%%+M2Z]QI.$5 MB3/IH.-L(C5NJ(M3";2OWX12=HXH46]CA8:9G[^Q?>.;8F*MS@F6>OON[C8: M((/Y. DFSM0*B0"!"&Q8RCO#,"VLHX>CJSR"W7DB,DG.J1%TT7_%=F:)BE\3 MHYS*R#P:AO.>FPU#RN+I<6SS!6VG0O>/JT,]5?@Z)IQDOWYTXBWJ*IUC*EXDBM!_!_=& M-%$P86+RGD#*H!MY]_'W'!I%W^$>&= X*XFV"^F==Q[R&+32X_9QI?0UFE,X M8TL33"/^!/$6:8"6?M:>@3& CI. N8P@N]<^76@/PY6R,/&+Q:9&VG8U"=V! MK1=?,03X&^-HLL8&8! L=%_KN-"?GW =E^ VIZ+8JBH9,HK:PV"DD@(G+I6A MNYV#:RF7!"QEW]%2"-]_.46YF]_H-=#D!&7MQ9LA6AK\4*]F^"J0974_*IJ8 M>TM;GHQ6]:=E0\MO1/T,O3?&(#8'B&H^4986)W+%$&2*FC8@.+-93.&.^'CC MU_VMC75?N-CQ; T)L$B=QSU_9B,WWW>H<] FBV?>8SH^LTLQX?\CHU(V#/[H MV+:UEZF-%JF'TK,YFM2KP;(Y?[+H4C38#MVKA9=5[Y>6R:GD8@-X(N._)H0!PM)!7WF:OPJ8 MD "JRR0@3F[.#0^2=SMF6(LA 8%)>FP^17.??3X?F&-"6_%ZEG['9ETV9RI\ M/?G%5H1/3-LF<"0#/V-Z/K8GT-#8 <\1@4VN#$)X5$S[%@MNOC4YYB7R&F;& M0+S=GT^195:'[U./$&V\TTT1B 1$H@]_Q=9L;G8CH\1G"&T? N; 4J),LS#= M^(XCC^2"X$W1X;D?#WYDWM@Y TG\>.^-&)_M";\S[AFLQT$$$ H19@:I 47 M9YCC8C"WVV]/(LF^H%$>C,K\4B#P, M\ _\[[8;I?\; @]9AWID^O!45B1@NO8;9:GB>]GNF9M5I!B=9$ZOQ,".TQDGK?@G]M@8WV MFA>^6@Q]#>*6@E&@MZB6GTWH>)( 6OXAM5$)G)7\H9&(/Z.ZGA0+16S/^SYN M%;>P"CXXNX^;R4#IJ&=ICJ-T;M%JW%G38P;8"B:B3:FITRW$7[P.2\]JOG:N MH -E=57,D-Z;\ZKLTYQ4-N\XIN.+^N\Z +]M7)D8=B&=)V2VQ^_%54^Z%+*) MK'I_,6:?C/9>?[;Y.)14.9M43S7IG1.%;Z^<'/FHW1Q3Z9AD=< M+>:WM<&(E6">=[6HDJLLF\N!5\QT^X7O.CWWRLUED2^;[WF=^]X[(> DM>AK M5S45"+JZ8T.XV9\#>R8Q>21R1N+3I[J:RD'7TC??I :N+3V^2,/X))C[95#E MRSEFYWPL5S189:Y!80+?GKR?A,([?KGQ6SZ>4'PJ5VDQ=L(]7:6H!>F2/=:5 M31RR+*L(Q9OJ7G,Z>$GS[H&U$#5M?>ET3Y= ?MT808-<<87.N 4<*?'W(RAM)S!3"VMNM;Y#MK;,=2$HJ4"U >LTIVJ44AW.LP6 MZE!?_^ZUP))J*\RQ P^2;Q#O3!?!M2D&KD]\/5EGDY?7NU!QH<^7.?&:_$VU MXQ]Q'ZA"*#=C:YGB/Y#-HK=Z3 PW(K79V%X=:A#-1L<7.A1XJ&K3\U!Q\NFL M00GP?+U1)'VMB]5\JHN1^);B4\6N-4/G M#':D7,&4TX1>=9B\!7M#7\M/OM#2;:SZ48$/GF483OTF M92S[L2[NU %UH\-[Q"Y?3#!1&(GE?(DJ89QMV:_:MTP*JZBN_UR%M%.7W:+J MH3L9 TKD>)?68GV-)F@Y@^)^\H$QUJN>L[I@3+X@"JY/[_.70 MUNV5Q(G&$H3CD=)=I_VGUBVGIVX)VU_4DI=:H'P#[LADTLI&&G3-"./R,(C? M9@G5/^)B6GF)66[\=8[?[%$111+9L4O:X_FF/^PNE8+.FN1[NPOH M^@/\I#F6CD([(GS]Z;OFTX0HGQZ,L.@56-PJYK7ZL)_+N:X4(J>DJ762]?F# M.FO=]D0B"V:OA 2\WD15'Y9LE,H(AAB(&$CFJKW<85<7?IEXQ?!I%Y ,3&9_ MWNMC76GD(_;Q1G6]F0B>\N(L+"NO*%?U*C0YN6OZX/GYHHN")[28$/Z#(":D M8K&-XU%(N2?K6-^^XTG M$UN=?30XO[8CZK)GA5-3DVN8DLX$Y_R5:K/1ZK)+4BGHBD#%M !3TP=L"_2* M#PHJ<&USDWV4T[B6RW@'I,JC+8[AX68'RQF3%U'T936L(BU?#,Z]545SN6JS M4XP;V6B5$/LMQ0KF0'Q0G*UQC!Z6,RB[[V.$ ;?#473J?0VM<^Z7B]_D?9O< MO$ZG&:JL?;>:0RP+KXOC:TO..PC=T[-!XSLL;[CS6^EBB!&%3K46DTUVE^Y+)1NM 0 >^&2$<.-EW!R&AB;!/17SR^E'M+FG76/CSR,;73\ MM\\]U/6Y;Q9G?[[82ZC\OOE\4!2($G:]7U5X)8EK@FK-6LOE:F5=('K"RBK% M(K"(NR#0SD+H16E4V; ^]YE[X<#RZ M>[!CD^V4=53"BW)ZCX.NA5U*VLLXJZ MW<:;GKJ(6GAW,_K@0F?X"2FJ:RTO-LV>W Y@LLY&KA%YZ9HS,'$DX '<>8JG M<4)^=H,B;SI-;L..4.:R3P(DUQN]W]WPAZ;4^XY'39F9H6=Y'!I/#IK='MT[ M5=&K4GJV$G^C>9U55S"*0O#,B9Y+70&7= V-;X[9BPH2.0,.S:_02'L_K-" MR]6!]J&\]+*<&<>XNS>*.?("K#5 &;QQM3[5$E.UD O?'P7A-6$J6/&04H)& MP5J?;&C)(*<2,OE%CVD\C]4#+?H^;IT\V6U?H\0G[><,VT\#NQ\E^RH0,3:G MARL@S$X1A5!S=12.:N:#2Y'#0157XB?F#CMG"Y0.LFH,?_>LZ=@<6\5\R3!2 M-W_9V]*DN[5#'['Y9M1O]]0?O*F94BO E<_W!2*Y MT'PEE(8_9$L])\UM:U-T!SW\IF^N/(!MQ'=7A6B>V]YNOO^TOJSV*<6RO-D; MF,UQ3@4$((BF=!Q)-&!9&@<7D0/B@[M6&S>[?4\PB>A)%^N722H+'L^+/77_ MAO36_KI1O^URQ^GJB[8)<^?B57?7;-]_LC^ZE+..8S M3E6"(@04^L'GT W0]AGF"(WA];D?CP8V8.<\.08UI.ZW7_]9J6C8?(&/D,VH MNMS[S'26!^GMR)F$3IF9A"G],@Q/\ M(2Z"&%A& F8AQU'D2M),[C@>+7MTNHL$P$C OOP_Q_\KQWW=-NQ)@ @),";7 MYA?@*]?-VA..A!'2(Z'>;GY%SEY>VJ][]R<_<$ID Q]1[P,H19L%%@OAK:V# M\.4:6!L?L< 9RR]C-A,TA@>:W?"Y\) M%UH#.>(AVP\%E/")<)S=I-;T!UQ_T,2Q:SN\G[WQ@-S=T1#4IT#'].3:* !! M-/?W'X!F0O^ ZP]:(%8_@"R?AOJ1@ 7*_P2MSSRWCY&_LBG;8P/&[)7[3EI/ M&H>RIF55RX)CWL44JB; _VE&_S2C_WJM._%M@1P&+7H^PZYC%KX8+E[^D?G- MC_'OT\$OVY)Q*#+#1 (^F301(SC&S3BRS%J.+F,8*@L5"'W&SW^-F M=N^C1I" W\=]?R-+USP+O2+K*G\2$))?V!\LO]4=U^0G_3TY?!'^^;=5LM?, M25'VB7!$I,L#VC[]#&G 6_[_[.3_ M?_SX[T_$&?CESLOOW7)7R:X7:R,$U:P.? _&LG>!J&;,/ONDXRMX' MKCL"TINUA_,CQ72X[O/\-/^@HF(:H!PN^9[X%-Y?W29 R>F? MX_^YX_]V2O"C7SSKSG!%@[O\MX(,HVAS8S'O6[9/**_@&W]0D"/=?^[>FG49 M$T/J%:.- LO,J_[\-5C],*:PW:(T [VJ@9_#MQ+#GN0;CY1I"6MG^0J>G:]\ M.OO[9QL3,IGB8+XH>/!10?/6:U,0@S_;E$.2(N=^('%P"-6P'RM*$%I5N/@J M[KOPLV#&6PYG @S.C%IA#-J.1#,Z\$5;(>GT/\!T&-SRH-;'B;[,NPZ<2&20*L\*OOB#5I+? MIE_XU.BVY^+YE$?CW4H\?TM]K8K[HE7X?@R+ Z?J^7Y/?JX[+UTK-J[/Z%J] ML\KI7#4)K3XY$L5.@2(!ISR@W#[Q'73>\_5T$::8.T^7D^TZ6DXZ53.T)V?/ MET\>2A0$\NKF=5XPX,GSR<:C$,UX#G)ZX"U.SHOU462X M*8^89,))"9:VL]_NN4X5(%!) 1<9Y/@ M#O?+L;Y6IQ6MJVVT-*Z8G)5\9=+92@)V(O6A$U_;.R,6R> M>V_*#7A6CXO0;F4$6XCY18) M8B *MZ!F@;4A%XQ-D;-;B=,$__8JA9%1YKSVE'WJ!^QBIH**9I456%O?!ES'#M*9[<%'4I*P#FW>?%8YX/9S)%0E 6N!2=00(+ MVA8209"]CYIEP55)!F,Z8SEFJYUH:#$)/L_K?>M[ MH^VK,^>#I3?O&-*\MR(!>?Z#U3\/\4RO2MHM-I9F]!9MAR"/8E1K!%)',3&A MGD4KC;(V!1DY3DHC)5*\=L/MHK?<.VRID,:%@JX&ET6?^-)Y!SEJBLZE+ZL30(NUWUY>$<<&2F_F"8LPL-[+GU&+2)15,W0_*7-I(6W M#<^0&TRKP'G(:FO8 ^^[X5*PPWUJ_GV.H^;4AL@[VX5 S5,GJ1\'^-C'($T* M8?K(,BQ3"$P239'O<_W;[6'>+9,!U]VU^F_Y9:,!"M&^$J9G2NH21X]+5'KUQS'RTRJ361\V!T_^=CD6J+^:KD&7>% MD:>G<_4$63F-$A!YRYE, ,YBSLH Y&RYV%3D$XI6#"M9&,S'X*#\#HEU-VY/ M?C?YN;TQ7U;Y_I.AS,IMRF#\4)IYZ-DH)?_) M*QXEZIJAK1./E3S?:%!TKVK=-$^_H'DC]BXX5#"RRGU7O+6/2==NGBE<0*QA M*+^J?M@S-Y#'/CC1XO&&R]D0E5J>AY?H0NX^!%V('6E0"@<.EPPPZ97N>"4< MC7J23F.HT4AEF@()N%/A[,WD\'F5#NY1+@/Q EC/?@=$&!DE!QM5K)T4X"<) M'D<:>3_W/TY(3WDE[G,.WM4?K+CUX?.5%F_!-T]RP&:^&@#L$!.CAI/-GKW< M%]#(H1B*U,E;^:PC4"#>9C7-Z6VB%EGT3.6M\G1Y5/C/%/% "H0@1C:0(#%# MAW/G>DGD7GO.U:GK*__!DXFU.M#-0S'JU9NJ[ /O\LGK\3E:2T5:#836YO/Q M(2!W(S60*N$>#HZ&L\+,(VX,K&_2O(*YY[<+N0'&YM-QORY)7X0)DX"STL^( MC9!]^]+DVHS?GTB[U@5QV9K@ZV@JA[=ET*VETP]X3,/-AY%Z]MEP^]7[^]WQ M(@5.EY36GPX4TH\;Q2?(4^SJ<6#V8C8NXO44.WOMYY#$TSAGV9B'@_'0H4H' M3[J?@X^+=1.$?MY\_^C%I.%CEJBN*Y.]OET;'-@=D^-L^%P*46Z88)(UZ9A^ M=A!\VR5S=5])M[Y%"@-5.]-6LTD11'_NP3."9@#DI@2B%S26/:D[ C/#QK=# M:,%7T2 J&%U,VVW'IP[^9Y&.(+P[LWQDF?SV9Q8^YJ==6XQ:TP*W\6*$!Z.J M)_U[J_WIL-.C!$,(*_ABD8T/Q 1VZ)4<7CR@=V_A>/;"Q[K]J?DSM%X&J33?C8A:HL'[H8Z#\N'W7F!N6HH\O2.(/O*(%-O7W" MOH4IDG>KQ0'Y+ ?7IX<5B+)'1RD=:#>%K$KL49PNV2N7?SSVAD-$YMEGYBZ> M3*:ATY+Q%;C*N1?JG>4^2J.=_J!:K(?RJ[J32KD,_BEFSURKF1;I9<4EFQ<; M;\2CO$,:^>$MMY'2+S+'>IV]T1#:58TI? PH"@8 M().I=AD1 IDKF*5#7O;-ABEA"2-RNNAZ"*>CI4G#O(W!SX['.W)U4GR$3(O MN$E%_DQ[P(QAQCTQUCZ\WRU*8 M6%AJF'Z5*&:\F1I5_Y9RS4ERIWY?<*3RJRHES!\KVZ8"@D:@VA%/FA@)LH4] MHXIO>A+[%HO]THB:"3FM(?=KH8E7Q9..@QK/X.3F$!T(P,<-#6KA-T,M=?(= MBZ&W-+!ZBTW2Z\];6,IJ&5RCA:O?:'8=/'X5H/J CR\ HN_P-[ZKP$(GVH@Z MKGDDX*X9";A94H1RPA?L?R(!<5;D[H:#! P6.>$LF^SGF@ZY^@AN)$ GC-"' MMB=$GX./DA_*NT4&@I_?5OM??$GZ-U^>[N:@((2X/FH2,,9+KO=OB'IZ=L/$ MR619S,WB*2U(P/*KTM*F]Q?A6QR0=A(@AX^7)9>(.41NHC:9HI_*K7_KY>^_ M7F4P'6*U%ME9=TE OTU5$5=[QIH'_(@$&!Q3+5,Z_:/'_PV,"WSAZ3!DK76( M!&C>'1E^,$$. C\_PD>#"XB1M9D,'R6R T[_E:L#$T,(&"4VRD!VGY'!X+2( M:LXD ,H%.KJZ?&*_J-C<00'N_ -14K$&O70%AO]@*K(CXADM/]7.T+/^D<;8 MG.)K_JQSLFN2;\'XS"IG5=+SR!*JMVP]'T1_A$<)BSCI6P<*E]'%<9CO4M=L MQ32>2D%#6MQX?;P&PIVXZNZV=FNL\0]^\#GSQ-?"A-L;W?@ :_^ZM,E1F5\. M'1IZJT^VS8UII5%D: /U9:=2AU!?7V]Z]WBKK/73SM!&B1K(4?6#O4 >8^K! M$YDL>0.P5Y10F(W\^=+5]U]-9 +>7*!#%!:9S/'*MNO2S;+ +'#E%/&F&!(0 M*J_KQP^V^L*M'VN9=AV50YD%KVA.W7GGK-S.-&+3L#]B>G/A21IHZU#Z]HHL39FF 9JSWW MI4&ZE7';VTO??,&%ML;?)PTYKP"I@$%FB?:"A;#9[83[;UX4S3=%*\5$@VVS MB$,NWO/GI)$LJ#0!/V40XZ3C?DNI@ LG3^J4_L![!KHY:$J. MFSHRV)$OT!#&9:),/4;L)4KNQANIIYH7A*3Z MZI<,:^XQW1DB6.0YI0L/[_)9(11-!VT#K2;ATEUORVDN\K>[N+0JXG/GS\P+ M5:XME B;8Q$!_J(PV^$]?IM)LY2VSS[/T?OHD6%;YV,1Z:\IO3$,/WMBM3=A M2!H']H"(L]=6X9CRRW=P*+!>81NYE&>W)[(+N;6?_4QLVEGDQ+,7'NJBZ-R9$,&W* MGH;W*#J+.KY@&FJM\]-R\L:0KACM1#BM[KV1E_B]PIKB3K-%9A2AJ3*H^KR8FE0BB\? M7X:P^=CJ0RE7)K[GE/I8M9HI[:VY13T(F;F06'U1/?Y,<9^4RYN/'RE$8JQQ M%%@V*ZS=4IB'M0GLVD>+%>KI=; . F>S=3W%,-KDQ0#R=LMI9%F%_;/V\."' M,3]O)P/[Y_^6SV8A?IL!-B8'$4?(+IO9:D@3"1#DUR4VY))CBA[@[_KO?>J= MZG_=1?'.?[C[XE^X*/:8?OV.3>TXLP+.LIHL$*,0XU*T6J>2ADJQ' 0K%^OD M.9DESMQ^N>_W>D9A*MJ(4"9EU3KOC8&D^/=P#:S8@!3E-K='MN]N\( [LQMD MT=1!<_"PWD='>Z6%CRHLA,/G]7ZX5JP@:R\NWABTTN,#NU1Z:[9_F+C$2 7X M;(Q&779[;2-6,>#A(HF6C585,/=YIM=458-IK'7.@]I\]5Y4TO5^)KJ7]IU3 MHO]\I^;BI<.\UX";@U)7N]@ X?*K\76"LLPG9!?4 *UF':&CE^TK.SN M6FP3P1ZNMV2QNP_K2Z]U8?;A0?>%LMUA7ZA+?3+ADCUE^0_7>W-), MD#;;G$PJ3Q9S2*IX?#,H#KAL?P=3T%9BWUQEPU3?G_OB1,>@U17;..V?E0G< MGWO95]'F/T_&+TJ&?A/PE:?X!L51(:FPY:BJ]ZA9/ER:/'[<#;%GP+0Z<3Q3 M*(,*'!^V8[76$2DLDL($\=9$19R53*!.LT/S6YD<9Q"$/5V*9V7RT"[^O?-U MB2L=7>.;EZ\I=Q8SJEFY703.G+QK2\GAW:;*TH\4QU[O:E< .<>U?E//T-.I ME%R+4C=,M"@(U[ID\&1+.+OX%)='*-^[>Z>',%N!JF=PM]N[;(;DBW (4\=2 MP4 K_/OB]9]OJU-$*W/CY3DW\;//KK_6/_AZ&*UV$<7^;H40+]H\FQ*Y:2Y+#T"7"]I=I1]=\[%-,0$@KF.DXZC M\G0?R#>>I:=U"RRD7J,1)\Q1':9GM,Q/7RATZH]O$]3*2/_6"J_)(F M>07I@H*?@*DU5#4,2U=&6%^? 95+[X<5V3@J2C,^^PFNBF_?UJ05$8[+C%/[ MFLFD$D%DHP73H*SYVH_TR_+U5057L XK:-TUJY*;UJKGC)=Y%JH2[]AK1#\\ M6>MEGI":*)*1O]81$I0SABMJULV_427 C$E5C&^Y5Y]NVAA[\N)5Z=2/'=(S MYE7HP0][",W?CLO6(ZZ3@(-F$L#[V\J=9T2V7D5\.0F8I?SMW<\_A_^SA^U_ M]\U'*W%PMGR+(*\9-'>LB(<364@ 3HN@9X>&**[#'7>(?4T'5W;87#=( %R< M&Y]?AZ!W3JPZJ"N.X[G>*^$Q2==TLMHZ<[[$ X1YZT@"9FI^V^H)CDL&=G3A MXUMDC)6>HYT9&\I;RIU-4#KP0YVN. V$D8!S? M!:*'HY0F20"M8D1*!W0B8QR$W4AYG;\-1D"62(!)M3_JH+PZ$E0(04F0"]$& M=Q(0$$<"L/+P5J,"$O!\G@10B)( M -E)TP9+YE!1;#&Q:(1C+@BMQ5--")-HSM,>M?C%!LFG1NDW8&T2VX3^@) LXQX"XUT4\H4L" MVOMI>N7\6Q7JN@(::7!\[0+G@ZPQWFWO>Z MOVEVDJ$]E:&9Z=UH_3\B@EJOH)5<+A OIW0J--)CCJLC\J?L1E&#FG@2 J^M0583B1-0J"'P7A:,D]$)L60907?E *P;!"B6(!5_ABQK>T MRW&4SN3T:#E2.]>KT&40W=UEACG>F8!.5O@(W1>Q>]K37!X=4UL^@CQ R:Z' MH9F88):#1&&"$:ZD$&:)50BVE^=7B:?[UI^K/ MXMAC,O^AU5F&?_U5 P-D4];,.%Z+(9Q,(@%AF0Q.DN)_AXO+A<49N)OR)&#K M+GQ.I(F@]T>7&LG^#/_/)@*,^%-?W$C$M>2-P;3[^T)[CSM3JY]\4H2.;W?? M?OSIZ\&%VN\]GO.7T1#,ER/[8R8N*$Z_EUP.2NYN M%8?2L'T(PWPZ7^^SR.YT84JM]/.TT&1)&T?5$I5D5;?LQCV M:R\WXE4MPB75]R1 O6.4R%8.QW8?;>WE2)" C-E#J:9#MIVF/:[73F008^400 M7S9M^\"WM7IWS09!O\I?XD^L' V\A?=M$1*AA-?P0J0&"5";/01##H47CR17 MF/XHIS\PA/;%A>BCD\)BOH&PF(9?K?KO+0 M\N.WN_@/"!:DHSMWH-LY[7XQE_D'5=H[JC;FD:!;!T60_V*"_FF#_[^SP3^I MW&C*_VORXPLZ@MB&;QS&+0:A^3S-*QERX7]']?I_FC6L05"N*7D%S2&85J(N M]_3:%4Q.\E!%-BM\&7[6FEZS=[F:S*W7^^,U!.$$64:O$:U85A-)???QZL., M81^EIWDA>?I.O1KBJ[&5&@_(=%GGPY^3!03DDY/,;]ONU-\B[HT2*?3("<;L MZHB+D7D3)LDQ8X;,0O.Y)EPX!"4S!&D@"R3@-AS+3O$/81A2#W-$_$I1#I%U M0PX_2FYBR?IG4>.[8RI+$)VP/RAMPIQV(PK%X'0K^K:LX7/LLP0-X/][ DQE MPR CRR1@CYAQ1#?P*Z3B-'B'$FS04<-R?J%!\VK%._?*AMO)P+I$,?3W0$"_ M< !,9)?!?^$"_BL#E$[A';\R8?0KVDR&CY)P)Y=3@OTT]__O-\G_ @),(E"@0PK$ M,>PN?'GIUT$+54ZL?@9U=.&&>WU?*J$J7J#\ZIE7!YF,K36@H-F3,&F,8NM1 MXDN4G^/9H4H&_2V3-/'S[=_/PC_NQ32J&#BYZI# M_.D(8 ,J!V8]F5>?I[[]A%Y(>*OVN,55JI(P/VA M4C 47:+;DLC:)8T(0LB43.I':K9D1Z6JR=B%G2X53O0V>'LBE]XL^Q\@ED3 M&/N1ZCD$W2%7USWVH*Y5LSL.N9'R5\NCAPYXKG,=N)\[#(*UIZ>>Q$);G%V> MM3NCI=G:CTC 2\*-_8%Q:R<;D-\CQ4^:YIWQZIXG^VN->RL)#6LU 2TZ',/_ M0"TT_)C9.:;01EXG59FFJH;AROI9CM?Z9>ZEUG1)=3XC&C/Z Y'%P5Z1@B8: M&H87+=KV;3'O<&0@]*J3)? 'X$745O#F9>IGD%2=%+?C\I6T=SSSEY>A?\]4 M4C[ Y 8\#3@=E':_"L9K#KG)I_AQT.Z;5==>\ U?OA/_\G' O9>!XS3" GYP M_/F5YZ$AI6!1\6B80R.0*.S:R**+=W<\$D (\)0]VH\G =Z0,F[F\Z^ M0&]J&\X STYQN/:_>_G9$+3L-2LB8KAS3]WACJ*@?=]WU1I0PHN+"UHD #Q* M/.38T5JW(@%R,<>U)&#C^5Y*WVO+J*:N#=GF-88/@Z[(RY[%R Z^/C:-9R=O M9FY.EC\NUIY,??EE64UY2PARN-AT\"7G2PS1%W&\+=D#<\9"S3'5,>!KN18. MWTI:\G&J;BS7[%RYK:>GZN\K=F0FJ'J[O)^9R']('^,G&@@@[4/R" MT;_1WNH#F:=.*B'P170==4Z?'IQHM4JSX7G'5O"-^F=]<%^QL980R+.0R(W# M6XRHLECA1COK8,_9DQ1VG+H,*@/-$K]_28QCC[WVR/>5LN(&I6S-^6@JP)MX M [[3"]^*U?H7="9\?:R.7@)G4J#I1^P#]RL5^V!\'@^ E)[W_&9N5_F+$K&0 MSME3.(V*9;?2K:4?;ANF^PS"MP:V9/?87'UV++_/<*4Q@]Z6"U+47 $;TKC] M*_'LOBPDH.\R6=4:3XATN)4Y@]>F==.=P6A=YT+Y*XG6QCJQ&QT!JH]NS#@A M$K_]U*FUHD_1GZN\W=94(?L2;%1J[FAJF;?PS$FD-,T3GFLS/KXJ75$E+9,? M?+96]-H](6_1:_??T&8RJ6\+DX!T9Q( "P>_)@%+R21@5JC&@ OFB7$+K"R* M$CK:)^+O5&K$;?9='T!X.DK%AAB5<@[RW#K=)L+C%4@A'/YUU/^7^[IHRA2_G![=3U8_JK7+I#:^#-F4O^4XS=@-[H#\:1B]2 M$J\#4\96[B>Y9:_%V[1\9$[D+=BWFW"L?LJL'2XY\MH*B53<'+E^:,KW-)?. M1@9W/!=S$A<^?_U'I>372F7S0>>QB@:A'4.K4[.;*D.3;4)6YT 7Y-CY-#=3 M^VG@_X%$U?-6$Y^/I#@7.AX8SII;MY=/3EMIBX0[C%&;:9ZY].;:R2?7BNY0 M@/YD4*+L_[U_C,T2RMNLKKQ. O(IFLE_+L+#2IY_'8#/'Y!]'#%[G,/Q+(-+ M50$G/@<)7?=L$G NP_GI-#3&Z(5L.MC%TF]3VYEN#U?1"[/V!G,OA .;#HBT M$OA<5D9YY6)HB=, P7BPL2NG^],T[=D:G??OWH#?65X4F0_:N5&JO,21@E[CL(6,,K%JVX"O7::$$\6-T MX\WT'.$KW"VE5ON&)" P<);@CP/-;QA8#7DT@-#08(^BDKN.GS3.6\Q,2KGV M]_&"@[NIK:,ITY\\50P 5*>RD9(HZ ;W4==Z4![!'INJD/@4?D^GQ(EYI?#K MJ;$S;Z.LQR(W@!-=\2/(@WVZXT\P$_Q-#70O'YKSY7U4!OL@PI,\@T-PV M1;\N^&&@WNRZ!2*J8C8%R["(F+?M0D'"/+>JNN6/; MF\@1^0^[\,IOA5(L%[7;M[6-+RQ\$#6^! A27_D*'(6$8^ 3*?N1/_Q/,U'Y MP%N5- K"B&=Q;>81^H,>NA\B'09.,+1OFB7=FZ_ 7<6!P4T^EJ:MY,M']8]#5S M/OV3 O%)FU>=G3^?K/BTI;P_# MG/UB2I,C<.P.58:W.?G,$E_:@,@9U)<$X/;\S#;NDSO\ZM^^S)0D 7FFPYA* M_P^MM8^8^ +3;FE<%LL=:2AAP^BK]LE)EUD?YB)PPK-D\52" MW4B &H*)7,* R:GX>0S.Q8"/!/1+DOM^'!.$! @@@.S&;WA*,O ,%@@Y<%@] MFSTZG;2WK4("B'RW.TG [FFRG(F4??]RNLT/;-/Q"23YR8 =$H!=Q9R6(#9W MDX-JN_JQ2Q]\^3QT],L!&?8?T>3\"5A1LT3.O^!EVJLFH\O\ (?^=:)CUND1 M1-@-R,C4 3$P[Q@6 _\S<9 _@4*>"(=\NM1TB&7^)Z?_SSAUADRR=7K)V6@G M/WIEN>IV]<"J-V"2XP+DQ= IB.5O)Y=\F(1D M]#KT:#*=S-.=)D3L%@G 3*23B[],LU#ROP+PWTYX42B((@'+'&17)M!DD( 8 MLP CK7UJ,Q*@*@1:<_4C%X[&Q$:M)K*G_\$Y0'^$94.A 1KC@1)PK^$EM5O' M5+I'AP+_\RW0K[3]^).;^5"QP^_9P7?09XE52TV['+)K"V2\?Z+,Z)]L_N>Q MJ>6.M_>90-,*N;_R_9]&BBASNZL1%NX:)0O71W/@W>JTC\F6M?$6(2 M+\D6&SAXX5CR9]UNTW@U4=<[N&FM(N-([.;.CE2\3%X@PIC=V.F2\["8'X\L MV]*5R#XZS5(Q_4L?3HYZ+,1K+6NP&T%?90QG_97&U;RJ:?NJ4\8>RI$$Y,@X M_V&:L9]ZF-U(C>JO7+^L;UUS*OMM*;T@.=$C(F)^VZRP4N,)G!_L^8%P$6> MAG Y*KR!&F0UU[T:.3CU76!$T;3V-'M0TU?6A*O-]W(#+S&Q85/VPS-0B!A_ MOA5+S^#&@JPULW-B#847Q?&JG8ZVE57OM>]1XXO>:6K?+Q.=CPQ@>II=4^_& M9^,$XI8EG',Y"1^OLXE@S'KQ],LD 1^6)AAEY76!=<;K?J"_PR$_5AXQ887Z M7HFP=#1-7O_N)M,;G)][9#WUW'KZBRCLG=O$61?)1*KKN;EQIWC(?63!@ T5 M=FL_A9S+@L%R6-FV=-[1?! K3"7+QN8X?5(W?<%Q6_1=3;A%1K>#[75^A8I< MX2I#UWMWGH,B&N5\K)H5>?TSBFUF[JXI/J%[O5O"I5LW+!MI3=\Y,7A.U+R: MWC?X^E+D$KD#*$0PX^!8_$VL68F_!WC[07 MCKZ@ ;@.V#@TJI1C:3K2&-MN8K-")K@KK9P1C"3@8;E,EDK]I%1ZYLSW%EVX]II8-:W)B.J&1[:R7[[RS&4*;73E*G>#A$5I[VD18[UH67B3Z M82L5:YS5SY:K[!3K%6;QR_ S\G!Z@BC.N]CGVYUD:[=V2[W<@4ESQQT;F]GO M(U]%\B5US6>T.G45VEL#Y5Z&;X+9YC=HT#+1$TFA6\1)MS/YM#EQYP33)PPI M+NK1AW]6%Z3/S0TOIJ2/=J#,_%M+RO\PY^-?Z/S;=^L_FM8F#(Y/]M,L;OS; MR=:ZOYOH^6NV_!]<(#UB1]/.%1(PF4$<+=EZ/4M381 V6W$0*HYU"Y0"6Z"* M#$[-"GTK<3SG9\\P9&/% 7R)C#BKA@/Y4=0_^@1_,'N8"M\@%T+.HT,>%#N5 M&:UXID 2P'OYV![5U'JL]'V2R(PLB7YYGSJ).LLGZ?$WV@0CVYV;N]/]+*F, MCO[,G4E-9RI5G%M4^;%6?O$&XSL6NS6.WHF)LJ>-S^;QOP^\@%< MR?Q:&)9%JK?W!8L& "O'1J"8(L$66..V9E,%&_M6)FXG2;0LF_5#LK>G&(98 M 9GW1!)BW.!^8?W!$U,3@.GJ17F(V\79C*E/P:SH65QNL(X/;%8;ZXV M%06TBBO#O7N3O0]*>?E!XJEYK:FE%_<=YM4/>IWO.@T2^' M\];>=_L]>\UN M8 T_)_:9]\O[I5GJVIX\(5:>S&>^\)[KB:/1/KN8(X7=%89-=D.:KEE,""X% M7;FT0?G"=DYWBS$?Z2&9IC!D&6#)[RM-)Q\FL_Y*3LK&R/0P0<3@PCE1K7(+ MPH-J[,_%F)PQ@C)6HW?-NO6@'Q=Q+4._:C#P@JW<70-0O%QGMP*=_=MR%\'@ M;S%6Y)Z(KE7U//QEW5:4!YS5Q[9]--1DM'2OB,'Y6K_KGD,E]R;WI=PHYS,A M/$+EZ)7L&Y"8[V"%GWQ2R9!H"E((/CZC^^B0FM7X$V5GJ M9H_]2< &=]$B%"?1U39MA8:V(4+J3)-0W[;86M-5!PM^2*T_SJVC=>"T2]0Q M84=?X*/O>IEN<'EWY)?'+0-4M.4OL;\"]%^U-C!!(>"*> M_&5F4C&%_9HB=U41?[?"'%NZY!YC.( 3WK?&T;GC+^ FYV/:M&$,+]P+G$;D MG&;.8(N5'I?3I9B]+ARRJZ6MT.$#KKM2A3WJDK0Q;_H,BI%MN@\/M9'%),9_ M]+&?%W^UFZ;9O:5=4QY'UV!P*]DO1JE;VT)=COWIE]R'FX)/N[563=@I#FO1 M&2$0%L(+/!NQ;Y9"?I;).9EA*6R"&ZE;.+U\0*W"^7VZIV0_-9BEUIW'?/IM M8X][ZLCZ;/E6)]-XT7XDSA%KN=/)U<3CXCH!H79^XI#.I,OSV*/:V#8ANU*V M42+-)(+CY.-K<:>ZEB^S4_SD-6A#A'/">4L)NB^P?GAUU&Z(@7AS$R9RHF-A M4>6CZA1?KPMB9_OJRB"RJS.=<72S:2Z;!# 2=!E#/^BAOD&IH)93SBP3VB-O M>@9KS6?N*4B^N79:7]]YU5*";^?)VMKS'--#68NPB^VR7 S((*JLT=4!0AV.*LL8@^( W8-M>&& M%@\CT-G[%O@4:0URVZP^FO@?[+UY/-3MUSC^ECTT(80RRE;6LJ0B0[(E(=F7 MJ<@V(=D91H2L$T*1+60+V67?A62-LL]8(\Q8AQDSOW%_GN_SW'4_]WU_/L_W M\WVVW_W'O%[SGCG7=>,%9(MF^QA M .$+UK E-1+*52N"UR3>I5BQ$C([-M_261IR2 .IAZ1*0I$4!'YX*?[R_ ,^4[<4,_5LPXK6W0F M,E^BZ9,_1MW7=YKXSGG8': 'OQGZ_5?T8<1A\+HF>=- -^SI.T 9#"<@Y2&$ MF E-8E41,<[4L/DS'D)- C[4(\CFX WM>00K9-99DU@GL2]\5^68X10XYC^Z M?_Q??[RAW\=(@$!-\]06>8=C%?#*^LTO7I6$<"QX.H$8TXL@&ZBSSH%D\ZN, M[(9G^CW156$CC"/L_SY3[H<;3P5Y;>4D(+K[-KDS!NU]3A=%[MM_;UK?7Y^8 MDOOYU86H/NHZ'Y5RK&!(SC?9_M"W12N9Y2D7@.#(H?PCODHRZQW?%S#0-HOS M.*D9!PC:-ZX]NRQLG.*G10N_7=)>[B6D@AN)CK/Q&/L4'*]X4^KW1,&"W M8;HRD ";60N ''4#L1OWH$!/>61,DS3@<_=]E-GROC0OI[BSARZ84;1^I7R5 MJ'!FQ :[TR2 T\CVI&U-E A;=<6Y6CHI!,F;6$0M,OL-55L&T,87B(\ M^PU Y91F,D1I'->YX,^TZ>)7;9B MEC&N.DU9:E]T7LY2Q[WCGCR3!HHC@*?W3=%%X0KR4YW3^YI-S+!O&>.V'HD% MV=%B/3UYZG=J[U\ZO"RJ4]&RD??6I[EX5 CO$4$"4(Q5N _R3/E(KI-W4\"' MZ4!C]2USOD],ST$:K<#VO914/#1:OLIDLZ"M",Y"-F)J&5#A(N&E[G!FM(," MOC64P!*6$%C!8HE"&@&IX7.A1M)T_9K M!QDJOOJ67HL482;\7=+ Q28J[X3ORR@?W!;R M.*Y^#]_N,36&A#E1=T2*??]>Z'BO4HWA7&EE6:6MY'VK_?7=B.+<4XIF>+?? MOUVCSX0@*EY.V/?1(+MKB0VW90Z2(RU!MU:$B &VE!ON"T0%@5_2NUP.R_JW M)+$_W 0$:6%I8BU!C1(,]LQ?33MRM'+'U<0&6E\;ZM8<[HUX=H4^UW4J8 _N M+1X->0J_:X.:T#-2B>^X&?]U3C2R63HJ>^/!:-G$%13!+%!>0FT M>CG6Y:Z+3)=&UEMNADL7J6ILCBL$9&L_G:3%7HA.ZT2OGD M&IMH Y\I6;UD,;W".;O1!QPI4#AJZ\>&0;86B.@,I=4T#/:D!>^7#0RT&NOW M"3(PSTMYP7G.QW:P/4\MJ<]\\ 247XWS;UI@8,[ZY. 2\43665"$U(HL($C"WC2]_5BL2F7-5%.)^J2P=KRW7GB[&+NA,E(P-[20VG[A M\O?X2>/!S0FCEFSZJ]/J50[=RQ&67[;2CO@HX_C>3'AJJHRX]7*TH!:WSLZ6 MFWJ]-3$T-KCZ6!4,!+ICG: E%$N%HV#*=$G3Q>,+9T6;^GK6UH S#0EC2?SG?D3S5[ MW.-F(8WK?^T9-8*F%CRRL;NW8IG XM]33H$)*G M)V]4&;%MKCK:I5EC:LF.Q::-O&<26KR$QW8JJ*4^OJI1/)LD^OB,BZ7 M#UNX9H2;'B#9:Y:MBORNZ4Q:&)DE8;> M;NV6.8%-EM87*QZ-C[>P!:8+4/">E0C6"Y#-Y75NZM$9)#+9Q>^IQLF&UMZW M045JZH>LL+NSCM:^C]AOCVLZQ.M+ E[P.I ]J6+-C_( $O:30\ MN2H-%GH9P^FSX)2[#5 R-#<<7BG7$KHU7-[+/+JHP%/Z'L]E+T(Y'OZR[K12 M\-THEV]CA1=J1:;SK\BU6@B7#FYI@5HKW/>H=K"36E:.Q_QI@%O=<]>E1L0J M^]:I08<)BIANG"J^V4]H4(8OO1P[)/IF8$[9Q1$W]FZ-PLAA5:WHY+EJ6:3\ M653J4<]$<_"-(0?I9&7EI!L54<;LQC<*C]&#^:EI.7G9.YP4*2JS_7JKS=L: M@H/6(ENRD)'9S.[%7.W%/PUHO^.LQ2_?^_9FE*UCV=*SF]6JL4$N!DM@:E<*)LO+* M&H-KXROW3"\^= M:^QNG1^?WL,H4MM"K+OGL&ZK"3[Y^PDW UKP*A(#[1K\\9)CSK-6Y^ZXQ"U= M7$Y<]W71#M<8EGB05ANB&SQI$"E>L%&BOR/O+%1E&C:4+%:Z(P6U+BL%$]=/CM_ M.S#B<6-G!^?%SAVA L#EU_GP??GP)[_X5GE6^;Y!3SE](0%#"N/D;7H9JD9V M+" D0%=,F7CPIFPK?Z'H2R71!HPG^\*C6YL/O.>3+Q0[9ZKEF'3FC34G2!F] M[;*)$A+-Y1/TH+X71-P)'[61+(04R1 &(Y&(,D(]#4(0$-)&#? MOC@7EN@8+A#A'9P.LQ381 _WBUL;];2V&;[98#6KMI5WV;ATC%$!NCA0XBH/OQ?L69P9%L1F].@((E0-NB!]10%!@ M$I 3GTX"$"1@[S-,;?B!O$K6J+VW_E9%]IN)]E+32>./)2W2#R0+HS*#;UT^ MZJQ5,B*]-F](4T(.K M/WNA]N"=@^DI4"/PD2>)90BR=O!H4IZ3QICZ1V,??NTOB?B!N"'$C_-M\DY> M:Z8 U#1"!)<,2]1WNA1!(Z6TD%W1!'PL=Q>K<*9$)^NK"MKNB-G'BNQ_TE48 M<'#- 4%\;1*R?_#3LBX)H".3<:T3\=7N.X/6?=CG#A[)PI@F39_4A0SJ^/_&$Z--H_HD+^@ 9F F7OY_F"5). M,L9>>/\&YZ$6%'=_2 96M>(P(]IT6SKF:%J,(J=\K.*1/Q[C6Q) 3]#!."'+ MDNH,6WC$^@AJ6:,LXA*NR=>Y<^XV=DYBB_4;.6GE5H)^::@)'S$%?&]-13'G9<9+9VCJ=V:Z):F"CO MBS%-MPQHF\>Q1_[TD8D7[ARGT2O;".8IH[#YXP7*CRO&%4PG:[8G\!PMQ48] M]D"/W6GWI6&Z2=OP%*"? )S./Z03XDL_1I'[)U3C EM-M)^4F=99F@U]WW00 M[)?O3MJ_BN(-8/LD*Q]U-:?S1.QD:N9RM=-3:9@Y5'-(S$U,<(FMJK*^+/E^ M@.W3#Z[1&@:W+E&=T/EC95B:M>SM_CY+.??;R'9U<)*D5[2%R<<2Y=,DP,M< M@\HGT,B/"9<[W?!TT*(%!>%85#@3WQI4@U0=FJZ!/=( U/FL1SVO./?UT:3^ M(??H*G)"_E!#%J@ 5C]I_IP?&!'5TF 3#0 MKD!UPKXS=%^XHB@H?]./^\,[KQ06_6+Z"8V"DV4EB%Q< Y>SP?WH^:,M=T9U M'][Z##4\*]$/-D>T&'GR$;,AA, M):B=[T(CHE6Y%Y$(P=%OC1!D0@(@2^0M\0.8X([$P4!4B*$%$O ,@EN!AZN MEZ(,1Z&>?\'_=X%W3\7?\I0BM/9G:]5*(B"9@I^ZO)_Y8FY2=' M5@RG7Q981R)0YT4_W'9\!2N3D)GDW^;'7=;%CB%_T!HKLA(&N$,F:95IH!/JCWH+\U>9_79L^S$@' ME!&NCK4.3?OVR#-%I":\H%M@XQJ?3L[WF_I? CNRX#"+!/P%$M#IB*G<=R?O MJ=X90INIUTQ2P[:N.5]=V0%OWG7C87V_!U)V)L)J8P MD8@A0STR%R,/#(E?/3CH0J/ ZH2!#[H%ML0"<#P_30R-T?XQMLR<;,$QCQ=74JD0KQ MBVGTKP_Y]F% VU___MZ_^4+-1/!&F9O3BI@2!'%Q-';:60IY_;L(1S-DG1*Z MAZLB ?V]BK1_L'":Z+7C=CS4?;/#,F--=]]T2)^[TJ*ZRI85=QIY2HF7(UK) MT?]$#,!O@!5JE3B"4[; #(>_M8\V6O+CKX[IOEX9;924&R,8]_PHG=GI\]U' MI1Z_>D=UJ.,/\.EUHK4N0UB:TF0Z"%KS93ZSEJE40G+T#X,88(SH$'L]LYFVMFV\5+V',PFPF6])]3- VCN4[\[ M(JFXPU;'&& ;H_*!,3W8=Y&2C\AVA, Q_\VR_K>'O#U(U .9(BY<>,M1 MY8<)>RP M6,!?'T4OX TF1WPCBYY;\IBM+\QZ;"BH-$T4[]TK*R^X)092JQ_*-O04G8Y! MJT0<:M/5/"JI^(FVX* (R^^L?9XV'2YFK-WO6#]F4CT^XE^%9?L4+5'LQ?1Q MK/O]?"=K+(1_=@:W7E%)!ZGA:%91ATV,B%K85;XW7Q; M]QCM\_U;ZJZQ3*VQ4K5(T6@C-;GS,:K/*A/I'3,C BC:)N'7!A!6^V"T0D). ML*^(MH:\!BJ?BM:MV5RS_.TIXD;XB'!>@YMC^G%T'6C;$^>!P"RC@IYS;8C6 M2WS.C#7&,G6=G'3,>.C1$SBA$\VUQV\K9Y#0ZA1 /(8K*,!)&6!Y4B0D:OGR M"HNS.CLZ+ZKJT*&-_M; (5[+-YW*VH8.BKV%A08ML#LX M'1+NSG]IR@6/%O9/+WP4ZG_H[6O]:4'8V7(0&)8B/J!P DE>PWM+%Q*IO$>> MRJO96#H)C)=H276<8(>).APZ779K;C9,^9WJ^??A(QYH<""1!RO;6G3$?M9LH=LT^LL7N-.=+G+"_[%[DE+]4SX85 M?X5D*JQ+UV"9X!=7BF$WSH@Y:WDOSUV3V__VN1; EO*#:W3RSJZ&W\!8W^K5HK7ZE43%]\YBH RV[!K+\Y<=[QB$8*"ANV] M>9R%RR1H((DL#$_OU<2V(+[&-V"0SQK//S:ZYD3;Y1Y:N['!1#0&UQ1HTQ _ M[0D%P;UR/ =V3$?@AFAS34T''N*&10JGP?QX]46H\,68BXUG'D8+"WV:S;46 MS#4F?MQS2(ZXS(Q-#<_&B#+6&P9:U_E_R;174H>C@%I;)[1-"Q:"Y'7O\H+UL@LO5TMCJI;.OU=DO\9G1 MA4LY[0Z),_DB++ +_JOU7'9YB$A*1\V2^A$K74 M2*\.\#1+=Q\E6FPQ*CY@$98#^^]11RB@PTLEZD\GN;;#OT*%S%)U+Y1G'M9SW%X@'1 M0>W:B@ -NJC9%[4S(NU/.(+5]37 (@YR>^"G4"X9!QB:S#OG:1IFG*AM+7@" M/FLM!!) +H5FT EMNA?!2=]E==I.V&*9DBA+I4XV J!\4P)]GY@?]03\K&F= M.LY[0:MJ8'(N"[ER[VSEVIVQ"X[2A'%R?+4%)+UBVV*");V<7FN M0\RG=7S+BFW[]K&)N;?]$Z:]S%:B8U:W#2F>3E2& 0484,?H"++V;$YGX9>E M<^;?JI]7,$\M768;CG"[J*\[\][4]+DQJPBOZHPC;LKI..6@2"I&XO'F6D@] M#U)]T&+)=8,_Q:?FVZA/4N[LO0$MT)[Z J\ITR<>&&V*#@R/K5T;.H^$LQ3A-5;@YYQGJB57EJL]3V0>&D\CG3VW]^+#W)8KN9:#PH.)PUP_A?3!5-X7J@?:W"3)GHQQDT5/A1-YOE7L5"3F>I1I<-\O?C&H>_C*QO!L^G:FS\P'<)V W3CH)BTA'3,7['AAT<_7H+[4T.V8X:&U^X6)6< MK)F[_&)F@W\&'[< P6A-A:6"ZMF(_94-#+6@&2&LX9-:\[2ODRW.8G5M58&F ME2$8O4[7CPR2 $LPM=&W!MK-KS):WOCK.*B(F>TVAYYI MF:S4S&SB+)V21\1ZS6' AVN9* 6GP)" =GP1C<722.)!K)B:<;C9P-;)T^H9 M*9=BB<;%,;(T@KL>XI=&:[&*;-*IHTDHO_?8O#64&#*40 *>7@A6NH#<3W6M MN: V+[L6<97OR274?O6(/\R" ;/S!#*=8T$5J]17UL.BI=V4&+>R83?L/)94 M$_QR1^NL"O?XCG6G0OEVN5=[ 49(<=A/WA;*;ETSE-#JK1!](=()=J(X7#58 M5?3CDLY[>&S "9 ]0)@B 0%A?H,FH';04PMIG&:!9S64&J?<9*!W0^Q46:)I M*LMRP&F'Z?'HZC8J1]4;04J7KGS.6-W2'I5 9H.98:#[F)E&Q5.8Z)RQ=KJDPJ- MM+/-NJV[2OD?I:N>,3:BH8B2I.NUM-!'3WT9::P_CU.;1E*,3RYO*S?I-B?2 MADJ/86'Y7^1MCUZ//4T]?IN1D/2( CA*!^P:X-$)00\0T\FI;'['>]*7((=K ME:9-^3'#&>EEH0B1R4]C&5]%/8V#NA/&6XY/+E KBCW&RRV:]+8TC"Y/^W@6 MH9@:&F_78+*&D0[[T?RRYW$I*W<-!!=;D )8?$_):NRC,_<\1;9(0 @)N-L0 MM"?;+,%&4*BO_ S7LD3GMDU6OH55KCCG3IF=I;F4\I#F)!VUN[_4J\#WI6HH MI^\2TVO!9,$J<^*RYY' 3K5JP92#4/W:D5M3*W1E[Y;+(ZOI!NU$.BY1!@"\ M1RDV?7\GP(I'!&^$Z!0;:E@.(P'?],OA8E#7GP/3_@OJQ/^]'[9OB%(G0OP: M V*$; K?B)N/^^F'N?FI=8E61 !T3_,*$4RFNQU$K"?+W4#T'K/*,<,-Y_V< MOR]Z#$8"^.)S28 %>^J>Y'Q%/OL(44U,CU@K!MF\WP,X_+V9=@TDGB!F:1JV ML,XD(".E(O]'G_4X">"$'VY@]6/U;&E^\MW!\OK[TBC%A[?4(@,NSCXJ*".R MK3N^S#'W&TDY\AZ'S&JW&JYE2K/K>7V&[SPN6(IM_[OQB4=WRRH?N#()8S\4 MO1=)QD!:IHX09 <4O\TB8EX%24E MKX4RUR2+9Q,_KBB;$'ZSZ?;5[TYDWJ9$UVIO<;/2 R]*!-7@W+H;W M]OHYKS10BI\D#J&#O9"*O[T\FATFKR(3'_A&TR;+T\U-X_5@P8U$MIJNEHC1P.-O-#,RM5NW:'O:P[EL(M:99<+P_,FOAF^ M9GET5Y:]I$U$+05>TN;R2:H'@*]D?%VV8,9%8IMG-+ WT]&:O70]:?;")5K5 M\YKJZ*H8&'= U4;2AQB=H-W.H"277.M-9NS9CC98*G>DGP'.ZU@J)KSS^*LD M9MY*/'2L [/PT:G4\>1-6L MTC^P.3&3?8P"-85)P34T[TRR8^4'[$<2JBN#Y W1+:BQI%Q.!IKB^*XO;54Y MYZ]U\]"JVM'-?4E&,,,O]'XG ?F>J]IA/*>36DL]'VD9.#%K%MQP?:E4N4%' M_#2U+5-Y=YT034OWB'_2(S7-D7 J$^J9=!W+.'QWRU=\%/WIT[3ZM KC/)_P M=UJ[\3OA,?37!ZGO*\:KNZ@ \L/\3*O+A:?F7^W(L HS,R7Y=3J>>. CBY=EVE-='!S2 MFBOV]-N3%3N6SW/.SQ; M;:E,Z[JF= ('A]0%2DWI]5(-Z2> [(>/7W2D_,]09OQWN7^B3NSPB#4^R)8S M9S1NL8KG@0='.) Z(A/T;>4N$W$=L_"/N &PN\Z'1R9_!CN,W%P*OQ@$M%' M>W!>2[8-">[(E:3>/6 )O+-.-AFBA@].A?=+O4B XDEE(M&4!&!'(15.D$7* M',14-X(H]\N9\ \H;(E?:TE VI&#(U\Q$H!;^>54>$PV=9-B"+(VUT "3F;@ MK3>(_I=#]@F5!^_=_W8X_1<9_P/)Z%[<*Q^8M)^UK?QDLL8OTK1.G#\?^-(; MFR(U7-;P:Y)4?[K_(8GX];]J/S+I02C/SP2#?R#VEU">'P@N0_Q(ZR^A/#_0 MV__3E/T24O07%?^'BHL@;KOM26F8KY QIF=_-=7Y6( I5.'XQR0+(2K)CW0M MPBD9V/GW()Q-4NL%.@O3?U0\5B6WBSZ0G?:RJCKL7 M*=E/$7\/Z.3U5<]+Q50:]F'&>VYSLG9?7H]44YTRK3?=2P*J%TE L#?. MEP1<&],[V$U)@-L(>5J:OV#4]H\<7*%MR@03S,&_P6B>:OH)LC 'K5=+WD]M M06S,AQ IM0E(^=]VUT\"&+

&)H138)"(00EXN424!0\31R[\1!AH) =0BN M&H)ZX,E'#)$X2'8P "**(PL6P!OK15.\Q%Y4P^X&N0%%-E'MGT>]VO &O=!C@?I0!(0GK'LU4$@Y.]\@)3BG(APM,\0V!=?9TN MDCN,\]NEW3XHT-R;",8Q0=;E-XB#L$ M0*"],IQ3A-G1?7FO^DM8=3PC;$[5/74S/39&&U%[Z;OT;_AF>!%QK):3:;NJ M%[U"SZXYL6AZZPD-5/!4],8C23H"$^R_?EA_R>Y?LON_7G9_R^1+W+U?=QJ9 MOWY:QBSB((5J-@7_ M- DH_QV&_U36\)7,G%+?XA]U8I9OO9P\9AWM)DHKH,0/*C_2H&30\#.#+OMQ MI,@5,=E)*9_N9HQ_5JW!36-PRS^ ;HFNX/*<5^&],L]0,M6W2(#4>ZM+\G'# M1Q*(%*!U>;4_6^3J,$AY*6B/+I5(+;$!WFL@>VE])R4('.!_M"UH"R%$-LLN M0W'BD%E/Y)_PK8_;,03,&KS)#"$C_#3%=119T-.3/!'UE2'>_X 6B[QKYA[.(%XC\7<@^ MQ0"9F*^',U-):3@3<]1Q[IO\PW^:OA.F*/,HL$!,P0U9Z2@+]'5U;J MJFU7W"5[Q*QD+L@BWB46S9* 35I-$D#=04 R_SU\[O@:N?*@A1A GO7'FH26 M?6@G"5@D+SL#'[T\E<$(%//HU9)_JX#0_83?D#Q=>NQBGC=*F6AZ]4/0: MQZ$[Z$;GV)S9 R^QDKPH3&GVKI.VB@ ;7?YU'<$EH92K-;O.#_=E"16AS M>:1PALRM%/;$& ^MJV??5-B-J0;BO?'$H!YM(M'DEY19E44-BV;D>5^;*R(! M/ 5Y(CU72CG^!.8,Y5\0?PC163%<1!LNPT%L'-*4B8;%[$[JE"6M M4'IOETN4U!<#L2)"E$GVOJ<)8K$[$?BISXP?^QM][7\>\1?$_QW$VU0&F&'T MXE)^FKTD4L'E/7]%A]2E#BG*#NWFFA^J8?91[->1E<#5^>P#5Q>!VP*/C4QM MBMLC=M9'2 #2(#@]S_C;N0Z9K7%V70W1A_P)+*+V ^I-?(H:QPR$/PN[" +'7&RGFRON.@=N,P-!.\RT2U3L:OH[S 8Y?\*@^0,P]J-+PWMF"<.=N>/* JT7M(1#,T,/ MBWS(36Z[W7FO=6]%ACSZ;NB MSA6-M,,_3H/N3Y/T(# Z^D.FA]'GER^$?320[:V=?8;$U'U"^2\9 ML)R@B+[W9/T\U0TE7C&4UG+1PEZ(MHK"M^:1UL=87SI(8! M[1"7Z^6VH$^Y;F_:?)S$,V G'HT;9^99!_&+\MDH/DJO4* _L?+ 59I"[;^G M#OC/@<@JA"44O%XZ#+^2RWMA_5"/0 5ME]?%Q/_<@+#ZI**7D!]R"/U'2T[^ M4'XR]C59)E8K20"T :\J//PVF8,(<6O8VR3-O M%G-&KZV(N4^IXJFS1J+/;=Q2G4SE6[L[-RW47?5N-PCPB63#UJ6NH&:^^?$N MD0"F0HB-@S^HPV%(U C(WZZ:3\ZGR'L\R%V/;RE^Z-YB)*_$6 +X[ M*GZ>Q,Y4UBUSEXXIM@?RU%BA#O"Q^B-&.-W".UA(A(F=N(-;Q*&[86BC#)@ROGC<.X5AJ""5]6 MMS0FT;":KRN,K$DD&],4MH T?*YS&Q4ZOM4.8[2U.84]N M(^_/,+%O&-8E+AD$V$8[\H+X6*BTR]V=-T0S&;D ?%>8"'JS% OV1TQG3H+[ M#='@B/(I$"ZAQ3NXW#E]F:LX5KOBN?J'4.IJ8=6G81FQ8!07[#!F37@Z"+P:.BDF9"X10Y,),G7%'OT:9&H\;2=>=/;%XSN#=0\HQF MX-P3V:[/R^"R[!4]&&8,-14R@X.?PG8@":ZOQYJJ?0/?=GJNINWGOH#77[-O MZGX(HA2FOP_LG0[#@;:%<"MO"7PX)FQE*^($W F!9D#2>E:O-J_NK6Z;-EM< M1&N?'OG8U-*E?HU"U?1UQ QX6Q^7C4UM)P&5UT8@+$YN)QG4L+*!@EB:N.G4 MRNL.9=UZCZ)-0WE15/BCQ0\<]Q?D-,ZD@5\__QV9\"SZ;99:W\'?G*678J"$ M\ 4BV9/-;"7:8*6(:L<:ELF6\, ;^V%W>?X+H_"!&>[J85**&32#B.Q/9 MMG[-4ET]IT"6F$Y1C-/^X[=D\_>JH2'TXXN&G;!4-.+E?F<""7A_8/8B^,D$ M/4I&_6F.OGI^$F":00)&]A"+$J;ZX6CMK6K(/B*;&'"06._OS.[TGY7I[R/! MM[_0K2AP\HPI7>W*K:X1_*TF@#^IQL TR8]V7R8(TC@2U9EKBNM&/\-UW!=* MSO+T(P&:F/W,I/86&V=ZV9@ VC-0G0JQ%*E[($61)5J5:,Z3RB*,;'R\R.L; M14<(5)C*("*C.?Q<"4K'A@EK*[*E%J;8WL*EC\C#W^,2"(3_O45-F.96+D5TA3L5&O"H0\9VKRH R MF*76>089<-DI4EJCUM(#71-:R_S6$ZD\7"["+5WWKKI$O>5M/M7Y%M$'CJ>L M/BK3R!I(5%D.KRDPX+R747Z1T]=D*[RMPYU@1UYZV3G/31I?JT")+;?C@55*M1:/[B :H\ M[%S)MT=),%NTXC5+N\-6DNH:_,73=$0%3QNT_%0I*)R@Y8NE6Y+EV&,=7^(Y M&7NSW%SXN!524LT>VRJN?#HU;BY1I\U+AWMNCWT&%87T0/=P0),+A:H&-GT* MCLC9'99F&1N7J=&8/VM6BLC@/ZWK.VOC/1M+>H49BQM&*1TY5;WRNZDU@8>>/L0\)\!/S#&E/5&MQ8M)$ MG/ [%P]KQ=X.MP_9\;9,\FD^&I C^/[R$:;K4WSXL31ER:ZT>U9-4^_\OWT8'=\YG82"!E9S!!)/>7:T&TA"%7+1 M2+X5G5X%O _B['4BZCR^;G;5[^8\T$<;25:%'$]K?:?)CFH*0U]Y T[IE#;E MM\E30UMB##=*-)*SJ?F"A\^>\K'5@PN7/Q%?F M6'2@5^Q[U3 3;^(\1;E[DE8X#!\J[AQ5A'A^XV\M:_N%9W2J=#+. M!I5*9U?-\=2-K WL_=@'+0>D2]FVRE^CX31_ MDX>SV;Z+J7@"=Q),SUFN/_L>FU5>RS4Q_![.'^/^1)WE]OG77N)4@8=XPU), MCMWFXZ<,Q\&PD-:'! W,?$1B+U+>(Q.F +\<013$^7J]%H\3;A[(Q(YS!FG%?O$S_&HA""K@.:R;+=0A!;D6%).6;7 4W\HG8/ MZ3_'5Q' YG$G'=ZIW!GAW^)BTY_S[QZ1_U>G:2QZLSRO_>,Y^#\C_LEJL0&+ M+R!KXS5B?UBMQW8M#E1$\,/T/I9> UG85;@L*IP;K%5Z-/JJY'1=+8_UEM;3 M79?:.T=IS:(MVGXTN-) -.4X!C0=Q"%_*D+,ZTTJ8\]T.08]&FJ%OU/%H7EA M/>F"EX^J5,,E(L\6NA+Z;BIJ?C^AG@\N:V[:DF&&!4F0 M1N@3"X&A36-Y5I3Q\$([LS%T/#,QX3EW9\#4T=PSFA7SUI'!2A:*,BZ&9,/% M'6>#@!$\C.:*>8# MC>5##CXA=]6)2 XB?02&=;((CRW_@]5.#5[7D_W18$X2 MD#M& LY"]NN1O^YMN>%7A?ZT/Y& 7]<[7"]GV](FG.O=OSFUJT$"5C81+8QD MB!42\#R5./6[)1;G[$664G^%9/$G_+];V+%KR/ S!-,"V9)#S F1C=8#(TV* M!.A5$F\A\+Z_7TXR+JA_7K0OU]!TB1L+_N'D?TPYM^K M6OD?7\5O$Y!M8;Q;>SH'0=!4H=-YU@8O(=?@CDS=&OE_]U/>W-I1DJ\'\=^=I$?*$;+AHRI-7]PX,LG\T[O,P MA__FU'HFENAI[F603PB7Y[O\NGZ_3;P!\5$*!C7 (%XA>N:PM=*M_4ZXF7^," M[=?+K9-Z#KP!E"L7^7C*9\ L?G*>^,:&$L.6C/L7/Q,O>BYU: ]*%VW:MJ^H M>NK/5]D&/*!G27#O^GZ<$^!:)0$.3B'U(KA2_"46F:U>+*C/;7I!FU-N2HY%H'EW8D&GYWQ5, MQRD-N^*V6I!R?CLIG;N[XM#*$T[NKC-4$@^9M!D(;KA K!R1OM<'"[HZ;-*! M=D]^;=;M A>==L???QXA1,..[/H8SO"0E?+C3%I!4>A46?![=-$A^(D^/VY[ MAOLS)"#,>=1\%"I0L(DJQ>_W4F;SIN:3/=E/%#8U0+@)W'WD8 MK!UOZWG[R\6\':ZWM/)HU=+GJWD3SNBSY03)3[MR,AQ@?O]*AS2(P MXM+1O3Q^ ]"397+[&H7RW*BSFP52U\MAMM$QJ(*(!'&KVXRMQ1;TO%9WCN!' MLZ-J]0N( \,\C(/?W59$6KP57E2G9.28BK_83GAC??_Q_0U^6%#X#@>=?)F: MY!G^74NQ!+P0_#Q6UM\2E_W6L^$F\>,PW'#&0#UR<'.H0'_D"%"U5 M]BIBPYP$/('+YIH0;F*)#3FFOBG<,Y:6V1^L##8<@5U7XN2-XYV1-Y1" MX#6^890[CY M8ZG:<:5YH#=HHF_1[PA6+:3!9HKMJXE=.MPA3[P\1\UFH9V^ICH1;?2LL\:& MQPI6XPY E12YB:=Q7[/L"C)-;;EN%LP4F!J4F-\372>,UD@D 8)X_:W:&*E24Q9 M;->4CF:[;J[%Z$0IZA]0LFHPL7[TZXFB4"*KYPRZ(GFF1[/5CSM$O2[);$!" M.EFXP\S':TWT0?RE)PY>CEU]GZQBI@]E4D<;SENU/J$<)HA@'[NM'5-.6R(R M8\&!$D6G8F9N.GC+.4GH1,D[K4].>EV]R%@PISG76 M&:8RU$F>%=;0BWUEL+W\)B_]U.QMK_AY]>>!^"_3MA^H ]FH\\,PX*9N* ML M8&J)AQ:[%L33/'Q_L*CV_LQRLK7ZJF HRB-LR)[C880:'_+\"]F+#)/1;D[A M?MPX$EJW6&Z.E_'RC-T&/L$US[5@BSJSP^R$^3V8EN1N/_;R! M+>W'1/ZAVON8U!:%4Y\+F3[/%]O+\,[+W%"1XKQ[XPSE7&2_M]5*9V=GX7R) M/#B]*(@@\-KV0UYHME&3;3YXXM#%S^>N5!5X V=>A_WF(QS<0-9U)S6)=>0= MJD\+^J-'*TVQ6_-/+R2)*'8B?()L+Y" \N5\7"AV1A,'Q2O;<@F%R]MD>&HW MRTX>KZUMK_1PLCE6&>KF&%IAK"[PQ$GH S>5U4Q$E-XVF=->=A#)I&S7>=_? M"70+;;!S +?9V20?FFKV2+2J]+.'5X(\'$X+?ER]I#X^R^@\PJ]#>P6%0";* MMCI% M$7PX/8P4FB8CS[?F^N<'HKQ8,]51@0SY@E[ M'M#G!=PW+_2QLHF,3A3?&['>Q%?C^[FIUN.K^,P3,SQ;',W(X)@6O!1.NU%! MO'C=&LI@LCA:\"S.*,/WY;TXRG3>9QY,7>HSO'W43N'0HS)/<$'3T! _EGI- MB:,P#Z8\>\, Z;BWKC[6>@]19FP3(F4&2^H7-\Q#SD9/P7C.%??!-=(61T*E M'RT[2!LD<*O%6$=!I#J%+AWI?UN8 MA+57)S?;7:A\YL\L[7,C*T?W?4599J>SD'QM%:\#X!W26D1-=IU\I_$3XF?; MHC*S'%V7]VLBDV=O\-#[KY5_UCC9KC2="!3G>\[<[*_5O9M^@Q^6GZ09OGO_ M5H"(G*=[<+RU-??MTKR(0QJ]QPWX>F0@HQG7!P@R$N%)33R228WT%.]YQ,.: M0272%S^\4+3AN,S=,D2Y&H+*9!,BV]F35 M/Z_G=;C5ZR_G-72EKFI%F8[@4IUJR",3SJF+(;_:-[NTZS,N-O%HUE(-DL-'"I="S7%;)_" M6SI4RRH4E18VX[S5C>OK87ZO.KA,1..9RR'%QX*RV^TU--CBYIC MIZ&LWX@4<2V*RG7+MWMG/TF#]0C:++AE53FX57=O8-RDEVS&Y*NI9\?XW-MM MQ-_0A;>>;3F:'4RV96VU#Q,N.$"N07$W:TUS<4FMH_M1R4P# EO=YJ/C58F3 MDB?HIJG./2T^')W]Z0,-K*(?[H45:C6)3[A#MH/G,2E?AY:JWY3F&8]_W>5; M"S_O(*4E4MRH)_T0.#+/R0U*]02A0.&NT-#)HY^+I%.%M-]A:2.<'*WQ-\1* MN)=+!3+N7!+RWO"GAZ(/VU(.;A9%71:Q31%HP JFYGIR(9@:*[T+4XO>"L(\ M3QIG/)>IC541KN^@[/:0>YY+$3R:BVI 'K4?K8BS*?"4:/.C#S1R9H_S18N8 MN@:L7WW;#5ZUB9Y^E*>N&10:NJLHMC["@;6<5BC&:K:!CZ7;MA6^+,2Y*%<, MKO&LH#0+#6DM4-8OL^-UP#)H>FY=JIW?T#\NT^J\ZL"W!2+ NQWI$ M2$@[R+98\";^\?!6KENI6\C=CGXUGH"7X[0XSJE_ M4O/#.5#?YM]];M-C1^0=^"XC9B^7?'U@4KO"YD%I7NJ6;M23O0#(8;+2I[8?,'6TF0P=I%'^"@*!$^TC HE0V"9B^C9CY M6R)%@43P/HTK><\XC"38DHVC4F6RS_8IE00\)GM(D7_+I1AOB]CD)-OD&&$( M-H/(T@,B!EY&$*G5B#+_DM'1.)V\]]B0W:7&'!+0CL1I2D/V&+^1 !P;&#?\ MMY2.?]'R[]#2->69?\W<1^OY,OLAF;"'O=N9C4+=C4(*'>L%()P6_ J9RA6R MUTI)U@/H/,VI74[IAKT99\),@?TOZ8]&6J8V>08A&$D(41CY,_S_R9'T%] _ M"6AF$\)AJS,%B]@;3@D76-T4,FX CIXZY:"I=DZF1..LP8&-1$'+T:$2!EB$#)8';V:Q($@FPZ$UB'G0/%[OO2&X()>O+M#H C$G$^1 # M1VV(-&HDH(VLA.F+0AH6K[Q!3%LA"/H.N@>ITOX"^>> &&A5AI<)8*TSS@^7 M85F-35Y_<,P8-=)XJ$Y[1?$^H:/ _>?D!_Z_V:YR?A+/BIPT1NA?0/\/@?*% MFB?%^PHVW33<"A2$-A;D+);./;1^!+*8#L2-W#6J9R8K-"X2,-+608SR!GZ2 MSHR?)?.7 -J_8/Z[PN29+$24T4N;*[&:#9J/3BJR.<[P)V<_[G'=4H8>;%Q9 M9,D<0"P*^D-D'1$S:.A.[T9.GFDJ#I>POT%8$OYW7R7]/9\]IU^_OO&5A4K^ M.LG?F\7?C;3X!SZ40BHD #GA1&Q ;$?H%QA?EB#X+2.V\&0KZEZA"WJA?8J* M0(O9CZJAEPI_/+TDM)L=#&,JCROWKH9QO7 4>7(FS!H\2Q M%A)0$CG2MO;D_?=1',:6!E'7[A_QTRL+C(@:HMB< M8%NW:4X=A:'AD&.U'I@:='PD"HS3W)1@!!\SL;< Q<]M[IY&7;N520)J#3OU MAJQL*(_+=/MU@3$ZIN013E$2?'.7O1T3,@B:F,(XM_S("W19FG)C]R-'.6?4 MGKU7["YN=/ET1!4#T(X]-PR"B^QG@(WVG[DV1!"E@@<^:7^GERFX>E*&\Q0W M94QT?@US3)[^0@"_M3-, M;(]30&Z_=Z,.$#Q[/$7CL.J)./X\544JH(.3%ZS3#^4C#B/*;2*(; 1[C&$+ M\M 2XHBKW I4L^JS4[EVJ.&CT2_-X;SJNOQ1^G(3\4J5,-;'$4![30.+!OYF MYS28KA/U!G>->.Y^E=/1BDPWY3>I+WQ??7U! KPB7T[->[1?3 /YOJZ_L1]! M NQ 86 N4&ND*?JR)T]W4SU;;>R-0'/,@+FRDX?\)5F6MPF2KQK#R]:$&WRN M4!3Z;+OLUVTA1J6VWPW#63,7V2L0C EJ[X=<'>ZAAUWKAIY(9=*X6=])T80D M O31I50!= #8_O<<\3EH&21,1IL:)[Y@W%_HUY%KJHS/K2WWK2D4ZZ\WH#J1 MS_QA#2J":-&%WR0!Z623D5\,@?OL>_8WH9\%#Z-H&4(;/[E]4]5.SJ_*'KC2 M3]A"\]@AFZS+OJ%@GYA=!\ON\Q?U7'F0.*+\&8'*J1="]/60@!CV!H(]$F^XQ3NZ?(%D=[ M?E=.QJ\'S4L"C*20>XQDG($"1)L\$O 3+C!F",K:L&A- CH9H$09"WT5\-=+ MB'U*LIA3('=I]YI>(?KN0PF<$AM7#']$1=YS@U_CDDF LBQ1_2#6/F\][PRQ MLYL$+/* <8R(#Y!AQAEBH# )F.Y$O%QJ^!&1VH^S;QBGJ[9]DZR9%8:,E M48GXS@:\R6E( F@T";WZOT$%^7'V:_/"("6/2, >;0B1$KS^SUSHP0*R;#F% MLI>8R5OPC8ZP>)6 WXV=["D31WS&-D>EQ$'^IPSD+X[]G\JQ>@+[V?6"6MSM M1('QJ,/O\-25Y$D:$UX?_7WB]Z"8X6T'351OD.,J]&-5U4#!_6@,S;RM3NSC MQMGMPICWVC_'0XQLU)\],Y(3,["V 2G&2#['/,\2A/D/X' B=^-.9' MWT+I_C_VWCNNJ67=&U^("((0%>DE* @J33K2(B(@(B(64%I40 2$2 \:"(* M@(" @(!($P$1(M*4%B 4I??>$GI/J %2?O&\YYZ[=>]]SO[=>^Y]S[WO_F/Q M(6O-FGGFF6>>^7YGS3Q#!;ZR(A=P$U1 5QUP1A;&A= LF0X![D688(?B;Y?B M=ZMS+'2/R#0Z2=R)%USF5WGMY'M128K[H>:^7;MJ0:Z74A\ M4?%0[0OP*R<@^MLQW^-$UUT#^[@$@<55XN-:Z,$-AP&8^ZS\V(&A@7U=\HI? M8B75R@SDF9B)DR994ZR*.VG^"@4BYM29"@9@U4&U@E+1)AT?2%H< MRXFP \;MI MO8IBAGR"37+ X0T0UCSXXPA1[75[9430G*09+]4@,%%61D01.*A$W6M_G@D M=B-I.1%G^,Q2AK!WL$#3)E-_;XDC0\5PC=[;V&5X^LUV[NCIZ#-N-Q@+J, ] M2(3QUNB!S@?E>LZYZI1\+US8Q5Z:@S#>=ESE>/WU!06#S@PM<) M)W$S'?*K#=3>N4JFY!H?^8(NDB'VE8(^>(G5\+Q#F5F9_L(39Q&84YR,;*G* M^1M//V^;G?)D+7)"6^N)$K7>PA4A?.9A^H:][I(7B'X&*G+R^+$F-Z?Q^QTQ M='"4B,%" -M[K/+^LWPJJ"7)M 4TZWJNH:X![&(EX7A@WJ:+=\C^9?G83X'7 MU$H.R9=!/$7L$Y449]RN^>IQ2*'OO\W'^P1EWIH3/$&HKW#%,JEI9D%G-XWS MU6/*(X&2:_6VYFK/1>ZPHA.H0-G#]_T\'="!O..$DEI)MX7%WE&1+BGY)27# M77!3>N*K=LL+N=,^:RWP.R_RV!GXHC]':B+OC3S6_-SU#I\9GMH^%5?3J\'> M^_9S!T.7A:8]O[:S8WR,X\P>NWKK6UW3YJF#GL!=!#\Y)4^>"OB-L:QC4X@Y M.)/GHGB=Q#S[G+=%Y26'M$68]ZXU>3HS><;T7CI5\+6.?ZE!89TQ0,WH'7P, MHV+R3-XL]?%;^]B.45-S!O'I\_,\EYGV\A^J!L(#*V&5Y,#"MGSXR?&XZAU* M=@K^? MXY4PWK%Y?W.P@3$ZK9^%[_BI%+#HF.NVT8RR04NA_Y<_]<^5 M;D?_2/[^*4='\_R2WJ'BD>/I8) [+!C)5LD[9PH-DBXW9(;O7DR^4I#_*6KV M>,JMV%O'KU][5O5 3G"?EUI?E^DOWLZU![8%V[#>!%K#)UK BPV9+4!L&/S2 M[9(^MCM'MN"V<= MIV@J\>A&U1L'X<O,$[/A/APDW0)6XN&NQ#$WBZ$>MY]I3=B]^\2I-(]TX>YU\U4/65+ M!EV.Z$S5VEAY7-V5J7W.HTN+J$ M37[GB%ZX<4AW)3'-W5CB^J'\?1>$P2G=5QA?VD'8*D_<(MF7$22WZE:60$&= M/&K)WQ=?RSEP1;_:S-I]"%,H1K=]G0N3EEY^?;G:>X]>>8,*OM^"BB("MAWO"VI Q\"JV2A2(&:E]#%U2B9VO3'MZ/89$_=)#$2,K'2)'94#15@ MD_=663,C)FN8-,VR8*FR-'Z-:4PM%W M$RT<-C6[*/1P_3H7HOCE0&7ATIZ[GW;U1QF0LDB9O9$S+=$28XJJ5OPF_HCC MY'B?TP@9F+L;2+&ZQ5W M_1E4QZG?G[>H0_YT0-P*9-!5K[)/0]"R?Z[8DS=@\6.$U&BO:*QN74N^\HV] MKP'#=E[B$(4#$D:#.08$1@HSK:?AQ#<%V5 7W^RQ=]5;JQC;NHM4)D8&H,P4 M,TY='XXK,!.E=+<:A\RCL=>(8Y2G8P>1XWE(RK$(XO7O>PI3E6K!1/%D*O , M5;HS"J;XZ*[H3D$'B&W;:](D!BH0V=AA84(ZA:0!H_9$'(C$T48%:FE(F_G[ M-LAU4:(_%6"@>1'"$6\8B I A+=2*&WUR#9:MY0FA?^!4M,7X,CM;7 %XZ:/ M' 5!0V]TR$F70I,;OU$"LB:3@";OKZ2!O6ISFB?3!IO1,&[;5_(LI("0O#8- M);+06&U,6BGJ5X7\K+$3?ZVJ)CGY.15(EJ4A5AJRRN7H^749^&P2C J<@SV# MX$T@5."0;B\-WZZM0AZ!%DFVI.TXRI[OI\O?S\OY51E4(,!P KG#CM"DF?T7 M*D ,T2BA675RY&X[TG8",M.,QG-1=,6UW:&_*N-7"M\HAY!($:/^NQ >*J!A M0Z,DZ-4SIN+O?UT&Y">%Y]+XR\RDSSKXG]:FWB?RO?IQ\/CE0'DF/QOE!J! MIOR\-]F\H696I(AHB^6^%Y:6H'ZL1?#,D1QQIBL'-6J%3PF4R7HZV*D3 M V,\0K;,CR(M56GT;TBNBD;ED+:T/PCS7GFRYRY?K9%9T[LYSLT.CXV/=QQ3P-..Y>< MTXC:H^V)M#MR@4W$:$KDN<=+2T917PU4)]*N;;^#QFE:*S8]]C9<@AXLU%-8 MXIU*C?BZ>E4D)CWR:?SA!P\?I@8QOHFO)M@NQ8\G[R;RPMGM[AS?Z\U/S/??IYY"A4-ZB M)- $(Z8MT)*Y*+];S2"O>3#V8U^'GH3IO6#.\WU[A?,$QAX834XXGV'D1MU' MA5;R$K5PHB@\%ZZO?I>%*W1"NM91UFR$K<,K[O+'"\^Z

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

QG^I/HQI+2ZAMK@S]?RX!2R0J $ M<."NPY5XZ][_>PD4 9V((9BC)Q!8IDXAOT@,+\0=>=*C8;I//KP M.L79(QIC/C/C=BM(PO9XHJ^H[TP$!\LCQX1R^$_(T8L/([NG;!Y*A3,K/'V9'/\?CL-S$$_['/=.I%TS3NN"_8$\\$5*5<'8D M&??&L5XJD4C,8"CE.?+SMJ,M@8.$IR8A/'/#R?2XHMIPW8PN<=T'&6_<%6N% MP$S I^';&6-'6X^ERG,IZ\M?[FGIZ830K7P%^1R%B1@'((B1I&>$[MC=J-KD ME:WN6R/I=FU3!I,BG9,"?"\:CY;)+W#&OSB-Q3*,2!>U:JN?+^ROZ9,(D':? M-V"TO?[M3/+;X9)_L*ITU$N$#Q20SUS[2CY'1;6)GAZQ[LZ[$!D@PG&E 5H] M=5VCL_\GV\L7 2QGPHZ^ M_,;:94N&5*,6U !FVIK&.D<(P4&F**QD&0__T"6HZ2 ZSM?DW$M/JLKK]MD7 MB,_F%UY<2QIJ9@9:R98T#(1@R1%'I%P:7M]U>,"\N"VOS8K3"DDPJ[T5FGH[ MY[QY6%;(V0"XB[#U$)3E$(2=WGPN*D;0::X@AI!>#E.4*W],%PY=1)\4,9<+ M%(_V2.H ]>0UZMU.%F@87SM]\AA.E',>U?GZ@K=9-G1I+J0CUPD_T$$- M-C5S&$=EK5HT!;$N:LZQO+W/>X?1DH'E ^@TR'HGB"P#Y./<$@]!KFB&T!1L M(BM'U!*A,VO9ZH.>VD\)XXCCW<2N._F(FB1H'H3(SD]U1-&<4FC ^!2$8*8T M@>X\!'U$M0)Z<.04;9X1>>8F&-MCG; MC;%X!)<_@G.^YFS& ]0EI>O2=Q+OVIF8M.IK3-I;%@[QQU!T.G,@.=9Y3C$U M<@JN2\RJ$M-C0P&>UB&#JZX#3_XL5*DFO?T/+$3YRS(;06H9Y!YB$D'J'1(< MGS-L+Y$8Y0,K#G1,N2KLRMV>]FZ!K6A)/!NF9I'LY,H8D[M<)N+H]E'X7-U# M'\A7X8DF/N[S[0VGLSS]'Y=*C,\,=*"FR+03?N1;\!_6%J%[6/:90] IF(Z' M%)+;X_SKVH0SQ6=J&U)=Y+H$N;Y?EWK G$& XJ&ZWID38>K6*64L32*'F&W M(.]:6=F-!V/R$3FGZMF87Z$T;2.5Q85^6J]7P Y!9"BB]0(=1"M-JXWY&.*5 MGHW?((IWQ\$-:6O@JM6*"=NW ZR)I/67T' M.IK;,;1=;]B5K%_\7/O,)_V2W^2;UU*GWZET&#!C.(-NJ=B&6P>1A1&M3W0U M*!)JS2S4THNVVF'O#.,.0758.;XJ[\C$*HWD58;JM8 P%='T/#=<-%L?"Y&B M\-PF"_IMRB(ETQ16D*]DOK7))><"I#_#W]5J'Z4%9D=NKQ;GW,U\1U:""B): MH70MRP\^!%4-M"$!*S!;4!0]/$O!]ZDYZ.3?LS>HUK3^>G^RA_$!4]EQWVLN M=J@4-+814>48B5LW-">HU3^NG+V*G2OSR, XIV+6^;L>'O6H%'DD_/:EN+JL M.%NO_5/$Q4.0FUD$5!2!K: _^!,2:L[4%]>5'ZJJ)!3ZW(DZEOG@A&7\F0"> M]:/23DL;\Y22>;?6NXSF&>?"BD\-!_I_#OH^,OIE:M)VU64T*#C^YL;4PUBA MX;+8&-L7(Y8/53&R_B$+9B%!A1C#04?3,KF#>@IG-HVY[R'9 F8$J2GNFCV[ MH>7CIB V'3%0#$ ML>/MZ^(XO_8G1T4N7/U9;CYL^NGI0V'/2VFCKW.JE7M<'W2D&E6L[)^\@/]N MS>_&U3$P6RPBT[WO= CJT9FGV4L\@9[P;Q:*#GB->U=AY*6)N(CN\6I#^&9,C%-@E,_:9^"\1+;6Y4=7[]$5ZMFW]5'%&O2-,Z!TI>. MO9M)>O;%GG?ECK4!-W]\"UX]EI$3'#16+)&:@(.NMQ1F+L0,XQFC4>(?R=XG_K015['MS,0N MAE/-LDY7BGD]CDN?"Y)=7GW10M!C*D$-H*8W:2;) M\%W@85>_U&UX<1\+9% "LA;)J2%D(;E*NH%.#CAYOLU0 =_K8>HA2+3RV)]\ MW.PCQ41Z7_%HZVX(XU*.S/.,^VV[0@EC=R0VLK:::4:UDD,W2;ITM!S=22@! M0JX0 Z&G:IX'HK@Q>FZX60/6^51V [SW_NVV%>-&W;$6IAS!WW+[V42#6N(J MUA6MWFK&"63;#E;"A/#YP8&\(WU7BU8(RE93].K'[G_9JNR??B&( M6WKCU"?LY'S3_)KR^,KY/Z6CM.]3R+7I8MJW/'E"H&!QNSV'(#3T61,/01]G,W4E=,\,TE;Q>LR=!$ I" 4/@A6J@4I /,? MA2D](4QW6(4O[,7/-1%Y;IO@A#I^+H:9V^>\J_E2^^;ZKU8]Y?F(I,AE*,%W MB_(X@<8<@A-22LX[.U:;X.7@95D/A)0!J5(FY$V6PF'%-]IE4C]XWQ_K$*+9 MO'ZXM?Z60YO^N%&(UDL(+#(KI0LS.4?2 V3(+!1APH]&(@<^*GPS;C>%G:(\ M5.Z[#E/"[3@84^0)]N55S$N"3][(&BPT!4D=BU]%8.M(X+J]YV;M#A>P'!3N M>A/J>_AI &'UA[GWU-A\M4.!G_CLZ0X5!GFU CEO ME\I-TETSP'T3D&7J]IO*@F+!VQ60YO3@OR3FO0#Z[[V>&6R/ME*_?IO'&AD_^RAAF@+C@!'T42 M;IH)PT?0HCME/H\^;)8%,*V(?1BE+2>%&[$T3+GMDM3X;.\_#)R,&9R_W MH RHZ7!&F"8P3<=:YX!=$>C?A98!B7D,O:">6CA)3!]$9WY"9ZS8J3+G=D$(V+&>]. MV^N=-6>0>5$&:HDG__@3RG.-0NZE1-HU%S\JNPN4=:U*CFQ>3.!/V+"\>H'O M#"A40/ODR!&FIXB%,WD0NJ_F-CX$#28Y_H;*4XX"(CAP#-VS#B1KB[SS#/\^ M5O>+=7@AV?2J56J84:JYO>+,RZW$DS/C@YB_*IVY+,1C!?FK\IG;_R+]?Z1* MG^[/_E(# /XGY3\I_TGY[Z&TSJ/X$PW;44\A)YKTBS3FYV[*"I&.#:!QBLKW]$%3+E-RL4)2$PW#]EGE7&(VCT*CP7)D9IPL1X:_TO= M/C?L'<8-I\#O?9"X+V#N].W4N[6M5Q:1$6:\^]EDET-0J[^N),PL:[45^BDF MNP10TGO@=(FZ._ZFS %UXZVY^0@G=6CS9ZQC>C^\F^XV#-!3[23T2#Z028S M;[8Z"HY(DO6[ON"OYSF8F;.%\,?/?@N>S=G_],JB,6#S-[1T 2YP_]-WV>^A M9:<^[C3H:?UPM(-"I4M-*/*4 16B$.=K?!Y#C/NEW?#^XAZPCD]Q3H[3BB6U M H&M1-0QK3=6(*,1K!5*37*X=7._:KM0BS8?B?&#C(UCCV[&2[RNN[XU=R)* MF-?;]:L)29;NP8_"S( $DIDH?+QAY->I0:3W>);K!V MKI[-@.J! %D1T:J!=D%-S-&>]8T81S+LPHQ-IX0@9'1/2 ]8,=/1R$#W1BO 2=:D<%'?- F G\*/4S2'FW2**MGZW/AFL9V==,^S>M?;0]R67C\1])EE6_' M#TJ4IVZ97/NW2BBM#(K^[NHV_TGYCT<)HV,D1C6ZKH73Z';L5/,IH)H4#[RA MAU1M(N7N=G?&]QQE"2,>/./FTOM<[C?%OX0)?SC:H\ZXORDZ%1=[O,P//J%TK?N8 M[6V]<^='*[YNY-:-T&!R!\ST)S:CL (R!">2/"&YF."YI6-"X^I7$8$ZC"?> M=VEN"NR(P\R>^NA^+6P_6"V@\_D^-^WL^T-0V>@AZ/O#0Q!&D,Q$8J1&[&Y. ME.$L]]J43E%"D5WA3IX^8?G>@T*FE^!$\D0+^4;KX&LFAH6I[TNY,W T/E: M@.%R/O\N8\[^E6MVK.3UTHKZ5UQ[CJ7J/@<3E/QVWU-X4=$!2?OSK84">H6Z M[NK\S;VFY#Z#H>99Q2="?]OW0 >6-O[OT>< M+#JP/-F84 ?K^"&14<<@G!G MB=Z7[J )RSY54^7.XY(Z+T-^RHL2JO[&!V?'I6 M<$AUO:%K;MZ/?LB%2Q^#/(Q9;JJ;.MBM4"V'K1T4L[8@K*H80!Q!X;W0<3"[ M]%Q;CZQC$H8H<3!Z]"0$DA3H&K;X,J&QBNPF426!M+#3/4*7+WY$ZU68=851 M06@9SB6:G2\]$-HIEG>3&^^''>"[4)ZR!:#O#>#S\S1U#YR]-]B![Q1 M22BT:G@^6E!Y.2MJ9^>K 9IAZS.@V;92K/UA+/-QK^#!%#--"@NO)F!H+ YT M,--*E,A:X\M3)EP[>A]M.>1*OID2^FAK/S%[O7#@M)'!IN7QYCQJ%IV;^ $1 M=Z3;3X0G.BKX8+8!YTSDB/I6U\#0J%,3VYN>0E8Z14*-K*)BF\'-=:F].S/] M;"7F-H6?Y2L+[D5P'..<:G:FOD-CXQ$?][I??1ZIV3P^&WK!+EM>U8SY^T=Q M2-GTI]@@:G'E%US(T0\%*=9V))SNSTU M2"-$> :R-&N*EN+# $XKX;%K&+IE.4Y]<0CR_(:K R#$[!O(.^F&%(NI-&K* M+8N9$Y)30TZ-AE^?K$ZN$M5)].]%G*"-(Y@DLCO C*H*$/RY]"-*IX=M;#VO MY^=DA]E[<78="]#BIH@US>&@%)Y8TB&(FD0QI'.=/REHUG5+03OJ"P'9H64? MD\HK[,-^UB3NHP9(=Y Z'!__Z[2+[8)4'"X1YJ6P?VY=>/65 Y,EM]U(^M-6O$C[AN%N'GA'"1]4/03% M-A2\MOKJ5:JT,^:+7'UP6SX,\BO%%047&;"LUFH MKB9U<>GN<-!"WI1T_I6-?C%EUEH]"5$#353_([C P);@KP&1V%="P3?'$^#F M])M?V+E1%K>EO9%9T_I 7$NN]O'%)OS:>+_([K]C"MLHKO?/&+;!M:*_ASEL M95=-A]\.5>@7-G[K/9W3NY"BN_A4_C]M?_+_MXO=:.X0- $AZ0#OB'[7@*6Y ME,GVUO#8^$"AGLJ*H,%Z6T?(FQ?8X^L>,4#5+(^18CZ6E=TAF(& MS,XEF'(;1\H)O*DW#5)4.1MS-B/C:DK#6V*J_Q%Q8CUIEZZ*#91P:GU0F"X[ MC&MH%\(>>HZ&M9M>#@^&6HR;B'RH9^J&E.'/!Y\'E>R%:NO3WPCR5G"F-OL^E"0 M#?DF&>0*=J#] !/\U+LP\5".^W2("4X8.P1Q*&V>)^6!1<&TX2_)8BKLK?SG MRY4.03=: X[LQ]?=>6S6R@&D8(KTLNWI$&OQK_"%*'PS XXM)NRF?;+C&(M56M1BKD'SN3DF/I1+OH>< M@C=<*1Z7K(9OVA H<&;U(XRF4E"QJ*)@>-\G;)//2^7'F$.2" MG@39A59N7Q=5)>8(06E#3X/8X+HGI1;F9)&+38-JW_? M+K?HF/O0D/;$?KI'(77+2/P K-#[:0W)\A&0-<[AOX;FV_/KK_N37='8^3\] M=^9?79\/08F(ZKU6I2F.]J6V0Y @C6\Y[]PGEFM&'R8D4HZ'UY@[P4QI0[RZ MNQ.W[091]NR6EOE2 @I9/JK+8T5!)8,=%H$KG<9*@:/#NS7Q*D_*860%PWIU)((&)A=SO' M<\&"+(EFL:$"*S^.T#B=9M2]SGR?5>[CRLHSC>?T?W#T00=KX1?ALPB"&120 M=5N/)IL!V7,^FVN3LA,.LT^RV\=2@0&#_LI',8(QJQ= RY6J'+G/?^=!68I)F?C-W(JQSS MNHK.<_F3DGV/=ZNUNTD!=!4<@4\BJLW:UH6PAZ#HX;:LL:2WTU3D#2CG[PNF M\OX;D@]4KFI?^Q!9^VCPL@@(Y40X!%&$(\E7IWWHGJ.,!",X;.ZAJS-*,Q_QGGP C(D"\#;GAP!W2BVH@(B550Y4WIN,176[G,_]'!UFCK MAG9IY1O;49L&+HU .ZH.D8G"+45GV?G[);2>9O84_U;:P#!C\<(\3V<(T?>5:?O#K -.3(ZSP"DA/:JDUX]>&5-? /&AH;^N4.H-HQA("*-)^43L0GMM+AP"E$4N32^ E2)'AO-$3T3\?Y MG^$20,.\E$/035I3;;DZ^V M>EL!QB/- 0AR*N+E#N8V,9*]3C;)+!5*3I;<_+.P'8[ (@]^8-:%#D&G?VMJ M'X+<0[V",:B7$NDS (+&JORG7H_(-QI)2JVO?9'L-**M5:I7OS+@R[^ENGT( MBD-@IP>>AFBA<3S4]TU0EYQUVL^/M0W=1<'RMI7@#C#!QZI*P(V 6@_S48.O MV<5&9,D_L56+Z?ZD<#^6E)DPX9? 9/!^BQXE971O MZ1+_'#:/!8F3J'R["#XN"KK2S:+49.KGB9!Y(]== P;DP.UF//1W,%) .*>P MA48:C\#./GE7D9OYW%LQU;U2=9&Z]?Y&5%F'$_5;JV9V/(5(_03!)D'X$$Z0 MR,Q#D!#%B]C7&C)EF=ZA1K33)WVNW#R7WE9^ZUU;%K@VF*8"K$9&@Q$0.*7)%;^01F#=52:[/JP#X, M0#$;W$KP[+WPR=->[C.IME;738NHE!#09"FOJ\XJ>,$\<3ZM\97BILCLJ\9? M!^"1=-YYR,?B=?T"^ 2TFBD&KC:I;8((\2+YG9K2'QJ_GFCPG8)I%5, M='=UE+*=U(I7H;C<4 B=\O=5"/:81#9AB8'*@,T#=ZTV#R/=WV5OW\?+O?[] MQT-"3B&P>\A]5>2S0Q#IEBJ8>I;G]O\H.'I*/W8:.QVQOZ*S&4&B>_OBGM6] M S0(@1WVVS=V6P\Y!/F!#V!Y:$3)7VI"FI3FU"D\*!(8.$(TF,;N=9I-2;5G M^=9M]8F6\I.B @S?O:I7%Q@1,>+3RQ>*S:X_$]F6,_X14.]J9@>2<(^5A&$Z M1-\W*/>&G*,^ZC:#J+F&VL;$G="%YV\D'#EDK^.?7EQ&L=.?-2(;T7HI\!#T M/!7&_Y7ZA<9MB =JV]_WX&*(N['3X[>YPXY_;UW0#/"P O(Z]OY=BFTM5U[EIL"$@2M MN%=:T^U/%]VF(, 4:9HZH$QD-2&*ON%=J[.V%O3Y]L@K2."H25A:;(RSA&_\ MYIMG%&9#VR;[. MT_H;AG#+#Y K;N68:)A:;8%S>R'X*5=/6%YDM4_9>:(:A]MT@7Y);C:F$3__ M:&E=G0<#T@@*OU/'(>B4[BPAEJ38T#!XT6"6?2_9^2KO[LJ.V*"9VF >(A01 M'G!>3#Q/BL9,MT/'[(!Z\NT9.\H#:D'1"$P*6Y;)KZRGDCX:U.G4&,#$]"VI M&JG:ZGJ,UUPHE!HK0=A3ZOEHHH[OS>O-(!:2%LE:=)/CBWJ\G^,]T+.=I]WM M"G2G^S?I5)C56J_IAU@/TWZ%(V33!^>SP#$(7Q0@M]>]K[20M]G!7]+JJRKT M_MX@1<>[^^SQ(]WZ1&$8:'P5$X$6V@R.;F:M^7M1B M[."S4L9>N.=JZ)21:M RLV&B'N!5@N).T+[6M?0*4;T%/($RB?"(YZ?2=FOJ M]ZQR]^MUDOFPPJ(F]JL3OQ_#[$=_V!4<@AKAZ%_AI+I6?1[KQ:5EO?]2\?F/ M74S9\"'H)Z6U?;*#>Y9?#-T]08_VX5G9Q7YO>"L<__+8]>7WOH]?^*H-F]:_ M,5;77' 22H;%TH3I+N58+QV;>!R"^OKL#D'SO0=Y\:3SL*O(A1U>-D7%"@V% M?,&T>.O1Y2R[O)M*9[]5[NY,=EE![,='3%0TWD\[%*=<:[2^[=!8/Z81/E5G)" MCI9$[D/B)M&'X?+PK]!/_(GTG@1K3JZ(E.>M/,UD8Y? M "_/Z!X#^N9BRG"/-V-^B56/*S59BRS%O8^'GOAU+O9";^K, GMA?WFO 8F% M.46"Q_O/[$8=^.@8H@I!X>QNQ? BL.\APIL7_9A:YUC[^7&81)B/CW^]>AXX ME8@?G,_Q]A W$K=RG[K,>V\K^0K(G:&;?MLLI #"R2P:4IW4(YG86-F5FAPOH=H=6 ME6J_-6P5Z@^&$F[%(=S0@ SD.>TH18*:11,#W+IUY0G%79LG0PE 0NM4C6 \ M8*W_\?6,@^/ (]_O=:L/!5E#G5R/AQ5<^=#'E@*^0.3&]0^LT>A3^$\'H1F!9K9?GFAKH5 LYY:#G)1^[D%2IX#UZGTTO0T],^O]A[[W# MFEK;]<&X%5$4V33IQ"U-BJ(@%D!B0P0V(" =B8IT 6D"$A(%!:1%041I$1!I M0D0ZA$1JI$LOH27T$D@H(9 VRYDS9^]SOOW]YGQSS9GK]YO9?ZSK6H3UKO6L M]WF?Y[[O=[U%%G19#6-%S3 9$60?,>K'\.78:SL(TB<9ZGR"096_1SY/M.OY M5'=SK6)S0Z?>^9Y"X2_JVR)'(5-C'O<8EHCZB]H^##-F2&]1>6<(+9J>3+IC MAU>%85TQY6I2%U7TO>"=0J?/FC9OFXJ^V"N?W(CC/HGS7*-?,&E&E_ZLV%_YI1$KOHBGA(N\:NFV M[[IO5^R[L3.7I128$JK4QA:<$&0J;1?9 )6B1\Q;5M,5J2;V]&#'?(?O#FZ? M53 OBZZ=69*)(/\&O?Y"SYW%BPX'WA(YXD@*7.D$TL(LL@DB#COCEQE42)J, MW_*.TL2^"!'3WZ3FB29,*-Z>*DSU<)55NNRD)GQ7E!\:_ , 0))M[@H_Q<.J M?S7 R4<-/Z@)GWN]7UJ:%N>\_TF$-]>A6>C3X_]P^2]6=13Z%Z,#&62-D+% MAY>=-+%)&234/X&5M.:Y]YHHJAD8.A$2=$R?$5)VM?[GFJWZ=\&_"_ZY8+%A MPR2E&./-RN: #B"C":;L[P/.?1J0KTM[Y#?X MS[;+NGL] %C9_<4.YO5$>]Y;J3 M?W$IK!C\MA8.14FK \BTRVX1OT&'"5/:2<;EQUDCIWC+/Y[<=-3"S85A%8#_ M/T74&S.M&$Y!R0V5T@EVT0=&)=8/N0\%#?6NR3QS/ KZ4*#FM+3Z#U* MANGXQ]RC#W2$?8S=XF+/^-\1-]Y^4_0I?H*\DS[^=L+ENPM\%@K'=Q 7OK\^?B;_YY6:LP&FUR M[(S4;S''YJR^3;T8:W1C^M-9#$OV*()B"8ZM0/"5&1W9I4W894V *7R1@:$) MG7K2_AV/I-Z 4TAFPKX^L_D$2YRC"1UX'[(6!\2E27^)H&HU.2C5A%_6?&TB M&,1P2"J6?7M7.$7T5L7B[('V%@M^@]GD67.&!$.578\KQ:W$3+V>6@MG2U55 MOGT )1LYDZ8#5K.FZ7.O]KQ.N*F[1T3!/39EM_4V$<*3V6ZD8NGD:4=WJ^2 M/NZJAF[Y_+X3U$=""KITFF+.04.3FTU5NX>F[@BEZ 0 M1F$J!>$B["!3'Z/ MCF;HR2%CM7VD1XK\US.!.58ZHF!IL*_"^?K@N[!M.AV ME'8B7V1R ^0@6\K50:37[.IB#CWP9D3;N/76/4FE@H-;S39_+TGR'R=%X2'> M?*.-C:@2]$H?"1RKF4.NI'U^7.1!#-4)%,/V?^2Z=[GNSFTV]=NBI%>(51(' M5'\%,57\L_/D/L$._4O0O2DJHDE5Y3-O!W7\G@_ M'_2-R&-H93=3.'%:>#MJDWS(DMI2Y")X/G%?B>UBC?:^V7MQG_S#QB0?Y51^ MOYU8]]5CZ]1ARH9@RHFY]X6W3_NX&W6N;Q2NH#UTR1TKY=O>?1O&JM,K.G:= M;V?=!IO;%D^<\M(;']U.F$QZ/#CN![1^UH9W1.(?;)(TE[IT]>"9#2 MAUD(;11 G2K'\J*MNW;VWEN'>[YDC:[ ' 'FU0NX+2:HKL-6MV_.',YG0++49R?6BH"O237>' MR'HKN"E1;0@%T?BD,AKBP@'QT;F;?=W.\/WJ6J/Q(D&N?/C.U^.',E M>T@J@QY=V;N)52.!^=932O"]#?>HY4I:AF_]"9;Z\@.YV09#E4:!>O,PN5?4 M03=C:_&J KJF_\ \6PZH2Z=6#1.AM<\[&[FHSM *-:JHX+LRW!E^N3G9LB$ MM$19_V_/GFT=C7I9N=QL>.]GORA@^$>F1ZV17A.82UO_48?O$%R%*HQ1>;^J MVT\R^2X(Q;ZQ:L2)E@19/*Q5S=9]^Y5/H!L#Z-M*5"FQ)V+!R%-)J/- M(NPGM@M8P9,[AB>!5-(3L)NM&T1'BP1-"U(LXR"4!@C#-_'2P_,O[,4BZ0MM M"%(:CC8D!'\4-,WF9;$RL-(PN2&,WI2;=C"5N^7HJ'WDE1\N0RLJ)XM7OQ-$ M'[M.#S^+ C@!'6 KPG#(.:'8VBP-:=X+O]E@D!54W[SR0 MSSTQZ!M8IRL_E&":9@95WEDQ=B%">9S5PY\[Z>K:]H^9P3W;U#R9Y-GJG7:@ MQNZRWD$ EP\32")1VGNI0U.Q-=Y/F4;NIXP6J.?>^ZIHB$;P,ZM.W:&J!,=% MY\\>[_HE 7(C+PNK'E6ZHBG MRA_@$HW9WY$F<>\S-B>N4Z(&HKZK6!]S 4EOZ<+D*";L0YE3D_SP06E15CP' MY $=;B?AO_$)PJX\-HG8QO%O+G!%1LGMV_.PM%%&)?"PC9#>!F]7GK5Z"W@1 M19"A?:4@5QPI!O/3"M':7"2 ;*NK?8WQB)[8)"Z=R0#!?T"Y/9D0Q\/SM^E] M4QH_IOJEK9RL/:_]WJWU-+:S_/$'0E78TF%I62 BDMQ&DV/@LHN04O3*,JD[ M6O-\?>&("EP^*++1JN)6LT?>M0,9\T9?#%^^+I<8/J[4VY0J;/CY_HTW[[YQ M][VQ4J H3",;@%0ZM1:IE39,QQ:"OB_Y?H[= M*Z.L#+HB//A_?$IX0>=FFQV0>C,*GFKHMZLQ^0IKN43TUK$C8_KF&#,R1 MO1+O2=D1#>9^^2<%#,@^TS[#VI6\*C>4W'^-)]>J+G\=W[P4V.*@ M3DEN[#XT&43 P^6^]FS&G=NKP<[)&_M\FM"B6:KU*XB\>E-XY^=.>T#3#UNA M)^(17O1KC*-WQEU'U;TB&'BS&_?KZAR>VRK.C? Q-[TGTF(/1+7N3-+"6#\W M/@'3E3B@%BU(Y).CD:'!GAH]WGSTO8VU<44%\=J+[Z9NMO%U^BCR5#\,=O>! M9D(H)GSTXU:-X)'N%8@P!^1VMH0:&3=-T"A^9][1=S98,ZR@D27OQ %E /*< M49AT!.':\ A_F!X<$0^)^EAX/P5SXD:G0@\6V64R;CNB_Q%^+9JD(S,]=OV+ MS;X[DFJ] >E]\'2KK.V,9!\KG:O ZX0BZD6PJO"!\^=PHCC7Q2TP3Y#2TA4_ M2;\PC3N/SHS7:#R"O2-89^OFI&*F] MUTN@8R,V>G'D9^]E'=^^O?&MO5HE)/&.D?#.I#"U(J"Y*H;DU*X/.SM- 7A0 M MQ[UBES&W.F?D3OT*T*:>T!<+,ITX29G+ SO@1X&_9LZ][_!)_-_EL^Q9'X M_G%Y&LA_'F!PBQOU%TL26DWQ_=7RA7_L2"+AXJ%V=5AN+OPOJ[&BT;2D']* [ EK!S>2O91\4!H=A)=BM*=U- M)M'LWZA>186NDXX@@'&J!\,%/PK]#*QMA$E2^!@"W)H*>])KL M:RRP@RZ)W-KA/;NF4G7YF-I5B)_\0 9<].9E"G)DC3;#JM,1H\.8$'H(P"V, MZ=T*<=I.17JJ+W5DF->'SBY,80>\#C^JR,\KKU8Y2;KU+NQ8OC#FX&$'V^/D MW6S:"U:MSAEXUV19Q7O*DWGV02K5 ^]P: !S26H UX2+&(6)?_S5?;^>56EU MV032JZ @;E[]%>S;+T2;I]PQ0/LXAYO*1I3CX^;HG0QQ1/T5'7$W31/\VC-Q M)7>KE,C(VQR0$[W1,$5,>LB\PN'/]D*V2^X:&V>?K[Y\H)'HO@D5Q:*#7P)<(=* M1(G#I<$\RUAU2GP2D8\W2'-][E!,G>J5DI2Y^= - N:51&U,3+58=KR^V8D/ MSV MCL? .C^WX>73.8>H!V/YF<:LZ$WT"*X%J]/[&>99L(PK'5][OID8X%*X M.!HA'VF J1Z3Z5.HK-X0L"D>%7TO]2 N-0DDN<84+R>=O+%,$Z1G4J8[_;*# M!&D)5(<7Q""_]2MWCW8MW,B(F1O_?5C2J;L._GZH'471@P[+6 ,N]F4W9$C2 MN:?3O0BWJ3DLUGP4_)C[X^OOO#0*1[1;FQX\JY8Q%=KSY7S4M;M>WW;CG_*L M$S@@@B/-K' X"0DXAV4*=YQ*N6\FM/UFOZ/Q@G5 M)U83?IUZ$" 1.0^]CFAP)")W>:]P0*%64; SE+7(311A'E\A;OG"Q?.7( E# M1=ZZ@N.*:N=N@NZZ[%U'A["[^CB@^18P8_/$+RBFO(XH!_2A'[P] *:\HSNR MPV\A)BW\&%HF'!!*%+'V(_N/TP\\B'^_Y/:?'FO1O4*&L&& D,!=1?YQ^E21 M _KC(E,.Z" R K*@PH_C#E*&7WO[CFEV_O?=:^Q@OFKC4_12BZ1/[<25I.-74*N3@ MGXH;);=@A2+.I7@^&><7*JW5^>59?^(H5A5(3N^!-'X+8%*0"$@IXB5,C %A MWJ?,1VD'%MNEJQJ;\$[D3-*>M/%T^O8V5O,G7"+<($\X*HAR@U,!IC:5 R[? M)NM3"AMPI;SE*R76!+>WHQ;CN9%%XVB,D=HS<8D(>TS.4]/94\($N7"!,[LF M1X*@39)77L0K668;M7Z:2W%7O-.JX%$'-$G+SM@!"4N4'_9B@MUT76-SU M\S\^;B)BAEQ#%'"#ER^:4KE7"AF\\#XPQJR1VIHO+P(=':4V6%+'#B0]P-87XA M4 'H&^BN59]C56WD!;Y#*K41QPNLGAAC/F^QU_2#Y595U[10%\.(#L>F'_[N M=T0V,5?7@X=GV42G9 .'Y8!J/@?HFUB8'><_"Z M%PWWOEP(^M%8?Y7?4E]9UIP#>HYO!&^*A[-WL]F"X,.('^Y\C*5BA(L;![0Q MSA?>H#0 M'I,_+D'2?X>=X8"NY$'6"JI9Z4"P=L="MA=,_SB]Q07YTS60/PPKF*<]!DBL MSFD.:#)3[T_GE_^V__^7]H>WZ/SVLXO]O!]I343[7$KHI^XR^]#7'T>J!T1F M=55\.[*?351!Z1[0D4AV9!""HA<(2&:/QHZJU(AUVZ6(>W'9-SS]3O3G'SB7 MZKYHH#^Z6$CV9TA'""IV^FR._WY..N!X.EK4P(!5G#ADD?M^ ?*7F=]*YN?& M%%.J2*:^)Q%\@)XB47=U#3%"YH"^>LE,EHL1YH+"8I5*9FC%RW\$<3&F\GR; M7\$1+#3JA:M"VZRQ3XJ1[,J8G56I,6&D>.X"YNCY/:;F3;U)%S5"#$Z=&E_I M[=-#O_Z7W&B5Y?OF_R&W8!AL\2$: &B9$V F_S@'1$V!$(L0SN!=*2* -E*3 M') 8.I$#@@:)L".JO)E@0T"07T)O^44A%HZ@V8=0.]+A_Q(H*R_S"?U78/R< MN&]8I].!O?EGHO\I[*MMV%",TU%D7BN#<"G8(LD>[HQ1I572=_*"%##FB9$JQ4VSR6;?UB=,^ M?K!>T]Y3IL9=5D^*!%U*$F>"F&O@PR>Y7)27E?,*Y;?<= 9MO4)P?TTIJ I, M#32> _JW:DO^66UW6$DX5QI5PB.?BB?M3Q2+6<&-(+PC!OLE=R:\>+*\%J7] MTGR6H7L:L5H4J(#+V:]+MPH-+"X6*46GW:V^/[NF;_&X[G-9H*?,HI_)D=*5 MPKW:MVL6DQ7C0)'E@)8TTG_C@,:JHC@@VTH^&A>>&<**V\&W?MF@6STX<\$= MMZ]OT^V=09(US-1CYMH_<>!]IB.U&$5));9D4[G9_%$!?"L3JXA1 <^EZV,L:S;)#B.M5797>JBK&)YD-J"L]XIRK<3RW-D::Z[6G\= M;%1D.*KB"(KJ0M))IS#8PMJ:"%ID.CN9E2>WSJQR,*F>*?8KE=*S9UA5 R3L MWS%V^=&0\ -)Z+.WZB>*R&XMQKSK73KK!D:V/C&C^A.#0Z%=*D/R'5]_OYH9 M%RD[.F>PN$"PPMC9??K7@'Q3X=W?P/"W_?\-]E>#1=D_$'M@>TB&J /TVJ8? MH^Y'4W5ZO%F)/O*=WXMQ:M=OS]J8<-" 2L="7V=/EH](S 8>*_](29-_DWVBK#_1RD@CV\@]I2>[(]\X1SPAU^RD_KD4 M]TZ-&H_L.Z;_DC\LF_Y+U>L'$65ZY#+EZ3YY/R< /+\O=8T!:>6 KF_LM/.4&4"8OI[P4&^[-.Q1+_PCS]TRG\E8JS>_^=&Z&#LAIJQ 2O0XI72CX2L,_1;) ?+ MR1T#Y( 0SX#0KC%INW=SDI,6V9II%3@5^Z)0] -RB-:3?\I9@K: >.V2Q@&-#!<$[)SL7)D76Y^@X90?UZ6CZ](K#CO; MO9MEXFRS-6%#E6?MO3W)_FB/PMU_E:H]P?/_DYJH>GAVEBNE[5=N,T?AJ__( M?4H+;>-$)SZ^L4HM>92K&=]CM,OW3TB?S'^-)&E[ ^1PF@-B'0&D]E1\.P<4 M.S2=9CB-YGZ$#;1201N7Z_?-8O(+?,/GHM_&#<0\-BOM<4_1F5>BK&EW4GYM M[DN3$7-H,S8PZ"PR"R<'%.,)?]W#8A4+;YX4POA07=@"4+JU^&?-2!IBF T$ MD@#]^#JS&X+8+;.?O[_5;:PU]!^@=_<\#_44=\RZ^$7L$;4X3-J' MU:R9RICRU-Z)R':7BY8RLAVY8<5]:2<#)I]X?$? M2+E_,5[GKY:&P*A^@ZR_^CD?:/AE#F*A!>W_X9=HY1D.2!I1;U;F'0GG[<=X MD_B>VZELMNME/ R*>?N-R+T+F7!\L;<_>F=L.7I=6KJ%^.C=;K&&C]I,CC!/ MHE\2J=KLN5/1O!#:HS+7O*_>22S",0(=E2E$U/4SJKZA=*8T$-;IYEK!L#-? MYE&>F=R'J+]]%BQ-5S"FKL90TN&->2,Y35YLF;UW99(<:7">M/S-8T/5096T M$M9;)E!>6(8 P;Z/E8RYDC>]*@5M^M7&97D6 MKZ/8@? WJKI@X_U'[:91.-X"6:2-T/V$4K ML3>G<$>< ?;>T!247A^$V'DYAQA_/CG=EDR"8X?>(AJAL.,<4$0-<)QA]W- MT6@V/Y2,QFKC<("+L=C ) 89M]&=PK2E;W% 7&&L$@[(5?'A1ZI\)K%.Q6W" M>T2FQ_]8IG9G*FX(\Y'5O.0Q7T'/IW*QCX-CN)L%.:"&JU[L/M8GX6O![_#C M+6..LX2XVJ"6"VAO!8I+K-+]$H\S<:)]MR>_^!2=5[3X6EF&_%*FF.L_*]:? M]+E?X^L.JJEVX5ZKVKDXGHT$T07 M_KFQ!ZN4#3(*48C0-LQ<4LX+AGH@K7\S-6;9Y"7@3?ADE3>2[<;!V -]+RT MW#^1>3"@'!;(4%RB029#99KY[[B,J;S2W7&AHJ_WX*9(?,.)IB\193!>JJ#) M*Q;5)]M6DR\S?O$ED-!U@T4G^2X,[>%6JA(KPR4,@%NOM.(2+L4J@"F/U?3- M6ZY =]!\+>XG&%W1]&[#G\,!X VV;7E?J4=*!!/;H&Z?#B.^I4UOY>FH(NI_ MYX"-1AS140735YKFEF!L6F@ MRZ\][Z15>])S7:/E6/Z4$0:AOT-D;\NO2Y[LEHD%??Y55N.5>!$$G); M1+F*-J8\I', =NTKW9QZS9!*R\PU#.2-1&$GCO)T8P_*B"K$'PJG6Q$W,3#\ MK=UX&;76G,@&TJ=I\=Z"L>![&CQ?#8=S59TG,8G&N^ LW!%*0,[+['!\2]$3 M?N/;_<)];^P_I-)2_'*RR?F[@KJP#4#<'::XL 0[ <+P2W8V6UILJGM7(267 MS:4'S40T/:#TL2, #/SFCECG[D+D86PXH,OH-20')!O*^P_%\Y!,(0_B;D+1 M5 CERHS$0D'V-%]$']WO ([A"^3]8[]7@:.SL6)HQA,(\_7F'>$- $W"WL). M[55H& (=^;CT"!$'FZ>N3:\UKD5-\@<@7^87VUC;C.&%XJ2Z,OG/J-PZ?D96 M$K$'$A4BKC:'7!VOQ5I?H7!< I2)L707VH[H=UJP,,: M-SQ5ELZ[>-VO?$. VM$>F7,%_L[4=_]F-%8?PLO;/< 4']7ZY4N3([C# 8<^AT[* M'>QFTY"*^P)QV7DP/\MP^F9\B?9]H-V= Z+XGF^>:UN E'I']*&2 MUC3L(C@@O!6X"YO+_0T3&C_XUMQ&=4WS-@#A S%,OKV"^#2^%_2-GT,= FZC MIL4]X0I++DW>L8@C.H*A2/91[BA -'! 9=K=7Q&9G:KO9\F3["()T8DZGZ'X MK18.J-&'W0XFX"BQB(;A2,:U%90[ TR[,_E^9G5DSK&545O5702_Q@1 /&R$ M_8,#DNK*"$!%Z!SYRNY0#WUSA;J MML28_(IW+&IUH]T^5S'5*"3Q>,=#,K5EC#E\<:=ZV7Y3&TPEG.XJ>16G+2]Q M2-SH1X!][L6!V;A,\Y';[J=]_3!9J:8&/8G.HNBCF%/U4Z?78PN'/L\E6>S+ M%NW#H$^$W"QVLWO;XRE/J+W)CM.19#K2 ?Y$1E'03#U6)@LURT*SCKAB<.J/ MN[>BJKM:%C/2:)^AT8CRP)5.RO6;J*/P2T$FEU-45DO[ X8%IA@J6I@6G7HC M.&AQ0I55J7-ZU,0MBQZ.3WD1D5U)/F/=[<,52^\:)_(T^%27H,SMI 5_3@QB M_W XKGRN3CHI2\878#DX 7VDT_,+W27'ZP[,I(G5!S^$#*W*UYLVWV#WIHL% MU_I>]4NRPH[*Q%&MA'Q.*4&7WEY[6:A+>!M@7M%.\HG.+:RKV\H- M[1Z 1*,H#KAA,)$#2O4FGO1HRE!/5Q-R%1?4Y?>^NATA?:G_?(7'7#=PE>]Y MY)IVNW<8HM3A=>Z>U\)KT1HOO0^%O+MK_9BEW;([% ?3 *QUAVGTK@H@8K * M@^5Y&V\K*2RFK3>3&U:Q+28]I;@;@,Z!"\-$?KX64_9F<2)-, 9:&^<[) X@ M[*3YJ<9!Y>?69X:R^'*"^[7==D_,QO?[?&UN#4C(YT+HN/9:7+M7 MYB MF9(JT)LY"NNSM&(.B+:N8TB-9 JCV3QNC*M+D8UP87I._DAY"ZQ(YML3 M@6NJD/&@U\40ZH;%656Z I@IK$[+[\^F%RXSJ)CRKZ&XT7?BAB]KFZKB&S''3!Z+7 MCF[U\":6E:&CW!P>6QR3:T1GS^TL#V5OI@-T_DBU&E=X]MS\4;:[=CR[*$/7 M>[_Z4G?J)71,(0?TJ. $,^W-T-AK^OEI[T/M4TA1]PS>JD$5C8-G"W<\Y>IZ MY]3L?J=6WW!-*TB^>J7Q[B\7)<5W^=@'%1CZ="C-D57./$]"2EI;5\05*R\$ M[KX8KU%WRYK),WSS6"SFX;.]7V2VC8ZA 2'O:EAD3LNMJ.QC:P9%6@X^)-_Z M;.LO7M<0N*HMID6Q'GXI_JU)<[ ML*I:I'=Q[-4=3$G+6.C6K>'I"R3)PWFUV7%NSIA9+&+R8)4T_E /66D/$0 M($%R#$'FM1KV&JVPT0F%%KC_14.5KAQ(-LJ?A2DPN*]YL$8T3*2O_,H+1=G4^_M@RRCQX%WK#Q:AGN!!C6 TW;368* 514MT"@ M1N2;=T2*6PE:8<44=H3N(] !#CD8<6#1)?L]#TM[ M>!;\'BV.B\%*$[?Q5W;/@W_@:L /\/N MLUX2AZ.(=>;-.K(EKOU!'@;\]3(BEYTM.V3]&.DHA7'9ZO0(\F'"=\^J4O7P0PXGAHRG$<43 M8;+5._$=,ZB:U%_]>KC@ 2ULB)/UX0H!8FM#4>#9E'RQJCS?-K(-WL'+HK:G M3A.-)CIP=6[$/EQT'K8==K>/R]\PPUTB)90O^?L^:1EUWX5\@!_F@.K-M=VF M^42;/S!=6$@-)->B7VM) $B9NU>\@V".ZL_>U-DJ%W@?%;*;F7]Q!G*Y+_U M$"U!//I6MUD9TZU!V^3'-W;L]XLZW?M.AJ8.?*.W3WENQVJ;!Y"NTWNFC92T MTE/]R6#;T_5'^BUVK+C%"%6,$HWU-,7-N X%9%I06)*&7M)([_/^ZC4)A>!6 MW_4-_SHR6H\\GW'TOMI*!61X(__EYSDTV<5 \6H7^8)96 VL8!#[F>6;A3N6 MR4IM0BSK:#,-$EEKPE_8-Y7Z(:6L-!=5JA]I7]H\'VF1 SIU!NJG^M&%"^]N M 6YGKL":M+6F6]!!%N1:[1^\SFU].LSF(38+])?1E M8$_OQ[B.UPU&M(2ME4(Z8V! M&.N<8=[@@%X84:9-Z>&LN)\0 "B^K-#LM@WMU@0(KKPD;F?AB>,$1I4MK,LJ=9F32+"W6X\ M[%^G?VY#\I'[15>&",MY+,=[B@K.H4M429K7ON:-0=KO$U?[%T<7QB:'MY->S5(7( M=ZIHW2D/\\:^62OS-ZE>JVL3WH8VWC5/P#!W*!B[S[4I#CH-?5[TF+561D\8 M.-,%B;XR\<4;\7!MA-O$46J(;$BA7." WNI/*\LC&+-."IOHUV7L9 MD"GO1#QXX95N_*7OS5XC\);),O7B8:R4BB)[,-<]>WU#'0KE@/A3XX#D6_NH M,QA6 ']C@N* ;GWA9Y_RN0J1Y8 T2W3BJED8#LAQ^9$!$_ZC&*!:.F:76N 9 M9A4(?'1W-1#.4>SO%2,$JHQI%9Y)IZM;577WM94_'(JV@S=!P"[XU*Q%(/,/ MW3%61S+F-> $V@$Z04=[7.]R)+MFL@VQ*1H'I@K"[-!,:GBP&\M4S^/&!,@^MCX13Z3IHGU#WBUTS8>39^'/3 M:P41>#&\T*CRC@DK>-K+RYNLKW<915Y.YGZ(XW8EL7855\;%?7@NZ;IKGU!K*3 MNPD!V^A%^+-5&LKJ9#B@,80Y(!8BGS(!^,_T:)JDV7& 9E>L[&0,$]:@_"05C#MJ/RD#EO=9H;J[M;V3>=-WM!.' M?,NVTHE\X?(-1]AT3+Z!KMBNMJ^@RX4LC[+.:_?67:-YL;**L'M.E;E04IAH-VT-R;R661Q[DEGR(316 MK /K')B:&EP3;.]Y:#O>KP4B2%E"\I,NM!\R^2U?/*BRNU71IAF^"AO"/, > M>5 WA)Z AS<'?&T3XW)__^+B[:SJX&PI619]=&+SR0@NV&U;.E&5*633_2OL MV-X,--H%F?O:POEGRU_N0/A0L#W![$M&J3O'BL/:V0<;*9\(8 ]Z]G3,ER,^ M&A,9U?.YJRO]#,LB%%-PF09_&OZ$+8.I;]W 7%%R8;, S#^.R\,-H#]>\D9> MR 3?Q&\V9E.;T^G>X/"3A1O) &MUR;@# -95^&\09A!=\ 8R'C:4Q $EGC1# MT$^(M*C!30X'/> +T0K_.=5@^ /K.<+Y C_+$#DF&]O4.WMB]L<$#+-,BER M)81QT0T?@&M\-P6C>%V)3^A=N.FDZ DEQ\.+]EO2)"MF&?'66,E3,"Y M7*AS,$,6&JL ,Z=XKCW#7/GH^FH$&@SWL[%M^\J;H!+.E7/WXI4,36=, ;:? M3F"H!\EO$'4*/\&4Z.8?>9^8@DK>*@>9W8N)&J&U_R8!O\P!-:FI:9&P01Q0 MA"8K&Z!$B%F';L V*Q)H00H95\70Z1_5YJ'S^0*3;S>+O<(Q>KQ3:'%@V*(:R^+,/>(6D3//)LU MAG:G0-6=A>^3RK_PM37Y:@U]R"7G,JYF$3%V#_$#97F0+"LC"IAF1$=EPZQZ MRU6CH8>+Y'YD;[#'I;8ZR7]7 M"N_6V2^;E@"3<^EF7T/_0)".TK.!Z-: G.;-4?-@$Y#/S#D3OO=_%D)+5Y#WN07N-9APCPY&.'A57?<:3]H!Y?90^R/O%6HID6!_=# MUI)%T1_7$%,)8(K)(29P+V>&[O?Z]0"6 83UR\S]KVC$5"Q@F#&C:$*O7J+P MX;2T7O263.4BEEBX&P8_2'TKPYJ/4@84?64!O/0U73TXDN"@P[6B+#!,V\C3R'4-!H=Y^L./^M0G8)(8S]$5I4[-P]$X'% M_%R]4(;]K=)F75L0;3=;RD )VDN&P&:K/A?BZ+]!5B[Z^AW.4*^<2;M&V@>) M[#Q8;,.23D)L?_:T1=%V6?=DPG*CTQ FK"&N%TCV8<2;+%A((.,A\Y>*"Y$. MV"H.J%CS 1#>5W^I03_G@"0Q!ZEI2V#*"T/_R9$(U3+6)T([!V2#\[IXD1$' MO3(.5.H>G*/64VTD&*;W]"EB8-E2%ER\+&//3>;F@/8AZ"\8%V'B@]HNC%^8 M%E0 +UX"_+Q?^U)1?>Z8E/'H&7G+7SR''K;C?-'4I^WMPL+SM3*G"I9T-.A7B(KWPTFH%E[E!N] U,H:V4ZBU7+92[M#HTS@.:%: M'><52$T[IR,,M)XW+!R$J 9P-3]:$8(M -9J93=P0,]/39(SG'U*6QGG6"/D MV"'"SQE=8>?8@[BRH08I/CP$D#UD0>Y(S.4&&T^8J@]1U"GDP /",Y4OAK\* MG-:5XZGHVA_H9;HAQOU4\HIDKV#'':4RX9WL@YWZC"+E\P=.RCFS9K-"5@+O M8U_1)1FGBO0B*!;L<@G?FB^?\M'!?HH:-K55&[()7K2%5+N40*"UN=QQY#9B M?6&+WZ[I..1P($DG"F-V/FE=ZL M@\MG1'T=2F*JF\9-WD,T1)E46-O7HQ@S^FOV%26 :WA9I?X4J#$5U;A,92KO M+WTOMU'48]X0E1"&Z#F/L(P,&>J 9)ZVG]V$;R>J)/8!W%>$_.H M11"EJ-#GY2D%2L2(8DAT3V)-#569E)@\]1W.2[?PT_**R%I8=@S@Y"I MEZC*U?>HDB#NZ_T^?2MP^0I EDT.&C1ZT^76F$*UWSJ@QG2I(H+G_./7)$,% M#JA'1':;#=_"0_9>,"&;-JOJX[>R.J>GNZ7-V*>L4:Q:2!^SNPSCR-!D>M%# MB;4H?GIE_;JM6T4M;U/CK3#=.UUY&-GG::4GI@*+CV+=3'Y.*=1'.&^FDA2: M $=#A+94#R\,EMI[:'J26<02U^N>[^7OS=W(%SMNU/'QEZ?4?C\<97-M-Q.Z MXP>P'0VX1S/VL,MM=5&]R"];2K=FK +IFP4B_FI(0!]?G@U[F?PW0L$%^9X! 26:OI\3:6Z^V.AO5V MJE7?-;'([_45Y/E5K^X*CQKHJ!TME5*XKX[Z*><@]^J2)NRA"8L5FT*7T 6: M7CK,8N!4!X(++C41%-)DFAERR0MO;M=Z4N383=BGBL;]5WLV^N!/GMD"$HO+ M!;C^M6O[[!UF:.WE&PV5&4)]$A?(C';SSA"8'#%9Z*[:(LOE-/II41=9W,C@ MU+FXC^.:/59>BX43/7K)30XZCWCM'\+S(ZR7[ LV'OF4%:])6(0]4=;*\0X) M&6.L&;%J=+2LI\E6XD9SD/EYXQ;$&N&D]R*.<@L-UD62$7M<@5P?LM+;?A2Q MEK6U4^<#6'2755HN-4G *E&Z/F6H2Q5;R][ODD Q8+%L$+S2:JBL)/-"(R3.9)^&Z%_G678 MAYC*LK5_)XYO:(^JLR58V$!NQ"'2 4,JUQH.?3Z5263!!Y#F--=T/9)L]R+T M=2Z;1Y%JCTPEXL(/MLIAVV&0*X'1\00V#R]5>SPX)3),6[/'D67Q.9 ?U3F+ MF+75NT"=!(+^S&UE#HA0 F4XJ;M2U\*LZQ:'N2CO_D5:U/W7VR1 ML^KPZ$.5H<[^9IOUW*EC351.ZT3SHE"9OC+XQT4=PX9W8]E\48WW\KO2%AM, MW^3C4TQ]C-622.FC;K7+H=WE.OO8?=*\ UB1Q4"$$/R$FQL:@J(1 V0?G6Y: MW]>69P&N/?C#;[#V!%N'*9!4@6[V!/F@4F_'(M2AB5!!0+::[&>J4,G;3\M1 M/$N!@M;!#D[-I7KEE4T)A_???7(!_.*^'N#>O70'N^V)(T-O',/R@2H;#<,] M;M4VHYK%&T7$^N8-1N<>NOWFXZQ&6]'%\UK5AB3/U1$Z[2%&*2?UOJ)EIX5B MBY]9Y,DWLA_[HK<]7>M$C/B&K=D7F*)O7N&.PLZ=89&]]C!'9 MMRF$Z>)QWS% ((/1> "MICZ #\3#)@\%O0X]-TI L3XK67- WNAPM;VU5ZCB MCHS!6WX[OWL,.)RDIX-CCIOTFG% YQ[E!5FH1FHA.Q'?]%9D$<)PD;;:+/KK M#Z>[U&J: -AR1DNQBB&N2($@.9@V!\0-_\WZ62 -1][[X&3Q,\+,3O 8NG(- M\KM+1A6ZZP3P--4P+[51."9MTP/(-1\_U2*>0Z0P?-22@+U3_77FGW:@;B(5 M1,B@-R'V3/>8=R_6)99I3>43:;18Z&]W"3=)WOZ1-GW"UN?)V43[R;U#;C!D M)O$AKK'#..2&J'U;AKQW2G]*S-RV4RAXO;#=*_('F#*,*PMD"4&9'VU^CF:E MF8PHT^*&F ^POWG'XOA70.4,!9H/EJ'QZ7SPA/.Y B]&?MJ\I'\W1,%*F!HY MW1T&/U"< 7/D8J)&X8$C+V)Y.* EFE?7G#WBLSU<8R=R?U M4HWSTQR0$YL0L,V51ZDVE4TH+$B:OW[T5N)XD;FPN+6[Q]NMV\>K0Q<(=JHO M1R'J6T<0<1!NSXUYF"5E]/4 HO)8]RRVP(1QA:G7M J0^3P9QW&-= MR9NP/;42_"O=K\E7&K_R"(2XB,NQ0+%Y#E(&_&C>7![(1.R58CBV1:&2OC MW@7$2\MY5KMR!-MT:.8YI++K69[^#*!M#VG$Y(Z!KJ(E-YXY5D<29;>9T>WN01.13"K?RW!\NK!1KU[!1%)1^'Y MA@PG>-?KV%RD@S$D7+^&7<)#]\*D=)/FR2Y%I\B': >IK!:]_5+'V5 $L71; M>%F#/A\3/ ]V@9K!#%_D7DL>#8&X#+*[,S@@3'YYMF=ER";K6F.L"1=)IYSU M+"K=SM=OH\6T$M_NY>Z_AGA"P[9[Y83&G"=O4VQ55GI@N@J0>D<^2%H#5A.M MB"O_N4X'X330Y.]W_NXUX]B8G#"]7&'K(.C(O%(?&O"HZ=A.':ILWJJ\+E<. MNP.=,7EY$7G :9EGH]ET$I4XTF)&2$RAV7I+0#M8_$ Z/D3)1TQ/-DC_YH6( M/R&";#"W )AVV NZ&*(?!AE(9>V0H$L>&V]W@+#+XV^=10UO0Z\&L_#/UL8< M^[2BV.5)P8 4X+H<;R[&2H*Y/O=CH"*&5B$0E6A6Z!SBICAJ?3T606[F@+ZK MK^?[()Z?Q"\05*&_0;[I\G*:8/).V8 MORG$'UH>GE\XANX\5&3%YG&/OYAN/(ZC=&1;)X;LJZ3 M1'3\?:<=&^[&BGW@%L*Q06-T[R^YS Y%/381SP&]43\8%$[D4MUY2\I9YX!6 M%QCGI[F;K.BE5!%3^C/Y5RI',F?F?IC,[1OAT=NN*/8KO:0UI.&@2 2/5C8@ M>)F_?:*'T%*H\CE9=$RC;.7@$_2+M6.O6EQ>72>8C2ER"=^PJKHX(X[C@'A' M&$H ES$'A(@4((M%T?.?EY\'+0NFW7*Y68DKIVRT MRA\D9;P$ESLYR 0%L)*O):LU]MB_*M=,6KSQR+[@1XJ?IX&ROCS!Z)))L8X8 M>SA#AVXS90C>X^H@T3-?^64#5EW<:T;&6KV:]W@V\'V79R"9QJ9W*XS]T#Z' M6ATQ1J2UX+38--;%Q#^@O9.:U *)6WH?D&]7A];&M2J*W2A53)H.Y MME^9$%N4CZC&@BN;Q-;]UX0^/2%3; ]S0#-U\)'$!SK**BA>XXN8A7KSL-L[ MXH\,E'ZXMTXHCP<.7:..33>CCN0Y#T>I%%NDI V5Q<3$LN;7FC?.3JN^U*AQ M0WTTAX]/2LXR8K+P>(H;F64_H(_SG$3VSKF4MG/:_ SEG23[Z)8[>-2#S7/'.]R;Q">-#W]=VOC CW[%(7DWGW0)2O+A M#5@4@R?QSR.:7*:L81<%X1C43#=6GE6*<'WO5XKGU\M(/9OJ!;G0Z4AOISVG M$ZE[&P-UI*B!,9]J^[PJ)*(0I5-Q=AZ%JHJB,G,6VM(#U-N0H6Z5>Z1/Z4VZ>1.T5&-.N(4N4J MJJ<*JZ?ZIR9I;I[98\O58G9[N2&*]_IR8&X<$)\Q!U0 Z)ED" ?D9S'.Q^:Q MHOHU#7DZ4K2(GW(R@^)DU&R6;2WS::U%0K_*WA,9^7+M-]?62]H=0[,C+L_A MQ\PZ\KJ*I7JBT^SRQ=^D?:A.FATX MM9L,#]FO=OW Y/L6N^3,9F%KP#!$XTUXWP_X(L:I(*SNVF+/_%8\DNZ.'G6 MC*.DQL,P]\IJ8>P2JT87-L_%GVL_?@54?>*T0G128MA7^I.Q+[MSDV<1C?VX MJ1S \57>\;MYBNNOV")]K:+3::/S$%L6@G69),K4UH^!*G) &P80X"Y1Y :3 MZ>]#XR8V2R[/)=D[C,"Y>.)'K^[+QX MH<<\*L'F.8N2@?>(X?>=?^Z/'&()Y( IUCCZB:-Z[ZGA)@%L6>\#;N_N+2!Z M +0PN_ 5PB=TG^V.8/;7!RU^2YB4,9S]WY^W9$*PHX5;'H:9NGY[K&E_ 9(P ME#C4]?.39"RK)I!/JV5W7R'3M'6*P5NTU71YZ#[""S=B+0F.ANY_@ MHNS%6DR6AII)ZJK()W[)I70MXYQJ-I3; 97Y2#7&07H.:EV3D[R^CA#(48+W M,B=YQ[Q;/0,KU5:?S#[Q9IZ=)&N@?3RG0Z\"8JH[(Q7 \(6J9MAGR,_GI/'] M^W,: 6NY X>]BHH^IJG"W5IZNV4[CWB'8V;W9+"Y>.[6XN&C1/[24\F;2RH MUFG5(2DW!)'E]&W,(C2Q%PHV+HQG0J<>YBZMAF6_NPC(H2,Y2AE=8[6$E+'M M/H_U.G+N&)3R#CYD"R#"C7Y8P*FUG8WH1<2FM709HN$0PVYYDKJ1$S3ZT\29 M[4,<4+:H52."0D!0;J^)<$!X9--:5++$+L)YH>-]=V[B@4VV/XH"X&(]5/O. MAO729!EO"UN/]E"\P04G;8;D@"S@KSF@7S]%*+#FSS8/[.3LM+G,3U+!>7JL MOA.&,SA#L"]RQ(/V;NC(,FJO0VOBX)KY_\;>>P UV7U[HU%4! 0$I)>H@"A% M+%0I41$!$;#1A:B -"'26T@4I)]YW[OF^<^:[,]_SU$KFI[D)'K^J1 M&2L2B+#'L#V03:7:#\AZR# )2CN'!>10,9#9[5:D6,GE/= UT08CR*8K"KIP M"SF#9EH)%O1 DE =*:( !&>UZ9HYN5..&JVN=#9IEN#VG'_O80I^/X.55:7I MIPRR1,\7ZR@8!-Q$SN^!)%?[8L$'X&XD7>\12 MA/9 %A=C-Y7;S;N1/%@',' .N6I$&GH ]/B1-M9;:T6-#JY4+_E\9NY%]/%I]( M5G;4]OG]\;SKO:JR.K/%@54"(E']B/FK,+'MPY'Q9WI[$H[_*D^<\_#*9X/X MCM:;55O]W@.Y8F\/QH?.->(&%0=]/K.B4+6%>X&M1I+=) PAQY?JG^8 MO7Q_H2[&77O+H->R4K B13>?,%]O&#I[S+L\5EJ])<-!4.BG@7&WK*K+I821 M4;/$@;Q?)^[J!H\O'/[?>2K?OU_P4:H[LEFW'D)5=-G%-&/#D5P^BA*TNY6 M0Z'_+W\[X^2C;A7%(EV6QCF?391*(XMQ'G.G=>>-),/9WYGY@';O19/PXQA* M'Q88(FO< 3C(ERG!9%CKNL@20J""S%8](C*X8C2LM/3KHD)[TES1AOP'_8]6 MZ@+G[LQZ/DY"R1%-@'-F&?G^U43C1.H5QH]&>2 G!R[2D-!)=(R$*PB(/(M1H\O2/C5R URR^ M65'0>F7Z!-DV22 K:[FJAD/SO%KWEV/Q>;+?FBY=*OMRB,?&X7^E#0@T9 ]$ MNJ?(U"CPXP/G]T!UP<6K,.H?'KJ])*,FC;Z(^8Z20#;7UO:UF0B[V*J16=OM5>@V;I@VC]ADKFZ7Q2*[,8T(4GN)>6D]0XK M6+PFA.KVK'[H_*"_%VDAO'F.FW8;L7(LGW(&:[1",;Y,ME8+=R>TCA4@'SR/ M,;J74%#PQP3G=:7P33OF*<%)!H%XN@DY3U#D^,+O^?O9-O?=)R?2JBMB0L-R M>MSUON>B+R7-N7KB<.CHQOU^3$BDJW757:*1<4)V,A+NG3B><(K[SZ2GNH0;1YKN8CIN4AS)IZW\[FO@1&BO'J^N0?: M<+H3R_QNM_E0\.#S\T=^J+NI:_])LD3P?IX%P*DX59KH%J%!(6+"?E#Y^!5Z M>=MV(9JZ]2QITM^.<3211-7SX?,W;[[U(3;5[FN#6E_N2I]$Y78O/VDGW#SU MZ1H=J=)I:K):[WZ*J>L/A.EWDK0+60W/]A214A$"G#X6+@I,YG\O%!FU$T2% M(YLO52 Y +G6S&,D='Q%,"_GO?D 3$?*S.*0WVO)L53+%+E4/XDK!;OF/1#2 M"GJW!+GS; ^T;838O/O0THYL]VJI[W +_";)0N:\TV"R0/SI6T;G VY5(ES* M/1-@TXES9J_7!28\S)='C SVOAHG!A[.L%W^UY= M?68Q^AV29(('SF0F$:%'@(AFB0M 7)[+2)K-3S[+X+KFI5.QQE+3:,V%N>_6 M+[:>;F$<1B SD?CRQCITM3BGJH]*)J_ 'FA7EN"Z%BA;1HL1%_GS_;*FPZVQ MW;*WRZ-YYPC!N>_3[U$>R(AX.%MJ/ZA)\T1LIOJG)-5K/O>_+?\X+.1NF#JN M6O[>1&;!VUR,;\FF<<\-5-^:(X-SE9ZF?#L=(@9U_K5=7OENEL&8_%IRGZG9 M0]T0)Q[:+T(JMB,5V!;/PR''9A#WLNBNFV71=$GY62[Y[L<].F!+S&Z F0]2 MI"Q=6U6T64P:E:+\D%^9<90*:1'[3$.336BB-K,<]HHS:%S/[89G\-+E1MZ$ M,6ZW@4G#G5D21@@89N;"*?H7QC' >+N3#RAOPOW(L+?[ RFO='V;SGVZ RLU MLH@-B+BI:?Y;RQ,KILE-W -%H8_6ZY+^-"&8,/'*W&QD,_]9,?R&TA_O$8E' MN,'X>H5M*<,O9OJ=+>OR'S\F=^YG[44@U^VT.EYZT^.1] M8P-+I?$9HJ;"3#6U/2(CN?[+YZ&DQFZO>8.&1)<>ORQ:]W*M-TX[WRMWLHNO MRU6C7;+YI+=\;HAIQ+%+:I*AMA$D1P+KF@[UI@MT#'_$.\ZOS?QN3>0$SN7% MI=>Q0.NW"RJ%8).WN^:+8)J.[A[(O' /]&YV#]2HO(XEF2@"4ITQ>Z!'X)AJ M_/%-&"Z/P:L@8S&8UF-)6@'D<0H_N!8=>.E51AC1!=;'W748T3*(!5&13^W) M)Z/>%VWW"J,BY&X5LY=<&O;*+9;04_N4/9D66_0K-PD]5R,83C,4&]83C\@W MX9;[M#22^U$<+!?8DZJ+6TE>LQUY1NM',=CV3]G4PD(U&7VV9[3*5:I=BG>4 MFY1ED_\A#OTG=M_!S0"2OF% MW5%"O*"=ZI(A$PNQ^]MX7P*\6)(N&CA7W!W5M_IS :F>V"&B!HE43:4MXY#- M/)"9C[>S4$T:IE+V^>3PI#=K[;V(K0$KB"A0[G"3">C5CGN@'C9;SN=8JV$T MO8&;88;@W@.UQF)GR3!^U=>B#PH6VFL7CD+>&"6@))B*D0TN1:Q RNTDT6AS! MW8-9*<.U/X/9DV_F@RSL#IV6?_XPU^F(0:,6F[?3WB MKK-(O8)">E46?.,2J_W42^?J0_F2G-\D\Z[MROW["9H.R'\[0+,8N>$0S$,J M)T2$(#AH6H,(?IKJX,?2_@J-NVX?+8V06@,AQPT>_)'Q>_/B!^BI&NC "Y H MV3S6/_;!8M_)_"MF]^['W?+&)>T$V'_L._/>36JVQ]EK>B5)IK<5P3.4M6:7 M\?FG25+S4+[2,.9[VO-H%W/C[=JY2K0*.CE3C(D%SQJE)S]H*]#S*^3._*[U M"Y^O82$'9%/6;'SCF 1GQ%^;[0"9>\TCW^8,PJ&,].PYKW:QSQF(+%TSNY$+ M&U7O$PF4EMF^>87SYNSOV*R$G1=@E*?O@2:*$(&+6)*[R6J.6S6#%QS+ M@-1U3E.E*'<<&;O5<'/K+";5QNZ!OJB\054C6]SR9QNV(U\[,NC7T;_,)RK, M4=!8M7(^\NP*O, (P98S]+%93%*/T'Q_IV,/E-'W'3VQS3@ZD>UK_UC[O^$&\#F+:^!DP<"W)#/TRV[/-Y%7/6SF\.\AA"ZD:3[ MT%T5-*V^ LJXC<%;R>$)&-X_#,&6!UD1L;)!!G^Z36T,NAHM.I%.";S@5 Y/:W4DYI>%$ O,]6V0OUJ%D M!\_)37RJ7?9OV%X]15)9Z['N*<:%^%LH'SZ)Q#L-H_V8V$P%[I[> WT JMLN MJA:5-\UN\+!O1\O-ETH(^@=$ QO=AK2+R &VT2N 7JU+]KO8B#;9E+BCGYE#),.'R*3GP4P>@!4GM$2)>:<)$.W<+E6 MKKD-$"4D2YJ&>""G\DT17&X(UH^&;><5/NZ!+@INQ4)V1-&IWN:33-;7"2U' MT?DPM,)I)'D90HC'.H)W9: [YO5,I3%,H^^!>,<[H9M\X7N@IF4F"4G<[ .B MZ[7V0-H%3!2XL ?ZU2? U-XA030#.-+)?T(G9K3K3R[#J;*0B3Z'5G^B&=?! M_!]0/W5RF'^E;M:8E8T-S)I1#?=NE)?/6S'+8TR<1;]_0!:-D:ET .OK;=W> M^=''8",0*CHI$6T]2\'P#"U)QK/A?]V-!A@=/T)MMSWU+KY.YN6!/="W&XS* MWYOFI3K->R#.Y\P4MV%=7E"DR]XFY'>*F9O#'S3>DMO0)T] QNQF=*LTJ39F MLXPZ%RGD(GOE+%X0:0>+NDC3^-+9FUS!%\)&O'%I->AQBEUIQMQ[^?""I:C\J]S9+KGUZS<\ K_.P.AY MG6^K_5%8Z./ZP-/#*L_[;7*M%3U]_PW,_[ ;90!Y .D(9G-" M?J.O32CS=94AA!^.KS\]=&?]=:Z?I+9F6Z/K14H)J1=O$7Y;^E;\UH\[S^>* M5Q?X_02]D]1PMFN)C;U+^54^G37S?F$/9#V';CT'"TROQ-10,Q_XN,^3P$V:A"MH#UO\_ M#EY8T-T_WX#]E]BIE\G<9W-6\[N-W;R,;?_<4ICV3,2=LZ(,N?V0'U7_7EY_ M'1.'UAR<,^YR2O>MN&==M2]9V>;_U<+;X5\;3Y@BX]]VGBSL@21R&$(K%&9) MS?;9 R4%]3&T;--UX>C=L";LIFPK]>7"+)+3;P1?9;M[_#R=?79D*A&6A1 M[,SD^LO,*^3>SJA&+CAL&,[_:>J'0^*UKP/F]Z*/O7_[\OO %9D/7JE,(=\M%PSUMTSD/8V-RB![&S/X,-#,''V&.V5K ME>+7'XSZ^.B.U)L4NJFJRM87Z9\X''W2TU=1:J;\(@@5E!T]>#Q,;:/=4ORK MIH2@8JL>=WC(*\DRZ.CT[MOSM'.$(-+A[?#5,TTG ZJ<)B4:=!ULX:* SN<0 M9>XPA"A:KF(')UYG'^B9(9>;'7%4:Z \S]@Z]_DHMEQP=33?G3% SZSG]/@* MFD:^*L)+XB^.V*ROFE+%70Y5XE<_D@BID?*SS2H'4,33O8%N_.FM_4'-P=^Z M"!?*IM\C?L&=J<^1S>H,Z95IWK+A?0;)NYAY^*2G/A;W3=S'F M!A%WQZOIH.I48L5<^KQ)"(1D @/DS>/K/6 ?:5#R2-),\&$9,&RX1%"_,2F[ MK_>7SC-4#;E?/38P)?="34XX*OET%53WAU&-ZJUT3YC9A$>=V_+4 M5F!TO5=@$N&*9;+LV],)#Y:(LM2DDJ,40JHX6*.*92OS.^XGNG7E M3C#M":R:+FZPGB3A 5_4JO@>Z&8S 47=[YYK _Z;.YOD/]H#+4PBYA@WH>.I M,-I.!.,@]MO?_+,75O!?O?182QC\*R*LJY4?E_#':.;>^=+A#7D64=G.DE)% M7NWGM_PGO(Z]K%%U?[A1O/F1OS>VRQ/>R2FO+KODK2JN#-U MREXN0E9"MS)'CS6\71W,@'BZ+.7UJ.'NNJF4I/DZ_F*E7="C,04>@T\1N FI MJ.#^LC,!(4A2?5$4K1HJ%8ZI<%M'R6@/;^.;N &9T59N5IKB8 44=U^'R2/! M M>+S^24 *&M9F4M"1"+XBPG2J>0D'#' DZX5A;3_];\3L[760GG M9GWS>9K?:@WUTN(,IR3%FR3]65R[ER J16$(A7F+^+5"(D2NL1H R&RK-T.K MNP_.Q>^!6K*K%C&?XF3OXL[!X^RNO](6^KBA\SAZ^%?',W?8#DQ-N'M^ MN, )=;RK>R+_?HZ$A=RIN1I;Z-O'#>%<::_\RI:I5;\G_CQCXEW_^CYD:?)1 M%IF\P1?.2F^ *SKFT0SCUV^/>B=Y9 -H ]QYMZ0:I_<7Y.1OO+BE>O)7X3DI M]#O$_JZ>&CR+)N=L#)(/;@?@"X!1HXKWAA*AL.R2]!. .IM&U$<_GB[ MT!PE&O*OFR UDO\:Q 31 M^[L(^UXP M6;EYN**\MHB>7X%K;6WVBJW,<%5Z>I*MF13[P?;CZAJ""<\MW[W0:QAX2&HA M+/5E7BS7/";(\4O85YE( OP[\H*]L?93.1OZ3&L7M4@G+\BVGMPZ4J =FO4M M7%W)]::9D(.KSTF4<9)[M/R[M-O=*4V9K&F73TQS#F98P+MQWC? -%^L+';F M ].KV!FMBWRK,^9-+K79#D/1PRM''F387338-)401Y@SN6 M[ =/'&%1WAW6]1IMO=NFEZQ/^O-#O$\UF,@[]<6-NR1R>-4OF<%;A8W>F+WS-2[T9KF2;K:^#LCBB.<, M?TMH+=:2$,+AU*9"RG6Z(GN6N=K1NE>$ BV<-IJ*8B(VIL5;:M5N;/FYU571 MIM&>!LS";)TYMG]2/U?.IR5 M\/,_ !4P4;GIX*?LZ/)\J:373,N._8_&JO_QZ;;>7P_%!C%_\=?VK+0#?^WC M^G]W6OG7A3W/A-M:_)>^-52V_Y_]SAX?&4W:9P9+MJC<(5>J7S8JT""C8_(B MVV$VCIF6Q9-E85\COCO[)MM,WW PY'?Z1+^!B87,9*$KD)V0L"OFG9 (R'&( M8Y^("YZC$O]R%#;#](V_R76;>].MIBI6K_RJJK_@DNM>JJ0;"/A&98.ZDJ_6 MOV#.\-!OYLC9B!Y\=5]3KR,QKP7/9>L$$6@4]%>9-2*C6O$G)D2#'75\=/W" M^F=[JP.*$Y]]\+$ID@S^ICG!X#0)F;V[W\+5WY4H4 [?3L/&PGV(-HZVC>]^ M)RR3M\X]#GBX!^*[$.9IY,;H@I0M1#=>0C:;*R)G/@7Z-;O=9Q:I$+=&T#C M(]IFY4A!?)PMUOUMEVETW?I,6ZFUSJ$[3<6>;WI.W3@%__IS6'$,0ECHZ ,D MMUL@4?A2VR2J*C#:B3-%Q57:^%&"&DB9">Y%6\$:=]KZE\Q3-%X%VE.VM9\8 M*D_H\$D6O2GW_,"2P8R)6;WNYRE$"_*$MEA B3?L(&+05JZ_7I$+H2]_<'SJ MZ- ?"(_G26V9ALS=&7'BW%TA7K(%4PRAH[=;T6#:%[%$RZ92EAL/9F[C=/X M6R)G1V603*I:[&M5*9?3+U2.D(\^XQP#W^T_8&N-I#Y#=%O9;.X^S2+WZ$03 M<4^C_3/-NJ\D")OT_#RN&YCTQ) T1&C;J/A#@PR(3\5H-":QR9O<,YXV L%S MT54+3%+41\&28>UH4;C[P&J]1I&_M?&7(9\+]DE/O\:E9FJ5YEPXZ94 VE2> M1K9.[']4M.F=IL@ V2+):10MQQE8,X3G1C+C)*!%< 5FW08^+D2L?60/M#^B M$VK)1(\>9LZ8T$4[7R))"?L?S#XX,([M =:'6*R"?(,E"95 MQ$R(85# R3)7!&042JL0;IHB7FATHT;P#_8_6A:=0RV@3V0GD$V,P$.,RFY M<(NI'N/N M_LTP5R68+N=V9ZYV;^3 H!,6.!"P!^IP8BJK:F3S%ZP)O\EYA#"&IYDC-J]8L0<%:0( 7H#T7\S._ __OO'?_\_]-\G+(V_ MA\'V/;: B4;@>36A(8S)0J0:QG0/% ZEIR$7IS4Y]D"ODM![(!$,/SWO7T]$ M7N @'>!0LRLFS8I'<$3K;Z?4WCH&?%=!SM82@*:OWW@1/[%6+V_ ML0!S_V^&RF$((RG.S*#ZDQ09O&9(FLL+S?*_"?7 W\3/]><>B)"R!WJ*WE5% M'63^++V_C_GSWXSR@5O^K[%6^DL(MR" Y/JY#'B9INP@,'^+M8"R-^,P-+S MUV"#_Q+"!I._S WUU_N#-OK^\=X_WOO'>_\KWAMC6E8")1D[FWLR?@:J+8!5 M,@(A[_F7L7\!5U,B]@MJEX0(MG6:#_1/__@.C_X[U_O/=_GO>Z(_Z-@-E?1.%0>M^$9:A7ML'H M-]%_+PA9&$R>>: $XHX5 SQG9U)>V0^MU?-_,H0]8HA67FB7U'#WT9$8MIM\ MF6@[_ _A_4/F"?O2C8T#.>%*T@FG)FL+Y1_E+]]XH 0 MT^9JYIW5OQU"_ Q4U:[:=V[*W_G"@S1!<:2_/\\07Q0TAY9OAT@GVP@,_THP M8;^ZOWC,#_>NA^\74'Q$4+?-(> MO;HRB4#A7T I8");P!,Y';J^.5()6=KE2J/J_ M3/E.'D[DE:VZZK V7?!7>#X]$TA!P?-"__Z4//>P%4V M,8]6D7;>PZ8@V<]-(&_0O8%_[Q]MWHNO@-%.3!"X5_'4A_"S]%B:+FFT4[!1 M"J@ALBDU<%O&M)99+U+63AC*%XTFKEJ.F\[N/.*=:13*/V2>CQB"5D2\@#A M7C%#(M1X:FSE2EA#13]N"2<87I&''59.7_K%8STV;BW3J]56=JG@0Y-8.;_N M4Y XG9^4UX0'SL-"->]2+?U=*2K[#:'MH-',R&J:SJ[-$GK[VH*O''A,9#LQ MN[JD>>G2Q^;NE^#O=:EWOCK&05=@.)U9]PBJ"HV%'-&)X7$NPUL!AJVC5FB* M6_D3UYW3L15FI<^104KIIZ^%IKRYR>5Q5;R8_P_KFNH>Z# GD$@Z9T="MV#' M[A-5.\#"2[4*C5FS<=R$GHD>1T)5PBF9PWBY63^M6T>\#;]\D*"C_J:KF ZVPXV1%5Y&,XH7CY%0$OX MZT#UPWY'%5S]O,97H2AU_R:Y2ZS4B*],/_[HR7!3T%;@?[H-K@@6J:TVU"@* M:%,[TDKBBI8OC+77CP%!-[[^A,FH-^D7KPW\\C1@>?ER./JS%.C9@"WW/IK3 ML8W"R.9;6$=?^B?MXX &M']36-/PL[- @+_!?S#EC\N1E?MMGUXW#-_C<5O2*P M/+*QK)8AH?_8;&.[H/Q(]PONLK,82CLU XY!:) 4([V% MP\-("TV[3VN(4!ZK^L0>RM1UXKRSTX-G4W^XV"C&O;EX2J*G4C8OM><'] MI 36L0=BATN26=MLQC4NN2S=8(XJ_]M*F8=W MM?@T*TY(9+=U%M^!/\;XP1RG$A73>)ZT'KEES2GRPSIU%7Z.,!%G3#&-5WG] M*OSP$^T'D,M)5SV2A4\<&!NPA5!9&..VK$R7AB"Z$+QT#$,$L#8=\ 8+*ZRF M/4TO"4"Z1LL%K<1<=>"Y?+IB7WNL@"ORUD1)B91;@"2&T8\6@^M[8SG]/8>?-F:JB5@Z^/G$GST5 MY3G8*U_R1D]DX_=R3C'(3\G\NU4U[<0;!B_< B>Z%S-S5U'S-M\_/[S<47)@VX:_'3$(%O6&C%?/ M@&.UM?QCC))W1UML)6J9!*K<+9T/VG7"(;LR)I0ZGCO.>TRL/OJ"5S09BH,Q MV$7),C/W.@F0,.27O#98K/;E(6_K8)U.$7!K2G5R7ZN;U'63LJX@SP&.] 2N M7]7AJJDYYR2E7.6MF[31)3 "K 5]E"9!6F4(DAY>_OBQXZ-'\,FO[[]->_V N9R<17+S0Q&<8YR.JX'=40?C3&M.)+RIVO0\IQW-"*X]#%W=C# M\!7#5V8.7%D#+\U.%D7Z=[%DD-'_JJZO(#-9VOO'AWD8,,LK)[$/;+&<4F5[ MLIZTFFRE>6?,JD^S\>&VJ,A25,2C"SF=?T+L%X^R#BK=A!?Z%]D1Q>B &H#TFCK=PLP,$)JHD9V3O0X6=5^?*M,#M#ZVM2O'5&DN]& M^#C6GV9(G@3?OPL50[3@29:*X=#*T37!$D8'F!_IB 73^(#.K"4D+K0)RK,J M&6UD8O*MM_W]0*EE2PB;T,,22]4"=9,[0#G5T[E1A)Z#)+S6/DR3_S1^Z1R4^T:P').R"P!M!\KU8.VQ M.#S!;RV.1*1VHKE._52B]K*VJ39*D"/"MK[=4S!L31M^GVDS@O83TM^) ^LGS)DX63E*X^^[0T?7!Q$5#]*. MT$,:+\,]3%B^F(#]0PGSK^(^.0T%&%[&26U<4$VYV[:XH<->G=)@^D[E09#J MZBFJ#Z(/2[J+'L?JTS]#GO;Z+J]<'99.P,WWW:L^/KV4\N:1D;.7T%,V6?=[ MS[\7,;^ZN]M8QCYCQ,EY:R@"-XAF3<:_A.M\^*ZD&*'-.J3M'(VH[RYT>?EN?3LX>F+KRM["^2?/7WHSQK*U#)5(K895"M AO* 7H!] MC(U!'@83,U;&:1?(>O%N1?9E(^XO114<5)B5PG*RPN6T]+C5#>Z*"TH'MGZG MDO):KNBUB]^?/?S^87X(W?NT'Z8'NBPL#<_]5_# M]0_AG2C@ 4,9\"*M&Y PE)%2LF"'S,V*2L'IJ^65T=WSE-_T'YW= MNISEH*\'YI*%ML^]%MEAI3#I?@@ P&9T7+"\FTRELM )$X$+D]:H$ZY8$9H6 MX>O->#/U8_>FM0FFU$ M43MA7&$SR#=:.MG,M8LBOUI IGUA>PX]]B!$[B?6&8/3:0*7H5N8LC,6>GS5 M)^/Z-,[)S7N-H]7J/GXYK7=SXVCQZK/BQ/E,HJ6PZ9U'7);1V>4@+D8TJU4^1J'7HZX@#0.CL:63$.*X9+$U:*3:@JXZ7*M#0LOD(:THS> MG&SN^9;#JO:!:Z146PJN35IHAQY<1G+1;$Y@/BV/='"TA]R+O_/:_W$_&:K% M&$*2[N"C( >3(6PT.7J8MB3\,3DS/7MB64*MGR'64%^%$'4^S1N<;#B1'/EP M\K6?=/W%^EYA V%)RR?X,62S%A;6]W+_57?D>%DG)1G@$2AT?GP^R^.3JX@$ MUNDD=F!+B'UG).5H4;>X3L[!HFN6Q\D)(-9R)YSII] 0;IS:2:[Q M4SS72TR\7LCVPJ=F(?\JO$>1S=?A3-EWB)C(K+RB[9G:I<.*S^JO!1#&Y2O\ ML[Y49@; :WZK* _Q<34]UD,M'.KJ!^D5P5HB_MFZ9WL>B,X'3OE9L! MZV/6# YI4@^EEIZ]A1]K)6)6MYF",@0IM*FE2+WCST'4>N5AD+^T(_RU/$U% M3NW.-4F.I)XS6WIG#U"T^,D+:TPQ>MCY)](1'WF%J<.Q+Y!?8!TF\9[ V;/D MWZ6DE>LWARHL8^74R_F^M:Z9NW)T2C:S5S6?/O*H[?-6WQB8LDE'0V9R(>7A MJ51C1&_M\*]=Z;7O57XX1/ZS4XV#L&R<0WE-[.5#22PY<";8+79_+V(#4?YA M\_\M-G\;N$\0ER3&YY-#?@AW5!8N?;&8KC.^_50HZNQ!7W6MH-%O^^X(&7,. M]%MSG4&/WZ<4T,,9"K03R&@_C".IM5U"O:HTH<>R]M"SRK S&70S<)0CO!1S$DI:PA2:,MN)*8#T 7S'Y( M:6"R&^I,W/P(UH MGP;:%D>2LZG?!'Q++1].3^%KQG;TLZH>"8(TRUHEYBZQ7)4(TT4@&0-($A3, M23OJ9DZT#?O7.X)KLR:AVN+8(#>_66A$O>K1@>[.4]'6=;K)ND&%-YZ;KT'K MHJ(38GLJTY=]Z96-!Y;!99]2J/;^DC:-9)/0>IV/5M. #?SR)P,?9''#P(.J MBLI*D/[V)?V>XU$A2<'-E$.>'R3*=>&6)#X&AUPNL$#Y,8!\#,5Y492!=))J MQ_3EH?,PAH1J_+WN(,CQ]H-*">WB[>\';R86.7VWZSE0[?SH>_0>R+F?ED)EM](XRFHE0E#O*8/JI$W=8T7_S1,A\AOOOGA[]VS.>O[D0OLR;/+ZZ M!XI(039K6XNA8M/FN>FM69A^!<>6:7$R)R.IP#5-2=!<1.+#*.[&T!FKP5_- MRC5)6J)=F?9]V_:/IQN9P!;R!; F;J.0^^\'E'''(P09?=.:9.-0$HJHG54$ MOS92H_I2\ MO9I/E0?RB-AXY4=5#%'2[\1/289Z;SB"2W8<_-/4E95IK*&V YPE060P M<':]V1H\$4$!Z*D01RS[6-$07!@(@Y%AQ",-O(Y4KH[O5YQ';M-SL?70Y M^ M0D5/7\>>["M%C.')O@P5FC ]86T/%.!6!!37PV:/ZDE2!5O[#O^\U3JP%55A M>I(T$!6A=KK1B)Z)=%>+(YA/:E[F%_'MLXJ$\-'T@KL2YZ_!\ MH:==V):-07$C[+0T6^03]C?63:]UYTZ?P99@D@&O9I(Q(2B>1O5&",0 M/DU)P7#X7?*?SM>N*1(\X@&]/@[XZ_[2J#'VWU%^AS47P>\T=@I_2V6666+Z0_7[; M$G!Q(CX67)G2O'ZX.AS6%PH7/_-Q%GW-$''2[- 3S7VW!QX3D^ MG+F/TR8,!N<;:A*E0*6M!\MKNL196:1F#NKM/XJ!<;?VQ6(/8AT@@G!1^@?$ M8?_.IL;3:&)U)%S7V9%HQ*6?\W5H_;QD@J#!J+?TSLG.>C6<\6!]/VL4LEFO M_C[5B+E,]E\$^30M2V=6N4"T.HXR:C+X0< W\W2T MA9W'LY?FW0>:'1^KZ\]#E8L;H#;T "FTZ5>0MJ?WU&8V?R MH!5ZG28Q4"ZX)1%VD.9;31K)(IB(^NNUI@3^2M-,LXE-3EC<3DZ^V^/#'L+P MOI1KQ,$F=KGPES@,D,Y;??P9\0,M@G7FQG$; %X>,V!6FC,0Y5#D?YDP]]/Y M1*VW .6T7/K.H^MFP^ONF0'M6&ZQZ_S/4>_Z65;3_G.6T2<$%/0T:XO4D8US M/BW[O1[O$"[V#I9UG4@U>)1E%W[8T=- _ BHA_<$+T@;M <*?=0$!<[$[7YN M @MKVKR K)X>WE:-INF2$BDN@#D1')DI7?N%-!I6H58ICH0VR)6=A7=)US'5 MLOK3 F]D_;EVB"IEU !9',MG@MQ&7Z('J,,>XFM #?U"0*";62X[NA6;BGY M3"193SEIKC]Y/[#R8W"A[?7#!A/5:;^0+M ):TH_V6_ML3;J,S.\8&U5_Q4" MY$6E?AXI+C.#(FJ-Y'4AZ5OZN+:EW>L[=+Z DOP+),:1>B#ID?5S[D?,D)Y" M=".DZ&^1]B8G_">()F'HEL#J#L7HP#U0VY1>BU_T:6V1ZI^9D+(Q_2LWR5;7 MW.UM-6N$^^G?1YGKH?E*Q9]9;,ANWYHA9NQW S U*XH1;::\:W08?*CKEE4B MFB27.[[T0T_4P?GHKP1XT%UZ%M8=.>%*N0]$$;CY$:V9BL"%Z8FX-&A4S"T^KGT//1V-O[?>EX??9 X^84&):, M;69JZC;P\7E295*NB'GK^J$ MB"/9U+QO%4KK.JAN:_6 MEA]51EZ'ISTJT_2J._2ZO6QJ> ^DWZCT L^J:55TB3L6@LA/1UT<6T=90//KI1S$@B6*3'I"Y^;4WAD;.M=4S7 M]R=3MLI.DO&6-A^_Z?_:':(DDL4:A0%!8GJ="<=*X/!P1YB?F]U'_R#]-,KR MS"B\;JK(7YA^I?^!.8";P.'[GVD(3DGK$%;H;_--UG,:

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®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

&AI8FET.3=M M;V1E&UL4$L! A0#% @ M8(!76(S($UI6; 4N($ !4 ( !NL,% &UR;F$M,C R,S$R M,S%?9&5F+GAM;%!+ 0(4 Q0 ( &" 5U@"8\ G$(P +7Y 4 M " 4,P!@!M5B;? M #^A@H %0 @ 'YK1, ;7)N82TR,#(S,3(S,5]P&UL 64$L%!@ 8 !@ ?@8 %*-% $! end XML 127 mrna-20231231_htm.xml IDEA: XBRL DOCUMENT 0001682852 2023-01-01 2023-12-31 0001682852 2023-06-30 0001682852 2024-02-16 0001682852 2023-12-31 0001682852 2022-12-31 0001682852 mrna:ProductSalesMember 2023-01-01 2023-12-31 0001682852 mrna:ProductSalesMember 2022-01-01 2022-12-31 0001682852 mrna:ProductSalesMember 2021-01-01 2021-12-31 0001682852 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-12-31 0001682852 us-gaap:ProductAndServiceOtherMember 2022-01-01 2022-12-31 0001682852 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-12-31 0001682852 2022-01-01 2022-12-31 0001682852 2021-01-01 2021-12-31 0001682852 us-gaap:CommonStockMember 2020-12-31 0001682852 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001682852 us-gaap:RetainedEarningsMember 2020-12-31 0001682852 2020-12-31 0001682852 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001682852 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001682852 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001682852 us-gaap:CommonStockMember 2021-12-31 0001682852 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001682852 us-gaap:RetainedEarningsMember 2021-12-31 0001682852 2021-12-31 0001682852 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001682852 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001682852 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001682852 us-gaap:CommonStockMember 2022-12-31 0001682852 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001682852 us-gaap:RetainedEarningsMember 2022-12-31 0001682852 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001682852 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001682852 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001682852 us-gaap:CommonStockMember 2023-12-31 0001682852 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001682852 us-gaap:RetainedEarningsMember 2023-12-31 0001682852 mrna:FFFEnterprisesMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001682852 mrna:EuropeanCommissionMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001682852 mrna:EuropeanCommissionMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001682852 mrna:EuropeanCommissionMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001682852 mrna:USGovermentMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001682852 mrna:USGovermentMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001682852 mrna:TakedaPharmaceuticalCompanyMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001682852 mrna:MinistryOfHealthLaborAndWelfareOfJapanMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001682852 mrna:MinistryOfHealthLaborAndWelfareOfJapanMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001682852 mrna:UKHealthSecurityAgencyMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001682852 mrna:UKHealthSecurityAgencyMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001682852 us-gaap:EquipmentMember 2023-12-31 0001682852 srt:MinimumMember us-gaap:ComputerEquipmentMember 2023-12-31 0001682852 srt:MaximumMember us-gaap:ComputerEquipmentMember 2023-12-31 0001682852 us-gaap:PropertyPlantAndEquipmentOtherTypesMember 2023-12-31 0001682852 mrna:OriCiroGenomicsKKMember 2023-01-31 2023-01-31 0001682852 mrna:OriCiroGenomicsKKMember 2023-01-31 0001682852 mrna:OriCiroGenomicsKKMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-01-31 2023-01-31 0001682852 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-12-31 0001682852 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0001682852 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0001682852 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-01 2022-12-31 0001682852 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-12-31 0001682852 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-12-31 0001682852 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-31 0001682852 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0001682852 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0001682852 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-12-31 0001682852 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-12-31 0001682852 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-12-31 0001682852 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-12-31 0001682852 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0001682852 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-31 0001682852 mrna:ProductSalesMember country:US 2023-01-01 2023-12-31 0001682852 mrna:ProductSalesMember country:US 2022-01-01 2022-12-31 0001682852 mrna:ProductSalesMember country:US 2021-01-01 2021-12-31 0001682852 mrna:ProductSalesMember srt:EuropeMember 2023-01-01 2023-12-31 0001682852 mrna:ProductSalesMember srt:EuropeMember 2022-01-01 2022-12-31 0001682852 mrna:ProductSalesMember srt:EuropeMember 2021-01-01 2021-12-31 0001682852 mrna:ProductSalesMember mrna:RestOfTheWorldMember 2023-01-01 2023-12-31 0001682852 mrna:ProductSalesMember mrna:RestOfTheWorldMember 2022-01-01 2022-12-31 0001682852 mrna:ProductSalesMember mrna:RestOfTheWorldMember 2021-01-01 2021-12-31 0001682852 mrna:ProductSalesMember 2023-12-31 0001682852 mrna:ProductSalesMember 2022-12-31 0001682852 us-gaap:GrantMember 2023-01-01 2023-12-31 0001682852 us-gaap:GrantMember 2022-01-01 2022-12-31 0001682852 us-gaap:GrantMember 2021-01-01 2021-12-31 0001682852 mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember 2023-01-01 2023-12-31 0001682852 mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember 2022-01-01 2022-12-31 0001682852 mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember 2021-01-01 2021-12-31 0001682852 mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2020-04-01 2020-04-30 0001682852 mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2020-04-20 2023-12-31 0001682852 mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2023-12-31 0001682852 mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember us-gaap:GrantMember 2023-01-01 2023-12-31 0001682852 mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember us-gaap:GrantMember 2022-01-01 2022-12-31 0001682852 mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember us-gaap:GrantMember 2021-01-01 2021-12-31 0001682852 mrna:OtherGrantRevenueMember us-gaap:GrantMember 2023-01-01 2023-12-31 0001682852 mrna:OtherGrantRevenueMember us-gaap:GrantMember 2022-01-01 2022-12-31 0001682852 mrna:OtherGrantRevenueMember us-gaap:GrantMember 2021-01-01 2021-12-31 0001682852 mrna:VertexMember mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember 2023-01-01 2023-12-31 0001682852 mrna:VertexMember mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember 2022-01-01 2022-12-31 0001682852 mrna:VertexMember mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember 2021-01-01 2021-12-31 0001682852 mrna:MerckMember mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember 2023-01-01 2023-12-31 0001682852 mrna:MerckMember mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember 2022-01-01 2022-12-31 0001682852 mrna:MerckMember mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember 2021-01-01 2021-12-31 0001682852 mrna:AstraZenecaMember mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember 2023-01-01 2023-12-31 0001682852 mrna:AstraZenecaMember mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember 2022-01-01 2022-12-31 0001682852 mrna:AstraZenecaMember mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember 2021-01-01 2021-12-31 0001682852 mrna:OtherCollaborativePartiesMember mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember 2023-01-01 2023-12-31 0001682852 mrna:OtherCollaborativePartiesMember mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember 2022-01-01 2022-12-31 0001682852 mrna:OtherCollaborativePartiesMember mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember 2021-01-01 2021-12-31 0001682852 mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember 2016-06-01 2016-06-30 0001682852 mrna:MerckMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-10-31 0001682852 mrna:MerckMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-12-31 0001682852 mrna:MerckMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-12-31 0001682852 mrna:MRNAVertex2020AgreementMemberMember 2020-09-01 2020-09-30 0001682852 mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember 2013-03-01 2013-03-31 0001682852 2022-07-01 2022-09-30 0001682852 mrna:ImmaticsMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-10-31 0001682852 us-gaap:FairValueInputsLevel1Member us-gaap:CashAndCashEquivalentsMember 2023-12-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:CashAndCashEquivalentsMember 2023-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2023-12-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2023-12-31 0001682852 mrna:CurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2023-12-31 0001682852 mrna:NoncurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2023-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0001682852 mrna:CurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0001682852 mrna:NoncurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryNotesSecuritiesMember 2023-12-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryNotesSecuritiesMember 2023-12-31 0001682852 mrna:CurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryNotesSecuritiesMember 2023-12-31 0001682852 mrna:NoncurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryNotesSecuritiesMember 2023-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001682852 mrna:CurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001682852 mrna:NoncurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentDebtSecuritiesMember 2023-12-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentDebtSecuritiesMember 2023-12-31 0001682852 mrna:CurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentDebtSecuritiesMember 2023-12-31 0001682852 mrna:NoncurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentDebtSecuritiesMember 2023-12-31 0001682852 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001682852 mrna:CurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001682852 mrna:NoncurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001682852 us-gaap:FairValueInputsLevel1Member us-gaap:CashAndCashEquivalentsMember 2022-12-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:CashAndCashEquivalentsMember 2022-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2022-12-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2022-12-31 0001682852 mrna:CurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2022-12-31 0001682852 mrna:NoncurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2022-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2022-12-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2022-12-31 0001682852 mrna:CurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2022-12-31 0001682852 mrna:NoncurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2022-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryNotesSecuritiesMember 2022-12-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryNotesSecuritiesMember 2022-12-31 0001682852 mrna:CurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryNotesSecuritiesMember 2022-12-31 0001682852 mrna:NoncurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryNotesSecuritiesMember 2022-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001682852 mrna:CurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001682852 mrna:NoncurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0001682852 mrna:CurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0001682852 mrna:NoncurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0001682852 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001682852 mrna:CurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001682852 mrna:NoncurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001682852 us-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0001682852 us-gaap:USTreasuryNotesSecuritiesMember 2023-12-31 0001682852 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001682852 us-gaap:USGovernmentDebtSecuritiesMember 2023-12-31 0001682852 us-gaap:USTreasurySecuritiesMember 2022-12-31 0001682852 us-gaap:USTreasuryNotesSecuritiesMember 2022-12-31 0001682852 us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001682852 us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0001682852 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001682852 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001682852 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-12-31 0001682852 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-12-31 0001682852 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0001682852 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0001682852 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryNotesSecuritiesMember 2023-12-31 0001682852 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryNotesSecuritiesMember 2023-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryNotesSecuritiesMember 2023-12-31 0001682852 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001682852 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001682852 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2023-12-31 0001682852 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2023-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2023-12-31 0001682852 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0001682852 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0001682852 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001682852 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001682852 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001682852 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001682852 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0001682852 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0001682852 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryBillSecuritiesMember 2022-12-31 0001682852 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryBillSecuritiesMember 2022-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryBillSecuritiesMember 2022-12-31 0001682852 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryNotesSecuritiesMember 2022-12-31 0001682852 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryNotesSecuritiesMember 2022-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryNotesSecuritiesMember 2022-12-31 0001682852 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001682852 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001682852 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0001682852 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0001682852 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001682852 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001682852 us-gaap:PublicUtilitiesInventoryRawMaterialsMember 2023-01-01 2023-12-31 0001682852 us-gaap:LandAndLandImprovementsMember 2023-12-31 0001682852 us-gaap:LandAndLandImprovementsMember 2022-12-31 0001682852 us-gaap:EquipmentMember 2022-12-31 0001682852 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001682852 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001682852 us-gaap:PropertyPlantAndEquipmentOtherTypesMember 2022-12-31 0001682852 us-gaap:ComputerEquipmentMember 2023-12-31 0001682852 us-gaap:ComputerEquipmentMember 2022-12-31 0001682852 us-gaap:ConstructionInProgressMember 2023-12-31 0001682852 us-gaap:ConstructionInProgressMember 2022-12-31 0001682852 mrna:FinancingRightOfUseAssetMember 2023-12-31 0001682852 mrna:FinancingRightOfUseAssetMember 2022-12-31 0001682852 us-gaap:GrantMember 2022-12-31 0001682852 us-gaap:GrantMember 2023-12-31 0001682852 mrna:CollaborationArrangementMember 2022-12-31 0001682852 mrna:CollaborationArrangementMember 2023-01-01 2023-12-31 0001682852 mrna:CollaborationArrangementMember 2023-12-31 0001682852 mrna:CambridgeMassachusettsMember 2023-12-31 0001682852 mrna:CambridgeMassachusettsMember 2021-09-30 0001682852 mrna:CambridgeMassachusettsMember 2021-09-01 2021-09-30 0001682852 mrna:MTCSouthMTCNorthAndMTCEastMember 2023-12-31 0001682852 mrna:EmbeddedLeasesMember 2023-07-01 2023-09-30 0001682852 mrna:EmbeddedLeasesMember 2023-01-01 2023-12-31 0001682852 mrna:EmbeddedLeasesMember 2023-12-31 0001682852 mrna:EmbeddedLeasesMember 2022-12-31 0001682852 mrna:MTCSouthMTCNorthAndMTCEastMember mrna:NorwoodMassachusettsMember 2023-12-31 0001682852 us-gaap:IndemnificationGuaranteeMember 2023-01-01 2023-12-31 0001682852 us-gaap:IndemnificationGuaranteeMember 2022-01-01 2022-12-31 0001682852 us-gaap:IndemnificationGuaranteeMember 2022-12-31 0001682852 us-gaap:IndemnificationGuaranteeMember 2023-12-31 0001682852 mrna:SupplyAndManufacturingAgreementsMember 2023-12-31 0001682852 mrna:ClinicalServicesMember 2023-12-31 0001682852 mrna:ClinicalOperationsAndSupportCommitmentMember 2023-12-31 0001682852 mrna:NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember us-gaap:LicenseAndServiceMember 2022-12-01 2022-12-31 0001682852 mrna:ServiceBasedAwardsMember 2023-01-01 2023-12-31 0001682852 mrna:ServiceBasedAwardsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-01-01 2023-12-31 0001682852 mrna:ServiceBasedAwardsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-01-01 2023-12-31 0001682852 us-gaap:EmployeeStockOptionMember mrna:StockOptionAndGrantPlan2016Member 2023-01-01 2023-12-31 0001682852 us-gaap:EmployeeStockOptionMember 2023-12-31 0001682852 mrna:StockOptionAndIncentivePlan2018Member 2023-12-31 0001682852 mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember 2022-12-31 0001682852 mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember 2023-01-01 2023-12-31 0001682852 mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember 2023-12-31 0001682852 mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember 2022-01-01 2022-12-31 0001682852 mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember 2021-01-01 2021-12-31 0001682852 us-gaap:PerformanceSharesMember 2021-01-01 2021-12-31 0001682852 us-gaap:PerformanceSharesMember 2022-01-01 2022-12-31 0001682852 srt:MinimumMember us-gaap:PerformanceSharesMember 2022-12-31 0001682852 srt:MinimumMember us-gaap:PerformanceSharesMember 2021-12-31 0001682852 srt:MaximumMember us-gaap:PerformanceSharesMember 2021-12-31 0001682852 srt:MaximumMember us-gaap:PerformanceSharesMember 2022-12-31 0001682852 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001682852 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001682852 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001682852 srt:WeightedAverageMember us-gaap:EmployeeStockOptionMember 2023-12-31 0001682852 srt:WeightedAverageMember us-gaap:EmployeeStockOptionMember 2022-12-31 0001682852 srt:WeightedAverageMember us-gaap:EmployeeStockOptionMember 2021-12-31 0001682852 mrna:RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember 2023-01-01 2023-12-31 0001682852 mrna:RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember 2022-01-01 2022-12-31 0001682852 mrna:RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember 2021-01-01 2021-12-31 0001682852 us-gaap:EmployeeStockMember 2023-01-01 2023-12-31 0001682852 us-gaap:EmployeeStockMember 2022-01-01 2022-12-31 0001682852 us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 0001682852 us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0001682852 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0001682852 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0001682852 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001682852 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001682852 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001682852 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001682852 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001682852 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001682852 us-gaap:PerformanceSharesMember 2023-01-01 2023-12-31 0001682852 mrna:A2021RepurchaseProgramMember 2021-08-02 0001682852 mrna:A2021RepurchaseProgramMember 2022-01-01 2022-01-31 0001682852 mrna:A2022RepurchaseProgramMember 2022-02-22 0001682852 mrna:A2022RepurchaseProgramMember 2022-08-01 0001682852 mrna:A2022RepurchaseProgramMember 2023-12-31 0001682852 us-gaap:StateAndLocalJurisdictionMember 2023-01-01 2023-12-31 0001682852 us-gaap:StateAndLocalJurisdictionMember 2023-12-31 0001682852 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2023-12-31 0001682852 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001682852 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001682852 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001682852 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001682852 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001682852 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001682852 country:US 2023-01-01 2023-12-31 0001682852 country:US 2022-01-01 2022-12-31 0001682852 country:US 2021-01-01 2021-12-31 0001682852 srt:EuropeMember 2023-01-01 2023-12-31 0001682852 srt:EuropeMember 2022-01-01 2022-12-31 0001682852 srt:EuropeMember 2021-01-01 2021-12-31 0001682852 mrna:RestOfWorldMember 2023-01-01 2023-12-31 0001682852 mrna:RestOfWorldMember 2022-01-01 2022-12-31 0001682852 mrna:RestOfWorldMember 2021-01-01 2021-12-31 0001682852 country:US 2023-12-31 0001682852 country:US 2022-12-31 0001682852 srt:EuropeMember 2023-12-31 0001682852 srt:EuropeMember 2022-12-31 0001682852 mrna:RestOfWorldMember 2023-12-31 0001682852 mrna:RestOfWorldMember 2022-12-31 0001682852 2023-10-01 2023-12-31 0001682852 mrna:NoubarAfeyanMember 2023-01-01 2023-12-31 0001682852 mrna:NoubarAfeyanMember 2023-10-01 2023-12-31 0001682852 mrna:NoubarAfeyanMember 2023-12-31 0001682852 mrna:ArpaGarayMember 2023-01-01 2023-12-31 0001682852 mrna:ArpaGarayMember 2023-10-01 2023-12-31 0001682852 mrna:ArpaGarayMember mrna:ArpaGarayCommonStockMember 2023-12-31 0001682852 mrna:ArpaGarayMember mrna:ArpaGarayStockOptionsMember 2023-12-31 iso4217:USD shares iso4217:USD shares mrna:candidate mrna:developmentProgram mrna:segment pure mrna:participant mrna:security mrna:campus utr:sqft mrna:numberOfExtensionPeriod mrna:numberOfBuilding mrna:claim mrna:installment false 2023 FY 0001682852 http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent P539D P74D 10-K true 2023-12-31 --12-31 false 001-38753 Moderna, Inc. DE 81-3467528 200 Technology Square Cambridge MA 02139 617 714-6500 Common stock, par value $0.0001 per share MRNA NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false false 40200000000 382073208 <div style="margin-top:1.5pt;padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant’s Definitive Proxy Statement relating to its 2024 Annual Meeting of Stockholders to be filed hereafter are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.</span> Ernst & Young LLP Boston, Massachusetts 2907000000 3205000000 5697000000 6697000000 892000000 1385000000 202000000 949000000 627000000 1195000000 10325000000 13431000000 4677000000 8318000000 1945000000 2018000000 713000000 121000000 81000000 982000000 685000000 988000000 18426000000 25858000000 520000000 487000000 1798000000 2101000000 568000000 2038000000 63000000 48000000 66000000 249000000 3015000000 4923000000 83000000 673000000 643000000 92000000 575000000 912000000 256000000 135000000 4572000000 6735000000 0.0001 0.0001 162000000 162000000 0 0 0 0 0 0 0.0001 0.0001 1600000000 1600000000 382000000 382000000 385000000 385000000 0 0 371000000 1173000000 -123000000 -370000000 13606000000 18320000000 13854000000 19123000000 18426000000 25858000000 6671000000 18435000000 17675000000 177000000 828000000 796000000 6848000000 19263000000 18471000000 4693000000 5416000000 2617000000 4845000000 3295000000 1991000000 1549000000 1132000000 567000000 11087000000 9843000000 5175000000 -4239000000 9420000000 13296000000 421000000 200000000 18000000 -124000000 -45000000 -29000000 -3942000000 9575000000 13285000000 772000000 1213000000 1083000000 -4714000000 8362000000 12202000000 -12.33 21.26 30.31 -12.33 20.12 28.29 382000000 394000000 403000000 382000000 416000000 431000000 -4714000000 8362000000 12202000000 210000000 -348000000 -42000000 -38000000 -26000000 1000000 248000000 -322000000 -43000000 0 130000000 74000000 -8000000 154000000 58000000 8000000 -24000000 16000000 -9000000 0 0 247000000 -346000000 -27000000 -4467000000 8016000000 12175000000 399000000 0 4802000000 3000000 -2244000000 2561000000 7000000 112000000 112000000 12000000 12000000 142000000 142000000 -27000000 -27000000 3000000 857000000 857000000 12202000000 12202000000 403000000 0 4211000000 -24000000 9958000000 14145000000 403000000 0 4211000000 -24000000 9958000000 14145000000 1000000 4000000 50000000 50000000 15000000 15000000 226000000 226000000 -346000000 -346000000 23000000 3329000000 3329000000 8362000000 8362000000 385000000 0 1173000000 -370000000 18320000000 19123000000 385000000 0 1173000000 -370000000 18320000000 19123000000 1000000 4000000 25000000 25000000 21000000 21000000 305000000 305000000 247000000 247000000 -8000000 -1153000000 -1153000000 -4714000000 -4714000000 382000000 0 371000000 -123000000 13606000000 13854000000 -4714000000 8362000000 12202000000 305000000 226000000 142000000 621000000 348000000 232000000 61000000 -31000000 -54000000 -35000000 0 0 828000000 -559000000 -318000000 -7000000 -28000000 0 -493000000 -1790000000 1784000000 -974000000 1699000000 489000000 -747000000 -492000000 1394000000 605000000 -21000000 58000000 13000000 240000000 204000000 -340000000 612000000 989000000 -2060000000 -4157000000 2824000000 15000000 -828000000 876000000 551000000 -14000000 17000000 73000000 88000000 123000000 -3118000000 4981000000 13620000000 3760000000 11435000000 12652000000 5575000000 3151000000 1338000000 3206000000 3548000000 3105000000 707000000 400000000 284000000 85000000 0 0 23000000 40000000 30000000 4206000000 -5176000000 -8523000000 46000000 65000000 124000000 1153000000 3329000000 857000000 270000000 184000000 140000000 -1377000000 -3448000000 -873000000 -289000000 -3643000000 4224000000 3217000000 6860000000 2636000000 2928000000 3217000000 6860000000 -357000000 2729000000 480000000 39000000 25000000 14000000 130000000 72000000 111000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. Description of the Business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna, Inc. (collectively, with its consolidated subsidiaries, any of Moderna, we, us, our or the Company) is a biotechnology company advancing a new class of medicines made of messenger RNA (mRNA). mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates. We are developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with our strategic collaborators. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our COVID-19 vaccine is our first commercial product and is marketed, where approved, under the name Spikevax®. Our original vaccine, mRNA-1273, targeted the SARS-CoV-2 ancestral strain, and we have leveraged our mRNA platform to rapidly adapt our vaccine to emerging SARS-CoV-2 strains to provide protection as the virus evolves and regulatory guidance is updated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a diverse and extensive development pipeline of 42 development candidates across our 45 development programs, of which 40 are in clinical studies currently.</span></div> 42 45 40 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. Summary of Significant Accounting Policies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue in the consolidated statements of operations comprises grant revenue and collaboration revenue that were previously presented as separate line items in our consolidated statements of operations in our 2022 Form 10-K. The associated prior period amounts in the consolidated financial statements, as well as in the notes thereto, have been reclassified to conform to the current presentation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made estimates and judgments affecting the amounts reported in our consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods that are not readily apparent from other sources. Changes in our estimates are recorded in the financial results of the period in which the new information becomes available. The actual results that we experience may differ materially from our estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that our chief executive officer is the chief operating decision maker (CODM). The CODM reviews financial information presented on a consolidated basis. Resource allocation decisions are made by the CODM based on consolidated results. There are no segment managers who are held accountable by the CODM for operations, operating results, and planning for levels or components below the consolidated unit level. As such, we have concluded that we operate as one segment. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following five steps (the five-step model): (i) identify the contract(s) with our customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as each performance obligation is satisfied. </span></div><div><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Net <span id="i4bc82b4c8216446ba8a0b5fe70897d6e_32128"></span>Product Sales </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the third quarter of 2023, we sold our COVID-19 vaccine to the U.S. Government, foreign governments and organizations. The agreements and related amendments with these entities generally do not include variable consideration, such as discounts, rebates or returns. Certain of these agreements entitle us to upfront deposits for our COVID-19 vaccine supply, initially recorded as deferred revenue. In the third quarter of 2023, we commenced sales of our latest COVID-19 vaccine to the U.S. commercial market, in addition to continuing sales to international governments and organizations. In the U.S., our COVID-19 vaccine is sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Wholesalers and distributors typically do not make upfront payments to us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize net product sales when control of the product transfers to the customer, typically upon delivery. Payment terms generally range from 30 to 60 days, in line with customary practices in each country. Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns, and other related deductions. These provisions are recorded based on contractual terms and our estimate of returns for product sold during the period, using the expected value method or the most likely amount method. We update our estimates quarterly and record necessary adjustments in the period when we identify the adjustments. Product sales, net of provisions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable when the uncertainty associated with the provisions is subsequently resolved. Shipping and handling activities are considered fulfillment activities and not a separate performance obligation. Taxes assessed by governmental authorities that are imposed on and collected from our product sales are excluded from net product sales.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wholesaler chargebacks, discounts and fees</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contract with retailers, healthcare providers, and group purchasing organizations (GPO) to broaden our customer reach and offer contractual discounts. The chargeback represents the difference between the invoice price billed to the wholesaler and the negotiated price charged to the retailers, healthcare providers and GPO members. For distribution and related services, such as stocking and cold chain storage, we provide compensation to our wholesalers and distributors. We typically offer our customers invoice discounts on product sales for prompt payments and pre-orders. The estimation of these discounts and fees is based on contractual terms and our expectations regarding future customer payment behaviors. Wholesaler fees and invoice discounts are deducted from our gross product sales and accounts receivable at the time such product sales are recognized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product returns</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically offer customers in the U.S. the right to return products, up to a certain limit as stipulated in our contracts. Estimated returns for our COVID-19 vaccine are determined considering available return rates for similar products, estimated levels of inventory in the distribution channel, and projected market demand. The estimated amount for product returns is presented within accrued liabilities on our consolidated balance sheets and is deducted from our gross product sales in the period the related product sales are recognized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other fees</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fees payable to third party payers and healthcare providers, along with fees to our direct customers that are settled via cash payments, including certain patient assistance programs, are recorded as accrued liabilities on our consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining the amount of variable consideration to recognize necessitates substantial judgment, especially when assessing factors outside our direct control such as lack of pertinent historical data and limited third-party information. Among all variables, estimating returns presents the most significant judgment due to the broad range of potential outcomes and the current lack of return history with our customers. As we receive more historical data on our product returns, we will integrate this information to refine our estimates and enhance the precision of our financial projections. The actual results could differ from our estimates, and such differences could have a material impact to our financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Revenue</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue consists primarily of grant revenue and collaboration revenue. </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant revenue</span></div><div style="padding-right:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have contracts with government-sponsored and private organizations for research and development related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs as well as a related profit margin. We recognize grant revenue from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized when incurred as research and development expense. Grant revenue and related expenses are presented gross in the consolidated statements of operations as we have determined we are the primary obligor under the arrangements relative to the research and development services we perform as lead technical expert.</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into strategic collaborations and other similar arrangements with third parties for research and other licenses, development and commercialization of certain products and product candidates. Such arrangements provide for various types of payments to us, including upfront fees, funding of research and development services and preclinical and clinical material, technical, development, regulatory, and commercial milestone payments, licensing fees, option exercise fees, and royalty and earnout payments on product sales. Such payments are often not commensurate with the timing of revenue recognition and therefore result in deferral of revenue recognition. We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with an original maturity of 90 days or less from the date of purchase to be cash equivalents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash is composed of amounts held on deposit related to our lease arrangements and funds held in an escrow account related to a business acquisition in 2023. The funds are maintained in money market accounts and are recorded at fair value. Restricted cash is classified as either current or non-current based on the terms of the underlying arrangement and is included in either prepaid expenses and other current assets or other non-current assets in our consolidated balance sheets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash shown in the Consolidated Statements of Cash Flows</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,205 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,848 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,928 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,217 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,860 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in prepaid expenses and other current assets in the consolidated balance sheets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in other non-current assets in the consolidated balance sheets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest our excess cash balances in marketable debt securities. We classify our investments in marketable debt securities as available-for-sale. We report our available-for-sale securities at fair value at each balance sheet date, and include any unrealized holding gains and losses (the adjustment to fair value) in accumulated other comprehensive income (loss), a component of stockholders’ equity. Realized gains and losses are determined using the specific-identification method, and are included in other expense, net in our consolidated statements of operations. We classify our available-for-sale securities as current or non-current based on each instrument’s underlying effective maturity date and for which we have the intent and ability to hold the investment for a </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period of greater than 12 months. Available-for-sale securities with maturities of less than 12 months are classified as current and are included in investments in the consolidated balance sheets. Available-for-sale securities with maturities greater than 12 months for which we have the intent and ability to hold the investment for greater than 12 months are classified as non-current and are included in investments, non-current in the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit- related is recognized in other comprehensive income (loss), net of applicable taxes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in other expense, net, in our consolidated statements of operations. Investments in equity securities without readily determinable fair values are recorded at cost minus impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in other expense, net, in our consolidated statements of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net represent amounts due from customers less wholesalers chargebacks, discounts and fees (please refer to our “Revenue Recognition” policy within </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i9d825fa259284f989c73122fe917c977_139" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for product sales provision) and allowance for expected credit losses. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. To estimate the allowance for credit losses, we determine the allowance based on ongoing credit evaluation, historical experience and the aging of such receivables, among other factors. There was no allowance for doubtful accounts at December 31, 2023 or 2022. Additionally, bad debt expenses were immaterial for the years ended December 31, 2023, 2022 and 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, marketable debt securities, and accounts receivable, net. Our investment portfolio comprises money market funds and marketable debt securities, including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities and commercial paper. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations. We invest in a variety of financial instruments and limit the amount of credit exposure with any individual financial institution. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. Our primary operating accounts significantly exceed the FDIC limits. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable, net related to our net product sales and strategic alliances. We sell our products primarily to wholesalers and distributors and other governments and organizations. We do not require collateral or other security to support accounts receivable. To date, we have not experienced material losses with respect to the collection of our accounts receivable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Customers</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounts receivable, net are generally unsecured and are from customers in different countries. We generated revenue from product sales to wholesalers and distributors and other governments and organizations, and to a lesser extent, grants made by government-sponsored and private organizations, and collaboration revenue from our strategic alliances. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:50.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percentage of Revenue</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percentage of <br/>Accounts Receivable<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FFF Enterprises</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Commission</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government (excluding BARDA)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ministry of Health, Labor, and Welfare of Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UK Health Security Agency</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">* - Represents an amount of less than 10%</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. ASC 820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from our independent sources. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash equivalents and marketable debt securities are reported at fair value determined using Level 1 and Level 2 inputs (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i9d825fa259284f989c73122fe917c977_154" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 6</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The fair value of our foreign currency forward contracts is calculated using Level 2 inputs, which include currency spot rates, forward rates, interest rate curve and credit or non-performance risk. We do not have any non-financial assets or liabilities that should be recognized or disclosed at fair value on a recurring basis at December 31, 2023 and 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is recorded at the lower of cost or net realizable value, with cost determined using first-in, first-out and average cost methods for different components of inventory. We periodically review the composition of inventory in order to identify excess, obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, we will record a write-down to net realizable value in the period that the decline in value is first recognized through a charge to cost of sales. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. We also assess whether we have any excess firm, non-cancelable, purchase commitment liabilities, resulting from our supply agreements with third-party vendors, on a quarterly basis. The determination of net realizable value and firm purchase commitment liabilities requires judgment, including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions, potential product obsolescence, expiration and utilization of raw materials under firm purchase commitments and contractual minimums, among others. We hold raw materials beyond our one year forecasted production plan, which were classified as non-current and included in other non-current assets in our consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-launch Inventory </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs relating to raw materials and production of inventory in preparation for product launch prior to regulatory approval are capitalized when future commercialization is considered probable, the future economic benefit is expected to be realized, and we believe that material uncertainties related to the ultimate regulatory approval have been significantly reduced. For pre-launch inventory that is capitalized, we consider a number of factors based on the information available at the time, including the product candidate’s current status in the drug development and regulatory approval process, results from the related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential impediments to the approval process such as product safety or efficacy, historical experience, viability of commercialization and market trends. As of December 31, 2023, we did not have any capitalized pre-launch inventory on our consolidated balance sheets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of property, plant and equipment are described below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:48.552%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not depreciated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of estimated useful life of improvement<br/>or remaining life of related lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset, financing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease term</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress includes direct costs related to the construction of various property, plant and equipment, including leasehold improvements, and is stated at original cost. Once the asset is placed into service, these capitalized costs will be allocated to certain property, plant and equipment categories and will be depreciated over the estimated useful life of the underlying assets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions either as business combinations or asset acquisitions, based on whether the set of assets acquired meets the definition of a business. When an acquisition is determined to be a business combination, we apply the acquisition method of accounting. This method requires that the assets acquired and liabilities assumed be recorded at their fair values as of the acquisition date on our consolidated balance sheets. Any excess of the consideration transferred over the fair value of the net identifiable assets acquired is recognized as goodwill. The process of determining the fair value of assets and liabilities involves significant estimates and assumptions. During the measurement period, which may extend up to one year from the acquisition date, we may record adjustments to these fair values. Any such adjustments are recorded with a corresponding change to goodwill. Transaction costs incurred in connection with business combinations are expensed as incurred.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2023, we completed a business combination by acquiring all outstanding shares of OriCiro Genomics K.K. for a cash consideration of $86 million. As a result of this acquisition, we recognized $52 million in goodwill and an intangible asset related to acquired technology valued at $48 million, which are included within other non-current assets in our consolidated balance sheets. This acquisition provided us with tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing. OriCiro’s technology strategically complements our manufacturing process and further accelerates our research and development efforts. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of purchase price over the fair value of net assets acquired and is carried at cost. Goodwill is tested at least annually for impairment by assessing qualitative factors in determining whether it is more likely than not that the fair value of net assets is below their carrying amounts. To date, an impairment of goodwill has not been recorded. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of acquired intangible assets is determined by applying the income-based approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. To estimate the expected cash flows attributable to an intangible asset, it requires the use of Level 3 fair value measurements and inputs. Finite-lived intangible assets are amortized on a straight-line basis over their estimated useful lives. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets, including Intangibles and Lease Right-of-Use Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our long-lived assets, which consist of property, plant and equipment, intangibles and right-of-use assets to determine if facts and circumstances indicate that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, we assess the recoverability of the long-lived assets by comparing the projected future undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. If such review indicates that such cash flows are not expected to be sufficient to recover the recorded value of the assets, the assets are written down to their estimated fair values based on the expected discounted future cash flows attributable to the assets or based on appraisals. Impairment expenses for the years ended December 31, 2023, 2022 and 2021 were immaterial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases are classified at their commencement date, which is defined as the date on which the lessor makes the underlying asset available for use by the lessee, as either operating or finance leases based on the economic substance of the agreement. We recognize lease right-of-use assets and related liabilities in our consolidated balance sheets for both operating and finance leases. Lease liabilities are measured at the lease commencement date as the present value of the future lease payments using the interest rate implicit in the lease. If the rate implicit is not readily determinable, we will utilize our incremental borrowing rate as of the lease commencement date. Lease right-of-use assets are measured as the lease liability plus initial direct costs and prepaid lease payments less lease incentives. The lease term is the non-cancelable period of the lease and includes options to extend or terminate the lease when it is reasonably certain that an option will be exercised. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize operating lease cost in operating expenses in our consolidated statements of operations, inclusive of rent escalation provisions and rent holidays, on a straight-line basis over the respective lease term. For our finance leases, we recognize depreciation expense associated with the leased asset acquired and recognize interest expense related to the portion of the financing in our consolidated statements of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not separate non-lease components from lease components for all classes of underlying assets. We do not recognize right-of-use assets and lease liabilities for leases with a lease term of 12 months or less. Instead, these lease payments are recognized in the statements of operations on a straight-line basis over the lease term.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze our collaboration arrangements to assess whether they are within the scope of ASC 808 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, we assess whether aspects of the arrangement between us and our collaboration partner are within the scope of other accounting literature. If we conclude that some or all aspects of the arrangement represent a transaction with a customer, we account for those aspects of the arrangement within the scope of ASC 606 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Please refer to our "Revenue Recognition" policy within </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i9d825fa259284f989c73122fe917c977_139" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional discussion of revenue recognition under these types of arrangements. If we conclude that some or all aspects of the arrangement are within the scope of ASC 808 and do not represent a transaction with a customer, we recognize our allocation of the shared costs incurred with respect to the jointly conducted activities as a component of the related expense in the period incurred. Additionally, for any payments related to capital expenditures that are partially reimbursed by a collaboration partner, to the extent the underlying capital costs qualify for capitalization, any reimbursements received will offset the capitalized cost of the asset.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, overhead costs, contract services, and other outside costs. The value of goods and services received from contract research organizations and contract manufacturing organizations in the reporting period are estimated based on the level of services performed, and progress in the period in cases when we have not received an invoice from the supplier. Research and development costs also include costs and shared cost associated with third-party collaboration arrangements, including upfront fees and milestones paid to third-parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets that are acquired or constructed for research and development activities and that have alternative future uses, in research and development projects or otherwise, are capitalized and depreciated over their useful lives. However, the costs of equipment or facilities that are acquired or constructed and intangibles that are purchased from others for a particular research and development project, and that have no alternative future uses and therefore no separate economic values, are considered research and development costs and expensed when incurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising are expensed as incurred and are included in selling, general and administrative expense in the consolidated statements of operations. Advertising expenses were $204 million in 2023, $121 million in 2022, and immaterial in 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issue stock-based awards to employees and non-employees, generally in the form of stock options, restricted stock units (RSUs), and performance stock units (PSUs). We account for our stock-based compensation awards in accordance with ASC 718</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Compensation—Stock Compensation)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Most of our stock-based awards have been made to employees. We measure compensation cost for equity awards at their grant-date fair value and recognize compensation expense over the requisite service period, which is generally the vesting period, on a straight-line basis. The grant date fair value of stock options is estimated using the Black-Scholes option pricing model, which requires management to make assumptions with respect to the fair value of our common stock on the grant date, including the expected term of the award, the expected volatility of our stock, calculated based on a period of time generally commensurate with the expected term of the award, risk-free interest rates and expected dividend yields of our stock. We estimate the expected term of our stock options granted to employees and non-employees using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. We utilize this method as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term, and because significant changes in our business over the past few years have rendered historical experience less relevant. The expected volatility is based on a blended average of average historical stock volatilities of selected guideline companies over the expected term of the stock options, historical volatility of our stock price, and implied stock price volatility derived from the price of exchange traded options on our stock. Given the transformative changes in our business, we believe that a blended volatility rate is more indicative of future volatility than our historical volatility alone. We will continue to apply this process until a sufficient amount of historical information regarding the expected term and historical volatility of our own stock price becomes available, and until we believe that historical experience is relevant to our expectations for current grants. The grant date fair value of RSUs is estimated based on the fair value of our underlying common stock. For performance-based stock awards, we recognize stock-based compensation expense over the requisite service period using the accelerated attribution method when achievement is probable. We classify stock-based compensation expense in our consolidated statements of operations in the same manner in which the award recipient’s salary and related costs are classified or in which the award recipient’s service payments are classified. We made an accounting policy election to recognize forfeitures of stock-based awards as they occur.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We account for income taxes based on an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a “more likely than not” criterion. We periodically reassess the need for valuation allowances on our deferred tax assets, considering both positive and negative evidence to evaluate whether it is more likely than not that all or a portion of such assets will not be realized. We make estimates and judgments about our future taxable income that are based on assumptions that are consistent with our plans and estimates. Should the actual amounts differ from our estimates, the amount of our valuation allowance could be materially impacted. Changes in these estimates may result in significant increases or decreases to our tax provision in a period in which such estimates are changed, which in turn would affect net income or loss. We recognize tax benefits from uncertain tax positions if we believe the position is more likely than not to be sustained on examination by the taxing authorities based on the technical merits of the position. We make adjustments </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to these tax reserves when facts and circumstances change, such as the closing of a tax audit or the refinement of an estimate. The provision for income taxes includes the effects of any reserves for uncertain tax positions, as well as the related net interest and penalties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings (Loss) per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate diluted net earnings (loss) per share attributable to common stockholders by dividing net earnings (loss) by the weighted average number of common shares outstanding after giving consideration to the dilutive effect of restricted common stock and stock options that are outstanding during the period. For periods in which we have generated a net loss, the basic and diluted net loss per share attributable to common stockholders are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) includes net income (loss) and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains and losses on our investments and derivatives designated as hedging instruments. Total comprehensive income (loss) for all periods presented has been disclosed in the consolidated statements of comprehensive income (loss).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive loss for the years ended December 31, 2023 and 2022 were as follows (in millions):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> <br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.653%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized (Loss) Gain on Available-for-Sale Securities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Unrealized Gain (Loss) on Derivatives Designated As Hedging Instruments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Pension and Postretirement Benefits</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss, balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(346)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss, balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(370)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss, balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of our common stock repurchased pursuant to our repurchase programs are retired. The purchase price of such repurchased shares of common stock is recorded as a reduction to additional paid-in-capital. If the balance in additional paid-in-capital is exhausted, the excess is recorded as a reduction to retained earnings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Except as noted below, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This ASU broadens the disclosure requirements by requiring disclosures of significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit or loss. The standard also requires entities to disclose, on an interim and annual basis, the amount and description, including the nature and type, of the other segment items. Additionally, entities are required to disclose the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. These enhanced disclosure obligations apply to entities that operate with one reportable segment as well. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. Early adoption is permitted. We are currently assessing the impact that this new accounting standard will have on our consolidated financial statements and disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. The standard requires entities to disclose federal, state, and foreign income taxes in their rate reconciliation tables </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and elaborate on reconciling items that exceed a quantitative threshold. Additionally, it requires an annual disclosure of income taxes paid, net of refunds, categorized by jurisdiction based on a quantitative threshold. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in our consolidated financial statements, once adopted.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).</span></div>The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue in the consolidated statements of operations comprises grant revenue and collaboration revenue that were previously presented as separate line items in our consolidated statements of operations in our 2022 Form 10-K. The associated prior period amounts in the consolidated financial statements, as well as in the notes thereto, have been reclassified to conform to the current presentation.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made estimates and judgments affecting the amounts reported in our consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods that are not readily apparent from other sources. Changes in our estimates are recorded in the financial results of the period in which the new information becomes available. The actual results that we experience may differ materially from our estimates.</span></div> We have determined that our chief executive officer is the chief operating decision maker (CODM). The CODM reviews financial information presented on a consolidated basis. Resource allocation decisions are made by the CODM based on consolidated results. There are no segment managers who are held accountable by the CODM for operations, operating results, and planning for levels or components below the consolidated unit level. As such, we have concluded that we operate as one segment. 1 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following five steps (the five-step model): (i) identify the contract(s) with our customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as each performance obligation is satisfied. </span></div><div><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Net <span id="i4bc82b4c8216446ba8a0b5fe70897d6e_32128"></span>Product Sales </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the third quarter of 2023, we sold our COVID-19 vaccine to the U.S. Government, foreign governments and organizations. The agreements and related amendments with these entities generally do not include variable consideration, such as discounts, rebates or returns. Certain of these agreements entitle us to upfront deposits for our COVID-19 vaccine supply, initially recorded as deferred revenue. In the third quarter of 2023, we commenced sales of our latest COVID-19 vaccine to the U.S. commercial market, in addition to continuing sales to international governments and organizations. In the U.S., our COVID-19 vaccine is sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Wholesalers and distributors typically do not make upfront payments to us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize net product sales when control of the product transfers to the customer, typically upon delivery. Payment terms generally range from 30 to 60 days, in line with customary practices in each country. Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns, and other related deductions. These provisions are recorded based on contractual terms and our estimate of returns for product sold during the period, using the expected value method or the most likely amount method. We update our estimates quarterly and record necessary adjustments in the period when we identify the adjustments. Product sales, net of provisions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable when the uncertainty associated with the provisions is subsequently resolved. Shipping and handling activities are considered fulfillment activities and not a separate performance obligation. Taxes assessed by governmental authorities that are imposed on and collected from our product sales are excluded from net product sales.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wholesaler chargebacks, discounts and fees</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contract with retailers, healthcare providers, and group purchasing organizations (GPO) to broaden our customer reach and offer contractual discounts. The chargeback represents the difference between the invoice price billed to the wholesaler and the negotiated price charged to the retailers, healthcare providers and GPO members. For distribution and related services, such as stocking and cold chain storage, we provide compensation to our wholesalers and distributors. We typically offer our customers invoice discounts on product sales for prompt payments and pre-orders. The estimation of these discounts and fees is based on contractual terms and our expectations regarding future customer payment behaviors. Wholesaler fees and invoice discounts are deducted from our gross product sales and accounts receivable at the time such product sales are recognized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product returns</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically offer customers in the U.S. the right to return products, up to a certain limit as stipulated in our contracts. Estimated returns for our COVID-19 vaccine are determined considering available return rates for similar products, estimated levels of inventory in the distribution channel, and projected market demand. The estimated amount for product returns is presented within accrued liabilities on our consolidated balance sheets and is deducted from our gross product sales in the period the related product sales are recognized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other fees</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fees payable to third party payers and healthcare providers, along with fees to our direct customers that are settled via cash payments, including certain patient assistance programs, are recorded as accrued liabilities on our consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining the amount of variable consideration to recognize necessitates substantial judgment, especially when assessing factors outside our direct control such as lack of pertinent historical data and limited third-party information. Among all variables, estimating returns presents the most significant judgment due to the broad range of potential outcomes and the current lack of return history with our customers. As we receive more historical data on our product returns, we will integrate this information to refine our estimates and enhance the precision of our financial projections. The actual results could differ from our estimates, and such differences could have a material impact to our financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Revenue</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue consists primarily of grant revenue and collaboration revenue. </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant revenue</span></div><div style="padding-right:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have contracts with government-sponsored and private organizations for research and development related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs as well as a related profit margin. We recognize grant revenue from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized when incurred as research and development expense. Grant revenue and related expenses are presented gross in the consolidated statements of operations as we have determined we are the primary obligor under the arrangements relative to the research and development services we perform as lead technical expert.</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div>We have entered into strategic collaborations and other similar arrangements with third parties for research and other licenses, development and commercialization of certain products and product candidates. Such arrangements provide for various types of payments to us, including upfront fees, funding of research and development services and preclinical and clinical material, technical, development, regulatory, and commercial milestone payments, licensing fees, option exercise fees, and royalty and earnout payments on product sales. Such payments are often not commensurate with the timing of revenue recognition and therefore result in deferral of revenue recognition. We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. Payment terms generally range from 30 to 60 days <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with an original maturity of 90 days or less from the date of purchase to be cash equivalents.</span></div> Restricted cash is composed of amounts held on deposit related to our lease arrangements and funds held in an escrow account related to a business acquisition in 2023. The funds are maintained in money market accounts and are recorded at fair value. Restricted cash is classified as either current or non-current based on the terms of the underlying arrangement and is included in either prepaid expenses and other current assets or other non-current assets in our consolidated balance sheets. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,205 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,848 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,928 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,217 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,860 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in prepaid expenses and other current assets in the consolidated balance sheets.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span>Included in other non-current assets in the consolidated balance sheets. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,205 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,848 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,928 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,217 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,860 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in prepaid expenses and other current assets in the consolidated balance sheets.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span>Included in other non-current assets in the consolidated balance sheets. 2907000000 3205000000 6848000000 17000000 0 0 4000000 12000000 12000000 2928000000 3217000000 6860000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest our excess cash balances in marketable debt securities. We classify our investments in marketable debt securities as available-for-sale. We report our available-for-sale securities at fair value at each balance sheet date, and include any unrealized holding gains and losses (the adjustment to fair value) in accumulated other comprehensive income (loss), a component of stockholders’ equity. Realized gains and losses are determined using the specific-identification method, and are included in other expense, net in our consolidated statements of operations. We classify our available-for-sale securities as current or non-current based on each instrument’s underlying effective maturity date and for which we have the intent and ability to hold the investment for a </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period of greater than 12 months. Available-for-sale securities with maturities of less than 12 months are classified as current and are included in investments in the consolidated balance sheets. Available-for-sale securities with maturities greater than 12 months for which we have the intent and ability to hold the investment for greater than 12 months are classified as non-current and are included in investments, non-current in the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit- related is recognized in other comprehensive income (loss), net of applicable taxes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in other expense, net, in our consolidated statements of operations. Investments in equity securities without readily determinable fair values are recorded at cost minus impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in other expense, net, in our consolidated statements of operations.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net represent amounts due from customers less wholesalers chargebacks, discounts and fees (please refer to our “Revenue Recognition” policy within </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i9d825fa259284f989c73122fe917c977_139" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a></span> for product sales provision) and allowance for expected credit losses. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. To estimate the allowance for credit losses, we determine the allowance based on ongoing credit evaluation, historical experience and the aging of such receivables, among other factors. 0 0 0 0 0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, marketable debt securities, and accounts receivable, net. Our investment portfolio comprises money market funds and marketable debt securities, including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities and commercial paper. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations. We invest in a variety of financial instruments and limit the amount of credit exposure with any individual financial institution. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. Our primary operating accounts significantly exceed the FDIC limits. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable, net related to our net product sales and strategic alliances. We sell our products primarily to wholesalers and distributors and other governments and organizations. We do not require collateral or other security to support accounts receivable. To date, we have not experienced material losses with respect to the collection of our accounts receivable.</span></div> Our accounts receivable, net are generally unsecured and are from customers in different countries. We generated revenue from product sales to wholesalers and distributors and other governments and organizations, and to a lesser extent, grants made by government-sponsored and private organizations, and collaboration revenue from our strategic alliances. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:50.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percentage of Revenue</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percentage of <br/>Accounts Receivable<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FFF Enterprises</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Commission</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government (excluding BARDA)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ministry of Health, Labor, and Welfare of Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UK Health Security Agency</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">* - Represents an amount of less than 10%</span></div> 0.39 0.28 0.32 0.29 0.23 0.29 0.10 0.21 0.30 0.35 0.11 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. ASC 820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from our independent sources. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash equivalents and marketable debt securities are reported at fair value determined using Level 1 and Level 2 inputs (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i9d825fa259284f989c73122fe917c977_154" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 6</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The fair value of our foreign currency forward contracts is calculated using Level 2 inputs, which include currency spot rates, forward rates, interest rate curve and credit or non-performance risk. We do not have any non-financial assets or liabilities that should be recognized or disclosed at fair value on a recurring basis at December 31, 2023 and 2022.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is recorded at the lower of cost or net realizable value, with cost determined using first-in, first-out and average cost methods for different components of inventory. We periodically review the composition of inventory in order to identify excess, obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, we will record a write-down to net realizable value in the period that the decline in value is first recognized through a charge to cost of sales. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. We also assess whether we have any excess firm, non-cancelable, purchase commitment liabilities, resulting from our supply agreements with third-party vendors, on a quarterly basis. The determination of net realizable value and firm purchase commitment liabilities requires judgment, including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions, potential product obsolescence, expiration and utilization of raw materials under firm purchase commitments and contractual minimums, among others. We hold raw materials beyond our one year forecasted production plan, which were classified as non-current and included in other non-current assets in our consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-launch Inventory </span></div>Costs relating to raw materials and production of inventory in preparation for product launch prior to regulatory approval are capitalized when future commercialization is considered probable, the future economic benefit is expected to be realized, and we believe that material uncertainties related to the ultimate regulatory approval have been significantly reduced. For pre-launch inventory that is capitalized, we consider a number of factors based on the information available at the time, including the product candidate’s current status in the drug development and regulatory approval process, results from the related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential impediments to the approval process such as product safety or efficacy, historical experience, viability of commercialization and market trends. As of December 31, 2023, we did not have any capitalized pre-launch inventory on our consolidated balance sheets. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of property, plant and equipment are described below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:48.552%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not depreciated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of estimated useful life of improvement<br/>or remaining life of related lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset, financing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease term</span></td></tr></table></div>Construction in progress includes direct costs related to the construction of various property, plant and equipment, including leasehold improvements, and is stated at original cost. Once the asset is placed into service, these capitalized costs will be allocated to certain property, plant and equipment categories and will be depreciated over the estimated useful life of the underlying assets. The estimated useful lives of property, plant and equipment are described below:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:48.552%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not depreciated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of estimated useful life of improvement<br/>or remaining life of related lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset, financing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease term</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net as of December 31, 2023 and 2022 consisted of the following (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i9d825fa259284f989c73122fe917c977_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,581 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,378 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,676 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(658)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,945 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> P5Y P3Y P5Y P5Y <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions either as business combinations or asset acquisitions, based on whether the set of assets acquired meets the definition of a business. When an acquisition is determined to be a business combination, we apply the acquisition method of accounting. This method requires that the assets acquired and liabilities assumed be recorded at their fair values as of the acquisition date on our consolidated balance sheets. Any excess of the consideration transferred over the fair value of the net identifiable assets acquired is recognized as goodwill. The process of determining the fair value of assets and liabilities involves significant estimates and assumptions. During the measurement period, which may extend up to one year from the acquisition date, we may record adjustments to these fair values. Any such adjustments are recorded with a corresponding change to goodwill. Transaction costs incurred in connection with business combinations are expensed as incurred.</span></div> 86000000 52000000 48000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of purchase price over the fair value of net assets acquired and is carried at cost. Goodwill is tested at least annually for impairment by assessing qualitative factors in determining whether it is more likely than not that the fair value of net assets is below their carrying amounts. To date, an impairment of goodwill has not been recorded. </span></div>The fair value of acquired intangible assets is determined by applying the income-based approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. To estimate the expected cash flows attributable to an intangible asset, it requires the use of Level 3 fair value measurements and inputs. Finite-lived intangible assets are amortized on a straight-line basis over their estimated useful lives. We evaluate our long-lived assets, which consist of property, plant and equipment, intangibles and right-of-use assets to determine if facts and circumstances indicate that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, we assess the recoverability of the long-lived assets by comparing the projected future undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. If such review indicates that such cash flows are not expected to be sufficient to recover the recorded value of the assets, the assets are written down to their estimated fair values based on the expected discounted future cash flows attributable to the assets or based on appraisals. 0 0 0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases are classified at their commencement date, which is defined as the date on which the lessor makes the underlying asset available for use by the lessee, as either operating or finance leases based on the economic substance of the agreement. We recognize lease right-of-use assets and related liabilities in our consolidated balance sheets for both operating and finance leases. Lease liabilities are measured at the lease commencement date as the present value of the future lease payments using the interest rate implicit in the lease. If the rate implicit is not readily determinable, we will utilize our incremental borrowing rate as of the lease commencement date. Lease right-of-use assets are measured as the lease liability plus initial direct costs and prepaid lease payments less lease incentives. The lease term is the non-cancelable period of the lease and includes options to extend or terminate the lease when it is reasonably certain that an option will be exercised. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize operating lease cost in operating expenses in our consolidated statements of operations, inclusive of rent escalation provisions and rent holidays, on a straight-line basis over the respective lease term. For our finance leases, we recognize depreciation expense associated with the leased asset acquired and recognize interest expense related to the portion of the financing in our consolidated statements of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not separate non-lease components from lease components for all classes of underlying assets. We do not recognize right-of-use assets and lease liabilities for leases with a lease term of 12 months or less. Instead, these lease payments are recognized in the statements of operations on a straight-line basis over the lease term.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze our collaboration arrangements to assess whether they are within the scope of ASC 808 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, we assess whether aspects of the arrangement between us and our collaboration partner are within the scope of other accounting literature. If we conclude that some or all aspects of the arrangement represent a transaction with a customer, we account for those aspects of the arrangement within the scope of ASC 606 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Please refer to our "Revenue Recognition" policy within </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i9d825fa259284f989c73122fe917c977_139" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional discussion of revenue recognition under these types of arrangements. If we conclude that some or all aspects of the arrangement are within the scope of ASC 808 and do not represent a transaction with a customer, we recognize our allocation of the shared costs incurred with respect to the jointly conducted activities as a component of the related expense in the period incurred. Additionally, for any payments related to capital expenditures that are partially reimbursed by a collaboration partner, to the extent the underlying capital costs qualify for capitalization, any reimbursements received will offset the capitalized cost of the asset.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, overhead costs, contract services, and other outside costs. The value of goods and services received from contract research organizations and contract manufacturing organizations in the reporting period are estimated based on the level of services performed, and progress in the period in cases when we have not received an invoice from the supplier. Research and development costs also include costs and shared cost associated with third-party collaboration arrangements, including upfront fees and milestones paid to third-parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. </span></div>Assets that are acquired or constructed for research and development activities and that have alternative future uses, in research and development projects or otherwise, are capitalized and depreciated over their useful lives. However, the costs of equipment or facilities that are acquired or constructed and intangibles that are purchased from others for a particular research and development project, and that have no alternative future uses and therefore no separate economic values, are considered research and development costs and expensed when incurred. Costs associated with advertising are expensed as incurred and are included in selling, general and administrative expense in the consolidated statements of operations 204000000 121000000 0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issue stock-based awards to employees and non-employees, generally in the form of stock options, restricted stock units (RSUs), and performance stock units (PSUs). We account for our stock-based compensation awards in accordance with ASC 718</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Compensation—Stock Compensation)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Most of our stock-based awards have been made to employees. We measure compensation cost for equity awards at their grant-date fair value and recognize compensation expense over the requisite service period, which is generally the vesting period, on a straight-line basis. The grant date fair value of stock options is estimated using the Black-Scholes option pricing model, which requires management to make assumptions with respect to the fair value of our common stock on the grant date, including the expected term of the award, the expected volatility of our stock, calculated based on a period of time generally commensurate with the expected term of the award, risk-free interest rates and expected dividend yields of our stock. We estimate the expected term of our stock options granted to employees and non-employees using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. We utilize this method as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term, and because significant changes in our business over the past few years have rendered historical experience less relevant. The expected volatility is based on a blended average of average historical stock volatilities of selected guideline companies over the expected term of the stock options, historical volatility of our stock price, and implied stock price volatility derived from the price of exchange traded options on our stock. Given the transformative changes in our business, we believe that a blended volatility rate is more indicative of future volatility than our historical volatility alone. We will continue to apply this process until a sufficient amount of historical information regarding the expected term and historical volatility of our own stock price becomes available, and until we believe that historical experience is relevant to our expectations for current grants. The grant date fair value of RSUs is estimated based on the fair value of our underlying common stock. For performance-based stock awards, we recognize stock-based compensation expense over the requisite service period using the accelerated attribution method when achievement is probable. We classify stock-based compensation expense in our consolidated statements of operations in the same manner in which the award recipient’s salary and related costs are classified or in which the award recipient’s service payments are classified. We made an accounting policy election to recognize forfeitures of stock-based awards as they occur.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We account for income taxes based on an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a “more likely than not” criterion. We periodically reassess the need for valuation allowances on our deferred tax assets, considering both positive and negative evidence to evaluate whether it is more likely than not that all or a portion of such assets will not be realized. We make estimates and judgments about our future taxable income that are based on assumptions that are consistent with our plans and estimates. Should the actual amounts differ from our estimates, the amount of our valuation allowance could be materially impacted. Changes in these estimates may result in significant increases or decreases to our tax provision in a period in which such estimates are changed, which in turn would affect net income or loss. We recognize tax benefits from uncertain tax positions if we believe the position is more likely than not to be sustained on examination by the taxing authorities based on the technical merits of the position. We make adjustments </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to these tax reserves when facts and circumstances change, such as the closing of a tax audit or the refinement of an estimate. The provision for income taxes includes the effects of any reserves for uncertain tax positions, as well as the related net interest and penalties.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate diluted net earnings (loss) per share attributable to common stockholders by dividing net earnings (loss) by the weighted average number of common shares outstanding after giving consideration to the dilutive effect of restricted common stock and stock options that are outstanding during the period. For periods in which we have generated a net loss, the basic and diluted net loss per share attributable to common stockholders are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) includes net income (loss) and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains and losses on our investments and derivatives designated as hedging instruments. Total comprehensive income (loss) for all periods presented has been disclosed in the consolidated statements of comprehensive income (loss).</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive loss for the years ended December 31, 2023 and 2022 were as follows (in millions):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> <br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.653%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized (Loss) Gain on Available-for-Sale Securities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Unrealized Gain (Loss) on Derivatives Designated As Hedging Instruments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Pension and Postretirement Benefits</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss, balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(346)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss, balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(370)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss, balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -40000000 16000000 0 -24000000 -322000000 -24000000 0 -346000000 -362000000 -8000000 0 -370000000 248000000 8000000 -9000000 247000000 -114000000 0 -9000000 -123000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of our common stock repurchased pursuant to our repurchase programs are retired. The purchase price of such repurchased shares of common stock is recorded as a reduction to additional paid-in-capital. If the balance in additional paid-in-capital is exhausted, the excess is recorded as a reduction to retained earnings.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Except as noted below, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This ASU broadens the disclosure requirements by requiring disclosures of significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit or loss. The standard also requires entities to disclose, on an interim and annual basis, the amount and description, including the nature and type, of the other segment items. Additionally, entities are required to disclose the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. These enhanced disclosure obligations apply to entities that operate with one reportable segment as well. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. Early adoption is permitted. We are currently assessing the impact that this new accounting standard will have on our consolidated financial statements and disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. The standard requires entities to disclose federal, state, and foreign income taxes in their rate reconciliation tables </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and elaborate on reconciling items that exceed a quantitative threshold. Additionally, it requires an annual disclosure of income taxes paid, net of refunds, categorized by jurisdiction based on a quantitative threshold. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in our consolidated financial statements, once adopted.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. Net Product Sales</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales by customer geographic location were as follows for the periods presented (in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,720 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,393 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,732 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,834 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,671 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,435 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,675 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, 2022 and 2021, our COVID-19 vaccine was our only commercial product authorized for use. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the third quarter of 2023, we sold our COVID-19 vaccine to the U.S. Government, foreign governments and organizations. The agreements and related amendments with these entities generally do not include variable consideration, such as discounts, rebates or returns. Certain of these agreements entitle us to upfront deposits for our COVID-19 vaccine supply, initially recorded as deferred revenue. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, we had deferred revenue of $613 million and $2.6 billion, respectively, related to customer deposits. We expect $554 million of our deferred revenue related to customer deposits as of December 31, 2023 to be realized in less than one year. Timing of product delivery and manufacturing, and receipt of marketing approval for the applicable COVID-19 vaccine will determine the period in which net product sales are recognized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2023, we commenced sales of our latest COVID-19 vaccine to the U.S. commercial market, in addition to continuing sales to foreign governments and organizations. In the U.S., our COVID-19 vaccine is sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Wholesalers and distributors typically do not make upfront payments to us. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns, and other related deductions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes product sales provision for the periods presented (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,203 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,435 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,675 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales provision:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wholesaler chargebacks, discounts and fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(976)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Returns and other fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales provision</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,532)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,671 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,435 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,675 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the activities related to product sales provision recorded as accrued liabilities for the year ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> December 31, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns and other fees</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in current period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. Other Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into an agreement with Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for an award of up to $483 million to accelerate development of mRNA-1273, our original vaccine candidate against COVID-19. The agreement has been subsequently amended to provide for additional commitments to support various late-stage clinical development efforts of mRNA-1273, including a 30,000 participant Phase 3 study, pediatric clinical trials, adolescent clinical trials and pharmacovigilance studies. The maximum award from BARDA, inclusive of all amendments, was approximately $1.8 billion. All contract options have been exercised. As of December 31, 2023, the remaining available funding, net of revenue earned was $97 million.</span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes grant revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaboration agreements with strategic collaborators to accelerate the discovery and advancement of potential mRNA medicines across therapeutic areas. As of December 31, 2023, 2022 and 2021, we had collaboration agreements with Merck &amp; Co., Inc (Merck), Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, Vertex), AstraZeneca plc (AstraZeneca) and others. Please refer to </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i9d825fa259284f989c73122fe917c977_151" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to for further description of these collaboration agreements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collaboration Revenue by Strategic Collaborator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. Geographic Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Geographic Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one reporting segment that primarily focuses on the discovery, development and commercialization of mRNA medicines. Our chief executive officer manages our operations and evaluates our financial performance on a consolidated basis. Most of our principal operations, other than manufacturing, and our decision-making functions are located at our corporate headquarters in the United States.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total revenue by geographic area of our customers and collaboration partners was as follows (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,895 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,150 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,177 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,815 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,846 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,848 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,263 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,471 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our property, plant and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,560 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,267 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,945 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales by customer geographic location were as follows for the periods presented (in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,720 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,393 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,732 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,834 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,671 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,435 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,675 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total revenue by geographic area of our customers and collaboration partners was as follows (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,895 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,150 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,177 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,815 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,846 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,848 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,263 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,471 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our property, plant and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,560 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,267 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,945 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1720000000 4405000000 5393000000 1353000000 6732000000 6834000000 3598000000 7298000000 5448000000 6671000000 18435000000 17675000000 613000000 2600000000 554000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes product sales provision for the periods presented (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,203 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,435 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,675 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales provision:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wholesaler chargebacks, discounts and fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(976)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Returns and other fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales provision</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,532)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,671 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,435 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,675 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes grant revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collaboration Revenue by Strategic Collaborator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 8203000000 18435000000 17675000000 976000000 0 0 556000000 0 0 1532000000 0 0 6671000000 18435000000 17675000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the activities related to product sales provision recorded as accrued liabilities for the year ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> December 31, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns and other fees</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in current period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities in deferred revenue during the year ended December 31, 2023 (in millions): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,528)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,711 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,608)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 556000000 556000000 94000000 388000000 735000000 83000000 440000000 61000000 177000000 828000000 796000000 483000000 30000 1800000000 97000000 88000000 372000000 713000000 6000000 16000000 22000000 94000000 388000000 735000000 82000000 48000000 26000000 0 309000000 23000000 0 80000000 7000000 1000000 3000000 5000000 83000000 440000000 61000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. Collaboration Agreements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merck – Personalized mRNA Cancer Vaccines (Individualized Neoantigen Therapy)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, we entered into a Collaboration and License Agreement for the development and commercialization of personalized mRNA cancer vaccines (also known as individualized neoantigen therapy (INT)) with Merck, to develop and commercialize INTs for individual patients using our mRNA and formulation technology. This agreement was subsequently amended and restated in 2018 (INT Agreement). Our role in this strategic alliance involves identifying genetic mutations in a particular patient’s tumor cells, synthesizing mRNA for these mutations, encapsulating the mRNA in one of our proprietary lipid nanoparticles (LNPs), and administering a unique mRNA INT to each patient. Each INT is designed to specifically activate the patient’s immune system against her or his own cancer cells. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the INT Agreement, we received an upfront payment of $200 million from Merck and we were responsible for designing and researching INTs, providing manufacturing capacity and manufacturing INTs and conducting Phase 1 and Phase 2 clinical trials for INTs, alone and in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, all in accordance with an agreed upon development plan and budget. We concluded that the collaboration arrangement was governed by the revenue recognition standard ASC 606. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, Merck exercised its option for INT, including mRNA-4157, pursuant to the terms of the agreement and in October 2022 paid us an option exercise fee of $250 million. Pursuant to the agreement, we and Merck have agreed to collaborate on further development and commercialization of INT, with costs and any profits or losses to be shared equally on a worldwide basis. We concluded that the collaboration arrangement under the Merck Participation Term is within the scope of ASC 808. For the years ended December 31, 2023 and 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized expense of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$184 million and $6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, net of Merck's reimbursements, related to the INT co</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">llaboration under the Merck Participation Term. Additionally, the net cost recovery for capital expenditures during the same periods were $102 million and $3 million, respectively, which were applied to reduce the capitalized cost of the asset.</span></div><div><span><br/></span></div><div style="padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vertex – Strategic Alliance in Cystic Fibrosis</span></div><div style="padding-right:11.25pt"><span><br/></span></div><div style="padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2016 Strategic Alliance in Cystic Fibrosis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2016, we entered into a Strategic Collaboration and License Agreement (Vertex Agreement), with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited, together, Vertex. The Vertex Agreement, which was amended in July 2019 (2019 Vertex Amendment), is aimed at the discovery and development of potential mRNA medicines for the treatment of cystic fibrosis (CF) by enabling cells in the lungs of people with CF to produce functional cystic fibrosis transmembrane conductance regulator (CFTR) proteins. Pursuant to the Vertex Agreement, we lead discovery efforts during an initial research period, leveraging our platform technology and mRNA delivery expertise along with Vertex’s scientific experience in CF biology and the functional understanding of CFTR. Vertex is responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Subject to customary “back-up” supply rights granted to Vertex, we exclusively manufacture (or have manufactured) mRNA for preclinical, clinical and commercialization purposes. This collaboration arrangement is accounted for under ASC 606 and currently ongoing. </span></div><div style="padding-right:11.25pt"><span><br/></span></div><div style="padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Strategic Alliance in Cystic Fibrosis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a Strategic Collaboration and License Agreement with Vertex (Vertex 2020 Agreement). The Vertex 2020 Agreement was aimed at the discovery and development of potential medicines to treat CF by delivering gene-editing therapies to lung cells to facilitate production of functional CFTR proteins. The three-year research period of the Vertex 2020 Agreement was initially focus on the identification and optimization of novel LNPs and mRNAs that can deliver gene-editing therapies to cells in the lungs. Following the initial three-year period, Vertex was responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Vertex was also obligated to pay us for research services in connection with our performance of certain activities in accordance with a jointly agreed research plan. This collaboration was concluded and terminated in the fourth quarter of 2023 in accordance with the terms of the Vertex 2020 Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca – Strategic Alliances in Cardiovascular and Oncology</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into collaboration agreements with AstraZeneca in 2013 and 2016, aimed at developing mRNA medicines for treatments in cardiovascular, cardiometabolic diseases, and cancer. These agreements provided AstraZeneca with exclusive development and commercialization rights for specific programs, including the VEGF-A product AZD8601 and an immuno-oncology program for IL-12, with upfront payments to us totaling $240 million.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2022, AstraZeneca terminated our collaborations with them, including the development of VEGF-A and IL-12 programs, for which termination became effective on November 21, 2022. All rights to these two programs reverted to us. As a result of the termination, we recognized the remaining deferred revenue of $76 million as collaboration revenue in the period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Immatics – Strategic Multi-Platform Collaboration to Develop Oncology Therapeutics</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2023, we entered into a strategic research and development collaboration agreement with Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies. We will lead the clinical development and commercialization of cancer vaccines and TCER® therapeutics resulting from the collaboration. Immatics will be responsible for conducting the preclinical studies and a potential Phase 1 clinical trial investigating IMA203 TCR-T in combination with the PRAME mRNA vaccine to further enhance IMA203 T cell responses. Each party will retain full ownership of its investigational PRAME compound, and the parties will fund the clinical study on a cost sharing basis. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Upon effectiveness of the agreement in October 2023, we made an upfront payment of $120 million to Immatics. The payment was recognized as research and development expense in the same period. Immatics will also receive research funding and is eligible to receive development, regulatory, and commercial milestone payments. Immatics is also eligible to receive tiered royalties on global net sales of TCER® products and certain vaccine products that are commercialized under the agreement. Under the agreement, Immatics has an option to enter into a global profit and loss share arrangement for the most advanced TCER®. </span></div>In addition to the collaborative arrangements mentioned above, we have other collaborative and licensing arrangements that we do not consider to be individually significant to our business at this time. Pursuant to these agreements, we may be required to make upfront payments and payments upon achievement of various development, regulatory and commercial milestones, which in the aggregate could be significant. Future milestone payments, if any, will be reflected in our consolidated financial statements when the corresponding events become probable. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized. 200000000 250000000 184000000 6000000 102000000 3000000 P3Y P3Y 240000000 76000000 120000000 <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. Financial Instruments and Fair Value Measurements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash and available-for-sale securities by significant investment category at December 31, 2023 and 2022 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Equivalents</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,907 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,907 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,907 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,407 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,664 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,067 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,989 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,426 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(151)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,281 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,907 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,697 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,677 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="45" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Equivalents</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,205 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,205 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,205 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(229)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,809 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,684 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(464)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,220 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,205 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,697 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,318 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and estimated fair value of available-for-sale securities, by contractual maturity at December 31, 2023 and 2022 were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,751 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,697 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,768 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,677 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,519 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,374 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,792 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,697 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,687 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,318 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,479 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,015 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for impairment at the end of each reporting period. We did not record any impairment charges related to our available-for-sale securities during the years ended December 31, 2023, 2022, and 2021. We did not recognize any credit-related allowance to available-for-sale securities as of December 31, 2023 and 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount of gross unrealized losses and the estimated fair value for our available-for-sale securities in an unrealized loss position by length of time the securities have been in an unrealized loss position at December 31, 2023 and 2022 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or More</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2023:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,644 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,013 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2022:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,505 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,635 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,524 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(464)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,159 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023 and 2022, we held 392 and 582 available-for-sale securities, respectively, out of our total investment portfolio that were in a continuous unrealized loss position. We neither intend to sell these investments nor conclude that we are more-likely-than-not that we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our financial assets measured at fair value on a recurring basis as of December 31, 2023 and 2022 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,308 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-770">Derivative instruments</span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,021 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-798">Derivative instruments</span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in other expense net, in our consolidated statements of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, we did not have non-financial assets or liabilities measured at fair value on a recurring basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2023, we recognized net losses of $35 million on equity investments from changes in fair value of the securities. We did not have equity investments in publicly traded securities with readily determinable fair values during 2022 and 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of December 31, 2023 and 2022, we had $42 million, at each balance sheet date, in equity investments without readily determinable fair values, which are recorded within other non-current assets in our consolidated balance sheets and excluded from the fair value measurement tables above.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash and available-for-sale securities by significant investment category at December 31, 2023 and 2022 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Equivalents</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,907 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,907 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,907 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,407 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,664 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,067 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,989 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,426 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(151)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,281 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,907 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,697 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,677 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="45" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Equivalents</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,205 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,205 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,205 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(229)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,809 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,684 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(464)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,220 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,205 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,697 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,318 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2907000000 2907000000 2907000000 27000000 0 0 27000000 0 27000000 0 807000000 0 0 807000000 0 807000000 0 4407000000 3000000 67000000 4343000000 0 2664000000 1679000000 5067000000 3000000 81000000 4989000000 0 2082000000 2907000000 211000000 0 3000000 208000000 0 117000000 91000000 13426000000 6000000 151000000 13281000000 2907000000 5697000000 4677000000 3205000000 3205000000 3205000000 188000000 0 0 188000000 0 188000000 0 767000000 0 0 767000000 0 767000000 0 7781000000 0 229000000 7552000000 0 4182000000 3370000000 6595000000 0 226000000 6369000000 0 1560000000 4809000000 148000000 0 9000000 139000000 0 0 139000000 18684000000 0 464000000 18220000000 3205000000 6697000000 8318000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and estimated fair value of available-for-sale securities, by contractual maturity at December 31, 2023 and 2022 were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,751 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,697 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,768 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,677 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,519 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,374 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,792 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,697 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,687 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,318 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,479 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,015 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5751000000 5697000000 4768000000 4677000000 10519000000 10374000000 6792000000 6697000000 8687000000 8318000000 15479000000 15015000000 0 0 0 0 0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount of gross unrealized losses and the estimated fair value for our available-for-sale securities in an unrealized loss position by length of time the securities have been in an unrealized loss position at December 31, 2023 and 2022 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or More</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2023:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,644 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,013 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2022:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,505 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,635 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,524 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(464)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,159 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 25000000 0 0 0 25000000 3000000 774000000 64000000 2983000000 67000000 3757000000 1000000 562000000 79000000 3518000000 80000000 4080000000 0 8000000 4000000 143000000 4000000 151000000 4000000 1369000000 147000000 6644000000 151000000 8013000000 0 128000000 0 0 0 128000000 101000000 3956000000 128000000 3541000000 229000000 7497000000 138000000 3505000000 88000000 1890000000 226000000 5395000000 2000000 46000000 7000000 93000000 9000000 139000000 241000000 7635000000 223000000 5524000000 464000000 13159000000 392 582 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our financial assets measured at fair value on a recurring basis as of December 31, 2023 and 2022 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,308 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-770">Derivative instruments</span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,021 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-798">Derivative instruments</span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in other expense net, in our consolidated statements of operations.</span></div> 1572000000 1572000000 0 27000000 0 27000000 1246000000 0 1246000000 4343000000 0 4343000000 5480000000 0 5480000000 208000000 0 208000000 24000000 24000000 0 4000000 0 4000000 12904000000 1596000000 11308000000 9000000 0 9000000 1079000000 1079000000 0 188000000 0 188000000 767000000 0 767000000 7552000000 0 7552000000 6369000000 0 6369000000 139000000 0 139000000 6000000 0 6000000 16100000000 1079000000 15021000000 32000000 0 32000000 -35000000 42000000 42000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. Inventory</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, as of December 31, 2023 and 2022 consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consisted of raw materials with an anticipated consumption beyond one year. Inventory, non-current is included in other non-current assets in the consolidated balance sheets. </span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory write-downs as a result of excess, obsolescence, scrap or other reasons, and losses on firm purchase commitments are recorded as a component of cost of sales in our consolidated statements of operations. For the years ended December 31, 2023 and 2022, inventory write-downs were $2.2 billion and $1.3 billion, respectively. Inventory write-downs were immaterial for the year ended December 31, 2021. For the years ended December 31, 2023 and 2022, losses on firm purchase commitments were $141 million and $617 million, respectively. There were no such charges in 2021. Inventory write-downs were mainly related to obsolete inventory due to shelf-life expiration and inventory in excess of expected demand. Losses on firm purchase commitments were primarily related to excess raw material purchase commitments that will expire before the anticipated consumption of those raw materials. These charges in 2023 were primarily driven by a continued shift in product demand to the latest variant-targeted COVID-19 vaccine and a decline in customer demand as the COVID-19 vaccine market continues to transition to an endemic seasonal market in 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2023, we completed our long-range financial planning process, incorporating revised forecasts of vaccination rates. This resulted in the reassessment of future demand for our COVID-19 vaccine, leading to a strategic initiative to resize our manufacturing cost structure. This initiative, launched in the same quarter, involved reassessing our inventory levels and renegotiating with our suppliers to reduce our purchase commitments related to raw materials which were not expected to be consumed before expiration. This initiative resulted in a raw materials write-down of $903 million, included in the total inventory write-down amount for the quarter.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and December 31, 2022, the accrued liability for losses on firm future purchase commitments in our consolidated balance sheets was $79 million and $268 million, respectively. As of December 31, 2023 and December 31, 2022, we had inventory on hand of $372 million and $1.9 billion, respectively. Our raw materials and work-in-progress inventory had variable shelf lives. We expect that the majority of this inventory will be consumed over the next three years. The shelf life of our COVID-19 vaccine product ranges from nine to twelve months.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, as of December 31, 2023 and 2022 consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span>Consisted of raw materials with an anticipated consumption beyond one year. Inventory, non-current is included in other non-current assets in the consolidated balance sheets. 163000000 575000000 15000000 205000000 24000000 169000000 202000000 949000000 170000000 910000000 2200000000 1300000000 0 141000000 617000000 0 903000000 79000000 268000000 372000000 1900000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. Property, Plant and Equipment, Net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net as of December 31, 2023 and 2022 consisted of the following (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i9d825fa259284f989c73122fe917c977_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,581 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,378 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,676 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(658)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,945 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the years ended December 31, 2023, 2022, and 2021 was $617 million, $348 million, and $232 million, respectively.</span></div> 22000000 11000000 345000000 284000000 522000000 460000000 26000000 21000000 74000000 38000000 860000000 281000000 529000000 1581000000 2378000000 2676000000 433000000 658000000 1945000000 2018000000 617000000 348000000 232000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. Other Balance Sheet Components</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, Net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net, as of December 31, 2023 and December 31, 2022 consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,584 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,385 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Wholesalers chargebacks, discounts and fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,385 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets, as of December 31, 2023 and 2022 consisted of the following (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Down payments to manufacturing vendors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Down payments for materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value added tax receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenant improvement allowance receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible note receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Non-Current Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets, as of December 31, 2023 and 2022 consisted of the following (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Down payments and prepayments, non-current</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consisted of raw materials with an anticipated consumption beyond one year. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities, as of December 31, 2023 and 2022 consisted of the following (in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"><tr><td style="width:1.0%"></td><td style="width:73.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.119%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions related to product sales (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i9d825fa259284f989c73122fe917c977_145" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation-related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external goods and services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on future firm purchase commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,798 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,101 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to losses that are expected to arise from firm, non-cancellable, commitments for future raw material purchases (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i9d825fa259284f989c73122fe917c977_160" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities, as of December 31, 2023 and 2022 consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"><tr><td style="width:1.0%"></td><td style="width:73.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.119%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - financing (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i9d825fa259284f989c73122fe917c977_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - operating (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i9d825fa259284f989c73122fe917c977_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities in deferred revenue during the year ended December 31, 2023 (in millions): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,528)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,711 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,608)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net, as of December 31, 2023 and December 31, 2022 consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,584 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,385 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Wholesalers chargebacks, discounts and fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,385 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1584000000 1385000000 -692000000 0 892000000 1385000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets, as of December 31, 2023 and 2022 consisted of the following (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Down payments to manufacturing vendors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Down payments for materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value added tax receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenant improvement allowance receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible note receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 182000000 216000000 100000000 229000000 68000000 219000000 61000000 11000000 59000000 61000000 50000000 140000000 19000000 10000000 0 42000000 0 187000000 0 36000000 88000000 44000000 627000000 1195000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets, as of December 31, 2023 and 2022 consisted of the following (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Down payments and prepayments, non-current</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span>Consisted of raw materials with an anticipated consumption beyond one year. 342000000 0 170000000 910000000 66000000 42000000 52000000 0 44000000 0 4000000 12000000 7000000 24000000 685000000 988000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities, as of December 31, 2023 and 2022 consisted of the following (in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"><tr><td style="width:1.0%"></td><td style="width:73.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.119%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions related to product sales (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i9d825fa259284f989c73122fe917c977_145" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation-related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external goods and services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on future firm purchase commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,798 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,101 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to losses that are expected to arise from firm, non-cancellable, commitments for future raw material purchases (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i9d825fa259284f989c73122fe917c977_160" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div> 556000000 0 245000000 190000000 175000000 319000000 167000000 400000000 140000000 88000000 137000000 264000000 122000000 203000000 94000000 5000000 79000000 268000000 56000000 48000000 27000000 316000000 1798000000 2101000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities, as of December 31, 2023 and 2022 consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"><tr><td style="width:1.0%"></td><td style="width:73.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.119%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - financing (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i9d825fa259284f989c73122fe917c977_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - operating (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i9d825fa259284f989c73122fe917c977_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0 161000000 25000000 35000000 41000000 53000000 66000000 249000000 2626000000 515000000 2528000000 613000000 4000000 2000000 2000000 4000000 81000000 31000000 78000000 34000000 2711000000 548000000 2608000000 651000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2042. Certain of these arrangements have free rent periods or escalating rent payment provisions. We recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have two main campuses in Massachusetts, our Cambridge campus and our Moderna Technology Center (MTC), located in Norwood. We also lease various parcels of land, office and lab spaces across the globe for our business operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cambridge Campus</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occupy a multi-building campus at Technology Square in Cambridge, Massachusetts with a mix of offices and research laboratory space totaling approximately 292,000 square feet. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we entered into a lease agreement for a building space, approximately 462,000 square feet, in Cambridge, Massachusetts. This space is designated to be the Moderna Science Center (MSC), housing a blend of office space and laboratories. Following an approximately two-year building project, the lease term is 15 years, with options for two additional seven-year extensions. During the third quarter of 2023, we commenced the lease and recognized the related right-of-use asset and lease liability on our consolidated balance sheets. Following the commencement of the MSC lease, we amended the expiration dates of our existing leases at Technology Square in the fourth quarter of 2023. Originally scheduled to expire ranging from 2024 to 2029, these leases have been adjusted to conclude in early 2025. All our Cambridge leases are classified as operating leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Technology Center</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an industrial technology center in Norwood, Massachusetts, our Moderna Technology Center (MTC), comprised of three buildings, MTC South, MTC North, and MTC East, totaling approximately 686,000 square feet. Our MTC leases expire in 2042 and we have the option to extend the term for three extension periods of five years each. All of our MTC leases are classified as finance leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Embedded Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into multiple contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. In the third quarter of 2023, as part of our strategic initiative to optimize our manufacturing footprint, we amended a contract manufacturing service agreement, resulting in decreases of $262 million in each of the right-of-use assets and lease liabilities. Additionally, it resulted in accelerated depreciation of the right-of-use assets of $323 million for the year ended December 31, 2023. As of December 31, 2023, we had no remaining right-of-use assets or lease liabilities due to embedded leases. As of December 31, 2022, we had right-of-use assets of $639 million and lease liabilities of $440 million related to embedded leases. All of our embedded leases were classified as finance leases.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2023 and 2022 were as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:f-975"><span style="-sec-ix-hidden:f-976"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) (4)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,149 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:f-981"><span style="-sec-ix-hidden:f-982"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:f-985"><span style="-sec-ix-hidden:f-986"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current lease liabilities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,243 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are real estate related assets, which include land, office and laboratory spaces.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net of accumulated amortization. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are real estate assets related to the MTC leases as well as assets related to contract manufacturing service agreements.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in property, plant and equipment in the consolidated balance sheets, net of accumulated depreciation.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in other current liabilities in the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the lease costs were as follows for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:59.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Amortization of right-of-use assets, financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Interest expense for financing lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financing lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information relating to our leases was as follows for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:63.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows used in financing leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in right-of-use assets related to lease modifications and reassessments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in right-of-use assets related to lease modifications and reassessments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for financing lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in financing lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Weighted average remaining lease terms and discount rates as of December 31, 2023 and 2022 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining lease term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancelable lease agreements as of December 31, 2023, were as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(465)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Include certain optional lease term extensions, predominantly related to the MTC leases, which represent a total of $668 million of undiscounted future lease payments.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2042. Certain of these arrangements have free rent periods or escalating rent payment provisions. We recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have two main campuses in Massachusetts, our Cambridge campus and our Moderna Technology Center (MTC), located in Norwood. We also lease various parcels of land, office and lab spaces across the globe for our business operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cambridge Campus</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occupy a multi-building campus at Technology Square in Cambridge, Massachusetts with a mix of offices and research laboratory space totaling approximately 292,000 square feet. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we entered into a lease agreement for a building space, approximately 462,000 square feet, in Cambridge, Massachusetts. This space is designated to be the Moderna Science Center (MSC), housing a blend of office space and laboratories. Following an approximately two-year building project, the lease term is 15 years, with options for two additional seven-year extensions. During the third quarter of 2023, we commenced the lease and recognized the related right-of-use asset and lease liability on our consolidated balance sheets. Following the commencement of the MSC lease, we amended the expiration dates of our existing leases at Technology Square in the fourth quarter of 2023. Originally scheduled to expire ranging from 2024 to 2029, these leases have been adjusted to conclude in early 2025. All our Cambridge leases are classified as operating leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Technology Center</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an industrial technology center in Norwood, Massachusetts, our Moderna Technology Center (MTC), comprised of three buildings, MTC South, MTC North, and MTC East, totaling approximately 686,000 square feet. Our MTC leases expire in 2042 and we have the option to extend the term for three extension periods of five years each. All of our MTC leases are classified as finance leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Embedded Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into multiple contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. In the third quarter of 2023, as part of our strategic initiative to optimize our manufacturing footprint, we amended a contract manufacturing service agreement, resulting in decreases of $262 million in each of the right-of-use assets and lease liabilities. Additionally, it resulted in accelerated depreciation of the right-of-use assets of $323 million for the year ended December 31, 2023. As of December 31, 2023, we had no remaining right-of-use assets or lease liabilities due to embedded leases. As of December 31, 2022, we had right-of-use assets of $639 million and lease liabilities of $440 million related to embedded leases. All of our embedded leases were classified as finance leases.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2023 and 2022 were as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:f-975"><span style="-sec-ix-hidden:f-976"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) (4)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,149 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:f-981"><span style="-sec-ix-hidden:f-982"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:f-985"><span style="-sec-ix-hidden:f-986"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current lease liabilities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,243 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are real estate related assets, which include land, office and laboratory spaces.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net of accumulated amortization. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are real estate assets related to the MTC leases as well as assets related to contract manufacturing service agreements.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in property, plant and equipment in the consolidated balance sheets, net of accumulated depreciation.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in other current liabilities in the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the lease costs were as follows for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:59.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Amortization of right-of-use assets, financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Interest expense for financing lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financing lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information relating to our leases was as follows for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:63.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows used in financing leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in right-of-use assets related to lease modifications and reassessments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in right-of-use assets related to lease modifications and reassessments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for financing lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in financing lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Weighted average remaining lease terms and discount rates as of December 31, 2023 and 2022 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining lease term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancelable lease agreements as of December 31, 2023, were as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(465)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Include certain optional lease term extensions, predominantly related to the MTC leases, which represent a total of $668 million of undiscounted future lease payments.</span></div> 2 292000 462000 P2Y P15Y 2 P7Y 3 686000 3 P5Y -262000000 -262000000 323000000 0 0 639000000 440000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2023 and 2022 were as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:f-975"><span style="-sec-ix-hidden:f-976"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) (4)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,149 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:f-981"><span style="-sec-ix-hidden:f-982"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:f-985"><span style="-sec-ix-hidden:f-986"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current lease liabilities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,243 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are real estate related assets, which include land, office and laboratory spaces.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net of accumulated amortization. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are real estate assets related to the MTC leases as well as assets related to contract manufacturing service agreements.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in property, plant and equipment in the consolidated balance sheets, net of accumulated depreciation.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in other current liabilities in the consolidated balance sheets.</span></div> 713000000 121000000 436000000 1150000000 1149000000 1271000000 25000000 35000000 0 161000000 25000000 196000000 643000000 92000000 575000000 912000000 1218000000 1004000000 1243000000 1200000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the lease costs were as follows for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:59.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Amortization of right-of-use assets, financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Interest expense for financing lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financing lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information relating to our leases was as follows for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:63.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows used in financing leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in right-of-use assets related to lease modifications and reassessments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in right-of-use assets related to lease modifications and reassessments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for financing lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in financing lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Weighted average remaining lease terms and discount rates as of December 31, 2023 and 2022 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining lease term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 88000000 48000000 24000000 500000000 280000000 189000000 38000000 29000000 17000000 538000000 309000000 206000000 2000000 0 49000000 113000000 165000000 100000000 93000000 57000000 19000000 39000000 25000000 14000000 292000000 184000000 140000000 67000000 0 -7000000 714000000 20000000 72000000 213000000 0 674000000 0 777000000 126000000 3000000 4000000 3000000 P14Y P6Y P33Y P22Y 0.075 0.075 0.042 0.036 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancelable lease agreements as of December 31, 2023, were as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(465)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Include certain optional lease term extensions, predominantly related to the MTC leases, which represent a total of $668 million of undiscounted future lease payments.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancelable lease agreements as of December 31, 2023, were as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(465)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Include certain optional lease term extensions, predominantly related to the MTC leases, which represent a total of $668 million of undiscounted future lease payments.</span></div> 72000000 20000000 67000000 22000000 67000000 22000000 70000000 23000000 72000000 23000000 785000000 1074000000 1133000000 1184000000 465000000 609000000 668000000 575000000 668000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. Commitments and Contingencies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various claims and legal proceedings of a nature considered ordinary course in our business. The outcome of any such proceedings, regardless of the merits, is inherently uncertain; therefore, assessing the likelihood of loss and any estimated damages is difficult and subject to considerable judgment. We are not currently a party to any legal proceedings for which a material loss is probable, or for which a loss is reasonably estimable at this time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Obligations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law, we indemnify our officers, directors, and employees for certain events, occurrences while the officer, or director is, or was, serving at our request in such capacity. The term of the indemnification is for the officer’s or director’s lifetime.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have standard indemnification arrangements in our leases for laboratory and office space that require us to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under our leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into indemnification provisions under our agreements with counterparties in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December 31, 2023 and 2022, we had not experienced any significant losses related to these indemnification obligations, and no material claims were outstanding. We do not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments and Purchase Orders</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into agreements in the normal course of business with vendors and contract manufacturing organizations (CMOs) for raw materials and manufacturing services and with vendors for preclinical research studies, clinical trials and other goods or services. As of December 31, 2023, we had $1.8 billion of non-cancelable purchase commitments related to raw materials and manufacturing agreements, which are expected to be paid through 2029. As of December 31, 2023, $79 million of the purchase commitments related to raw materials was recorded as an accrued liability for loss on future firm purchase commitments. As of December 31, 2023, we had $261 million of non-cancelable purchase commitments related to clinical services and other goods and services which are expected to be paid through 2039. These amounts represent our minimum contractual obligations, including termination fees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to purchase commitments, we have agreements with third parties for various services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or wind down costs. Under such agreements, we are contractually obligated to make certain payments to vendors, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation. At December 31, 2023, we had cancelable open purchase orders of $3.0 billion in total under such agreements for our significant clinical operations and support and contract manufacturing. These amounts represent only our estimate of those items for which we had a contractual commitment to pay at December 31, 2023, assuming we would not cancel these agreements. The actual amounts we pay in the future to the vendors under such agreements may differ from the purchase order amounts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licenses to Patented Technology</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into sublicense agreements with Cellscript, LLC and its affiliate, mRNA RiboTherapeutics, Inc. to sublicense certain patent rights. Pursuant to each agreement, we are required to pay certain license fees, annual maintenance fees, minimum royalties on future net sales and milestone payments contingent on achievement of certain development, regulatory and commercial milestones for specified products, on a product-by-product basis. Commercial milestone payments and royalties based on annual net sales of licensed products for therapeutic and prophylactic products are accounted for as additional expense of the related net product sales in the period in which the corresponding sales occur. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2022, we entered into a non-exclusive patent license agreement with the National Institute of Allergy and Infectious Diseases (NIAID), an Institute or Center of the National Institutes of Health (NIH) to license certain patent rights concerning </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">stabilizing prefusion coronavirus spike proteins and the resulting stabilized proteins for use in COVID-19 vaccine products. Pursuant to the agreement, we have agreed to pay low single-digit royalties on future net sales, a minimum annual royalty payment, and certain contingent development, regulatory and commercial milestone payments on a licensed product-by-licensed product basis. In addition, in December 2022, we made a catch-up royalty payment of $400 million to NIAID, which was recorded to cost of sales in our consolidated statements of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, 2022, and 2021 we recognized $301 million, $1.1 billion, and $641 million, respectively, of royalties and commercial milestone payments associated with our net product sales, which was recorded to cost of sales in our consolidated statements of operations.</span></div>Additionally, we have other in-license agreements with third parties which require us to make future development, regulatory and commercial milestone payments for specified products associated with the agreements. The achievement of these milestones have not yet occurred as of December 31, 2023. 0 0 0 0 0 0 1800000000 79000000 261000000 3000000000 400000000 301000000 1100000000 641000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. Stock-Based Compensation and Share Repurchase Programs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with our initial public offering (IPO), we adopted the 2018 Stock Option and Incentive Plan (the 2018 Equity Plan) in November 2018. The 2018 Equity Plan became effective on the date immediately prior to the effective date of the IPO and replaced our 2016 Stock Option and Incentive Plan (the 2016 Equity Plan). The 2018 Equity Plan provides flexibility to our compensation committee to use various equity-based incentive awards as compensation tools to motivate our workforce. The shares of common stock underlying any awards that are forfeited, canceled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2018 Equity Plan and the 2016 Equity Plan will be added back to the shares of common stock available for issuance under the 2018 Equity Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors may grant to employees, nonemployee directors, consultants and independent advisors equity-based awards during their period of service, generally in the form of stock options, restricted stock units, and performance stock units. The terms and conditions of stock-based awards are defined at the sole discretion of our Board of Directors. We issue service-based awards, vesting over a defined period of service, and performance-based awards, vesting upon achievement of defined conditions. Service based awards generally vest over a four-year period, with the first 25% of such awards vesting following twelve months of continued employment or service. The remaining awards vest in twelve quarterly installments over the following twelve quarters. Stock options granted under the 2018 Equity Plan and the 2016 Equity Plan expire ten years from the date of grant and the exercise price must be at least equal to the fair market value of common stock on the grant date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we had a total of 47 million shares reserved for future issuance under our Equity Plans, of which 31 million shares were reserved for equity awards previously granted, and 16 million shares were available for future grants under the 2018 Equity Plan. No additional awards will be granted under the 2016 Equity Plan as it was replaced by the 2018 Equity Plan.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted options generally through the 2018 Equity Plan and 2016 Equity Plan. The following table summarizes our option activity during the year ended December 31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.987%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Options <br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.93 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.23 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,478 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.03 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.98 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of December 31, 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was $413 million, $714 million, and $1.6 billion for the years ended December 31, 2023, 2022, and 2021, respectively. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period. The excess tax benefits realized from tax deductions from option exercises were $84 million, $144 million, and $325 million during the years ended December 31, 2023, 2022, and 2021 respectively. The total consideration recorded as a result of stock option exercises was approximately $25 million, $50 million, and $112 million for the years ended December 31, 2023, 2022, and 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Common Stock Units (RSUs) and Performance Stock Units (PSUs)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted RSUs and PSUs generally through the 2018 Equity Plan. The following table summarizes our RSU and PSU activity during the year ended December 31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:72.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.836%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date Fair Value per Unit</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.25 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total grant date fair value of RSUs and PSUs vested during the years ended December 31, 2023, 2022, and 2021, was $99 million, $55 million, and $18 million, respectively. The total intrinsic value of RSUs and PSUs vested during the years ended December 31, 2023, 2022, and 2021, was $120 million, $125 million and $141 million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, 2022 and 2021, we granted an immaterial amount of PSUs, respectively, primarily to certain senior executives with vesting that is contingent upon the achievement of specified preestablished goals over the performance period, generally three years. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from 0% to 200%. The estimated fair value of PSUs is based on the grant date fair value.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation and Stock-Based Compensation Expense</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for options granted under our Equity Plans is determined using the Black-Scholes option pricing model. The weighted-average assumptions used to estimate the fair value of options granted for the years ended December 31, 2023, 2022, and 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.986%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Expected volatility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Expected dividends</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Weighted average fair value per share</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.02 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of stock-based compensation expense for the years ended December 31, 2023, 2022, and 2021 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2023, 2022, and 2021, we recognized stock-based compensation expense of $17 million, $18 million, and $16 million, respectively, related to performance-based awards, including awards with vesting or commencement contingent upon our IPO. Stock-based compensation expenses related to non-employee awards were immaterial for the years ended December 31, 2023, 2022, and 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, there were $835 million of total unrecognized compensation cost related to non-vested stock-based compensation with respect to options, RSUs and PSUs granted. That cost is expected to be recognized over a weighted-average period of 2.6 years at December 31, 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Programs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2021, our Board of Directors authorized a Share Repurchase Program (2021 Repurchase Program) of our common stock, with an expiration date no later than August 2, 2023. Pursuant to the 2021 Repurchase Program, we were authorized to repurchase up to $1.0 billion of our outstanding common stock. By the end of January 2022, we had repurchased the entire $1.0 billion of common stock that was authorized under the 2021 Repurchase Program. On February 22, 2022, our Board of Directors authorized an additional share repurchase program of our common stock, with no expiration date, for up to $3.0 billion. On August 1, 2022, our Board of Directors authorized an increase of $3.0 billion under the repurchase program for our common stock, with no expiration date (collectively with the February 22, 2022 authorization, the 2022 Repurchase Programs). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, $1.7 billion of our Board of Directors’ authorization for repurchases of our common stock remains outstanding (the 2022 Repurchase Programs), with no expiration date. The timing and actual number of shares repurchased under the 2022 Repurchase Programs will depend on a variety of factors, including price, general business and market conditions, and other investment opportunities, and shares may be repurchased through open market purchases through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to our share repurchase programs (in millions, except per share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares repurchased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining authorization at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,814 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Average price paid per share includes related expenses and excise tax, applicable beginning January 1, 2023.</span></div> P4Y 0.25 P12M 12 P10Y 47000000 31000000 16000000 The following table summarizes our option activity during the year ended December 31, 2023:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.987%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Options <br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.93 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.23 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,478 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.03 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.98 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of December 31, 2023.</span></div> 24930000 42.23 P5Y8M12D 3478000000 4360000 113.03 3110000 8.13 680000 130.23 25500000 56.14 P5Y7M6D 1437000000 18980000 33.34 P4Y6M 1378000000 6520000 122.50 P8Y10M24D 59000000 413000000 714000000 1600000000 84000000 144000000 325000000 25000000 50000000 112000000 The following table summarizes our RSU and PSU activity during the year ended December 31, 2023:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:72.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.836%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date Fair Value per Unit</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.25 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table> 2900000 132.25 3710000 107.23 1010000.00 98.68 420000 130.01 5180000 121.02 99000000 55000000 18000000 120000000 125000000 141000000 P3Y P3Y 0 0 2 2 The weighted-average assumptions used to estimate the fair value of options granted for the years ended December 31, 2023, 2022, and 2021 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.986%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Expected volatility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Expected dividends</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Weighted average fair value per share</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.02 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 0.0413 0.0246 0.0084 P6Y25D P6Y1M17D P6Y1M6D 0.48 0.50 0.46 0 0 0 57.87 76.02 91.84 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of stock-based compensation expense for the years ended December 31, 2023, 2022, and 2021 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 136000000 123000000 96000000 161000000 97000000 42000000 8000000 6000000 4000000 305000000 226000000 142000000 37000000 45000000 22000000 157000000 93000000 68000000 111000000 88000000 52000000 305000000 226000000 142000000 17000000 18000000 16000000 835000000 P2Y7M6D 1000000000 1000000000 3000000000 3000000000 1700000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to our share repurchase programs (in millions, except per share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares repurchased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining authorization at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,814 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Average price paid per share includes related expenses and excise tax, applicable beginning January 1, 2023.</span></div> 8000000 23000000 3000000 143.26 142.83 245.76 1153000000 3329000000 857000000 1667000000 2814000000 143000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Loss) income before income taxes for the years ended December 31, 2023, 2022, and 2021 consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,433 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,108 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Loss) income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,942)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,575 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,285 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for the years ended December 31, 2023, 2022, and 2021 consisted of the following components (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,791 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(569)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31, 2023, 2022, and 2021 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation windfall</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal research and development credits</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for the year ended December 31, 2023 was (19.6)% and was higher than the federal statutory tax rate, primarily due to an increase in valuation allowance against deferred tax assets. The effective tax rates for the year ended December 31, 2023 also include tax benefits from research and development credits and stock-based compensation. Our effective tax rate for the year ended December 31, 2022 was lower than the federal statutory tax rate, primarily due to the tax benefit of the foreign-derived intangible income deduction (FDII) and excess tax benefit related to stock-based compensation. Our effective tax rate for the year ended December 31, 2021 was lower than the federal statutory tax rate, primarily due to the tax benefits related to the release of the valuation allowance on most of our deferred tax assets, FDII and stock-based compensation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022, pursuant to the Tax Cuts and Jobs Act of 2017 (“TCJA”), research and development costs in the current period are required to be amortized over five or fifteen years, depending on where the research is conducted. The new capitalization requirement significantly increased our deferred tax assets and cash tax liabilities, but also decreased our effective tax rate by increasing the foreign-derived intangible income deduction.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The President signed into law the Inflation Reduction Act (the “IRA”) on August 16, 2022. The Act includes a new 15% corporate minimum tax and a 1% excise tax on the value of corporate stock repurchases, net of new share issuances, after December 31, 2022. We do not expect these provisions to have a material impact on our consolidated financial position; however, we will continue to evaluate their impact as further information becomes available.</span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting and the amounts used for income tax purposes, tax credit carryforwards and the tax effect of net operating loss carryforwards. Significant components of our deferred tax assets and tax liabilities as of December 31, 2023 and 2022 were as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:77.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized licenses, research and development and start-up costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory reserve and capitalization </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wholesaler chargebacks, discounts and fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Returns and other fees</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,678 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,224)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax (liabilities) assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes changes in the valuation allowance for deferred tax assets for the periods presented (in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">millions</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases recorded as benefit to income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(722)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at December 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,224 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We periodically reassess the need for valuation allowances on our deferred tax assets, considering both positive and negative evidence to evaluate whether it is more likely than not that all or a portion of such assets will not be realized. During 2023, following the completion of our long-range financial planning process, we reassessed the evidence and concluded that a valuation allowance was necessary due to the preponderance of negative evidence, including: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A pre-tax loss for the full year 2023, serving as a significant source of objectively verifiable negative evidence in accordance with ASC 740 (Income Taxes).</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A projected three-year cumulative loss resulting from our long-range financial planning process. This projection is due to a significant decrease in expected sales of our COVID-19 vaccine as we transition to a seasonal market. Additionally, we anticipate substantial research and development expenses for our on-going Phase 3 clinical trials and to advance our product candidates into later-stage development. These factors contribute additional negative evidence with respect to the realizability of our deferred tax assets. The projections are based upon revenue from our currently approved drug product, which we believe can be reasonably estimated. In contrast, future taxable income projections from our investigational medicines are deemed inherently subjective and not objectively verifiable; they are insufficient to override negative evidence, and therefore, they are not assigned any weight in our valuation allowance analysis assessment.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our evaluation also included whether there were other sources of taxable income that would allow us to realize our deferred tax assets, such as taxable income in carryback years, available tax planning strategies and the future reversals of taxable temporary differences. After assessing these strategies and all evidence, we determined it was more likely than not that we will not realize all of our deferred tax assets and therefore increased the valuation allowance by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.1 billion</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during 2023.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, we reassessed the valuation allowance noting the increase in positive evidence, including significant revenue growth, expectations regarding future profitability, and successful supply chain and manufacturing capabilities to meet global product demand. After assessing both the positive evidence and negative evidence, we determined it was more likely than not that we would realize the majority of our deferred tax assets, and we released the valuation allowance on the majority of our deferred tax assets, accordingly. The release of the valuation allowance was based on the then-prevailing positive outlook, which has since shifted significantly by 2023 due to the factors outlined above, leading to the reinstatement of a full valuation allowance.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required in assessing the realizability of our deferred tax assets. In the event that actual results differ from our estimates, we adjust our estimates in future periods and we may need to modify our valuation allowance, which could materially impact our financial position and results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023, we had $1.6 billion of state net operating loss carryforwards, which begin to expire in 2030. At December 31, 2023, we also had state research and development tax credit carryforwards of $178 million, the majority of which will begin to expire in 2030.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize, in our financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. A reconciliation of the beginning and ending amounts of unrecognized tax benefits during the years ended December 31, 2023, 2022, and 2021 were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease due to prior positions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions for prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiration of statutes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements with tax authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase due to current year tax positions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions for current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions for prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at end of the period </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we had $231 million of net unrecognized tax benefits, which would affect our tax rate if recognized. Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. We do not anticipate a material change to our unrecognized tax benefits over the next twelve months that would have an adverse effect on our consolidated operating results. We recognize interest and penalties, if applicable, related to uncertain tax positions as a component of income tax expense. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. All tax years since our date of incorporation remain open to examination by the major taxing jurisdictions, as carryforward attributes generated in past years may be adjusted upon examination by the Internal Revenue Service or the state authorities. There are no open tax examinations at this time.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Loss) income before income taxes for the years ended December 31, 2023, 2022, and 2021 consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,433 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,108 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Loss) income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,942)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,575 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,285 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -4056000000 9433000000 13108000000 114000000 142000000 177000000 -3942000000 9575000000 13285000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for the years ended December 31, 2023, 2022, and 2021 consisted of the following components (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,791 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(569)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -225000000 1687000000 1304000000 72000000 47000000 35000000 24000000 57000000 40000000 -129000000 1791000000 1379000000 888000000 -569000000 -288000000 8000000 -7000000 -6000000 5000000 -2000000 -2000000 901000000 -578000000 -296000000 772000000 1213000000 1083000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31, 2023, 2022, and 2021 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation windfall</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal research and development credits</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.210 0.210 0.210 -0.526 0 -0.054 -0.002 0.074 0.048 0.024 -0.016 -0.026 -0.046 0.005 0.007 0.057 0.004 0.005 -0.004 0 0 -0.005 0.008 0.001 -0.196 0.127 0.081 -0.196 Significant components of our deferred tax assets and tax liabilities as of December 31, 2023 and 2022 were as follows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:77.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized licenses, research and development and start-up costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory reserve and capitalization </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wholesaler chargebacks, discounts and fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Returns and other fees</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,678 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,224)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax (liabilities) assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 90000000 59000000 111000000 68000000 1449000000 704000000 140000000 97000000 154000000 26000000 139000000 135000000 34000000 106000000 250000000 86000000 92000000 0 129000000 0 90000000 85000000 2678000000 1366000000 2224000000 155000000 454000000 1211000000 106000000 117000000 160000000 26000000 107000000 85000000 15000000 1000000 388000000 229000000 66000000 982000000 <div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes changes in the valuation allowance for deferred tax assets for the periods presented (in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">millions</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases recorded as benefit to income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(722)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at December 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,224 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 155000000 149000000 823000000 0 12000000 722000000 2069000000 18000000 48000000 2224000000 155000000 149000000 2100000000 1600000000 178000000 A reconciliation of the beginning and ending amounts of unrecognized tax benefits during the years ended December 31, 2023, 2022, and 2021 were as follows (in millions):<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease due to prior positions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions for prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiration of statutes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements with tax authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase due to current year tax positions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions for current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions for prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at end of the period </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 128000000 68000000 0 0 1000000 0 0 0 0 27000000 0 0 44000000 57000000 54000000 86000000 4000000 14000000 231000000 128000000 68000000 231000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. (Loss) Earnings per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computation of basic earnings (loss) per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and potential dilutive common shares outstanding during the period as determined by using the treasury stock method.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted EPS for the years ended December 31, 2023, 2022 and 2021 were calculated as follows (in millions, except per share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:61.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.002%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,362 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents, presented based on amounts outstanding as of December 31, 2023, 2022 and 2021, were excluded from the calculation of diluted net (loss) income per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted EPS for the years ended December 31, 2023, 2022 and 2021 were calculated as follows (in millions, except per share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:61.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.002%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,362 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -4714000000 8362000000 12202000000 382000000 394000000 403000000 0 22000000 28000000 382000000 416000000 431000000 -12.33 21.26 30.31 -12.33 20.12 28.29 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents, presented based on amounts outstanding as of December 31, 2023, 2022 and 2021, were excluded from the calculation of diluted net (loss) income per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 26000000 3000000 1000000 5000000 0 0 31000000 3000000 1000000 1 1895000000 5150000000 6177000000 1355000000 6815000000 6846000000 3598000000 7298000000 5448000000 6848000000 19263000000 18471000000 1560000000 1267000000 126000000 714000000 259000000 37000000 1945000000 2018000000 false false <div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 7, 2023, Noubar Afeyan, our Chairman, amended a trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Afeyan 10b5-1 Plan). The Afeyan 10b5-1 Plan was amended to increase certain price triggers under the plan. The Afeyan 10b5-1 Plan, as amended, is scheduled to commence </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">on February 28, 2024,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">will</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> run through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">August 20, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The aggregate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">maximum </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">number of shares of common stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">that may</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> be sold pursuant to the Afeyan 10b5-1 Plan is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">745,000, which represents the shares remaining under the original plan that have not been sold to date</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div> November 7, 2023 Noubar Afeyan Chairman true 745000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 6, 2023, Arpa Garay, our former Chief Commercial Officer, terminated a trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Garay 10b5-1 Plan). The Garay 10b5-1 Plan was entered into on August 24, 2023, and was scheduled to commence on November 27, 2023, with a termination date of August 30, 2024. The Garay 10b5-1 Plan provided for the potential sale of approximately 4,540 shares of common stock and for the potential exercise of vested stock options and the associated sale of up to 24,897 shares. No shares of common stock were sold, and no options to purchase shares of common stock were exercised, under the Garay 10b5-1 Plan prior to its termination.</span></div> November 6, 2023 Arpa Garay former Chief Commercial Officer true August 24, 2023 4540 24897 42